<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39306468</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>404</Volume><Issue>10458</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.</ArticleTitle><Pagination><StartPage>1107</StartPage><EndPage>1118</EndPage><MedlinePgn>1107-1118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(24)01595-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(24)01595-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival.</AbstractText><AbstractText Label="METHODS">TransMet was a multicentre, open-label, prospective, randomised controlled trial done in 20 tertiary centres in Europe. Patients aged 18-65 years, with Eastern Cooperative Oncology Group performance score 0-1, permanently unresectable colorectal liver metastases from resected BRAF-non-mutated colorectal cancer responsive to systemic chemotherapy (&#x2265;3 months, &#x2264;3 lines), and no extrahepatic disease, were eligible for enrolment. Patients were randomised (1:1) to liver transplantation plus chemotherapy or chemotherapy alone, using block randomisation. The liver transplantation plus chemotherapy group underwent liver transplantation for 2 months or less after the last chemotherapy cycle. At randomisation, the liver transplantation plus chemotherapy group received a median of 21&#xb7;0 chemotherapy cycles (IQR 18&#xb7;0-29&#xb7;0) versus 17&#xb7;0 cycles (12&#xb7;0-24&#xb7;0) in the chemotherapy alone group, in up to three lines of chemotherapy. During first-line chemotherapy, 64 (68%) of 94 patients had received doublet chemotherapy and 30 (32%) of 94 patients had received triplet regimens; 76 (80%) of 94 patients had targeted therapy. Transplanted patients received tailored immunosuppression (methylprednisolone 10 mg/kg intravenously on day 0; tacrolimus 0&#xb7;1 mg/kg via gastric tube on day 0, 6-10 ng/mL days 1-14; mycophenolate mofetil 10 mg/kg intravenously day 0 to &lt;2 months and switch to everolimus 5-8 ng/mL), and postoperative chemotherapy, and the chemotherapy group had continued chemotherapy. The primary endpoint was 5-year overall survival analysed in the intention to treat and per-protocol population. Safety events were assessed in the as-treated population. The study is registered with ClinicalTrials.gov (NCT02597348), and accrual is complete.</AbstractText><AbstractText Label="FINDINGS">Between Feb 18, 2016, and July 5, 2021, 94 patients were randomly assigned and included in the intention-to-treat population, with 47 in the liver transplantation plus chemotherapy group and 47 in the chemotherapy alone group. 11 patients in the liver transplantation plus chemotherapy group and nine patients in the chemotherapy alone group did not receive the assigned treatment; 36 patients and 38 patients in each group, respectively, were included in the per-protocol analysis. Patients had a median age of 54&#xb7;0 years (IQR 47&#xb7;0-59&#xb7;0), and 55 (59%) of 94 patients were male and 39 (41%) were female. Median follow-up was 59&#xb7;3 months (IQR 42&#xb7;4-60&#xb7;2). In the intention-to-treat population, 5-year overall survival was 56&#xb7;6% (95% CI 43&#xb7;2-74&#xb7;1) for liver transplantation plus chemotherapy and 12&#xb7;6% (5&#xb7;2-30&#xb7;1) for chemotherapy alone (HR 0&#xb7;37 [95% CI 0&#xb7;21-0&#xb7;65]; p=0&#xb7;0003) and 73&#xb7;3% (95% CI 59&#xb7;6-90&#xb7;0) and 9&#xb7;3% (3&#xb7;2-26&#xb7;8), respectively, for the per-protocol population. Serious adverse events occurred in 32 (80%) of 40 patients who underwent liver transplantation (from either group), and 69 serious adverse events were observed in 45 (83%) of 54 patients treated with chemotherapy alone. Three patients in the liver transplantation plus chemotherapy group were retransplanted, one of whom died postoperatively of multi-organ failure.</AbstractText><AbstractText Label="INTERPRETATION">In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases.</AbstractText><AbstractText Label="FUNDING">French National Cancer Institute and Assistance Publique-H&#xf4;pitaux de Paris.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, AP-HP H&#xf4;pital Paul-Brousse, University of Paris-Saclay, Villejuif, France; Department of Oncology, UPR Chronotherapy, Cancers and Transplantation, Faculty of Medicine, University of Paris-Saclay, Villejuif, France. Electronic address: rene.adam@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piedvache</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, AP-HP H&#xf4;pital Kremlin Bic&#xea;tre, University of Paris-Saclay, Le Kremlin Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiche</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, H&#xf4;pital Haut-L&#xe9;v&#xea;que, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Jean Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, H&#xf4;pital Haut-L&#xe9;v&#xea;que, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salam&#xe9;</LastName><ForeName>Ephrem</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive, Hepatobiliary and Pancreatic Surgery, Regional University Hospital, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucur</LastName><ForeName>Petru</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Digestive, Hepatobiliary and Pancreatic Surgery, Regional University Hospital, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherqui</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, AP-HP H&#xf4;pital Paul-Brousse, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scatton</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, AP-HP H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Victoire</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Digestive Oncology, University Hospital Grenoble, Universit&#xe9; Grenoble Alpes Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducreux</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cillo</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery and Liver Transplant Unit, University Hospital Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauchy</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery Unit, AP-HP H&#xf4;pital Beaujon, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabrut</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Liver Transplantation, H&#xf4;pital de la Croix-Rousse, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verslype</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coubeau</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Abdominal Surgery and Transplantation, University Hospital Saint Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardwigsen</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Digestive, Hepatobiliary and Transplantation Surgery, Marseille University Hospital Timone, Marseilles, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boleslawski</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery and Transplantation, University Hospital Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muscari</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, H&#xf4;pital Rangueil, University Hospitals Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeddou</LastName><ForeName>Heithem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Digestive Surgery, University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pezet</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Surgery, University Hospital Clermont-Ferrand, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyd</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Digestive and Oncological Surgery, Regional University Hospital Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucidi</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery and Transplantation, H&#xf4;pital Universitaire de Bruxelles, Universit&#xe9; Libre de Bruxelles, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geboes</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology/Digestive Oncology, University Hospital Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerut</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Research, Catholic University of Louvain, Louvain, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majno</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, University of Italian Switzerland, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimaldi</LastName><ForeName>Lamiae</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, AP-HP H&#xf4;pital Kremlin Bic&#xea;tre, University of Paris-Saclay, Le Kremlin Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levi</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology, UPR Chronotherapy, Cancers and Transplantation, Faculty of Medicine, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewin</LastName><ForeName>Ma&#xef;t&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, UPR Chronotherapy, Cancers and Transplantation, Faculty of Medicine, University of Paris-Saclay, Villejuif, France; Department of Radiology, H&#xf4;pital Paul-Brousse, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelli</LastName><ForeName>Maximiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Surgery and Interventional Radiology, Gustave Roussy Hospital, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Collaborative TransMet group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02597348</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2024 Sep 21;404(10458):1078-1079. doi: 10.1016/S0140-6736(24)01926-3.</RefSource><PMID Version="1">39306454</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):271-274. doi: 10.21037/hbsn-2025-51.</RefSource><PMID Version="1">40342761</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adam</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piedvache</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiche</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adam</LastName><ForeName>Jean Philippe</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salam&#xe9;</LastName><ForeName>Ephrem</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bucur</LastName><ForeName>Petru</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherqui</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scatton</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Granger</LastName><ForeName>Victoire</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducreux</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cillo</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cauchy</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mabrut</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cauchy</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mabrut</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verslype</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coubeau</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardwigsen</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boleslawski</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muscari</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeddou</LastName><ForeName>Heithem</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pezet</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyd</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucidi</LastName><ForeName>Valerio</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geboes</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerut</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majno</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimaldi</LastName><ForeName>Lamiae</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levi</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewin</LastName><ForeName>Ma&#xef;t&#xe9;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelli</LastName><ForeName>Maximiliano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soubrane</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesurtel</LastName><ForeName>Mickael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachet</LastName><ForeName>Jean Baptsite</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesourd</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jary</LastName><ForeName>Marine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouattour</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonardi</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hebbar</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boudjema</LastName><ForeName>Karim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chirica</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecomte</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borg</LastName><ForeName>Chirstophe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimbaud</LastName><ForeName>Rosine</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taieb</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burra</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rougier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueras</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>22</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>22</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39306468</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)01595-2</ArticleId><ArticleId IdType="pii">S0140-6736(24)01595-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37499670</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>402</Volume><Issue>10408</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.</ArticleTitle><Pagination><StartPage>1133</StartPage><EndPage>1146</EndPage><MedlinePgn>1133-1146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(23)00961-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(23)00961-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.</AbstractText><AbstractText Label="METHODS">This randomised, open-label, international phase 3 trial (CARES-310) was done at 95 study sites across 13 countries and regions worldwide. Patients with unresectable or metastatic hepatocellular carcinoma who had not previously received any systemic treatment were randomly assigned (1:1) to receive either camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily or sorafenib 400 mg orally twice daily. Randomisation was done via a centralised interactive response system. The primary endpoints were progression-free survival, as assessed by the blinded independent review committee per Response Evaluation Criteria in Solid Tumours version 1.1, and overall survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of the study drugs. We report the findings from the prespecified primary analysis for progression-free survival and interim analysis for overall survival. This study is registered with ClinicalTrials.gov (NCT03764293).</AbstractText><AbstractText Label="FINDINGS">Between June 28, 2019, and March 24, 2021, 543 patients were randomly assigned to the camrelizumab-rivoceranib (n=272) or sorafenib (n=271) group. At the primary analysis for progression-free survival (May 10, 2021), median follow-up was 7&#xb7;8 months (IQR 4&#xb7;1-10&#xb7;6). Median progression-free survival was significantly improved with camrelizumab-rivoceranib versus sorafenib (5&#xb7;6 months [95% CI 5&#xb7;5-6&#xb7;3] vs 3&#xb7;7 months [2&#xb7;8-3&#xb7;7]; hazard ratio [HR] 0&#xb7;52 [95% CI 0&#xb7;41-0&#xb7;65]; one-sided p&lt;0&#xb7;0001). At the interim analysis for overall survival (Feb 8, 2022), median follow-up was 14&#xb7;5 months (IQR 9&#xb7;1-18&#xb7;7). Median overall survival was significantly extended with camrelizumab-rivoceranib versus sorafenib (22&#xb7;1 months [95% CI 19&#xb7;1-27&#xb7;2] vs 15&#xb7;2 months [13&#xb7;0-18&#xb7;5]; HR 0&#xb7;62 [95% CI 0&#xb7;49-0&#xb7;80]; one-sided p&lt;0&#xb7;0001). The most common grade 3 or 4 treatment-related adverse events were hypertension (102 [38%] of 272 patients in the camrelizumab-rivoceranib group vs 40 [15%] of 269 patients in the sorafenib group), palmar-plantar erythrodysaesthesia syndrome (33 [12%] vs 41 [15%]), increased aspartate aminotransferase (45 [17%] vs 14 [5%]), and increased alanine aminotransferase (35 [13%] vs eight [3%]). Treatment-related serious adverse events were reported in 66 (24%) patients in the camrelizumab-rivoceranib group and 16 (6%) in the sorafenib group. Treatment-related death occurred in two patients: one patient in the camrelizumab-rivoceranib group (ie, multiple organ dysfunction syndrome) and one patient in the sorafenib group (ie, respiratory failure and circulatory collapse).</AbstractText><AbstractText Label="INTERPRETATION">Camrelizumab plus rivoceranib showed a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma, presenting as a new and effective first-line treatment option for this population.</AbstractText><AbstractText Label="FUNDING">Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Shukui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine and Nanjing Medical University, Nanjing, China. Electronic address: qinsk@csco.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Shanzhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhenggang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhendong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Weidong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Anhui Provincial Hospital, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yongdong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yabing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Liver Cancer Centre, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Integrative Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Peking University International Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Jilin Cancer Hospital, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Jianping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University and Institute for Viral Hepatitis, Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hepatology, The Sixth People's Hospital of Shenyang, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Cancer Centre, The First Hospital of Jilin University, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yajin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultanbaev</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Antitumor Drug Therapy, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazgan-Simon</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infecious Disease and Hepatology, Wroclaw Medical University, Centrum Bada&#x144; Klinicznych Piotr Napora, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisetska</LastName><ForeName>Margaryta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Liver and Pancreas Gland Oncosurgery, Regional Centre of Oncology, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melisi</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Investigational Cancer Therapeutics Clinical Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponomarenko</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, State Budgetary Institution of Healthcare Regional Oncology Dispensary, Irkutsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osypchuk</LastName><ForeName>Yurii</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Odesa, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinielnikov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council, Lutsk, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tsai-Sheng</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chunxia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Linna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ann-Lii</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaseb</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Centre, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Arndt</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CARES-310 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03764293</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73096E137E</RegistryNumber><NameOfSubstance UI="C000631724">camrelizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>9ZOQ3TZI87</RegistryNumber><NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance></Chemical><Chemical><RegistryNumber>5S371K6132</RegistryNumber><NameOfSubstance UI="C553458">apatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2023 Sep 30;402(10408):1108-1110. doi: 10.1016/S0140-6736(23)01297-7.</RefSource><PMID Version="1">37499669</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Clin Oncol. 2023 Nov;20(11):733. doi: 10.1038/s41571-023-00812-8.</RefSource><PMID Version="1">37563429</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2024 Feb;166(2):350. doi: 10.1053/j.gastro.2023.09.003.</RefSource><PMID Version="1">37683705</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2024 Oct 12;404(10461):1403-1404. doi: 10.1016/S0140-6736(24)01770-7.</RefSource><PMID Version="1">39396344</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2024 Oct 12;404(10461):1404-1405. doi: 10.1016/S0140-6736(24)01771-9.</RefSource><PMID Version="1">39396345</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2024 Oct 12;404(10461):1405. doi: 10.1016/S0140-6736(24)01772-0.</RefSource><PMID Version="1">39396347</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests SLC reports honoraria from AstraZeneca, Eisai, Merck Sharp &amp; Dohme, Roche, and Bayer; consulting or advisory roles for AstraZeneca, Eisai, Merck Sharp &amp; Dohme, Bristol Myers Squibb, and Roche; and research funding from Eisai and Ipsen. A-LC reports consulting or advisory roles for Merck Sharp &amp; Dohme, Bristol Myers Squibb, Bayer Healthcare, AstraZeneca, Genentech/Roche, IPSEN Innovation, BeiGene, and EXE; speaker's bureau for Ono Pharmaceutical, Bayer Yakuhin, Novartis, Amgen Taiwan, and Chugai Pharmaceutical; expert testimony for Merck Sharp &amp; Dohme, Ono Pharmaceutical, Eisai, and IPSEN Innovation; and participation on an advisory board for Abbisko Therapeutics. AV reports personal fees from AstraZeneca, Amgen, BeiGene, B&#xf6;hringer Mannheim, Bristol Myers Squibb, BTG, Daiichi Sankyo, Eisai, Incyte, Ipsen, Merck Sharp &amp; Dohme, PierreFabre, Roche, Servier, Sirtex, Tahio, Terumo, Jiangsu Hengrui Pharmaceuticals, GSK, and Imaging Equipment (Advanced Accelerator Applications). XLia, CC, and LW were employees of Jiangsu Hengrui Pharmaceuticals at the time of the study. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Qin</LastName><ForeName>Shukui</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ann-Lii</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaseb</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogel</LastName><ForeName>Arndt</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Shanzhi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bai</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhenggang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhendong</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jia</LastName><ForeName>Weidong</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Yongdong</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guo</LastName><ForeName>Yabing</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meng</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Jianping</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ren</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Yajin</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sultanbaev</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pazgan-Simon</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pisetska</LastName><ForeName>Margaryta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melisi</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponomarenko</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Osypchuk</LastName><ForeName>Yurii</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinielnikov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Tsai-Sheng</ForeName><Initials>TS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Chunxia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Linna</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mingxiang</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuan</LastName><ForeName>Xianglin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Da</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ying</LastName><ForeName>Jierer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jingdong</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Kangsheng</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yifu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hao</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Da</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shu</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xing</LastName><ForeName>Baocai</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Baihong</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhai</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Houjie</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cybulska-Stopa</LastName><ForeName>Bozena</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dvorkin</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stroyakovskiy</LastName><ForeName>Daniil</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nechaeva</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yen</LastName><ForeName>Chia-Jui</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Wei-Wen</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Yen-Hao</ForeName><Initials>YH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bondarenko</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fang</LastName><ForeName>Weijia</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Martin</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryu</LastName><ForeName>Min-Hee</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Han-Sang</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Jee-Hyun</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarubenkov</LastName><ForeName>Oleg</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orlova</LastName><ForeName>Rashida</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poddubskaya</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fadeeva</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makarova</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chao</LastName><ForeName>Yee</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hung</LastName><ForeName>Chao-Hung</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neffa</LastName><ForeName>Maryna</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vynnychenko</LastName><ForeName>Oleksandr</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgoyne</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hao</LastName><ForeName>Chunyi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohr</LastName><ForeName>Raphael U</ForeName><Initials>RU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Beveridge</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feliu-Batlle</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cubillo-Gracian</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Ann-Shing</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniele</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonuzzo</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sangiovanni</LastName><ForeName>Angelo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasbarrini</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scartozzi</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahn</LastName><ForeName>Mi Sun</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oh</LastName><ForeName>Sung-Yong</ForeName><Initials>SY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orlov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harputluoglu</LastName><ForeName>Hakan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oksuzoglu</LastName><ForeName>Berna</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chiun</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rau</LastName><ForeName>Kun-Ming</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krechkovskyi</LastName><ForeName>Oleksandr</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yareshko</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Fa-Chyi</ForeName><Initials>FC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yixing</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabayan</LastName><ForeName>Afshin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crow</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Steenkiste</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verset</LastName><ForeName>Gontran</ForeName><Initials>G</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37499670</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(23)00961-3</ArticleId><ArticleId IdType="pii">S0140-6736(23)00961-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">31613449</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK547669</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2025</Year><Month>01</Month></PubDate><BeginningDate><Year>2025</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-29832">Systemic Inflammatory Response Syndrome</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Baddam</LastName><ForeName>Sujatha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Huntsville Hospital, Huntsville</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Bracken</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>East Tennessee State University (ETSU)</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText><b>Systemic Inflammatory Response Syndrome</b> Systemic inflammatory response syndrome (SIRS) is an exaggerated defense response of the body to a noxious stressor, which can include infection, trauma, surgery, acute inflammation, ischemia or reperfusion, or malignancy, aimed at localizing and then eliminating the endogenous or exogenous source of the insult. This response involves the release of acute-phase reactants, which are direct mediators of widespread autonomic, endocrine, hematological, and immunological alterations in the subject. Even though the purpose is defensive, the dysregulated cytokine storm can cause a massive inflammatory cascade leading to reversible or irreversible end-organ dysfunction and even death. <b>&#xa0;</b>Objectively, SIRS is defined by the presence of any 2 of the following criteria: Body temperature &gt;100.4&#xa0;&#xb0;F (38 &#xb0;C)&#xa0;or &lt;96.8 &#xb0;F (36 &#xb0;C). Heart rate &gt;90 bpm. Respiratory rate &gt;20 breaths/minute or PaCO<sub>2</sub> &lt;32 mm Hg (4.3 kPa). Leukocyte count &gt;12,000/&#x3bc;L, &lt;4,000/&#x3bc;L, or &gt;10% immature forms (bands). <b>Sepsis, Septic Shock, and Multiple Organ Dysfunction Syndrome&#xa0;</b> SIRS with a suspected infectious source is termed sepsis. Culture confirmation is not required early in diagnosis. Historically, "severe sepsis" described sepsis with organ dysfunction; however, the Sepsis-3 task force removed this category in 2016, consolidating it under the revised definition of sepsis as "life-threatening organ dysfunction caused by a dysregulated host response to infection. This distinction is no longer used clinically but may appear in older literature. Septic shock represents the most severe form, marked by circulatory, cellular, and metabolic abnormalities that persist despite adequate fluid resuscitation. Together, sepsis and septic shock are considered a continuum of worsening host response to infection. The American College of Chest Physicians/Society of Critical Care Medicine-sponsored sepsis definitions consensus conference also identified the entity of multiple organ dysfunction syndrome (MODS) as the presence of altered organ function in acutely ill septic patients such that homeostasis is not maintainable without intervention. In the pediatric population, the definition is modified to a mandatory requirement of abnormal leukocyte count or temperature to establish the diagnosis, as abnormal heart rate and respiratory rates are more common in children.&#xa0;Recent survey data show that most pediatric clinicians define sepsis as infection with life-threatening organ dysfunction, moving away from older pediatric criteria that relied on SIRS and the redundant term "severe sepsis." The SCCM task force now recommends using the Phoenix Sepsis Score, where a score &#x2265;2 in a child with suspected infection indicates sepsis due to dysfunction in respiratory, cardiovascular, coagulation, or neurologic systems. Septic shock is defined by cardiovascular dysfunction, marked by hypotension for age, lactate &gt;5 mmol/L, or need for vasoactive support. In summary, almost all septic patients exhibit SIRS, but not all patients with SIRS are septic. Kaukonen et al explained exceptions to this theory by suggesting that there are subgroups of hospitalized patients, particularly at extremes of age, who do not meet the criteria for SIRS on presentation but progress to severe infection, multiple organ dysfunction, and death. Establishing laboratory indices to identify such subgroups of patients and the clinical criteria that we currently rely upon has been gaining prominence over recent years. Several scores exist to assess the severity of damage to individual organ systems. The Acute Physiology and Chronic Health Evaluation (APACHE) score version II and III, multiple organ dysfunction (MOD) score, sequential organ failure assessment (SOFA), and logistic organ dysfunction (LOD) score are to name a few. <b>Historical Evolution of&#xa0;Systemic Inflammatory Response Syndrome</b> The emergence of new insights into the pathophysiology and treatment of sepsis in the early 1990s highlighted the growing need to identify a uniform group of potential subjects for clinical trials exploring novel therapeutic strategies. In response to the surge of ongoing research, a consensus has emerged emphasizing the importance of a time-sensitive approach to diagnosis and intervention, aiming to improve patient survival and reduce morbidity. The ability to recognize individuals affected by various conditions across different care settings using standardized, easy-to-apply clinical parameters became essential. To address this, the American College of Chest Physicians and the Society of Critical Care Medicine convened a consensus conference on sepsis definitions in Chicago, Illinois, in August 1991, with the intention of establishing a standard set of clinical criteria for broad application. This effort led to the introduction of the SIRS definition. A second consensus meeting, held in Washington, DC, in 2001, expanded on this foundation by introducing a conceptual framework for staging sepsis using the PIRO model&#x2014;predisposition, insult or infection, response, and organ dysfunction. This model aimed to enhance the understanding and clinical categorization of sepsis, offering a more structured approach to guide research and therapeutic decisions. The goal of the initial definition was to be highly sensitive using easily available parameters across all healthcare settings. An unavoidable corollary of such a definition was, therefore, the lack of specificity. Additional limitations of the SIRS definition include&#xa0;the following: 1. The universal prevalence of the parameters in an ICU setting. 2. Lack of ability to distinguish between beneficial host response from pathologic host response that contributes to organ dysfunction. 3. Distinguishing between infectious and noninfectious etiology purely based on the definition. 4. Lack of weight to each criterion, eg, fever and elevated respiratory rate, has precisely the same significance as leukocytosis or tachycardia by the SIRS definition. 5. Inability to predict organ dysfunction&#xa0;. Kaukonen et al, in their study of over 130,000 septic patients, established that 1 out of 8 patients in their observational study of sepsis did not meet &#x2265;2 SIRS criteria. They also established that each criterion in the SIRS definition does not translate to an equivalent risk of organ dysfunction or death. <b>Sequential organ failure assessment</b> In 2016, following this debate, the European Society of Intensive Care Medicine and the Society of Critical Care Medicine (SCCM) established a task force that proposed Sepsis-3, a revised definition for sepsis. The new definition excluded the establishment of SIRS criteria to define sepsis and made it more nonspecific, as any life-threatening organ dysfunction caused by the dysregulated host response to infection. The task force claimed that the sequential organ failure assessment (SOFA) has better predictive validity for sepsis than the SIRS criteria. It has better prognostic accuracy and the ability to predict in-hospital mortality. To reduce the complexity of calculating the SOFA, a simplified version of the SOFA, known as qSOFA, was introduced. The qSOFA score is a modified version of the SOFA. A score &#x2265;2 is associated with the following poor outcomes due to sepsis: A systolic blood pressure of &#x2264;100 mm Hg indicates a potential problem with the cardiovascular system&#xa0;. A respiratory rate of &#x2265;22&#xa0;breaths/min suggests possible respiratory distress. A Glasgow Coma Scale score of &lt;15 indicates a change in the patient's level of consciousness. Although the validity of qSOFA is limited in an ICU setting, it has consistently outperformed SIRS criteria in predicting organ dysfunction in a non-ICU and ER setting. The use of vasopressors, mechanical ventilation, and aggressive therapeutic interventions in the ICU limits the efficacy of qSOFA.&#xa0;Interestingly, Hague et al, in their study of the utility of SIRS criteria in gastrointestinal surgery, also found it a useful criterion for identifying postoperative complications. A 2023 systematic review comparing qSOFA and SIRS in emergency and critical care settings found that while qSOFA excels in predicting mortality with greater specificity and AUROC values, SIRS criteria are met significantly faster, which may offer practical advantages for early triage. These findings underscore the trade-off between early detection and prognostic accuracy, guiding clinicians in tailoring their approach according to the specific setting and resource availability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s10">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s11">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s12">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s13">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s14">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s15">References</SectionTitle></Section></Sections><ContributionDate><Year>2025</Year><Month>6</Month><Day>20</Day></ContributionDate><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlapbach LJ, Watson RS, Sorce LR, Argent AC, Menon K, Hall MW, Akech S, Albers DJ, Alpern ER, Balamuth F, Bembea M, Biban P, Carrol ED, Chiotos K, Chisti MJ, DeWitt PE, Evans I, Flauzino de Oliveira C, Horvat CM, Inwald D, Ishimine P, Jaramillo-Bustamante JC, Levin M, Lodha R, Martin B, Nadel S, Nakagawa S, Peters MJ, Randolph AG, Ranjit S, Rebull MN, Russell S, Scott HF, de Souza DC, Tissieres P, Weiss SL, Wiens MO, Wynn JL, Kissoon N, Zimmerman JJ, Sanchez-Pinto LN, Bennett TD, Society of Critical Care Medicine Pediatric Sepsis Definition Task Force International Consensus Criteria for Pediatric Sepsis and Septic Shock. JAMA. 2024 Feb 27;331(8):665-674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10900966</ArticleId><ArticleId IdType="pubmed">38245889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015 Apr 23;372(17):1629-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">25776936</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013 Mar 02;381(9868):774-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4535310</ArticleId><ArticleId IdType="pubmed">23472921</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, Rochwerg B, Seely AJE. Clinical implications of the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). CMAJ. 2018 Sep 10;190(36):E1058-E1059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6131078</ArticleId><ArticleId IdType="pubmed">30201611</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelsztein EJ, Jones DS, Ma KC, Pab&#xf3;n MA, Delgado T, Nakahira K, Arbo JE, Berlin DA, Schenck EJ, Choi AM, Siempos II. Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Crit Care. 2017 Mar 26;21(1):73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5366240</ArticleId><ArticleId IdType="pubmed">28342442</ArticleId></ArticleIdList></Reference><Reference><Citation>Koirala U, Thapa PB, Joshi MR, Singh DR, Sharma SK. Systemic Inflammatory Response Syndrome following Gastrointestinal Surgery. JNMA J Nepal Med Assoc. 2017 Apr-Jun;56(206):221-225.</Citation><ArticleIdList><ArticleId IdType="pubmed">28746319</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen M, Steindal SA, Hamilton Larsen M, Trygg Solberg M. Comparison of the systematic Inflammatory response syndrome and the quick sequential organ failure assessment for prognostic accuracy in detecting sepsis in the emergency department: A systematic review. Int Emerg Nurs. 2023 Jan;66:101242.</Citation><ArticleIdList><ArticleId IdType="pubmed">36571931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover L, Bochicchio GV, Napolitano LM, Joshi M, Bochicchio K, Meyer W, Scalea TM. Systemic inflammatory response syndrome and nosocomial infection in trauma. J Trauma. 2006 Aug;61(2):310-6; discussion 316-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917443</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996 Apr;109(4):1033-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, Lawler PR, van Diepen S, Henry TD, Menon V, Baran DA, D&#x17e;av&#xed;k V, Barsness GW, Holmes DR, Kashani KB. Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. Circ Cardiovasc Qual Outcomes. 2020 Dec;13(12):e006956.</Citation><ArticleIdList><ArticleId IdType="pubmed">33280435</ArticleId></ArticleIdList></Reference><Reference><Citation>Horeczko T, Green JP, Panacek EA. Epidemiology of the Systemic Inflammatory Response Syndrome (SIRS) in the emergency department. West J Emerg Med. 2014 May;15(3):329-36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4025532</ArticleId><ArticleId IdType="pubmed">24868313</ArticleId></ArticleIdList></Reference><Reference><Citation>Churpek MM, Zadravecz FJ, Winslow C, Howell MD, Edelson DP. Incidence and Prognostic Value of the Systemic Inflammatory Response Syndrome and Organ Dysfunctions in Ward Patients. Am J Respir Crit Care Med. 2015 Oct 15;192(8):958-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642209</ArticleId><ArticleId IdType="pubmed">26158402</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med. 1995 Apr;21(4):302-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7650252</ArticleId></ArticleIdList></Reference><Reference><Citation>Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest. 2006 Apr;129(4):968-78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608946</ArticleId></ArticleIdList></Reference><Reference><Citation>Comstedt P, Storgaard M, Lassen AT. The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med. 2009 Dec 27;17:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806258</ArticleId><ArticleId IdType="pubmed">20035633</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmor M, Hydo L, Barie PS. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: effect of intensive care unit resuscitation. Arch Surg. 1999 Jan;134(1):81-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9927137</ArticleId></ArticleIdList></Reference><Reference><Citation>NeSmith EG, Weinrich SP, Andrews JO, Medeiros RS, Hawkins ML, Weinrich MC. Demographic differences in systemic inflammatory response syndrome score after trauma. Am J Crit Care. 2012 Jan;21(1):35-41; quiz 42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22210698</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry MA, Bland KI, Chaudry IH. Trauma and immune response--effect of gender differences. Injury. 2007 Dec;38(12):1382-91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692838</ArticleId><ArticleId IdType="pubmed">18048037</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997 Jul;112(1):235-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin Chim Acta. 2012 Nov 12;413(21-22):1737-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22789964</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005 Nov;23(5):479-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey KJ. The inflammatory reflex. Nature. 2002 Dec 19-26;420(6917):853-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayampanathan AA. Systematic review of complications and outcomes of diabetic patients with burn trauma. Burns. 2016 Dec;42(8):1644-1651.</Citation><ArticleIdList><ArticleId IdType="pubmed">27595452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochicchio GV, Napolitano LM, Joshi M, McCarter RJ, Scalea TM. Systemic inflammatory response syndrome score at admission independently predicts infection in blunt trauma patients. J Trauma. 2001 May;50(5):817-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11379594</ArticleId></ArticleIdList></Reference><Reference><Citation>Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin--a new indicator of the systemic response to severe infections. Infection. 1997 Nov-Dec;25(6):329-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102374</ArticleId><ArticleId IdType="pubmed">9427049</ArticleId></ArticleIdList></Reference><Reference><Citation>Martiny P, Goggs R. Biomarker Guided Diagnosis of Septic Peritonitis in Dogs. Front Vet Sci. 2019;6:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610427</ArticleId><ArticleId IdType="pubmed">31316998</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrejaitiene J, Sirvinskas E, Zebrauskiene I. [Procalcitonin: a new infection marker. Its use in intensive care]. Medicina (Kaunas) 2002;38(5):491-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12474679</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Sepsis Biomarkers. J Pediatr Intensive Care. 2019 Mar;8(1):11-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506678</ArticleId><ArticleId IdType="pubmed">31073503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Wang Y, Yang Q, Dong Y. Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis. BMC Infect Dis. 2017 Jul 24;17(1):514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5525369</ArticleId><ArticleId IdType="pubmed">28738787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Tripathy S, Jyoti A, Singh SG. Recent advances in biosensors for diagnosis and detection of sepsis: A comprehensive review. Biosens Bioelectron. 2019 Jan 15;124-125:205-215.</Citation><ArticleIdList><ArticleId IdType="pubmed">30388563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciriello V, Gudipati S, Stavrou PZ, Kanakaris NK, Bellamy MC, Giannoudis PV. Biomarkers predicting sepsis in polytrauma patients: Current evidence. Injury. 2013 Dec;44(12):1680-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119650</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis. 2011 Aug;53(4):379-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810753</ArticleId></ArticleIdList></Reference><Reference><Citation>Selberg O, Hecker H, Martin M, Klos A, Bautsch W, K&#xf6;hl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med. 2000 Aug;28(8):2793-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10966252</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddam S, Tubben RE. StatPearls [Internet] StatPearls Publishing; Treasure Island (FL): 2025. Apr 28, Lactic Acidosis.</Citation></Reference><Reference><Citation>Hu L, Shi Q, Shi M, Liu R, Wang C. Diagnostic Value of PCT and CRP for Detecting Serious Bacterial Infections in Patients With Fever of Unknown Origin: A Systematic Review and Meta-analysis. Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):e61-e69.</Citation><ArticleIdList><ArticleId IdType="pubmed">28885233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf TA, Wimalawansa SJ, Razzaque MS. Procalcitonin as a biomarker for critically ill patients with sepsis: Effects of vitamin D supplementation. J Steroid Biochem Mol Biol. 2019 Oct;193:105428.</Citation><ArticleIdList><ArticleId IdType="pubmed">31323346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracho-Riquelme RL, Reyes-Romero MA. Leptin in sepsis: a well-suited biomarker in critically ill patients? Crit Care. 2010;14(2):138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887146</ArticleId><ArticleId IdType="pubmed">20392294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef AA, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study. Crit Care. 2010;14(2):R33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887140</ArticleId><ArticleId IdType="pubmed">20230641</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou AG, Mastora Z, Orfanos SE, Jahaj E, Maniatis NA, Koutsoukou A, Armaganidis A, Kotanidou A. Elevated biomarkers of endothelial dysfunction/activation at ICU admission are associated with sepsis development. Cytokine. 2014 Oct;69(2):240-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25016133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussap M, Cibecchini F, Noto A, Fanos V. In search of biomarkers for diagnosing and managing neonatal sepsis: the role of angiopoietins. J Matern Fetal Neonatal Med. 2013 Oct;26 Suppl 2:24-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24059548</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H. Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013 Jan;61(1):112-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou YQ, Xu P, Zhang M, Han D, Peng L, Liang DY, Yang S, Zhang Z, Hong J, Lou XL, Zhang L, Kim S. Serum decoy receptor 3, a potential new biomarker for sepsis. Clin Chim Acta. 2012 Apr 11;413(7-8):744-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22280900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Mi L, Zhang L. Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. Diagn Microbiol Infect Dis. 2012 Aug;73(4):312-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396789</ArticleId><ArticleId IdType="pubmed">22647538</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA, Xia J, Fjell CD, Boyd JH, Hancock RE. An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation. EBioMedicine. 2014 Nov 01;1(1):64-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326653</ArticleId><ArticleId IdType="pubmed">25685830</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, M&#xf8;ller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625125</ArticleId></ArticleIdList></Reference><Reference><Citation>De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts. Intensive Care Med. 2020 Feb;46(2):236-244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224113</ArticleId><ArticleId IdType="pubmed">32025778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725385</ArticleId><ArticleId IdType="pubmed">26679628</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, Fran&#xe7;ois B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Boh&#xe9; J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E, CRICS-TRIGGERSEP Network Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018 Mar 01;378(9):809-818.</Citation><ArticleIdList><ArticleId IdType="pubmed">29490185</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurmyshkina OV, Bogdanova AA, Volkova TO, Poltoraka AN. [Septic Shock: Innate Molecular Genetic Mechanisms of the Development of Generalized Inflammation]. Ontogenez. 2015 Jul-Aug;46(4):225-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">26480482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995 Jan 11;273(2):117-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799491</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro N, Howell MD, Bates DW, Angus DC, Ngo L, Talmor D. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med. 2006 Nov;48(5):583-90, 590.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">17052559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochicchio GV, Napolitano LM, Joshi M, Knorr K, Tracy JK, Ilahi O, Scalea TM. Persistent systemic inflammatory response syndrome is predictive of nosocomial infection in trauma. J Trauma. 2002 Aug;53(2):245-50; discussion 250-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169929</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26 Suppl 1(Suppl 1):S64-74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094973</ArticleId><ArticleId IdType="pubmed">10786961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao A, Chou WH, Chang CJ, Lin YJ, Fan SZ, Chao AS. The admission systemic inflammatory response syndrome predicts outcome in patients undergoing emergency surgery. Asian J Surg. 2013 Jul;36(3):99-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23810158</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen DP, Laursen CB, Hallas J, Pedersen C, Lassen AT. Time to initial antibiotic administration, and short-term mortality among patients admitted with community-acquired severe infections with and without the presence of systemic inflammatory response syndrome: a follow-up study. Emerg Med J. 2015 Nov;32(11):846-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25762652</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31613449</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39798579</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>405</Volume><Issue>10474</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>232</EndPage><MedlinePgn>216-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(24)02551-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(24)02551-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.</AbstractText><AbstractText Label="METHODS">In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries. Eligible patients were randomly assigned (1:1:1), stratified by TACE method, region, and portal vein invasion, using an interactive voice response or web response system, to TACE plus either durvalumab plus bevacizumab (1500 mg intravenous durvalumab once every 4 weeks, then 1120 mg durvalumab plus 15 mg/kg intravenous bevacizumab once every 3 weeks), durvalumab plus placebo (same regimen using placebo instead of bevacizumab), or placebo alone (same regimen using placebo instead of durvalumab and instead of bevacizumab). Participants, investigators, and those assessing outcomes were masked to treatment assignment until data analysis. The primary endpoint was progression-free survival, by blinded independent central review (BICR), and per RECIST version 1.1, with durvalumab plus bevacizumab versus placebo alone in the intention-to-treat population (ITT; ie, all participants assigned to treatment). Key secondary endpoints were progression-free survival by BICR per RECIST version 1.1 with durvalumab plus placebo versus placebo alone, overall survival, and time to deterioration in select patient-reported outcomes. Participants continue to be followed up for overall survival, and overall survival and patient-reported outcomes will be reported in a later publication. Safety was assessed in the safety analysis set, which included all participants assigned to treatment who received any study treatment (ie, any durvalumab, bevacizumab, or placebo) by treatment received. This study is registered with ClinicalTrials.gov, NCT03778957, and is closed to accrual.</AbstractText><AbstractText Label="FINDINGS">Between Nov 30, 2018, and July 19, 2021, 887 patients were screened, of whom 616 were randomly assigned to durvalumab plus bevacizumab (n=204), durvalumab plus placebo (n=207), or placebo alone (n=205; ITT population). Median age was 65&#xb7;0 years (IQR 59&#xb7;0-72&#xb7;0), 135 (22%) of 616 participants were female, 481 (78%) were male, 375 (61%) were Asian, 176 (29%) were White, 22 (4%) were American Indian or Alaska Native, nine (1%) were Black or African American, one (&lt;1%) was native Hawaiian or other Pacific Islander, and 33 (5%) were other races. As of data cutoff (Sept 11, 2023) median follow-up for progression-free survival was 27&#xb7;9 months (95% CI 27&#xb7;4-30&#xb7;4), median progression-free survival was 15&#xb7;0 months (95% CI 11&#xb7;1-18&#xb7;9) with durvalumab plus bevacizumab, 10&#xb7;0 months (9&#xb7;0-12&#xb7;7) with durvalumab, and 8&#xb7;2 months (6&#xb7;9-11&#xb7;1) with placebo. Progression-free survival hazard ratio was 0&#xb7;77 (95% CI 0&#xb7;61-0&#xb7;98; two-sided p=0&#xb7;032) for durvalumab plus bevacizumab versus placebo, and 0&#xb7;94 (0&#xb7;75-1&#xb7;19; two-sided p=0&#xb7;64) for durvalumab plus placebo versus placebo. The most common maximum grade 3-4 adverse events were hypertension in participants who received durvalumab and bevacizumab (nine [6%] of 154 participants), anaemia in participants who received durvalumab and placebo (ten [4%] of 232 participants), and post-embolisation syndrome in participants who received placebo alone (eight [4%] of 200 participants). Study treatment-related adverse events that led to death occurred in none of 154 participants who received durvalumab and bevacizumab, three (1%) of 232 who received durvalumab and placebo (n=1 for arterial haemorrhage, liver injury, and multiple organ dysfunction syndrome), and three (2%) of 200 who received placebo alone (n=1 for oesophageal varices haemorrhage, upper gastrointestinal haemorrhage, and dermatomyositis).</AbstractText><AbstractText Label="INTERPRETATION">Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including the final overall survival data and patient-reported outcomes, will help to further characterise the potential clinical benefits of durvalumab plus bevacizumab plus TACE in hepatocellular carcinoma amenable to embolisation.</AbstractText><AbstractText Label="FUNDING">AstraZeneca.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sangro</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Liver Unit and HPB Oncology Area, Cl&#xed;nica Universidad de Navarra and CIBEREHD, Pamplona, Spain. Electronic address: bsangro@unav.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erinjeri</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Shukui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Center of Nanjing, Jinling Hospital, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhenggang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Prince of Wales Hospital, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Yasuaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, National Cancer Center, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Anh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>General Surgery Department, Nhan Dan Gia Dinh Hospital, Ho Chi Minh City, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escobar</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital San Lucas Cardiol&#xf3;gica del Sureste, Chiapas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Chuken</LastName><ForeName>Yamil Alonso</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>I Can Oncology Centre, New Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jung-Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tak</LastName><ForeName>Won Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breder</LastName><ForeName>Valeriy V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, N N Blokhin National Medical Research Center of Oncology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suttichaimongkol</LastName><ForeName>Tanita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouattour</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liver Cancer and Innovative Therapy, AP-HP H&#xf4;pital Beaujon, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shi-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peron</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hepatology Unit, Rangueil University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Quang T</ForeName><Initials>QT</Initials><AffiliationInfo><Affiliation>Friendship Hospital, Hanoi, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Lunan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chang-Fang</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Cancer Center and Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Florinda A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veluvolu</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Willis-Knighton Hematology/Oncology, A Department of Willis-Knighton Medical Center, Shreveport, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thungappa</LastName><ForeName>Satheesh Chiradoni</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, HCG Oncology, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology, Pindara Private Hospital, Benowa, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x17b;otkiewicz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology Biometrics, Late Oncology Statistics, AstraZeneca, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udoye</LastName><ForeName>Stephanie I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurland</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Gordon J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lencioni</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EMERALD-1 Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03778957</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber><NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>28X28X9OKV</RegistryNumber><NameOfSubstance UI="C000613593">durvalumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2025 Jan 18;405(10474):174-176. doi: 10.1016/S0140-6736(24)02680-1.</RefSource><PMID Version="1">39798580</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="Y">Bevacizumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016461" MajorTopicYN="Y">Chemoembolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests BS reports consultancy fees from AstraZeneca, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Merck Sharp &amp; Dohme, Roche, and Sanofi; payment or honoraria from AstraZeneca, Eisai, Roche, and Sirtex Medical; and support for travel or attending meetings from AstraZeneca and Roche. MK reports grants or contracts from AbbVie, Chugai Pharmaceutical, Eisai, GE HealthCare Japan, Otsuka Pharmaceutical, and Taiho Pharmaceutical; consultancy fees from AstraZeneca, Chugai Pharmaceutical, Eisai, and Roche; and payment or honoraria from AstraZeneca, Chugai Pharmaceutical, Eisai, Eli Lilly, and Takeda. JPE reports consultancy fees from AstraZeneca and fees for participation on a data safety monitoring board or advisory board from AstraZeneca. ZR reports consultancy fees from AstraZeneca, Merck Sharp &amp; Dohme, and Roche; and fees for participation on a data safety monitoring board or advisory board from AstraZeneca, Merck Sharp &amp; Dohme, and Roche. SLC reports grants or contracts from Celleron, Genorbio, Ipsen, Merck Sharp &amp; Dohme, Novartis, and Sirtex Medical; consultancy fees from AstraZeneca, Autem Therapeutics, Eisai, and Merck Sharp &amp; Dohme; payment or honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Hutchison MediPharma, Ipsen, Merck Sharp &amp; Dohme, and Roche; and support for travel or attending meetings from AstraZeneca, Eisai, Ipsen, and Roche. YA reports payment or honoraria from AstraZeneca and fees for participation on a data safety monitoring board or advisory board from AstraZeneca. JH reports grants or contracts from Roche; consultancy fees from AbbVie Korea, GlaxoSmithKline, and Immunocore; payment or honoraria from AstraZeneca, Gilead Sciences, Oncolys BioPharma, Roche, and Yuhan Korea; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from AstraZeneca. JE reports grants or contracts from AstraZeneca, Bristol Myers Squibb, and Merck Sharp &amp; Dohme; payment or honoraria from Asofarma Pharma; support for travel or attending meetings from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Janssen, Merck Sharp &amp; Dohme and Roche; and being a board member for Sociedad Mexicana de Oncolog&#xed;a. J-HY reports grants or contracts from Dicerna Pharmaceuticals, GlaxoSmithKline, Mediver, Merck Sharp &amp; Dohme, NewG-Lab Pharma, Pharmicell, Roche, and Vir Biotechnology. VVB reports consultancy fees, payment or honoraria, and fees for participation on a data safety monitoring board or advisory board from AstraZeneca, Bayer, Eisai, and Roche. TS reports payment or honoraria from American Taiwan Biopharm, AstraZeneca (Thailand), Berlin Pharmaceutical Industry, DKSH (Thailand), Janssen, Reckitt Benckiser (Thailand), Roche Thailand, Roche Diagnostics (Thailand), Sandoz (Thailand), Takeda (Thailand), and Thai Otsuka Pharmaceutical; and support for travel or attending meetings from American Taiwan Biopharm, AstraZeneca (Thailand), Berlin Pharmaceutical Industry, DKSH (Thailand), Ferring Pharmaceuticals, Reckitt Benckiser (Thailand), Roche Thailand, Roche Diagnostics (Thailand), Takeda (Thailand), and Thai Meiji. MB reports consultancy fees from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Merck Sharp &amp; Dohme, Roche, Sirtex Medical, and Taiho Pharmaceutical; and payment or honoraria from Bayer and Sirtex Medical. S-ML reports honoraria from Roche; support for travel or attending meetings from AstraZeneca and Roche; fees for participation on an advisory board from AstraZeneca; and an unpaid position as President and Honoured President of the Taiwan Liver Cancer Association. J-MP reports grants or contracts, consultancy fees, payment or honoraria, and support for travel or attending meetings from AbbVie, Bayer, Gilead Sciences, Ipsen, and Roche. C-FC reports grants or contracts from AbbVie, Aceta Pharma, AstraZeneca, Bayer, Bristol Meyers Squibb, Genentech, Translational Research In Oncology, and Roche; payment or honoraria from Roche; fees for participation on a data safety monitoring board or advisory board from Roche; and a role as an expert on the Committee of National Health Insurance Administration (Taiwan). MM reports support for travel or attending meetings from AstraZeneca. M&#x17b; is an employee of AstraZeneca. SIU and GJC are employees of AstraZeneca and hold stock in AstraZeneca. JFK is an employee of AstraZeneca; holds stock in AstraZeneca; reports support for travel or attending meetings from ASCO Breakthrough; and is listed as co-inventor with MedImmune as the applicant on patents PCT/US2018/018513 (WO2018/152415), filed Feb 16, 2018, and with AstraZeneca as the applicant on patents PCT/EP2021/062695 (WO2021/228978), filed May 12, 2021, and PCT/EP2022/079828 (2023/174569), filed Oct 25, 2022. RL reports consultancy fees from AstraZeneca. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Abdalla</LastName><ForeName>Kathia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allaire</LastName><ForeName>Manon</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antunes</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assenat</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barreto</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beg</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertollo</LastName><ForeName>Glaucio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanc</LastName><ForeName>Jean-Frederic</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouattour</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boya</LastName><ForeName>Rakesh Reddy</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breder</LastName><ForeName>Valery</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bronowicki</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buranachokphaisan</LastName><ForeName>Manoch</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgoyne</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Ting-Tsung</ForeName><Initials>TT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chao</LastName><ForeName>Yee</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chang-Fang</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Minsig</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Sunghee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coburn</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Contreras</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dayyani</LastName><ForeName>Farshid</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decaens</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dechaphunkul</LastName><ForeName>Arunee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Consuelo Diaz</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dev</LastName><ForeName>Anouk</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dutra</LastName><ForeName>Jamille</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eastgate</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escobar</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estfan</LastName><ForeName>Bassam</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frin</LastName><ForeName>Anne-Claire</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganguly</LastName><ForeName>Sandip</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganta</LastName><ForeName>Ranga Raman</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Shanzhi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guo</LastName><ForeName>Yabing</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagihara</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeong</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chih-Hung</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inaba</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>Shikha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonker</LastName><ForeName>Derek</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>K</LastName><ForeName>Rajeev L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kate</LastName><ForeName>Shruti</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kato</LastName><ForeName>Naoya</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawaoka</LastName><ForeName>Tomokazu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kee</LastName><ForeName>Kwong-Ming</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Seung Up</ForeName><Initials>SU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kioka</LastName><ForeName>Kiyohide</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koga</LastName><ForeName>Hironori</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kudo</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Hidekatsu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le</LastName><ForeName>Phuong</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Han-Chu</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Joon Hyeok</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Teng-Yu</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Dongliang</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Hailiang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Cheng-Yao</ForeName><Initials>CY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Shi-Ming</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Yamil</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Ligong</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mai</LastName><ForeName>Anh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mamontov</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maneenil</LastName><ForeName>Kunlatida</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manikhas</LastName><ForeName>Aleksei</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masi</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matilla</LastName><ForeName>Ana Maria</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matos</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzaferro</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meng</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohapatra</LastName><ForeName>Prabrajya Narayan</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moiseyenko</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molina</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montero</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Manabu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Motola</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mukhametshina</LastName><ForeName>Guzel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Hayato</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nault</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Quang</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicoll</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noriega</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okusaka</LastName><ForeName>Takuji</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onishi</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostwal</LastName><ForeName>Vikas Sureshchand</ForeName><Initials>VS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pan</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Joong-Won</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Ankit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peron</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qin</LastName><ForeName>Shukui</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhenggang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Runglodvatana</LastName><ForeName>Yotsawaj</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sangro</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>Florinda</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saxena</LastName><ForeName>Ravi Kumar</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shao</LastName><ForeName>Guoliang</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shields</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shirokova</LastName><ForeName>Oksana</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shreenivas</LastName><ForeName>Aditya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sisani</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skoropad</LastName><ForeName>Vitalii</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strasser</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suksombooncharoen</LastName><ForeName>Thatthan</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suttichaimongkol</LastName><ForeName>Tanita</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tai</LastName><ForeName>Wai Meng</ForeName><Initials>WM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tak</LastName><ForeName>Won Young</ForeName><Initials>WY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teng</LastName><ForeName>Gaojun</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thungappa</LastName><ForeName>Satheesh Chiradoni</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>Nguyen</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trinh</LastName><ForeName>Son</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuchiya</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Kunihiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ugarteburu</LastName><ForeName>Idoia</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ungtrakul</LastName><ForeName>Teerapat</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaccaro</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veluvolu</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vo</LastName><ForeName>Truc</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wada</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weir</LastName><ForeName>Alva</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Aibing</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yan</LastName><ForeName>Lvnan</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jung-Hwan</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarubenkov</LastName><ForeName>Oleg</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yongyi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yonghong</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xu</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>20</Day><Hour>22</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>12</Day><Hour>15</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>11</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39798579</ArticleId><ArticleId IdType="mid">NIHMS2089825</ArticleId><ArticleId IdType="pmc">PMC12282661</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)02551-0</ArticleId><ArticleId IdType="pii">S0140-6736(24)02551-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (suppl 4): iv238&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">30285213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: an Asian perspective comparison. Clin Mol Hepatol 2023; 29: 252&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10121305</ArticleId><ArticleId IdType="pubmed">36907570</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12540794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong B-Y, Jin Z-C, Chen J-J, Zhu H-D, Zhu X-L. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol 2023; 11: 480&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9817054</ArticleId><ArticleId IdType="pubmed">36643046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">23397536</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691343</ArticleId><ArticleId IdType="pubmed">25752327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 2014; 60: 1697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">24996197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21664811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016; 64: 1090&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26809111</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 2021; 73 (suppl 1): 158&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">32430997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69: 1492&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398460</ArticleId><ArticleId IdType="pubmed">31801872</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">28648803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilagan CH, Goldman DA, G&#xf6;nen M, et al. Recurrence of hepatocellular carcinoma after complete radiologic response to trans-arterial embolization: a retrospective study on patterns, treatments, and prognoses. Ann Surg Oncol 2022; 29: 6815&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9509465</ArticleId><ArticleId IdType="pubmed">35838903</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Lee D, Shim JH, et al. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. PLoS One 2020; 15: e0229696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055892</ArticleId><ArticleId IdType="pubmed">32130270</ArticleId></ArticleIdList></Reference><Reference><Citation>Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019; 19: 795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693268</ArticleId><ArticleId IdType="pubmed">31409405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Cheng A-L, Park J-W, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018; 3: 37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28988687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568538</ArticleId></ArticleIdList></Reference><Reference><Citation>Britten CD, Gomes AS, Wainberg ZA, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer 2012; 12: 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292503</ArticleId><ArticleId IdType="pubmed">22244160</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinter M, Ulbrich G, Sieghart W, et al. Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology 2015; 277: 903&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26131911</ArticleId></ArticleIdList></Reference><Reference><Citation>Montasser A, Beaufr&#xe8;re A, Cauchy F, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021; 79: 36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">33326644</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1: EVIDoa2100070.</Citation><ArticleIdList><ArticleId IdType="pubmed">38319892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020; 21: 808&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">32502443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23: 77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">34914889</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">32402160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021; 22: 977&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">34143971</ArticleId></ArticleIdList></Reference><Reference><Citation>Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. J Clin Oncol 2024; 42 (suppl 17): LBA4008 (abstr).</Citation></Reference><Reference><Citation>Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 2025; published online Jan 8. 10.1016/S0140-6736(24)02575-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)02575-3</ArticleId><ArticleId IdType="pubmed">39798578</ArticleId></ArticleIdList></Reference><Reference><Citation>Peck-Radosavljevic M, Kudo M, Raoul J-L, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis. J Clin Oncol 2018; 36 (suppl 15): 4018 (abstr).</Citation></Reference><Reference><Citation>Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: a review. JAMA 2023; 329: 1589&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10843851</ArticleId><ArticleId IdType="pubmed">37159031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HY, Heo J, Kim T-Y, et al. 
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: results from the phase 2 study 22 (NCT02519348). J Clin Oncol
2022; 40: 436 (abstr).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32615109</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.</ArticleTitle><Pagination><StartPage>947</StartPage><EndPage>956</EndPage><MedlinePgn>947-956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30224-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30224-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging.</AbstractText><AbstractText Label="METHODS">We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian tertiary care and transplantation centres. Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision. After an observation period of 3 months, during which sorafenib was allowed, patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors were randomly assigned (1:1) by an interactive web-response system to liver transplantation or non-transplantation therapies (control group). A block randomisation (block size of 2), stratified by centre and compliance to sorafenib treatment, was applied. Liver transplantation was done with whole or split organs procured from brain-dead donors. The control group received sequences of locoregional and systemic treatment at the time of demonstrated tumour progression. The primary outcomes were 5-year tumour event-free survival for phase 2b and overall survival for phase 3. Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503.</AbstractText><AbstractText Label="FINDINGS">Between March 1, 2011, and March 31, 2015, 74 patients were enrolled. Median duration of downstaging was 6 months (IQR 4-11). 29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group. At data cutoff on July 31, 2019, median follow-up was 71 months (IQR 60-85). 5-year tumour event-free survival was 76&#xb7;8% (95% CI 60&#xb7;8-96&#xb7;9) in the transplantation group versus 18&#xb7;3% (7&#xb7;1-47&#xb7;0) in the control group (hazard ratio [HR] 0&#xb7;20, 95% CI 0&#xb7;07-0&#xb7;57; p=0&#xb7;003). 5-year overall survival was 77&#xb7;5% (95% CI 61&#xb7;9-97&#xb7;1) in the transplantation group versus 31&#xb7;2% (16&#xb7;6-58&#xb7;5) in the control group (HR 0&#xb7;32, 95% CI 0&#xb7;11-0&#xb7;92; p=0&#xb7;035). The most common registered grade 3-4 serious adverse events were hepatitis C virus recurrence (three [13%] of 23 patients) and acute transplant rejection (two [9%]) in the transplantation group, and post-embolisation syndrome (two [9%] of 22 patients) in the control group. Treatment-related deaths occurred in four patients: two (8%) of 23 patients in the transplantation group (myocardial infarction and multi-organ failure) versus two (9%) of 22 patients in the control group (liver decompensation).</AbstractText><AbstractText Label="INTERPRETATION">Although results must be interpreted with caution owing to the early closing of the trial, after effective and sustained downstaging of eligible hepatocellular carcinomas beyond the Milan criteria, liver transplantation improved tumour event-free survival and overall survival compared with non-transplantation therapies Post-downstaging tumour response could contribute to the expansion of hepatocellular carcinoma transplantation criteria.</AbstractText><AbstractText Label="FUNDING">Italian Ministry of Health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzaferro</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: vincenzo.mazzaferro@istitutotumori.mi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citterio</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhoori</LastName><ForeName>Sherrie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongini</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miceli</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carlis</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colledan</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salizzoni</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romagnoli</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General and Liver Transplant Surgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivarelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tisone</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruttadauria</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Sandro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carlis</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luc&#xe0;</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Giorgio</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirabella</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagiuoli</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iavarone</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, CRC A M and A Migliavacca Center for Liver Disease, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svegliati Baroni</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelico</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginanni Corradini</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpes</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regalia</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droz Dit Busset</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sposito</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01387503</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2020 Jul;21(7):867-869. doi: 10.1016/S1470-2045(20)30333-8.</RefSource><PMID Version="1">32615100</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Oncol. 2020 Aug;21(8):e373. doi: 10.1016/S1470-2045(20)30387-9.</RefSource><PMID Version="1">32758474</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32615109</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(20)30224-2</ArticleId><ArticleId IdType="pii">S1470-2045(20)30224-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25698099</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1983</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical nutrition (Edinburgh, Scotland)</Title><ISOAbbreviation>Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Identifying critically-ill patients who will benefit most from nutritional therapy: Further validation of the "modified NUTRIC" nutritional risk assessment tool.</ArticleTitle><Pagination><StartPage>158</StartPage><EndPage>162</EndPage><MedlinePgn>158-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2015.01.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0261-5614(15)00037-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Better tools are needed to assist in the identification of critically ill patients most likely to benefit from artificial nutrition therapy. Recently, the Nutrition Risk in Critically ill (NUTRIC) score has been developed for such purpose. The objective of this study was to externally validate a modified version of the NUTRIC score in a second database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a post hoc analysis of a database of a randomized control trial of intensive care unit (ICU) patients with multi-organ failure. Data for all variables of the NUTRIC score with the exception of IL-6 levels were collected. These included age, APACHE II score, SOFA score, number of co-morbidities, days from hospital admission to ICU admission. The NUTRIC score was calculated using the exact same thresholds and point system as developed previously except the IL-6 item was omitted. A logistic model including the NUTRIC score, the nutritional adequacy and their interaction was estimated to assess if the NUTRIC score modified the association between nutritional adequacy and 28-day mortality. We also examined the association of elevated NUTRIC scores and 6-month month mortality and the interaction between NUTRIC score and nutritional adequacy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1199 patients were analyzed. The mean total calories prescribed was 1817 cal (SD 312) with total mean protein prescribed of 98.3 g (SD 23.6). The number of patients who received PN was 9.5%. The overall 28-day mortality rate in this validation sample was 29% and the mean NUTRIC score was 5.5 (SD 1.6). Based on the logistic model, the odds of mortality at 28 days was multiplied by 1.4 (95% CI, 1.3-1.5) for every point increase on the NUTRIC score. The mean (SD) nutritional adequacy was 50.2 (29.5) with an interquartile range from 24.8 to 74.1. The test for interaction confirmed that the association between nutritional adequacy and 28-day mortality is significantly modified by the NUTRIC score (test for interaction p = 0.029). In particular, there is a strong positive association between nutritional adequacy and 28 day survival in patients with a high NUTRIC score but this association diminishes with decreasing NUTRIC score. Higher NUTRIC scores are also significantly associated with higher 6-month mortality (p &lt; 0.0001) and again the positive association between nutritional adequacy and 6 month survival was significantly stronger (and perhaps only present) in patients with higher NUTRIC score (test for interaction p = 0.038).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The NUTRIC scoring system is externally validated and may be useful in identifying critically ill patients most likely to benefit from optimal amounts of macronutrients when considering mortality as an outcome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Western Ontario, London, Ontario, Canada; Gastroenterology, St. Joseph's Healthcare Centre/London Health Sciences Centre, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Rana M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwala</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Section of Critical Care Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Western Ontario, London, Ontario, Canada; Critical Care/Trauma Centre, London Health Sciences Centre, Victoria Campus, Canada; Lawson Health Research Institute, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyland</LastName><ForeName>Daren K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada; Department of Community Health and Epidemiology, Queen's University, Kingston, Ontario, Canada; Department of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: dkh2@queensu.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Nutr</MedlineTA><NlmUniqueID>8309603</NlmUniqueID><ISSNLinking>0261-5614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044342" MajorTopicYN="N">Malnutrition</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015596" MajorTopicYN="Y">Nutrition Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009752" MajorTopicYN="Y">Nutritional Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Critically ill patients</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Nutrition</Keyword><Keyword MajorTopicYN="N">Nutritional risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25698099</ArticleId><ArticleId IdType="doi">10.1016/j.clnu.2015.01.015</ArticleId><ArticleId IdType="pii">S0261-5614(15)00037-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30442501</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.</ArticleTitle><Pagination><StartPage>1617</StartPage><EndPage>1629</EndPage><MedlinePgn>1617-1629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(18)30578-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(18)30578-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab beta alone in children and young people with high-risk neuroblastoma.</AbstractText><AbstractText Label="METHODS">We did an international, open-label, phase 3, randomised, controlled trial in patients with high-risk neuroblastoma at 104 institutions in 12 countries. Eligible patients were aged 1-20 years and had MYCN-amplified neuroblastoma with stages 2, 3, or 4S, or stage 4 neuroblastoma of any MYCN status, according to the International Neuroblastoma Staging System. Patients were eligible if they had been enrolled at diagnosis in the HR-NBL1/SIOPEN trial, had completed the multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, with or without topotecan, vincristine, and doxorubicin), had achieved a disease response that fulfilled prespecified criteria, had received high-dose therapy (busulfan and melphalan or carboplatin, etoposide, and melphalan) and had received radiotherapy to the primary tumour site. In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m<sup>2</sup> per day as an 8 h infusion for 5 consecutive days) or dinutuximab beta plus subcutaneous IL-2 (6&#x2008;&#xd7;&#x2008;10<sup>6</sup> IU/m<sup>2</sup> per day on days 1-5 and days 8-12 of each cycle) with the minimisation method to balance randomisation for national groups and type of high-dose therapy. All participants received oral isotretinoin (160 mg/m<sup>2</sup> per day for 2 weeks) before the first immunotherapy cycle and after each immunotherapy cycle, for six cycles. The primary endpoint was 3-year event-free survival, analysed by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT01704716, and EudraCT, number 2006-001489-17, and recruitment to this randomisation is closed.</AbstractText><AbstractText Label="FINDINGS">Between Oct 22, 2009, and Aug 12, 2013, 422 patients were eligible to participate in the immunotherapy randomisation, of whom 406 (96%) were randomly assigned to a treatment group (n=200 to dinutuximab beta and n=206 to dinutuximab beta with subcutaneous IL-2). Median follow-up was 4&#xb7;7 years (IQR 3&#xb7;9-5&#xb7;3). Because of toxicity, 117 (62%) of 188 patients assigned to dinutuximab beta and subcutaneous IL-2 received their allocated treatment, by contrast with 160 (87%) of 183 patients who received dinutuximab beta alone (p&lt;0&#xb7;0001). 3-year event-free survival was 56% (95% CI 49-63) with dinutuximab beta (83 patients had an event) and 60% (53-66) with dinutuximab beta and subcutaneous IL-2 (80 patients had an event; p=0&#xb7;76). Four patients died of toxicity (n=2 in each group); one patient in each group while receiving immunotherapy (n=1 congestive heart failure and pulmonary hypertension due to capillary leak syndrome; n=1 infection-related acute respiratory distress syndrome), and one patient in each group after five cycles of immunotherapy (n=1 fungal infection and multi-organ failure; n=1 pulmonary fibrosis). The most common grade 3-4 adverse events were hypersensitivity reactions (19 [10%] of 185 patients in the dinutuximab beta group vs 39 [20%] of 191 patients in the dinutuximab plus subcutaneous IL-2 group), capillary leak (five [4%] of 119 vs 19 [15%] of 125), fever (25 [14%] of 185 vs 76 [40%] of 190), infection (47 [25%] of 185 vs 64 [33%] of 191), immunotherapy-related pain (19 [16%] of 122 vs 32 [26%] of 124), and impaired general condition (30 [16%] of 185 vs 78 [41%] of 192).</AbstractText><AbstractText Label="INTERPRETATION">There is no evidence that addition of subcutaneous IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, improved outcomes in patients with high-risk neuroblastoma who had responded to standard induction and consolidation treatment. Subcutaneous IL-2 with dinutuximab beta was associated with greater toxicity than dinutuximab beta alone. Dinutuximab beta and isotretinoin without subcutaneous IL-2 should thus be considered the standard of care until results of ongoing randomised trials using a modified schedule of dinutuximab beta and subcutaneous IL-2 are available.</AbstractText><AbstractText Label="FUNDING">European Commission 5th Frame Work Grant, St. Anna Kinderkrebsforschung, Fondation ARC pour la recherche sur le Cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladenstein</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>St Anna Children's Hospital, Vienna, Austria; Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria. Electronic address: ruth.ladenstein@ccri.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xf6;tschger</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valteau-Couanet</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luksch</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castel</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaniv</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Unit, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Petach Tikvah, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laureys</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology/Oncology and Stem Cell Transplantation University Hospital Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Penelope</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Great Ormond Street Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michon</LastName><ForeName>Jean Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Children, Adolescent and Young Adults Department, Institut Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owens</LastName><ForeName>Cormac</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Haemato-Oncology, Our Lady's Children's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trahair</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Godfrey Chi Fung</ForeName><Initials>GCF</Initials><AffiliationInfo><Affiliation>Department of Paediatrics &amp; Adolescent Medicine, Queen Mary Hospital, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruud</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Paediatric Medicine, Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University Hospital of Aarhus, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck Popovic</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Paediatric Surgery, Paediatric Haematology Oncology Unit, University Hospital Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreier</LastName><ForeName>Guenter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loibner</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Apeiron Biologics AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambros</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biology, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Paediatric Surgery, St George's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Maria Rita</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaze</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Oncology, University College London Hospitals NHS Foundation Trust, National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaventa</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oncology Unit, Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>Andrew D J</ForeName><Initials>ADJ</Initials><AffiliationInfo><Affiliation>Paediatric and Adolescent Drug Development Team, Oak Centre for Children and Young People, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lode</LastName><ForeName>Holger N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Paediatric Haematology-Oncology Department, University Medicine Greifswald, Greifswald, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01704716</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>8177</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>7SQY4ZUD30</RegistryNumber><NameOfSubstance UI="C112746">dinutuximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EH28UP18IF</RegistryNumber><NameOfSubstance UI="D015474">Isotretinoin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2018 Dec;19(12):1549-1551. doi: 10.1016/S1470-2045(18)30627-2.</RefSource><PMID Version="1">30442498</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015474" MajorTopicYN="N">Isotretinoin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30442501</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(18)30578-3</ArticleId><ArticleId IdType="pii">S1470-2045(18)30578-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36012630</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Expression of MicroRNAs in Sepsis-Related Organ Dysfunction: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9354</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23169354</ELocationID><Abstract><AbstractText>Sepsis is a critical condition characterized by increased levels of pro-inflammatory cytokines and proliferating cells such as neutrophils and macrophages in response to microbial pathogens. Such processes lead to an abnormal inflammatory response and multi-organ failure. MicroRNAs (miRNA) are single-stranded non-coding RNAs with the function of gene regulation. This means that miRNAs are involved in multiple intracellular pathways and thus contribute to or inhibit inflammation. As a result, their variable expression in different tissues and organs may play a key role in regulating the pathophysiological events of sepsis. Thanks to this property, miRNAs may serve as potential diagnostic and prognostic biomarkers in such life-threatening events. In this narrative review, we collect the results of recent studies on the expression of miRNAs in heart, blood, lung, liver, brain, and kidney during sepsis and the molecular processes in which they are involved. In reviewing the literature, we find at least 122 miRNAs and signaling pathways involved in sepsis-related organ dysfunction. This may help clinicians to detect, prevent, and treat sepsis-related organ failures early, although further studies are needed to deepen the knowledge of their potential contribution.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maiese</LastName><ForeName>Aniello</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scatena</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8727-9769</Identifier><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantino</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3377-7997</Identifier><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiti</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1053-5661</Identifier><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Occhipinti</LastName><ForeName>Carla</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0476-7394</Identifier><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Russa</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3433-7122</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turillazzi</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frati</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0358-7965</Identifier><AffiliationInfo><Affiliation>Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fineschi</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1686-3236</Identifier><AffiliationInfo><Affiliation>Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blood</Keyword><Keyword MajorTopicYN="N">brain</Keyword><Keyword MajorTopicYN="N">heart</Keyword><Keyword MajorTopicYN="N">kidney</Keyword><Keyword MajorTopicYN="N">liver</Keyword><Keyword MajorTopicYN="N">lungs</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36012630</ArticleId><ArticleId IdType="pmc">PMC9409129</ArticleId><ArticleId IdType="doi">10.3390/ijms23169354</ArticleId><ArticleId IdType="pii">ijms23169354</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.-D., Coopersmith C.M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801&#x2013;810. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L., Rhodes A., Alhazzani W., Antonelli M., Coopersmith C.M., French C., Machado F.R., Mcintyre L., Ostermann M., Prescott H.C., et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensiv. Care Med. 2021;47:1181&#x2013;1247. doi: 10.1007/s00134-021-06506-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06506-y</ArticleId><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann-Struzek C., Mellhammar L., Rose N., Cassini A., Rudd K.E., Schlattmann P., Allegranzi B., Reinhart K. Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis. Intensiv. Care Med. 2020;46:1552&#x2013;1562. doi: 10.1007/s00134-020-06151-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06151-x</ArticleId><ArticleId IdType="pmc">PMC7381468</ArticleId><ArticleId IdType="pubmed">32572531</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoli C.J., Reynolds M.A., Sinha M., Gitlin M., Crouser E. Epidemiology and Costs of Sepsis in the United States&#x2014;An Analysis Based on Timing of Diagnosis and Severity Level. Crit. Care Med. 2018;46:1889&#x2013;1897. doi: 10.1097/CCM.0000000000003342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003342</ArticleId><ArticleId IdType="pmc">PMC6250243</ArticleId><ArticleId IdType="pubmed">30048332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotts J.E., Matthay M.A. Sepsis: Pathophysiology and clinical management. BMJ. 2016;353:i1585. doi: 10.1136/bmj.i1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i1585</ArticleId><ArticleId IdType="pubmed">27217054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pool R., Gomez H., Kellum J.A. Mechanisms of Organ Dysfunction in Sepsis. Crit. Care Clin. 2018;34:63&#x2013;80. doi: 10.1016/j.ccc.2017.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2017.08.003</ArticleId><ArticleId IdType="pmc">PMC6922007</ArticleId><ArticleId IdType="pubmed">29149942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R.S., Monneret G., Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 2013;13:862&#x2013;874. doi: 10.1038/nri3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecconi M., Evans L., Levy M., Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75&#x2013;87. doi: 10.1016/S0140-6736(18)30696-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30696-2</ArticleId><ArticleId IdType="pubmed">29937192</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasiadou E., Jacob L.S., Slack F.J. Non-coding RNA networks in cancer. Nat. Rev. Cancer. 2018;18:5&#x2013;18. doi: 10.1038/nrc.2017.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2017.99</ArticleId><ArticleId IdType="pmc">PMC6337726</ArticleId><ArticleId IdType="pubmed">29170536</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui M., Corey D.R. Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 2017;16:167&#x2013;179. doi: 10.1038/nrd.2016.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.117</ArticleId><ArticleId IdType="pmc">PMC5831170</ArticleId><ArticleId IdType="pubmed">27444227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Gregory R.I. MicroRNA biogenesis pathways in cancer. Nat. Cancer. 2015;15:321&#x2013;333. doi: 10.1038/nrc3932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3932</ArticleId><ArticleId IdType="pmc">PMC4859809</ArticleId><ArticleId IdType="pubmed">25998712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel D.P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004;116:281&#x2013;297. doi: 10.1016/S0092-8674(04)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00045-5</ArticleId><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardekani A.M., Naeini M.M. The Role of MicroRNAs in Human Diseases. Avicenna J. Med. Biotechnol. 2010;2:161&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558168</ArticleId><ArticleId IdType="pubmed">23407304</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P.A., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration. BMJ (Clin. Res. Ed.) 2009;339:b2700. doi: 10.1136/bmj.b2700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins R.O. Acquired Brain Injury Following Sepsis. Crit. Care Med. 2019;47:1658&#x2013;1659. doi: 10.1097/CCM.0000000000003981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003981</ArticleId><ArticleId IdType="pubmed">31609262</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudreau R., Jiang P., Gilmore B.L., Spengler R., Tirabassi R., Nelson J.A., Ross C.A., Xing Y., Davidson B.L. Transcriptome-wide Discovery of microRNA Binding Sites in Human Brain. Neuron. 2014;81:294&#x2013;305. doi: 10.1016/j.neuron.2013.10.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.062</ArticleId><ArticleId IdType="pmc">PMC4108341</ArticleId><ArticleId IdType="pubmed">24389009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-F., Li Y., Wang Y.-Q., Li H.-J., Dou L. MicroRNA-494-3p alleviates inflammatory response in sepsis by targeting TLR6. Eur. Rev. Med. Pharmacol. Sci. 2019;23:2971&#x2013;2977.</Citation><ArticleIdList><ArticleId IdType="pubmed">31002148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L., Tang C., Cai C., Guan X. Upregulation of the microRNA rno-miR-146b-5p may be involved in the development of intestinal injury through inhibition of Kruppel-like factor 4 in intestinal sepsis. Bioengineered. 2020;11:1334&#x2013;1349. doi: 10.1080/21655979.2020.1851476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2020.1851476</ArticleId><ArticleId IdType="pmc">PMC8291882</ArticleId><ArticleId IdType="pubmed">33200654</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong R., Hu D., Li Q., Xu T., Sui Y., Qu Y. Protective effects of microRNA-181b on aged rats with sepsis-induced hippocampus injury in vivo. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31:857&#x2013;861. doi: 10.3760/cma.j.issn.2095-4352.2019.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.2095-4352.2019.07.012</ArticleId><ArticleId IdType="pubmed">31441410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.-L., Cai G.-X., Ding H.-G., Liu X.-Q., Wang Z.-H., Jing Y.-W., Han Y.-L., Jiang W.-Q., Wen M.-Y. JAK/STAT signaling pathway-mediated microRNA-181b promoted blood-brain barrier impairment by targeting sphingosine-1-phosphate receptor 1 in septic rats. Ann. Transl. Med. 2020;8:1458. doi: 10.21037/atm-20-7024.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-7024</ArticleId><ArticleId IdType="pmc">PMC7723536</ArticleId><ArticleId IdType="pubmed">33313203</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Chen J., Yang H., Chen S., Wang Z. Overexpression of miR-200a-3p promoted inflammation in sepsis-induced brain injury through ROS-induced NLRP3. Int. J. Mol. Med. 2019;44:1811&#x2013;1823. doi: 10.3892/ijmm.2019.4326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2019.4326</ArticleId><ArticleId IdType="pmc">PMC6777670</ArticleId><ArticleId IdType="pubmed">31485604</ArticleId></ArticleIdList></Reference><Reference><Citation>Visitchanakun P., Tangtanatakul P., Trithiphen O., Soonthornchai W., Wongphoom J., Tachaboon S., Srisawat N., Leelahavanichkul A. Plasma miR-370-3P as a Biomarker of Sepsis-Associated Encephalopathy, the Transcriptomic Profiling Analysis of Microrna-Arrays from Mouse Brains. Shock. 2020;54:347&#x2013;357. doi: 10.1097/SHK.0000000000001473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001473</ArticleId><ArticleId IdType="pubmed">31743302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B., Guaregua V., Chen X., Zhao C., Yeow W., Berg N.K., Eltzschig H.K., Yuan X. Characterization of a Murine Model System to Study MicroRNA-147 During Inflammatory Organ Injury. Inflammation. 2021;44:1426&#x2013;1440. doi: 10.1007/s10753-021-01427-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01427-w</ArticleId><ArticleId IdType="pmc">PMC7873671</ArticleId><ArticleId IdType="pubmed">33566257</ArticleId></ArticleIdList></Reference><Reference><Citation>Nong A., Li Q., Huang Z., Xu Y., He K., Jia Y., Cen Z., Liao L., Huang Y. MicroRNA miR-126 attenuates brain injury in septic rats via NF-&#x3ba;B signaling pathway. Bioengineered. 2021;12:2639&#x2013;2648. doi: 10.1080/21655979.2021.1937905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1937905</ArticleId><ArticleId IdType="pmc">PMC8806573</ArticleId><ArticleId IdType="pubmed">34115555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani A., Barter J., Kumar A., Stortz J.A., Hollen M., Nacionales D., Moldawer L.L., Efron P.A., Foster T.C. Influence of age and sex on microRNA response and recovery in the hippocampus following sepsis. Aging. 2022;14:728&#x2013;746. doi: 10.18632/aging.203868.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203868</ArticleId><ArticleId IdType="pmc">PMC8833110</ArticleId><ArticleId IdType="pubmed">35094981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L., He J., Gu L., Shahror R.A., Li Y., Cao T., Wang S., Zhu J., Huang H., Chen F., et al. Brain innate immune response via miRNA-TLR7 sensing in polymicrobial sepsis. Brain Behav. Immun. 2022;100:10&#x2013;24. doi: 10.1016/j.bbi.2021.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.11.007</ArticleId><ArticleId IdType="pmc">PMC8766937</ArticleId><ArticleId IdType="pubmed">34808293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Mo M., Ding W., Liu W., Yan D., Deng J., Luo X., Liu J. High-mobility group box 1 (HMGB1) impaired cardiac excitation&#x2013;contraction coupling by enhancing the sarcoplasmic reticulum (SR) Ca2+ leak through TLR4&#x2013;ROS signaling in cardiomyocytes. J. Mol. Cell. Cardiol. 2014;74:260&#x2013;273. doi: 10.1016/j.yjmcc.2014.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2014.06.003</ArticleId><ArticleId IdType="pubmed">24937603</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto B.B., Dyson A., Umbrello M., Carre J., Ritter C., Clatworthy I., Duchen M.R., Singer M. Improved Survival in a Long-Term Rat Model of Sepsis Is Associated with Reduced Mitochondrial Calcium Uptake Despite Increased Energetic Demand. Crit. Care Med. 2017;45:e840&#x2013;e848. doi: 10.1097/CCM.0000000000002448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002448</ArticleId><ArticleId IdType="pubmed">28410346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince C., Mayeux P.R., Nguyen T., Gomez H., Kellum J.A., Ospina-Tasc&#xf3;n G.A., Hernandez G., Murray P., De Backer D. The Endothelium in Sepsis. Shock. 2016;45:259&#x2013;270. doi: 10.1097/SHK.0000000000000473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000473</ArticleId><ArticleId IdType="pmc">PMC5281063</ArticleId><ArticleId IdType="pubmed">26871664</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellinga N.A.R., Boerma E.C., Koopmans M., Donati A., Dubin A., Shapiro N.I., Pearse R., Machado F.R., Fries M., Akarsu-Ayazoglu T., et al. International Study on Microcirculatory Shock Occurrence in Acutely Ill Patients*. Crit. Care Med. 2015;43:48&#x2013;56. doi: 10.1097/CCM.0000000000000553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000553</ArticleId><ArticleId IdType="pubmed">25126880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg S.M., Piotrowski M.J., Parrillo J.E. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats. Am. J. Physiol. Integr. Comp. Physiol. 1997;272:R969&#x2013;R974. doi: 10.1152/ajpregu.1997.272.3.R969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.1997.272.3.R969</ArticleId><ArticleId IdType="pubmed">9087662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 2006;6:813&#x2013;822. doi: 10.1038/nri1943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1943</ArticleId><ArticleId IdType="pubmed">17039247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brealey D., Brand M., Hargreaves I., Heales S., Land J., Smolenski R., Davies N.A., Cooper C.E., Singer M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360:219&#x2013;223. doi: 10.1016/S0140-6736(02)09459-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)09459-X</ArticleId><ArticleId IdType="pubmed">12133657</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouser E.D. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion. 2004;4:729&#x2013;741. doi: 10.1016/j.mito.2004.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2004.07.023</ArticleId><ArticleId IdType="pubmed">16120428</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanzani G., Duchen M.R., Singer M. The role of mitochondria in sepsis-induced cardiomyopathy. Biochim. Biophys. Acta (BBA)&#x2014;Mol. Basis Dis. 2019;1865:759&#x2013;773. doi: 10.1016/j.bbadis.2018.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.10.011</ArticleId><ArticleId IdType="pubmed">30342158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg S.M., Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat. Rev. Cardiol. 2021;18:424&#x2013;434. doi: 10.1038/s41569-020-00492-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-00492-2</ArticleId><ArticleId IdType="pubmed">33473203</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway-Morris A., Wilson J., Shankar-Hari M. Immune Activation in Sepsis. Crit. Care Clin. 2018;34:29&#x2013;42. doi: 10.1016/j.ccc.2017.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2017.08.002</ArticleId><ArticleId IdType="pubmed">29149940</ArticleId></ArticleIdList></Reference><Reference><Citation>Manetti A.C., Maiese A., Di Paolo M., De Matteis A., La Russa R., Turillazzi E., Frati P., Fineschi V. MicroRNAs and Sepsis-Induced Cardiac Dysfunction: A Systematic Review. Int. J. Mol. Sci. 2020;22:321. doi: 10.3390/ijms22010321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22010321</ArticleId><ArticleId IdType="pmc">PMC7794809</ArticleId><ArticleId IdType="pubmed">33396834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Thota V., Dee L., Olson J., Uretz E., Parrillo J.E. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 1996;183:949&#x2013;958. doi: 10.1084/jem.183.3.949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.183.3.949</ArticleId><ArticleId IdType="pmc">PMC2192364</ArticleId><ArticleId IdType="pubmed">8642298</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilescu C., Rossi S., Shimizu M., Tudor S., Veronese A., Ferracin M., Nicoloso M., Barbarotto E., Popa M., Stanciulea O., et al. MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. PLoS ONE. 2009;4:e7405. doi: 10.1371/journal.pone.0007405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007405</ArticleId><ArticleId IdType="pmc">PMC2756627</ArticleId><ArticleId IdType="pubmed">19823581</ArticleId></ArticleIdList></Reference><Reference><Citation>Roderburg C., Luedde M., Cardenas D.V., Vucur M., Scholten D., Frey N., Koch A., Trautwein C., Tacke F., Luedde T. Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis. PLoS ONE. 2013;8:e54612. doi: 10.1371/journal.pone.0054612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054612</ArticleId><ArticleId IdType="pmc">PMC3555785</ArticleId><ArticleId IdType="pubmed">23372743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.-F., Yu M.-L., Yu G., Bian J.-J., Deng X.-M., Wan X.-J., Zhu K.-M. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem. Biophys. Res. Commun. 2010;394:184&#x2013;188. doi: 10.1016/j.bbrc.2010.02.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.02.145</ArticleId><ArticleId IdType="pubmed">20188071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Meng K., Chen W.J., Feng D., Jia Y., Xie L. Serum miR-574-5p. Shock. 2012;37:263&#x2013;267. doi: 10.1097/SHK.0b013e318241baf8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318241baf8</ArticleId><ArticleId IdType="pubmed">22344312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Vilanova D., Atalar K., Delfour O., Edgeworth J., Ostermann M., Hern&#xe1;ndez-Fuentes M., Razafimahatratra S., Michot B., Persing D.H., et al. Genome-Wide Sequencing of Cellular microRNAs Identifies a Combinatorial Expression Signature Diagnostic of Sepsis. PLoS ONE. 2013;8:e75918. doi: 10.1371/journal.pone.0075918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075918</ArticleId><ArticleId IdType="pmc">PMC3797812</ArticleId><ArticleId IdType="pubmed">24146790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Icli B., Wara A.K., Belkin N., He S., Kobzik L., Hunninghake G.M., Pinilla-Vera M., Blackwell T.S., Baron R.M., et al. MicroRNA-181b regulates NF-&#x3ba;B&#x2013;mediated vascular inflammation. J. Clin. Investig. 2012;122:1973&#x2013;1990. doi: 10.1172/JCI61495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI61495</ArticleId><ArticleId IdType="pmc">PMC3366408</ArticleId><ArticleId IdType="pubmed">22622040</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Dalli J., Chiang N., Baron R.M., Quintana C., Serhan C.N. Plasticity of Leukocytic Exudates in Resolving Acute Inflammation Is Regulated by MicroRNA and Proresolving Mediators. Immunity. 2013;39:885&#x2013;898. doi: 10.1016/j.immuni.2013.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.10.011</ArticleId><ArticleId IdType="pmc">PMC3888517</ArticleId><ArticleId IdType="pubmed">24238341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacke F., Roderburg C., Benz F., Cardenas D.V., Luedde M., Hippe H.-J., Frey N., Vucur M., Gautheron J., Koch A., et al. Levels of Circulating miR-133a Are Elevated in Sepsis and Predict Mortality in Critically Ill Patients. Crit. Care Med. 2014;42:1096&#x2013;1104. doi: 10.1097/CCM.0000000000000131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000131</ArticleId><ArticleId IdType="pubmed">24413579</ArticleId></ArticleIdList></Reference><Reference><Citation>Benz F., Roy S., Trautwein C., Roderburg C., Luedde T. Circulating MicroRNAs as Biomarkers for Sepsis. Int. J. Mol. Sci. 2016;17:78. doi: 10.3390/ijms17010078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17010078</ArticleId><ArticleId IdType="pmc">PMC4730322</ArticleId><ArticleId IdType="pubmed">26761003</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar-Hari M., Lord G.M. How might a diagnostic microRNA signature be used to speed up the diagnosis of sepsis? Expert Rev. Mol. Diagn. 2014;14:249&#x2013;251. doi: 10.1586/14737159.2014.899151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.2014.899151</ArticleId><ArticleId IdType="pubmed">24649814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruparelia N., Chai J.T., Fisher E.A., Choudhury R.P. Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nat. Rev. Cardiol. 2017;14:133&#x2013;144. doi: 10.1038/nrcardio.2016.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2016.185</ArticleId><ArticleId IdType="pmc">PMC5525550</ArticleId><ArticleId IdType="pubmed">27905474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yende S., Linde-Zwirble W., Mayr F., Weissfeld L.A., Reis S., Angus D.C. Risk of Cardiovascular Events in Survivors of Severe Sepsis. Am. J. Respir. Crit. Care Med. 2014;189:1065&#x2013;1074. doi: 10.1164/rccm.201307-1321OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201307-1321OC</ArticleId><ArticleId IdType="pmc">PMC4098105</ArticleId><ArticleId IdType="pubmed">24456535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.-F., Chen Y.-J., Lin Y.-J., Chen S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 2015;12:230&#x2013;243. doi: 10.1038/nrcardio.2015.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.2</ArticleId><ArticleId IdType="pubmed">25622848</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltr&#xe1;n-Garc&#xed;a J., Osca-Verdegal R., N&#xe1;cher-Sendra E., Cardona-Monzon&#xed;s A., Sanchis-Gomar F., Carbonell N., Pallard&#xf3; F.V., Lavie C.J., Garc&#xed;a-Gim&#xe9;nez J.L. Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis. Prog. Cardiovasc. Dis. 2021;68:70&#x2013;77. doi: 10.1016/j.pcad.2021.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2021.07.005</ArticleId><ArticleId IdType="pubmed">34265333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Huang W., Yang Y., Wang Y., Peng T., Chang J., Caldwell C.C., Zingarelli B., Fan G.-C. Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis. Biochim. Biophys. Acta (BBA)&#x2014;Mol. Basis Dis. 2014;1842:701&#x2013;711. doi: 10.1016/j.bbadis.2014.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.01.012</ArticleId><ArticleId IdType="pmc">PMC3959587</ArticleId><ArticleId IdType="pubmed">24486439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Zhang P., Chen W., Feng D., Jia Y., Xie L. Serum MicroRNA Signatures Identified by Solexa Sequencing Predict Sepsis Patients&#x2019; Mortality: A Prospective Observational Study. PLoS ONE. 2012;7:e38885. doi: 10.1371/journal.pone.0038885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0038885</ArticleId><ArticleId IdType="pmc">PMC3376145</ArticleId><ArticleId IdType="pubmed">22719975</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Wang Z., Wang H., Ren F., Li Y., Zou S., Xu J., Xie L. The protective role of miR-223 in sepsis-induced mortality. Sci. Rep. 2020;10:17691. doi: 10.1038/s41598-020-74965-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-74965-2</ArticleId><ArticleId IdType="pmc">PMC7572423</ArticleId><ArticleId IdType="pubmed">33077816</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#x2019;Baya-Moutoula E., Louvet L., Molini&#xe9; R., Guerrera I.C., Cerutti C., Fourdinier O., Nourry V., Gutierrez L., Morli&#xe8;re P., Mesnard F., et al. A multi-omics analysis of the regulatory changes induced by miR-223 in a monocyte/macrophage cell line. Biochim. Biophys. Acta (BBA)&#x2014;Mol. Basis Dis. 2018;1864:2664&#x2013;2678. doi: 10.1016/j.bbadis.2018.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.05.010</ArticleId><ArticleId IdType="pubmed">29778662</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue W.-L., Bai X., Zhang L. rhTNFR:Fc increases Nrf2 expression via miR-27a mediation to protect myocardium against sepsis injury. Biochem. Biophys. Res. Commun. 2015;464:855&#x2013;861. doi: 10.1016/j.bbrc.2015.07.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2015.07.051</ArticleId><ArticleId IdType="pubmed">26171875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kensler T.W., Wakabayashi N., Biswal S. Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway. Annu. Rev. Pharmacol. Toxicol. 2007;47:89&#x2013;116. doi: 10.1146/annurev.pharmtox.46.120604.141046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.46.120604.141046</ArticleId><ArticleId IdType="pubmed">16968214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M., Wang X., Zhang X., Ha T., Ma H., Liu L., Kalbfleisch J.H., Gao X., Kao R.L., Williams D.L., et al. Attenuation of Cardiac Dysfunction in Polymicrobial Sepsis by MicroRNA-146a Is Mediated via Targeting of IRAK1 and TRAF6 Expression. J. Immunol. 2015;195:672&#x2013;682. doi: 10.4049/jimmunol.1403155.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1403155</ArticleId><ArticleId IdType="pmc">PMC4490963</ArticleId><ArticleId IdType="pubmed">26048146</ArticleId></ArticleIdList></Reference><Reference><Citation>An R., Feng J., Xi C., Xu J., Sun L. miR-146a Attenuates Sepsis-Induced Myocardial Dysfunction by Suppressing IRAK1 and TRAF6 via Targeting ErbB4 Expression. Oxidative Med. Cell. Longev. 2018;2018:7163057. doi: 10.1155/2018/7163057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7163057</ArticleId><ArticleId IdType="pmc">PMC6129849</ArticleId><ArticleId IdType="pubmed">30224945</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Zhang L., Fan X., Dong X., Zhang Z., Fan W. MicroRNA-146a improves sepsis-induced cardiomyopathy by regulating the TLR-4/NF-&#x3ba;B signaling pathway. Exp. Ther. Med. 2019;18:779&#x2013;785. doi: 10.3892/etm.2019.7657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.7657</ArticleId><ArticleId IdType="pmc">PMC6591494</ArticleId><ArticleId IdType="pubmed">31281454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Yu Y. MiR-146b protect against sepsis induced mice myocardial injury through inhibition of Notch1. Histochem. J. 2018;49:411&#x2013;417. doi: 10.1007/s10735-018-9781-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10735-018-9781-4</ArticleId><ArticleId IdType="pubmed">29951922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Wang X., Ha T., Gao M., Liu L., Wang R., Yu K., Kalbfleisch J.H., Kao R.L., Williams D.L., et al. MicroRNA-125b Prevents Cardiac Dysfunction in Polymicrobial Sepsis by Targeting TRAF6-Mediated Nuclear Factor &#x3ba;B Activation and p53-Mediated Apoptotic Signaling. J. Infect. Dis. 2016;214:1773&#x2013;1783. doi: 10.1093/infdis/jiw449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw449</ArticleId><ArticleId IdType="pmc">PMC5144735</ArticleId><ArticleId IdType="pubmed">27683819</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S., Liu Q. Long noncoding RNA MALAT1 modulates sepsis-induced cardiac inflammation through the miR-150-5p/NF-&#x3ba;B axis. Int. J. Clin. Exp. Pathol. 2019;12:3311&#x2013;3319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949863</ArticleId><ArticleId IdType="pubmed">31934174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X.G., Zhang T.N., Wen R., Liu C.F. Overexpression of miR-150-5p Alleviates Apoptosis in Sepsis-Induced Myocardial Depression. BioMed Res. Int. 2020;2020:3023186. doi: 10.1155/2020/3023186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3023186</ArticleId><ArticleId IdType="pmc">PMC7477614</ArticleId><ArticleId IdType="pubmed">32908879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Bei Y., Shen S., Huang P., Shi J., Zhang J., Sun Q., Chen Y., Yang Y., Xu T., et al. miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2. J. Mol. Cell. Cardiol. 2016;94:43&#x2013;53. doi: 10.1016/j.yjmcc.2016.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2016.03.014</ArticleId><ArticleId IdType="pubmed">27033308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Bei Y., Huang P., Zhou Q., Shi J., Sun Q., Zhong J., Li X., Kong X., Xiao J. Inhibition of miR-155 Protects Against LPS-induced Cardiac Dysfunction and Apoptosis in Mice. Mol. Ther. Nucleic Acids. 2016;5:e374. doi: 10.1038/mtna.2016.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2016.80</ArticleId><ArticleId IdType="pmc">PMC5095684</ArticleId><ArticleId IdType="pubmed">27727247</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao X., Sun S. PMicroRNA-124a regulates LPS-induced septic cardiac dysfunction by targeting STX2. Biotechnol. Lett. 2017;39:1335&#x2013;1342. doi: 10.1007/s10529-017-2368-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-017-2368-4</ArticleId><ArticleId IdType="pubmed">28560580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G., Pan M., Jin W., Jin G., Huang Y. MicroRNA-135a is up-regulated and aggravates myocardial depression in sepsis via regulating p38 MAPK/NF-&#x3ba;B pathway. Int. Immunopharmacol. 2017;45:6&#x2013;12. doi: 10.1016/j.intimp.2017.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2017.01.029</ArticleId><ArticleId IdType="pubmed">28147298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Song Y., Shaikh Z., Li H., Zhang H., Caudle Y., Zheng S., Yan H., Hu D., Stuart C., et al. MicroRNA-155 attenuates late sepsis-induced cardiac dysfunction through JNK and &#x3b2;-arrestin 2. Oncotarget. 2017;8:47317&#x2013;47329. doi: 10.18632/oncotarget.17636.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.17636</ArticleId><ArticleId IdType="pmc">PMC5564567</ArticleId><ArticleId IdType="pubmed">28525390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge C., Liu J., Dong S. miRNA-214 Protects Sepsis-Induced Myocardial Injury. Shock. 2018;50:112&#x2013;118. doi: 10.1097/SHK.0000000000000978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000978</ArticleId><ArticleId IdType="pubmed">28858140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang Z., Zhang P., Wei Y., Dong S. miR-214-3p Attenuates Sepsis-Induced Myocardial Dysfunction in Mice by Inhibiting Autophagy through PTEN/AKT/mTOR Pathway. BioMed Res. Int. 2020;2020:1409038. doi: 10.1155/2020/1409038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1409038</ArticleId><ArticleId IdType="pmc">PMC7359738</ArticleId><ArticleId IdType="pubmed">32714974</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Hu J., Wang Z., Zong H., Zhang L., Zhang R., Sun L. LncRNA H19 functions as an Aquaporin 1 competitive endogenous RNA to regulate microRNA-874 expression in LPS sepsis. Biomed. Pharmacother. 2018;105:1183&#x2013;1191. doi: 10.1016/j.biopha.2018.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.06.007</ArticleId><ArticleId IdType="pubmed">30021355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Li F., Sun Y., Lei L., Zhou H., Lei T., Xia Y., Verkman A.S., Yang B. Aquaporin-1 retards renal cyst development in polycystic kidney disease by inhibition of Wnt signaling. FASEB J. 2015;29:1551&#x2013;1563. doi: 10.1096/fj.14-260828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-260828</ArticleId><ArticleId IdType="pmc">PMC4396615</ArticleId><ArticleId IdType="pubmed">25573755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yan M., Jiang H., Wang Q., Guan X., Chen J., Wang C. Protective effects of puerarin on acute lung and cerebrum injury induced by hypobaric hypoxia via the regulation of aquaporin (AQP) via NF-&#x3ba;B signaling pathway. Int. Immunopharmacol. 2016;40:300&#x2013;309. doi: 10.1016/j.intimp.2016.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2016.09.010</ArticleId><ArticleId IdType="pubmed">27643664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita Y., Dorward H., Yool A.J., Smith E., Townsend A.R., Price T.J., Hardingham J.E. Role of Aquaporin 1 Signalling in Cancer Development and Progression. Int. J. Mol. Sci. 2017;18:299. doi: 10.3390/ijms18020299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18020299</ArticleId><ArticleId IdType="pmc">PMC5343835</ArticleId><ArticleId IdType="pubmed">28146084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B., Xuan L., Tang M., Wang H., Zhou J., Liu J., Wu S., Li M., Wang X., Zhang H. miR-93-3p alleviates lipopolysaccharide-induced inflammation and apoptosis in H9c2 cardiomyocytes by inhibiting toll-like receptor 4. Pathol. Res. Pract. 2018;214:1686&#x2013;1693. doi: 10.1016/j.prp.2018.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2018.08.024</ArticleId><ArticleId IdType="pubmed">30195636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y., Sun F., Lei M. miR-25 inhibits sepsis-induced cardiomyocyte apoptosis by targetting PTEN. Biosci. Rep. 2018;38:BSR20171511. doi: 10.1042/BSR20171511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20171511</ArticleId><ArticleId IdType="pmc">PMC5897747</ArticleId><ArticleId IdType="pubmed">29440462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P., Kong L., Li J. MicroRNA-494-3p protects rat cardiomyocytes against septic shock via PTEN. Exp. Ther. Med. 2018;17:1706&#x2013;1716. doi: 10.3892/etm.2018.7116.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2018.7116</ArticleId><ArticleId IdType="pmc">PMC6364176</ArticleId><ArticleId IdType="pubmed">30783439</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Caudle Y., Shaikh A., Yao B., Yin D. Inhibition of microRNA-23b prevents polymicrobial sepsis-induced cardiac dysfunction by modulating TGIF1 and PTEN. Biomed. Pharmacother. 2018;103:869&#x2013;878. doi: 10.1016/j.biopha.2018.04.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.04.092</ArticleId><ArticleId IdType="pubmed">29710503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Liu Q., Xiao J., Lei J., Liu Y., Xu H., Hong Z. Molecular validation of the precision-cut kidney slice (PCKS) model of renal fibrosis through assessment of TGF-&#x3b2;1-induced Smad and p38/ERK signaling. Int. Immunopharmacol. 2016;34:32&#x2013;36. doi: 10.1016/j.intimp.2016.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2016.01.026</ArticleId><ArticleId IdType="pubmed">26919280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A.K., Quaggin S.E., Vaughan D.E. Molecular basis of organ fibrosis: Potential therapeutic approaches. Exp. Biol. Med. 2013;238:461&#x2013;481. doi: 10.1177/1535370213489441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370213489441</ArticleId><ArticleId IdType="pubmed">23856899</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C., Zhang Y., Chai Y., Wang L., Yin C., Shou S., Jin H. Attenuation of Sepsis-Induced Cardiomyopathy by Regulation of MicroRNA-23b Is Mediated Through Targeting of MyD88-Mediated NF-&#x3ba;B Activation. Inflammation. 2019;42:973&#x2013;986. doi: 10.1007/s10753-019-00958-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-019-00958-7</ArticleId><ArticleId IdType="pubmed">30734878</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H., Tang L., Xu J., Lin C., Ling X., Lu C., Liu Z. MicroRNA-495 serves as a diagnostic biomarker in patients with sepsis and regulates sepsis-induced inflammation and cardiac dysfunction. Eur. J. Med. Res. 2019;24:37. doi: 10.1186/s40001-019-0396-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-019-0396-3</ArticleId><ArticleId IdType="pmc">PMC6878688</ArticleId><ArticleId IdType="pubmed">31771650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Lin X., Yan C., Yang S., Zhu Z. microRNA-98 protects sepsis mice from cardiac dysfunction, liver and lung injury by negatively regulating HMGA2 through inhibiting NF-&#x3ba;B signaling pathway. Cell Cycle. 2019;18:1948&#x2013;1964. doi: 10.1080/15384101.2019.1635869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2019.1635869</ArticleId><ArticleId IdType="pmc">PMC6681783</ArticleId><ArticleId IdType="pubmed">31234706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang H., Tan Y., Li Q., Xia F., Xiao X., Zheng S., Lu J., Zhong J., Hu Y. MicroRNA-208-5p regulates myocardial injury of sepsis mice via targeting SOCS2-mediated NF-&#x3ba;B/HIF-1&#x3b1; pathway. Int. Immunopharmacol. 2020;81:106204. doi: 10.1016/j.intimp.2020.106204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106204</ArticleId><ArticleId IdType="pubmed">32086130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Luan C., Guo L., Zhang B., Liu Y. Low expression of microRNA-328 can predict sepsis and alleviate sepsis-induced cardiac dysfunction and inflammatory response. Braz. J. Med. Biol. Res. 2020;53:e9501. doi: 10.1590/1414-431x20209501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1414-431x20209501</ArticleId><ArticleId IdType="pmc">PMC7307893</ArticleId><ArticleId IdType="pubmed">32578720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T.-N., Yang N., Goodwin J.E., Mahrer K., Li D., Xia J., Wen R., Zhou H., Zhang T., Song W.-L., et al. Characterization of Circular RNA and microRNA Profiles in Septic Myocardial Depression: A Lipopolysaccharide-Induced Rat Septic Shock Model. Inflammation. 2019;42:1990&#x2013;2002. doi: 10.1007/s10753-019-01060-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-019-01060-8</ArticleId><ArticleId IdType="pubmed">31332662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen T.B., Jensen T.I., Clausen B.H., Bramsen J.B., Finsen B., Damgaard C.K., Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384&#x2013;388. doi: 10.1038/nature11993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11993</ArticleId><ArticleId IdType="pubmed">23446346</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Sun A., Meng T., Li H. RETRACTED: Protective role of long noncoding RNA CRNDE in myocardial tissues from injury caused by sepsis through the microRNA-29a/SIRT1 axis. Life Sci. 2020;255:117849. doi: 10.1016/j.lfs.2020.117849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117849</ArticleId><ArticleId IdType="pubmed">32473249</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y.-X., Ou Y.-M., Zhou J.-Y. Gracillin inhibits apoptosis and inflammation induced by lipopolysaccharide (LPS) to alleviate cardiac injury in mice via improving miR-29a. Biochem. Biophys. Res. Commun. 2020;523:580&#x2013;587. doi: 10.1016/j.bbrc.2019.11.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.11.129</ArticleId><ArticleId IdType="pubmed">31941605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Zhu C., Ye C. LncRNA CYTOR attenuates sepsis-induced myocardial injury via regulating miR-24/XIAP. Cell Biochem. Funct. 2020;38:976&#x2013;985. doi: 10.1002/cbf.3524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3524</ArticleId><ArticleId IdType="pubmed">32181504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F., Yuan W., Wu H., Chen G., Sun Y., Yuan L., Zhang W., Lei M. LncRNA KCNQ1OT1 attenuates sepsis-induced myocardial injury via regulating miR-192-5p/XIAP axis. Exp. Biol. Med. 2020;245:620&#x2013;630. doi: 10.1177/1535370220908041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370220908041</ArticleId><ArticleId IdType="pmc">PMC7153215</ArticleId><ArticleId IdType="pubmed">32102564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J.-L., Wu C.-J., Chen J.-J., Shang F.-T., Guo S.-G., Zhang X.-C., Liu H. LncRNA NEAT1 promotes the progression of sepsis-induced myocardial cell injury by sponging miR-144-3p. Eur. Rev. Med. Pharmacol. Sci. 2020;24:851&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">32016991</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing P.-C., An P., Hu G.-Y., Wang D.-L., Zhou M.-J. LncRNA MIAT Promotes Inflammation and Oxidative Stress in Sepsis-Induced Cardiac Injury by Targeting miR-330-5p/TRAF6/NF-&#x3ba;B Axis. Biochem. Genet. 2020;58:783&#x2013;800. doi: 10.1007/s10528-020-09976-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10528-020-09976-9</ArticleId><ArticleId IdType="pubmed">32556678</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Cai Y., Lai X., Wang Z., Wei S., Tan K., Xu M., Xie H. lncRNA RMRP Prevents Mitochondrial Dysfunction and Cardiomyocyte Apoptosis via the miR-1-5p/hsp70 Axis in LPS-Induced Sepsis Mice. Inflammation. 2020;43:605&#x2013;618. doi: 10.1007/s10753-019-01141-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-019-01141-8</ArticleId><ArticleId IdType="pubmed">31900829</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Yi N., Chen R., Meng Y., Wang Y., Liu H., Cao W., Hu Y., Gu Y., Tong C., et al. miR-29b-3p protects cardiomyocytes against endotoxin-induced apoptosis and inflammatory response through targeting FOXO3A. Cell. Signal. 2020;74:109716. doi: 10.1016/j.cellsig.2020.109716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2020.109716</ArticleId><ArticleId IdType="pubmed">32707074</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Y., Tang L., Chen J., Chen D., Wen W., Han F. Inhibition of miR-101-3p protects against sepsis-induced myocardial injury by inhibiting MAPK and NF-&#x3ba;B pathway activation via the upregulation of DUSP1. Int. J. Mol. Med. 2021;47:20. doi: 10.3892/ijmm.2021.4853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2021.4853</ArticleId><ArticleId IdType="pmc">PMC7849984</ArticleId><ArticleId IdType="pubmed">33448324</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu L., Zhang J. Protective role of matrine in sepsis-associated cardiac dysfunction through regulating the lncRNA PTENP1/miR-106b-5p axis. Biomed. Pharmacother. 2021;134:111112. doi: 10.1016/j.biopha.2020.111112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.111112</ArticleId><ArticleId IdType="pubmed">33341669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Yu L., Sheng Y. Clinical value and role of microRNA-29c-3p in sepsis-induced inflammation and cardiac dysfunction. Eur. J. Med. Res. 2021;26:90. doi: 10.1186/s40001-021-00566-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00566-y</ArticleId><ArticleId IdType="pmc">PMC8353850</ArticleId><ArticleId IdType="pubmed">34376255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Wen K. Predictive value and regulatory mechanism of serum miR-499a-5p on myocardial dysfunction in sepsis. J. Cardiothorac. Surg. 2021;16:301. doi: 10.1186/s13019-021-01679-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-021-01679-5</ArticleId><ArticleId IdType="pmc">PMC8518260</ArticleId><ArticleId IdType="pubmed">34654440</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriquez-Camacho C., Losa J. Biomarkers for Sepsis. BioMed Res. Int. 2014;2014:547818. doi: 10.1155/2014/547818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/547818</ArticleId><ArticleId IdType="pmc">PMC3985161</ArticleId><ArticleId IdType="pubmed">24800240</ArticleId></ArticleIdList></Reference><Reference><Citation>Limper M., de Kruif M., Duits A., Brandjes D., van Gorp E. The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J. Infect. 2010;60:409&#x2013;416. doi: 10.1016/j.jinf.2010.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2010.03.016</ArticleId><ArticleId IdType="pubmed">20347867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Tripathy S., Jyoti A., Singh S.G. Recent advances in biosensors for diagnosis and detection of sepsis: A comprehensive review. Biosens. Bioelectron. 2018;124&#x2013;125:205&#x2013;215. doi: 10.1016/j.bios.2018.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2018.10.034</ArticleId><ArticleId IdType="pubmed">30388563</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy B., Hassan U., Seymour C., Angus D.C., Isbell T.S., White K., Weir W., Yeh L., Vincent A., Bashir R. Point-of-care sensors for the management of sepsis. Nat. Biomed. Eng. 2018;2:640&#x2013;648. doi: 10.1038/s41551-018-0288-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-018-0288-9</ArticleId><ArticleId IdType="pubmed">31015684</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.-M., Zhang H., Zuo Y.-J. MicroRNA-218 alleviates sepsis inflammation by negatively regulating VOPP1 via JAK/STAT pathway. Eur. Rev. Med. Pharmacol. Sci. 2018;22:5620&#x2013;5626. doi: 10.26355/eurrev_201809_15827.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_201809_15827</ArticleId><ArticleId IdType="pubmed">30229837</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Khier N.A., Zaki M.E., Alkasaby N.M. Study of MicroRNA-122 as a Diagnostic Biomarker of Sepsis. Egypt. J. Immunol. 2019;26:105&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">31926500</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Z., Xi Q., Liu H., Guo X., Zhang J., Zhang Z., Li Y., Yang G., Zhou D., Yang H., et al. miR-21 promotes NLRP3 inflammasome activation to mediate pyroptosis and endotoxic shock. Cell Death Dis. 2019;10:461. doi: 10.1038/s41419-019-1713-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1713-z</ArticleId><ArticleId IdType="pmc">PMC6561921</ArticleId><ArticleId IdType="pubmed">31189875</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia P., Wu X., Dai Y., Teng J., Fang Y., Hu J., Zou J., Liang M., Ding X. MicroRNA-21 Is Required for Local and Remote Ischemic Preconditioning in Multiple Organ Protection Against Sepsis*. Crit. Care Med. 2017;45:e703&#x2013;e710. doi: 10.1097/CCM.0000000000002363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002363</ArticleId><ArticleId IdType="pubmed">28437377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao M., Cui B., Zhang W., Ma W., Zhao G., Xing L. Exosomal miR-21 secreted by IL-1&#x3b2;-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis. Life Sci. 2021;264:118658. doi: 10.1016/j.lfs.2020.118658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118658</ArticleId><ArticleId IdType="pubmed">33115604</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Yang D., Gao J., Xiang X., Hu X., Li S., Wu W., Cai J., Tang C., Zhang D., et al. Discovery and validation of miR-452 as an effective biomarker for acute kidney injury in sepsis. Theranostics. 2020;10:11963&#x2013;11975. doi: 10.7150/thno.50093.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.50093</ArticleId><ArticleId IdType="pmc">PMC7667674</ArticleId><ArticleId IdType="pubmed">33204323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A., Chiti E., Maiese A., Turillazzi E., Spinetti I. MicroRNAs: An Update of Applications in Forensic Science. Diagnostics. 2020;11:32. doi: 10.3390/diagnostics11010032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11010032</ArticleId><ArticleId IdType="pmc">PMC7823886</ArticleId><ArticleId IdType="pubmed">33375374</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese A., Manetti A.C., Iacoponi N., Mezzetti E., Turillazzi E., Di Paolo M., La Russa R., Frati P., Fineschi V. State-of-the-Art on Wound Vitality Evaluation: A Systematic Review. Int. J. Mol. Sci. 2022;23:6881. doi: 10.3390/ijms23136881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23136881</ArticleId><ArticleId IdType="pmc">PMC9266385</ArticleId><ArticleId IdType="pubmed">35805886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M.-H., Zhang L., Song M.-J., Sun W.-J. MicroRNA-218 prevents lung injury in sepsis by inhibiting RUNX2. Eur. Rev. Med. Pharmacol. Sci. 2018;22:8438&#x2013;8446.</Citation><ArticleIdList><ArticleId IdType="pubmed">30556885</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmel T., Sch&#xe4;fer S.T., Frey U., Adamzik M., Peters J. Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria. PLoS ONE. 2018;13:e0197637. doi: 10.1371/journal.pone.0197637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197637</ArticleId><ArticleId IdType="pmc">PMC5962092</ArticleId><ArticleId IdType="pubmed">29782519</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Wu X., Li C., Sun G., Ding P., Li Y., Yang P., Zhang M., Wang L. Identification and Validation of Immune-Related Biomarker Gene and Construction of ceRNA Networks in Septic Cardiomyopathy. Front. Cell. Infect. Microbiol. 2022;12:912492. doi: 10.3389/fcimb.2022.912492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.912492</ArticleId><ArticleId IdType="pmc">PMC9243365</ArticleId><ArticleId IdType="pubmed">35782126</ArticleId></ArticleIdList></Reference><Reference><Citation>Na L., Ding H., Xing E., Zhang Y., Gao J., Liu B., Yu J., Zhao Y. The predictive value of microRNA-21 for sepsis risk and its correlation with disease severity, systemic inflammation, and 28-day mortality in sepsis patients. J. Clin. Lab. Anal. 2020;34:e23103. doi: 10.1002/jcla.23103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23103</ArticleId><ArticleId IdType="pmc">PMC7083453</ArticleId><ArticleId IdType="pubmed">31778243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin R., Hu H., Li L., Chen G., Luo L., Rao P. The potential of microRNA-126 in predicting disease risk, mortality of sepsis, and its correlation with inflammation and sepsis severity. J. Clin. Lab. Anal. 2020;34:e23408. doi: 10.1002/jcla.23408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23408</ArticleId><ArticleId IdType="pmc">PMC7521265</ArticleId><ArticleId IdType="pubmed">32484987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D., Li S., Cui J., Wang L., Ma X., Li Y. Plasma miR-125a and miR-125b in sepsis: Correlation with disease risk, inflammation, severity, and prognosis. J. Clin. Lab. Anal. 2020;34:e23036. doi: 10.1002/jcla.23036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23036</ArticleId><ArticleId IdType="pmc">PMC7031612</ArticleId><ArticleId IdType="pubmed">32077163</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Dou H., Li X., Zhao X., Li Y., Liu D., Ji J., Liu F., Ding L., Ni Y., et al. Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1&#x3b2;-Primed Mesenchymal Stem Cells Against Sepsis. Stem Cells. 2017;35:1208&#x2013;1221. doi: 10.1002/stem.2564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2564</ArticleId><ArticleId IdType="pubmed">28090688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Yu L., Zhang R., Zhu L., Shen W. Correlation of microRNA-146a/b with disease risk, biochemical indices, inflammatory cytokines, overall disease severity, and prognosis of sepsis. Medicine. 2020;99:e19754. doi: 10.1097/MD.0000000000019754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000019754</ArticleId><ArticleId IdType="pubmed">32481361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X., Zhang J., Cao M., Han S., Liu Y., Wang K., Han F., Li X., Jia Y., Wang X., et al. MicroRNA-146a protects against LPS-induced organ damage by inhibiting Notch1 in macrophage. Int. Immunopharmacol. 2018;63:220&#x2013;226. doi: 10.1016/j.intimp.2018.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.07.040</ArticleId><ArticleId IdType="pubmed">30103197</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudecki L., Ferguson D.A., McCall C.E., El Gazzar M. MicroRNA-146a and RBM4 form a negative feed-forward loop that disrupts cytokine mRNA translation following TLR4 responses in human THP-1 monocytes. Immunol. Cell Biol. 2013;91:532&#x2013;540. doi: 10.1038/icb.2013.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2013.37</ArticleId><ArticleId IdType="pmc">PMC3770753</ArticleId><ArticleId IdType="pubmed">23897118</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Meng J., Das S., Krishnan A., Haworth J., Charboneau R., Zeng Y., Ramakrishnan S., Roy S. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci. Rep. 2013;3:1977. doi: 10.1038/srep01977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01977</ArticleId><ArticleId IdType="pmc">PMC3679508</ArticleId><ArticleId IdType="pubmed">23756365</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;hnle P., Sch&#xfc;tz S.V., van der Heide V., H&#xfc;bner M., Luchting B., Sedlbauer J., Limbeck E., Hinske L.C., Briegel J., Kreth S. MicroRNA-146a controls Th1-cell differentiation of human CD4+ T lymphocytes by targeting PRKC&#x3b5;. Eur. J. Immunol. 2015;45:260&#x2013;272. doi: 10.1002/eji.201444667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201444667</ArticleId><ArticleId IdType="pubmed">25308712</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik S., Choe J.H., Choi G.-E., Kim J.-E., Kim J.-M., Song G.Y., Jo E.-K. Rg6, a rare ginsenoside, inhibits systemic inflammation through the induction of interleukin-10 and microRNA-146a. Sci. Rep. 2019;9:4342. doi: 10.1038/s41598-019-40690-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40690-8</ArticleId><ArticleId IdType="pmc">PMC6416268</ArticleId><ArticleId IdType="pubmed">30867482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N., Gao Y., Yu S., Sun X., Shen K. Berberine attenuates A&#x3b2;42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells. Life Sci. 2020;252:117637. doi: 10.1016/j.lfs.2020.117637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117637</ArticleId><ArticleId IdType="pubmed">32251633</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao N.G.N., Dong L.D.L. MicroRNA-146 regulates the inflammatory cytokines expression in vascular endothelial cells during sepsis. Die Pharm. Int. J. Pharm. Sci. 2017;72:700&#x2013;704. doi: 10.1691/PH.2017.7600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1691/PH.2017.7600</ArticleId><ArticleId IdType="pubmed">29442046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Q., Zhao S., Wu Q., Wang H., He X., Liu C. Correlation analysis of microRNA-126 expression in peripheral blood lymphocytes with apoptosis and prognosis in patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:938&#x2013;942. doi: 10.3760/cma.j.cn121430-20200213-00181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn121430-20200213-00181</ArticleId><ArticleId IdType="pubmed">32912406</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang C.P., Leelahavanichkul A. Over-expression of miR-223 induces M2 macrophage through glycolysis alteration and attenuates LPS-induced sepsis mouse model, the cell-based therapy in sepsis. PLoS ONE. 2020;15:e0236038. doi: 10.1371/journal.pone.0236038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236038</ArticleId><ArticleId IdType="pmc">PMC7357756</ArticleId><ArticleId IdType="pubmed">32658933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L., Liu Z., Zhu J., Li B., Chai C., Tian Y. Clinical evaluation of circulating microRNA-25 level change in sepsis and its potential relationship with oxidative stress. Int. J. Clin. Exp. Pathol. 2015;8:7675&#x2013;7684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4555662</ArticleId><ArticleId IdType="pubmed">26339334</ArticleId></ArticleIdList></Reference><Reference><Citation>Manetti A.C., Maiese A., Baronti A., Mezzetti E., Frati P., Fineschi V., Turillazzi E. MiRNAs as New Tools in Lesion Vitality Evaluation: A Systematic Review and Their Forensic Applications. Biomedicines. 2021;9:1731. doi: 10.3390/biomedicines9111731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9111731</ArticleId><ArticleId IdType="pmc">PMC8615694</ArticleId><ArticleId IdType="pubmed">34829960</ArticleId></ArticleIdList></Reference><Reference><Citation>Benz F., Tacke F., Luedde M., Trautwein C., Luedde T., Koch A., Roderburg C. Circulating MicroRNA-223 Serum Levels Do Not Predict Sepsis or Survival in Patients with Critical Illness. Dis. Markers. 2015;2015:384208. doi: 10.1155/2015/384208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/384208</ArticleId><ArticleId IdType="pmc">PMC4355123</ArticleId><ArticleId IdType="pubmed">25810564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Yang J., Yu L., Long D. Plasma miRNA-223 correlates with risk, inflammatory markers as well as prognosis in sepsis patients. Medicine. 2018;97:e11352. doi: 10.1097/MD.0000000000011352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011352</ArticleId><ArticleId IdType="pmc">PMC6076081</ArticleId><ArticleId IdType="pubmed">29979415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W., Wang J., Li Z., Li J., Sang M. MicroRNA-205-5b inhibits HMGB1 expression in LPS-induced sepsis. Int. J. Mol. Med. 2016;38:312&#x2013;318. doi: 10.3892/ijmm.2016.2613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2016.2613</ArticleId><ArticleId IdType="pubmed">27246725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Li P., Goodwin A.J., Cook J.A., Halushka P.V., Zingarelli B., Fan H. miR-145a Regulation of Pericyte Dysfunction in a Murine Model of Sepsis. J. Infect. Dis. 2020;222:1037&#x2013;1045. doi: 10.1093/infdis/jiaa184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa184</ArticleId><ArticleId IdType="pmc">PMC7430167</ArticleId><ArticleId IdType="pubmed">32285112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F., Li Z., Cao J., Kong X., Gong G. A TGFBR2/SMAD2/DNMT1/miR-145 negative regulatory loop is responsible for LPS-induced sepsis. Biomed. Pharmacother. 2019;112:108626. doi: 10.1016/j.biopha.2019.108626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.108626</ArticleId><ArticleId IdType="pubmed">30784922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Zhang C., Zhang X., Chen Y., Zhang H. MiR-145 negatively regulates TGFBR2 signaling responsible for sepsis-induced acute lung injury. Biomed. Pharmacother. 2019;111:852&#x2013;858. doi: 10.1016/j.biopha.2018.12.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.12.138</ArticleId><ArticleId IdType="pubmed">30841464</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Wang J., Xue Y., Zhao J., Li D., Zhang S., Li K., Hou Y., Fan H. GSKJ4 Protects Mice Against Early Sepsis via Reducing Proinflammatory Factors and Up-Regulating MiR-146a. Front. Immunol. 2018;9:2272. doi: 10.3389/fimmu.2018.02272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02272</ArticleId><ArticleId IdType="pmc">PMC6179039</ArticleId><ArticleId IdType="pubmed">30337925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisti F., Wang S., Brandt S.L., Glosson-Byers N., Mayo L.D., Son Y.M., Sturgeon S., Filgueiras L., Jancar S., Wong H., et al. Nuclear PTEN enhances the maturation of a microRNA regulon to limit MyD88-dependent susceptibility to sepsis. Sci. Signal. 2018;11:eaai9085. doi: 10.1126/scisignal.aai9085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aai9085</ArticleId><ArticleId IdType="pmc">PMC8147521</ArticleId><ArticleId IdType="pubmed">29717063</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X. MiR-125b but not miR-125a is upregulated and exhibits a trend to correlate with enhanced disease severity, inflammation, and increased mortality in sepsis patients. J. Clin. Lab. Anal. 2020;34:e23094. doi: 10.1002/jcla.23094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23094</ArticleId><ArticleId IdType="pmc">PMC7083454</ArticleId><ArticleId IdType="pubmed">31696556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Sun X., Chen J., Liao X., He Y., Wang J., Chen R., Hu S., Qiu C. microRNA-27b shuttled by mesenchymal stem cell-derived exosomes prevents sepsis by targeting JMJD3 and downregulating NF-&#x3ba;B signaling pathway. Stem Cell Res. Ther. 2021;12:14. doi: 10.1186/s13287-020-02068-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-02068-w</ArticleId><ArticleId IdType="pmc">PMC7791667</ArticleId><ArticleId IdType="pubmed">33413595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G., Qiu G., Ge M., Meng J., Zhang G., Wang J., Huang R., Shu Q., Xu J. miR-10a in Peripheral Blood Mononuclear Cells Is a Biomarker for Sepsis and Has Anti-Inflammatory Function. Mediat. Inflamm. 2020;2020:4370983. doi: 10.1155/2020/4370983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/4370983</ArticleId><ArticleId IdType="pmc">PMC7077053</ArticleId><ArticleId IdType="pubmed">32214905</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Shi K., Chen M., Xu L., Hong J., Hu B., Yang X., Sun R. Elevated miR-155 expression induces immunosuppression via CD39+ regulatory T-cells in sepsis patient. Int. J. Infect. Dis. 2015;40:135&#x2013;141. doi: 10.1016/j.ijid.2015.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2015.09.016</ArticleId><ArticleId IdType="pubmed">26433115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Jia J., Liu Z., Si D., Ma L., Zhang G. Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0. BMC Pulm. Med. 2019;19:93. doi: 10.1186/s12890-019-0836-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-019-0836-4</ArticleId><ArticleId IdType="pmc">PMC6518454</ArticleId><ArticleId IdType="pubmed">31088429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X., Jiang Y., Zhou H., Ma D., Chen Z.K. MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. Med. Sci. Monit. 2015;21:1548&#x2013;1555. doi: 10.12659/MSM.894321.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.894321</ArticleId><ArticleId IdType="pmc">PMC4459571</ArticleId><ArticleId IdType="pubmed">26017478</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Liu X., Ni H. Clinical significance of miR-19b-3p in patients with sepsis and its regulatory role in the LPS-induced inflammatory response. Eur. J. Med. Res. 2020;25:9. doi: 10.1186/s40001-020-00408-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-020-00408-3</ArticleId><ArticleId IdType="pmc">PMC7079357</ArticleId><ArticleId IdType="pubmed">32188465</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Wang Y., Zheng Q., Dong X., Xie Z., Panayi A., Bai X., Li Z. MicroRNA-150 inhibits myeloid-derived suppressor cells proliferation and function through negative regulation of ARG-1 in sepsis. Life Sci. 2021;278:119626. doi: 10.1016/j.lfs.2021.119626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119626</ArticleId><ArticleId IdType="pubmed">34004247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng B., Zhao L., Zang X., Zhen J., Chen W. miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling. Biomed. Pharmacother. 2017;86:254&#x2013;261. doi: 10.1016/j.biopha.2016.11.147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2016.11.147</ArticleId><ArticleId IdType="pubmed">28006751</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure C., Brudecki L., Ferguson D.A., Yao Z.Q., Moorman J.P., McCall C.E., El Gazzar M. MicroRNA 21 (miR-21) and miR-181b Couple with NFI-A to Generate Myeloid-Derived Suppressor Cells and Promote Immunosuppression in Late Sepsis. Infect. Immun. 2014;82:3816&#x2013;3825. doi: 10.1128/IAI.01495-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.01495-14</ArticleId><ArticleId IdType="pmc">PMC4187818</ArticleId><ArticleId IdType="pubmed">24980967</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure C., McPeak M.B., Youssef D., Yao Z.Q., McCall C.E., El Gazzar M. Stat3 and C/EBP&#x3b2; synergize to induce miR-21 and miR-181b expression during sepsis. Immunol. Cell Biol. 2017;95:42&#x2013;55. doi: 10.1038/icb.2016.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2016.63</ArticleId><ArticleId IdType="pmc">PMC5209283</ArticleId><ArticleId IdType="pubmed">27430527</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Dai Q.-C., Shen H.-L., Zhang X.-W. Diagnostic value of elevated serum miRNA-143 levels in sepsis. J. Int. Med. Res. 2016;44:875&#x2013;881. doi: 10.1177/0300060516645003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060516645003</ArticleId><ArticleId IdType="pmc">PMC5536632</ArticleId><ArticleId IdType="pubmed">27225861</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Liu Y., Zhang L., Chen Y., Du H., Wen Z., Wang T., Chen D. Down-regulation of circDMNT3B is conducive to intestinal mucosal permeability dysfunction of rats with sepsis via sponging miR-20b-5p. J. Cell. Mol. Med. 2020;24:6731&#x2013;6740. doi: 10.1111/jcmm.15324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15324</ArticleId><ArticleId IdType="pmc">PMC7299677</ArticleId><ArticleId IdType="pubmed">32383354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Z.-R., Xue W.-L., Zhang L. Schisandrin B Attenuates Inflammation in LPS-Induced Sepsis Through miR-17-5p Downregulating TLR4. Inflammation. 2019;42:731&#x2013;739. doi: 10.1007/s10753-018-0931-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-018-0931-3</ArticleId><ArticleId IdType="pubmed">30506107</ArticleId></ArticleIdList></Reference><Reference><Citation>Szil&#xe1;gyi B., Fejes Z., P&#xf3;liska S., P&#xf3;csi M., Czimmerer Z., Patsalos A., Fenyvesi F., Ruszny&#xe1;k &#xc1;., Nagy G., Kerekes G., et al. Reduced miR-26b Expression in Megakaryocytes and Platelets Contributes to Elevated Level of Platelet Activation Status in Sepsis. Int. J. Mol. Sci. 2020;21:866. doi: 10.3390/ijms21030866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030866</ArticleId><ArticleId IdType="pmc">PMC7036890</ArticleId><ArticleId IdType="pubmed">32013235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Chen Y., Dai L., Wang N. MiR-96-5p alleviates inflammatory responses by targeting NAMPT and regulating the NF-&#x3ba;B pathway in neonatal sepsis. Biosci. Rep. 2020;40:BSR20201267. doi: 10.1042/BSR20201267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20201267</ArticleId><ArticleId IdType="pmc">PMC7335832</ArticleId><ArticleId IdType="pubmed">32618342</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Ruan Z., Mao Y., Dong W., Zhang Y., Yin N., Jiang L. miR-27a is up regulated and promotes inflammatory response in sepsis. Cell. Immunol. 2014;290:190&#x2013;195. doi: 10.1016/j.cellimm.2014.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2014.06.006</ArticleId><ArticleId IdType="pubmed">25043848</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Zhang D., Li Y., Li Y., Li Y. Paclitaxel alleviated liver injury of septic mice by alleviating inflammatory response via microRNA-27a/TAB3/NF-&#x3ba;B signaling pathway. Biomed. Pharmacother. 2018;97:1424&#x2013;1433. doi: 10.1016/j.biopha.2017.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.11.003</ArticleId><ArticleId IdType="pubmed">29156532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Cao K., Jin G., Zhang J. Hsa-miR-346 plays a role in the development of sepsis by downregulating SMAD3 expression and is negatively regulated by lncRNA MALAT1. Mol. Cell. Probes. 2019;47:101444. doi: 10.1016/j.mcp.2019.101444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2019.101444</ArticleId><ArticleId IdType="pubmed">31494280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X., Li J., Li L., Liu M., Liu Y., Cao M., Tao K., Xie S., Hu D. Extracellular Vesicles from Adipose Tissue-Derived Stem Cells Affect Notch-miR148a-3p Axis to Regulate Polarization of Macrophages and Alleviate Sepsis in Mice. Front. Immunol. 2020;11:1391. doi: 10.3389/fimmu.2020.01391.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01391</ArticleId><ArticleId IdType="pmc">PMC7347748</ArticleId><ArticleId IdType="pubmed">32719678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Xiang L. Honokiol alleviates sepsis-induced acute kidney injury in mice by targeting the miR-218-5p/heme oxygenase-1 signaling pathway. Cell. Mol. Biol. Lett. 2019;24:15. doi: 10.1186/s11658-019-0142-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-019-0142-4</ArticleId><ArticleId IdType="pmc">PMC6387556</ArticleId><ArticleId IdType="pubmed">30833971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Xu L.-Y., Sun Q.-H., Wan X.-Y., Li B. Inhibition of miR-1298-5p attenuates sepsis lung injury by targeting SOCS6. Mol. Cell. Biochem. 2021;476:3745&#x2013;3756. doi: 10.1007/s11010-021-04170-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-021-04170-w</ArticleId><ArticleId IdType="pubmed">34100174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W., Wen D., Lu H., Zhang A., Wang H., Du J., Zeng L., Jiang J. MiR-608 Exerts Anti-inflammatory Effects by Targeting ELANE in Monocytes. J. Clin. Immunol. 2020;40:147&#x2013;157. doi: 10.1007/s10875-019-00702-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-019-00702-8</ArticleId><ArticleId IdType="pubmed">31749032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wang C.-J., Tang X.-M., Wei Y.-K. Urinary miR-26b as a potential biomarker for patients with sepsis-associated acute kidney injury: A Chinese population-based study. Eur. Rev. Med. Pharmacol. Sci. 2018;22:4604&#x2013;4610.</Citation><ArticleIdList><ArticleId IdType="pubmed">30058697</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo R., Dai M., Fan Y., Zhou J.-Z., Li L., Zu J. Predictive value of miRNA-29a and miRNA-10a-5p for 28-day mortality in patients with sepsis-induced acute kidney injury. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:646&#x2013;651. doi: 10.3969/j.issn.1673-4254.2017.05.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1673-4254.2017.05.13</ArticleId><ArticleId IdType="pmc">PMC6780479</ArticleId><ArticleId IdType="pubmed">28539288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y.-Y., Wang Z., Wang Z.-H., Jiang X.-G., Lu W.-H. Inhibition of miR-155 alleviates sepsis-induced inflammation and intestinal barrier dysfunction by inactivating NF-&#x3ba;B signaling. Int. Immunopharmacol. 2021;90:107218. doi: 10.1016/j.intimp.2020.107218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107218</ArticleId><ArticleId IdType="pubmed">33296782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F., Liu F., Ding L., You M., Yue H., Zhou Y., Hou Y. Anti-inflammatory effects of curcumin are associated with down regulating microRNA-155 in LPS-treated macrophages and mice. Pharm. Biol. 2017;55:1263&#x2013;1273. doi: 10.1080/13880209.2017.1297838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13880209.2017.1297838</ArticleId><ArticleId IdType="pmc">PMC6130682</ArticleId><ArticleId IdType="pubmed">28264607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li T., Wu B., Liu H., Luo J., Feng D., Shi Y. STAT1 Regulates MD-2 Expression in Monocytes of Sepsis via miR-30a. Inflammation. 2014;37:1903&#x2013;1911. doi: 10.1007/s10753-014-9922-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-014-9922-1</ArticleId><ArticleId IdType="pubmed">24858600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei L., He M., Zhang C., Miao J., Wen Q., Liu X., Xu Q., Ye S., Ye P., Huang H., et al. Paeonol attenuates inflammation by targeting HMGB1 through upregulating miR-339-5p. Sci. Rep. 2019;9:19370. doi: 10.1038/s41598-019-55980-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-55980-4</ArticleId><ArticleId IdType="pmc">PMC6920373</ArticleId><ArticleId IdType="pubmed">31852965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Hao L., Bu H.-F., Scott A.W., Tian K., Liu F., De Plaen I.G., Liu Y., Mirkin C.A., Tan X.-D. Spherical nucleic acid targeting microRNA-99b enhances intestinal MFG-E8 gene expression and restores enterocyte migration in lipopolysaccharide-induced septic mice. Sci. Rep. 2016;6:31687. doi: 10.1038/srep31687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31687</ArticleId><ArticleId IdType="pmc">PMC4990839</ArticleId><ArticleId IdType="pubmed">27538453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y., Xu K., Sun Y., Tian T., Shen W., Sun F., Yuan W., Wu H., Chen G., Yuan L., et al. MiR-215-5p inhibits the inflammation injury in septic H9c2 by regulating ILF3 and LRRFIP1. Int. Immunopharmacol. 2020;78:106000. doi: 10.1016/j.intimp.2019.106000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.106000</ArticleId><ArticleId IdType="pubmed">31806569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Zhang P., Chen W., Feng D., Jia Y., Xie L.-X. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. Clin. Chem. Lab. Med. (CCLM) 2012;50:1423&#x2013;1428. doi: 10.1515/cclm-2011-0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2011-0826</ArticleId><ArticleId IdType="pubmed">22868808</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang G., Wu Y., Guan Y., Dong Y., Jiang L., Mao G., Wu R., Huang Z., Jiang H., Qi L., et al. The correlations between the serum expression of miR-206 and the severity and prognosis of sepsis. Ann. Palliat. Med. 2020;9:3222&#x2013;3234. doi: 10.21037/apm-20-1391.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-20-1391</ArticleId><ArticleId IdType="pubmed">32921119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wang H., Zhang C., Zhang C., Yang H., Gao R., Tong Z. Plasma Hsa-miR-92a-3p in correlation with lipocalin-2 is associated with sepsis-induced coagulopathy. BMC Infect. Dis. 2020;20:155. doi: 10.1186/s12879-020-4853-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-4853-y</ArticleId><ArticleId IdType="pmc">PMC7031893</ArticleId><ArticleId IdType="pubmed">32075600</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Zemans R.L., Zimmerman G.A., Arabi Y., Beitler J.R., Mercat A., Herridge M., Randolph A.G., Calfee C.S. Acute respiratory distress syndrome. Nat. Rev. Dis. Prim. 2019;5:18. doi: 10.1038/s41572-019-0069-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0069-0</ArticleId><ArticleId IdType="pmc">PMC6709677</ArticleId><ArticleId IdType="pubmed">30872586</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson B.T., Chambers R.C., Liu K.D. Acute Respiratory Distress Syndrome. N. Engl. J. Med. 2017;377:562&#x2013;572. doi: 10.1056/NEJMra1608077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1608077</ArticleId><ArticleId IdType="pubmed">28792873</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan E., Brodie D., Slutsky A.S. Acute Respiratory Distress Syndrome. JAMA. 2018;319:698&#x2013;710. doi: 10.1001/jama.2017.21907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.21907</ArticleId><ArticleId IdType="pubmed">29466596</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyland D., Muscedere J., Wischmeyer P.E., Cook D., Jones G., Albert M., Elke G., Berger M.M., Day A.G. A Randomized Trial of Glutamine and Antioxidants in Critically Ill Patients. N. Engl. J. Med. 2013;368:1489&#x2013;1497. doi: 10.1056/NEJMoa1212722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1212722</ArticleId><ArticleId IdType="pubmed">23594003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard G.R., Wheeler A.P., Arons M.M., Morris P.E., Paz H.L., Russell J.A., Wright P.E. A Trial of Antioxidants N-acetylcysteine and Procysteine in ARDS. Chest. 1997;112:164&#x2013;172. doi: 10.1378/chest.112.1.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.112.1.164</ArticleId><ArticleId IdType="pubmed">9228372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jepsen S., Herlevsen P., Knudsen P., Bud M.I., Klausen N.-O. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome. Crit. Care Med. 1992;20:918&#x2013;923. doi: 10.1097/00003246-199207000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199207000-00004</ArticleId><ArticleId IdType="pubmed">1617983</ArticleId></ArticleIdList></Reference><Reference><Citation>ARDS Clinical Trials Network. National Institutes of Health Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit. Care Med. 2002;30:1&#x2013;6. doi: 10.1097/00003246-200201000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200201000-00001</ArticleId><ArticleId IdType="pubmed">11902249</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E., Baughman R., Fletcher E., Heard S., Lamberti J., Levy H., Nelson L., Rumbak M., Steingrub J., Taylor J., et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome. Crit. Care Med. 1999;27:1478&#x2013;1485. doi: 10.1097/00003246-199908000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199908000-00013</ArticleId><ArticleId IdType="pubmed">10470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone R.C., Slotman G., Maunder R., Silverman H., Hyers T.M., Kerstein M.D., Ursprung J.J. Randomized Double-Blind, Multicenter Study of Prostaglandin E1 in Patients with the Adult Respiratory Distress Syndrome. Chest. 1989;96:114&#x2013;119. doi: 10.1378/chest.96.1.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.96.1.114</ArticleId><ArticleId IdType="pubmed">2661155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeiher B.G., Artigas A., Vincent J.-L., Dmitrienko A., Jackson K., Thompson B.T., Bernard G. Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. Crit. Care Med. 2004;32:1695&#x2013;1702. doi: 10.1097/01.CCM.0000133332.48386.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000133332.48386.85</ArticleId><ArticleId IdType="pubmed">15286546</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.D., Levitt J., Zhuo H., Kallet R.H., Brady S., Steingrub J., Tidswell M., Siegel M.D., Soto G., Peterson M.W., et al. Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. Am. J. Respir. Crit. Care Med. 2008;178:618&#x2013;623. doi: 10.1164/rccm.200803-419OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200803-419OC</ArticleId><ArticleId IdType="pmc">PMC2542435</ArticleId><ArticleId IdType="pubmed">18565951</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Truwit J.D., Bernard G.R., Steingrub J., Matthay M.A., Liu K.D., Albertson T.E., Brower R.G., Shanholtz C., Rock P., et al. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. N. Engl. J. Med. 2014;370:2191&#x2013;2200. doi: 10.1056/nejmoa1401520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1401520</ArticleId><ArticleId IdType="pmc">PMC4241052</ArticleId><ArticleId IdType="pubmed">24835849</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley D.F., Laffey J.G., O&#x2019;Kane C.M., Perkins G.D., Mullan B., Trinder T.J., Johnston P., Hopkins P.A., Johnston A.J., McDowell C., et al. Simvastatin in the Acute Respiratory Distress Syndrome. N. Engl. J. Med. 2014;371:1695&#x2013;1703. doi: 10.1056/NEJMoa1403285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1403285</ArticleId><ArticleId IdType="pubmed">25268516</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley D.F., Cross L.M., Hamid U., Gardner E., Elborn J.S., Cullen K.M., Dushianthan A., Grocott M., Matthay M.A., O&#x2019;Kane C. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir. Med. 2017;5:484&#x2013;491. doi: 10.1016/S2213-2600(17)30171-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(17)30171-6</ArticleId><ArticleId IdType="pubmed">28526233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig N., Leidinger P., Becker K., Backes C., Fehlmann T., Pallasch C.P., Rheinheimer S., Meder B., St&#xe4;hler C., Meese E., et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44:3865&#x2013;3877. doi: 10.1093/nar/gkw116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw116</ArticleId><ArticleId IdType="pmc">PMC4856985</ArticleId><ArticleId IdType="pubmed">26921406</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Nie C., Zhao N., Wang Y., Liu Y., Li Y., Zeng Z., Ding C., Shao Q., Qing C., et al. MiR-155 Alleviates Septic Lung Injury by Inducing Autophagy Via Inhibition of Transforming Growth Factor-&#x3b2;-Activated Binding Protein 2. Shock. 2017;48:61&#x2013;68. doi: 10.1097/SHK.0000000000000839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000839</ArticleId><ArticleId IdType="pubmed">28125526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang K., Yang J., Guo S., Zhao G., Wu H., Deng G. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation. Mol. Ther. 2019;27:1758&#x2013;1771. doi: 10.1016/j.ymthe.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6822235</ArticleId><ArticleId IdType="pubmed">31405809</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z., Syed M.A., Panchal D., Joo M., Bedi C., Lim S., &#xd6;ny&#xfc;ksel H., Rubinstein I., Colonna M., Sadikot R.T. TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine. Am. J. Physiol. Cell. Mol. Physiol. 2016;310:L426&#x2013;L438. doi: 10.1152/ajplung.00195.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00195.2015</ArticleId><ArticleId IdType="pmc">PMC4773843</ArticleId><ArticleId IdType="pubmed">26684249</ArticleId></ArticleIdList></Reference><Reference><Citation>Liau N.P.D., Laktyushin A., Lucet I.S., Murphy J.M., Yao S., Whitlock E., Callaghan K., Nicola N.A., Kershaw N.J., Babon J.J. The molecular basis of JAK/STAT inhibition by SOCS1. Nat. Commun. 2018;9:1558. doi: 10.1038/s41467-018-04013-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04013-1</ArticleId><ArticleId IdType="pmc">PMC5908791</ArticleId><ArticleId IdType="pubmed">29674694</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.-F., Wu Y.-L., Tseng T.-L., Chao S.-W., Lin H., Chen H.-H. Inhibition of miR-155 potentially protects against lipopolysaccharide-induced acute lung injury through the IRF2BP2-NFAT1 pathway. Am. J. Physiol. Cell Physiol. 2020;319:C1070&#x2013;C1081. doi: 10.1152/ajpcell.00116.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00116.2020</ArticleId><ArticleId IdType="pubmed">33052070</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Li Y., Jiang Y. The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients. Clin. Lab. 2016;62:2355&#x2013;2360. doi: 10.7754/Clin.Lab.2016.160511.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2016.160511</ArticleId><ArticleId IdType="pubmed">28164567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergadi E., Vaporidi K., Theodorakis E.E., Doxaki C., Lagoudaki E., Ieronymaki E., Alexaki V.I., Helms M., Kondili E., Soennichsen B., et al. Akt2 Deficiency Protects from Acute Lung Injury via Alternative Macrophage Activation and miR-146a Induction in Mice. J. Immunol. 2014;192:394&#x2013;406. doi: 10.4049/jimmunol.1300959.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300959</ArticleId><ArticleId IdType="pubmed">24277697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Z., Gong H., Li Y., Jie K., Ding C., Shao Q., Liu F., Zhan Y., Nie C., Zhu W., et al. Upregulation of miR-146a contributes to the suppression of inflammatory responses in LPS-induced acute lung injury. Exp. Lung Res. 2013;39:275&#x2013;282. doi: 10.3109/01902148.2013.808285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01902148.2013.808285</ArticleId><ArticleId IdType="pubmed">23848342</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R., Shao Z., Cao Q. MicroRNA-144-3p enhances LPS induced septic acute lung injury in mice through downregulating Caveolin-2. Immunol. Lett. 2021;231:18&#x2013;25. doi: 10.1016/j.imlet.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2020.12.015</ArticleId><ArticleId IdType="pubmed">33418009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren H., Mu W., Xu Q. miR-19a-3p inhibition alleviates sepsis-induced lung injury via enhancing USP13 expression. Acta Biochim. Pol. 2021;68:201&#x2013;206. doi: 10.18388/abp.2020_5505.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2020_5505</ArticleId><ArticleId IdType="pubmed">33966370</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Guan H., Zhang J.-L., Zheng Z., Wang H.-T., Tao K., Han S.-C., Su L.-L., Hu D. Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1. Am. J. Physiol. Physiol. 2018;314:C449&#x2013;C455. doi: 10.1152/ajpcell.00173.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00173.2017</ArticleId><ArticleId IdType="pubmed">29351405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Ding R., Hu Z., Yin X., Xiao F., Zhang W., Yan S., Lv C. MicroRNA-34a Inhibition Alleviates Lung Injury in Cecal Ligation and Puncture Induced Septic Mice. Front. Immunol. 2020;11:1829. doi: 10.3389/fimmu.2020.01829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01829</ArticleId><ArticleId IdType="pmc">PMC7438583</ArticleId><ArticleId IdType="pubmed">32903604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H.-C., Song W.-W., Zhao M.-L., Zhang R.-M., Tian X. Effect of miR-132 on lung injury in sepsis rats via regulating Sirt1 expression. Eur. Rev. Med. Pharmacol. Sci. 2021;25:1042&#x2013;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">33577060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao Y., Zhang T., Zhang C., Ji H., Tong X., Xia R., Wang W., Ma Z., Shi X. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Crit. Care. 2021;25:356. doi: 10.1186/s13054-021-03775-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03775-3</ArticleId><ArticleId IdType="pmc">PMC8507252</ArticleId><ArticleId IdType="pubmed">34641966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Li Y.-H., Yang Z.-T., Cheng N.-T., Tang H.-X., Xu M. The function and mechanism of microRNA-92a-3p in lipopolysaccharide-induced acute lung injury. Immunopharmacol. Immunotoxicol. 2022;44:47&#x2013;57. doi: 10.1080/08923973.2021.2001497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923973.2021.2001497</ArticleId><ArticleId IdType="pubmed">34783628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Mao M., Zhen Y.-Y. miRNA-23a has effects to improve lung injury induced by sepsis in vitro and vivo study. Biomed. Pharmacother. 2018;107:81&#x2013;89. doi: 10.1016/j.biopha.2018.07.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.07.097</ArticleId><ArticleId IdType="pubmed">30081205</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L., Cao H., Wan C., Jiang L. MiR-539-5p alleviates sepsis-induced acute lung injury by targeting ROCK1. Folia Histochem. Cytobiol. 2020;57:168&#x2013;178. doi: 10.5603/FHC.a2019.0019.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/FHC.a2019.0019</ArticleId><ArticleId IdType="pubmed">31825519</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W., Wei N., Xu W., Wang G., Gong F., Li N. MicroRNA-124 alleviates the lung injury in mice with septic shock through inhibiting the activation of the MAPK signaling pathway by downregulating MAPK14. Int. Immunopharmacol. 2019;76:105835. doi: 10.1016/j.intimp.2019.105835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.105835</ArticleId><ArticleId IdType="pubmed">31476692</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng C., Sun J., Xin K., Ge J., Liu P., Feng X. High expression of miR-483-5p aggravates sepsis-induced acute lung injury. J. Toxicol. Sci. 2020;45:77&#x2013;86. doi: 10.2131/jts.45.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.2131/jts.45.77</ArticleId><ArticleId IdType="pubmed">32062619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou W., Yan J., Wang W. Downregulation of miR-497-5p Improves Sepsis-Induced Acute Lung Injury by Targeting IL2RB. BioMed Res. Int. 2021;2021:6624702. doi: 10.1155/2021/6624702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6624702</ArticleId><ArticleId IdType="pmc">PMC8057895</ArticleId><ArticleId IdType="pubmed">33954185</ArticleId></ArticleIdList></Reference><Reference><Citation>You Q., Wang J., Jia D., Jiang L., Chang Y., Li W. MiR-802 alleviates lipopolysaccharide-induced acute lung injury by targeting Peli2. Agents Actions. 2020;69:75&#x2013;85. doi: 10.1007/s00011-019-01295-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-019-01295-z</ArticleId><ArticleId IdType="pmc">PMC7223969</ArticleId><ArticleId IdType="pubmed">31696241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Yan J., Yang F., Wang D., Lu Y., Liu L. MicroRNA-326 prevents sepsis-induced acute lung injury via targeting TLR4. Free Radic. Res. 2020;54:408&#x2013;418. doi: 10.1080/10715762.2020.1781847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715762.2020.1781847</ArticleId><ArticleId IdType="pubmed">32530324</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P., Xiong W., Chen X., Liu J., Ye Z. Overexpression of miR-129-5p Mitigates Sepsis-Induced Acute Lung Injury by Targeting High Mobility Group Box 1. J. Surg. Res. 2020;256:23&#x2013;30. doi: 10.1016/j.jss.2020.05.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2020.05.101</ArticleId><ArticleId IdType="pubmed">32682121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Lin Z., Lin L. MiR-490 alleviates sepsis-induced acute lung injury by targeting MRP4 in new-born mice. Acta Biochim. Pol. 2021;68:151&#x2013;158. doi: 10.18388/abp.2020_5397.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2020_5397</ArticleId><ArticleId IdType="pubmed">33751878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao W., Xu L., Jia X., Li S., Wei L. MicroRNA-129 plays a protective role in sepsis-induced acute lung injury through the suppression of pulmonary inflammation via the modulation of the TAK1/NF-&#x3ba;B pathway. Int. J. Mol. Med. 2021;48:139. doi: 10.3892/ijmm.2021.4972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2021.4972</ArticleId><ArticleId IdType="pmc">PMC8175065</ArticleId><ArticleId IdType="pubmed">34080641</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie T., Liang J., Liu N., Wang Q., Li Y., Noble P.W., Jiang D. MicroRNA-127 Inhibits Lung Inflammation by Targeting IgG Fc&#x3b3; Receptor I. J. Immunol. 2012;188:2437&#x2013;2444. doi: 10.4049/jimmunol.1101070.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101070</ArticleId><ArticleId IdType="pmc">PMC3288289</ArticleId><ArticleId IdType="pubmed">22287715</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Ni J., Shen G., Xia Z., Zhang L., Xia S., Pan S., Qu H., Li X. Upregulation of endothelial cell-derived exosomal microRNA-125b-5p protects from sepsis-induced acute lung injury by inhibiting topoisomerase II alpha. Agents Actions. 2021;70:205&#x2013;216. doi: 10.1007/s00011-020-01415-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01415-0</ArticleId><ArticleId IdType="pmc">PMC7776283</ArticleId><ArticleId IdType="pubmed">33386874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Li J., Yao H., Li T. Restoring microRNA-499-5p Protects Sepsis-Induced Lung Injury Mice Via Targeting Sox6. Nanoscale Res. Lett. 2021;16:89. doi: 10.1186/s11671-021-03534-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11671-021-03534-x</ArticleId><ArticleId IdType="pmc">PMC8140057</ArticleId><ArticleId IdType="pubmed">34019224</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Zhang D., Liu H., Xu H. miR-942-5p prevents sepsis-induced acute lung injury via targeting TRIM37. Int. J. Exp. Pathol. 2021;102:192&#x2013;199. doi: 10.1111/iep.12413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12413</ArticleId><ArticleId IdType="pmc">PMC8576636</ArticleId><ArticleId IdType="pubmed">34716956</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J., Han B., Shen Y. LncRNA NEAT1 inhibition upregulates miR-16-5p to restrain the progression of sepsis-induced lung injury via suppressing BRD4 in a mouse model. Int. Immunopharmacol. 2021;97:107691. doi: 10.1016/j.intimp.2021.107691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107691</ArticleId><ArticleId IdType="pubmed">33962228</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu N., Xu X., He Y. LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1. BMC Pulm. Med. 2020;20:49. doi: 10.1186/s12890-020-1084-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-020-1084-3</ArticleId><ArticleId IdType="pmc">PMC7036216</ArticleId><ArticleId IdType="pubmed">32087725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-R., Guo X.-Y., Liu X.-Y., Song X. Down-regulation of lncRNA CASC9 aggravates sepsis-induced acute lung injury by regulating miR-195-5p/PDK4 axis. Agents Actions. 2020;69:559&#x2013;568. doi: 10.1007/s00011-020-01316-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01316-2</ArticleId><ArticleId IdType="pubmed">32221619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., Shi D., Cao J., Song L. LncRNA CASC2 Alleviates Sepsis-induced Acute Lung Injury by Regulating the miR-152-3p/PDK4 Axis. Immunol. Investig. 2022;51:1257&#x2013;1271. doi: 10.1080/08820139.2021.1928693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2021.1928693</ArticleId><ArticleId IdType="pubmed">34165388</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H., Chai H., Du X., Cui R., Dong Y. Overexpressing long non-coding RNA OIP5-AS1 ameliorates sepsis-induced lung injury in a rat model via regulating the miR-128-3p/Sirtuin-1 pathway. Bioengineered. 2021;12:9723&#x2013;9738. doi: 10.1080/21655979.2021.1987132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1987132</ArticleId><ArticleId IdType="pmc">PMC8809967</ArticleId><ArticleId IdType="pubmed">34592882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Hu X., Li R., Liu B., Zheng X., Fang Z., Chen L., Chen W., Min L., Hu S. LncRNA THRIL aggravates sepsis-induced acute lung injury by regulating miR-424/ROCK2 axis. Mol. Immunol. 2020;126:111&#x2013;119. doi: 10.1016/j.molimm.2020.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2020.07.021</ArticleId><ArticleId IdType="pubmed">32818819</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Chen F., Cheng N.T., Tang Z., Wang X.G., Xu M. MicroRNA-1224-5p Aggravates Sepsis-Related Acute Lung Injury in Mice. Oxid Med Cell Longev. 2022;2022:9493710. doi: 10.1155/2022/9493710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9493710</ArticleId><ArticleId IdType="pmc">PMC9256451</ArticleId><ArticleId IdType="pubmed">35799888</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Yin J., Zou B., Guo H. WIN55212-2 alleviates acute lung injury by inhibiting macrophage glycolysis through the miR-29b-3p/FOXO3/PFKFB3 axis. Mol Immunol. 2022;149:119&#x2013;128. doi: 10.1016/j.molimm.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2022.06.005</ArticleId><ArticleId IdType="pubmed">35810663</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Li J., Bao Y., Yuan D., Huang Z. Xuebijing injection alleviates cytokine-induced inflammatory liver injury in CLP-induced septic rats through induction of suppressor of cytokine signaling 1. Exp. Ther. Med. 2016;12:1531&#x2013;1536. doi: 10.3892/etm.2016.3476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2016.3476</ArticleId><ArticleId IdType="pmc">PMC4998358</ArticleId><ArticleId IdType="pubmed">27602076</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.-B., Chen W.-W., Chen H.-P., Cai S.-X., Lin J.-D., Qiu L.-Z. MiR-155 aggravated septic liver injury by oxidative stress-mediated ER stress and mitochondrial dysfunction via targeting Nrf-2. Exp. Mol. Pathol. 2018;105:387&#x2013;394. doi: 10.1016/j.yexmp.2018.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2018.09.003</ArticleId><ArticleId IdType="pubmed">30218645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling L., Zhang S.-H., Zhi L.-D., Li H., Wen Q.-K., Li G., Zhang W.-J. MicroRNA-30e promotes hepatocyte proliferation and inhibits apoptosis in cecal ligation and puncture-induced sepsis through the JAK/STAT signaling pathway by binding to FOSL2. Biomed. Pharmacother. 2018;104:411&#x2013;419. doi: 10.1016/j.biopha.2018.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.05.042</ArticleId><ArticleId IdType="pubmed">29787988</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F., Chen Y., Zhao Y., Liu Z., Nan C., Zheng B., Liu X., Chen X. microRNA-30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS-1 in rats with sepsis. J. Cell. Physiol. 2019;234:17839&#x2013;17853. doi: 10.1002/jcp.28410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28410</ArticleId><ArticleId IdType="pubmed">30972748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Xia Q. Inhibition of miR-103a-3p suppresses lipopolysaccharide-induced sepsis and liver injury by regulating FBXW7 expression. Cell Biol. Int. 2020;44:1798&#x2013;1810. doi: 10.1002/cbin.11372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11372</ArticleId><ArticleId IdType="pmc">PMC7496651</ArticleId><ArticleId IdType="pubmed">32369227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Lu Q., Deng F., Peng S., Yuan J., Liu C., Du X. miR-103a-3p Could Attenuate Sepsis-Induced Liver Injury by Targeting HMGB1. Inflammation. 2020;43:2075&#x2013;2086. doi: 10.1007/s10753-020-01275-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01275-0</ArticleId><ArticleId IdType="pubmed">32556802</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhu H., Pan L., Zhang B., Che H. microRNA-103a-3p confers protection against lipopolysaccharide-induced sepsis and consequent multiple organ dysfunction syndrome by targeting HMGB1. Infect. Genet. Evol. 2021;89:104681. doi: 10.1016/j.meegid.2020.104681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104681</ArticleId><ArticleId IdType="pubmed">33333289</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu C., Hou C., Zhang S. miR-425-5p improves inflammation and septic liver damage through negatively regulating the RIP1-mediated necroptosis. Agents Actions. 2020;69:299&#x2013;308. doi: 10.1007/s00011-020-01321-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01321-5</ArticleId><ArticleId IdType="pubmed">32002587</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y.-X., Han W.-W., Song D.-D., Li Z.-P., Ding H.-J., Zhou T., Jiang L., Hu E.-C. Effect of miR-10a on sepsis-induced liver injury in rats through TGF-&#x3b2;1/Smad signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 2020;24:862&#x2013;869. doi: 10.26355/eurrev_202001_20070.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202001_20070</ArticleId><ArticleId IdType="pubmed">32016992</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N., Chen Y.-S., Zhu H., Li W.-S., Sun Z.-W., Zhang H.-B., Li X.-Y., Zhang B., Zhang C., Wen Z.-Q., et al. Upregulation of miR-142-5p induced by lipopolysaccharide contributes to apoptosis of hepatocytes and hepatic failure. Eur. Rev. Med. Pharmacol. Sci. 2021;25:5293&#x2013;5303. doi: 10.26355/eurrev_202108_26550.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202108_26550</ArticleId><ArticleId IdType="pubmed">34486705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Luo H., Li C., Liang Z. Evidence for the circulating microRNA hsa-let-7d-3p as a potential new biomarker for sepsis in human subjects. Eur J Med Res. 2022;27:137. doi: 10.1186/s40001-022-00763-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-022-00763-3</ArticleId><ArticleId IdType="pmc">PMC9338616</ArticleId><ArticleId IdType="pubmed">35907902</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., He Y., He X.-J., Bi M.-R., Qi Y.-H., Zhu W.-W. Down-regulation of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis. Exp. Mol. Pathol. 2020;117:104562. doi: 10.1016/j.yexmp.2020.104562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2020.104562</ArticleId><ArticleId IdType="pubmed">33129786</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Song J., Xie Z., Liu M., Sun K. Long noncoding RNA colorectal neoplasia differentially expressed alleviates sepsis-induced liver injury via regulating miR-126-5p. IUBMB Life. 2020;72:440&#x2013;451. doi: 10.1002/iub.2230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.2230</ArticleId><ArticleId IdType="pubmed">32031750</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Song D. LPS promotes the progression of sepsis by activation of lncRNA HULC/miR-204-5p/TRPM7 network in HUVECs. Biosci. Rep. 2020;40:BSR20200740. doi: 10.1042/BSR20200740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20200740</ArticleId><ArticleId IdType="pmc">PMC7295636</ArticleId><ArticleId IdType="pubmed">32484206</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S., Li Z., Ji P., Jia Y., Bai X., Cai W., Li X., Yang C., Yang Y., Yang K., et al. MCPIP1 alleviated lipopolysaccharide-induced liver injury by regulating SIRT1 via modulation of microRNA-9. J. Cell. Physiol. 2019;234:22450&#x2013;22462. doi: 10.1002/jcp.28809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28809</ArticleId><ArticleId IdType="pubmed">31099043</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese A., Bolino G., Mastracchio A., Frati P., Fineschi V. An immunohistochemical study of the diagnostic value of TREM-1 as marker for fatal sepsis cases. Biotech Histochem. 2019;94:159&#x2013;166. doi: 10.1080/10520295.2018.1535138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10520295.2018.1535138</ArticleId><ArticleId IdType="pubmed">30388897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G.-X., Pan J.-Y., Wang Y.-J., Huang T.-C., Li X.-F. MiR-640 inhibition alleviates acute liver injury via regulating WNT signaling pathway and LRP1. Eur. Rev. Med. Pharmacol. Sci. 2020;24:8988&#x2013;8996. doi: 10.26355/eurrev_202009_22841.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202009_22841</ArticleId><ArticleId IdType="pubmed">32964988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A., Gomez H., Kellum J.A. Sepsis-induced acute kidney injury revisited: Pathophysiology, prevention and future therapies. Curr. Opin. Crit. Care. 2014;20:588&#x2013;595. doi: 10.1097/MCC.0000000000000153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0000000000000153</ArticleId><ArticleId IdType="pmc">PMC4495653</ArticleId><ArticleId IdType="pubmed">25320909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla L.S., Bellomo R., Bihorac A., Goldstein S.L., Siew E.D., Bagshaw S.M., Bittleman D., Cruz D., Endre Z., Fitzgerald R.L., et al. Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 2017;13:241&#x2013;257. doi: 10.1038/nrneph.2017.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.2</ArticleId><ArticleId IdType="pubmed">28239173</ArticleId></ArticleIdList></Reference><Reference><Citation>Negi S., Koreeda D., Kobayashi S., Yano T., Tatsuta K., Mima T., Shigematsu T., Ohya M. Acute kidney injury: Epidemiology, outcomes, complications, and therapeutic strategies. Semin. Dial. 2018;31:519&#x2013;527. doi: 10.1111/sdi.12705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sdi.12705</ArticleId><ArticleId IdType="pubmed">29738093</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann M.C., Scherag A., Adhikari N.K.J., Hartog C.S., Tsaganos T., Schlattmann P., Angus D.C., Reinhart K., on behalf of International Forum of Acute Care Trialists Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am. J. Respir. Crit. Care Med. 2016;193:259&#x2013;272. doi: 10.1164/rccm.201504-0781OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201504-0781OC</ArticleId><ArticleId IdType="pubmed">26414292</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez H., Kellum J.A. Sepsis-induced acute kidney injury. Curr. Opin. Crit. Care. 2016;22:546&#x2013;553. doi: 10.1097/MCC.0000000000000356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0000000000000356</ArticleId><ArticleId IdType="pmc">PMC5654474</ArticleId><ArticleId IdType="pubmed">27661757</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H.-J. Signaling Danger: Toll-Like Receptors and their Potential Roles in Kidney Disease. J. Am. Soc. Nephrol. 2004;15:854&#x2013;867. doi: 10.1097/01.ASN.0000121781.89599.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000121781.89599.16</ArticleId><ArticleId IdType="pubmed">15034087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Akira S. Signaling to NF-&#x3ba;B by Toll-like receptors. Trends Mol. Med. 2007;13:460&#x2013;469. doi: 10.1016/j.molmed.2007.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2007.09.002</ArticleId><ArticleId IdType="pubmed">18029230</ArticleId></ArticleIdList></Reference><Reference><Citation>Petejova N., Martinek A., Zadrazil J., Kanova M., Klementa V., Sigutova R., Kacirova I., Hrabovsky V., Svagera Z., Stejskal D. Acute Kidney Injury in Septic Patients Treated by Selected Nephrotoxic Antibiotic Agents&#x2014;Pathophysiology and Biomarkers&#x2014;A Review. Int. J. Mol. Sci. 2020;21:7115. doi: 10.3390/ijms21197115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197115</ArticleId><ArticleId IdType="pmc">PMC7583998</ArticleId><ArticleId IdType="pubmed">32993185</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Bhatt K., He H.-Z., Mi Q.-S., Haase V.H., Dong Z. Targeted Deletion of Dicer from Proximal Tubules Protects against Renal Ischemia-Reperfusion Injury. J. Am. Soc. Nephrol. 2010;21:756&#x2013;761. doi: 10.1681/ASN.2009070718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2009070718</ArticleId><ArticleId IdType="pmc">PMC2865746</ArticleId><ArticleId IdType="pubmed">20360310</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G., Mo L., Wu C., Shen X., Dong H., Yu L., Pan P., Pan K. The miR-15a-5p-XIST-CUL3 regulatory axis is important for sepsis-induced acute kidney injury. Ren. Fail. 2019;41:955&#x2013;966. doi: 10.1080/0886022X.2019.1669460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2019.1669460</ArticleId><ArticleId IdType="pmc">PMC6830252</ArticleId><ArticleId IdType="pubmed">31658856</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu D., Dong J., Li P., Tang C., Cheng W., Xu Z., Zhou W., Ge J., Xia C., Zhang Z. MiRNA-21 has effects to protect kidney injury induced by sepsis. Biomed. Pharmacother. 2017;94:1138&#x2013;1144. doi: 10.1016/j.biopha.2017.07.098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.07.098</ArticleId><ArticleId IdType="pubmed">28821165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Yao Y.-Y., Bi H.-Y., Zhai Z., Gao Y. miR-21 protects against lipopolysaccharide-stimulated acute kidney injury and apoptosis by targeting CDK6. Ann. Transl. Med. 2020;8:303. doi: 10.21037/atm.2020.03.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2020.03.01</ArticleId><ArticleId IdType="pmc">PMC7186673</ArticleId><ArticleId IdType="pubmed">32355747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z., Liu Z., Wang X., Qiu C., Zheng S. MiR-21-3p Plays a Crucial Role in Metabolism Alteration of Renal Tubular Epithelial Cells during Sepsis Associated Acute Kidney Injury via AKT/CDK2-FOXO1 Pathway. BioMed Res. Int. 2019;2019:2821731. doi: 10.1155/2019/2821731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/2821731</ArticleId><ArticleId IdType="pmc">PMC6541977</ArticleId><ArticleId IdType="pubmed">31223614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Yao Y., Bi H., Xu W., Gao Y. Circular RNA circ_0068,888 protects against lipopolysaccharide-induced HK-2 cell injury via sponging microRNA-21&#x2013;5p. Biochem. Biophys. Res. Commun. 2021;540:1&#x2013;7. doi: 10.1016/j.bbrc.2020.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.12.018</ArticleId><ArticleId IdType="pubmed">33429194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z., Lin Q., Yang H., Liu Z., Zheng S. Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis. BioMed Res. Int. 2020;2020:2370253. doi: 10.1155/2020/2370253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/2370253</ArticleId><ArticleId IdType="pmc">PMC7453242</ArticleId><ArticleId IdType="pubmed">32923478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv K.-T., Liu Z., Feng J., Zhao W., Hao T., Ding W.-Y., Chu J.-P., Gao L.-J. MiR-22-3p Regulates Cell Proliferation and Inhibits Cell Apoptosis through Targeting the eIF4EBP3 Gene in Human Cervical Squamous Carcinoma Cells. Int. J. Med. Sci. 2018;15:142&#x2013;152. doi: 10.7150/ijms.21645.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.21645</ArticleId><ArticleId IdType="pmc">PMC5765727</ArticleId><ArticleId IdType="pubmed">29333098</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Yi L., Qu S., Dai J., Li X., Liu B., Li H., Ai K., Zheng P., Qiu S., et al. The Biomarker TCONS_00016233 Drives Septic AKI by Targeting the miR-22-3p/AIFM1 Signaling Axis. Mol. Ther. Nucleic Acids. 2020;19:1027&#x2013;1042. doi: 10.1016/j.omtn.2019.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.12.037</ArticleId><ArticleId IdType="pmc">PMC7016165</ArticleId><ArticleId IdType="pubmed">32059335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Wang Y., Kong M., Yang J. MiR-22-3p suppresses sepsis-induced acute kidney injury by targeting PTEN. Biosci. Rep. 2020;40:BSR20200527. doi: 10.1042/BSR20200527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20200527</ArticleId><ArticleId IdType="pmc">PMC7268257</ArticleId><ArticleId IdType="pubmed">32412059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J., Feng H., Peng Z. miR-23a-3p inhibits sepsis-induced kidney epithelial cell injury by suppressing Wnt/&#x3b2;-catenin signaling by targeting wnt5a. Braz. J. Med. Biol. Res. 2022;55:e11571. doi: 10.1590/1414-431x2021e11571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1414-431x2021e11571</ArticleId><ArticleId IdType="pmc">PMC8905671</ArticleId><ArticleId IdType="pubmed">35239776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhou X., Wu Y. The miR-26a-5p/IL-6 axis alleviates sepsis-induced acute kidney injury by inhibiting renal inflammation. Ren. Fail. 2022;44:551&#x2013;561. doi: 10.1080/0886022X.2022.2056486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2022.2056486</ArticleId><ArticleId IdType="pmc">PMC9067948</ArticleId><ArticleId IdType="pubmed">35491874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha Z., Yu Z. Downregulation of miR -29b-3p aggravates podocyte injury by targeting HDAC4 in LPS-induced acute kidney injury. Kaohsiung J. Med. Sci. 2021;37:1069&#x2013;1076. doi: 10.1002/kjm2.12431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12431</ArticleId><ArticleId IdType="pmc">PMC11896236</ArticleId><ArticleId IdType="pubmed">34369661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding G., An J., Li L. MicroRNA-103a-3p enhances sepsis-induced acute kidney injury via targeting CXCL12. Bioengineered. 2022;13:10288&#x2013;10298. doi: 10.1080/21655979.2022.2062195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2022.2062195</ArticleId><ArticleId IdType="pmc">PMC9278413</ArticleId><ArticleId IdType="pubmed">35510354</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Yu J., Jing Y., Zhang J. MiR-106a aggravates sepsis-induced acute kidney injury by targeting THBS2 in mice model. Acta Cir. Bras. 2019;34:e201900602. doi: 10.1590/s0102-865020190060000002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0102-865020190060000002</ArticleId><ArticleId IdType="pmc">PMC6705346</ArticleId><ArticleId IdType="pubmed">31432993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Zhang Z., Wang J., Miao H. MiR-107 induces TNF-&#x3b1; secretion in endothelial cells causing tubular cell injury in patients with septic acute kidney injury. Biochem. Biophys. Res. Commun. 2017;483:45&#x2013;51. doi: 10.1016/j.bbrc.2017.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.01.013</ArticleId><ArticleId IdType="pubmed">28063928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Wu H., Qian J., Sun L., Sang L., Wang P., Yuan B., Zhang J. The regulation of LPCAT3 by miR-124-3p.1 in acute kidney injury suppresses cell proliferation by disrupting phospholipid metabolism. Biochem. Biophys. Res. Commun. 2022;604:37&#x2013;42. doi: 10.1016/j.bbrc.2022.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.03.009</ArticleId><ArticleId IdType="pubmed">35286868</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Zhang Y., Xia Y., Li C., Song Z., Zhu J. MiR-150-5p protects against septic acute kidney injury via repressing the MEKK3/JNK pathway. Cell. Signal. 2021;86:110101. doi: 10.1016/j.cellsig.2021.110101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2021.110101</ArticleId><ArticleId IdType="pubmed">34333083</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Luo F., Liu X., Lu L., Xu H., Yang Q., Xue J., Shi L., Li J., Zhang A., et al. NF-kB-regulated exosomal miR-155 promotes the inflammation associated with arsenite carcinogenesis. Cancer Lett. 2017;388:21&#x2013;33. doi: 10.1016/j.canlet.2016.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2016.11.027</ArticleId><ArticleId IdType="pubmed">27913196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y., Cui Y., Xiong X., Wang C., Zhang Y. Inhibition of microRNA-155 alleviates lipopolysaccharide-induced kidney injury in mice. Int. J. Clin. Exp. Pathol. 2017;10:9362&#x2013;9371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965969</ArticleId><ArticleId IdType="pubmed">31966808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Ding Y., Song S., Li M., Wang T., Guo F. Expression patterns and prognostic value of miR-210, miR-494, and miR-205 in middle-aged and old patients with sepsis-induced acute kidney injury. Bosn. J. Basic Med. Sci. 2019;19:249&#x2013;256. doi: 10.17305/bjbms.2019.4131.</Citation><ArticleIdList><ArticleId IdType="doi">10.17305/bjbms.2019.4131</ArticleId><ArticleId IdType="pmc">PMC6716103</ArticleId><ArticleId IdType="pubmed">30997877</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang Z., Dong S., Zhang P., Wei Y. miR-214 ameliorates sepsis-induced acute kidney injury via PTEN/AKT/mTOR-regulated autophagy. Mol. Med. Rep. 2021;24:683. doi: 10.3892/mmr.2021.12322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2021.12322</ArticleId><ArticleId IdType="pmc">PMC8365606</ArticleId><ArticleId IdType="pubmed">34328194</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C., Ye F., Jian Y., Liu C., Tu Z., Yang D. MicroRNA -214-5p aggravates sepsis-related acute kidney injury in mice. Drug Dev. Res. 2022;83:339&#x2013;350. doi: 10.1002/ddr.21863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21863</ArticleId><ArticleId IdType="pubmed">34370322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Chen Q., Dai Z., Pan H. miR-22 alleviates sepsis-induced acute kidney injury via targeting the HMGB1/TLR4/NF-&#x3ba;B signaling pathway. Int Urol Nephrol. 2022 doi: 10.1007/s11255-022-03321-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-022-03321-2</ArticleId><ArticleId IdType="pmc">PMC9859886</ArticleId><ArticleId IdType="pubmed">35960478</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y., Han Y., Chen C., Xue Y., Jiao N., Li X. Inhibition of microRNA-665 Alleviates Septic Acute Kidney Injury by Targeting Bcl-2. J. Healthc. Eng. 2022;2022:2961187. doi: 10.1155/2022/2961187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/2961187</ArticleId><ArticleId IdType="pmc">PMC8913057</ArticleId><ArticleId IdType="pubmed">35281537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Q.-M., Huang C.-M., Zhu X.-Y., Bian F., Pan S.-M. Differentially expressed miRNAs in sepsis-induced acute kidney injury target oxidative stress and mitochondrial dysfunction pathways. PLoS ONE. 2017;12:e0173292. doi: 10.1371/journal.pone.0173292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0173292</ArticleId><ArticleId IdType="pmc">PMC5351858</ArticleId><ArticleId IdType="pubmed">28296904</ArticleId></ArticleIdList></Reference><Reference><Citation>Caserta S., Kern F., Cohen J., Drage S., Newbury S.F., Llewelyn M. Circulating Plasma microRNAs can differentiate Human Sepsis and Systemic Inflammatory Response Syndrome (SIRS) Sci. Rep. 2016;6:28006. doi: 10.1038/srep28006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28006</ArticleId><ArticleId IdType="pmc">PMC4913253</ArticleId><ArticleId IdType="pubmed">27320175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y.-F., Wen D., Zhao Q., Shen P.-Y., Shi H., Chen Y.-X., Zhang W. Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia&#x2013;reperfusion-induced kidney injury. Exp. Biol. Med. 2017;242:657&#x2013;667. doi: 10.1177/1535370216685005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370216685005</ArticleId><ArticleId IdType="pmc">PMC5685255</ArticleId><ArticleId IdType="pubmed">28056546</ArticleId></ArticleIdList></Reference><Reference><Citation>Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010;11:597&#x2013;610. doi: 10.1038/nrg2843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2843</ArticleId><ArticleId IdType="pubmed">20661255</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S., Tapmeier T.T., Rahmioglu N., Kirtley S., Zondervan K.T., Becker C.M. The miRNA Mirage: How Close Are We to Finding a Non-Invasive Diagnostic Biomarker in Endometriosis? A Systematic Review. Int. J. Mol. Sci. 2018;19:599. doi: 10.3390/ijms19020599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19020599</ArticleId><ArticleId IdType="pmc">PMC5855821</ArticleId><ArticleId IdType="pubmed">29463003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav K.B., Nagraj S.K., Arora S. miRNA for the assessment of lymph node metastasis in patients with oral squamous cell carcinoma: Systematic review and metanalysis. J. Oral Pathol. Med. 2021;50:345&#x2013;352. doi: 10.1111/jop.13134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jop.13134</ArticleId><ArticleId IdType="pubmed">33220092</ArticleId></ArticleIdList></Reference><Reference><Citation>Leo C.G., Mincarone P., Tumolo M.R., Panico A., Guido M., Zizza A., Guarino R., De Santis G., Sedile R., Sabina S. MiRNA expression profiling in HIV pathogenesis, disease progression and response to treatment: A systematic review. Epigenomics. 2021;13:1653&#x2013;1671. doi: 10.2217/epi-2021-0237.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/epi-2021-0237</ArticleId><ArticleId IdType="pubmed">34693727</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarbrick S., Wragg N., Ghosh S., Stolzing A. Systematic Review of miRNA as Biomarkers in Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2019;56:6156&#x2013;6167. doi: 10.1007/s12035-019-1500-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1500-y</ArticleId><ArticleId IdType="pmc">PMC6682547</ArticleId><ArticleId IdType="pubmed">30734227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong S., Golpon H., Zardo P., Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl. Res. 2021;230:164&#x2013;196. doi: 10.1016/j.trsl.2020.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.11.012</ArticleId><ArticleId IdType="pubmed">33253979</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques-Rocha J.L., Samblas-Garc&#xed;a M., Milagro F.I., Bressan J., Mart&#xed;nez J.A., Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 2015;29:3595&#x2013;3611. doi: 10.1096/fj.14-260323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-260323</ArticleId><ArticleId IdType="pubmed">26065857</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahamtan A., Teymoori-Rad M., Nakstad B., Salimi V. Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment. Front. Immunol. 2018;9:1377. doi: 10.3389/fimmu.2018.01377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01377</ArticleId><ArticleId IdType="pmc">PMC6026627</ArticleId><ArticleId IdType="pubmed">29988529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wang L., Chen C., Chu X. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol. Cancer. 2018;17:22. doi: 10.1186/s12943-018-0766-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0766-4</ArticleId><ArticleId IdType="pmc">PMC5804051</ArticleId><ArticleId IdType="pubmed">29415727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi M.E., Crippa M.P., Manfredi A.A., Mezzapelle R., Querini P.R., Venereau E. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol. Rev. 2017;280:74&#x2013;82. doi: 10.1111/imr.12601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12601</ArticleId><ArticleId IdType="pubmed">29027228</ArticleId></ArticleIdList></Reference><Reference><Citation>Tak P.P., Firestein G.S. NF-&#x3ba;B: A key role in inflammatory diseases. J. Clin. Investig. 2001;107:7&#x2013;11. doi: 10.1172/JCI11830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI11830</ArticleId><ArticleId IdType="pmc">PMC198552</ArticleId><ArticleId IdType="pubmed">11134171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura A., Suzuki M., Sakaguchi R., Hanada T., Yasukawa H. SOCS, Inflammation, and Autoimmunity. Front. Immunol. 2012;3:20. doi: 10.3389/fimmu.2012.00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00020</ArticleId><ArticleId IdType="pmc">PMC3342034</ArticleId><ArticleId IdType="pubmed">22566904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.B., Coon T.A., Glasser J.R., McVerry B.J., Zhao J., Zhao Y., Zou C., Ellis B., Sciurba F.C., Zhang Y., et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat. Immunol. 2013;14:470&#x2013;479. doi: 10.1038/ni.2565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2565</ArticleId><ArticleId IdType="pmc">PMC3631463</ArticleId><ArticleId IdType="pubmed">23542741</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel L., Pass I., Coxon P., Downes C., Smith S.A., Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPAR&#x3b3; agonists are mediated via upregulation of PTEN. Curr. Biol. 2001;11:764&#x2013;768. doi: 10.1016/S0960-9822(01)00225-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(01)00225-1</ArticleId><ArticleId IdType="pubmed">11378386</ArticleId></ArticleIdList></Reference><Reference><Citation>Karar J., Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front. Mol. Neurosci. 2011;4:51. doi: 10.3389/fnmol.2011.00051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2011.00051</ArticleId><ArticleId IdType="pmc">PMC3228996</ArticleId><ArticleId IdType="pubmed">22144946</ArticleId></ArticleIdList></Reference><Reference><Citation>Seminerio I., Descamps G., Dupont S., de Marrez L., Laigle J.-A., Lechien J.R., Kindt N., Journe F., Saussez S. Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Cancers. 2019;11:227. doi: 10.3390/cancers11020227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11020227</ArticleId><ArticleId IdType="pmc">PMC6406934</ArticleId><ArticleId IdType="pubmed">30781400</ArticleId></ArticleIdList></Reference><Reference><Citation>de Moraes G.N., Carneiro L.D.T., Maia R.C., Lam E.W.-F., Sharrocks A.D. FOXK2 Transcription Factor and Its Emerging Roles in Cancer. Cancers. 2019;11:393. doi: 10.3390/cancers11030393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11030393</ArticleId><ArticleId IdType="pmc">PMC6468357</ArticleId><ArticleId IdType="pubmed">30897782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurnari C., Falconi G., De Bellis E., Voso M.T., Fabiani E. The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. Cancers. 2019;11:865. doi: 10.3390/cancers11060865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11060865</ArticleId><ArticleId IdType="pmc">PMC6627614</ArticleId><ArticleId IdType="pubmed">31234353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair D., Guarente L. Unlocking the Secrets of Longevity Genes. Sci. Am. 2006;294:48&#x2013;51, 54&#x2013;57. doi: 10.1038/scientificamerican0306-48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/scientificamerican0306-48</ArticleId><ArticleId IdType="pubmed">16502611</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy D.E., Lee C.-K. What does Stat3 do? J. Clin. Investig. 2002;109:1143&#x2013;1148. doi: 10.1172/JCI0215650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0215650</ArticleId><ArticleId IdType="pmc">PMC150972</ArticleId><ArticleId IdType="pubmed">11994402</ArticleId></ArticleIdList></Reference><Reference><Citation>Condrat C.E., Thompson D.C., Barbu M.G., Bugnar O.L., Boboc A., Cretoiu D., Suciu N., Cretoiu S.M., Voinea S.C. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020;9:276. doi: 10.3390/cells9020276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020276</ArticleId><ArticleId IdType="pmc">PMC7072450</ArticleId><ArticleId IdType="pubmed">31979244</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano M., Trotta M.C., Ciarambino T., D&#x2019;Amico M., Schettini F., Di Sisto A., D&#x2019;Auria V., Voza A., Malatino L.S., Biolo G., et al. Circulating miRNA-195-5p and -451a in Patients with Acute Hemorrhagic Stroke in Emergency Department. Life. 2022;12:763. doi: 10.3390/life12050763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12050763</ArticleId><ArticleId IdType="pmc">PMC9146117</ArticleId><ArticleId IdType="pubmed">35629429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tribolet L., Kerr E., Cowled C., Bean A.G.D., Stewart C.R., Dearnley M., Farr R.J. MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing. Front. Microbiol. 2020;11:1197. doi: 10.3389/fmicb.2020.01197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01197</ArticleId><ArticleId IdType="pmc">PMC7286131</ArticleId><ArticleId IdType="pubmed">32582115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37268222</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0641</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of hepatology</Title><ISOAbbreviation>J Hepatol</ISOAbbreviation></Journal><ArticleTitle>Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>92</EndPage><MedlinePgn>79-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2023.03.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-8278(23)00188-5</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">Acute-on-chronic liver failure (ACLF) is characterized by severe systemic inflammation, multi-organ failure and high mortality rates. Its treatment is an urgent unmet need. DIALIVE is a novel liver dialysis device that aims to exchange dysfunctional albumin and remove damage- and pathogen-associated molecular patterns. This first-in-man randomized-controlled trial was performed with the primary aim of assessing the safety of DIALIVE in patients with ACLF, with secondary aims of evaluating its clinical effects, device performance and effect on pathophysiologically relevant biomarkers.</AbstractText><AbstractText Label="METHODS">Thirty-two patients with alcohol-related ACLF were included. Patients were treated with DIALIVE for up to 5 days and end points were assessed at Day 10. Safety was assessed in all patients (n&#xa0;= 32). The secondary aims were assessed in a pre-specified subgroup that had at least three treatment sessions with DIALIVE (n&#xa0;= 30).</AbstractText><AbstractText Label="RESULTS">There were no significant differences in 28-day mortality or occurrence of serious adverse events between the groups. Significant reduction in the severity of endotoxemia and improvement in albumin function was observed in the DIALIVE group, which translated into a significant reduction in the CLIF-C (Chronic Liver Failure consortium) organ failure (p&#xa0;= 0.018) and CLIF-C ACLF scores (p&#xa0;= 0.042) at Day 10. Time to resolution of ACLF was significantly faster in DIALIVE group (p&#xa0;= 0.036). Biomarkers of systemic inflammation such as IL-8 (p&#xa0;= 0.006), cell death [cytokeratin-18: M30 (p&#xa0;= 0.005) and M65 (p&#xa0;= 0.029)], endothelial function [asymmetric dimethylarginine (p&#xa0;= 0.002)] and, ligands for Toll-like receptor 4 (p&#xa0;= 0.030) and inflammasome (p&#xa0;= 0.002) improved significantly in the DIALIVE group.</AbstractText><AbstractText Label="CONCLUSIONS">These data indicate that DIALIVE appears to be safe and impacts positively on prognostic scores and pathophysiologically relevant biomarkers in patients with ACLF. Larger, adequately powered studies are warranted to further confirm its safety and efficacy.</AbstractText><AbstractText Label="IMPACT AND IMPLICATIONS">This is the first-in-man clinical trial which tested DIALIVE, a novel liver dialysis device for the treatment of cirrhosis and acute-on-chronic liver failure, a condition associated with severe inflammation, organ failures and a high risk of death. The study met the primary endpoint, confirming the safety of the DIALIVE system. Additionally, DIALIVE reduced inflammation and improved clinical parameters. However, it did not reduce mortality in this small study and further larger clinical trials are required to re-confirm its safety and to evaluate efficacy.</AbstractText><AbstractText Label="CLINICAL TRIAL NUMBER">NCT03065699.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Banwari</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Royal Free Hospital, London, UK; Institute for Liver &amp; Digestive Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;izares</LastName><ForeName>Rafael Ba&#xf1;ares</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Gregorio Mara&#xf1;&#xf3;n General University Hospital, Spain; Health Research Institute Gregorio Mara&#xf1;&#xf3;n, Department of Medicine Complutense University of Madrid, Spain; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saliba</LastName><ForeName>Faouzi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AP-HP H&#xf4;pital Paul Brousse, Centre H&#xe9;pato-Biliaire, INSERM unit N&#xb0; 1193, Universit&#xe9; Paris-Saclay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballester</LastName><ForeName>Maria Pilar</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>INCLIVA Biomedical Research Institute, Hospital Cl&#xed;nico Universitario de Valencia, Spain; Digestive Disease Department, Hospital Cl&#xed;nico Universitario de Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomescu</LastName><ForeName>Dana Rodica</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Carol Davila University of Medicine and Pharmacy, Romania; Fundeni Clinical Institute Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Peninsula Medical School, University of Plymouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadlbauer</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology und Hepatology, Medical University of Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Basildon and Thurrock University Hospital, Mid and South Essex NHS Foundation Trust, Basildon, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Liver &amp; Digestive Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Carrie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Yaqrit Ltd, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzola</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Etera Solutions, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavin</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Boston Biostatistics Research Foundation, Inc, Framingham MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Yaqrit Ltd, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Changi General Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacleux</LastName><ForeName>Sophie Caroline</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>AP-HP H&#xf4;pital Paul Brousse, Centre H&#xe9;pato-Biliaire, INSERM unit N&#xb0; 1193, Universit&#xe9; Paris-Saclay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilcher</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology und Hepatology, Medical University of Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koball</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Hospital Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tudor</LastName><ForeName>Andrada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundeni Clinical Institute Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minten</LastName><ForeName>Jaak</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>FAKKEL-bvba, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domenech</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Statistics Core Facility IDIBAPS - Hospital Clinic, Barcelona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aragones</LastName><ForeName>Juan Jose</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Medical Statistics Core Facility IDIBAPS - Hospital Clinic, Barcelona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oettl</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paar</LastName><ForeName>Margret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterstradt</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MedInnovation GmbH, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bode-Boger</LastName><ForeName>Stefanie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Klinische Pharmakologie Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ib&#xe1;&#xf1;ez-Samaniego</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Gregorio Mara&#xf1;&#xf3;n General University Hospital, Spain; Health Research Institute Gregorio Mara&#xf1;&#xf3;n, Department of Medicine Complutense University of Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gander</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tissue Access for Patient Benefit, Royal Free Hospital, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chivu</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stange</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Hospital Rostock, Germany; Fraunhofer IZI, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamprecht</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University, Medical Center, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Moises</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IBM, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mookerjee</LastName><ForeName>Rajeshwar P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Institute for Liver &amp; Digestive Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Liver &amp; Digestive Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Liver &amp; Digestive Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavesi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreola</LastName><ForeName>Fausto</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Liver &amp; Digestive Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albillos</LastName><ForeName>Agustin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Department of Gastroenterology and Hepatology, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Spain; Universidad de Alcal&#xe1;, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordingley</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Perioperative Medicine - Critical Care, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Transplant Medicine, University Hospital Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbonell-Asins</LastName><ForeName>Juan Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>INCLIVA Biomedical Research Institute, Hospital Cl&#xed;nico Universitario de Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroyo</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Liver ICU, Liver Unit, Hospital Clinic Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitzner</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fraunhofer IZI, Germany; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University, Medical Center, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalan</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Liver &amp; Digestive Health, University College London, London, UK; European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, USA. Electronic address: r.jalan@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03065699</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Hepatol</MedlineTA><NlmUniqueID>8503886</NlmUniqueID><ISSNLinking>0168-8278</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065290" MajorTopicYN="Y">Acute-On-Chronic Liver Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058625" MajorTopicYN="Y">End Stage Liver Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059039" MajorTopicYN="N">Standard of Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albumin</Keyword><Keyword MajorTopicYN="N">DIALIVE</Keyword><Keyword MajorTopicYN="N">acute-on-chronic liver failure</Keyword><Keyword MajorTopicYN="N">extracorporeal liver dialysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>3</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37268222</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2023.03.013</ArticleId><ArticleId IdType="pii">S0168-8278(23)00188-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31748953</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8726</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>World journal of urology</Title><ISOAbbreviation>World J Urol</ISOAbbreviation></Journal><ArticleTitle>Complications of ureteroscopy: a complete overview.</ArticleTitle><Pagination><StartPage>2147</StartPage><EndPage>2166</EndPage><MedlinePgn>2147-2166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-019-03012-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this paper was to give a complete overview of all published complications associated with ureteroscopy and their according management and prevention in current urological practice.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This review was registered in PROSPERO with registration number CRD42018116273. A bibliographic search of the Medline, Scopus, Embase and Web of Science databases was performed by two authors (V.D.C. and E.X.K.). According to the Population, Intervention, Comparator, Outcome (PICO) study design approach and Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) standards, a consensus between these authors was found relating to the thematic structure of this review.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ureteral stent discomfort, ureteral wall injury and stone migration are the most frequently reported complications. The worst complications include urosepsis, multi-organ failure and death. Incidence rates on these and other complications varied&#xa0;extensively between the reviewed reports.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Ureteroscopy seems to be associated with more complications than currently reported.&#xa0;The present overview may help urologists to prevent, recognize and solve complications of ureteroscopy. It may also stimulate colleagues to perform prospective studies using standardized systems for classifying complications. These are warranted to compare results among different studies, to conduct meta-analyses, to inform health care workers and to counsel patients correctly about possible risks of ureteroscopy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Coninck</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Service d'Urologie, Assistance-Publique H&#xf4;pitaux de Paris, H&#xf4;pital Tenon, 4 rue de la Chine, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Groupe de Recherche Clinique Sur La Lithiase Urinaire, Sorbonne Universit&#xe9;, GRC n&#xb0;20, H&#xf4;pital Tenon, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, AZ Klina, Brasschaat, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Etienne Xavier</ForeName><Initials>EX</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Service d'Urologie, Assistance-Publique H&#xf4;pitaux de Paris, H&#xf4;pital Tenon, 4 rue de la Chine, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Groupe de Recherche Clinique Sur La Lithiase Urinaire, Sorbonne Universit&#xe9;, GRC n&#xb0;20, H&#xf4;pital Tenon, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somani</LastName><ForeName>Bhaskar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospital Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giusti</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, IRCCS San Raffaele Hospital, Ville Turro Division, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proietti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, IRCCS San Raffaele Hospital, Ville Turro Division, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Socarras</LastName><ForeName>Moises</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ICUA (Instituto de Cirugia Urologica Avazada), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Monsalve</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Urolog&#xed;a, Puerta de Hierro University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doizi</LastName><ForeName>Steeve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Service d'Urologie, Assistance-Publique H&#xf4;pitaux de Paris, H&#xf4;pital Tenon, 4 rue de la Chine, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Groupe de Recherche Clinique Sur La Lithiase Urinaire, Sorbonne Universit&#xe9;, GRC n&#xb0;20, H&#xf4;pital Tenon, 75020, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ventimiglia</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Service d'Urologie, Assistance-Publique H&#xf4;pitaux de Paris, H&#xf4;pital Tenon, 4 rue de la Chine, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Groupe de Recherche Clinique Sur La Lithiase Urinaire, Sorbonne Universit&#xe9;, GRC n&#xb0;20, H&#xf4;pital Tenon, 75020, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traxer</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Service d'Urologie, Assistance-Publique H&#xf4;pitaux de Paris, H&#xf4;pital Tenon, 4 rue de la Chine, 75020, Paris, France. olivier.traxer@aphp.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Groupe de Recherche Clinique Sur La Lithiase Urinaire, Sorbonne Universit&#xe9;, GRC n&#xb0;20, H&#xf4;pital Tenon, 75020, Paris, France. olivier.traxer@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>World J Urol</MedlineTA><NlmUniqueID>8307716</NlmUniqueID><ISSNLinking>0724-4983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018666" MajorTopicYN="N">Ureteroscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Nephrolithiasis</Keyword><Keyword MajorTopicYN="N">Overview</Keyword><Keyword MajorTopicYN="N">Retrograde intrarenal surgery</Keyword><Keyword MajorTopicYN="N">Ureteroscopy</Keyword><Keyword MajorTopicYN="N">Urolithiasis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31748953</ArticleId><ArticleId IdType="doi">10.1007/s00345-019-03012-1</ArticleId><ArticleId IdType="pii">10.1007/s00345-019-03012-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35969260</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10-11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>Review: the role of GSDMD in sepsis.</ArticleTitle><Pagination><StartPage>1191</StartPage><EndPage>1202</EndPage><MedlinePgn>1191-1202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-022-01624-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Gasdermin D (GSDMD) is a cytoplasmic protein that is encoded by the gasdermin family GSDMD gene and is the ultimate executor of pyroptosis. Pyroptosis is a mode of lysis and inflammation that regulates cell death, ultimately leading to cell swelling and rupture. In sepsis, a dysregulated host response to infection frequently results in hyperinflammatory responses and immunosuppression, eventually leading to multiple organ dysfunction. Pyroptosis regulates innate immune defenses and plays an important role in the process of inflammatory cell death, and the absence of any link in the entire pathway from GSDMD to pyroptosis causes bacterial clearance to be hampered. Under normal conditions, the process of pyroptosis occurs much faster than apoptosis, and the threat to the body is also much greater.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted a systematic review of relevant reviews and experimental articles using the keywords sepsis, Gasdermin D, and Pyroptosis in the PubMed, Scopus, Google Scholar, and Web of Science databases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Combined with the pathogenesis of sepsis, it is not difficult to find that pyroptosis plays a key role in bacterial inflammation and sepsis. Therefore, GSDMD inhibitors may be used as targeted drugs to treat sepsis by reducing the occurrence of pyroptosis. This review mainly discusses the key role of GSDMD in sepsis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Ruifei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Xiran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jinfang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Deyuan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical School, Kunming University of Science and Technology, Kunming, 650500, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guobing</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, The First People's Hospital of Yunnan Province, Xishan District, No 157 Jinbi Road, Kunming, 650032, China. rocktom38chen@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First People' Hospital of Yunnan Province, Xishan District, No 157 Jinbi Road, Kunming, 650032, People's Republic of China. jlh15198763375@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021LCZXXF-HX03</GrantID><Agency>Yunnan Clinical Medical Center Open Project</Agency><Country/></Grant><Grant><GrantID>No. 82160366</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>202105AG070032</GrantID><Agency>Yunnan Key Laboratory of Traditional Chinese Medicine Transformation and Application</Agency><Country/></Grant><Grant><GrantID>No. 81960068</GrantID><Agency>National Natural Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028044">Phosphate-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498366">GSDMD protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028044" MajorTopicYN="N">Phosphate-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="Y">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gasdermin D</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Pyroptosis</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. The authors declared that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>15</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35969260</ArticleId><ArticleId IdType="pmc">PMC9376580</ArticleId><ArticleId IdType="doi">10.1007/s00011-022-01624-9</ArticleId><ArticleId IdType="pii">10.1007/s00011-022-01624-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM. The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315(8):775&#x2013;787. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney PJ. Sepsis and septic shock. Emergency medicine clinics of North America. Lancet. 2018;392(10141):75&#x2013;87. doi: 10.1016/S0140-6736(18)30696-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30696-2</ArticleId><ArticleId IdType="pubmed">23915595</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz AC, Nawaratne U, Mcmann D, Ellsworth M, Boukas K. Late-onset neonatal sepsis in a patient with covid-19. N Engl J Med. 2020;382(19):e49. doi: 10.1056/NEJMc2010614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2010614</ArticleId><ArticleId IdType="pmc">PMC7207075</ArticleId><ArticleId IdType="pubmed">32320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson S, Varpula M, Ruokonen E, Pettil V, Parviainen I, Ala-Kokko TI, Kolho E, Rintala EM. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33(3):435&#x2013;443. doi: 10.1007/s00134-006-0504-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0504-z</ArticleId><ArticleId IdType="pubmed">17225161</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Reinhart K. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259&#x2013;272. doi: 10.1164/rccm.201504-0781OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201504-0781OC</ArticleId><ArticleId IdType="pubmed">26414292</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkey AJ, Kirkpatrick AR, Summer RS. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;373(9):1629&#x2013;1638. doi: 10.1056/NEJMoa1415236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1415236</ArticleId><ArticleId IdType="pubmed">26308695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob JA. New sepsis diagnostic guidelines shift focus to organ dysfunction. JAMA. 2016;315(8):739. doi: 10.1001/jama.2016.0736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0736</ArticleId><ArticleId IdType="pubmed">26903319</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Luo R, Li J, Wang S, Ding J, Zhao K, Lu B, Zhou W. Intrinsic radical species scavenging activities of tea polyphenols nanoparticles block pyroptosis in endotoxin-induced sepsis. ACS Nano. 2022;16(2):2429&#x2013;2441. doi: 10.1021/acsnano.1c08913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c08913</ArticleId><ArticleId IdType="pubmed">35133795</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao E, Leaf I, Treuting P, Mao D, Sarkar A, Wewers M, Aderem A. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11(12):1136&#x2013;1142. doi: 10.1038/ni.1960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1960</ArticleId><ArticleId IdType="pmc">PMC3058225</ArticleId><ArticleId IdType="pubmed">21057511</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Chen W, Gong F, Chen Y, Chen E. The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: a review. Front Immunol. 2021;12:711939. doi: 10.3389/fimmu.2021.711939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.711939</ArticleId><ArticleId IdType="pmc">PMC8293747</ArticleId><ArticleId IdType="pubmed">34305952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526(7575):666&#x2013;671. doi: 10.1038/nature15541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15541</ArticleId><ArticleId IdType="pubmed">26375259</ArticleId></ArticleIdList></Reference><Reference><Citation>He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, Yang ZH. Gasdermin D is an executor of pyroptosis and required for interleukin-1&#x3b2; secretion. Cell Res. 2015;25(12):1285&#x2013;1298. doi: 10.1038/cr.2015.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2015.139</ArticleId><ArticleId IdType="pmc">PMC4670995</ArticleId><ArticleId IdType="pubmed">26611636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jianjin S, Yue Z, Kun W, Xuyan S, Yue W, Huanwei H, Yinghua Z, Tao C, Fengchao W, Feng S. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660&#x2013;665. doi: 10.1038/nature15514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15514</ArticleId><ArticleId IdType="pubmed">26375003</ArticleId></ArticleIdList></Reference><Reference><Citation>Cierra N, Casson J, Yu V, Reyes M, Frances O. Human caspase-4 mediates noncanonical inflammasome activation against gram-negative bacterial pathogens. Proc Natl Acad Sci USA. 2015;112(21):6688&#x2013;6693. doi: 10.1073/pnas.1421699112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1421699112</ArticleId><ArticleId IdType="pmc">PMC4450384</ArticleId><ArticleId IdType="pubmed">25964352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science. 2013;341(6151):1250&#x2013;1253. doi: 10.1126/science.1240988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1240988</ArticleId><ArticleId IdType="pmc">PMC3931427</ArticleId><ArticleId IdType="pubmed">24031018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature. 1992;358(6382):167&#x2013;169. doi: 10.1038/358167a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/358167a0</ArticleId><ArticleId IdType="pubmed">1614548</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan MA, Cookson BT. Salmonella induces macrophage death by caspase-1-dependent necrosis. Molecular Microbiology Mol Microbiol. 2000;38(1):31&#x2013;40. doi: 10.1046/j.1365-2958.2000.02103.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2958.2000.02103.x</ArticleId><ArticleId IdType="pubmed">11029688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113&#x2013;114. doi: 10.1016/s0966-842x(00)01936-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0966-842x(00)01936-3</ArticleId><ArticleId IdType="pubmed">11303500</ArticleId></ArticleIdList></Reference><Reference><Citation>Muendlein HI, David J, Connolly WM, Eidell KP, Zoie M, Irina S, Alexander P. cFLIPL protects macrophages from LPS-induced pyroptosis via inhibition of complex II formation. Science. 2020;367(6484):1379&#x2013;1384. doi: 10.1126/science.aay3878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay3878</ArticleId><ArticleId IdType="pmc">PMC7375259</ArticleId><ArticleId IdType="pubmed">32193329</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Zeng L, Zhu S, Liu J, Kang R. cAMP metabolism controls caspase-11 inflammasome activation and pyroptosis in sepsis. Sci Adv. 2019 doi: 10.1126/sciadv.aav5562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aav5562</ArticleId><ArticleId IdType="pmc">PMC6531004</ArticleId><ArticleId IdType="pubmed">31131320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori Y, Takano KI, Teramae H, Yamamoto S, Yokoo H, Matsuda N. Insights into sepsis therapeutic design based on the apoptotic death pathway. J Pharmacol Sci. 2010;114(4):354&#x2013;365. doi: 10.1254/jphs.10r04cr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.10r04cr</ArticleId><ArticleId IdType="pubmed">21081836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang R, Ling Z, Shan Z, Xie Y, Liu J, Wen Q, Cao L, Min X, Ran Q, Guido K. Lipid peroxidation drives gasdermin d-mediated pyroptosis in lethal polymicrobial sepsis. Cell Host Microbe. 2018;24(1):97&#x2013;108.e4. doi: 10.1016/j.chom.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.05.009</ArticleId><ArticleId IdType="pmc">PMC6043361</ArticleId><ArticleId IdType="pubmed">29937272</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Wang Y, Ding J, Wang C, Liu Z. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421&#x2013;426. doi: 10.1038/s41586-020-2079-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2079-1</ArticleId><ArticleId IdType="pubmed">32188939</ArticleId></ArticleIdList></Reference><Reference><Citation>Melanie F, G&#xfc;nther S, Robin S, Marie-Christine A, Fabian S, Paul WJ, Schiffmann LM, Neil S, Hannah S, Seeger JM. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683&#x2013;687. doi: 10.1038/s41586-019-1770-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1770-6</ArticleId><ArticleId IdType="pubmed">31748744</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Kroemer G. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25(3):486&#x2013;541. doi: 10.1038/s41418-017-0012-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-017-0012-4</ArticleId><ArticleId IdType="pmc">PMC5864239</ArticleId><ArticleId IdType="pubmed">29362479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Yang T, Xiao J, Xu C, Alippe Y, Sun K, Kanneganti T, Monahan J, Abu-Amer Y, Lieberman J, Mbalaviele G. NLRP3 inflammasome activation triggers gasdermin D-independent inflammation. Sci Immunol. 2021 doi: 10.1126/sciimmunol.abj3859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj3859</ArticleId><ArticleId IdType="pmc">PMC8780201</ArticleId><ArticleId IdType="pubmed">34678046</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Zhao Y, Wang Y, Gao W, Ding J, Peng L, Hu L, Shao F. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. 2014;514(7521):187&#x2013;192. doi: 10.1038/nature13683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13683</ArticleId><ArticleId IdType="pubmed">25119034</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S. Gasdermins: making pores for pyroptosis. Nat Rev Immunol. 2021;21(10):620&#x2013;621. doi: 10.1038/s41577-021-00602-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00602-2</ArticleId><ArticleId IdType="pubmed">34580452</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Zhang Z, Magupalli VG, Pablo JL, Wu H. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature. 2021;593(7860):607&#x2013;611. doi: 10.1038/s41586-021-03478-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03478-3</ArticleId><ArticleId IdType="pmc">PMC8588876</ArticleId><ArticleId IdType="pubmed">33883744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YL, Zhai JH, Chai YF. Recent advances in the molecular mechanisms underlying pyroptosis in sepsis. Mediators Inflamm. 2018;2018:5823823. doi: 10.1155/2018/5823823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5823823</ArticleId><ArticleId IdType="pmc">PMC5863298</ArticleId><ArticleId IdType="pubmed">29706799</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Kanneganti T. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19(4):197&#x2013;214. doi: 10.1038/s41568-019-0123-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-019-0123-y</ArticleId><ArticleId IdType="pmc">PMC6953422</ArticleId><ArticleId IdType="pubmed">30842595</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417&#x2013;426. doi: 10.1016/s1097-2765(02)00599-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1097-2765(02)00599-3</ArticleId><ArticleId IdType="pubmed">12191486</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Alnemri T, Yu J, Datta P, Wu J, Alnemri E. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458(7237):509&#x2013;513. doi: 10.1038/nature07710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07710</ArticleId><ArticleId IdType="pmc">PMC2862225</ArticleId><ArticleId IdType="pubmed">19158676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey D, Latz E, Fitzgerald K. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458(7237):514&#x2013;518. doi: 10.1038/nature07725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07725</ArticleId><ArticleId IdType="pmc">PMC2726264</ArticleId><ArticleId IdType="pubmed">19158675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Shao F. SnapShot: The noncanonical inflammasome. Cell. 2017;168(3):544&#x2013;544. doi: 10.1016/j.cell.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.01.008</ArticleId><ArticleId IdType="pubmed">28129545</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh M, Katoh M. Identification and characterization of human DFNA5L, mouse Dfna5l, and rat Dfna5l genes in silico. Int J Oncol. 2004;25(3):765&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289881</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang Z, Ruan J, Pan Y, Magupalli V, Wu H, Lieberman J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535(7610):153&#x2013;158. doi: 10.1038/nature18629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18629</ArticleId><ArticleId IdType="pmc">PMC5539988</ArticleId><ArticleId IdType="pubmed">27383986</ArticleId></ArticleIdList></Reference><Reference><Citation>Gro O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1&#x3b1; secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity. 2012;36(3):388&#x2013;400. doi: 10.1016/j.immuni.2012.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.01.018</ArticleId><ArticleId IdType="pubmed">22444631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya K, Hosojima S, Hara H, Kushiyama H, Mahib M, Kinoshita T, Suda T. Gasdermin D mediates the maturation and release of IL-1&#x3b1; downstream of inflammasomes. Cell Rep. 2021;34(12):108887. doi: 10.1016/j.celrep.2021.108887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108887</ArticleId><ArticleId IdType="pubmed">33761363</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Li L, Xue M, Liu X, Jiang C, Wang W, Tang L, Feng L, Liu P. Gasdermin D inhibits coronavirus infection by promoting the noncanonical secretion of beta interferon. MBio. 2022 doi: 10.1128/mbio.03600-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03600-21</ArticleId><ArticleId IdType="pmc">PMC8805026</ArticleId><ArticleId IdType="pubmed">35100869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99&#x2013;103. doi: 10.1038/nature22393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22393</ArticleId><ArticleId IdType="pubmed">28459430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Shi P, Wang Y, Zou D, Wu X, Wang D, Hu Q, Zou Y, Huang Z, Ren J. GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity. J Mol Cell Biol. 2019;11(6):496&#x2013;508. doi: 10.1093/jmcb/mjy056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjy056</ArticleId><ArticleId IdType="pmc">PMC6734491</ArticleId><ArticleId IdType="pubmed">30321352</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Li Y, Wu M, Jin Q, Jia Z. Gasdermin E deficiency attenuates acute kidney injury by inhibiting pyroptosis and inflammation. Cell Death Dis. 2021;12(2):139. doi: 10.1038/s41419-021-03431-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03431-2</ArticleId><ArticleId IdType="pmc">PMC7862699</ArticleId><ArticleId IdType="pubmed">33542198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Kambara H, Guo R, Kanneganti A, Luo HR. Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macrophages. Nat Commun. 2021;12(1):6699. doi: 10.1038/s41467-021-27034-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27034-9</ArticleId><ArticleId IdType="pmc">PMC8602704</ArticleId><ArticleId IdType="pubmed">34795266</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald B, Davis R, Kim S, Tse M, Esmon C, Kolaczkowska E, Jenne C. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood. 2017;129(10):1357&#x2013;1367. doi: 10.1182/blood-2016-09-741298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-741298</ArticleId><ArticleId IdType="pmc">PMC5345735</ArticleId><ArticleId IdType="pubmed">28073784</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteleone M, Stanley AC, Chen KW, Brown DL, Bezbradica JS, von Pein JB, et al. Interleukin-1&#x3b2; maturation triggers its relocation to the plasma membrane for gasdermin-D-dependent and -independent secretion. Cell Rep. 2018;24(6):1425&#x2013;1433. doi: 10.1016/j.celrep.2018.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.07.027</ArticleId><ArticleId IdType="pubmed">30089254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Lu W, Zhang Y, Zhang G, Li Z. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity. 2019;50(6):1401&#x2013;1411. doi: 10.1016/j.immuni.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6791531</ArticleId><ArticleId IdType="pubmed">31076358</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Cheng X, Tang Y, Qiu X, Lu B. Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure. Immunity. 2019;51(6):983&#x2013;996.e6. doi: 10.1016/j.immuni.2019.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.11.005</ArticleId><ArticleId IdType="pubmed">31836429</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009;12(6):646&#x2013;652. doi: 10.1097/MCO.0b013e3283312956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0b013e3283312956</ArticleId><ArticleId IdType="pubmed">19710611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med. 2004;10(11):1216&#x2013;1221. doi: 10.1038/nm1124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1124</ArticleId><ArticleId IdType="pubmed">15502843</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M, Tang Y, Li W, Wang X, Lu B. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity. 2018;49(4):740&#x2013;753. doi: 10.1016/j.immuni.2018.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.016</ArticleId><ArticleId IdType="pmc">PMC6300139</ArticleId><ArticleId IdType="pubmed">30314759</ArticleId></ArticleIdList></Reference><Reference><Citation>Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X, Loike JD, Jenkins RE, Antoine DJ, Schwabe RF. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2019;130(4):1802. doi: 10.1172/JCI126976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI126976</ArticleId><ArticleId IdType="pmc">PMC6436855</ArticleId><ArticleId IdType="pubmed">30829652</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Deng M, Loughran PA, Yang M, Scott MJ. LPS induces active HMGB1 release from hepatocytes into exosomes through the coordinated activities of TLR4 and caspase-11/GSDMD signaling. Front Immunol. 2020;11:229. doi: 10.3389/fimmu.2020.00229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00229</ArticleId><ArticleId IdType="pmc">PMC7160675</ArticleId><ArticleId IdType="pubmed">32328059</ArticleId></ArticleIdList></Reference><Reference><Citation>Starling S. Neutrophils: interfering with intestinal inflammation. Nat Rev Immunol. 2017;17(10):594. doi: 10.1038/nri.2017.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.113</ArticleId><ArticleId IdType="pubmed">28920586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159&#x2013;175. doi: 10.1038/nri3399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3399</ArticleId><ArticleId IdType="pubmed">23435331</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, O&#x2019;&#x2019;Leary CE, Oliver PM, Kolls JK, Weiser JN, Worthen GS. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med. 2014;20(5):524&#x2013;530. doi: 10.1038/nm.3542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3542</ArticleId><ArticleId IdType="pmc">PMC4016187</ArticleId><ArticleId IdType="pubmed">24747744</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmakar M, Minns M, Greenberg EN, Diaz-Aponte J, Pearlman E. N-GSDMD trafficking to neutrophil organelles facilitates IL-1&#x3b2; release independently of plasma membrane pores and pyroptosis. Nat Commun. 2020;11(1):2212. doi: 10.1038/s41467-020-16043-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16043-9</ArticleId><ArticleId IdType="pmc">PMC7200749</ArticleId><ArticleId IdType="pubmed">32371889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambara H, Fei L, Zhang X, Peng L, Bajrami B, Yan T, Li Z, Zhou S, Yu H, Zhou W. Gasdermin D exerts anti-inflammatory effects by promoting neutrophil death. Cell Rep. 2018;22(11):2924&#x2013;2936. doi: 10.1016/j.celrep.2018.02.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.02.067</ArticleId><ArticleId IdType="pmc">PMC5878047</ArticleId><ArticleId IdType="pubmed">29539421</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker M. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100(4):483&#x2013;490. doi: 10.7326/0003-4819-100-4-483.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-100-4-483</ArticleId><ArticleId IdType="pubmed">6703540</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieillard-Ba RA, Cecconi M. Understanding cardiac failure in sepsis. Intensive Care Med. 2014;40(10):1560&#x2013;1563. doi: 10.1007/s00134-014-3367-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-014-3367-8</ArticleId><ArticleId IdType="pubmed">24966063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Gao Y, Dong Z, Yang J, Ge J. GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury. Circ Res. 2021;129(3):383&#x2013;396. doi: 10.1161/CIRCRESAHA.120.318629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.318629</ArticleId><ArticleId IdType="pmc">PMC8291144</ArticleId><ArticleId IdType="pubmed">34015941</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Zhou H, Wu H, Wu Q, Tang Q. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019;24:101215. doi: 10.1016/j.redox.2019.101215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101215</ArticleId><ArticleId IdType="pmc">PMC6529775</ArticleId><ArticleId IdType="pubmed">31121492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, Sun H, Wang DC, Shao F. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535(7610):111&#x2013;116. doi: 10.1038/nature18590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18590</ArticleId><ArticleId IdType="pubmed">27281216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Gong W, Huang W, Xue J, Zhu Q, Ma N, Chen W, Fu X, Gao X, Lin Z. Acinar cell NLRP3 inflammasome and GSDMD activation mediates pyroptosis and systemic inflammation in acute pancreatitis. Br J Pharmacol. 2021;178(17):3533&#x2013;3552. doi: 10.1111/bph.15499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15499</ArticleId><ArticleId IdType="pubmed">33871879</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai S, Ye B, Zhong L, Chen Y, Hong G, Zhao G, Su L, Lu Z. GSDMD mediates LPS-induced septic myocardial dysfunction by regulating ROS-dependent NLRP3 inflammasome activation. Front Cell Dev Biol. 2021 doi: 10.3389/fcell.2021.779432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.779432</ArticleId><ArticleId IdType="pmc">PMC8606561</ArticleId><ArticleId IdType="pubmed">34820388</ArticleId></ArticleIdList></Reference><Reference><Citation>Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol. 2012;12(3):201&#x2013;213. doi: 10.1038/nri3169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3169</ArticleId><ArticleId IdType="pubmed">22362353</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513&#x2013;1524. doi: 10.1053/j.gastro.2014.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.01.020</ArticleId><ArticleId IdType="pmc">PMC3996054</ArticleId><ArticleId IdType="pubmed">24440671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamun AA, Wu Y, Jia C, Munir F, Xiao J. Role of pyroptosis in liver diseases. Int Immunopharmacol. 2020;84:106489. doi: 10.1016/j.intimp.2020.106489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106489</ArticleId><ArticleId IdType="pubmed">32304992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P, Zhong J, Liao H, Loughran P, Mulla J, Fu G, Tang D, Fan J, Billiar TR, Gao W. Hepatocytes are resistant to cell death from canonical and non-canonical inflammasome-activated pyroptosis. Cell Mol Gastroenterol Hepatol. 2022;13(3):739&#x2013;757. doi: 10.1016/j.jcmgh.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8783146</ArticleId><ArticleId IdType="pubmed">34890842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Du Y, Guo Y, Wang Z, Li R. TLR4-NLRP3-GSDMD-mediated pyroptosis plays an important role in aggravated liver injury of CD38-/- sepsis mice. J Immunol Res. 2021;2021:6687555. doi: 10.1155/2021/6687555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6687555</ArticleId><ArticleId IdType="pmc">PMC8026301</ArticleId><ArticleId IdType="pubmed">33860064</ArticleId></ArticleIdList></Reference><Reference><Citation>Alverdy J, Holbrook C, Rocha F, Seiden L, Licheng R, Musch M, Chang E, Ohman D, Suh S. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host. Ann Surg. 2000;232(4):480&#x2013;489. doi: 10.1097/00000658-200010000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200010000-00003</ArticleId><ArticleId IdType="pmc">PMC1421180</ArticleId><ArticleId IdType="pubmed">10998646</ArticleId></ArticleIdList></Reference><Reference><Citation>My A, Bb B, Mn A, Amz A, Ddo A, Ear A, Jn A, Mm A, Ap A, Db A. Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant - ScienceDirect. J Heart Lung Transplant. 2020;39(9):880&#x2013;890. doi: 10.1016/j.healun.2020.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2020.02.004</ArticleId><ArticleId IdType="pmc">PMC7423693</ArticleId><ArticleId IdType="pubmed">32139154</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H, Cao M, Yao Y, Hu W, Sun H, Zhang Y, Zeng C, Tang J, Luan S, Chen P. Dysregulated microbiota-driven gasdermin D activation promotes colitis development by mediating IL-18 release. Front Immunol. 2021;12:750841. doi: 10.3389/fimmu.2021.750841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.750841</ArticleId><ArticleId IdType="pmc">PMC8551709</ArticleId><ArticleId IdType="pubmed">34721422</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer R, Jiao H, Wachsmuth L, Tresch A, Pasparakis M. FADD and caspase-8 regulate gut homeostasis and inflammation by controlling MLKL- and GSDMD-mediated death of intestinal epithelial cells. Immunity. 2020;52(6):978&#x2013;993.e6. doi: 10.1016/j.immuni.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.002</ArticleId><ArticleId IdType="pubmed">32362323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulek K, Zhao J, Liao Y, Rana N, Li X. Epithelial-derived gasdermin D mediates nonlytic IL-1&#x3b2; release during experimental colitis. J Clin Invest. 2020;130(8):4218&#x2013;4234. doi: 10.1172/JCI138103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138103</ArticleId><ArticleId IdType="pmc">PMC7410065</ArticleId><ArticleId IdType="pubmed">32597834</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AE, Kiarash S, Lugo KA, Jacques D, Roberts AW, Lee BL, Barton GM. A map of toll-like receptor expression in the intestinal epithelium reveals distinct spatial, cell type-specific, and temporal patterns. Immunity. 2018;49(3):560&#x2013;575. doi: 10.1016/j.immuni.2018.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.07.016</ArticleId><ArticleId IdType="pmc">PMC6152941</ArticleId><ArticleId IdType="pubmed">30170812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevransky, Investigators. Brokowski C. Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial. JAMA. 2021;325(8):742&#x2013;750. doi: 10.1001/jama.2020.24505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.24505</ArticleId><ArticleId IdType="pmc">PMC7903252</ArticleId><ArticleId IdType="pubmed">33620405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee AK, Opal SM, Palardy JE, Drabick JJ, Hugh C, Robert T, Amos C, Cross AS. Affinity-purified escherichia coli j5 lipopolysaccharide-specific igg protects neutropenic rats against gram-negative bacterial sepsis. J Infect Dis. 1994;170(3):622&#x2013;629. doi: 10.1093/infdis/170.3.622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/170.3.622</ArticleId><ArticleId IdType="pubmed">8077720</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomerenke A, Lea S, Herrick S, Lindsay M, Singh D. Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants. Int J Chron Obstruct Pulmon Dis. 2016;11:2409&#x2013;2417. doi: 10.2147/COPD.S105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S105156</ArticleId><ArticleId IdType="pmc">PMC5047739</ArticleId><ArticleId IdType="pubmed">27729782</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CM, Wanderley CW, Veras FP, Sonego F, Nascimento DC, Gonalves AV, Martins TV, C&#xf3;lon D, Borges VF, Brauer VS. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation. Blood. 2021;138(25):2702&#x2013;2713. doi: 10.1182/blood.2021011525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021011525</ArticleId><ArticleId IdType="pmc">PMC8703366</ArticleId><ArticleId IdType="pubmed">34407544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21(7):736&#x2013;745. doi: 10.1038/s41590-020-0669-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0669-6</ArticleId><ArticleId IdType="pmc">PMC7316630</ArticleId><ArticleId IdType="pubmed">32367036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, Calabresi PA, Snyder SH. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360(6387):449&#x2013;453. doi: 10.1126/science.aan4665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan4665</ArticleId><ArticleId IdType="pmc">PMC5924419</ArticleId><ArticleId IdType="pubmed">29599194</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Fitzgerald KA. Succination inactivates gasdermin D and blocks pyroptosis. Science. 2020;369(6511):1633&#x2013;1637. doi: 10.1126/science.abb9818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb9818</ArticleId><ArticleId IdType="pmc">PMC8744141</ArticleId><ArticleId IdType="pubmed">32820063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathkey JK, Zhao J, Liu Z, Chen Y, Jie Y, Kondolf HC, Benson BL, Chirieleison SM, Huang AY, Dubyak GR. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol. 2018 doi: 10.1126/sciimmunol.aat2738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aat2738</ArticleId><ArticleId IdType="pmc">PMC6462819</ArticleId><ArticleId IdType="pubmed">30143556</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Zheng J, Hu Q, Zhao C, Lin Z. Magnesium protects against sepsis by blocking gasdermin D N-terminal-induced pyroptosis. Cell Death Differ. 2020;27(2):466&#x2013;481. doi: 10.1038/s41418-019-0366-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-019-0366-x</ArticleId><ArticleId IdType="pmc">PMC7206066</ArticleId><ArticleId IdType="pubmed">31209359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gou X, Xu W, Liu Y, Peng Y, Xu W, Yin Y, Zhang X. IL-6 prevents lung macrophage death and lung inflammation injury by inhibiting GSDME- and GSDMD-mediated pyroptosis during pneumococcal pneumosepsis. Microbiol Spectr. 2022;10(2):e0204921. doi: 10.1128/spectrum.02049-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02049-21</ArticleId><ArticleId IdType="pmc">PMC9045248</ArticleId><ArticleId IdType="pubmed">35297653</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W, Li Y, Liu X, Wang S, Li J. TRIM21 regulates pyroptotic cell death by promoting Gasdermin D oligomerization. Cell Death Differ. 2022;29(2):439&#x2013;450. doi: 10.1038/s41418-021-00867-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00867-z</ArticleId><ArticleId IdType="pmc">PMC8817046</ArticleId><ArticleId IdType="pubmed">34511601</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J, Payen D, Opal SM. Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19. Lancet. 2020;396(10259):e61&#x2013;e62. doi: 10.1016/S0140-6736(20)32132-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32132-2</ArticleId><ArticleId IdType="pmc">PMC7546712</ArticleId><ArticleId IdType="pubmed">33045189</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36966323</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-7922</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>World journal of emergency surgery : WJES</Title><ISOAbbreviation>World J Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>The effect of hyperbaric oxygen therapy on the clinical outcomes of necrotizing soft tissue infections: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>23</StartPage><MedlinePgn>23</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13017-023-00490-y</ELocationID><Abstract><AbstractText Label="BACKGROUND">To determine the efficacy of hyperbaric oxygen therapy&#xa0;(HBO) in the treatment of necrotizing soft tissue infections (NSTI), we conducted a meta-analysis of the available evidence.</AbstractText><AbstractText Label="METHODS">Data sources were PubMed, Embase, Web of Science, Cochrane Library, and reference lists. The study included observational trials that compared HBO with non-HBO, or standard care. The primary outcome was the mortality rate. Secondary outcomes were the number of debridement, amputation rate and complication rate. Relative risks or standardized mean differences with 95% confidence intervals were calculated for dichotomous and continuous outcomes, respectively.</AbstractText><AbstractText Label="RESULTS">A total of retrospective cohort and case-control studies were included, including 49,152 patients, 1448 who received HBO and 47,704 in control. The mortality rate in the HBO group was significantly lower than that in the non-HBO group [RR&#x2009;=&#x2009;0.522, 95% CI (0.403, 0.677), p&#x2009;&lt;&#x2009;0.05]. However, the number of debridements performed in the HBO group was higher than in the non-HBO group [SMD&#x2009;=&#x2009;0.611, 95% CI (0.012, 1.211), p&#x2009;&lt;&#x2009;0.05]. There was no significant difference in amputation rates between the two groups [RR&#x2009;=&#x2009;0.836, 95% CI (0.619, 1.129), p&#x2009;&gt;&#x2009;0.05]. In terms of complications, the incidence of MODS was lower in the HBO group than in the non-HBO group [RR&#x2009;=&#x2009;0.205, 95% CI (0.164, 0.256), p&#x2009;&lt;&#x2009;0.05]. There was no significant difference in the incidence of other complications, such as sepsis, shock, myocardial infarction, pulmonary embolism, and pneumonia, between the two groups (p&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION">The current evidence suggests that the use of HBO in the treatment of NSTI can significantly reduce the mortality rates and the incidence rates of complications. However, due to the retrospective nature of the studies, the evidence is weak, and further research is needed to establish its efficacy. It is also important to note that HBO is not available in all hospitals, and its use should be carefully considered based on the patient's individual circumstances. Additionally, it is still worthwhile to stress the significance of promptly evaluating surgical risks to prevent missing the optimal treatment time.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chengzi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anorectum, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Yilian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anorectum, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Chaochi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anorectum, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anorectum, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China. lylapothecary@swmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anorectum, The Affiliated Hospital of Southwest Medical University, Luzhou, China. ljadoctor2@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Emerg Surg</MedlineTA><NlmUniqueID>101266603</NlmUniqueID><ISSNLinking>1749-7922</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018461" MajorTopicYN="Y">Soft Tissue Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003646" MajorTopicYN="N">Debridement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complication</Keyword><Keyword MajorTopicYN="N">Fournier gangrene</Keyword><Keyword MajorTopicYN="N">Hyperbaric oxygen therapy</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Necrotizing fasciitis</Keyword><Keyword MajorTopicYN="N">Necrotizing soft tissue infection</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36966323</ArticleId><ArticleId IdType="pmc">PMC10040118</ArticleId><ArticleId IdType="doi">10.1186/s13017-023-00490-y</ArticleId><ArticleId IdType="pii">10.1186/s13017-023-00490-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilson B. Necrotizing fasciitis. Am Surg. 1952;18:416&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">14915014</ArticleId></ArticleIdList></Reference><Reference><Citation>Faun&#xf8; Thrane J, Ovesen T. Scarce evidence of efficacy of hyperbaric oxygen therapy in necrotizing soft tissue infection: a systematic review. Infect Dis (Lond) 2019;51(7):485&#x2013;492. doi: 10.1080/23744235.2019.1597983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2019.1597983</ArticleId><ArticleId IdType="pubmed">30985236</ArticleId></ArticleIdList></Reference><Reference><Citation>Mladenov A, Diehl K, M&#xfc;ller O, von Heymann C, Kopp S, Peitsch WK. Outcome of necrotizing fasciitis and Fournier's gangrene with and without hyperbaric oxygen therapy: a retrospective analysis over 10 years. World J Emerg Surg. 2022;17(1):43. doi: 10.1186/s13017-022-00448-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-022-00448-6</ArticleId><ArticleId IdType="pmc">PMC9356491</ArticleId><ArticleId IdType="pubmed">35932075</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LE, Shaye DA. Noma and necrotizing fasciitis of the face and neck. Fac Plast Surg. 2021;37(4):439&#x2013;445. doi: 10.1055/s-0041-1722894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1722894</ArticleId><ArticleId IdType="pubmed">33517575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihiczak GG, Schwartz RA, Kapila R. Necrotizing fasciitis: a deadly infection. J Eur Acad Dermatol. 2006;20(4):365&#x2013;369. doi: 10.1111/j.1468-3083.2006.01487.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-3083.2006.01487.x</ArticleId><ArticleId IdType="pubmed">16643131</ArticleId></ArticleIdList></Reference><Reference><Citation>Salcido RS, Ahn C. Necrotizing fasciitis: reviewing the causes and treatment strategies. Adv Skin Wound Care. 2007;20(5):294&#x2013;295. doi: 10.1097/01.ASW.0000269317.76380.3b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASW.0000269317.76380.3b</ArticleId><ArticleId IdType="pubmed">17473566</ArticleId></ArticleIdList></Reference><Reference><Citation>Anheuser P, M&#xfc;hlst&#xe4;dt S, Kranz J, Schneidewind L, Steffens J, Fornara P. Significance of hyperbaric oxygenation in the treatment of fournier's gangrene: a comparative study. Urol Int. 2018;101(4):467&#x2013;471. doi: 10.1159/000493898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493898</ArticleId><ArticleId IdType="pubmed">30326483</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AT, Saadai P, Greenstein A, Divino CM. Postprocedural necrotizing fasciitis: a 10-year retrospective review. Am Surg. 2008;74(5):405&#x2013;409. doi: 10.1016/j.jds.2020.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jds.2020.04.010</ArticleId><ArticleId IdType="pubmed">18481496</ArticleId></ArticleIdList></Reference><Reference><Citation>Naseer U, Steinbakk M, Blystad H, Caugant DA. Epidemiology of invasive group a streptococcal infections in Norway 2010&#x2013;2014: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2016;35(10):1639&#x2013;1648. doi: 10.1007/s10096-016-2704-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-016-2704-y</ArticleId><ArticleId IdType="pubmed">27311458</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and softtissueinfections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147&#x2013;159. doi: 10.1093/cid/ciu296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu296</ArticleId><ArticleId IdType="pubmed">24947530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, et al. WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections. World J Emerg Surg. 2022;17(1):3. doi: 10.1186/s13017-022-00406-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-022-00406-2</ArticleId><ArticleId IdType="pmc">PMC8761341</ArticleId><ArticleId IdType="pubmed">35033131</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummelkamp WH, Hogendyk J, Boerema I. Treatment of anaerobic infections by drenching the tissue with oxygen under high atmospheric pressure. Surgery. 1961;49(3):299&#x2013;302. doi: 10.1016/S0039-6109(16)37192-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6109(16)37192-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowersox JC, Strauss MB, Hart GB. Clinical experience with hyperbaric oxygen therapy in the salvage of ischemic skin grafts and flaps. J Hyperb Med. 1986;1:141&#x2013;149.</Citation></Reference><Reference><Citation>Cianci P, Sato R. Adjunctive hyperbaric oxygen therapy in the treatment of thermal burns: a review. Burns. 1994;20(1):5&#x2013;14. doi: 10.1016/0305-4179(94)90099-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0305-4179(94)90099-x</ArticleId><ArticleId IdType="pubmed">8148076</ArticleId></ArticleIdList></Reference><Reference><Citation>Flam F, Boijsen M, Lind F. Necrotizing fasciitis following transobturator tape treated by extensive surgery and hyperbaric oxygen. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(1):113&#x2013;115. doi: 10.1007/s00192-008-0653-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00192-008-0653-4</ArticleId><ArticleId IdType="pubmed">18509584</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Guidelines Committee. Colorectal Surgeons Branch of Chinese Medical Doctor Association Chinese expert consensus on diagnosis and treatment of perianal necrotizing fasciitis. Chin J Gastrointest Surg. 2019;7(22):689&#x2013;93. doi: 10.3760/cma.j.issn.1671&#x2043;0274.2019.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1671&#x2043;0274.2019.07.017</ArticleId><ArticleId IdType="pubmed">31302971</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ga Wells BS, O&#x2019;connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada (2014). Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation></Reference><Reference><Citation>Tutino R, Colli F, Rizzo G, Bonventre S, Scerrino G, Salamone G, et al. Which role for hyperbaric oxygen therapy in the treatment of Fournier's Gangrene? a retrospective study. Front Surg. 2022;6(9):850378. doi: 10.3389/fsurg.2022.850378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fsurg.2022.850378</ArticleId><ArticleId IdType="pmc">PMC9018989</ArticleId><ArticleId IdType="pubmed">35465423</ArticleId></ArticleIdList></Reference><Reference><Citation>Feres O, Feitosa MR, Ribeiro da Rocha JJ, Miranda JM, Dos Santos LE, et al. Hyperbaric oxygen therapy decreases mortality due to Fournier's gangrene: a retrospective comparative study. Med Gas Res. 2021;11(1):18&#x2013;23. doi: 10.4103/2045-9912.310055.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2045-9912.310055</ArticleId><ArticleId IdType="pmc">PMC8103972</ArticleId><ArticleId IdType="pubmed">33642333</ArticleId></ArticleIdList></Reference><Reference><Citation>Creta M, Longo N, Arcaniolo D, Giannella R, Cai T, Cicalese A, et al. Hyperbaric oxygen therapy reduces mortality in patients with Fournier's Gangrene. Results from a multi-institutional observational study. Minerva Urol Nefrol. 2020;2(2):223&#x2013;8. doi: 10.23736/S0393-2249.20.03696-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0393-2249.20.03696-6</ArticleId><ArticleId IdType="pubmed">32083420</ArticleId></ArticleIdList></Reference><Reference><Citation>Faun&#xf8; TJ, Pikelis A, Ovesen T. Hyperbaric oxygen may only be optional in head and neck necrotizing fasciitis: a retrospective analysis of 43 cases and review of the literature. Infect Dis (Lond) 2017;49(11&#x2013;12):792&#x2013;798. doi: 10.1080/23744235.2017.1342142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2017.1342142</ArticleId><ArticleId IdType="pubmed">28644692</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaney B, Frawley G, Frawley L, Pilcher DV. Necrotising soft tissue infections: the effect of hyperbaric oxygen on mortality. Anaesth Intensive Care. 2015;43(6):685&#x2013;692. doi: 10.1177/0310057X1504300604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0310057X1504300604</ArticleId><ArticleId IdType="pubmed">26603791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung MC, Chou CL, Cheng LC, Ho CH, Niu KC, Chen HL, et al. The role of hyperbaric oxygen therapy in treating extensive Fournier's gangrene. Urol Sci. 2016 doi: 10.1016/j.urols.2015.06.294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urols.2015.06.294</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhou X, Liu LF, Qi F, Chen JB, Zu XB. Hyperbaric oxygen therapy as an adjuvant therapy for comprehensive treatment of Fournier's gangrene. Urol Int. 2015;94(4):453&#x2013;458. doi: 10.1159/000366137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000366137</ArticleId><ArticleId IdType="pubmed">25677386</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw JJ, Psoinos C, Emhoff TA, Shah SA, Santry HP. Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect (Larchmt) 2014;15(3):328&#x2013;335. doi: 10.1089/sur.2012.135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2012.135</ArticleId><ArticleId IdType="pmc">PMC4696431</ArticleId><ArticleId IdType="pubmed">24786980</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh CR, Pietrobon R, Freiberger JJ, Chew ST, Rajgor D, Gandhi M, et al. Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States nationwide inpatient sample. Intensive Care Med. 2012;38(7):1143&#x2013;1151. doi: 10.1007/s00134-012-2558-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-012-2558-4</ArticleId><ArticleId IdType="pubmed">22527074</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey PR, Sakran JV, Mills AM, Sarani B, Aufhauser DD, Jr, Sims CA, et al. Hyperbaric oxygen therapy in necrotizing soft tissue infections. J Surg Res. 2012;177(1):146&#x2013;151. doi: 10.1016/j.jss.2012.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2012.03.016</ArticleId><ArticleId IdType="pubmed">22487383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan Z, Mullins RF, Friedman BC, Shaver JR, Brandigi C, Alam B, et al. Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. Undersea Hyperb Med. 2010;37(2):115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">20462144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehl AA, Nogueira Filho DC, Mantovani LM, Grippa MM, Berger R, Krauss D, et al. Management of Fournier's gangrene: experience of a university hospital of Curitiba. Rev Col Bras Cir. 2010;37(6):435&#x2013;441. doi: 10.1590/s0100-69912010000600010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0100-69912010000600010</ArticleId><ArticleId IdType="pubmed">21340259</ArticleId></ArticleIdList></Reference><Reference><Citation>George ME, Rueth NM, Skarda DE, Chipman JG, Quickel RR, Beilman GJ. Hyperbaric oxygen does not improve outcome in patients with necrotizing soft tissue infection. Surg Infect (Larchmt) 2009;10(1):21&#x2013;28. doi: 10.1089/sur.2007.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2007.085</ArticleId><ArticleId IdType="pubmed">18991520</ArticleId></ArticleIdList></Reference><Reference><Citation>Krenk L, Nielsen HU, Christensen ME. Necrotizing fasciitis in the head and neck region: an analysis of standard treatment effectiveness. Eur Arch Otorhinolaryngol. 2007;264(8):917&#x2013;922. doi: 10.1007/s00405-007-0275-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-007-0275-3</ArticleId><ArticleId IdType="pubmed">17340128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindrup SR, Kealey GP, Fallon B. Hyperbaric oxygen for the treatment of fournier's gangrene. J Urol. 2005;173(6):1975&#x2013;1977. doi: 10.1097/01.ju.0000158129.56571.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000158129.56571.05</ArticleId><ArticleId IdType="pubmed">15879795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg. 2004;139(12):1339&#x2013;1345. doi: 10.1001/archsurg.139.12.1339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.139.12.1339</ArticleId><ArticleId IdType="pubmed">15611459</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahm P, Roland FH, Vaslef SN, Moon RE, Price DT, Georgiade GS, et al. Outcome analysis in patients with primary necrotizing fasciitis of the male genitalia. Urology. 2000;56(1):31&#x2013;35. doi: 10.1016/s0090-4295(00)00604-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(00)00604-x</ArticleId><ArticleId IdType="pubmed">10869615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollabaugh RS, Jr, Dmochowski RR, Hickerson WL, Cox CE. Fournier's gangrene: therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg. 1998;101(1):94&#x2013;100. doi: 10.1097/00006534-199801000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006534-199801000-00016</ArticleId><ArticleId IdType="pubmed">9427921</ArticleId></ArticleIdList></Reference><Reference><Citation>Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S. Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy? Surgery. 1995;118(5):873&#x2013;878. doi: 10.1016/s0039-6060(05)80278-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0039-6060(05)80278-8</ArticleId><ArticleId IdType="pubmed">7482275</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg. 1994;167(5):485&#x2013;489. doi: 10.1016/0002-9610(94)90240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9610(94)90240-2</ArticleId><ArticleId IdType="pubmed">8185032</ArticleId></ArticleIdList></Reference><Reference><Citation>Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990;108(5):847&#x2013;850. doi: 10.1016/0002-9610(94)90240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9610(94)90240-2</ArticleId><ArticleId IdType="pubmed">2237764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hysong AA, Posey SL, Blum DM, Benvenuti MA, Benvenuti TA, Johnson SR, et al. Necrotizing fasciitis: pillaging the acute phase response. J Bone Joint Surg Am. 2020;102(6):526&#x2013;37. doi: 10.2106/JBJS.19.00591.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.19.00591</ArticleId><ArticleId IdType="pmc">PMC8590823</ArticleId><ArticleId IdType="pubmed">31977818</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotizing fasciitis. Br J Surg. 2014;101:e119&#x2013;e125. doi: 10.1002/bjs.9371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9371</ArticleId><ArticleId IdType="pubmed">24338771</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan G, Kapoor R, Dhamija A, Singh R, Monga B, Calabrese EJ. Necrotizing fasciitis: low-dose radiotherapy as a potential adjunct treatment. Dose Response. 2019;17(3):1559325819871757. doi: 10.1177/1559325819871757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1559325819871757</ArticleId><ArticleId IdType="pmc">PMC6716184</ArticleId><ArticleId IdType="pubmed">31496924</ArticleId></ArticleIdList></Reference><Reference><Citation>McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg. 1995;221(5):558&#x2013;563. doi: 10.1097/00000658-199505000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199505000-00013</ArticleId><ArticleId IdType="pmc">PMC1234638</ArticleId><ArticleId IdType="pubmed">7748037</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen K, Hirn M, Niinikoski J. Hyperbaric oxygen in the treatment of Fournier's gangrene. Eur J Surg. 1998;164(4):251&#x2013;255. doi: 10.1080/110241598750004463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/110241598750004463</ArticleId><ArticleId IdType="pubmed">9641365</ArticleId></ArticleIdList></Reference><Reference><Citation>Capelli-Schellpfeffer M, Gerber GS. The use of hyperbaric oxygen in urology. J Urol. 1999;162(3):647&#x2013;654. doi: 10.1097/00005392-199909010-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005392-199909010-00002</ArticleId><ArticleId IdType="pubmed">10458334</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Waili NS, Butler GJ, Lee BY, Carrey Z, Petrillo R. Possible application of hyperbaric oxygen technology in the management of urogenital and renal diseases. J Med Eng Technol. 2009;33(7):507&#x2013;515. doi: 10.1080/03091900701249554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03091900701249554</ArticleId><ArticleId IdType="pubmed">19484683</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Yu X, Zhang K, Liu T. A retrospective case series of Fournier's gangrene: necrotizing fasciitis in perineum and perianal region. BMC Surg. 2020;20(1):259. doi: 10.1186/s12893-020-00916-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-020-00916-3</ArticleId><ArticleId IdType="pmc">PMC7602356</ArticleId><ArticleId IdType="pubmed">33126879</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik D, Jebasingh FK, Thomas N, Raveendran S, Raj Pallapati SC, Prakash JJ, et al. Necrotizing soft tissue infection of the upper extremities in patients with diabetes mellitus in a tertiary care center-a retrospective study. Diabetes Metab Syndr. 2020;14(5):1071&#x2013;1075. doi: 10.1016/j.dsx.2020.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.05.032</ArticleId><ArticleId IdType="pubmed">32650278</ArticleId></ArticleIdList></Reference><Reference><Citation>Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007;38(5):19&#x2013;26. doi: 10.1016/j.injury.2007.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.030</ArticleId><ArticleId IdType="pubmed">18048033</ArticleId></ArticleIdList></Reference><Reference><Citation>Menichetti F. Skin and skin tissue infections: main clinical attern/pictures. Infez Med. 2009;17(4):30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkarainen TW, Kopari NM, Pham TN, Evans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg. 2014;51(8):344&#x2013;362. doi: 10.1067/j.cpsurg.2014.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/j.cpsurg.2014.06.001</ArticleId><ArticleId IdType="pmc">PMC4199388</ArticleId><ArticleId IdType="pubmed">25069713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayan F, Sunamak O, Paksoy SM, Polat SS, As A, Sakoglu N, et al. Fournier's gangrene: a retrospective clinical study on forty-one patients. ANZ J Surg. 2005;75(12):1055&#x2013;1058. doi: 10.1111/j.1445-2197.2005.03609.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-2197.2005.03609.x</ArticleId><ArticleId IdType="pubmed">16398810</ArticleId></ArticleIdList></Reference><Reference><Citation>Tharakaram S, Keckes K. Necrotising fasciitis:a report of 5 patients. Int J Dermatol. 1988;27:585&#x2013;588. doi: 10.1111/j.1365-4362.1988.tb02410.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-4362.1988.tb02410.x</ArticleId><ArticleId IdType="pubmed">3209321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36913877</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of Chengqi-series decoctions in treating severe acute pancreatitis: A Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>154727</StartPage><MedlinePgn>154727</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2023.154727</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(23)00085-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence suggests that Dachengqi and its modified decoctions are effective for treating abdominal pain, multiple organ dysfunction syndrome (MODS) and inflammation in various disease conditions. We performed a meta-analysis to ascertain the effectiveness of a series of chengqi decoctions in patients with severe acute pancreatitis (SAP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched Pubmed, Embase, Cochrane library, Web of Science, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, Wanfang database and China Science and Technology Journal Database before August 2022 to identify eligible randomized controlled trials (RCTs). Mortality and MODS were chosen as primary outcomes. Secondary outcomes included time until relief of abdominal pain, APACHE II score, complications, effectiveness, IL-6 and TNF-&#x3b1; levels. The risk ratio (RR) and standardized mean difference (SMD) with a 95% confidence interval (CI) were selected as effect measures. The quality of evidence was independently assessed by two reviewers using Grading of Recommendations Assessment Development and Evaluation (GRADE) system.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-three RCTs (n&#xa0;=&#xa0;1865) were finally included. The results showed that, compared with routine therapies, chengqi-series decoctions (CQSDs) treatment groups were associated with lower mortality rate (RR: 0.41, 95%CI: 0.32 to 0.53, p&#xa0;=&#xa0;0.992) and incidence of MODS (RR: 0.48, 95%CI: 0.36 to 0.63, p&#xa0;=&#xa0;0.885). They also reduced remission time of abdominal pain (SMD: -1.66, 95%CI: -1.98 to -1.35, p&#xa0;=&#xa0;0.000), complications (RR: 0.52, 95%CI: 0.39 to 0.68, p&#xa0;=&#xa0;0.716), APACHE II score (SMD: -1.04, 95%CI:-1.55 to -0.54, p&#xa0;=&#xa0;0.003), IL-6 (SMD: -1.5, 95%CI: -2.16 to -0.85, p&#xa0;=&#xa0;0.000), TNF-&#x3b1; (SMD: -1.18, 95%CI: -1.71 to -0.65, p&#xa0;=&#xa0;0.000), and improved curative effectiveness (RR:1.22, 95%CI: 1.14 to 1.31, p&#xa0;=&#xa0;0.757). The certainty of the evidence for these outcomes was low to moderate.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CQSDs seem to be effective therapy for SAP patients with notable reductions in mortality, MODS and abdominal pain, with low quality evidence. Large-scale, multi-center RCTs that are more meticulous are advised in order to produce superior evidence.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre and West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Chenxia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre and West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Siwei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Burn and Plastic Surgery, West China Hospital, Sichuan University, Chengdu 610000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Advanced Mass Spectrometry Center, Research Core Facility, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: dudan1520@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre and West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: Xiaqing@medmail.com.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chengqi-series decoctions</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Severe acute pancreatitis</Keyword><Keyword MajorTopicYN="N">Traditional Chinese medicine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>13</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36913877</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2023.154727</ArticleId><ArticleId IdType="pii">S0944-7113(23)00085-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33657926</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-9116</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Vascular and endovascular surgery</Title><ISOAbbreviation>Vasc Endovascular Surg</ISOAbbreviation></Journal><ArticleTitle>The Impact of COVID-19 on Vascular Surgery Practice: A Systematic Review.</ArticleTitle><Pagination><StartPage>601</StartPage><EndPage>611</EndPage><MedlinePgn>601-611</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1538574421998212</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 is characterized by a pulmonary interstitial compromise which can require intensive care unit (ICU) and mechanical ventilation. Covid patients develop a wide range of pathologies. This study aims to identify the impact of COVID-19 in diseases commonly treated by vascular surgeons.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four conditions were selected: venous thromboembolism (VTE), pulmonary embolism (PE), peripheral arterial disease (PAD), and microangiopathy. A systematic review of the literature using PRISMA guidelines was.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 1195 papers reviewed for conditions in COVID-19 patients relevant to routine vascular surgery practice, 43 papers were included and analyzed. Venous thrombosis was found to be the most common COVID-19 associated pathology with a cumulative incidence of 25% at 7 days and 48% at 14 days. Additionally, D-dimer levels proved to be a good predictor, even in the early stages of the disease with a sensitivity of 85%, specificity of 88.5% and a negative predictive value of 94.7%. Patients in the ICU demonstrated a significantly higher risk of developing VTE, even when receiving pharmacologic thromboprophylaxis. Although evidence of arterial thrombosis was less common (1% to 16.3%), its consequences were typically more serious, including limb loss and death even in young individuals (OR = 25, 95% CI). Finally, microangiopathy has a wide spectrum of clinical presentations from retinal microangiopathy to other more severe manifestations such as myocardial injury, pulmonary compromise and potential multiple organ dysfunction syndrome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the pathophysiological pathway by which COVID-19 produces thrombosis is not completely clear, the incidence of both arterial and venous thrombosis is increased. D-dimer screening should be done in all COVID-19 patients, as a predictor of thrombotic complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulloa</LastName><ForeName>Jorge H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>27991Universidad de los Andes, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Valentin</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-6410-8430</Identifier><AffiliationInfo><Affiliation>173061Hospital Universitario de la Fundacion Santa Fe de Bogota, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cifuentes</LastName><ForeName>Juan Sebastian</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-6180-7455</Identifier><AffiliationInfo><Affiliation>27991Universidad de los Andes, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>27991Universidad de los Andes, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lurie</LastName><ForeName>Fedor</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0644-0560</Identifier><AffiliationInfo><Affiliation>92661Jobst Vascular Institute, Toledo, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vasc Endovascular Surg</MedlineTA><NlmUniqueID>101136421</NlmUniqueID><ISSNLinking>1538-5744</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058729" MajorTopicYN="N">Peripheral Arterial Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057049" MajorTopicYN="N">Thrombotic Microangiopathies</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014656" MajorTopicYN="N">Vascular Surgical Procedures</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">microangiopathy</Keyword><Keyword MajorTopicYN="N">peripheral arterial disease</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33657926</ArticleId><ArticleId IdType="doi">10.1177/1538574421998212</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34970680</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>1 Suppl 1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatrics</Title><ISOAbbreviation>Pediatrics</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.</ArticleTitle><Pagination><StartPage>S53</StartPage><EndPage>S58</EndPage><MedlinePgn>S53-S58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2021-052888H</ELocationID><Abstract><AbstractText Label="CONTEXT">Prior criteria to define pediatric multiple organ dysfunction syndrome (MODS) did not include gastrointestinal dysfunction.</AbstractText><AbstractText Label="OBJECTIVES">Our objective was to evaluate current evidence and to develop consensus criteria for gastrointestinal dysfunction in critically ill children.</AbstractText><AbstractText Label="DATA SOURCES">Electronic searches of PubMed and EMBASE were conducted from January 1992 to January 2020, using medical subject heading terms and text words to define gastrointestinal dysfunction, pediatric critical illness, and outcomes.</AbstractText><AbstractText Label="STUDY SELECTION">Studies were included if they evaluated critically ill children with gastrointestinal dysfunction, performance characteristics of assessment/scoring tools to screen for gastrointestinal dysfunction, and assessed outcomes related to mortality, functional status, organ-specific outcomes, or other patient-centered outcomes. Studies of adults or premature infants, animal studies, reviews/commentaries, case series with sample size &#x2264;10, and non-English language studies with inability to determine eligibility criteria were excluded.</AbstractText><AbstractText Label="DATA EXTRACTION">Data were abstracted from each eligible study into a standard data extraction form along with risk of bias assessment by a task force member.</AbstractText><AbstractText Label="RESULTS">The systematic review supports the following criteria for severe gastrointestinal dysfunction: 1a) bowel perforation, 1b) pneumatosis intestinalis, or 1c) bowel ischemia, present on plain abdominal radiograph, computed tomography (CT) scan, magnetic resonance imaging (MRI), or gross surgical inspection, or 2) rectal sloughing of gut mucosa.</AbstractText><AbstractText Label="LIMITATIONS">The validity of the consensus criteria for gastrointestinal dysfunction are limited by the quantity and quality of current evidence.</AbstractText><AbstractText Label="CONCLUSIONS">Understanding the role of gastrointestinal dysfunction in the pathophysiology and outcomes of MODS is important in pediatric critical illness.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and the Steele Children's Research Center, University of Arizona College of Medicine, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Sharon Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathan</LastName><ForeName>Nazima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University of Cambridge and Kings College, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Ann-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Healthcare of Atlanta, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK106462</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PG/09/084/27993</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatrics</MedlineTA><NlmUniqueID>0376422</NlmUniqueID><ISSNLinking>0031-4005</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>FINANCIAL DISCLOSURES: The authors have indicated they have no financial relationships relevant to this article to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bembea</LastName><ForeName>Melania M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agus</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akcan-Arikan</LastName><ForeName>Ayse</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Peta</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basu</LastName><ForeName>Rajit</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohn</LastName><ForeName>Desmond</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>Leonardo R</ForeName><Initials>LR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carcillo</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Checchia</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheifetz</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornell</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eckerle</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erickson</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farris</LastName><ForeName>Reid W D</ForeName><Initials>RWD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faustino</LastName><ForeName>E Vincent S</ForeName><Initials>EVS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuhrman</LastName><ForeName>Dana Y</ForeName><Initials>DY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giuliano</LastName><ForeName>John S</ForeName><Initials>JS</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Guilliams</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaies</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorga</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson</LastName><ForeName>Sheila J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassinger</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeffries</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouvet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kannan</LastName><ForeName>Sujatha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karam</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khemani</LastName><ForeName>Robinder G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kissoon</LastName><ForeName>Niranjan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laussen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclerc</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jan Hau</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobner</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKiernan</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monagle</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odetola</LastName><ForeName>Folafoluwa</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineda</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowan</LastName><ForeName>Courtney M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryerson</LastName><ForeName>Lindsay M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlapbach</LastName><ForeName>Luregn J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selewski</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shekerdemian</LastName><ForeName>Lara S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lincoln S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squires</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squires</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sutherland</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellette</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spaeder</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasker</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiagarajan</LastName><ForeName>Ravi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tissieres</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traube</LastName><ForeName>Chani</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wainwright</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Shan L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitney</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willson</LastName><ForeName>Doug</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wynn</LastName><ForeName>James L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yehya</LastName><ForeName>Nadir</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34970680</ArticleId><ArticleId IdType="mid">NIHMS1843068</ArticleId><ArticleId IdType="pmc">PMC9662164</ArticleId><ArticleId IdType="doi">10.1542/peds.2021-052888H</ArticleId><ArticleId IdType="pii">184292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klingensmith NJ, Coopersmith CM. The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness. Crit Care Clin. 2016;32(2):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808565</ArticleId><ArticleId IdType="pubmed">27016162</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JR. Intestinal mucosal barrier function in health and disease. NatRevImmunol. 2009;9(11):799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">19855405</ArticleId></ArticleIdList></Reference><Reference><Citation>Reintam A, Parm P, Kitus R, Starkopf J, Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study. Crit Care. 2008;12(4):R90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575570</ArticleId><ArticleId IdType="pubmed">18625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Asrani VM, Brown A, Huang W, Bissett I, Windsor JA. Gastrointestinal Dysfunction in Critical Illness: A Review of Scoring Tools. JPEN J Parenter Enteral Nutr. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31350771</ArticleId></ArticleIdList></Reference><Reference><Citation>Eveleens RD, Joosten KFM, de Koning BAE, Hulst JM, Verbruggen S. Definitions, predictors and outcomes of feeding intolerance in critically ill children: A systematic review. Clin Nutr. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30962102</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Larmonier CB, Deschenes J, Redford D, Kiela PR, Ghishan FK. Clinical characteristics associated with postoperative intestinal epithelial barrier dysfunction in children with congenital heart disease. Pediatr Crit Care Med. 2015;16(1):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286428</ArticleId><ArticleId IdType="pubmed">25162512</ArticleId></ArticleIdList></Reference><Reference><Citation>Derikx JP, Bijker EM, Vos GD, et al. Gut mucosal cell damage in meningococcal sepsis in children: relation with clinical outcome. Crit Care Med. 2010;38(1):133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">19730255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tume LN, Bickerdike A, Latten L, et al. Routine gastric residual volume measurement and energy target achievement in the PICU: a comparison study. Eur J Pediatr. 2017;176(12):1637&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682857</ArticleId><ArticleId IdType="pubmed">28921175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, McAleer D, Hamilton S, et al. Challenges to optimal enteral nutrition in a multidisciplinary pediatric intensive care unit. JPEN JParenterEnteral Nutr. 2010;34(1):38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902117</ArticleId><ArticleId IdType="pubmed">19903872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurbegov AC, Sondheimer JM. Pneumatosis intestinalis in non-neonatal pediatric patients. Pediatrics. 2001;108(2):402&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO. Gastrointestinal complications associated with the surgical treatment of heart disease in children. J Pediatr Surg. 2017;52(3):414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Yan DC, Lai JY, et al. Strangulated small bowel obstruction in children. J Pediatr Surg. 2017;52(8):1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">28318600</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehghani SM, Nikeghbalian S, Kazemi K, et al. Outcome of bowel perforation after pediatric liver transplantation. Pediatr Transplant. 2008;12(2):146&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanada Y, Mizuta K, Wakiya T, et al. Bowel perforation after pediatric living donor liver transplantation. Pediatr Surg Int. 2011;27(1):23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20848288</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked A, Vargas J, Csete ME, et al. Diagnosis and treatment of bowel perforation following pediatric orthotopic liver transplantation. Arch Surg. 1993;128(9):994&#x2013;998; discussion 998&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">8368937</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan B, Dasgupta M, Gajewski K, et al. Low near infrared spectroscopic somatic oxygen saturation at admission is associated with need for lifesaving interventions among unplanned admissions to the pediatric intensive care unit. J Clin Monit Comput. 2018;32(1):89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulueta JL, Vida VL, Perisinotto E, Pittarello D, Stellin G. Role of intraoperative regional oxygen saturation using near infrared spectroscopy in the prediction of low output syndrome after pediatric heart surgery. J Card Surg. 2013;28(4):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">23734582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailov TA, Kuhn EM, Manzi J, et al. Early enteral nutrition is associated with lower mortality in critically ill children. JPEN J Parenter Enteral Nutr. 2014;38(4):459&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">24403379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, Bechard LJ, Cahill N, et al. Nutritional practices and their relationship to clinical outcomes in critically ill children--an international multicenter cohort study*. Crit Care Med. 2012;40(7):2204&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704225</ArticleId><ArticleId IdType="pubmed">22564954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, Skillman HE, Irving SY, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017;41(5):706&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">28686844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisti MJ, Shahid AS, Shahunja KM, et al. Ileus in children presenting with diarrhea and severe acute malnutrition: A chart review. PLoS Negl Trop Dis. 2017;11(5):e0005603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441652</ArticleId><ArticleId IdType="pubmed">28493871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaibou M, Tucci M, Dugas MA, Farrell CA, Proulx F, Lacroix J. Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: a prospective study. Pediatrics. 1998;102(4 Pt 1):933&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">9755268</ArticleId></ArticleIdList></Reference><Reference><Citation>Je BK, Kim HK, Horn PS. Abdominal Compartment Syndrome in Children: Clinical and Imaging Features. AJR Am J Roentgenol. 2019;212(3):655&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">30645165</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Bougmiza IM, Chehab MS, Bafaqih HA, AlMohaimeed SA, Malbrain ML. Incidence, Risk Factors, and Prognosis of Intra-Abdominal Hypertension in Critically Ill Children: A Prospective Epidemiological Study. J Intensive Care Med. 2016;31(6):403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013;39(7):1190&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680657</ArticleId><ArticleId IdType="pubmed">23673399</ArticleId></ArticleIdList></Reference><Reference><Citation>Horoz OO, Yildizdas D, Sari Y, Unal I, Ekinci F, Petmezci E. The relationship of abdominal perfusion pressure with mortality in critically ill pediatric patients. J Pediatr Surg. 2019;54(9):1731&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MB, Firek B, Shi M, et al. Disruption of the microbiota across multiple body sites in critically ill children. Microbiome. 2016;4(1):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5200963</ArticleId><ArticleId IdType="pubmed">28034303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeyesekera A, Wagner J, De Goffau M, et al. Multi-Compartment Profiling of Bacterial and Host Metabolites Identifies Intestinal Dysbiosis and Its Functional Consequences in the Critically Ill Child. Crit Care Med. 2019;47(9):e727&#x2013;e734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6699985</ArticleId><ArticleId IdType="pubmed">31169619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Ogura H, Hamasaki T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci. 2011;56(4):1171&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059822</ArticleId><ArticleId IdType="pubmed">20931284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoseph BP, Klingensmith NJ, Liang Z, et al. Mechanisms of Intestinal Barrier Dysfunction in Sepsis. Shock. 2016;46(1):52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910519</ArticleId><ArticleId IdType="pubmed">27299587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31484468</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Pterins as Diagnostic Markers of Mechanical and Impact-Induced Trauma: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1383</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm8091383</ELocationID><Abstract><AbstractText>We performed a systematic review of the literature to evaluate pterins as biomarkers of mechanical and impact-induced trauma. MEDLINE and Scopus were searched in March 2019. We included in vivo human studies that measured a pterin in response to mechanical or impact-induced trauma with no underlying prior disease or complication. We included 40 studies with a total of 3829 subjects. Seventy-seven percent of studies measured a significant increase in a pterin, primarily neopterin or total neopterin (neopterin + 7,8-dihydroneopterin). Fifty-one percent of studies measured an increase within 24 h or trauma, while 46% measured increases beyond 48 h. Pterins also showed promise as predictors of post-trauma complications such as sepsis, multi-organ failure and mortality. Exercise-induced trauma and traumatic brain injury caused an immediate increase in neopterin or total neopterin, while patients of multiple trauma had elevated pterin levels that remained above baseline for several days. Pterin concentration changes in response to surgery were variable with patients undergoing cardiac surgery having immediate and sustained pterin increases, while hysterectomy, liver resection or hysterectomy showed no change. This review provides systematic evidence that pterins, in particular neopterin and total neopterin, increase in response to multiple forms of mechanical or impact-induced trauma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindsay</LastName><ForeName>Angus</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institution for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia. a.lindsay@deakin.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baxter-Parker</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3862-1385</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, University of Canterbury, Christchurch 8140, New Zealand. greg.parker@pg.canterbury.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gieseg</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0002-3862-1385</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, University of Canterbury, Christchurch 8140, New Zealand. greg.parker@pg.canterbury.ac.nz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of Otago Christchurch, PO Box 4345, Christchurch 8011, New Zealand. greg.parker@pg.canterbury.ac.nz.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biopterin</Keyword><Keyword MajorTopicYN="N">exercise</Keyword><Keyword MajorTopicYN="N">neopterin</Keyword><Keyword MajorTopicYN="N">surgery</Keyword><Keyword MajorTopicYN="N">tetrahydrobiopterin</Keyword><Keyword MajorTopicYN="N">trauma</Keyword><Keyword MajorTopicYN="N">traumatic brain injury</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31484468</ArticleId><ArticleId IdType="pmc">PMC6780259</ArticleId><ArticleId IdType="doi">10.3390/jcm8091383</ArticleId><ArticleId IdType="pii">jcm8091383</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wachter H., Fuchs D., Hausen A., Reibnegger G., Werner E.R. Neopterin as marker for activation of cellular immunity: Immunologic basis and clinical application. Adv. Clin. Chem. 1989;27:1&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">2667296</ArticleId></ArticleIdList></Reference><Reference><Citation>Gieseg S.P., Baxter-Parker G., Lindsay A. Neopterin, Inflammation, and Oxidative Stress: What Could We Be Missing? Antioxidants. 2018;7:80. doi: 10.3390/antiox7070080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox7070080</ArticleId><ArticleId IdType="pmc">PMC6071275</ArticleId><ArticleId IdType="pubmed">29949851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick P.F. Tetrahydropterin-Dependent Amino Acid Hydroxylases. Annu. Rev. Biochem. 1999;68:355&#x2013;381. doi: 10.1146/annurev.biochem.68.1.355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.68.1.355</ArticleId><ArticleId IdType="pubmed">10872454</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins F.G. Note on a yellow pigment in butterflies. Nature. 1889;40:335.</Citation></Reference><Reference><Citation>Fuchs D., Weiss G., Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int. Arch. Allergy Immunol. 1993;101:1&#x2013;6. doi: 10.1159/000236491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000236491</ArticleId><ArticleId IdType="pubmed">8499767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Janmale T., Draper N., Gieseg S.P. Measurement of changes in urinary neopterin and total neopterin in body builders using SCX HPLC. Pteridines. 2014;25:53&#x2013;63. doi: 10.1515/pteridines-2014-0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pteridines-2014-0003</ArticleId></ArticleIdList></Reference><Reference><Citation>Murr C., Fuith L.C., Widner B., Wirleitner B., Baier-Bitterlich G., Fuchs D. Increased neopterin concentrations in patients with cancer: Indicator of oxidative stress? Anticancer Res. 1999;19:1721&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">10470106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Schmiechen A., Chamberlain C.M., Ervasti J.M., Lowe D.A. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function. Exp. Physiol. 2018;103:995&#x2013;1009. doi: 10.1113/EP087031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP087031</ArticleId><ArticleId IdType="pmc">PMC6026059</ArticleId><ArticleId IdType="pubmed">29791760</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs D., Chiodi F., Albert J., Asj&#xf6; B., Hagberg L., Hausen A., Norkrans G., Reibnegger G., Werner E.R., Wachter H. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS. 1989;3:285&#x2013;288. doi: 10.1097/00002030-198905000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-198905000-00006</ArticleId><ArticleId IdType="pubmed">2504232</ArticleId></ArticleIdList></Reference><Reference><Citation>Baydar T., Yuksel O., Sahin T.T., Dikmen K., Girgin G., Sipahi H., Kurukahvecioglu O., Bostanci H., Sare M. Neopterin as a prognostic biomarker in intensive care unit patients. J. Crit. Care. 2009;24:318&#x2013;321. doi: 10.1016/j.jcrc.2008.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2008.06.013</ArticleId><ArticleId IdType="pubmed">19327301</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks E.C.A., Wilkinson T.M., Frampton C.M., Skelton L., Pilbrow A.P., Yandle T.G., Pemberton C.J., Doughty R.N., Whalley G.A., Ellis C.J., et al. Plasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromes. BMC Cardiovasc. Disord. 2018;18:169. doi: 10.1186/s12872-018-0894-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0894-1</ArticleId><ArticleId IdType="pmc">PMC6094571</ArticleId><ArticleId IdType="pubmed">30111293</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner-Felmayer G., Golderer G., Werner E.R. Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects. Curr. Drug Metab. 2002;3:159&#x2013;173. doi: 10.2174/1389200024605073.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389200024605073</ArticleId><ArticleId IdType="pubmed">12003348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A., Franklin G.A., Cheadle W.G. Systemic inflammation after trauma. Injury. 2007;38:1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold L., Henry A., Poron F., Baba-Amer Y., Rooijen N., van Plonquet A., Gherardi R.K., Chazaud B. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 2007;204:1057&#x2013;1069. doi: 10.1084/jem.20070075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20070075</ArticleId><ArticleId IdType="pmc">PMC2118577</ArticleId><ArticleId IdType="pubmed">17485518</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis P. V Current concepts of the inflammatory response after major trauma: An update. Injury. 2003;34:397&#x2013;404. doi: 10.1016/S0020-1383(02)00416-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(02)00416-3</ArticleId><ArticleId IdType="pubmed">12767787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirmali M., T&#xfc;r&#xfc;t H., Top&#xe7;u S., G&#xfc;lhan E., Yazici U., Kaya S., Ta&#x15f;tepe I. A comprehensive analysis of traumatic rib fractures: Morbidity, mortality and management. Eur. J. Cardiothorac. Surg. 2003;24:133&#x2013;138. doi: 10.1016/S1010-7940(03)00256-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(03)00256-2</ArticleId><ArticleId IdType="pubmed">12853057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs J., Sch&#xe4;fer A. Endothelial dysfunction in heart failure: Mechanisms and therapeutic approaches. Curr. Vasc. Pharmacol. 2004;2:115&#x2013;124. doi: 10.2174/1570161043476447.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570161043476447</ArticleId><ArticleId IdType="pubmed">15320512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruen R.L., Jurkovich G.J., McIntyre L.K., Foy H.M., Maier R.V. Patterns of errors contributing to trauma mortality: Lessons learned from 2594 deaths. Ann. Surg. 2006;244:371&#x2013;380. doi: 10.1097/01.sla.0000234655.83517.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000234655.83517.56</ArticleId><ArticleId IdType="pmc">PMC1856538</ArticleId><ArticleId IdType="pubmed">16926563</ArticleId></ArticleIdList></Reference><Reference><Citation>Grob P., Holch M., Fierz W., Glinz W., Geroulanos S. Immunodeficiency after major trauma and selective surgery. Pediatr. Infect. Dis. J. 1988;7:S37&#x2013;S42. doi: 10.1097/00006454-198805001-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-198805001-00009</ArticleId><ArticleId IdType="pubmed">3399284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A.J.C. Ph.D. Thesis. University of Canterbury; Christchurch, New Zealand: 2015. Acute and Chronic Individualised Psychophysiological Stress Assessment of Elite Athletes through Non-Invasive Biochemical Analysis.</Citation></Reference><Reference><Citation>Gunga H.C., Machotta A., Schobersberger W., Mittermayr M., Kirsch K., Koralewski E., R&#xf6;cker L. Neopterin, IgG, IgA, IgM, and plasma volume changes during long-distance running. Pteridines. 2002;13:15&#x2013;20. doi: 10.1515/pteridines.2002.13.1.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pteridines.2002.13.1.15</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Lewis J., Scarrott C., Draper N., Gieseg S.P. Changes in acute biochemical markers of inflammatory and structural stress in rugby union. J. Sports Sci. 2014;33:882&#x2013;891. doi: 10.1080/02640414.2014.971047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02640414.2014.971047</ArticleId><ArticleId IdType="pubmed">25358055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Draper N., Lewis J.G., Gieseg S.P., Gill N. Positional demands of professional rugby. Eur. J. Sport Sci. 2015;15:480&#x2013;487. doi: 10.1080/17461391.2015.1025858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17461391.2015.1025858</ArticleId><ArticleId IdType="pubmed">25830235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Lewis J., Gill N., Gieseg S.P., Draper N. Effect of varied recovery interventions on markers of psychophysiological stress in professional rugby union. Eur. J. Sport Sci. 2015;15:543&#x2013;549. doi: 10.1080/17461391.2015.1029982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17461391.2015.1029982</ArticleId><ArticleId IdType="pubmed">25854282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Lewis J.G., Gill N., Gieseg S.P., Draper N. Immunity, inflammatory and psychophysiological stress response during a competition of professional rugby union. Pteridines. 2015;26:153&#x2013;160. doi: 10.1515/pterid-2015-0012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pterid-2015-0012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Lewis J.G., Scarrott C., Gill N., Gieseg S.P., Draper N. Assessing the Effectiveness of Selected Biomarkers in the Acute and Cumulative Physiological Stress Response in Professional Rugby Union through Non-invasive Assessment. Int. J. Sports Med. 2015;36:446&#x2013;454. doi: 10.1055/s-0034-1398528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1398528</ArticleId><ArticleId IdType="pubmed">25760150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Carr S., Othman M.I., Marks E., Davies S., Petersen C., Draper N., Gieseg S.P. The physiological and mononuclear cell activation response to cryotherapy following a mixed martial arts contest: A pilot study. Pteridines. 2015;26:143&#x2013;151. doi: 10.1515/pterid-2015-0010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pterid-2015-0010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Healy J., Mills W., Lewis J.G., Gill N., Draper N., Gieseg S.P. Impact-induced muscle damage and urinary pterins in professional rugby: 7,8-dihydroneopterin oxidation by myoglobin. Scand. J. Med. Sci. Sport. 2015;26:329&#x2013;337. doi: 10.1111/sms.12436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sms.12436</ArticleId><ArticleId IdType="pubmed">25772829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Othman M.I., Prebble H., Davies S., Gieseg S.P. Repetitive cryotherapy attenuates the in vitro and in vivo mononuclear cell activation response. Exp. Physiol. Exp. Physiol. 2016;101:851&#x2013;865. doi: 10.1113/EP085795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP085795</ArticleId><ArticleId IdType="pubmed">27094349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Carr S., Cross S., Petersen C., Lewis J.G., Gieseg S.P. The physiological response to cold-water immersion following a mixed martial arts training session. Appl. Physiol. Nutr. Metab. 2017;42:529&#x2013;536. doi: 10.1139/apnm-2016-0582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/apnm-2016-0582</ArticleId><ArticleId IdType="pubmed">28177718</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz G., K&#xe4;&#xe4;b S., Kreuzer E., Werdan K. Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection. 1994;22:8&#x2013;17. doi: 10.1007/BF01780757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01780757</ArticleId><ArticleId IdType="pubmed">8181848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bog&#x103; M., Islamo&#x11f;lu F., Badak I., Cikirik&#xe7;io&#x11f;lu M., Bakalim T., Ya&#x11f;di T., B&#xfc;ket S., Hamulu A. The effects of modified hemofiltration on inflammatory mediators and cardiac performance in coronary artery bypass grafting. Perfusion. 2000;15:143&#x2013;150. doi: 10.1177/026765910001500209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/026765910001500209</ArticleId><ArticleId IdType="pubmed">10789569</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerin A., Pozar-Lukanovic N., Sojar V., Stanisavljevic D., Paver-Erzen V., Osredkar J. Neopterin&#x2014;An early marker of surgical stress and hypoxic reperfusion damage during liver surgery. Clin. Chem. Lab. Med. 2002;40:663&#x2013;666. doi: 10.1515/CCLM.2002.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM.2002.113</ArticleId><ArticleId IdType="pubmed">12241010</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab R., Eissele S., Br&#xfc;ckner U.B., Gebhard F., Becker H.P. Systemic inflammatory response after endoscopic (TEP) vs Shouldice groin hernia repair. Hernia. 2004;8:226&#x2013;232. doi: 10.1007/s10029-004-0216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10029-004-0216-7</ArticleId><ArticleId IdType="pubmed">15042432</ArticleId></ArticleIdList></Reference><Reference><Citation>Brki&#x107; K., Uni&#x107; D., Sutli&#x107; Z., Biocina B., Rudez I., Bari&#x107; D., Luki&#x107; I.K. Neopterin kinetics after cardiac surgery with or without cardiopulmonary bypass. Coll. Antropol. 2006;30:395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">16848157</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrak P., Kovacikova L., Kunovsky P. Procalcitonin, neopterin and C-reactive protein after pediatric cardiac surgery with cardiopulmonary bypass. Bratisl. Lek. Listy. 2007;108:501&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309639</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest C.M., Mackay G.M., Oxford L., Millar K., Darlington L.G., Higgins M.J., Stone T.W. Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery. J. Neurochem. 2011;119:136&#x2013;152. doi: 10.1111/j.1471-4159.2011.07414.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07414.x</ArticleId><ArticleId IdType="pubmed">21819405</ArticleId></ArticleIdList></Reference><Reference><Citation>Osse R.J., Fekkes D., Tulen J.H.M., Wierdsma A.I., Bogers A.J.J.C., Mast R.C., Hengeveld M.W. High Preoperative Plasma Neopterin Predicts Delirium After Cardiac Surgery in Older Adults. J. Am. Geriatr. Soc. 2012;60:661&#x2013;668. doi: 10.1111/j.1532-5415.2011.03885.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2011.03885.x</ArticleId><ArticleId IdType="pubmed">22316274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hol J.W., Stolker R.J., Klimek M., Stronks D.L., Fekkes D. The tryptophan kynurenine pathway, neopterin and IL-6 during vulvectomy and abdominal hysterectomy. J. Biomed. Sci. 2014;21:102. doi: 10.1186/s12929-014-0102-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-014-0102-2</ArticleId><ArticleId IdType="pmc">PMC4300209</ArticleId><ArticleId IdType="pubmed">25526661</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg K.S., Stenseth R., Pleym H., Wahba A., Videm V. Neopterin predicts cardiac dysfunction following cardiac surgery. Interact. Cardiovasc. Thorac. Surg. 2015;21:598&#x2013;603. doi: 10.1093/icvts/ivv219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivv219</ArticleId><ArticleId IdType="pubmed">26265068</ArticleId></ArticleIdList></Reference><Reference><Citation>Enger T.B., Pleym H., Stenseth R., Greiff G., Wahba A., Videm V. A Preoperative Multimarker Approach to Evaluate Acute Kidney Injury After Cardiac Surgery. J. Cardiothorac. Vasc. Anesth. 2017;31:837&#x2013;846. doi: 10.1053/j.jvca.2016.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2016.10.005</ArticleId><ArticleId IdType="pubmed">28024933</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen M.H.E., Fadnes D.J., R&#xf8;st T.H., Pedersen E.R., Andersen J.R., V&#xe5;ge V., Ulvik A., Midttun &#xd8;., Ueland P.M., Nyg&#xe5;rd O.K., et al. Inflammatory markers, the tryptophan-kynurenine pathway, and vitamin B status after bariatric surgery. PLoS ONE. 2018;13:e0192169. doi: 10.1371/journal.pone.0192169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192169</ArticleId><ArticleId IdType="pmc">PMC5798786</ArticleId><ArticleId IdType="pubmed">29401505</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter-Parker G., Roffe L., Cross S., Frampton C., Hooper G.J., Gieseg S.P. Knee replacement surgery significantly elevates the urinary inflammatory biomarkers neopterin and 7,8-dihydroneopterin. Clin. Biochem. 2019;63:39&#x2013;45. doi: 10.1016/j.clinbiochem.2018.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2018.11.002</ArticleId><ArticleId IdType="pubmed">30399370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzlinger P.M., Hans V.H., J&#xf6;ller-Jemelka H.I., Trentz O., Morganti-Kossmann M.C., Kossmann T. Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans. J. Neurotrauma. 2001;18:479&#x2013;489. doi: 10.1089/089771501300227288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/089771501300227288</ArticleId><ArticleId IdType="pubmed">11393251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzlinger P.M., Marx A., Trentz O., Kossmann T., Morganti-Kossmann M.C. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J. Neuroimmunol. 2002;122:167&#x2013;174. doi: 10.1016/S0165-5728(01)00466-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(01)00466-0</ArticleId><ArticleId IdType="pubmed">11777556</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl M., Pscheidl E., Amann W., Barjasic A., Pasch T. Biochemical and hormonal parameters in patients with multiple trauma. Prog. Clin. Biol. Res. 1989;308:743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">2780726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger C., Sch&#xfc;tt C., Obertacke U., Joka T., M&#xfc;ller F.E., Kn&#xf6;ller J., K&#xf6;ller M., K&#xf6;nig W., Sch&#xf6;nfeld W. Serum CD14 levels in polytraumatized and severely burned patients. Clin. Exp. Immunol. 1991;85:297&#x2013;301. doi: 10.1111/j.1365-2249.1991.tb05722.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.1991.tb05722.x</ArticleId><ArticleId IdType="pmc">PMC1535761</ArticleId><ArticleId IdType="pubmed">1713813</ArticleId></ArticleIdList></Reference><Reference><Citation>Strohmaier W., Mauritz W., Gaudernak T., Gr&#xfc;nwald C., Sch&#xfc;ller W., Schlag G. Septic focus localized by determination of arterio-venous difference in neopterin blood levels. Circ. Shock. 1992;38:219&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1292886</ArticleId></ArticleIdList></Reference><Reference><Citation>Waydhas C., Nast-Kolb D., Jochum M., Trupka A., Lenk S., Fritz H., Duswald K.H., Schweiberer L. Inflammatory mediators, infection, sepsis, and multiple organ failure after severe trauma. Arch. Surg. 1992;127:460&#x2013;467. doi: 10.1001/archsurg.1992.01420040106019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1992.01420040106019</ArticleId><ArticleId IdType="pubmed">1348412</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumen R.M., Redl H., Schlag G., Zilow G., Sandtner W., Koller W., Hendriks T., Goris R.J. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit. Care Med. 1995;23:474&#x2013;480. doi: 10.1097/00003246-199503000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199503000-00010</ArticleId><ArticleId IdType="pubmed">7874897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobisch-Hagen P., Wiedermann F., Mayr A., Fries D., Jelkmann W., Fuchs D., Hasibeder W., Mutz N., Klingler A., Schobersberger W. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit. Care Med. 2001;29:743&#x2013;747. doi: 10.1097/00003246-200104000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200104000-00009</ArticleId><ArticleId IdType="pubmed">11373460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensler T., Sauerland S., Lefering R., Nagelschmidt M., Bouillon B., Andermahr J., Neugebauer E.A.M. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock. 2003;20:420&#x2013;426. doi: 10.1097/01.shk.0000093541.78705.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000093541.78705.38</ArticleId><ArticleId IdType="pubmed">14560105</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger G., Aigner R., Glasner A., Hofer H.P., Mitterhammer H., Zelzer S. Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: Comparison with various inflammation parameters. Intensive Care Med. 2004;30:331&#x2013;334. doi: 10.1007/s00134-003-2111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-2111-6</ArticleId><ArticleId IdType="pubmed">14727016</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.S., Thavichaigarn P., Pattanapanyasat K., Siritongtaworn P., Kongcharoen P., Tongtawe P., Yongvanitchit K., Jiarakul N., Dheeradhada C., Pearce F.J., et al. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. J. Surg. Res. 2005;129:221&#x2013;230. doi: 10.1016/j.jss.2005.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2005.05.003</ArticleId><ArticleId IdType="pubmed">16045935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploder M., Pelinka L., Schmuckenschlager C., Wessner B., Ankersmit H.J., Fuerst W., Redl H., Roth E., Spittler A. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock. 2006;25:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploder M., Neurauter G., Spittler A., Schroecksnadel K., Roth E., Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids. 2008;35:303&#x2013;307. doi: 10.1007/s00726-007-0625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-007-0625-x</ArticleId><ArticleId IdType="pubmed">18163176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploder M., Spittler A., Schroecksnadel K., Neurauter G., Pelinka L.E., Roth E., Fuchs D. Tryptophan degradation in multiple trauma patients: Survivors compared with non-survivors. Clin. Sci. 2009;116:593&#x2013;598. doi: 10.1042/CS20080319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20080319</ArticleId><ArticleId IdType="pubmed">18986303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploder M., Spittler A., Kurz K., Neurauter G., Pelinka L.E., Roth E., Fuchs D. Accelerated tryptophan degradation predicts poor survival in trauma and sepsis patients. Int. J. Tryptophan Res. 2010;3:61&#x2013;67. doi: 10.4137/IJTR.S3983.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/IJTR.S3983</ArticleId><ArticleId IdType="pmc">PMC3195245</ArticleId><ArticleId IdType="pubmed">22084588</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall R.J., Watne L.O., Idland A.-V., Raeder J., Frihagen F., MacLullich A.M.J., Staff A.C., Wyller T.B., Fekkes D. Cerebrospinal fluid levels of neopterin are elevated in delirium after hip fracture. J. Neuroinflamm. 2016;13:170. doi: 10.1186/s12974-016-0636-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0636-1</ArticleId><ArticleId IdType="pmc">PMC4928278</ArticleId><ArticleId IdType="pubmed">27357281</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen M., Bayard C., Lepetitcorps H., Cohen-Bittan J., Appay V., Boddaert J., Sauce D. Elevated Neopterin Levels Predict Early Death in Older Hip-fracture Patients. EBioMedicine. 2017;26:157&#x2013;164. doi: 10.1016/j.ebiom.2017.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2017.11.003</ArticleId><ArticleId IdType="pmc">PMC5832560</ArticleId><ArticleId IdType="pubmed">29157836</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T., Nixon J.C. Analysis of reduced forms of biopterin in biological tissues and fluids. Anal. Biochem. 1980;102:176&#x2013;188. doi: 10.1016/0003-2697(80)90336-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(80)90336-X</ArticleId><ArticleId IdType="pubmed">7356152</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavall E.A., Crone E.M., Moore G.A., Gieseg S.P. Dissociation of neopterin and 7, 8-dihydroneopterin from plasma components before HPLC analysis. J. Chromatogr. B. 2008;863:167&#x2013;171. doi: 10.1016/j.jchromb.2007.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2007.12.019</ArticleId><ArticleId IdType="pubmed">18234568</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs D., Milstien S., Kr&#xe4;mer A., Reibnegger G., Werner E.R., Goedert J.J., Kaufman S., Wachter H. Urinary neopterin concentrations vs total neopterins for clinical utility. Clin. Chem. 1989;35:2305&#x2013;2307.</Citation><ArticleIdList><ArticleId IdType="pubmed">2591046</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen D.G., Whitehead N.P., Froehner S.C. Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol. Rev. 2016;96:253&#x2013;305. doi: 10.1152/physrev.00007.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00007.2015</ArticleId><ArticleId IdType="pmc">PMC4698395</ArticleId><ArticleId IdType="pubmed">26676145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bay&#x131;r H., Kochanek P.M., Kagan V.E. Oxidative Stress in Immature Brain after Traumatic Brain Injury. Dev. Neurosci. 2006;28:420&#x2013;431. doi: 10.1159/000094168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000094168</ArticleId><ArticleId IdType="pubmed">16943665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelman S.I. Disturbances in Hepatic Blood Flow During Anesthesia and Surgery. Arch. Surg. 1976;111:881. doi: 10.1001/archsurg.1976.01360260049012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1976.01360260049012</ArticleId><ArticleId IdType="pubmed">942299</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Bilt J.D.W., Borel Rinkes I.H.M. Surgery and angiogenesis. Biochim. Biophys. Acta Rev. Cancer. 2004;1654:95&#x2013;104. doi: 10.1016/j.bbcan.2004.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2004.01.003</ArticleId><ArticleId IdType="pubmed">14984770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., McCourt P.M., Karachunski P., Lowe D.A., Ervasti J.M. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy. Free Radic. Biol. Med. 2018;129:364&#x2013;371. doi: 10.1016/j.freeradbiomed.2018.10.404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.10.404</ArticleId><ArticleId IdType="pmc">PMC6599518</ArticleId><ArticleId IdType="pubmed">30312761</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan C.P., Lovell D.I., Gass G.C. Biochemical and endocrine responses to impact and collision during elite rugby league match play. J. Strength Cond. Res. 2011;25:1553&#x2013;1562. doi: 10.1519/JSC.0b013e3181db9bdd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1519/JSC.0b013e3181db9bdd</ArticleId><ArticleId IdType="pubmed">21602645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay A., Carr S., Draper N., Gieseg S.P. Urinary myoglobin quantification by high-performance liquid chromatography: An alternative measurement for exercise-induced muscle damage. Anal. Biochem. 2015;491:37&#x2013;42. doi: 10.1016/j.ab.2015.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2015.09.001</ArticleId><ArticleId IdType="pubmed">26363103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunniffe B., Hore A.J., Whitcombe D.M., Jones K.P., Baker J.S., Davies B. Time course of changes in immuneoendocrine markers following an international rugby game. Eur. J. Appl. Physiol. 2010;108:113&#x2013;122. doi: 10.1007/s00421-009-1200-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00421-009-1200-9</ArticleId><ArticleId IdType="pubmed">19756700</ArticleId></ArticleIdList></Reference><Reference><Citation>Asimakopoulos G. Systemic inflammation and cardiac surgery: An update. Perfusion. 2001;16:353&#x2013;360. doi: 10.1177/026765910101600505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/026765910101600505</ArticleId><ArticleId IdType="pubmed">11565890</ArticleId></ArticleIdList></Reference><Reference><Citation>Morganti-Kossmann M.C., Rancan M., Stahel P.F., Kossmann T. Inflammatory response in acute traumatic brain injury: A double-edged sword. Curr. Opin. Crit. Care. 2002;8:101&#x2013;105. doi: 10.1097/00075198-200204000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00075198-200204000-00002</ArticleId><ArticleId IdType="pubmed">12386508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelius C., Crupi R., Calabrese V., Graziano A., Milone P., Pennisi G., Radak Z., Calabrese E.J., Cuzzocrea S. Traumatic Brain Injury: Oxidative Stress and Neuroprotection. Antioxid. Redox Signal. 2013;19:836&#x2013;853. doi: 10.1089/ars.2012.4981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4981</ArticleId><ArticleId IdType="pubmed">23547621</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas A.I.R., Lingsma H.F. ALERT-TBI study on biomarkers for TBI: Has science suffered? Lancet Neurol. 2018;17:737&#x2013;738. doi: 10.1016/S1474-4422(18)30275-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30275-8</ArticleId><ArticleId IdType="pubmed">30054150</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton C., Shi H., Ma Y. Normalization of urinary pteridines by urine specific gravity for early cancer detection. Clin. Chim. Acta. 2014;435:42&#x2013;47. doi: 10.1016/j.cca.2014.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2014.04.022</ArticleId><ArticleId IdType="pubmed">24792383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganau L., Prisco L., Ligarotti G.K.I., Ambu R., Ganau M. Understanding the Pathological Basis of Neurological Diseases Through Diagnostic Platforms Based on Innovations in Biomedical Engineering: New Concepts and Theranostics Perspectives. Medicines. 2018;5:22. doi: 10.3390/medicines5010022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5010022</ArticleId><ArticleId IdType="pmc">PMC5874587</ArticleId><ArticleId IdType="pubmed">29495320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganau M., Paris M., Syrmos N., Ganau L., Ligarotti G.K.I., Moghaddamjou A., Prisco L., Ambu R., Chibbaro S. How Nanotechnology and Biomedical Engineering Are Supporting the Identification of Predictive Biomarkers in Neuro-Oncology. Medicines. 2018;5:23. doi: 10.3390/medicines5010023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5010023</ArticleId><ArticleId IdType="pmc">PMC5874588</ArticleId><ArticleId IdType="pubmed">29495368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganau M., Syrmos N., Paris M., Ganau L., Ligarotti G.K.I., Moghaddamjou A., Chibbaro S., Soddu A., Ambu R., Prisco L. Current and Future Applications of Biomedical Engineering for Proteomic Profiling: Predictive Biomarkers in Neuro-Traumatology. Medicines. 2018;5:19. doi: 10.3390/medicines5010019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5010019</ArticleId><ArticleId IdType="pmc">PMC5874584</ArticleId><ArticleId IdType="pubmed">29401743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32519533</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1827-1839</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International angiology : a journal of the International Union of Angiology</Title><ISOAbbreviation>Int Angiol</ISOAbbreviation></Journal><ArticleTitle>Abdominal compartment syndrome after r-EVAR: a systematic review with meta-analysis on incidence and mortality.</ArticleTitle><Pagination><StartPage>411</StartPage><EndPage>421</EndPage><MedlinePgn>411-421</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23736/S0392-9590.20.04406-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Endovascular aneurysm repair for ruptured abdominal aortic aneurysms (r-EVAR) sometimes complicates with abdominal compartment syndrome (ACS) due to extensive retroperitoneal hematoma, with significant prognostic implications. This systematic review aimed to analyze the incidence of the syndrome and assess the impact of ACS on mortality. Mortality after decompressive laparotomy was also assessed.</AbstractText><AbstractText Label="EVIDENCE ACQUISITION" NlmCategory="METHODS">Two databases were searched: Medline and Web of Science. The search was conducted through October 2019. The titles and abstracts of the retrieved articles were independently reviewed. All studies reporting on the ACS incidence after r-EVAR were initially included. From each study, eligibility was determined and descriptive, methodological, and outcome data was extracted. The incidence was calculated with summary proportion. Odds ratio was used to compare the mortality rate. Meta-analysis was performed with fixed effect model when calculating the ACS incidence in r-EVAR patients and when assessing the impacts of ACS and DL in the mortality rate.</AbstractText><AbstractText Label="EVIDENCE SYNTHESIS" NlmCategory="RESULTS">A total of 46 studies were included, with a cumulative cohort of 3064 patients. Two hundred and fifty-two (8.2%) patients developed ACS. The ACS pooled incidence was 9% with a 95% confidence interval of [0.08; 0.11]. Among the 46 included studies, 19 studies reported data on the mortality rate, corresponding to 1825 of the 3064 patients. Of these, 169 (9.3%) had developed ACS and 94 (55.6%) of them died by multi organ failure. Among the 1656 patients without ACS, 328 died (19.8%). The mortality odds ratio meta-analysis was 6.25 with a 95% confidence interval of [4.44, 8.80]. Decompressive laparotomy was performed in 41 patients, decreasing mortality in 47%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ACS affects approximately 9% of patients submitted to r-EVAR, and significantly increases perioperative mortality. Close postoperative surveillance to clinical signs of ACS is vital in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xc1;</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Oliveira-Pinto</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>- oliveirapintoj89@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansilha</LastName><ForeName>Armando</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Int Angiol</MedlineTA><NlmUniqueID>8402693</NlmUniqueID><ISSNLinking>0392-9590</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017544" MajorTopicYN="Y">Aortic Aneurysm, Abdominal</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001019" MajorTopicYN="Y">Aortic Rupture</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019917" MajorTopicYN="Y">Blood Vessel Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="Y">Endovascular Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059325" MajorTopicYN="Y">Intra-Abdominal Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32519533</ArticleId><ArticleId IdType="doi">10.23736/S0392-9590.20.04406-5</ArticleId><ArticleId IdType="pii">S0392-9590.20.04406-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37226426</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1489</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of intensive care medicine</Title><ISOAbbreviation>J Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Use of Perioperative Extracorporeal Membranous Oxygenation in Pulmonary Endarterectomy Cases: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>785</StartPage><EndPage>796</EndPage><MedlinePgn>785-796</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08850666231178262</ELocationID><Abstract><AbstractText><b>Introduction:</b> Pulmonary endarterectomy (PEA) is known to be a curative intervention for chronic thromboembolic pulmonary hypertension (CTEPH). Its complications include endobronchial bleeding, persistent pulmonary arterial hypertension, right ventricular failure, and reperfusion lung injury. Extracorporeal membranous oxygenation (ECMO) is a perioperative salvage method for PEA. Although risk factors and outcomes have been reported in several studies, overall trends remain unknown. We performed a systematic review and study-level meta-analysis to understand the outcomes of ECMO utilization in the perioperative period of PEA. <b>Methods:</b> We performed a literature search with PubMed and EMBASE on 11/18/2022. We included studies including patients who underwent perioperative ECMO in PEA. We collected data including baseline demographics, hemodynamic measurements, and outcomes such as mortality and weaning of ECMO and performed a study-level meta-analysis. <b>Results:</b> Eleven studies with 2632 patients were included in our review. ECMO insertion rate was 8.7% (225/2,625, 95% CI 5.9-12.5) in total, VV-ECMO was performed as the initial intervention in 1.1% (41/2,625, 95% CI 0.4-1.7) (Figure 3), and VA-ECMO was performed as an initial intervention in 7.1% (184/2,625, 95% CI 4.7-9.9). Preoperative hemodynamic measurements showed higher pulmonary vascular resistance, mean pulmonary arterial pressure, and lower cardiac output in the ECMO group. Mortality rates were 2.8% (32/1238, 95% CI: 1.7-4.5) in the non-ECMO group and 43.5% (115/225, 95% CI: 30.8-56.2) in the ECMO group. The proportion of patients with successful weaning of ECMO was 72.6% (111/188, 95% CI: 53.4-91.7). Regarding complications of ECMO, the incidence of bleeding and multi-organ failure were 12.2% (16/79, 95% CI: 13.0-34.8) and 16.5% (15/99, 95% CI: 9.1-28.1), respectively. <b>Conclusion:</b> Our systematic review showed a higher baseline cardiopulmonary risk in patients with perioperative ECMO in PEA, and its insertion rate was 8.7%. Further studies that compare the use of ECMO in high-risk patients who undergo PEA are anticipated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishisaka</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4937-5260</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth, Israel.</Affiliation><Identifier Source="RINGGOLD">22524</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8781-0329</Identifier><AffiliationInfo><Affiliation>Division of Hospital Medicine, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.</Affiliation><Identifier Source="RINGGOLD">68320</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.</Affiliation><Identifier Source="RINGGOLD">26357</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation><Identifier Source="RINGGOLD">21611</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.</Affiliation><Identifier Source="RINGGOLD">12255</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2487-8366</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.</Affiliation><Identifier Source="RINGGOLD">2013</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Intensive Care Med</MedlineTA><NlmUniqueID>8610344</NlmUniqueID><ISSNLinking>0885-0666</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004691" MajorTopicYN="N">Endarterectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic thromboembolic pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">extracorporeal membranous oxygenation</Keyword><Keyword MajorTopicYN="N">pulmonary endarterectomy</Keyword><Keyword MajorTopicYN="N">pulmonary hypertension</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37226426</ArticleId><ArticleId IdType="doi">10.1177/08850666231178262</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40375154</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-230X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC gastroenterology</Title><ISOAbbreviation>BMC Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.</ArticleTitle><Pagination><StartPage>374</StartPage><MedlinePgn>374</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">374</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12876-025-03954-4</ELocationID><Abstract><AbstractText>This systematic review aims to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). A search of PubMed, Web of Science, and Cochrane databases was conducted to identify all relevant randomized controlled trials (RCTs), prospective, or retrospective cohort studies on HTG-AP. Data related to epidemiology and risk factors for severity and recurrence of HTG-AP were extracted and analyzed. Seventy-seven studies met the inclusion criteria, comprising 1 RCT, 21 prospective studies, and 55 retrospective studies. A total of 56,617 acute pancreatitis (AP) patients were included, of which 19.99% were diagnosed with HTG-AP (n&#x2009;=&#x2009;11,315). Compared to non-HTG-AP patients, HTG-AP patients were more likely to be male (68.7% vs. 57.3%) and younger (mean age 41.47&#x2009;&#xb1;&#x2009;4.32 vs. 50.25&#x2009;&#xb1;&#x2009;7.70&#xa0;years). HTG-AP patients exhibited higher mortality rates (up to 20% vs. 15.2%), increased severity (8.3% to 100% vs. 3.8% to 47.2%), and higher recurrence rates (up to 64.8% vs. 23.3%). Analysis of temporal trends from 2002 to 2023 showed a range of HTG-AP prevalence in overall AP patients from 1.6% to 47.6%, with a slight upward trend that was not statistically significant (P&#x2009;=&#x2009;0.1081). Regional analysis indicated relatively stable prevalence in North America (P&#x2009;=&#x2009;0.5787), Europe (P&#x2009;=&#x2009;0.0881), other regions (P&#x2009;=&#x2009;0.738), while prevalence in China showed a significant increase (P&#x2009;=&#x2009;0.0119). Thirteen studies investigated risk factors affecting HTG-AP severity, with elevated serum triglyceride (TG) levels associated with increased risk of complications such as pancreatic necrosis, systemic inflammatory response syndrome (SIRS), shock, and multi-organ failure. Additional factors including high neutrophil-to-lymphocyte ratio (NLR), elevated levels of amylase and C-reactive protein (CRP), hypocalcemia, and hypoalbuminemia were also implicated in HTG-AP severity. Smoking history, poor lipid control (TG&#x2009;&gt;&#x2009;3.1&#xa0;mmol/L), or recurrent hypertriglyceridemia during follow-up were identified as potential predictors of HTG-AP recurrence. Our findings indicate a stable global prevalence of HTG-AP within AP patients, but a notable increase in China, possibly attributed to socio-economic and dietary factors.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Jiongdi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Wentong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Kaixin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Kedong</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi Province, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi Province, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zipeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pancreatic Center, Department of Gastroenterology, Yangzhou Key Laboratory of Pancreatic Disease, Institute of Digestive Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, 225100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Guotao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pancreatic Center, Department of Gastroenterology, Yangzhou Key Laboratory of Pancreatic Disease, Institute of Digestive Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, 225100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wen</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China. wenli7007@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China. wenli7007@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cao</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. f.cao@xwhosp.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China. f.cao@xwhosp.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Chinese Hypertriglyceridemia-Associated Pancreatitis Study Group (CHPSG)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PX20250806</GrantID><Agency>Research and Cultivation Project of Beijing Municipal Hospital Administration</Agency><Country/></Grant><Grant><GrantID>PX2023030</GrantID><Agency>Research and Cultivation Project of Beijing Municipal Hospital Administration</Agency><Country/></Grant><Grant><GrantID>2020-1-2012</GrantID><Agency>Capital Medical Development and Research Special Project</Agency><Country/></Grant><Grant><GrantID>7242069</GrantID><Agency>Natural Science Foundation of Beijing Municipality</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Gastroenterol</MedlineTA><NlmUniqueID>100968547</NlmUniqueID><ISSNLinking>1471-230X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015228" MajorTopicYN="Y">Hypertriglyceridemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypertriglyceridemia-induced Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Recurrence</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All data used for the secondary analysis in our manuscript are from published, ethically reviewed studies that have ensured patient privacy protection and data anonymization. Therefore, ethical statements are not applicable in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40375154</ArticleId><ArticleId IdType="pmc">PMC12082898</ArticleId><ArticleId IdType="doi">10.1186/s12876-025-03954-4</ArticleId><ArticleId IdType="pii">10.1186/s12876-025-03954-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>B&#xe1;lint ER, F&#x171;r G, Kiss L, et al. Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis. Sci Rep. 2020;10(1):17936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578029</ArticleId><ArticleId IdType="pubmed">33087766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mederos MA, Reber HA, Girgis MD. Acute Pancreatitis: A Review. JAMA. 2021;325(4):382&#x2013;90.&#xa0;</Citation><ArticleIdList><ArticleId IdType="pubmed">33496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkeg&#xe5;rd J, Cronin-Fenton D, Heide-J&#xf8;rgensen U, et al. Acute pancreatitis and pancreatic cancer risk: a nationwide matched-cohort study in Denmark. Gastroenterology. 2018;154(6):1729&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">29432727</ArticleId></ArticleIdList></Reference><Reference><Citation>Munigala S, Almaskeen S, Subramaniam DS, et al. Acute pancreatitis recurrences augment long-term pancreatic cancer risk. Am J Gastroenterol. 2023;118(4):727&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045975</ArticleId><ArticleId IdType="pubmed">36473072</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannuzzi JP, King JA, Leong JH, et al. Global incidence of acute pancreatitis is increasing over time: a systematic review and meta-analysis. Gastroenterology. 2022;162(1):122&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">34571026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosztbacher D, Han&#xe1;k L, Farkas N, et al. Hypertriglyceridemia-induced acute pancreatitis: a prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases. Pancreatology. 2020;20(4):608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">32402696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Deng L, Jin T, et al. Hypertriglyceridaemia-associated acute pancreatitis: diagnosis and impact on severity. HPB (Oxford). 2019;21(9):1240&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30885545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110(10):1497&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">26323188</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr RA, Rejowski BJ, Cote GA, et al. Systematic review of hypertriglyceridemia-induced acute pancreatitis: a more virulent etiology? Pancreatology. 2016;16(4):469&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">27012480</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XL, Li F, Zhen YM, et al. Clinical study of 224 patients with hypertriglyceridemia pancreatitis. Chin Med J (Engl). 2015;128(15):2045&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4717952</ArticleId><ArticleId IdType="pubmed">26228216</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothoulakis I, Paragomi P, Archibugi L, et al. Clinical features of hypertriglyceridemia-induced acute pancreatitis in an international, multicenter, prospective cohort (APPRENTICE consortium). Pancreatology. 2020;20(3):325&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">32107193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, He J, Ma S, et al. The role of comorbid hypertriglyceridemia and abdominal obesity in the severity of acute pancreatitis: a retrospective study. Lipids Health Dis. 2021;20(1):171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627607</ArticleId><ArticleId IdType="pubmed">34838056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu W, Luo G, Chen T, et al. A 5-year retrospective cohort study: epidemiology, etiology, severity, and outcomes of acute pancreatitis. Pancreas. 2020;49(9):1161&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32897999</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Zhou Z, Li H, et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. Pancreas. 2015;44(3):409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25438072</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Wang G, Yu B, et al. Elevated hypertriglyceridemia and decreased gallstones in the etiological composition ratio of acute pancreatitis as affected by seasons and festivals: a two-center real-world study from China. Front Cell Infect Microbiol. 2022;12:976816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9730824</ArticleId><ArticleId IdType="pubmed">36506025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S, Vege SS, Sheth SG, et al. American college of gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024;119(3):419&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">38857482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandra S, Virlos IT, King NK, et al. Hyperlipidaemia and outcome in acute pancreatitis. Int J Clin Pract. 2006;60(2):156&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16451286</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Wang S, Zhang Z. A 23-year, single-center, retrospective analysis of 36 cases of acute pancreatitis in pregnancy. Int J Gynaecol Obstet. 2015;130(2):123&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25983209</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Liu J, Lu Y, et al. Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a retrospective study. J Clin Apher. 2016;31(6):571&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Dai CY, Hou NJ, et al. Etiology, severity and recurrence of acute pancreatitis in southern Taiwan. J Formos Med Assoc. 2006;105(7):550&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877234</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhoda S, Zimrin AB, Baer MR, et al. Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis. Transfus Apher Sci. 2017;56(2):123&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27789124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Fuentes HE, Attar BM, et al. Evaluation of the prognostic value of neutrophil to lymphocyte ratio in patients with hypertriglyceridemia-induced acute pancreatitis. Pancreatology. 2017;17(6):893&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29030078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual I, Sanahuja A, Garc&#xed;a N, et al. Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: cohort analysis of 1457 patients. Pancreatology. 2019;19(5):623&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31229460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Kang H, Kim EJ, et al. Clinical features and outcomes of hypertriglyceridemia-induced acute pancreatitis: propensity score matching analysis from a prospective acute pancreatitis registry. Pancreatology. 2020;20(4):617&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">32265135</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Huang Y, Yu H, et al. The association of parameters of body composition and laboratory markers with the severity of hypertriglyceridemia-induced pancreatitis. Lipids Health Dis. 2021;20(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879630</ArticleId><ArticleId IdType="pubmed">33573658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothoulakis I, Paragomi P, Tuft M, et al. Association of serum triglyceride levels with severity in acute pancreatitis: results from an international, multicenter cohort study. Digestion. 2021;102(5):809&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9191264</ArticleId><ArticleId IdType="pubmed">33477149</ArticleId></ArticleIdList></Reference><Reference><Citation>Dancu G, Bende F, Danila M, et al. Hypertriglyceridaemia-induced acute pancreatitis: a different disease phenotype. Diagnostics (Basel). 2022;12(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9028994</ArticleId><ArticleId IdType="pubmed">35453916</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Pan S, Zhang D, et al. Hyperlipemia pancreatitis onset time affects the association between elevated serum triglyceride levels and disease severity. Lipids Health Dis. 2022;21(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9153118</ArticleId><ArticleId IdType="pubmed">35637538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin XY, Zeng Y, Zhang ZC, et al. Incidence and clinical characteristics of hypertriglyceridemic acute pancreatitis: a retrospective single-center study. World J Gastroenterol. 2022;28(29):3946&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9367230</ArticleId><ArticleId IdType="pubmed">36157550</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K, Guo C, He L, et al. Different clinical characteristics between recurrent and non-recurrent acute pancreatitis: a retrospective cohort study from a tertiary hospital. Saudi J Gastroenterol. 2022;28(4):282&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9408740</ArticleId><ArticleId IdType="pubmed">35259860</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K, Wu Z, Meng J, et al. Hypertriglyceridemia as a risk factor for complications of acute pancreatitis and the development of a severity prediction model. HPB (Oxford). 2023;25(9):1065&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">37211462</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang JX, Hu LS, Liu P, et al. Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis. World J Gastroenterol. 2017;23(47):8387&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743509</ArticleId><ArticleId IdType="pubmed">29307998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Niu X, Zhang W, et al. Comparison of the development and prognosis in patients of hypertriglyceridemic pancreatitis with and without diabetes. Gastroenterol Res Pract. 2021;2021:8895268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677390</ArticleId><ArticleId IdType="pubmed">34925505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L, Guan L, Li X, et al. Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: a prospective cohort study. J Clin Lipidol. 2023;17(1).</Citation><ArticleIdList><ArticleId IdType="pubmed">36697323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan L, Ding L, Wan J, et al. Serum triglyceride levels are associated with recurrence in patients with acute hypertriglyceridemic pancreatitis. Front Med. 2023;10:1079637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050706</ArticleId><ArticleId IdType="pubmed">37007797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Jia Q, Liu N, et al. Lipid metabolism for predicting the recurrence of hypertriglyceridemic acute pancreatitis. Heliyon. 2023;9(6):e17443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10333607</ArticleId><ArticleId IdType="pubmed">37441413</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo SI, Chang JH, Kim TH, et al. Subsets associated with developing acute pancreatitis in patients with severe hypertriglyceridemia and the severity of pancreatitis. Pancreatology. 2019;19(6):795&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">31421975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for diagnosis and treatment of acute pancreatitis in China (2021). Zhonghua Wai Ke Za Zhi. 2021;59(7):578&#x2013;587. Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">34256457</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M, Zhou X, Zippi M, et al. Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis. Ann Med. 2023;55(2):2265939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10563627</ArticleId><ArticleId IdType="pubmed">37813108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen SEJ, Varbo A, Nordestgaard BG, et al. Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms. Clin Chem. 2023;69(10):1132&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">37530032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu BU, Batech M, Dong EY, et al. Influence of ambulatory triglyceride levels on risk of recurrence in patients with hypertriglyceridemic pancreatitis. Dig Dis Sci. 2019;64(3):890&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30094622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanloo J, B&#xe9;land-Bonenfant S, Paquette M, et al. Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; a 7-year retrospective cohort study at Canadian quaternary care hospitals. J Clin Lipidol. 2022;16(4):455&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">35659855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Bai X, Chen X, et al. A 16-year trend of etiology in acute pancreatitis: the increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis. J Clin Lipidol. 2019;13(6).</Citation><ArticleIdList><ArticleId IdType="pubmed">31735687</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Chen Y, Liu S, et al. Early plasmapheresis among patients with hypertriglyceridemia-associated acute pancreatitis. JAMA Netw Open. 2023;6(6):e2320802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10308255</ArticleId><ArticleId IdType="pubmed">37378979</ArticleId></ArticleIdList></Reference><Reference><Citation>Opoku S, Gan Y, Fu W, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019;19(1):1500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849283</ArticleId><ArticleId IdType="pubmed">31711454</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016;248:2&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26978581</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer J, Singh VP, Pitchumoni CS, et al. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939000</ArticleId><ArticleId IdType="pubmed">24172179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Xu P, Li F, et al. Internal migration and regional differences of population aging: an empirical study of 287 cities in China. Biosci Trends. 2018;12(2):132&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">29607873</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2).</Citation><ArticleIdList><ArticleId IdType="pubmed">28437620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YC, Hsiao FC, Lin CP, et al. High triglyceride variability increases the risk of first attack of acute pancreatitis. Am J Gastroenterol. 2023;118(6):1080&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10226468</ArticleId><ArticleId IdType="pubmed">36716230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss L, F&#x171;r G, Pisipati S, et al. Mechanisms linking hypertriglyceridemia to acute pancreatitis. Acta Physiol (Oxf). 2023;237(3):e13916.</Citation><ArticleIdList><ArticleId IdType="pubmed">36599412</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto K, Horibe M, Sanui M, et al. Plasmapheresis therapy has no triglyceride-lowering effect in patients with hypertriglyceridemic pancreatitis. Intensive Care Med. 2017;43(6):949&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28233051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20(5):795&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">32571534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafrir B, Saliba W, Jubran A, et al. Severe hypertriglyceridemia-related pancreatitis: characteristics and predictors of recurrence. Pancreas. 2019;48(2):182&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30629026</ArticleId></ArticleIdList></Reference><Reference><Citation>Aune D, Mahamat-Saleh Y, Norat T, et al. Diabetes mellitus and the risk of pancreatitis: a systematic review and meta-analysis of cohort studies. Pancreatology. 2020;20(4):602&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32409279</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson A, Park WG. Acute pancreatitis and diabetes mellitus: a review. Korean J Intern Med. 2021Jan;36(1):15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820652</ArticleId><ArticleId IdType="pubmed">33147904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39337869</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>Clinical Outcomes of Angiotensin II Therapy in Vasoplegic Shock: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1085</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14091085</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Angiotensin II is a peptide hormone vasopressor that activates angiotensin type 1 (AT1) receptors leading to vasoconstriction, the augmentation of arterial blood pressure (ABP), and organ perfusion. Angiotensin II was found to increase the ABP in catecholamine-refractory vasodilatory shock. Whether this effect improves the chances of survival or not remains inconclusive. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of angiotensin II in vasoplegic shock.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the clinical significance of angiotensin II effects in vasoplegic shock concerning the hemodynamic impact, mortality outcomes, and side effects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following PRISMA guidelines, we searched PubMed and EMBASE for experimental and observational studies published in English exploring the clinical outcomes of angiotensin II use in vasodilatory shock till 1 July 2024. Two independent authors assessed the quality and risk of bias of the included studies. A random effect model (Mantel-Haenszel) was used to combine data. The primary outcome was in-hospital mortality associated with angiotensin II use in comparison to standard therapy, while the secondary outcomes were mean arterial pressure (MAP) change, multi-organ failure (MOF), and the incidence of atrial fibrillation (AF). The Q test and I<sup>2</sup> were used to examine heterogeneity, with I<sup>2</sup> &gt; 50% indicating marked heterogeneity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of eight studies (<i>n</i> = 974) comparing angiotensin II to standard therapy in vasoplegic shock were included in the systematic review, with three studies comprising 461 patients included in the final analysis of the primary outcome. Only one study evaluated the use of angiotensin II as a primary vasopressor, while the rest reported angiotensin II use in catecholamine-refractory vasodilatory shock. Overall, angiotensin II use was associated with similar in-hospital mortality compared to standard therapy (risk ratio [RR] = 0.83; 95% CI, 0.68-1.02, I<sup>2</sup> = 0%). Likewise, there was no difference in MOF and AF (MOF: RR = 1.01; 95% CI, 0.61-1.65, I<sup>2</sup> = 0%; AF: RR = 1.27; 95% CI, 0.38-4.23, I<sup>2</sup> = 5%). However, angiotensin II use demonstrated a significant MAP increase (mean difference = -9.60; 95% CI, -9.71, -9.49, I<sup>2</sup> = 0%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In vasodilatory shock, angiotensin II use demonstrated comparable in-hospital mortality compared to standard therapy. Nevertheless, it resulted in significant MAP change, which may encourage clinicians to use it in cases of profound hypotension.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alamami</LastName><ForeName>Ans</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6918-7350</Identifier><AffiliationInfo><Affiliation>Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahhal</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2631-0184</Identifier><AffiliationInfo><Affiliation>Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alqudah</LastName><ForeName>Bara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shebani</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0001-5046-2903</Identifier><AffiliationInfo><Affiliation>Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alammora</LastName><ForeName>Abdelkarim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammad</LastName><ForeName>Hashim</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4769-2254</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omar</LastName><ForeName>Amr S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0001-8560-2745</Identifier><AffiliationInfo><Affiliation>Cardiac ICU, Department of Cardiothoracic Surgery, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shehatta</LastName><ForeName>Ahmed Labib</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-1863-0484</Identifier><AffiliationInfo><Affiliation>Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiotensin II</Keyword><Keyword MajorTopicYN="N">distributive shock</Keyword><Keyword MajorTopicYN="N">shock</Keyword><Keyword MajorTopicYN="N">vasoplegia</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337869</ArticleId><ArticleId IdType="pmc">PMC11432909</ArticleId><ArticleId IdType="doi">10.3390/life14091085</ArticleId><ArticleId IdType="pii">life14091085</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vincent J.-L., De Backer D. Circulatory Shock. N. Engl. J. Med. 2013;369:1726&#x2013;1734. doi: 10.1056/NEJMra1208943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1208943</ArticleId><ArticleId IdType="pubmed">24171518</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.-D., Coopersmith C.M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801&#x2013;810. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaefi S., Mittel A., Klick J., Evans A., Ivascu N.S., Gutsche J., Augoustides J.G. Vasoplegia After Cardiovascular Procedures&#x2014;Pathophysiology and Targeted Therapy. J. Cardiothorac. Vasc. Anesth. 2018;32:1013&#x2013;1022. doi: 10.1053/j.jvca.2017.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2017.10.032</ArticleId><ArticleId IdType="pubmed">29223724</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer G.W., Levin M.A. Vasoplegia During Cardiac Surgery: Current Concepts and Management. Semin. Thorac. Cardiovasc. Surg. 2010;22:140&#x2013;144. doi: 10.1053/j.semtcvs.2010.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semtcvs.2010.09.007</ArticleId><ArticleId IdType="pubmed">21092891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. N. Engl. J. Med. 2001;345:1368&#x2013;1377. doi: 10.1056/NEJMoa010307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa010307</ArticleId><ArticleId IdType="pubmed">11794169</ArticleId></ArticleIdList></Reference><Reference><Citation>The PRISM Investigators Early, Goal-Directed Therapy for Septic Shock&#x2014;A Patient-Level Meta-Analysis. N. Engl. J. Med. 2017;376:2223&#x2013;2234. doi: 10.1056/NEJMoa1701380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1701380</ArticleId><ArticleId IdType="pubmed">28320242</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus D.C., Barnato A.E., Bell D., Bellomo R., Chong C.-R., Coats T.J., Davies A., Delaney A., Harrison D.A., Holdgate A., et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: The ARISE, ProCESS and ProMISe Investigators. Intensive Care Med. 2015;41:1549&#x2013;1560. doi: 10.1007/s00134-015-3822-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3822-1</ArticleId><ArticleId IdType="pubmed">25952825</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumi Y., Iwao H. Handbook of Biologically Active Peptides. Academic Press; Cambridge, MA, USA: 2013. Angiotensin II Peptides; pp. 1369&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385095-9.00186-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A., English S.W., Wang X.S., Ham K., Tumlin J., Szerlip H., Busse L.W., Altaweel L., Albertson T.E., Mackey C., et al. Angiotensin II for the Treatment of Vasodilatory Shock. N. Engl. J. Med. 2017;377:419&#x2013;430. doi: 10.1056/NEJMoa1704154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1704154</ArticleId><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahhal A., Kasem M., Orabi B., Hamou F., Abuyousef S., Mahfouz A., Alyafei S., Shoukry A.E., Ahmed E. Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis. Curr. Probl. Cardiol. 2023;48:101412. doi: 10.1016/j.cpcardiol.2022.101412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2022.101412</ArticleId><ArticleId IdType="pubmed">36170910</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdu Y., Rahhal A., Ahmed K., Adli N., Abdou M., Ali E.A.H., Al-Kindi S., Al Rasheed M., Altooq J., Bougmiza I., et al. The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis. Blood Rev. 2024;65:101183. doi: 10.1016/j.blre.2024.101183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2024.101183</ArticleId><ArticleId IdType="pubmed">38388223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Hern&#xe1;n M.A., Reeves B.C., Savovi&#x107; J., Berkman N.D., Viswanathan M., Henry D., Altman D.G., Ansari M.T., Boutron I., et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Altman D.G., G&#xf8;tzsche P.C., J&#xfc;ni P., Moher D., Oxman A.D., Savovi&#x107; J., Schulz K.F., Weeks L., Sterne J.A.C., et al. The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Sutton A.J., Ioannidis J.P.A., Terrin N., Jones D.R., Lau J., Carpenter J., R&#xfc;cker G., Harbord R.M., Schmid C.H., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136/bmj.d4002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Klijian A., Khanna A.K., Reddy V.S., Friedman B., Ortoleva J., Evans A.S., Panwar R., Kroll S., Greenfeld C.R., Chatterjee S. Treatment with Angiotensin II Is Associated with Rapid Blood Pressure Response and Vasopressor Sparing in Patients with Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study. J. Cardiothorac. Vasc. Anesth. 2021;35:51&#x2013;58. doi: 10.1053/j.jvca.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.08.001</ArticleId><ArticleId IdType="pubmed">32868152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla L.S., Busse L., Brasha-Mitchell E., Davison D., Honiq J., Alotaibi Z., Seneff M.G. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study. Crit. Care. 2014;18:534. doi: 10.1186/s13054-014-0534-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-014-0534-9</ArticleId><ArticleId IdType="pmc">PMC4212099</ArticleId><ArticleId IdType="pubmed">25286986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieruszewski P.M., Wittwer E.D., Kashani K.B., Brown D.R., Butler S.O., Clark A.M., Cooper C.J., Davison D.L., Gajic O., Gunnerson K.J., et al. Angiotensin II Infusion for Shock. Chest. 2021;159:596&#x2013;605. doi: 10.1016/j.chest.2020.08.2074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.08.2074</ArticleId><ArticleId IdType="pmc">PMC7856533</ArticleId><ArticleId IdType="pubmed">32882250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieruszewski P.M., Seelhammer T.G., Barreto E.F., Busse L.W., Chow J.H., Davison D.L., Gaglani B., Khanna A.K., Lohuis C.C.T., Mara K.C., et al. Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support. J. Intensive Care Med. 2023;38:464&#x2013;471. doi: 10.1177/08850666221145864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666221145864</ArticleId><ArticleId IdType="pubmed">36524274</ArticleId></ArticleIdList></Reference><Reference><Citation>See E.J., Clapham C., Liu J., Khasin M., Liskaser G., Chan J.W., Neto A.S., Pinto R.C., Bellomo R. A pilot study of Angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension: The aramis study. Shock. 2023;59:691&#x2013;696. doi: 10.1097/SHK.0000000000002109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000002109</ArticleId><ArticleId IdType="pubmed">36930693</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S.E., Newsome A.S., Guo Y., Hecht J., McCurdy M.T., Mazzeffi M.A., Chow J.H., Kethireddy S. A Multicenter Observational Cohort Study of Angiotensin II in Shock. J. Intensive Care Med. 2022;37:75&#x2013;82. doi: 10.1177/0885066620972943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066620972943</ArticleId><ArticleId IdType="pmc">PMC8559525</ArticleId><ArticleId IdType="pubmed">33231111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A., Landoni G., Beretta L., Morselli F., Neto A.S., Bellomo R., The COVID-BioB Study Group Angiotensin II infusion in COVID-19-associated vasodilatory shock: A case series. Crit. Care. 2020;24:227. doi: 10.1186/s13054-020-02928-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02928-0</ArticleId><ArticleId IdType="pmc">PMC7228670</ArticleId><ArticleId IdType="pubmed">32414393</ArticleId></ArticleIdList></Reference><Reference><Citation>Picod A., Garcia B., Van Lier D., Pickkers P., Herpain A., Mebazaa A., Azibani F. Impaired angiotensin II signaling in septic shock. Ann. Intensive Care. 2024;14:89. doi: 10.1186/s13613-024-01325-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-024-01325-y</ArticleId><ArticleId IdType="pmc">PMC11178728</ArticleId><ArticleId IdType="pubmed">38877367</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia B., Zarbock A., Bellomo R., Legrand M. The alternative renin&#x2013;angiotensin system in critically ill patients: Pathophysiology and therapeutic implications. Crit. Care. 2023;27:453. doi: 10.1186/s13054-023-04739-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04739-5</ArticleId><ArticleId IdType="pmc">PMC10662652</ArticleId><ArticleId IdType="pubmed">37986086</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L., Rhodes A., Alhazzani W., Antonelli M., Coopersmith C.M., French C., Machado F.R., Mcintyre L., Ostermann M., Prescott H.C., et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181&#x2013;1247. doi: 10.1007/s00134-021-06506-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06506-y</ArticleId><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Permpikul C., Tongyoo S., Viarasilpa T., Trainarongsakul T., Chakorn T., Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am. J. Respir. Crit. Care Med. 2019;199:1097&#x2013;1105. doi: 10.1164/rccm.201806-1034OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201806-1034OC</ArticleId><ArticleId IdType="pubmed">30704260</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia B., Su F., Dewachter L., Favory R., Khaldi A., Moiroux-Sahraoui A., Annoni F., Vasques-N&#xf3;voa F., Rocha-Oliveira E., Roncon-Albuquerque R., et al. Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock. Crit. Care. 2022;26:281. doi: 10.1186/s13054-022-04161-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04161-3</ArticleId><ArticleId IdType="pmc">PMC9482744</ArticleId><ArticleId IdType="pubmed">36117167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.-S., Cui J.-R., Meng X.-L., Wang S.-H., Wei W., Gao Y.-L., Shou S.-T., Liu Y.-C., Chai Y.-F. Angiotensin-(1&#x2013;7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-&#x3ba;B and MAPK pathways. J. Transl. Med. 2023;21:2. doi: 10.1186/s12967-022-03842-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03842-5</ArticleId><ArticleId IdType="pmc">PMC9807106</ArticleId><ArticleId IdType="pubmed">36593471</ArticleId></ArticleIdList></Reference><Reference><Citation>Nong Y., Wei X., Yu D. Inflammatory mechanisms and intervention strategies for sepsis-induced myocardial dysfunction. Immun. Inflamm. Dis. 2023;11:e860. doi: 10.1002/iid3.860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.860</ArticleId><ArticleId IdType="pmc">PMC10187025</ArticleId><ArticleId IdType="pubmed">37249297</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich J.O., Harhay M.O., Angus D.C., Burns K.E.A., Cook D.J., Fergusson D.A., Finfer S., H&#xe9;bert P., Rowan K., Rubenfeld G., et al. Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients. Crit. Care Med. 2023;51:222&#x2013;230. doi: 10.1097/CCM.0000000000005721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005721</ArticleId><ArticleId IdType="pubmed">36661450</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni G., Cortegiani A., Bignami E., De Pascale G., Donadello K., Donati A., Grasselli G., Guarracino F., Monti G., Paternoster G., et al. The use of angiotensin II for the management of distributive shock: Expert consensus statements. J. Anesth. Analg. Crit. Care. 2024;4:56. doi: 10.1186/s44158-024-00186-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s44158-024-00186-y</ArticleId><ArticleId IdType="pmc">PMC11328364</ArticleId><ArticleId IdType="pubmed">39152516</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36446397</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2522-7963</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>3</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Lymphology</Title><ISOAbbreviation>Lymphology</ISOAbbreviation></Journal><ArticleTitle>Therapeutic thoracic duct drainage: A systematic review of the Eastern European experience and future potential.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>109</EndPage><MedlinePgn>86-109</MedlinePgn></Pagination><Abstract><AbstractText>Thoracic duct drainage (TDD) is gaining renewed interest, largely due to accumulation of evidence supporting the gut-lymph model, where toxic mesenteric lymph from the intestine contributes to development of multi-organ failure in acute and critical illness (ACI). Advances in minimally invasive TDD have added to this growing interest. The English TDD literature has been previously reviewed, but the more extensive Eastern European literature has not been available to English readers. Therefore, we undertook a systematic search of Eastern European human TDD studies using Scopus and PubMed databases and Russian language websites. Indications for TDD, clinical outcomes, and complications were reviewed. 113 studies, published between 1965 and 2015, were reviewed. The most common indications for TDD were hepatic failure, acute pancreatitis, and peritonitis. It was often used late and when other treatment options had been exhausted. Human TDD appeared safe and probably effective, especially when combined with lymphosorption. The benefit appeared to correlate with the volume of lymph drained. A randomized controlled trial (and some case-control studies) showed reduced mortality in patients with ACI with TDD. Other benefits included rapid normalization of blood parameters and decreased organ edema. This review provides further support for the gut-lymph model and justification for high quality randomized controlled trials of TDD in ACI. It also highlights other potential indications for TDD, such as bridging patients with liver failure to surgery or transplant.</AbstractText><CopyrightInformation>Copyright by International Society of Lymphology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Applied Surgery and Metabolism Laboratory, School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical and Translational Research Centre, Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nachkebia</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Applied Surgery and Metabolism Laboratory, School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado-Zimbron</LastName><ForeName>V E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Applied Surgery and Metabolism Laboratory, School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical and Translational Research Centre, Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuklin</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimel'farb</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Computer Science, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Applied Surgery and Metabolism Laboratory, School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical and Translational Research Centre, Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>N D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Surgery, Penn Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itkin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Lymphatic Disorders, Penn Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>A Rj</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Applied Surgery and Metabolism Laboratory, School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical and Translational Research Centre, Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windsor</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Surgical and Translational Research Centre, Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lymphology</MedlineTA><NlmUniqueID>0155112</NlmUniqueID><ISSNLinking>0024-7766</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013897" MajorTopicYN="N">Thoracic Duct</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="Y">Lymphatic Vessels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Eastern Europe</Keyword><Keyword MajorTopicYN="N">critical illness</Keyword><Keyword MajorTopicYN="N">gut-lymph model</Keyword><Keyword MajorTopicYN="N">lymph</Keyword><Keyword MajorTopicYN="N">thoracic duct drainage</Keyword></KeywordList><CoiStatement>The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>29</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36446397</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36406804</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2231-3796</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India</Title><ISOAbbreviation>Indian J Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Outcome of Tracheostomy in COVID-19 Patients.</ArticleTitle><Pagination><StartPage>404</StartPage><EndPage>408</EndPage><MedlinePgn>404-408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12070-022-03248-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Since the start of the COVID-19 pandemic 2019, quite a few patients became critical and needed ICU admission with ventilator assistance. Tracheostomy, which was initially performed late during the course of patient on ventilator, has now been considered a procedure that can be performed relatively early as this leads to early weaning of patients and overcomes the shortage of critical beds.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aims to focus on the outcomes of tracheotomised COVID-19 patients in terms of survival and any tracheostomy related morbidity.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A prospective study was performed on COVID-19 patients undergoing tracheostomy at this tertiary care teaching hospital, which also was a dedicated centre for treating COVID-19 patients. The duration of this study was from April 2020 to September 2021. Following tracheostomy, all patients were followed up regularly and clinical changes were recorded. Points that were specifically noted were timing of the tracheostomy, change in ventilator settings, tracheostomy related complications, requirement of oxygen, days needed to wean the patient, decanulation, and, if death, the cause of death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 136 surgical open tracheostomies were performed on COVID-19 patients over the study period. The mean duration of intubation (timing of tracheostomy) was 12 days. A total of 73 out of 136 (53.6%) patients survived. 51 patients (37.5%) got decannulated during the course of the hospital stay. 9 patients were decanulated during the follow up visits and 13 patients were lost to follow up. 63 out of 136 (46.3%) patients died due to COVID pneumonia. Most of the patients who died had gone into multi-organ failure. Air leak syndromes (pneumothorax and pneumomediastinum) were common findings. 10 patients already had surgical emphysema before taking up for tracheostomy and 6 developed 2-3 days after tracheostomy. The most common complication was bleeding, which was seen in 28 out of 136 patients. The Median weaning of period of patients who survived was 5 days.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Performing tracheostomy early in COVID-19 patients helps in early weaning of the patient from the ventilator and makes nursing care easier and increases the availability of ICU beds. The mortality rate was 46% amongst the 136 tracheostomies done in COVID-19 patients. Local site bleeding was the most common complication and surgical emphysema was also seen more than routine tracheostomies.</AbstractText><AbstractText Label="SUPPLEMENTARY INFORMATION" NlmCategory="UNASSIGNED">The online version contains supplementary material available at 10.1007/s12070-022-03248-1.</AbstractText><CopyrightInformation>&#xa9; Association of Otolaryngologists of India 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Prasun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Department of Otorhinolaryngology, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jedge</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Dept of Critical Care Medicine, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Krutika V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Department of Otorhinolaryngology, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galagali</LastName><ForeName>Jeevan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Department of Otorhinolaryngology, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaikwad</LastName><ForeName>Viraj</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Department of Otorhinolaryngology, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R</LastName><ForeName>Chethna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Department of Otorhinolaryngology, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushik</LastName><ForeName>Maitri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pune, Maharashtra India Department of Otorhinolaryngology, Bharati Vidyapeeth Medical College.</Affiliation><Identifier Source="GRID">grid.411681.b</Identifier><Identifier Source="ISNI">0000 0004 0503 0903</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>9422551</NlmUniqueID><ISSNLinking>2231-3796</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID 19</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">Tracheostomy</Keyword></KeywordList><CoiStatement>Conflict of interestNone.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>21</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36406804</ArticleId><ArticleId IdType="pmc">PMC9665024</ArticleId><ArticleId IdType="doi">10.1007/s12070-022-03248-1</ArticleId><ArticleId IdType="pii">3248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>https://covid19.who.int/</Citation></Reference><Reference><Citation>Wu Z, Mc Googan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</Citation></Reference><Reference><Citation>Bier-Laning C, Cramer JD, Roy S, et al. (2021) Tracheostomy during the COVID-19 pandemic: Comparison of international perioperative carTracheostomy during the COVID-19 pandemic: Comparison of international perioperative care protocols and practices in 26 countries.e protocols and practices in 26 countries. Otolaryngol Head Neck Surg. 020:194599820961985. PubMedGoogle Scholar</Citation><ArticleIdList><ArticleId IdType="pubmed">33138722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P, Jedge P, Kaushik M, Artham P, Kumari S. Our experience of tracheostomy in COVID-19 patients [published online ahead of print, 2020 Aug 10] Indian J Otolaryngol Head Neck Surg. 2020;10:1&#x2013;4. doi: 10.1007/s12070-020-02036-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12070-020-02036-z</ArticleId><ArticleId IdType="pmc">PMC7416582</ArticleId><ArticleId IdType="pubmed">32837948</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriolo BN, Andriolo RB, Saconato H, Atallah &#xc1;N, Valente O Early versus late tracheostomy for critically ill patients. Cochrane Database Syst Rev. 2015 Jan 12;1(1):CD007271. doi: 10.1002/14651858.CD007271.pub3. PMID: 25581416; PMCID: PMC6517297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517297</ArticleId><ArticleId IdType="pubmed">25581416</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles BA, Schiff B, Ganly I, Ow T, Cohen E, Genden E, Culliney B, Mehrotra B, Savona S, Wong RJ, Haigentz M. Tracheostomy during SARS-Cov-2 pandemic: Recommendations from the New York. Head Neck Society Head &amp; Neck. 2020;42(6):1282&#x2013;1290. doi: 10.1002/hed.26166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26166</ArticleId><ArticleId IdType="pmc">PMC7264578</ArticleId><ArticleId IdType="pubmed">32304119</ArticleId></ArticleIdList></Reference><Reference><Citation>Michetti CP, Burlew CC, Bulger EM, Davis KA, Spain DA. Performing tracheostomy during the Covid-19 pandemic: Guidance and recommendations from Critical Care and Acute Care Surgery Committees of the American Association for the Surgery of Trauma. Trauma Surg Acute Care Open. 2020;5(1):e000482. doi: 10.1136/tsaco-2020-000482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2020-000482</ArticleId><ArticleId IdType="pmc">PMC7186881</ArticleId><ArticleId IdType="pubmed">32368620</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz MJ, Pattnaik R, Dondrorp AM. Walking the line between benefit and harm from tracheostomy in COVID-19. The Lancer Respiratory Medicine. 2020;8(7):656&#x2013;657. doi: 10.1016/S2213-2600(20)30231-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30231-9</ArticleId><ArticleId IdType="pmc">PMC7228697</ArticleId><ArticleId IdType="pubmed">32422179</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada M, Moreno E, Leal S, Pita-Romero R, Sanduende Y, Rama P, Cid M, Seona-Pillado T. Long term outcome after tracheotomy for COVID-19. Arch dr Bronconeumol. 2021;57:54. doi: 10.1016/j.arbres.2021.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2021.01.014</ArticleId><ArticleId IdType="pmc">PMC8046359</ArticleId><ArticleId IdType="pubmed">34629652</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Wu Y, Zhu F, Yang X, Huang C, Hou G, Xu W, Hu M, Zhang L, Cheng, Xu Z. Tracheostomy in 80 COVID-19 patients: A multicenter, retrospective observational study. Front Med. 2020;7:994. doi: 10.3389/fmed.2020.615845.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.615845</ArticleId><ArticleId IdType="pmc">PMC7793766</ArticleId><ArticleId IdType="pubmed">33425960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuazua-Gonzalez A, Collazo-Lorduy T, Coello-Casariego G, Collazo-Lorduy A, Leon-Soriano E, Torralba-Moron A, et al. Surgical tracheostomies in COVID-19 patients: Indication technique, and results in a second level Spanish hospital. OTO Open. 2020;4(3):2473974X20957636. doi: 10.1177/2473974X20957636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2473974X20957636</ArticleId><ArticleId IdType="pmc">PMC7495941</ArticleId><ArticleId IdType="pubmed">32974425</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35465416</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-875X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in surgery</Title><ISOAbbreviation>Front Surg</ISOAbbreviation></Journal><ArticleTitle>Selective Hepatic Vascular Exclusion versus Pringle Maneuver in Major Hepatectomy: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>860721</StartPage><MedlinePgn>860721</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">860721</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fsurg.2022.860721</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Mortality and morbidity following hepatic resection is significantly affected by major intra-operative blood loss. This systematic review and meta-analysis evaluates whether selective hepatic vascular exclusion (SHVE) compared to a Pringle maneuver in hepatic resection reduces rates of morbidity and mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic review and meta-analysis were conducted according to the PRISMA guidelines by screening EMBASE, MEDLINE/PubMed, CENTRAL and SCOPUS for comparative studies meeting the inclusion criteria. Pooled odds ratios or mean differences were calculated for outcomes using either fixed- or random-effects models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Six studies were identified: three randomised controlled trials and three observational studies reporting a total of 2,238 patients. Data synthesis showed significantly decreased rates of mortality, overall complications, blood loss, transfusion requirements, air embolism, liver failure and multi-organ failure in the SHVE group. Rates of hepatic vein rupture, post-operative hemorrhage, operative and warm ischemia time, length of stay in hospital and intensive care unit were not statistically significant between the two groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Performing SHVE in major hepatectomy may result in reduced rates of morbidity and mortality when compared to a Pringle maneuver. The results of this meta-analysis are based on studies where tumors were adjacent to major vessels. Further RCTs are required to validate these results.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="UNASSIGNED">PROSPERO (CRD42020212372) https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=212372.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Mobarak, Stott, Tarazi, Varley, Dav&#xe9;, Baltatzis and Satyadas.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mobarak</LastName><ForeName>Shahd</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hepato-Pancreato-Biliary Surgery, Manchester Royal Infirmary, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stott</LastName><ForeName>Martyn C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Hepato-Pancreato-Biliary Surgery, Manchester Royal Infirmary, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarazi</LastName><ForeName>Munir</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varley</LastName><ForeName>Rebecca J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Hepato-Pancreato-Biliary Surgery, Manchester Royal Infirmary, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dav&#xe9;</LastName><ForeName>Madhav S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Hepato-Pancreato-Biliary Surgery, Manchester Royal Infirmary, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baltatzis</LastName><ForeName>Minas</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Upper GI Surgery, Salford Royal Hospital, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satyadas</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hepato-Pancreato-Biliary Surgery, Manchester Royal Infirmary, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Surg</MedlineTA><NlmUniqueID>101645127</NlmUniqueID><ISSNLinking>2296-875X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systematic (Literature) Review</Keyword><Keyword MajorTopicYN="N">hepatectomy</Keyword><Keyword MajorTopicYN="N">liver resection</Keyword><Keyword MajorTopicYN="N">pringle</Keyword><Keyword MajorTopicYN="N">selective hepatic vascular exclusion (SHVE)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>25</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35465416</ArticleId><ArticleId IdType="pmc">PMC9026334</ArticleId><ArticleId IdType="doi">10.3389/fsurg.2022.860721</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. (2000) 191(1):38&#x2013;46. 10.1016/S1072-7515(00)00261-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1072-7515(00)00261-1</ArticleId><ArticleId IdType="pubmed">10898182</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. (2002) 236(4):397&#x2013;406. 10.1097/00000658-200210000-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200210000-00001</ArticleId><ArticleId IdType="pmc">PMC1422593</ArticleId><ArticleId IdType="pubmed">12368667</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. (2003) 138(11):1198&#x2013;206. 10.1001/archsurg.138.11.1198</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.138.11.1198</ArticleId><ArticleId IdType="pubmed">14609867</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. (2011) 253(4):745&#x2013;58. 10.1097/SLA.0b013e3182111195</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3182111195</ArticleId><ArticleId IdType="pubmed">21475015</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada M, Matsumata T, Akazawa K, Kamakura T, Itasaka H, Sugimachi K, et al. Estimation of risk of major complications after hepatic resection. Am J Surg. (1994) 167:399&#x2013;403. 10.1016/0002-9610(94)90124-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9610(94)90124-4</ArticleId><ArticleId IdType="pubmed">8179084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg. (2003) 90(1):33&#x2013;41. 10.1002/bjs.4018</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.4018</ArticleId><ArticleId IdType="pubmed">12520572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringle JHV. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg. (1908) 48(4):541&#x2013;9. 10.1097/00000658-190810000-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-190810000-00005</ArticleId><ArticleId IdType="pmc">PMC1406963</ArticleId><ArticleId IdType="pubmed">17862242</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon E, Vollmer CM, Jr, Bathe OF, Sutherland F. Vascular occlusion to decrease blood loss during hepatic resection. Am J Surg. (2005) 190(1): 75&#x2013;86. 10.1016/j.amjsurg.2004.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2004.10.007</ArticleId><ArticleId IdType="pubmed">15972177</ArticleId></ArticleIdList></Reference><Reference><Citation>Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg. (1999) 229(3):369&#x2013;75. 10.1097/00000658-199903000-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199903000-00010</ArticleId><ArticleId IdType="pmc">PMC1191702</ArticleId><ArticleId IdType="pubmed">10077049</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaney JP, Stanton WK, Halbert DS, Seidel J, Vice T. An improved technic for vascular isolation of the liver: experimental study and case reports. Ann Surg. (1989) 163:237&#x2013;41. 10.1097/00000658-196602000-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-196602000-00013</ArticleId><ArticleId IdType="pmc">PMC1477087</ArticleId><ArticleId IdType="pubmed">4286023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bismuth H, Castaing D, Garden OJ. Major hepatic resection under total vascular exclusion. Ann Surg. (1989) 210:13&#x2013;9. 10.1097/00000658-198907000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-198907000-00002</ArticleId><ArticleId IdType="pmc">PMC1357759</ArticleId><ArticleId IdType="pubmed">2742411</ArticleId></ArticleIdList></Reference><Reference><Citation>Berney T, Mentha G, Morel P. Total vascular exclusion of the liver for the resection of lesions in contact with the vena cava or the hepatic veins. Br J Surg. (1998) 85:485&#x2013;58. 10.1046/j.1365-2168.1998.00659.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2168.1998.00659.x</ArticleId><ArticleId IdType="pubmed">9607528</ArticleId></ArticleIdList></Reference><Reference><Citation>Delva E, Barberousse JP, Nordlinger B, Ollivier JM, Vacher B, Guilmet C, et al. Hemodynamic and biochemical monitoring during major liver resection with use of hepatic vascular exclusion. Surgery. (1984) 95(3): 309&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">6701787</ArticleId></ArticleIdList></Reference><Reference><Citation>Belghiti J, Noun R, Zante E, Ballet T, Sauvanet A. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg. (1996) 224:155&#x2013;61. 10.1097/00000658-199608000-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199608000-00007</ArticleId><ArticleId IdType="pmc">PMC1235336</ArticleId><ArticleId IdType="pubmed">8757378</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias D, Lasser P, Debaene B, Doidy L, Billard V, Spencer A, et al. Intermittent vascular exclusion of the liver (without vena cava clamping) during major hepatectomy. Br J Surg. (1995) 82(11):1535&#x2013;9. 10.1002/bjs.1800821126</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.1800821126</ArticleId><ArticleId IdType="pubmed">8535812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherqui D, Malassagne B, Colau PI, Brunetti F, Rotman N, Fagniez PL. Hepatic vascular exclusion with preservation of the caval flow for liver resections. Ann Surg. (1999) 230(1):24&#x2013;30. 10.1097/00000658-199907000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199907000-00004</ArticleId><ArticleId IdType="pmc">PMC1420840</ArticleId><ArticleId IdType="pubmed">10400032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan &#x2013; a web and mobile app for systematic reviews. Syst Rev. (2016) 5:210. 10.1186/s13643-016-0384-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. (2005) 5:13. 10.1186/1471-2288-5-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Review Manager (RevMan) [computer program]. Version 5.4. The Cochrane Collaboration (2020).</Citation></Reference><Reference><Citation>Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. (1959) 22(4):719&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>IBM SPSS Statistics for Windows [computer program]. Version 23.0. Armonk, NY (2015).</Citation></Reference><Reference><Citation>Smyrniotis VE, Kostopanagiotou GG, Contis JC, Farantos CI, Voros DC, Kannas DC, et al. Selective hepatic vascular exclusion versus Pringle maneuver in major liver resections: prospective study. World J Surg. (2003) 27(7):765&#x2013;9. 10.1007/s00268-003-6978-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-003-6978-8</ArticleId><ArticleId IdType="pubmed">14509502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Li A, Pan Z, Fu S, Yang Y, Tang L, et al. Selective hepatic vascular exclusion and Pringle maneuver: a comparative study in liver resection. Eur J Surg Oncol. (2008) 34(1):49&#x2013;54. 10.1016/j.ejso.2007.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2007.07.001</ArticleId><ArticleId IdType="pubmed">17709229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Lai EC, Zhou WP, Fu S, Pan Z, Yang Y, et al. Selective hepatic vascular exclusion versus Pringle maneuver in liver resection for tumors encroaching on major hepatic veins. Br J Surg. (2012) 99(7):973&#x2013;7. 10.1002/bjs.8764</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.8764</ArticleId><ArticleId IdType="pubmed">22539200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Zhao LH, Fu SY, Lau WY, Lai EC, Gu FM, et al. Selective hepatic vascular exclusion versus pringle maneuver in partial hepatectomy for liver hemangioma compressing or involving the major hepatic veins. Am Surg. (2014) 80(3):236&#x2013;40. 10.1177/000313481408000317</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000313481408000317</ArticleId><ArticleId IdType="pubmed">24666863</ArticleId></ArticleIdList></Reference><Reference><Citation>Si-Yuan F, Yee LW, Yuan Y, Sheng-Xian Y, Zheng-Guang W, Gang H, et al. Pringle maneuver versus selective hepatic vascular exclusion in partial hepatectomy for tumors adjacent to the hepatocaval junction: a randomized comparative study. Int J Surg. (2014) 12(8):768&#x2013;73. 10.1016/j.ijsu.2014.05.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2014.05.068</ArticleId><ArticleId IdType="pubmed">24907420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tongsiri N, Siripornadulsilp S, Impool T. Comparison of early clinical outcomes between intermittent vascular inflow occlusion versus intermittent selective hepatic vascular exclusion in hepatic resections for cholangiocarcinoma patients: a prospective randomized controlled trial study. J Med Assoc Thai. (2020) 103:521&#x2013;8. 10.35755/jmedassocthai.2020.06.11023</Citation><ArticleIdList><ArticleId IdType="doi">10.35755/jmedassocthai.2020.06.11023</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahbari NN, Koch M, Mehrabi A, Weidmann K, Motschall E, Kahlert C, et al. Portal triad clamping versus vascular exclusion for vascular control during hepatic resection: a systematic review and meta-analysis. J Gastrointest Surg. (2009) 13(3):558&#x2013;68. 10.1007/s11605-008-0588-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-008-0588-6</ArticleId><ArticleId IdType="pubmed">18622655</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38313014</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2167-8359</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PeerJ</Title><ISOAbbreviation>PeerJ</ISOAbbreviation></Journal><ArticleTitle>Association between lactic acidosis and multiple organ dysfunction syndrome after cardiopulmonary bypass.</ArticleTitle><Pagination><StartPage>e16769</StartPage><MedlinePgn>e16769</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e16769</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7717/peerj.16769</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The relationship between hyperlactatemia and prognosis after cardiopulmonary bypass (CPB) is controversial, and some studies ignore the presence of lactic acidosis in patients with severe hyperlactacemia. This study explored the association between lactic acidosis (LA) and the occurrence of multiple organ dysfunction syndrome (MODS) after cardiopulmonary bypass.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study was a <i>post hoc</i> analysis of patients who underwent cardiac surgery between February 2017 and August 2018 and participated in a prospective study at Taizhou Hospital. The data were collected at: ICU admission (H0), and 4, 8, 12, 24, and 48 h after admission. Blood lactate levels gradually increased after CPB, peaking at H8 and then gradually decreasing. The patients were grouped as LA, hyperlactatemia (HL), and normal control (NC) based on blood test results 8 h after ICU admission. Basic preoperative, perioperative, and postoperative conditions were compared between the three groups, as well as postoperative perfusion and oxygen metabolism indexes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 22 (19%), 73 (64%), and 19 (17%) patients in the LA, HL, and NC groups, respectively. APACHE II (24h) and SOFA (24h) scores were the highest in the LA group (<i>P</i>&#xa0;&lt;&#xa0;0.05). ICU stay duration was the longest for the LA group (48.5 (42.5, 50) h), compared with the HL (27 (22, 48) h) and NC (27 (25, 46) h) groups (<i>P</i>&#xa0;=&#xa0;0.012). The LA group had the highest incidence of MODS (36%), compared with the HL (14%) and NC (5%) groups (<i>P</i>&#xa0;=&#xa0;0.015). In the LA group, the oxygen extraction ratio (O<sub>2</sub>ER) was lower (21.5 (17.05, 32.8)%) than in the HL (31.3 (24.8, 37.6)%) and the NC group (31.3 (29.0, 35.4) %) (<i>P</i>&#xa0;=&#xa0;0.018). In the univariable analyses, patient age (OR = 1.054, 95% CI [1.003-1.109], <i>P</i>&#xa0;=&#xa0;0.038), the LA group (<i>vs.</i> the NC group, (OR = 10.286, 95% CI [1.148-92.185], <i>P</i>&#xa0;=&#xa0;0.037), and &#x394;PCO2 at H8 (OR = 1.197, 95% CI [1.022-1.401], <i>P</i>&#xa0;=&#xa0;0.025) were risk factor of MODS after CPB.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We speculated that there was correlation between lactic acidosis and MODS after CPB. In addition, LA should be monitored intensively after CPB.</AbstractText><CopyrightInformation>&#xa9;2024 Zheng et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Guo-Liang</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiao-Min</ForeName><Initials>QM</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chun-Guo</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PeerJ</MedlineTA><NlmUniqueID>101603425</NlmUniqueID><ISSNLinking>2167-8359</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000140" MajorTopicYN="Y">Acidosis, Lactic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065906" MajorTopicYN="Y">Hyperlactatemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acidosis</Keyword><Keyword MajorTopicYN="N">Cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">Hyperlactatemia</Keyword><Keyword MajorTopicYN="N">Lactic</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword></KeywordList><CoiStatement>The authors declare there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38313014</ArticleId><ArticleId IdType="pmc">PMC10838087</ArticleId><ArticleId IdType="doi">10.7717/peerj.16769</ArticleId><ArticleId IdType="pii">16769</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aktar N, Asif&#xa0;Rahim AM, Shahidullah AYM, Iftekher&#xa0;Hossain AHM, Ahmed F. Blood lactate level as predictor of early outcome after off-pump coronary artery bypass grafting. Journal of Cardiovascular Medicine. 2020;12:120&#x2013;125. doi: 10.3329/cardio.v12i2.47989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3329/cardio.v12i2.47989</ArticleId></ArticleIdList></Reference><Reference><Citation>Asim M, Amin F, El-Menyar A. Multiple organ dysfunction syndrome: contemporary insights on the clinicopathological spectrum. Qatar Medical Journal. 2020;2020:22. doi: 10.5339/qmj.2020.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.5339/qmj.2020.22</ArticleId><ArticleId IdType="pmc">PMC7884906</ArticleId><ArticleId IdType="pubmed">33628712</ArticleId></ArticleIdList></Reference><Reference><Citation>Azad MA, Islam KS, Quasem MA. Evaluation of blood lactate level as predictor of early adverse outcome after cardiac surgery under cardiopulmonary bypass. Bangladesh Heart Journal. 2019;34:25&#x2013;30. doi: 10.3329/bhj.v34i1.41904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3329/bhj.v34i1.41904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker J, Gris P, Coffernils M, Kahn RJ, Vincent JL. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. American Journal of Surgery. 1996;171:221&#x2013;226. doi: 10.1016/S0002-9610(97)89552-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(97)89552-9</ArticleId><ArticleId IdType="pubmed">8619454</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzer F, Sander M, Simon M, Spies C, Habicher M, Treskatsch S, Mezger V, Schirmer U, Heringlake M, Wernecke KD, Grubitzsch H, von Heymann C. High central venous saturation after cardiac surgery is associated with increased organ failure and long-term mortality: an observational cross-sectional study. Critical Care. 2015;19:168. doi: 10.1186/s13054-015-0889-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0889-6</ArticleId><ArticleId IdType="pmc">PMC4415351</ArticleId><ArticleId IdType="pubmed">25888321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj V, Kapoor PM, Irpachi K, Ladha S, Chowdhury UK. Basic arterial blood gas biomarkers as a predictor of mortality in tetralogy of Fallot patients. Annals of Cardiac Anaesthesia. 2017;20:67&#x2013;71. doi: 10.4103/0971-9784.197839.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0971-9784.197839</ArticleId><ArticleId IdType="pmc">PMC5290699</ArticleId><ArticleId IdType="pubmed">28074799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock B, Benham MD. Bacterial sepsis. StatPearls; Treasure Island (FL): 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">30725739</ArticleId></ArticleIdList></Reference><Reference><Citation>Carl M, Alms A, Braun J, Dongas A, Erb J, Goetz A, Goepfert M, Gogarten W, Grosse J, Heller AR, Heringlake M, Kastrup M, Kroener A, Loer SA, Marggraf G, Markewitz A, Reuter D, Schmitt DV, Schirmer U, Wiesenack C, Zwissler B, Spies C. S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system. German Medical Science. 2010;8:Doc12. doi: 10.3205/000101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3205/000101</ArticleId><ArticleId IdType="pmc">PMC2890209</ArticleId><ArticleId IdType="pubmed">20577643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang BB, Stevens K, Etoch SW, Cerrito P, Gray&#xa0;Jr LA, Dowling RD. Blood lactic acid levels after artificial heart implantation. ASAIO Journal. 2001;47:683&#x2013;685. doi: 10.1097/00002480-200111000-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002480-200111000-00022</ArticleId><ArticleId IdType="pubmed">11730211</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RS, Jacobs JP, Badhwar V, Fernandez FG, Paone G, Wormuth DW, Shahian DM. The society of thoracic surgeons adult cardiac surgery database: 2018 update on outcomes and quality. Annals of Thoracic Surgery. 2018;105:15&#x2013;23. doi: 10.1016/j.athoracsur.2017.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.10.035</ArticleId><ArticleId IdType="pubmed">29233331</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker NAM, Veerhoek D, Koning NJ, van Leeuwen ALI, Elbers PWG, van&#xa0;den Brom CE, Vonk ABA, Boer C. Postoperative microcirculatory perfusion and endothelial glycocalyx shedding following cardiac surgery with cardiopulmonary bypass. Anaesthesia. 2019;74:609&#x2013;618. doi: 10.1111/anae.14577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.14577</ArticleId><ArticleId IdType="pmc">PMC6590376</ArticleId><ArticleId IdType="pubmed">30687934</ArticleId></ArticleIdList></Reference><Reference><Citation>den Os MM, van&#xa0;den Brom CE, van Leeuwen ALI, Dekker NAM. Microcirculatory perfusion disturbances following cardiopulmonary bypass: a systematic review. Critical Care. 2020;24:218. doi: 10.1186/s13054-020-02948-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02948-w</ArticleId><ArticleId IdType="pmc">PMC7222340</ArticleId><ArticleId IdType="pubmed">32404120</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi PB, Park AY, Banuelos RC, Akkanti BH, Darger BF, Macaluso A, Thangam M, Chambers KA. The incidence and outcome differences in severe sepsis with and without lactic acidosis. Journal of Emergencies, Trauma, and Shock. 2018;11:165&#x2013;169. doi: 10.4103/JETS.JETS_102_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/JETS.JETS_102_17</ArticleId><ArticleId IdType="pmc">PMC6182972</ArticleId><ArticleId IdType="pubmed">30429622</ArticleId></ArticleIdList></Reference><Reference><Citation>Foucher CD, Tubben RE. Lactic acidosis. StatPearls; Treasure Island (FL): 2022.</Citation></Reference><Reference><Citation>Garcia-Camacho C, Marin-Paz AJ, Lagares-Franco C, Abellan-Hervas MJ, Sainz-Otero AM. Continuous ultrafiltration during extracorporeal circulation and its effect on lactatemia: a randomized controlled trial. PLOS ONE. 2020;15:e0242411. doi: 10.1371/journal.pone.0242411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0242411</ArticleId><ArticleId IdType="pmc">PMC7682870</ArticleId><ArticleId IdType="pubmed">33227001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinoni L, Vasques F, Camporota L, Meessen J, Romitti F, Pasticci I, Duscio E, Vassalli F, Forni LG, Payen D, Cressoni M, Zanella A, Latini R, Quintel M, Marini JJ. Understanding lactatemia in human sepsis, potential impact for early management. American Journal of Respiratory and Critical Care Medicine. 2019;200:582&#x2013;589. doi: 10.1164/rccm.201812-2342OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201812-2342OC</ArticleId><ArticleId IdType="pubmed">30985210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillies RJ, Pilot C, Marunaka Y, Fais S. Targeting acidity in cancer and diabetes. Biochimica et Biophysica Acta&#x2014;Reviews on Cancer. 2019;1871:273&#x2013;280. doi: 10.1016/j.bbcan.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2019.01.003</ArticleId><ArticleId IdType="pmc">PMC6525044</ArticleId><ArticleId IdType="pubmed">30708040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, Li CS. [Sepsis and mitochondrial dysfunction] Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013;25:254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">23660105</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood JC, Jang DH, Spelde AE, Gutsche JT, Horak J, Acker MA, Kilbaugh TJ, Shofer FS, Augoustides JGT, Bakker J, Abella BS. Low microcirculatory perfused vessel density and high heterogeneity are associated with increased intensity and duration of lactic acidosis after cardiac surgery with cardiopulmonary bypass. Shock. 2021;56:245&#x2013;254. doi: 10.1097/SHK.0000000000001713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001713</ArticleId><ArticleId IdType="pmc">PMC9887933</ArticleId><ArticleId IdType="pubmed">33394972</ArticleId></ArticleIdList></Reference><Reference><Citation>Janotka M, Ostadal P. Biochemical markers for clinical monitoring of tissue perfusion. Molecular and Cellular Biochemistry. 2021;476:1313&#x2013;1326. doi: 10.1007/s11010-020-04019-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-020-04019-8</ArticleId><ArticleId IdType="pmc">PMC7921020</ArticleId><ArticleId IdType="pubmed">33387216</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, Kashani KB, Wiley BM, Patel PC, Baran DA, Barsness GW, Henry TD, Van&#xa0;Diepen S. Laboratory markers of acidosis and mortality in cardiogenic shock: developing a definition of hemometabolic shock. Shock. 2022;57:31&#x2013;40. doi: 10.1097/SHK.0000000000001812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001812</ArticleId><ArticleId IdType="pubmed">33988540</ArticleId></ArticleIdList></Reference><Reference><Citation>Joudi M, Fathi M, Soltani G, Izanloo A. Factors affecting on serum lactate after cardiac surgery. Anesthesia and Pain Medicine. 2014;4:e18514. doi: 10.5812/aapm.18514.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/aapm.18514</ArticleId><ArticleId IdType="pmc">PMC4295123</ArticleId><ArticleId IdType="pubmed">25632379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa T, Egi M, Shimizu K, Toda Y, Iwasaki T, Morimatsu H. Intraoperative change of lactate level is associated with postoperative outcomes in pediatric cardiac surgery patients: retrospective observational study. BMC Anesthesiology. 2015;15:29. doi: 10.1186/s12871-015-0007-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-015-0007-y</ArticleId><ArticleId IdType="pmc">PMC4354761</ArticleId><ArticleId IdType="pubmed">25759606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedziora A, Wierzbicki K, Piatek J, Hymczak H, Gorkiewicz-Kot I, Milaniak I, Tomsia P, Sobczyk D, Drwila R, Kapelak B. Postoperative hyperlactatemia and serum lactate level trends among heart transplant recipients. PeerJ. 2020;8:e8334. doi: 10.7717/peerj.8334.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.8334</ArticleId><ArticleId IdType="pmc">PMC7007971</ArticleId><ArticleId IdType="pubmed">32071799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmoun A, Novy E, Auchet T, Ducrocq N, Levy B. Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside. Critical Care. 2015;19:175. doi: 10.1186/s13054-015-0896-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0896-7</ArticleId><ArticleId IdType="pmc">PMC4391479</ArticleId><ArticleId IdType="pubmed">25887061</ArticleId></ArticleIdList></Reference><Reference><Citation>Koning NJ, Simon LE, Asfar P, Baufreton C, Boer C. Systemic microvascular shunting through hyperdynamic capillaries after acute physiological disturbances following cardiopulmonary bypass. American Journal of Physiology-Heart and Circulatory Physiology. 2014;307:H967&#x2013;H975. doi: 10.1152/ajpheart.00397.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00397.2014</ArticleId><ArticleId IdType="pubmed">25063797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraut JA, Madias NE. Lactic acidosis. New England Journal of Medicine. 2014;371:2309&#x2013;2319. doi: 10.1056/NEJMra1309483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1309483</ArticleId><ArticleId IdType="pubmed">25494270</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Zielske D, Bouillon B, Hauser C, Levy H. Lactic acidosis is associated with multiple organ failure and need for ventilator support in patients with severe hemorrhage from trauma. European Journal of Trauma and Emergency Surgery. 2013;39:487&#x2013;493. doi: 10.1007/s00068-013-0285-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-013-0285-3</ArticleId><ArticleId IdType="pubmed">26815445</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Xiao J, Duan X, Lu X, Gong X, Chen J, Xiong M, Yin S, Guo X, Wu Z. The multivariable prognostic models for severe complications after heart valve surgery. BMC Cardiovascular Disorders. 2021;21:491. doi: 10.1186/s12872-021-02268-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-021-02268-z</ArticleId><ArticleId IdType="pmc">PMC8504034</ArticleId><ArticleId IdType="pubmed">34635052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak NT, Iqbal S, de&#xa0;Varennes B, Khwaja K. Outcomes of post-cardiac surgery patients with persistent hyperlactatemia in the intensive care unit: a matched cohort study. Journal of Cardiothoracic Surgery. 2016;11:33. doi: 10.1186/s13019-016-0411-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-016-0411-5</ArticleId><ArticleId IdType="pmc">PMC4765137</ArticleId><ArticleId IdType="pubmed">26906890</ArticleId></ArticleIdList></Reference><Reference><Citation>Minton J, Sidebotham DA. Hyperlactatemia and cardiac surgery. The Journal of ExtraCorporeal Technology. 2017;49:7&#x2013;15. doi: 10.1051/ject/201749007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/ject/201749007</ArticleId><ArticleId IdType="pmc">PMC5347225</ArticleId><ArticleId IdType="pubmed">28298660</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik R, George G, Karuppiah S, Philip MA. Hyperlactatemia in patients undergoing adult cardiac surgery under cardiopulmonary bypass: causative factors and its effect on surgical outcome. Annals of Cardiac Anaesthesia. 2016;19:668&#x2013;675. doi: 10.4103/0971-9784.191579.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0971-9784.191579</ArticleId><ArticleId IdType="pmc">PMC5070327</ArticleId><ArticleId IdType="pubmed">27716698</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Kim SJ, Lee SW, Lee EJ, Han KS, Moon SW, Hong YS. Initial low oxygen extraction ratio is related to severe organ dysfunction and high in-hospital mortality in severe sepsis and septic shock patients. Journal of Emergency Medicine. 2015;49:261&#x2013;267. doi: 10.1016/j.jemermed.2015.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jemermed.2015.02.038</ArticleId><ArticleId IdType="pubmed">26037480</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope JV, Jones AE, Gaieski DF, Arnold RC, Trzeciak S, Shapiro NI, Emergency Medicine Shock Research&#xa0;Network I Multicenter study of central venous oxygen saturation (ScvO(2)) as a predictor of mortality in patients with sepsis. Annals of Emergency Medicine. 2010;55:40&#x2013;46. doi: 10.1016/j.annemergmed.2009.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2009.08.014</ArticleId><ArticleId IdType="pmc">PMC2828585</ArticleId><ArticleId IdType="pubmed">19854541</ArticleId></ArticleIdList></Reference><Reference><Citation>Radelfahr F, Klopstock T. Mitochondrial diseases. Nervenarzt. 2019;90:121&#x2013;130. doi: 10.1007/s00115-018-0666-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00115-018-0666-2</ArticleId><ArticleId IdType="pubmed">30643957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M, De&#xa0;Toffol B, Isgr&#xf2; G, Romitti F, Conti D, Vicentini M. Hyperlactatemia during cardiopulmonary bypass: determinants and impact on postoperative outcome. Critical Care. 2006;10:R167. doi: 10.1186/cc5113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc5113</ArticleId><ArticleId IdType="pmc">PMC1794481</ArticleId><ArticleId IdType="pubmed">17134504</ArticleId></ArticleIdList></Reference><Reference><Citation>Renew JR, Barbara DW, Hyder JA, Dearani JA, Rivera M, Pulido JN. Frequency and outcomes of severe hyperlactatemia after elective cardiac surgery. Journal of Thoracic and Cardiovascular Surgery. 2016;151:825&#x2013;830. doi: 10.1016/j.jtcvs.2015.10.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2015.10.063</ArticleId><ArticleId IdType="pubmed">26687885</ArticleId></ArticleIdList></Reference><Reference><Citation>Rixen D, Siegel JH. Bench-to-bedside review: oxygen debt and its metabolic correlates as quantifiers of the severity of hemorrhagic and post-traumatic shock. Critical Care. 2005;9:441&#x2013;453. doi: 10.1186/cc3526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc3526</ArticleId><ArticleId IdType="pmc">PMC1297598</ArticleId><ArticleId IdType="pubmed">16277731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnick MR, Blair GJ, Kuschner WG, Barr J. Lactic acidosis and the role of sodium bicarbonate: a narrative opinion. Shock. 2020;53:528&#x2013;536. doi: 10.1097/SHK.0000000000001415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001415</ArticleId><ArticleId IdType="pubmed">31318832</ArticleId></ArticleIdList></Reference><Reference><Citation>Senst B, Kumar A, Diaz RR. Cardiac surgery. StatPearls; Treasure Island (FL): 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">30422530</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens EH, Epting CL, Backer CL, Wald EL. Hyperlactatemia: an update on postoperative lactate. World Journal for Pediatric and Congenital Heart Surgery. 2020;11:316&#x2013;324. doi: 10.1177/2150135120903977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2150135120903977</ArticleId><ArticleId IdType="pubmed">32294015</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppe C, McDonald B, Benstoem C, Elke G, Meybohm P, Whitlock R, Fremes S, Fowler R, Lamarche Y, Jiang X, Day AG, Heyland DK. Evaluation of persistent organ dysfunction plus death as a novel composite outcome in cardiac surgical patients. Journal of Cardiothoracic and Vascular Anesthesia. 2016;30:30&#x2013;38. doi: 10.1053/j.jvca.2015.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2015.07.035</ArticleId><ArticleId IdType="pubmed">26847748</ArticleId></ArticleIdList></Reference><Reference><Citation>Teloh JK, Dohle DS, Sonmez S, Tsagakis K, Verhaegh R, Petersen M, Jakob H, de&#xa0;Groot H. Transient dilutional acidosis but no lactic acidosis upon cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Archives of Medical Science. 2017;13:585&#x2013;590. doi: 10.5114/aoms.2016.58144.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2016.58144</ArticleId><ArticleId IdType="pmc">PMC5420618</ArticleId><ArticleId IdType="pubmed">28507572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zante B, Reichenspurner H, Kubik M, Kluge S, Schefold JC, Pfortmueller CA. Base excess is superior to lactate-levels in prediction of ICU mortality after cardiac surgery. PLOS ONE. 2018;13:e0205309. doi: 10.1371/journal.pone.0205309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0205309</ArticleId><ArticleId IdType="pmc">PMC6173442</ArticleId><ArticleId IdType="pubmed">30289956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zheng D, Chu XQ, Jiang YP, Wang CG, Zhang QM, Qian LZ, Yang WY, Zhang WY, Tung TH, Lin RH. DeltaPCO(2) and DeltaPCO(2)/C((a-cv))O(2) are not predictive of organ dysfunction after cardiopulmonary bypass. Frontiers in Cardiovascular Medicine. 2021;8:759826. doi: 10.3389/fcvm.2021.759826.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.759826</ArticleId><ArticleId IdType="pmc">PMC8671605</ArticleId><ArticleId IdType="pubmed">34926611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao PY, Xia Y, Tao ZB, Li SY, Mao Z, Yang XP, Yao RQ, Du XH. Global research status of multiple organ dysfunction syndrome during 2001&#x2013;2021: a 20-year bibliometric analysis. Frontiers in Medicine (Lausanne) 2022;9:814381. doi: 10.3389/fmed.2022.814381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.814381</ArticleId><ArticleId IdType="pmc">PMC8931214</ArticleId><ArticleId IdType="pubmed">35308515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30815028</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1749-7922</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>World journal of emergency surgery : WJES</Title><ISOAbbreviation>World J Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Pre-hospital plasma in haemorrhagic shock management: current opinion and meta-analysis of randomized trials.</ArticleTitle><Pagination><StartPage>6</StartPage><MedlinePgn>6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13017-019-0226-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Trauma-induced coagulopathy is one of the most difficult issues to manage in severely injured patients. The plasma efficacy in treating haemorrhagic-shocked patients is well known. The debated issue is the timing at which it should be administered. Few evidences exist regarding the effects on mortality consequent to the use of plasma alone given in pre-hospital setting. Recently, two randomized trials reported interesting and discordant results. The present paper aims to analyse data from those two randomized trials in order to obtain more univocal results.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review with meta-analysis of randomized controlled trials (RCTs) of pre-hospital plasma vs. usual care in patients with haemorrhagic shock.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two high-quality RCTs have been included with 626 patients (295 in plasma and 331 in usual care arm). Twenty-four-hour mortality seems to be reduced in pre-hospital plasma group (RR&#x2009;=&#x2009;0.69; 95% CI&#x2009;=&#x2009;0.48-0.99). Pre-hospital plasma has no significant effect on 1-month mortality (RR&#x2009;=&#x2009;0.86; 95% CI&#x2009;=&#x2009;0.68-1.11) as on acute lung injury and on multi-organ failure rates (OR&#x2009;=&#x2009;1.03; 95% CI&#x2009;=&#x2009;0.71-1.50, and OR&#x2009;=&#x2009;1.30; 95% CI&#x2009;=&#x2009;0.92-1.86, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pre-hospital plasma infusion seems to reduce 24-h mortality in haemorrhagic shock patients. It does not seem to influence 1-month mortality, acute lung injury and multi-organ failure rates.<b>Level of evidence:</b> Level I<b>Study type:</b> Systematic review with Meta-analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coccolini</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1General, Emergency and Trauma Surgery, Bufalini Hospital, Viale Ghirotti 268, 47521 Cesena, Italy.</Affiliation><Identifier Source="ISNI">0000 0004 1758 8744</Identifier><Identifier Source="GRID">grid.414682.d</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzilli</LastName><ForeName>Giacinto</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2ICU department, Bufalini Hospital, Cesena, Italy.</Affiliation><Identifier Source="ISNI">0000 0004 1758 8744</Identifier><Identifier Source="GRID">grid.414682.d</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbella</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>3ICU department, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation><Identifier Source="ISNI">0000 0004 1757 8431</Identifier><Identifier Source="GRID">grid.460094.f</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sartelli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Surgery department, Macerata Hospital, Macerata, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agnoletti</LastName><ForeName>Vanni</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>2ICU department, Bufalini Hospital, Cesena, Italy.</Affiliation><Identifier Source="ISNI">0000 0004 1758 8744</Identifier><Identifier Source="GRID">grid.414682.d</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agostini</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>5Transfusional and Immunohaematological disorders department, Bufalini hospital, Cesena, Italy.</Affiliation><Identifier Source="ISNI">0000 0004 1758 8744</Identifier><Identifier Source="GRID">grid.414682.d</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baiocchi</LastName><ForeName>Gian Luca</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>6Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation><Identifier Source="ISNI">0000000417571846</Identifier><Identifier Source="GRID">grid.7637.5</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansaloni</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1General, Emergency and Trauma Surgery, Bufalini Hospital, Viale Ghirotti 268, 47521 Cesena, Italy.</Affiliation><Identifier Source="ISNI">0000 0004 1758 8744</Identifier><Identifier Source="GRID">grid.414682.d</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catena</LastName><ForeName>Fausto</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>7Emergency surgery department, Parma University Hospital, Parma, Italy.</Affiliation><Identifier Source="GRID">grid.411482.a</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Emerg Surg</MedlineTA><NlmUniqueID>101266603</NlmUniqueID><ISSNLinking>1749-7922</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004632" MajorTopicYN="N">Emergency Medical Services</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="Y">Plasma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Haemorrhagic</Keyword><Keyword MajorTopicYN="N">Management</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Pre-hospital</Keyword><Keyword MajorTopicYN="N">Shock</Keyword><Keyword MajorTopicYN="N">Trauma</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Not applicableNot applicableThe authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30815028</ArticleId><ArticleId IdType="pmc">PMC6377767</ArticleId><ArticleId IdType="doi">10.1186/s13017-019-0226-5</ArticleId><ArticleId IdType="pii">226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smith IM, James RH, Dretzke J, Midwinter MJ. Prehospital blood product resuscitation for trauma: a systematic review. Shock. 2016;1:3&#x2013;16. doi: 10.1097/SHK.0000000000000569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000569</ArticleId><ArticleId IdType="pmc">PMC4933578</ArticleId><ArticleId IdType="pubmed">26825635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashuk JL, Moore EE, Johnson JL, Haenel J, Wilson M, Moore JB, Cothren CC, Biffl WL, Banerjee A, Sauaia A. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma. 2008;65(2):261&#x2013;270. doi: 10.1097/TA.0b013e31817de3e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31817de3e1</ArticleId><ArticleId IdType="pubmed">18695460</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JB, Cohen MJ, Minei JP, Maier RV, West MA, Billiar TR, Peitzman AB, Moore EE, Cushieri J, Inflammation SJL, Host response to injury I Debunking the survival bias myth: characterization of mortality during the initial 24 hours for patients requiring massive transfusion. J Trauma Acute Care Surg. 2012;73(2):358&#x2013;364. doi: 10.1097/TA.0b013e31825889ba.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31825889ba</ArticleId><ArticleId IdType="pubmed">22846940</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma. 1997;42(5):857&#x2013;861. doi: 10.1097/00005373-199705000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199705000-00016</ArticleId><ArticleId IdType="pubmed">9191667</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder CW, Weinberg JA, McGwin G, Jr, Melton SM, George RL, Reiff DA, Cross JM, Hubbard-Brown J, Rue LW, 3rd, Kerby JD. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma. 2009;66(2):358&#x2013;362. doi: 10.1097/TA.0b013e318196c3ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318196c3ac</ArticleId><ArticleId IdType="pubmed">19204508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri J, Rosengart MR, Maier RV, Billiar TR, Peitzman AB, Moore EE, Inflammation the host response to injury I An FFP:PRBC transfusion ratio &gt;/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma. 2008;65(5):986&#x2013;993. doi: 10.1097/TA.0b013e3181878028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181878028</ArticleId><ArticleId IdType="pubmed">19001962</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62:307&#x2013;310. doi: 10.1097/TA.0b013e3180324124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3180324124</ArticleId><ArticleId IdType="pubmed">17297317</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen HH, Elaheh Rahbar E, Baer LA, Holcomb JB, Cotton BA, Steinmetz J. Pre-hospital transfusion of plasma in hemorrhaging trauma patients independently improves hemostatic competence and acidosis. Scand J Trauma Resusc Emerg Med. 2016;24:145. doi: 10.1186/s13049-016-0327-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-016-0327-z</ArticleId><ArticleId IdType="pmc">PMC5148857</ArticleId><ArticleId IdType="pubmed">27938373</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore HB, Moore EE, Chapman MP, McVaney K, Bryskiewicz G, Blechar R, et al. Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial. Lancet. 2018;392(10144):283&#x2013;291. doi: 10.1016/S0140-6736(18)31553-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31553-8</ArticleId><ArticleId IdType="pmc">PMC6284829</ArticleId><ArticleId IdType="pubmed">30032977</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry JL, Guyette FX, Brown JB, Yazer MH, Triulzi DJ, Early-Young BJ, et al. Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. N Engl J Med. 2018;379(4):315&#x2013;326. doi: 10.1056/NEJMoa1802345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1802345</ArticleId><ArticleId IdType="pubmed">30044935</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, J&#xfc;ni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6(3):341&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">3616287</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussmann B, Lefering R, Waydhas C, et al. Does increased prehospital replacement volume lead to a poor clinical course and an increased mortality? A matched-pair analysis of 1896 patients of the Trauma Registry of the German Society for Trauma Surgery who were managed by an emergency doctor at the accident site. Injury. 2013;44:611&#x2013;617. doi: 10.1016/j.injury.2012.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2012.02.004</ArticleId><ArticleId IdType="pubmed">22377276</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EE, Chin TL, Chapman MC, Gonzalez E, Moore HB, Silliman CC. Plasma first in the field for postinjury hemorrhagic shock. Shock. 2014;41(0 1):35&#x2013;38. doi: 10.1097/SHK.0000000000000110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000110</ArticleId><ArticleId IdType="pmc">PMC4004607</ArticleId><ArticleId IdType="pubmed">24317352</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs. a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313:471&#x2013;482. doi: 10.1001/jama.2015.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.12</ArticleId><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma. 2007;62:112&#x2013;119. doi: 10.1097/01.ta.0000250497.08101.8b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ta.0000250497.08101.8b</ArticleId><ArticleId IdType="pubmed">17215741</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Critical Care. 2013;17:R76. doi: 10.1186/cc12685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc12685</ArticleId><ArticleId IdType="pmc">PMC4056078</ArticleId><ArticleId IdType="pubmed">23601765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurusamy KS, Rossi M, Davidson BR. Percutaneous cholecystostomy for high-risk surgical patients with acute calculous cholecystitis. Cochrane Database Syst Rev. 2013;8:CD007088.</Citation><ArticleIdList><ArticleId IdType="pubmed">23939652</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann DN, Hazeldine J, Davies DJ, et al. Endotheliopathy of trauma is an on-scene phenomenon, and is associated with multiple organ dysfunction syndrome: a prospective observational study. Shock. 2018;49:420&#x2013;428. doi: 10.1097/SHK.0000000000000999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000999</ArticleId><ArticleId IdType="pubmed">28945676</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann DN, Hazeldine J, Dinsdale RJ, et al. Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: a prospective observational study. PLoS One. 2017;12(12):e0189870. doi: 10.1371/journal.pone.0189870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0189870</ArticleId><ArticleId IdType="pmc">PMC5736230</ArticleId><ArticleId IdType="pubmed">29261771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton BA, Reddy N, Hatch QM, et al. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Ann Surg. 2011;254:598&#x2013;605. doi: 10.1097/SLA.0b013e318230089e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e318230089e</ArticleId><ArticleId IdType="pmc">PMC3816774</ArticleId><ArticleId IdType="pubmed">21918426</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time varying treatment with competing risks. JAMA Surg. 2013;148:127&#x2013;136. doi: 10.1001/2013.jamasurg.387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamasurg.387</ArticleId><ArticleId IdType="pmc">PMC3740072</ArticleId><ArticleId IdType="pubmed">23560283</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckbert SR, Vedder NB, Hoffman W, et al. Outcome after hemorrhagic shock in trauma patients. J Trauma. 1998;45:545&#x2013;549. doi: 10.1097/00005373-199809000-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199809000-00022</ArticleId><ArticleId IdType="pubmed">9751548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33622196</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-2928</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Redox report : communications in free radical research</Title><ISOAbbreviation>Redox Rep</ISOAbbreviation></Journal><ArticleTitle>Contribution of oxidative stress in the mechanisms of postoperative complications and multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>35</StartPage><EndPage>44</EndPage><MedlinePgn>35-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13510002.2021.1891808</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The extent of the damage following surgery has been subject of study for several years. Numerous surgical complications can impact postoperative quality of life of patients and even can cause mortality. Although these complications are generally due to multifactorial mechanisms, oxidative stress plays a key pathophysiological role. Moreover, oxidative stress could be an unavoidable effect derived even from the surgical procedure itself.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review was performed following an electronic search of Pubmed and ScienceDirect databases. Keywords such as sepsis, oxidative stress, organ dysfunction, antioxidants, outcomes in postoperative complications, among others, were used. Review articles were preferably used between the years 2015 onwards, not excluding older ones.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The vast majority point to the role of oxidative stress in generating greater damage and worse prognosis in postoperative patients without the necessary care and precautions, taking importance on the use of antioxidants to prevent this problem.</AbstractText><AbstractText Label="DISCUSSIONS" NlmCategory="CONCLUSIONS">Oxidative stress represents a common final pathway related to pathological processes such as inflammation or ischemia-reperfusion, among others. The expression of greater severity of these complications can result in multiple organ dysfunction or sepsis. The aim of this study was to present an update of the role of oxidative stress on surgical postoperative complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toro-P&#xe9;rez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0924-9561</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigo</LastName><ForeName>Ram&#xf3;n</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1724-571X</Identifier><AffiliationInfo><Affiliation>Molecular and Clinical Pharmacology Program, Faculty of Medicine, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Redox Rep</MedlineTA><NlmUniqueID>9511366</NlmUniqueID><ISSNLinking>1351-0002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Surgery</Keyword><Keyword MajorTopicYN="N">antioxidants</Keyword><Keyword MajorTopicYN="N">organ failure</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33622196</ArticleId><ArticleId IdType="pmc">PMC7906620</ArticleId><ArticleId IdType="doi">10.1080/13510002.2021.1891808</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000;85:109&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">10927999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo NE, Feldman L, Scott S, et al. . Impact of preoperative change in physical function on postoperative recovery: argument supporting prehabilitation for colorectal surgery. Surgery. 2011;150(3):505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">21878237</ArticleId></ArticleIdList></Reference><Reference><Citation>Donz&#xe9; J, Aujesky D, Williams D, et al. . Potentially avoidable 30-day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA Intern Med. 2013;173(8):632&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">23529115</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubert CE, Folly A, Mancinetti M, et al. . Performance-based functional impairment and readmission and death: a prospective study. BMJ Open. 2017;7:e016207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726050</ArticleId><ArticleId IdType="pubmed">28600376</ArticleId></ArticleIdList></Reference><Reference><Citation>Story DA. Postoperative mortality and complications. BP &amp; RC Anaesthesiol. 2011;25(3):319&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">21925399</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustarini D, Dalle-Donne I, Tsikas D, et al. . Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci. 2009;46:241&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">19958214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Giordano S, Zhang J.. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. The Biochemical J. 2012;441(2):523&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258656</ArticleId><ArticleId IdType="pubmed">22187934</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger DN, Kvietys PR.. Reperfusion injury and reactive oxygen species: the evolution of a concept. Redox Biol. 2015;6:524&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625011</ArticleId><ArticleId IdType="pubmed">26484802</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Vrishni S, Singh BK, et al. . Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res. 2010;44(11):1267&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">20815789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DD, Hannink M.. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23(22):8137&#x2013;8151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC262403</ArticleId><ArticleId IdType="pubmed">14585973</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SD, Reed TT, Venditti P, et al. . Role of ROS and RNS sources in physiological and pathological conditions. Oxidat M Cel Long. 2016;2016:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4960346</ArticleId><ArticleId IdType="pubmed">27478531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Xiang W, Potts J, et al. . Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic Biol Med. 2006;41:1384&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023265</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo G, Turner T, Rodrigo R.. Myocardial reperfusion injury: novel pathophysiological bases for therapy. In: Myocardial infarction. Chapter 4. Berlin: Avid Science; 2017. p. 2&#x2013;32.</Citation></Reference><Reference><Citation>Gutteridge JM, Mitchell J.. Redox imbalance in the critically ill. Brit M Bullet. 1999;55(1):49&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10695079</ArticleId></ArticleIdList></Reference><Reference><Citation>Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth. 2011;107(1):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">21596843</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JL, Feelisch M, Martin DS.. Perioperative oxidative stress. Anesth Analg. 2019;129(6):1749&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pubmed">31743197</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday KR, Hurt JB, Harrelson P, et al. . Evaluating postoperative fever. J Amer Acad Phys Assist. 2016;29(10):23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">27623291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard K, Krause KH.. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007;87:245&#x2013;313. doi: 10.1152/physrev.00044.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00044.2005</ArticleId><ArticleId IdType="pubmed">17237347</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet JM, Reeves G, Billman GE, et al. . Inflammation-nature&#x2019;s way to efficiently respond to all types of challenges: implications for understanding and managing &#x201c;the epidemic&#x201d; of chronic diseases. Front Med. 2018;5:316. doi: 10.3389/fmed.2018.00316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00316</ArticleId><ArticleId IdType="pmc">PMC6277637</ArticleId><ArticleId IdType="pubmed">30538987</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnani ND, Marchini T, Calabr&#xf3; V, et al. . Role of mitochondria in the redox signaling network and its outcomes in high impact inflammatory syndromes. Front. Endocrinol. 2020;11:568305. doi: 10.3389/fendo.2020.568305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.568305</ArticleId><ArticleId IdType="pmc">PMC7538663</ArticleId><ArticleId IdType="pubmed">33071976</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen L, Mengozzi M, Hanschmann E-M, et al. . How the redox state regulates immunity. Free Radical Biol Med. 2019. doi:10.1016/j.freeradbiomed.2019.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2019.12.022</ArticleId><ArticleId IdType="pubmed">31899344</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschopp J. Mitochondria: sovereign of inflammation? Eur J Immunol. 2011;41:1196&#x2013;1202. doi: 10.1002/eji.201141436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201141436</ArticleId><ArticleId IdType="pubmed">21469137</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialkow L, Wang Y, Downey GP.. Reactive oxygen and nitrogen species as signaling regulating neutrophil function. Free Radic Biol Med. 2007;42:153&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17189821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills CD. Anatomy of a discovery: m1 and m2 macrophages. Front. Immunol. 2015;6:212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419847</ArticleId><ArticleId IdType="pubmed">25999950</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. . Macrophage plasticity, polarization, and function in health and disease. J Cell. Physiol. 2018;233(9):6425&#x2013;6440.</Citation><ArticleIdList><ArticleId IdType="pubmed">29319160</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn GS, Lee KW, Choi SY, et al. . Overexpression of HDAC6 induces proinflammatory responses by regulating ROS-MAPK-NF-kappaB/AP-1 signaling pathways in macrophages. Free Radic Biol Med. 2016;97:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">27208785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Yang CH, Tsai YF, et al. . Ugonin U stimulates NLRP3 inflammasome activation and enhances inflammasome-mediated pathogen clearance. Redox Biol. 2017;11:263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198739</ArticleId><ArticleId IdType="pubmed">28012441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M-Y, Yiang G-T, Liao W-T, et al. . Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46:1650&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pubmed">29694958</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchon CA, El-Gabalawy HS.. Oxidation in rheumatoid arthritis. Arthritis Res Ther. 2004;6:265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1064874</ArticleId><ArticleId IdType="pubmed">15535839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatauret N, Badet L, Barrou B, et al. . Ischemia reperfusion: from cell biology to acute kidney injury. Progr&#xe8;s en Urologie. 2014;24(1):4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24950932</ArticleId></ArticleIdList></Reference><Reference><Citation>Carden DL. Granger DN: pathophysiology of ischaemia&#x2013;reperfusion injury. J Pathol. 2000;190:255&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10685060</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigo R, Hasson D, Prieto JC, et al. . The effectiveness of antioxidant vitamins C and E in reducing myocardial infarct size in patients subjected to percutaneous coronary angioplasty (PREVEC trial): study protocol for a pilot randomized double-blind controlled trial. Trials. 2014;15:192. doi:10.1186/1745-6215-15-192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-15-192</ArticleId><ArticleId IdType="pmc">PMC4050098</ArticleId><ArticleId IdType="pubmed">24885600</ArticleId></ArticleIdList></Reference><Reference><Citation>Pile JC. Evaluating postoperative fever: a focused approach. Cleve Clin J Med. 2006;73(1):62&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16570551</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JD, Grocott HP, Phillips-Bute B, et al. . Cytokine secretion after cardiac surgery and its relationship to postoperative fever. Cytokine. 2007;38(1):37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572096</ArticleId></ArticleIdList></Reference><Reference><Citation>Garami A, Steiner AA, Romanovsky AA.. Fever and hypothermia in systemic inflammation. Handb Clin Neurol. 2018: 565&#x2013;597. doi:10.1016/b978-0-444-64074-1.00034-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-444-64074-1.00034-3</ArticleId><ArticleId IdType="pubmed">30459026</ArticleId></ArticleIdList></Reference><Reference><Citation>Avner JR. Acute fever. Pediatr Rev. 2009;30(1):5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118137</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JM, Badwey JA.. Production of active oxygen species by phagocytic leukocytes. Immunol Ser. 1994;60:159&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">8251566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JY, Tsou MY, Chen TH, et al. . Therapeutic effects of melatonin on peritonitis-induced septic shock with multiple organ dysfunction syndrome in rat. J. Pineal Res. 2008;45:106&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">18298464</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim Biophys Acta. 2001;1504(1):46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11239484</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrades M, Ritter C, Moreira JCF, et al. . Oxidative parameters differences during non-lethal and lethal sepsis development. J Surg Res. 2005;125:68&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836852</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion. 2004;4:729&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">16120428</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605959</ArticleId><ArticleId IdType="pubmed">19061483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Gayosso I, Platts SH, Duling BR.. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Amer J Phys H C Phys. 2006;290(6):H2247&#x2013;H2256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399871</ArticleId></ArticleIdList></Reference><Reference><Citation>Prauchner CA. Oxidative stress in sepsis: pathophysiological implications justifying antioxidant co-therapy. Burns. 2017;43(3):471&#x2013;485. doi:10.1016/j.burns.2016.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.09.023</ArticleId><ArticleId IdType="pubmed">28034666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov AV, Bahrami S, Calzia E, et al. . Mitochondrial dysfunction and biogenesis: do ICU patients die from mitochondrial failure? Ann Intensive Care. 2011;1:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224479</ArticleId><ArticleId IdType="pubmed">21942988</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendyala S, Gorshkova IA, Usatyuk PV, et al. . Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells. Antioxid Redox Signal. 2009;11:747&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850303</ArticleId><ArticleId IdType="pubmed">18783311</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Bellissant E, Cavaillon J-M.. Septic shock. The Lancet. 2005;365(9453):63&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639681</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, van der Poll T.. Severe sepsis and septic shock. New Engl J Med. 2013;369(9):840&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">23984731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonomini F, Rodella LF, Rezzani R.. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis. 2015;6:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365955</ArticleId><ArticleId IdType="pubmed">25821639</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao J, Arthur JF, Gardiner EE, et al. . Regulation of platelet activation and thrombus formation by reactive oxygen species. Redox Biol. 2018;14:126&#x2013;130. doi:10.1016/j.redox.2017.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.08.021</ArticleId><ArticleId IdType="pmc">PMC5596263</ArticleId><ArticleId IdType="pubmed">28888895</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur JF, Shen Y, Gardiner EE, et al. . TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J. Thromb. Haemost. 2011;9:163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">20946164</ArticleId></ArticleIdList></Reference><Reference><Citation>Begonja AJ, Gambaryan S, Geiger J, et al. . Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood. 2005;106:2757&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15976180</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhananjayan R, Koundinya KS, Malati T, et al. . Endothelial dysfunction in type 2 diabetes mellitus. Indian J Clin Biochem. 2016;31(4):372&#x2013;379. doi:10.1007/s12291-015-0516-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-015-0516-y</ArticleId><ArticleId IdType="pmc">PMC4992481</ArticleId><ArticleId IdType="pubmed">27605734</ArticleId></ArticleIdList></Reference><Reference><Citation>Incalza MA, D&#x2019;Oria R, Natalicchio A, et al. . Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1&#x2013;19. doi:10.1016/j.vph.2017.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2017.05.005</ArticleId><ArticleId IdType="pubmed">28579545</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Anderson TJ.. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105(5):546&#x2013;549. doi:10.1161/hc0502.104540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc0502.104540</ArticleId><ArticleId IdType="pubmed">11827916</ArticleId></ArticleIdList></Reference><Reference><Citation>Touyz RM, Montezano AC.. Vascular Nox4: a multifarious NADPH oxidase. Circ Res. 2012;110:1159&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, Vincent JL, Adhikari NK, et al. . Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">25932591</ArticleId></ArticleIdList></Reference><Reference><Citation>Yellon DM, Hausenloy DJ.. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrakos C, Vincent JL.. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875530</ArticleId><ArticleId IdType="pubmed">20144219</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles PE, Gibot S.. Predicting outcome in patients with sepsis: new biomarkers for old expectations. Crit Care. 2014;18:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056609</ArticleId><ArticleId IdType="pubmed">24517597</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Engelen TSR, Wiersinga WJ, Scicluna BP, et al. . Biomarkers in sepsis. Crit Care Clin. 2018;34(1):139&#x2013;152. doi:10.1016/j.ccc.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2017.08.010</ArticleId><ArticleId IdType="pubmed">29149935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese-Krott MM, Koning A, Kuhnle GGC, et al. . The reactive species interactome: evolutionary emergence, biological significance, and opportunities for redox metabolomics and personalized medicine. Antioxid Redox Signal. 2017;27:684&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576088</ArticleId><ArticleId IdType="pubmed">28398072</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki O, Matsumura Y, Inoue T, et al. . Association of perioperative redox balance on long-term outcome in patients undergoing lung resection. Ann Thorac Cardiovasc Surg. 2018;24:13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833135</ArticleId><ArticleId IdType="pubmed">29129842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez M. Multiple organ dysfunction syndrome. Curr Problem Pediatr Adolesc Health Care. 2013;43:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendel M, Heller a R, Koch T.. Pathomechanisms of organ failure. mitochondrial dysfunction in sepsis. Anaesthesist. 2009;58:343&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">19384532</ArticleId></ArticleIdList></Reference><Reference><Citation>Vera S, Mart&#xed;nez R, Gormaz JG, et al. . Novel relationships between oxidative stress and angiogenesis-related factors in sepsis: New biomarkers and therapies. Ann Med. 2015;47(4):289&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">25998489</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RS, Jacobs JP, Badhwar V, et al. . The society of thoracic surgeons adult cardiac surgery database: 2019 update on outcomes and quality. Ann Thorac Surg. 2019;107(1):24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">30423335</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakkar M, Ascione R, James AF, et al. . In&#xfb02;ammation, oxidative stress and postoperative atrial &#xfb01;brillation in cardiac surgery. Pharmacol Ther. 2015;154:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26116810</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn JY, Zhang J, Zhang Y, et al. . Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol. 2013;62:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735724</ArticleId><ArticleId IdType="pubmed">23643589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YM, Guzik TJ, Zhang YH, et al. . A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005;97:629636.</Citation><ArticleIdList><ArticleId IdType="pubmed">16123335</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhadi RH, Gurm HS, Van Wagoner DR, et al. . Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol. 2004;93:1176&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">15110218</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Pol A, van Gilst WH, Voors AA, et al. . Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2018. doi:10.1002/ejhf.1320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1320</ArticleId><ArticleId IdType="pmc">PMC6607515</ArticleId><ArticleId IdType="pubmed">30338885</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymes C, Bendall JK, Ratajczak P, et al. . Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164&#x2013;2171.</Citation><ArticleIdList><ArticleId IdType="pubmed">12821241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajamieh H, Merino N, Candelario-Jalil E, et al. . Similar protective e&#xfb00;ect of ischaemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. Pharmacol R. 2002;45(4):333&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">12030798</ArticleId></ArticleIdList></Reference><Reference><Citation>Starlinger P, Pereyra D, Haegele S, et al. . Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. Hepatology. 2018;67(4):1516&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">29140542</ArticleId></ArticleIdList></Reference><Reference><Citation>Senoner T, Schindler S, St&#xe4;ttner S, et al. . Associations of oxidative stress and postoperative outcome in liver surgery with an outlook to future potential therapeutic options. Oxidat Med Cell Long. 2019;2019:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393879</ArticleId><ArticleId IdType="pubmed">30906502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricksten SE, Bragadottir G, Redfors B.. Renal oxygenation in clinical acute kidney injury. Crit Care. 2013;17:221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672481</ArticleId><ArticleId IdType="pubmed">23514538</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodowski SD, Wagener G.. New insights into the mechanisms of acute kidney injury in the intensive care unit. Jl of Clinic Anesth. 2015;27(2):175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">25480306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Bellomo R.. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13(11):697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">28869251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovcanin B, Medic B, Kocic G, et al. . Molecular dissection of renal ischemia-reperfusion: oxidative stress and cellular events. Curr Med Chem. 2016;23(19):1965&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">26758795</ArticleId></ArticleIdList></Reference><Reference><Citation>Prowle JR, et al. . Combination of biomarkers for diagnosis of acute kidney injury after cardiopulmonary bypass. Ren Fail. 2015;37:408&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544762</ArticleId><ArticleId IdType="pubmed">25585949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotomayor C, Cortes I, Gormaz J, et al. . Role of oxidative stress in renal transplantation: bases for an n-3 PUFA strategy against delayed graft function. Curr Med Chem. 2017;24(14):1469&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">28245764</ArticleId></ArticleIdList></Reference><Reference><Citation>Lameire N, Van Biesen W, Vanholder R.. Acute renal failure. Lancet. 2005;365(9457):417&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680458</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolisetty S, Agarwal A.. Neutrophils in acute kidney injury: not neutral any more. Kidney Int. 2009;75:674&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">19282858</ArticleId></ArticleIdList></Reference><Reference><Citation>Travica N, Ried K, Sali A, et al. . Vitamin C status and cognitive function: a systematic review. Nutrients. 2017;9(9):960. doi: 10.3390/nu9090960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9090960</ArticleId><ArticleId IdType="pmc">PMC5622720</ArticleId><ArticleId IdType="pubmed">28867798</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisoschi AM, Pop A.. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015;97:55&#x2013;74. doi:10.1016/j.ejmech.2015.04.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2015.04.040</ArticleId><ArticleId IdType="pubmed">25942353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-Y, Lee S-M.. Effect of ascorbic acid on hepatic vasoregulatory gene expression during polymicrobial sepsis. Life Sci. 2004;75:2015&#x2013;2026.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306168</ArticleId></ArticleIdList></Reference><Reference><Citation>Descamps-Latscha B, Dr&#xfc;eke T, Witko-Sarsat V.. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin. Dialysis. 2001;14:193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422926</ArticleId></ArticleIdList></Reference><Reference><Citation>Himmelfarb J, Hakim RM.. Oxidative stress in uremia. Curr. Opin. Nephrol. Hyp. 2003;12:593&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">14564195</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaraj S, Jialal I.. The effects of alpha-tocopherol on critical cells in atherogenesis. Curr. Opin. Lipidol. 1998;9:11&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9502329</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu B-G, Lee R-P, Yang F-L, et al. . Posttreatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci. 2006;79:2010&#x2013;2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">16860347</ArticleId></ArticleIdList></Reference><Reference><Citation>Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, et al. . N-Acetyl cysteine targets hepatic lipid accumulation to curb oxidative stress and inflammation in NAFLD: A comprehensive analysis of the literature. Antioxidants (Basel). 2020;9(12):1283. doi: 10.3390/antiox9121283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9121283</ArticleId><ArticleId IdType="pmc">PMC7765616</ArticleId><ArticleId IdType="pubmed">33339155</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwell TS, Blackwell TR, Holden EP, et al. . In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol. 1996;157(4):1630&#x2013;1637.</Citation><ArticleIdList><ArticleId IdType="pubmed">8759749</ArticleId></ArticleIdList></Reference><Reference><Citation>Prauchner CA. A import&#xe2;ncia do sel&#xea;nio para a agropecu&#xe1; ria e sa&#xfa; de humana. Santa Maria (RS/Brasil): Editora UFSM; 2014.</Citation></Reference><Reference><Citation>Prabhu KS, Zamamiri-Davis F, Stewart JB, et al. . Selenium deficiency increases the expression of inducible nitric oxide synthase in RAW 264.7 macrophages: role of nuclear factor-kB in up-regulation. Biochem J. 2002;366:203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222757</ArticleId><ArticleId IdType="pubmed">12006087</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigo R, Korantzopoulos P, Cereceda M, et al. . A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol. 2013;62(16):1457&#x2013;1465. doi:10.1016/j.jacc.2013.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.07.014</ArticleId><ArticleId IdType="pubmed">23916928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31638914</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-230X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC gastroenterology</Title><ISOAbbreviation>BMC Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Minimally invasive drainage versus open surgical debridement in SAP/SMAP - a network meta-analysis.</ArticleTitle><Pagination><StartPage>168</StartPage><MedlinePgn>168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12876-019-1078-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The efficacy of some therapeutic methods (open surgical debridement (OSD), conservative treatment (CST) and minimally invasive drainage (MID)) for severe acute pancreatitis (SAP) and moderately severe acute pancreatitis (MSAP) has been widely evaluated. However, the results remained controversial. We performed this study to illuminate whether any difference in incidence exists on patients with SAP/MSAP treated with OSD and MID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eligible articles were collected base of a comprehensive review of PUBMED, EMBASE, COCHRANE, CKNI and WANGFANG for published randomized controlled trials. Two steps of meta-analysis were performed, routine pair-wise meta-analysis and network meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen studies were included in this study. Participants were classed as 5 groups, CST, early MID (EMID), late MID (LMID), early OSD (EOSD) and late OSD (LOSD). And MID contains endoscopic drainage (ESD), percutaneous catheter drainage (PCD) and minimally invasive surgery (MIS). Compared with CST, MID could decrease both mortality and multiple organ dysfunction syndrome (MODS) rate but OSD couldn't. Both EMID and MID can significantly decrease the mortality and MODS rate compared to CST. PCD might be most likely to have a benefit compared to CST.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Existing evidence for the use of MID in SAP/MSAP is reliable and it can be used as early treatment. OSD, if necessary, should be avoided or delayed as long as possible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pancreatic Center &amp; Department of General Surgery, The First Affliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreas Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaole</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pancreatic Center &amp; Department of General Surgery, The First Affliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreas Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Chaoqun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pancreatic Center &amp; Department of General Surgery, The First Affliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreas Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Chenyuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pancreatic Center &amp; Department of General Surgery, The First Affliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreas Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5129-2603</Identifier><AffiliationInfo><Affiliation>Pancreatic Center &amp; Department of General Surgery, The First Affliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. miaoyi@njmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreas Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. miaoyi@njmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Pancreatic Center &amp; Department of General Surgery, The First Affliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. liqiang020202@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreas Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. liqiang020202@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JX10231801</GrantID><Agency>the Priority Academic Program Development of Jiangsu Higher Education Institutions</Agency><Country/></Grant><Grant><GrantID>No. BM2015004</GrantID><Agency>The Innovation Capability Development Project of Jiangsu Province</Agency><Country/></Grant><Grant><GrantID>BM2015004</GrantID><Agency>Jiangsu Biobank of Clinical Resource</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Gastroenterol</MedlineTA><NlmUniqueID>100968547</NlmUniqueID><ISSNLinking>1471-230X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072700" MajorTopicYN="N">Conservative Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003646" MajorTopicYN="Y">Debridement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004724" MajorTopicYN="N">Endoscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Investigations</Keyword><Keyword MajorTopicYN="N">Network meta-analysis</Keyword><Keyword MajorTopicYN="N">Organ failure</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31638914</ArticleId><ArticleId IdType="pmc">PMC6802312</ArticleId><ArticleId IdType="doi">10.1186/s12876-019-1078-x</ArticleId><ArticleId IdType="pii">10.1186/s12876-019-1078-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662544</ArticleId><ArticleId IdType="pubmed">23622135</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman M, Friedman LS, Brandt LJ, et al. Sleisenger and Fordtran&#x2019;s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 10. Philadelphia: Saunders/Elsevier; 2015.</Citation></Reference><Reference><Citation>Bradley EL., III A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586&#x2013;590. doi: 10.1001/archsurg.1993.01420170122019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1993.01420170122019</ArticleId><ArticleId IdType="pubmed">8489394</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Party of the British Society of Gastroenterology, Association of Surgeons of Great Britain and Ireland, Pancreatic Society of Great Britain and Ireland, Association of Upper GI Surgeons of Great Britain and Ireland UK guidelines for the management of acute pancreatitis. Gut. 2005;54:iii1&#x2013;iii9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867800</ArticleId><ArticleId IdType="pubmed">15831893</ArticleId></ArticleIdList></Reference><Reference><Citation>Toouli J, Brooke-Smith M, Bassi C, et al. Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol. 2002;17:15&#x2013;39. doi: 10.1046/j.1440-1746.17.s1.2.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1746.17.s1.2.x</ArticleId><ArticleId IdType="pubmed">12000591</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl W, Warshaw A, Imrie C, et al. IAP guidelines for the surgical management of acute pancreatitis. Pancreatology. 2002;2:565&#x2013;573. doi: 10.1159/000067684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000067684</ArticleId><ArticleId IdType="pubmed">12435871</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner J, Feuerbach S, Uhl W, et al. Management of acute pancreatitis: from surgery to interventional intensive care. Gut. 2005;54:426&#x2013;436. doi: 10.1136/gut.2003.035907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.035907</ArticleId><ArticleId IdType="pmc">PMC1774421</ArticleId><ArticleId IdType="pubmed">15710995</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenvi S, Gupta R, Kang M. Timing of surgical intervention in patients of infected necrotizing pancreatitis not responding to percutaneous catheter drainage. Pancreatology. 2016;16(5):778&#x2013;787. doi: 10.1016/j.pan.2016.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2016.08.006</ArticleId><ArticleId IdType="pubmed">27592206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H-k, Du X-j, Li A, Ke N-w, Hu W-m. A minimally invasive management for abdominal compartment syndrome in severe acute pancreatitis. Pak J Med Sci. 2013;29:231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809173</ArticleId><ArticleId IdType="pubmed">24353548</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;chler MW, Gloor B, M&#xfc;ller CA, et al. Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg. 2000;232(5):619&#x2013;626. doi: 10.1097/00000658-200011000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200011000-00001</ArticleId><ArticleId IdType="pmc">PMC1421214</ArticleId><ArticleId IdType="pubmed">11066131</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieuwenhuijs VB, Besselink MG, van Minnen LP, et al. Surgical management of acute necrotizing pancreatitis: a 13-year experience and a systematic review. Scand J Gastroenterol Suppl. 2003;239:111&#x2013;116. doi: 10.1080/00855920310002799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00855920310002799</ArticleId><ArticleId IdType="pubmed">14743893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rau B, Bothe A, Beger HG. Surgical treatment of necrotizing pancreatitis by necrosectomy and closed lavage: changing patient characteristics and outcome in a 19-year, single-center series. Surgery. 2005;138:28&#x2013;39. doi: 10.1016/j.surg.2005.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2005.03.010</ArticleId><ArticleId IdType="pubmed">16003313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc. 1994;8:408&#x2013;410. doi: 10.1007/BF00642443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00642443</ArticleId><ArticleId IdType="pubmed">7915434</ArticleId></ArticleIdList></Reference><Reference><Citation>Song KB, Kim SC, Hwang DW, et al. Matched case-control analysis comparing laparoscopic and open pylorus-preserving pancreaticoduodenectomy in patients with periampullary tumors. Ann Surg. 2015;262:146&#x2013;155. doi: 10.1097/SLA.0000000000001079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001079</ArticleId><ArticleId IdType="pubmed">25563866</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362:1491e502.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410514</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. March, 2011. http://www.cochrane-handbook.org (Accessed 9 Apr 2015).</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Clin Trials. 1986;7:177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80&#x2013;97. doi: 10.1002/jrsm.1037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1037</ArticleId><ArticleId IdType="pubmed">26062083</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic. Int J Epidemiol. 2012;41(3):818&#x2013;827. doi: 10.1093/ije/dys041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dys041</ArticleId><ArticleId IdType="pmc">PMC3396310</ArticleId><ArticleId IdType="pubmed">22461129</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700 reviews. Int J Epidemiol. 2012;41:818&#x2013;827. doi: 10.1093/ije/dys041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dys041</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker OJ, van Santvoort HC, van Brunschot S, et al. Dutch Pancreatitis Study Group Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA. 2012;307:1053&#x2013;1061. doi: 10.1001/jama.2012.276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.276</ArticleId><ArticleId IdType="pubmed">22416101</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rooij T, Klompmaker S, Abu Hilal M, et al. Laparoscopic pancreatic surgery for benign and malignant disease. Nat Rev Gastroenterol Hepatol. 2016;13:227&#x2013;238. doi: 10.1038/nrgastro.2016.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2016.17</ArticleId><ArticleId IdType="pubmed">26882881</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola A, Stauffer JA, Asbun HJ. Laparoscopic pancreatoduodenectomy: current status and future directions. Updat Surg. 2016;68:217&#x2013;224. doi: 10.1007/s13304-016-0402-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13304-016-0402-z</ArticleId><ArticleId IdType="pubmed">27815783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wu X, Zhu F, et al. Systematic review and metaanalysis of minimally invasive versus open approach for pancreaticoduodenectomy. Surg Endosc. 2016;30:5173&#x2013;5184. doi: 10.1007/s00464-016-4864-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-016-4864-3</ArticleId><ArticleId IdType="pubmed">27005287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cai H, Meng L, et al. Minimally invasive pancreaticoduodenectomy: a comprehensive review. Int J Surg. 2016;35:139&#x2013;146. doi: 10.1016/j.ijsu.2016.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2016.09.016</ArticleId><ArticleId IdType="pubmed">27664556</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H, Qiu J, Zhao Y, et al. Does minimally-invasive pancreaticoduodenectomy have advantages over its open method? A meta-analysis of retrospective studies. PLoS One. 2014;9:e104274. doi: 10.1371/journal.pone.0104274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104274</ArticleId><ArticleId IdType="pmc">PMC4132100</ArticleId><ArticleId IdType="pubmed">25119463</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Group IAP/APA Acute Pancreatitis Guidelines IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 a 2):e1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400&#x2013;1416. doi: 10.1038/ajg.2013.218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2013.218</ArticleId><ArticleId IdType="pubmed">23896955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai X, Qian X, Pan W, et al. Ultrasound-guided percutaneous drainage may decrease the mortality of severe acute pancreatitis. J Gastroenterol. 2010;45(1):77. doi: 10.1007/s00535-009-0129-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-009-0129-4</ArticleId><ArticleId IdType="pubmed">19787287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X-Q, Wu J, Liu X-C, et al. Clinical contrast study of endoscopic treatment for acute biliary pancreatitis. World Chin J Digestol. 2007;15(3):298&#x2013;301.</Citation></Reference><Reference><Citation>Lin F. Clinical control study of early endoscopic therapy for severe gallstone pancreatitis. Chin J Gastroenterol Hepatol. 2016;25(8):903&#x2013;905.</Citation></Reference><Reference><Citation>Liu H, Chen K, Xiang G'a, et al. Laparoscopy combined with endoscopic and digital subtraction angiography for treatment of severe acute pancreatitis. J South Med Univ. 2009;29(8):1620&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726310</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Yan H, Liu W, et al. Abdominal paracentesis drainage does not increase infection in severe acute pancreatitis: A prospective study [J] J Clin Gastroenterol. 2015;49(9):757. doi: 10.1097/MCG.0000000000000358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000358</ArticleId><ArticleId IdType="pubmed">26053169</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;der T, Sainio V, Kivisaari L, et al. Pancreatic resection versus peritoneal lavage in acute necrotizing pancreatitis. Ann Surg. 1991;214(6):663&#x2013;666. doi: 10.1097/00000658-199112000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199112000-00004</ArticleId><ArticleId IdType="pmc">PMC1358489</ArticleId><ArticleId IdType="pubmed">1741645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Guiliang, Liu Hai, Xu Linfang, Wen Ping, Wen Jianbo, Zhou Shu-feng, Xiao Xianzhong. Effect of Laparoscopic Peritoneal Lavage and Drainage and Continuous Venovenous Diahemofiltration on Severe Acute Pancreatitis. Journal of Laparoendoscopic &amp; Advanced Surgical Techniques. 2017;27(11):1145&#x2013;1150. doi: 10.1089/lap.2016.0637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/lap.2016.0637</ArticleId><ArticleId IdType="pubmed">28586262</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Liu L, Sun L, et al. Efficacy of continuous peritoneal lavage for severe acute pancreatitis:a prospective randomized controlled study of 104 cases. Chin J Pancreatol. 2007;7(6):353&#x2013;356.</Citation></Reference><Reference><Citation>Zhang J, Yang Z'A, Li X, et al. Therapeutic effects of percutaneous catheter drainage for treatment of severe acute pancreatitis complocated with peripancreatic fluid collections. Chongqing Med. 2011;40(35):3543&#x2013;3544.</Citation></Reference><Reference><Citation>Wang Z, He Y, He C. The application of laparoscopic lavage drainage in early treatment of severe acute pancreatitis. J Guangxi Med Univ. 2006;23(6):981&#x2013;982.</Citation></Reference><Reference><Citation>Zhong Y, Cui N. The comparison of efficacy between early non-surgical treatment and early endoscopic treatment in biliary severe acute pancreatitis. Chin J Surg Integ Tradit West Med. 2013;4:361&#x2013;364.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31849646</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</ArticleTitle><Pagination><StartPage>1370</StartPage><MedlinePgn>1370</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1370</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2019.01370</ELocationID><Abstract><AbstractText><b>Background:</b> Ulinastatin has been prescribed to treat sepsis. However, there is doubt regarding the extent of any improvement in outcomes to guide future decision making. <b>Objectives:</b> To evaluate the effects of ulinastatin on mortality and related outcomes in sepsis patients. <b>Methods:</b> Thirteen randomized controlled trials and two prospective studies published before September 1, 2018, that included 1358 patients with sepsis, severe sepsis, or septic shock were evaluated. The electronic databases searched in this study were PubMed, Medline, Embase, and China National Knowledge Infrastructure (CNKI) for Chinese Technical Periodicals. <b>Results:</b> Ulinastatin significantly decreased the all-cause mortality {odds ratio (OR) = 0.48, 95% confidence interval (CI) [0.35-0.66], p &lt; 0.00001, I<sup>2</sup> = 13%}, Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score {mean difference (MD) = -2.40, 95% CI [-4.37, -0.44], p = 0.02, I<sup>2</sup> = 66%}, and reduced the incidence of multiple organ dysfunction syndrome (MODS) (OR = 0.3, 95% CI [0.18, 0.49], p &lt; 0.00001, I<sup>2</sup> = 0%). Ulinastatin also decreased the serum levels of IL-6 (MD = -88.5, 95% CI [-123.97, -53.04], p &lt; 0.00001), TNF-&#x3b1; (MD = -56.22, 95% CI [-72.11, -40.33], p &lt; 0.00001), and increased the serum levels of IL-10 (MD = 37.73, 95% CI [16.92, 58.54], p = 0.0004). Ulinastatin administration did not lead to any difference in the occurrence of adverse events. <b>Conclusions:</b> Ulinastatin improved all-cause mortality and other related outcomes in patients with sepsis or septic shock. The results of this meta-analysis suggest that ulinastatin may be an effective treatment for sepsis and septic shock.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Wang, Liu, Tang, Chang, Yao, Huang, Lodato and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huifang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Emergency Department, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Lishuai</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgical, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodato</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Pulmonary, Critical Care, and Sleep Medicine, Medical School, University of Texas Health Science Center at Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhanguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Pharmacol. 2020 Feb 21;10:1697. doi: 10.3389/fphar.2019.01697.</RefSource><PMID Version="1">32153390</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immune system</Keyword><Keyword MajorTopicYN="N">inflammatory cytokine</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">ulinastatin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31849646</ArticleId><ArticleId IdType="pmc">PMC6893897</ArticleId><ArticleId IdType="doi">10.3389/fphar.2019.01370</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angus D. C., Linde-Zwirble W. T., Lidicker J., Clermont G., Carcillo J., Pinsky M. R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29 (7), 1303&#x2013;1310. 10.1097/00003246-200107000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200107000-00002</ArticleId><ArticleId IdType="pubmed">11445675</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong B. A., Betzold R. D., May A. K. (2017). Sepsis and septic shock strategies. Surg. Clin. North Am. 97 (6), 1339&#x2013;1379. 10.1016/j.suc.2017.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suc.2017.07.003</ArticleId><ArticleId IdType="pubmed">29132513</ArticleId></ArticleIdList></Reference><Reference><Citation>Atal S. S., Atal S. (2016). Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome. J. Basic Clin. Physiol. Pharmacol. 27 (2), 91&#x2013;99. 10.1515/jbcpp-2015-0003</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jbcpp-2015-0003</ArticleId><ArticleId IdType="pubmed">26565549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang P., Liu J., Yu Y., Cui S. Y., Guo Z. H., Chen G. M. (2017. a). Alpha-lipoic acid suppresses extracellular histone-induced release of the infammatory mediator tumor necrosis factor-alpha by macrophages. Cell Physiol. Biochem. 42 (6), 2559&#x2013;2568. 10.1159/000480217</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000480217</ArticleId><ArticleId IdType="pubmed">28848097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang P., Mo B., Cauvi D. M., Yu Y., Guo Z., Zhou J. (2017. b). Grape seed proanthocyanidin extract protects lymphocytes against histone-induced apoptosis. PeerJ 5, e3108. 10.7717/peerj.3108</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.3108</ArticleId><ArticleId IdType="pmc">PMC5363264</ArticleId><ArticleId IdType="pubmed">28344907</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Peng S., Chen Y. (2015). Comparative observation of curative effects by ulinastatin and conventional method in the treatment of severe sepsis. Chinese J. Modern Drug App. 9 (7), 1&#x2013;2, 3. 10.14164/j.cnki.cn11-5581/r.2015.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.14164/j.cnki.cn11-5581/r.2015.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhuri A. H., Tyagi R., Tyagi R., Agarwal D., Uppal R. (2015). Early use of ulinastatin reduces Multiorgan Dysfunction (MODS) in septic shock following anastomotic failure. Clin. Therapeutics 37 (8), e112.</Citation></Reference><Reference><Citation>Chousterman B. G., Swirski F. K., Weber G. F. (2017). Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 39 (5), 517&#x2013;528. 10.1007/s00281-017-0639-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0639-8</ArticleId><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Q. X., Wang C. H. (2016). Effects of urinary trypsin inhibitor on serum levels of TNF-a, IL-8 and IL-10 in patients with severe sepsis. Chinese J. Biochem. Pharmaceutics 36 (3), 146&#x2013;148. 10.3969/j.issn.1005-1678.2016.03.48</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1005-1678.2016.03.48</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Q., Chen P. (2005). A Study on clinical efficacy of ulinastatin in severe sepsis patients and its mechanism of action. Chinese J. Of Infect. And Chemother. 5 (1), 13&#x2013;16. 10.3321/j.issn:1009-7708.2005.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.3321/j.issn:1009-7708.2005.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Q., Zhao X. (2017). Clinical effect of combined ulinastatin and continuous renal replacement therapy on management of severe sepsis with acute kidney injury. Tropical J. Pharmaceutical Res. 16 (4), 925&#x2013;930. 10.4314/tjpr.v16i4.26</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/tjpr.v16i4.26</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang M., Zhong W.-H., Song W.-L., Deng Y.-Y., Yang D.-M., Xiong B. (2018). Ulinastatin ameliorates pulmonary capillary endothelial permeability induced by sepsis through protection of tight junctions via inhibition of TNF-alpha and related pathways. Front. Pharmacol. 9, 823. 10.3389/fphar.2018.00823</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00823</ArticleId><ArticleId IdType="pmc">PMC6099086</ArticleId><ArticleId IdType="pubmed">30150933</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Shi Q., Fan Y., Wang Q., Yin W. (2016). Ulinastatin and/or thymosin alpha1 for severe sepsis: a systematic review and meta-analysis. J. Trauma Acute Care Surg. 80 (2), 335&#x2013;340. 10.1097/ta.0000000000000909</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ta.0000000000000909</ArticleId><ArticleId IdType="pubmed">26517783</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardot T., Rimmele T., Venet F., Monneret G. (2017). Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis 22 (2), 295&#x2013;305. 10.1007/s10495-016-1325-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-016-1325-3</ArticleId><ArticleId IdType="pubmed">27812767</ArticleId></ArticleIdList></Reference><Reference><Citation>Han D., Shang W., Wang G., Sun L., Zhang Y., Wen H. (2015). Ulinastatin- and thymosin alpha1-based immunomodulatory strategy for sepsis: a meta-analysis. Int. Immunopharmacol. 29 (2), 377&#x2013;382. 10.1016/j.intimp.2015.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2015.10.026</ArticleId><ArticleId IdType="pubmed">26522590</ArticleId></ArticleIdList></Reference><Reference><Citation>Harjai M., Bogra J., Kohli M., Pant A. B. (2013). Is suppression of apoptosis a new therapeutic target in sepsis?. Anaesth. Intensive Care 41 (2), 175&#x2013;183. 10.1177/0310057X1304100207</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0310057X1304100207</ArticleId><ArticleId IdType="pubmed">23530784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R. S., Crouser E. (2015). Imaging apoptosis in sepsis&#x2013;A technology we would die for!. Crit. Care Med. 43 (11), 2506&#x2013;2508. 10.1097/ccm.0000000000001289</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0000000000001289</ArticleId><ArticleId IdType="pmc">PMC4837329</ArticleId><ArticleId IdType="pubmed">26468702</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R. S., Nicholson D. W. (2006). Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6 (11), 813&#x2013;822. 10.1038/nri1943</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1943</ArticleId><ArticleId IdType="pubmed">17039247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R. S., Monneret G., Payen D. (2013). Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13 (12), 862&#x2013;874. 10.1038/nri3552</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui L., Shen F., Chang H., Li X., Gao G., Ma J. (2014). Effects of ulinastatin on cerebral oxygen metabolism and CRP levels in patients with severe traumatic brain injury. Exp. Therapeutic Med. 7 (6), 1683&#x2013;1686. 10.3892/etm.2014.1666</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.1666</ArticleId><ArticleId IdType="pmc">PMC4043583</ArticleId><ArticleId IdType="pubmed">24926366</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K.-I., Takano H. (2010). Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin. Investig. Drugs 19 (4), 513&#x2013;520. 10.1517/13543781003649533</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543781003649533</ArticleId><ArticleId IdType="pubmed">20367192</ArticleId></ArticleIdList></Reference><Reference><Citation>Itaba S., Nakamura K., Aso A., Tokunaga S., Akiho H., Ihara E. (2013). Prospective, randomized, double-blind, placebo-controlled trial of ulinastatin for prevention of hyperenzymemia after double balloon endoscopy via the antegrade approach. Dig. Endosc. 25 (4), 421&#x2013;427. 10.1111/den.12014</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/den.12014</ArticleId><ArticleId IdType="pubmed">23368820</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin. Trials 17 (1), 1&#x2013;12. 10.1016/0197-2456(95)00134-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L. Y., Hong Y. L., Xing C. J. (2006). The effect of Ulinastatin on the delivery of cytokines in patients with septic shock. Chinese J. Of Emergency Med. 15 (1671-0282), 1136&#x2013;1138. 10.3760/j.issn:1671-0282.2006.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/j.issn:1671-0282.2006.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W., Yu X., Sun T., Chai Y., Chang P., Chen Z. (2018). ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study): study protocol for a randomized controlled trial. Trials 19 (1), 133. 10.1186/s13063-018-2513-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-018-2513-y</ArticleId><ArticleId IdType="pmc">PMC5822617</ArticleId><ArticleId IdType="pubmed">29467017</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnad D. R., Bhadade R., Verma P. K., Moulick N. D., Daga M. K., Chafekar N. D. (2014). Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 40 (6), 830&#x2013;838. 10.1007/s00134-014-3278-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-014-3278-8</ArticleId><ArticleId IdType="pmc">PMC4028549</ArticleId><ArticleId IdType="pubmed">24737258</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Li T., Li Y., Cai S., Zhang Z., Zeng Z. (2014). Ulinastatin inhibits oxidant-induced endothelial hyperpermeability and apoptotic signaling. Int. J. Clin. Exp. Pathol. 7 (11), 7342&#x2013;7350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270631</ArticleId><ArticleId IdType="pubmed">25550770</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Bo L., Liu Q., Jin F. (2015). Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int. J. Infect. Dis. 33, 90&#x2013;96. 10.1016/j.ijid.2014.12.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.12.032</ArticleId><ArticleId IdType="pubmed">25532482</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Ma D., Chen M., Zhang L., Zhang L., Zhang J. (2016). Ulinastatin attenuates LPS-induced human endothelial cells oxidative damage through suppressing JNK/c-Jun signaling pathway. Biochem. Biophys. Res. Commun. 474 (3), 572&#x2013;578. 10.1016/j.bbrc.2016.04.104</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.04.104</ArticleId><ArticleId IdType="pubmed">27109479</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A., Altman D. G., Tetzlaff J., Mulrow C., Gotzsche P. C., Ioannidis J. P. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700. 10.1136/bmj.b2700</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder A., Russell J. A. (2014). An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med. 40 (8), 1164&#x2013;1167. 10.1007/s00134-014-3366-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-014-3366-9</ArticleId><ArticleId IdType="pubmed">24990495</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z.-G., Zhang J., He Y., Chang P., Gu D.-S., Luo Y.-W. (2011). Impact of transfusion of apoptotic and necrotic thymocytes on the survival of mice with sepsis. J. Of Southern Med. Univ. 31 (6), 960&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">21690045</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z. G., Ni S. Y., Chen G. M., Cai J., Guo Z. H., Chang P. (2013). Histones-mediated lymphocyte apoptosis during sepsis is dependent on p38 phosphorylation and mitochondrial permeability transition. PLoS One 8 (10), e77131. 10.1371/journal.pone.0077131</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077131</ArticleId><ArticleId IdType="pmc">PMC3805602</ArticleId><ArticleId IdType="pubmed">24167561</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Yu Z., Yin J., Chen Y., Zhang H., Fan X. (2017). Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients. J. Crit. Care 39, 285&#x2013;287. 10.1016/j.jcrc.2017.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2017.02.005</ArticleId><ArticleId IdType="pubmed">28283220</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin G. S., Mannino D. M., Eaton S., Moss M. (2003). The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348 (16), 1546&#x2013;1554. 10.1056/NEJMoa022139</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa022139</ArticleId><ArticleId IdType="pubmed">12700374</ArticleId></ArticleIdList></Reference><Reference><Citation>Minasyan H. (2017). Sepsis and septic shock: Pathogenesis and treatment perspectives. J. Crit. Care 40, 229&#x2013;242. 10.1016/j.jcrc.2017.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2017.04.015</ArticleId><ArticleId IdType="pubmed">28448952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni H. Y., Fang Q., Zhang Y. S. (2008). Effects of ulinastatin on Inflammatory response and curative effect in severe sepsis patients. Chinese J. Of Crit. Care Med. 28 (4), 342&#x2013;344. 10.3969/j.issn.1002-1949.2008.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1002-1949.2008.04.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Patera A. C., Drewry A. M., Chang K., Beiter E. R., Osborne D., Hotchkiss R. S. (2016). Frontline Science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J. Leukoc. Biol. 100 (6), 1239&#x2013;1254. 10.1189/jlb.4HI0616-255R</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.4HI0616-255R</ArticleId><ArticleId IdType="pmc">PMC5110001</ArticleId><ArticleId IdType="pubmed">27671246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavan Kumar Rao N., Sv S., Nayak K. S. (2017). Use of ulinastatin in renal failure patients developing sepsis. Indian J. Nephrol. 27, S68&#x2013;S69.</Citation></Reference><Reference><Citation>Rajaee A., Barnett R., Cheadle W. G. (2018). Pathogen- and danger-associated molecular patterns and the cytokine response in sepsis. Surg. Infect. (Larchmt) 19 (2), 107&#x2013;116. 10.1089/sur.2017.264</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2017.264</ArticleId><ArticleId IdType="pubmed">29364781</ArticleId></ArticleIdList></Reference><Reference><Citation>Servillo G., Vargas M., Pastore A., Procino A., Iannuzzi M., Capuano A. (2013). Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data. Biomed. Res. Int. 2013, 108951. 10.1155/2013/108951</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/108951</ArticleId><ArticleId IdType="pmc">PMC3736510</ArticleId><ArticleId IdType="pubmed">23971020</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Y. M., Zhang L. Q., Deng L. H., Yao H. G. (2005). [Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 17 (4), 228&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836828</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu H., Liu K., He Q., Zhong F., Yang L., Li Q. (2014). Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery. Blood Transfus. 12 Suppl 1, s109&#x2013;s118. 10.2450/2013.0224-12</Citation><ArticleIdList><ArticleId IdType="doi">10.2450/2013.0224-12</ArticleId><ArticleId IdType="pmc">PMC3934215</ArticleId><ArticleId IdType="pubmed">23736923</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C. S., Seymour C. W., Shankar-Hari M., Annane D., Bauer M. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama 315 (8), 801&#x2013;810. 10.1001/jama.2016.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J. E., Kang W. S., Kim D. K., Yoon T. G., Kim T. Y., Bang Y. S. (2011). The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass. J. Int. Med. Res. 39 (4), 1201&#x2013;1210. 10.1177/147323001103900408</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/147323001103900408</ArticleId><ArticleId IdType="pubmed">21986122</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoller J., Halpin L., Weis M., Aplin B., Qu W., Georgescu C. (2016). Epidemiology of severe sepsis: 2008-2012. J. Crit. Care 31 (1), 58&#x2013;62. 10.1016/j.jcrc.2015.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2015.09.034</ArticleId><ArticleId IdType="pubmed">26601855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun R., Zhang Y., Lv Q., Liu B., Jin M., Zhang W. (2011). Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J. Biol. Chem. 286 (18), 15918&#x2013;15928. 10.1074/jbc.M110.178798</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.178798</ArticleId><ArticleId IdType="pmc">PMC3091201</ArticleId><ArticleId IdType="pubmed">21367858</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung W. M., Sung W. L., Yun S. H., Dae W. P., Ik J. J., Young H. Y. (2009). The effects of urinary trypsin inhibitor on the outcomes of severe sepsis and septic shock patients. Korean Emergency Medical J. 20, 80&#x2013;85.</Citation></Reference><Reference><Citation>Tang J. (2013). The clinical effect analysis of treating septicopyemia patients with ulinastatin. Guide China Med. (15), 439&#x2013;440. 10.3969/j.issn.1671-8194.2013.15.333</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1671-8194.2013.15.333</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida M., Abe T., Ono K., Tamiya N. (2018). Ulinastatin did not reduce mortality in elderly multiple organ failure patients: a retrospective observational study in a single center ICU. Acute Med. Surg. 5 (1), 90&#x2013;97. 10.1002/ams2.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ams2.304</ArticleId><ArticleId IdType="pmc">PMC5797838</ArticleId><ArticleId IdType="pubmed">29445506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li X., Kexi L. (2007). Influence of Ulinastatin on cytokines of patients with sepsis. Modern Med. J. Of China 9 (11), 23&#x2013;25. 10.3969/j.issn.1672-9463.2007.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1672-9463.2007.11.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F. Y., Fang B., Qiang X. H., Yu T. O., Zhong J. R., Cao J., et al. (2016). The efficacy and immunomodulatory effects of ulinastatin and thymosin alpha1 for sepsis: a systematic review and meta-analysis. Biomed. Res. Int. 2016, 9508493. 10.1155/2016/9508493</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9508493</ArticleId><ArticleId IdType="pmc">PMC4906180</ArticleId><ArticleId IdType="pubmed">27340674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedow O., Meyer-Hoffert U. (2005). Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J. Intern. Med. 257 (4), 319&#x2013;328. 10.1111/j.1365-2796.2005.01476.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2005.01476.x</ArticleId><ArticleId IdType="pubmed">15788001</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W. W. (1998). ICE family proteases in inflammation and apoptosis. Agents Actions Suppl 49, 5&#x2013;13. 10.1007/978-3-0348-8857-8_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-0348-8857-8_2</ArticleId><ArticleId IdType="pubmed">9426822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Zhou L., Liu J., Ma G., Kou Q., He Z. (2013. a). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17 (1), R8. 10.1186/cc11932</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11932</ArticleId><ArticleId IdType="pmc">PMC4056079</ArticleId><ArticleId IdType="pubmed">23327199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T. J., Zhang L. N., Kang C. C. (2013. b). The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 25 (4), 219&#x2013;223. 10.3760/cma.j.issn.2095-4352.2013.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.2095-4352.2013.04.010</ArticleId><ArticleId IdType="pubmed">23660098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Cui Z. B., Kang H. S., Zhao Y. Y., Liu S. H. (2016). Effect of ulinastatin on the serum levels of tumor necrosis factor &#x3b1;, interleukin 10,troponin I and C-reactive protein. J. Bengbu Med. College 41 (12), 1635&#x2013;1638. 10.13898/j.cnki.issn.1000-2200.2016.12.031</Citation><ArticleIdList><ArticleId IdType="doi">10.13898/j.cnki.issn.1000-2200.2016.12.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q., Yan Q., Chen S. (2018). Ulinastatin is effective in reducing mortality for critically ill patients with sepsis: a causal mediation analysis. Sci. Rep. 8 (1), 14360. 10.1038/s41598-018-32533-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-32533-9</ArticleId><ArticleId IdType="pmc">PMC6156583</ArticleId><ArticleId IdType="pubmed">30254204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Mao Y., Lu X., Sang X., Du S., Zhao H. (2011). The effects of urinary trypsin inhibitor on liver function and inflammatory factors in patients undergoing hepatectomy: a prospective, randomized, controlled clinical study. Am. J. Surg. 202 (2), 151&#x2013;157. 10.1016/j.amjsurg.2010.07.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2010.07.044</ArticleId><ArticleId IdType="pubmed">21718959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhou Y., Lou J., Li J., Bo L., Zhu K. (2010). PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit. Care 14 (6), R220. 10.1186/cc9354</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9354</ArticleId><ArticleId IdType="pmc">PMC3220038</ArticleId><ArticleId IdType="pubmed">21118528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Tan C., Wang X., Kang D., Chen Y., Xiong J. (2016). Preventive effects of ulinastatin on complications related to pancreaticoduodenectomy: a Consort-prospective, randomized, double-blind, placebo-controlled trial. Med. (Baltimore) 95 (24), e3731. 10.1097/md.0000000000003731</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000003731</ArticleId><ArticleId IdType="pmc">PMC4998438</ArticleId><ArticleId IdType="pubmed">27310952</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38062303</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-0961</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Neurocritical care</Title><ISOAbbreviation>Neurocrit Care</ISOAbbreviation></Journal><ArticleTitle>Multiorgan Dysfunction Syndrome in Abusive and Accidental Pediatric Traumatic Brain Injury.</ArticleTitle><Pagination><StartPage>1099</StartPage><EndPage>1108</EndPage><MedlinePgn>1099-1108</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12028-023-01887-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Abusive head trauma (AHT) is a mechanism of pediatric traumatic brain injury (TBI) with high morbidity and mortality. Multiorgan dysfunction syndrome (MODS), defined as organ dysfunction in two or more organ systems, is also associated with morbidity and mortality in critically ill children. Our objective was to compare the frequency of MODS and evaluate its association with outcome between AHT and accidental TBI (aTBI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a single center, retrospective cohort study including children under 3 years old admitted to the pediatric intensive care unit with nonpenetrating TBI between 2014 and 2021. Presence or absence of MODS on days 1, 3, and 7 using the Pediatric Logistic Organ Dysfunction-2 score and new impairment status (Functional Status Scale score change&#x2009;&gt;&#x2009;1 compared with preinjury) at hospital discharge (HD), short-term timepoint, and long-term timepoint&#xa0;were abstracted from the electronic health record. Multiple logistic regression was performed to examine the association between MODS and TBI mechanism with new impairment status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 576 children, 215 (37%) had AHT and 361 (63%) had aTBI. More children with AHT had MODS on days 1 (34% vs. 23%, p&#x2009;=&#x2009;0.003), 3 (28% vs. 6%, p&#x2009;&lt;&#x2009;0.001), and 7 (17% vs. 3%, p&#x2009;&lt;&#x2009;0.001) compared with those with aTBI. The most common organ failures were cardiovascular ([AHT] 66% vs. [aTBI] 66%, p&#x2009;=&#x2009;0.997), neurologic (33% vs. 16%, p&#x2009;&lt;&#x2009;0.001), and respiratory (34% vs. 15%, p&#x2009;&lt;&#x2009;0.001). MODS was associated with new impairment in multivariable logistic regression at HD (odds ratio 19.1 [95% confidence interval 9.8-38.6, p&#x2009;&lt;&#x2009;0.001]), short-term discharge (7.4 [3.7-15.2, p&#x2009;&lt;&#x2009;0.001]), and long-term discharge (4.3 [2.0-9.4, p&#x2009;&lt;&#x2009;0.001])]. AHT was also associated with new impairment at HD (3.4 [1.6-7.3, p&#x2009;=&#x2009;0.001]), short-term discharge (2.5 [1.3-4.7, p&#x2009;=&#x2009;0.005]), and long-term discharge (2.1 [1.1-4.1, p&#x2009;=&#x2009;0.036]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Abusive head trauma as a mechanism was associated with MODS following TBI. Both AHT mechanism and MODS were associated with new impairment at all time points.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Caitlin R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. mcnamaracr@upmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Even</LastName><ForeName>Katelyn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, Pennsylvania State University, State College, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinowski</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horvat</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaines</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Division of Pediatric Surgery, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Ward M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Surgery, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochanek</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Rachel P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Ericka L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 HD040686</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32HD040686-22</GrantID><Agency>Foundation for the National Institutes of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurocrit Care</MedlineTA><NlmUniqueID>101156086</NlmUniqueID><ISSNLinking>1541-6933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002649" MajorTopicYN="Y">Child Abuse</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081084" MajorTopicYN="N">Accidental Injuries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Child abuse</Keyword><Keyword MajorTopicYN="N">Long-term effects</Keyword><Keyword MajorTopicYN="N">Multiorgan dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Pediatric intensive care units</Keyword><Keyword MajorTopicYN="N">Traumatic brain injury</Keyword></KeywordList><CoiStatement>Conflicts of interest. No authors have any personal or financial affiliations that could present a conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>4</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38062303</ArticleId><ArticleId IdType="mid">NIHMS1956554</ArticleId><ArticleId IdType="pmc">PMC11147737</ArticleId><ArticleId IdType="doi">10.1007/s12028-023-01887-y</ArticleId><ArticleId IdType="pii">10.1007/s12028-023-01887-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rebbe R, Mienko JA, Martinson ML. Incidence and risk factors for abusive head trauma: a population-based study. Child Abuse Rev. 2020;29(3):195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567009</ArticleId><ArticleId IdType="pubmed">33071539</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan ME, Zolotor AJ, Parrish JW, Barr RG, Runyan DK. National, regional, and state abusive head trauma: Application of the CDC algorithm. Pediatrics. 2013;132(6):e1546&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074669</ArticleId><ArticleId IdType="pubmed">24276842</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T, Yokota H, Morita A. Pediatric traumatic brain injury: characteristic features, diagnosis, and management. Neurol Med Chir (Tokyo). 2017;57(2):82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341344</ArticleId><ArticleId IdType="pubmed">28111406</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson C, Xu L, Florence C, Parks SE. Annual cost of US hospital visits for pediatric abusive head trauma. Child Maltreat. 2015;20(3):162&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675617</ArticleId><ArticleId IdType="pubmed">25911437</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Runyan DK, Nocera M. Child outcomes and family characteristics 1 year after severe inflicted or noninflicted traumatic brain injury. Pediatrics. 2006;117(2):317&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367124</ArticleId><ArticleId IdType="pubmed">16452349</ArticleId></ArticleIdList></Reference><Reference><Citation>Haviland J, Ross Russell RI. Outcome after severe non-accidental head injury. Arch Dis Child. 1997;77(6):504&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1717403</ArticleId><ArticleId IdType="pubmed">9496184</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JE, Beres AL, Theodorou CM, Ugiliweneza B, Boakye M, Nu&#xf1;o M. Long-term impact of abusive head trauma in young children: Outcomes at 5 and 11 years old. J Pediatr Surg. 2021;56(12):2318&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8374003</ArticleId><ArticleId IdType="pubmed">33714452</ArticleId></ArticleIdList></Reference><Reference><Citation>Eismann EA, Theuerling J, Cassedy A, Curry PA, Colliers T, Makoroff KL. Early developmental, behavioral, and quality of life outcomes following abusive head trauma in infants. Child Abuse Negl. 2020;108:104643.</Citation><ArticleIdList><ArticleId IdType="pubmed">32739598</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Clark A, Holubkov R, Ewing-Cobbs L. Longitudinal Developmental Outcomes of Infants and Toddlers With Traumatic Brain Injury. JAMA Netw Open [Internet]. 2023;6(1):e2251195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856699</ArticleId><ArticleId IdType="pubmed">36648943</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller Ferguson N, Sarnaik A, Miles D, Shafi N, Peters MJ, Truemper E, et al. Abusive head trauma and mortality-an analysis from an international comparative effectiveness study of children with severe traumatic brain injury. Crit Care Med. 2017;45(8):1398&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511066</ArticleId><ArticleId IdType="pubmed">28430697</ArticleId></ArticleIdList></Reference><Reference><Citation>Paek D, Kwon DI. A review on four different paths to respiratory arrest from brain injury in children; implications for child abuse. J Forensic Leg Med. 2020;1:71.</Citation><ArticleIdList><ArticleId IdType="pubmed">32342908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, Glass NL, Yeh TS. Outcome of pediatric patients with multiple organ system failure. Crit Care Med [Internet]. 1986;14(4):271&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Glass NL, Kanter RK, Katz RW, Steinhart CM. Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr. 1987;111(3):324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3625400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna K, Hamidi M, Vartanyan P, Henry M, Castanon L, Tang A, et al. Non-neurologic organ dysfunction plays a major role in predicting outcomes in pediatric traumatic brain injury &#x2606;. J Pediatr Surg [Internet]. 2020;55(8):1590&#x2013;5. 10.1016/j.jpedsurg.2020.01.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpedsurg.2020.01.051</ArticleId><ArticleId IdType="pubmed">32081358</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Petersen NJ, Markovitz BPMMM. Day one MODS is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatr Crit Care Med. 2009;10(5):562&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780005</ArticleId><ArticleId IdType="pubmed">19741445</ArticleId></ArticleIdList></Reference><Reference><Citation>Killien EY, Zahlan JM, Lad H, Watson RS, Vavilala MS, Huijsmans RLN, et al. Epidemiology and outcomes of multiple organ dysfunction syndrome following pediatric trauma. J Trauma Acute Care Surg [Internet]. 2022;93(6):829&#x2013;37. 10.1097/TA.0000000000003616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003616</ArticleId><ArticleId IdType="pmc">PMC9525450</ArticleId><ArticleId IdType="pubmed">35358103</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JB, Gestring ML, Leeper CM, Sperry JL, Peitzman AB, Billiar TR, et al. The value of the injury severity score in pediatric trauma: Time for a new definition of severe injury? J Trauma Acute Care Surg. 2017;82(6):995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464600</ArticleId><ArticleId IdType="pubmed">28328674</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F. PELOD-2: an update of the PEdiatric logistic organ dysfunction score. Crit Care Med. 2013;41(7):1761&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wu Y, Huang H, Liu C, Cheng Y, Xu L, et al. Performance of PRISM III, PELOD-2, and P-MODS scores in two pediatric intensive care units in China. Front Pediatr. 2021;9:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113391</ArticleId><ArticleId IdType="pubmed">33996681</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamalin D, Hamlin I, Shults J, Katherine Henry M, Campbell KA, Anderst JD, et al. (2023) Predictors of making a referral to child protective services prior to expert consultation. Acad Pediatr.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10638459</ArticleId><ArticleId IdType="pubmed">37178908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JN, Henry MK, Berger RP, Lindberg DM, Anderst JD, Song L, et al. Use and utility of skeletal surveys to evaluate for occult fractures in young injured children. Acad Pediatr [Internet]. 2018. 10.1016/j.acap.2018.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acap.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6377846</ArticleId><ArticleId IdType="pubmed">30121318</ArticleId></ArticleIdList></Reference><Reference><Citation>Petridou ET, Antonopoulos CN. Injury epidemiology. Int Encycloped Public Health. 2017;1:258&#x2013;74.</Citation></Reference><Reference><Citation>Pollack MM, Holubkov R. The functional status score (FSS): a new pediatric outcome measure. Pediatrics. 2009;124(1):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191069</ArticleId><ArticleId IdType="pubmed">19564265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy JM, Ma J, Lyden ER, Haney SB. Abusive head trauma and a delay in presentation for care. Pediatr Emerg Care. 2020;38(1):e170&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32675710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulhan S, Lyon KA, Shapiro LA, Huang JH. Neuroinflammation and blood&#x2013;brain barrier disruption following traumatic brain injury: pathophysiology and potential therapeutic targets. J Neurosci Res. 2020;98:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437022</ArticleId><ArticleId IdType="pubmed">30259550</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017;18(3):S32&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333491</ArticleId><ArticleId IdType="pubmed">28248832</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas A, Krishnan P, Albalkhi I, Mankad K, Shroff M. Imaging of Abusive Head Trauma in Children. W.B. Saunders: Neuroimaging Clinics of North America; 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">36965952</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingman AL, Stence NV, O&#x2019;Neill BR, Sillau SH, Chapman KE. Seizure severity is correlated with severity of hypoxic-ischemic injury in abusive head trauma. Pediatr Neurol [Internet]. 2018;82:29&#x2013;35. 10.1016/j.pediatrneurol.2017.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2017.12.003</ArticleId><ArticleId IdType="pubmed">29625848</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh A, Olson LD, Chern JJ, Kim H. Clinical characteristics and nonconvulsive seizures in young children with abusive head trauma. J Child Neurol. 2019;34(12):713&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31185789</ArticleId></ArticleIdList></Reference><Reference><Citation>Komisarow JM, Chen F, Vavilala MS, Laskowitz D, James ML, Krishnamoorthy V. Epidemiology and outcomes of acute respiratory distress syndrome following isolated severe traumatic brain injury. J Intensive Care Med. 2022;37(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33191844</ArticleId></ArticleIdList></Reference><Reference><Citation>Humayun M, Premraj L, Shah V, Cho SM. Mechanical ventilation in acute brain injury patients with acute respiratory distress syndrome. Front Med (Lausanne) [Internet]. 2022;6:9. 10.3389/fmed.2022.999885/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.999885/full</ArticleId><ArticleId IdType="pmc">PMC9582443</ArticleId><ArticleId IdType="pubmed">36275802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18:424&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">33473203</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiaans SC, Duhachek-Stapelman AL, Russell RT, Lisco SJ, Kerby JD, Pittet JF. Coagulopathy after severe pediatric trauma. Shock. 2014;41:476&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024323</ArticleId><ArticleId IdType="pubmed">24569507</ArticleId></ArticleIdList></Reference><Reference><Citation>Almuqamam M, Novi B, Rossini CJ, Mammen A, DeSanti RL. Association of hyperchloremia and acute kidney injury in pediatric patients with moderate and severe traumatic brain injury. Child&#x2019;s Nervous Syst. 2023;39:1267&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">36595084</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vlieger G, Meyfroidt G. Kidney dysfunction after traumatic brain injury: pathophysiology and general management, Neurocritical Care. Berlin: Springer; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9629888</ArticleId><ArticleId IdType="pubmed">36324003</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Carcillo JA, Leclerc F, Leteurtre S, Schlapbach LJ, Tissieres P, et al. Refining the Pediatric Multiple Organ Dysfunction Syndrome. Pediatrics. 2022;1:149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9084565</ArticleId><ArticleId IdType="pubmed">34970671</ArticleId></ArticleIdList></Reference><Reference><Citation>Radermacher P, Billiar TR, Ghezzi P, Martin L, Thiemermann C. Editorial: translational insights into mechanisms and therapy of organ dysfunction in sepsis and trauma. Front Immunol. 2020;11:1987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546816</ArticleId><ArticleId IdType="pubmed">33101267</ArticleId></ArticleIdList></Reference><Reference><Citation>. Asim M, Amin F, El-Menyar A. Multiple organ dysfunction syndrome: Contemporary insights on the clinicopathological spectrum. Qatar Med J. 2020;2020(2):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884906</ArticleId><ArticleId IdType="pubmed">33628712</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson LW, Bass KD, Agyei JO, Naseem HUR, Borngraber E, Wang J, et al. Incidence of nonaccidental head trauma in infants: a call to revisit prevention strategies. J Neurosurg Pediatr [Internet]. 2019;24(6):689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">31629317</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlapbach LJ, Weiss SL, Bembea MM, Carcillo JA, Leclerc F, Leteurtre S, et al. Scoring systems for organ dysfunction and multiple organ dysfunction: the PODIUM consensus conference. Pediatrics [Internet]. 2022;149:S23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9703039</ArticleId><ArticleId IdType="pubmed">34970683</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembea MM, Agus M, Akcan-Arikan A, Alexander P, Basu R, Bennett TD, et al. Pediatric organ dysfunction information update mandate (PODIUM) contemporary organ dysfunction criteria: executive summary. Pediatrics [Internet]. 2022;149:S1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9599725</ArticleId><ArticleId IdType="pubmed">34970673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32242947</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1449</StartPage><EndPage>1459</EndPage><MedlinePgn>1449-1459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25822</ELocationID><Abstract><AbstractText Label="BACKGROUND">Currently, the epidemic of coronavirus disease 2019 (COVID-19) has begun to spread worldwide. We aim to explore reliable evidence for the diagnosis and treatment of the COVID-19 by analyzing all the published studies by Chinese scholars on the clinical and imaging features in novel coronavirus pneumonia caused by SARS-CoV-2.</AbstractText><AbstractText Label="METHODS">We searched five medical databases including two Chinese and three English databases for all published articles on COVID-19 since the outbreak. A random-effects model was designed, and the imaging and clinical data from all studies were collected for meta-analysis.</AbstractText><AbstractText Label="RESULTS">Overall, 31 articles and 46&#x2009;959 patients were included, including 10 English articles and 21 Chinese articles. The results of meta-analysis showed that the most common clinical manifestations were fever (87.3%; 0.838-0.909), cough (58.1%; 0.502-0.660), dyspnea (38.3%; 0.246-0.520), muscle soreness or fatigue (35.5%; 0.253-0.456), and chest distress (31.2%; -0.024 to 0.648). The main imaging findings were bilateral pneumonia (75.7%; 0.639-0.871) and ground-glass opacification (69.9%; 0.602-0.796). Among the patients, the incidence that required intensive care unit (ICU) was (29.3%; 0.190-0.395), the incidence with acute respiratory distress syndrome was (28.8%; 0.147-0.429), the incidence with multiple organ dysfunction syndrome was (8.5%; -0.008 to 0.179), and the case fatality rate of patients with COVID-19 was (6.8%; 0.044-0.093).</AbstractText><AbstractText Label="CONCLUSION">COVID-19 is a new clinical infectious disease that mainly causes bilateral pneumonia and lung function deteriorates rapidly. Nearly a third of patients need to be admitted to the ICU, and patients are likely to present respiratory failure or even death.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yinghao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Liyuan Hospital, Tongji Medical College, Huazhong University of Since and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nosocomial Infection Management, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Kailin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2572-0907</Identifier><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BB/N013468/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>02.03.2019-111</GrantID><Agency>Free Innovation Pre-research Fund and Platform Scientific Research Fund in 2019</Agency><Country>International</Country></Grant><Grant><GrantID>2018CFC884</GrantID><Agency>Science and Technology Department of Hubei Province</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019 novel coronavirus pneumonia</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">imaging finding</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32242947</ArticleId><ArticleId IdType="pmc">PMC7228215</ArticleId><ArticleId IdType="doi">10.1002/jmv.25822</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457&#x2010;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089049</ArticleId><ArticleId IdType="pubmed">32009228</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus&#x2010;infected pneumonia. N Engl J Med. 2020;382(13):1199&#x2010;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2010;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID&#x2010;19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Health Economics . Quality Appraisal of Case Series Studies Checklist; 2014.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507&#x2010;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019&#x2010;nCoV). Radiology. 2020;295(1):202&#x2010;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194022</ArticleId><ArticleId IdType="pubmed">32017661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x2010;infected pneumonia in Wuhan, China. JAMA. 2020;233(3):104&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Fang Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;3(4):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147277</ArticleId><ArticleId IdType="pubmed">32044814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092&#x2010;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042871</ArticleId><ArticleId IdType="pubmed">32031568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma X, Wang HY, et al. Computed tomography features of patients with novel coronavirus pneumonia. Shanghai Med J. 2020;43(2):1&#x2010;10.</Citation></Reference><Reference><Citation>Liu YX, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019&#x2010;nCoV infected patients linked to viral loads and lung injury (Chinese). Sci China Life Sci. 2020;50(3):258&#x2010;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Zhang JP, Du YH, et al. CT features of patients with imported 2019&#x2010;nCoV&#x2010;pneumonia. J Xi'an Jiaotong Univ (Med Sci) 2020;41(2):187.</Citation></Reference><Reference><Citation>Gong XM, Li H, Song L, et al. Preliminary explore on CT characteristics of coronavirus disease 2019 (COVID&#x2010;19). Radiol Prac. 2020;35(3):261&#x2010;265.</Citation></Reference><Reference><Citation>Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019&#x2010;nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;133(21):146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087663</ArticleId><ArticleId IdType="pubmed">32055945</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhang D, Tang S, et al. The epidemiological and clinical characteristics of 2019 novel coronavirus infection in Changsha, China. Preprint Lancet. 2020;50(2):342&#x2010;346.</Citation></Reference><Reference><Citation>Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID&#x2010;19) pneumonia. Radiology. 2020;35(1):200370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MQ, Wang XH, Chen YL, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jiehe He Huxi Zazhi. 2020;43(0):E013.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061066</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng K, Yun YX, Wang XF, et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection. Chin J Pediatr. 2020;58(3):E007.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XF, Yuan J, Zheng YJ, et al. Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Chin J Pediatr. 2020;58(1):E008.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062875</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel Coronavirus Pneumonia Emergency Response Epidemiology Team . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID&#x2010;19) in China. J. Chin Epi. 2020;41(2):145&#x2010;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392929</ArticleId><ArticleId IdType="pubmed">34594836</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu FM, Ding HL, Gong XM, et al. Chest CT performance and clinical characteristics of coronavirus disease 2019 (COVID&#x2010;19). Radiol Prac. 2020;35(3):266&#x2010;268.</Citation></Reference><Reference><Citation>Zhuang YJ, Chen Z, Li J. Clinical and epidemiological characteristics of 26 patients dia gnosed with novel coronavirus pneumonia. Chin J Nosocomiology. 2020;23(6):826&#x2010;829.</Citation></Reference><Reference><Citation>Wang K, Kang SR, Tian RH, et al. CT characteristic appearances of patients with novel coronavirus pneumonia. J Clin Med. 2020;1(27):27&#x2010;31.</Citation></Reference><Reference><Citation>Chen M, An W, Xia F, et al. Retrospective analysis of COVID&#x2010;19 patients with different clinical subtypes. Herald Med. 2020;41(5):1&#x2010;12.</Citation></Reference><Reference><Citation>Zhong FY, Zhang HF, Wang BC, et al. CT findings in 2019 novel coronavirus disease (COVID&#x2010;19) patients. Med J Wuhan Univ. 2020;31(1):1&#x2010;5.</Citation></Reference><Reference><Citation>Fu GZ, Xu CY, Sun HC, et al. Application of chest CT examination in screening of patients with novel coronavirus pneumonia. Med J Wenzhou Univ. 2020;20(2):1&#x2010;9.</Citation></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS&#x2010;CoV&#x2010;2 pneumonia in Wuhan, China: a single&#x2010;centered, retrospective, observational study. Lancet Respir Med. 2020;8(4):E26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji GH, Huang MH, Zhang Q, et al. CT manifestations and dynamic changes of coronavirus disease 2019. Chin J Med Imaging Technol. 2020;36(2):242&#x2010;247.</Citation></Reference><Reference><Citation>Chen L, Feng SY, Wang FX, et al. Clinical diagnosis and treatment of critical patients with novel coronavirus pneumonia (report of 12 cases). J Clin Med. 2020;27(1):32&#x2010;35.</Citation></Reference><Reference><Citation>Zeng GF, Yang HP, Zhang XY, et al. Analysis of clinical and imaging features of novel coronavirus pneumonia in Chongqing traditional Chinese medicine system. J Emerg Tradit Chin Med. 2020;29(3):377&#x2010;380.</Citation></Reference><Reference><Citation>Cao J, Zhou J, Liao XN, et al. Clinical characteristics and CT signs of coronavirus disease 2019 (COVID&#x2010;19) in the elderly. Med J Wuhan Univ. 2020;4(2):1&#x2010;4.</Citation></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;213(42):543&#x2010;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu XT, Ye H, Yang SF, et al. Chest CT features of COVID&#x2010;19. J Pract Med. 2020;2(3):1&#x2010;3.</Citation></Reference><Reference><Citation>Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis. 2020;43(0):E005.</Citation><ArticleIdList><ArticleId IdType="pubmed">32026671</ArticleId></ArticleIdList></Reference><Reference><Citation>Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine . An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID&#x2010;19). J. Chin Epi. 2020;41(2):139.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Wang RS, Qu GQ, et al. Systematic solution of new coronavirus pneumonia in dead cadavers. J Forensic Sci. 2020;36(1):19&#x2010;21.</Citation></Reference><Reference><Citation>Guan GW, Gao L, Wang JW, et al. Study on the mechanism of liver enzyme abnormality in pneumonia infected by novel coronavirus. J Hepatol. 2020;28(2):E002.</Citation><ArticleIdList><ArticleId IdType="pubmed">32077659</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237&#x2010;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457962</ArticleId><ArticleId IdType="pubmed">27578435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj B, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801&#x2010;8811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC167208</ArticleId><ArticleId IdType="pubmed">12885899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727&#x2010;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019&#x2010;nCoV) causing an outbreak of pneumonia. Clin Chem. 2020;66(4):549&#x2010;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108203</ArticleId><ArticleId IdType="pubmed">32031583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT&#x2010;PCR testing in coronavirus disease 2019 (COVID&#x2010;19) in China: a report of 1014 cases. Radiology. 2020;24(3):200642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233399</ArticleId><ArticleId IdType="pubmed">32101510</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldog P, Tekeli T, Vizi Z, D&#xe9;nes A, Bartha FA, R&#xf6;st G. Risk assessment of novel coronavirus COVID&#x2010;19 outbreaks outside China. J Clin Med. 2020;9(2):571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073711</ArticleId><ArticleId IdType="pubmed">32093043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019&#x2010;nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020;395(10225):689&#x2010;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159271</ArticleId><ArticleId IdType="pubmed">32014114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands P, Mundaca&#x2010;Shah C, Dzau VJ. The neglected dimension of global security&#x2014;a framework for countering infectious&#x2010;disease crises. N Engl J Med. 2016;374(13):1281&#x2010;1287.</Citation><ArticleIdList><ArticleId IdType="pubmed">26761419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26862016</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1238</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Antithrombin&#xa0;III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis.</ArticleTitle><Pagination><StartPage>505</StartPage><EndPage>520</EndPage><MedlinePgn>505-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00134-016-4225-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95% CI 0.88-1.03, I (2) = 0%, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95% Cl 0.88-1.03, I (2) = 0%, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95% CI 1.35-1.84, I (2) = 0%, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allingstrup</LastName><ForeName>Mikkel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, K&#xf8;ge Sygehus, Copenhagen University Hospital, Copenhagen, Denmark. mikkel.allingstrup@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. mikkel.allingstrup@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetterslev</LastName><ForeName>J&#xf8;rn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravn</LastName><ForeName>Frederikke B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Ann Merete</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group, University of Copenhagen Herlev Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group, University of Copenhagen Herlev Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000991">Antithrombins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9000-94-6</RegistryNumber><NameOfSubstance UI="D000990">Antithrombin III</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000990" MajorTopicYN="N">Antithrombin III</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000991" MajorTopicYN="N">Antithrombins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004211" MajorTopicYN="N">Disseminated Intravascular Coagulation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antithrombin&#xa0;III</Keyword><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">DIC</Keyword><Keyword MajorTopicYN="N">Multi organ failure</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword></KeywordList><CoiStatement>Mikkel Allingstrup, Frederikke B. Ravn, Ann Merete M&#xf8;ller and Arash Afshari declare that there are no conflicts of interest. J&#xf8;rn Wetterslev declares that he is a member of the task force on TSA at Copenhagen Trial Unit developing and programming TSA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26862016</ArticleId><ArticleId IdType="pmc">PMC7095103</ArticleId><ArticleId IdType="doi">10.1007/s00134-016-4225-7</ArticleId><ArticleId IdType="pii">10.1007/s00134-016-4225-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wunsch H, Angus D, Harrison D, et al. Variation in critical care services across North America and Western Europe. Crit Care Med. 2008;36:2787&#x2013;2793. doi: 10.1097/CCM.0b013e318186aec8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318186aec8</ArticleId><ArticleId IdType="pubmed">18766102</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, De Jonge E, Van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36:41&#x2013;49. doi: 10.1080/07853890310017251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890310017251</ArticleId><ArticleId IdType="pubmed">15000346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr F, Yende S, Angus D. Epidemiology of severe sepsis. Virulence. 2014;5:4&#x2013;11. doi: 10.4161/viru.27372.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.27372</ArticleId><ArticleId IdType="pmc">PMC3916382</ArticleId><ArticleId IdType="pubmed">24335434</ArticleId></ArticleIdList></Reference><Reference><Citation>Periti P. Current treatment of sepsis and endotoxaemia. Expert Opin Pharmacother. 2000;1:1203&#x2013;1217. doi: 10.1517/14656566.1.6.1203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.1.6.1203</ArticleId><ArticleId IdType="pubmed">11249488</ArticleId></ArticleIdList></Reference><Reference><Citation>Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet. 2004;363:1721&#x2013;1723. doi: 10.1016/S0140-6736(04)16259-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16259-4</ArticleId><ArticleId IdType="pubmed">15158636</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000;89:160&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798271</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz R, Moffett BS, Karabinas S, et al. Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. J Pediatr. 2015;167:645&#x2013;649. doi: 10.1016/j.jpeds.2015.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2015.06.006</ArticleId><ArticleId IdType="pubmed">26148660</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 2002;30:325&#x2013;331. doi: 10.1097/00003246-200205001-00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200205001-00024</ArticleId><ArticleId IdType="pubmed">12004255</ArticleId></ArticleIdList></Reference><Reference><Citation>Rublee D, Opal SM, Schramm W, et al. Quality of life effects of antithrombin&#xa0;III in sepsis survivors: results from the KyberSept trial. Crit Care. 2002;6:349&#x2013;356. doi: 10.1186/cc1529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc1529</ArticleId><ArticleId IdType="pmc">PMC125322</ArticleId><ArticleId IdType="pubmed">12225612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43:511&#x2013;518. doi: 10.1097/CCM.0000000000000763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000763</ArticleId><ArticleId IdType="pubmed">25493972</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch&#xfc;nemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924&#x2013;926. doi: 10.1136/bmj.39489.470347.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://www.cochrane-handbook.org. Accessed March 2011</Citation></Reference><Reference><Citation>Afshari A, Wetterslev J, Brok J, M&#xf8;ller A. Antithrombin&#xa0;III for critically ill patients. Cochrane Database Syst Rev. 2008;16(3):5370.</Citation><ArticleIdList><ArticleId IdType="pubmed">18646125</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cochrane Collaboration (2014) Review Manager (RevMan), version 5.3.5. The Nordic Cochrane Centre, Copenhagen</Citation></Reference><Reference><Citation>Thorlund K, Engstr&#xf8;m J, Wetterslev J, Brok J, Imberger G, Gluud C (2011) User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, pp 1&#x2013;115. http://www.ctu.dk/tsa/files/tsa_manual.pdf</Citation></Reference><Reference><Citation>Albert J, Blomqvist H, Gardlund B, et al. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand. 1992;36:745&#x2013;752. doi: 10.1111/j.1399-6576.1992.tb03557.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.1992.tb03557.x</ArticleId><ArticleId IdType="pubmed">1466208</ArticleId></ArticleIdList></Reference><Reference><Citation>Balk RA, Bedrosian C, McCormick L, et al. Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. Intensive Care Med. 1995;21:17.</Citation></Reference><Reference><Citation>Baudo F, DeGasperi A, De Cataldo F, et al. Antithrombin&#xa0;III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res. 1992;68:409&#x2013;416. doi: 10.1016/0049-3848(92)90099-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(92)90099-V</ArticleId><ArticleId IdType="pubmed">1290169</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudo F, Caimi TM, De Cataldo F, et al. Antithrombin&#xa0;III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24:336&#x2013;342. doi: 10.1007/s001340050576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050576</ArticleId><ArticleId IdType="pubmed">9609411</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin&#xa0;III in shock and DIC: a randomized study. Thromb Res. 1985;39:81&#x2013;89. doi: 10.1016/0049-3848(85)90123-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(85)90123-9</ArticleId><ArticleId IdType="pubmed">4035650</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Cremades JM, Lorenzo R, S&#xe1;nchez M, et al. Use of antithrombin&#xa0;III in critical patients. Intensive Care Med. 1994;20:577&#x2013;580. doi: 10.1007/BF01705725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01705725</ArticleId><ArticleId IdType="pubmed">7706571</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele B, Lamy M, Thijs LG, et al. Antithrombin&#xa0;III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin&#xa0;III in severe sepsis. Intensive Care Med. 1998;24:663&#x2013;672. doi: 10.1007/s001340050642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050642</ArticleId><ArticleId IdType="pubmed">9722035</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin&#xa0;III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882&#x2013;888. doi: 10.1378/chest.104.3.882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.104.3.882</ArticleId><ArticleId IdType="pubmed">8365305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulia F, Cordaro S, Meo P, et al. Can the administration of antithrombin&#xa0;III decrease the risk of cerebral hemorrhage in premature infants. Biol Neonate. 2003;83:1&#x2013;5. doi: 10.1159/000067005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000067005</ArticleId><ArticleId IdType="pubmed">12566675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:297. doi: 10.1186/cc13163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc13163</ArticleId><ArticleId IdType="pmc">PMC4057033</ArticleId><ArticleId IdType="pubmed">24342495</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenander A, Bredbacka S, Rydvall A, et al. Antithrombin treatment in patients with traumatic brain injury: a pilot study. J Neurosurg Anesthesiol. 2001;13:49&#x2013;56. doi: 10.1097/00008506-200101000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008506-200101000-00010</ArticleId><ArticleId IdType="pubmed">11145479</ArticleId></ArticleIdList></Reference><Reference><Citation>Haire WD, Ruby EI, Stephens LC, et al. A prospective randomized double-blind trial of antithrombin&#xa0;III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 1998;4:142&#x2013;150. doi: 10.1016/S1083-8791(98)50003-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1083-8791(98)50003-1</ArticleId><ArticleId IdType="pubmed">9923412</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper PL, Williamson L, Park G, et al. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfus Med. 1991;1:121&#x2013;128. doi: 10.1111/j.1365-3148.1991.tb00020.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3148.1991.tb00020.x</ArticleId><ArticleId IdType="pubmed">9259838</ArticleId></ArticleIdList></Reference><Reference><Citation>Inthorn D, Hoffmann JN, Hartl WH, et al. Antithrombin&#xa0;III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock. 1997;8:328&#x2013;334. doi: 10.1097/00024382-199711000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-199711000-00003</ArticleId><ArticleId IdType="pubmed">9361342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Terao T, Ikenoue T, et al. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost. 2003;29:645&#x2013;652. doi: 10.1055/s-2004-815632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2004-815632</ArticleId><ArticleId IdType="pubmed">14719181</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley PG, Hughes RD, Forbes A, et al. Controlled trial of antithrombin&#xa0;III supplementation in fulminant hepatic failure. J Hepatol. 1993;17:326&#x2013;331. doi: 10.1016/S0168-8278(05)80213-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(05)80213-2</ArticleId><ArticleId IdType="pubmed">8315261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrentieva A, Kontakiotis T, Bitzani M, et al. The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost. 2008;100:286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">18690349</ArticleId></ArticleIdList></Reference><Reference><Citation>Maki M, Kobayashi T, Terao T, et al. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thromb Haemost. 2000;84:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">11057854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888870</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntean W, Rossegger H. Antithrombin&#xa0;III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract) Thromb Haemost. 1989;62:288.</Citation></Reference><Reference><Citation>Neporada E, Vorobyeva N, Nedashkovsky E. Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatol. 2008;5:49&#x2013;54. doi: 10.15360/1813-9779-2008-5-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.15360/1813-9779-2008-5-49</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med. 2012;30:1219&#x2013;1223. doi: 10.1016/j.ajem.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2011.06.003</ArticleId><ArticleId IdType="pubmed">22204993</ArticleId></ArticleIdList></Reference><Reference><Citation>Palareti G, Legnani C, Coccheri S, et al. Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support&#x2014;a controlled, double-blind, randomized multicenter study. Thromb Haemost. 1995;73:1251.</Citation></Reference><Reference><Citation>Schmidt B, Gillie P, Mitchell L, et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med. 1998;158:470&#x2013;476. doi: 10.1164/ajrccm.158.2.9712116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.158.2.9712116</ArticleId><ArticleId IdType="pubmed">9700123</ArticleId></ArticleIdList></Reference><Reference><Citation>Schorr M, Siebeck M, Zugel N, et al. Antithrombin&#xa0;III and local serum application: adjuvant therapy in peritonitis. Eur J Clin Invest. 2000;30:359&#x2013;366. doi: 10.1046/j.1365-2362.2000.00630.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2362.2000.00630.x</ArticleId><ArticleId IdType="pubmed">10759886</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster HP, Eisele B, Keinecke HO, et al. S-AT&#xa0;III study: antithrombin&#xa0;III in patients with sepsis. Intensive Care Med. 1997;23(Suppl 1):76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9722035</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Erichsen N, Aasen AO, Kongsgaard UE, et al. The effect of antithrombin&#xa0;III substitution therapy on components of the plasma protease systems in surgical patients. Clin Intensive Care. 1996;7:291&#x2013;296. doi: 10.3109/tcic.7.6.291.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/tcic.7.6.291.296</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobyeva N, Neporada E, Turundaevskaia O, Mel&#x2019;nikova G. Place of antithrombin&#xa0;III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziol Reanimatol. 2007;2:42&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17563999</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin&#xa0;III in severe sepsis, a randomized controlled trial. JAMA. 2001;286:1869&#x2013;1878. doi: 10.1001/jama.286.15.1869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.15.1869</ArticleId><ArticleId IdType="pubmed">11597289</ArticleId></ArticleIdList></Reference><Reference><Citation>Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High-dose antithrombin&#xa0;III treatment of severely injured patients: results of a prospective study. J Trauma. 1998;45:931&#x2013;940. doi: 10.1097/00005373-199811000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199811000-00015</ArticleId><ArticleId IdType="pubmed">9820705</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo A, Valsecchi L (2015) High-dose antithrombin supplementation in early pre-eclampsia: a double-blind, placebo controlled study (on behalf of the AT&#xa0;III-EPAS study group). http://abstract.mci-group.com/cgi-bin/mc/printabs.pl?APP=ISTH2009ABS-abstract&amp;TEMPLATE=&amp;keyf=0771&amp;showHide=show&amp;client. Accessed 21 April 2015</Citation></Reference><Reference><Citation>Gotzsche PC. Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ. 2000;321:585&#x2013;586. doi: 10.1136/bmj.321.7261.585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.321.7261.585</ArticleId><ArticleId IdType="pmc">PMC1118486</ArticleId><ArticleId IdType="pubmed">10977820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33076353</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Pancreatitis Associated with Viral Hepatitis: Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3309</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm9103309</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We conducted a systematic review in order to summarize the available data on pancreatitis associated with viral hepatitis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search of Medline, Scopus and ISI Web of Science databases was conducted and papers eligible for the inclusion identified.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 46 studies reporting data on 73 patients were included in the analysis. Most of the cases were diagnosed in Asia (57.53%), followed by North America (23.29%), and Europe (13.70%). Most of the patients were affected by hepatitis A virus (HAV) (42.47%), followed by hepatitis E virus (HEV) (28.77%), hepatitis B virus (HBV) (8.22%), and hepatitis C virus (HCV) (1.37%), while 17.81% at the time of diagnosis were classified as affected by "hepatitis virus". Pancreatitis was severe in 32.88% of cases. The respiratory system was affected in 2.74% of patients, 6.85% experienced renal failure, while 5.48% experienced a multiorgan dysfunction syndrome (MODS). Four patients (5.48%) needed pancreatic surgery. Despite the treatment, 21.92% of patients died. We identified fulminant hepatitis (<i>p</i> &lt; 0.0001), MODS (<i>p</i> &lt; 0.0001) and severe pancreatitis (<i>p</i> &lt; 0.0001) to be significantly more present in patients who died in comparison to cured ones.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Increased awareness of pancreatic involvement in viral hepatitis is needed because it can have a substantial impact on therapeutic approaches and outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panic</LastName><ForeName>Nikola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Digestive Endoscopy Unit, University Clinic "Dr Dragisa Misovic-Dedinje", 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Digestive Diseases, Karolinska University Hospital, 14186 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihajlovic</LastName><ForeName>Sladjana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9013-0401</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vujasinovic</LastName><ForeName>Miroslav</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6496-295X</Identifier><AffiliationInfo><Affiliation>Department for Digestive Diseases, Karolinska University Hospital, 14186 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulajic</LastName><ForeName>Milutin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Mater Olbia, 07026 Olbia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;hr</LastName><ForeName>Johannes-Matthias</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-7647-198X</Identifier><AffiliationInfo><Affiliation>Department for Digestive Diseases, Karolinska University Hospital, 14186 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CLINTEC, Karolinska Institutet, 14186 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hepatitis</Keyword><Keyword MajorTopicYN="N">pancreatitis</Keyword><Keyword MajorTopicYN="N">viral</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33076353</ArticleId><ArticleId IdType="pmc">PMC7602572</ArticleId><ArticleId IdType="doi">10.3390/jcm9103309</ArticleId><ArticleId IdType="pii">jcm9103309</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peery A.F., Dellon E.S., Lund J., Crockett S.D., McGowan C.E., Bulsiewicz W.J., Gangarosa L.M., Thiny M.T., Stizenberg K., Morgan D.R., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179&#x2013;1187. doi: 10.1053/j.gastro.2012.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.08.002</ArticleId><ArticleId IdType="pmc">PMC3480553</ArticleId><ArticleId IdType="pubmed">22885331</ArticleId></ArticleIdList></Reference><Reference><Citation>van Santvoort H.C., Bakker O.J., Bollen T.L., Besselink M.G., Ahmed Ali U., Schrijver A.M., Boermeester M.A., van Goor H., Dejong C.H., van Eijck C.H., et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. Gastroenterology. 2011;141:1254&#x2013;1263. doi: 10.1053/j.gastro.2011.06.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.06.073</ArticleId><ArticleId IdType="pubmed">21741922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gullo L., Migliori M., Ol&#xe1;h A., Farkas G., Levy P., Arvanitakis C., Lankisch P., Beger H. Acute pancreatitis in five European countries: Etiology and mortality. Pancreas. 2002;24:223&#x2013;227. doi: 10.1097/00006676-200204000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006676-200204000-00003</ArticleId><ArticleId IdType="pubmed">11893928</ArticleId></ArticleIdList></Reference><Reference><Citation>Parenti D.M., Steinberg W., Kang P. Infectious causes of acute pancreatitis. Pancreas. 1996;13:356&#x2013;371. doi: 10.1097/00006676-199611000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006676-199611000-00005</ArticleId><ArticleId IdType="pubmed">8899796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazerbachi F., Haffar S., Garg S.K., Lake J.R. Extra-hepatic manifestations associated with hepatitis E virus infection: A comprehensive review of the literature. Gastroenterol. Rep. 2016;4:1&#x2013;15. doi: 10.1093/gastro/gov042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gastro/gov042</ArticleId><ArticleId IdType="pmc">PMC4760069</ArticleId><ArticleId IdType="pubmed">26358655</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffar S., Bazerbachi F., Prokop L., Watt K.D., Murad M.H., Chari S.T. Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: A systematic review. Pancreatology. 2017;17:166&#x2013;175. doi: 10.1016/j.pan.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2017.02.008</ArticleId><ArticleId IdType="pubmed">28236520</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira L.C., Rezende P.B., Ferreira A.L., de Freitas A.A., de Carvalho A.M., Guedes C.A., Costa W.O. Concurrent acute hepatitis and pancreatitis associated with hepatitis B virus: Case report. Pancreas. 1998;16:559&#x2013;561. doi: 10.1097/00006676-199805000-00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006676-199805000-00019</ArticleId><ArticleId IdType="pubmed">9598823</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvares-Da-Silva M.R., Francisconi C.F., Waechter F.L. Acute hepatitis C complicated by pancreatitis: Another extrahepatic manifestation of hepatitis C virus? J. Viral Hepat. 2000;7:84&#x2013;86. doi: 10.1046/j.1365-2893.2000.00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2893.2000.00176.x</ArticleId><ArticleId IdType="pubmed">10718948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura M., Sakurai I., Shimoda T., Abe K., Okano T., Shikata T. Detection of HBsAg in the pancreas. Acta Pathol. Jpn. 1981;31:711&#x2013;717. doi: 10.1111/j.1440-1827.1981.tb02767.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1827.1981.tb02767.x</ArticleId><ArticleId IdType="pubmed">7025575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui C.Y., Burch G.E., Harb J.M. Pancreatitis in mice infected with coxsackievirus B1. Arch. Pathol. 1972;93:379&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">5020687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ede R.J., Moore K.P., Marshall W.J., Williams R. Frequency of pancreatitis in fulminant hepatic failure using isoenzyme markers. Gut. 1988;29:778&#x2013;781. doi: 10.1136/gut.29.6.778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.29.6.778</ArticleId><ArticleId IdType="pmc">PMC1433740</ArticleId><ArticleId IdType="pubmed">2454877</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Jha R., Lakhtakia S., Narayan G. Acute pancreatitis following kidney transplantation&#x2014;Role of viral infections. Clin. Transplant. 2003;17:32&#x2013;36. doi: 10.1034/j.1399-0012.2003.02041.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-0012.2003.02041.x</ArticleId><ArticleId IdType="pubmed">12588319</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaroszewicz J., Flisiak R., Kalinowska A., Wierzbicka I., Prokopowicz D. Acute hepatitis E complicated by acute pancreatitis: A case report and literature review. Pancreas. 2005;30:382&#x2013;384. doi: 10.1097/01.mpa.0000160962.06333.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mpa.0000160962.06333.17</ArticleId><ArticleId IdType="pubmed">15841052</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain P., Nijhawan S., Rai R.R., Nepalia S., Mathur A. Acute pancreatitis in acute viral hepatitis. World J. Gastroenterol. 2007;13:5741&#x2013;5744. doi: 10.3748/wjg.v13.i43.5741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v13.i43.5741</ArticleId><ArticleId IdType="pmc">PMC4171261</ArticleId><ArticleId IdType="pubmed">17963301</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa R., Biswas B., Mallick D., Ghosh A. Acute pancreatitis&#x2014;Complicating hepatitis E virus infection in a 7-year-old boy with glucose 6 phosphate dehydrogenase deficiency. Clin. Pediatr. 2009;48:199&#x2013;201. doi: 10.1177/0009922808327107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0009922808327107</ArticleId><ArticleId IdType="pubmed">19129425</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter J., Stallmach A., Tannapfel A., Bruns T. Acute-on-Chronic Liver Failure with Complicating Pancreatitis After Autochthonous Hepatitis E Infection. Hepat. Mon. 2017;17:e14039. doi: 10.5812/hepatmon.14039.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/hepatmon.14039</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani S.K., Ghosh A., Awasthi G. Severe acute pancreatitis with pseudocyst bleeding due to hepatitis E virus infection. Clin. J. Gastroenterol. 2009;2:39&#x2013;42. doi: 10.1007/s12328-008-0035-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12328-008-0035-y</ArticleId><ArticleId IdType="pubmed">26191807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagat S., Wadhawan M., Sud R., Arora A. Hepatitis viruses causing pancreatitis and hepatitis: A case series and review of literature. Pancreas. 2008;36:424&#x2013;427. doi: 10.1097/MPA.0b013e31815d9d53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0b013e31815d9d53</ArticleId><ArticleId IdType="pubmed">18437090</ArticleId></ArticleIdList></Reference><Reference><Citation>Deniel C., Coton T., Brardjanian S., Guisset M., Nicand E., Simon F. Acute pancreatitis: A rare complication of acute hepatitis E. J. Clin. Virol. 2011;51:202&#x2013;204. doi: 10.1016/j.jcv.2011.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.04.009</ArticleId><ArticleId IdType="pubmed">21628104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A., Saigal S., Gupta R., Sarin S.K. Acute pancreatitis associated with viral hepatitis: A report of six cases with review of literature. Am. J. Gastroenterol. 1999;94:2292&#x2013;2295. doi: 10.1111/j.1572-0241.1999.01318.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.1999.01318.x</ArticleId><ArticleId IdType="pubmed">10445566</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak H.K., Kamble N.L., Raizada N., Garg S., Daga M.K. Acute pancreatitis complicating acute hepatitis e virus infection: A case report and review. Case Rep. Hepatol. 2013;2013:531235. doi: 10.1155/2013/531235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/531235</ArticleId><ArticleId IdType="pmc">PMC4208387</ArticleId><ArticleId IdType="pubmed">25374721</ArticleId></ArticleIdList></Reference><Reference><Citation>Makharia G.K., Garg P.K., Tandon R.K. Acute pancreatitis associated with acute hepatitis E infection. Trop. Gastroenterol. 2003;24:200&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15164533</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity S.G., Ray G. Severe acute pancreatitis in acute hepatitis E. Indian J. Gastroenterol. 2002;21:37&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11871840</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder A.K., Halder A., Talapatra D.S., Bhaduri S. Hepatitis E associated with acute pancreatitis with pseudocyst. J. Assoc. Physicians India. 1999;47:1207&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11225230</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanth S.S., Khan Z., Rau N.R., Rao K. Acute hepatitis E complicated by acute pancreatitis and multiorgan dysfunction. BMJ Case Rep. 2014;2014 doi: 10.1136/bcr-2014-203875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2014-203875</ArticleId><ArticleId IdType="pmc">PMC4054478</ArticleId><ArticleId IdType="pubmed">24899005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarawgi S., Gupta A.K., Arora D.S., Jasuja S. Acute renal failure associated with nonfulminant acute viral hepatitis A. Indian J. Nephrol. 2008;18:77&#x2013;79. doi: 10.4103/0971-4065.42344.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0971-4065.42344</ArticleId><ArticleId IdType="pmc">PMC2813126</ArticleId><ArticleId IdType="pubmed">20142908</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas R., Batool S., Pothugunta K., Batke M. Acalculous Cholecystitis and Pancreatitis Induced by Hepatitis A: 831. Am. J. Gastroenterol. 2011;106:S310. doi: 10.14309/00000434-201110002-00831.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/00000434-201110002-00831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin V., Selimoglu M.A., Konak M., Orbak Z. Association of hepatitis a and acute pancreatitis presenting as acute abdomen. Pancreas. 2005;31:298&#x2013;299. doi: 10.1097/01.mpa.0000180904.28365.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mpa.0000180904.28365.58</ArticleId><ArticleId IdType="pubmed">16163069</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis T.V., Keeffe E.B. Acute pancreatitis associated with acute hepatitis A. Am. J. Gastroenterol. 1992;87:1648&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pubmed">1442693</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayed R., El-Karaksy H. Acute pancreatitis complicating acute hepatitis A virus infection. Arab J. Gastroenterol. 2012;13:184&#x2013;185. doi: 10.1016/j.ajg.2012.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajg.2012.08.002</ArticleId><ArticleId IdType="pubmed">23432988</ArticleId></ArticleIdList></Reference><Reference><Citation>Moleta D.B., Kakitani F.T., Lima A.S., Fran&#xe7;a J.C., Raboni S.M. Acute pancreatitis associated with acute viral hepatitis: Case report and review of literature. Rev. Inst. Med. Trop. Sao Paulo. 2009;51:349&#x2013;351. doi: 10.1590/S0036-46652009000600008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0036-46652009000600008</ArticleId><ArticleId IdType="pubmed">20209272</ArticleId></ArticleIdList></Reference><Reference><Citation>Garty B.Z., Kanner D., Danon Y.L. Pancreatitis associated with hepatitis A viral infection. J. Pediatr. 1995;127:669. doi: 10.1016/S0022-3476(95)70142-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(95)70142-7</ArticleId><ArticleId IdType="pubmed">7562301</ArticleId></ArticleIdList></Reference><Reference><Citation>Haviv Y.S., Sharkia M., Galun E., Safadi R. Pancreatitis following hepatitis A vaccination. Eur. J. Med. Res. 2000;5:229&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806126</ArticleId></ArticleIdList></Reference><Reference><Citation>Arafat S.M., Azad A.K., Basher A., Ananna M.A., Islam M.S., Abdullah S., Abdullah A.M., Islam M.A. Acute pancreatitis associated with acute viral hepatitis A (HAV)&#x2014;A case report. Mymensingh Med. J. 2013;22:192&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">23416831</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrier L.A., Karpen S.J., McEvoy C. Acute pancreatitis associated with acute hepatitis A in a young child. J. Pediatr. 1995;126:57&#x2013;59. doi: 10.1016/S0022-3476(95)70501-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(95)70501-5</ArticleId><ArticleId IdType="pubmed">7815225</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna S., Vij J.C. Severe acute pancreatitis due to hepatitis A virus infection in a patient of acute viral hepatitis. Trop. Gastroenterol. 2003;24:25&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12974211</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra Y., Chakravarty S., Bhatt G. Severe acute pancreatitis associated with acute hepatitis A: A case report. Trop. Gastroenterol. 2003;24:27&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">12974212</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarapurkar D.N., Begani M.M., Mirchandani K. Acute pancreatitis in hepatitis A infection. Trop. Gastroenterol. 1996;17:30&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">8693583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood A., Midha V. Hepatitis A and acute pancreatitis. J. Assoc. Physicians India. 1999;47:736&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10778600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Morante A., Rodriguez de Lope C., San Miguel G., Pons Romero F. Acute pancreatitis in hepatitis A infection. Postgrad. Med. J. 1986;62:407&#x2013;408. doi: 10.1136/pgmj.62.727.407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.62.727.407</ArticleId><ArticleId IdType="pmc">PMC2418721</ArticleId><ArticleId IdType="pubmed">3763554</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal K.S., Puliyel J.M., Mathew A., Lahoti D., Gupta R. Acute pancreatitis with cholestatic hepatitis: An unusual manifestation of hepatitis A. Ann. Trop. Paediatr. 1999;19:391&#x2013;394. doi: 10.1080/02724939992257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02724939992257</ArticleId><ArticleId IdType="pubmed">10716035</ArticleId></ArticleIdList></Reference><Reference><Citation>Basaranoglu M., Balci N.C., Kl&#xf6;r H.U. Gallbladder sludge and acute pancreatitis induced by acute hepatitis A. Pancreatology. 2006;6:141&#x2013;144. doi: 10.1159/000090255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000090255</ArticleId><ArticleId IdType="pubmed">16354962</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallari A., Vivarelli M., D&#x2019;Errico A., Bellusci R., Scarani P., De Raffele E., Nardo B., Gozzetti G. Acute necrotizing pancreatitis due to hepatitis B virus reinfection in a liver transplant recipient. Transplant. Proc. 1994;26:3649&#x2013;3650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7998306</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo K.S., Lee K.H., Huh K.R., Choi W.S., Jeon G., Ha J.W., Kim K.O., Park C.H., Hahn T., Park S.H., et al. Acute pancreatitis complicating spontaneous acute exacerbation of chronic hepatitis B virus infection: Case report and review of the literature. Gut Liver. 2009;3:64&#x2013;66. doi: 10.5009/gnl.2009.3.1.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2009.3.1.64</ArticleId><ArticleId IdType="pmc">PMC2871560</ArticleId><ArticleId IdType="pubmed">20479905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshiro Y., Tawata M., Takasu N. Acute pancreatitis and exacerbation of hepatitis B following reduced dose of prednisolone. Qjm. 2003;96:868&#x2013;869. doi: 10.1093/qjmed/hcg139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcg139</ArticleId><ArticleId IdType="pubmed">14566043</ArticleId></ArticleIdList></Reference><Reference><Citation>Geokas M.C., Olsen H., Swanson V., Rinderknecht H. The association of viral hepatitis and acute pancreatitis. Calif. Med. 1972;117:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518512</ArticleId><ArticleId IdType="pubmed">5070694</ArticleId></ArticleIdList></Reference><Reference><Citation>Achord J.L. Acute pancreatitis with infectious hepatitis. JAMA. 1968;205:837&#x2013;840. doi: 10.1001/jama.1968.03140380041008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1968.03140380041008</ArticleId><ArticleId IdType="pubmed">5695505</ArticleId></ArticleIdList></Reference><Reference><Citation>Eugene C., Cadranel J.F., Bergue A., Anciaux M.L. Acute pancreatitis associated with non-A-non-B hepatitis. Report of a case. J. Clin. Gastroenterol. 1990;12:195&#x2013;197. doi: 10.1097/00004836-199004000-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004836-199004000-00018</ArticleId><ArticleId IdType="pubmed">2109006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesh G., Nair A.S., Narayanan V.A., Balakrishnan V. Acute pancreatitis in viral infections, with possible progression to chronic pancreatitis. Indian J. Gastroenterol. 2008;27:162&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18974468</ArticleId></ArticleIdList></Reference><Reference><Citation>Shlomovitz E., Davies W., Cairns E., Brintnell W.C., Goldszmidt M., Dresser G.K. Severe necrotizing pancreatitis following combined hepatitis A and B vaccination. Cmaj. 2007;176:339&#x2013;342. doi: 10.1503/cmaj.060360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.060360</ArticleId><ArticleId IdType="pmc">PMC1780095</ArticleId><ArticleId IdType="pubmed">17261831</ArticleId></ArticleIdList></Reference><Reference><Citation>Himanshu K., Pathak S.K., Das J.L. An unusual case of acute pancreatitis associated with acute hepatitis E virus infection. J. Evol. Med. Dent. Sci. 2016;5:5324&#x2013;5325. doi: 10.14260/jemds/2016/1206.</Citation><ArticleIdList><ArticleId IdType="doi">10.14260/jemds/2016/1206</ArticleId></ArticleIdList></Reference><Reference><Citation>G Ray D.B. Severe acute pancreatitis complicating acute hepatitis A in a child. Internet J. Pediatr. Neonatol. 2008;11 doi: 10.1201/b15853-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/b15853-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert A.R., Valencia R., Smereck J.A. Acute Hepatitis B with Pancreatitis and Cholecystitis Leading to Acute Liver Failure and Death. Clin. Pract. Cases Emerg. Med. 2018;2:304&#x2013;308. doi: 10.5811/cpcem.2018.7.38344.</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/cpcem.2018.7.38344</ArticleId><ArticleId IdType="pmc">PMC6230352</ArticleId><ArticleId IdType="pubmed">30443612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana S.K., Singh R., Aggarwal B., Kumar S. Acute pancreatitis in hepatitis A infection in a 10-year-old boy. Pediatr. Infect. Dis. 2013;5:172&#x2013;174. doi: 10.1016/j.pid.2013.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pid.2013.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wands J.R., Salyer D.C., Boitnott J.K., Maddrey W.C. Fulminant hepatitis complicated by pancreatitis. Johns Hopkins Med. J. 1973;133:156&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">4542282</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Shi O., Zhang T., Jin L., Chen X. Disease burden of viral hepatitis A, B, C, and E: A systematic analysis. J. Viral Hepat. 2020 doi: 10.1111/jvh.13371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13371</ArticleId><ArticleId IdType="pubmed">32741034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmeister M.G., Foster M.A., Teshale E.H. Epidemiology and Transmission of Hepatitis A Virus and Hepatitis E Virus Infections in the United States. Cold Spring Harb. Perspect. Med. 2019;9 doi: 10.1101/cshperspect.a033431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a033431</ArticleId><ArticleId IdType="pmc">PMC6444696</ArticleId><ArticleId IdType="pubmed">29712684</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo-Santisteve P., Tavoschi L., Severi E., Bonfigli S., Edelstein M., Bystr&#xf6;m E., Lopalco P. Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: A systematic review. Lancet. Infect. Dis. 2017;17:e306&#x2013;e319. doi: 10.1016/S1473-3099(17)30392-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30392-4</ArticleId><ArticleId IdType="pubmed">28645862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrzljak A., Dinjar-Kujundzic P., Jemersic L., Prpic J., Barbic L., Savic V., Stevanovic V., Vilibic-Cavlek T. Epidemiology of hepatitis E in South-East Europe in the "One Health" concept. World J. Gastroenterol. 2019;25:3168&#x2013;3182. doi: 10.3748/wjg.v25.i25.3168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i25.3168</ArticleId><ArticleId IdType="pmc">PMC6626717</ArticleId><ArticleId IdType="pubmed">31333309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohenberger P. Detection of HBs-Ag in the pancreas in cases of pancreatic carcinoma. Hepatol. Gastroenterol. 1984;31:239&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">6510882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pischke S., Hartl J., Pas S.D., Lohse A.W., Jacobs B.C., Van der Eijk A.A. Hepatitis E virus: Infection beyond the liver? J. Hepatol. 2017;66:1082&#x2013;1095. doi: 10.1016/j.jhep.2016.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2016.11.016</ArticleId><ArticleId IdType="pubmed">27913223</ArticleId></ArticleIdList></Reference><Reference><Citation>Dembi&#x144;ski A., Warzecha Z., Ceranowicz P., Stachura J., Tomaszewska R., Konturek S.J., Sendur R., Dembi&#x144;ski M., Pawlik W.W. Pancreatic damage and regeneration in the course of ischemia-reperfusion induced pancreatitis in rats. J. Physiol. Pharmacol. 2001;52:221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">11453102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusterer K., Enghofer M., Zendler S., Bl&#xf6;chle C., Usadel K.H. Microcirculatory changes in sodium taurocholate-induced pancreatitis in rats. Am. J. Physiol. 1991;260:G346&#x2013;G351. doi: 10.1152/ajpgi.1991.260.2.G346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.1991.260.2.G346</ArticleId><ArticleId IdType="pubmed">1996652</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoefel W.T., Kollias N., Warshaw A.L., Waldner H., Nishioka N.S., Rattner D.W. Pancreatic microcirculatory changes in experimental pancreatitis of graded severity in the rat. Surgery. 1994;116:904&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">7940196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Barb&#xe1;chano E., San Rom&#xe1;n J.I., L&#xf3;pez M.A., Cove&#xf1;as R., L&#xf3;pez-Novoa J.M., Calvo J.J. Beneficial effects of vasodilators in preventing severe acute pancreatitis shock. Pancreas. 2006;32:335&#x2013;342. doi: 10.1097/01.mpa.0000220856.47754.c4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mpa.0000220856.47754.c4</ArticleId><ArticleId IdType="pubmed">16670614</ArticleId></ArticleIdList></Reference><Reference><Citation>Maduzia D., Ceranowicz P., Cieszkowski J., Ga&#x142;&#x105;zka K., Ku&#x15b;nierz-Cabala B., Warzecha Z. Pretreatment with Warfarin Attenuates the Development of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats. Molecules. 2020;25:2493. doi: 10.3390/molecules25112493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25112493</ArticleId><ArticleId IdType="pmc">PMC7321200</ArticleId><ArticleId IdType="pubmed">32471279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonardo A., Grisendi A., Bonilauri S., Rambaldi M., Selmi I., Tondelli E. Ischaemic necrotizing pancreatitis after cardiac surgery. A case report and review of the literature. Ital. J. Gastroenterol. Hepatol. 1999;31:872&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">10669996</ArticleId></ArticleIdList></Reference><Reference><Citation>Arafa A., Eshak E.S., Abdel Rahman T.A., Anwar M.M. Hepatitis C virus infection and risk of pancreatic cancer: A meta-analysis. Cancer Epidemiol. 2020;65:101691. doi: 10.1016/j.canep.2020.101691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2020.101691</ArticleId><ArticleId IdType="pubmed">32088651</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J.H., Fu J.J., Wang X.L., Zhu J.Y., Ye X.H., Chen S.D. Hepatitis B or C viral infection and risk of pancreatic cancer: A meta-analysis of observational studies. World J. Gastroenterol. 2013;19:4234&#x2013;4241. doi: 10.3748/wjg.v19.i26.4234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v19.i26.4234</ArticleId><ArticleId IdType="pmc">PMC3710428</ArticleId><ArticleId IdType="pubmed">23864789</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejean A., Lugassy C., Zafrani S., Tiollais P., Brechot C. Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. Pt 3J. Gen. Virol. 1984;65:651&#x2013;655. doi: 10.1099/0022-1317-65-3-651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-65-3-651</ArticleId><ArticleId IdType="pubmed">6699625</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan F.M., Chen A.S., Hao F., Zhao X.P., Gu C.H., Zhao L.B., Yang D.L., Hao L.J. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J. Gastroenterol. 2000;6:805&#x2013;811. doi: 10.3748/wjg.v6.i6.805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v6.i6.805</ArticleId><ArticleId IdType="pmc">PMC4728266</ArticleId><ArticleId IdType="pubmed">11819700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta S.H., Brancati F.L., Sulkowski M.S., Strathdee S.A., Szklo M., Thomas D.L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 2000;133:592&#x2013;599. doi: 10.7326/0003-4819-133-8-200010170-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-133-8-200010170-00009</ArticleId><ArticleId IdType="pubmed">11033586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangiorgio L., Attardo T., Gangemi R., Rubino C., Barone M., Lunetta M. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res. Clin. Pr. 2000;48:147&#x2013;151. doi: 10.1016/S0168-8227(99)00135-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8227(99)00135-7</ArticleId><ArticleId IdType="pubmed">10802152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38460546</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Effect of haemoadsorption during cardiac surgery for Staphylococcus aureus endocarditis: a REMOVE trial post hoc analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ezae093</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ejcts/ezae093</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Multi-organ failure is one of the leading causes of mortality after cardiac surgery for infective endocarditis (IE). Although the randomized evidence does not support the use of haemoadsorption during cardiac surgery for IE, observational studies suggest a beneficial effect in selected patient groups. Staphylococcus aureus is the most common pathogen, and its presence is an independent mortality predictor. We aimed to analyse the effect of haemoadsorption in patients with IE caused by S. aureus.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a post hoc analysis of the REMOVE trial that randomized 288 patients with IE who underwent cardiac surgery with haemoadsorption using CytoSorb&#xae; or control. The primary outcome was &#x394;Sequential Organ Failure Assessment (SOFA), defined as the difference between the mean total postoperative and baseline SOFA score within 24&#x2009;h of surgery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the total of 282 patients included in the modified intention-to-treat analysis of the REMOVE trial, 73 (25.9%) had S. aureus IE (38 patients in the haemoadsorption group and 35 patients in the control group). The overall &#x394;SOFA did not differ between the intervention groups in patients with S. aureus IE (mead difference = -0.4, 95% confidence interval -2.3 to 1.4, P&#x2009;=&#x2009;0.66) and neither did 30-day mortality (hazard ratios = 1.32, 95% confidence interval 0.53-3.28, P&#x2009;=&#x2009;0.55). No differences were observed with regard to any of the other secondary outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Based on a post hoc analysis from REMOVE trial, the intraoperative use of haemoadsorption in patients with S. aureus IE was not associated with reduction of postoperative organ dysfunction, 30-day mortality or other major clinical end points.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caldonazo</LastName><ForeName>Tulio</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5697-2659</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Eynde</LastName><ForeName>Jef</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5606-376X</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doenst</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6411-909X</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirov</LastName><ForeName>Hristo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franz</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6543-4684</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Infectious Diseases and Infection Control, Jena University Hospital, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Medical Statistics, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diab</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Herz- und Kreislaufzentrum, Rotenburg an der Fulda, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>REMOVE Trial Investigators
</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>413668513</GrantID><Agency>Clinician Scientist Program OrganAge</Agency><Country/></Grant><Grant><Agency>Deutsche Herzstiftung</Agency><Country/></Grant><Grant><Agency>Interdisciplinary Center of Clinical Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004697" MajorTopicYN="Y">Endocarditis, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="Y">Endocarditis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013203" MajorTopicYN="Y">Staphylococcal Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Staphylococcus aureus</Keyword><Keyword MajorTopicYN="N">Haemoadsorption</Keyword><Keyword MajorTopicYN="N">Heart surgery</Keyword><Keyword MajorTopicYN="N">Infective endocarditis</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Diab</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bothe</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akhyari</LastName><ForeName>Payam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Platzer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendt</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deppe</LastName><ForeName>Antje-Christin</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauch</LastName><ForeName>Justus</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Albrecht</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faerber</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sponholz</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franz</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scherag</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velichkov</LastName><ForeName>Ilia</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silaschi</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fassl</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Britt</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schramm</LastName><ForeName>Rene</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fritz</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szabo</LastName><ForeName>Gabor</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wahlers</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matschke</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenberg</LastName><ForeName>Artur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pletz</LastName><ForeName>Mathias W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gummert</LastName><ForeName>Jan F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagl</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borger</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunkhorst</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doenst</LastName><ForeName>Torsten</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiller</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winter</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eichhorn</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helbig</LastName><ForeName>Aicko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ri&#xdf;ner</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdyvasiev</LastName><ForeName>Kubanychbek</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moschovas</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freiburger</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safarov</LastName><ForeName>Rauf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargenda</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirov</LastName><ForeName>Hristo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richter</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandhaus</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeynalov</LastName><ForeName>Natig</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaluza</LastName><ForeName>Mirko</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xf6;semann</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boog</LastName><ForeName>Swen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostermann</LastName><ForeName>Romanus</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulze</LastName><ForeName>P Christian</ForeName><Initials>PC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamadanchi</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Musleh</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witte</LastName><ForeName>Otto W</ForeName><Initials>OW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloos</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwope</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolanos</LastName><ForeName>Steffi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knuhr-Kohlberg</LastName><ForeName>Karina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haucke</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmann-Pohl</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cizmic</LastName><ForeName>Amila</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grathwohl</LastName><ForeName>Corinna</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sindhu</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaschek</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baier</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaub</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gro&#xdf;kurth</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herr&#xe9;</LastName><ForeName>Eranya Sone</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vlasov</LastName><ForeName>Andrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podanev</LastName><ForeName>Dimitry</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plettenberg</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;hlbauer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tunggal</LastName><ForeName>Irawati</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eichler</LastName><ForeName>Madlen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosic</LastName><ForeName>Jasmina</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolf</LastName><ForeName>Vera</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krause</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krischer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thielmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiese</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hillmer</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Manstein</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deus</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ljesic</LastName><ForeName>Dusko</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roloff</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ristau</LastName><ForeName>Tim Alabowicz Wolfgang</ForeName><Initials>TAW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spangel</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kroll</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ballazhi</LastName><ForeName>Fatos</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kondov</LastName><ForeName>Stoyan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siepe</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rylski</LastName><ForeName>Bartosz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheumann</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inka</LastName><ForeName>Matthias D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eschenhagen</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Hamami</LastName><ForeName>Yasir</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Nils</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thoma</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rambach</LastName><ForeName>Albena</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziemann</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>Gustavo Fernandez Baca</ForeName><Initials>GFB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morlock</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benk</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klink</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maltes</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lechner</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bl&#xfc;mel</LastName><ForeName>Veronika</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heizmann</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kotzjan</LastName><ForeName>Priscilla</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haldenwang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elghannam</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Useini</LastName><ForeName>Dritan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchwald</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchwald</LastName><ForeName>B&#xe4;rbel</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schr&#xf6;ter</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Binner</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartung</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holzhey</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Misfeld</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Etz</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davierwala</LastName><ForeName>Piroze</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leontyev</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfannm&#xfc;ller</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garbade</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Aspern</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saeed</LastName><ForeName>Diyar</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aydin</LastName><ForeName>Muhammed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herzfeld</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feder</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiefer</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeburger</LastName><ForeName>Joerg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prehl</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ginther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koch</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hecht</LastName><ForeName>Salome</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winkler</LastName><ForeName>Hannes</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fritzsche</LastName><ForeName>Berit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winata</LastName><ForeName>Johann</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labus</LastName><ForeName>Jakob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frei</LastName><ForeName>Isabell</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pl&#xf6;tze</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schal</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Immohr</LastName><ForeName>Moritz</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugimura</LastName><ForeName>Yukiharu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gietmann</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simm</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xf6;pfner</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stiller</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helms</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sunavsky</LastName><ForeName>Jakub</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf6;tte</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudloff</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xf6;nbrodt</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fink</LastName><ForeName>Swetlana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albrecht</LastName><ForeName>Ina-Maria</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nnanga</LastName><ForeName>Alice Huguette Minko</ForeName><Initials>AHM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Carola</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schilling</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maier</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xfc;hnel</LastName><ForeName>Ralf-Uwe</ForeName><Initials>RU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ioannou</LastName><ForeName>Stelios</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Necaev</LastName><ForeName>Anna-Maria</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Torsten</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bienek</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Treede</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohistani</LastName><ForeName>Zaki</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmadpour</LastName><ForeName>Touraj</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friese</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oberbach</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luehr</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joskowiak</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xfc;ch</LastName><ForeName>Joscha</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>9</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38460546</ArticleId><ArticleId IdType="doi">10.1093/ejcts/ezae093</ArticleId><ArticleId IdType="pii">7625107</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30003491</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Gut-origin sepsis in the critically ill patient: pathophysiology and treatment.</ArticleTitle><Pagination><StartPage>751</StartPage><EndPage>760</EndPage><MedlinePgn>751-760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-018-1178-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Gut permeability is increased in critically ill patients, and associated with the development of the systemic inflammatory response syndrome and multiple organ dysfunction syndrome (MODS). The pathogenetic link(s) and potential therapies are an area of intense research over the last decades.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We thoroughly reviewed the literature on gut-origin sepsis and MODS in critically ill patients, with emphasis on the implicated pathophysiological mechanisms and therapeutic interventions.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Intestinal barrier failure leading to systemic bacterial translocation associated with MODS was the predominant pathophysiological theory for several years. However, clinical studies with critically ill patients failed to provide the evidence of systemic spread of gut-derived bacteria and/or their products as a cause of MODS. Newer experimental data highlight the role of the mesenteric lymph as a carrier of gut-derived danger-associated molecular patterns (DAMPs) to the lung and the systemic circulation. These substances are recognized by pattern recognition receptor-bearing cells in diverse tissues and promote proinflammatory pathways and the development MODS. Therefore, the gut becomes a pivotal proinflammatory organ, driving the systemic inflammatory response through DAMPs release in mesenteric lymph, without the need for systemic bacterial translocation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is an emerging need for application of sensitive non-invasive and easily measured biomarkers of early intestinal injury (e.g., citrulline, intestinal fatty acid protein, and zonulin) in our everyday clinical practice, guiding the early pharmacological intervention in critically ill patients to restore or prevent intestinal injury and improve their outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assimakopoulos</LastName><ForeName>Stelios F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases, University of Patras Medical School, 26504, Patras, Greece. sassim@upatras.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triantos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology, University of Patras Medical School, 26504, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomopoulos</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology, University of Patras Medical School, 26504, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fligou</LastName><ForeName>Fotini</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, University of Patras Medical School, 26504, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maroulis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Patras Medical School, 26504, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marangos</LastName><ForeName>Markos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases, University of Patras Medical School, 26504, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gogos</LastName><ForeName>Charalambos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases, University of Patras Medical School, 26504, Patras, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007410" MajorTopicYN="N">Intestinal Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bacterial translocation</Keyword><Keyword MajorTopicYN="N">Danger-associated molecular patterns</Keyword><Keyword MajorTopicYN="N">Gut-lymph hypothesis</Keyword><Keyword MajorTopicYN="N">Gut-origin sepsis</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">Intestinal barrier</Keyword><Keyword MajorTopicYN="N">Intestinal permeability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30003491</ArticleId><ArticleId IdType="doi">10.1007/s15010-018-1178-5</ArticleId><ArticleId IdType="pii">10.1007/s15010-018-1178-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Infect Immun. 1979 Feb;23(2):403-11</Citation><ArticleIdList><ArticleId IdType="pubmed">154474</ArticleId></ArticleIdList></Reference><Reference><Citation>Minerva Anestesiol. 2016 Mar;82(3):320-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25969140</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Crit Care. 2016 Apr;22(2):152-60</Citation><ArticleIdList><ArticleId IdType="pubmed">26808138</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25444751</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3492</ISSN><JournalIssue CitedMedium="Internet"><Volume>440</Volume><PubDate><Year>2015</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Clinica chimica acta; international journal of clinical chemistry</Title><ISOAbbreviation>Clin Chim Acta</ISOAbbreviation></Journal><ArticleTitle>Novel markers predict death and organ failure following hemorrhagic shock.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>92</EndPage><MedlinePgn>87-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cca.2014.10.045</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0009-8981(14)00492-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ADAMTS 13, sP-Selectin and HSP27 have been investigated as potential prognostic markers in patients with hemorrhagic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was part of a double-blind, randomized, parallel-group, controlled trial and included seventeen trauma patients presented to ED with severe hemorrhagic. The sera for testing were collected from these patients at the time of admission. Investigators and laboratory personnel performing testing were blinded to the patients' identity and clinical course.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prognostic value of ADAMTS13, sP-Selectin, and HSP27 was compared to prognostic value of systolic blood pressure (SBP), base deficit estimation (BD), heart rate (HR), shock index (SI) and tissue oxygen saturation (StO2) by constructing the receiver operation characteristics (ROC). The area under the curve (AUC) of the ROC for HSP27 (0.92) was greater than for SBP (0.45), BD (0.89), HR (0.61), SI (0.45) and StO2 (0.46). AUC for sP-Selectin (0.86) and for ADAMTS13 antigen (0.74) were comparable with BD one, but greater than for the rest of currently used tests.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Serum concentrations of ADAMTS13, HSP27 and sP-Selectin measured during the admission, appear to be comparable to or better than SBP, BD, SI, HR and StO2 in predicting MODS and death after hemorrhage from trauma. These potential new markers deserve further investigation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furmaga</LastName><ForeName>Wieslaw</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States. Electronic address: furmaga@uthscsa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prihoda</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Valery</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arar</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Chim Acta</MedlineTA><NlmUniqueID>1302422</NlmUniqueID><ISSNLinking>0009-8981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C057725">HSPB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="D000071120">ADAMTS13 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="C099604">ADAMTS13 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071120" MajorTopicYN="N">ADAMTS13 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055551" MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019007" MajorTopicYN="N">P-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADAMTS13</Keyword><Keyword MajorTopicYN="N">HSP27</Keyword><Keyword MajorTopicYN="N">Hemorrhagic shock</Keyword><Keyword MajorTopicYN="N">Hemorrhagic shock markers</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">sP-Selectin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25444751</ArticleId><ArticleId IdType="doi">10.1016/j.cca.2014.10.045</ArticleId><ArticleId IdType="pii">S0009-8981(14)00492-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16020935</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1424-3903</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4-5</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</Title><ISOAbbreviation>Pancreatology</ISOAbbreviation></Journal><ArticleTitle>Potential role of reactive oxygen species in pancreatitis-associated multiple organ dysfunction.</ArticleTitle><Pagination><StartPage>492</StartPage><EndPage>500</EndPage><MedlinePgn>492-500</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute pancreatitis is still associated with substantial morbidity and mortality. Experimental and clinical studies have demonstrated that reactive oxygen species (ROS) represent early occurring inflammatory mediators contributing to cell dysfunction, both locally in the pancreas and remote organs.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A systematic literature review was conducted to investigate the potential roles of intra- and intercellular, as well as interorgan signaling of ROS in the development of pancreatitis-associated multiple organ dysfunction syndrome (MODS). A text word search of the Medline, PubMed and Cochrane databases, and a manual search of the citations from these references, was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ROS directly compromise cellular damage and regulate intercellular signals in pancreatitis-associated MODS. ROS are involved in leukocyte activation, production of cytokines, endothelial barrier dysfunction, and microcirculatory barrier dysfunction in acute pancreatitis. Beside effects on intercellular signaling, ROS also affect intracellular events and activate the transcription factor nuclear factor kappa B that regulates inflammatory cytokine expression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ROS is a critical factor responsible for the development of pancreatitis-induced remote organ dysfunction via intercellular and interorgan signaling. The role of antioxidant treatment, included as a part of multimodal management, remains to be investigated.</AbstractText><CopyrightInformation>Copyright 2005 S. Karger AG, Basel and IAP.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Changbin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lund University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xia</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiangdong</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pancreatology</MedlineTA><NlmUniqueID>100966936</NlmUniqueID><ISSNLinking>1424-3903</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016239" MajorTopicYN="N">MEDLINE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039781" MajorTopicYN="N">PubMed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>79</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16020935</ArticleId><ArticleId IdType="doi">10.1159/000087063</ArticleId><ArticleId IdType="pii">S1424-3903(05)80028-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31086552</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1682-024X</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Pakistan journal of medical sciences</Title><ISOAbbreviation>Pak J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Spontaneous lumbar artery rupture and massive retroperitoneal hematoma, successfully treated with arteriographic embolization.</ArticleTitle><Pagination><StartPage>569</StartPage><EndPage>574</EndPage><MedlinePgn>569-574</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12669/pjms.35.2.639</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Massive retroperitoneal hematoma caused by lumbar artery rupture is generally associated with trauma or retroperitoneal malignancy. However, despite recent advances in technologies and tools, spontaneous lumbar artery rupture is a very rare disease entity but remains a challenging problem because it is frequently associated with significantly high mortality and morbidity and is very difficult to make a correct diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the databases of the PubMed, Embase, Cochrane Central Register of Controlled Trial, Google Scholar, the KoreaMed and the Research Information Sharing Service databases, and a detailed systematic review was performed by searching in PubMed. The initial search was performed on 3 February 2018 and a second search conducted in 29 January 2019.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 10 case reports on massive hemoperitoneum caused by spontaneous lumbar artery rupture were identified. Of the 10 case reports involving 14 patients, eight were male and six were female under 62.71 &#xb1; 13.93. Of the 14 patients, 9 (64.3%) surviving with transcatheter arterial embolization, three (21.4%) died of multi-organ failure or hypovolemia, and two (14.3%) had no definite records on survival or death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A massive retroperitoneal hematoma caused by lumbar artery rupture should be considered in patients with late-onset shock accompanied by blunt abdominal/pelvic trauma. Furthermore, early detection and urgent embolization would prevent further complications and eliminate the need for surgical interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Jin Yong Kim, M.D. Department of Emergency Medicine, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Song Am</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Song Am Lee, M.D., Ph.D. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jae Joon</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Jae Joon Hwang, M.D., Ph.D. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jae Bum</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Jae Bum Park, M.D., Ph.D. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang Woo</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Sang Woo Park, M.D., Ph.D. Department of Radiology, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yo Han</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Yo Han Kim, M.D., Ph.D. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Hyeong Ju</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Hyeong Ju Moon, R.N. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Woo Surng</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Woo Surng Lee, M.D., Ph.D. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Pakistan</Country><MedlineTA>Pak J Med Sci</MedlineTA><NlmUniqueID>100913117</NlmUniqueID><ISSNLinking>1681-715X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiography</Keyword><Keyword MajorTopicYN="N">Embolization</Keyword><Keyword MajorTopicYN="N">Hypovolemic Shock</Keyword><Keyword MajorTopicYN="N">Lumbar Artery</Keyword><Keyword MajorTopicYN="N">Retroperitoneal Hematoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31086552</ArticleId><ArticleId IdType="pmc">PMC6500815</ArticleId><ArticleId IdType="doi">10.12669/pjms.35.2.639</ArticleId><ArticleId IdType="pii">PJMS-35-569</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sclafani SJ, Florence LO, Phillips TF, Scalea TM, Glanz S, Goldstein AS, et al. Lumbar arterial injury:radiologic diagnosis and management. Radiology. 1987;165:709&#x2013;714. doi:10.1148/radiology.165.3.3685349.</Citation><ArticleIdList><ArticleId IdType="pubmed">3685349</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan WX, Deng ZX, Liu F, Liu RB, He L, Amrit B, et al. Spontaneous retroperitoneal hemorrhage after hemodialysis involving anticoagulant agents. J Zhejiang Univ Sci B. 2012;13:408&#x2013;412. doi:10.1631/jzus.B1100357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348233</ArticleId><ArticleId IdType="pubmed">22556180</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartey B, Nelson J. Massive spontaneous retroperitoneal hemorrhage induced by enoxaparin and subsequent abdominal compartment syndrome requiring surgical decompression:A case report and literature review. Int J Case Rep Imag. 2011;2:14&#x2013;18. doi:10.5348/ijcri-2011-10-60-CR-4.</Citation></Reference><Reference><Citation>Fortina M, Carta S, Del Vecchio EO, Crainz E, Urgelli S, Ferrata P. Retroperitoneal hematoma due to spontaneous lumbar artery rupture during fondaparinux treatment. Case Report and Review of the Literature. Acta Biomed. 2007;78:46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">17687817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathi R, Voyvodic F, Thompson WR. Spontaneous extraperitoneal haemorrhage:computed tomography diagnosis and treatment by selective arterial embolization. Australas Radiol. 2004;48:123&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">15230743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang NK, Rhee H, Kim IY, Seong EY, Lee DW, Lee SB, et al. Three cases of spontaneous lumbar artery rupture in hemodialysis patients. Hemodial Int. 2017;21:E18&#x2013;E21. doi:10.1111/hdi.12491.</Citation><ArticleIdList><ArticleId IdType="pubmed">27670146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinowski EA, Trerotola SO. Postcatheterization retroperitoneal hematoma due to spontaneous lumbar arterial hemorrhage. Cardiovasc Intervent Radiol. 1998;21:337&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">9688804</ArticleId></ArticleIdList></Reference><Reference><Citation>Halak M, Kligman M, Loberman Z, Eyal E, Karmeli R. Spontaneous ruptured lumbar artery in a chronic renal failure patient. Eur J Vasc Endovasc Surg. 2001;21:569&#x2013;571. doi:10.1053/ejvs.2001.1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">11397035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyo SH, Seo JW, Park JH, Kim KP, Kim SH, Chang JW, et al. Spontaneous rupture of lumbar artery &amp;inferior epigastric artery in a hemodialysis patient. Korean J Nephrol. 2004;23:992&#x2013;996.</Citation></Reference><Reference><Citation>Anderson S, Brenner BM. Progressive renal disease:A disorder of adaptation. Q J Med. 1989;70:185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">2690171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamura M, Morioka T, Yamamoto T, Kaneda K, Mizobata Y. Spontaneous retroperitoneal bleeding:A case series. BMC Res Notes. 2014;7:659&#x2013;662. doi:10.1186/1756-0500-7-659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177246</ArticleId><ArticleId IdType="pubmed">25236774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Lee W. Hypovolemic shock caused by delayed-onset superior gluteal artery rupture, successfully treated with arteriographic embolization. Acta Chir Belg. 2017;4:1&#x2013;4. doi:10.1080/00015458.2017.1385895.</Citation><ArticleIdList><ArticleId IdType="pubmed">28978258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliffe JF. The arterial anatomy of the adult human lumbar vertebral body:A microarteriographic study. J Anat. 1980;131:57&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1233287</ArticleId><ArticleId IdType="pubmed">7440404</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Kim SH, Kim HJ, Lee DH. Spontaneous lumbar artery bleeding and retroperitoneal hematoma in a patient treated with continuous renal replacement therapy. Korean J Crit Care Med. 2015;30:318&#x2013;322. doi:10.4266/kjccm.2015.30.4.318.</Citation></Reference><Reference><Citation>Surani S, Estement B, Manchandan S, Sudhakaran S, Varon J. Spontaneous extraperitoneal lumbar artery hemorrhage. J Emerg Med. 2011;40:e111&#x2013;e114. doi:10.1016/j.jemermed.2008.01.029.</Citation><ArticleIdList><ArticleId IdType="pubmed">18922660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun PL, Lee YC, Chiu KC. Retroperitoneal hemorrhage caused by enoxaparin-induced spontaneous lumbar artery bleeding and treated by transcatheter arterial embolization:a case report. Cases J. 2009;22(2):9375. doi:10.1186/1757-1626-2-9375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806395</ArticleId><ArticleId IdType="pubmed">20072679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama Y, Iwasaki Y, Kawaguchi A. Spontaneous rupture of the lumbar artery. Intern Med. 2004;43:759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15468982</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster F, Stosslein F, Steinbach F. Spontaneous rupture of a lumbar artery. A rare etiology of retroperitoneal hematoma. Urologe A. 2003;42:840&#x2013;844. doi:10.1007/s00120-003-0298-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12851777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38827548</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0970-9134</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>Suppl 1</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Indian journal of thoracic and cardiovascular surgery</Title><ISOAbbreviation>Indian J Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Haemoadsorption in infective endocarditis: a systematic review.</ArticleTitle><Pagination><StartPage>69</StartPage><EndPage>77</EndPage><MedlinePgn>69-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12055-024-01701-0</ELocationID><Abstract><AbstractText Label="UNLABELLED">Infective endocarditis surgical patients suffer from high rates of severe complications such as systemic inflammatory response, septic shock, and multi-organ failure leading to high mortality. Systemic inflammatory response based on cytokines as messengers plays an important role in these patients. The concept of intraoperative haemoadsorption has been proposed to remove such elevated cytokines in patients undergoing cardiac surgery for infective endocarditis. Haemoadsorption offers the possibility to stabilise haemodynamics, reduce sepsis-related mortality, and protect organ function. However, until now, there has been no general opinion and consensus regarding the clinical effectiveness of adjunctive intraoperative haemoadsorption in infective endocarditis. Therefore, we reviewed the current literature evaluating haemoadsorption in infective endocarditis patients undergoing cardiac surgery. The review was registered at PROSPERO (CRD42023457632).</AbstractText><AbstractText Label="SUPPLEMENTARY INFORMATION" NlmCategory="UNASSIGNED">The online version contains supplementary material available at 10.1007/s12055-024-01701-0.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thielmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart &amp; Vascular Center Essen, Hufelandstr. 55, 45122 Essen, Germany.</Affiliation><Identifier Source="ROR">https://ror.org/05aw6p704</Identifier><Identifier Source="GRID">grid.478151.e</Identifier><Identifier Source="ISNI">0000 0004 0374 462X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dohle</LastName><ForeName>Daniel-Sebastian</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation><Identifier Source="GRID">grid.410607.4</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czerny</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation><Identifier Source="ROR">https://ror.org/0245cg223</Identifier><Identifier Source="GRID">grid.5963.9</Identifier><Identifier Source="ISNI">0000 0004 0491 7203</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonaros</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation><Identifier Source="GRID">grid.5361.1</Identifier><Identifier Source="ISNI">0000 0000 8853 2677</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendt</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0008-1074-7200</Identifier><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart &amp; Vascular Center Essen, Hufelandstr. 55, 45122 Essen, Germany.</Affiliation><Identifier Source="ROR">https://ror.org/05aw6p704</Identifier><Identifier Source="GRID">grid.478151.e</Identifier><Identifier Source="ISNI">0000 0004 0374 462X</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>CytoSorbents Europe GmbH, Berlin, Germany.</Affiliation><Identifier Source="GRID">grid.491626.e</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folliguet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Henri Mondor Hospital, Paris, France.</Affiliation><Identifier Source="GRID">grid.412116.1</Identifier><Identifier Source="ISNI">0000 0004 1799 3934</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baufreton</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, University Hospital, Angers, France.</Affiliation><Identifier Source="GRID">grid.411147.6</Identifier><Identifier Source="ISNI">0000 0004 0472 0283</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebreton</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, Paris, France.</Affiliation><Identifier Source="GRID">grid.411439.a</Identifier><Identifier Source="ISNI">0000 0001 2150 9058</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>8700105</NlmUniqueID><ISSNLinking>0970-9134</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">CytoSorb&#xae;</Keyword><Keyword MajorTopicYN="N">Haemoadsorption</Keyword><Keyword MajorTopicYN="N">Infective endocarditis</Keyword></KeywordList><CoiStatement>Conflict of interestMT, CB, and GL received speaker honoraria and travel fees from CytoSorbents Europe GmbH; DW is a full-time employee of CytoSorbents Europe GmbH.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38827548</ArticleId><ArticleId IdType="pmc">PMC11139808</ArticleId><ArticleId IdType="doi">10.1007/s12055-024-01701-0</ArticleId><ArticleId IdType="pii">1701</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. Crit Care. 2020;24:36. doi: 10.1186/s13054-020-2743-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-2743-8</ArticleId><ArticleId IdType="pmc">PMC7001322</ArticleId><ArticleId IdType="pubmed">32019600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim P, Le Maistre M, Campanini LB, De Roux Q, Mongardon N, Landon V, et al. Vasoplegic syndrome after cardiac surgery for infective endocarditis. J Clin Med. 2022;11:5523. doi: 10.3390/jcm11195523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195523</ArticleId><ArticleId IdType="pmc">PMC9573652</ArticleId><ArticleId IdType="pubmed">36233404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Yang R, Liu S, Ge D, Su X. Study on the characteristics of early cytokine storm response to cardiac surgery. J Interferon Cytokine Res. 2023;43:351&#x2013;358. doi: 10.1089/jir.2023.0044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2023.0044</ArticleId><ArticleId IdType="pubmed">37566476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu VH, Cabell CH, Benjamin DK, Jr, Kuniholm EF, Fowler VG, Jr, Engemann J, et al. Early predictors of in-hospital death in infective endocarditis. Circulation. 2004;109:1745&#x2013;1749. doi: 10.1161/01.CIR.0000124719.61827.7F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000124719.61827.7F</ArticleId><ArticleId IdType="pubmed">15037538</ArticleId></ArticleIdList></Reference><Reference><Citation>Farag M, Borst T, Sabashnikov A, Zeriouh M, Schmack B, Arif R, et al. Surgery for infective endocarditis: outcomes and predictors of mortality in 360 consecutive patients. Med Sci Monit. 2017;23:3617&#x2013;26. doi: 10.12659/msm.902340.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.902340</ArticleId><ArticleId IdType="pmc">PMC5539855</ArticleId><ArticleId IdType="pubmed">28740070</ArticleId></ArticleIdList></Reference><Reference><Citation>Tr&#xe4;ger K, Skrabal C, Fischer G, Datzmann T, Schroeder J, Fritzler D, et al. Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass - a case series. Int J Artif Organs. 2017;40:240&#x2013;249. doi: 10.5301/ijao.5000583.</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/ijao.5000583</ArticleId><ArticleId IdType="pmc">PMC6159853</ArticleId><ArticleId IdType="pubmed">28525670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhne LU, Binczyk R, Riess FC. Comparison of intraoperative versus intraoperative plus postoperative hemoadsorption therapy in cardiac surgery patients with endocarditis. Int J Artif Organs. 2019;42:194&#x2013;200. doi: 10.1177/0391398819831301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0391398819831301</ArticleId><ArticleId IdType="pubmed">30803290</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidari Z, Wendt D, Thielmann M, Mackowiak M, Neuhauser M, Jakob H, et al. Intraoperative hemoadsorption in patients with native mitral valve infective endocarditis. Ann Thorac Surg. 2020;110:890&#x2013;896. doi: 10.1016/j.athoracsur.2019.12.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2019.12.067</ArticleId><ArticleId IdType="pubmed">32059855</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801&#x2013;810. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Santer D, Miazza J, Koechlin L, Gahl B, Rrahmani B, Hollinger A, et al. Hemoadsorption during cardiopulmonary bypass in patients with endocarditis undergoing valve surgery: a retrospective single-center study. J Clin Med. 2021;10:564. doi: 10.3390/jcm10040564.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10040564</ArticleId><ArticleId IdType="pmc">PMC7913197</ArticleId><ArticleId IdType="pubmed">33546164</ArticleId></ArticleIdList></Reference><Reference><Citation>Asch S, Kaufmann TP, Walter M, Leistner M, Danner BC, Perl T, et al. The effect of perioperative hemadsorption in patients operated for acute infective endocarditis - a randomized controlled study. Artif Organs. 2021;45:1328&#x2013;1337. doi: 10.1111/aor.14019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.14019</ArticleId><ArticleId IdType="pubmed">34152632</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmen A, Corderfeldt A, Lannemyr L, Dellgren G, Hansson EC. Whole blood adsorber during CPB and need for vasoactive treatment after valve surgery in acute endocarditis: a randomized controlled study. J Cardiothorac Vasc Anesth. 2022;36:3015&#x2013;3020. doi: 10.1053/j.jvca.2022.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2022.02.028</ArticleId><ArticleId IdType="pubmed">35341666</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab M, Lehmann T, Bothe W, Akhyari P, Platzer S, Wendt D, et al. Cytokine Hemoadsorption During Cardiac Surgery Versus Standard Surgical Care for Infective Endocarditis (REMOVE): results from a multicenter randomized controlled trial. Circulation. 2022;145:959&#x2013;968. doi: 10.1161/CIRCULATIONAHA.121.056940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056940</ArticleId><ArticleId IdType="pubmed">35213213</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidari Z, Demircioglu E, Boss K, Tyczynski B, Thielmann M, Schmack B, et al. Intraoperative hemoadsorption in high-risk patients with infective endocarditis. PLoS ONE. 2022;17:e0266820. doi: 10.1371/journal.pone.0266820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266820</ArticleId><ArticleId IdType="pmc">PMC9333242</ArticleId><ArticleId IdType="pubmed">35900987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalisnik JM, Leiler S, Mamdooh H, Zibert J, Bertsch T, Vogt FA, et al. Single-centre retrospective evaluation of intraoperative hemoadsorption in left-sided acute infective endocarditis. J Clin Med. 2022;11:3954. doi: 10.3390/jcm11143954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11143954</ArticleId><ArticleId IdType="pmc">PMC9317304</ArticleId><ArticleId IdType="pubmed">35887719</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidari Z, Leiler S, Mamdooh H, Fittkau M, Boss K, Tyczynski B, et al. Effect of intraoperative haemoadsorption therapy on cardiac surgery for active infective endocarditis with confirmed Staphylococcus aureus bacteraemia. Interdiscip Cardiovasc Thorac Surg. 2023;36:ivad.010. doi: 10.1093/icvts/ivad010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivad010</ArticleId><ArticleId IdType="pmc">PMC9931064</ArticleId><ArticleId IdType="pubmed">36802263</ArticleId></ArticleIdList></Reference><Reference><Citation>Piskovatska V, Navarrete Santos A, Kalies K, Korca E, Stiller M, Szabo G, et al. Proteins adsorbed during intraoperative hemoadsorption and their in vitro effects on endothelium. Healthcare (Basel) 2023;11:310. doi: 10.3390/healthcare11030310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11030310</ArticleId><ArticleId IdType="pmc">PMC9914797</ArticleId><ArticleId IdType="pubmed">36766885</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao C, Preissing F, Thielmann M, Wendt D, Haidari Z, Kalisnik JM, et al. Hemoadsorption using CytoSorb((R)) in patients with infective endocarditis: a German-based budget impact analysis. J Cardiovasc Dev Dis. 2023;10:366. doi: 10.3390/jcdd10090366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd10090366</ArticleId><ArticleId IdType="pmc">PMC10531588</ArticleId><ArticleId IdType="pubmed">37754795</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruka V, Salmasi MY, Arjomandi Rad A, Marczin N, Lazopoulos G, Moscarelli M, et al. Use of cytokine filters during cardiopulmonary bypass: systematic review and meta-analysis. Heart Lung Circ. 2022;31:1493&#x2013;1503. doi: 10.1016/j.hlc.2022.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2022.07.015</ArticleId><ArticleId IdType="pubmed">36041987</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen A, Waalders NJB, van Lier DPT, Kox M, Pickkers P. CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care. 2023;27:117. doi: 10.1186/s13054-023-04391-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04391-z</ArticleId><ArticleId IdType="pmc">PMC10029173</ArticleId><ArticleId IdType="pubmed">36945034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruda MC, Ruggeberg KG, O'Sullivan P, Guliashvili T, Scheirer AR, Golobish TD, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads. PLoS ONE. 2018;13:e0191676. doi: 10.1371/journal.pone.0191676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191676</ArticleId><ArticleId IdType="pmc">PMC5784931</ArticleId><ArticleId IdType="pubmed">29370247</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss K, Jahn M, Wendt D, Haidari Z, Demircioglu E, Thielmann M, et al. Extracorporeal cytokine adsorption: significant reduction of catecholamine requirement in patients with AKI and septic shock after cardiac surgery. PLoS ONE. 2021;16:e0246299. doi: 10.1371/journal.pone.0246299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246299</ArticleId><ArticleId IdType="pmc">PMC7870055</ArticleId><ArticleId IdType="pubmed">33556101</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf C, Weinelt F, Schroeder I, Paal M, Weigand M, Zoller M, et al. Does the cytokine adsorber CytoSorb((R)) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? A prospective observational study. Ann Intensive Care. 2022;12:44. doi: 10.1186/s13613-022-01017-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-022-01017-5</ArticleId><ArticleId IdType="pmc">PMC9124739</ArticleId><ArticleId IdType="pubmed">35599248</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler T, Schwier E, Kirchner C, Winde G, Henzler D, Eickmeyer C. Hemoadsorption with CytoSorb((R)) and the early course of linezolid plasma concentration during septic shock. J Artif Organs. 2022;25:86&#x2013;90. doi: 10.1007/s10047-021-01274-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10047-021-01274-4</ArticleId><ArticleId IdType="pmc">PMC8866295</ArticleId><ArticleId IdType="pubmed">34047868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28275227</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1827-1596</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Minerva anestesiologica</Title><ISOAbbreviation>Minerva Anestesiol</ISOAbbreviation></Journal><ArticleTitle>Halogenated volatile anesthetics in the intensive care unit: current knowledge on an upcoming practice.</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>748</EndPage><MedlinePgn>737-748</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23736/S0375-9393.17.11735-9</ELocationID><Abstract><AbstractText>The aim of this narrative review was to highlight key points of volatile anesthetics administration in the intensive care unit (ICU), including AnaConDa&#xae; and Mirus&#xae; devices characteristics and the reported findings on clinical outcomes in critically ill patients. Intravenous sedation in the ICU is associated with issues, such as over- and under-sedation. Halogenated compounds, which can be safely administered by inserting a device in any ICU ventilation circuit, have interesting pharmacodynamic and pharmacokinetic profiles for patients with multi-organ failure. Moreover, analysis of the concentration of exhaled volatile compounds could help evaluation of sedation depth. A recent meta-analysis confirmed that rapid washout of the volatile anesthetics improved both extubation readiness and quality of awakening when compared to intravenous sedation. When administered for a long period, volatile anesthetics improved sedation stability with fewer dose adjustments. Pre- and post-conditioning properties of halogenated compounds are interesting and long-term exposition to this compound is investigated for a potential impact on mortality rate and ICU/hospital length of stay. For now, psychomotor side effects have been reported, mostly in infants, but there were no hepatic or renal injuries. Findings regarding hemodynamic stability are conflicting. Apart from sedation, volatile anesthetics were therapeutic in case reports of status asthmaticus and epilepticus and data are cumulating for benefits in cases of acute respiratory distress syndrome. According to current literature, they should be withheld in cerebral injury. To summarize, the use of volatile anesthetics for sedation is yet only approved by German guidelines, but could spread due to its potential benefits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laferriere-Langlois</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Medicine and Health Sciences Faculty, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada - pascal.laferriere-langlois@usherbrooke.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'ARAGON</LastName><ForeName>Frederick</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Medicine and Health Sciences Faculty, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzanares</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Faculty of Medicine, UDELAR, Hospital de Cl&#xed;nicas (H&#xf4;pital Universitaire), Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Anestesiol</MedlineTA><NlmUniqueID>0375272</NlmUniqueID><ISSNLinking>0375-9393</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006219">Halogens</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Minerva Anestesiol. 2017 Jul;83(7):679-681. doi: 10.23736/S0375-9393.17.12141-3.</RefSource><PMID Version="1">28528539</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000769" MajorTopicYN="N">Anesthesia, Inhalation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018685" MajorTopicYN="N">Anesthetics, Inhalation</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054810" MajorTopicYN="N">Deep Sedation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006219" MajorTopicYN="N">Halogens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014835" MajorTopicYN="N">Volatilization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28275227</ArticleId><ArticleId IdType="doi">10.23736/S0375-9393.17.11735-9</ArticleId><ArticleId IdType="pii">S0375-9393.17.11735-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19715753</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4596</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Free radical biology &amp; medicine</Title><ISOAbbreviation>Free Radic Biol Med</ISOAbbreviation></Journal><ArticleTitle>A systematic review of experimental treatments for mitochondrial dysfunction in sepsis and multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>1517</StartPage><EndPage>1525</EndPage><MedlinePgn>1517-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.freeradbiomed.2009.08.019</ELocationID><Abstract><AbstractText>Sepsis and multiple organ dysfunction syndrome (MODS) are major causes of morbidity and mortality in the intensive care unit. Recently mitochondrial dysfunction has been proposed as a key early cellular event in critical illness. A growing body of experimental evidence suggests that mitochondrial therapies are effective in sepsis and MODS. The aim of this article is to undertake a systematic review of the current experimental evidence for the use of therapies for mitochondrial dysfunction during sepsis and MODS and to classify these mitochondrial therapies. A search of the MEDLINE and PubMed databases (1950 to July 2009) and a manual review of reference lists were conducted to find experimental studies containing data on the efficacy of mitochondrial therapies in sepsis and sepsis-related MODS. Fifty-one studies were included in this review. Five categories of mitochondrial therapies were defined-substrate provision, cofactor provision, mitochondrial antioxidants, mitochondrial reactive oxygen species scavengers, and membrane stabilizers. Administration of mitochondrial therapies during sepsis was associated with improvements in mitochondrial electron transport system function, oxidative phosphorylation, and ATP production and a reduction in cellular markers of oxidative stress. Amelioration of proinflammatory cytokines, caspase activation, and prevention of the membrane permeability transition were reported. Restoration of mitochondrial bioenergetics was associated with improvements in hemodynamic parameters, organ function, and overall survival. A substantial body of evidence from experimental studies at both the cellular and the organ level suggests a beneficial role for the administration of mitochondrial therapies in sepsis and MODS. We expect that mitochondrial therapies will have an increasingly important role in the management of sepsis and MODS. Clinical trials are now required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dare</LastName><ForeName>Anna J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand. anna.dare@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Anthony R J</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Hickey</LastName><ForeName>Anthony J R</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Anubhav</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Loveday</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Nichola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Windsor</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Free Radic Biol Med</MedlineTA><NlmUniqueID>8709159</NlmUniqueID><ISSNLinking>0891-5849</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003067">Coenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015687" MajorTopicYN="N">Cell Hypoxia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003067" MajorTopicYN="N">Coenzymes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>107</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19715753</ArticleId><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.08.019</ArticleId><ArticleId IdType="pii">S0891-5849(09)00506-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26438223</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1238</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Effects of packed red blood cell storage duration on post-transfusion clinical outcomes: a meta-analysis and systematic review.</ArticleTitle><Pagination><StartPage>2087</StartPage><EndPage>2097</EndPage><MedlinePgn>2087-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00134-015-4078-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There is substantial conjecture regarding the clinical significance of packed red blood cell (PRBC) changes that occur during in vitro storage. Here, we present a meta- and systematic analysis of adult studies published between 1994 and 2015 with the aim of updating existing quantitative reviews and providing a comprehensive cover of the six most commonly studied outcomes-mortality, infection, renal dysfunction, multiple organ dysfunction syndrome (MODS), thrombotic complications and prolonged hospital length of stay.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Computerised searches of Pubmed and EMBASE identified publications that reported target outcomes and PRBC storage duration prior to transfusion. Bibliographies of relevant literature were manually searched to incorporate missed studies. Randomised controlled trial (RCT) data was meta-analysed using a random effects model with Cochrane Collaboration Review Manager (RevMan) version 5.1 software. Observational investigations were systematically reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-four papers were selected covering 462,581 patients with the majority of studies being observational in nature. Meta-analysis of eight RCTs demonstrated a trend towards decreased mortality with stored PRBC transfusion; albeit this effect was not statistically significant (OR 0.91, 95 % CI 0.78-1.05, p = 0.20). In a small subset of intensive care unit (ICU), cardiac surgery and trauma patients; observational studies suggested that prolonged storage may be correlated with increased mortality. Trauma and cardiac surgery patients appeared to be most susceptible to the potential infectious complications of stored PRBCs. Stored PRBCs were unlikely to affect thrombotic complications or hospital length of stay. There were inadequate data to determine whether stored PRBCs had clinically relevant effects on renal dysfunction and MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although literature presents a concerning picture of potential storage complications, current findings are too inconsistent to drive changes in clinical practice. Results from current RCTs will likely play a role in PRBC age guidelines for cardiac surgery and ICU patients. However, these studies may be less efficacious at detecting small effects that are limited to specific subpopulations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Monica Suet Ying</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-0431-9110</Identifier><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. monica.ng91@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. monica.ng91@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Brisbane, QLD, Australia. monica.ng91@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Angela Suet Yeung</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. angela.ng1@uqconnect.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. angela.ng1@uqconnect.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. jessica.chan4@uqconnect.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tung</LastName><ForeName>John-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. JTung@redcrossblood.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. JTung@redcrossblood.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Brisbane, QLD, Australia. JTung@redcrossblood.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>John Francis</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. TPCH-CCRG@health.qld.gov.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. TPCH-CCRG@health.qld.gov.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="N">Blood Preservation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="Y">Erythrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood storage</Keyword><Keyword MajorTopicYN="N">Erythrocyte transfusion</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Red blood cells</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26438223</ArticleId><ArticleId IdType="doi">10.1007/s00134-015-4078-5</ArticleId><ArticleId IdType="pii">10.1007/s00134-015-4078-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Thromb Haemost. 2011 Mar;9(3):574-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21166993</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Hemother. 2008 Oct;35(5):359-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21512625</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2012 Apr 15;185(8):842-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22281833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Dec;65(6):1411-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19077635</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jun;52(6):1196-202</Citation><ArticleIdList><ArticleId IdType="pubmed">22082281</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Apr 9;372(15):1419-29</Citation><ArticleIdList><ArticleId IdType="pubmed">25853746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Aug;65(2):279-82; discussion 282-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18695462</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Dec;51(12):2695-702</Citation><ArticleIdList><ArticleId IdType="pubmed">21645005</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2012 Feb;203(2):198-204</Citation><ArticleIdList><ArticleId IdType="pubmed">21924400</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Nov;51(11):2286-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21564106</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2010 May;159(5):737-743.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">20435180</ArticleId></ArticleIdList></Reference><Reference><Citation>J Burn Care Res. 2014 Mar-Apr;35(2):186-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23799480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2002 Nov;53(5):1023-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12435963</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2004 Oct;44(10):1468-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15383020</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2013 Oct 04;17(5):R222</Citation><ArticleIdList><ArticleId IdType="pubmed">24093554</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2010 May;159(5):876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">20435199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2011 Jan;141(1):231-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20621313</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2011 May;106(5):643-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21414977</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2014 May;41 Suppl 1:98-101</Citation><ArticleIdList><ArticleId IdType="pubmed">24662781</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2012 Oct;36(10):2436-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22714578</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jul 16;8(7):e68820</Citation><ArticleIdList><ArticleId IdType="pubmed">23874777</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2008 Mar 20;358(12):1229-39</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2011 Mar;39(3):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20702101</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Transfus. 2012 May;10 Suppl 2:s7-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22890271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2011 Jan;35(1):3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20823694</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2009;13(5):R151</Citation><ArticleIdList><ArticleId IdType="pubmed">19772604</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2013 Jan;118(1):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23154297</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver Transpl. 2013 Nov;19(11):1181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23813754</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Jul;49(7):1375-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2011 Apr;35(4):355-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21192282</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jun;52(6):1203-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22257314</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Anesthesiol. 2014 Oct 21;14:95</Citation><ArticleIdList><ArticleId IdType="pubmed">25352766</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Dec;49(12):2599-603</Citation><ArticleIdList><ArticleId IdType="pubmed">20163690</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2013 Jan;53(1):34-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22519710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hematol. 2013 Dec;92(12):1701-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23832235</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jun;52(6):1184-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22188419</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Cardiothorac Vasc Anesth. 2012 Sep;16(3):160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22556036</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Rev. 2013 Jan;27(1):36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22902231</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver Transpl. 2012 Apr;18(4):475-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22238247</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Jul;49(7):1384-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19453985</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Nov;51(11):2488-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21569047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2010 Aug;69(2):330-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20699741</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Hemother. 2012 Aug;39(4):271-276</Citation><ArticleIdList><ArticleId IdType="pubmed">22969697</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2010 Mar;50(3):600-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2005 Sep;71(9):781-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16468518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Am. 2014 Feb 19;96(4):272-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24553882</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Apr 9;372(15):1410-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25853745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2002 Jun;52(6):1224-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12045660</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2014 Jun 17;5:214</Citation><ArticleIdList><ArticleId IdType="pubmed">24987374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intensive Care. 2013 Jan 15;3(1):2</Citation><ArticleIdList><ArticleId IdType="pubmed">23316800</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2011;15(2):R116</Citation><ArticleIdList><ArticleId IdType="pubmed">21496231</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2010 Feb;98(2):124-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19754522</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Apher Sci. 2010 Aug;43(1):95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2013 Apr 08;17(2):R66</Citation><ArticleIdList><ArticleId IdType="pubmed">23566599</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2012 Feb 01;16(1):R19</Citation><ArticleIdList><ArticleId IdType="pubmed">22297161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 2001 Jul;44(7):955-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11496075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Exp Toxicol. 2012 Jul;31(7):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22249389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Oct;65(4):794-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18849793</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Transfus. 2012 Jul;10(3):290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22395349</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2011 Jan;100(1):36-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21175654</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jul;52(7):1410-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22233290</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2002 Jun;137(6):711-6; discussion 716-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12049543</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2006 Oct;46(10):1712-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2011 May;100(4):418-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21488881</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 May;51(5):1122-3</Citation><ArticleIdList><ArticleId IdType="pubmed">21545596</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2008 Apr;36(4):1290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18379257</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2013 Jun;44(6):747-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2010 Jun;50(6):1185-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20158690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematology Am Soc Hematol Educ Program. 2011;2011:475-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22160077</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2011;15(6):R263</Citation><ArticleIdList><ArticleId IdType="pubmed">22044745</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33320284</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Geriatric polytrauma patients should not be excluded from aggressive injury treatment based on age alone.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>365</EndPage><MedlinePgn>357-365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-020-01567-y</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Age in severely injured patients has been increasing for decades. Older age is associated with increasing mortality. However, morbidity and mortality could possibly be reduced when accurate and aggressive treatment is provided. This study investigated age-related morbidity and mortality in polytrauma including age-related decisions in initial injury management and withdrawal of life-sustaining therapy (WLST).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 6.5-year prospective cohort study included consecutive severely injured&#xa0;trauma patients admitted to a Level-1 Trauma Center ICU. Demographics, data on physiology, resuscitation, MODS/ARDS, and infectious complications were prospectively collected. Patients were divided into age subgroups (&lt;&#x2009;25, 25-49, 50-69, and&#x2009;&#x2265;&#x2009;70&#xa0;years) to make clinically relevant comparisons.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">391 patients (70% males) were included with median ISS of 29 (22-36), 95% sustained blunt injuries. There was no difference in injury severity, resuscitation, urgent surgeries, nor in ventilator days, ICU-LOS, and H-LOS between age groups. Adjusted odds of MODS, ARDS and infectious complications were similar between age groups. 47% of patients&#x2009;&#x2265;&#x2009;70&#xa0;years died, compared to 10-16% in other age groups (P&#x2009;&lt;&#x2009;0.001). WLST increased with older age, contributing to more than half of deaths&#x2009;&#x2265;&#x2009;70&#xa0;years. TBI was the most common cause of death and decision for treatment withdrawal in all age groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients&#x2009;&#x2265;&#x2009;70&#xa0;years had higher mortality risk even though injury severity and complication rates were similar to other age groups. WLST increased with age with the vast majority due to brain injury. More than half of patients&#x2009;&#x2265;&#x2009;70&#xa0;years survived suggesting geriatric polytrauma patients should not be excluded from aggressive injury treatment based on age alone.</AbstractText><CopyrightInformation>&#xa9; 2020. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Trauma Surgeon, Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. kwessem@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials><AffiliationInfo><Affiliation>Professor of Trauma Surgery, Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggressive treatment</Keyword><Keyword MajorTopicYN="N">Geriatric polytrauma</Keyword><Keyword MajorTopicYN="N">Withdrawal of life-sustaining therapy</Keyword></KeywordList><CoiStatement>All authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33320284</ArticleId><ArticleId IdType="pmc">PMC7736672</ArticleId><ArticleId IdType="doi">10.1007/s00068-020-01567-y</ArticleId><ArticleId IdType="pii">10.1007/s00068-020-01567-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuhne CA, Ruchholtz S, Kaiser GM, Nast-Kolb D. Working group on multiple trauma of the german society of trauma. Mortality in severely injured elderly trauma patients&#x2013;when does age become a risk factor? World J Surg. 2005;29(11):1476&#x2013;1482. doi: 10.1007/s00268-005-7796-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-005-7796-y</ArticleId><ArticleId IdType="pubmed">16228923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima M, Endo A, Shiraishi A, Otomo Y. Age-related characteristics and outcomes for patients with severe trauma: analysis of Japan's nationwide trauma registry. Ann Emerg Med. 2019;73(3):281&#x2013;290. doi: 10.1016/j.annemergmed.2018.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2018.09.034</ArticleId><ArticleId IdType="pubmed">30447945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nenberger A, Billeter AT, Seifert B, Neuhaus V, Trentz O, Turina M. Opportunities for improved trauma care of the elderly - a single center analysis of 2090 severely injured patients. Arch Gerontol Geriatr. 2012;55(3):660&#x2013;666. doi: 10.1016/j.archger.2012.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2012.02.013</ArticleId><ArticleId IdType="pubmed">22465302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammy I, Lecky F, Sutton A, Leaviss J, O'Cathain A. Factors affecting mortality in older trauma patients-A systematic review and meta-analysis. Injury. 2016;47(6):1170&#x2013;1183. doi: 10.1016/j.injury.2016.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2016.02.027</ArticleId><ArticleId IdType="pubmed">27015751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitriou R, Calori GM, Giannoudis PV. Polytrauma in the elderly: specific considerations and current concepts of management. Eur J Trauma Emerg Surg. 2011;37(6):539&#x2013;548. doi: 10.1007/s00068-011-0137-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-011-0137-y</ArticleId><ArticleId IdType="pubmed">26815464</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Court-Brown C, Pape HC. Severe and multiple trauma in older patients; incidence and mortality. Injury. 2009;40(4):362&#x2013;367. doi: 10.1016/j.injury.2008.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2008.10.016</ArticleId><ArticleId IdType="pubmed">19217104</ArticleId></ArticleIdList></Reference><Reference><Citation>Friese RS, Wynne J, Joseph B, et al. Age and mortality after injury: is the association linear? Eur J Trauma Emerg Surg. 2014;40(5):567&#x2013;572. doi: 10.1007/s00068-014-0380-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-014-0380-0</ArticleId><ArticleId IdType="pubmed">26814513</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodmanson NW, Rosengart MR, Barnato AE, Sperry JL, Peitzman AB, Marshall GT. Defining geriatric trauma: when does age make a difference? Surgery. 2012;152(4):668&#x2013;675. doi: 10.1016/j.surg.2012.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2012.08.017</ArticleId><ArticleId IdType="pmc">PMC4070315</ArticleId><ArticleId IdType="pubmed">23021136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand F, Pape HC, Horst K, et al. Impact of age on the clinical outcomes of major trauma. Eur J Trauma Emerg Surg. 2016;42(3):317&#x2013;332. doi: 10.1007/s00068-015-0557-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-015-0557-1</ArticleId><ArticleId IdType="pubmed">26253883</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler CR, Woschek M, Verboket RD, et al. Registry-based mortality analysis reveals a high proportion of patient decrees and presumed limitation of therapy in severe geriatric trauma. J Clin Med. 2020;9(9):E2686. doi: 10.3390/jcm9092686.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9092686</ArticleId><ArticleId IdType="pmc">PMC7565431</ArticleId><ArticleId IdType="pubmed">32825084</ArticleId></ArticleIdList></Reference><Reference><Citation>Spering C, Lefering R, Bouillon B, et al. It is time for a change in the management of elderly severely injured patients! An analysis of 126,015 patients from the TraumaRegister DGU&#xae;. Eur J Trauma Emerg Surg. 2020;46(3):487&#x2013;497. doi: 10.1007/s00068-019-01229-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-019-01229-8</ArticleId><ArticleId IdType="pubmed">31520156</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterino JM, Valasek T, Werman HA. Identification of an age cutoff for increased mortality in patients with elderly trauma. Am J Emerg Med. 2010;28(2):151&#x2013;158. doi: 10.1016/j.ajem.2008.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2008.10.027</ArticleId><ArticleId IdType="pubmed">20159383</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatovich DM, Jacobs IG, Langford SA, Phillips M. The effect of age, severity, and mechanism of injury on risk of death from major trauma in Western Australia. J Trauma Acute Care Surg. 2013;74(2):647&#x2013;651. doi: 10.1097/TA.0b013e3182788065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182788065</ArticleId><ArticleId IdType="pubmed">23354264</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzunegui T, Grad&#xed;n C, Fort&#xfa;n M, Cabodevilla A, Barbachano A, Sanz JA. Major trauma registry of Navarre (Spain): the accuracy of different survival prediction models. Am J Emerg Med. 2013;31(9):1382&#x2013;1388. doi: 10.1016/j.ajem.2013.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2013.06.026</ArticleId><ArticleId IdType="pubmed">23891602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, Leenen LPH. Demographic patterns and outcomes of patients in level-1 trauma centers in three international trauma systems. World J Surg. 2015;39(11):2677&#x2013;2684. doi: 10.1007/s00268-015-3162-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3162-x</ArticleId><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg. 2013;74(3):774&#x2013;779. doi: 10.1097/TA.0b013e31827a6e69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg. 2014;77:624&#x2013;629. doi: 10.1097/TA.0000000000000406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000406</ArticleId><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39&#x2013;45. doi: 10.1001/archsurg.1994.01420250051006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, et al. ARDS definition task force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Hietbrink F, Leenen LPH. Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured. Trauma Surg Acute Care Open. 2020;5(1):e000398. doi: 10.1136/tsaco-2019-000398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2019-000398</ArticleId><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="pubmed">32154377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the glasgow outcome scale and the extended glasgow outcome scale: guidelines for their use. J Neurotrauma. 1998;15(8):573&#x2013;585. doi: 10.1089/neu.1998.15.573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1998.15.573</ArticleId><ArticleId IdType="pubmed">9726257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton GE, McNutt MK, Cotton BA, Hudson JA, Wade CE, Kao LS. Age-dependent association of occult hypoperfusion and outcomes in trauma. J Am Coll Surg. 2020;230(4):417&#x2013;425. doi: 10.1016/j.jamcollsurg.2019.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2019.12.011</ArticleId><ArticleId IdType="pmc">PMC7719288</ArticleId><ArticleId IdType="pubmed">31954820</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RM. Immunity, trauma and the elderly. Injury. 2007;38(12):1401&#x2013;1404. doi: 10.1016/j.injury.2007.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.013</ArticleId><ArticleId IdType="pubmed">18045600</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochems D, van Wessem KJP, Houwert RM, et al. Outcome in patients with isolated moderate to severe traumatic brain injury. Crit Care Res Pract. 2018;2018:3769418. doi: 10.1155/2018/3769418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3769418</ArticleId><ArticleId IdType="pmc">PMC6174733</ArticleId><ArticleId IdType="pubmed">30345113</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm A, Maegele M, Wendt K, Lefering R, Wyen H, TraumaRegister DGU. Pre-hospital rescue times and interventions in severe trauma in Germany and the Netherlands: a matched-pairs analysis. Eur J Trauma Emerg Surg. 2019;45(6):1059&#x2013;1067. doi: 10.1007/s00068-018-0978-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-018-0978-8</ArticleId><ArticleId IdType="pubmed">30014270</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19136822</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9697</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>3-4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Annals of nutrition &amp; metabolism</Title><ISOAbbreviation>Ann Nutr Metab</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of enteral nutrition versus total parenteral nutrition in patients with severe acute pancreatitis.</ArticleTitle><Pagination><StartPage>268</StartPage><EndPage>275</EndPage><MedlinePgn>268-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000189382</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the safety of enteral nutrition and total parenteral nutrition in nutrition support of patients with severe acute pancreatitis.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Medline, Embase, and manual search.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">295 articles were screened for randomized controlled studies (RCTs) that compared enteral nutrition with total parenteral nutrition in patients with severe acute pancreatitis. Finally, six RCTs were identified and included in the meta-analysis.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">six RCTs with 224 participants were analyzed. The main outcome were infections, artificial nutrition-related complications, pancreatitis-related complications, non-pancreatitis-related complications, organ failure and mortality. The meta-analysis was performed with the fixed effects model or random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with total parenteral nutrition, enteral nutrition was associated with a significantly lower risk of infections [odds ratio (OR) 0.236; 95% confidence interval (95% CI) 0.120-0.464, p&lt;0.001], pancreatitis-related complications (0.456; 0.234-0.888, p=0.021), organ failure (0.334; 0.167-0.670, p=0.002), multiple organ dysfunction syndrome (0.306; 0.128-0.736, p=0.008), and mortality (0.251; 0.095-0.666, p=0.005). There were no significant differences in artificial nutrition-related complications (0.642; 0.354-1.162, p=0.143), and non-pancreatitis-related complications (0.716; 0.325-1.576, p=0.406) between the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Enteral nutrition appears safer than total parenteral nutrition in nutrition support of patients with severe acute pancreatitis.</AbstractText><CopyrightInformation>Copyright 2009 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yunfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal and Anal Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yinglong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tingna</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Zengnan</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Ann Nutr Metab</MedlineTA><NlmUniqueID>8105511</NlmUniqueID><ISSNLinking>0250-6807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="Y">Enteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010288" MajorTopicYN="Y">Parenteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010289" MajorTopicYN="N">Parenteral Nutrition, Total</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>57</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19136822</ArticleId><ArticleId IdType="doi">10.1159/000189382</ArticleId><ArticleId IdType="pii">000189382</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32780121</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children.</ArticleTitle><Pagination><StartPage>e209271</StartPage><MedlinePgn>e209271</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e209271</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.9271</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Multiple organ dysfunction syndrome (MODS) is a dynamic and heterogeneous process associated with high morbidity and mortality in critically ill children.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether data-driven phenotypes of MODS based on the trajectories of 6 organ dysfunctions have prognostic and therapeutic relevance in critically ill children.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study included 20&#x202f;827 pediatric intensive care encounters among 14&#x202f;285 children admitted to 2 large academic pediatric intensive care units (PICUs) between January 2010 and August 2016. Patients were excluded if they were older than 21 years or had undergone cardiac surgery. The 6 subscores of the pediatric Sequential Organ Failure Assessment (pSOFA) score were calculated for the first 3 days, including the subscores for respiratory, cardiovascular, coagulation, hepatic, neurologic, and renal dysfunctions. MODS was defined as a pSOFA subscore of at least 2 in at least 2 organs. Encounters were split in a 80:20 ratio for derivation and validation, respectively. The trajectories of the 6 subscores were used to derive a set of data-driven phenotypes of MODS using subgraph-augmented nonnegative matrix factorization in the derivation set. Data analysis was conducted from March to October 2019.</AbstractText><AbstractText Label="EXPOSURES">The primary exposure was phenotype membership. In the subset of patients with vasoactive-dependent shock, the interaction between hydrocortisone and phenotype membership and its association with outcomes were examined in a matched cohort.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was in-hospital mortality. Secondary outcomes included persistent MODS on day 7, and vasoactive-free, ventilator-free, and hospital-free days. Regression analysis was used to adjust for age, severity of illness, immunocompromised status, and study site.</AbstractText><AbstractText Label="RESULTS">There were 14&#x202f;285 patients with 20&#x202f;827 encounters (median [interquartile range] age 5.2 years [1.5-12.7] years; 11&#x202f;409 [54.8%; 95% CI, 54.1%-55.5%] male patients). Of these, 5297 encounters (25.4%; 95% CI, 24.8%-26.0%) were with patients who had MODS, of which 5054 (95.4%) met the subgraph count threshold and were included in the analysis. Subgraph augmented nonnegative matrix factorization uncovered 4 data-driven phenotypes of MODS, characterized by a combination of neurologic, respiratory, coagulation, and cardiovascular dysfunction, as follows: phenotype 1, severe, persistent encephalopathy (1019 patients [19.2%]); phenotype 2, moderate, resolving hypoxemia (1828 patients [34.5%]); phenotype 3, severe, persistent hypoxemia and shock (1012 patients [19.1%]); and phenotype 4, moderate, persistent thrombocytopenia and shock (1195 patients [22.6%]). These phenotypes were reproducible in a validation set of encounters, had distinct clinical characteristics, and were independently associated with outcomes. For example, using phenotype 2 as reference, the adjusted hazard ratios (aHRs) for death by 28 days were as follows: phenotype 1, aHR of 3.0 (IQR, 2.1-4.3); phenotype 3, aHR of 2.8 (IQR, 2.0-4.1); and phenotype 4, aHR of 1.8 (IQR, 1.2-2.6). Interaction analysis in a matched cohort of patients with vasoactive-dependent shock revealed that hydrocortisone had differential treatment association with vasoactive-free days across phenotypes. For example, patients in phenotype 3 who received hydrocortisone had more vasoactive-free days than those who did not (23 days vs 18 days; P for interaction&#x2009;&lt;&#x2009;.001), whereas patients in other phenotypes who received hydrocortisone either had no difference or had less vasoactive-free days.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, data-driven phenotyping in critically ill children with MODS uncovered 4 distinct and reproducible phenotypes with prognostic relevance and possible therapeutic relevance. Further validation and characterization of these phenotypes is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Critical Care, Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health and Biomedical Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Driskill Graduate Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pendergrast</LastName><ForeName>Tricia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Neethi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Section of Critical Care, Department of Pediatrics, The University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Health and Biomedical Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 LM012203</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 LM012618</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD096402</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="Y">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32780121</ArticleId><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.9271</ArticleId><ArticleId IdType="pii">2769144</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tamburro RF, Jenkins TL. Multiple organ dysfunction syndrome: a challenge for the pediatric critical care community. Pediatr Crit Care Med. 2017;18(3_suppl)(suppl 1):S1-S3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28248828</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Pinto NP, Sanchez-Pinto LN. Association of organ dysfunction scores and functional outcomes following pediatric critical illness. Pediatr Crit Care Med. 2019;20(8):722-727. doi:10.1097/PCC.0000000000001999</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001999</ArticleId><ArticleId IdType="pubmed">31398181</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F; Groupe Francophone de R&#xe9;animation et d&#x2019;Urgences P&#xe9;diatriques (GFRUP) . PELOD-2: an update of the Pediatric Logistic Organ Dysfunction score. Crit Care Med. 2013;41(7):1761-1773. doi:10.1097/CCM.0b013e31828a2bbd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, et al. ; Sepsis Prevalence, Outcomes, and Therapy Study Investigators . New or progressive multiple organ dysfunction syndrome in pediatric severe sepsis: a sepsis phenotype with higher morbidity and mortality. Pediatr Crit Care Med. 2017;18(1):8-16. doi:10.1097/PCC.0000000000000978</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000978</ArticleId><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Deken V, Lacroix J, Leclerc F; Groupe Francophone de R&#xe9;animation et Urgences P&#xe9;diatriques . Daily estimation of the severity of organ dysfunctions in critically ill children by using the PELOD-2 score. Crit Care. 2015;19:324. doi:10.1186/s13054-015-1054-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-1054-y</ArticleId><ArticleId IdType="pmc">PMC4570178</ArticleId><ArticleId IdType="pubmed">26369662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Gavrilin MA, Knatz NL, Duncan MD, Fernandez SA, Wewers MD. Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr Res. 2007;62(5):597-603. doi:10.1203/PDR.0b013e3181559774</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e3181559774</ArticleId><ArticleId IdType="pubmed">17805202</ArticleId></ArticleIdList></Reference><Reference><Citation>Upperman JS, Lacroix J, Curley MA, et al. . Specific etiologies associated with the multiple organ dysfunction syndrome in children: part 1. Pediatr Crit Care Med. 2017;18(3_suppl)(suppl 1):S50-S57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333126</ArticleId><ArticleId IdType="pubmed">28248834</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Podd B, Aneja R, et al. . Pathophysiology of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017;18(3_suppl)(suppl 1):S32-S45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333491</ArticleId><ArticleId IdType="pubmed">28248832</ArticleId></ArticleIdList></Reference><Reference><Citation>Seely AJ, Christou NV. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med. 2000;28(7):2193-2200. doi:10.1097/00003246-200007000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200007000-00003</ArticleId><ArticleId IdType="pubmed">10921540</ArticleId></ArticleIdList></Reference><Reference><Citation>An G, Nieman G, Vodovotz Y. Computational and systems biology in trauma and sepsis: current state and future perspectives. Int J Burns Trauma. 2012;2(1):1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415970</ArticleId><ArticleId IdType="pubmed">22928162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Sherwood ER. Immunology: getting sepsis therapy right. Science. 2015;347(6227):1201-1202. doi:10.1126/science.aaa8334</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8334</ArticleId><ArticleId IdType="pmc">PMC4398343</ArticleId><ArticleId IdType="pubmed">25766219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. . Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191(3):309-315. doi:10.1164/rccm.201410-1864OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201410-1864OC</ArticleId><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Berg RA, Wessel D, et al. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network . A multicenter network assessment of three inflammation phenotypes in pediatric sepsis-induced multiple organ failure. Pediatr Crit Care Med. 2019;20(12):1137-1146. doi:10.1097/PCC.0000000000002105</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000002105</ArticleId><ArticleId IdType="pmc">PMC8121153</ArticleId><ArticleId IdType="pubmed">31568246</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Kennedy JN, Wang S, et al. . Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003-2017. doi:10.1001/jama.2019.5791</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.5791</ArticleId><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. Intensive Care Med. 2015;41(5):814-822. doi:10.1007/s00134-015-3764-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3764-7</ArticleId><ArticleId IdType="pmc">PMC4607311</ArticleId><ArticleId IdType="pubmed">25851384</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network . Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620. doi:10.1016/S2213-2600(14)70097-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(14)70097-9</ArticleId><ArticleId IdType="pmc">PMC4154544</ArticleId><ArticleId IdType="pubmed">24853585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney TE, Azad TD, Donato M, et al. . Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018;46(6):915-925. doi:10.1097/CCM.0000000000003084</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003084</ArticleId><ArticleId IdType="pmc">PMC5953807</ArticleId><ArticleId IdType="pubmed">29537985</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gomez H, Chang CH, et al. . Precision medicine for all? challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21(1):257. doi:10.1186/s13054-017-1836-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1836-5</ArticleId><ArticleId IdType="pmc">PMC5648512</ArticleId><ArticleId IdType="pubmed">29047353</ArticleId></ArticleIdList></Reference><Reference><Citation>Saria S, Goldenberg A. Subtyping: what it is and its role in precision medicine. IEEE Intell Syst. 2015;30(4):70-75. doi:10.1109/MIS.2015.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MIS.2015.60</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulam P, Wigley F, Saria S Clustering longitudinal clinical marker trajectories from electronic health data: applications to phenotyping and endotype discovery. Paper presented at: 29th Conference on Artificial Intelligence; January 25-30, 2015; Austin, TX.</Citation></Reference><Reference><Citation>Luo Y, Xin Y, Joshi R, Celi LA, Szolovits P Predicting ICU mortality risk by grouping temporal trends from a multivariate panel of physiologic measurements. Paper presented at: 30th AAAI Conference; February 12-17, 2016; Phoenix, AZ.</Citation></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019;200(3):327-335. doi:10.1164/rccm.201806-1197OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201806-1197OC</ArticleId><ArticleId IdType="pmc">PMC6680307</ArticleId><ArticleId IdType="pubmed">30789749</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno R, Vincent J-L, Matos R, et al. . The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care: results of a prospective, multicentre study, Working Group on Sepsis-Related Problems of the ESICM. Intensive Care Med. 1999;25(7):686-696. doi:10.1007/s001340050931</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050931</ArticleId><ArticleId IdType="pubmed">10470572</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric Sequential Organ Failure Assessment score and evaluation of the Sepsis-3 definitions in critically ill children. JAMA Pediatr. 2017;171(10):e172352. doi:10.1001/jamapediatrics.2017.2352</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2017.2352</ArticleId><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743-752. doi:10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14(1):199. doi:10.1186/1471-2431-14-199</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-14-199</ArticleId><ArticleId IdType="pmc">PMC4134331</ArticleId><ArticleId IdType="pubmed">25102958</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgelt C, Meinl T, Berthold M. MoSS: a program for molecular substructure mining. Proc First Int Workshop on Open Source Data Mining. 2005:6-15. doi:10.1145/1133905.1133908</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1133905.1133908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11(1):367. doi:10.1186/1471-2105-11-367</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-11-367</ArticleId><ArticleId IdType="pmc">PMC2912887</ArticleId><ArticleId IdType="pubmed">20598126</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33(7):1484-1491. doi:10.1097/01.CCM.0000170943.23633.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000170943.23633.47</ArticleId><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, et al. . Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making. 1999;19(4):399-410. doi:10.1177/0272989X9901900408</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9901900408</ArticleId><ArticleId IdType="pubmed">10520678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. . Endotype transitions during the acute phase of pediatric septic shock reflect changing risk and treatment response. Crit Care Med. 2018;46(3):e242-e249. doi:10.1097/CCM.0000000000002932</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002932</ArticleId><ArticleId IdType="pmc">PMC5825261</ArticleId><ArticleId IdType="pubmed">29252929</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Renault A, Brun-Buisson C, et al. ; CRICS-TRIGGERSEP Network . Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809-818. doi:10.1056/NEJMoa1705716</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705716</ArticleId><ArticleId IdType="pubmed">29490185</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon K, McNally JD. Corticosteroids in pediatric septic shock are helpful. Crit Care Med. 2018;46(4):635-636. doi:10.1097/CCM.0000000000002979</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002979</ArticleId><ArticleId IdType="pubmed">29360665</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon K, McNally JD, Choong K, et al. . A survey of stated physician practices and beliefs on the use of steroids in pediatric fluid and/or vasoactive infusion-dependent shock. Pediatr Crit Care Med. 2013;14(5):462-466. doi:10.1097/PCC.0b013e31828a7287</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31828a7287</ArticleId><ArticleId IdType="pubmed">23628832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprung CL, Annane D, Keh D, et al. ; CORTICUS Study Group . Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124. doi:10.1056/NEJMoa071366</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa071366</ArticleId><ArticleId IdType="pubmed">18184957</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh B, Finfer S, Cohen J, et al. ; ADRENAL Trial Investigators and the Australian&#x2013;New Zealand Intensive Care Society Clinical Trials Group . Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797-808. doi:10.1056/NEJMoa1705835</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705835</ArticleId><ArticleId IdType="pubmed">29347874</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, S&#xe9;bille V, Bellissant E; Ger-Inf-05 Study Group . Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22-30. doi:10.1097/01.CCM.0000194723.78632.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000194723.78632.62</ArticleId><ArticleId IdType="pubmed">16374152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tongyoo S, Permpikul C, Mongkolpun W, et al. . Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329. doi:10.1186/s13054-016-1511-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1511-2</ArticleId><ArticleId IdType="pmc">PMC5065699</ArticleId><ArticleId IdType="pubmed">27741949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochanek PM, Tasker RC, Carney N, et al. . Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation guidelines. Pediatr Crit Care Med. 2019;20(3S)(suppl 1):S1-S82. doi:10.1097/PCC.0000000000001735</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001735</ArticleId><ArticleId IdType="pubmed">30829890</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald JC, Weiss SL, Maude SL, et al. . Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124-e131. doi:10.1097/CCM.0000000000002053</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002053</ArticleId><ArticleId IdType="pmc">PMC5452983</ArticleId><ArticleId IdType="pubmed">27632680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Knatz NL, Vetterly C, et al. . Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525-532. doi:10.1007/s00134-010-2088-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2088-x</ArticleId><ArticleId IdType="pmc">PMC5224706</ArticleId><ArticleId IdType="pubmed">21153402</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoory B, Carcillo JA, Chatham WW, et al. . Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior phase III trial. Crit Care Med. 2016;44(2):275-281. doi:10.1097/CCM.0000000000001402</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001402</ArticleId><ArticleId IdType="pmc">PMC5378312</ArticleId><ArticleId IdType="pubmed">26584195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26140005</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>24</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Management of duodenal stump fistula after gastrectomy for gastric cancer: Systematic review.</ArticleTitle><Pagination><StartPage>7571</StartPage><EndPage>7576</EndPage><MedlinePgn>7571-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v21.i24.7571</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To identify the most effective treatment of duodenal stump fistula (DSF) after gastrectomy for gastric cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review of the literature was performed. PubMed, EMBASE, Cochrane Library, CILEA Archive, BMJ Clinical Evidence and UpToDate databases were analyzed. Three hundred eighty-eight manuscripts were retrieved and analyzed and thirteen studies published between 1988 and 2014 were finally selected according to the inclusion criteria, for a total of 145 cases of DSF, which represented our group of study. Only patients with DSF after gastrectomy for malignancy were selected. Data about patients' characteristics, type of treatment, short and long-term outcomes were extracted and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the 13 studies different types of treatment were proposed: conservative approach, surgical approach, percutaneous approach and endoscopic approach (3 cases). The overall mortality rate was 11.7% for the entire cohort. The more frequent complications were sepsis, abscesses, peritonitis, bleeding, pneumonia and multi-organ failure. Conservative approach was performed in 6 studies for a total of 79 patients, in patients with stable general condition, often associated with percutaneous approach. A complete resolution of the leakage was achieved in 92.3% of these patients, with a healing time ranging from 17 to 71 d. Surgical approach included duodenostomy, duodeno-jejunostomy, pancreatoduodenectomy and the use of rectus muscle flap. In-hospital stay of patients who underwent relaparotomy ranged from 1 to 1035 d. The percutaneous approach included drainage of abscesses or duodenostomy (32 cases) and percutaneous biliary diversion (13 cases). The median healing time in this group was 43 d.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Conservative approach is the treatment of choice, eventually associated with percutaneus drainage. Surgical approach should be reserved for severe cases or when conservative approaches fail.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aurello</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirimarco</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magistri</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucciani</LastName><ForeName>Niccol&#xf2;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berardi</LastName><ForeName>Giammauro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amato</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasparrini</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Angelo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nigri</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramacciato</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Paolo Aurello, Dario Sirimarco, Paolo Magistri, Niccol&#xf2; Petrucciani, Giammauro Berardi, Silvia Amato, Marcello Gasparrini, Francesco D'Angelo, Giuseppe Nigri, Giovanni Ramacciato, Department of General Surgery, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="N">Anastomotic Leak</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004378" MajorTopicYN="N">Duodenal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004386" MajorTopicYN="N">Duodenum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005743" MajorTopicYN="N">Gastrectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007412" MajorTopicYN="N">Intestinal Fistula</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Duodenal stump fistula</Keyword><Keyword MajorTopicYN="N">Duodenal stump leak</Keyword><Keyword MajorTopicYN="N">Gastrectomy</Keyword><Keyword MajorTopicYN="N">Gastric cancer</Keyword><Keyword MajorTopicYN="N">Management</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26140005</ArticleId><ArticleId IdType="pmc">PMC4481454</ArticleId><ArticleId IdType="doi">10.3748/wjg.v21.i24.7571</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Capocaccia R, De Angelis R. Regional estimates of stomach cancer burden in Italy. Tumori. 2007;93:367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">17899867</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurello P, Bellagamba R, Rossi Del Monte S, D&#x2019;Angelo F, Nigri G, Cicchini C, Ravaioli M, Ramacciato G. Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg. 2009;75:1183&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">19999909</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurello P, Magistri P, Nigri G, Petrucciani N, Novi L, Antolino L, D&#x2019;Angelo F, Ramacciato G. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res. 2014;34:6283&#x2013;6288.</Citation><ArticleIdList><ArticleId IdType="pubmed">25368226</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin RC, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002;194:568&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12025834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrazzani C, Marrelli D, Rampone B, De Stefano A, Corso G, Fotia G, Pinto E, Roviello F. Postoperative complications and functional results after subtotal gastrectomy with Billroth II reconstruction for primary gastric cancer. Dig Dis Sci. 2007;52:1757&#x2013;1763.</Citation><ArticleIdList><ArticleId IdType="pubmed">17404848</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulloch P, Ward J, Tekkis PP. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327:1192&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC274052</ArticleId><ArticleId IdType="pubmed">14630753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzaglio L, Coladonato M, Biffi R, Coniglio A, Corso V, Dionigi P, Gianotti L, Mazzaferro V, Morgagni P, Rosa F, et al. Duodenal fistula after elective gastrectomy for malignant disease: an italian retrospective multicenter study. J Gastrointest Surg. 2010;14:805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">20143272</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzaglio L, Cimino M, Mauri G, Ardito A, Pedicini V, Poretti D, Brambilla G, Sacchi M, Melis A, Doci R. Percutaneous transhepatic biliary drainage and occlusion balloon in the management of duodenal stump fistula. J Gastrointest Surg. 2011;15:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">21913043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi JA, Sollenberger LL, Rege RV, Glenn J, Joehl RJ. External duodenal fistula. Causes, complications, and treatment. Arch Surg. 1986;121:908&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">3729708</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu BI, Finch JG. Current status in the multidisciplinary management of duodenal fistula. Surgeon. 2013;11:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">23375490</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SK, Lam YH, Lau JY, Lee DW, Chan AC, Chung SC. Diagnostic and therapeutic fistuloscopy: an adjuvant management in postoperative fistulas and abscesses after upper gastrointestinal surgery. Endoscopy. 2000;32:311&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyzer S, Binyamini Y, Melki Y, Ohana G, Koren R, Chaimoff C, Wolloch Y. Comparative study of the early postoperative course and complications in patients undergoing Billroth I and Billroth II gastrectomy. World J Surg. 1997;21:763&#x2013;76; discussion 767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9276708</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio G, Badas R, Miraglia R, Barresi L, Tarantino I, Traina M. Duodenal stump fistula following Roux-en-Y gastrectomy, treated with single-balloon enteroscopy using the tulip bundle technique and fibrin glue injection. Endoscopy. 2012;44 Suppl 2 UCTN:E364&#x2013;E365.</Citation><ArticleIdList><ArticleId IdType="pubmed">23012024</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SJ, Choi WB, Song J, Hyung WJ, Choi SH, Noh SH. Complications requiring reoperation after gastrectomy for gastric cancer: 17 years experience in a single institute. J Gastrointest Surg. 2009;13:239&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">18850251</ArticleId></ArticleIdList></Reference><Reference><Citation>Garden OJ, Dykes EH, Carter DC. Surgical and nutritional management of postoperative duodenal fistulas. Dig Dis Sci. 1988;33:30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">3123177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarzour JG, Christein JD, Drelichman ER, Oser RF, Hawn MT. Percutaneous transhepatic duodenal diversion for the management of duodenal fistulae. J Gastrointest Surg. 2008;12:1103&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">18172607</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio G, Traina M, Panarello G, Barresi L, Tarantino I, Arcadipane A, Gridelli B. Refractory gastric ulcer bleeding treated with new endoloop/clips technique. Dig Endosc. 2011;23:203&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">21429034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocciaro F, Curcio G, Tarantino I, Barresi L, Spada M, Petri SL, Traina M. Tulip bundle technique and fibrin glue injection: unusual treatment of colonic perforation. World J Gastroenterol. 2011;17:1088&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057155</ArticleId><ArticleId IdType="pubmed">21451724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch P, Gompel H. Treatment of postoperative duodenal fistulae by transparietal abdominal endoscopic intubation. Surg Endosc. 1989;3:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">2814780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Ryu KW, Cho SJ, Kim CG, Choi IJ, Kim MJ, Lee JS, Kim HB, Lee JH, Kim YW. Endoscopic clipping of duodenal stump leakage after Billroth II gastrectomy in gastric cancer patient. J Surg Oncol. 2009;100:80&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19373865</ArticleId></ArticleIdList></Reference><Reference><Citation>Devereaux CE, Binmoeller KF. Endoclip: closing the surgical gap. Gastrointest Endosc. 1999;50:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">10462677</ArticleId></ArticleIdList></Reference><Reference><Citation>Blouhos K, Boulas KA, Konstantinidou A, Salpigktidis II, Katsaouni SP, Ioannidis K, Hatzigeorgiadis A. Early rupture of an ultralow duodenal stump after extended surgery for gastric cancer with duodenal invasion managed by tube duodenostomy and cholangiostomy. Case Rep Surg. 2013;2013:430295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789440</ArticleId><ArticleId IdType="pubmed">24159410</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsenigo E, Bissolati M, Socci C, Chiari D, Muffatti F, Nifosi J, Staudacher C. Duodenal stump fistula after gastric surgery for malignancies: a retrospective analysis of risk factors in a single centre experience. Gastric Cancer. 2014;17:733&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">24399492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH, Kim MC, Jung GJ. Risk factors for duodenal stump leakage after gastrectomy for gastric cancer and management technique of stump leakage. Hepatogastroenterology. 2014;61:1446&#x2013;1453.</Citation><ArticleIdList><ArticleId IdType="pubmed">25436323</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasiliadis K, Fortounis K, Kokarhidas A, Papavasiliou C, Nimer AA, Stratilati S, Makridis C. Delayed duodenal stump blow-out following total gastrectomy for cancer: Heightened awareness for the continued presence of the surgical past in the present is the key to a successful duodenal stump disruption management. A case report. Int J Surg Case Rep. 2014;5:1229&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275811</ArticleId><ArticleId IdType="pubmed">25437683</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr. 2009;28:378&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">19464088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler JT, Deitel M. Management of duodenal fistulas. Can J Surg. 1981;24:124&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">6784906</ArticleId></ArticleIdList></Reference><Reference><Citation>Weimann A, Braga M, Harsanyi L, Laviano A, Ljungqvist O, Soeters P, Jauch KW, Kemen M, Hiesmayr JM, Horbach T, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr. 2006;25:224&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Li R, Chen L, Wu X. [Nutritional support of duodenal stump leakage after gastrectomy for gastric carcinoma] Zhonghua Wei Chang Wai Ke Zazhi. 2008;11:47&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18197494</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21371695</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-229X</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical radiology</Title><ISOAbbreviation>Clin Radiol</ISOAbbreviation></Journal><ArticleTitle>Embolization for non-variceal upper gastrointestinal tract haemorrhage: a systematic review.</ArticleTitle><Pagination><StartPage>500</StartPage><EndPage>509</EndPage><MedlinePgn>500-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.crad.2010.11.016</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the published evidence on the endovascular treatment of non-variceal upper gastrointestinal haemorrhage.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An Ovid Medline search of published literature was performed (1966-2009). Non-English literature, experimental studies, variceal haemorrhage and case series with fewer than five patients were excluded. The search yielded 1888 abstracts. Thirty-five articles were selected for final analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The total number of pooled patients was 927. The technical and clinical success of embolization ranged from 52-100% and 44-100%, respectively. The pooled mean technical/clinical success rate in primary upper gastrointestinal tract haemorrhage (PUGITH) only, trans-papillary haemorrhage (TPH) only, and mixed studies were 84%/67%, 93%/89%, and 93%/64%, respectively. Clinical outcome was adversely affected by multi-organ failure, shock, corticosteroids, transfusion, and coagulopathy. The anatomical source of haemorrhage and procedural variables did not affect the outcome. A successful embolization improved survival by 13.3 times. Retrospective comparison with surgery demonstrated equivalent mortality and clinical success, despite embolization being applied to a more elderly population with a higher prevalence of co-morbidities.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Embolization is effective in this very difficult cohort of patients with outcomes similar to surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirsadraee</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leeds General Infirmary, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirukonda</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Everett</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Radiol</MedlineTA><NlmUniqueID>1306016</NlmUniqueID><ISSNLinking>0009-9260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016099" MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016558" MajorTopicYN="N">Hemostasis, Endoscopic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21371695</ArticleId><ArticleId IdType="doi">10.1016/j.crad.2010.11.016</ArticleId><ArticleId IdType="pii">S0009-9260(11)00033-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27762438</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2044</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Anaesthesia</Title><ISOAbbreviation>Anaesthesia</ISOAbbreviation></Journal><ArticleTitle>The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a Cochrane Systematic Review with trial sequential analysis.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>117</EndPage><MedlinePgn>106-117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/anae.13628</ELocationID><Abstract><AbstractText>Acute respiratory distress syndrome is associated with high mortality and morbidity. Inhaled nitric oxide has been used to improve oxygenation but its role remains controversial. Our primary objective in this systematic review was to examine the effects of inhaled nitric oxide administration on mortality in adults and children with acute respiratory distress syndrome. We included all randomised, controlled trials, irrespective of date of publication, blinding status, outcomes reported or language. Our primary outcome measure was all-cause mortality. We performed several subgroup and sensitivity analyses to assess the effect of inhaled nitric oxide. There was no statistically significant effect of inhaled nitric oxide on longest follow-up mortality (inhaled nitric oxide group 250/654 deaths (38.2%) vs. control group 221/589 deaths (37.5%; relative risk (95% CI) 1.04 (0.9-1.19)). We found a significant improvement in PaO<sub>2</sub> /F<sub>I</sub> O<sub>2</sub> ratio at 24 h (mean difference (95% CI) 15.91 (8.25-23.56)), but not at 48 h or 72 h, while four trials indicated improved oxygenation in the inhaled nitric oxide group at 96 h (mean difference (95% CI) 14.51 (3.64-25.38)). There were no statistically significant differences in ventilator-free days, duration of mechanical ventilation, resolution of multi-organ failure, quality of life, length of stay in intensive care unit or hospital, cost-benefit analysis and methaemoglobin and nitrogen dioxide levels. There was an increased risk of renal impairment (risk ratio (95% CI) 1.59 (1.17-2.16)) with inhaled nitric oxide. In conclusion, there is insufficient evidence to support inhaled nitric oxide in any category of critically ill patients with acute respiratory distress syndrome despite a transient improvement in oxygenation, since mortality is not reduced and it may induce renal impairment.</AbstractText><CopyrightInformation>&#xa9; 2016 The Association of Anaesthetists of Great Britain and Ireland.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>O</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6606-1736</Identifier><AffiliationInfo><Affiliation>Paediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebistorf</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Paediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetterslev</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group and Copenhagen Trial Unit and Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anaesthesia</MedlineTA><NlmUniqueID>0370524</NlmUniqueID><ISSNLinking>0003-2409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">nitric oxide</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27762438</ArticleId><ArticleId IdType="doi">10.1111/anae.13628</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28331537</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1749-7922</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>World journal of emergency surgery : WJES</Title><ISOAbbreviation>World J Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Combined totally mini-invasive approach in necrotizing pancreatitis: a case report and systematic literature review.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13017-017-0126-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Currently, both the step-up approach, combining percutaneous drainage (PD) and video-assisted retroperitoneal debridement (VARD), and endoscopic transgastric necrosectomy (ETN) are mini-invasive techniques for infected necrosis in severe acute pancreatitis. A combination of these approaches could maximize the management of necrotizing pancreatitis, conjugating the benefits from both the experiences. However, reporting of this combined strategy is anecdotal. This is the first reported case of severe necrotizing pancreatitis complicated by biliary fistula treated by a combination of ETN, PD, VARD, and endoscopic biliary stenting. Moreover, a systematic literature review of comparative studies on minimally invasive techniques in necrotizing pancreatitis has been provided.</AbstractText><AbstractText Label="CASE PRESENTATION">A 59-year-old patient was referred to our center for acute necrotizing pancreatitis associated with multi-organ failure. No invasive procedures were attempted in the first month from the onset: enteral feeding by a naso-duodenal tube was started, and antibiotics were administered to control sepsis. After 4&#xa0;weeks, CT scans showed a central walled-off pancreatic necrosis (WOPN) of pancreatic head communicating bilateral retroperitoneal collections. ETN was performed, and bile leakage was found at the right margin of the WOPN. Endoscopic retrograde cholangiopancreatography confirmed the presence of a choledocal fistula within the WOPN, and a biliary stent was placed. An ultrasound-guided PD was performed on the left retroperitoneal collection. Due to the subsequent repeated onset of septic shocks and the evidence of size increase of the right retroperitoneal collection, a VARD was decided. The CT scans documented the resolution of all the collections, and the patient promptly recovered from sepsis. After 6&#xa0;months, the patient is in good clinical condition.</AbstractText><AbstractText Label="CONCLUSIONS">No mini-invasive technique has demonstrated significantly better outcomes over the others, and each technique has specific indications, advantages, and pitfalls. Indeed, ETN could be suitable for central WOPNs, while VARD or PD could be suggested for lateral collections. A combination of different approaches is feasible and could significantly optimize the clinical management in critically ill patients affected by complicated necrotizing pancreatitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiara</LastName><ForeName>Osvaldo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutignani</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digestive Endoscopy Service, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sammartano</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brioschi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimbanassi</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Emerg Surg</MedlineTA><NlmUniqueID>101266603</NlmUniqueID><ISSNLinking>1749-7922</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002760" MajorTopicYN="N">Cholangiopancreatography, Endoscopic Retrograde</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003646" MajorTopicYN="N">Debridement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020535" MajorTopicYN="N">Video-Assisted Surgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endoscopic transgastric necrosectomy</Keyword><Keyword MajorTopicYN="N">Percutaneous drainage</Keyword><Keyword MajorTopicYN="N">Severe pancreatitis</Keyword><Keyword MajorTopicYN="N">Step-up approach</Keyword><Keyword MajorTopicYN="N">Video-assisted retroperitoneal debridement</Keyword><Keyword MajorTopicYN="N">Walled-off pancreatic necrosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28331537</ArticleId><ArticleId IdType="pmc">PMC5356234</ArticleId><ArticleId IdType="doi">10.1186/s13017-017-0126-5</ArticleId><ArticleId IdType="pii">126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trikudanathan G, Attam R, Arain MA, Mallery S, Freeman ML. Endoscopic interventions for necrotizing pancreatitis. Am J Gastroenterol. 2014;109(7):969&#x2013;81. doi: 10.1038/ajg.2014.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.130</ArticleId><ArticleId IdType="pubmed">24957157</ArticleId></ArticleIdList></Reference><Reference><Citation>Werge M, Novovic S, Schmidt PN, Gluud LL. Infection increases mortality in necrotizing pancreatitis: a systematic review and meta-analysis. Pancreatology. 2016; Jul 9 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pubmed">27449605</ArticleId></ArticleIdList></Reference><Reference><Citation>Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;2(8656):201&#x2013;5. doi: 10.1016/S0140-6736(89)90381-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)90381-4</ArticleId><ArticleId IdType="pubmed">2568529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagniez PL, Panis Y. Surgical treatment of acute pancreatitis. Rev Prat. 1996;46(6):704&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8731737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackert T, B&#xfc;chler MW. Decision making in necrotizing pancreatitis. Dig Dis. 2016;34(5):517&#x2013;24. doi: 10.1159/000445232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445232</ArticleId><ArticleId IdType="pubmed">27332898</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JA, Carter CR. Minimally invasive necrosectomy techniques in severe acute pancreatitis: role of percutaneous necrosectomy and video-assisted retroperitoneal debridement. Gastroenterol Res Pract. 2015;2015:693040. doi: 10.1155/2015/693040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/693040</ArticleId><ArticleId IdType="pmc">PMC4637484</ArticleId><ArticleId IdType="pubmed">26587018</ArticleId></ArticleIdList></Reference><Reference><Citation>van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, van Ramshorst B, Nieuwenhuijs VB, Timmer R, Lam&#xe9;ris JS, Kruyt PM, Manusama ER, van der Harst E, van der Schelling GP, Karsten T, Hesselink EJ, van Laarhoven CJ, Rosman C, Bosscha K, de Wit RJ, Houdijk AP, van Leeuwen MS, Buskens E, Gooszen HG, Dutch Pancreatitis Study Group A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362(16):1491&#x2013;502. doi: 10.1056/NEJMoa0908821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908821</ArticleId><ArticleId IdType="pubmed">20410514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagenholz PJ, Thabet A, Mueller PR, Forcione DG. Combined endoscopic trangastric drainage and video assisted retroperitoneal pancreatic debridement&#x2014;the best of both worlds for extensive pancreatic necrosis with enteric fistulae. Pancreatology 2016; Jun 19 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pubmed">27344627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary A, Sachdev A, Negi S. Biliary complications of pancreatic necrosis. Int J Pancreatol. 2001;29(3):129&#x2013;31. doi: 10.1385/IJGC:29:3:129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/IJGC:29:3:129</ArticleId><ArticleId IdType="pubmed">12067215</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CR, McKay CJ, Imrie CW. Percutaneous necrosectomy and sinus tract endoscopy in the management of infected pancreatic necrosis: an initial experience. Ann Surg. 2000;232(2):175&#x2013;80. doi: 10.1097/00000658-200008000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200008000-00004</ArticleId><ArticleId IdType="pmc">PMC1421126</ArticleId><ArticleId IdType="pubmed">10903593</ArticleId></ArticleIdList></Reference><Reference><Citation>van Santvoort HC, Besselink MG, Bollen TL, Buskens E, van Ramshorst B, Gooszen HG, Dutch Acute Pancreatitis Study Group Case-matched comparison of the retroperitoneal approach with laparotomy for necrotizing pancreatitis. World J Surg. 2007;31(8):1635&#x2013;42. doi: 10.1007/s00268-007-9083-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-007-9083-6</ArticleId><ArticleId IdType="pubmed">17572838</ArticleId></ArticleIdList></Reference><Reference><Citation>Raraty MG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, Sutton R, Neoptolemos JP. Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. Ann Surg. 2010;251(5):787&#x2013;93. doi: 10.1097/SLA.0b013e3181d96c53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181d96c53</ArticleId><ArticleId IdType="pubmed">20395850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Y, Jiao H, Tan X, Sun L, Zhang W. Laparotomy versus retroperitoneal laparoscopy in debridement and drainage of retroperitoneal infected necrosis in severe acute pancreatitis. Surg Endosc. 2013;27(11):4217&#x2013;23. doi: 10.1007/s00464-013-3026-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-013-3026-0</ArticleId><ArticleId IdType="pubmed">23793802</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lu H, Hu W, Zhang Z. A retroperitoneal approach for infected pancreatic necrosis. Scand J Gastroenterol. 2013;48(2):225&#x2013;30. doi: 10.3109/00365521.2012.749514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2012.749514</ArticleId><ArticleId IdType="pubmed">23215866</ArticleId></ArticleIdList></Reference><Reference><Citation>Senthil Kumar P, Ravichandran P, Jeswanth S. Case matched comparison study of the necrosectomy by retroperitoneal approach with transperitoneal approach for necrotizing pancreatitis in patients with CT severity score of 7 and above. Int J Surg. 2012;10(10):587&#x2013;92. doi: 10.1016/j.ijsu.2012.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2012.09.027</ArticleId><ArticleId IdType="pubmed">23022952</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupelis G, Fokin V, Zeiza K, Plaudis H, Suhova A, Drozdova N, Boka V. Focused open necrosectomy in necrotizing pancreatitis. HPB (Oxford) 2013;15(7):535&#x2013;40. doi: 10.1111/hpb.12004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hpb.12004</ArticleId><ArticleId IdType="pmc">PMC3692024</ArticleId><ArticleId IdType="pubmed">23458703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluck M, Ross A, Irani S, Lin O, Gan SI, Fotoohi M, Hauptmann E, Crane R, Siegal J, Robinson DH, Traverso LW, Kozarek RA. Dual modality drainage for symptomatic walled-off pancreatic necrosis reduces length of hospitalization, radiological procedures, and number of endoscopies compared to standard percutaneous drainage. J Gastrointest Surg. 2012;16(2):248&#x2013;56. doi: 10.1007/s11605-011-1759-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-011-1759-4</ArticleId><ArticleId IdType="pubmed">22125167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner TB, Chahal P, Papachristou GI, Vege SS, Petersen BT, Gostout CJ, Topazian MD, Takahashi N, Sarr MG, Baron TH. A comparison of direct endoscopic necrosectomy with transmural endoscopic drainage for the treatment of walled-off pancreatic necrosis. Gastrointest Endosc. 2009;69(6):1085&#x2013;94. doi: 10.1016/j.gie.2008.06.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2008.06.061</ArticleId><ArticleId IdType="pubmed">19243764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Conwell DL, Thompson CC. Direct endoscopic necrosectomy versus step-up approach for walled-off pancreatic necrosis: comparison of clinical outcome and health care utilization. Pancreas. 2014;43(8):1334&#x2013;9. doi: 10.1097/MPA.0000000000000213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0000000000000213</ArticleId><ArticleId IdType="pmc">PMC5019103</ArticleId><ArticleId IdType="pubmed">25083997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan V, Charachon A, Lescot T, Chafa&#xef; N, Le Baleur Y, Delchier JC, Paye F. Endoscopic transgastric versus surgical necrosectomy in infected pancreatic necrosis. Clin Res Hepatol Gastroenterol. 2014;38(6):770&#x2013;6. doi: 10.1016/j.clinre.2014.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2014.06.016</ArticleId><ArticleId IdType="pubmed">25153999</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo S, Walklin R, Wewelwala C, Berry R, Devonshire D, Croagh D. Interventional management of necrotizing pancreatitis: an Australian experience. ANZ J Surg. 2015 Nov 24 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">26603130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker OJ, van Santvoort HC, van Brunschot S, Geskus RB, Besselink MG, Bollen TL, van Eijck CH, Fockens P, Hazebroek EJ, Nijmeijer RM, Poley JW, van Ramshorst B, Vleggaar FP, Boermeester MA, Gooszen HG, Weusten BL, Timmer R, Dutch Pancreatitis Study Group Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA. 2012;307(10):1053&#x2013;61. doi: 10.1001/jama.2012.276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.276</ArticleId><ArticleId IdType="pubmed">22416101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bausch D, Wellner U, Kahl S, Kuesters S, Richter-Schrag HJ, Utzolino S, Hopt UT, Keck T, Fischer A. Minimally invasive operations for acute necrotizing pancreatitis: comparison of minimally invasive retroperitoneal necrosectomy with ETN. Surgery. 2012;152(3):S128&#x2013;34. doi: 10.1016/j.surg.2012.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2012.05.021</ArticleId><ArticleId IdType="pubmed">22770962</ArticleId></ArticleIdList></Reference><Reference><Citation>van Brunschot S, van Grinsven J, Voermans RP, Bakker OJ, Besselink MG, Boermeester MA, Bollen TL, Bosscha K, Bouwense SA, Bruno MJ, Cappendijk VC, Consten EC, Dejong CH, Dijkgraaf MG, van Eijck CH, Erkelens GW, van Goor H, Hadithi M, Haveman JW, Hofker SH, Jansen JJ, Lam&#xe9;ris JS, van Lienden KP, Manusama ER, Meijssen MA, Mulder CJ, Nieuwenhuis VB, Poley JW, de Ridder RJ, Rosman C, Schaapherder AF, Scheepers JJ, Schoon EJ, Seerden T, Spanier BW, Straathof JW, Timmer R, Venneman NG, Vleggaar FP, Witteman BJ, Gooszen HG, van Santvoort HC, Fockens P, Dutch Pancreatitis Study Group Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): design and rationale of a randomised controlled multicenter trial [ISRCTN09186711] BMC Gastroenterol. 2013;13:161. doi: 10.1186/1471-230X-13-161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-161</ArticleId><ArticleId IdType="pmc">PMC4222267</ArticleId><ArticleId IdType="pubmed">24274589</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasch S, Phillip V, Reichel S, Rau B, Zapf C, Rosendahl J, Halm U, Zach&#xe4;us M, M&#xfc;ller M, Kleger A, Neesse A, Hampe J, Ellrichmann M, R&#xfc;ckert F, Strau&#xdf; P, Arlt A, Ellenrieder V, Gress TM, Hartwig W, Klar E, M&#xf6;ssner J, Post S, Schmid RM, Seufferlein T, Siech M, Werner J, Will U, Alg&#xfc;l H. Open surgical versus minimal invasive necrosectomy of the pancreas&#x2014;a retrospective multicenter analysis of the German Pancreatitis Study Group. PLoS One. 2016;11(9):e0163651. doi: 10.1371/journal.pone.0163651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0163651</ArticleId><ArticleId IdType="pmc">PMC5036800</ArticleId><ArticleId IdType="pubmed">27668746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang JY, Holt BA, Hawes RH, Hasan MK, Arnoletti JP, Christein JD, Wilcox CM, Varadarajulu S. Outcomes after implementing a tailored endoscopic step-up approach to walled-off necrosis in acute pancreatitis. Br J Surg. 2014;101(13):1729&#x2013;38. doi: 10.1002/bjs.9664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9664</ArticleId><ArticleId IdType="pubmed">25333872</ArticleId></ArticleIdList></Reference><Reference><Citation>Besselink MG. The &#x2018;step-up approach&#x201d; to infected necrotizing pancreatitis: delay, drain, debride. Dig Liver Dis. 2011;43(6):421&#x2013;2. doi: 10.1016/j.dld.2011.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2011.04.001</ArticleId><ArticleId IdType="pubmed">21531639</ArticleId></ArticleIdList></Reference><Reference><Citation>Doctor N, Philip S, Gandhi V, Hussain M, Barreto SG. Analysis of the delayed approach to the management of infected pancreatic necrosis. World J Gastroenterol. 2011;17(3):366&#x2013;71. doi: 10.3748/wjg.v17.i3.366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i3.366</ArticleId><ArticleId IdType="pmc">PMC3022298</ArticleId><ArticleId IdType="pubmed">21253397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulagendra Perumal S, Pillai SA, Perumal S, Sathyanesan J, Palaniappan R. Outcome of video-assisted translumbar retroperitoneal necrosectomy and closed lavage for severe necrotizing pancreatitis. ANZ J Surg. 2014;84(4):270&#x2013;4. doi: 10.1111/ans.12107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.12107</ArticleId><ArticleId IdType="pubmed">23458245</ArticleId></ArticleIdList></Reference><Reference><Citation>Besselink MG, van Santvoort HC, Nieuwenhuijs VB, Boermeester MA, Bollen TL, Buskens E, Dejong CH, van Eijck CH, van Goor H, Hofker SS, Lameris JS, van Leeuwen MS, Ploeg RJ, van Ramshorst B, Schaapherder AF, Cuesta MA, Consten EC, Gouma DJ, van der Harst E, Hesselink EJ, Houdijk LP, Karsten TM, van Laarhoven CJ, Pierie JP, Rosman C, Bilgen EJ, Timmer R, van der Tweel I, de Wit RJ, Witteman BJ, Gooszen HG, Dutch Acute Pancreatitis Study Group Minimally invasive &#x2018;step-up approach&#x2019; versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868] BMC Surg. 2006;6:6. doi: 10.1186/1471-2482-6-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2482-6-6</ArticleId><ArticleId IdType="pmc">PMC1508161</ArticleId><ArticleId IdType="pubmed">16606471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakorafas GH, Sarr MG, Farnell MB. Pancreaticobiliary fistula: an unusual complication of necrotising pancreatitis. Eur J Surg. 2001;167(2):151&#x2013;3. doi: 10.1080/110241501750070655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/110241501750070655</ArticleId><ArticleId IdType="pubmed">11266259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar R, Singh I, Brar P, Prasad A, Doley RP, Wig JD. Pancreatic choledochal fistula complicating acute pancreatitis. Am J Case Rep. 2012;13:47&#x2013;50. doi: 10.12659/AJCR.882600.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.882600</ArticleId><ArticleId IdType="pmc">PMC3616175</ArticleId><ArticleId IdType="pubmed">23569486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhall JC, Marwah S, Singh RB, Marwah N, Mathur SK. Extra-hepatic biliary-ductal necrosis in acute pancreatitis: a rare complication. Pediatr Surg Int. 2000;16(3):209&#x2013;10. doi: 10.1007/s003830050725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003830050725</ArticleId><ArticleId IdType="pubmed">10786984</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BM, Traverso LW, Freeny PC. Intrapancreatic communication of bile and pancreatic ducts secondary to pancreatic necrosis. Arch Surg. 1988;123(8):1000&#x2013;3. doi: 10.1001/archsurg.1988.01400320086017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1988.01400320086017</ArticleId><ArticleId IdType="pubmed">3395229</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Ali JA, Chung H, Munk PL, Byrne MF. Pancreatic pseudocyst with fistula to the common bile duct resolved by combined biliary and pancreatic stenting&#x2014;a case report and literature review. Can J Gastroenterol. 2009;23(8):557&#x2013;9. doi: 10.1155/2009/597208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2009/597208</ArticleId><ArticleId IdType="pmc">PMC2732178</ArticleId><ArticleId IdType="pubmed">19668801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki AP, McKay CJ, Carter CR. Infected pancreatic necrosis: minimizing the cut. ANZ J Surg. 2010;80(1-2):58&#x2013;70. doi: 10.1111/j.1445-2197.2009.05177.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-2197.2009.05177.x</ArticleId><ArticleId IdType="pubmed">20575882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40259139</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2614</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical monitoring and computing</Title><ISOAbbreviation>J Clin Monit Comput</ISOAbbreviation></Journal><ArticleTitle>Heart rate variability as a marker of multiple organ dysfunction syndromes: a systematic review.</ArticleTitle><Pagination><StartPage>717</StartPage><EndPage>729</EndPage><MedlinePgn>717-729</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10877-025-01296-w</ELocationID><Abstract><AbstractText>Multiple organ dysfunction syndrome (MODS) can be caused by many factors. Assessments of the severity of MODS are currently based on occasional measurements of several clinical variables (laboratory data, vital signs, etc.). The analysis of heart rate variability (HRV) as a guide to autonomic nervous system activity might be of value in the continuous assessment of the severity of MODS. We systematically reviewed publications on the value of HRV variables for the diagnosis of MODS in patients of any age admitted to the ICU. Two investigators independently searched the PubMed, Embase, Cochrane and Science Direct databases for articles in English or French published between 2004 and 2024. Ten studies were included and rated for endpoint bias (MODS or mortality), using the revised Quality Assessment of Diagnostic Accuracy Studies. Nine studies assessed MODS, and six assessed mortality. All the studies evidenced low HRV in patients with MODS and in non-survivors. The results of our review show that HRV indices are influenced by the severity of MODS and might serve as a tool for predicting mortality in patients with MODS. However, patient characteristics, and treatments and HRV processing methods must be taken into account when interpreting the results. In order to clarify the impact of MODS on HRV variables, methodologically rigorous studies are now needed.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wojtanowski</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC IT 1403, 59000, Lille, France. anne.wojtanowski@chu-lille.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 2694 METRICS, 59000, Lille, France. anne.wojtanowski@chu-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hureau</LastName><ForeName>Maxence</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Department, CHU Lille, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 7365 GRITA, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeanne</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC IT 1403, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Department, CHU Lille, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 7365 GRITA, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bureau</LastName><ForeName>C&#xf4;me</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHU Lille, Service de M&#xe9;decine Intensive-R&#xe9;animation, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recher</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, ULR 2694 METRICS, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, CHU Lille, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jonckheere</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC IT 1403, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 2694 METRICS, 59000, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Monit Comput</MedlineTA><NlmUniqueID>9806357</NlmUniqueID><ISSNLinking>1387-1307</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="Y">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001341" MajorTopicYN="N">Autonomic Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autonomic nervous system</Keyword><Keyword MajorTopicYN="N">Heart rate variability</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: Mathieu Jeanne is a member of the editorial board of the Journal of Clinical Monitoring and Computing. Other authors have no relevant financial or non-financial interests to disclose. Ethical Standards: Not applicable. Informed Consent: This paper concerns a systematic review of already published studies. This research doesn't involve human subjects and doesn't require informed consent.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>22</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>21</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40259139</ArticleId><ArticleId IdType="pmc">PMC12304018</ArticleId><ArticleId IdType="doi">10.1007/s10877-025-01296-w</ArticleId><ArticleId IdType="pii">10.1007/s10877-025-01296-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gourd NM, Nikitas N. Multiple organ dysfunction syndrome. J Intensive Care Med. 2020;35(12):1564&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">31455133</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#xe7;a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix). Intensive Care Med. 1996;22(7):707&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F. PELOD-2: an update of the PEdiatric Logistic Organ Dysfunction Score. Crit Care Med. 2013;41(7):1761&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Butruille L, Blouin A, De Jonckheere J, Mur S, Margez T, Rakza T, et al. Impact of skin-to-skin contact on the autonomic nervous system in the preterm infant and his mother. Infant Behav Dev. 2017;49:83&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28777974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommel D, Nandrino JL, De Jonckheere J, Swierczek M, Dodin V, Logier R. Maintenance of parasympathetic inhibition following emotional induction in patients with restrictive type anorexia nervosa. Psychiatry Res. 2015;225(3):651&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25500345</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598068</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam J, Rupprecht S, K&#xfc;nstler ECS, Hoyer D. Heart rate variability as a marker and predictor of inflammation, nosocomial infection, and sepsis&#x2014;a systematic review. Auton Neurosci Basic Clin. 2023;249: 103116.</Citation><ArticleIdList><ArticleId IdType="pubmed">37651781</ArticleId></ArticleIdList></Reference><Reference><Citation>Arag&#xf3;n-Bened&#xed; C, Oliver-Forni&#xe9;s P, Galluccio F, Yamak Altinpulluk E, Ergonenc T, El Sayed AA, et al. Is the heart rate variability monitoring using the analgesia nociception index a predictor of illness severity and mortality in critically ill patients with COVID-19? A pilot study. PLoS ONE. 2021;16(3): e0249128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990300</ArticleId><ArticleId IdType="pubmed">33760875</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castilho FM, Ribeiro ALP, Nobre V, Barros G, de Sousa MR. Heart rate variability as predictor of mortality in sepsis: a systematic review. PLoS ONE. 2018;13(9): e0203487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6133362</ArticleId><ArticleId IdType="pubmed">30204803</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, M&#xfc;ller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, et al. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups*. Crit Care Med. 2005;33(9):1994&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">16148471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer D, Friedrich H, Zwiener U, Pompe B, Baranowski R, Werdan K, et al. Prognostic impact of autonomic information flow in multiple organ dysfunction syndrome patients. Int J Cardiol. 2006;108(3):359&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer D, Frank B, G&#xf6;tze C, Schmidt H, Baranowski R, &#x17b;ebrowski JJ, et al. Complex autonomic dysfunction in cardiovascular, intensive care, and schizophrenic patients assessed by autonomic information flow. Biomed Tech Eng. 2006;51(4):182&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17061934</ArticleId></ArticleIdList></Reference><Reference><Citation>Papaioannou VE, Maglaveras N, Houvarda I, Antoniadou E, Vretzakis G. Investigation of altered heart rate variability, nonlinear properties of heart rate signals, and organ dysfunction longitudinally over time in intensive care unit patients. J Crit Care. 2006;21(1):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616632</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Hoyer D, Hennen R, Heinroth K, Rauchhaus M, Prondzinsky R, et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome*. Crit Care Med. 2008;36(3):967&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18431287</ArticleId></ArticleIdList></Reference><Reference><Citation>Green GC, Bradley B, Bravi A, Seely AJE. Continuous multiorgan variability analysis to track severity of organ failure in critically ill patients. J Crit Care. 2013;28(5):879.e1-879.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726387</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Lotze U, Ghanem A, Anker SD, Said SM, Braun-Dullaeus R, et al. Relation of impaired interorgan communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome. J Crit Care. 2014;29(3):367&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24529299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou J, Ke L, Nie Y, Tong Z, Li W, et al. Role of heart rate variability in predicting the severity of severe acute pancreatitis. Dig Dis Sci. 2014;59(10):2557&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24821463</ArticleId></ArticleIdList></Reference><Reference><Citation>Badke CM, Marsillio LE, Carroll MS, Weese-Mayer DE, Sanchez-Pinto LN. Development of a heart rate variability risk score to predict organ dysfunction and death in critically Ill children. Pediatr Crit Care Med. 2021;22(8):e437&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">33710071</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Gao H, Yu X, Jiang Z, Yang W. Spectral analysis of heart rate variability for trauma outcome prediction: an analysis of 210 ICU multiple trauma patients. Eur J Trauma Emerg Surg. 2021;47(1):153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">31209555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer D, Friedrich H, Frank B, Pompe B, Baranowski R, Zebrowski JJ, et al. Autonomic information flow improves prognostic impact of task force HRV monitoring. Comput Methods Programs Biomed. 2006;81(3):246&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16483685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontet J, Contreras P, Curbelo A, Medina J, Noveri S, Bentancourt S, et al. Heart rate variability as early marker of multiple organ dysfunction syndrome in septic patients. J Crit Care. 2003;18(3):156&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595568</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrard CS, Kontoyannis DA, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clin Auton Res Off J Clin Auton Res Soc. 1993;3(1):5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8386574</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin MP, O&#x2019;Shea TM, Bissonette EA, Harrell FE, Lake DE, Moorman JR. Abnormal heart rate characteristics preceding neonatal sepsis and sepsis-like illness. Pediatr Res. 2003;53(6):920&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646726</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin MP, Moorman JR. Toward the early diagnosis of neonatal sepsis and sepsis-like illness using novel heart rate analysis. Pediatrics. 2001;107(1):97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134441</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris PR, Ozdas A, Cao H, Williams AE, Harrell FE, Jenkins JM, et al. Cardiac uncoupling and heart rate variability stratify ICU patients by mortality: a study of 2088 trauma patients. Ann Surg. 2006;243(6):804&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570581</ArticleId><ArticleId IdType="pubmed">16772784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley BD, Green G, Ramsay T, Seely AJE. Impact of sedation and organ failure on continuous heart and respiratory rate variability monitoring in critically ill patients: a pilot study*. Crit Care Med. 2013;41(2):433&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">23263615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert TJ, Muzi M, Berens R, Goff D, Kampine JP. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. Anesthesiology. 1992;76(5):725&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">1575340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bari V, Vaini E, Pistuddi V, Fantinato A, Cairo B, De Maria B, et al. Comparison of causal and non-causal strategies for the assessment of baroreflex sensitivity in predicting acute kidney dysfunction after coronary artery bypass grafting. Front Physiol. 2019;10:1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813722</ArticleId><ArticleId IdType="pubmed">31681021</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhle R, Burghardt M, Zaunseder S, Wessel N, Koch T, Malberg H, et al. Effects of awareness and nociception on heart rate variability during general anaesthesia. Physiol Meas. 2012;33(2):207&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22260880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33970455</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Resuscitative Effect of Centhaquine (Lyfaquin<sup>&#xae;</sup>) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial.</ArticleTitle><Pagination><StartPage>3223</StartPage><EndPage>3265</EndPage><MedlinePgn>3223-3265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-021-01760-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Centhaquine (Lyfaquin<sup>&#xae;</sup>) showed significant efficacy as a resuscitative agent in animal models of haemorrhagic shock. Its safety and tolerability were confirmed in healthy human volunteers. In this study, our primary objective was to determine the safety, and the secondary objective was to assess the efficacy of centhaquine in patients with hypovolemic shock.</AbstractText><AbstractText Label="METHODS">A prospective, multicentre, randomized phase II study was conducted in male and female patients aged 18-70 years with hypovolemic shock having systolic BP&#x2009;&#x2264;&#x2009;90 mmHg. Patients were randomized in a 1:1 ratio to either the control or centhaquine group. The control group received 100 ml of normal saline infusion over 1 h, while the centhaquine group received 0.01 mg/kg of centhaquine in 100 ml normal saline infusion over 1 h. Every patient received standard of care (SOC) and was followed for 28 days.</AbstractText><AbstractText Label="RESULTS">Fifty patients were included, and 45 completed the trial: 22 in the control group and 23 in the centhaquine group. The demographics of patients in both groups were comparable. No adverse event related to centhaquine was recorded in the 28-day observation period. The baseline, Injury Scoring System score, haemoglobin, and haematocrit were similar in both groups. However, 91% of the patients in the centhaquine group needed major surgery, whereas only 68% in the control group (p&#x2009;=&#x2009;0.0526). Twenty-eight-day all-cause mortality was 0/23 in the centhaquine group and 2/22 in the control group. The percent time in ICU and ventilator support was less in the centhaquine group than in the control group. The total amount of vasopressors needed in the first 48 h of resuscitation was lower in the centhaquine group than in the control group (3.12&#x2009;&#xb1;&#x2009;2.18 vs. 9.39&#x2009;&#xb1;&#x2009;4.28 mg). An increase in systolic and diastolic BP from baseline through 48 h was more marked in the centhaquine group than in the control group. Compared with the control group, blood lactate level was lower by 1.75&#x2009;&#xb1;&#x2009;1.07 mmol/l in the centhaquine group on day 3 of resuscitation. Improvements in base deficit, multiple organ dysfunction syndrome (MODS) score and adult respiratory distress syndrome (ARDS) were greater in the centhaquine group than in the control group.</AbstractText><AbstractText Label="CONCLUSION">When added to SOC, centhaquine is a well-tolerated and effective resuscitative agent. It improves the clinical outcome of patients with hypovolemic shock.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov identifier number: NCT04056065.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gulati</LastName><ForeName>Anil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7420-4554</Identifier><AffiliationInfo><Affiliation>Professor Emeritus, Midwestern University, Downers Grove, IL, USA. agulati@midestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dayanand Medical College &amp; Hospital, Civil Lines, Tagore Nagar, Ludhiana, Punjab, 141001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Nilesh Radheshyam</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, New Era Hospital, Near Jalaram Mandir, Queta Colony, Telephone Exchange Chowk, Central Avenue Road, Nagpur, Maharashtra, 440008, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahate</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Seven Star Hospital Jagnade Square, KDK College Road, Nagpur, Maharashtra, 440009, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhuri</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Institute of Post-Graduate Medical Education and Research and SSKM Hospital, 244 A.J.C. Bose Road, Kolkata, West Bengal, 700020, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Soumen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Institute of Post-Graduate Medical Education and Research and SSKM Hospital, 244 A.J.C. Bose Road, Kolkata, West Bengal, 700020, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhibar</LastName><ForeName>Deba Prasad</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nehru Hospital, Post-Graduate Institute of Medical Education and Research (PGIMER), Sector-12, Chandigarh, 160 012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhu</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, KLE's Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehru Nagar, Belgaum, Karnataka, 590010, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haveri</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, KLE's Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehru Nagar, Belgaum, Karnataka, 590010, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, ORIANA Hospital, Plot No.: 6, 7, 8 Ravindrapuri Bhelpur, Varanasi, Uttar Pradesh, 221005, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavhale</LastName><ForeName>Manish S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Pharmazz India Private Limited, Greater Noida, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04056065</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>57961-90-7</RegistryNumber><NameOfSubstance UI="C045913">centhaquine</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="Y">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Centhaquine</Keyword><Keyword MajorTopicYN="N">Haemorrhage</Keyword><Keyword MajorTopicYN="N">Hypovolemia</Keyword><Keyword MajorTopicYN="N">Resuscitative agent</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>10</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33970455</ArticleId><ArticleId IdType="pmc">PMC8189997</ArticleId><ArticleId IdType="doi">10.1007/s12325-021-01760-4</ArticleId><ArticleId IdType="pii">10.1007/s12325-021-01760-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taghavi S, Jones G, Duchesne J, McGrew P, Guidry C, Schroll R, et al. Impact of trauma center volume on major vascular injury: an analysis of the National Trauma Data Bank (NTDB) Am J Surg. 2020;220(3):787&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JW. Hemorrhagic shock. N Engl J Med. 2018;378(4):370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Haut ER, Kalish BT, Cotton BA, Efron DT, Haider AH, Stevens KA, et al. Prehospital intravenous fluid administration is associated with higher mortality in trauma patients: a National Trauma Data Bank analysis. Ann Surg. 2011;253(2):371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">21178760</ArticleId></ArticleIdList></Reference><Reference><Citation>Haut ER, Kalish BT, Cotton BA, Efron DT, Haider AH, Stevens KA, et al. Reply to letter: "Prehospital intravenous fluid administration is associated with higher mortality in trauma patients". Ann Surg. 2014;259(2):e20&#x2013;e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24398926</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nederpelt CJ, El Hechi MW, Kongkaewpaisan N, Kokoroskos N, Mendoza AE, Saillant NN, et al. Fresh frozen plasma-to-packed red blood cell ratio and mortality in traumatic hemorrhage: nationwide analysis of 4,427 patients. J Am Coll Surg. 2020;230(6):893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">31759164</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel C, Arrich J, Losert H, Gamper G, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2011;11(5):003709.</Citation><ArticleIdList><ArticleId IdType="pubmed">21563137</ArticleId></ArticleIdList></Reference><Reference><Citation>Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med. 2000;28(4):947&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Abe T, Saitoh D, Hagiwara S, Oshima K. Use of vasopressor increases the risk of mortality in traumatic hemorrhagic shock: a nationwide cohort study in Japan. Crit Care Med. 2018;46(12):e1145&#x2013;e1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">30199392</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgoff PE, Nikolian VC, Higgins G, Chtraklin K, Eidy H, Ghandour MH, et al. Valproic acid induces prosurvival transcriptomic changes in swine subjected to traumatic injury and hemorrhagic shock. J Trauma Acute Care Surg. 2018;84(4):642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">29251706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganster F, Burban M, de la Bourdonnaye M, Fizanne L, Douay O, Loufrani L, et al. Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care. 2010;14(5):R165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219260</ArticleId><ArticleId IdType="pubmed">20836847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wepler M, Merz T, Wachter U, Vogt J, Calzia E, Scheuerle A, et al. The mitochondria-targeted H2S-Donor AP39 in a murine model of combined hemorrhagic shock and blunt chest trauma. Shock. 2019;52(2):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">29927788</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakral S, Wolf A, Beilman GJ, Suryanarayanan R. Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock. Int J Pharm. 2018;537(1&#x2013;2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">29274369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP. Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats. Shock. 1998;9(1):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP, Sharma AC, Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat. Am J Physiol. 1997;273(2 Pt 2):H827&#x2013;H836.</Citation><ArticleIdList><ArticleId IdType="pubmed">9277500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282(19):1857&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg MD, Philbin NB, Gao W, Group DCTHSS, European HI. Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010;68(5):1158&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20145575</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Privalle CT, Singer M, Lorente JA, Boehm E, Meier-Hellmann A, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX) Crit Care Med. 2015;43(1):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25083980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A. Vascular endothelium and hypovolemic shock. Curr Vasc Pharmacol. 2016;14(2):187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">26638794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Lavhale M, Giri R, Andurkar S, Xanthos T. Centhaquine citrate. Alpha2B-Adrenoceptor ligand, resuscitative agent for hypovolemic shock. Drugs Fut. 2020;45(3):153&#x2013;163.</Citation></Reference><Reference><Citation>Gulati A, Lavhale MS, Garcia DJ, Havalad S. Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. J Surg Res. 2012;178(1):415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">22487389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Zhang Z, Murphy A, Lavhale MS. Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med. 2013;31(9):1315&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23871440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontouli Z, Staikou C, Iacovidou N, Mamais I, Kouskouni E, Papalois A, et al. Resuscitation with centhaquin and 6% hydroxyethyl starch 130/04 improves survival in a swine model of hemorrhagic shock: a randomized experimental study. Eur J Trauma Emerg Surg. 2019;45(6):1077&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">30006694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavhale MS, Havalad S, Gulati A. Resuscitative effect of centhaquin after hemorrhagic shock in rats. J Surg Res. 2013;179(1):115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22964270</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapanagiotou P, Xanthos T, Gulati A, Chalkias A, Papalois A, Kontouli Z, et al. Centhaquin improves survival in a swine model of hemorrhagic shock. J Surg Res. 2016;200(1):227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216751</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds PS, Michael MJ, Cochran ED, Wegelin JA, Spiess BD. Prehospital use of plasma in traumatic hemorrhage (The PUPTH Trial): study protocol for a randomised controlled trial. Trials. 2015;30(16):321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518517</ArticleId><ArticleId IdType="pubmed">26220293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, Schreiber MA, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;253(3):431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232054</ArticleId><ArticleId IdType="pubmed">21178763</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">2281232</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan NR, Eckert M, Martin MJ. Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities. JAMA Surg. 2014;149(9):904&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K. Aggressive fluid management in the critically ill: Pro. J Intensive Care. 2019;7:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6359791</ArticleId><ArticleId IdType="pubmed">30761213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi L, Costantini TW, Coimbra R. Hypovolemic shock resuscitation. Surg Clin N Am. 2012;92(6):1403&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23153876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Voshtina E, Zhang Z, Murphy A. Alpha adrenergic receptors mediate resuscitative effect of centhaquin in hemorrhaged rats. Crit Care Med. 2012;40(12):U162&#x2013;U163.</Citation></Reference><Reference><Citation>Berlin DA, Bakker J. Understanding venous return. Intensive Care Med. 2014;40(10):1564&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JR, Maas JJ, Pinsky MR. Bedside assessment of mean systemic filling pressure. Curr Opin Crit Care. 2010;16(3):231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">20168223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias A, Koutsovasilis A, Laou E, Papalois A, Xanthos T. Measurement of mean systemic filling pressure after severe hemorrhagic shock in swine anesthetized with propofol-based total intravenous anesthesia: implications for vasopressor-free resuscitation. Acute Crit Care. 2020;35(2):93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280792</ArticleId><ArticleId IdType="pubmed">32506874</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Baker K. Venous return and clinical hemodynamics: how the body works during acute hemorrhage. Adv Physiol Educ. 2015;39(4):267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">26628647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen AJ, leNoble PJ, Steegers EA, van Rhenen DJ, Duvekot JJ. Relationship between haemoglobin change and estimated blood loss after delivery. BJOG. 2007;114(5):657.</Citation><ArticleIdList><ArticleId IdType="pubmed">17439585</ArticleId></ArticleIdList></Reference><Reference><Citation>Yefet E, Yossef A, Suleiman A, Hatokay A, Nachum Z. Hemoglobin drop following postpartum hemorrhage. Sci Rep. 2020;10(1):21546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725815</ArticleId><ArticleId IdType="pubmed">33298992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439620</ArticleId><ArticleId IdType="pubmed">30772908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla LS, Ostermann M, Forni L, Tidmarsh GF. Broad spectrum vasopressors: a new approach to the initial management of septic shock? Crit Care. 2019;23(1):124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469125</ArticleId><ArticleId IdType="pubmed">30992045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazmuri RJ, Whitehouse K, Whittinghill K, Baetiong A, Shah K, Radhakrishnan J. Early and sustained vasopressin infusion augments the hemodynamic efficacy of restrictive fluid resuscitation and improves survival in a liver laceration model of hemorrhagic shock. J Trauma Acute Care Surg. 2017;82(2):317&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">27906869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">27483065</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lat I, Coopersmith CM, De Backer D, Research Committee of the Surviving Sepsis C, Members of the Surviving Sepsis Campaign Research Committee contributing to this article are as f, Co-chair AGA, et al. The surviving sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. Crit Care Med. 2021;49(4):623&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963440</ArticleId><ArticleId IdType="pubmed">33731607</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Zhang Z, Arshad K. Centhaquin decreases the requirement of norepinephrine, maintains blood pressure and improves survival following resuscitation of hemorrhaged rats. Crit Care Med. 2011;39(12):114.</Citation></Reference><Reference><Citation>Odom SR, Howell MD, Silva GS, Nielsen VM, Gupta A, Shapiro NI, et al. Lactate clearance as a predictor of mortality in trauma patients. J Trauma Acute Care Surg. 2013;74(4):999&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511137</ArticleId></ArticleIdList></Reference><Reference><Citation>Doran CM, Doran CA, Woolley T, Carter A, Male K, Midwinter MJ, et al. Targeted resuscitation improves coagulation and outcome. J Trauma Acute Care Surg. 2012;72(4):835&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">22491594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33149707</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1535</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Hepatic medicine : evidence and research</Title><ISOAbbreviation>Hepat Med</ISOAbbreviation></Journal><ArticleTitle>Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>172</EndPage><MedlinePgn>153-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/HMER.S264231</ELocationID><Abstract><AbstractText>The use of albumin in patients with cirrhosis has been extensively discussed over recent years. Current treatment approaches depend on targeting related complications, aiming to treat and/or prevent circulatory dysfunction, bacterial infections and multi-organ failure. Albumin has been shown to prolong survival and reduce complications in patients with cirrhosis. This review aims to ascertain whether the use of albumin is justified in patients with cirrhosis. A systematic review of randomized controlled trials (RCTs) and meta-analyses evaluating albumin use in patients with cirrhosis published between 1985 and February 2020 was conducted; the quality and risk of bias of the included studies were assessed. In total, 45 RCTs and 10 meta-analyses were included. Based on the included evidence, albumin is superior at preventing and controlling the incidence of cirrhosis complications vs other plasma expanders. Recent studies reported that long-term albumin administration to patients with decompensated cirrhosis improves survival with a 38% reduction in the mortality hazard ratio compared with standard medical treatment alone. Albumin infusions are justified for routine use in patients with cirrhosis, and the use of albumin either alone or in combination with other treatments leads to clinical benefits. Long-term administration of albumin should be considered in some patients.</AbstractText><CopyrightInformation>&#xa9; 2020 Zaccherini et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaccherini</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3219-6963</Identifier><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna 40138, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tufoni</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8588-193X</Identifier><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna 40138, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardi</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1308-5440</Identifier><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna 40138, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Hepat Med</MedlineTA><NlmUniqueID>101544801</NlmUniqueID><ISSNLinking>1179-1535</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">albumin</Keyword><Keyword MajorTopicYN="N">ascites</Keyword><Keyword MajorTopicYN="N">hepatorenal syndrome</Keyword><Keyword MajorTopicYN="N">liver cirrhosis</Keyword><Keyword MajorTopicYN="N">paracentesis</Keyword><Keyword MajorTopicYN="N">peritonitis</Keyword></KeywordList><CoiStatement>Dr Giacomo Zaccherini reports being a part of speaker bureau for Octapharma AG and Grifols SA, outside the submitted work. Dr Manuel Tufoni reports personal fees from Grifols SA and Octapharma AG, outside the submitted work; Grifols SA (speaker bureau). Professor Mauro Bernardi reports personal fees from Grifols SA, Shire/Takeda, CLS Behring GmbH, PPTA, Martin Pharmaceuticals, and Octapharma AG, during the conduct of the study; CSL Behring GmbH (consultant, speaker bureau), Grifols SA (consultant, speaker bureau), Takeda (speaker bureau), PPTA (speaker bureau), Octapharma AG (speaker bureau), Martin Pharmaceuticals (consultant). The authors report no other potential conflicts of interest for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33149707</ArticleId><ArticleId IdType="pmc">PMC7602890</ArticleId><ArticleId IdType="doi">10.2147/HMER.S264231</ArticleId><ArticleId IdType="pii">264231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749&#x2013;1761. doi:10.1016/S0140-6736(14)60121-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60121-5</ArticleId><ArticleId IdType="pubmed">24480518</ArticleId></ArticleIdList></Reference><Reference><Citation>Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122&#x2013;128. doi:10.1002/hep.1840070124</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.1840070124</ArticleId><ArticleId IdType="pubmed">3804191</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217&#x2013;231. doi:10.1016/j.jhep.2005.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2005.10.013</ArticleId><ArticleId IdType="pubmed">16298014</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(Suppl 6):vi1&#x2013;12. doi:10.1136/gut.2006.099580</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2006.099580</ArticleId><ArticleId IdType="pmc">PMC1860002</ArticleId><ArticleId IdType="pubmed">16966752</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426&#x2013;1437, 1437 e1421&#x2013;1429. doi:10.1053/j.gastro.2013.02.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.02.042</ArticleId><ArticleId IdType="pubmed">23474284</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo V. Acute-on-chronic liver failure in cirrhosis requires expedited decisions for liver transplantation. Gastroenterology. 2019;156(5):1248&#x2013;1249. doi:10.1053/j.gastro.2019.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.004</ArticleId><ArticleId IdType="pubmed">30849314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014;60(6):1310&#x2013;1324. doi:10.1016/j.jhep.2014.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2014.01.024</ArticleId><ArticleId IdType="pubmed">24530646</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272&#x2013;1284. doi:10.1016/j.jhep.2015.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.07.004</ArticleId><ArticleId IdType="pubmed">26192220</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151&#x2013;1157. doi:10.1002/hep.1840080532</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.1840080532</ArticleId><ArticleId IdType="pubmed">2971015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol. 2018;15(12):753&#x2013;764. doi:10.1038/s41575-018-0045-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-018-0045-2</ArticleId><ArticleId IdType="pubmed">30026556</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211&#x2013;1219. doi:10.1002/hep.20720</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20720</ArticleId><ArticleId IdType="pubmed">15915465</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfus. 2013;11(Suppl 4):s18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853979</ArticleId><ArticleId IdType="pubmed">24333308</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836&#x2013;1846. doi:10.1002/hep.26338</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26338</ArticleId><ArticleId IdType="pubmed">23423799</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen JH, Siemssen O, Krintel JJ, Malchow-Moller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol. 2001;34(1):53&#x2013;60. doi:10.1016/S0168-8278(00)00009-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(00)00009-X</ArticleId><ArticleId IdType="pubmed">11211908</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol. 1993;88(4):514&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">8470631</ArticleId></ArticleIdList></Reference><Reference><Citation>Oettl K, Birner-Gruenberger R, Spindelboeck W, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol. 2013;59(5):978&#x2013;983. doi:10.1016/j.jhep.2013.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2013.06.013</ArticleId><ArticleId IdType="pubmed">23811308</ArticleId></ArticleIdList></Reference><Reference><Citation>Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60(6):1851&#x2013;1860. doi:10.1002/hep.27322</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27322</ArticleId><ArticleId IdType="pubmed">25048618</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarre M, Domenicali M, Naldi M, et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep. 2016;6:35987. doi:10.1038/srep35987</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep35987</ArticleId><ArticleId IdType="pmc">PMC5080612</ArticleId><ArticleId IdType="pubmed">27782157</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology. 2009;50(2):555&#x2013;564. doi:10.1002/hep.22913</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.22913</ArticleId><ArticleId IdType="pubmed">19642174</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannone FA, Domenicali M, Baldassarre M, et al. Ischaemia-modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver Int. 2015;35(11):2425&#x2013;2432. doi:10.1111/liv.12860</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.12860</ArticleId><ArticleId IdType="pubmed">25939693</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406&#x2013;460. doi:10.1016/j.jhep.2018.03.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.03.024</ArticleId><ArticleId IdType="pubmed">29653741</ArticleId></ArticleIdList></Reference><Reference><Citation>American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012; 2013. 
Available from:
https://www.aasld.org/sites/default/files/2019-06/AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf. Accessed May 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463403</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264&#x2013;269, W264. doi:10.7326/0003-4819-151-4-200908180-00135</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00135</ArticleId><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Scottish Intercollegiate Guidelines Network (SIGN). SIGN GRADING SYSTEM 1999 &#x2013; 2012. Available from:
https://www.sign.ac.uk/assets/sign_grading_system_1999_2012.pdf. Accessed May 2020
2012.</Citation></Reference><Reference><Citation>Sola E, Sole C, Simon-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018;69(6):1250&#x2013;1259. doi:10.1016/j.jhep.2018.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.08.006</ArticleId><ArticleId IdType="pubmed">30138685</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome Type 1. Gastroenterology. 2016;150(7):1579&#x2013;1589. doi:10.1053/j.gastro.2016.02.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.026</ArticleId><ArticleId IdType="pubmed">26896734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bari K, Minano C, Shea M, et al. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol. 2012;10(10):1169&#x2013;1175. doi:10.1016/j.cgh.2012.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.06.027</ArticleId><ArticleId IdType="pmc">PMC3678262</ArticleId><ArticleId IdType="pubmed">22801062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987;93(2):234&#x2013;241. doi:10.1016/0016-5085(87)91007-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(87)91007-9</ArticleId><ArticleId IdType="pubmed">3297907</ArticleId></ArticleIdList></Reference><Reference><Citation>Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94(6):1493&#x2013;1502. doi:10.1016/0016-5085(88)90691-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(88)90691-9</ArticleId><ArticleId IdType="pubmed">3360270</ArticleId></ArticleIdList></Reference><Reference><Citation>Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111(4):1002&#x2013;1010. doi:10.1016/S0016-5085(96)70068-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(96)70068-9</ArticleId><ArticleId IdType="pubmed">8831595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403&#x2013;409. doi:10.1056/NEJM199908053410603</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908053410603</ArticleId><ArticleId IdType="pubmed">10432325</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez J, Angeli P, Trebicka J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2020;18(4):963&#x2013;973e914. doi:10.1016/j.cgh.2019.07.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2019.07.055</ArticleId><ArticleId IdType="pubmed">31394283</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417&#x2013;2429. doi:10.1016/S0140-6736(18)30840-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30840-7</ArticleId><ArticleId IdType="pubmed">29861076</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006;12(9):1403&#x2013;1407. doi:10.3748/wjg.v12.i9.1403</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i9.1403</ArticleId><ArticleId IdType="pmc">PMC4124318</ArticleId><ArticleId IdType="pubmed">16552809</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol. 1999;30(4):639&#x2013;645. doi:10.1016/S0168-8278(99)80194-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(99)80194-9</ArticleId><ArticleId IdType="pubmed">10207805</ArticleId></ArticleIdList></Reference><Reference><Citation>Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study. Ind J Gastroenterol. 2018;37(5):424&#x2013;429. doi:10.1007/s12664-018-0876-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12664-018-0876-3</ArticleId><ArticleId IdType="pubmed">30178092</ArticleId></ArticleIdList></Reference><Reference><Citation>Salman TA, Edrees AM, El-Said HH, El-Abd OL, El-Azab GI. Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2016;28(7):777&#x2013;785. doi:10.1097/MEG.0000000000000635</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000635</ArticleId><ArticleId IdType="pubmed">27097354</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevenot T, Bureau C, Oberti F, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol. 2015;62(4):822&#x2013;830. doi:10.1016/j.jhep.2014.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2014.11.017</ArticleId><ArticleId IdType="pubmed">25463545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdy H, ElBaz AA, Hassan A, Hassanin O. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. J Clin Gastroenterol. 2014;48(2):184&#x2013;188. doi:10.1097/MCG.0b013e31829ae376</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31829ae376</ArticleId><ArticleId IdType="pubmed">23842215</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Talero M, Garcia-Martinez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59(6):1184&#x2013;1192. doi:10.1016/j.jhep.2013.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2013.07.020</ArticleId><ArticleId IdType="pubmed">23872605</ArticleId></ArticleIdList></Reference><Reference><Citation>Guevara M, Terra C, Nazar A, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012;57(4):759&#x2013;765. doi:10.1016/j.jhep.2012.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2012.06.013</ArticleId><ArticleId IdType="pubmed">22732511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Wang WT, Yan LN, Xu MQ, Yang JY. Alternatives to albumin administration in hepatocellular carcinoma patients undergoing hepatectomy: an open, randomized clinical trial of efficacy and safety. Chin Med J. 2011;124(10):1458&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">21740798</ArticleId></ArticleIdList></Reference><Reference><Citation>Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Digest Liver Dis. 2011;43(11):881&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">21741331</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103(6):1399&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">18547224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal AJ, Boyer T, Garcia&#x2013;Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360&#x2013;1368. doi:10.1053/j.gastro.2008.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.02.014</ArticleId><ArticleId IdType="pmc">PMC3730280</ArticleId><ArticleId IdType="pubmed">18471513</ArticleId></ArticleIdList></Reference><Reference><Citation>Appenrodt B, Wolf A, Grunhage F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008;28(7):1019&#x2013;1025. doi:10.1111/j.1478-3231.2008.01734.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2008.01734.x</ArticleId><ArticleId IdType="pubmed">18410283</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">18471512</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med. 2006;260(1):62&#x2013;68. doi:10.1111/j.1365-2796.2006.01654.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2006.01654.x</ArticleId><ArticleId IdType="pubmed">16789980</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int. 2006;26(1):46&#x2013;54. doi:10.1111/j.1478-3231.2005.01188.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2005.01188.x</ArticleId><ArticleId IdType="pubmed">16420509</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology. 2005;42(3):627&#x2013;634. doi:10.1002/hep.20829</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20829</ArticleId><ArticleId IdType="pubmed">16108036</ArticleId></ArticleIdList></Reference><Reference><Citation>Degoricija V, Zjacic-Rotkvic V, Marout J, Sefer S, Troskot B. Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial. Croat Med J. 2003;44(2):178&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">12698509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37(5):1147&#x2013;1153. doi:10.1053/jhep.2003.50169</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2003.50169</ArticleId><ArticleId IdType="pubmed">12717396</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Compean D, Blanc P, Larrey D, et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol. 2002;1(1):29&#x2013;35. doi:10.1016/S1665-2681(19)32189-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1665-2681(19)32189-1</ArticleId><ArticleId IdType="pubmed">15114293</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002;50(1):90&#x2013;94. doi:10.1136/gut.50.1.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.50.1.90</ArticleId><ArticleId IdType="pmc">PMC1773081</ArticleId><ArticleId IdType="pubmed">11772973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yuan C, Wang D, Li X. Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chin Med J. 2000;113(1):27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11775204</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology. 1995;22(3):753&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">7657279</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Compean D, Zacarias Villarreal J, Bahena Cuevas H, et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver. 1993;13(5):233&#x2013;238. doi:10.1111/j.1600-0676.1993.tb00637.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0676.1993.tb00637.x</ArticleId><ArticleId IdType="pubmed">8259034</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno S, Borzio M, Romagnoni M, et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ. 1992;304(6843):1655&#x2013;1658. doi:10.1136/bmj.304.6843.1655</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.304.6843.1655</ArticleId><ArticleId IdType="pmc">PMC1882361</ArticleId><ArticleId IdType="pubmed">1633517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassio E, Terg R, Landeira G, et al. Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol. 1992;14(2&#x2013;3):310&#x2013;316. doi:10.1016/0168-8278(92)90176-P</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8278(92)90176-P</ArticleId><ArticleId IdType="pubmed">1380024</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology. 1991;13(4):707&#x2013;713. doi:10.1002/hep.1840130416</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.1840130416</ArticleId><ArticleId IdType="pubmed">1826281</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology. 1990;99(6):1736&#x2013;1744. doi:10.1016/0016-5085(90)90481-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(90)90481-F</ArticleId><ArticleId IdType="pubmed">1699835</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat &#x2018;tense&#x2019; ascites in cirrhotic patients. A safe alternative therapy. J Hepatol. 1987;5(1):102&#x2013;108. doi:10.1016/S0168-8278(87)80067-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(87)80067-3</ArticleId><ArticleId IdType="pubmed">3655306</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakar T, Demir M, Dogan O, Parlakgumus A, Ozer B, Serin E. High dose oral furosemide with salt ingestion in the treatment of refractory ascites of liver cirrhosis. Clin Invest Med. 2016;39(6):27502.</Citation><ArticleIdList><ArticleId IdType="pubmed">27917793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yosry A, Soliman ZA, Eletreby R, Hamza I, Ismail A, Elkady MA. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. Eur J Gastroenterol Hepatol. 2019;31(3):345&#x2013;351. doi:10.1097/MEG.0000000000001277</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000001277</ArticleId><ArticleId IdType="pubmed">30312183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62(2):567&#x2013;574. doi:10.1002/hep.27709</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27709</ArticleId><ArticleId IdType="pubmed">25644760</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006;21(1):303&#x2013;307. doi:10.1111/j.1440-1746.2006.04182.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2006.04182.x</ArticleId><ArticleId IdType="pubmed">16460491</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaak D, Paquet KJ, Kuhn R. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol. 2001;39(1):5&#x2013;10. doi:10.1055/s-2001-10707</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2001-10707</ArticleId><ArticleId IdType="pubmed">11215366</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol. 1998;10(1):5&#x2013;10. doi:10.1097/00042737-199801000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-199801000-00002</ArticleId><ArticleId IdType="pubmed">9512946</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue HP, Lin B, Mo JZ, Li JQ. Effect of albumin infusion on preventing the deterioration of renal function in patients with spontaneous bacterial peritonitis. Chin J Digest Dis. 2002;6:100&#x2013;101.</Citation></Reference><Reference><Citation>Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019;9:CD013103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740336</ArticleId><ArticleId IdType="pubmed">31513287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172&#x2013;1181. doi:10.1002/hep.24786</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24786</ArticleId><ArticleId IdType="pubmed">22095893</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11(2):123&#x2013;130. doi:10.1016/j.cgh.2012.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.11.007</ArticleId><ArticleId IdType="pubmed">23178229</ArticleId></ArticleIdList></Reference><Reference><Citation>Leao GS, John Neto G, Jotz RF, Mattos AA, Mattos AZ. Albumin for cirrhotic patients with extraperitoneal infections: a meta-analysis. J Gastroenterol Hepatol. 2019;34(12):2071&#x2013;2076. doi:10.1111/jgh.14791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.14791</ArticleId><ArticleId IdType="pubmed">31353630</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo TT, Yang Y, Song Y, Ren Y, Liu ZX, Cheng G. Effects of midodrine in patients with ascites due to cirrhosis: systematic review and meta-analysis. J Dig Dis. 2016;17(1):11&#x2013;19. doi:10.1111/1751-2980.12304</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-2980.12304</ArticleId><ArticleId IdType="pubmed">26630543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok CS, Krupa L, Mahtani A, et al. Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int. 2013;2013:295153. doi:10.1155/2013/295153</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/295153</ArticleId><ArticleId IdType="pmc">PMC3816020</ArticleId><ArticleId IdType="pubmed">24222902</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol. 2015;15:167. doi:10.1186/s12876-015-0389-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-015-0389-9</ArticleId><ArticleId IdType="pmc">PMC4660686</ArticleId><ArticleId IdType="pubmed">26606982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutting F, Schubert J, Franklin J, et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC-free cirrhotic patients undergoing large volume paracentesis. J Gastroenterol Hepatol. 2017;32(2):327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">27149296</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev. 2019;6:CD004039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598734</ArticleId><ArticleId IdType="pubmed">31251387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon P, Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2011;9(3):260&#x2013;265. doi:10.1016/j.cgh.2010.11.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2010.11.038</ArticleId><ArticleId IdType="pmc">PMC3713475</ArticleId><ArticleId IdType="pubmed">21145427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez J, Claria J, Amoros A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology. 2019;157(1):149&#x2013;162. doi:10.1053/j.gastro.2019.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.021</ArticleId><ArticleId IdType="pubmed">30905652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113(2):579&#x2013;586. doi:10.1053/gast.1997.v113.pm9247479</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.1997.v113.pm9247479</ArticleId><ArticleId IdType="pubmed">9247479</ArticleId></ArticleIdList></Reference><Reference><Citation>Licata G, Tuttolomondo A, Licata A, et al. Clinical Trial: high-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Aliment Pharmacol Ther. 2009;30(3):227&#x2013;235. doi:10.1111/j.1365-2036.2009.04040.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04040.x</ArticleId><ArticleId IdType="pubmed">19438847</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttolomondo A, Di Raimondo D, Bellia C, et al. Immune-inflammatory and metabolic effects of high dose furosemide plus Hypertonic Saline Solution (HSS) Treatment in cirrhotic subjects with refractory ascites. PLoS One. 2016;11(12):e0165443. doi:10.1371/journal.pone.0165443</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165443</ArticleId><ArticleId IdType="pmc">PMC5152809</ArticleId><ArticleId IdType="pubmed">27941973</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartog CS, Natanson C, Sun J, Klein HG, Reinhart K. Concerns over use of hydroxyethyl starch solutions. BMJ. 2014;349:g5981. doi:10.1136/bmj.g5981</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g5981</ArticleId><ArticleId IdType="pmc">PMC4707718</ArticleId><ArticleId IdType="pubmed">25385352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi M, Caraceni P, Navickis RJ. Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis? Expert Rev Gastroenterol Hepatol. 2017;11(3):191&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">28004601</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531&#x2013;537. doi:10.1136/gutjnl-2014-308874</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-308874</ArticleId><ArticleId IdType="pubmed">25631669</ArticleId></ArticleIdList></Reference><Reference><Citation>Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279&#x2013;1290. doi:10.1056/NEJMra0809139</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0809139</ArticleId><ArticleId IdType="pubmed">19776409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36(4 Pt 1):941&#x2013;948. doi:10.1053/jhep.2002.35819</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2002.35819</ArticleId><ArticleId IdType="pubmed">12297842</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Society of Hepatology CMA, Xu X, Duan Z, et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatol Int. 2019;13(1):1&#x2013;21. doi:10.1007/s12072-018-09923-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-018-09923-2</ArticleId><ArticleId IdType="pubmed">30656520</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int. 2019;39(1):98&#x2013;105. doi:10.1111/liv.13968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.13968</ArticleId><ArticleId IdType="pubmed">30230204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola E, Sole C, Gines P. New strategies for the management of decompensated cirrhosis: long-term albumin administration for everyone? Hepatology. 2019;69(5):2289&#x2013;2291. doi:10.1002/hep.30357</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.30357</ArticleId><ArticleId IdType="pubmed">30468512</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733&#x2013;744. doi:10.2165/00019053-200826090-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200826090-00004</ArticleId><ArticleId IdType="pubmed">18767894</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol. 2020. doi:10.1016/j.jhep.2020.08.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.08.021</ArticleId><ArticleId IdType="pubmed">32853747</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraceni P, Angeli P, Prati D, et al. AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfusion. 2016;14(1):8&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731339</ArticleId><ArticleId IdType="pubmed">26820615</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358(2):125&#x2013;139. doi:10.1056/NEJMoa070716</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa070716</ArticleId><ArticleId IdType="pubmed">18184958</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer&#x2019;s acetate in severe sepsis. N Engl J Med. 2012;367(2):124&#x2013;134. doi:10.1056/NEJMoa1204242</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1204242</ArticleId><ArticleId IdType="pubmed">22738085</ArticleId></ArticleIdList></Reference><Reference><Citation>Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901&#x2013;1911. doi:10.1056/NEJMoa1209759</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209759</ArticleId><ArticleId IdType="pubmed">23075127</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA). PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients; 2013. 
Available from:
https://www.ema.europa.eu/en/news/prac-confirms-hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-burn. Accessed May 2020.</Citation></Reference><Reference><Citation>Cohen D. EMA calls for hydroxyethyl starch solutions to be taken off market. BMJ. 2018;360:k225. doi:10.1136/bmj.k225</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k225</ArticleId><ArticleId IdType="pubmed">29339531</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA). Assessment report for solutions for infusion containing hydroxyethyl starch. Available from:https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-prac-assessment-report_en.pdf.Accessed May 2020.</Citation></Reference><Reference><Citation>US Food and Drug Adminstration. Highlights of Prescribing Information: voluven (HES).
2014. 
Available from:
https://www.fda.gov/media/72764/download. Accessed May 2020</Citation></Reference><Reference><Citation>Vincent JL, Russell JA, Jacob M, et al. Albumin administration in the acutely ill: what is new and where next? Critical Care. 2014;18(4):231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223404</ArticleId><ArticleId IdType="pubmed">25042164</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51(2):576&#x2013;584. doi:10.1002/hep.23286</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23286</ArticleId><ArticleId IdType="pubmed">19885875</ArticleId></ArticleIdList></Reference><Reference><Citation>Banares R, Bernardi M. Long-term albumin administration in patients with decompensated cirrhosis. It is time for a reappraisal. Liver Int. 2019;39(1):45&#x2013;48. doi:10.1111/liv.13996</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.13996</ArticleId><ArticleId IdType="pubmed">30576080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkel HG, Labby DH, Ahrens EH, Shank RE, Hoagland CL. The use of concentrated human serum albumin in the treatment of cirrhosis of the liver. J Clin Invest. 1948;27(3 Pt 1):305&#x2013;319. doi:10.1172/JCI101959</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI101959</ArticleId><ArticleId IdType="pmc">PMC438869</ArticleId><ArticleId IdType="pubmed">16695611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet. 1962;2(7266):1125&#x2013;1129. doi:10.1016/S0140-6736(62)90895-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(62)90895-4</ArticleId><ArticleId IdType="pubmed">14000766</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37937109</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1895-5770</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Przeglad gastroenterologiczny</Title><ISOAbbreviation>Prz Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the effect of probiotics on septic complications in patients with severe acute pancreatitis. A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>291</EndPage><MedlinePgn>281-291</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5114/pg.2022.118164</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Severe acute pancreatitis (SAP) with major complications such as necrosis and multiple organ dysfunction syndrome (MODS) often leads to high mortality rates despite intensive treatment.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">To evaluate the effect of symbiotics (probiotics) on septic complications in patients with SAP.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">We searched the PubMed, Cochrane CENTRAL, SCOPUS, and Web of Science databases for relevant clinical trials and excluded observational studies. Quality appraisal was evaluated according to GRADE, and we assessed the risk of bias using Cochrane's risk of bias tool. We included the following outcomes: C-reactive protein (CRP), APACHE II score, hospital stay, multiorgan failure (MOF), systemic inflammatory response syndrome, infected pancreatic necrosis, septicaemia, need for operation, and death. We performed the analysis of homogeneous data under a fixed-effects model, while analysis of heterogeneous data were analysed under a random-effects model. We performed the analysis of dichotomous outcomes using the risk ratio (RR) and relative 95% confidence interval (CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We included a total of 7 clinical trials. We found that there was no significant difference between both groups regarding MOF (RR = 0.60 (0.25, 1.44), <i>p</i> = 0.26), septicaemia (RR = 0.66 (0.29, 1.50), <i>p</i> = 0.32), death (RR = 0.66 (0.19, 2.26), <i>p</i> = 0.51), infected pancreatic necrosis (RR = 0.50 (0.18, 1.38), <i>p</i> = 0.18), SIRS (RR = 0.81 (0.29, 2.23), <i>p</i> = 0.68), CRP, APACHE II score, and hospital stay.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Contrary to some published trials, our meta-analysis concludes that the use of probiotics in patients with SAP is not effective in reducing the mortality rate, septic complications, and need for operation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Termedia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mountain Vista Medical Center, Mesa, AZ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amjad</LastName><ForeName>Waseem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farooq</LastName><ForeName>Umer</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>MacNeal Hospital, Berwyn, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleem</LastName><ForeName>Saad Saleem</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Sunrise Hospital and Medical Center, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Muhammad Imran</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Airedale General Hospital West, Yorkshire, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Prz Gastroenterol</MedlineTA><NlmUniqueID>101280380</NlmUniqueID><ISSNLinking>1895-5770</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">pancreatic necrosis</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword><Keyword MajorTopicYN="N">severe acute pancreatitis</Keyword><Keyword MajorTopicYN="N">symbiotics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>4</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37937109</ArticleId><ArticleId IdType="pmc">PMC10626380</ArticleId><ArticleId IdType="doi">10.5114/pg.2022.118164</ArticleId><ArticleId IdType="pii">47497</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bazerbachi F, Haffar S, Hussain MT, et al. Systematic review of acute pancreatitis associated with interferon-alpha or pegylated interferon-alpha: possible or definitive causation? Pancreatology 2018; 18: 691-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30061072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006; 33: 323-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079934</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Party of the British Society of G, Association of Surgeons of Great B, Ireland, et al. UK guidelines for the management of acute pancreatitis. Gut 2005; 54 Suppl 3: iii1-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867800</ArticleId><ArticleId IdType="pubmed">15831893</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey CF, Zhou H, Harvey DJ, et al. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006; 33: 336-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengmark S. Bio-ecological control of acute pancreatitis: the role of enteral nutrition, pro and synbiotics. Curr Opin Clin Nutr Metab Care 2005; 8: 557-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16079629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AP, Mourad MM, Bramhall SR. Acute pancreatitis: current perspectives on diagnosis and management. J Inflamm Res 2018; 11: 77-85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849938</ArticleId><ArticleId IdType="pubmed">29563826</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsmark CE, Baillie J, Practice AGAIC, et al. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007; 132: 2022-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484894</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol 2013; 108: 1400-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23896955</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg JA, Hsu J, Bawazeer M, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg 2016; 59: 128-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4814287</ArticleId><ArticleId IdType="pubmed">27007094</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Santamaria DM, Taxonera C, Giner M. Update on pathogenesis and clinical management of acute pancreatitis. World J Gastrointest Pathophysiol 2012; 3: 60-70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382704</ArticleId><ArticleId IdType="pubmed">22737590</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber A, Frakes C, Arora Z, et al. Mechanisms and management of acute pancreatitis. Gastroenterol Res Pract 2018; 2018: 6218798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5875055</ArticleId><ArticleId IdType="pubmed">29736167</ArticleId></ArticleIdList></Reference><Reference><Citation>Manes G, Uomo I, Menchise A, et al. Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. Am J Gastroenterol 2006; 101: 1348-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16771960</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89: 1103-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12190674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotel A, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria &#x2013; Joint FAO/WHO Expert Consultation. Prevention 2001.</Citation></Reference><Reference><Citation>Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42: 2-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1726957</ArticleId><ArticleId IdType="pubmed">9505873</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonkers D, Stockbr&#xfc;gger R. Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007; 26: 133-48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18081657</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics&#x2013;a review. J Food Sci Technol 2015; 52: 7577-87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4648921</ArticleId><ArticleId IdType="pubmed">26604335</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervenis C, Smailis D, Hatzitheoklitos E. Bacterial translocation and its prevention in acute pancreatitis. J Hepatobiliary Pancreat Surg 2003; 10: 415-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14714160</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman SH, Carton JA, McMahon MJ. Letter 2: Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis (Br J Surg 2002; 89: 1103-1107) [5]. Br J Surg 2003; 90: 123.</Citation><ArticleIdList><ArticleId IdType="pubmed">12520593</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Diaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, et al. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients 2017; 9: 555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490534</ArticleId><ArticleId IdType="pubmed">28555037</ArticleId></ArticleIdList></Reference><Reference><Citation>Title T. PRISMA 2009 Checklist PRISMA 2009 Checklist. PLoS Med 2009.</Citation></Reference><Reference><Citation>Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series 2008.</Citation></Reference><Reference><Citation>Higgins J, Altman D. Assessing risk of bias. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series. 2008.</Citation></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18279948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ol&#xe1;h A, Bel&#xe1;gyi T, P&#xf3;t&#xf3; L, et al. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 2007; 54: 590-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17523328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma B, Srivastava S, Singh N, et al. Role of probiotics on gut permeability and endotoxemia in patients with acute pancreatitis: a double-blind randomized controlled trial. J Clin Gastroenterol 2011; 45: 442-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21135704</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaudis H, Pupelis G, Zeiza K, et al. Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study. Acta Chir Belg 2012; 112: 131-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22571076</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin HL, Zheng JJ, Tong DN, et al. Effect of Lactobacillus plantarum enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis. Eur J Clin Nutr 2007; 62: 923-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17579653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Wen J, Xu L, et al. Effect of enteral nutrition and ecoimmunonutrition on bacterial translocation and cytokine production in patients with severe acute pancreatitis. J Surg Res 2013; 183: 592-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gou S, Yang Z, Liu T, et al. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2014; 18: R57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056604</ArticleId><ArticleId IdType="pubmed">24684832</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932917</ArticleId><ArticleId IdType="pubmed">20806430</ArticleId></ArticleIdList></Reference><Reference><Citation>Asemi Z, Zare Z, Shakeri H, et al. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 2013; 63: 1-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23899653</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, et al. Prognosis in acute organ-system failure. Ann Surg 1985; 202: 685-93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250999</ArticleId><ArticleId IdType="pubmed">4073980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37658072</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and mortality in patients hospitalized for burns in Catalonia, Spain.</ArticleTitle><Pagination><StartPage>14364</StartPage><MedlinePgn>14364</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-40198-2</ELocationID><Abstract><AbstractText>Burn injuries are one of the leading causes of morbidity worldwide. Although the overall incidence of burns and burn-related mortality is declining, these factors have not been analysed in our population for 25 years. The aim of this study has been to determine whether the epidemiological profile of patients hospitalized for burns has changed over the past 25 years. We performed a retrospective cohort study of patients hospitalised between 1 January 2011 and 31 December 2018 with a primary diagnosis of burns. The incidence of burns in our setting was 3.68/10<sup>5</sup> population. Most patients admitted for burns were men (61%), aged between 35 and 45 years (16.8%), followed by children aged between 0 and 4 years (12.4%). Scalding was the most prevalent mechanism of injury, and the region most frequently affected was the hands. The mean burned total body surface (TBSA) area was 8.3%, and the proportion of severely burned patients was 9.7%. Obesity was the most prevalent comorbidity (39.5%). The median length of stay was 1.8 days. The most frequent in-hospital complications were sepsis (16.6%), acute kidney injury (7.9%), and cardiovascular complications (5.9%). Risk factors for mortality were advanced age, high abbreviated burn severity index score, smoke inhalation, existing cardiovascular disease full-thickness burn, and high percentage of burned TBSA. Overall mortality was 4.3%. Multi-organ failure was the most frequent cause of death, with an incidence of 49.5%. The population has aged over the 25 years since the previous study, and the number of comorbidities has increased. The incidence and severity of burns, and the percentage of burned TBSA have all decreased, with scalding being the most prevalent mechanism of injury. The clinical presentation and evolution of burns differs between children and adults. Risk factors for mortality were advanced age, smoke inhalation, existing cardiovascular disease, full-thickness burn, and high percentage of burned TBSA.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abarca</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Vall d'Hebron, 08035, Barcelona, Spain. labarcavilchez@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilabert</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Alicante, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Us&#xfa;a</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Vall d'Hebron, 08035, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barret</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Plastic Surgery Department and Burn Centre, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colomina</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Clinic, Hospital Universitari de Bellvitge, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012906">Smoke</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012906" MajorTopicYN="N">Smoke</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>PG honorary for lectures from Baxter Spain. MJC fees for lectures from Baxter Spain.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37658072</ArticleId><ArticleId IdType="pmc">PMC10474035</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-40198-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-40198-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, et al. Epidemiology of injuries from fire, heat and hot substances: Global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study. Inj. Prev. 2019 doi: 10.1136/injuryprev-2019-043299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/injuryprev-2019-043299</ArticleId><ArticleId IdType="pmc">PMC7571358</ArticleId><ArticleId IdType="pubmed">31857422</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolle C, Cambiaso-Daniel J, Forbes AA, Wurzer P, Hundeshagen G, Branski LK, et al. Recent trends in burn epidemiology worldwide: A systematic review. Burns. 2017 doi: 10.1016/j.burns.2016.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.08.013</ArticleId><ArticleId IdType="pmc">PMC5616188</ArticleId><ArticleId IdType="pubmed">27600982</ArticleId></ArticleIdList></Reference><Reference><Citation>Haikonen K, Lillsunde PM, Vuola J. Inpatient costs of fire-related injuries in Finland. Burns. 2014 doi: 10.1016/j.burns.2014.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.03.016</ArticleId><ArticleId IdType="pubmed">24742781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger E, Kowal S, Pinar Bilir S, Han E, Foster K. Relationship between patient characteristics and number of procedures as well as length of stay for patients surviving severe burn injuries: Analysis of the american burn association national burn repository. J. Burn Care Res. 2020;41:1037&#x2013;1044. doi: 10.1093/jbcr/iraa040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/iraa040</ArticleId><ArticleId IdType="pmc">PMC7510847</ArticleId><ArticleId IdType="pubmed">32221517</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilabert P, Us&#xfa;a G, Mart&#xed;n N, Abarca L, Barret JP, Colomina MJ. Fluid resuscitation management in patients with burns: Update. Br. J. Anaesth. 2016;117:284&#x2013;296. doi: 10.1093/bja/aew266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aew266</ArticleId><ArticleId IdType="pubmed">27543523</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;kerlund E, Huss FRM, Sj&#xf6;berg F. Burns in Sweden: An analysis of 24 538 cases during the period 1987&#x2013;2004. Burns. 2007;33:31&#x2013;36. doi: 10.1016/j.burns.2006.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2006.10.002</ArticleId><ArticleId IdType="pubmed">17223486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dokter J, Vloemans AF, Beerthuizen GIJM, van der Vlies CH, Boxma H, Breederveld R, et al. Epidemiology and trends in severe burns in the Netherlands. Burns. 2014;40:1406&#x2013;1414. doi: 10.1016/j.burns.2014.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.03.003</ArticleId><ArticleId IdType="pubmed">24703338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederer IA, Hacker S, Sternat N, Waldmann A, Salameh O, Radtke C, et al. Gender has no influence on mortality after burn injuries: A 20-year single center study with 839 patients. Burns. 2019;45:205&#x2013;212. doi: 10.1016/j.burns.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.08.012</ArticleId><ArticleId IdType="pubmed">30170774</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Moser EM, Pfortmueller CA, Olariu R, Lehmann B, Exadaktylos AK. Aetiology of adult burns treated from 2000 to 2012 in a Swiss University Hospital. Burns. 2016;42:919&#x2013;925. doi: 10.1016/j.burns.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.03.005</ArticleId><ArticleId IdType="pubmed">27061890</ArticleId></ArticleIdList></Reference><Reference><Citation>Onarheim H, Jensen SA, Rosenberg BE, Guttormsen AB. The epidemiology of patients with burn injuries admitted to Norwegian hospitals in 2007. Burns. 2009 doi: 10.1016/j.burns.2009.06.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2009.06.191</ArticleId><ArticleId IdType="pubmed">19748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieptu V, Moscalu R, Mihai A, Moscalu M, Pieptu D, Azoic&#x103;i D. Epidemiology of hospitalized burns in Romania: A 10-year study on 92,333 patients. Burns. 2021 doi: 10.1016/j.burns.2021.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2021.05.020</ArticleId><ArticleId IdType="pubmed">34670711</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiefer JL, Perbix W, Grigutsch D, Zinser M, Demir E, Fuchs PC, et al. Etiology, incidence and gender-specific patterns of severe burns in a German Burn Center&#x2014;Insights of 25 years. Burns. 2016;42:687&#x2013;696. doi: 10.1016/j.burns.2015.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2015.10.031</ArticleId><ArticleId IdType="pubmed">26708237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanttula K, Haikonen K, Vuola J. Hospitalized burns in Finland: 36 305 cases from 1980&#x2013;2010. Burns. 2018;44:651&#x2013;657. doi: 10.1016/j.burns.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.09.001</ArticleId><ArticleId IdType="pubmed">29029854</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodorou P, Xu W, Weinand C, Perbix W, Maegele M, Lefering R, et al. Incidence and treatment of burns: A twenty-year experience from a single center in Germany. Burns. 2013;39:49&#x2013;54. doi: 10.1016/j.burns.2012.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.05.003</ArticleId><ArticleId IdType="pubmed">22673118</ArticleId></ArticleIdList></Reference><Reference><Citation>van Yperen DT, van Lieshout EMM, Verhofstad MHJ, van der Vlies CH. Epidemiology of burn patients admitted in the Netherlands: A nationwide registry study investigating incidence rates and hospital admission from 2014 to 2018. Eur. J. Trauma Emerg. Surg. 2021 doi: 10.1007/s00068-021-01777-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-021-01777-y</ArticleId><ArticleId IdType="pmc">PMC9192419</ArticleId><ArticleId IdType="pubmed">34463772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayakova Y, Vajarov I, Stanev A, Nenkova N, Hristov H. Epidemiological analysis of burn patients in East Bulgaria. Burns. 2014;40:683&#x2013;688. doi: 10.1016/j.burns.2013.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2013.08.016</ArticleId><ArticleId IdType="pubmed">24035580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Pinto R, Kraft R, Nathens AB, Finnerty CC, Gamelli RL, et al. Morbidity and survival probability in burn patients in modern burn care. Crit. Care Med. 2015;43:808&#x2013;815. doi: 10.1097/CCM.0000000000000790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000790</ArticleId><ArticleId IdType="pmc">PMC4359665</ArticleId><ArticleId IdType="pubmed">25559438</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlin L, Stanford L, Moore D, Cairns B, Charles A. The measured effect magnitude of co-morbidities on burn injury mortality. Burns. 2016;42:1433&#x2013;1438. doi: 10.1016/j.burns.2016.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.03.007</ArticleId><ArticleId IdType="pmc">PMC5278667</ArticleId><ArticleId IdType="pubmed">27593340</ArticleId></ArticleIdList></Reference><Reference><Citation>Low ZK, Ng WY, Fook-Chong S, Tan BK, Chong SJ, Hwee J, et al. Comparison of clinical outcomes in diabetic and non-diabetic burns patients in a national burns referral centre in southeast Asia: A 3-year retrospective review. Burns. 2017;43:436&#x2013;444. doi: 10.1016/j.burns.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.06.004</ArticleId><ArticleId IdType="pubmed">28159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayampanathan AA. Systematic review and meta-analysis of complications and outcomes of obese patients with burns. Burns. 2016;42:1634&#x2013;1643. doi: 10.1016/j.burns.2016.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.05.008</ArticleId><ArticleId IdType="pubmed">27268011</ArticleId></ArticleIdList></Reference><Reference><Citation>Barret JP, Gomez P, Solano I, Gonzalez-Dorrego M, Crisol FJ. Epidemiology and mortality of adult burns in Catalonia 1999. Burns. 1999;25:325&#x2013;329. doi: 10.1016/S0305-4179(98)00190-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(98)00190-9</ArticleId><ArticleId IdType="pubmed">10431980</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, Gamelli RL, Palmieri TL, Horton JW, et al. American burn association consensus conference to define sepsis and infection in burns. J. Burn Care Res. 2007;28:776&#x2013;790. doi: 10.1097/BCR.0b013e3181599bc9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Putra ON, Saputro ID, Diana D. Rifle criteria for acute kidney injury in burn patients: prevalence and risk factors. Ann. Burns Fire Disasters. 2021;34:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534303</ArticleId><ArticleId IdType="pubmed">34744541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartotto R, Li Z, Hanna S, Spano S, Wood D, Chung K, et al. The Acute Respiratory Distress Syndrome (ARDS) in mechanically ventilated burn patients: An analysis of risk factors, clinical features, and outcomes using the Berlin ARDS definition. Burns. 2016;42:1423&#x2013;1432. doi: 10.1016/j.burns.2016.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.01.031</ArticleId><ArticleId IdType="pubmed">27520712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JLA, Bastida JL, Mart&#xed;nez MM, Moreno JMM, Chamorro JJ. Socio-economic cost and health-related quality of life of burn victims in Spain. Burns. 2008;34:975&#x2013;981. doi: 10.1016/j.burns.2007.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2007.12.011</ArticleId><ArticleId IdType="pubmed">18472221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa D, Ceniceros A, Galeiras R, P&#xe9;rtega-D&#xed;az S, Guti&#xe9;rrez-Urb&#xf3;n JM, Rodr&#xed;guez-Mayo M, et al. Microbiology in burns patients with blood stream infections: Trends over time and during the course of hospitalization. Infect. Dis. 2018;50:289&#x2013;296. doi: 10.1080/23744235.2017.1397738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2017.1397738</ArticleId><ArticleId IdType="pubmed">29105600</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusselaers N, Monstrey S, Vogelaers D, Hoste E, Blot S. Severe burn injury in Europe: A systematic review of the incidence, etiology, morbidity, and mortality. Crit. Care. 2010 doi: 10.1186/cc9300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9300</ArticleId><ArticleId IdType="pmc">PMC3219295</ArticleId><ArticleId IdType="pubmed">20958968</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Wood F, Semmens J, Edgar DW, Spilsbury K, Hendrie D, et al. A study of burn hospitalizations for children younger than 5 years of age: 1983&#x2013;2008. Pediatrics. 2011 doi: 10.1542/peds.2010-3136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-3136</ArticleId><ArticleId IdType="pubmed">21382945</ArticleId></ArticleIdList></Reference><Reference><Citation>Harats M, Peleg K, Givon A, Kornhaber R, Goder M, Jaeger M, et al. Burns in Israel, comparative study: Demographic, etiologic and clinical trends 1997&#x2013;2003 versus 2004&#x2013;2010. Burns. 2016;42:500&#x2013;507. doi: 10.1016/j.burns.2015.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2015.05.023</ArticleId><ArticleId IdType="pubmed">26410362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop MJ, Wijnen BFM, Nieuwenhuis MK, Dokter J, Middelkoop E, Polinder S, et al. Economic burden of burn injuries in the Netherlands: A 3 months follow-up study. Injury. 2016;47:203&#x2013;210. doi: 10.1016/j.injury.2015.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2015.09.009</ArticleId><ArticleId IdType="pubmed">26454627</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios Garc&#xed;a P, Pacheco Compa&#xf1;a FJ, Rodr&#xed;guez P&#xe9;rez E, Bugallo Sanz JI, Fern&#xe1;ndez-Quinto A, Avellaneda-Oviedo EM. Trends in burn injuries in Galicia (Spain): An epidemiological study. Int. Wound J. 2020;17:1717&#x2013;1724. doi: 10.1111/iwj.13456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iwj.13456</ArticleId><ArticleId IdType="pmc">PMC7949175</ArticleId><ArticleId IdType="pubmed">32662941</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JM, Rea S, Boyd JH, Randall SM, Wood FM. Mortality after burn injury in children: A 33-year population-based study. Pediatrics. 2015;135:e903&#x2013;e910. doi: 10.1542/peds.2014-3140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-3140</ArticleId><ArticleId IdType="pubmed">25802351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavlin D, Chegireddy V, Boukovalas S, Nia AM, Branski LK, Friedman JD, et al. Multi-institutional analysis of independent predictors for burn mortality in the United States. Burns Trauma. 2018 doi: 10.1186/s41038-018-0127-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-018-0127-y</ArticleId><ArticleId IdType="pmc">PMC6103989</ArticleId><ArticleId IdType="pubmed">30151396</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang S, Tan J, Zhou J, Wu J, Luo G. Epidemiology of pediatric burns in southwest China from 2011 to 2015. Burns. 2017;43:1306&#x2013;1317. doi: 10.1016/j.burns.2017.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.03.004</ArticleId><ArticleId IdType="pubmed">28372828</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong M, Wheeler KK, Shi J, Thakkar RK, Fabia RB, Groner JI, et al. Epidemiology and trend of US pediatric burn hospitalizations, 2003&#x2013;2016. Burns. 2021;47:551&#x2013;559. doi: 10.1016/j.burns.2020.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2020.05.021</ArticleId><ArticleId IdType="pubmed">33781634</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EL, Maguire S, Holl&#xe9;n LI, Nuttall D, Rea D, Kemp AM. Agents, mechanisms and clinical features of non-scald burns in children: A prospective UK study. Burns. 2017;43:1218&#x2013;1226. doi: 10.1016/j.burns.2017.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.036</ArticleId><ArticleId IdType="pubmed">28645715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu L, Javed MU, Eales M, Hemington-Gorse S. A 10 year epidemiological study of paediatric burns at the Welsh Centre for burns and plastic surgery. Burns. 2017;43:632&#x2013;637. doi: 10.1016/j.burns.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.10.004</ArticleId><ArticleId IdType="pubmed">27816410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li D, Shen C, Chai J, Zhu H, Lin Y, et al. Epidemiology of burns in pediatric patients of Beijing City. BMC Pediatr. 2016 doi: 10.1186/s12887-016-0686-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-016-0686-7</ArticleId><ArticleId IdType="pmc">PMC5070381</ArticleId><ArticleId IdType="pubmed">27756257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendrick D, Young B, Mason-Jones AJ, Ilyas N, Achana FA, Cooper NJ, et al. Home safety education and provision of safety equipment for injury prevention. Cochrane Database of Syst. Rev. 2012 doi: 10.1002/14651858.CD005014.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005014.pub3</ArticleId><ArticleId IdType="pmc">PMC9758703</ArticleId><ArticleId IdType="pubmed">22972081</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopenko M, Reed AJM, Chicco M, Issa F. Preventable burns from domestic tap water. Eur. Burn J. 2022;3:362&#x2013;369. doi: 10.3390/ebj3020031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ebj3020031</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JV, Viana J, Oliveira A, Ramalho A, Sousa-Teixeira J, Duke J, et al. Hospitalisations with burns in children younger than five years in Portugal, 2011&#x2013;2015. Burns. 2019;45:1223&#x2013;1230. doi: 10.1016/j.burns.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.01.003</ArticleId><ArticleId IdType="pubmed">30686698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SH, Chen YC, Chen TJ, Ma H. Epidemiology of burns in Taiwan: A nationwide report including inpatients and outpatients. Burns. 2014;40:1397&#x2013;1405. doi: 10.1016/j.burns.2014.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.01.014</ArticleId><ArticleId IdType="pubmed">24518304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Shen C, Zhao D, Li D, Shang Y. Epidemiology of hospitalized burn patients in China: A systematic review. Burns Open. 2018;2:8&#x2013;16. doi: 10.1016/j.burnso.2017.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burnso.2017.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Ma B, Zeng D, Fang X, Li H, Xiao S, et al. Burns in a major burns center in East China from 2005 to 2014: Incidence and outcome. Burns. 2017;43:1586&#x2013;1595. doi: 10.1016/j.burns.2017.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.033</ArticleId><ArticleId IdType="pubmed">28855061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasiak J, Spinks A, Ashby K, Clapperton A, Cleland H, Gabbe B. The epidemiology of burn injuries in an Australian setting, 2000&#x2013;2006. Burns. 2009;35:1124&#x2013;1132. doi: 10.1016/j.burns.2009.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2009.04.016</ArticleId><ArticleId IdType="pubmed">19482430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, He X, Xian J, Liao J, Chen X, Luo Y, et al. Development of a framework for managing severe burns through a 17-year retrospective analysis of burn epidemiology and outcomes. Sci. Rep. 2021 doi: 10.1038/s41598-021-88507-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88507-x</ArticleId><ArticleId IdType="pmc">PMC8087787</ArticleId><ArticleId IdType="pubmed">33931691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland H, Fernando DT, Gabbe BJ. Trends in Victorian burn injuries 2008&#x2013;2017. Burns. 2021 doi: 10.1016/j.burns.2021.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2021.06.007</ArticleId><ArticleId IdType="pubmed">34304930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura A, Tsurumi A, Que YA, Almpani M, Zheng H, Tompkins RG, et al. Associations between clinical characteristics and the development of multiple organ failure after severe burns in adult patients. Burns. 2019;45:1775&#x2013;1782. doi: 10.1016/j.burns.2019.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.02.014</ArticleId><ArticleId IdType="pubmed">31690472</ArticleId></ArticleIdList></Reference><Reference><Citation>Brink C, Isaacs Q, Scriba MF, Nathire MEH, Rode H, Martinez R. Infant burns: A single institution retrospective review. Burns. 2019;45:1518&#x2013;1527. doi: 10.1016/j.burns.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.11.005</ArticleId><ArticleId IdType="pubmed">30638666</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlin L, Reid T, Williams F, Cairns B, Charles A. Burn mortality in patients with preexisting cardiovascular disease. Burns. 2017;43:949&#x2013;955. doi: 10.1016/j.burns.2017.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.026</ArticleId><ArticleId IdType="pmc">PMC5912170</ArticleId><ArticleId IdType="pubmed">28189352</ArticleId></ArticleIdList></Reference><Reference><Citation>Observatorio Espa&#xf1;ol de las Drogas y las Adicciones. Informe 2021. Alcohol, tabaco y drogas ilegales en Espa&#xf1;a. Madrid: Ministerio de Sanidad. Delegaci&#xf3;n del Gobierno para el Plan Nacional sobre Drogas. 243 p. (2021).</Citation></Reference><Reference><Citation>Eiroa-Orosa FJ, Giannoni-Pastor A, Fidel-Kinori SG, Arg&#xfc;ello JM. Substance use and misuse in burn patients: Testing the classical hypotheses of the interaction between post-traumatic symptomatology and substance use. J. Addict. Dis. 2016;35:194&#x2013;204. doi: 10.1080/10550887.2015.1127717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10550887.2015.1127717</ArticleId><ArticleId IdType="pubmed">26670348</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Rodrigo C, Herv&#xe1;s B&#xe1;rbara G, Gianzo Citores M, Aranceta-Bartrina J. Prevalence of obesity and associated cardiovascular risk factors in the Spanish population: The ENPE study. Revista Espa&#xf1;ola de Cardiolog&#xed;a (English Edition) 2021 doi: 10.1016/j.rec.2020.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2020.12.020</ArticleId><ArticleId IdType="pubmed">33773941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018 Key findings Data from the National Health and Nutrition Examination Survey. 2017.</Citation></Reference><Reference><Citation>Mild Obesity Is Protective After Severe Burn Injury n.d.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963145</ArticleId><ArticleId IdType="pubmed">23877367</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A, Neyra JA, Madni T, Imran J, Phelan H, Arnoldo B, et al. Acute kidney injury after burn. Burns. 2017;43:898&#x2013;908. doi: 10.1016/j.burns.2017.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.023</ArticleId><ArticleId IdType="pubmed">28412129</ArticleId></ArticleIdList></Reference><Reference><Citation>Demsey D, Mordhorst A, Griesdale DEG, Papp A. Improved outcomes of renal injury following burn trauma. Burns. 2019;45:1024&#x2013;1030. doi: 10.1016/j.burns.2019.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.04.001</ArticleId><ArticleId IdType="pubmed">31054958</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkestad T, Brurberg KG, Nordhuus KM, Tveiten CK, Guttormsen AB, Os I, et al. Acute kidney injury in burn patients admitted to the intensive care unit: A systematic review and meta-analysis. Crit. Care. 2020 doi: 10.1186/s13054-019-2710-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2710-4</ArticleId><ArticleId IdType="pmc">PMC6941386</ArticleId><ArticleId IdType="pubmed">31898523</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski W, Kawecki M, Surowiecka-Pastewka A, Klimm W, Szamotulska K, Niemczyk S. Early and late acute kidney injury in severely burned patients. Med. Sci. Monit. 2016;22:3755&#x2013;3763. doi: 10.12659/MSM.895875.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.895875</ArticleId><ArticleId IdType="pmc">PMC5070618</ArticleId><ArticleId IdType="pubmed">27746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Xiao Y, Wang C, Hong X, Sun Y, Ma B, et al. Risk factors for acute kidney injury in patients with burn injury: A meta-analysis and systematic review. J. Burn Care Res. 2017;38:271&#x2013;282. doi: 10.1097/BCR.0000000000000438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0000000000000438</ArticleId><ArticleId IdType="pubmed">27617407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo G, Yang SY, Chuang SS, Fan PC, Chang CH, Hsiao YC, et al. Using acute kidney injury severity and scoring systems to predict outcome in patients with burn injury. J. Formos. Med. Assoc. 2016;115:1046&#x2013;1052. doi: 10.1016/j.jfma.2016.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2016.10.012</ArticleId><ArticleId IdType="pubmed">27923537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Chor Lip H, Tan JH, Thomas M, Imran FH, Azmah Tuan Mat TN. Survival analysis and mortality predictors of hospitalized severe burn victims in a Malaysian burns intensive care unit. Burns Trauma. 2019 doi: 10.1186/s41038-018-0140-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-018-0140-1</ArticleId><ArticleId IdType="pmc">PMC6348617</ArticleId><ArticleId IdType="pubmed">30705904</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JM, Randall SM, Wood FM, Boyd JH, Fear MW. Burns and long-term infectious disease morbidity: A population-based study. Burns. 2017;43:273&#x2013;281. doi: 10.1016/j.burns.2016.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.10.020</ArticleId><ArticleId IdType="pubmed">28041752</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz-Pasteur A, Hussein K, Finkelstein R, Ullmann Y, Egozi D. Blood stream infections (BSI) in severe burn patients-early and late BSI: A 9-year study. Burns. 2013 doi: 10.1016/j.burns.2012.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.09.015</ArticleId><ArticleId IdType="pubmed">23159703</ArticleId></ArticleIdList></Reference><Reference><Citation>Costescu Strachinaru DI, Gallez JL, Fran&#xe7;ois PM, Baekelandt D, Paridaens MS, Pirnay JP, et al. Epidemiology and etiology of blood stream infections in a Belgian burn wound center. Acta Clin. Belg. Int. J. Clin. Lab. Med. 2021 doi: 10.1080/17843286.2021.1872309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.2021.1872309</ArticleId><ArticleId IdType="pubmed">33432871</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand&#xe3;o C. The role of comorbidities on outcome prediction in acute burn patients place des comorbidit&#xe9;s dans les crit&#xe8;res pronostiques des patients br&#xfb;l&#xe9;s. Ann. Burns Fire Disasters. 2021;34:323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8717902</ArticleId><ArticleId IdType="pubmed">35035325</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster NA, Zingg M, Haile SR, K&#xfc;nzi W, Giovanoli P, Guggenheim M. 30 years later&#x2014;Does the ABSI need revision? Burns. 2011;37:958&#x2013;963. doi: 10.1016/j.burns.2011.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2011.03.009</ArticleId><ArticleId IdType="pubmed">21493008</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomar M, &#xc1;lvarez-Lerma F, Riera A, D&#xed;az MT, Torres F, Agra Y, et al. Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: The Spanish experience. Crit. Care Med. 2013;41:2364&#x2013;2372. doi: 10.1097/CCM.0b013e3182923622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182923622</ArticleId><ArticleId IdType="pubmed">23939352</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SF, Bessey PQ, Schurr MJ, Browning SM, Jeng JC, Caruso DM, et al. National burn repository 2005: A ten-year review. J. Burn Care Res. 2006;27:411&#x2013;436. doi: 10.1097/01.BCR.0000226260.17523.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BCR.0000226260.17523.22</ArticleId><ArticleId IdType="pubmed">16819343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallinen O, Maisniemi K, B&#xf6;hling T, Tukiainen E, Koljonen V. Multiple organ failure as a cause of death in patients with severe burns. J. Burn Care Res. 2012;33:206&#x2013;211. doi: 10.1097/BCR.0b013e3182331e73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3182331e73</ArticleId><ArticleId IdType="pubmed">21979843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel KJ, Omeis T, Papp A. Demographics and clinical outcomes of adult burn patients admitted to a single provincial burn centre: A 40-year review. Burns. 2020;46:1958&#x2013;1967. doi: 10.1016/j.burns.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2020.06.020</ArticleId><ArticleId IdType="pubmed">32660831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Nie C, Zhang H, Zeng X, Yu H, Wei Z, et al. Epidemiological characteristics and factors affecting length of hospital stay for children and adults with burns in Zunyi, China: A retrospective study. PeerJ. 2018 doi: 10.7717/peerj.5740.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.5740</ArticleId><ArticleId IdType="pmc">PMC6173946</ArticleId><ArticleId IdType="pubmed">30310756</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom L, Klingberg A, Laflamme L, Wallis L, Hasselberg M. Gender differences in burns: A study from emergency centres in the Western Cape, South Africa. Burns. 2016;42:1600&#x2013;1608. doi: 10.1016/j.burns.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.05.003</ArticleId><ArticleId IdType="pubmed">27262931</ArticleId></ArticleIdList></Reference><Reference><Citation>Toppi J, Cleland H, Gabbe B. Severe burns in Australian and New Zealand adults: Epidemiology and burn centre care. Burns. 2019;45:1456&#x2013;1461. doi: 10.1016/j.burns.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.04.006</ArticleId><ArticleId IdType="pubmed">31053412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta K, Arega H, Smith NL, Li K, Gause E, Lee J, et al. Gender-based disparities in burn injuries, care and outcomes: A World Health Organization (WHO) Global Burn Registry cohort study. Am. J. Surg. 2021 doi: 10.1016/j.amjsurg.2021.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2021.07.041</ArticleId><ArticleId IdType="pmc">PMC8688305</ArticleId><ArticleId IdType="pubmed">34330521</ArticleId></ArticleIdList></Reference><Reference><Citation>Obed D, Schroeter A, Gruber L, Bucher F, Salim M, Bingoel AS, et al. Epidemiology and outcome analysis of 1359 intensive care burn patients: A 13-year retrospective study in a major burn center in Germany. Burns. 2022 doi: 10.1016/j.burns.2022.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2022.08.022</ArticleId><ArticleId IdType="pubmed">36195487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurczyk K, Chrisco LP, di Corpo M, Nizamani R, Sljivic S, Calvert CT, et al. Work-Related burn injuries in a tertiary care burn center, 2013 to 2018. J. Burn Care Res. 2020;41:1009&#x2013;1014. doi: 10.1093/jbcr/iraa105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/iraa105</ArticleId><ArticleId IdType="pubmed">32598473</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes JA, Cleland H, Tracy LM, Darton A, Wood FM, Perrett T, et al. Epidemiology of work-related burn injuries presenting to burn centres in Australia and New Zealand. Burns. 2019;45:484&#x2013;493. doi: 10.1016/j.burns.2018.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.09.011</ArticleId><ArticleId IdType="pubmed">30274814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32998744</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-7922</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>World journal of emergency surgery : WJES</Title><ISOAbbreviation>World J Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Global changes in mortality rates in polytrauma patients admitted to the ICU-a systematic review.</ArticleTitle><Pagination><StartPage>55</StartPage><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">55</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13017-020-00330-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Many factors of trauma care have changed in the last decades. This review investigated the effect of these changes on global all-cause and cause-specific mortality in polytrauma patients admitted to the intensive care unit (ICU). Moreover, changes in trauma mechanism over time and differences between continents were analyzed.</AbstractText><AbstractText Label="MAIN BODY">A systematic review of literature on all-cause mortality in polytrauma patients admitted to ICU was conducted. All-cause and cause-specific mortality rates were extracted as well as trauma mechanism of each patient. Poisson regression analysis was used to model time trends in all-cause and cause-specific mortality. Thirty studies, which reported mortality rates for 82,272 patients, were included and showed a decrease of 1.8% (95% CI 1.6-2.0%) in all-cause mortality per year since 1966. The relative contribution of brain injury-related death has increased over the years, whereas the relative contribution of death due to multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome, and sepsis decreased. MODS was the most common cause of death in North America, and brain-related death was the most common in Asia, South America, and Europe. Penetrating trauma was most often reported in North America and Asia.</AbstractText><AbstractText Label="CONCLUSIONS">All-cause mortality in polytrauma patients admitted to the ICU has decreased over the last decades. A shift from MODS to brain-related death was observed. Geographical differences in cause-specific mortality were present, which may provide region-specific learning possibilities resulting in improvement of global trauma care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Breugel</LastName><ForeName>Johanna M M</ForeName><Initials>JMM</Initials><Identifier Source="ORCID">0000-0003-0307-303X</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3585 GA, Utrecht, The Netherlands. j.m.m.vanbreugel-4@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niemeyer</LastName><ForeName>Menco J S</ForeName><Initials>MJS</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3585 GA, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houwert</LastName><ForeName>Roderick M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3585 GA, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groenwold</LastName><ForeName>Rolf H H</ForeName><Initials>RHH</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3585 GA, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3585 GA, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Emerg Surg</MedlineTA><NlmUniqueID>101266603</NlmUniqueID><ISSNLinking>1749-7922</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Polytrauma patients</Keyword><Keyword MajorTopicYN="N">Trauma care</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32998744</ArticleId><ArticleId IdType="pmc">PMC7526208</ArticleId><ArticleId IdType="doi">10.1186/s13017-020-00330-3</ArticleId><ArticleId IdType="pii">10.1186/s13017-020-00330-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation, Health topics - injury, 2014.</Citation></Reference><Reference><Citation>Lansink KW, Gunning AC, Spijkers AT, et al. Evaluation of trauma care in a mature level I trauma center in the Netherlands: outcomes in a Dutch mature level I trauma center. World J Surg. 2013;37:2353&#x2013;2359. doi: 10.1007/s00268-013-2103-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-013-2103-9</ArticleId><ArticleId IdType="pubmed">23708318</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer R, Tarkin IS, Rocos B, et al. Patterns of mortality and causes of death in polytrauma patients--has anything changed? Injury. 2009;40:907&#x2013;911. doi: 10.1016/j.injury.2009.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2009.05.006</ArticleId><ArticleId IdType="pubmed">19540488</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker CC, Oppenheimer L, Stephens B, et al. Epidemiology of trauma deaths. Am J Surg. 1980;140:144&#x2013;150. doi: 10.1016/0002-9610(80)90431-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9610(80)90431-6</ArticleId><ArticleId IdType="pubmed">7396078</ArticleId></ArticleIdList></Reference><Reference><Citation>Trunkey DD. Trauma. Accidental and intentional injuries account for more years of life lost in the U.S. than cancer and heart disease. Among the prescribed remedies are improved preventive efforts, speedier surgery and further research. Sci Am. 1983;249:28&#x2013;35. doi: 10.1038/scientificamerican0883-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/scientificamerican0883-28</ArticleId><ArticleId IdType="pubmed">6623052</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JA, van Wessem KJ, McDougall D, et al. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surg. 2010;34:158&#x2013;163. doi: 10.1007/s00268-009-0266-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-009-0266-1</ArticleId><ArticleId IdType="pubmed">19882185</ArticleId></ArticleIdList></Reference><Reference><Citation>(PRISMA) PRIfSRaM-A, 2015.</Citation></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi: 10.1186/s13643-016-0384-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Programme CAS Checklist, 2018.</Citation></Reference><Reference><Citation>Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712&#x2013;716. doi: 10.1046/j.1445-2197.2003.02748.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauwers LF, Rosseel P, Roelants A, et al. A retrospective study of 130 consecutive multiple trauma patients in an intensive care unit. Intensive Care Med. 1986;12:296&#x2013;301. doi: 10.1007/BF00261739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00261739</ArticleId><ArticleId IdType="pubmed">3760319</ArticleId></ArticleIdList></Reference><Reference><Citation>Regel G, Lobenhoffer P, Grotz M, et al. Treatment results of patients with multiple trauma: an analysis of 3406 cases treated between 1972 and 1991 at a German level I trauma center. J Trauma. 1995;38:70&#x2013;78. doi: 10.1097/00005373-199501000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199501000-00020</ArticleId><ArticleId IdType="pubmed">7745664</ArticleId></ArticleIdList></Reference><Reference><Citation>Aufmkolk M, Majetschak M, Voggenreiter G, et al. Follow-up and prognosis of severe accidental trauma in the aged. Unfallchirurg. 1997;100:477&#x2013;482. doi: 10.1007/s001130050145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001130050145</ArticleId><ArticleId IdType="pubmed">9333959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dereeper E, Ciardelli R, Vincent JL. Fatal outcome after polytrauma: multiple organ failure or cerebral damage? Resuscitation. 1998;36:15&#x2013;18. doi: 10.1016/S0300-9572(97)00080-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0300-9572(97)00080-4</ArticleId><ArticleId IdType="pubmed">9547838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield RJ, Parr MJ, Manara AR. Late deaths in multiple trauma patients receiving intensive care. Resuscitation. 2001;49:279&#x2013;281. doi: 10.1016/S0300-9572(00)00364-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0300-9572(00)00364-6</ArticleId><ArticleId IdType="pubmed">11719122</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast-Kolb D, Aufmkolk M, Rucholtz S, et al. Multiple organ failure still a major cause of morbidity but not mortality in blunt multiple trauma. J Trauma. 2001;51:835&#x2013;841. doi: 10.1097/00005373-200111000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200111000-00003</ArticleId><ArticleId IdType="pubmed">11706328</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignesh TA, S A, Kamat V. Outcome in patients with blunt chest trauma and pulmonary contusions. Indian Journal of Critical Care Medicine. 2004;8:73&#x2013;77.</Citation></Reference><Reference><Citation>Ciesla DJ, Moore EE, Johnson JL, et al. A 12-year prospective study of postinjury multiple organ failure: has anything changed? Arch Surg. 2005;140:432&#x2013;438. doi: 10.1001/archsurg.140.5.432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.140.5.432</ArticleId><ArticleId IdType="pubmed">15897438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LY, Yao YZ, Jiang DP, et al. Surgical treatment strategy for multiple injury patients in ICU. Chin J Traumatol. 2011;14:42&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21276367</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Wang J, Feng QL, et al. The treatment of severe and multiple injuries in intensive care unit: report of 80 cases. Eur Rev Med Pharmacol Sci. 2014;18:3797&#x2013;3801.</Citation><ArticleIdList><ArticleId IdType="pubmed">25555869</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Saverio S, Gambale G, Coccolini F, et al. Changes in the outcomes of severe trauma patients from 15-year experience in a Western European trauma ICU of Emilia Romagna region (1996&#x2013;2010). A population cross-sectional survey study. Langenbecks Arch Surg. 2014;399:109&#x2013;126. doi: 10.1007/s00423-013-1143-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00423-013-1143-9</ArticleId><ArticleId IdType="pubmed">24292078</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Reduction in mortality rates of postinjury multiple organ dysfunction ayndrome: a shifting paradigm? A prospective population-based cohort study. Shock. 2018;49:33&#x2013;38. doi: 10.1097/SHK.0000000000000938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId><ArticleId IdType="pubmed">28682941</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore PG, James OF. Byth PL, et al. Factors affecting outcome after chest injury. Anaesth Intensive Care. 1985;13:362&#x2013;369. doi: 10.1177/0310057X8501300405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0310057X8501300405</ArticleId><ArticleId IdType="pubmed">4073448</ArticleId></ArticleIdList></Reference><Reference><Citation>Herve C, Gaillard M, Huguenard P. Early medical care and mortality in polytrauma. J Trauma. 1987;27:1279&#x2013;1285. doi: 10.1097/00005373-198711000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198711000-00013</ArticleId><ArticleId IdType="pubmed">3682039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivioja A. Factors affecting the prognosis of multiply injured patients: an analysis of 1169 consecutive cases. Injury. 1989;20:77&#x2013;80. doi: 10.1016/0020-1383(89)90144-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0020-1383(89)90144-7</ArticleId><ArticleId IdType="pubmed">2592083</ArticleId></ArticleIdList></Reference><Reference><Citation>Goins WA, Reynolds HN, Nyanjom D, et al. Outcome following prolonged intensive care unit stay in multiple trauma patients. Crit Care Med. 1991;19:339&#x2013;345. doi: 10.1097/00003246-199103000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199103000-00010</ArticleId><ArticleId IdType="pubmed">1999094</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst C, Pape HC, Hildebrand F, et al. 30&#x2009;years of polytrauma care: an analysis of the change in strategies and results of 4849 cases treated at a single institution. Injury. 2009;40:77&#x2013;83. doi: 10.1016/j.injury.2008.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2008.10.004</ArticleId><ArticleId IdType="pubmed">19117558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wafaisade A, Lefering R, Bouillon B, et al. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. Crit Care Med. 2011;39:621&#x2013;628. doi: 10.1097/CCM.0b013e318206d3df.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318206d3df</ArticleId><ArticleId IdType="pubmed">21242798</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, et al. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg. 2013;74:774&#x2013;779. doi: 10.1097/TA.0b013e31827a6e69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich M, Lefering R, Probst C, et al. Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg. 2014;76:921&#x2013;927. doi: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Incidence of acute respiratory distress syndrome and associated mortality in a polytrauma population. Trauma Surg Acute Care Open. 2018;3:e000232. doi: 10.1136/tsaco-2018-000232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2018-000232</ArticleId><ArticleId IdType="pmc">PMC6307585</ArticleId><ArticleId IdType="pubmed">30623025</ArticleId></ArticleIdList></Reference><Reference><Citation>Brilej D, Stropnik D, Lefering R, et al. Algorithm for activation of coagulation support treatment in multiple injured patients&#x2013;&#x2013;cohort study. European Journal of Trauma and Emergency Surgery. 2017;43:423&#x2013;430. doi: 10.1007/s00068-016-0726-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-016-0726-x</ArticleId><ArticleId IdType="pubmed">27658942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehne MG, Sablotzki A, M&#xfc;hling J, et al. Long-term monitoring of renal function in poly-traumatized intensive care patients. Renal failure. 2002;24:493&#x2013;504. doi: 10.1081/JDI-120006776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1081/JDI-120006776</ArticleId><ArticleId IdType="pubmed">12212829</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Lefering R, Butcher N, et al. The definition of polytrauma revisited: an international consensus process and proposal of the new &#x2018;Berlin definition'. J Trauma Acute Care Surg. 2014;77:780&#x2013;786. doi: 10.1097/TA.0000000000000453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000453</ArticleId><ArticleId IdType="pubmed">25494433</ArticleId></ArticleIdList></Reference><Reference><Citation>Regel G, Grotz M, Weltner T, et al. Pattern of organ failure following severe trauma. World J Surg. 1996;20:422&#x2013;429. doi: 10.1007/s002689900067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002689900067</ArticleId><ArticleId IdType="pubmed">8662130</ArticleId></ArticleIdList></Reference><Reference><Citation>P DM, K H, H H, et al. Acute physiology and chronic health evaluation (APACHE) III score compared to trauma-injury severity score (TRISS) in predicting mortality of trauma patients. Emergency. 2016;4:88&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893757</ArticleId><ArticleId IdType="pubmed">27274519</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiletto R, H&#xfc;nerkopf M, Schnabel M, et al. Continuous stroke volume monitoring as &#x201c;hemodynamic online monitoring&#x201d; in polytrauma intensive care patients: technically possible--clinically necessary? Der Unfallchirurg. 2001;104:1043&#x2013;1047. doi: 10.1007/s001130170018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001130170018</ArticleId><ArticleId IdType="pubmed">11760335</ArticleId></ArticleIdList></Reference><Reference><Citation>Rixen D, Siegel JH. Metabolic correlates of oxygen debt predict posttrauma early acute respiratory distress syndrome and the related cytokine response. The Journal of trauma. 2000;49:392&#x2013;403. doi: 10.1097/00005373-200009000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200009000-00003</ArticleId><ArticleId IdType="pubmed">11003314</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas AD, Franzon O. Lactate as predictor of mortality in polytrauma. Arquivos brasileiros de cirurgia digestiva: ABCD = Brazilian archives of digestive surgery. 2015;28:163&#x2013;166. doi: 10.1590/S0102-67202015000300004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0102-67202015000300004</ArticleId><ArticleId IdType="pmc">PMC4737353</ArticleId><ArticleId IdType="pubmed">26537138</ArticleId></ArticleIdList></Reference><Reference><Citation>R C, M X, M, L L, et al. Characteristics of trauma patients admitted to the intensive care unit of a general hospital in Chile. Caracter&#xed;sticas de los pacientes traumatizados que ingresan a la UCI de un hospital general en Chile. 2013;141:1389&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">24718464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscelli P, Buccoliero F. Outcomes in polytrauma: comparison between the results achieved in the Cesena Trauma Centre and in the Regional Registry of a (RRGT) of Emilia Romagna, Italy. Annali italiani di chirurgia. 2014;85:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24755813</ArticleId></ArticleIdList></Reference><Reference><Citation>H-C P, D R, M G, et al. Reticuloendothelial system activity and organ failure in patients with multiple injuries. Arch Surg. 1999;134:421&#x2013;427. doi: 10.1001/archsurg.134.4.421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.134.4.421</ArticleId><ArticleId IdType="pubmed">10199317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansink KW, Leenen LP. History, development and future of trauma care for multiple injured patients in the Netherlands. Eur J Trauma Emerg Surg. 2013;39:3&#x2013;7. doi: 10.1007/s00068-012-0223-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-012-0223-9</ArticleId><ArticleId IdType="pubmed">26814917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermolov AS, Abakumov MM, Sokolov VA, et al. Structure of hospital lethality in polytrauma and ways to reduce it. Khirurgiia (Mosk). 2006:16&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047627</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier J, Habler O. The polytrauma patient in the intensive care unit. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007;42:724&#x2013;730. doi: 10.1055/s-2007-993022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-993022</ArticleId><ArticleId IdType="pubmed">17968770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen T, Soreide K, Ringdal KG, et al. Trauma systems and early management of severe injuries in Scandinavia: review of the current state. Injury. 2010;41:444&#x2013;452. doi: 10.1016/j.injury.2009.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2009.05.027</ArticleId><ArticleId IdType="pubmed">19540486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995;38:185&#x2013;193. doi: 10.1097/00005373-199502000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199502000-00006</ArticleId><ArticleId IdType="pubmed">7869433</ArticleId></ArticleIdList></Reference><Reference><Citation>van Olden GD, Meeuwis JD, Bolhuis HW, et al. Clinical impact of advanced trauma life support. Am J Emerg Med. 2004;22:522&#x2013;525. doi: 10.1016/j.ajem.2004.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2004.08.013</ArticleId><ArticleId IdType="pubmed">15666253</ArticleId></ArticleIdList></Reference><Reference><Citation>van Olden GD, Meeuwis JD, Bolhuis HW, et al. Advanced trauma life support study: quality of diagnostic and therapeutic procedures. J Trauma. 2004;57:381&#x2013;384. doi: 10.1097/01.TA.0000096645.13484.E6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000096645.13484.E6</ArticleId><ArticleId IdType="pubmed">15345989</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne J, Coats TJ, Lloyd DA, et al. High quality acute care for the severely injured is not consistently available in England, Wales and Northern Ireland: report of a survey by the Trauma Committee, The Royal College of Surgeons of England. Ann R Coll Surg Engl. 2006;88:103&#x2013;107. doi: 10.1308/003588406X94850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1308/003588406X94850</ArticleId><ArticleId IdType="pmc">PMC1964077</ArticleId><ArticleId IdType="pubmed">16551394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecky F, Woodford M, Yates DW. Trends in trauma care in England and Wales 1989-97. UK Trauma Audit and Research Network. Lancet. 2000;355:1771&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">10832827</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondo MF, Schwab CW, McGonigal MD, et al. &#x2018;Damage control&#x2019;: an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma. 1993;35:375&#x2013;382. doi: 10.1097/00005373-199309000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199309000-00008</ArticleId><ArticleId IdType="pubmed">8371295</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreide K. Epidemiology of major trauma. Br J Surg. 2009;96:697&#x2013;698. doi: 10.1002/bjs.6643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.6643</ArticleId><ArticleId IdType="pubmed">19526611</ArticleId></ArticleIdList></Reference><Reference><Citation>Paffrath T, Lefering R, Flohe S, et al. How to define severely injured patients? -- an Injury Severity Score (ISS) based approach alone is not sufficient. Injury. 2014;45(Suppl 3):S64&#x2013;S69. doi: 10.1016/j.injury.2014.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2014.08.020</ArticleId><ArticleId IdType="pubmed">25284238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresing K, Armstrong VW, Leip C-L, et al. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. Clinical biochemistry. 2007;40:1194&#x2013;1200. doi: 10.1016/j.clinbiochem.2007.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2007.06.013</ArticleId><ArticleId IdType="pubmed">17707362</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29138874</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Using IL-6 concentrations in the first 24&#xa0;h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis.</ArticleTitle><Pagination><StartPage>679</StartPage><EndPage>687</EndPage><MedlinePgn>679-687</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-017-0880-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In previous studies, interleukin-6 (IL-6) has been shown to have a high predictive value for the development of complications and mortality after trauma; however, there is some uncertainty around these results. The aim of this meta-analysis was to assess the value of early IL-6 levels (within the first 24&#xa0;h after trauma) for predicting post-traumatic complications [acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), sepsis, multiple organ failure (MOF), and multiple organ dysfunction syndrome (MODS)] and mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systemic literature review (from January 01, 1990, to June 03, 2017) of English-language articles was carried out using Pubmed, the Cochrane Central Register of Controlled Trials, Embase, and Web of Science. The search terms used were IL-6 (IL6, IL-6, interleukin 6, or interleukin-6); trauma (trauma*, polytrauma*, multitrauma*, injury, or injury severity score); complications (complication*, ARDS, SIRS, sepsis, MOF, or MODS); and mortality (survival, death). Eleven publications (775 patients) out of 1812 fulfilled the criteria. Fixed-effective models were used for data analysis. Statistical heterogeneity was estimated by a Chi-squared Q test and I <sup>2</sup> statistics, and publication bias was assessed with Egger's test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results showed that the concentrations of IL-6 within the first 24&#xa0;h after trauma were significantly higher in the group of patients who had complications or who died [standardized mean difference (SMD)&#x2009;=&#x2009;0.399; 95% confidence interval (CI) 0.217, 0.580; I <sup>2</sup>&#x2009;=&#x2009;0.0%; P(heterogeneity)&#x2009;=&#x2009;0.489]. Subgroup results showed a significant correlation for mortality [SMD&#x2009;=&#x2009;0.610; 95% CI 0.322, 0.898; I <sup>2</sup>&#x2009;=&#x2009;0.0%; P(heterogeneity)&#x2009;=&#x2009;0.708] and MOF/MODS [SMD&#x2009;=&#x2009;0.334; 95% CI 0.028, 0.639; I <sup>2</sup>&#x2009;=&#x2009;0.0%; P(heterogeneity)&#x2009;=&#x2009;0.512] with IL-6, but not for sepsis [SMD&#x2009;=&#x2009;0.194; 95% CI -&#xa0;0.095, 0.484; I <sup>2</sup>&#x2009;=&#x2009;0.0%; P(heterogeneity)&#x2009;=&#x2009;0.512]. Significance was also found in both ISS&#x2009;&#x2265;&#x2009;9 [SMD&#x2009;=&#x2009;0.461, 95% CI 0.131, 0.791, I <sup>2</sup>&#x2009;=&#x2009;5.6%, P(heterogeneity)&#x2009;=&#x2009;0.365] and ISS&#x2009;&#x2265;&#x2009;16 [SMD&#x2009;=&#x2009;0.372, 95% CI 0.155, 0.588, I <sup>2</sup>&#x2009;=&#x2009;1.5%, P(heterogeneity)&#x2009;=&#x2009;0.413].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In conclusion, this meta-analysis showed that serum concentration of IL-6 within the first 24&#xa0;h after trauma could be useful for the prediction of post-traumatic complications, particularly MOF/MODS and mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany. Qiaozhi_1988@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weikang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Luxu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greven</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horst</LastName><ForeName>Klemens</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstreet 30, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>201508080049</GrantID><Agency>China Scholarship Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">MODS</Keyword><Keyword MajorTopicYN="N">MOF</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Trauma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29138874</ArticleId><ArticleId IdType="doi">10.1007/s00068-017-0880-9</ArticleId><ArticleId IdType="pii">10.1007/s00068-017-0880-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Surg. 1996 Nov;172(5):425-9; discussed 429-31</Citation><ArticleIdList><ArticleId IdType="pubmed">8942538</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Surg Res. 2005 Nov-Dec;37(6):360-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16465061</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Crit Care Med. 2016 Aug 04;5(3):187-200</Citation><ArticleIdList><ArticleId IdType="pubmed">27652210</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunobiology. 2016 Mar;221(3):427-31</Citation><ArticleIdList><ArticleId IdType="pubmed">26688509</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2011;15(1):R20</Citation><ArticleIdList><ArticleId IdType="pubmed">21232130</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunobiology. 2016 Aug;221(8):904-10</Citation><ArticleIdList><ArticleId IdType="pubmed">27017325</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Trauma Resusc Emerg Med. 2012 Jan 05;20:2</Citation><ArticleIdList><ArticleId IdType="pubmed">22221511</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2007 Sep-Oct;24(5):955-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18029320</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 1995 Oct;23(10):1638-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1996 Apr;40(4):501-10; discussion 510-2</Citation><ArticleIdList><ArticleId IdType="pubmed">8614027</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intensive Care Med. 2011 Mar-Apr;26(2):73-87</Citation><ArticleIdList><ArticleId IdType="pubmed">21464062</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2016 Jul;8(8):959-70</Citation><ArticleIdList><ArticleId IdType="pubmed">27381687</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Trauma Emerg Surg. 2017 Jun;43(3):363-370</Citation><ArticleIdList><ArticleId IdType="pubmed">27169526</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 1985 Oct;120(10):1109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2013 Dec;44(12):1680-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24119650</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2016 Mar;47(3):640-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26850862</ArticleId></ArticleIdList></Reference><Reference><Citation>Technol Health Care. 2010;18(2):89-100</Citation><ArticleIdList><ArticleId IdType="pubmed">20495248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Surg. 2012 Apr;214(4):478-86; discussion 486-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22342787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Dec;65(6):1385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19077631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 1992 Jun;101(6):1644-55</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Br. 2004 Apr;86(3):313-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15125116</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Res. 2009 Jul 22;14(7):284-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19661010</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2007 Jun;62(6):1396-403; discussion 1403-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17563655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2007 Dec;28(6):668-674</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2012 Feb;147(2):152-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22351910</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Trauma Resusc Emerg Med. 2009 Sep 27;17:49</Citation><ArticleIdList><ArticleId IdType="pubmed">19781105</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2003 Jan;24(1):25-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12495721</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2012 Mar;37(3):253-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22266966</ArticleId></ArticleIdList></Reference><Reference><Citation>Metabolism. 2009 Apr;58(4):449-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19303963</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1990 Feb 1;265(3):621-36</Citation><ArticleIdList><ArticleId IdType="pubmed">1689567</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Surg. 2008 Apr;51(2):97-102</Citation><ArticleIdList><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2010 Oct;34(4):346-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Orthop Scand. 1998 Apr;69(2):184-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9602781</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Surg. 2009 Sep;209(3):320-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19717036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2000 Mar;135(3):291-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40414542</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>435</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Sex differences on the effect of hemoadsorption during cardiac surgery - A REMOVE trial post-hoc analysis.</ArticleTitle><Pagination><StartPage>133371</StartPage><MedlinePgn>133371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2025.133371</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(25)00414-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Multi-organ failure is one of the leading causes of mortality after cardiac surgery for infective endocarditis (IE). Although the randomized evidence does not support the use of hemoadsorption during cardiac surgery for IE, observational studies suggest a beneficial effect in selected patient groups. We aimed to analyze the effect of sex differences on hemoadsorption in patients with IE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a post-hoc analysis of the REMOVE-trial that randomized patients with IE who underwent cardiac surgery with hemoadsorption using CytoSorb&#xae; or control. The primary endpoint was variation of Sequential Organ Failure Assessment (&#x394;SOFA), defined as the difference between the mean total postoperative and baseline SOFA score within 24&#xa0;h of surgery. The secondary endpoints were 30-day mortality and other usual postoperative outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 282 patients, 73 (25.9&#xa0;%) were females (38 and 35 patients in the hemoadsorption and control group, respectively) and 209 (74.1&#xa0;%) were males (98 and 111 patients in the hemoadsorption and control group, respectively). The overall &#x394;SOFA did not differ significantly between the intervention groups in both female and male subgroups (MD: -2.13, 95&#xa0;% CI -5.20 to 0.93, p&#xa0;=&#xa0;0.163; MD: 0.31, 95&#xa0;% CI -0.91 to 1.53, p&#xa0;=&#xa0;0.612, respectively) and neither did 30-day mortality (HR&#xa0;=&#xa0;0.54, 95&#xa0;% CI 0.23 to 1.24, p&#xa0;=&#xa0;0.132; HR 1.17, 95&#xa0;% CI 0.61 to 2.21, p&#xa0;=&#xa0;0.634, respectively).&#xa0;No significant differences were observed concerning the other secondary outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The intraoperative use of hemoadsorption was not associated with reduction of postoperative organ dysfunction, 30-day mortality, or other major clinical endpoints in both sex subgroups.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caldonazo</LastName><ForeName>Tulio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany. Electronic address: tulio.caldonazo@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doenst</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazzini</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirov</LastName><ForeName>Hristo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Infectious Diseases and Infection Control, Friedrich-Schiller-University Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Clinical Studies, UniversityHospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saha</LastName><ForeName>Shekhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boburg</LastName><ForeName>Rodrigo Sandoval</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freiburger</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rustenbach</LastName><ForeName>Christian J&#xf6;rg</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin-Cuartas</LastName><ForeName>Mateo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diab</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Helios-University-Wuppertal, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>REMOVE Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="Y">Endocarditis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart surgery</Keyword><Keyword MajorTopicYN="N">Hemoadsorption</Keyword><Keyword MajorTopicYN="N">Infective endocarditis</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>7</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>19</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40414542</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2025.133371</ArticleId><ArticleId IdType="pii">S0167-5273(25)00414-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34061314</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin<sup>&#xae;</sup>) as a Resuscitative Agent in Hypovolemic Shock Patients.</ArticleTitle><Pagination><StartPage>1079</StartPage><EndPage>1100</EndPage><MedlinePgn>1079-1100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-021-01547-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Centhaquine (Lyfaquin<sup>&#xae;</sup>) showed significant safety and efficacy in preclinical and clinical phase I and II studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, multicentric, randomized phase III study was conducted in patients with hypovolemic shock, systolic blood pressure (SBP) &#x2264; 90 mmHg, and blood lactate levels &#x2265; 2 mmol/L. Patients were randomized in a 2:1 ratio to the centhaquine group (n = 71) or the control (saline) group (n = 34). Every patient received standard of care (SOC) and was followed for 28 days. The study drug (normal saline or centhaquine 0.01 mg/kg) was administered in 100 mL of normal saline infusion over 1 h. The primary objectives were to determine changes (mean through 48 h) in SBP, diastolic blood pressure (DBP), blood lactate levels, and base deficit. The secondary objectives included the amount of fluids, blood products, and vasopressors administered in the first 48 h, duration of hospital stay, time in intensive care units, time on ventilator support, change in acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), and the proportion of patients with 28-day all-cause mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The demographics of patients and baseline vitals in both groups were comparable. The cause of hypovolemic shock was trauma in 29.4 and 47.1% of control group and centhaquine group patients, respectively, and gastroenteritis in 44.1 and 29.4%, respectively. Shock index (SI) and quick sequential organ failure assessment at baseline were similar in the two groups. An equal amount of fluids and blood products were administered in both groups during the first 48 h of resuscitation. A lesser amount of vasopressors was needed in the first 48 h of resuscitation in the centhaquine group. An increase in SBP from baseline was consistently higher up to 48 h (12.9% increase in area under the curve from 0 to 48 h [AUC<sub>0-48</sub>]) in the centhaquine group than in the control group. A significant increase in pulse pressure (48.1% increase in AUC<sub>0-48</sub>) in the centhaquine group compared with the control group suggests improved stroke volume due to centhaquine. The SI was significantly lower in the centhaquine group from 1 h (p&#x2009;=&#x2009;0.032) to 4 h (p&#x2009;=&#x2009;0.049) of resuscitation. Resuscitation with centhaquine resulted in a significantly greater number of patients with improved blood lactate (control 46.9%; centhaquine 69.3%; p&#x2009;=&#x2009;0.03) and the base deficit (control 43.7%; centhaquine 69.8%; p&#x2009;=&#x2009;0.01) than in the control group. ARDS and MODS improved with centhaquine, and an 8.8% absolute reduction in 28-day all-cause mortality was observed in the centhaquine group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Centhaquine is an efficacious resuscitative agent for treating hypovolemic shock. The efficacy of centhaquine in distributive shock is being explored.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinical Trials Registry, India; ctri.icmr.org.in, CTRI/2019/01/017196; clinicaltrials.gov, NCT04045327.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gulati</LastName><ForeName>Anil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7420-4554</Identifier><AffiliationInfo><Affiliation>Pharmazz, Inc., 50 West 75th Street, Suite 105, Willowbrook, IL, 60527, USA. anil.gulati@pharmazz.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhuri</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Postgraduate Medical Education and Research/SSKM Hospital, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chiranjeev Medical Centre, Jhansi, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>S K Noushad</ForeName><Initials>SKN</Initials><AffiliationInfo><Affiliation>ACSR Government Medical College and Hospital, Nellore, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidhu</LastName><ForeName>Gursaran Kaur</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Sidhu Hospital Pvt. Ltd., Ludhiana, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Parvez David</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Christian Medical College and Hospital, Ludhiana, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahate</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Seven Star Hospital, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bothra</LastName><ForeName>Aditya R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Rahate Surgical Hospital and ICU, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Gyan P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>King George's Medical University, Lucknow, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maheshwari</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jawahar Lal Nehru Medical College and Attached Hospital, Ajmer, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeswani</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Criticare Hospital and Research Institute, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haveri</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>KLE's Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Apurva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GSVM Medical College, Uttar Pradesh, Kanpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Nilesh Radheshyam</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>New Era Hospital, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04045327</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058647">Adrenergic alpha-2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>57961-90-7</RegistryNumber><NameOfSubstance UI="C045913">centhaquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 May 09:2020.07.30.20068114. doi: 10.1101/2020.07.30.20068114.</RefSource><PMID Version="1">33173916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D058647" MajorTopicYN="N">Adrenergic alpha-2 Receptor Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Anil Gulati has issued and pending patents and is an employee and stockholder of Pharmazz, Inc. Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S.K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R. Bothra, Gyan P. Singh, Sanjiv Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, and Nilesh Radheshyam Agrawal have no conflicts of interest that are directly relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34061314</ArticleId><ArticleId IdType="pmc">PMC8167383</ArticleId><ArticleId IdType="doi">10.1007/s40265-021-01547-5</ArticleId><ArticleId IdType="pii">10.1007/s40265-021-01547-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gulati A. Vascular endothelium and hypovolemic shock. Curr Vasc Pharmacol. 2016;14(2):187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">26638794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi L, Costantini TW, Coimbra R. Hypovolemic shock resuscitation. Surg Clin North Am. 2012;92(6):1403&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23153876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JW. Hemorrhagic shock. N Engl J Med. 2018;378(4):370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman EJ, Richmond TS, Wiebe DJ, Jacoby SF, Holena DN. Patient experiences of trauma resuscitation. JAMA Surg. 2017;152(9):843&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710455</ArticleId><ArticleId IdType="pubmed">28564706</ArticleId></ArticleIdList></Reference><Reference><Citation>Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;2:CD000567.</Citation><ArticleIdList><ArticleId IdType="pubmed">23450531</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgoff PE, Nikolian VC, Higgins G, Chtraklin K, Eidy H, Ghandour MH, et al. Valproic acid induces prosurvival transcriptomic changes in swine subjected to traumatic injury and hemorrhagic shock. J Trauma Acute Care Surg. 2018;84(4):642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">29251706</ArticleId></ArticleIdList></Reference><Reference><Citation>Causey MW, Miller S, Hoffer Z, Hempel J, Stallings JD, Jin G, et al. Beneficial effects of histone deacetylase inhibition with severe hemorrhage and ischemia-reperfusion injury. J Surg Res. 2013;184(1):533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">23683808</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Dai X, Zhu D, Xu X, Gao C, Wu C. An exogenous hydrogen sulphide donor, NaHS, inhibits the apoptosis signaling pathway to exert cardio-protective effects in a rat hemorrhagic shock model. Int J Clin Exp Pathol. 2015;8(6):6245&#x2013;6254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525835</ArticleId><ArticleId IdType="pubmed">26261501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganster F, Burban M, de la Bourdonnaye M, Fizanne L, Douay O, Loufrani L, et al. Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care. 2010;14(5):R165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219260</ArticleId><ArticleId IdType="pubmed">20836847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wepler M, Merz T, Wachter U, Vogt J, Calzia E, Scheuerle A, et al. The mitochondria-targeted H2S-donor AP39 in a Murine model of combined hemorrhagic shock and blunt chest trauma. Shock. 2019;52(2):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">29927788</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakral S, Wolf A, Beilman GJ, Suryanarayanan R. Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock. Int J Pharm. 2018;537(1&#x2013;2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">29274369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Lusczek ER, Beilman GJ. Hibernation-based approaches in the treatment of hemorrhagic shock. Shock. 2018;50(1):14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29283978</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP. Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats. Shock. 1998;9(1):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP, Sharma AC, Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat. Am J Physiol. 1997;273(2 Pt 2):H827&#x2013;H836.</Citation><ArticleIdList><ArticleId IdType="pubmed">9277500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282(19):1857&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg MD, Philbin NB, Gao W, Group DCTHSS, European HI Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010;68(5):1158&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">20145575</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AT, Lucas A, Muller CR, Munoz C, Bolden-Rush C, Palmer AF, et al. Resuscitation from hemorrhagic shock with fresh and stored blood and polymerized hemoglobin. Shock. 2020;54:464&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442586</ArticleId><ArticleId IdType="pubmed">32097242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould SA, Moore EE, Moore FA, Haenel JB, Burch JM, Sehgal H, et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma. 1997;43(2):325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291380</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Privalle CT, Singer M, Lorente JA, Boehm E, Meier-Hellmann A, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX) Crit Care Med. 2015;43(1):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25083980</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy JH, Goodnough LT, Greilich PE, Parr GV, Stewart RW, Gratz I, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002;124(1):35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091806</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EE, Moore FA, Fabian TC, Bernard AC, Fulda GJ, Hoyt DB, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg. 2009;208(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19228496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Barve A, Sen AP. Pharmacology of hemoglobin therapeutics. J Lab Clin Med. 1999;133(2):112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989762</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des. 2005;11(31):4099&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16378514</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nederpelt CJ, El Hechi MW, Kongkaewpaisan N, Kokoroskos N, Mendoza AE, Saillant NN, et al. Fresh frozen plasma-to-packed red blood cell ratio and mortality in traumatic hemorrhage: nationwide analysis of 4,427 patients. J Am Coll Surg. 2020;230(6):893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">31759164</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel C, Arrich J, Losert H, Gamper G, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2011;5:CD003709.</Citation><ArticleIdList><ArticleId IdType="pubmed">21563137</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hesayen A, Parker JD. The effects of dobutamine on renal sympathetic activity in human heart failure. J Cardiovasc Pharmacol. 2008;51(5):434&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">18398381</ArticleId></ArticleIdList></Reference><Reference><Citation>Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med. 2000;28(4):947&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Abe T, Saitoh D, Hagiwara S, Oshima K. Use of vasopressor increases the risk of mortality in traumatic hemorrhagic shock: a nationwide cohort study in Japan. Crit Care Med. 2018;46(12):e1145&#x2013;e1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">30199392</ArticleId></ArticleIdList></Reference><Reference><Citation>Santry HP, Alam HB. Fluid resuscitation: past, present, and the future. Shock. 2010;33(3):229&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4988844</ArticleId><ArticleId IdType="pubmed">20160609</ArticleId></ArticleIdList></Reference><Reference><Citation>Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996;273(5276):803&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">8670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszkat M, Kurnik D, Solus J, Sofowora GG, Xie HG, Jiang L, et al. Variation in the alpha2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genom. 2005;15(6):407&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">15900214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. Resuscitative effect of centhaquine (Lyfaquin&#xae;) in hypovolemic shock patients: a randomized, multicentric, controlled trial. Adv Ther. 2021 doi: 10.1007/s12325-021-01760-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01760-4</ArticleId><ArticleId IdType="pmc">PMC8189997</ArticleId><ArticleId IdType="pubmed">33970455</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias A, Koutsovasilis A, Laou E, Papalois A, Xanthos T. Measurement of mean systemic filling pressure after severe hemorrhagic shock in swine anesthetized with propofol-based total intravenous anesthesia: implications for vasopressor-free resuscitation. Acute Crit Care. 2020;35(2):93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280792</ArticleId><ArticleId IdType="pubmed">32506874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Hussain G, Srimal RC. Effect of repeated administration of centhaquin, a centrally acting hypotensive drug, on adrenergic, cholinergic (Muscarinic), dopaminergic, and serotonergic receptors in brain-regions of rat. Drug Dev Res. 1991;23(4):307&#x2013;323.</Citation></Reference><Reference><Citation>Gulati A, Lavhale MS, Garcia DJ, Havalad S. Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. J Surg Res. 2012;178(1):415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">22487389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Zhang Z, Murphy A, Lavhale MS. Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med. 2013;31(9):1315&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23871440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavhale MS, Havalad S, Gulati A. Resuscitative effect of centhaquin after hemorrhagic shock in rats. J Surg Res. 2013;179(1):115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22964270</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapanagiotou P, Xanthos T, Gulati A, Chalkias A, Papalois A, Kontouli Z, et al. Centhaquin improves survival in a swine model of hemorrhagic shock. J Surg Res. 2016;200(1):227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontouli Z, Staikou C, Iacovidou N, Mamais I, Kouskouni E, Papalois A, et al. Resuscitation with centhaquin and 6% hydroxyethyl starch 130/0.4 improves survival in a swine model of hemorrhagic shock: a randomized experimental study. Eur J Trauma Emerg Surg. 2019;45(6):1077&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">30006694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Lavhale M, Giri R, Andurkar S, Xanthos T. Centhaquine citrate. Alpha2B-adrenoceptor ligand, resuscitative agent for hypovolemic shock. Drugs Fut. 2020;45(3):153&#x2013;163.</Citation></Reference><Reference><Citation>Birkhahn RH, Gaeta TJ, Terry D, Bove JJ, Tloczkowski J. Shock index in diagnosing early acute hypovolemia. Am J Emerg Med. 2005;23(3):323&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15915406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rady MY, Rivers EP, Martin GB, Smithline H, Appelton T, Nowak RM. Continuous central venous oximetry and shock index in the emergency department: use in the evaluation of clinical shock. Am J Emerg Med. 1992;10(6):538&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">1388378</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YS, Chiu IM, Tsai MT, Lin CF, Lin CF. Delta shock index during emergency department stay is associated with in hospital mortality in critically ill patients. Front Med (Lausanne). 2021;8:648375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8100221</ArticleId><ArticleId IdType="pubmed">33968957</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulden R, Hoyle MC, Monis J, Railton D, Riley V, Martin P, et al. qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. Emerg Med J. 2018;35(6):345&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">29467173</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315(8):762&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138(3):720&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">3202424</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan NR, Eckert M, Martin MJ. Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities. JAMA Surg. 2014;149(9):904&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029432</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob M, Sahu S, Singh YP, Mehta Y, Yang KY, Kuo SW, et al. A prospective observational study of rational fluid therapy in Asian intensive care units: another puzzle piece in fluid therapy. Indian J Crit Care Med. 2020;24(11):1028&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751049</ArticleId><ArticleId IdType="pubmed">33384507</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin DA, Bakker J. Understanding venous return. Intensive Care Med. 2014;40(10):1564&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JR, Maas JJ, Pinsky MR. Bedside assessment of mean systemic filling pressure. Curr Opin Crit Care. 2010;16(3):231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">20168223</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Baker K. Venous return and clinical hemodynamics: how the body works during acute hemorrhage. Adv Physiol Educ. 2015;39(4):267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">26628647</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Menyar A, Goyal P, Tilley E, Latifi R. The clinical utility of shock index to predict the need for blood transfusion and outcomes in trauma. J Surg Res. 2018;227:52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">29804862</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenco CW, Lammers DT, Morte KR, Bingham JR, Martin MJ, Eckert MJ. Shock index as a predictor of massive transfusion and emergent surgery on the modern battlefield. J Surg Res. 2020;16(256):112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">32683051</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyette F, Suffoletto B, Castillo JL, Quintero J, Callaway C, Puyana JC. Prehospital serum lactate as a predictor of outcomes in trauma patients: a retrospective observational study. J Trauma. 2011;70(4):782&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">21610386</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Peng M, Liao C, Hu X, Wang A, Li X. Relative efficacy and safety of early lactate clearance-guided therapy resuscitation in patients with sepsis: a meta-analysis. Medicine (Baltimore) 2019;98(8):e14453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408023</ArticleId><ArticleId IdType="pubmed">30813144</ArticleId></ArticleIdList></Reference><Reference><Citation>Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-DeRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res. 2016;202(1):182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">27083965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditzel RM, Jr, Anderson JL, Eisenhart WJ, Rankin CJ, DeFeo DR, Oak S, et al. A review of transfusion- and trauma-induced hypocalcemia: Is it time to change the lethal triad to the lethal diamond? J Trauma Acute Care Surg. 2020;88(3):434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">31876689</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz CA, Pereira AJ, Celis E, Vincent JL. Which multicenter randomized controlled trials in critical care medicine have shown reduced mortality? A systematic review. Crit Care Med. 2019;47(12):1680&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">31567349</ArticleId></ArticleIdList></Reference><Reference><Citation>Divatia JV, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S, et al. Intensive care in India: the Indian intensive care case mix and practice patterns study. Indian J Crit Care Med. 2016;20(4):216&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859158</ArticleId><ArticleId IdType="pubmed">27186054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandarkar P, Patil P, Soni KD, O'Reilly GM, Dharap S, Mathew J, et al. An analysis of 30-day in-hospital trauma mortality in four urban university hospitals using the Australia india trauma registry. World J Surg. 2021;45(2):380&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773616</ArticleId><ArticleId IdType="pubmed">33084947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Wu M, Lu X, Zhong Y, Kang X, Song Y, et al. Is restrictive fluid resuscitation beneficial not only for hemorrhagic shock but also for septic shock?: a meta-analysis. Medicine (Baltimore) 2021;100(12):e25143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282070</ArticleId><ArticleId IdType="pubmed">33761680</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignon P, Laterre PF, Daix T, Francois B. New agents in development for sepsis: any reason for hope? Drugs. 2020;80(17):1751&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7502152</ArticleId><ArticleId IdType="pubmed">32951149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkwarf KJ, Cotton BA. Resuscitation for hypovolemic shock. Surg Clin N Am. 2017;97(6):1307&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">29132511</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SK, Choupoo NS, Ray S. Reducing vasopressor exposure in patients with vasodilatory hypotension. JAMA. 2020;324(9):897&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">32870290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">37210541</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Biomarker-based risk model to predict persistent multiple organ dysfunctions after congenital heart surgery: a prospective observational cohort study.</ArticleTitle><Pagination><StartPage>193</StartPage><MedlinePgn>193</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">193</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-023-04494-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Multiple organ dysfunction syndrome (MODS) is an important cause of post-operative morbidity and mortality for children undergoing cardiac surgery requiring cardiopulmonary bypass (CPB). Dysregulated inflammation is widely regarded as a key contributor to bypass-related MODS pathobiology, with considerable overlap of pathways associated with septic shock. The pediatric sepsis biomarker risk model (PERSEVERE) is comprised of seven protein biomarkers of inflammation and reliably predicts baseline risk of mortality and organ dysfunction among critically ill children with septic shock. We aimed to determine if PERSEVERE biomarkers and clinical data could be combined to derive a new model to assess the risk of persistent CPB-related MODS in the early post-operative period.</AbstractText><AbstractText Label="METHODS">This study included 306 patients&#x2009;&lt;&#x2009;18&#xa0;years old admitted to a pediatric cardiac ICU after surgery requiring cardiopulmonary bypass (CPB) for congenital heart disease. Persistent MODS, defined as dysfunction of two or more organ systems on postoperative day 5, was the primary outcome. PERSEVERE biomarkers were collected 4 and 12&#xa0;h after CPB. Classification and regression tree methodology were used to derive a model to assess the risk of persistent MODS.</AbstractText><AbstractText Label="RESULTS">The optimal model containing interleukin-8 (IL-8), chemokine ligand 3 (CCL3), and age as predictor variables had an area under the receiver operating characteristic curve (AUROC) of 0.86 (0.81-0.91) for differentiating those with or without persistent MODS and a negative predictive value of 99% (95-100). Ten-fold cross-validation of the model yielded a corrected AUROC of 0.75 (0.68-0.84).</AbstractText><AbstractText Label="CONCLUSIONS">We present a novel risk prediction model to assess the risk for development of multiple organ dysfunction after pediatric cardiac surgery requiring CPB. Pending prospective validation, our model may facilitate identification of a high-risk cohort to direct interventions and studies aimed at improving outcomes via mitigation of post-operative organ dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benscoter</LastName><ForeName>Alexis L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA. alexis.benscoter@cchmc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alten</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atreya</LastName><ForeName>Mihir R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrnes</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollberding</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Hector R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35GM126943</GrantID><Agency>National Institution of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2023 Jan 27:rs.3.rs-2488327. doi: 10.21203/rs.3.rs-2488327/v1.</RefSource><PMID Version="1">36747744</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="Y">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006330" MajorTopicYN="Y">Heart Defects, Congenital</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction</Keyword><Keyword MajorTopicYN="N">Pediatric cardiac critical care</Keyword><Keyword MajorTopicYN="N">Risk stratification</Keyword></KeywordList><CoiStatement>During the time of this study and manuscript preparation, H.R.W. and the Cincinnati Children&#x2019;s Hospital Research Foundation hold US patents for the PERSEVERE biomarkers.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>21</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>20</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37210541</ArticleId><ArticleId IdType="pmc">PMC10199562</ArticleId><ArticleId IdType="doi">10.1186/s13054-023-04494-7</ArticleId><ArticleId IdType="pii">10.1186/s13054-023-04494-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1&#x2014;mechanisms of pathogenesis. J Card Vasc Anesth. 2009;23:223&#x2013;231. doi: 10.1053/j.jvca.2008.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2008.08.007</ArticleId><ArticleId IdType="pubmed">18930659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybdahl B, Wahba A, Lien E, et al. The inflammatory response after open heart surgery release of heat-shock protein 70 and signaling through toll-like receptor 4. Circ. 2002;105:685&#x2013;690. doi: 10.1161/hc0602.103617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc0602.103617</ArticleId><ArticleId IdType="pubmed">11839622</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Visvanathan K, et al. Cardiopulmonary bypass elicits a prominent innate immune response in children with congenital heart disease. J Thorac Cardiovasc Surg. 2004;127:1523&#x2013;1525. doi: 10.1016/j.jtcvs.2003.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.11.027</ArticleId><ArticleId IdType="pubmed">15116021</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Horton SB, et al. The influence of bypass temperature on the systemic inflammatory response and organ injury after pediatric open surgery: a randomized trial. J Thorac Cardiovasc Surg. 2011;142:174&#x2013;180. doi: 10.1016/j.jtcvs.2011.01.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2011.01.059</ArticleId><ArticleId IdType="pubmed">21420106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahle WT, Matthews E, Kanter KR, et al. Inflammatory response after neonatal cardiac surgery and its relationship to clinical outcomes. Ann Thorac Surg. 2014;97:950&#x2013;956. doi: 10.1016/j.athoracsur.2013.10.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.10.069</ArticleId><ArticleId IdType="pubmed">24424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan CK, Newburger JW, McGrath E, et al. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010;111:1244&#x2013;1251. doi: 10.1213/ANE.0b013e3181f333aa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e3181f333aa</ArticleId><ArticleId IdType="pubmed">20829561</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC. The clinical implications of the systemic inflammatory reaction related to cardiac operations in children. Cardiol Young. 2003;13:228&#x2013;239. doi: 10.1017/S1047951103000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1047951103000465</ArticleId><ArticleId IdType="pubmed">12903869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubicki R, Grohmann J, Siepe M, et al. Early prediction of capillary leak syndrome in infants after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2013;44:275&#x2013;281. doi: 10.1093/ejcts/ezt028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezt028</ArticleId><ArticleId IdType="pubmed">23389476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Jeffries HE, Zimmerman JJ, et al. Sepsis in the pediatric cardiac intensive care unit. World J Pediatr Congenit Heart Surg. 2011;2:393&#x2013;39912. doi: 10.1177/2150135111403781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2150135111403781</ArticleId><ArticleId IdType="pmc">PMC3277844</ArticleId><ArticleId IdType="pubmed">22337571</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartmann ME, et al. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017;18(3):S4&#x2013;S16. doi: 10.1097/PCC.0000000000001047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001047</ArticleId><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Lacroix JR. Monitoring severity of multiple organ dysfunction syndrome: new and progressive multiple organ dysfunction syndrome, scoring systems. Pediatr Crit Care Med. 2017;18(3):S17&#x2013;S23. doi: 10.1097/PCC.0000000000001049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001049</ArticleId><ArticleId IdType="pubmed">28248830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich N, Allen GL, et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med. 2009;37:1558&#x2013;1566. doi: 10.1097/CCM.0b013e31819fcc08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819fcc08</ArticleId><ArticleId IdType="pmc">PMC2747356</ArticleId><ArticleId IdType="pubmed">19325468</ArticleId></ArticleIdList></Reference><Reference><Citation>Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9:71&#x2013;79. doi: 10.1586/eri.10.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.10.154</ArticleId><ArticleId IdType="pmc">PMC3033193</ArticleId><ArticleId IdType="pubmed">21171879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12:165&#x2013;173. doi: 10.1097/PCC.0b013e3181e28876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181e28876</ArticleId><ArticleId IdType="pmc">PMC2924462</ArticleId><ArticleId IdType="pubmed">20473243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Salsibury S, Xiao Q, et al. The pediatric sepsis biomarker risk model. Crit Care. 2012;16:R147&#x2013;R183. doi: 10.1186/cc11652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11652</ArticleId><ArticleId IdType="pmc">PMC3682273</ArticleId><ArticleId IdType="pubmed">23025259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Caldwell JT, Cvijanovich NZ, et al. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model. Sci Transl Med. 2019;11(518):eaax9000. doi: 10.1126/scitranslmed.aax9000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax9000</ArticleId><ArticleId IdType="pmc">PMC7720682</ArticleId><ArticleId IdType="pubmed">31723040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Genetics and genomics in pediatric septic shock. Crit Care Med. 2012;40:1618&#x2013;1626. doi: 10.1097/CCM.0b013e318246b546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318246b546</ArticleId><ArticleId IdType="pmc">PMC3329642</ArticleId><ArticleId IdType="pubmed">22511139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Weiss SL, Giuliano JS, Jr, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS ONE. 2014;9:e86242. doi: 10.1371/journal.pone.0086242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086242</ArticleId><ArticleId IdType="pmc">PMC3906040</ArticleId><ArticleId IdType="pubmed">24489704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. AJRCCM. 2014 doi: 10.1164/rccm.201410-1864OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201410-1864OC</ArticleId><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Lindsell CJ, Pettila V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med. 2014;42:781&#x2013;789. doi: 10.1097/CCM.0000000000000106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000106</ArticleId><ArticleId IdType="pmc">PMC4620515</ArticleId><ArticleId IdType="pubmed">24335447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Sawa Y, Fukuyama N, et al. Preoperative glutamine administration induces heat-shock protein 70 expression and attenuates cardiopulmonary bypass-induced inflammatory response by regulating nitric oxide synthase activity. Circulation. 2002;106(20):260&#x2013;267. doi: 10.1161/01.CIR.0000035651.72240.07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000035651.72240.07</ArticleId><ArticleId IdType="pubmed">12427658</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Warszawska JM, Schenk P, et al. Intraoperative ventilation strategy during cardiopulmonary bypass attenuates the release of matrix metalloproteinases and improves oxygenation. J Surg Res. 2015;195(1):294&#x2013;302. doi: 10.1016/j.jss.2014.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2014.12.022</ArticleId><ArticleId IdType="pubmed">25577145</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Szerafin T, Mitterbauer A, et al. Low tidal volume ventilation during cardiopulmonary bypass reduces postoperative chemokine serum concentrations. Thorac Cardiovasc Surg. 2014;62(8):677&#x2013;682. doi: 10.1055/s-0034-1387824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1387824</ArticleId><ArticleId IdType="pubmed">25226360</ArticleId></ArticleIdList></Reference><Reference><Citation>Khabar KSA, ElBarbary MA, Khouqeer F, et al. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clin Immunol Immunopathol. 1997;85(1):97&#x2013;103. doi: 10.1006/clin.1997.4413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1997.4413</ArticleId><ArticleId IdType="pubmed">9325075</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhok AB, Ojamaa K, Haridas V, et al. Cytokine response in children undergoing surgery for congenital heart disease. Pediatr Cardiol. 2006;27:408&#x2013;413. doi: 10.1007/s00246-006-0934-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-006-0934-y</ArticleId><ArticleId IdType="pubmed">16830075</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona F, Manso PH, Vincente WVA, et al. Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine. 2008;42(3):317&#x2013;324. doi: 10.1016/j.cyto.2008.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.03.005</ArticleId><ArticleId IdType="pubmed">18417355</ArticleId></ArticleIdList></Reference><Reference><Citation>deFontnouvelle CA, Greenberg JH, Thiessen-Philbrook HR, et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury after pediatric surgery. Ann Thorac Surg. 2017;104:2072&#x2013;2079. doi: 10.1016/j.athoracsur.2017.04.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.04.038</ArticleId><ArticleId IdType="pmc">PMC5696070</ArticleId><ArticleId IdType="pubmed">28821332</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien SM, Clarke DR, Jacobs JP, et al. An empirically based tool for analyzing mortality associated with congenital heart disease. J Thorac Cardiovasc Surg. 2009;138(5):1139&#x2013;1153. doi: 10.1016/j.jtcvs.2009.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.03.071</ArticleId><ArticleId IdType="pubmed">19837218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JP, O'Brien SM, Pasquali SK, et al. Variation in outcomes for risk-stratified pediatric cardiac surgical operations: as analysis of the STS Congenital Heart Surgery Database. Ann Thorac Surg. 2012;94(2):564&#x2013;571. doi: 10.1016/j.athoracsur.2012.01.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.01.105</ArticleId><ArticleId IdType="pmc">PMC4006082</ArticleId><ArticleId IdType="pubmed">22704799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM. Intensive Care Med. 2002;28:204&#x2013;207. doi: 10.1007/s00134-001-1185-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-001-1185-2</ArticleId><ArticleId IdType="pubmed">11907665</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2&#x2013;8. doi: 10.1097/01.PCC.0000149131.72248.E6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell RA, Ghanayem NS, Kuhn EM, et al. Relationship between risk-adjustment tools and the pediatric logistic organ dysfunction score. World J Pediatr Congenit Heart Surg. 2014;15:16&#x2013;21. doi: 10.1177/2150135113510008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2150135113510008</ArticleId><ArticleId IdType="pubmed">24403350</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, et al. PELOD-2: an update of the Pediatric logistic organ dysfunction score. Crit Care Med. 2013;41:1761&#x2013;1773. doi: 10.1097/CCM.0b013e31828a2bbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Umsted TM, Lu CK, Freeman WM, et al. The kinetics of cardiopulmonary bypass: a dual-platform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Artif Organs. 2012;36(1):E1&#x2013;E20. doi: 10.1111/j.1525-1594.2011.01412.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2011.01412.x</ArticleId><ArticleId IdType="pubmed">22250822</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller R, Mockel M. Logistic regression and CART in the analysis of multimarker studies. Clin Chim Acta. 2008;394:1&#x2013;6. doi: 10.1016/j.cca.2008.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2008.04.007</ArticleId><ArticleId IdType="pubmed">18455512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout D, Pagel C, et al. Incidence and risk factors for important early morbidities associated with pediatric cardiac surgery in a UK population. J Thorac Cardiovasc Surg. 2019;158(4):1185&#x2013;1196.e736. doi: 10.1016/j.jtcvs.2019.03.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2019.03.139</ArticleId><ArticleId IdType="pubmed">31353100</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med. 2003;31:28&#x2013;33. doi: 10.1097/00003246-200301000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200301000-00004</ArticleId><ArticleId IdType="pubmed">12544989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11(2):234&#x2013;238. doi: 10.1097/PCC.0b013e3181b806fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b806fc</ArticleId><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Jeffries HE, Niebler RA, et al. Vasoactive-inotropic score is associated with outcome after infant cardiact surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System registries. Pediatr Crit Care Med. 2014;15(6):529&#x2013;537. doi: 10.1097/PCC.0000000000000153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000153</ArticleId><ArticleId IdType="pmc">PMC4159673</ArticleId><ArticleId IdType="pubmed">24777300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessler P, Pfenninger J, Pfammatter JP, et al. Plasma levels of interleukin-8 and expression of interleukin-8 receptors on circulating neutrophils and monocytes after cardiopulmonary bypass in children. J Thorac Cardiovasc Surg. 2003;126(3):718&#x2013;725. doi: 10.1016/S0022-5223(03)00685-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(03)00685-8</ArticleId><ArticleId IdType="pubmed">14502144</ArticleId></ArticleIdList></Reference><Reference><Citation>Drennan SE, Burge KY, Szyld EG, et al. Clinical and laboratory predictors for the development of low cardiac output syndrome in infants undergoing cardiopulmonary bypass: a pilot study. J Clin Med. 2021;10(4):712. doi: 10.3390/jcm10040712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10040712</ArticleId><ArticleId IdType="pmc">PMC7916966</ArticleId><ArticleId IdType="pubmed">33670210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorjipour F, Totonchi Z, Dehaki MG, et al. Serum levels of interleukin-6, interleukin-8, interleukin-10 and tumor necrosis factor-&#x3b1;, renal function biochemical parameters and clinical outcomes in pediatric cardiopulmonary bypass surgery. Perfusion. 2019;34(8):651&#x2013;659. doi: 10.1177/0267659119842470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659119842470</ArticleId><ArticleId IdType="pubmed">31027462</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KD, Altmann C, Smits G, et al. Serum interleukin-6 and interleukin-8 are early predictors of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care. 2009;13(4):R104. doi: 10.1186/cc7940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7940</ArticleId><ArticleId IdType="pmc">PMC2750143</ArticleId><ArticleId IdType="pubmed">19570208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenburger M, Tjan TDT, Schneider M, et al. The impact of the pro- and anti-inflammatory immune response on ventilation time after cardiac surgery. Cytometry B Clin Cytom. 2003;53(1):70&#x2013;74. doi: 10.1002/cyto.b.10027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.b.10027</ArticleId><ArticleId IdType="pubmed">12717694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavasar I, Miller CS, Al-Sabbagh M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. Gen Methods Biomark Res Appl 2015;223&#x2013;249.</Citation></Reference><Reference><Citation>Wolpe SD, Davatelis G, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1988;167(2):570&#x2013;581. doi: 10.1084/jem.167.2.570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.167.2.570</ArticleId><ArticleId IdType="pmc">PMC2188834</ArticleId><ArticleId IdType="pubmed">3279154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Lindsell CJ, et al. PERSEVERE II: Redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med. 2016;44(11):2010&#x2013;2017. doi: 10.1097/CCM.0000000000001852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001852</ArticleId><ArticleId IdType="pmc">PMC5201138</ArticleId><ArticleId IdType="pubmed">27513537</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata H, Murakami A, Tomotaki A, et al. Predictors of 90-day mortality after congenital heart surgery: the first report of risk models from a Japanese database. J Thorac Cardiovasc Surg. 2014;148:2201&#x2013;2206. doi: 10.1016/j.jtcvs.2013.01.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2013.01.053</ArticleId><ArticleId IdType="pubmed">25444193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill KD, Kannankeril PJ, Jacobs JP, et al., for the STRESS Network Investigators. Methylprednisolone for heart surgery in infants&#x2014;a randomized, controlled trial. N Engl J Med. 2022;387:2138&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843240</ArticleId><ArticleId IdType="pubmed">36342116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasser WC, Dabal RJ, Askenazi DJ, et al. Prophylactic peritoneal dialysis following cardiopulmonary bypass in children is associated with decreased inflammation and improved clinical outcomes. Congenit Heart Dis. 2014;9(2):106&#x2013;115. doi: 10.1111/chd.12072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/chd.12072</ArticleId><ArticleId IdType="pubmed">23647999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20308882</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Impact of selective decontamination of the digestive tract on multiple organ dysfunction syndrome: systematic review of randomized controlled trials.</ArticleTitle><Pagination><StartPage>1370</StartPage><EndPage>1376</EndPage><MedlinePgn>1370-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e3181d9db8c</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We examined the impact of selective decontamination of the digestive tract on multiple organ dysfunction syndrome.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">We searched MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, previous meta-analyses, and meetings proceedings.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">We included all randomized trials comparing both oropharyngeal and intestinal administration of antibiotics in selective decontamination of the digestive tract with or without a parenteral component, with placebo or standard therapy used in the controls.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Two reviewers independently applied selection criteria, performed quality assessment, and extracted the data. The primary end point was the number of patients with multiple organ dysfunction syndrome developing during intensive care unit stay. Secondary end points were overall mortality and multiple organ dysfunction syndrome-related mortality. Odds ratios were pooled with the random effect model.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">We identified seven randomized trials including 1270 patients. Multiple organ dysfunction syndrome was found in 132 of 637 patients (20.7%) in the selective decontamination of the digestive tract group and in 219 of 633 patients (34.6%) in the control group (odds ratio, 0.50; 95% confidence interval, 0.34-0.74; p &lt; .001). Overall mortality for selective decontamination of the digestive tract vs. control patients was 119 of 637 (18.7%) and 145 of 633 (22.9%), respectively, demonstrating a nonsignificant reduction in the odds of death (odds ratio, 0.82; 95% confidence interval, 0.51-1.32; p = .41). In five studies including 472 patients, multiple organ dysfunction syndrome-related mortality was demonstrated in 31 of 239 (13%) patients in selective decontamination of the digestive tract group and 37 of 233 (15.9%) in the controls (odds ratio, 0.84; 95% confidence interval, 0.48-1.41; p = .54).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Selective decontamination of the digestive tract reduces the number of patients with multiple organ dysfunction syndrome. Mortality was not significantly reduced, probably because of the small sample size.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silvestri</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Emergency, Unit of Anesthesia and Intensive Care, Presidio Ospedaliero, Gorizia, Italy. lucianosilvestri@yahoo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Saene</LastName><ForeName>Hendrick K F</ForeName><Initials>HK</Initials></Author><Author ValidYN="Y"><LastName>Zandstra</LastName><ForeName>Durk F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Gregori</LastName><ForeName>Dario</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gullo</LastName><ForeName>Antonino</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2010 May;38(5):1386-7. doi: 10.1097/CCM.0b013e3181da47d1.</RefSource><PMID Version="1">20404637</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006088" MajorTopicYN="N">Gram-Negative Aerobic Bacteria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20308882</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3181d9db8c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39381578</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2287-1683</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of trauma and injury</Title><ISOAbbreviation>J Trauma Inj</ISOAbbreviation></Journal><ArticleTitle>Traumatic degloving injuries: a prospective study to assess injury patterns, management, and outcomes at a single center in northern India.</ArticleTitle><Pagination><StartPage>385</StartPage><EndPage>392</EndPage><MedlinePgn>385-392</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20408/jti.2023.0032</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">This study investigated the epidemiology, management, outcomes, and postoperative disabilities of degloving soft tissue injuries (DSTIs) treated at a tertiary care center in northern India.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A prospective study of patients with DSTIs was conducted over 15 months. The type of degloving injury, the mechanism of injury, and any associated injuries were analyzed using the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 along with the management, outcomes, and disabilities at a 3-month follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 75 patients with DSTIs, the average age was 27.5 years, 80.0% were male, and 76.0% had been injured in traffic accidents. The majority (93.3%) were open degloving injuries. Lower limbs were affected most often (62.7%), followed by upper limbs (32.0%). Fractures were the most commonly associated injuries (72.0%). Most patients required more than two procedures, including secondary debridement (41.3%), split skin grafting (80.0%), flap coverage (12.0%), or vacuum-assisted closure (24.0%), while five patients underwent conservative management for closed degloving injuries. Postoperative complications included surgical site infections (14.7%) and skin necrosis (10.7%). Two patients died due to septic shock and multiple organ dysfunction syndrome. The mean length of hospital stay was 11.5&#xb1;8.1 days, with injuries affecting the lower limbs and perineum requiring longer hospital stays. The mean WHODAS 2.0 disability score at 3 months was 19. Most patients had mild disabilities. Time away from work depended largely upon the site and severity of the injury. Approximately 75% of patients resumed their previous job or study, 14% changed their job, and 8% stopped working completely due to residual disability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">DSTIs are common injuries in trauma and management is challenging. Although open DSTI are clinically evident at secondary survey, closed degloving injuries may be missed in the primary survey, necessitating a high index of suspicion, thorough clinical examination, and protocol-based management. Primary preventive strategies (e.g., road safety protocols, preplacement training, and proper protective equipment in industries) are also needed to reduce the incidence of these injuries.</AbstractText><CopyrightInformation>&#xa9; 2023 The Korean Society of Traumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jayant</LastName><ForeName>Divij</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1839-228X</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parashar</LastName><ForeName>Atul</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1617-6732</Identifier><AffiliationInfo><Affiliation>Department of Plastic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6078-4714</Identifier><AffiliationInfo><Affiliation>Department of Plastic Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Trauma Inj</MedlineTA><NlmUniqueID>101647847</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Avulsion</Keyword><Keyword MajorTopicYN="N">Debridement</Keyword><Keyword MajorTopicYN="N">Degloving soft tissue injury</Keyword><Keyword MajorTopicYN="N">Disability</Keyword><Keyword MajorTopicYN="N">Wounds and injuries</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381578</ArticleId><ArticleId IdType="pmc">PMC11309239</ArticleId><ArticleId IdType="doi">10.20408/jti.2023.0032</ArticleId><ArticleId IdType="pii">jti-2023-0032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krishnamoorthy R, Karthikeyan G. Degloving injuries of the hand. Indian J Plast Surg. 2011;44:227&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193635</ArticleId><ArticleId IdType="pubmed">22022033</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou D, Kyriakidis A, Zaharopoulos A, Moskoklaidis S. Degloving injury: report of two cases and review of the literature. Eur J Trauma. 2005;31:593&#x2013;6.</Citation></Reference><Reference><Citation>Wojcicki P, Wojtkiewicz W, Drozdowski P. Severe lower extremities degloving injuries: medical problems and treatment results. Pol Przegl Chir. 2011;83:276&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22166481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Gao W, Li Z, et al. The management of degloving injury of lower extremities: technical refinement and classification. J Trauma Acute Care Surg. 2013;74:604&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">23354258</ArticleId></ArticleIdList></Reference><Reference><Citation>Latifi R, El-Hennawy H, El-Menyar A, et al. The therapeutic challenges of degloving soft-tissue injuries. J Emerg Trauma Shock. 2014;7:228&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126125</ArticleId><ArticleId IdType="pubmed">25114435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ustun TB, Kostanjsek N, Chatterji S, Rehm J, editors. Measuring health and disability: manual for WHO Disability Assessment Schedule (WHODAS 2.0). World Health Organization; 2010.</Citation></Reference><Reference><Citation>Khan M, Aziz A, Naz S, et al. Plastic surgical trauma: a single-centre experience. Indian J Plast Surg. 2012;45:538&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580356</ArticleId><ArticleId IdType="pubmed">23450198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim S, Ahmed K, El-Menyar A, et al. Patterns and management of degloving injuries: a single national level 1 trauma center experience. World J Emerg Surg. 2016;11:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962500</ArticleId><ArticleId IdType="pubmed">27468300</ArticleId></ArticleIdList></Reference><Reference><Citation>Milcheski DA, Ferreira MC, Nakamoto HA, Tuma P, Gemperli R. Degloving injuries of lower extremity: proposal of a treatment protocol. Rev Col Bras Cir. 2010;37:199&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">21079892</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnez ZM, Khan U, Tyler MP. Classification of soft-tissue degloving in limb trauma. J Plast Reconstr Aesthet Surg. 2010;63:1865&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20056504</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Gao W, Li Z, et al. The management of degloving injury of lower extremities: technical refinement and classification. J Trauma Acute Care Surg. 2013;74:604&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">23354258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarun G, Ramu M. Prevention of industrial accidents: measures and challenges. Int J Pure Appl Math. 2018;120:491&#x2013;8.</Citation></Reference><Reference><Citation>Mandel MA. The management of lower extremity degloving injuries. Ann Plast Surg. 1981;6:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7011158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomenstein RB. Viability prediction in pedicle flaps by infrared thermometry. Plast Reconstr Surg. 1968;42:252&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">4878462</ArticleId></ArticleIdList></Reference><Reference><Citation>Eccles S, Handley B, Khan U, McFadyen I, Nanchahal J, Nayagam S, editors. Standards for the management of open fractures. Oxford University Press; 2020.</Citation></Reference><Reference><Citation>Latifi R. The diagnostic and therapeutic challenges of degloving soft-tissue injuries. SOJ Surg. 2013;1:01.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126125</ArticleId><ArticleId IdType="pubmed">25114435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hak DJ, Olson SA, Matta JM. Diagnosis and management of closed internal degloving injuries associated with pelvic and acetabular fractures: the Morel-Lavall&#xe9;e lesion. J Trauma. 1997;42:1046&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9210539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai G, Suzuki T, Hishikawa T, Shirai Y, Kurozumi T, Shindo M. Primary reattachment of avulsed skin flaps with negative pressure wound therapy in degloving injuries of the lower extremity. Injury. 2017;48:137&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">27788928</ArticleId></ArticleIdList></Reference><Reference><Citation>Alet JM, Weigert R, Castede JC, Casoli V. Management of traumatic soft tissue defects with dermal regeneration template: a prospective study. Injury. 2014;45:1042&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24405974</ArticleId></ArticleIdList></Reference><Reference><Citation>Meara JG, Guo L, Smith JD, Pribaz JJ, Breuing KH, Orgill DP. Vacuum-assisted closure in the treatment of degloving injuries. Ann Plast Surg. 1999;42:589&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10382793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong LK, Nesbit RD, Turner LA, Sargent LA. Management of a circumferential lower extremity degloving injury with the use of vacuum-assisted closure. South Med J. 2006;99:628&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16800422</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini M, Quercioli F, Mori A, Romano GF, Lee AQ, Agostini T. Vacuum-assisted closure, dermal regeneration template and degloved cryopreserved skin as useful tools in subtotal degloving of the lower limb. Injury. 2012;43:957&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21492856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickerson TP, Zielinski MD, Jenkins DH, Schiller HJ. The Mayo Clinic experience with Morel-Lavall&#xe9;e lesions: establishment of a practice management guideline. J Trauma Acute Care Surg. 2014;76:493&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24458056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ustun TB, Kostanjsek N, Chatterji S, Rehm J, editors. Measuring health and disability: manual for WHO Disability Assessment Schedule (WHODAS 2.0) World Health Organization; 2010.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26274754</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1478-7083</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of the Royal College of Surgeons of England</Title><ISOAbbreviation>Ann R Coll Surg Engl</ISOAbbreviation></Journal><ArticleTitle>A prospective cohort study of risk prediction in simultaneous pancreas and kidney transplantation.</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>450</EndPage><MedlinePgn>445-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1308/rcsann.2015.0001</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Current risk prediction scoring systems in pancreas transplantation are limited to organ factors and are specific to predicting graft outcome. They do not consider recipient factors or inform regarding recipient morbidity. The aim of this study was to assess the utility of commonly used general surgical risk prediction models (P-POSSUM [Portsmouth Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity], MODS [multiple organ dysfunction score], Charlson co-morbidity index, revised cardiac risk index, ASA [American Society of Anesthesiologists] grade and Waterlow score), and to correlate them with total length of hospital stay (LOS) and critical care unit (CCU) LOS, important surrogate markers of patient outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All risk prediction scores were calculated prospectively for all simultaneous pancreas and kidney (SPK) transplant recipients from November 2011 to October 2013, and correlated with outcome measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 57 SPK transplant recipients were analysed. The mean age was 42.0 years (standard deviation [SD]: 7.60 years), 27 (52%) were male and the mean body mass index was 25.43kg/m(2) (SD: 3.11kg/m(2)). The mean pancreas and kidney cold ischaemic times were 703 minutes (SD: 182 minutes) and 850 minutes (SD: 192 minutes) respectively. The median total LOS and mean CCU LOS was 17 days (range: 8-79 days) and 7 days (SD: 4.04 days) respectively. When correlated with risk prediction scores, Waterlow score was the only significant predictor of total LOS and CCU LOS (p&lt;0.001 [Spearman's correlation] and p=0.001 [Pearson's correlation] respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preoperative risk prediction plays an important part in planning perioperative care. To date, no validated risk prediction scoring system exists for SPK transplantation. This prospective study indicates that Waterlow score identifies high risk individuals and has value in the prediction of outcome following SPK transplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khambalia</LastName><ForeName>H A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moinuddin</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Summers</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavakoli</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pararajasingam</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhanda</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forgacs</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dellen</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann R Coll Surg Engl</MedlineTA><NlmUniqueID>7506860</NlmUniqueID><ISSNLinking>0035-8843</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016035" MajorTopicYN="N">Pancreas Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Outcome assessment</Keyword><Keyword MajorTopicYN="N">Pancreas transplantation</Keyword><Keyword MajorTopicYN="N">Risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26274754</ArticleId><ArticleId IdType="pmc">PMC5126239</ArticleId><ArticleId IdType="doi">10.1308/rcsann.2015.0001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Charlson ME, Sax FL, MacKenzie CR, et al. . Morbidity during hospitalization: can we predict it?&#xa0;J Chronic Dis&#xa0;1987; : 705&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">3110198</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg&#xa0;1991; : 355&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">2021856</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, et al. . Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med&#xa0;1995; : 1,638&#x2013;1,652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis&#xa0;1987; : 373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Marcantonio ER, Mangione CM, et al. . Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation&#xa0;1999; : 1,043&#x2013;1,049.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak PH, Campbell RC, Irwin MG. The ASA Physical Status Classification: inter-observer consistency. Anaesth Intensive Care&#xa0;2002; : 633&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RS, Kumar KS, Russo MW, et al. . Model for end-stage liver disease and Child&#x2013;Turcotte&#x2013;Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl&#xa0;2002; : 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910574</ArticleId></ArticleIdList></Reference><Reference><Citation>Braat AE, Blok JJ, Putter H, et al. . The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant&#xa0;2012; : 2,789&#x2013;2,796.</Citation><ArticleIdList><ArticleId IdType="pubmed">22823098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorina P, La Rocca E, Astorri E, et al. . Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care&#xa0;2000; : 1,804&#x2013;1,810.</Citation><ArticleIdList><ArticleId IdType="pubmed">11128357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra S, Tavakoli M, Kallinikos PA, et al. . Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care&#xa0;2007; 30: ,608&#x2013;2,612.</Citation><ArticleIdList><ArticleId IdType="pubmed">17623821</ArticleId></ArticleIdList></Reference><Reference><Citation>Woeste G, Wullstein C, Prid&#xf6;hl O, et al. . Incidence of minor and major amputations after pancreas/kidney transplantation. Transpl Int&#xa0;2003; : 128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">12595975</ArticleId></ArticleIdList></Reference><Reference><Citation>Humar A, Ramcharan T, Kandaswamy R, et al. . Technical failures after pancreas transplants: why grafts fail and the risk factors &#x2013; a multivariate analysis. Transplantation&#xa0;2004; : 1,188&#x2013;1,192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502718</ArticleId></ArticleIdList></Reference><Reference><Citation>Troppmann C. Complications after pancreas transplantation. Curr Opin Organ Transplant&#xa0;2010; : 112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">20009931</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal HP, Garland L, Novak K, et al. . Risk factors for postimplantation pancreatitis and pancreatic thrombosis in pancreas transplant recipients. Transplantation&#xa0;1993; : 609&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8212156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall CG, Sandrasegaran K, Maglinte DT, Fridell JA. Bowel complications seen on CT after pancreas transplantation with enteric drainage. Am J Roentgenol2006; : 1,288&#x2013;1,295.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetti M, Salvalaggio PR, Topal J, et al. . Incidence, timing and site of infections among pancreas transplant recipients. J Hosp Infect&#xa0;2004; : 184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003665</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinkers MT, Rahmel AO, Slot MC, et al. . How to recognize a suitable pancreas donor: a Eurotransplant study of preprocurement factors. Transplant Proc&#xa0;2008; : 1,275&#x2013;1,278.</Citation><ArticleIdList><ArticleId IdType="pubmed">18589086</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod DA, Sung RS, Meyer KH, et al. . Systematic evaluation of pancreas allograft quality, outcomes and geographic variation in utilization. Am J Transplant&#xa0;2010; : 837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">20121753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland DE, Gruessner RW, Dunn DL, et al. . Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg&#xa0;2001; : 463&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421277</ArticleId><ArticleId IdType="pubmed">11303130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant&#xa0;2004; : 2,018&#x2013;2,026.</Citation><ArticleIdList><ArticleId IdType="pubmed">15575904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio MS, Reddy PN, Kuo HT, et al. . Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation&#xa0;2010; : 1,117&#x2013;1,125.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablorsu E, Ghazanfar A, Mehra S, et al. . Outcome of pancreas transplantation in recipients older than 50 years: a single-centre experience. Transplantation&#xa0;2008; : 1,511&#x2013;1,514.</Citation><ArticleIdList><ArticleId IdType="pubmed">19077882</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterlow J. Pressure sores: a risk assessment card. Nurs Times&#xa0;1985; : 49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">3853163</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorn CC, Smith M, Aziz O, Holme TC. The Waterlow score for risk assessment in surgical patients. Ann R Coll Surg Engl&#xa0;2013; : 52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964640</ArticleId><ArticleId IdType="pubmed">23317729</ArticleId></ArticleIdList></Reference><Reference><Citation>Khuri SF, Henderson WG, DePalma RG, et al. . Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg&#xa0;2005; : 326&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1357741</ArticleId><ArticleId IdType="pubmed">16135919</ArticleId></ArticleIdList></Reference><Reference><Citation>Noori N, Kopple JD. Effect of diabetes mellitus on protein-energy wasting and protein wasting in end-stage renal disease. Semin Dial&#xa0;2010; : 178&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasticci F, Fantuzzi AL, Pegoraro M, et al. . Nutritional management of stage 5 chronic kidney disease. J Ren Care&#xa0;2012; : 50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">22369595</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenvinkel P, Barany P, Chung SH, et al. . A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrol Dial Transplant&#xa0;2002; : 1,266&#x2013;1,274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105251</ArticleId></ArticleIdList></Reference><Reference><Citation>Weimann A, Braga M, Harsanyi L, et al. . ESPEN guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr&#xa0;2006; : 224&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698152</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden S, Todd C, Hill J, Lal S. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. Cochrane Database Syst Rev&#xa0;2012; : CD008879.</Citation><ArticleIdList><ArticleId IdType="pubmed">23152265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31471407</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>In vivo (Athens, Greece)</Title><ISOAbbreviation>In Vivo</ISOAbbreviation></Journal><ArticleTitle>Predictive Value of Osteoprotegerin and Neutrophil Gelatinase-associated Lipocalin on Multiple Organ Failure in Multiple Trauma.</ArticleTitle><Pagination><StartPage>1573</StartPage><EndPage>1580</EndPage><MedlinePgn>1573-1580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21873/invivo.11639</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Multiple organ dysfunction syndrome (MODS) is the leading cause of late posttraumatic mortality. This study analyzed the prognostic values of osteoprotegerin (OPG) and neutrophil gelatinase-associated lipocalin (NGAL/lipocalin 2) compared to interleukin-6 (IL-6) in multiply injured patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A retrospective observational cohort study on multiply injured patients with an injury severity score (ISS) of &#x2265;16 was performed. OPG, NGAL and IL-6 blood concentrations were measured. Statistical analysis comprised receiver-operating-characteristic (ROC) analysis with the corresponding area under the curve (AUC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine patients with a mean ISS of 34&#xb1;11 were included. Fourteen patients (36%) developed MODS and 8 patients (21%) died. Plasma levels of NGAL, OPG, and IL-6 were significantly elevated in the MODS+ group. Each biomarker positively correlated with MODS score and diagnosis of MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NGAL and OPG might be indicative of MODS and could have the potential to be biomarkers in the early detection of patients at risk of posttraumatic MODS.</AbstractText><CopyrightInformation>Copyright&#xa9; 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macke</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mommsen</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeckey</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General, Trauma and Reconstructive Surgery, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clausen</LastName><ForeName>Jan-Dierk</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krettek</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neunaber</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkelmann</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany winkelmann.marcel@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>In Vivo</MedlineTA><NlmUniqueID>8806809</NlmUniqueID><ISSNLinking>0258-851X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489506">LCN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071068">Lipocalin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506030">TNFRSF11B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071068" MajorTopicYN="N">Lipocalin-2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Multiple organ failure</Keyword><Keyword MajorTopicYN="N">lipocalin</Keyword><Keyword MajorTopicYN="N">multiple injury</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">multiple trauma</Keyword></KeywordList><CoiStatement>The Authors declare that there is no conflict of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31471407</ArticleId><ArticleId IdType="pmc">PMC6754992</ArticleId><ArticleId IdType="doi">10.21873/invivo.11639</ArticleId><ArticleId IdType="pii">33/5/1573</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ciesla DJ, Moore EE, Johnson JL, Burch JM, Cothren CC, Sauaia A. A 12-year prospective study of postinjury multiple organ failure: Has anything changed. Arch Surg. 2005;140(5):432&#x2013;438. PMID: 15897438. DOI: 10.1001/archsurg.140.5.432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15897438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury. 2009;40(9):912&#x2013;918. PMID: 19541301. DOI: 10.1016/j.injury.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="pubmed">19541301</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast-Kolb D, Aufmkolk M, Rucholtz S, Obertacke U, Waydhas C. Multiple organ failure still a major cause of morbidity but not mortality in blunt multiple trauma. J Trauma. 2001;51(5):835&#x2013;841. discussion 841-832 PMID: 11706328.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706328</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattstrom O, Granath F, Rossi P, Oldner A. Early predictors of morbidity and mortality in trauma patients treated in the intensive care unit. Acta Anaesthesiol Scand. 2010;54(8):1007&#x2013;1017. PMID: 20626360. DOI: 10.1111/j.1399-6576.2010. 02266.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626360</ArticleId></ArticleIdList></Reference><Reference><Citation>Minei JP, Cuschieri J, Sperry J, Moore EE, West MA, Harbrecht BG, O&#x2019;Keefe GE, Cohen MJ, Moldawer LL, Tompkins RG, Maier RV, Inflammation and the Host Response to Injury Collaborative Research P The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock. Crit Care Med. 2012;40(4):1129&#x2013;1135. PMID: 22020243. DOI: 10.1097/CCM.0b013e3182376e9f.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343366</ArticleId><ArticleId IdType="pubmed">22020243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahl JE, Calvo RY, Sise MJ, Sise CB, Thorndike JF, Shackford SR. The changing nature of death on the trauma service. J Trauma Acute Care Surg. 2013;75(2):195&#x2013;201. PMID: 23823614. DOI: 10.1097/TA.0b013e3182997865.</Citation><ArticleIdList><ArticleId IdType="pubmed">23823614</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, Sakka SG, Bouillon B, Wafaisade A, Committee on Emergency Medicine IC , Trauma Management of the German Trauma Society Sektion NIS Epidemiology and risk factors of multiple-organ failure after multiple trauma: An analysis of 31,154 patients from the traumaregister dgu. J Trauma Acute Care Surg. 2014;76(4):921&#x2013;927. discussion 927-928 PMID: 24662853. DOI: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Chin TL, Banerjee A, Sperry JL, Maier RV, Burlew CC. Temporal trends of postinjury multiple-organ failure: Still resource intensive, morbid, and lethal. J Trauma Acute Care Surg. 2014;76(3):582&#x2013;592, discussion 592-583. PMID: 24553523. DOI: 10.1097/TA.0000000 000000147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4116088</ArticleId><ArticleId IdType="pubmed">24553523</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts CS, Pape HC, Jones AL, Malkani AL, Rodriguez JL, Giannoudis PV. Damage control orthopaedics: Evolving concepts in the treatment of patients who have sustained orthopaedic trauma. Instr Course Lect. 2005;54:447&#x2013;462. PMID: 15948472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sears BW, Stover MD, Callaci J. Pathoanatomy and clinical correlates of the immunoinflammatory response following orthopaedic trauma. J Am Acad Orthop Surg. 2009;17(4):255&#x2013;265. PMID: 19307674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675552</ArticleId><ArticleId IdType="pubmed">19307674</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpin G, Cohen M, Assaf M, Meir T, Katz R, Pollack S. Cytokine levels (il-4, il-6, il-8 and tgfbeta) as potential biomarkers of systemic inflammatory response in trauma patients. Int Orthop. 2014;38(6):1303&#x2013;1309. PMID: 24402554. DOI: 10.1007/s00264-013-2261-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037528</ArticleId><ArticleId IdType="pubmed">24402554</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;1652. PMID: 7587228.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The sofa (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996;22(7):707&#x2013;710. PMID: 8844239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28(6):668&#x2013;674. PMID: 18092384.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between il-6 levels and the systemic inflammatory response score: Can an il-6 cutoff predict a sirs state. J Trauma. 2008;65(3):646&#x2013;652. PMID: 18784579. DOI: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51(2):97&#x2013;102. PMID: 18377749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jastrow KM 3rd, Gonzalez EA, McGuire MF, Suliburk JW, Kozar RA, Iyengar S, Motschall DA, McKinley BA, Moore FA, Mercer DW. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg. 2009;209(3):320&#x2013;331. PMID: 19717036. DOI: 10.1016/j.jamcollsurg.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717036</ArticleId></ArticleIdList></Reference><Reference><Citation>Haasper C, Kalmbach M, Dikos GD, Meller R, Muller C, Krettek C, Hildebrand F, Frink M. Prognostic value of procalcitonin (pct) and/or interleukin-6 (il-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (mods) or sepsis. Technol Health Care. 2010;18(2):89&#x2013;100. PMID: 20495248. DOI: 10.3233/THC-2010-0571.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165&#x2013;176. PMID: 9568710.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (ocif) and osteoprotegerin (opg): A mechanism by which opg/ocif inhibits osteoclasto-genesis in vitro. Endocrinology. 1998;139(3):1329&#x2013;1337. PMID: 9492069. DOI: 10.1210/endo.139.3.5837.</Citation><ArticleIdList><ArticleId IdType="pubmed">9492069</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T. Osteoclast differentiation factor (odf) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246(1):199&#x2013;204. PMID: 9600092. DOI: 10.1006/bbrc.1998.8586.</Citation><ArticleIdList><ArticleId IdType="pubmed">9600092</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. Trance is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188(5):997&#x2013;1001. PMID: 9730902. DOI: 10.1084/jem.188.5.997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213394</ArticleId><ArticleId IdType="pubmed">9730902</ArticleId></ArticleIdList></Reference><Reference><Citation>Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand trail. J Biol Chem. 1998;273(23):14363&#x2013;14367. PMID: 9603945. DOI: 10.1074/jbc.273.23.14363.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603945</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid P, Holen I. Pathophysiological roles of osteoprotegerin (opg) Eur J Cell Biol. 2009;88(1):1&#x2013;17. PMID: 18707795. DOI: 10.1016/j.ejcb.2008.06.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">18707795</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the tnf receptor and its ligand enhance t-cell growth and dendritic-cell function. Nature. 1997;390(6656):175&#x2013;179. PMID: 9367155. DOI: 10.1038/ 36593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9367155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y. Trance (tumor necrosis factor [tnf]-related activation-induced cytokine), a new tnf family member predominantly expressed in t cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186(12):2075&#x2013;2080. PMID: 9396779. DOI: 10.1084/jem.186.12.2075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199171</ArticleId><ArticleId IdType="pubmed">9396779</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE, Clark EA. Opg/fdcr-1, a tnf receptor family member, is expressed in lymphoid cells and is up-regulated by ligating cd40. J Immunol. 1998;161(11):6113&#x2013;6121. PMID: 9834095.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834095</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoppet M, Henser S, Ruppert V, Stubig T, Al-Fakhri N, Maisch B, Hofbauer LC. Osteoprotegerin expression in dendritic cells increases with maturation and is nf-kappab-dependent. J Cell Biochem. 2007;100(6):1430&#x2013;1439. PMID: 17171649. DOI: 10.1002/jcb.21129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17171649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates b cell development and function. J Immunol. 2001;166(3):1482&#x2013;1491. PMID: 11160187. DOI: 10.4049/jimmunol. 166.3.1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160187</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari-Lacraz S, Ferrari S. Do rankl inhibitors (denosumab) affect inflammation and immunity. Osteoporos Int. 2011;22(2):435&#x2013;446. PMID: 20571772. DOI: 10.1007/s00198-010-1326-y.</Citation><ArticleIdList><ArticleId IdType="pubmed">20571772</ArticleId></ArticleIdList></Reference><Reference><Citation>To M, Ito K, Ausin PM, Kharitonov SA, Barnes PJ. Osteoprotegerin in sputum is a potential biomarker in copd. Chest. 2011;140(1):76&#x2013;83. PMID: 21127170; DOI: 10.1378/ chest.10-1608.</Citation><ArticleIdList><ArticleId IdType="pubmed">21127170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco C. N-gal: Diagnosing aki as soon as possible. Crit Care. 2007;11(6):173&#x2013;173. PMID: 18001501. DOI: 10.1186/cc6162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246201</ArticleId><ArticleId IdType="pubmed">18001501</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD, Passik CS, Swaminathan M, Garg AX, Consortium T-A. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748&#x2013;1757. PMID: 21836147. DOI: 10.1681/ASN.2010111163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171945</ArticleId><ArticleId IdType="pubmed">21836143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering JW, Endre ZH. The clinical utility of plasma neutrophil gelatinase-associated lipocalin in acute kidney injury. Blood Purif. 2013;35(4):295&#x2013;302. PMID: 23712081. DOI: 10.1159/000351542.</Citation><ArticleIdList><ArticleId IdType="pubmed">23712081</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: A critical evaluation of current status. Ann Clin Biochem. 2014;51(Pt 3):335&#x2013;351. PMID: 24518531. DOI: 10.1177/0004 563214521795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104776</ArticleId><ArticleId IdType="pubmed">24518531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco C, Legrand M, Goldstein SL, Hur M, Tran N, Howell EC, Cantaluppi V, Cruz DN, Damman K, Bagshaw SM, Di Somma S, Lewington A. Neutrophil gelatinase-associated lipocalin: Ready for routine clinical use? An international perspective. Blood Purif. 2014;37(4):271&#x2013;285. PMID: 25012891. DOI: 10.1159/000360689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842016</ArticleId><ArticleId IdType="pubmed">25012891</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart IJ, Glass KR, Howard JT, Morrow BD, Sosnov JA, Siew ED, Wickersham N, Latack W, Kwan HK, Heegard KD, Diaz C, Henderson AT, Saenz KK, Ikizler TA, Chung KK. The potential utility of urinary biomarkers for risk prediction in combat casualties: A prospective observational cohort study. Crit Care. 2015;19:252&#x2013;252. PMID: 26077788. DOI: 10.1186/s13054-015-0965-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487799</ArticleId><ArticleId IdType="pubmed">26077788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennarelli TA, Wodzin E, Medicine AftAoA Abbreviated injury scale 2005: Association for the Advancement of Automotive Medicine. Barrington. 2008; Update 2008 ISBN-13: 978-0000002020.</Citation></Reference><Reference><Citation>Baker SP, O&#x2019;Neill B, Haddon W Jr., Long WB. The injury severity score: A method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14(3):187&#x2013;196. PMID: 4814394.</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Kruger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stuber F, Weiler N, Weimann A, Werdan K, Welte T, German Sepsis S , German Interdisciplinary Association of Intensive C and Emergency M Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of s-2k guidelines of the german sepsis society (deutsche sepsis-gesellschaft e.V. (dsg)) and the german interdisciplinary association of intensive care and emergency medicine (deutsche interdisziplinare vereinigung fur intensiv- und notfallmedizin (divi)). Ger Med Sci. 2010;8 DOI: 10.3205/000103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899863</ArticleId><ArticleId IdType="pubmed">20628653</ArticleId></ArticleIdList></Reference><Reference><Citation>Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: The berlin definition. JAMA. 2012;307(23):2526&#x2013;2533. PMID: 22797452. DOI: 10.1001/jama.2012.5669.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32&#x2013;35. PMID: 15405679. DOI: 10.1002/1097-0142(1950) 3:1&lt; 32::aid-cncr2820030106&gt;3.0.co;2-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, STARD Group Stard 2015: An updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527&#x2013;h5527. PMID: 26511519. DOI: 10.1136/bmj.h5527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623764</ArticleId><ArticleId IdType="pubmed">26511519</ArticleId></ArticleIdList></Reference><Reference><Citation>Frink M, Pape HC, van Griensven M, Krettek C, Chaudry IH, Hildebrand F. Influence of sex and age on mods and cytokines after multiple injuries. Shock. 2007;27(2):151&#x2013;156. PMID: 17224789. DOI: 10.1097/01.shk.0000239767.64786.de.</Citation><ArticleIdList><ArticleId IdType="pubmed">17224789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38(12):1336&#x2013;1345. PMID: 18048040. DOI: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong DY, Lee JH, Park SO, Baek KJ, Lee KR. Plasma neutrophil gelatinase-associated lipocalin as early biomarker for acute kidney injury in burn patients. J Burn Care Res. 2013;34(6):e326&#x2013;e332. PMID: 23511281. DOI: 10.1097/BCR.0b013 e31827d1f36.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavuz S, Anarat A, Acarturk S, Dalay AC, Kesiktas E, Yavuz M, Acarturk TO. Neutrophil gelatinase associated lipocalin as an indicator of acute kidney injury and inflammation in burned children. Burns. 2014;40(4):648&#x2013;654. PMID: 24060429. DOI: 10.1016/j.burns.2013.09.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">24060429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Godwin ZR, Palmieri T, Greenhalgh D, Steele AN, Tran NK. Whole blood neutrophil gelatinase-associated lipocalin predicts acute kidney injury in burn patients. J Surg Res. 2015;196(2):382&#x2013;387. PMID: 25890435. DOI: 10.1016/j.jss.2015.03.033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447708</ArticleId><ArticleId IdType="pubmed">25890435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjortrup PB, Haase N, Wetterslev M, Perner A. Clinical review: Predictive value of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care patients. Crit Care. 2013;17(2):211&#x2013;211. PMID: 23680259. DOI: 10.1186/cc11855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672520</ArticleId><ArticleId IdType="pubmed">23680259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15846719</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2005</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults.</ArticleTitle><Pagination><StartPage>CD004539</StartPage><MedlinePgn>CD004539</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD004539</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Secondary peritonitis is associated with a high mortality rate and if not treated successfully leads to development of abscesses, severe sepsis and multi-organ failure. Source control and adjunctive antibiotics are the mainstay of treatment. However, no conclusive evidence suggest that one antibiotic regimen is better than any other but at the same time have a lower toxicity.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To ascertain the efficacy and adverse effects of different antibiotic regimens in treating intra-abdominal infections in adults. Outcomes were divided into primary (clinical success and effectiveness in reducing mortality) and secondary (microbiological success, preventing wound infection, intra-abdominal abscess, clinical sepsis, remote infection, superinfection, adverse reactions, duration of treatment required, effectiveness in reducing hospitalised stay, and time to defervescence).</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, Issue 4, 2004), MEDLINE (from 1966 to November 2004), EMBASE (from 1980 to November 2004) and Cochrane Colorectal Cancer Group specialised register SR-COLOCA. Bibliographies of identified studies were screened for further relevant trials.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised and quasi-randomised controlled trials comparing different antibiotic regimens in the treatment of secondary peritonitis in adults were selected. Trials reporting gynaecological or traumatic peritonitis were excluded from this review. Ambiguity regarding suitability of trials were discussed among the review team.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Six reviewers independently assessed trial quality and extracted data. Data collection was standardised using data collection form to ensure uniformity among reviewers. Statistical analyses were performed using the random effects model and the results expressed as odds ratio for dichotomous outcomes, or weight mean difference for continuous data with 95% confidence intervals.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Fourty studies with 5094 patients met the inclusion criteria. Sixteen different comparative antibiotic regimens were reported. All antibiotics showed equivocal comparability in terms of clinical success. Mortality did not differ between the regimens. Despite the potential high toxicity profile of regimens using aminoglycosides, this was not demonstrated in this review. The reason for this could be the inherent bias within clinical trials in the form of patient selection and stringency in monitoring drug levels.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">No specific recommendations can be made for the first line treatment of secondary peritonitis in adults with antibiotics, as all regimens showed equivocal efficacy. Other factors such as local guidelines and preferences, ease of administration, costs and availability must therefore be taken into consideration in deciding the antibiotic regimen of choice. Future trials should attempt to stratify patients and perform intention-to-treat analysis to allow better external validity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>P F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Professorial Unit of Surgery, University Hospital of North Tees, Hardwick, Stockton on Tees, UK, TS19 8PE. pwong@doctors.net.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilliam</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shenfine</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>O'Dair</LastName><ForeName>G N</ForeName><Initials>GN</Initials></Author><Author ValidYN="Y"><LastName>Leaper</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.1002/14651858.CD004539</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007416" MajorTopicYN="N">Intestinal Perforation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The Professorial Unit of Surgery of whom Professor Leaper was the lead clinician, received a one&#x2010;off limited and unconditional educational grant from Merck Sharpe &amp; Dohme, which was meant for antibiotic trials. The reviewers can however assure that under no circumstances has this grant or Merck Sharpe &amp; Dohme influenced the review or reviewers in any form. The company concerned certainly had no input into the wordings, opinions or conjectures of this review.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15846719</ArticleId><ArticleId IdType="pmc">PMC11297476</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004539.pub2</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Angeras 1996 {published data only}</Title><Reference><Citation>Angeras MH, Darle N, Hamnstrom K, Ekelund M, Engstrom L, Takala J, et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra&#x2010;abdominal infections. Scandinavian Journal of Infectious Diseases 1996;28(5):513&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953684</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Basoli 1997 {published data only}</Title><Reference><Citation>Basoli A, Meli EZ, Mazzocchi P, Speranza V and Study Group. Imipenem/cilastatin (1.5g daily) versus meropenem (3.0g daily) in patients with intra&#x2010;abdominal infections: results of a prospective, randomized, multicentre trial. Scand J of Infect Dis 1997;29:503&#x2010;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435041</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1982 {published data only}</Title><Reference><Citation>Berne TV, Yellin AW, Appleman MD, Heseltine PNR. Antibiotic management of surgically treated gangrenous or perforated appendicitis. The American Journal of Surgery 1982;144(1):8&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">6211996</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1987 {published data only}</Title><Reference><Citation>Berne TV, Appleman MD, Chenella FC, Yellin AE, Gill MA, Heseltine PNR. Surgically treated gangrenous or perforated appendicitis. Ann Surg 1987;205(2):133&#x2010;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1492815</ArticleId><ArticleId IdType="pubmed">3545106</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1993 {published data only}</Title><Reference><Citation>Berne TV, Yellin AE, Appleman MD, Heseltine PNR, Gill MA. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surgery, Gynecology &amp; Obstetrics 1993;177(Suppl):18&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8256187</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1996 {published data only}</Title><Reference><Citation>Berne TV, Yellin AE, Appleman MD, Heseltine PNR, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. Journal of the American College of Surgeons 1996;182(5):403&#x2010;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">8620275</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brismar 1992 {published data only}</Title><Reference><Citation>Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, et al. Piperacillin&#x2010;tazobactam versus imipenem&#x2010;cilastatin for treatment of intra&#x2010;abdominal infections. Antimicrobial Agents and Chemotherapy 1992;36(12):2766&#x2010;2773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC245542</ArticleId><ArticleId IdType="pubmed">1336347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brismar 1995 {published data only}</Title><Reference><Citation>Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing O, et al. Meropenem versus imipenem/cilastatin in the treatment of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1995;35(1):139&#x2010;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">7768761</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brismar 1996 {published data only}</Title><Reference><Citation>Brismar B, Akerlund J&#x2010;E, Sjostedt S, Johansson C, Tornqvist A, Backstrand B, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intra&#x2010;abdominal infections: Report from a Swedish study group. Scandinavian Journal of Infectious Diseases 1996;28(5):507&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953683</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Busuttil 1984 {published data only}</Title><Reference><Citation>Busuttil RW, McGrattan MA, Freischlag J. A comparative study of cefamandole versus gentamicin plus clindamycin in the treatment of documented or suspected bacterial peritonitis. Surgery, Gynecology &amp; Obstetrics 1984;158(1):1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6362043</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Christou 1996 {published data only}</Title><Reference><Citation>Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M, et al. Management of intra&#x2010;abdominal infections: The case for intraoperative cultures and comprehensive broad&#x2010;spectrum antibiotic coverage. Archives of Surgery 1996;131(11):1193&#x2010;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8911260</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cohn 2000 {published data only}</Title><Reference><Citation>Cohn SM, Lipsett PA, Buchmann TG, Cheadle WG, Milsom JW, O'Marro S, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery 2000;232(2):254&#x2010;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421138</ArticleId><ArticleId IdType="pubmed">10903605</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>de Groot 1993 {published data only}</Title><Reference><Citation>Groot HGW, Hustinx PA, Lampe AS, Oosterwijk WM. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1993;32(3):491&#x2010;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">8262872</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dupont 2000 {published data only}</Title><Reference><Citation>Dupont H, Carbon C, Carlet J for The Severe Generalized Peritonitis Study Group. Monotherapy with a broad&#x2010;spectrum beta&#x2010;lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrobial Agents and Chemotherapy 2000;44(8):2028&#x2010;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC90009</ArticleId><ArticleId IdType="pubmed">10898671</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Eckhauser 1992 {published data only}</Title><Reference><Citation>Eckhauser FE, Knol JA, Raper SE, Mulholland MW, Helzerman P. Efficacy of two comparative antibiotic regimens in the treatment of serious intra&#x2010;abdominal infections: Results of a multicenter study. Clinical Therapeutics 1992;14(1):97&#x2010;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">1576632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gozenbach 1987 {published data only}</Title><Reference><Citation>Gozenbach HR, Simmen HP, Amgwerd R. Imipenem (N&#x2010;F&#x2010;Thienamycin) versus netilmicin plus clindamycin: A controlled and randomized comparison in intra&#x2010;abdominal infections. Annals of Surgery 1987;205(3):271&#x2010;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1492722</ArticleId><ArticleId IdType="pubmed">3548611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Greenberg 1994 {published data only}</Title><Reference><Citation>Greenberg RN, Cayavec P, Danko LS, Bowen K, Montazemi R, Kearney PA, et al. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1994;34(3):391&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">7829413</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hopkins 1994 {published data only}</Title><Reference><Citation>Hopkins JA, Wilson SE, Bobey DG. Adjunctive antimicrobial therapy for complicated appendicitis: Bacterial overkill by combination therapy. World Journal of Surgery 1994;18(6):933&#x2010;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">7846922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Investigators 1994 {published data only}</Title><Reference><Citation>Investigators of the Piperacillin/Tazobactam Intra&#x2010;abdominal Infection Study Group. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra&#x2010;abdominal infections. European Journal of Surgery Supplement 1994, (573):61&#x2010;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">7524798</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jaccard 1998 {published data only}</Title><Reference><Citation>Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem/cilastatin and piperacillin/tazobactam in nosocomial pneumonia and peritonitis. Antimicrobial Agents and Chemotherapy 1998;42(11):2966&#x2010;2972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC105974</ArticleId><ArticleId IdType="pubmed">9797234</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jauregui 1990 {published data only}</Title><Reference><Citation>Jauregui LE, Appelbaum PC, Fabian TC, Hageage G, Strausbaugh L, Martin LF. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1990;25(3):423&#x2010;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">2187014</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kanellakopoulou 1993 {published data only}</Title><Reference><Citation>Kanellakopoulou K, Giamarellou H, Papadothomakos P, Tsipras H, Chloroyiannis J, Theakou R, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. European Journal of Clinical Microbiological Infectious Diseases 1993;12(6):449&#x2010;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">8359165</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kempf 1996 {published data only}</Title><Reference><Citation>Kempf P, Bauernfeind A, Muller A, Blum J. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra&#x2010;abdominal infections. Infection 1996;24(6):473&#x2010;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007598</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leal del Rosal 1995 {published data only}</Title><Reference><Citation>Leal del Rosal P. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra&#x2010;abdominal infections. Journal of Chemotherapy 1995;7(2):143&#x2010;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8622103</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leaper 1987 {published data only}</Title><Reference><Citation>Leaper DJ, Kennedy RH, Sutton A, Johnson E, Roberts N. Treatment of acute bacterial peritonitis: A trial of imipenem/cilastatin against ampicillin&#x2010;metronidazole&#x2010;gentamicin. Scandinavian Journal of Infectious Diseases 1987;52(Suppl):7&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">3331045</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Malangoni 1985 {published data only}</Title><Reference><Citation>Malangoni MA, Condon RE, Spiegel CA. Treatment of intra&#x2010;abdominal infections is appropriate with single&#x2010;agent or combination antibiotic therapy. Surgery 1985;98(4):648&#x2010;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">3901372</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Paakkonen 1991 {published data only}</Title><Reference><Citation>Paakkonen M, Alhava EM, Huttunen R, Karjalainen K, Lahtinen J, Miettinen P, et al. Piperacillin compared with cefuroxime plus metronidazole in diffuse peritonitis. European Journal of Surgery 1991;157(9):535&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">1683578</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Poenaru 1990 {published data only}</Title><Reference><Citation>Poenaru D, Santis M, Christou NV. Imipenem versus tobramycin&#x2010;antianaerobe antibiotic therapy in intra&#x2010;abdominal infections. Canadian Journal of Surgery 1990;33(5):415&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">2224663</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scandinavian 1984 {published data only}</Title><Reference><Citation>Report from a Scandinavian Study Group. Imipenem/cilastatin versus gentamicin/clindamycin for the treatment of serious bacterial infections. The Lancet 1984;8382(1):868&#x2010;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">6143185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scott 1987 {published data only}</Title><Reference><Citation>Scott SD, Saddler B, Lowes JA, Karran SJ. Comparison of cefotetan versus combination therapy in peritonitis and serious intra&#x2010;abdominal sepsis. Chemioterapia 1987;6(Pt 2 S):475&#x2010;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">3334604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shyr 1995 {published data only}</Title><Reference><Citation>Shyr YM, Lui WY, Su CH, Wang LS, Liu CY. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra&#x2010;abdominal infections. Chinese Medical Journal 1995;56(2):102&#x2010;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">7553416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1980 {published data only}</Title><Reference><Citation>Smith JA, Skidmore AG, Forward AD, Clarke AM, Sutherland E. Prospective, randomized, double&#x2010;blinded comparison of metronidazole and tobramycin with clindamycin and tobramycin in the treatment of intra&#x2010;abdominal sepsis. Annals of Surgery 1980;192(2):213&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1344856</ArticleId><ArticleId IdType="pubmed">6996625</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 2001 {published data only}</Title><Reference><Citation>Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Annals of Surgery 2001;233(1):79&#x2010;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421170</ArticleId><ArticleId IdType="pubmed">11141229</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Study 1986 {published data only}</Title><Reference><Citation>Study Group of Intra&#x2010;abdominal Infections. A randomized controlled trial of ampicillin plus sulbactam versus gentamicin and clindamycin in the treatment of intraabdominal infections: a preliminary report. Reviews of Infectious Diseases 1986;8(Suppl 5):S583&#x2010;S588.</Citation><ArticleIdList><ArticleId IdType="pubmed">2879345</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Swedish 1990 {published data only}</Title><Reference><Citation>Report from a Swedish Study Group. A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1990;26(Suppl B):173&#x2010;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">2258346</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tornqvist 1985 {published data only}</Title><Reference><Citation>Tornqvist A, Forsgren A, Leandoer L, Ursing J. Antibiotic treatment during surgery for diffuse peritonitis: a prospective randomized study comparing the effects of cefuroxime and of a cefuroxime and metronidazole combination. British Journal of Surgery 1985;72(4):261&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">3986473</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Torres 1999 {published data only}</Title><Reference><Citation>Torres AJ, Valladares LD, Jover JM, Sanchez&#x2010;Pernaute A, Frias J, Carcas AJ, et al. Cefminox versus metronidazole plus gentamicin in intra&#x2010;abdominal infections: A prospective randomized controlled clinical trial. Infections 2000;28(5):318&#x2010;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11073141</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Walker 1993 {published data only}</Title><Reference><Citation>Walker AP, Nichols RL, Wilson RF, Bivens BA, Trunkey DD, Edmiston CE, et al. Efficacy of a beta&#x2010;lactamase inhibitor combination for serious intra&#x2010;abdominal infections. Annals of Surgery 1993;217(2):115&#x2010;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242749</ArticleId><ArticleId IdType="pubmed">8439209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yellin 1985 {published data only}</Title><Reference><Citation>Yellin AE, Heseltine PNR, Berne TV, Appleman MD, Gill MA, Riggio CE, et al. The role of pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surgery, Gynecology &amp; Obstetrics 1985;161(4):303&#x2010;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">2996161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zanetti 1999 {published data only}</Title><Reference><Citation>Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra&#x2010;abdominal infections. International Journal of Antimicrobial Agents 1999;11(2):107&#x2010;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221413</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Allo 1999 {published data only}</Title><Reference><Citation>Allo MD, Bennion RS, Kathir K, Thompson JE, Lentz M, Meute M, et al. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. The American Surgeon 1999;65(2):99&#x2010;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">9926739</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Andaker 1987 {published data only}</Title><Reference><Citation>Andaker L, Hojer H, Kihlstrom E, Lindagen J. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Acta Chirurgica Scandinavica 1987;153(3):185&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">3300120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Arguedas 1996 {published data only}</Title><Reference><Citation>Arguedas A, Sifuentes&#x2010;Osornio J, Loaiza C, Herrera M, Corrales JC, Mohs E, et al. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra&#x2010;abdominal infections. Journal of Chemotherapy 1996;8(2):130&#x2010;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">8708744</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Baird 1983 {published data only}</Title><Reference><Citation>Baird IM. Multicentered study of cefoperazone for treatment of intraabdominal infections and comparison of cefoperazone with cefamandole and clindamycin plus gentamicin for treatment of appendicitis and peritonitis. Reviews of Infectious Diseases 1983;5(Suppl.):S165&#x2010;S172.</Citation><ArticleIdList><ArticleId IdType="pubmed">6221387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ball 1981 {published data only}</Title><Reference><Citation>Ball P, Watson T, Mehtar S. Amoxycillin and clavulanic acid in intra&#x2010;abdominal and pelvic sepsis. Journal of Antimicrobial Chemotherapy 1981;7(4):441&#x2010;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">7251526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball P, Watson T, Mehtar S. Amoxycillin and clavulanic acid in intra&#x2010;abdominal and pelvic sepsis. Journal of Antimicrobial Chemotherapy 1981;7(4):441&#x2010;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">7251526</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barboza 1994 {published data only}</Title><Reference><Citation>Barboza E, Castillo M, Yi A, Gotuzzo E. Clindamycin plus amikacin versus clindamycin plus aztreonam in established intraabdominal infections. Surgery 1994;116(1):28&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">8023265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barie 1997 {published data only}</Title><Reference><Citation>Barie PS, Vogel SB, Dellinger EP, Rotstein OD, Solomkin JS, Yang JY, et al. A randomized, double&#x2010;blind clinical trial comparing cefepime plus metronidazole with imipenem&#x2010;cilastatin in the treatment of complicated intra&#x2010;abdominal infections. Arch Surg 1997;132(12):1294&#x2010;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403533</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bennion 1990 {published data only}</Title><Reference><Citation>Bennion RS, Thompson JE, Baron EJ, Finegold SM. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clinical Therapeutics 1990;12(Suppl. C):31&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">2202510</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Birolini 1985 {published data only}</Title><Reference><Citation>Birolini D, Moraes MF, Souza OS. Aztreonam plus clindamycin versus tobramycin plus clindamycin for the treatment of intraabdominal infections. Reviews of Infectious Diseases 1985;7(Suppl 4):S724&#x2010;S728.</Citation><ArticleIdList><ArticleId IdType="pubmed">3909330</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Birolini 1989 {published data only}</Title><Reference><Citation>Birolini D, Moraes MF, Souza OS. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra&#x2010;abdominal infections. Chemotherapy 1989;35(Suppl 1):49&#x2010;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">2659290</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Biron 1984 {published data only}</Title><Reference><Citation>Biron S, Brochu G, Beland L, Bourque RA, Marceau P, Piche P, et al. Short&#x2010;term antibiotherapy for peritonitis: prospective, randomized trial comparing cefotaxime&#x2010;metronidazole and clindamycin&#x2010;tobramycin. Journal of Antimicrobial Chemotherapy 1984;12(Suppl B):213&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">6094442</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bubrick 1990 {published data only}</Title><Reference><Citation>Bubrick MP, Heim&#x2010;Duthoy KL, Yellin AE, Berne TV, Heseltine PNR, Appleman MD, et al. Ceftazidime/clindamycin versus tobramycin/clindamycin in the treatment of intra&#x2010;abdominal infections. The American Surgeon 1990;56(10):613&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">2221611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Busuttil 1982 {published data only}</Title><Reference><Citation>Busuttil RW, McGrattan MA, Winston DJ. Moxalactam in the treatment of intraabdominal sepsis and other surgical infections. Review of Infectious Diseases 1982;4(Suppl):S676&#x2010;S682.</Citation><ArticleIdList><ArticleId IdType="pubmed">6218582</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cakmakci 1993 {published data only}</Title><Reference><Citation>Cakmakci M, Stern A, Schilling J, Christen D, Roggo A, Geroulanos S. Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra&#x2010; and post&#x2010;operative infections. Drugs Experimental in Clinical Research 1993;19(5):223&#x2010;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">8174495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Canadian 1983 {published data only}</Title><Reference><Citation>Canadian Metronidazole&#x2010;Clindamycin Study Group. Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra&#x2010;abdominal infection. Surgery 1983;93(1 (Part 2)):221&#x2010;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chin 1990 {published data only}</Title><Reference><Citation>Chin A, Gill MA, Ito MK, Yellin AE, Berne TV, Heseltine PN, et al. Treatment of intra&#x2010;abdominal infections: cost comparison of ampicillin/sulbactam and clindamycin/gentamicin. Hospital Formulary 1990;25(3):295&#x2010;296, 303&#x2010;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10103837</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Christen 1987 {published data only}</Title><Reference><Citation>Christen D, Buchmann P, Geroulanos S. Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections. Scandinavian Journal of Infectious Diseases 1987;52(Suppl 1):11&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">3331039</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Colardyn 1996 {published data only}</Title><Reference><Citation>Colardyn F and Faulkner KL on behalf of the Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Journal of Antimicrobial Chemotherapy 1996;38(3):523&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">8889726</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Collier 1981 {published data only}</Title><Reference><Citation>Collier J, Colhoun EM, Hill PL. A multicentre comparison of clindamycin and metronidazole in the treatment of anaerobic infections. Scandinavian Journal of Infectious Diseases Supplement 1981;26:96&#x2010;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">6941465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cometta 1994 {published data only}</Title><Reference><Citation>Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial Agents and Chemotherapy 1994;38(6):1309&#x2010;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188203</ArticleId><ArticleId IdType="pubmed">8092830</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Condon 1995 {published data only}</Title><Reference><Citation>Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC, Nichols RL, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double&#x2010;blind clinical trial. Clinical Infectious Diseases 1995;21(3):544&#x2010;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">8527541</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Danish 1984 {published data only}</Title><Reference><Citation>The Danish Multicenter Study Group. A Danish multicenter study: cefoxitin versus ampicillin + metronidazole in perforated appendicitis. British Journal of Surgery 1984;71(2):144&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">6692110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Danziger 1988 {published data only}</Title><Reference><Citation>Danziger LH, Creger RJ, Shwed JA, Stellato TA, Hau T. Randomized trial of imipenem/cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections. Pharmacotherapy 1988;8(6):315&#x2010;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3222164</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>de Vries 1990 {published data only}</Title><Reference><Citation>Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once&#x2010;daily versus thrice&#x2010;daily netilmicin regimens in patients with intraabdominal infections. European Journal of Clinical Microbiological Infectious Diseases 1990;9(3):161&#x2010;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">2186909</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Donahue 1998 {published data only}</Title><Reference><Citation>Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR and the Trovafloxacin Surgical Group. Trovafloxacin in the treatment of intra&#x2010;abdominal infections: Results of a double&#x2010;blind, multicenter comparison with imipenem/cilastatin. American Journal of Surgery 1998;176(Suppl 6A):53S&#x2010;61S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9935258</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dougherty 1995 {published data only}</Title><Reference><Citation>Dougherty SH, Sirinek KR. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra&#x2010;abdominal infections in pediatric and adult patients. American Surgeon 1995;61(4):297&#x2010;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7893090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Drusano 1982 {published data only}</Title><Reference><Citation>Drusano GL, Warren JW, Saah AJ, Caplan ES, Tenney JH, Hansen S, et al. A prospective randomized controlled trial of cefoxitin versus clindamycin&#x2010;aminoglycoside in mixed anaerobic&#x2010;aerobic infections. Surgery, Gynecology &amp; Obstetrics 1982;154(5):715&#x2010;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">7041297</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Eklund 1993 {published data only}</Title><Reference><Citation>Eklund A&#x2010;E, Nord CE and Swedish Study Group. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl A):79&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8383657</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fink 1989 {published data only}</Title><Reference><Citation>Fink MP, Helsmoortel CM, Arous EJ, Doern GV, Moriarty KP, Fairchild PG, et al. Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/gentamicin in serious intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1989;24(Suppl B):147&#x2010;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">2691476</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fink 1991 {published data only}</Title><Reference><Citation>Fink MP. Antibiotic therapy of intra&#x2010;abdominal sepsis in the elderly: Experience with ticarcillin and clavulanic acid. Surgery, Gynecology &amp; Obstetrics 1991;172(Suppl):36&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2024225</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Geroulanos 1995 {published data only}</Title><Reference><Citation>Geroulanos SJ and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra&#x2010;abdominal infections requiring surgery. Journal of Antimicrobial Chemotherapy 1995;36(Suppl A):191&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8543495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harding 1982 {published data only}</Title><Reference><Citation>Harding G, Vincelette J, Rachlis A, Fong I, Mandell L, Feld R, et al. A preliminary report on the use of ceftizoxime vs. clindamycin/tobramycin for the therapy of intra&#x2010;abdominal and pelvic infections. Journal of Antimicrobial Chemotherapy 1982;10(Suppl C):191&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">6296005</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Henning 1984 {published data only}</Title><Reference><Citation>Henning C, Meden&#x2010;Britth G, Frolander F, Karlsson J, Dornbusch K. Comparative study of netilmicin/tinidazole versus netilmicin/clindamycin in the treatment of severe abdominal infections. Scandinavian Journal of Infectious Diseases 1984;16(3):297&#x2010;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">6494811</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Henry 1985 {published data only}</Title><Reference><Citation>Henry SA. Overall clinical experience with aztreonam in the treatment of intraabdominal infections. Reviews of Infectious Diseases 1985;7(Suppl 4):S729&#x2010;S733.</Citation><ArticleIdList><ArticleId IdType="pubmed">3909331</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Heseltine 1986 {published data only}</Title><Reference><Citation>Heseltine PNR, Yellin AE, Appleman MD, Gill MA, Chenella FC, Berne TV, et al. Imipenem therapy for perforated and gangrenous appendicitis. Surgery, Gynecoloy &amp; Obstetrics 1986;162(1):43&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">3455671</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hollender 1989 {published data only}</Title><Reference><Citation>Hollender LF, Bahnini J, Manzini N, Lau WY, Fan ST, Hermansyur K, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1989;23(5):773&#x2010;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">2668247</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Holloway 1989 {published data only}</Title><Reference><Citation>Holloway WJ, Winslow DL, Reinhardt JF. Cefmetazole treatment of intra&#x2010;abdominal infection. Journal of Antimicrobial Chemotherapy 1989;23(Suppl D):47&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">2722723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hoogkamp 1995 {published data only}</Title><Reference><Citation>Hoogkamp&#x2010;Korstanje JAA. Ciprofloxacin versus cefotaxime regimens for the treatment of intra&#x2010;abdominal infections. Infections 1995;23(5):278&#x2010;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557385</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Huizinga 1988 {published data only}</Title><Reference><Citation>Huizinga WKJ, Baker LW, Kadwa H, Ende J, Francis AJ, Francis GM. Management of severe intra&#x2010;abdominal sepsis: Single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole. British Journal of Surgery 1988;75(11):1134&#x2010;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">3061561</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Huizinga 1995 {published data only}</Title><Reference><Citation>Huizinga WKJ, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp&#x2010;Korstanjep JAA, et al. Antibiotic monotherapy with meropenem in the surgical management of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1995;36(Suppl A):179&#x2010;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">8543493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Inthorn 1989 {published data only}</Title><Reference><Citation>Inthorn D, Muhlbayer D, Hartl WH. Ticarcillin/clavulanate in the treatment of severe peritonitis. Journal of Antimicrobial Chemotherapy 1989;24(Suppl B):141&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">2691475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jaspers 1998 {published data only}</Title><Reference><Citation>Jaspers CAJJ, Kieft H, Speelberg B, Buiting A, Marwijk Kooij M, Ruys GJHM, et al. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrobial Agents and Chemotherapy 1998;42(5):1233&#x2010;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC105786</ArticleId><ArticleId IdType="pubmed">9593156</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Joshi 1986 {published data only}</Title><Reference><Citation>Joshi M, Fitzpatrick BJ, Warren JW, Caplan ES, Tenney JH. A randomized controlled rial of moxalactam versus clindamycin/tobramycin in the treatment of mixed anaerobic/aerobic infections. The American Surgeon 1986;52(9):467&#x2010;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">3530075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kasholm&#x2010;Tengve 1986 {published data only}</Title><Reference><Citation>Kasholm&#x2010;Tengve B, Bartholdson P. Antibiotics in acute abdominal surgery. A clinical trial comparing the combination of ampicillin, mecillinam and metronidazole with cefoxitin alone. Acta Chirurgica Scandinavica 1986;152:267&#x2010;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">3526773</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kirkpatrick 1983 {published data only}</Title><Reference><Citation>Kirkpatrick JR, Anderson BJ, Louie JJ, Stiver HG. Double&#x2010;blind comparison of metronidazole plus gentamicin and clindamycin plus gentamicin in intra&#x2010;abdominal infection. Surgery 1983;93(1 Pt 2):215&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849208</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kooi 1990 {published data only}</Title><Reference><Citation>Kooi GH, Pit S. Ceftazidime/metronidazole versus netilmicin/metronidazole in the treatment of perforated appendicitis in children. Clinical Therapeutics 1990;12(1):54&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">2183940</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leal del Rosal 1989 {published data only}</Title><Reference><Citation>Leal del Rosal P, Leal del Rosal L, Riosvelasco A, Nesbitt FC, Alanis VS. Brief report: Prospective, controlled, randomized, non&#x2010;blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of severe surgical infections. The American Journal of Medicine 1989;87(Suppl 5A):183S&#x2010;184S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2686420</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lennard 1985 {published data only}</Title><Reference><Citation>Lennard ES, Minshew BH, Dellinger EP, Wertz MJ, Heimbach DM, Counts GW, et al. Stratified outcome comparison of clindamycin&#x2010;gentamicin versus chloramphenicol&#x2010;gentamicin for treatment of intra&#x2010;abdominal sepsis. Archives of Surgery 1985;120(8):889&#x2010;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">3893387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levine 1989 {published data only}</Title><Reference><Citation>Levine DP, McNeil P, Lerner SA. Randomized, double&#x2010;blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. The American Journal of Medicine 1989;87(Suppl 5A):160S&#x2010;163S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2686416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lou 1982 {published data only}</Title><Reference><Citation>Lou MA, Chen DF, Bansal M, Balasubramaniam S, Thadepalli H. Evaluation of ceftizoxime in acute peritonitis. Journal of Antimicrobial Chemotherapy 1982;10(Suppl C):183&#x2010;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">6296004</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Luke 1991 {published data only}</Title><Reference><Citation>Luke M, Iversen J, Sondergaard J, Kvist E, Lund P, Andersen F, et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. European Journal of Surgery 1991;157:397&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">1681917</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Luke 1999 {published data only}</Title><Reference><Citation>Luke DR, Peterson J. Treatment of complicated intra&#x2010;abdominal infections: Comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. International Journal of Clinical Practice 1999;53(3):166&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">10665126</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marra 1998 {published data only}</Title><Reference><Citation>Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, et al. Piperacillin/tazobactam versus imipenem: A double&#x2010;blind, randomized formulary feasibility study at a major teaching hospital. Diagnostic Microbiology &amp; infectious Diseases 1998;31(2):355&#x2010;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9635910</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mehtar 1997 {published data only}</Title><Reference><Citation>Mehtar S, Dewar EP, Leaper DJ, Taylor EW. A multi&#x2010;centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. Journal of Antimicrobial Chemotherapy 1997;39(5):631&#x2010;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184363</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Messick 1998 {published data only}</Title><Reference><Citation>Messick CR, Mamdani M, McNicholl IR, Danziger LH, Rodvold KA, Condon RE, et al. Pharmacoeconomic analysis of ampicillin&#x2010;sulbactam versus cefoxitin in the treatment of intraabdominal infections. Pharmacotherapy 1998;18(1):175&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9469691</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mullick 1987 {published data only}</Title><Reference><Citation>Mullick RN, Zissis NP. Piperacillin versus gentamicin&#x2010;clindamycin combination in intra&#x2010;abdominal infections. Current Therapeutic Research &#x2010; Clinical and Experimental 1987;41(4):536&#x2010;541.</Citation></Reference></ReferenceList><ReferenceList><Title>Najem 1983 {published data only}</Title><Reference><Citation>Najem AZ, Kaminski ZC, Spillert CR, Lazaro EJ. Comparative study of parenteral piperacillin and cefoxitin in the treatment of surgical infections of the abdomen. Surgery, Gynecology &amp; Obstetrics 1983;157(5):423&#x2010;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">6635912</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Niinikoski 1993 {published data only}</Title><Reference><Citation>Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra&#x2010;abdominal infections. Surgery, Gynecology &amp; Obstetrics 1993;176(3):255&#x2010;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">8382381</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ohlin 1999 {published data only}</Title><Reference><Citation>Ohlin B, Cederberg A, Forssell H, Solhaug JH, Tveit E. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra&#x2010;abdominal infections. European Journal of Surgery 1999;165(9):875&#x2010;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">10533765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Polk 1993 {published data only}</Title><Reference><Citation>Polk HC, Fink MP, Laverdiere M, Wilson SE, Garber GE, Barie JS, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra&#x2010;abdominal infection. American Surgeon 1993;59(9):598&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">8396374</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Poularas 1988 {published data only}</Title><Reference><Citation>Poularas J, Giamarellou H, Vlachos G, Theakou R, Patoulis J, Lekakos N, et al. The treatment of gynaecological and intra&#x2010;abdominal infections: A comparative study of cefotetan versus netilmicin plus clindamycin. Chemioterapia 1988;7(4):253&#x2010;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">3180305</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Raahave 1970 {published data only}</Title><Reference><Citation>Raahave D, Poulsen PE. Perforated appendicitis and antibiotics. A survey and a controlled clinical trial. Acta Chirurgica Scandinavica 1970;136(8):715&#x2010;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">4931922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rohrborn 2000 {published data only}</Title><Reference><Citation>Rohrborn A, Wacha H, Schoffel U, Billing A, Aeberhard P, Gebhard B, et al. Coverage of enterococci in community acquired secondary peritonitis: Results of a randomized trial. Surgical Infections 2000;1(2):95&#x2010;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12594897</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schein 1994 {published data only}</Title><Reference><Citation>Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. British Journal of Surgery 1994;81(7):989&#x2010;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">7922094</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scheinin 1994 {published data only}</Title><Reference><Citation>Scheinin H, Havia T, Pekkala E, Huovinen P, Klossner J, Lehto H, et al. Aspoxicillin versus piperacillin in severe abdominal infections &#x2010; a comparative phase III study. Journal of Antimicrobial Chemotherapy 1994;34(5):813&#x2010;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706179</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schentag 1983 {published data only}</Title><Reference><Citation>Schentag JJ, Wels PB, Reitberg DP, Walczak P, Tyle JH, Lascola RJ. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Annals of Surgery 1983;198(1):35&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352928</ArticleId><ArticleId IdType="pubmed">6222710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scott 1987a {published data only}</Title><Reference><Citation>Scott SD, Karran SJ. Cefotetan in the treatment of serious intra&#x2010;abdominal sepsis: a controlled clinical trial. International Journal of Clinical Pharmacological Research 1987;VII(3):229&#x2010;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">3298087</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sirinek 1987 {published data only}</Title><Reference><Citation>Sirinek KR, Levine BA. Antimicrobial management of surgically treated gangrenous or perforated appendicitis: comparison of cefoxitin and clindamycin&#x2010;gentamicin. Clinical Therapeutics 1987;9(4):420&#x2010;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">3607822</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sirinek 1991 {published data only}</Title><Reference><Citation>Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surgery, Gynecology &amp; Obstetrics 1991;172(Suppl):30&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">2024224</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1982 {published data only}</Title><Reference><Citation>Smith JA, Forward AD, Skidmore AG, Bell GA, Murphy JM. Metronidazole and tobramycin in intra&#x2010;abdominal sepsis. Surgery, Gynecology &amp; Obstetrics 1982;155(2):235&#x2010;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">7101115</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1983 {published data only}</Title><Reference><Citation>Smith JA, Forward AD, Skidmore AG, Bell GA, Murphy JM, Sutherland E. Metronidazole in the treatment of intra&#x2010;abdominal sepsis. Surgery 1983;93(1 Part 2):217&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">6336865</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1984 {published data only}</Title><Reference><Citation>Smith CR, Ambinder R, Lipsky JJ, Petty BG, Israel E, Levitt R, et al. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double&#x2010;blind trial. Annals of Internal Medicine 1984;101(4):469&#x2010;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">6089633</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 1985 {published data only}</Title><Reference><Citation>Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. The American Journal of Medicine 1985;78(Suppl 6A):85&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">3890538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 1990 {published data only}</Title><Reference><Citation>Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra&#x2010;abdominal infections. Annals of Surgery 1990;212(5):581&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1358185</ArticleId><ArticleId IdType="pubmed">2241313</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 1996 {published data only}</Title><Reference><Citation>Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra&#x2010;abdominal infections. Annals of Surgery 1996;223(3):303&#x2010;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235120</ArticleId><ArticleId IdType="pubmed">8604912</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 2003 {published data only}</Title><Reference><Citation>Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery 2003;237(2):235&#x2010;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1522141</ArticleId><ArticleId IdType="pubmed">12560782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stellato 1988 {published data only}</Title><Reference><Citation>Stellato TA, Danziger LH, Hau T, Gauderer MWL, Ferron JL, Gordon N. Moxalactam versus tobramycin&#x2010;clindamycin. A randomized trial in secondary peritonitis. Archives of Surgery 1988;123(6):714&#x2010;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">3285809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1975 {published data only}</Title><Reference><Citation>Stone HH, Kolb LD, Geheber CE, Currie CA. Treatment of surgical infections with tobramycin. The American Surgeon 1975;41(5):301&#x2010;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">1130763</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1978 {published data only}</Title><Reference><Citation>Stone HH, Guest BS, Geheber CE, Kolb LD. Cefamandole in treatment of peritonitis. Journal of Infectious Diseases 1978;137(Suppl):S103&#x2010;S109.</Citation><ArticleIdList><ArticleId IdType="pubmed">649995</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1981 {published data only}</Title><Reference><Citation>Stone HH, Geheber CE, Kolb LD, Dunlop WE. Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft&#x2010;tissue surgical sepsis. Clinical Therapeutics 1981;4(Suppl A):67&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">6275999</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1982a {published data only}</Title><Reference><Citation>Stone HH, Geheber CE, Kolb LD, Strom PR. Clinical evaluation of cefotaxime versus gentamicin plus clindamycin in the treatment of polymicorbial peritonitis. Clinical Therapeutics 1982;5(A):1&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6293712</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1982b {published data only}</Title><Reference><Citation>Stone HH, Morris ES, Geheber CE, Kolb LD, Dunlop WE. Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft tissue infections. Reviews of Infectious Diseases 1982;4(Suppl):S439&#x2010;S443.</Citation><ArticleIdList><ArticleId IdType="pubmed">6294796</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1983a {published data only}</Title><Reference><Citation>Stone HH. Metronidazole in the treatment of surgical sepsis. Surgery 1983;93(1 Pt 2):230&#x2010;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849210</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1983b {published data only}</Title><Reference><Citation>Stone HH, Strom PR, Fabian TC, Dunlop WE. Third generation cephalosporins for polymicrobial surgical sepsis. Archives of Surgery 1983;118(2):193&#x2010;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">6295339</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1984 {published data only}</Title><Reference><Citation>Stone HH, Mullins RJ, Strom PR, Bourneuf AA, Geheber CE. Ceftriaxone versus combined gentamicin and clindamycin for polymicrobial surgical sepsis. The American Journal of Surgery 1984;148(4A):30&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">6091478</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tally 1981 {published data only}</Title><Reference><Citation>Tally FP, McGowan K, Kellum JM, Gorbach SL, O'Donnell TF. A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis. Annals of Surgery 1981;193(3):318&#x2010;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345068</ArticleId><ArticleId IdType="pubmed">7011222</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tally 1986 {published data only}</Title><Reference><Citation>Tally FP, Kellum JM, Ho JL, O'Donnell TF, Barza M, Gorbach SL. Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections. Antimicrobial Agents and Chemotherapy 1986;29(2):244&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC176385</ArticleId><ArticleId IdType="pubmed">3717931</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Taylor 2000 {published data only}</Title><Reference><Citation>Taylor E, Dev V, Shah D, Festekjian J, Gaw F. Complicated appendicitis: Is there a minimum intravenous antibiotic requirement? A prospective randomized trial. The American Surgeon 2000;66(9):887&#x2010;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993623</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tellado 2002 {published data only}</Title><Reference><Citation>Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H. Ertapenem versus piperacillin&#x2010;tazobactam for treatment of mixed anaerobic complicated intra&#x2010;abdominal, complicated skin and skin structure, and acute pelvic infections. Surgical Infections 2002;3(4):303&#x2010;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697078</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Teppler 2004 {published data only}</Title><Reference><Citation>Teppler H, Meibohm AR, Woods GL. Management of complicated appendicitis and comparison of outcome with other primary sites of intra&#x2010;abdominal infections: Results of a trial comparing ertapenem and piperacillin&#x2010;tazobactam. Journal of Chemotherapy 2004;16(1):62&#x2010;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078001</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vestweber 1994 {published data only}</Title><Reference><Citation>Vestweber K&#x2010;H, Grundel E. Efficacy and safety of piperacillin/tazobactam in intra&#x2010;abdominal infections. European Journal of Surgery 1994;Suppl 573:57&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7524797</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Walters 1999 {published data only}</Title><Reference><Citation>Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem&#x2010;cilastatin in the treatment of intra&#x2010;abdominal infections. Pharmacoeconomics 1999;16(5 Pt 2):551&#x2010;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">10662480</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Williams 1991 {published data only}</Title><Reference><Citation>Williams RR, Hotchkin D. Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections. Reviews of Infectious Diseases 1991;13(Suppl 7):S629&#x2010;S633.</Citation><ArticleIdList><ArticleId IdType="pubmed">2068472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wilson 1988a {published data only}</Title><Reference><Citation>Wilson SE, Boswick JA Jr, Duma RJ, Echols RM, Jemsek JG, Lerner R, et al. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam and cefoxitin. The American Journal of Surgery 1988;155(5A):61&#x2010;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">3287971</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wilson 1997 {published data only}</Title><Reference><Citation>Wilson SE. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra&#x2010;abdominal infections. Clinical Infectious Diseases 1997;24(Suppl 2):S197&#x2010;S206.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Winston 1980 {published data only}</Title><Reference><Citation>Winston DJ, Murphy W, Young LS, Hewitt WL. Piperacillin therapy for serious bacterial infections. The American Journal of Medicine 1980;69(2):255&#x2010;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">6447455</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yellin 1993 {published data only}</Title><Reference><Citation>Yellin AE, Berne TV, Heseltine PNR, Appleman MD, Gill M, Chin A, et al. Prospective randomized study of two different doses of clindamycin admixed with gentamicin in the management of perforated appendicitis. The American Surgeon 1993;59(4):248&#x2010;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489087</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yellin 2002 {published data only}</Title><Reference><Citation>Yellin AE, Hassett JM, Fernandez A, Geib J, Adeyi B, Woods GL, et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra&#x2010;abdominal infections in adults. International Journal of Antimicrobial Agents 2002;20(3):165&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12385694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yoshioka 1991 {published data only}</Title><Reference><Citation>Yoshioka K, Youngs DJ, Keighley MRB. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra&#x2010;abdominal infection. Infection 1991;19(1):25&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">2013505</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Alderson 2004</Title><Reference><Citation>Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers&#x2019; Handbook 4.2.2 [updated March 2004]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd, 2004.</Citation></Reference></ReferenceList><ReferenceList><Title>Bohnen 1983</Title><Reference><Citation>Bohnen J, Boulanger M, Meakins JL, McLean AP. Prognosis in generalized peritonitis. Relation to cause and risk factors. Archives of Surgery 1983;118(3):285&#x2010;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">6824428</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bohnen 1992</Title><Reference><Citation>Bohnen JMA, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti&#x2010;infective agents for intra&#x2010;abdominal infection. A Surgical Infection Society policy statement. Archives of Surgery 1992;127:83&#x2010;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734854</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bosscha 1999</Title><Reference><Citation>Bosscha K, Vroonhoven TJMV, Werken C. Surgical management of severe secondary peritonitis. British Journal of Surgery 1999;86(11):1371&#x2010;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">10583280</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Christou 1993</Title><Reference><Citation>Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra&#x2010;abdominal infection study. Prospective evaluation of management techniques and outcome. Archives of Surgery 1993;128(2):193&#x2010;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Copeland 2002</Title><Reference><Citation>Copeland GP. The POSSUM system of surgical audit. Archives of Surgery 2002;137(1):15&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11772209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Egger 2001</Title><Reference><Citation>Egger M, Smith GD, Altman DG. Systematic reviews in health care: Meta&#x2010;analysis in context. Second Edition. London: BMJ Publishing Group, 2001.</Citation></Reference></ReferenceList><ReferenceList><Title>Holzheimer 2001</Title><Reference><Citation>Holzheimer RG, Dralle H. Antibiotic therapy in intra&#x2010;abdominal infections: a review on randomised clinical trials. European Journal of Medical Research 2001;6(7):277&#x2010;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11485888</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jones 1992</Title><Reference><Citation>Jones DR, Copeland GP, Cossart L. Comparison of POSSUM with APACHE II for prediction of outcome from a surgical high&#x2010;dependency unit. British Journal of Surgery 1992;79(12):1293&#x2010;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">1486421</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knaus 1985</Title><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985;13(10):818&#x2010;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mazuski 2002a</Title><Reference><Citation>Mazuski JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA and Yowler C for The Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra&#x2010;abdominal infections: an executive summary. Surgical Infections 2002;3(3):161&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mazuski 2002b</Title><Reference><Citation>Mazuski JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA and Yowler C for The Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra&#x2010;abdominal infections: evidence for the recommendations. Surgical Infections 2002;3(3):175&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542923</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mc Lauchlan 1995</Title><Reference><Citation>McLauchlan GJ, Anderson ID, Grant IS, Fearon KCH. Outcome of patients with abdominal sepsis treated in an intensive care unit. British Journal of Surgery 1995;82(4):524&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7613902</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mulier 2003</Title><Reference><Citation>Mulier S, Penninckx F, Verwaest C, Filez L, Aerts R, Fieuws S, Lauwers P. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World Journal of Surgery 2003;27(4):379&#x2010;384. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">12658477</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nichols 1992</Title><Reference><Citation>Nichols RL, Muzik AC. Enterococcal infection in surgical patients: the mystery continues. Clinical Infectious Diseases 1992;15(1):72&#x2010;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1617075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ohmann 1993</Title><Reference><Citation>Ohmann C, Wittmann DH, Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. European Journal of Surgery 1993;159(5):267&#x2010;274. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">8103360</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pacelli 1996</Title><Reference><Citation>Pacelli F, Doglietto GB, Alfieri S, Piccioni E, Sgadari A, Gui D, Crucitti F. Prognosis in intra&#x2010;abdominal infections. Multivariate analysis on 604 patients. Archives of Surgery 1996;131(6):641&#x2010;645. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">8645072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schein 2002</Title><Reference><Citation>Schein M, Marshall JC. Source control: A guide to the management of surgical infections. Italy: Springer&#x2010;Verlag, 2002.</Citation></Reference></ReferenceList><ReferenceList><Title>Solomkin 1984</Title><Reference><Citation>Solomkin JS, Meakin JL, Alo MD, Dellinger EP, Simmons RL. Antibiotics trials in intra&#x2010;abdominal infections. A critical evaluation of study design and outcome reporting. Annals of Surgery 1984;200:29&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250388</ArticleId><ArticleId IdType="pubmed">6375597</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tellado 2000</Title><Reference><Citation>Tellado JM, Christou NV. Intra&#x2010;abdominal infections. Madrid: Harcourt, 2000.</Citation></Reference></ReferenceList><ReferenceList><Title>Wittmann 1990</Title><Reference><Citation>Wittmann DH, Aprahamian C, Bergstein JM. Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure. World Journal of Surgery 1990;14(2):218&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2183485</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wittmann 1996</Title><Reference><Citation>Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Annals of Surgery 1996;224(1):10&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235241</ArticleId><ArticleId IdType="pubmed">8678610</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25616698</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2015</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>Surgical treatment of ipsilateral multi-level femoral fractures.</ArticleTitle><Pagination><StartPage>7</StartPage><MedlinePgn>7</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-014-0149-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Concurrent ipsilateral fractures of the proximal and shaft of the femur are rare complex fracture combinations. In this prospective cohort study, we evaluated clinical and radiological long-term results after operative treatment using several surgical strategies: the so-called "rendezvous" surgical technique, e.g., the combination of retrograde intramedullary nailing and dynamic hip screw (DHS) osteosynthesis, or the all-in-one device technique, e.g., long cephalomedullary nail, compared with two non-overlapping implants (e.g., conventional technique).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a 10-year-period from 2004 to 2013, we treated 65 patients with complex ipsilateral multi-level femoral fractures. Median age was 45&#xa0;years (range 19-90 years). Fractures were classified according to the AO/OTA classification. Four patients died during intensive care unit treatment due to multi-organ failure prior to definitive osteosynthesis. Clinical long-term outcome using the functional system of Friedman/Wyman as well as radiological outcome was evaluated 2&#xa0;years after trauma (range 13-42 months).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All-in-one device was used in 36 patients, "rendezvous" technique in 9 patients, and the conventional technique in the remaining 16 patients. Two years after trauma, complete fracture healing was found in 57 out of 61 patients ("rendezvous": 9, all-in-one device: 33, conventional: 15; p-value: 0.66). There was no significant difference regarding the complication rate in the cohort groups ("rendezvous": 3, all-in-one device: 13, conventional: 5; p-value: 0.94). Using the functional assessment system of Friedman/Wyman 2&#xa0;years after trauma, a good clinical result was found in 77.7% in the "rendezvous" group, in 77.8% in the all-in-one device group, and in 75% in the conventional group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The indication for operative stabilization of ipsilateral multi-level femoral fractures is considered an urgent and emergency procedure. Based on the successful long-term results of this study, we prefer the "rendezvous" technique with fracture stabilization from distally to proximally. Both fracture components require stable fixation. It is advisable to stabilize the shaft fracture primarily using external fixation (damage control orthopedics) and the proximal femoral fracture using early definitive internal fixation. In a second and staged operation, the external fixator is removed and the shaft fracture is stabilized using retrograde nail osteosynthesis with overlapping of the DHS and nail implants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von R&#xfc;den</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. christian.vonrueden@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tauber</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. markus.tauber@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltmann</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. alexander.woltmann@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friederichs</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. jan.friederichs@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackl</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. simon.hackl@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;hren</LastName><ForeName>Volker</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. volker.buehren@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hierholzer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. christian.hierholzer@bgu-murnau.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005264" MajorTopicYN="N">Femoral Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005594" MajorTopicYN="N">Fracture Fixation, Intramedullary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069076" MajorTopicYN="N">Fractures, Multiple</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25616698</ArticleId><ArticleId IdType="pmc">PMC4335365</ArticleId><ArticleId IdType="doi">10.1186/s13018-014-0149-5</ArticleId><ArticleId IdType="pii">s13018-014-0149-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chaturvedi S, Sahu SC. Ipsilateral concomitant fractures of the femoral neck and shaft. Injury. 1993;24:243&#x2013;6. doi: 10.1016/0020-1383(93)90178-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0020-1383(93)90178-9</ArticleId><ArticleId IdType="pubmed">8325681</ArticleId></ArticleIdList></Reference><Reference><Citation>Alho A, Ekeland A, Grogaard B, Dokke JR. A locked hip screw-intramedullary nail (cephalomedullary nail) for the treatment of fractures of the proximal part of the femur combined with fractures of the femoral shaft. J Trauma. 1996;40:10&#x2013;6. doi: 10.1097/00005373-199601000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199601000-00003</ArticleId><ArticleId IdType="pubmed">8576969</ArticleId></ArticleIdList></Reference><Reference><Citation>Alho A. Concurrent ipsilateral fractures of the hip and shaft of the femur: a systematic review of 722 cases. Ann Chir Gynaecol. 1997;86:326&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas NP, Sch&#xfc;tz M, Mauch C, Hoffmann R, S&#xfc;dkamp NP. Management of ipsilateral fractures of the femur shaft and proximal femur - therapy overview and current management. Zentralbl Chir. 1995;120:856&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8533480</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman RJ, Wyman ET. Ipsilateral hip and femoral shaft fractures. Clin Orthop Relat Res. 1986;208:188&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">3720122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuler TE, Gruen GS, DiTano O, Riemer BL. Ipsilateral proximal and shaft femoral fractures: spectrum of injury involving the femoral neck. Injury. 1997;28(4):293&#x2013;7. doi: 10.1016/S0020-1383(96)00199-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(96)00199-4</ArticleId><ArticleId IdType="pubmed">9282185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SH, Lo CW, Cheng SC, Kuo MY, Chin LS. Use of reconstruction nails to manage ipsilateral displaced femoral neck-shaft fractures: assessment of a new approach. J Orthop Surg. 2002;20:185&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493933</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Labler L, Trentz O. &#x201c;Damage control&#x201d; in severely injured patients. Why, when, and how? Eur J Trauma Emerg Surg. 2005;31:212&#x2013;21. doi: 10.1007/s00068-005-2034-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-005-2034-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover GK, Browner BD, Cole JD, Comstock CP, Cotler HB. Initial experience with a second generation locking femoral nail: the Russel-Taylor reconstruction nail. Contemp Orthop. 1991;23(3):199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10149652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali K, Gahlot N, Aggarwal S, Goni V. Cephalomedullary fixation for femoral neck/intertrochanteric and ipsilateral shaft fractures: surgical tips and pitfalls. Chin J Traumatol. 2013;16(1):40&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23384870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsarouhas A, Hantes ME, Karachalios T, Bargiotas K, Malizos KN. Reconstruction nailing for ipsilateral femoral neck and shaft fractures. Strategies Traum Limb Reconstr. 2011;6:69&#x2013;75. doi: 10.1007/s11751-011-0117-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11751-011-0117-0</ArticleId><ArticleId IdType="pmc">PMC3150652</ArticleId><ArticleId IdType="pubmed">21779894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadegone WM, Lokhande V, Salphale Y, Ramteke A. Long proximal femoral nail in ipsilateral fractures of proximal femur and shaft of femur. Indian J Orthop. 2013;47(3):272&#x2013;7. doi: 10.4103/0019-5413.109441.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5413.109441</ArticleId><ArticleId IdType="pmc">PMC3687904</ArticleId><ArticleId IdType="pubmed">23798758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MC, Wu CC, Hsiao CW, Huang JW, Kao HK, Hsu YT. Reconstruction intramedullary nailing for ipsilateral femoral neck and shaft fractures: main factors determining prognosis. Chang Gung Med J. 2009;32(5):563&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19840514</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KS, So WS, Lam TP, Leung PC. Treatment of ipsilateral femoral shaft fractures and hip fractures. Injury. 1993;24(1):41&#x2013;5. doi: 10.1016/0020-1383(93)90082-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0020-1383(93)90082-H</ArticleId><ArticleId IdType="pubmed">8432574</ArticleId></ArticleIdList></Reference><Reference><Citation>Okcu G, Aktuglu K. Antegrade nailing of femoral shaft fractures combined with neck or distal femur fractures. Arch Orthop Trauma Surg. 2003;123:544&#x2013;50. doi: 10.1007/s00402-003-0584-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-003-0584-y</ArticleId><ArticleId IdType="pubmed">13680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Anup K, Mehra MM. Retrograde femoral interlocking nail in complex fractures. J Orthop Surg. 2002;10(1):17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Chen TB, Cheng YM, Chang JK, Lin SY, Hung SH. Ipsilateral fractures of the femoral neck and shaft. Injury. 2000;31:719&#x2013;22. doi: 10.1016/S0020-1383(00)00096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(00)00096-6</ArticleId><ArticleId IdType="pubmed">11084160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37808065</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-2736</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JTCVS open</Title><ISOAbbreviation>JTCVS Open</ISOAbbreviation></Journal><ArticleTitle>Effect of red blood cell storage time in pediatric cardiac surgery patients: A subgroup analysis of a randomized controlled trial.</ArticleTitle><Pagination><StartPage>454</StartPage><EndPage>467</EndPage><MedlinePgn>454-467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xjon.2023.04.022</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to determine whether or not transfusion of fresh red blood cells (RBCs) reduced the incidence of new or progressive multiple organ dysfunction syndrome compared with standard-issue RBCs in pediatric patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Preplanned secondary analysis of the Age of Blood in Children in Pediatric Intensive Care Unit study, an international randomized controlled trial. This study included children enrolled in the Age of Blood in Children in Pediatric Intensive Care Unit trial and admitted to a pediatric intensive care unit after cardiac surgery with cardiopulmonary bypass. Patients were randomized to receive either fresh (stored &#x2264;7&#xa0;days) or standard-issue RBCs. The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured up to 28&#xa0;days postrandomization or at pediatric intensive care unit discharge, or death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">One hundred seventy-eight patients (median age, 0.6&#xa0;years; interquartile range, 0.3-2.6 years) were included with 89 patients randomized to the fresh RBCs group (median length of storage, 5&#xa0;days; interquartile range, 4-6&#xa0;days) and 89 to the standard-issue RBCs group (median length of storage, 18&#xa0;days; interquartile range, 13-22&#xa0;days). There were no statistically significant differences in new or progressive multiple organ dysfunction syndrome between fresh (43 out of 89 [48.3%]) and standard-issue RBCs groups (38 out of 88 [43.2%]), with a relative risk of 1.12 (95% CI, 0.81 to 1.54; <i>P</i>&#xa0;=&#xa0;.49) and an unadjusted absolute risk difference of 5.1% (95% CI, -9.5% to 19.8%; <i>P</i>&#xa0;=&#xa0;.49).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In neonates and children undergoing cardiac surgery with cardiopulmonary bypass, the use of fresh RBCs did not reduce the incidence of new or progressive multiple organ dysfunction syndrome compared with the standard-issue RBCs. A larger trial is needed to confirm these results.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Sophie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinella</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Departments of Surgery and Critical Care Medicine, Pittsburgh University, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de recherche clinique appliqu&#xe9;e, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freed</LastName><ForeName>Darren H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivarajan</LastName><ForeName>Venkatesan B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Pediatric Cardiac Intensive Care, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Divisions of Hematology/Oncology and Critical Care, Department of Pediatrics, University of Minnesota, Minneapolis, Minn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willems</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Intensive Care, Leiden University Hospital, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia Guerra</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care, Department of Pediatrics, Alberta Children's Hospital; University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Age of Blood in Children in Pediatric Intensive Care Unit Trial Investigators</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Canadian Critical Care Trials Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Pediatric Acute Lung Injury and Sepsis Investigators Network</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>BloodNet Pediatric Critical Care Blood Research Network</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Groupe Francophone de R&#xe9;animation et Urgences P&#xe9;diatriques</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL116383</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JTCVS Open</MedlineTA><NlmUniqueID>101768541</NlmUniqueID><ISSNLinking>2666-2736</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">critical care medicine</Keyword><Keyword MajorTopicYN="N">erythrocyte</Keyword><Keyword MajorTopicYN="N">length of storage</Keyword><Keyword MajorTopicYN="N">pediatric cardiac surgery</Keyword><Keyword MajorTopicYN="N">red blood cell</Keyword><Keyword MajorTopicYN="N">transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37808065</ArticleId><ArticleId IdType="pmc">PMC10556812</ArticleId><ArticleId IdType="doi">10.1016/j.xjon.2023.04.022</ArticleId><ArticleId IdType="pii">S2666-2736(23)00116-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spinella P.C., Dressler A., Tucci M., Carroll C.L., Rosen R.S., Hume H., et al. Survey of transfusion policies at US and Canadian children&#x2019;s hospitals in 2008 and 2009. Transfusion. 2010;50:2328&#x2013;2335. doi: 10.1111/j.1537-2995.2010.02708.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02708.x</ArticleId><ArticleId IdType="pubmed">20529008</ArticleId></ArticleIdList></Reference><Reference><Citation>Flegel W.A., Natanson C., Klein H.G. Does prolonged storage of red blood cells cause harm? Br J Haematol. 2014;165:3&#x2013;16. doi: 10.1111/bjh.12747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12747</ArticleId><ArticleId IdType="pmc">PMC5515544</ArticleId><ArticleId IdType="pubmed">24460532</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella P.C., Tucci M., Fergusson D.A., Lacroix J., H&#xe9;bert P.C., Leteurtre S., et al. Effect of fresh vs standard-issue red blood cell transfusions on multiple organ dysfunction syndrome in critically ill pediatric patients: a randomized clinical trial. JAMA. 2019;322:2179&#x2013;2190. doi: 10.1001/jama.2019.17478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.17478</ArticleId><ArticleId IdType="pmc">PMC7081749</ArticleId><ArticleId IdType="pubmed">31821429</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D.A., H&#xe9;bert P., Hogan D.L., LeBel L., Rouvinez-Bouali N., Smyth J.A., et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308:1443&#x2013;1451. doi: 10.1001/2012.jama.11953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2012.jama.11953</ArticleId><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabangi A., Ainomugisha B., Cserti-Gazdewich C., Ddungu H., Kyeyune D., Musisi E., et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial. JAMA. 2015;314:2514&#x2013;2523. doi: 10.1001/jama.2015.13977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.13977</ArticleId><ArticleId IdType="pubmed">26637812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholette J.M., Willems A., Valentine S.L., Bateman S.T., Schwartz S.M. Recommendations on RBC transfusion in infants and children with acquired and congenital heart disease from the pediatric critical care transfusion and anemia expertise initiative. Pediatr Crit Care Med. 2018;19:S137&#x2013;S148. doi: 10.1097/PCC.0000000000001603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001603</ArticleId><ArticleId IdType="pmc">PMC6126364</ArticleId><ArticleId IdType="pubmed">30161069</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltsavias I., Faraoni D., Willems A., El Kenz H., Melot C., De Hert S., et al. Blood storage duration and morbidity and mortality in children undergoing cardiac surgery. A retrospective analysis. Eur J Anaesthesiol. 2014;31:310&#x2013;316. doi: 10.1097/EJA.0000000000000024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000024</ArticleId><ArticleId IdType="pubmed">24492183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawase H., Egi M., Kanazawa T., Shimizu K., Toda Y., Iwasaki T., et al. Storage duration of transfused red blood cells is not significantly associated with postoperative adverse events in pediatric cardiac surgery patients. Transfus Apher Sci. 2016;54:111&#x2013;116. doi: 10.1016/j.transci.2016.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2016.01.027</ArticleId><ArticleId IdType="pubmed">26856639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishnoi A.K., Garg P., Patel K., Ananthanarayanan C., Shah R., Solanki A., et al. Effect of red blood cell storage duration on outcome after paediatric cardiac surgery: a prospective observational study. Heart Lung Circ. 2019;28:784&#x2013;791. doi: 10.1016/j.hlc.2018.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2018.03.012</ArticleId><ArticleId IdType="pubmed">29706495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholette J.M., Pietropaoli A.P., Henrichs K.F., Alfieris G.M., Powers K.S., Phipps R., et al. Longer RBC storage duration is associated with increased postoperative infections in pediatric cardiac surgery. Pediatr Crit Care Med. 2015;16:227&#x2013;235. doi: 10.1097/PCC.0000000000000320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000320</ArticleId><ArticleId IdType="pmc">PMC4351137</ArticleId><ArticleId IdType="pubmed">25607740</ArticleId></ArticleIdList></Reference><Reference><Citation>Manlhiot C., McCrindle B.W., Menjak I.B., Yoon H., Holtby H.M., Brand&#xe3;o L.R., et al. Longer blood storage is associated with suboptimal outcomes in high-risk pediatric cardiac surgery. Ann Thorac Surg. 2012;93:1563&#x2013;1569. doi: 10.1016/j.athoracsur.2011.08.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2011.08.075</ArticleId><ArticleId IdType="pubmed">22137242</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner M.E., Ness P.M., Assmann S.F., Triulzi D.J., Sloan S.R., Delaney M., et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015;372:1419&#x2013;1429. doi: 10.1056/NEJMoa1414219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="pubmed">25853746</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch C.G., Sessler D.I., Duncan A.E., Mascha E.J., Li L., Yang D., et al. Effect of red blood cell storage duration on major postoperative complications in cardiac surgery: a randomized trial. J Thorac Cardiovasc Surg. 2020;160:1505&#x2013;1514.e3. doi: 10.1016/j.jtcvs.2019.09.165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2019.09.165</ArticleId><ArticleId IdType="pubmed">31813538</ArticleId></ArticleIdList></Reference><Reference><Citation>Heddle N.M., Cook R.J., Arnold D.M., Liu Y., Barty R., Crowther M.A., et al. Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016;375:1937&#x2013;1945. doi: 10.1056/NEJMoa1609014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609014</ArticleId><ArticleId IdType="pubmed">27775503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M., Lacroix J., Fergusson D., Doctor A., H&#xe9;bert P., Berg R.A., et al. The age of blood in pediatric intensive care units (ABC PICU): study protocol for a randomized controlled trial. Trials. 2018;19:404. doi: 10.1186/s13063-018-2809-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-018-2809-y</ArticleId><ArticleId IdType="pmc">PMC6064163</ArticleId><ArticleId IdType="pubmed">30055634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., H&#xe9;bert P., Fergusson D., Tinmouth A., Blajchman M.A., Callum J., et al. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev. 2011;25:197&#x2013;205. doi: 10.1016/j.tmrv.2011.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2011.03.001</ArticleId><ArticleId IdType="pubmed">21550205</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F., Fayon M., Farrell C.A., Lacroix J., Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109:1033&#x2013;1037. doi: 10.1378/chest.109.4.1033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., H&#xe9;bert P.C., Hutchison J.S., Hume H.A., Tucci M., Ducruet T., et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609&#x2013;1619. doi: 10.1056/NEJMoa066240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066240</ArticleId><ArticleId IdType="pubmed">17442904</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S., Duhamel A., Salleron J., Grandbastien B., Lacroix J., Leclerc F. PELOD-2: an update of the Pediatric Logistic Organ Dysfunction Score. Crit Care Med. 2013;41:1761&#x2013;1773. doi: 10.1097/CCM.0b013e31828a2bbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas N.J., Shaffer M.L., Willson D.F., Shih M.C., Curley M.A. Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med. 2010;11:12&#x2013;17. doi: 10.1097/PCC.0b013e3181b0653d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b0653d</ArticleId><ArticleId IdType="pmc">PMC2936504</ArticleId><ArticleId IdType="pubmed">19561556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard G.R., Artigas A., Brigham K.L., Carlet J., Falke K., Hudson L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818&#x2013;824. doi: 10.1164/ajrccm.149.3.7509706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.149.3.7509706</ArticleId><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies M.G., Gurney J.G., Yen A.H., Napoli M.L., Gajarski R.J., Ohye R.G., et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11:234&#x2013;238. doi: 10.1097/PCC.0b013e3181b806fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b806fc</ArticleId><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien S.M., Clarke D.R., Jacobs J.P., Jacobs M.L., Lacour-Gayet F.G., Pizarro C., et al. An empirically based tool for analyzing mortality associated with congenital heart surgery. J Thorac Cardiovasc Surg. 2009;138:1139&#x2013;1153. doi: 10.1016/j.jtcvs.2009.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.03.071</ArticleId><ArticleId IdType="pubmed">19837218</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B., Giroir B., Randolph A. International Consensus Conference on&#xa0;Pediatric Sepsis. International Pediatric Sepsis Consensus Conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit&#xa0;Care Med. 2005;6:2&#x2013;8. doi: 10.1097/01.PCC.0000149131.72248.E6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., Gauvin F., Skippen P., Cox P., Langley J.M., Matlow A.G. Nosocomial infections in the pediatric intensive care unit: epidemiology and control. Pediatr Crit Care. 2006;103:1394&#x2013;1421.</Citation></Reference><Reference><Citation>CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis. 1989;139:1058&#x2013;1059. doi: 10.1164/ajrccm/139.4.1058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/139.4.1058</ArticleId><ArticleId IdType="pubmed">2539031</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandra T., Cohen J. International Sepsis Forum definition of infection in the ICUCC. The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538&#x2013;1548. doi: 10.1097/01.ccm.0000168253.91200.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccm.0000168253.91200.83</ArticleId><ArticleId IdType="pubmed">16003060</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper D.J., McQuilten Z.K., Nichol A., Ady B., Aubron C., Bailey M., et al. Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377:1858&#x2013;1867. doi: 10.1056/NEJMoa1707572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707572</ArticleId><ArticleId IdType="pubmed">28952891</ArticleId></ArticleIdList></Reference><Reference><Citation>Redlin M., Habazettl H., Schoenfeld H., Kukucka M., Boettcher W., Kuppe H., et al. Red blood cell storage duration is associated with various clinical outcomes in pediatric cardiac surgery. Transfus Med Hemother. 2014;41:146&#x2013;151. doi: 10.1159/000357998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000357998</ArticleId><ArticleId IdType="pmc">PMC4025050</ArticleId><ArticleId IdType="pubmed">24847191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Carlucci C., Isgr&#xf2; G., Boncilli A., De Benedetti D., De la Torre T., et al. Duration of red blood cell storage and outcomes in pediatric cardiac surgery: an association found for pump prime blood. Crit Care. 2009;13:R207. doi: 10.1186/cc8217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8217</ArticleId><ArticleId IdType="pmc">PMC2811896</ArticleId><ArticleId IdType="pubmed">20025760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholette JM, Henrichs KF, Alfieris GM, Powers K.S., Phipps R., Spinelli S.L., et al. Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial. Pediatr Crit Care Med. 2012;13:290&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839819</ArticleId><ArticleId IdType="pubmed">21926663</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander P.E., Barty R., Fei Y., Vandvik P.O., Pai M., Siemieniuk R.A., et al. Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood. 2016;127:400&#x2013;410. doi: 10.1182/blood-2015-09-670950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-09-670950</ArticleId><ArticleId IdType="pubmed">26626995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36305702</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2037-7452</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>European journal of translational myology</Title><ISOAbbreviation>Eur J Transl Myol</ISOAbbreviation></Journal><ArticleTitle>Cortical bridging a union predictor: A prospective study after intramedullary nailing of the femoral shaft fractures.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10835</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4081/ejtm.2022.10835</ELocationID><Abstract><AbstractText>Early prediction of the union helps for timely intervention, reduction of hospitalization, treatment costs, and disability in cases of nonunion. With this in mind, we tried to find how long any cortical bridging predicts the union in femoral shaft fractures. A prospective study of 113 femoral shaft fractures treated with reamed, locked intramedullary nailing was performed. Radiographs were taken during months 2 to 4, 6, 9, and one-year follow-up. The cortical bridging (presence and number) was assessed by anterior-posterior and lateral views. The ROC curve provides the prediction of the union. The overall nonunion rate was 10.6% (12 of 113 fractures). Age and diabetes mellitus were statistically significant with nonunion (p value &lt; 0.001). The final analysis demonstrated that any cortical bridging at four months postoperatively was the most accurate and earlier indicator (105 of 113, 92.9% accuracy), while it was 84.9% at six months in bicortical and 80.5% accuracy at nine months in tricortical bridging. Low-cost and simple radiographic imaging presents cortical bridging in any form 4 months after surgery that precisely predicts a union in femoral shaft fractures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Najafi</LastName><ForeName>Arvin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Arvin.najafi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahbazi</LastName><ForeName>Parmida</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Parmida.shabazi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azarsina</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. salmanazarsina@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zargar</LastName><ForeName>Danoosh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. danooshzargar@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahrizi</LastName><ForeName>Mohammad Saeed</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Miladkahrizi1994@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadavi</LastName><ForeName>Dorsa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Hadavidorsa@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minaei-Noshahr</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bone, Joint and Related Tissues Research Center, Shahid Beheshti University of Medical Sciences, Tehran. reza.minaie@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur J Transl Myol</MedlineTA><NlmUniqueID>101576208</NlmUniqueID><ISSNLinking>2037-7452</ISSNLinking></MedlineJournalInfo><CoiStatement>We confirm that we have read the Journal&#x2019;s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. <b>M</b>idshaft femoral fractures, with an incidence of 10 in 100000 per year, are one of the most reasons for morbidity and mortality in lower extremity injuries. High-energy traumas, including falls, motor vehicle and motorcycle accidents, and high-velocity bullets in gunshots, are important causes of adult femoral shaft fractures. Another population suffering from these fractures are elderly females with a history of osteoporosis, experiencing low-energy traumas such as ground-level falls. Common crucial complications of femoral shaft fractures which could cause death include acute respiratory distress syndrome, fat embolism syndrome, and multi-organ failure.<sup>,</sup> Patients with femoral fractures complain about major physical impairments due to treatments such as fracture shortening or malalignment (resulting in limping and post-traumatic arthritis) and prolonged immobilization. The most important goal of the treatments is that the patients start their regular physical activities as soon as possible. While various treatment methods are available, interlocking intramedullary nailing is preferred for femoral shaft fracture fixation (successful union in 85-100%). As the beneficial results of this technique are assessed in an enormous number of studies, open reduction and plating do not assume to be the proper treatment for these fractures. One of the painful complications after the fixation surgery is nonunion, defined as proximal and distal segments' failure to unite after eight months or more than six months with no progression in the last three months.<sup>,</sup> It is worth noting that despite these timelines, some kinds of literature with more strict guidelines would suggest that we should consider the nonunion diagnosis as early as two months after the surgery. Nonunion is a common problem for most surgeons as it requires much more time to recover and increases the costs of multiple hospitalizations and healthcare services.<sup>,</sup> A method used to assess the union is radiographic cortical bridging in the cortices of the femur, which by various studies has been considered a reliable source of information to predict the union better than measuring the callus area and its quality. Although a healed fracture is described as the complete construction of all three cortices of the femur, there is still a lack of information about the cortical bridging exact numbers in different postoperative intervals to evaluate and consider the healing process as a successful result in that proper timeline. [Table: see text] The main purpose of this study was to collect precise data about the number of cortical bridgings in different intervals to obtain the accuracy of any cortical bridging callus as well as bicortical and tricortical bridging for the prediction of union or nonunion in the final results of healed fractures. [Figure: see text]</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36305702</ArticleId><ArticleId IdType="pmc">PMC9830402</ArticleId><ArticleId IdType="doi">10.4081/ejtm.2022.10835</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asplund CA, Mezzanotte TJ. Midshaft femur fractures in adults. UpToDate, Medilib, 2021. https://www.medilib.ir/uptodate/show/228</Citation></Reference><Reference><Citation>Rahman AF. The burden of road traffic injuries in South Asia: a commentary. J Coll Physicians Surg Pak. 2004;14(12):707-8. doi: 12.2004/jcpsp. 707708</Citation><ArticleIdList><ArticleId IdType="pubmed">15610625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan IA, Ahmad S, Shah MA, Ahmed S, Shafiq M, Shafaq SA. Static versus dynamic interlocking intramedullary nailing in fractures shaft of femur. Gomal Journal of Medical Sciences. 2015;13(2).</Citation></Reference><Reference><Citation>Omerovic D, Lazovic F, Hadzimehmedagic A. Static or dynamic intramedullary nailing of femur and tibia. Med Arch. 2015. Apr;69(2):110-3. doi: 10.5455/medarh.2015.69.110-113. Epub 2015 Apr 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430006</ArticleId><ArticleId IdType="pubmed">26005261</ArticleId></ArticleIdList></Reference><Reference><Citation>Karadimas EJ, Papadimitriou G, Theodoratos G, Papanikolaou A, Maris J. The effectiveness of the antegrade reamed technique: the experience and complications from 415 traumatic femoral shaft fractures. Strategies Trauma Limb Reconstr. 2009. Dec;4(3):113-21. doi: 10.1007/s11751-009-0071-2. Epub 2009 Nov 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787205</ArticleId><ArticleId IdType="pubmed">19936887</ArticleId></ArticleIdList></Reference><Reference><Citation>Basumallick MN, Bandopadhyay A. Effect of dynamization in open interlocking nailing of femoral fractures. A prospective randomized comparative study of 50 cases with a 2-year follow-up. Acta Orthop Belg. 2002. Feb;68(1):42-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11915458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shroeder JE, Mosheiff R, Khoury A, Liebergall M, Weil YA. The outcome of closed, intramedullary exchange nailing with reamed insertion in the treatment of femoral shaft nonunions. J Orthop Trauma. 2009. Oct;23(9):653-7. doi: 10.1097/BOT.0b013e3181a2a337.</Citation><ArticleIdList><ArticleId IdType="pubmed">19897987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher W, Hamblen D. Problems and pitfalls of compression fixation of long bone fractures: a review of results and complications. Injury. 1979;10(2):99-107. doi: 10.1016/s0020-1383(79)80069-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">730343</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCoster TA, Miller RA. Closed locked intramedullary nailing of femoral shaft fractures in the elderly. Iowa Orthop J. 2003;23:43-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888404</ArticleId><ArticleId IdType="pubmed">14575248</ArticleId></ArticleIdList></Reference><Reference><Citation>Devnani AS. Open reamed femoral intramedullary nailing&#x2013;revisited. Eastern J Med. 2003;8(1):7-11.</Citation></Reference><Reference><Citation>Meena R, Kundnani V, Hussain Z. Fracture of the shaft of the femur: Close vs open interlocking nailing. Indian J Orthop. 2006;40(4):243.</Citation></Reference><Reference><Citation>Bashir A, Mir B, Halwai M, Qayum A. First experience with locked intramedullary nailing of femur in Kashmir. Internet J Orthop Surg. 2008;8:1.</Citation></Reference><Reference><Citation>Nicoll E. Fractures of the tibial shaft. J Bone Joint Surg Br. 1964. Aug;46:373-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">14216447</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller ME, Perren S, Allg&#xf6;wer M, M&#xfc;ller ME, Schneider R, Willenegger H. Manual of internal fixation: techniques recommended by the AO-ASIF group: Springer Science &amp; Business Media; 1991.</Citation></Reference><Reference><Citation>Bishop JA, Palanca AA, Bellino MJ, Lowenberg DW. Assessment of compromised fracture healing. J Am Acad Orthop Surg. 2012. May;20(5):273-82. doi: 10.5435/JAAOS-20-05-273.</Citation><ArticleIdList><ArticleId IdType="pubmed">22553099</ArticleId></ArticleIdList></Reference><Reference><Citation>Canale ST, Beaty JH. Campbell's operative orthopaedics e-book: Elsevier Health Sciences; 2012.</Citation></Reference><Reference><Citation>Tay WH, de Steiger R, Richardson M, Gruen R, Balogh ZJ. Health outcomes of delayed union and nonunion of femoral and tibial shaft fractures. Injury. 2014. Oct;45(10):1653-8. doi: 10.1016/ j.injury.2014.06.025. Epub 2014 Jul 7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25062602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierholzer C, Glowalla C, Herrler M, von R&#xfc;den C, Hungerer S, B&#xfc;hren V, Friederichs J. Reamed intramedullary exchange nailing: treatment of choice of aseptic femoral shaft nonunion. J Orthop Surg Res. 2014. Oct 10;9:88. doi: 10.1186/s13018-014-0088-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201668</ArticleId><ArticleId IdType="pubmed">25300373</ArticleId></ArticleIdList></Reference><Reference><Citation>DiSilvio Jr F, Foyil S, Schiffman B, Bernstein M, Summers H, Lack WD. Long bone union accurately predicted by cortical bridging within 4 months. JBJS Open Access. 2018;3(4). doi: 10.2106/JBJS.OA.18.00012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6400511</ArticleId><ArticleId IdType="pubmed">30882051</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000. Jul;82(5):655-8. doi: 10.1302/0301-620x.82b5.9899.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963160</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik MH, Harwood P, Diggle P, Khan SA. Factors affecting rates of infection and nonunion in intramedullary nailing. J Bone Joint Surg Br. 2004. May;86(4):556-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174553</ArticleId></ArticleIdList></Reference><Reference><Citation>Strotman PK, Karunakar MA, Seymour R, Lack WD. Any Cortical Bridging Predicts Healing of Supracondylar Femur Fractures After Treatment With Locked Plating. J Orthop Trauma. 2017. Oct;31(10):538-544. doi: 10.1097/BOT.00000000 00000887.</Citation><ArticleIdList><ArticleId IdType="pubmed">28538286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma YG, Hu GL, Hu W, Liang F. Surgical factors contributing to nonunion in femoral shaft fracture following intramedullary nailing. Chin J Traumatol. 2016. Apr 1;19(2):109-12. doi: 10.1016/j.cjtee.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897920</ArticleId><ArticleId IdType="pubmed">27140219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zura R, Mehta S, Della Rocca GJ, Steen RG. Biological Risk Factors for Nonunion of Bone Fracture. JBJS Rev. 2016. Jan 5;4(1):e5. doi: 10.2106/JBJS.RVW.O.00008.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson RG, Clement RGE, Edwards KL, Scammell BE. Do smokers have greater risk of delayed and non-union after fracture, osteotomy and arthrodesis? A systematic review with meta-analysis. BMJ Open. 2016;6(11):e010303. doi: 10.1136/bmjopen-2015-010303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5129177</ArticleId><ArticleId IdType="pubmed">28186922</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36747744</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>Biomarker-based risk model to predict persistent multiple organ dysfunctions after congenital heart surgery &#xe2;&#x20ac;" A prospective observational cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-2488327</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-2488327/v1</ELocationID><Abstract><AbstractText><b>Background:</b> Multiple organ dysfunction syndrome (MODS) is an important cause of post-operative morbidity and mortality for children undergoing cardiac surgery requiring cardiopulmonary bypass (CPB). Dysregulated inflammation is widely regarded as a key contributor to bypass-related MODS pathobiology, with considerable overlap of pathways associated with septic shock. The pediatric sepsis biomarker risk model (PERSEVERE) is comprised of seven protein biomarkers of inflammation, and reliably predicts baseline risk of mortality and organ dysfunction among critically ill children with septic shock. We aimed to determine if PERSEVERE biomarkers and clinical data could be combined to derive a new model to assess the risk of persistent CPB-related MODS in the early post-operative period. <b>Methods:</b> This study included 306 patients &lt;18 years old admitted to a pediatric cardiac ICU after surgery requiring cardiopulmonary bypass (CPB) for congenital heart disease. Persistent MODS, defined as dysfunction of two or more organ systems on postoperative day 5, was the primary outcome. PERSEVERE biomarkers were collected 4 and 12 hours after CPB. Classification and Regression Tree methodology was used to derive a model to assess the risk of persistent MODS. <b>Results:</b> The optimal model containing interleukin-8 (IL-8), chemokine ligand 3 (CCL3), and age as predictor variables, had an area under the receiver operating characteristic curve (AUROC) of 0.86 (0.81-0.91) for differentiating those with or without persistent MODS, and a negative predictive value of 99% (95-100). Ten-fold cross-validation of the model yielded a corrected AUROC of 0.75. <b>Conclusions:</b> We present a novel risk prediction model to assess the risk for development of multiple organ dysfunction after pediatric cardiac surgery requiring CPB. Pending prospective validation, our model may facilitate identification of a high-risk cohort to direct interventions and studies aimed at improving outcomes via mitigation of post-operative organ dysfunction. <b>Clinical Trial Registration Number:</b> This study does not meet criteria for a clinical trial per the WHO International Clinical Trials Registry Platform as no intervention was performed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benscoter</LastName><ForeName>Alexis L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alten</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atreya</LastName><ForeName>Mihir R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>University of Cincinnati, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrnes</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>University of Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollberding</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>University of Cincinnati, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Hector R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>University of Cincinnati, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM126943</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Crit Care. 2023 May 20;27(1):193. doi: 10.1186/s13054-023-04494-7.</RefSource><PMID Version="1">37210541</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Competing interests. During the time of this study and manuscript preparation, H.R.W. and the Cincinnati Children&#x2019;s Hospital Research Foundation hold U.S. patents for the PERSEVERE biomarkers.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36747744</ArticleId><ArticleId IdType="pmc">PMC9901021</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-2488327/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-2488327</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1&#x2014;mechanisms of pathogenesis. J Card Vasc Anesth 2009,23:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybdahl B, Wahba A, Lien E. et al. The inflammatory response after open heart surgery release of heat-shock protein 70 and signaling through toll-like receptor 4. Circ 2002,105:685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839622</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Visvanathan K, et al. Cardiopulmonary bypass elicits a prominent innate immune response in children with congenital heart disease. J Thorac Cardiovasc Surg 2004,127:1523&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116021</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Horton SB, et al. The influence of bypass temperature on the systemic inflammatory response and organ injury after pediatric open surgery: a randomized trial. J Thorac Cardiovasc Surg 2011,142:174&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">21420106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahle WT, Matthews E, Kanter KR, et al. Inflammatory response after neonatal cardiac surgery and its relationship to clinical outcomes. Ann Thorac Surg 2014,97:950&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">24424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan CK, Newburger JW, McGrath E, et al. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg 2010,111:1244&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">20829561</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC. The clinical implications of the systemic inflammatory reaction related to cardiac operations in children. Cardiol Young 2003, 13:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">12903869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubicki R, Grohmann J, Siepe M, et al. Early prediction of capillary leak syndrome in infants after cardiopulmonary bypass. Eur J Cardiothorac Surg 2013,44:275&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">23389476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Jeffries HE, Zimmerman JJ, et al. Sepsis in the pediatric cardiac intensive care unit. World J Pediatr Congenit Heart Surg 2011,2:393&#x2013;39912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277844</ArticleId><ArticleId IdType="pubmed">22337571</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartmann ME, et al. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med 2017,18(3):S4&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Lacroix JR. Monitoring severity of multiple organ dysfunction syndrome: new and progressive multiple organ dysfunction syndrome, scoring systems. Pediatr Crit Care Med 2017,18(3)S17&#x2013;S23.</Citation><ArticleIdList><ArticleId IdType="pubmed">28248830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich N, Allen GL, et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 2009,37:1558&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747356</ArticleId><ArticleId IdType="pubmed">19325468</ArticleId></ArticleIdList></Reference><Reference><Citation>Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 2011,9:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033193</ArticleId><ArticleId IdType="pubmed">21171879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011,12:165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924462</ArticleId><ArticleId IdType="pubmed">20473243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Salsibury S, Qiang Xiao, et al. The pediatric sepsis biomarker risk model. Critical Care 2012,16:R147&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682273</ArticleId><ArticleId IdType="pubmed">23025259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Caldwell JT, Cvijanovich NZ, et al. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model. Sci Transl Med 2019,11(518): eaax9000. doi: 10.1126/scitranslmed.aax9000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax9000</ArticleId><ArticleId IdType="pmc">PMC7720682</ArticleId><ArticleId IdType="pubmed">31723040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Genetics and genomics in pediatric septic shock. Crit Care Med 2012,40:1618&#x2013;1626</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329642</ArticleId><ArticleId IdType="pubmed">22511139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Weiss SL, Giuliano JS Jr, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS ONE 2014,9:e86242. doi:10.1371/journal.pone.0086242</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086242</ArticleId><ArticleId IdType="pmc">PMC3906040</ArticleId><ArticleId IdType="pubmed">24489704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. AJRCCM Articles in Press 2014,doi:10.1164/rccm.201410-1864OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201410-1864OC</ArticleId><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Lindsell CJ, Pettila V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 2014,42:781&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620515</ArticleId><ArticleId IdType="pubmed">24335447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Sawa Y, Fukuyama N, et al. Preoperative glutamine administration induces heat-shock protein 70 expression and attenuates cardiopulmonary bypass-induced inflammatory response by regulating nitric oxide synthase activity. Circ 2002,106(20):260&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427658</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Warszawska JM, Schenk P, et al. Intraoperative ventilation strategy during cardiopulmonary bypass attenuates the release of matrix metalloproteinases and improves oxygenation. J Surg Research 2015,195(1):294&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">25577145</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Szerafin T, Mitterbauer A, et al. Low tidal volume ventilation during cardiopulmonary bypass reduces postoperative chemokine serum concentrations. Thorac Cardiovasc Surg 2014. 62(8):677&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">25226360</ArticleId></ArticleIdList></Reference><Reference><Citation>Khabar KSA, ElBarbary MA, Khouqeer F, et al. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clinical Immunology and Immunopathology 1997,85(1):97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9325075</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhok AB, Ojamaa K, Haridas V, et al. Cytokine response in children undergoing surgery for congenital heart disease. Pediatri Cardiol 2006, 27:408&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">16830075</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona F, Manso PH, Vincente WVA, et al. Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine 2008,42(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">18417355</ArticleId></ArticleIdList></Reference><Reference><Citation>deFontnouvelle CA, Greenberg JH, Thiessen-Philbrook HR, et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury after pediatric surgery. Ann Thorac Surg 2017,104:2072&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696070</ArticleId><ArticleId IdType="pubmed">28821332</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien SM, Clarke DR, Jacobs JP, et al. An empirically based tool for analyzing mortality associated with congenital heart disease. J Thorac Cardiovasc Surg 2009, 138(5): 1139&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">19837218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JP, O&#x2019;Brien SM, Pasquali SK, et al. Variation in outcomes for risk-stratified pediatric cardiac surgical operations: as analysis of the STS Congenital Heart Surgery Database. Ann Thorac Surg 2012,94(2):564&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006082</ArticleId><ArticleId IdType="pubmed">22704799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM. Intensive Care Med 2002,28:204&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11907665</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005,6:2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell RA, Ghanayem NS, Kuhn EM, et al. Relationship between risk-adjustment tools and the pediatric logistic organ dysfunction score. World J Pediatr Congenit Heart Surg 2014,15:16&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">24403350</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, et al. PELOD-2: an update of the Pediatric logistic organ dysfunction score. Crit Care Med 2013,41:1761&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Umsted TM, Lu CK, Freeman WM, et al. The kinetics of cardiopulmonary bypass: a dual-platform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Artificial Organs 2012,36(1):E1&#x2013;E20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22250822</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller R, Mockel M. Logistic regression and CART in the analysis of multimarker studies. Clinica Chimica Acta 2008,394_1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18455512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout D, Pagel C, et al. Incidence and risk factors for important early morbidities associated with pediatric cardiac surgery in a UK population. J Thorac Cardiovasc Surg 2019, 158(4):1185&#x2013;1196.e736.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353100</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med 2003, 31:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010,11(2):234&#x2013;238.37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Jeffries HE, Niebler RA, et al. Vasoactive-inotropic score is associated with outcome after infant cardiact surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System registries. Pediatr Crit Care Med 2014,15(6):529&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159673</ArticleId><ArticleId IdType="pubmed">24777300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessler P, Pfenninger J, Pfammatter JP, et al. Plasma levels of interleukin-8 and expression of interleukin-8 receptors on circulating neutrophils and monocytes after cardiopulmonary bypass in children. J Thorac Cardiovasc Surg 2003,126(3):718&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">14502144</ArticleId></ArticleIdList></Reference><Reference><Citation>Drennan SE, Burge KY, Szyld EG, et al. Clinical and laboratory predictors for the development of low cardiac output syndrome in infants undergoing cardiopulmonary bypass: A pilot study. J Clin Med 2021,10(4)712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7916966</ArticleId><ArticleId IdType="pubmed">33670210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorjipour F, Totonchi Z, Dehaki MG, et al. Serum levels of interleukin-6, interleukin-8, interleukin-10 and tumor necrosis factor-a, renal function biochemical parameters and clinical outcomes in pediatric cardiopulmonary bypass surgery. Perfusion 2019,34(8):651&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">31027462</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KD, Altmann C, Smits G, et al. Serum interleukin-6 and interleukin-8 are early predictors of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care 2009,13(4)R104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750143</ArticleId><ArticleId IdType="pubmed">19570208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenburger M, Tjan TDT, Schneider M, et al. The impact of the pro- and anti-inflammatory immune response on ventilation time after cardiac surgery. Cytometry B Clin Cytom 2003,53(1):70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavasar I, Miller CS, Al-Sabbagh M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. General Methods in Biomarker Research and their Applications 2015. 223&#x2013;249.</Citation></Reference><Reference><Citation>Wolpe SD, Davatelis G, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988,167(2):570&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2188834</ArticleId><ArticleId IdType="pubmed">3279154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Lindsell CJ, et al. PERSEVERE II: Redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med 2016,44(11):2010&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5201138</ArticleId><ArticleId IdType="pubmed">27513537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasser WC, Dabal RJ, Askenazi DJ, et al. Prophylactic peritoneal dialysis following cardiopulmonary bypass in children is associated with decreased inflammation and improved clinical outcomes. Congenit Heart Dis 2014,9(2):106&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">23647999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26022940</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-6749</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Medicina intensiva</Title><ISOAbbreviation>Med Intensiva</ISOAbbreviation></Journal><ArticleTitle>Predictive scoring systems in multiorgan failure: A cohort study.</ArticleTitle><Pagination><StartPage>145</StartPage><EndPage>153</EndPage><MedlinePgn>145-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medin.2015.03.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5691(15)00079-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">An evaluation is made of the hospital mortality predicting capacity of the main predictive scoring systems.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A 2-year retrospective cohort study was carried out.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A third level ICU with surgical and medical patients.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients with multiorgan failure during the first day in the ICU.</AbstractText><AbstractText Label="MAIN VARIABLES" NlmCategory="METHODS">APACHE II and IV, SAPS II and III, MPM II and hospital mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 568 patients were included. Mortality rate: 39.8% (226 patients). Discrimination (area under the ROC curve; 95% CI): APACHE IV (0.805; 0.751-0.858), SAPS II (0.755; 0.697-0.814), MPM II (0.748; 0.688-0.809), SAPS III (0.737; 0.675-0.799) and APACHE II (0.699; 0.633-0.765). MPM II showed the best calibration, followed by SAPS III. APACHE II, SAPS II and APACHE IV showed very poor calibration. Standard mortality ratio (95% CI): APACHE IV 1.9 (1.78-2.02); APACHE II 1.1 (1.07-1.13); SAPS III 1.1 (1.06-1.14); SAPS II 1.03 (1.01-1.05); MPM 0.9 (0.86-0.94).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">APACHE IV showed the best discrimination, with poor calibration. MPM II showed good discrimination and the best calibration. SAPS II, in turn, showed the second best discrimination, with poor calibration. The APACHE II calibration and discrimination values currently disadvise its use. SAPS III showed good calibration with modest discrimination. Future studies at regional or national level and in certain critically ill populations are needed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Espa&#xf1;a, S.L.U. and SEMICYUC. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xe1;nchez-Casado</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos, Complejo Hospitalario de Toledo, Toledo, Espa&#xf1;a. Electronic address: mmsc16@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hostig&#xfc;ela-Mart&#xed;n</LastName><ForeName>V A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos, Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raigal-Ca&#xf1;o</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos, Complejo Hospitalario de Toledo, Toledo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labajo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario La Paz, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Tello</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos, Hospital Moncloa, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-G&#xf3;mez</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos, Complejo Hospitalario de Toledo, Toledo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilera-Cerna</LastName><ForeName>F M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos, Complejo Hospitalario de Toledo, Toledo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Intensiva</MedlineTA><NlmUniqueID>9207689</NlmUniqueID><ISSNLinking>0210-5691</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="Y">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APACHE</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n multiorg&#xe1;nica</Keyword><Keyword MajorTopicYN="N">Escalas pron&#xf3;sticas</Keyword><Keyword MajorTopicYN="N">Hospital mortality</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">MPM</Keyword><Keyword MajorTopicYN="N">Mortalidad hospitalaria</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">Predictive scoring systems</Keyword><Keyword MajorTopicYN="N">SAPS</Keyword><Keyword MajorTopicYN="N">UCI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26022940</ArticleId><ArticleId IdType="doi">10.1016/j.medin.2015.03.005</ArticleId><ArticleId IdType="pii">S0210-5691(15)00079-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36053068</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1529-7535</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title><ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Derivation and Validation of Vasoactive Inotrope Score Trajectory Groups in Critically Ill Children With Shock.</ArticleTitle><Pagination><StartPage>1017</StartPage><EndPage>1026</EndPage><MedlinePgn>1017-1026</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0000000000003070</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To determine whether there are clinically relevant and reproducible Vasoactive Inotrope Score (VIS) trajectories in children with shock during the acute phase of critical illness.</AbstractText><AbstractText Label="DESIGN">Retrospective, observational cohort study.</AbstractText><AbstractText Label="SETTING">Two tertiary, academic PICUs.</AbstractText><AbstractText Label="PATIENTS">Children (&lt; 18 yr old) who required vasoactive infusions within 24 hours of admission to the PICU. Those admitted post cardiac surgery were excluded.</AbstractText><AbstractText Label="INTERVENTIONS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">An hourly VIS was calculated for the first 72 hours after initiation of vasoactives. Group-based trajectory modeling (GBTM) was applied to a derivation set (75% of encounters) and compared with the trajectories in a validation set (25% of encounters) using the same variables. The primary outcome was in-hospital mortality, and the secondary outcome was multiple organ dysfunction syndrome (MODS) on day 7. A total of 1,828 patients met inclusion criteria, and 309 (16.9%) died. GBTM identified four subgroups that were reproducible in the validation set: "Mild, fast resolving shock" ( n = 853 [47%]; mortality 9%), "Moderate, slow resolving shock" ( n = 422 [23%]; mortality 15%), "Moderate, prolonged shock" ( n = 312 [17%]; mortality 21%), and "Severe, prolonged shock" ( n = 241 [13%]; mortality 40%). There was a significant difference in mortality, MODS on day 7, and suspected infection ( p &lt; 0.001) across groups. The "Mild, fast resolving shock" and "Severe, prolonged shock" groups were identifiable within the first 24 hours. The "Moderate, slow resolving" and "Moderate, prolonged shock" groups were indistinguishable in the first 24 hours after initiation of vasoactives but differed in in-hospital mortality and MODS on day 7. Hydrocortisone administration was independently associated with poor outcomes in the "Mild, fast resolving shock" group.</AbstractText><AbstractText Label="CONCLUSIONS">We uncovered four distinct and reproducible VIS trajectory groups that were associated with different risk factors, response to therapy, and outcomes in children with shock. Characterizing VIS trajectory groups in the acute phase of critical illness may enable better prognostication and more targeted management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perizes</LastName><ForeName>Elitsa N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Critical Care, University of Chicago Medicine Comer Children's Hospital, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine (Health and Biomedical Informatics), Northwestern University Feinberg School of Medicine, Chicago, IL., Current affiliation for Dr. Perizes: Division of Critical Care Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD105939</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD096402</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Crit Care Med</MedlineTA><NlmUniqueID>100954653</NlmUniqueID><ISSNLinking>1529-7535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Sanchez-Pinto&#x2019;s institution received funding from National Institutes of Health (NIH) grant R01HD105939 and R21HD096402, and he received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36053068</ArticleId><ArticleId IdType="mid">NIHMS1825960</ArticleId><ArticleId IdType="pmc">PMC9722555</ArticleId><ArticleId IdType="doi">10.1097/PCC.0000000000003070</ArticleId><ArticleId IdType="pii">00130478-202212000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis*. Pediatr Crit Care Med. 2013;14(7):686&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">23897242</ArticleId></ArticleIdList></Reference><Reference><Citation>Balamuth F, Weiss SL, Neuman MI, Scott H, Brady PW, Paul R, et al. Pediatric severe sepsis in U.S. children&#x2019;s hospitals. Pediatr Crit Care Med. 2014;15(9):798&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4221502</ArticleId><ArticleId IdType="pubmed">25162514</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020;21(2):e52&#x2013;e106.</Citation><ArticleIdList><ArticleId IdType="pubmed">32032273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellazzi R, Zupan B. Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform. 2008;77(2):81&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188928</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children. JAMA Netw Open. 2020;3(8):e209271-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="pubmed">32780121</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gomez H, Chang C-CH, Clermont G, Kellum JA, Kennedy J, et al. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648512</ArticleId><ArticleId IdType="pubmed">29047353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha RM, Elmer J, Zusman BE, Desai S, Puccio AM, Okonkwo DO, et al. Intracranial Pressure Trajectories: A Novel Approach to Informing Severe Traumatic Brain Injury Phenotypes. Crit Care Med. 2018;46(11):1792&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6185785</ArticleId><ArticleId IdType="pubmed">30119071</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying Novel Sepsis Subphenotypes Using Temperature Trajectories. Am J Respir Crit Care Med. 2019;200(3):327&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680307</ArticleId><ArticleId IdType="pubmed">30789749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernovsky G, Mayer JE Jr, Jonas RA, Hanley FL, Blackstone EH, Kirklin JW, et al. Factors influencing early and late outcome of the arterial switch operation for transposition of the great arteries. J Thorac Cardiovasc Surg. 1995;109(2):289&#x2013;301; discussion &#x2212;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">7853882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11(2):234&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Jeffries HE, Niebler RA, Pasquali SK, Donohue JE, Yu S, et al. Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System Registries. Pediatr Crit Care Med. 2014;15(6):529&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159673</ArticleId><ArticleId IdType="pubmed">24777300</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh AM, Tong S, Deakyne SJ, Davidson JA, Scott HF. Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis. Pediatr Crit Care Med. 2017;18(8):750&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5548505</ArticleId><ArticleId IdType="pubmed">28486385</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bulletin of the World Health Organization. 2007;85:867&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636253</ArticleId><ArticleId IdType="pubmed">18038077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembea MM, Agus M, Akcan-Arikan A, Alexander P, Basu R, Bennett TD, et al. Pediatric organ dysfunction information update mandate (PODIUM) contemporary organ dysfunction criteria: executive summary. Pediatrics. 2022;149(Supplement_1):S1&#x2013;S12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9599725</ArticleId><ArticleId IdType="pubmed">34970673</ArticleId></ArticleIdList></Reference><Reference><Citation>Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134331</ArticleId><ArticleId IdType="pubmed">25102958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children. JAMA Netw Open. 2020;3(8):e209271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="pubmed">32780121</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. JAMA Pediatr. 2017:e172352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. New England Journal of Medicine. 2017;377(5):419&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson J, Nelson D, Holst A, Hellgren E, Friman O, Oldner A. Temporal patterns of organ dysfunction after severe trauma. Critic Care. 2021;25(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8101241</ArticleId><ArticleId IdType="pubmed">33952314</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen J-T, Phillips KM, et al. Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock. Crit Care Med. 2020;48(10):1445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32706559</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;nser MW, Ruokonen E, Pettil&#xe4; V, Ulmer H, Torgersen C, Schmittinger CA, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care. 2009;13(6):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811945</ArticleId><ArticleId IdType="pubmed">19917106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Atkinson SJ, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, et al. Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Crit Care Med. 2016;44(10):e1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026540</ArticleId><ArticleId IdType="pubmed">27270179</ArticleId></ArticleIdList></Reference><Reference><Citation>Alobaidi R, Morgan C, Basu RK, Stenson E, Featherstone R, Majumdar SR, et al. Association between fluid balance and outcomes in critically ill children: a systematic review and meta-analysis. JAMA Pediatr. 2018;172(3):257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885847</ArticleId><ArticleId IdType="pubmed">29356810</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikan AA, Zappitelli M, Goldstein SL, Naipaul A, Jefferson LS, Loftis LL. Fluid overload is associated with impaired oxygenation and morbidity in critically ill children. Pediatr Crit Care Med. 2012;13(3):253&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760565</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine SL, Sapru A, Higgerson RA, Spinella PC, Flori HR, Graham DA, et al. Fluid balance in critically ill children with acute lung injury. Crit Care Med. 2012;40(10):2883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3455114</ArticleId><ArticleId IdType="pubmed">22824936</ArticleId></ArticleIdList></Reference><Reference><Citation>Abulebda K, Cvijanovich NZ, Thomas NJ, Allen GL, Anas N, Bigham MT, et al. Post-intensive care unit admission fluid balance and pediatric septic shock outcomes: A risk-stratified analysis. Crit Care Med. 2014;42(2):397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947064</ArticleId><ArticleId IdType="pubmed">24145842</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis Subclasses: A Framework for Development and Interpretation. Crit Care Med. 2021. May 1;49(5):748&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627188</ArticleId><ArticleId IdType="pubmed">33591001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19615062</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2009</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>BioGlue and Peri-strips in lung volume reduction surgery: pilot randomised controlled trial.</ArticleTitle><Pagination><StartPage>37</StartPage><MedlinePgn>37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1749-8090-4-37</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both tissue sealants and buttressing have been advocated to reduce alveolar air leaks from staple lines following Lung Volume Reduction Surgery (LVRS). However, the long term detrimental effects of buttressing material are increasingly apparent. We performed a pilot prospective randomised self controlled trial in patients undergoing LVRS comparing BioGlue and Peri-strips as adjuncts in preventing alveolar air-leaks.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A pilot prospective self controlled clinical trial was conducted in patients undergoing LVRS. Each patient was treated with BioGlue on one side and pericardial buttress on the other side as an adjunct to the staple line. The sides were randomised for adjuncts with each patient acting as his own control. Duration of air leak, intercostal drainage and time to chest drain removal were the study end points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">10 patients undergoing the procedure were recruited between December 2005 and October 2007. There were 6 men and the mean age was 59.8 +/- 4.9 years. There was one mortality due to multi-organ failure. The BioGlue treated side had a shorter mean duration of air-leak (3.0 +/- 4.6 versus 6.5 +/- 6.9 days), lesser chest drainage volume (733 +/- 404 ml versus 1001 +/- 861) and shorter time to chest drain removal (9.7 +/- 10.6 versus 11.5 +/- 11.1 days) compared with Peri-strips.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates comparable efficacy of BioGlue and Peri-strips, however there is a trend favouring the BioGlue treated side in terms of reduction in air-leak, chest drainage volumes, duration of chest drainage and significant absence of complications. A larger sample size is needed to validate this result.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rathinam</LastName><ForeName>Sridhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regional Department of Thoracic Surgery, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, UK. srathinam@rcsed.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Babu V</ForeName><Initials>BV</Initials></Author><Author ValidYN="Y"><LastName>Nanjaiah</LastName><ForeName>Prakash</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Loubani</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kalkat</LastName><ForeName>Maninder S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Rajesh</LastName><ForeName>Pala B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C472676">Bio-glue</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014014">Tissue Adhesives</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011013" MajorTopicYN="N">Pneumonectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011650" MajorTopicYN="N">Pulmonary Alveoli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014014" MajorTopicYN="N">Tissue Adhesives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19615062</ArticleId><ArticleId IdType="pmc">PMC2722608</ArticleId><ArticleId IdType="doi">10.1186/1749-8090-4-37</ArticleId><ArticleId IdType="pii">1749-8090-4-37</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney PA, Sundaresan RS, Roper CL. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1995;109:106&#x2013;116. doi: 10.1016/S0022-5223(95)70426-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(95)70426-4</ArticleId><ArticleId IdType="pubmed">7815786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059&#x2013;2073. doi: 10.1056/NEJMoa030287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030287</ArticleId><ArticleId IdType="pubmed">12759479</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCamp MM, Blackstone EH, Naunheim KS, Krasna MJ, Wood DE, Meli YM, McKenna RJ., Jr Patient and surgical factors influencing air leak after lung volume reduction surgery: lessons learned from the National Emphysema Treatment Trial. Ann Thorac Surg. 2006;82:197&#x2013;206. doi: 10.1016/j.athoracsur.2006.02.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.02.050</ArticleId><ArticleId IdType="pubmed">16798215</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, MacNeill SJ, Goldstraw P. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med. 2000;343:239&#x2013;245. doi: 10.1056/NEJM200007273430402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200007273430402</ArticleId><ArticleId IdType="pubmed">10911005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD. Technique to reduce air leaks after resection of emphysematous lung. Ann Thorac Surg. 1994;57:1038&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">8166510</ArticleId></ArticleIdList></Reference><Reference><Citation>Stammberger U, Klepetko W, Stamatis G, Hamacher J, Schmid RA, Wisser W, Hillerjan L, Weder W. Buttressing the staple line in lung volume reduction surgery: a randomized three-center study. Ann Thorac Surg. 2000;70:1820&#x2013;1825. doi: 10.1016/S0003-4975(00)01903-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(00)01903-2</ArticleId><ArticleId IdType="pubmed">11156078</ArticleId></ArticleIdList></Reference><Reference><Citation>Porte HL, Jany t, Akkad R, Conti M, Gillet PA, Guidat A, Wurtz AJ. Randomized controlled trial of a synthetic sealent for preventing alveolar airleaks after lobectomy. Ann Thorac Surg. 2001;71:1618&#x2013;1622. doi: 10.1016/S0003-4975(01)02468-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(01)02468-7</ArticleId><ArticleId IdType="pubmed">11383810</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra-Mitjans M, Belda-Sanchis J, Rami-Porta R. Surgical sealent for preventing air leaks after pulmonary resections in patients with lung cancer update of Cochrane Database Syst Rev 2001. Cochrane Database Syst Rev. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16034884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansley P, Al-Mulhim F, Lim E, Ladas G, Goldstraw P. A prospective, randomized, controlled trial of the effectiveness of BioGlue in treating alveolar air leaks. J Thorac Cardiovasc Surg. 2006;132:105&#x2013;112. doi: 10.1016/j.jtcvs.2006.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2006.02.022</ArticleId><ArticleId IdType="pubmed">16798309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney PA, Sundaresan RS, Roper CL. Trial of a novel synthetic sealent in preventing air leaks after lung resection. Ann Thorac Surg . 2000;71:1623&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">11383811</ArticleId></ArticleIdList></Reference><Reference><Citation>Brantigan OC, Mueller E. Surgical treatment of pulmonary emphysema. Am Surg. 1957;23:789&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">13470332</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna RJ, Jr, Benditt JO, DeCamp M, Deschamps C, Kaiser L, Lee SM, Mohsenifar Z, Piantadosi S, Ramsey S, Reilly J, Utz J. Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. J Thorac Cardiovasc Surg. 2004;127:1350&#x2013;1360. doi: 10.1016/j.jtcvs.2003.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.11.025</ArticleId><ArticleId IdType="pubmed">15115992</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell GI, Solin P, Chin W, Rabinov M, Williams TJ, Esmore DS, Smith JA. Lung volume reduction surgery for emphysema. Med J Aust. 1997;167:529&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">9397040</ArticleId></ArticleIdList></Reference><Reference><Citation>Weder W, Schmid RA, Russi EW. Thoracoscopic lung volume reduction surgery for emphysema. Int Surg. 1996;81:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9028978</ArticleId></ArticleIdList></Reference><Reference><Citation>Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, Fishman AP. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006;82:431&#x2013;443. doi: 10.1016/j.athoracsur.2006.05.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.05.069</ArticleId><ArticleId IdType="pubmed">16888872</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Yoshinaga Y, Shirakusa T. Successful removal of bovine pericardium by bronchoscope after lung volume reduction surgery. Ann Thorac Surg. 2004;78:2156&#x2013;2157. doi: 10.1016/S0003-4975(03)01467-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(03)01467-X</ArticleId><ArticleId IdType="pubmed">15561058</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencher S, Deslauriers J. Late complication of bovine pericardium patches used for lung volume reduction surgery. Eur J Cardiothorac Surg. 2003;23:1059&#x2013;1061. doi: 10.1016/S1010-7940(03)00155-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(03)00155-6</ArticleId><ArticleId IdType="pubmed">12829092</ArticleId></ArticleIdList></Reference><Reference><Citation>Oey I, Waller DA. Metalloptysis: a late complication of lung volume reduction surgery. Ann Thorac Surg. 2001;71:1694&#x2013;1695. doi: 10.1016/S0003-4975(00)02303-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(00)02303-1</ArticleId><ArticleId IdType="pubmed">11383832</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamji MF, Maziak DE, Shamji FM, Matzinger FR, Perkins DG. Surgical staple metalloptysis after apical bullectomy: a reaction to bovine pericardium? Ann Thorac Surg. 2002;74:258&#x2013;261. doi: 10.1016/S0003-4975(02)03541-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(02)03541-5</ArticleId><ArticleId IdType="pubmed">12118780</ArticleId></ArticleIdList></Reference><Reference><Citation>Potaris K, Mihos P, Gakidis I. Preliminary results with the use of an albumin-glutaraldehyde tissue adhesive in lung surgery. Med Sci Monit . 2003;9:PI79&#x2013;PI83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12883462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15854933</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-6259</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>The Annals of thoracic surgery</Title><ISOAbbreviation>Ann Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Daily assessment of organ dysfunction and survival in intensive care unit cardiac surgical patients.</ArticleTitle><Pagination><StartPage>1555</StartPage><EndPage>1562</EndPage><MedlinePgn>1555-62</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study was to develop a specific postoperative score for intensive care unit (ICU) cardiac surgical patients for assessment of organ dysfunction and survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study consisted of all consecutive adult patients admitted after cardiac surgery to our ICU over a period of 3 years. Evaluation of variables was performed using the first year patients who stayed in the ICU for at least 24 hours. The reproducibility was then tested in two validation sets using all patients. Performance was assessed with the Hosmer-Lemeshow (chi2 statistics) goodness-of-fit test and receiver operating characteristic (ROC) curves and compared with the Acute Physiology and Chronic Health Evaluation (APACHE II) and Multiple Organ Dysfunction Score (MODS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3,230 patients were admitted to the ICU after cardiac surgery. Mean chi2 values for the new score were 5.8 (APACHE II, 11.3; MODS, 9.7) for the construction set, 7.2 (APACHE II, 8.0; MODS, 4.5) for the validation set I, and 5.9 for the validation set II. The mean area under the ROC curve was 0.91 (APACHE II, 0.86; MODS, 0.84) for the new score in the construction set, 0.88 (APACHE II, 0.84; MODS, 0.84) in the validation set I, and 0.92 in the validation set II.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our new 10-variable risk index performs very well, with calibration and discrimination very high, better than general severity systems; and it is an appropriate tool for daily risk stratification in ICU cardiac surgery patients. Thus, it may serve as an "expert system" for diagnosing organ failure, decision making, resource evaluation, and predicting mortality among ICU cardiac surgical patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hekmat</LastName><ForeName>Khosro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany. khosro.hekmat@uk-koeln.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroener</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stuetzer</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schwinger</LastName><ForeName>Robert H G</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Kampe</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennink</LastName><ForeName>Gerardus B W E</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Mehlhorn</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Thorac Surg</MedlineTA><NlmUniqueID>15030100R</NlmUniqueID><ISSNLinking>0003-4975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="N">Heart Transplantation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15854933</ArticleId><ArticleId IdType="doi">10.1016/j.athoracsur.2004.10.017</ArticleId><ArticleId IdType="pii">S0003-4975(04)02119-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15148271</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4539</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>22</Issue><PubDate><Year>2004</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery.</ArticleTitle><Pagination><StartPage>2755</StartPage><EndPage>2760</EndPage><MedlinePgn>2755-60</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Leukocytes in allogeneic blood transfusions are believed to be the cause of immunomodulatory events. A few trials on leukocyte removal from transfusions in cardiac surgery have been conducted, and they showed inconclusive results. We found in a previous study a decrease in mortality rates and number of infections in a subgroup of more heavily transfused patients.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Patients (n=496) undergoing valve surgery (with or without CABG) were randomly assigned in a double-blind fashion to receive standard buffy coat-depleted (PC) or prestorage, by filtration, leukocyte-depleted erythrocytes (LD). The primary end point was mortality at 90 days, and secondary end points were in-hospital mortality, multiple organ dysfunction syndrome, infections, intensive care unit stay, and hospital stay. The difference in mortality at 90 days was not significant (PC 12.7% versus LD 8.4%; odds ratio [OR], 1.52; 95% confidence interval [CI], 0.84 to 2.73). The in-hospital mortality rate was almost twice as high in the PC group (10.1% versus 5.5% in the LD group; OR, 1.99; 95% CI, 0.99 to 4.00). The incidence of multiple organ dysfunction syndrome in both groups was similar, although more patients with multiple organ dysfunction syndrome died in the PC group. LD was associated with a significantly reduced infection rate (PC 31.6% versus LD 21.6%; OR, 1.64; 95% CI, 1.08 to 2.49). In both groups, intensive care unit stay and hospital stay were similar, and postoperative complications increased with the number of transfused units.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mortality at 90 days was not significantly different; however, a beneficial effect of LD in valve surgery was found for the secondary end points of in-hospital mortality and infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilgin</LastName><ForeName>Y M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. m.y.bilgin@lumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>L M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Eijsman</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Versteegh</LastName><ForeName>M I M</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van Oers</LastName><ForeName>M H J</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006351" MajorTopicYN="N">Heart Valves</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047589" MajorTopicYN="N">Leukocyte Reduction Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15148271</ArticleId><ArticleId IdType="doi">10.1161/01.CIR.0000130162.11925.21</ArticleId><ArticleId IdType="pii">01.CIR.0000130162.11925.21</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40840228</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-0631</ISSN><JournalIssue CitedMedium="Internet"><Volume>274</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pathology, research and practice</Title><ISOAbbreviation>Pathol Res Pract</ISOAbbreviation></Journal><ArticleTitle>The role of Heme oxygenase-1 (HO-1) in sepsis-associated organ damage: A systematic review.</ArticleTitle><Pagination><StartPage>156175</StartPage><MedlinePgn>156175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prp.2025.156175</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0344-0338(25)00368-1</ELocationID><Abstract><AbstractText>Sepsis-induced myopathy is a significant cause of intensive care unit-acquired weakness (ICUAW) and a leading cause of mortality in ICU patients. ICUAW primarily affects the respiratory muscles and limb skeletal muscles, leading to prolonged mechanical ventilation and bedridden periods. This condition increases the risk of complications such as pneumonia, atelectasis, and lower extremity venous thrombosis, thereby impacting patients' quality of life and, in severe cases, jeopardizing their lives. The pathogenesis of sepsis-induced myopathy is complex, and currently, there are no effective preventive or therapeutic measures available. Heme oxygenase-1 (HO-1) catalyzes the metabolism of heme, resulting in the production of carbon monoxide (CO), biliverdin, and ferritin. It possesses anti-inflammatory, antioxidant stress response, anti-apoptotic, and tissue perfusion improvement functions. Studies have demonstrated a correlation between HO-1 and the occurrence and progression of multiple organ dysfunction syndrome in sepsis, as well as its ability to ameliorate skeletal muscle dysfunction caused by various diseases. Based on the existing literature on HO-1, sepsis, and skeletal muscle myopathy, this review aims to explore the potential mechanisms and therapeutic potential of HO-1 in the treatment of sepsis-induced myopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tonghan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongfang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ligang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhikai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhanfei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Xiangjun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergency Medicine Center&#xff0c;The First Affiliated Hospital of Shihezi University, Shihezi 832008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yukun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: annine.liu1989@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuchang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Emergency Surgery &amp; Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: tjwangyuchang@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pathol Res Pract</MedlineTA><NlmUniqueID>7806109</NlmUniqueID><ISSNLinking>0344-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.14.18</RegistryNumber><NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051547" MajorTopicYN="Y">Heme Oxygenase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009135" MajorTopicYN="Y">Muscular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heme oxygenase-1 (HO-1)</Keyword><Keyword MajorTopicYN="N">ICU-acquired weakness (ICUAW)</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Sepsis-induced myopathy</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>6</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840228</ArticleId><ArticleId IdType="doi">10.1016/j.prp.2025.156175</ArticleId><ArticleId IdType="pii">S0344-0338(25)00368-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30948879</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0975-7651</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Indian journal of surgical oncology</Title><ISOAbbreviation>Indian J Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>Perioperative Mortality in Cancer Esophagus-a Case Control Study at a High-Volume Regional Cancer Center in South India.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>90</EndPage><MedlinePgn>83-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13193-018-0825-8</ELocationID><Abstract><AbstractText>Surgery for esophageal cancers carries high rates of morbidity and mortality despite improvements in perioperative care especially with increasingly safe anesthesia and postoperative ICU care. A case control study was conducted on 713 patients operated for esophageal cancer over a period of 8&#xa0;years (2009-2016). Multiple preoperative, intraoperative, and postoperative clinical and laboratory parameters were compared between patients who succumbed to the surgery, i.e., 30-day mortality, and those who did not. Of the preoperative parameters, age&#x2009;&gt;&#x2009;58.5&#xa0;years (<i>p</i>&#x2009;=&#x2009;0.01), history of dysphagia with significant weight loss (<i>p</i>&#x2009;=&#x2009;0.028), diabetes (<i>p</i>&#x2009;=&#x2009;0.002), ischemic cardiac disease (<i>p</i>&#x2009;=&#x2009;0.0001), low FEV1&#x2009;&lt;&#x2009;69.5% (<i>p</i>&#x2009;=&#x2009;0.036), preoperative length of hospital stay&#x2009;&gt;&#x2009;6.94&#xa0;days (<i>p</i>&#x2009;=&#x2009;0.001), involvement of gastroesophageal junction (<i>p</i>&#x2009;=&#x2009;0.04), and ASA score&#x2009;&gt;&#x2009;2 (<i>p</i>&#x2009;=&#x2009;0.002) were significantly associated with perioperative mortality. Intraoperatively, blood loss (<i>p</i>&#x2009;=&#x2009;0.003), intraoperative (<i>p</i>&#x2009;=&#x2009;0.015) and postoperative (<i>p</i>&#x2009;=&#x2009;0.0001) blood transfusion, splenectomy (<i>p</i>&#x2009;=&#x2009;0.0001), and excessive intraoperative intravenous fluids (<i>p</i>&#x2009;=&#x2009;0.003) were associated with mortality. Decreased postoperative day 1 serum albumin level&#x2009;&lt;&#x2009;2.38&#xa0;mg/dl (<i>p</i>&#x2009;=&#x2009;0.0001), increased ICU stay&#x2009;&gt;&#x2009;7.32&#xa0;days (SD+/-&#x2009;=&#x2009;6.28, <i>p</i>&#x2009;=&#x2009;0.03), number of positive lymph nodes&#x2009;&gt;&#x2009;2.97 (SD+/-&#x2009;=&#x2009;4.19, <i>p</i>&#x2009;=&#x2009;0.013), conduit necrosis (<i>p</i>&#x2009;=&#x2009;0.0001), recurrent laryngeal nerve palsy (<i>p</i>&#x2009;=&#x2009;0.013), pulmonary venous thromboembolism (<i>p</i>&#x2009;=&#x2009;0.0001), multiple organ dysfunction syndrome (<i>p</i>&#x2009;=&#x2009;0.0001), LRTI (<i>p</i>&#x2009;=&#x2009;0.0001), arrhythmia (<i>p</i>&#x2009;=&#x2009;0.005), sepsis (<i>p</i>&#x2009;=&#x2009;0.0001), and ARDS (<i>p</i>&#x2009;=&#x2009;0.0001) were the postoperative complications that were significantly associated with mortality. Comprehensive patient care involving preoperative optimization, improved surgical skills, rigorous intraoperative fluid management, and dedicated intensive care units will continue to play a major role in further minimizing mortality and morbidity associated with esophageal cancer surgeries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chowdappa</LastName><ForeName>Ramachandra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Kidwai Cancer Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwari</LastName><ForeName>Ajeet Ramamani</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Kidwai Cancer Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arjunan</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Kidwai Cancer Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Althaf</LastName><ForeName>Syed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Kidwai Cancer Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rekha V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kidwai Cancer Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chunduri</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Kidwai Cancer Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Surg Oncol</MedlineTA><NlmUniqueID>101532448</NlmUniqueID><ISSNLinking>0975-7651</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">30-day mortality</Keyword><Keyword MajorTopicYN="N">Esophageal cancer</Keyword><Keyword MajorTopicYN="N">Perioperative morbidity</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList><CoiStatement>Compliance with Ethical StandardsThe authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30948879</ArticleId><ArticleId IdType="pmc">PMC6414576</ArticleId><ArticleId IdType="doi">10.1007/s13193-018-0825-8</ArticleId><ArticleId IdType="pii">825</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karamanou M, Markatos K, Papaioannou TG, Zografos G, Androutsos G. Hallmarks in history of esophageal carcinoma. J BUON. 2017;22(4):1088&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">28952239</ArticleId></ArticleIdList></Reference><Reference><Citation>Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004;240(5):791&#x2013;800. doi: 10.1097/01.sla.0000143123.24556.1c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000143123.24556.1c</ArticleId><ArticleId IdType="pmc">PMC1356484</ArticleId><ArticleId IdType="pubmed">15492560</ArticleId></ArticleIdList></Reference><Reference><Citation>Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G, Davies A, D'Journo XB, Gisbertz SS, Griffin SM, Hardwick R, Hoelscher A, Hofstetter W, Jobe B, Kitagawa Y, Law S, Mariette C, Maynard N, Morse CR, Nafteux P, Pera M, Pramesh CS, Puig S, Reynolds JV, Schroeder W, Smithers M, Wijnhoven BPL (2017) Benchmarking complications associated with esophagectomy. Ann Surg. 10.1097/SLA.0000000000002611</Citation><ArticleIdList><ArticleId IdType="pubmed">29206677</ArticleId></ArticleIdList></Reference><Reference><Citation>Abunasra H, Lewis S, Beggs L, Duffy J, Beggs D, Morgan E. Predictors of operative death after oesophagectomy for carcinoma. Br J Surg. 2005;92(8):1029&#x2013;1033. doi: 10.1002/bjs.5049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.5049</ArticleId><ArticleId IdType="pubmed">15931662</ArticleId></ArticleIdList></Reference><Reference><Citation>Backemar L, Lagergren P, Johar A, Lagergren J. Impact of co-morbidity on mortality after oesophageal cancer surgery. Br J Surg. 2015;102(9):1097&#x2013;1105. doi: 10.1002/bjs.9854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9854</ArticleId><ArticleId IdType="pubmed">26059747</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeh M, Ghadban T, Dedow J, Vettorazzi E, Uzunoglu FG, Nentwich M, Kluge S, Izbicki JR, Vashist YK. Allogenic blood transfusion is associated with poor perioperative and long-term outcome in esophageal cancer. World J Surg. 2017;41(1):208&#x2013;215. doi: 10.1007/s00268-016-3730-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-016-3730-8</ArticleId><ArticleId IdType="pubmed">27730355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosumi K, Baba Y, Harada K, Yoshida N, Watanabe M, Baba H. Perioperative blood transfusion, age at surgery, and prognosis in a database of 526 upper gastrointestinal cancers. Dig Surg. 2015;32(6):445&#x2013;453. doi: 10.1159/000433609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000433609</ArticleId><ArticleId IdType="pubmed">26550999</ArticleId></ArticleIdList></Reference><Reference><Citation>Terp Fjederholt K, Svendsen LB, Mortensen FV. Perioperative blood transfusions increases the risk of anastomotic leakage after surgery for GEJ-cancer. Am J Surg. 2017;214(2):293&#x2013;298. doi: 10.1016/j.amjsurg.2017.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2017.01.022</ArticleId><ArticleId IdType="pubmed">28259203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan AM, Hearty A, Prichard RS, Cunningham A, Rowley SP, Reynolds JV. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. J Gastrointest Surg. 2007;11(10):1355&#x2013;1360. doi: 10.1007/s11605-007-0223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-007-0223-y</ArticleId><ArticleId IdType="pubmed">17682826</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou DZ, Serna-Gallegos D, Mirocha J, Bairamian V, Alban RF, Soukiasian HJ. Predictors of failure to rescue after esophagectomy. Ann Thorac Surg. 2018;105(3):871&#x2013;878. doi: 10.1016/j.athoracsur.2017.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.10.022</ArticleId><ArticleId IdType="pubmed">29397102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33931112</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>The potential of adipokines in identifying multiple trauma patients at risk of developing multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>38</StartPage><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">38</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-021-00511-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) and the consecutive multiple organ failure (MOF) are severe and dreaded complications with a high mortality in multiple trauma patients. The aim of this study was to investigate the potential of the adipokines leptin, resistin, interleukin-17A and interleukin-33 as possible biomarkers in the early posttraumatic inflammatory response and for identifying severely traumatized patients at risk of developing MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In total, 14 multiple trauma patients with an injury severity score (ISS)&#x2009;&#x2265;&#x2009;16 as well as a control group of 14 non-multiple trauma patients were included in this study and blood samples were taken at the time points 0, 6, 24, 48 and 72&#xa0;h after admission. For the trauma patients, the SIRS and Denver MOF score were determined daily. The quantitative measurement of the plasma concentrations of the adipokines was performed using ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the statistical analysis, the multiple trauma patients showed statistically significant higher plasma concentrations of leptin, resistin, IL-17A and IL-33 compared to the control group. In addition, there was a statistically significant positive correlation between the concentrations of resistin, IL-17A and IL-33 and the corresponding SIRS scores and between the concentrations of resistin, IL-17A and IL-33 and the corresponding Denver MOF scores. Finally, ROC curve analysis revealed that the adipokines leptin and IL-17A are suitable diagnostic markers for the discrimination between multiple trauma patients with and without MOF.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Leptin and IL-17A could be suitable diagnostic markers to identify severely injured patients with a developing SIRS and MOF earlier, to adjust surgical therapy planning and intensive care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2608-3444</Identifier><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany. julian1haupt@bundeswehr.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Neuherbergstrasse 11, 80937, Munich, Germany. julian1haupt@bundeswehr.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krysiak</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogner-Flatz</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Hospital Munich, Ludwig-Maximilians-University, Nussbaumstrasse 20, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanschen</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology-Inspired Tissue Engineering (cBITE), MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haug</LastName><ForeName>Alexander T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedics and Sports Orthopedics, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054392">Adipokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054392" MajorTopicYN="N">Adipokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adipokines</Keyword><Keyword MajorTopicYN="N">Interleukin-17A</Keyword><Keyword MajorTopicYN="N">Interleukin-33</Keyword><Keyword MajorTopicYN="N">Leptin</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Multiple organ failure</Keyword><Keyword MajorTopicYN="N">Multiple trauma</Keyword><Keyword MajorTopicYN="N">Resistin</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33931112</ArticleId><ArticleId IdType="pmc">PMC8086117</ArticleId><ArticleId IdType="doi">10.1186/s40001-021-00511-z</ArticleId><ArticleId IdType="pii">10.1186/s40001-021-00511-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wick M, Ekkernkamp A, Muhr G. The epidemiology of multiple trauma. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 1997. 68(11):1053&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9518193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R. Das schwere Trauma. Notfall+ Rettungsmedizin. 2008;11(6):373&#x2013;6.</Citation></Reference><Reference><Citation>Ornato JP, Craren EJ, Nelson NM, Kimball KF. Impact of improved emergency medical services and emergency trauma care on the reduction in mortality from trauma. J Trauma. 1985;25(7):575&#x2013;579. doi: 10.1097/00005373-198507000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198507000-00001</ArticleId><ArticleId IdType="pubmed">4009762</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker CC. Epidemiology of trauma: the civilian perspective. Ann Emerg Med. 1986;15(12):1389&#x2013;1391. doi: 10.1016/S0196-0644(86)80921-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0196-0644(86)80921-0</ArticleId><ArticleId IdType="pubmed">3777610</ArticleId></ArticleIdList></Reference><Reference><Citation>Regel G, Lobenhoffer P, Grotz M, Pape H, Lehmann U, Tscherne H. Treatment results of patients with multiple trauma: an analysis of 3406 cases treated between 1972 and 1991 at a German Level I Trauma Center. J Trauma Acute Care Surg. 1995;38(1):70&#x2013;78. doi: 10.1097/00005373-199501000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199501000-00020</ArticleId><ArticleId IdType="pubmed">7745664</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36(6):691&#x2013;709. doi: 10.1016/j.injury.2004.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.12.037</ArticleId><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>van Griensven M, Krettek C, Pape H-C. Immune Reactions afterTrauma. Eur J Trauma. 2003;29(4):181&#x2013;192. doi: 10.1007/s00068-001-1324-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-001-1324-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Lezotte DC. Early risk factors for postinjury multiple organ failure. World J Surg. 1996;20(4):392&#x2013;400. doi: 10.1007/s002689900062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002689900062</ArticleId><ArticleId IdType="pubmed">8662125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A. Validation of postinjury multiple organ failure scores. Shock (Augusta, Ga) 2009;31(5):438. doi: 10.1097/SHK.0b013e31818ba4c6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31818ba4c6</ArticleId><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury. 2009;40(9):912&#x2013;918. doi: 10.1016/j.injury.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2009.05.024</ArticleId><ArticleId IdType="pubmed">19541301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644&#x2013;1655. doi: 10.1378/chest.101.6.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85&#x2013;97. doi: 10.1038/nri2921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2921</ArticleId><ArticleId IdType="pmc">PMC3518031</ArticleId><ArticleId IdType="pubmed">21252989</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939&#x2013;949. doi: 10.1161/01.RES.0000163635.62927.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000163635.62927.34</ArticleId><ArticleId IdType="pubmed">15890981</ArticleId></ArticleIdList></Reference><Reference><Citation>Javier C, Morena S, Rodolfo G, Ver&#xf3;nica L, Jes&#xfa;s GRJ, Francisca L, et al. Adipokines: Biofactors from white adipose tissue A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37(6):413&#x2013;420. doi: 10.1002/biof.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.185</ArticleId><ArticleId IdType="pubmed">22038756</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68(4):437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">11037963</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371&#x2013;379. doi: 10.1038/nri1350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1350</ArticleId><ArticleId IdType="pubmed">15122202</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck BN, Johnson RW. Tumor necrosis factor (TNF)-&#x3b1; induces leptin production through the p55 TNF receptor. Am J Physiol Regulatory Integrative Comparative Physiol. 2000;278(2):R537&#x2013;R543. doi: 10.1152/ajpregu.2000.278.2.R537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.2000.278.2.R537</ArticleId><ArticleId IdType="pubmed">10666158</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Alvarez J, Goberna R, S&#xe1;nchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol. 1999;194(1):6&#x2013;11. doi: 10.1006/cimm.1999.1490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cimm.1999.1490</ArticleId><ArticleId IdType="pubmed">10357875</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrin LL, Jahn A, van Griensven M. Leptin protects against mortality and organ dysfunction in a two-hit trauma/sepsis model and is IL-6-dependent. Shock. 2017;48(1):130&#x2013;137. doi: 10.1097/SHK.0000000000000837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000837</ArticleId><ArticleId IdType="pubmed">28114167</ArticleId></ArticleIdList></Reference><Reference><Citation>Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001;98(2):502&#x2013;506. doi: 10.1073/pnas.98.2.502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.502</ArticleId><ArticleId IdType="pmc">PMC14616</ArticleId><ArticleId IdType="pubmed">11209052</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300(2):472&#x2013;476. doi: 10.1016/S0006-291X(02)02841-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)02841-3</ArticleId><ArticleId IdType="pubmed">12504108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309(2):286&#x2013;290. doi: 10.1016/j.bbrc.2003.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.07.003</ArticleId><ArticleId IdType="pubmed">12951047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9):5789&#x2013;5795. doi: 10.4049/jimmunol.174.9.5789.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.9.5789</ArticleId><ArticleId IdType="pubmed">15843582</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149&#x2013;162. doi: 10.1016/j.immuni.2011.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.02.012</ArticleId><ArticleId IdType="pubmed">21349428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402&#x2013;407. doi: 10.1016/j.cyto.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.07.017</ArticleId><ArticleId IdType="pmc">PMC2582446</ArticleId><ArticleId IdType="pubmed">18701318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat R, Witte E, Witte K, Wolk K. IL-22 and IL-17: An Overview. In: Quesniaux V, Ryffel B, Padova F, editors. IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. Basel: Springer Basel; 2013. pp. 11&#x2013;35.</Citation></Reference><Reference><Citation>Mitsdoerffer M, Lee Y, J&#xe4;ger A, Kim H-J, Korn T, Kolls JK, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci. 2010;107(32):14292&#x2013;14297. doi: 10.1073/pnas.1009234107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1009234107</ArticleId><ArticleId IdType="pmc">PMC2922571</ArticleId><ArticleId IdType="pubmed">20660725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479&#x2013;490. doi: 10.1016/j.immuni.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.09.015</ArticleId><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384(1):105&#x2013;109. doi: 10.1016/j.bbrc.2009.04.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.04.081</ArticleId><ArticleId IdType="pubmed">19393621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31(1):5&#x2013;7. doi: 10.1016/j.immuni.2009.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.06.011</ArticleId><ArticleId IdType="pubmed">19604486</ArticleId></ArticleIdList></Reference><Reference><Citation>Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37(10):2779&#x2013;2786. doi: 10.1002/eji.200737547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200737547</ArticleId><ArticleId IdType="pubmed">17853410</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484&#x2013;1490. doi: 10.1016/j.jaci.2008.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2008.04.005</ArticleId><ArticleId IdType="pmc">PMC2821937</ArticleId><ArticleId IdType="pubmed">18539196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennarelli T, Wodzin E, Barrington I. Association for the Advancement of Automotive Medicine: The Abbreviated Injury Scale 2005. Update. 2008.</Citation></Reference><Reference><Citation>Keller WK, Dillihunt R, Fenner H, Jolley F, Keeney A, Weygandt P, et al. Rating the severity of tissue damage: I The abbreviated injury scale. JAMA. 1971;215(2):277&#x2013;280. doi: 10.1001/jama.1971.03180150059012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1971.03180150059012</ArticleId><ArticleId IdType="pubmed">5107365</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, O'Neill B, Haddon W, Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma Acute Care Surg. 1974;14(3):187&#x2013;196. doi: 10.1097/00005373-197403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197403000-00001</ArticleId><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, O'Neill B. The injury severity score: an update. J Trauma Acute Care Surg. 1976;16(11):882&#x2013;885. doi: 10.1097/00005373-197611000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197611000-00006</ArticleId><ArticleId IdType="pubmed">994270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sektion Notfall- &amp; Intensivmedizin, Schwerverletztenversorgung (NIS) der Deutschen Gesellschaft f&#xfc;r Unfallchirurgie (DGU). TraumaRegister Jahresbericht 2015. 2015.</Citation></Reference><Reference><Citation>Fr&#xf6;hlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, et al. Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg. 2014;76(4):921&#x2013;928. doi: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz M, van Griensven M, Stalp M, Kaufmann U, Hildebrand F, Pape H. Scoring des Multiorganversagens nach schwerem Trauma Vergleich des Goris- Marshall-und Moore-Scores Der Chirurg. 2001;72(6):723&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">11469095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major trauma: a comparison of the Denver, Sequential Organ Failure Assessment and Marshall scoring systems. J Trauma Acute Care Surg. 2017;82(3):534. doi: 10.1097/TA.0000000000001328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000001328</ArticleId><ArticleId IdType="pmc">PMC5328408</ArticleId><ArticleId IdType="pubmed">28030507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chachkhiani I, Gurlich R, Maruna P, Frasko R, Lindner J. The postoperative stress response and its reflection in cytokine network and leptin plasma levels. Physiol Res. 2005;54(3):279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection. J Surg Res. 2006;133(2):102&#x2013;112. doi: 10.1016/j.jss.2005.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2005.10.025</ArticleId><ArticleId IdType="pubmed">16386757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef AAAM, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-&#x3b1; in critically ill patients: a prospective observational study. Crit Care. 2010;14(2):R33. doi: 10.1186/cc8911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8911</ArticleId><ArticleId IdType="pmc">PMC2887140</ArticleId><ArticleId IdType="pubmed">20230641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AM, Sattar N, Mcmillan DC. The co-ordinated cytokine/hormone response to acute injury incorporates leptin. Cytokine. 2000;12(7):1042&#x2013;1045. doi: 10.1006/cyto.2000.0674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2000.0674</ArticleId><ArticleId IdType="pubmed">10880250</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X-Q, Yang S-B, Zhu F-L, Lv Q-W, Zhang G-H, Huang H-B. Resistin is associated with mortality in patients with traumatic brain injury. Crit Care. 2010;14(5):R190. doi: 10.1186/cc9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9307</ArticleId><ArticleId IdType="pmc">PMC3219297</ArticleId><ArticleId IdType="pubmed">21029428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade CE, Mora AG, Shields BA, Pidcoke HF, Baer LA, Chung KK, et al. Signals from fat after injury: plasma adipokines and ghrelin concentrations in the severely burned. Cytokine. 2013;61(1):78&#x2013;83. doi: 10.1016/j.cyto.2012.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2012.08.031</ArticleId><ArticleId IdType="pmc">PMC3505238</ArticleId><ArticleId IdType="pubmed">23021431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sund&#xe9;n-Cullberg J, Nystr&#xf6;m T, Lee ML, Mullins GE, Tokics L, Andersson J, et al. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med. 2007;35(6):1536&#x2013;1542. doi: 10.1097/01.CCM.0000266536.14736.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000266536.14736.03</ArticleId><ArticleId IdType="pubmed">17452927</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud A, Namas RA, Ramadan M, Mi Q, Almahmoud K, Abdul-Malak O, et al. Computational analysis supports an early, type 17 cell-associated divergence of blunt trauma survival and mortality. Crit Care Med. 2016;44(11):e1074. doi: 10.1097/CCM.0000000000001951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001951</ArticleId><ArticleId IdType="pmc">PMC5201164</ArticleId><ArticleId IdType="pubmed">27513538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefele F, Ditsch A, Krysiak N, Caldwell C, Biberthaler P, van Griensven M, et al. Trauma induces interleukin-17A expression on Th17 Cells and CD4+ regulatory T cells as well as platelet dysfunction. Front Immunol. 2019;10:2389. doi: 10.3389/fimmu.2019.02389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02389</ArticleId><ArticleId IdType="pmc">PMC6797820</ArticleId><ArticleId IdType="pubmed">31681282</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelkader A, El-Sayed M, Eladawy A, Elsayed R, Mukhtar A, Hammimy W. Interleukin-17a as a predictor of occurrence of sepsis in polytrauma patients: a prospective observational study. Intensive Care Med Exp. 2015;3(1):A790. doi: 10.1186/2197-425X-3-S1-A790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2197-425X-3-S1-A790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsiger S, Simmen H-P, Werner CM, Wanner GA, Rittirsch D. Danger signals activating the immune response after trauma. Mediators of inflammation. 2012;2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388465</ArticleId><ArticleId IdType="pubmed">22778496</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Guardado J, Hoffman R, Xu H, Namas R, Vodovotz Y, et al. IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PLoS Med. 2017;14(7):e1002365. doi: 10.1371/journal.pmed.1002365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002365</ArticleId><ArticleId IdType="pmc">PMC5526517</ArticleId><ArticleId IdType="pubmed">28742815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35506746</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-4029</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of forensic sciences</Title><ISOAbbreviation>J Forensic Sci</ISOAbbreviation></Journal><ArticleTitle>Perimortem dynamics of blood potassium concentration in patients dying in intensive care unit: A prospective nested cohort study.</ArticleTitle><Pagination><StartPage>1550</StartPage><EndPage>1556</EndPage><MedlinePgn>1550-1556</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1556-4029.15054</ELocationID><Abstract><AbstractText>To enable diagnosis of hyperkalemia from the perimortem blood sample, we aim to describe the natural dynamics of blood potassium [K<sup>+</sup> ] in patients dying after withdrawal of care while in an intensive care unit. In a nested sub-study of international Death Prediction and Physiology after Removal of Therapy (DePPaRT) project, we obtained serial whole-blood samples and analyzed ions and acid-base parameters in 23 patients just before life-sustaining treatment withdrawal, at the time of death, and after 5 and 30&#x2009;min after death. Of the 631 patients in the DePPaRT study, we obtained consent and enrolled 23 subjects in the [K<sup>+</sup> ] sub-study (12&#x2009;M, 11F, aged 73&#x2009;&#xb1;&#x2009;14&#x2009;years), mostly dying from irreversible brain damage or multi-organ failure. Blood [K<sup>+</sup> ] rose from the median 4.3 (IQR 3.9; 4.8) mEq/L at treatment withdrawal to 5.2 (IQR 5.0; 6.8) mEq/L at death and then to 5.85 (IQR 5.2; 6.8) mEq/L after 30&#x2009;min (mean rise of +0.64&#x2009;mEq.L<sup>-1</sup> .h<sup>-1</sup> ). These changes were associated with progressive lactic and hypercapnic acidemia. After correcting the measured [K+] for pH by subtracting 0.6&#xa0;mEq/L from [K+] for every 0.1 pH decrease from 7.40, the calculated [K+] remained normal or decreased from that measured at treatment withdrawal. In contrast to the late autolysis phase, the early changes of blood [K<sup>+</sup> ] after death are slow and can be fully explained by progressive acidemia. Our data suggest that the diagnosis of hyperkalemia at death from a blood sample obtained within 30&#x2009;min after death can be made by adjusting the [K+] concentration to a pH&#xa0;7.40.</AbstractText><CopyrightInformation>&#xa9; 2022 American Academy of Forensic Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matou&#x161;</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0605-6393</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldauf</LastName><ForeName>Petr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4668-5837</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krbec</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2692-6904</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du&#x161;ka</LastName><ForeName>Franti&#x161;ek</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1559-4078</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1004120</GrantID><Agency>Grantov&#xe1; Agentura, Univerzita Karlova</Agency><Country/></Grant><Grant><GrantID>COOPERATIO ICM</GrantID><Agency>Univerzita Karlova v Praze</Agency><Country/></Grant><Grant><Agency>the Karel Pavlik Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Forensic Sci</MedlineTA><NlmUniqueID>0375370</NlmUniqueID><ISSNLinking>0022-1198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007477">Ions</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006947" MajorTopicYN="Y">Hyperkalemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007477" MajorTopicYN="N">Ions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="Y">Potassium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dynamics of blood potassium</Keyword><Keyword MajorTopicYN="N">forensic pathology</Keyword><Keyword MajorTopicYN="N">hyperkalemia</Keyword><Keyword MajorTopicYN="N">perimortem blood potassium</Keyword><Keyword MajorTopicYN="N">perimortem changes</Keyword><Keyword MajorTopicYN="N">physiology of dying</Keyword><Keyword MajorTopicYN="N">postmortem chemistry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35506746</ArticleId><ArticleId IdType="doi">10.1111/1556-4029.15054</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373(1):60-72. https://doi.org/10.1056/NEJMra1313341</Citation></Reference><Reference><Citation>Hunter RW, Bailey MA. Hyperkalemia: Pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34((Suppl 3)):iii2-11. https://doi.org/10.1093/ndt/gfz206</Citation></Reference><Reference><Citation>Fejfar Z. A practical approach to cardiac anesthesia, 2nd edition. Edited by Frederick a. Hensley, Jr., and Donald E. Martin. Little, Brown and Company, Boston (1995) 7 13 pages, illustrated, $59.95 ISBN: 0-316-35786-3. Clin Cardiol. 1996;19(7):601-2. https://doi.org/10.1002/clc.4960190718</Citation></Reference><Reference><Citation>Gawande A, Denno DW, Truog RD, Waisel D. Physicians and execution-highlights from a discussion of lethal injection. N Engl J Med. 2008;358(5):448-51. https://doi.org/10.1056/NEJMp0800378</Citation></Reference><Reference><Citation>Kothari D, Kothari S, Agrawal J. Potassium chloride: a high risk drug for medication error. Indian J Anaesth. 2012;56(1):90-1. https://doi.org/10.4103/0019-5049.93357</Citation></Reference><Reference><Citation>Palmiere C, Scarpelli MP, Varlet V, Baumann P, Michaud K, Augsburger M. Fatal intravenous injection of potassium: is postmortem biochemistry useful for the diagnosis? Forensic Sci Int. 2017;274:27-32. https://doi.org/10.1016/j.forsciint.2016.11.035</Citation></Reference><Reference><Citation>Coulibaly B, Piercecchi-Marti M-D, Bartoli C, Liprandi A, L&#xe9;onetti G, Pellissier J-F. Lethal injection of potassium chloride: first description of the pathological appearance of organs. J Appl Toxicol. 2010;30(4):378-80. https://doi.org/10.1002/jat.1500</Citation></Reference><Reference><Citation>Bertol E, Politi L, Mari F. Death by potassium chloride intravenous injection: evaluation of analytical detectability. J Forensic Sci. 2012;57(1):273-5. https://doi.org/10.1111/j.1556-4029.2011.01907.x</Citation></Reference><Reference><Citation>Dhanani S, Hornby L, van Beinum A, Scales NB, Hogue M, Baker A, et al. Resumption of cardiac activity after withdrawal of life-sustaining measures. N Engl J Med. 2021;384(4):345-52. https://doi.org/10.1056/NEJMoa2022713</Citation></Reference><Reference><Citation>Larivi&#xe8;re S. When is dead really dead? The death prediction and physiology after removal of therapy study (DePPaRT study). Canadian Donation and Transplantation Research Program. [cited 2022 Apr 16]. Available from: https://cdtrp.ca/en/deppart-study/</Citation></Reference><Reference><Citation>Burnell JM, Scribner BH, Uyeno BT, Villamil MF. The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest. 1956;35(9):935-9. https://doi.org/10.1172/JCI103352</Citation></Reference><Reference><Citation>Adrogu&#xe9; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981;71(3):456-67. https://doi.org/10.1016/0002-9343(81)90182-0</Citation></Reference><Reference><Citation>CLSI standards &amp; guidelines: Shop for CLSI standards. Clinical &amp; Laboratory Standards Institute. [cited 2021 Oct 5]. Available from: https://clsi.org/standards/</Citation></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran&#xe7;ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686. https://doi.org/10.21105/joss.01686</Citation></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1-48. https://doi.org/10.18637/jss.v067.i01</Citation></Reference><Reference><Citation>Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82(13):1-26. https://doi.org/10.18637/jss.v082.i13</Citation></Reference><Reference><Citation>emmeans package - RDocumentation. [cited 2022 Apr 16]. Available from: https://www.rdocumentation.org/packages/emmeans/versions/1.7.3</Citation></Reference><Reference><Citation>R: The R project for statistical computing [cited 2021 Oct 18]. Available from: https://www.r-project.org/</Citation></Reference><Reference><Citation>Makoff DL, da Silva JA, Rosenbaum BJ, Levy SE, Maxwell MH. Hypertonic expansion: acid-base and electrolyte changes. Am J Physiol. 1970;218(4):1201-7. https://doi.org/10.1152/ajplegacy.1970.218.4.1201</Citation></Reference><Reference><Citation>Somers VK, Mark AL, Abboud FM. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J Clin Invest. 1991;87(6):1953-7. https://doi.org/10.1172/JCI115221</Citation></Reference><Reference><Citation>Williams ME, Rosa RM, Silva P, Brown RS, Epstein FH. Impairment of extrarenal potassium disposal by alpha-adrenergic stimulation. N Engl J Med. 1984;311(3):145-9. https://doi.org/10.1056/NEJM198407193110303</Citation></Reference><Reference><Citation>Ellingsen O. Myocardial potassium balance during adrenergic stimulation. J Oslo City Hosp. 1989;39(4-5):39-51.</Citation></Reference><Reference><Citation>Walia BN, Chandra RK, Sarin GS, Ghai OP. Preterminal and postmortem changes in serum-potassium of children. Lancet Lond Engl. 1963;1(7292):1187-8. https://doi.org/10.1016/s0140-6736(63)92481-4</Citation></Reference><Reference><Citation>Singh D, Prashad R, Parkash C, Bansal YS, Sharma SK, Pandey AN. Linearization of the relationship between serum sodium, potassium concentration, their ratio and time since death in Chandigarh zone of north-West India. Forensic Sci Int. 2002;130(1):1-7. https://doi.org/10.1016/s0379-0738(02)00267-0</Citation></Reference><Reference><Citation>Jashnani KD, Kale SA, Rupani AB. Vitreous humor: biochemical constituents in estimation of postmortem interval. J Forensic Sci. 2010;55(6):1523-7. https://doi.org/10.1111/j.1556-4029.2010.01501.x</Citation></Reference><Reference><Citation>Bortolotti F, Pascali JP, Davis GG, Smith FP, Brissie RM, Tagliaro F. Study of vitreous potassium correlation with time since death in the postmortem range from 2 to 110 hours using capillary ion analysis. Med Sci Law. 2011;51(Suppl 1):S20-3. https://doi.org/10.1258/msl.2010.010063</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32035159</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of allergy and clinical immunology</Title><ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness.</ArticleTitle><Pagination><StartPage>1673</StartPage><EndPage>1680.e11</EndPage><MedlinePgn>1673-1680.e11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2020.01.040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-6749(20)30179-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Decreased TNF-&#x3b1; production in whole blood after ex&#xa0;vivo LPS stimulation indicates suppression of the Toll-like receptor (TLR)4 pathway. This is associated with increased mortality in pediatric influenza critical illness. Whether antiviral immune signaling pathways are also suppressed in these patients is unclear.</AbstractText><AbstractText Label="OBJECTIVES">We sought to evaluate suppression of the TLR4 and the antiviral retinoic acid-inducible gene-I (RIG-I) pathways with clinical outcomes in children with severe influenza infection.</AbstractText><AbstractText Label="METHODS">In this 24-center, prospective, observational cohort study of children with confirmed influenza infection, blood was collected within 72 hours of intensive care unit admission. Ex&#xa0;vivo whole blood stimulations were performed with matched controls using the viral ligand polyinosinic-polycytidylic acid-low-molecular-weight/LyoVec and LPS to evaluate IFN-&#x3b1; and TNF-&#x3b1; production capacities (RIG-I and TLR4 pathways, respectively).</AbstractText><AbstractText Label="RESULTS">Suppression of either IFN-&#x3b1; or TNF-&#x3b1; production capacity was associated with longer duration of mechanical ventilation and hospitalization, and increased organ dysfunction. Children with suppression of both RIG-I and TLR4 pathways (n&#xa0;= 33 of 103 [32%]) were more likely to have prolonged (&#x2265;7 days) multiple-organ dysfunction syndrome (30.3% vs 8.6%; P&#xa0;= .004) or prolonged hypoxemic respiratory failure (39.4% vs 11.4%; P&#xa0;= .001) compared with those with single- or no pathway suppression.</AbstractText><AbstractText Label="CONCLUSIONS">Suppression of both RIG-I and TLR4 signaling pathways, essential for respective antiviral and antibacterial responses, is common in previously immunocompetent children with influenza-related critical illness and is associated with bacterial coinfection and adverse outcomes. Prospective testing of both pathways may aid in risk-stratification and in immune monitoring.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass; Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Department of Anesthesia, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital, Division of Critical Care Medicine, Department of Pediatrics, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Division of Immunology and Harvard Medical School Department of Pediatrics, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newhams</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mistry</LastName><ForeName>Anushay J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panoskaltsis-Mortari</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cytokine Reference Laboratory, Department of Pediatrics, University of Minnesota, Minneapolis, Minn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mourani</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Section of Critical Care Medicine, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loftis</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Section of Critical Care Medicine, Department of Pediatrics, Texas Children's Hospital, Houston, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarquinio</LastName><ForeName>Keiko M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Children's Healthcare of Atlanta at Egleston, Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, Los Angeles, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, St Louis Children's Hospital, St Louis, Mo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Orange County, Orange, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junger</LastName><ForeName>Wolfgang G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randolph</LastName><ForeName>Adrienne G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass; Department of Anesthesia, Harvard Medical School, Boston. Electronic address: adrienne.randolph@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PALISI Pediatric Intensive Care Influenza (PICFLU) Network Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM103702</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI084011</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD095228</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM136429</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD098363</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI084011</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM116162</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol</MedlineTA><NlmUniqueID>1275002</NlmUniqueID><ISSNLinking>0091-6749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C452820">RIGI protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="N">DEAD Box Protein 58</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IFN-&#x3b1;</Keyword><Keyword MajorTopicYN="N">LPS</Keyword><Keyword MajorTopicYN="N">Polyinosinic:polycytidylic acid</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">Toll-like receptor 4</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">retinoic acid&#x2013;inducible gene-I</Keyword><Keyword MajorTopicYN="N">suppression</Keyword></KeywordList><CoiStatement><b>COI Statement:</b> Dr. Novak reports grants from NIH and Boston
Children&#x2019;s Hospital during the conduct of the study; Dr. Hall reports
grants from NIH during the conduct of the study; personal fees from LaJolla
Pharmaceuticals and personal fees from Bristol Myers-Squibb outside the
submitted work; Dr. Randolph reports grants from NIH during the conduct of the
study and grants from Genentech Inc. outside the submitted work and personal
fees from LaJolla Pharmaceuticals; Dr. Junger reports grants from NIH during the
conduct of the study; Dr. Mourani reports grants from NIH during the conduct of
the study; Dr. Panoskaltsis-Mortari reports grants from NIH during the conduct
of the study; Dr. Weiss reports grants from NIGMS outside the submitted work;
All other authors have no COI to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Irby</LastName><ForeName>Olivia K</ForeName><Initials>OK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefley</LastName><ForeName>Glenda</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tellez</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flori</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cvijanovich</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anas</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas-Shiraishi</LastName><ForeName>Ofelia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapru</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillen</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Czaja</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mourani</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paden</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarquinio</LastName><ForeName>Keiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wardenburg</LastName><ForeName>Juliane Bubeck</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinto</LastName><ForeName>Neethi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Vicki</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Janice E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Randolph</LastName><ForeName>Adrienne G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agan</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ash</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mistry</LastName><ForeName>Anushay</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newhams</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurachek</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truemper</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahapatra</LastName><ForeName>Sidharth</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawson</LastName><ForeName>Machelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ackerman</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daugherty</LastName><ForeName>L Eugene</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nofziger</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shein</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steele</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson-Huber</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Neal J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spear</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Jenny L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgerson</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christie</LastName><ForeName>LeeAnn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loftis</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaimon</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gedeit</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murkowski</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32035159</ArticleId><ArticleId IdType="mid">NIHMS1573421</ArticleId><ArticleId IdType="pmc">PMC7323584</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2020.01.040</ArticleId><ArticleId IdType="pii">S0091-6749(20)30179-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coffin SE, Zaoutis TE, Rosenquist AB, Heydon K, Herrera G, Bridges CB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007;119(4):740&#x2013;748. DOI: 10.1542/peds.2006-2679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-2679</ArticleId><ArticleId IdType="pubmed">17403845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BM, Feng CG, McLean AS. Understanding the role of host response in influenza pneumonitis. Intensive Care Med. 2019;45(7):1012&#x2013;1014. DOI: 10.1007/s00134-019-05582-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05582-5</ArticleId><ArticleId IdType="pubmed">31020362</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053&#x2013;2063. DOI: 10.1084/jem.20101664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20101664</ArticleId><ArticleId IdType="pmc">PMC2947062</ArticleId><ArticleId IdType="pubmed">20837696</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5(9):675&#x2013;687. DOI: 10.1038/nri1684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1684</ArticleId><ArticleId IdType="pubmed">16110316</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun. 2014;5:3864 DOI: 10.1038/ncomms4864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4864</ArticleId><ArticleId IdType="pmc">PMC4033792</ArticleId><ArticleId IdType="pubmed">24844667</ArticleId></ArticleIdList></Reference><Reference><Citation>Huys L, Van Hauwermeiren F, Dejager L, Dejonckheere E, Lienenklaus S, Weiss S, et al. Type I interferon drives tumor necrosis factor-induced lethal shock. J Exp Med. 2009;206(9):1873&#x2013;1882. DOI: 10.1084/jem.20090213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20090213</ArticleId><ArticleId IdType="pmc">PMC2737160</ArticleId><ArticleId IdType="pubmed">19687227</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol. 2012;86(22):12304&#x2013;12312. DOI: 10.1128/JVI.01269-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01269-12</ArticleId><ArticleId IdType="pmc">PMC3486468</ArticleId><ArticleId IdType="pubmed">22951826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest. 2011;121(9):3657&#x2013;3665. DOI: 10.1172/JCI57762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57762</ArticleId><ArticleId IdType="pmc">PMC3163966</ArticleId><ArticleId IdType="pubmed">21841308</ArticleId></ArticleIdList></Reference><Reference><Citation>Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208(12):2357&#x2013;2366. DOI: 10.1084/jem.20111171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111171</ArticleId><ArticleId IdType="pmc">PMC3256967</ArticleId><ArticleId IdType="pubmed">22065672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother. 1995;39(11):2574&#x2013;2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162988</ArticleId><ArticleId IdType="pubmed">8585749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Huang S, Zhao X, Chen M, Lin Y, Xia Y, et al. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol. 2014;88(18):10421&#x2013;10431. DOI: 10.1128/JVI.00996-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00996-14</ArticleId><ArticleId IdType="pmc">PMC4178898</ArticleId><ArticleId IdType="pubmed">24920792</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Garcia-Sastre A. Differential recognition of viral RNA by RIG-I. Virulence. 2011;2(2):166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100765</ArticleId><ArticleId IdType="pubmed">21422808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008;205(7):1601&#x2013;1610. DOI: 10.1084/jem.20080091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20080091</ArticleId><ArticleId IdType="pmc">PMC2442638</ArticleId><ArticleId IdType="pubmed">18591409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2013;41(1):224&#x2013;236. DOI: 10.1097/CCM.0b013e318267633c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318267633c</ArticleId><ArticleId IdType="pmc">PMC3705720</ArticleId><ArticleId IdType="pubmed">23222256</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph AG, Agan AA, Flanagan RF, Meece JK, Fitzgerald JC, Loftis LL, et al. Optimizing Virus Identification in Critically Ill Children Suspected of Having an Acute Severe Viral Infection. Pediatr Crit Care Med. 2016;17(4):279&#x2013;286. DOI: 10.1097/PCC.0000000000000661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000661</ArticleId><ArticleId IdType="pubmed">26895562</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore-Gartland A, Panoskaltsis-Mortari A, Agan AA, Mistry AJ, Thomas PG, Matthay MA, et al. Cytokine Profiles of Severe Influenza Virus-Related Complications in Children. Front Immunol. 2017;8:1423 DOI: 10.3389/fimmu.2017.01423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01423</ArticleId><ArticleId IdType="pmc">PMC5681736</ArticleId><ArticleId IdType="pubmed">29163498</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Sinicato NA, Pelicari KO, Marini R, Lavras Costallat LT, Appenzeller S. Clinical and serological manifestations associated with interferon-alpha levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo). 2012;67(2):157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275113</ArticleId><ArticleId IdType="pubmed">22358241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011;9:113 DOI: 10.1186/1479-5876-9-113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-113</ArticleId><ArticleId IdType="pmc">PMC3146842</ArticleId><ArticleId IdType="pubmed">21774806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology. 1988;64(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1385178</ArticleId><ArticleId IdType="pubmed">2454881</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahin D, El-Refaey AM, El-Hawary AK, Salam AA, Machaly S, Abousamra N, et al. Serum interferon-alpha level in first degree relatives of systemic lupus erythematosus patients: Correlation with autoantibodies titers. Egyptian Journal of Medical Human Genetics. 2011;12(2):139&#x2013;146. DOI: 10.1016/j.ejmhg.2011.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmhg.2011.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell TT, Sun L, Hall MW, Gurney JG, Ashbrook MJ, Ohye RG, et al. Clinical implications and molecular mechanisms of immunoparalysis after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2012;143(5):1160&#x2013;1166 e1161 DOI: 10.1016/j.jtcvs.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3262077</ArticleId><ArticleId IdType="pubmed">21996297</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525&#x2013;532. DOI: 10.1007/s00134-010-2088-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2088-x</ArticleId><ArticleId IdType="pmc">PMC5224706</ArticleId><ArticleId IdType="pubmed">21153402</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszynski JA, Nofziger R, Moore-Clingenpeel M, Greathouse K, Anglim L, Steele L, et al. Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis. Am J Respir Crit Care Med. 2018;198(3):361&#x2013;369. DOI: 10.1164/rccm.201710-2006OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201710-2006OC</ArticleId><ArticleId IdType="pmc">PMC6835060</ArticleId><ArticleId IdType="pubmed">29470918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul F, Pellegrini S, Uze G. IFNA2: The prototypic human alpha interferon. Gene. 2015;567(2):132&#x2013;137. DOI: 10.1016/j.gene.2015.04.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.04.087</ArticleId><ArticleId IdType="pmc">PMC5629289</ArticleId><ArticleId IdType="pubmed">25982860</ArticleId></ArticleIdList></Reference><Reference><Citation>Reder AT, Feng X. Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology. Front Immunol. 2013;4:281 DOI: 10.3389/fimmu.2013.00281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00281</ArticleId><ArticleId IdType="pmc">PMC3775461</ArticleId><ArticleId IdType="pubmed">24062747</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsharifi M, Regner M, Blanden R, Lobigs M, Lee E, Koskinen A, et al. Exhaustion of type I interferon response following an acute viral infection. J Immunol. 2006;177(5):3235&#x2013;3241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920963</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya Y, Mullbacher A. Type I IFN exhaustion is a host defence protecting against secondary bacterial infections. Scand J Immunol. 2013;78(5):395&#x2013;400. DOI: 10.1111/sji.12107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12107</ArticleId><ArticleId IdType="pmc">PMC7169485</ArticleId><ArticleId IdType="pubmed">24006947</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Xu F, Lung WY, Meyerson C, Ghaffari AA, Cheng G, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS One. 2012;7(9):e41879 DOI: 10.1371/journal.pone.0041879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041879</ArticleId><ArticleId IdType="pmc">PMC3433467</ArticleId><ArticleId IdType="pubmed">22962579</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, et al. Critically ill children during the 2009&#x2013;2010 influenza pandemic in the United States. Pediatrics. 2011;128(6):e1450&#x2013;1458. DOI: 10.1542/peds.2011-0774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2011-0774</ArticleId><ArticleId IdType="pmc">PMC3387899</ArticleId><ArticleId IdType="pubmed">22065262</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnking K, Klemm C, Loffler B, Niemann S, van Kruchten A, Peters G, et al. Super-infection with Staphylococcus aureus inhibits influenza virus-induced type I IFN signalling through impaired STAT1-STAT2 dimerization. Cell Microbiol. 2015;17(3):303&#x2013;317. DOI: 10.1111/cmi.12375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12375</ArticleId><ArticleId IdType="pubmed">25293394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu M, Zhou M, Jiang C, Chen X, Guo L, Zhang M, et al. Staphylococcus aureus Phenol-Soluble Modulins alpha1-alpha3 Act as Novel Toll-Like Receptor (TLR) 4 Antagonists to Inhibit HMGB1/TLR4/NF-kappaB Signaling Pathway. Front Immunol. 2018;9:862 DOI: 10.3389/fimmu.2018.00862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00862</ArticleId><ArticleId IdType="pmc">PMC5996891</ArticleId><ArticleId IdType="pubmed">29922279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35656036</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0972-5229</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine</Title><ISOAbbreviation>Indian J Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Patient Characteristics and Outcomes in Necrotizing Soft-tissue Infections: Results from a Prospective Cohort Study in a Tertiary Care Center Intensive Care Unit in South India.</ArticleTitle><Pagination><StartPage>452</StartPage><EndPage>456</EndPage><MedlinePgn>452-456</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5005/jp-journals-10071-24153</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Necrotizing soft tissue infections (NSTIs) are life-threatening infections characterized by progressive destruction of muscle, fascia, and overlying subcutaneous tissue. Prospective studies in the field are few, and data from the Indian subcontinent are bleak. Prompt diagnosis and timely treatment are critical for optimal outcomes. The aims of this study are to provide detailed information on the clinical profile of patients with NSTIs and to identify predictors of mortality in order to pick up reversible factors that may improve outcomes.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">This study was a prospective cohort study of adult patients with NSTIs in a tertiary center in South India. All patients who were admitted to the surgical intensive care unit (ICU) of the institute with a diagnosis of NSTI were screened and enrolled. All patients were managed according to the local protocol for treatment of NSTIs and intensive care support.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In our cohort of patients, simple and multiple logistic regression analysis showed that four factors, namely, AKIN stage 3, shock, need for mechanical ventilation for more than 3 days, and low serum albumin values were found to be significantly associated with higher mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The successful management of these patients calls for early diagnosis, resuscitation, surgical debridement, appropriate and timely antibiotics, and early ventilatory weaning before multi-organ failure associated with shock and AKI occurs.</AbstractText><AbstractText Label="HOW TO CITE THIS ARTICLE" NlmCategory="UNASSIGNED">Kurian GP, Korula PJ, Jacob JM, Desha AMK, Karuppusami R, Kandasamy S. Patient Characteristics and Outcomes in Necrotizing Soft-tissue Infections: Results from a Prospective Cohort Study in a Tertiary Care Center Intensive Care Unit in South India. Indian J Crit Care Med 2022;26(4):452-456.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022; Jaypee Brothers Medical Publishers (P) Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurian</LastName><ForeName>George Prashanth</ForeName><Initials>GP</Initials><Identifier Source="ORCID">0000-0001-8398-7194</Identifier><AffiliationInfo><Affiliation>Division of Critical Care and Surgical ICU, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korula</LastName><ForeName>Pritish John</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-9544-8427</Identifier><AffiliationInfo><Affiliation>Division of Critical Care and Surgical ICU, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Jubin Merin</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-5810-2136</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desha</LastName><ForeName>Ashok Madhu Kumar</ForeName><Initials>AMK</Initials><Identifier Source="ORCID">0000-0003-3526-2556</Identifier><AffiliationInfo><Affiliation>Jaiswi Hospital, Tadipatri, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karuppusami</LastName><ForeName>Reka</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9913-2713</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandasamy</LastName><ForeName>Subramani</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7628-5335</Identifier><AffiliationInfo><Affiliation>Division of Critical Care and Surgical ICU, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Crit Care Med</MedlineTA><NlmUniqueID>101208863</NlmUniqueID><ISSNLinking>0972-5229</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AKIN stage 3</Keyword><Keyword MajorTopicYN="N">Hypoalbuminemia</Keyword><Keyword MajorTopicYN="N">Mechanical ventilation</Keyword><Keyword MajorTopicYN="N">Necrotizing fasciitis</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList><CoiStatement>Source of support: Fluid Research Grant, CMC, Vellore. Conflict of interest: None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35656036</ArticleId><ArticleId IdType="pmc">PMC9067491</ArticleId><ArticleId IdType="doi">10.5005/jp-journals-10071-24153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stevens DL, Bryant AE. Necrotizing soft-tissue infections. N Engl J Med. 2017;377(23):2253&#x2013;65. doi: 10.1056/NEJMra1600673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1600673</ArticleId><ArticleId IdType="pubmed">29211672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. Infect Dis Clin North Am. 2017;31(3):497&#x2013;511. doi: 10.1016/j.idc.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2017.05.011</ArticleId><ArticleId IdType="pmc">PMC5656282</ArticleId><ArticleId IdType="pubmed">28779832</ArticleId></ArticleIdList></Reference><Reference><Citation>Das DK, Baker MG, Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990&#x2013;2006. J Infect. 2011;63(6):429&#x2013;433. doi: 10.1016/j.jinf.2011.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2011.07.019</ArticleId><ArticleId IdType="pubmed">21864570</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen MB, Skrede S, Perner A, Arnell P, Nekludov M, Bruun T, et al. Patient's characteristics and outcomes in necrotising soft-tissue infections: results from a Scandinavian, multicentre, prospective cohort study. Intensive Care Med. 2019;45(9):1241&#x2013;1251. doi: 10.1007/s00134-019-05730-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05730-x</ArticleId><ArticleId IdType="pubmed">31440795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie CM, Miclau T. Necrotizing soft tissue infections of the extremities and back. Clin Orthop Relat Res. 2006;447:179&#x2013;186. doi: 10.1097/01.blo.0000218734.46376.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.blo.0000218734.46376.89</ArticleId><ArticleId IdType="pubmed">16672902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter OL, Guillamondegui OD, May AK, Diaz JJ. Outcome of necrotizing skin and soft tissue infections. Surg Infect (Larchmt) 2008;9(4):443&#x2013;4450. doi: 10.1016/j.cmi.2019.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.06.031</ArticleId><ArticleId IdType="pubmed">18759681</ArticleId></ArticleIdList></Reference><Reference><Citation>Endorf FW, Klein MB, Mack CD, Jurkovich GJ, Rivara FP. Necrotizing soft-tissue infections: differences in patients treated at burn centers and non-burn centers. J Burn Care Res. 2008;29(6):933&#x2013;938. doi: 10.1097/BCR.0b013e31818ba112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e31818ba112</ArticleId><ArticleId IdType="pmc">PMC3042354</ArticleId><ArticleId IdType="pubmed">18997557</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya DA, Bulger EM, Kwon YS, Kao LS, Evans H, Nathens AB. Predicting death in necrotizing soft tissue infections: a clinical score. Surg Infect (Larchmt) 2009;10(6):517&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001332</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass GE, Sheil F, Ruston JC, Butler PEM. Necrotising soft tissue infection in a UK metropolitan population. Ann R Coll Surg Engl. 2015;97(1):46&#x2013;51. doi: 10.1308/003588414X14055925058553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1308/003588414X14055925058553</ArticleId><ArticleId IdType="pmc">PMC4473899</ArticleId><ArticleId IdType="pubmed">25519266</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari V, Yogi V, Ghori HU, Singh OP, Peepre K, Yadav S, et al. Identifying the factors causing delayed presentation of cancer patients to a government medical college of Central India. J Clin Diagn Res. 2015;9(9):XC09&#x2013;XC12. doi: 10.7860/JCDR/2015/15104.6512.</Citation><ArticleIdList><ArticleId IdType="doi">10.7860/JCDR/2015/15104.6512</ArticleId><ArticleId IdType="pmc">PMC4606325</ArticleId><ArticleId IdType="pubmed">26500996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal NP, Latenser BA, Born JM, Liao J. Trends in 393 necrotizing acute soft tissue infection patients 2000&#x2013;2008. Burns. 2012;38(2):252&#x2013;260. doi: 10.1016/j.burns.2011.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2011.07.008</ArticleId><ArticleId IdType="pubmed">22030440</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14):1445&#x2013;1453. doi: 10.1056/NEJMoa042683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa042683</ArticleId><ArticleId IdType="pubmed">15814880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucca K, Spencer R, Orford N, Cattigan C, Athan E, McDonald A. Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study. ANZ J Surg. 2013;83(5):365&#x2013;370. doi: 10.1111/j.1445-2197.2012.06251.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-2197.2012.06251.x</ArticleId><ArticleId IdType="pubmed">22989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon N, Anjana RM, Mohan V, Kaur T, Afshin A, Ong K, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease study 1990&#x2013;2016. The Lancet Global Health. 2018;6(12):e1352&#x2013;e1362. doi: 10.1016/S2214-109X(18)30387-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(18)30387-5</ArticleId><ArticleId IdType="pmc">PMC6227383</ArticleId><ArticleId IdType="pubmed">30219315</ArticleId></ArticleIdList></Reference><Reference><Citation>Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007;38(Suppl 5):S19&#x2013;S26. doi: 10.1016/j.injury.2007.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.030</ArticleId><ArticleId IdType="pubmed">18048033</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh G, Sinha SK, Adhikary S, Babu KS, Ray P, Khanna SK. Necrotising infections of soft tissues&#x2014;a clinical profile. Eur J Surg. 2003;168(6):366&#x2013;371. doi: 10.1080/11024150260284897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/11024150260284897</ArticleId><ArticleId IdType="pubmed">12428876</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh N. Necrotizing fasciitis: a decade of surgical intensive care experience. Ind J of Critic Care Med. 2006;10(4):225&#x2013;229. doi: 10.4103/0972-5229.29840.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.29840</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador VBDG, San Juan MD, Salisi JA, Consunji RJ. Clinical and microbiological spectrum of necrotizing fasciitis in surgical patients at a Philippine university medical centre. Asian J Surg. 2010;33(1):51&#x2013;58. doi: 10.1016/S1015-9584(10)60009-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1015-9584(10)60009-7</ArticleId><ArticleId IdType="pubmed">20497883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao LS, Lew DF, Arab SN, Todd SR, Awad SS, Carrick MM, et al. Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study. Am J Surg. 2011;202(2):139&#x2013;145. doi: 10.1016/j.amjsurg.2010.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2010.07.041</ArticleId><ArticleId IdType="pmc">PMC3150284</ArticleId><ArticleId IdType="pubmed">21545997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudarsky LA, Laschinger JC, Coppa GF, Spencer FC. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg. 1987;206(5):661&#x2013;665. doi: 10.1097/00000658-198711000-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-198711000-00018</ArticleId><ArticleId IdType="pmc">PMC1493283</ArticleId><ArticleId IdType="pubmed">3314752</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44(5):705&#x2013;710. doi: 10.1086/511638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/511638</ArticleId><ArticleId IdType="pubmed">17278065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C-H, Chang H-C, Pasupathy S, Khin L-W, Tan J-L, Low C-O. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85(8):1454&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925624</ArticleId></ArticleIdList></Reference><Reference><Citation>Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schal&#xe9;n C, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis. 2007;45(4):450&#x2013;458. doi: 10.1086/519936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519936</ArticleId><ArticleId IdType="pubmed">17638193</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil MH, Henning RJ, Puri VK. Colloid oncotic pressure: clinical significance. Crit Care Med. 1979;7(3):113&#x2013;116. doi: 10.1097/00003246-197903000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-197903000-00006</ArticleId><ArticleId IdType="pubmed">436426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975;11(6):824&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">1207674</ArticleId></ArticleIdList></Reference><Reference><Citation>On the sulfhydryl group of human plasma albumin-PubMed [Internet]. doi: 10.1016/j.redox.2017.10.007. [cited 2020 Oct 17].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.007</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA. 1992;89(16):7674&#x2013;7677. doi: 10.1073/pnas.89.16.7674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.16.7674</ArticleId><ArticleId IdType="pmc">PMC49773</ArticleId><ArticleId IdType="pubmed">1502182</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves RB. Temperature-induced changes in blood acid-base status: Donnan rCl and red cell volume. J Appl Physiol. 1976;40(5):762&#x2013;767. doi: 10.1152/jappl.1976.40.5.762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1976.40.5.762</ArticleId><ArticleId IdType="pubmed">6425</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois M-J, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med. 2006;34(10):2536&#x2013;2540. doi: 10.1097/01.CCM.0000239119.57544.0C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000239119.57544.0C</ArticleId><ArticleId IdType="pubmed">16915107</ArticleId></ArticleIdList></Reference><Reference><Citation>Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247&#x2013;2256. doi: 10.1056/NEJMoa040232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa040232</ArticleId><ArticleId IdType="pubmed">15163774</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis. 2018;67(9):1434&#x2013;1436. doi: 10.1093/cid/ciy401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy401</ArticleId><ArticleId IdType="pmc">PMC6186853</ArticleId><ArticleId IdType="pubmed">29788397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25536735</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-0144</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Turkish journal of medical sciences</Title><ISOAbbreviation>Turk J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Thromboelastography in the evaluation of coagulation disorders in patients with sepsis.</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>272</EndPage><MedlinePgn>267-72</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Unbalanced hemostasis and disseminated intravenous coagulopathy serve as key participants in organ dysfunction and disability. In this study we evaluated the coagulation profiles of patients diagnosed with systemic inflammatory syndrome (SIRS)-sepsis and multiple organ dysfunction syndrome. We also researched coagulation in sepsis by comparing thromboelastography (TEG) data with those of nonsepsis patients to determine the usefulness of the TEG device.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Data were collected from 55 anesthesiology and surgery intensive care unit (ICU) patients: 21 with SIRS-sepsis (Group S) and 34 patients without SIRS-sepsis (Group C). Blood samples were taken upon admission to the ICU (t1) and on day 3 of the ICU stay (t2). TEG data (R = reaction time, K = coagulation time, a = alpha angle, and MA = maximum amplitude) were recorded. TEG parameters were compared with routine coagulation and hemogram studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean R value in Group C was higher than that of Group S at both t1 and t2. Group S had a significantly lower K value and higher alpha angle at t1 compared to Group C (P &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hypercoagulability was observed in SIRS-sepsis patients in the ICU, as measured with TEG. We believe that TEG will be a useful tool in the evaluation of coagulation disorders developing in septic critically ill patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kili&#xe7;</LastName><ForeName>Yeliz</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Top&#xe7;u</LastName><ForeName>&#x130;smet</ForeName><Initials>&#x130;</Initials></Author><Author ValidYN="Y"><LastName>Bambal</LastName><ForeName>Hamza</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Civi</LastName><ForeName>Melek</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk J Med Sci</MedlineTA><NlmUniqueID>9441758</NlmUniqueID><ISSNLinking>1300-0144</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance UI="D002116">Calcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002116" MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006400" MajorTopicYN="N">Hematocrit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019934" MajorTopicYN="N">International Normalized Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010314" MajorTopicYN="N">Partial Thromboplastin Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011517" MajorTopicYN="N">Prothrombin Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013916" MajorTopicYN="Y">Thrombelastography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25536735</ArticleId><ArticleId IdType="doi">10.3906/sag-1210-99</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34405362</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2568</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Digestive diseases and sciences</Title><ISOAbbreviation>Dig Dis Sci</ISOAbbreviation></Journal><ArticleTitle>Assessing the Efficacy and Outcomes Following Irrigation with Streptokinase Versus&#xa0;Hydrogen Peroxide in Necrotizing Pancreatitis: A Randomized Pilot Study.</ArticleTitle><Pagination><StartPage>4146</StartPage><EndPage>4153</EndPage><MedlinePgn>4146-4153</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-021-07201-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Percutaneous catheter drainage (PCD's) are prone to blockage because of necrosum. To improve the efficacy of PCD, necrolytic agents have been used. The present study compared the use of Streptokinase with H<sub>2</sub>O<sub>2</sub> in saline irrigation.</AbstractText><AbstractText Label="MATERIALS AND METHODS">This is a single-center randomized pilot study (from July 2018 to Dec 2019). Patients with infected pancreatic necrosis not showing response to PCD and saline irrigation were included in the study. Patients received either Streptokinase (Streptokinase group 50,000&#xa0;IU in 100&#xa0;ml normal saline) or 3% H<sub>2</sub>O<sub>2</sub> (3% H<sub>2</sub>O<sub>2</sub> in 100&#xa0;ml normal saline in 1:10 dilution). Primary endpoints were the need for surgery and mortality while secondary endpoints were hospital stay and complications attributable to necrolytic agents.</AbstractText><AbstractText Label="RESULTS">There were 30 patients in the study, 15 in each arm. Organ failure was seen in 23 (76.6%), single organ failure was present in 11 (47%), and multi-organ failure in 12 (53%). Bleeding complications (20% in H<sub>2</sub>O<sub>2</sub> vs 6.6% in Streptokinase), need for surgery (73% in H<sub>2</sub>O<sub>2</sub> vs 33.3% in Streptokinase) and mortality (60% in H<sub>2</sub>O<sub>2</sub> vs 33% in Streptokinase) were higher in H<sub>2</sub>O<sub>2</sub> group but the difference was not significant statistically. Post-irrigation hospital stay was lesser in the Streptokinase group compared to H<sub>2</sub>O<sub>2</sub> group but the difference did not reach statistical significance (14.1&#x2009;&#xb1;&#x2009;7.7 vs 19.2&#x2009;&#xb1;&#x2009;11.7, p&#x2009;=&#x2009;0.09) CONCLUSIONS: Streptokinase irrigation led to a trend for reduced need for necrosectomy and mortality. H<sub>2</sub>O<sub>2</sub> group had more bleeding complications<sub>.</sub> Post-irrigation hospital stay was lesser in Streptokinase group.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhargava</LastName><ForeName>M Venu</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Rana</LastName><ForeName>Surinder Singh</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorsi</LastName><ForeName>Ujjwal</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Radio Diagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radio Diagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6585-1725</Identifier><AffiliationInfo><Affiliation>Department of Surgical Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. rajsarakshi@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dig Dis Sci</MedlineTA><NlmUniqueID>7902782</NlmUniqueID><ISSNLinking>0163-2116</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077330">Saline Solution</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D013300">Streptokinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="Y">Drainage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="Y">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="Y">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077330" MajorTopicYN="N">Saline Solution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013300" MajorTopicYN="N">Streptokinase</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Irrigation of cavity with hydrogen peroxide</Keyword><Keyword MajorTopicYN="N">Irrigation with streptokinase</Keyword><Keyword MajorTopicYN="N">Necrotizing pancreatitis</Keyword><Keyword MajorTopicYN="N">PCD failure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34405362</ArticleId><ArticleId IdType="doi">10.1007/s10620-021-07201-0</ArticleId><ArticleId IdType="pii">10.1007/s10620-021-07201-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freeny PC, Hauptmann E, Althaus SJ, Traverso LW, Sinanan M. Percutaneous CT-guided catheter drainage of infected acute necrotizing pancreatitis: techniques and results. AJR Am J Roentgenol 1998;170:969&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/ajr.170.4.9530046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollemans RA, Bakker OJ, Boermeester MA, Bollen TL, Bosscha K, Bruno MJ, et al. Superiority of Step-up Approach vs Open Necrosectomy in Long-term Follow-up of Patients With Necrotizing Pancreatitis. Gastroenterology [Internet]. 2019;156 (4):1016&#x2013;26. https://doi.org/10.1053/j.gastro.2018.10.045</Citation></Reference><Reference><Citation>Babu RY, Gupta R, Kang M, Bhasin DK, Rana SS, Singh R. Predictors of surgery in patients with severe acute pancreatitis managed by the step-up approach. Ann Surg. 2013;257:737&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e318269d25d</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenvi S, Gupta R, Kang M, Khullar M, Singh S, Singh R, et al. Pancreatology Timing of surgical intervention in patients of infected necrotizing pancreatitis not responding to percutaneous catheter drainage. Pancreatology [Internet]. 2016; https://doi.org/10.1016/j.pan.2016.08.006</Citation></Reference><Reference><Citation>Banks PA, Freeman ML, Fass R, Baroni DS, Mutlu EA, Bernstein DE et al. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379&#x2013;2400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00856.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal D, Mortele KJ, Banks PA, Silverman SG. Acute necrotizing pancreatitis&#x202f;: role of CT-guided percutaneous catheter drainage. 2007; (May):351&#x2013;61.</Citation></Reference><Reference><Citation>Nepogodiev D, Bhangu A, Glasbey JC, Li E, Omar OM, Simoes JF et al. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31182-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Besselink MGH, Verwer TJ, Schoenmaeckers EJP, Buskens E, Ridwan BU, Visser MR et al. Timing of surgical intervention in necrotizing pancreatitis. Arch Surg. 2007;142:1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.142.12.1194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollemans RA, Bakker OJ, Ali UA, Van Goor H, Gooszen HG, Besselink MG et al. Predicting Success of Catheter Drainage in Infected Necrotizing Pancreatitis. 2015;00:1&#x2013;6.</Citation></Reference><Reference><Citation>Gupta R, Shenvi SD, Nada R, Rana SS, Khullar M, Kang M, et al. Streptokinase may play role in expanding non-operative management of infected walled off pancreatic necrosis: Preliminary results. Pancreatology [Internet]. 2014;14 (5):415&#x2013;8. https://doi.org/10.1016/j.pan.2014.07.012</Citation></Reference><Reference><Citation>Vaswani P, Gupta R, Kang M, Rana SS, Krishnamurthy G, Bhasin DK, et al. Assessing Role of Higher dose of Streptokinase for Improving the Efficacy of Percutaneous Drainage in Pancreatic Necrosis. Gastroenterology [Internet]. 2017;152 (5):S289. https://doi.org/10.1016/S0016-5085(17)31254-4</Citation></Reference><Reference><Citation>Gupta R, Gupta R, Kang M, Bhasin DK, Khullar M, Singh R. Mo1342 Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis: A Double Blinded Randomized Controlled Trial. Gastroenterology [Internet]. 2015;148 (4):S-677. https://doi.org/10.1016/S0016-5085(15)32286-1</Citation></Reference><Reference><Citation>Bergh NP, Ekroth R, Larsson S, Nagy P. Intrapleural Streptokinase in the treatment of haemothorax and empyema. Scand J Thorac Cardiovasc Surg. 1977;11:265&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">594722</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhafez M, Elnegouly M, Allah MSH, Elshazli M, Mikhail HMS, Yosry A. Transluminal retroperitoneal endoscopic necrosectomy with the use of hydrogen peroxide and without external irrigation: a novel approach for the treatment of walled-off pancreatic necrosis. 2013</Citation></Reference><Reference><Citation>Othman MO, Elhanafi S, Saadi M, Yu C, Davis BR. Extended Cystogastrostomy with Hydrogen Peroxide Irrigation Facilitates Endoscopic Pancreatic Necrosectomy. Diagn Ther Endosc. 2017;2017.</Citation></Reference><Reference><Citation>Browne RH. On the use of a pilot sample for sample size determination. Stat Med. 1995;14:1933&#x2013;1940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780141709</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines SJ, Lapointe M. Fibrinolytic agents in the treatment of intraventricular hemorrhage in adults. Crit Rev Neurosurg. 1998;8:169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003290050074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Cao F, Li A, Gao X, Wang XH, Liu DG et al. Predictive factors of pancreatic necrosectomy following percutaneous catheter drainage as a primary treatment of patients with infected necrotizing pancreatitis. Exp Ther Med. 2017;14:4397&#x2013;4404.</Citation><ArticleIdList><ArticleId IdType="pubmed">29104650</ArticleId><ArticleId IdType="pmc">5658722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternby H, Bolado F, Canaval-Zuleta HJ, Marra-L&#xf3;pez C, Hernando-Alonso AI, Del-Val-Anto&#xf1;ana A et al. Determinants of Severity in Acute Pancreatitis: A Nation-wide Multicenter Prospective Cohort Study. Ann Surg. 2019;270:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellam BL, Samanta J, Gupta P, Kumar M P, Sharma V, Dhaka N, et al. Predictors of outcome of percutaneous catheter drainage in patients with acute pancreatitis having acute fluid collection and development of a predictive model. Pancreatology [Internet]. 2019;19 (5):658&#x2013;64. https://doi.org/10.1016/j.pan.2019.05.467</Citation></Reference><Reference><Citation>Jain S, Padhan R, Bopanna S, Jain SK, Dhingra R, Dash NR, et al. Percutaneous Endoscopic Step-Up Therapy Is an Effective Minimally Invasive Approach for Infected Necrotizing Pancreatitis. Dig Dis Sci [Internet]. 2020;65 (2):615&#x2013;22. https://doi.org/10.1007/s10620-019-05696-2</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27652210</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2220-3141</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>World journal of critical care medicine</Title><ISOAbbreviation>World J Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Predictive value of cytokines for developing complications after polytrauma.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>200</EndPage><MedlinePgn>187-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5492/wjccm.v5.i3.187</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate posttraumatic cytokine alterations and their value for predicting complications and mortality in polytraumatized patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Studies on the use of specific cytokines to predict the development of complications and mortality were identified in MEDLINE, EMBASE, Web of Science and the Cochrane Library. Of included studies, relevant data were extracted and study quality was scored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-two studies published between 1988 and 2015 were identified, including 28 cohort studies and 14 "nested" case-control studies. Most studies investigated the cytokines interleukin (IL)-6, IL-8, IL-10 and tumor necrosis factor (TNF-&#x3b1;). IL-6 seems related to muliorgan dysfunction syndrome, multiorgan failure (MOF) and mortality; IL-8 appears altered in acute respiratory distress syndrome, MOF and mortality; IL-10 alterations seem to precede sepsis and MOF; and TNF-&#x3b1; seems related to MOF.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cytokine secretion patterns appear to be different for patients developing complications when compared to patients with uneventful posttraumatic course. More research is needed to strengthen the evidence for clinical relevance of these cytokines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dekker</LastName><ForeName>Anne-Britt E</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Anne-Britt E Dekker, Pieta Krijnen, Inger B Schipper, Department of Trauma Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krijnen</LastName><ForeName>Pieta</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Anne-Britt E Dekker, Pieta Krijnen, Inger B Schipper, Department of Trauma Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schipper</LastName><ForeName>Inger B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Anne-Britt E Dekker, Pieta Krijnen, Inger B Schipper, Department of Trauma Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Crit Care Med</MedlineTA><NlmUniqueID>101622182</NlmUniqueID><ISSNLinking>2220-3141</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Muli-organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">Multiple trauma</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27652210</ArticleId><ArticleId IdType="pmc">PMC4986547</ArticleId><ArticleId IdType="doi">10.5492/wjccm.v5.i3.187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Floh&#xe9; S, Floh&#xe9; SB, Schade FU, Waydhas C. Immune response of severely injured patients--influence of surgical intervention and therapeutic impact. Langenbecks Arch Surg. 2007;392:639&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">17605036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury. 2009;40:912&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">19541301</ArticleId></ArticleIdList></Reference><Reference><Citation>Frink M, van Griensven M, Kobbe P, Brin T, Zeckey C, Vaske B, Krettek C, Hildebrand F. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med. 2009;17:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763001</ArticleId><ArticleId IdType="pubmed">19781105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F, Koenderman L, Rijkers G, Leenen L. Trauma: the role of the innate immune system. World J Emerg Surg. 2006;1:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1481567</ArticleId><ArticleId IdType="pubmed">16759367</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36:691&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschoeke SK, Ertel W. Immunoparalysis after multiple trauma. Injury. 2007;38:1346&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciriello V, Gudipati S, Stavrou PZ, Kanakaris NK, Bellamy MC, Giannoudis PV. Biomarkers predicting sepsis in polytrauma patients: Current evidence. Injury. 2013;44:1680&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119650</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Hildebrand F, Pape HC. Inflammatory serum markers in patients with multiple trauma. Can they predict outcome? J Bone Joint Surg Br. 2004;86:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">15125116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand F, Pape HC, Krettek C. The importance of cytokines in the posttraumatic inflammatory reaction. Unfallchirurg. 2005;108:793&#x2013;794, 796-803.</Citation><ArticleIdList><ArticleId IdType="pubmed">16175346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sears BW, Stover MD, Callaci J. Pathoanatomy and clinical correlates of the immunoinflammatory response following orthopaedic trauma. J Am Acad Orthop Surg. 2009;17:255&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675552</ArticleId><ArticleId IdType="pubmed">19307674</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank J, Maier M, Koenig J, Rose S, Bouma M, Buurman WA, Marzi I. Circulating inflammatory and metabolic parameters to predict organ failure after multiple trauma. Eur J Trauma. 2002;28:333&#x2013;339.</Citation></Reference><Reference><Citation>DeLong WG, Born CT. Cytokines in patients with polytrauma. Clin Orthop Relat Res. 2004;(422):57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendemans S, Kreuzfelder E, Waydhas C, Nast-Kolb D, Floh&#xe9; S. Clinical course and prognostic significance of immunological and functional parameters after severe trauma. Unfallchirurg. 2004;107:203&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">14999368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry RM, Cue JI, Goddard JK, Parramore JB, DiPiro JT. Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma. 1996;40:613&#x2013;666; discussion 616-617.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614042</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Schregenberger N, Steckholzer U, Ungeth&#xfc;m U, Kenney J, Trentz O, Ertel W. Endotoxin tolerance after severe injury and its regulatory mechanisms. J Trauma. 1996;41:430&#x2013;47; discussion 430-437; 437-438.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810959</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbr&#xe8;re JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg. 1985;120:1109&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Norris JM, Lezotte DC, Hamman RF. Multiple organ failure can be predicted as early as 12 hours after injury. J Trauma. 1998;45:291&#x2013;301; discussion 301-303.</Citation><ArticleIdList><ArticleId IdType="pubmed">9715186</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore FA, Moore EE, Poggetti R, McAnena OJ, Peterson VM, Abernathy CM, Parsons PE. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma. 1991;31:629&#x2013;636; discussion 636-638.</Citation><ArticleIdList><ArticleId IdType="pubmed">2030509</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Goris RJ, van Nieuwenhoven EJ, Neugebauer E. Revision of the multiple organ failure score. Langenbecks Arch Surg. 2002;387:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11981679</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz M, von Griensven M, Stalp M, Kaufmann U, Hildebrand F, Pape HC. Scoring multiple organ failure after severe trauma. Comparison of the Goris, Marshall and Moore scores. Chirurg. 2001;72:723&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">11469095</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresing K, Armstrong VW, Leip CL, Streit F, Burchardi H, St&#xfc;rmer KM, Oellerich M. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. Clin Biochem. 2007;40:1194&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707362</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Haasper C, Kalmbach M, Dikos GD, Meller R, M&#xfc;ller C, Krettek C, Hildebrand F, Frink M. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care. 2010;18:89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevi&#x107; Z, Vukovi&#x107; G, Stojimirovi&#x107; B, Trbojevi&#x107;-Stankovi&#x107; J, Resanovi&#x107; V, Lausevic M. Kinetics of C-reactive protein, interleukin-6 and -10, and phospholipase A2-II in severely traumatized septic patients. Vojnosanit Pregl. 2010;67:893&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">21268514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mommsen P, Frink M, Pape HC, van Griensven M, Probst C, Gaulke R, Krettek C, Hildebrand F. Elevated systemic IL-18 and neopterin levels are associated with posttraumatic complications among patients with multiple injuries: a prospective cohort study. Injury. 2009;40:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">19054512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa M, Katabami K, Wada T, Minami Y, Sugano M, Shimojima H, Kubota N, Uegaki S, Sawamura A, Gando S. Imbalance between macrophage migration inhibitory factor and cortisol induces multiple organ dysfunction in patients with blunt trauma. Inflammation. 2011;34:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">20499270</ArticleId></ArticleIdList></Reference><Reference><Citation>Jastrow KM, Gonzalez EA, McGuire MF, Suliburk JW, Kozar RA, Iyengar S, Motschall DA, McKinley BA, Moore FA, Mercer DW. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg. 2009;209:320&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O&#x2019;Keefe G, Sperry J, et al. Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock. 2010;34:346&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Billeter A, Turina M, Seifert B, Mica L, Stocker R, Keel M. Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg. 2009;33:558&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">19148699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogner V, Keil L, Kanz KG, Kirchhoff C, Leidel BA, Mutschler W, Biberthaler P. Very early posttraumatic serum alterations are significantly associated to initial massive RBC substitution, injury severity, multiple organ failure and adverse clinical outcome in multiple injured patients. Eur J Med Res. 2009;14:284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458638</ArticleId><ArticleId IdType="pubmed">19661010</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly TJ, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994;22:768&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">8181284</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger G, Aigner R, Glasner A, Hofer HP, Mitterhammer H, Zelzer S. Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: comparison with various inflammation parameters. Intensive Care Med. 2004;30:331&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">14727016</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores JM, Jim&#xe9;nez PI, Rinc&#xf3;n MD, M&#xe1;rquez JA, Navarro H, Arteta D, Murillo F. Early risk factors for sepsis in patients with severe blunt trauma. Injury. 2001;32:5&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164394</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Br&#xfc;ckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135:291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, H&#xe4;rter L, Reding T, Sun LK, Hersberger M, Seifert B, Bimmler D, Graf R. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Crit Care Med. 2009;37:1642&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19325491</ArticleId></ArticleIdList></Reference><Reference><Citation>Law MM, Cryer HG, Abraham E. Elevated levels of soluble ICAM-1 correlate with the development of multiple organ failure in severely injured trauma patients. J Trauma. 1994;37:100&#x2013;109; discussion 109-110.</Citation><ArticleIdList><ArticleId IdType="pubmed">7913140</ArticleId></ArticleIdList></Reference><Reference><Citation>Liener UC, Br&#xfc;ckner UB, Kn&#xf6;ferl MW, Steinbach G, Kinzl L, Gebhard F. Chemokine activation within 24 hours after blunt accident trauma. Shock. 2002;17:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11900333</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg. 1988;123:1309&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">3140765</ArticleId></ArticleIdList></Reference><Reference><Citation>Meade P, Shoemaker WC, Donnelly TJ, Abraham E, Jagels MA, Cryer HG, Hugli TE, Bishop MH, Wo CC. Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury. J Trauma. 1994;36:651&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">8189465</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberholzer A, Keel M, Zellweger R, Steckholzer U, Trentz O, Ertel W. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. J Trauma. 2000;48:932&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823539</ArticleId></ArticleIdList></Reference><Reference><Citation>Paunel-G&#xf6;rg&#xfc;l&#xfc; A, Floh&#xe9; S, Scholz M, Windolf J, L&#xf6;gters T. Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. Crit Care. 2011;15:R20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222054</ArticleId><ArticleId IdType="pubmed">21232130</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymondos K, Martin MU, Schmudlach T, Baus S, Weilbach C, Welte T, Krettek C, Frink M, Hildebrand F. Early alveolar and systemic mediator release in patients at different risks for ARDS after multiple trauma. Injury. 2012;43:189&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">21703617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick M, Kollig E, Walz M, Muhr G, K&#xf6;ller M. [Does liberation of interleukin-12 correlate with the clinical course of polytraumatized patients?] Chirurg. 2000;71:1126&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">11043131</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R, Wollbrueck M, Hempelmann G. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med. 1999;27:733&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa A, Raposo F, Fonseca S, Valente L, Duarte F, Gon&#xe7;alves M, Tuna D, Paiva JA. Measurement of cytokines and adhesion molecules in the first 72 hours after severe trauma: association with severity and outcome. Dis Markers. 2015;2015:747036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4377365</ArticleId><ArticleId IdType="pubmed">25861153</ArticleId></ArticleIdList></Reference><Reference><Citation>Heizmann O, Koeller M, Muhr G, Oertli D, Schinkel C. Th1- and Th2-type cytokines in plasma after major trauma. J Trauma. 2008;65:1374&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pubmed">19077629</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel-Ch&#xe9;ron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS One. 2012;7:e33095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3303782</ArticleId><ArticleId IdType="pubmed">22431998</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidhardt R, Keel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, Ertel W. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma. 1997;42:863&#x2013;870; discussion 870-871.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191668</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Mouktaroudi M, Tsaganos T, Koutoukas P, Spyridaki E, Pelekanou A, Kotzampassi K. Evidence for the participation of soluble triggering receptor expressed on myeloid cells-1 in the systemic inflammatory response syndrome after multiple trauma. J Trauma. 2008;65:1385&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">19077631</ArticleId></ArticleIdList></Reference><Reference><Citation>Partrick DA, Moore FA, Moore EE, Biffl WL, Sauaia A, Barnett CC. Jack A. Barney Resident Research Award winner. The inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure. Am J Surg. 1996;172:425&#x2013;429; discussed 429-431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8942538</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielmann S, Kerner T, Ahlers O, Keh D, Gerlach M, Gerlach H. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand. 2001;45:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook KM, Sifri ZC, Baranski GM, Mohr AM, Livingston DH. The role of plasma granulocyte colony stimulating factor and bone marrow dysfunction after severe trauma. J Am Coll Surg. 2013;216:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541679</ArticleId><ArticleId IdType="pubmed">23063381</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangen TM, Bogdanski D, Schinkel C, Roetman B, K&#xe4;licke T, Muhr G, K&#xf6;ller M. Systemic IL-17 after severe injuries. Shock. 2008;29:462&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909455</ArticleId></ArticleIdList></Reference><Reference><Citation>Roetman B, Schinkel C, Wick M, Frangen T, Muhr G, K&#xf6;ller M. Elevated systemic interleukin-18 in multiple injured patients is not related to clinical outcome. J Interferon Cytokine Res. 2008;28:741&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">18937548</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel C, Wick M, Muhr G, K&#xf6;ller M. Analysis of systemic interleukin-11 after major trauma. Shock. 2005;23:30&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15614128</ArticleId></ArticleIdList></Reference><Reference><Citation>Svoboda P, Kantorov&#xe1; I, Ochmann J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma. 1994;36:336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8145312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagmur Y, Ozturk H, Unaldi M, Gedik E. Relation between severity of injury and the early activation of interleukins in multiple-injured patients. Eur Surg Res. 2005;37:360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">16465061</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlstedt SG, Lyte M, Rodriguez JL. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock. 2002;17:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12069178</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, Haslett C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet. 1993;341:643&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">8095568</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Baker CS, Evans TW, Haslam PL. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J. 2000;15:895&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">10853855</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis. 1992;145:1016&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">1586041</ArticleId></ArticleIdList></Reference><Reference><Citation>Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21:S447&#x2013;S463.</Citation><ArticleIdList><ArticleId IdType="pubmed">8403983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk H, Yagmur Y, Ozturk H. The prognostic importance of serum IL-1beta, IL-6, IL-8 and TNF-alpha levels compared to trauma scoring systems for early mortality in children with blunt trauma. Pediatr Surg Int. 2008;24:235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18060414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensler T, Heidecke CD, Hecker H, Heeg K, Bartels H, Zantl N, Wagner H, Siewert JR, Holzmann B. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J Immunol. 1998;161:2655&#x2013;2659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9725269</ArticleId></ArticleIdList></Reference><Reference><Citation>Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, Huang S, Aguet M, Anderson TD, Ryffel B. Role of interferon-gamma in interleukin 12-induced pathology in mice. Am J Pathol. 1995;147:1693&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869961</ArticleId><ArticleId IdType="pubmed">7495294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryffel B. Interleukin-12: role of interferon-gamma in IL-12 adverse effects. Clin Immunol Immunopathol. 1997;83:18&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9073529</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanuilidis K, Weighardt H, Matevossian E, Heidecke CD, Ulm K, Bartels H, Siewert JR, Holzmann B. Differential regulation of systemic IL-18 and IL-12 release during postoperative sepsis: high serum IL-18 as an early predictive indicator of lethal outcome. Shock. 2002;18:301&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392271</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberholzer A, Steckholzer U, Kurimoto M, Trentz O, Ertel W. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock. 2001;16:411&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20203290</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-3365</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of sports medicine</Title><ISOAbbreviation>Am J Sports Med</ISOAbbreviation></Journal><ArticleTitle>A new histology scoring system for the assessment of the quality of human cartilage repair: ICRS II.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>890</EndPage><MedlinePgn>880-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0363546509359068</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A reliable and reproducible method is needed to assess cartilage repair.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study was undertaken to test the reproducibility of 2 established histological scoring systems, the Modified O'Driscoll Scale (MODS) and International Cartilage Research Society (ICRS) Visual Assessment Scale (ICRS I), and subsequently to develop and evaluate a new grading system for cartilage repair.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Cohort study; Level of evidence, 2.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 107 cartilage biopsy specimens were graded using MODS and ICRS I, and the reader variability was measured. The new grading system, ICRS II, was developed and the inter- and intrareader variability determined by 3 independent readers. Collagen type II deposition was assessed immunohistochemically.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The MODS and ICRS I demonstrated high interreader variability, with MODS also showing high intrareader variability. A new histological scoring system, ICRS II, was developed comprising 14 criteria to assess parameters related to chondrocyte phenotype and tissue structure. The ICRS II demonstrated lower inter- and intrareader variability compared with MODS or ICRS I. The overall assessment and matrix staining scores had the best correlation coefficients for inter- and intrareader variability (r = .81 and .82, respectively). The extent of collagen type II in cartilage, considered a marker of differentiation toward hyaline cartilage, could represent a measure of good cartilage repair. A correlation coefficient of .56 was obtained between the extent of collagen type II staining and the overall assessment score.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ICRS II represents an improvement over current histological cartilage repair grading systems in terms of reader reproducibility. The clinical relevance and its ability to predict long-term repair durability will be assessed once long-term clinical data become available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mainil-Varlet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Pathology, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Boudewijn</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nesic</LastName><ForeName>Dobrila</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Knutsen</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kandel</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Sports Med</MedlineTA><NlmUniqueID>7609541</NlmUniqueID><ISSNLinking>0363-5465</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Sports Med. 2010 May;38(5):877-9. doi: 10.1177/0363546510369651.</RefSource><PMID Version="1">20436051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002358" MajorTopicYN="N">Cartilage, Articular</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006652" MajorTopicYN="Y">Histological Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019637" MajorTopicYN="N">Orthopedic Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="Y">Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20203290</ArticleId><ArticleId IdType="doi">10.1177/0363546509359068</ArticleId><ArticleId IdType="pii">0363546509359068</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23530720</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1445-2197</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>ANZ journal of surgery</Title><ISOAbbreviation>ANZ J Surg</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal complications after cardiac surgery: 10-year experience of a single Australian centre.</ArticleTitle><Pagination><StartPage>651</StartPage><EndPage>656</EndPage><MedlinePgn>651-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ans.12134</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gastrointestinal (GI) complications after cardiac surgery are uncommon, but are associated with high morbidity and mortality as well as significant hospital resource utilization.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed a prospectively collected database containing all adult cardiac surgery procedures performed from July 2001 to March 2011 at Monash Medical Centre and Jessie McPherson Private Hospital. Patients with post-operative GI complications were compared to patients without GI complications who were operated in the same period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of GI complications was 1.1% (61 out of 5382 patients) with an overall 30-day mortality of 33% (versus 3% in the non-GI complication group). The most common complications were GI bleeding, gastroenteritis and bowel ischaemia. Patients who had GI complications were significantly older, had higher incidence of renal impairment, chronic lung disease and anticoagulation therapy and were more likely to be in cardiogenic shock. Emergency procedures, combined coronary artery bypass grafting and valve surgery and aortic dissection cases were more common in the GI complication group. The GI complication group also had higher incidence of return to theatre, renal failure, stroke, septicaemia and multi-organ failure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GI complications after cardiac surgery remain an uncommon but dreadful complication associated with high mortality. Our findings should prompt a high degree of clinical vigilance in order to make an early diagnosis especially in high risk patients. Further studies aiming to identify independent predictors for GI complications after cardiac surgery are warranted.</AbstractText><CopyrightInformation>&#xa9; 2013 The Authors. ANZ Journal of Surgery &#xa9; 2013 Royal Australasian College of Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viana</LastName><ForeName>Fabiano F</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Monash Medical Centre, Clayton, Victoria, Australia. ff_viana@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Aubrey A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Heather D</ForeName><Initials>HD</Initials></Author><Author ValidYN="Y"><LastName>Cochrane</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Julian A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>ANZ J Surg</MedlineTA><NlmUniqueID>101086634</NlmUniqueID><ISSNLinking>1445-1433</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041881" MajorTopicYN="N">Cholecystitis, Acute</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017091" MajorTopicYN="N">Colitis, Ischemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="N">Gastroenteritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048550" MajorTopicYN="N">Hepatic Insufficiency</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045823" MajorTopicYN="N">Ileus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007416" MajorTopicYN="N">Intestinal Perforation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014739" MajorTopicYN="N" Type="Geographic">Victoria</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">gastrointestinal tract</Keyword><Keyword MajorTopicYN="N">post-operative complications</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23530720</ArticleId><ArticleId IdType="doi">10.1111/ans.12134</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31270381</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Systemic release of heat-shock protein 27 and 70 following severe trauma.</ArticleTitle><Pagination><StartPage>9595</StartPage><MedlinePgn>9595</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9595</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-46034-w</ELocationID><Abstract><AbstractText>Trauma represents a major cause of morbidity and mortality worldwide. The endogenous inflammatory response to trauma remains not fully elucidated. Pro-inflammation in the early phase is followed by immunosuppression leading to infections, multi-organ failure and mortality. Heat-shock proteins (HSPs) act as intracellular chaperons but exert also extracellular functions. However, their role in acute trauma remains unknown. The aim of this study was to evaluate serum concentrations of HSP 27 and HSP 70 in severely injured patients. We included severely injured patients with an injury severity score of at least 16 and measured serum concentration of both markers at admission and on day two. We found significantly increased serum concentrations of both HSP 27 and HSP 70 in severely injured patients. Concomitant thoracic trauma lead to a further increase of both HSPs. Also, elevated concentrations of HSP 27 and HSP 70 were associated with poor outcome in these patients. Standard laboratory parameters did not correlate with neither HSP 27, nor with HSP 70. Our findings demonstrate involvement of systemic release of HSP 27 and HSP 70 after severe trauma and their potential as biomarker in polytraumatized patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haider</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3192-8453</Identifier><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.a.haider@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simader</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gl&#xfc;ck</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ankersmit</LastName><ForeName>Hendrik J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajdu</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negrin</LastName><ForeName>Lukas L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-7195-2223</Identifier><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055551" MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013898" MajorTopicYN="N">Thoracic Injuries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31270381</ArticleId><ArticleId IdType="pmc">PMC6610099</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-46034-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-46034-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380, 2095-2128 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich Matthias, Lefering Rolf, Probst Christian, Paffrath Thomas, Schneider Marco M., Maegele Marc, Sakka Samir G., Bouillon Bertil, Wafaisade Arasch. Epidemiology and risk factors of multiple-organ failure after multiple trauma. Journal of Trauma and Acute Care Surgery. 2014;76(4):921&#x2013;928. doi: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider T, Halat G, Heinz T, Hajdu S, Negrin LL. Thoracic trauma and acute respiratory distress syndrome in polytraumatized patients: a retrospective analysis. Minerva Anestesiol. 2017;83:1026&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">28402091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, N. S., Casserly, B. &amp; Ayala, A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med29, 617&#x2013;625, viii (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786900</ArticleId><ArticleId IdType="pubmed">18954697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 2014;20:224&#x2013;233. doi: 10.1016/j.molmed.2014.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2014.01.002</ArticleId><ArticleId IdType="pmc">PMC3976785</ArticleId><ArticleId IdType="pubmed">24485901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862&#x2013;874. doi: 10.1038/nri3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz DH, et al. Inflammatory alterations in a novel combination model of blunt chest trauma and hemorrhagic shock. J Trauma. 2011;70:189&#x2013;196. doi: 10.1097/TA.0b013e3181d7693c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181d7693c</ArticleId><ArticleId IdType="pubmed">20495485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnthaller C, et al. The molecular fingerprint of lung inflammation after blunt chest trauma. Eur J Med Res. 2015;20:70. doi: 10.1186/s40001-015-0164-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-015-0164-y</ArticleId><ArticleId IdType="pmc">PMC4548898</ArticleId><ArticleId IdType="pubmed">26303896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebherz-Eichinger D, et al. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clin Chim Acta. 2012;413:282&#x2013;286. doi: 10.1016/j.cca.2011.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2011.10.010</ArticleId><ArticleId IdType="pubmed">22032827</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari S, et al. Extracellular HSP27 acts as a signaling molecule to activate NF-kappaB in macrophages. Cell Stress Chaperones. 2013;18:53&#x2013;63. doi: 10.1007/s12192-012-0356-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-012-0356-0</ArticleId><ArticleId IdType="pmc">PMC3508120</ArticleId><ArticleId IdType="pubmed">22851137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruden G, et al. Serum levels of heat shock protein 27 in patients with acute ischemic stroke. Cell Stress Chaperones. 2013;18:531&#x2013;533. doi: 10.1007/s12192-013-0403-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-013-0403-5</ArticleId><ArticleId IdType="pmc">PMC3682014</ArticleId><ArticleId IdType="pubmed">23334892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankersmit H, et al. Increased serum levels of HSP27 as a marker for incipient chronic obstructive pulmonary disease in young smokers. Respiration. 2012;83:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">22469636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann M, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study. Clin Chim Acta. 2012;413:1115&#x2013;1120. doi: 10.1016/j.cca.2012.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2012.03.008</ArticleId><ArticleId IdType="pubmed">22465083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacker S, et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal. 2009;23:372&#x2013;379. doi: 10.1002/jcla.20348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.20348</ArticleId><ArticleId IdType="pmc">PMC6649135</ArticleId><ArticleId IdType="pubmed">19927353</ArticleId></ArticleIdList></Reference><Reference><Citation>Janik S, et al. HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications. Sci Rep. 2016;6:24267. doi: 10.1038/srep24267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24267</ArticleId><ArticleId IdType="pmc">PMC4838882</ArticleId><ArticleId IdType="pubmed">27097982</ArticleId></ArticleIdList></Reference><Reference><Citation>ArdsDefinitionTaskForce, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrin LL, et al. Soluble Receptor for Advanced Glycation End Products Quantifies Lung Injury in Polytraumatized Patients. Ann Thorac Surg. 2017;103:1587&#x2013;1593. doi: 10.1016/j.athoracsur.2016.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.09.021</ArticleId><ArticleId IdType="pubmed">27865475</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider, T. et al. Increased serum concentrations of soluble ST2 are associated with pulmonary complications and mortality in polytraumatized patients. Clin Chem Lab Med (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29341938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, et al. Assessment of the clinical course with inflammatory parameters. Injury. 2007;38:1358&#x2013;1364. doi: 10.1016/j.injury.2007.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.026</ArticleId><ArticleId IdType="pubmed">18048038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38:1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J Immunol. 2000;165:3951&#x2013;3958. doi: 10.4049/jimmunol.165.7.3951.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.7.3951</ArticleId><ArticleId IdType="pubmed">11034403</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Dynamic activity of NF-kappaB in multiple trauma patients and protective effects of ulinastain. Chin J Traumatol. 2011;14:354&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">22152139</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo AP, et al. Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal. 2005;7:414&#x2013;422. doi: 10.1089/ars.2005.7.414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2005.7.414</ArticleId><ArticleId IdType="pubmed">15706088</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderwood SK, Gong J, Murshid A. Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. Front Immunol. 2016;7:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842758</ArticleId><ArticleId IdType="pubmed">27199984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mambula SS, Calderwood SK. Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. Int J Hyperthermia. 2006;22:575&#x2013;585. doi: 10.1080/02656730600976042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02656730600976042</ArticleId><ArticleId IdType="pubmed">17079215</ArticleId></ArticleIdList></Reference><Reference><Citation>Batulan Z, et al. Extracellular Release and Signaling by Heat Shock Protein 27: Role in Modifying Vascular Inflammation. Front Immunol. 2016;7:285. doi: 10.3389/fimmu.2016.00285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00285</ArticleId><ArticleId IdType="pmc">PMC4960997</ArticleId><ArticleId IdType="pubmed">27507972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin RP, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 2002;23:130&#x2013;135. doi: 10.1016/S1471-4906(01)02168-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4906(01)02168-8</ArticleId><ArticleId IdType="pubmed">11864840</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc. 2005;2:403&#x2013;411. doi: 10.1513/pats.200508-090JS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/pats.200508-090JS</ArticleId><ArticleId IdType="pmc">PMC2713330</ArticleId><ArticleId IdType="pubmed">16322590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenauer M, et al. Transient hypoxia leads to increased serum levels of heat shock protein-27, -70 and caspase-cleaved cytokeratin 18. Clin Lab. 2014;60:323&#x2013;328. doi: 10.7754/Clin.Lab.2013.130303.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2013.130303</ArticleId><ArticleId IdType="pubmed">24660549</ArticleId></ArticleIdList></Reference><Reference><Citation>Guisasola MC, Ortiz A, Chana F, Alonso B, Vaquero J. Early inflammatory response in polytraumatized patients: Cytokines and heat shock proteins. A pilot study. Orthop Traumatol Surg Res. 2015;101:607&#x2013;611. doi: 10.1016/j.otsr.2015.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2015.03.014</ArticleId><ArticleId IdType="pubmed">26068807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi N, et al. Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. J Trauma. 2001;51:1104&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740261</ArticleId></ArticleIdList></Reference><Reference><Citation>Flohe SB, et al. Origin of immunomodulation after soft tissue trauma: potential involvement of extracellular heat-shock proteins. Shock. 2007;27:494&#x2013;502. doi: 10.1097/shk.0b013e31802dec51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/shk.0b013e31802dec51</ArticleId><ArticleId IdType="pubmed">17438454</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet Jean-Fran&#xe7;ois, Lee H., Morabito Diane, Howard M. B., Welch William J., Mackersie Robert C. Serum Levels of Hsp 72 Measured Early after Trauma Correlate with Survival. The Journal of Trauma: Injury, Infection, and Critical Care. 2002;52(4):611&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956372</ArticleId></ArticleIdList></Reference><Reference><Citation>Guisasola MC, Alonso B, Bravo B, Vaquero J, Chana F. An overview of cytokines and heat shock response in polytraumatized patients. Cell Stress Chaperones. 2018;23:483&#x2013;489. doi: 10.1007/s12192-017-0859-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-017-0859-9</ArticleId><ArticleId IdType="pmc">PMC6045557</ArticleId><ArticleId IdType="pubmed">29101529</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxler D, Lainscak M, Simader E, Ankersmit HJ, Jug B. Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients. Clin Chim Acta. 2017;473:127&#x2013;132. doi: 10.1016/j.cca.2017.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.08.028</ArticleId><ArticleId IdType="pubmed">28844461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M, et al. Hsp-27 levels and thrombus burden relate to clinical outcomes in patients with ST-segment elevation myocardial infarction. Oncotarget. 2017;8:73733&#x2013;73744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650295</ArticleId><ArticleId IdType="pubmed">29088740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa F, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol. 2008;26:659&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">18799101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39244800</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-3984</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><PubDate><Year>2024</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Geriatric nursing (New York, N.Y.)</Title><ISOAbbreviation>Geriatr Nurs</ISOAbbreviation></Journal><ArticleTitle>Predicting mortality of elderly patients undergoing open heart surgery with delirium using sequential organ failure assessment (SOFA), multi-organ dysfunction (MODS), and logistic organ dysfunction system (LODS) scores.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>149</EndPage><MedlinePgn>146-149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gerinurse.2024.08.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4572(24)00265-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aims to assess the predictive accuracy of SOFA, MODS, and LODS scores in determining the mortality of elderly undergoing open heart surgery with delirium.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study involved 111 elderly patients who met the inclusion criteria. Data were collected using scoring systems: SOFA, MODS, and LODS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Upon final follow-up, 86.5 % of the patients had recovered, 13.5 % had died. Sensitivity, specificity, negative, and positive predictive values for predicting mortality in elderly patients were calculated for the SOFA score as 99 %, 73 %, 98 %, and 76 %, respectively. For the MODS score, these values were 95 %, 60 %, 95 %, and 67 %; for the LODS score, they were 92 %, 73 %, 92 %, and 75 %, respectively. The overall accuracy of the three scores-SOFA, MODS, and LODS-was 84 %, 76 %, and 82 %, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicated that the SOFA score exhibited the highest sensitivity and specificity in predicting mortality among elderly individuals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mousabeygi</LastName><ForeName>Elaheh</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmati</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salari</LastName><ForeName>Nader</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalali</LastName><ForeName>Rostam</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: ks_jalali@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Geriatr Nurs</MedlineTA><NlmUniqueID>8309633</NlmUniqueID><ISSNLinking>0197-4572</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="Y">Delirium</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="Y">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Delirium</Keyword><Keyword MajorTopicYN="N">Lods</Keyword><Keyword MajorTopicYN="N">Mods</Keyword><Keyword MajorTopicYN="N">Open heart surgery</Keyword><Keyword MajorTopicYN="N">Organ dysfunction scores</Keyword><Keyword MajorTopicYN="N">Sofa</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>8</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>8</Day><Hour>22</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>8</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39244800</ArticleId><ArticleId IdType="doi">10.1016/j.gerinurse.2024.08.023</ArticleId><ArticleId IdType="pii">S0197-4572(24)00265-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18564662</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0250-636X</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Tropical gastroenterology : official journal of the Digestive Diseases Foundation</Title><ISOAbbreviation>Trop Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>A prospective study of the aetiology, severity and outcome of acute pancreatitis in Eastern India.</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>22</EndPage><MedlinePgn>20-2</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute pancreatitis is a common cause of hospital admission. The aim of this study was to evaluate the aetiology, severity and outcome of acute pancreatitis in our tertiary referral center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between August 2002 and December 2003, 45 cases of acute pancreatitis were admitted to the hospital. Diagnosis was ascertained by clinical examination and investigations (hyperamylasaemia). The severity was assessed by the Acute Physiology and Chronic Health Evaluation scoring system and contrast enhanced computed tomography scan. The patients were treated according to a designed protocol. The data related to aetiology, severity and outcome were noted for subsequent analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 45 patients, 33 were male and 12 were female. The mean age was 30 years. Of the 45 patients, 34 patients had mild pancreatitis and 11 had severe pancreatitis. The aetiology spectrum of mild pancreatitis included the following: alcoholism in 14 (41.1%), gallstones in 8 (23.5%), trauma in 6 (17.6%), idiopathic in 4 (11.7%) and post-endoscopic retrograde cholangiopancreatography in 2 (5.8%). The causes of severe acute pancreatitis came under the following headers: trauma in 3 (27.2%), idiopathic in 2 (18.1%), gallstones in 2 (18.1%), alcoholism in 2 (18.1%) and post-endoscopic retrograde cholangiopancreatography in 2(18.1%). Mild pancreatitis led on to the following: pancreatic abscess in 1, pseudocyst in 3 and readmission for pain relapse within 6 months in 10 patients. The remainder had uneventful recoveries. There was no mortality in this group. Severe acute pancreatitis led on to the following: symptomatic sterile pancreatic necrosis in 2, infected pancreatic necrosis in 2, pancreatic abscess in 2 and presentation 8 months later with colonic stricture in 1 patient. There were 2 deaths in this group due to multi-organ failure.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although gallstones have largely been implicated as a common cause of acute pancreatitis our study found alcoholism as the main aetiological factor. Blunt abdominal trauma was also seen as a common cause of acute severe pancreatitis, particularly severe acute pancreatitits, as seen in our series. The outcome in mild pancreatitis was good, severe acute pancreatitis leads to more complications and greater mortality, thus requiring careful medical and surgical management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baig</LastName><ForeName>Sarfaraz Jalil</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical College Kolkata, India. docsarfarazbaig@yahoo.co.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahed</LastName><ForeName>Abdur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Trop Gastroenterol</MedlineTA><NlmUniqueID>8107122</NlmUniqueID><ISSNLinking>0250-636X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002760" MajorTopicYN="N">Cholangiopancreatography, Endoscopic Retrograde</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042882" MajorTopicYN="N">Gallstones</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007049" MajorTopicYN="N">Iatrogenic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019512" MajorTopicYN="N">Pancreatitis, Alcoholic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18564662</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27867562</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Analysis of risk factors for and the prognosis of postoperative acute respiratory distress syndrome in patients with Stanford type A aortic dissection.</ArticleTitle><Pagination><StartPage>2862</StartPage><EndPage>2871</EndPage><MedlinePgn>2862-2871</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To explore the risk factors for and the prognosis of postoperative acute respiratory distress syndrome (ARDS) in patients with Stanford type A aortic dissection (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective nested case-control study included 527 Stanford type A AD patients who were divided into ARDS groups and non-ARDS groups. The clinical features of the groups were examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The fifty-nine patients in the ARDS group exhibited extended durations of cardiopulmonary bypass (CPB) (P=0.004), deep hypothermic circulatory arrest (DHCA) (P=0.000), ventilator support (P=0.013) and intensive care unit (ICU) stay (P=0.045), higher hospital costs (P=0.000), larger perioperative transfusions volumes [red blood cells (RBC): P=0.002, platelets (PLT): P=0.040, fresh frozen plasma (FFP): P=0.001], more frequent pulmonary infection (P=0.018) and multiple organ dysfunction syndrome (MODS) (P=0.040) and a higher rate of in-hospital mortality (P=0.020). The ARDS group exhibited worse statuses in terms of oxygenation index (OI) values (P=0.000) and Apache II scores (P=0.000). DHCA [P=0.000, odds ratio (OR) =2.589] and perioperative transfusion (RBC: P=0.000, OR =2.573; PLT: P=0.027, OR =1.571; FFP: P=0.002, OR =1.929) were independent risk factors for postoperative ARDS. The survival rates and median survival times after discharge were similar between the two groups (P=0.843).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">DHCA duration and perioperative transfusion volume were independent risk factors for postoperative ARDS which warrants greater attention by the cardiac surgeons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Fang</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Liang-Wan</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">adult</Keyword><Keyword MajorTopicYN="N">aortic aneurysm</Keyword><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">circulatory arrest</Keyword><Keyword MajorTopicYN="N">deep hypothermia induced</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27867562</ArticleId><ArticleId IdType="pmc">PMC5107558</ArticleId><ArticleId IdType="doi">10.21037/jtd.2016.10.10</ArticleId><ArticleId IdType="pii">jtd-08-10-2862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pierrakos C, Karanikolas M, Scolletta S, et al. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J Clin Med Res 2012;4:7-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279495</ArticleId><ArticleId IdType="pubmed">22383921</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller-Redetzky HC, Felten M, Hellwig K, et al. Increasing the inspiratory time and I:E ratio during mechanical ventilation aggravates ventilator-induced lung injury in mice. Crit Care 2015;19:23. 10.1186/s13054-015-0759-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0759-2</ArticleId><ArticleId IdType="pmc">PMC4336519</ArticleId><ArticleId IdType="pubmed">25888164</ArticleId></ArticleIdList></Reference><Reference><Citation>Makita S, Ohira A, Tachieda R, et al. Behavior of C-reactive protein levels in medically treated aortic dissection and intramural hematoma. Am J Cardiol 2000;86:242-4. 10.1016/S0002-9149(00)00869-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9149(00)00869-9</ArticleId><ArticleId IdType="pubmed">10913496</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto N, Morimoto K, Morimoto Y, et al. Sivelestat attenuates postoperative pulmonary dysfunction after total arch replacement under deep hypothermia. Eur J Cardiothorac Surg 2008;34:798-804. 10.1016/j.ejcts.2008.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2008.07.010</ArticleId><ArticleId IdType="pubmed">18722781</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-31. 10.1053/j.jvca.2008.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2008.08.007</ArticleId><ArticleId IdType="pubmed">18930659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortelliti MP, Manning HL. Acute respiratory distress syndrome. Am Fam Physician 2002;65:1823-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12018805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZG, Sun LZ, Chang Q, et al. Should the "elephant trunk" be skeletonized? Total arch replacement combined with stented elephant trunk implantation for Stanford type A aortic dissection. J Thorac Cardiovasc Surg 2006;131:107-13. 10.1016/j.jtcvs.2005.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2005.09.015</ArticleId><ArticleId IdType="pubmed">16399301</ArticleId></ArticleIdList></Reference><Reference><Citation>ARDS Definition Task Force , Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RL. Indications for dialysis in the ICU: renal replacement vs. renal support. Blood Purif 2001;19:227-32. 10.1159/000046946</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000046946</ArticleId><ArticleId IdType="pubmed">11150815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LW, Dai XF, Zhang GC, et al. Total aortic arch reconstruction with open placement of triple-branched stent graft for acute type A dissection. J Thorac Cardiovasc Surg 2010;139:1654-1655.e1. 10.1016/j.jtcvs.2009.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.10.022</ArticleId><ArticleId IdType="pubmed">20074749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma WG, Zhu JM, Zheng J, et al. Sun's procedure for complex aortic arch repair: total arch replacement using a tetrafurcate graft with stented elephant trunk implantation. Ann Cardiothorac Surg 2013;2:642-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791186</ArticleId><ArticleId IdType="pubmed">24109575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553-64. 10.1016/S0140-6736(07)60604-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60604-7</ArticleId><ArticleId IdType="pubmed">17482987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli V, Vlachou A, Ghannadian S, et al. Acute respiratory distress syndrome: new definition, current and future therapeutic options. J Thorac Dis 2013;5:326-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698298</ArticleId><ArticleId IdType="pubmed">23825769</ArticleId></ArticleIdList></Reference><Reference><Citation>Milberg JA, Davis DR, Steinberg KP, et al. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995;273:306-9. 10.1001/jama.1995.03520280052039</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03520280052039</ArticleId><ArticleId IdType="pubmed">7815658</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds HN, McCunn M, Borg U, et al. Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base. Crit Care 1998;2:29-34. 10.1186/cc121</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc121</ArticleId><ArticleId IdType="pmc">PMC28999</ArticleId><ArticleId IdType="pubmed">11056707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge QG, Hou J, Zhou H, et al. Multiple organ failure induced by acute respiration distress syndrome: a report of 15 cases. Mod Surg 2000;6:41-4.</Citation></Reference><Reference><Citation>He X, Han B, Mura M, et al. Anti-human tissue factor antibody ameliorated intestinal ischemia reperfusion-induced acute lung injury in human tissue factor knock-in mice. PLoS One 2008;3:e1527. 10.1371/journal.pone.0001527</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001527</ArticleId><ArticleId IdType="pmc">PMC2211395</ArticleId><ArticleId IdType="pubmed">18231608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hei ZQ, Gan XL, Huang HQ, et al. Protective effects of cromolyn sodium on intestinal ischaemia-reperfusion-triggered lung injury in rats. Br J Anaesth 2007;98:407-8. 10.1093/bja/ael383</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/ael383</ArticleId><ArticleId IdType="pubmed">17307785</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkin DW, Arnold R, Hoper M. Anti-endotoxin hyperimmune globulin attenuates portal cytokinaemia, phagocytic cell priming, and acute lung injury after lower limb ischaemia-reperfusion injury. Eur J Vasc Endovasc Surg 2007;33:330-9. 10.1016/j.ejvs.2006.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejvs.2006.10.024</ArticleId><ArticleId IdType="pubmed">17161961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao DQ, Chen YP, Chang YT, et al. Effects of aminoguanidine on the lung injury induced by the total hepatic ischemia-reperfusion in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006;31:94-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16562685</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller MC, Tuinman PR, Vlaar AP, et al. Contribution of damage-associated molecular patterns to transfusion-related acute lung injury in cardiac surgery. Blood Transfus 2014;12:368-75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111819</ArticleId><ArticleId IdType="pubmed">24887223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkawa T, Sato N, Kojika M, et al. Significance of measuring S100A12 and sRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg 2010;27:307-12. 10.1159/000313687</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000313687</ArticleId><ArticleId IdType="pubmed">20689292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39317599</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1424-3911</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</Title><ISOAbbreviation>Pancreatology</ISOAbbreviation></Journal><ArticleTitle>Early selective enteral feeding in combination with active decompression of duodenum in treatment of moderate and severe acute pancreatitis - A proof-of-concept clinical study.</ArticleTitle><Pagination><StartPage>1012</StartPage><EndPage>1020</EndPage><MedlinePgn>1012-1020</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pan.2024.09.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1424-3903(24)00746-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute pancreatitis (AP) is a significant clinical challenge with rising global incidence and substantial mortality rates, necessitating effective treatment strategies. Current guidelines recommend pain and fluid management and early enteral feeding to mitigate complications, yet optimal feeding route remains debated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective, randomized, controlled trial at nine centers from October 2020 to May 2023, enrolling 154 patients with moderate to severe AP. Patients were stratified into biliary and non-biliary categories and randomized 1:1 to receive either standard of care (SoC) or SoC plus PandiCath&#xae;, a novel catheter enabling selective enteral feeding and duodenal decompression. The primary clinical endpoint (PCE) was a composite of de novo multiple organ dysfunction syndrome (MODS), infectious complications, pancreatic and intestinal fistula formation, bleeding, abdominal compartment syndrome, obstructive jaundice, and AP-related mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the primary modified intention-to-treat analysis, PandiCath&#xae; significantly reduced the PCE compared to SoC alone (P&#xa0;=&#xa0;0.032). The Relative Risk (RR&#xa0;=&#xa0;0.469, 95&#xa0;% CI 0.228-0.964) and Number Needed to Treat (NNT&#xa0;=&#xa0;6.384, 95&#xa0;% CI 3.349-68.167) indicated its substantial clinical benefit, primarily driven by reduced rates of de novo MODS and infectious complications. These findings were further supported by the evaluation of other populations, including the standard intention-to-treat analysis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PandiCath&#xae;, facilitating targeted enteral feeding while isolating and decompressing the duodenum, demonstrates promise in improving outcomes for AP patients at risk of severe complications. Further studies are warranted to validate these findings and explore optimal timing and patient selection for this intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kashintsev</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>PANDICA LTD, 22 Great James Street, London, WC1N 3ES, UK. Electronic address: alexey.kashintsev@pandica.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunda</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept of Advanced Interventional Endoscopy, Dept of Surgery (HPB), Dept of Gastroenterology and Hepatology, Brussels University Hospital (UZB), Vrije Universiteteit Brussel (VUB), Brussels, Belgium. Electronic address: rastikunda@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proutski</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>PANDICA LTD, 22 Great James Street, London, WC1N 3ES, UK. Electronic address: vitali.proutski@pandica.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pancreatology</MedlineTA><NlmUniqueID>100966936</NlmUniqueID><ISSNLinking>1424-3903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="Y">Enteral Nutrition</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019299" MajorTopicYN="Y">Decompression, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004386" MajorTopicYN="Y">Duodenum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">Duodenal Decompression</Keyword><Keyword MajorTopicYN="N">Enteral feeding</Keyword><Keyword MajorTopicYN="N">Multimodal treatment approach</Keyword><Keyword MajorTopicYN="N">Nutritional support</Keyword></KeywordList><CoiStatement>Declaration of competing interest Kunda R. received compensation from PANDICA LTD for consultancy services.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>21</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39317599</ArticleId><ArticleId IdType="doi">10.1016/j.pan.2024.09.013</ArticleId><ArticleId IdType="pii">S1424-3903(24)00746-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37035317</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.</ArticleTitle><Pagination><StartPage>1122367</StartPage><MedlinePgn>1122367</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1122367</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1122367</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Mid-regional pro-adrenomedullin (MR-proADM), an endothelium-related peptide, is a predictor of death and multi-organ failure in respiratory infections and sepsis and seems to be effective in identifying COVID-19 severe forms. The study aims to evaluate the effectiveness of MR-proADM in comparison to routine inflammatory biomarkers, lymphocyte subpopulations, and immunoglobulin (Ig) at an intensive care unit (ICU) admission and over time in predicting mortality in patients with severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">All adult patients with COVID-19 pneumonia admitted between March 2020 and June 2021 in the ICUs of a university hospital in Italy were enrolled. MR-proADM, lymphocyte subpopulations, Ig, and routine laboratory tests were measured within 48 h and on days 3 and 7. The log-rank test was used to compare survival curves with MR-proADM cutoff value of &gt;1.5 nmol/L. Predictive ability was compared using the area under the curve (AUC) and 95% confidence interval (CI) of different receiver-operating characteristic curves.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 209 patients, with high clinical severity [SOFA 7, IQR 4-9; SAPS II 52, IQR 41-59; median viral pneumonia mortality score (MuLBSTA)-11, IQR 9-13] were enrolled. ICU and overall mortality were 55.5 and 60.8%, respectively. Procalcitonin, lactate dehydrogenase, D-dimer, the N-terminal prohormone of brain natriuretic peptide, myoglobin, troponin, neutrophil count, lymphocyte count, and natural killer lymphocyte count were significantly different between survivors and non-survivors, while lymphocyte subpopulations and Ig were not different in the two groups. MR-proADM was significantly higher in non-survivors (1.17 &#xb1; 0.73 vs. 2.31 &#xb1; 2.63, <i>p</i> &lt; 0.0001). A value of &gt;1.5 nmol/L was an independent risk factor for mortality at day 28 [odds ratio of 1.9 (95% CI: 1.220-3.060)] after adjusting for age, lactate at admission, SOFA, MuLBSTA, superinfections, cardiovascular disease, and respiratory disease. On days 3 and 7 of the ICU stay, the MR-proADM trend evaluated within 48 h of admission maintained a correlation with mortality (<i>p</i> &lt; 0.0001). Compared to all other biomarkers considered, the MR-proADM value within 48 h had the best accuracy in predicting mortality at day 28 [AUC = 0.695 (95% CI: 0.624-0.759)].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">MR-proADM seems to be the best biomarker for the stratification of mortality risk in critically ill patients with COVID-19. The Ig levels and lymphocyte subpopulations (except for natural killers) seem not to be correlated with mortality. Larger, multicentric studies are needed to confirm these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Montrucchio, Sales, Balzani, Lombardo, Giaccone, Cant&#xf9;, D'Antonio, Rumbolo, Corcione, Simonetti, Bonetto, Zanierato, Fanelli, Filippini, Mengozzi and Brazzi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montrucchio</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sales</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balzani</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cant&#xf9;</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Antonio</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rumbolo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Biochemistry Laboratory, Department of Laboratory Medicine, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcione</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanierato</LastName><ForeName>Marinella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanelli</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengozzi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Biochemistry Laboratory, Department of Laboratory Medicine, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brazzi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MR-proADM</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adrenomedullin</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">immunoglobulins</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">lymphocyte subpopulations</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37035317</ArticleId><ArticleId IdType="pmc">PMC10080079</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1122367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weidmann MD, Ofori K, Rai AJ. Laboratory biomarkers in the management of patients with COVID-19. Am J Clin Pathol. (2021) 155:333&#x2013;42. 10.1093/ajcp/aqaa205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa205</ArticleId><ArticleId IdType="pmc">PMC7665296</ArticleId><ArticleId IdType="pubmed">33107558</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. . Biomarkers and outcomes of COVID-19 hospitalizations: systematic review and meta-analysis. BMJ Evid Based Med. (2021) 26:107&#x2013;8. 10.1136/bmjebm-2020-111536</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjebm-2020-111536</ArticleId><ArticleId IdType="pmc">PMC7493072</ArticleId><ArticleId IdType="pubmed">32934000</ArticleId></ArticleIdList></Reference><Reference><Citation>Keddie S, Ziff O, Chou MKL, Taylor RL, Heslegrave A, Garr E, et al. . Laboratory biomarkers associated with COVID-19 severity and management. Clin Immunol. (2020) 221:108614. 10.1016/j.clim.2020.108614</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108614</ArticleId><ArticleId IdType="pmc">PMC7581344</ArticleId><ArticleId IdType="pubmed">33153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg OHM, Bergenzaun L, Ryd&#xe9;n J, Rosenqvist M, Melander O, Chew MS. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit Care. (2016) 20:178. 10.1186/s13054-016-1361-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1361-y</ArticleId><ArticleId IdType="pmc">PMC4899903</ArticleId><ArticleId IdType="pubmed">27282767</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wang C, Pang S. The diagnostic accuracy of mid-regional pro-adrenomedullin for sepsis: a systematic review and meta-analysis. Minerva Anestesiol. (2021) 87:1117&#x2013;27. 10.23736/S0375-9393.21.15585-3</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0375-9393.21.15585-3</ArticleId><ArticleId IdType="pubmed">34134460</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed K, Legramante JM, Angeletti S, Curcio F, Miguens I, Poole S, et al. . Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department. Expert Rev Mol Diagn. (2021) 21:397&#x2013;404. 10.1080/14737159.2021.1902312</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2021.1902312</ArticleId><ArticleId IdType="pubmed">33736553</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a de Guadiana-Romualdo L, Calvo Nieves MD, Rodr&#xed;guez Mulero MD, Calcerrada Alises I, Hern&#xe1;ndez Olivo M, Trapiello Fern&#xe1;ndez W, et al. . MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur J Clin Invest. (2021) 51:e13511. 10.1111/eci.13511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13511</ArticleId><ArticleId IdType="pmc">PMC7995076</ArticleId><ArticleId IdType="pubmed">33569769</ArticleId></ArticleIdList></Reference><Reference><Citation>de Montmollin E, Peoc'h K, Marzouk M, Ruckly S, Wicky PH, Patrier J, et al. . Mid-regional pro-adrenomedullin as a prognostic factor for severe COVID-19 ARDS. Antibiotics. (2022) 11:1166. 10.3390/antibiotics11091166</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11091166</ArticleId><ArticleId IdType="pmc">PMC9495198</ArticleId><ArticleId IdType="pubmed">36139946</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Balzani E, Lombardo D, Giaccone A, Vaninetti A, D'Antonio G, et al. . Proadrenomedullin in the management of COVID-19 critically ill patients in intensive care unit: a systematic review and meta-analysis of evidence and uncertainties in existing literature. J Clin Med. (2022) 11:4543. 10.3390/jcm11154543</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11154543</ArticleId><ArticleId IdType="pmc">PMC9369672</ArticleId><ArticleId IdType="pubmed">35956159</ArticleId></ArticleIdList></Reference><Reference><Citation>He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. . The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. (2020) 127:104361. 10.1016/j.jcv.2020.104361</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104361</ArticleId><ArticleId IdType="pmc">PMC7152870</ArticleId><ArticleId IdType="pubmed">32344320</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. (2020) 9:1123&#x2013;30. 10.1080/22221751.2020.1770129</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. . Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. (2020) 11:827. 10.3389/fimmu.2020.00827</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, et al. . Immune parameters and COVID-19 infection - associations with clinical severity and disease prognosis. Front Cell Infect Microbiol. (2020) 10:364. 10.3389/fcimb.2020.00364</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00364</ArticleId><ArticleId IdType="pmc">PMC7338601</ArticleId><ArticleId IdType="pubmed">32695683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamura APD, Tavares da Silva MR, H&#xfc;mmelgen AL, Soeiro Pereira PV, Falcai A, Grumach AS, et al. . Immunity and inflammatory biomarkers in COVID-19: a systematic review. Rev Med Virol. (2021) 31:e2199. 10.1002/rmv.2199</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2199</ArticleId><ArticleId IdType="pubmed">34260778</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Sales G, Rumbolo F, Palmesino F, Fanelli V, Urbino R, et al. . Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: an observational prospective study. PLoS ONE. (2021) 16:e0246771. 10.1371/journal.pone.0246771</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246771</ArticleId><ArticleId IdType="pmc">PMC7870047</ArticleId><ArticleId IdType="pubmed">33556140</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization&#x2013;Laboratory Testing Strategy Recommendations for COVID-19: Interim Guidance. Available online at: https://www.who.int/publications/i/item/laboratorytesting-strategy-recommendations-for-covid-19-interim-guidance (accessed November 30, 2022).</Citation></Reference><Reference><Citation>IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available online at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (accessed November 30, 2022).</Citation></Reference><Reference><Citation>The National Institutes of Health. Available online at: https://www.covid19treatmentguidelines.nih.gov/ (accessed November 30, 2022).</Citation></Reference><Reference><Citation>Surveillance of Healthcare-Associated Infections and Prevention Indicators in European Intensive Care Units. Available online at: https://www.ecdc.europa.eu/sites/default/files/documents/HAI-Net-ICU-protocol-v2.2_0.pdf (accessed November 30, 2022).</Citation></Reference><Reference><Citation>Istituto Superiore di Sanit&#xe0;. Available online at: https://www.iss.it/web/guest/long-covid-linee-guida (accessed November 30, 2022).</Citation></Reference><Reference><Citation>Siemieniuk RA, Bartoszko JJ, D&#xed;az Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. . Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. (2021) 374:n2231. 10.1136/bmj.n2231</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2231</ArticleId><ArticleId IdType="pmc">PMC8459162</ArticleId><ArticleId IdType="pubmed">34556486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. (2017) 45:486&#x2013;552. 10.1097/CCM.0000000000002255</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002255</ArticleId><ArticleId IdType="pubmed">28098591</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. (2021) 47:1181&#x2013;247. 10.1007/s00134-021-06506-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06506-y</ArticleId><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vidal C, Sanjuan G, Moreno-Garc&#xed;a E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. . Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. (2021) 27:83&#x2013;8. 10.1016/j.cmi.2020.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.041</ArticleId><ArticleId IdType="pmc">PMC7836762</ArticleId><ArticleId IdType="pubmed">32745596</ArticleId></ArticleIdList></Reference><Reference><Citation>Godinjak A, Iglica A, Rama A, Tan&#x10d;ica I, Jusufovi&#x107; S, Ajanovi&#x107; A, et al. . Predictive value of SAPS II and APACHE II scoring systems for patient outcome in a medical intensive care unit. Acta Med Acad. (2016) 45:97&#x2013;103. 10.5644/ama2006-124.165</Citation><ArticleIdList><ArticleId IdType="doi">10.5644/ama2006-124.165</ArticleId><ArticleId IdType="pubmed">28000485</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. . Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol. (2019) 10:2752. 10.3389/fmicb.2019.02752</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02752</ArticleId><ArticleId IdType="pmc">PMC6901688</ArticleId><ArticleId IdType="pubmed">31849894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartsonaki C. Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19. medRxiv. [Preprint]. (2021).</Citation></Reference><Reference><Citation>COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study . Infection. (2021) 49:889&#x2013;905. 10.1007/s15010-021-01599-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01599-5</ArticleId><ArticleId IdType="pmc">PMC8231091</ArticleId><ArticleId IdType="pubmed">34170486</ArticleId></ArticleIdList></Reference><Reference><Citation>ISARIC Clinical Characterisation Group. Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, et al. . Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. Elife. (2021) 10:e70970. 10.7554/eLife.70970</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.70970</ArticleId><ArticleId IdType="pmc">PMC8791638</ArticleId><ArticleId IdType="pubmed">34812731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. . Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. (2021) 72:e206&#x2013;e14. 10.1093/cid/ciaa1012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1012</ArticleId><ArticleId IdType="pmc">PMC7454425</ArticleId><ArticleId IdType="pubmed">32674114</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. (2020) 24:179. 10.1186/s13054-020-02902-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02902-w</ArticleId><ArticleId IdType="pmc">PMC7187660</ArticleId><ArticleId IdType="pubmed">32345311</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. . Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. (2020) 180:1345&#x2013;55. 10.1001/jamainternmed.2020.3539</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3539</ArticleId><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicka V, Januskeviciute E, Miskinyte S, Ringaitiene D, Serpytis M, Klimasauskas A, et al. . Comparison of mortality risk evaluation tools efficacy in critically ill COVID-19 patients. BMC Infect Dis. (2021) 21:1173. 10.1186/s12879-021-06866-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06866-2</ArticleId><ArticleId IdType="pmc">PMC8607225</ArticleId><ArticleId IdType="pubmed">34809594</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gallo E, Merson L, Kennon K, Kelly S, Citarella BW, Fryer DV, et al. . ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19. Sci Data. (2022) 9:454. 10.1038/s41597-022-01534-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-022-01534-9</ArticleId><ArticleId IdType="pmc">PMC9339000</ArticleId><ArticleId IdType="pubmed">35908040</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K, et al. . Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health. (2021) 11:98&#x2013;104. 10.2991/jegh.k.200928.001</Citation><ArticleIdList><ArticleId IdType="doi">10.2991/jegh.k.200928.001</ArticleId><ArticleId IdType="pmc">PMC7958266</ArticleId><ArticleId IdType="pubmed">33095982</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco M, De Corte T, Ercole A, Antonelli M, Azoulay E, Citerio G, et al. . Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study. Intensive Care Med. (2022) 48:690&#x2013;705. 10.1007/s00134-022-06705-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06705-1</ArticleId><ArticleId IdType="pmc">PMC9123859</ArticleId><ArticleId IdType="pubmed">35596752</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodeir MM, Shabana HA, Alkhamiss AS, Rasheed Z, Alsoghair M, Alsagaby SA, et al. . Early prediction keys for COVID-19 cases progression: a meta-analysis. J Infect Public Health. (2021) 14:561&#x2013;9. 10.1016/j.jiph.2021.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7934660</ArticleId><ArticleId IdType="pubmed">33848885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Li Y, Ma Y, Zhang H, Deng Y, Zhu Z. Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection. Int J Med Sci. (2021) 18:2789&#x2013;98. 10.7150/ijms.58742</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.58742</ArticleId><ArticleId IdType="pmc">PMC8241766</ArticleId><ArticleId IdType="pubmed">34220307</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo AKG, Milby KM, Caparroz A, Pinto A, Santos RRP, Rocha AP, et al. . Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: a living systematic review and meta-analysis. PLoS ONE. (2021) 16:e0253894. 10.1371/journal.pone.0253894</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253894</ArticleId><ArticleId IdType="pmc">PMC8241122</ArticleId><ArticleId IdType="pubmed">34185801</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmesfeld-Wollbr&#xfc;ck B, Brell B, D&#xe1;vid I, Dorenberg M, Adolphs J, Schmeck B, et al. . Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. (2007) 33:703&#x2013;10. 10.1007/s00134-007-0561-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-007-0561-y</ArticleId><ArticleId IdType="pubmed">17318497</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmesfeld-Wollbr&#xfc;ck B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Haemost. (2007) 98:944&#x2013;51. 10.1160/TH07-02-0128</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH07-02-0128</ArticleId><ArticleId IdType="pubmed">18000597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bima P, Montrucchio G, Caramello V, Rumbolo F, Dutto S, Boasso S, et al. . Prognostic value of mid-regional Proadrenomedullin sampled at presentation and after 72 hours in septic patients presenting to the emergency department: an observational two-center study. Biomedicines. (2022) 10:719. 10.3390/biomedicines10030719</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10030719</ArticleId><ArticleId IdType="pmc">PMC8945269</ArticleId><ArticleId IdType="pubmed">35327521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sozio E, Moore NA, Fabris M, Ripoli A, Rumbolo F, Minieri M, et al. . Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Respir Res. (2022) 23:221. 10.1186/s12931-022-02151-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02151-1</ArticleId><ArticleId IdType="pmc">PMC9420187</ArticleId><ArticleId IdType="pubmed">36031619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620&#x2013;9. 10.1172/JCI137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. (2020) 19:102537. 10.1016/j.autrev.2020.102537</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497&#x2013;506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020) 180:934&#x2013;43. 10.1001/jamainternmed.2020.0994</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. (2021) 184:861&#x2013;80. 10.1016/j.cell.2021.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al. . Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. (2020) 97:772&#x2013;6. 10.1002/cyto.a.24172</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24172</ArticleId><ArticleId IdType="pmc">PMC7323417</ArticleId><ArticleId IdType="pubmed">32542842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Du W, Yang T, Zhao L, Xiong R, Li Y, et al. . Lymphocyte subsets as a predictor of severity and prognosis in COVID-19 patients. Int J Immunopathol Pharmacol. (2021) 35:20587384211048567. 10.1177/20587384211048567</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20587384211048567</ArticleId><ArticleId IdType="pmc">PMC8504275</ArticleId><ArticleId IdType="pubmed">34619994</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. . Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. (2020) 17:1281&#x2013;92. 10.7150/ijms.46614</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.46614</ArticleId><ArticleId IdType="pmc">PMC7294915</ArticleId><ArticleId IdType="pubmed">32547323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. . Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. (2015) 136:1186&#x2013;205.e 1&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26371839</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. . Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. (2020) 81:318&#x2013;56. 10.1016/j.jinf.2020.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.044</ArticleId><ArticleId IdType="pmc">PMC7151471</ArticleId><ArticleId IdType="pubmed">32283154</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain-Syed F, Vad&#xe1;sz I, Wilhelm J, Walmrath HD, Seeger W, Birk HW, et al. . Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. Am J Physiol Lung Cell Mol Physiol. (2021) 320:L590&#x2013;l9. 10.1152/ajplung.00359.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00359.2020</ArticleId><ArticleId IdType="pmc">PMC8057306</ArticleId><ArticleId IdType="pubmed">33237794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Yue D, Wang Y, Wang F, Wu S, Hou H. The dynamics of immune response in COVID-19 patients with different illness severity. J Med Virol. (2021) 93:1070&#x2013;7. 10.1002/jmv.26504</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26504</ArticleId><ArticleId IdType="pubmed">32910461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Combes A, Lo Coco V, De Piero ME, Belohlavek J. ECMO for COVID-19 patients in Europe and Israel. Intensive Care Med. (2021) 47:344&#x2013;8. 10.1007/s00134-020-06272-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06272-3</ArticleId><ArticleId IdType="pmc">PMC7796689</ArticleId><ArticleId IdType="pubmed">33420797</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Sales G, Urbino R, Simonetti U, Bonetto C, Cura Stura E, et al. . ECMO support and operator safety in the context of COVID-19 outbreak: a regional center experience. Membranes. (2021) 11:334. 10.3390/membranes11050334</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/membranes11050334</ArticleId><ArticleId IdType="pmc">PMC8147243</ArticleId><ArticleId IdType="pubmed">33946566</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Di Mauro M, Pellegrini C, Monterosso C, Pelenghi S, Degani A, et al. . Extracorporeal membrane oxygenation for COVID-19 respiratory distress syndrome: an Italian society for cardiac surgery report. ASAIO J. (2021) 67:385&#x2013;91. 10.1097/MAT.0000000000001399</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001399</ArticleId><ArticleId IdType="pubmed">33470643</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli V, Giani M, Grasselli G, Mojoli F, Martucci G, Grazioli L, et al. . Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study. Crit Care. (2022) 26:34. 10.1186/s13054-022-03906-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03906-4</ArticleId><ArticleId IdType="pmc">PMC8817653</ArticleId><ArticleId IdType="pubmed">35123562</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Corcione S, Lupia T, Shbaklo N, Olivieri C, Poggioli M, et al. . The burden of carbapenem-resistant Acinetobacter baumannii in ICU COVID-19 patients: a regional experience. J Clin Med. (2022) 11:5208. 10.3390/jcm11175208</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11175208</ArticleId><ArticleId IdType="pmc">PMC9456723</ArticleId><ArticleId IdType="pubmed">36079137</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Corcione S, Sales G, Curtoni A, De Rosa FG, Brazzi L. Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball. J Glob Antimicrob Resist. (2020) 23:398&#x2013;400. 10.1016/j.jgar.2020.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7682477</ArticleId><ArticleId IdType="pubmed">33242674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupia T, Montrucchio G, Gaviraghi A, Musso G, Puppo M, Bolla C, et al. . A Regional observational study on COVID-19-associated pulmonary aspergillosis (CAPA) within intensive care unit: trying to break the mold. J Fungi. (2022) 8:1264. 10.3390/jof8121264</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof8121264</ArticleId><ArticleId IdType="pmc">PMC9785727</ArticleId><ArticleId IdType="pubmed">36547597</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38004042</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>13</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Risk Factors of Postoperative Hospital-Acquired Pneumonia in Patients Undergoing Cardiac Surgery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1993</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina59111993</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>. Hospital-acquired pneumonia is one of the complications that may occur in the postoperative period in patients undergoing heart valve surgery, which may result in prolonged hospitalization, development of respiratory failure requiring mechanical ventilation or even death. This study investigated the preoperative risk factors of postoperative pneumonia after heart valve surgery. <i>Materials and Methods</i>: This was a prospective study in a group of consecutive patients with hemodynamically significant valvular heart disease undergoing valve surgery. The primary endpoint at the in-hospital follow-up was hospital-acquired pneumonia after heart valve surgery. Logistic regression analysis was used to assess which variables were predictive of the primary endpoint, and odds ratios (ORdis) were calculated with a 95% confidence interval (CI). Multivariate analysis was based on the results of single-factor logistic regression, i.e., in further steps all statistically significant variables were taken into consideration. <i>Results</i>: The present study included 505 patients. Postoperative pneumonia occurred in 23 patients. The mean time to diagnosis of pneumonia was approximately 3 days after heart valve surgery (&#xb1;2 days). In multivariate analysis, preoperative level of high-sensitivity Troponin T (hs-TnT) (OR 2.086; 95% CI 1.211-3.593; <i>p</i> = 0.008) and right ventricular systolic pressure (RVSP) (OR 1.043; 95% CI 1.018-1.067; p 0.004) remained independent predictors of the postoperative pneumonia. Of the patients with postoperative pneumonia, 3 patients died due to the development of multiple organ dysfunction syndrome (MODS). <i>Conclusions</i>: Preoperative determination of serum hs-TnT concentration and echocardiographic measurement of the RVSP parameter may be useful in predicting postoperative pneumonia in patients undergoing heart valve surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duchnowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ambulatory Care Unit, Cardinal Wyszynski National Institute of Cardiology, 04-628 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x15a;migielski</LastName><ForeName>Witold</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ambulatory Care Unit, Cardinal Wyszynski National Institute of Cardiology, 04-628 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">high-sensitivity Troponin T (hs-TnT)</Keyword><Keyword MajorTopicYN="N">hospital-acquired pneumonia</Keyword><Keyword MajorTopicYN="N">right ventricular systolic pressure (RVSP)</Keyword><Keyword MajorTopicYN="N">valve surgery</Keyword></KeywordList><CoiStatement>The author reports no conflict of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38004042</ArticleId><ArticleId IdType="pmc">PMC10672909</ArticleId><ArticleId IdType="doi">10.3390/medicina59111993</ArticleId><ArticleId IdType="pii">medicina59111993</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thompson M.P., Cabrera L., Strobel R.J., Harrington S.D., Zhang M., Wu X., Prager R.L., Likosky D.S. Association Between Postoperative Pneumonia and 90-Day Episode Payments and Outcomes Among Medicare Beneficiaries Undergoing Cardiac Surgery. Circ. Cardiovasc. Qual. Outcomes. 2018;11:e004818. doi: 10.1161/CIRCOUTCOMES.118.004818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.118.004818</ArticleId><ArticleId IdType="pubmed">30354549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D.S., Huang X.F., Wang H.F., Le S., Du X.L. Clinical risk score for postoperative pneumonia following heart valve surgery. Chin. Med. J. 2021;134:2447&#x2013;2456. doi: 10.1097/CM9.0000000000001715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001715</ArticleId><ArticleId IdType="pmc">PMC8654438</ArticleId><ArticleId IdType="pubmed">34669637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Huang X., Wang H., Le S., Yang H., Wang F., Du X. Risk factors for postoperative pneumonia after cardiac surgery: A prediction model. J. Thorac. Dis. 2021;13:2351&#x2013;2362. doi: 10.21037/jtd-20-3586.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd-20-3586</ArticleId><ArticleId IdType="pmc">PMC8107540</ArticleId><ArticleId IdType="pubmed">34012584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Cheng D., Sun B., Sun M., Wu C., Chen J., Li X., Lei Y., Su Y. Nomogram and risk calculator for severe hypoxemia after heart valve surgery. Front. Cardiovasc. Med. 2022;9:972449. doi: 10.3389/fcvm.2022.972449.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.972449</ArticleId><ArticleId IdType="pmc">PMC9386119</ArticleId><ArticleId IdType="pubmed">35990967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Lu Y., Sun M., Huang X., Du X., Jiao Z., Sun F., Xie F. Pneumonia After Cardiovascular Surgery: Incidence, Risk Factors and Interventions. Front. Cardiovasc. Med. 2022;9:911878. doi: 10.3389/fcvm.2022.911878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.911878</ArticleId><ArticleId IdType="pmc">PMC9280273</ArticleId><ArticleId IdType="pubmed">35845037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ailawadi G., Chang H.L., O&#x2019;Gara P.T., O&#x2019;sullivan K., Woo Y.J., DeRose J.J., Jr., Parides M.K., Thourani V.H., Robichaud S., Gillinov A.M., et al. Pneumonia After Cardiac Surgery: Experience of the NIH/CIHR Cardiothoracic Surgical Trials Network. J. Thorac. Cardiovasc. Surg. 2017;153:1384&#x2013;1391. doi: 10.1016/j.jtcvs.2016.12.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2016.12.055</ArticleId><ArticleId IdType="pmc">PMC5439299</ArticleId><ArticleId IdType="pubmed">28341473</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., An Z., Chen J., Liu Y., Tang Y., Han Q., Lu F., Tang H., Xu Z. Risk factors for noninvasive ventilation failure in patients with post-extubation acute respiratory failure after cardiac surgery. J. Thorac. Dis. 2018;10:3319&#x2013;3328. doi: 10.21037/jtd.2018.05.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2018.05.96</ArticleId><ArticleId IdType="pmc">PMC6051816</ArticleId><ArticleId IdType="pubmed">30069328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng W., Xing Q.-S., Hou W.-M., Sun L., Niu Z.-Z., Lin M.-S., Chi Y.-F. Independent risk factors for ventilator-associated pneumonia after cardiac surgery. J. Investig. Surg. 2014;27:256&#x2013;261. doi: 10.3109/08941939.2014.892652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08941939.2014.892652</ArticleId><ArticleId IdType="pubmed">24660655</ArticleId></ArticleIdList></Reference><Reference><Citation>Allou N., Bronchard R., Guglielminotti J., Dilly M.P., Provenchere S., Lucet J.C., Laou&#xe9;nan C., Montravers P. Risk factors for postoperative pneumonia after cardiac surgery and development of a preoperative risk score. Crit. Care Med. 2014;42:1150&#x2013;1156. doi: 10.1097/CCM.0000000000000143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000143</ArticleId><ArticleId IdType="pubmed">24351376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonten M.J. Healthcare epidemiology: Ventilator-associated pneumonia: Preventing the inevitable. Clin. Infect. Dis. 2011;52:115&#x2013;121. doi: 10.1093/cid/ciq075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq075</ArticleId><ArticleId IdType="pubmed">21148529</ArticleId></ArticleIdList></Reference><Reference><Citation>Safdar N., Crnich C.J., Maki D.G. The pathogenesis of ventilator-associated pneumonia: Its relevance to developing effective strategies for prevention. Respir. Care. 2005;50:725&#x2013;739; discussion 739&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">15913465</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Hryniewiecki T., Ku&#x15b;mierczyk M., Szyma&#x144;ski P. High-Sensitivity Troponin T Predicts Postoperative Cardiogenic Shock Requiring Mechanical Circulatory Support in Patients with Valve Disease. Shock. 2020;53:175&#x2013;178. doi: 10.1097/SHK.0000000000001360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001360</ArticleId><ArticleId IdType="pubmed">31162290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gali&#xe8; N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur. Heart J. 2016;37:67&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">26320113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan S.D., Shlobin O.A., Barnett S.D., Saggar R., Belperio J.A., Ross D.J., Ahmad S., Saggar R., Libre E., Lynch J.P., et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir. Med. 2008;102:1305&#x2013;1310. doi: 10.1016/j.rmed.2008.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2008.03.022</ArticleId><ArticleId IdType="pmc">PMC2649722</ArticleId><ArticleId IdType="pubmed">18619825</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.-L., Currie P.J., Seward J.B., Hagler D.J., Mair D.D., Tajik A.J. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J. Am. Coll. Cardiol. 1987;9:549&#x2013;554. doi: 10.1016/S0735-1097(87)80047-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(87)80047-5</ArticleId><ArticleId IdType="pubmed">3546460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher B.J., Himelman R.B., Schiller N.B. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am. J. Cardiol. 1990;66:493&#x2013;496. doi: 10.1016/0002-9149(90)90711-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(90)90711-9</ArticleId><ArticleId IdType="pubmed">2386120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S.N., Syed F.M., Porembka D.T. Echocardiographic evaluation of hemodynamic parameters. Crit. Care Med. 2007;35:S323&#x2013;S329. doi: 10.1097/01.CCM.0000270242.03536.D3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000270242.03536.D3</ArticleId><ArticleId IdType="pubmed">17667456</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakura K., Mitsuboshi S., Tsuji M., Sakamaki H., Otake S., Matsuda S., Kaseda K., Watanabe K. Pulmonary arterial enlargement predicts cardiopulmonary complications after pulmonary resection for lung cancer: A retrospective cohort study. J. Cardiothorac. Surg. 2015;10:113. doi: 10.1186/s13019-015-0315-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-015-0315-9</ArticleId><ArticleId IdType="pmc">PMC4564964</ArticleId><ArticleId IdType="pubmed">26353804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiatchoosakun S., Wongvipaporn C., Nanagara R., Hoit B.D. Right ventricular systolic pressure assessed by echocardiography: A predictive factor of mortality in patients with scleroderma. Clin. Cardiol. 2011;34:488&#x2013;493. doi: 10.1002/clc.20920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.20920</ArticleId><ArticleId IdType="pmc">PMC6652343</ArticleId><ArticleId IdType="pubmed">21717471</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Taniguchi H., Ando M., Sakamoto K., Kondoh Y., Watanabe N., Kimura T., Kataoka K., Suzuki A., Ito S., et al. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: A retrospective cohort study. BMC Pulm. Med. 2016;16:55. doi: 10.1186/s12890-016-0207-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-016-0207-3</ArticleId><ArticleId IdType="pmc">PMC4837628</ArticleId><ArticleId IdType="pubmed">27094018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rams J.J., Harrison R.W., Fry W.A., Moulder P.V., Adams W.E. Operative pulmonary artery pressure measurements as a guide to postoperative management and prognosis following pneumonectomy. Dis. Chest. 1962;41:85&#x2013;90. doi: 10.1378/chest.41.1.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.41.1.85</ArticleId><ArticleId IdType="pubmed">14490200</ArticleId></ArticleIdList></Reference><Reference><Citation>Fee H.J., Holmes E.C., Gewirtz H.S., Ramming K.P., Alexander J.M. Role of pulmonary vascular resistance measurements in preoperative evaluation of candidates for pulmonary resection. J. Thorac. Cardiovasc. Surg. 1978;75:519&#x2013;524. doi: 10.1016/S0022-5223(19)41235-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(19)41235-X</ArticleId><ArticleId IdType="pubmed">642548</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce R.J., Sharpe K., Johns J., Thompson B. Pulmonary artery pressure and blood flow as predictors of outcome from lung cancer resection. Respirology. 2005;10:620&#x2013;628. doi: 10.1111/j.1440-1843.2005.00759.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1843.2005.00759.x</ArticleId><ArticleId IdType="pubmed">16268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonneau G., Gali&#xe8; N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., Gibbs S., Lebrec D., Speich R., Beghetti M., et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2004;43:S5&#x2013;S12. doi: 10.1016/j.jacc.2004.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2004.02.037</ArticleId><ArticleId IdType="pubmed">15194173</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Hryniewiecki T., Ku&#x15b;mierczyk M., Szyma&#x144;ski P. The usefulness of selected biomarkers in patients with valve disease. Biomark. Med. 2018;12:1341&#x2013;1346. doi: 10.2217/bmm-2018-0101.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2018-0101</ArticleId><ArticleId IdType="pubmed">30520658</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin. Chest Med. 2007;28:233&#x2013;241. doi: 10.1016/j.ccm.2006.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2006.12.001</ArticleId><ArticleId IdType="pubmed">17338938</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension; ESC/ERS Scientific Document Group. Eur. Heart J. 2022;43:3618&#x2013;3731. doi: 10.1093/eurheartj/ehac237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac237</ArticleId><ArticleId IdType="pubmed">36017548</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado J.F., Conde E., Sanchez V., Lopez-Rios F., Gomez-Sanchez M.A., Escribano P., Sotelo T., de la Camara A.G., Cortina J., de la Calzada C.S. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur. J. Heart Fail. 2005;7:1011&#x2013;1016. doi: 10.1016/j.ejheart.2004.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2004.10.021</ArticleId><ArticleId IdType="pubmed">16227139</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Hryniewiecki T., Zatorska K., &#x17b;ebrowska A., Ku&#x15b;mierczyk M., Szyma&#x144;ski P. High-sensitivity troponin T as a prognostic marker in patients undergoing aortic valve replacement. Pol. Arch. Intern. Med. 2017;127:628&#x2013;630. doi: 10.20452/pamw.4107.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.4107</ArticleId><ArticleId IdType="pubmed">28984283</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann F., Herrmann S., St&#xf6;rk S., Niemann M., Frantz S., Lange V., Beer M., Gattenl&#xf6;hner S., Voelker W., Ertl G., et al. Impact of myocardial fibro-sis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120:577&#x2013;584. doi: 10.1161/CIRCULATIONAHA.108.847772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.847772</ArticleId><ArticleId IdType="pubmed">19652094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin C.W.L., Shah A.S.V., McAllister D.A., Cowell S.J., Alam S., Langrish J.P., Strachan F.E., Hunter A.L., Choy A.M., Lang C.C., et al. High -sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur. Heart J. 2014;35:2312&#x2013;2321. doi: 10.1093/eurheartj/ehu189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu189</ArticleId><ArticleId IdType="pmc">PMC4156973</ArticleId><ArticleId IdType="pubmed">24829362</ArticleId></ArticleIdList></Reference><Reference><Citation>Eug&#xe8;ne M., Duchnowski P., Prendergast B., Wendler O., Laroche C., Monin J.-L., Jobic Y., A Popescu B., Bax J.J., Vahanian A., et al. Contemporary Management of Severe Symptomatic Aortic Stenosis. J. Am. Coll. Cardiol. 2021;78:2131&#x2013;2143. doi: 10.1016/j.jacc.2021.09.864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.09.864</ArticleId><ArticleId IdType="pubmed">34823655</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P. The Role of the N-Terminal of the Prohormone Brain Natriuretic Peptide in Predicting Postoperative Multiple Organ Dysfunction Syndrome. J. Clin. Med. 2022;11:7217. doi: 10.3390/jcm11237217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11237217</ArticleId><ArticleId IdType="pmc">PMC9740192</ArticleId><ArticleId IdType="pubmed">36498791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26770361</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1940-5901</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>International journal of clinical and experimental medicine</Title><ISOAbbreviation>Int J Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>Heart calcium sensitizer on morbidity and mortality of high-risk surgical patients with MODS: systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>17712</StartPage><EndPage>17720</EndPage><MedlinePgn>17712-20</MedlinePgn></Pagination><Abstract><AbstractText>A total of 440 patients from 10 studies were included in a systematic review to evaluate the association between improved survivals from multiple organ dysfunction syndromes in patients undergoing surgical operation. Health Inter Network Initiatives (HINARI), MEDLINE and EMBASE were searched. Exclusion criteria were duplicate publications, non-human experimental studies, and no mortality data. The primary endpoint was postoperative mortality. Levosimendan was found to be associated with a reduction in postoperative mortality (11/235 [4.7%] in the levosimendan group v 26/205 [12.7%] in the control, odds ratio of 0.35 [0.18-0.71], P for effect as 0.003, P for heterogeneity 0.22, and I(2) as 27.4% (440 patients included), cardiac troponin release, and atrial fibrillation. No difference was found in terms of myocardial infarction, acute renal failure, time on mechanical ventilation, intensive care unit, and hospital stay. Calcium-sensitizer for congestive heart failure; Levosimendan has cardioprotective effects that could result in a reduced operative mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Air Force General Hospital of PLA Beijing 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chengshan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aviation Medicine Research Laboratory, Air Force General Hospital, PLA Beijing 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinji</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Air Force General Hospital, PLA Beijing 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Air Force General Hospital of PLA Beijing 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Air Force General Hospital of PLA Beijing 100142, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Clin Exp Med</MedlineTA><NlmUniqueID>101471010</NlmUniqueID><ISSNLinking>1940-5901</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">dysfunction</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">operative</Keyword><Keyword MajorTopicYN="N">organ</Keyword><Keyword MajorTopicYN="N">surgical</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26770361</ArticleId><ArticleId IdType="pmc">PMC4694261</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992;101:1481&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">1600757</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares M, Feres GA, Salluh JI. Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo) 2009;64:479&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694253</ArticleId><ArticleId IdType="pubmed">19488615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizock BA. The multiple organ dysfunction syndrome. Dis Mon. 2009;55:476&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595297</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Curr Med Res Opin. 2011;27:1673&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pubmed">21718097</ArticleId></ArticleIdList></Reference><Reference><Citation>Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323:42&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1120670</ArticleId><ArticleId IdType="pubmed">11440947</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">2727467</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Mackey ME, Carroli G, Donner A. Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models. Stat Med. 2001;20:3635&#x2013;3647.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746343</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">16596572</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatala R, Keitz S, Wyer P, Guyatt G. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ. 2005;172:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC550638</ArticleId><ArticleId IdType="pubmed">15738493</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002;21:1503&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111916</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez J, Taboada M, Rodriguez J, Caruezo V, Bouzada M, Campana O, Bascuas B, Perez-Paz J, Ginesta V. [Hemodynamic effects of levosimendan following cardiac surgery] . Rev Esp Anestesiol Reanim. 2005;52:389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">16200918</ArticleId></ArticleIdList></Reference><Reference><Citation>De Hert SG, Lorsomradee S, vanden Eede H, Cromheecke S, Van der Linden PJ. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth. 2008;22:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">18922426</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvela K, Maaranen P, Sisto T, Ruokonen E. Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth. 2008;22:693&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">18922425</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, Tanus E, del Mazo CD. [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome] . Rev Esp Cardiol. 2008;61:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">18462650</ArticleId></ArticleIdList></Reference><Reference><Citation>Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med. 2007;35:707&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">17255859</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J, Ginesta V, Rubio J, Garcia-Bengoechea JB, Gonzalez-Juanatey JR. [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery] . Rev Esp Cardiol. 2006;59:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709386</ArticleId></ArticleIdList></Reference><Reference><Citation>du Toit E, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart. 2001;86:81&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1729816</ArticleId><ArticleId IdType="pubmed">11410569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung PT, Galin MA. [Trabecular microsurgery in glaucoma] . Taiwan Yi Xue Hui Za Zhi. 1975;74:697&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">1062496</ArticleId></ArticleIdList></Reference><Reference><Citation>De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007;104:766&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17377079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE, Singer M, Pietropaoli P. Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study. Br J Anaesth. 2006;96:694&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah B, Sharma P, Brahmbhatt A, Shah R, Rathod B, Shastri N, Patel J, Malhotra A. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian J Pharmacol. 2014;46:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912803</ArticleId><ArticleId IdType="pubmed">24550581</ArticleId></ArticleIdList></Reference><Reference><Citation>Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin&#x2019;s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol. 2005;34:224&#x2013;225. author reply 225.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompan L, Kremzar B, Gadzijev E, Prosek M. Effects of early enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury. Intensive Care Med. 1999;25:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C, De Santis V, Tritapepe L, Landoni G. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009;23:474&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">19217315</ArticleId></ArticleIdList></Reference><Reference><Citation>Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">12133653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">16387630</ArticleId></ArticleIdList></Reference><Reference><Citation>Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167393</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108:979&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">18497597</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34527712</PMID><DateRevised><Year>2021</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Thoracic Endovascular Aortic Repair for Retrograde Type A Aortic Intramural Hematoma.</ArticleTitle><Pagination><StartPage>712524</StartPage><MedlinePgn>712524</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">712524</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2021.712524</ELocationID><Abstract><AbstractText><b>Objectives:</b> To evaluate the effects of thoracic endovascular aortic repair (TEVAR) in descending aorta for retrograde type A aortic intramural hematoma (re-TAIMH). <b>Methods:</b> From January 2013 to September 2019, 65 consecutive patients diagnosed with re-TAIMH and treated by TEVAR were enrolled in this retrospective cohort study, of whom 44 patients presented with entry tear in descending aorta (Group A) and 21 with penetrating atherosclerotic ulcer (Group B). The clinical data, including baseline characteristics, adverse events, aortic remolding, and overall survival were reviewed. <b>Results:</b> The mean age of all the patients was 52.0 &#xb1; 8.3 years, and 54 (83.1%) patients were men. The mean maximal ascending aortic diameter (MAAD) was 43.1 &#xb1; 5.4 mm, and the mean maximal ascending aortic hematoma thickness (MAAHT) was 9.6 &#xb1; 4.7 mm. TEVAR was performed under general anesthesia in 53 (81.5%) patients, while 12 (18.5%) patients were treated under local anesthesia. There were two deaths during hospitalization (one with rupture and another with multiple organ dysfunction syndrome), and overall survival at 1, 4, and 7 years for all 65 patients was 93.8, 92.0, and 87.4%, respectively. The MAAD and MAATH decreased significantly after TEVAR (<i>p</i> &lt; 0.05) in the two groups, so did the mean descending aortic diameter at the pulmonary bifurcation level. Type I endoleak, dialysis, progression to type A aortic dissection, and enlargement in MAAHT and MAAD were more common complications, which occurred in four, three, two, and two patients, respectively. <b>Conclusion:</b> Patients with retrograde TAIMH treated by TEVAR had a favorable prognosis including late survival and aortic remolding. However, some post-intervention complications were not negligible.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Li, Xu, Li and Xiong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Sizheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic dissection</Keyword><Keyword MajorTopicYN="N">aortic remodeling</Keyword><Keyword MajorTopicYN="N">endovascular repair</Keyword><Keyword MajorTopicYN="N">penetrating atherosclerotic ulcer</Keyword><Keyword MajorTopicYN="N">type A aortic intramural hematoma</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>16</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34527712</ArticleId><ArticleId IdType="pmc">PMC8435682</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2021.712524</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krukenberg E. Beitrage zur Frage des Aneurysma dissecans. Beitr Pathol Anat Allg Pathol. (1920) 67:329&#x2013;51.</Citation></Reference><Reference><Citation>Tsai TT, Nienaber CA, Eagle KA. Acute aortic syndromes. Circulation. (2005) 112:3802&#x2013;13. 10.1161/CIRCULATIONAHA.105.534198</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.534198</ArticleId><ArticleId IdType="pubmed">16344407</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel R, Aboyans V, Boileau C, Bossone E, Di Bartolomeo R, Eggebrecht H, et al. . 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. (2014) 35: 2873&#x2013;926. 10.1093/eurheartj/ehu281</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu281</ArticleId><ArticleId IdType="pubmed">25173340</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CP, Walker TG, Kalva SP. Natural history and CT appearances of aortic intramural hematoma. Radiographics. (2009) 29:791&#x2013;804. 10.1148/rg.293085122</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.293085122</ArticleId><ArticleId IdType="pubmed">19448116</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira AH. Intramural hematoma and penetrating atherosclerotic ulcers of the aorta: uncertainties and controversies. J Vasc Bras. (2019) 18:e20180119. 10.1590/1677-5449.180119</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1677-5449.180119</ArticleId><ArticleId IdType="pmc">PMC6636911</ArticleId><ArticleId IdType="pubmed">31360153</ArticleId></ArticleIdList></Reference><Reference><Citation>Oderich GS, Karkkainen JM, Reed NR, Tenorio ER, Sandri GA. Penetrating aortic ulcer and intramural hematoma. Cardiovasc Intervent Radiol. (2019) 42:321&#x2013;34. 10.1007/s00270-018-2114-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00270-018-2114-x</ArticleId><ArticleId IdType="pubmed">30413917</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm M, Loewe C, Gottardi R, Funovics M, Zimpfer D, Rodler S, et al. . Novel insights into the mechanisms and treatment of intramural hematoma affecting the entire thoracic aorta. Ann Thor Surg. (2008) 86:453&#x2013;6. 10.1016/j.athoracsur.2008.03.078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2008.03.078</ArticleId><ArticleId IdType="pubmed">18640315</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenen FWN, Van der Weijde E, Vos JA, Heijmen RH. Retrograde type A intramural hematoma treated endovascularly in two cases. Ann Vasc Surg. (2019) 59: 312.e15&#x2013;8. 10.1016/j.avsg.2018.12.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2018.12.107</ArticleId><ArticleId IdType="pubmed">31009724</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-Y, Yen H-T, Wu C-C, Huang DK-R. Thoracic endovascular aortic repair for type A intramural hematoma and retrograde thrombosed type A aortic dissection: a single-center experience. Ann Vasc Surg. (2020) 65:224&#x2013;31. 10.1016/j.avsg.2019.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2019.11.016</ArticleId><ArticleId IdType="pubmed">31743779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryoi O, Lin CH, Chen JM, Hsieh YK, Wang SS, Wu IH. Endovascular repair for retrograde type A intramural haematoma with intimal tear in the descending thoracic aorta. Eur J Vasc Endovasc Surg. (2020) 60:386&#x2013;93. 10.1016/j.ejvs.2020.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejvs.2020.05.021</ArticleId><ArticleId IdType="pubmed">32741679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauta F, de Beaufort H, Mussa FF, De Vincentiis C, Omura A, Matsuda H, et al. . Management of retrograde type A IMH with acute arch tear/type B dissection. Ann Cardiothorac Surg. (2019) 8:531&#x2013;9. 10.21037/acs.2019.08.05</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2019.08.05</ArticleId><ArticleId IdType="pmc">PMC6785497</ArticleId><ArticleId IdType="pubmed">31667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y-L, Ye J-C, Yancu H, Liu B, Wang Y-Z, Wang W-J, et al. . Thoracic endovascular aortic repair for type B aortic dissection associated with retrograde type A intramural hematoma. J Vasc Interv Radiol. (2020) 31:1334&#x2013;41. 10.1016/j.jvir.2020.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvir.2020.01.017</ArticleId><ArticleId IdType="pubmed">32127315</ArticleId></ArticleIdList></Reference><Reference><Citation>Qanadli SD, Malekzadeh S, Villard N, Jouannic A-M, Bodenmann D, Tozzi P, et al. . A new clinically driven classification for acute aortic dissection. Front Surg. (2020) 7:37. 10.3389/fsurg.2020.00037</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fsurg.2020.00037</ArticleId><ArticleId IdType="pmc">PMC7324626</ArticleId><ArticleId IdType="pubmed">32656225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and management, an update. Eur Heart J. (2018) 39:739&#x2013;49d. 10.1093/eurheartj/ehx319</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx319</ArticleId><ArticleId IdType="pubmed">29106452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitai T, Kaji S, Yamamuro A, Tani T, Tamita K, Kinoshita M, et al. . Clinical outcomes of medical therapy and timely operation in initially diagnosed type A aortic intramural hematoma: a 20-year experience. Circulation. (2009) 120:S292&#x2013;8. 10.1161/circulationaha.108.843615</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.108.843615</ArticleId><ArticleId IdType="pubmed">19752382</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashigawa T, Kato N, Nakajima K, Chino S, Hashimoto T, Ouchi T, et al. . Thoracic endovascular aortic repair for retrograde type A aortic dissection. J Vasc Surg. (2019) 69:1685&#x2013;93. 10.1016/j.jvs.2018.08.193</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2018.08.193</ArticleId><ArticleId IdType="pubmed">30612823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu C, Wang T, Li Q-M, Li M, Jiang X-H, Luo M-Y, et al. . Thoracic endovascular aortic repair for retrograde type A aortic dissection with an entry tear in the descending aorta. J Vasc Interv Radiol. (2012) 23:453&#x2013;60.e1. 10.1016/j.jvir.2011.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvir.2011.12.023</ArticleId><ArticleId IdType="pubmed">22464711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato N, Shimono T, Hirano T, Ishida M, Yada I, Takeda K. Transluminal placement of endovascular stent-grafts for the treatment of type A aortic dissection with an entry tear in the descending thoracic aorta. J Vasc Surg. (2001) 34:1023&#x2013;8. 10.1067/mva.2001.118808</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mva.2001.118808</ArticleId><ArticleId IdType="pubmed">11743555</ArticleId></ArticleIdList></Reference><Reference><Citation>Monnin-Bares V, Thony F, Rodiere M, Bach V, Hacini R, Blin D, et al. . Endovascular stent-graft management of aortic intramural hematomas. J Vasc Interv Radiol. (2009) 20:713&#x2013;21. 10.1016/j.jvir.2009.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvir.2009.02.013</ArticleId><ArticleId IdType="pubmed">19398351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons O, Clough R, Patel A, Saha P, Carrell T, Taylor P. Endovascular management of Stanford type A dissection or intramural hematoma with a distal primary entry tear. J Endovasc Ther. (2011) 18:591&#x2013;600. 10.1583/11-3468.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1583/11-3468.1</ArticleId><ArticleId IdType="pubmed">21861752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan C-B, Chang R-Y, Chang J-P. Optimal initial treatment and clinical outcome of type A aortic intramural hematoma: a clinical review. Eur J Cardio Thor Surg. (2008) 33:1002&#x2013;6. 10.1016/j.ejcts.2008.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2008.02.016</ArticleId><ArticleId IdType="pubmed">18346906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhu HK, Tanaka A, Charlton-Ouw KM, Afifi RO, Miller CC, III, Safi HJ, et al. . Outcomes and management of type A intramural hematoma. Ann Cardiothorac Surg. (2016) 5:317&#x2013;27. 10.21037/acs.2016.07.06</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs.2016.07.06</ArticleId><ArticleId IdType="pmc">PMC4973130</ArticleId><ArticleId IdType="pubmed">27563544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagenais F, Dumont E, Voisine P. Intramural hematoma of the arch and ascending aorta owing to acute aortic syndrome of the descending aorta: to stent or not to stent? J Endovasc Ther. (2008) 15:544&#x2013;9. 10.1583/08-2468.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1583/08-2468.1</ArticleId><ArticleId IdType="pubmed">18840049</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhang N, Xu S, Fan Z, Zhu J, Huang L, et al. . Acute type A aortic intramural hematoma and type A aortic dissection: correlation between the intimal tear features and pathogenesis. Quant Imaging Med Surg. (2020) 10:1504&#x2013;14. 10.21037/qims-20-191</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/qims-20-191</ArticleId><ArticleId IdType="pmc">PMC7358420</ArticleId><ArticleId IdType="pubmed">32676368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitai T, Kaji S, Yamamuro A, Tani T, Kinoshita M, Ehara N, et al. . Detection of intimal defect by 64-row multidetector computed tomography in patients with acute aortic intramural hematoma. Circulation. (2011) 124:S174&#x2013;8. 10.1161/circulationaha.111.037416</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.111.037416</ArticleId><ArticleId IdType="pubmed">21911809</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelzel JM, Braverman AC, Hirsch AT, Harris KM. International heterogeneity in diagnostic frequency and clinical outcomes of ascending aortic intramural hematoma. J Am Soc Echocardiogr. (2007) 20:1260&#x2013;8. 10.1016/j.echo.2007.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2007.03.018</ArticleId><ArticleId IdType="pubmed">17614252</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida K, Imoto K, Karube N, Minami T, Cho T, Goda M, et al. . Intramural haematoma should be referred to as thrombosed-type aortic dissection. Eur J Cardio Thorac Surg. (2013) 44:366&#x2013;9. 10.1093/ejcts/ezt040</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezt040</ArticleId><ArticleId IdType="pubmed">23515169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko JP, Goldstein JM, Latson LA, Azour L, Gozansky EK, Moore W, et al. . Chest CT angiography for acute aortic pathologic conditions: pearls and pitfalls. Radiographics. (2021) 41:399&#x2013;424. 10.1148/rg.2021200055</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.2021200055</ArticleId><ArticleId IdType="pubmed">33646903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sueyoshi E, Matsuoka Y, Imada T, Okimoto T, Sakamoto I, Hayashi K. New development of an ulcerlike projection in aortic intramural hematoma: CT evaluation. Radiology. (2002) 224:536&#x2013;41. 10.1148/radiol.2242011009</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2242011009</ArticleId><ArticleId IdType="pubmed">12147853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu KK, Lal A, Mishra AK. Additional insights regarding aortic intramural hematoma. Can J Anaesth. (2020) 67:382&#x2013;3. 10.1007/s12630-019-01490-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-019-01490-w</ArticleId><ArticleId IdType="pubmed">31576515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogendoorn W, Schl&#xf6;sser FJV, Muhs BE, Popescu WM. Surgical and anesthetic considerations for the endovascular treatment of ruptured descending thoracic aortic aneurysms. Curr Opin Anaesthesiol. (2014) 27:12&#x2013;20. 10.1097/ACO.0000000000000028</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0000000000000028</ArticleId><ArticleId IdType="pubmed">24256918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33725958</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of alanyl glutamine in nutritional support therapy for patients with sepsis: A protocol for systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e24861</StartPage><MedlinePgn>e24861</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e24861</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000024861</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sepsis is a systemic inflammatory response caused by infection, which is a common complication after severe infection, trauma, shock, and surgery, and is also an important factor in inducing septic shock and multiple organ dysfunction syndrome (MODS), and has become one of the important causes of death in critically ill patients. Septic patients with gastrointestinal transport function weakened, are prone to malnutrition, resulting in decreased immune function, thereby affecting the therapeutic effect. Clinical practice shows that the nutritional metabolism and immune response of patients with sepsis can be effectively improved by giving alanyl glutamine nutritional support treatment, but there is no evidence of evidence-based medicine. The study carried out in this protocol aims to evaluate the effectiveness of alanyl glutamine in nutritional support therapy for patients with sepsis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Cochrane Library, PubMed, Embase, Web of Science, WHO International Clinical Trials Registry Platform, CNKI, CBM, VIP, and Wanfang databases were searched by computer, to retrieve all randomized controlled trials (RCTs) on nutritional support for the treatment of sepsis with alanyl glutamine from the date of database establishment to December 2020. Two researchers independently selected the study, extracted and managed the data. RevMan5.3 software was used to analyze the included literature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study observed the changes of serum albumin (ALB), prealbumin (PAB), hemoglobin (Hb), C-reactive protein (CRP), immunoglobulin (IgG, IgA, and IgM), APACHE II score before and after treatment to evaluate the efficacy of alanyl glutamine in nutritional support therapy for patients with sepsis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study will provide reliable evidence for the application of alanyl glutamine in nutritional support therapy for patients with sepsis.</AbstractText><AbstractText Label="OSF REGISTRATION NUMBER" NlmCategory="UNASSIGNED">DOI 10.17605/OSF.IO/VRZPJ.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-0646-5653</Identifier><AffiliationInfo><Affiliation>Dalian Municipal Central Hospital, Dalian, Liaoning Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuemeng</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Shiquan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No.2019-ZD-0302</GrantID><Agency>the Natural Science Foundation of Liaoning Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>U5JDO2770Z</RegistryNumber><NameOfSubstance UI="C054122">alanylglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066891" MajorTopicYN="N">Critical Care Outcomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33725958</ArticleId><ArticleId IdType="pmc">PMC7982144</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000024861</ArticleId><ArticleId IdType="pii">00005792-202103190-00039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. . The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Rello J, Valenzuela-S&#xe1;nchez F, Ruiz-Rodriguez M, et al. . Sepsis: a review of advances in management. Adv Ther 2017;34:2393&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5702377</ArticleId><ArticleId IdType="pubmed">29022217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian HC, Zhou JF, Weng L, et al. . Epidemiology of Sepsis-3 in a sub-district of Beijing: secondary analysis of a population-based database. Chin Med J (Engl) 2019;132:2039&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793784</ArticleId><ArticleId IdType="pubmed">31425273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 2014;5:4&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916382</ArticleId><ArticleId IdType="pubmed">24335434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischmeyer PE. Nutrition therapy in sepsis. Crit Care Clin 2018;34:107&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447319</ArticleId><ArticleId IdType="pubmed">29149933</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao QW, Zhuo HS, Xie XH. Clinical study on nutritional support of alanyl glutamine for patients with sepsis. J Taishan Med Coll 2015;36:765&#x2013;7.</Citation></Reference><Reference><Citation>Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990;48:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">2080048</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton KD, Wischmeyer PE. Glutamine's protection against sepsis and lung injury is dependent on heat shock protein 70 expression. Am J Physiol Regul Integr Comp Physiol 2007;292:R1839&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17234954</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WH. Effectiveness analysis of alanyl glutamine in nutritional support therapy for patients with sepsis. Mod Diagn Treat 2017;28:2687&#x2013;8.</Citation></Reference><Reference><Citation>Sun H. The efficacy of glutamine in nutritional support therapy for patients with sepsis. J Med Forum 2018;39:157&#x2013;9.</Citation></Reference><Reference><Citation>Chao YL, Hu WW, Wang ZW, et al. . To investigate the efficacy of alanyl glutamine in the treatment of sepsis. China Foreign Med Treat 2016;35:39&#x2013;41.</Citation></Reference><Reference><Citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">1597042</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey S, Karim HMR, Yunus M, et al. . Relationship of on admission hypocalcaemia and illness severity as measured by APACHE-II and SOFA score in intensive care patients&#x2019;. J Clin Diagn Res 2017;11:UC01&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427407</ArticleId><ArticleId IdType="pubmed">28511481</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins D, Best D, Briss PA, et al. . Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC428525</ArticleId><ArticleId IdType="pubmed">15205295</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Doruk N, Buyukakilli B, Atici S, et al. . The effect of preventive use of alanyl-glutamine on diaphragm muscle function in cecal ligation and puncture-induced sepsis model. JPEN J Parenter Enteral Nutr 2005;29:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang K, Shang FT, Zhang XC. Application of alanine-glutamine in early parenteral nutrition support in critically ill patients. Jiangsu Med J 2013;39:1599&#x2013;600.</Citation></Reference><Reference><Citation>Yin HY, Wei JR, Zhang R, et al. . Effect of glutamine on caspase-3 mRNA and protein expression in the myocardium of rats with sepsis. Am J Med Sci 2014;348:315&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24642654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernerman J. Clinical use of glutamine supplementation. J Nutr 2008;138:2040S&#x2013;4S.</Citation><ArticleIdList><ArticleId IdType="pubmed">18806121</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Si JG. Advances in clinical application of alanyl glutamine. China Pharm 2016;27:3739&#x2013;41.</Citation></Reference><Reference><Citation>Boelens PG, Nijveldt RJ, Houdijk AP, et al. . Glutamine alimentation in catabolic state. J Nutr 2001;131: 9 Suppl: 2569S&#x2013;77S. discussion 2590S.</Citation><ArticleIdList><ArticleId IdType="pubmed">11533315</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevastiadou S, Malamitsi-Puchner A, Costalos C, et al. . The impact of oral glutamine supplementation on the intestinal permeability and incidence of necrotizing enterocolitis/septicemia in premature neonates. J Matern Fetal Neonatal Med 2011;24:1294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">21463215</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares AD, Costa KA, Wanner SP, et al. . Dietary glutamine prevents the loss of intestinal barrier function and attenuates the increase in core body temperature induced by acute heat exposure. Br J Nutr 2014;112:1601&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">25322775</ArticleId></ArticleIdList></Reference><Reference><Citation>Manhart N, Vierlinger K, Spittler A, et al. . Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer's patches in endotoxemic mice. Ann Surg 2001;234:92&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421953</ArticleId><ArticleId IdType="pubmed">11420488</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabot GP, Carvalhal GF, Marroni NP, et al. . Glutamine prevents oxidative stress in a model of mesenteric ischemia and reperfusion. World J Gastroenterol 2014;20:11406&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145783</ArticleId><ArticleId IdType="pubmed">25170229</ArticleId></ArticleIdList></Reference><Reference><Citation>De Waele E, Malbrain MLNG, Spapen H. Nutrition in sepsis: a bench-to-bedside review. Nutrients 2020;12:395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7071318</ArticleId><ArticleId IdType="pubmed">32024268</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38394174</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Traditional herbal medicine use doubled the risk of multi-organ dysfunction syndrome in children: A prospective cohort study.</ArticleTitle><Pagination><StartPage>e0286233</StartPage><MedlinePgn>e0286233</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0286233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0286233</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional herbal medicine (THM) is frequently used in pediatric populations in many low-income countries as a form of healthcare and has been associated with a range of adverse events, including liver toxicity, renal failure, and allergic reactions. Despite these concerns, its impact on multi-organ dysfunction syndrome (MODS) risk has not been thoroughly investigated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the incidence and predictors of MODS in a pediatric intensive care unit (PICU) in Ethiopia, with a focus on the association between THM use and the risk of MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a single-center prospective cohort study conducted at a PICU in the university of Gondar Comprehensive Specialized hospital, Northwest Ethiopia. The study enrolled eligible patients aged one month to 18 years admitted to the PICU during the study period. Data on demographic characteristics, medical history, clinical and laboratory data, and outcome measures using standard case record forms, physical examination, and patient document reviews. The predictors of MODS were assessed using Cox proportional hazards models, with a focus on the association between traditional herbal medicine use and the risk of MODS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 310 patients were included in the final analysis, with a median age of 48 months and a male-to-female ratio of 1.5:1. The proportion and incidence of MODS were 30.96% (95% CI:25.8, 36.6) and 7.71(95% CI: 6.10, 9.40) per 100-person-day observation respectively. Renal failure (17.74%), neurologic failure (15.16%), and heart failure (14.52%) were the leading organ failures identified. Nearly one-third of patients (32.9%) died in the PICU, of which 59.8% had MODS. The rate of mortality was higher in patients with MODS than in those without. The Cox proportional hazards model identified renal disease (AHR = 6.32 (95%CI: 3.17,12.61)), intake of traditional herbal medication (AHR = 2.45, 95% CI:1.29,4.65), modified Pediatric Index of Mortality 2 (mPIM 2) score (AHR = 1.54 (95% CI: 1.38,1.71), and critical illness diagnoses (AHR = 2.68 (95% CI: 1.77,4.07)) as predictors of MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incidence of MODS was high. Renal disease, THM use, mPIM 2 scores, and critical illness diagnoses were independent predictors of MODS. A more than twofold increase in the risk of MODS was seen in patients who used TMH. Healthcare providers should be aware of risks associated with THM, and educate caregivers about the potential harms of these products. Future studies with larger sample sizes and more comprehensive outcome measures are needed.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Teshager et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teshager</LastName><ForeName>Nahom Worku</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amare</LastName><ForeName>Ashenafi Tazebew</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamirat</LastName><ForeName>Koku Sisay</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeleke</LastName><ForeName>Mulualem Endeshaw</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taddese</LastName><ForeName>Asefa Adimasu</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051437" MajorTopicYN="Y">Renal Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There were no competing interests, and patients/public were not involved in the research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38394174</ArticleId><ArticleId IdType="pmc">PMC10889611</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0286233</ArticleId><ArticleId IdType="pii">PONE-D-23-14246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. In: Pediatric Critical Care Medicine. 2005. doi: 10.1097/01.PCC.0000149131.72248.E6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109(4):1033&#x2013;7. doi: 10.1378/chest.109.4.1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tantale&#xe1;n JA, Le&#xf3;n RJ, Santos AA, S&#xe1;nchez E. Multiple organ dysfunction syndrome in children. Pediatr Crit Care Med. 2003;4(2):181&#x2013;5. doi: 10.1097/01.PCC.0000059421.13161.88</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000059421.13161.88</ArticleId><ArticleId IdType="pubmed">12749649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti E, Di Nardo M, Ricci Z. Multiple Organ Dysfunction in the Pediatric Intensive Care Unit. In: Critical Care Nephrology: Third Edition. 2017.</Citation></Reference><Reference><Citation>Typpo KV, Petersen NJ, Markovitz BP MM. Day one MODS is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatr Crit Care Med. 2009;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780005</ArticleId><ArticleId IdType="pubmed">19741445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler M, Swinger N, Rahrig AL, Skiles J, Rowan CM. Multiple Organ Dysfunction and Critically Ill Children With Acute Myeloid Leukemia: Single-Center Retrospective Cohort Study. Pediatr Crit Care Med. 2022; doi: 10.1097/PCC.0000000000003153</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000003153</ArticleId><ArticleId IdType="pmc">PMC10081947</ArticleId><ArticleId IdType="pubmed">36728709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LW, Oster RA, Tofil NM, Tolwani AJ. Outcomes of critically ill children requiring continuous renal replacement therapy. J Crit Care. 2009; doi: 10.1016/j.jcrc.2008.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2008.12.017</ArticleId><ArticleId IdType="pubmed">19327959</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartman ME, Lacroix J, Odetola FO. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017; doi: 10.1097/PCC.0000000000001047</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001047</ArticleId><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenk J, G&#xf3;mez-Dant&#xe9;s O. The Triple Burden Disease in Developing Nations. Harvard Int Rev. 2011;</Citation></Reference><Reference><Citation>Berendes S, Heywood P, Oliver S, Garner P. Quality of private and public ambulatory health care in low and middle income countries: Systematic review of comparative studies. PLoS Med. 2011; doi: 10.1371/journal.pmed.1000433</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000433</ArticleId><ArticleId IdType="pmc">PMC3075233</ArticleId><ArticleId IdType="pubmed">21532746</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Bestati N, Duhamel A, Proulx F, Grandbastien B, Lacroix J, et al.. 1218 Differences in Organ Dysfunctions Between Neonates and Other Children. Pediatr Res. 2010;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219976</ArticleId><ArticleId IdType="pubmed">21062434</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink EL, Kissoon N. Pediatric multiple organ dysfunction in resource limited settings. Pediatric Critical Care Medicine. 2017. doi: 10.1097/PCC.0000000000001045</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001045</ArticleId><ArticleId IdType="pubmed">28248837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated pediatric risk of mortality score. Crit Care Med. 1996; doi: 10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Wong HR, Shanley TP. Pediatric critical care medicine: Volume 1: Care of the critically ill or injured child, second edition. Pediatr Crit Care Med Vol 1 Care Crit Ill or Inj Child, Second Ed. 2014;1&#x2013;771.</Citation></Reference><Reference><Citation>Emr BM, Alcamo AM, Carcillo JA, Aneja RK, Mollen KP. Pediatric Sepsis Update: How Are Children Different? Surg Infect (Larchmt). 2018;</Citation><ArticleIdList><ArticleId IdType="pubmed">29394150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Neurology. 2014. doi: 10.3389/fphar.2013.00177</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2013.00177</ArticleId><ArticleId IdType="pmc">PMC3887317</ArticleId><ArticleId IdType="pubmed">24454289</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA, Steenkamp V, Stewart MJ. Acute renal failure associated with the use of traditional folk remedies in South Africa. Ren Fail. 2005;</Citation><ArticleIdList><ArticleId IdType="pubmed">15717633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM, et al.. Corrigendum: Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol. 2016; doi: 10.1038/ajg.2016.349</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.349</ArticleId><ArticleId IdType="pmc">PMC5516923</ArticleId><ArticleId IdType="pubmed">27045922</ArticleId></ArticleIdList></Reference><Reference><Citation>K.A. O, I.O. S, O.F. N, A. S. Use of complementary and alternative medicines for children with chronic health conditions in Lagos, Nigeria. BMC Complementary and Alternative Medicine. 2008. doi: 10.1186/1472-6882-8-66</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-8-66</ArticleId><ArticleId IdType="pmc">PMC2628640</ArticleId><ArticleId IdType="pubmed">19113999</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med. 1994; doi: 10.1097/00003246-199406000-00023</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199406000-00023</ArticleId><ArticleId IdType="pubmed">8205810</ArticleId></ArticleIdList></Reference><Reference><Citation>Khilnani P, Sarma D, Zimmerman J. Epidemiology and peculiarities of pediatric multiple organ dysfunction syndrome in New Delhi, India. Intensive Care Med. 2006; doi: 10.1007/s00134-006-0373-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0373-5</ArticleId><ArticleId IdType="pubmed">16977482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, Tucci M, Bush JL, Nadkarni VM, et al.. New or Progressive Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis. Pediatr Crit Care Med. 2017;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingma JG, Simard D, Rouleau JR, Drolet B, Simard C. The physiopathology of cardiorenal syndrome: A review of the potential contributions of inflammation. Journal of Cardiovascular Development and Disease. 2017. doi: 10.3390/jcdd4040021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd4040021</ArticleId><ArticleId IdType="pmc">PMC5753122</ArticleId><ArticleId IdType="pubmed">29367550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SA, Cozzi M, Bush EL, Rabb H. Distant Organ Dysfunction in Acute Kidney Injury: A Review. American Journal of Kidney Diseases. 2018. doi: 10.1053/j.ajkd.2018.03.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2018.03.028</ArticleId><ArticleId IdType="pmc">PMC6252108</ArticleId><ArticleId IdType="pubmed">29866457</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain-Syed F, Rosner MH, Ronco C. Distant organ dysfunction in acute kidney injury. Acta Physiologica. 2020. doi: 10.1111/apha.13357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13357</ArticleId><ArticleId IdType="pubmed">31379123</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzarino V, Lesser J, Cassani FA. Pediatric Chronic Kidney Disease. Advances in Pediatrics. 2022. doi: 10.1016/j.yapd.2022.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yapd.2022.03.008</ArticleId><ArticleId IdType="pubmed">35985704</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;n E, Akova B&#x15e;, Botan E, &#xc7;elik DB, Balaban B, &#xd6;zen H, et al.. Clinical features and outcomes of children admitted to the pediatric intensive care unit due to posterior reversible encephalopathy syndrome. Clin Neurol Neurosurg. 2022;</Citation><ArticleIdList><ArticleId IdType="pubmed">36265243</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JF, Mott AR, Dickerson HA, Jefferies JL, Nelson DP, Chang AC, et al.. Worsening renal function in children hospitalized with decompensated heart failure: Evidence for a pediatric cardiorenal syndrome? Pediatr Crit Care Med. 2008; doi: 10.1097/PCC.0b013e31816c6ed1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31816c6ed1</ArticleId><ArticleId IdType="pubmed">18446113</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley A J. Gebhard D, Akcan-Arikan A. Acute Kidney Injury in Pediatric Heart Failure. Curr Cardiol Rev. 2016; doi: 10.2174/1573403x12666151119165628</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403x12666151119165628</ArticleId><ArticleId IdType="pmc">PMC4861941</ArticleId><ArticleId IdType="pubmed">26585035</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PMF, de Carvalho ST, Fradico PF, Cazumb&#xe1; MLB, Campos RGB, Sim&#xf5;es e Silva AC. Hepatorenal syndrome in children: a review. Pediatric Nephrology. 2021. doi: 10.1007/s00467-020-04762-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-020-04762-6</ArticleId><ArticleId IdType="pmc">PMC7527294</ArticleId><ArticleId IdType="pubmed">33001296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; C, Sol&#xe0; E, Huelin P, Carol M, Moreira R, Cereijo U, et al.. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver Int. 2019; doi: 10.1111/liv.14037</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14037</ArticleId><ArticleId IdType="pmc">PMC6767546</ArticleId><ArticleId IdType="pubmed">30597709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazory A, Ronco C. Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. CardioRenal Medicine. 2019. doi: 10.1159/000492791</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492791</ArticleId><ArticleId IdType="pubmed">30223273</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney International. 2013. doi: 10.1038/ki.2012.440</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.440</ArticleId><ArticleId IdType="pubmed">23325079</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA. Nephrotoxicity of Alternative Medicine Practice. Advances in Chronic Kidney Disease. 2012. doi: 10.1053/j.ackd.2012.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2012.04.005</ArticleId><ArticleId IdType="pubmed">22578672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KC, Lu R, Iqbal U, Hsu KC, Chen BL, Nguyen PA, et al.. Interactions between traditional Chinese medicine and western drugs in Taiwan: A population-based study. Comput Methods Programs Biomed. 2015; doi: 10.1016/j.cmpb.2015.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2015.09.006</ArticleId><ArticleId IdType="pubmed">26470816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakerink JA, Gospe SM, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics. 1996;</Citation><ArticleIdList><ArticleId IdType="pubmed">8909490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam PCA, Liew S. Traditional Chinese herbal medicine and anaesthesia. Anaesthesia. 2002. doi: 10.1046/j.1365-2044.2002.02823.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2044.2002.02823.x</ArticleId><ArticleId IdType="pubmed">12392455</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpan EE, Ekrikpo UE. Acute Renal Failure Induced by Chinese Herbal Medication in Nigeria. Case Rep Med. 2015; doi: 10.1155/2015/150204</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/150204</ArticleId><ArticleId IdType="pmc">PMC4496464</ArticleId><ArticleId IdType="pubmed">26199625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MZ, Saleh MA, Alkhayyat M, Roberts DE, Lindenmeyer CC. Multiorgan Dysfunction Related to Kratom Ingestion. ACG Case Reports J. 2021; doi: 10.14309/crj.0000000000000647</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/crj.0000000000000647</ArticleId><ArticleId IdType="pmc">PMC8389947</ArticleId><ArticleId IdType="pubmed">34476274</ArticleId></ArticleIdList></Reference><Reference><Citation>Perazella MA. Renal vulnerability to drug toxicity. Clinical Journal of the American Society of Nephrology. 2009. doi: 10.2215/CJN.02050309</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02050309</ArticleId><ArticleId IdType="pubmed">19520747</ArticleId></ArticleIdList></Reference><Reference><Citation>George P. Concerns regarding the safety and toxicity of medicinal plants&#x2014;An overview. J Appl Pharm Sci. 2011;</Citation></Reference><Reference><Citation>Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology. 2001; doi: 10.1053/jhep.2001.27445</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2001.27445</ArticleId><ArticleId IdType="pubmed">11526548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers SL, Kronenfeld JJ. Delays in seeking conventional medical care and complementary and alternative medicine utilization. Health Serv Res. 2012; doi: 10.1111/j.1475-6773.2012.01406.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1475-6773.2012.01406.x</ArticleId><ArticleId IdType="pmc">PMC3513619</ArticleId><ArticleId IdType="pubmed">22985034</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997; doi: 10.1002/j.1552-4604.1997.tb04312.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1552-4604.1997.tb04312.x</ArticleId><ArticleId IdType="pubmed">9115061</ArticleId></ArticleIdList></Reference><Reference><Citation>Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): An overview of systematic reviews. European Journal of Clinical Pharmacology. 2013. doi: 10.1007/s00228-012-1353-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-012-1353-z</ArticleId><ArticleId IdType="pubmed">22843016</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyman T, Stewart MJ, Grove A, Steenkamp V. Adulteration of South African traditional herbal remedies. Ther Drug Monit. 2005; doi: 10.1097/00007691-200502000-00015</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007691-200502000-00015</ArticleId><ArticleId IdType="pubmed">15665751</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian Journal of Medical and Biological Research. 2000. doi: 10.1590/s0100-879x2000000200004</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0100-879x2000000200004</ArticleId><ArticleId IdType="pubmed">10657057</ArticleId></ArticleIdList></Reference><Reference><Citation>Efferth T, Kaina B. Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine. Curr Drug Metab. 2011; doi: 10.2174/138920011798062328</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920011798062328</ArticleId><ArticleId IdType="pubmed">21892916</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh AYT, Chan PWK, Lum LCS. Sepsis, severe sepsis and septic shock in paediatric multiple organ dysfunction syndrome. J Paediatr Child Health. 1999; doi: 10.1046/j.1440-1754.1999.355409.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1754.1999.355409.x</ArticleId><ArticleId IdType="pubmed">10571765</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al.. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015; doi: 10.1164/rccm.201412-2323OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201412-2323OC</ArticleId><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: A prospective national survey. Intensive Care Med. 2008; doi: 10.1007/s00134-008-1148-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1148-y</ArticleId><ArticleId IdType="pubmed">18500425</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al.. Validation of the paediatric logistic organ dysfunction (PELOD) score: Prospective, observational, multicentre study. Lancet. 2003; doi: 10.1016/S0140-6736(03)13908-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)13908-6</ArticleId><ArticleId IdType="pubmed">12885479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, Cotting J. Severity of illness and organ dysfunction scoring in children. Pediatric Critical Care Medicine. 2005. doi: 10.1097/01.PCC.0000161287.61028.D4</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000161287.61028.D4</ArticleId><ArticleId IdType="pubmed">15857545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulla K, Sachdev A. Illness severity and organ dysfunction scoring in Pediatric Intensive Care Unit. Indian J Crit Care Med. 2016; doi: 10.4103/0972-5229.173685</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.173685</ArticleId><ArticleId IdType="pmc">PMC4759990</ArticleId><ArticleId IdType="pubmed">26955214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33854308</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1178-1998</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Clinical interventions in aging</Title><ISOAbbreviation>Clin Interv Aging</ISOAbbreviation></Journal><ArticleTitle>Association Between High-Sensitivity Troponin T on Admission and Organ Dysfunction During Hospitalization in Patients Aged 80 Years and Older with Hip Fracture: A Single-Centered Prospective Cohort Study.</ArticleTitle><Pagination><StartPage>583</StartPage><EndPage>591</EndPage><MedlinePgn>583-591</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CIA.S303246</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prognostic evaluation of elderly patients with hip fracture is an issue that has been highly concerned by clinicians. Only a few studies have focused on organ dysfunction after hip fracture in the elderly. This study aimed to investigate the association between high-sensitivity troponin T (hs-TnT) at admission and organ dysfunction during hospitalization in elderly patients with hip fracture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 168 patients with hip fracture who were aged 80 years and older at Geriatric Orthopaedic Center of Sichuan Provincial Orthopedic Hospital between January 2020 and August 2020. Baseline characteristics, perioperative information, and short-term clinical outcomes were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 208 patients admitted during the study period, 168 met the inclusion criteria; of these, 91 (54.2%) had higher hs-TnT than the 99th percentile in the normal population. After adjustment for confounders, elevated hs-TnT was independently associated with multiple organ dysfunction syndrome in the elderly (MODSE) (adjusted OR, 5.76; 95% CI, 1.74-19.10; <i>P</i> = 0.004), heart dysfunction (adjusted OR, 7.48; 95% CI, 2.17-25.82; <i>P</i> = 0.001), MODS severity score &gt; 3 (adjusted OR, 5.22; 95% CI, 1.32-20.60; <i>P</i> = 0.018), and length of hospital stay &gt; 14 days (adjusted OR, 2.38; 95% CI, 1.05-5.36; <i>P</i> = 0.037).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Increased hs-TnT on admission is an independent risk factor for MODSE after hip fracture in patients aged 80 years and older. Effective measures should be applied to avoid progression of MODSE from pre-failure stage to failure stage.</AbstractText><CopyrightInformation>&#xa9; 2021 Qin et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Zhi-Jun</ForeName><Initials>ZJ</Initials><Identifier Source="ORCID">0000-0003-3664-090X</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qian-Yun</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xuan-Di</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheng-Jie</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Geriatric Orthopedics, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Jun-Feng</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Geriatric Orthopedics, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Interv Aging</MedlineTA><NlmUniqueID>101273480</NlmUniqueID><ISSNLinking>1176-9092</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020107">Troponin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="N">Hip Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020107" MajorTopicYN="N">Troponin T</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">high-sensitivity troponin T</Keyword><Keyword MajorTopicYN="N">hip fracture</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome in the elderly</Keyword><Keyword MajorTopicYN="N">short-term outcomes</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>7</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33854308</ArticleId><ArticleId IdType="pmc">PMC8039433</ArticleId><ArticleId IdType="doi">10.2147/CIA.S303246</ArticleId><ArticleId IdType="pii">303246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leer-Salvesen S, Enges&#xe6;ter LB, Dybvik E, Furnes O, Kristensen TB, Gjertsen JE. Does time from fracture to surgery affect mortality and intraoperative medical complications for hip fracture patients? An observational study of 73 557 patients reported to the Norwegian hip fracture register. Bone Joint J. 2019;101-B(9):1129&#x2013;1137. doi:10.1302/0301-620X.101B9.BJJ-2019-0295.R1</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.101B9.BJJ-2019-0295.R1</ArticleId><ArticleId IdType="pubmed">31474142</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaupre LA, Khong H, Smith C, et al. The impact of time to surgery after hip fracture on mortality at 30- and 90-days: does a single benchmark apply to all? Injury. 2019;50(4):950&#x2013;955. doi:10.1016/j.injury.2019.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2019.03.031</ArticleId><ArticleId IdType="pubmed">30948037</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa KA, G&#xe9;lvez AG, Torres LP, Garc&#xed;a MF, Pe&#xf1;a OR. Pre-operative factors associated with increased mortality in elderly patients with a hip fracture: a cohort study in a developing country. Injury. 2018;49(6):1162&#x2013;1168. doi:10.1016/j.injury.2018.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.04.007</ArticleId><ArticleId IdType="pubmed">29674111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson MH, Bentzer P, Turkiewicz A, Hommel A. Accuracy of the physiological and operative severity score for the enUmeration of mortality and morbidity score and the Nottingham risk score in hip fracture patients in Sweden &#x2013; a prospective observational study. Acta Anaesthesiol Scand. 2018;62(8):1057&#x2013;1063. doi:10.1111/aas.13131</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13131</ArticleId><ArticleId IdType="pmc">PMC6099275</ArticleId><ArticleId IdType="pubmed">29687439</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns WL, Strong B, Kates S, Patel NK. POSSUM and P-POSSUM scoring in hip fracture mortalities. Geriatr Orthop Surg Rehabil. 2020;11:2151459320931674. doi:10.1177/2151459320931674</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2151459320931674</ArticleId><ArticleId IdType="pmc">PMC7290268</ArticleId><ArticleId IdType="pubmed">32577320</ArticleId></ArticleIdList></Reference><Reference><Citation>Laulund AS, Lauritzen JB, Duus BR, Mosfeldt M, J&#xf8;rgensen HL. Routine blood tests as predictors of mortality in hip fracture patients. Injury. 2012;43(7):1014&#x2013;1020. doi:10.1016/j.injury.2011.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2011.12.008</ArticleId><ArticleId IdType="pubmed">22236368</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Lv H, Li Y, et al. Hip fracture patients who experience a greater fluctuation in RDW during hospital course are at heightened risk for all-cause mortality: a prospective study with 2-year follow-up. Osteoporos Int. 2018;29(7):1559&#x2013;1567. doi:10.1007/s00198-018-4516-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-018-4516-7</ArticleId><ArticleId IdType="pubmed">29656346</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot B, Verdoorn RC, Lameijer J, van der Velden J. High-sensitivity cardiac troponin T is an independent predictor of inhospital mortality in emergency department patients with suspected infection: a prospective observational derivation study. Emerg Med J. 2014;31(11):882&#x2013;888. doi:10.1136/emermed-2013-202865</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emermed-2013-202865</ArticleId><ArticleId IdType="pubmed">23965276</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf8;iseth AD, Brynildsen J, Hagve TA, et al. The influence of heart failure co-morbidity on high-sensitivity troponin T levels in COPD exacerbation in a prospective cohort study: data from the akershus cardiac examination (ACE) 2 study. Biomarkers. 2016;21(2):173&#x2013;179. doi:10.3109/1354750X.2015.1126645</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1354750X.2015.1126645</ArticleId><ArticleId IdType="pubmed">26754170</ArticleId></ArticleIdList></Reference><Reference><Citation>Neukamm A, Einvik G, Didrik h&#xf8;iseth A, et al. The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. BMC Pulm Med. 2016;16(1):164. doi:10.1186/s12890-016-0319-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-016-0319-9</ArticleId><ArticleId IdType="pmc">PMC5124304</ArticleId><ArticleId IdType="pubmed">27887619</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, Wang J, Dong W. The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke. BMC Neurol. 2018;18(1):118. doi:10.1186/s12883-018-1121-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1121-5</ArticleId><ArticleId IdType="pmc">PMC6102797</ArticleId><ArticleId IdType="pubmed">30124165</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P, Hryniewiecki T, Ku&#x15b;mierczyk M, Szyma&#x144;ski P. High-sensitivity troponin T predicts postoperative cardiogenic shock requiring mechanical circulatory support in patients with valve disease. Shock. 2020;53(2):175&#x2013;178. doi:10.1097/SHK.0000000000001360</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001360</ArticleId><ArticleId IdType="pubmed">31162290</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P, Hryniewiecki T, Ku&#x15b;mierczyk M, Szymanski P. Red cell distribution width as a predictor of multiple organ dysfunction syndrome in patients undergoing heart valve surgery. Biol Open. 2018;7(10):bio036251. doi:10.1242/bio.036251</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.036251</ArticleId><ArticleId IdType="pmc">PMC6215413</ArticleId><ArticleId IdType="pubmed">30127093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391&#x2013;e479. doi:10.1161/CIRCULATIONAHA.109.192065</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.192065</ArticleId><ArticleId IdType="pubmed">19324966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580&#x2013;586. doi:10.1378/chest.93.3.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.93.3.580</ArticleId><ArticleId IdType="pubmed">3342669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira D, Reis E. Swallowing disorders in nursing home residents: how can the problem be explained? Clin Interv Aging. 2013;8:221&#x2013;227. doi:10.2147/CIA.S39452</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S39452</ArticleId><ArticleId IdType="pmc">PMC3581290</ArticleId><ArticleId IdType="pubmed">23449951</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SW, Wang JD, Chen KJ, Wang YT, Wang XD, Mu CS. Diagnostic criteria of multiple organ dysfunction syndrome in elderly (Draft, 2003). Chin Crit Care Med. 2004;16(1):1. doi:10.3760/cma.j.issn.1003-0603.2004.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1003-0603.2004.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Society of Combining Traditional Chinese and Western Medicine Professional Committee of Emergency Medicine. [Replacing &#x201c;Lushan conference in 1995&#x201d; guideline of the staging diagnosis and severity score standard of multiple organ dysfunction syndrome (2015)]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016;28(2):99&#x2013;101. Chinese. doi:10.3760/cma.j.issn.2095-4352.2016.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.2095-4352.2016.02.002</ArticleId><ArticleId IdType="pubmed">26911937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargani L, Pang PS, Frassi F, et al. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study. Cardiovasc Ultrasound. 2015;13:40. doi:10.1186/s12947-015-0033-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12947-015-0033-4</ArticleId><ArticleId IdType="pmc">PMC4558829</ArticleId><ArticleId IdType="pubmed">26337295</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P, Szyma&#x144;ski P, Ku&#x15b;mierczyk M, Hryniewiecki T. Usefulness of FRAIL scale in heart valve diseases. Clin Interv Aging. 2020;15:1071&#x2013;1075. doi:10.2147/CIA.S239054</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S239054</ArticleId><ArticleId IdType="pmc">PMC7358089</ArticleId><ArticleId IdType="pubmed">32753858</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113(14):1708&#x2013;1718. doi:10.1093/cvr/cvx183</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvx183</ArticleId><ArticleId IdType="pmc">PMC5852618</ArticleId><ArticleId IdType="pubmed">29016754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SJ, Wang Q, Cui YJ, et al. High-sensitivity cardiac troponin T in geriatric inpatients. Arch Gerontol Geriatr. 2016;65:111&#x2013;115. doi:10.1016/j.archger.2016.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2016.03.010</ArticleId><ArticleId IdType="pubmed">27017416</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Li DX, Wang Q, Xu Y, Cui YJ. Relationship between high-sensitivity cardiac troponin T and the prognosis of elderly inpatients with non-acute coronary syndromes. Clin Interv Aging. 2018;13:1091&#x2013;1098. doi:10.2147/CIA.S157048</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S157048</ArticleId><ArticleId IdType="pmc">PMC5995414</ArticleId><ArticleId IdType="pubmed">29922047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinaels EP, Daamen MA, Bekers O, et al. Clinical interpretation of elevated concentrations of cardiac troponin T, but not troponin I, in nursing home residents. J Am Med Dir Assoc. 2015;16(10):884&#x2013;891. doi:10.1016/j.jamda.2015.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2015.06.026</ArticleId><ArticleId IdType="pubmed">26255708</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65&#x2013;75. doi:10.1161/CIRCULATIONAHA.111.080770</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.080770</ArticleId><ArticleId IdType="pubmed">22615345</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pablos L, Jorge-Brito RA, Amarnani V, Jim&#xe9;nez-Sosa A, Harmand MG, Dom&#xed;nguez-Rodr&#xed;guez A. Delirium in patients with heart failure: influence of attendance times in an emergency department. Rev Esp Cardiol (Engl Ed). 2019;72(1):82&#x2013;84. doi:10.1016/j.rec.2017.10.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2017.10.045</ArticleId><ArticleId IdType="pubmed">29373255</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JA, Moffitt P, Perez-Moreno AC, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail. 2017;23(6):464&#x2013;475. doi:10.1016/j.cardfail.2017.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2017.04.007</ArticleId><ArticleId IdType="pubmed">28433667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatabe N, Takeuchi K, Izumi M, et al. Decreased cognitive function is associated with dysphagia risk in nursing home older residents. Gerodontology. 2018;35(4):376&#x2013;381. doi:10.1111/ger.12366</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ger.12366</ArticleId><ArticleId IdType="pubmed">30028036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghannouchi I, Speyer R, Doma K, Cordier R, Verin E. Swallowing function and chronic respiratory diseases: systematic review. Respir Med. 2016;117:54&#x2013;64. doi:10.1016/j.rmed.2016.05.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2016.05.024</ArticleId><ArticleId IdType="pubmed">27492514</ArticleId></ArticleIdList></Reference><Reference><Citation>Suttrup I, Warnecke T. Dysphagia in parkinson&#x2019;s disease. Dysphagia. 2016;31(1):24&#x2013;32. doi:10.1007/s00455-015-9671-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-015-9671-9</ArticleId><ArticleId IdType="pubmed">26590572</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A, Srikusalanukul W, Fisher L, Smith P. The neutrophil to lymphocyte ratio on admission and short-term outcomes in orthogeriatric patients. Int J Med Sci. 2016;13(8):588&#x2013;602. doi:10.7150/ijms.15445</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.15445</ArticleId><ArticleId IdType="pmc">PMC4974907</ArticleId><ArticleId IdType="pubmed">27499691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33546739</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.</ArticleTitle><Pagination><StartPage>116</StartPage><MedlinePgn>116</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-021-05072-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endocytosis by AP2-associated protein kinase 1 (AAK1) inhibition. We propose the use of baricinitib to prevent the progression of the respiratory insufficiency in SARS-CoV2 pneumonia in onco-haematological patients. In this phase Ib/II study, the primary objective in the safety cohort is to describe the incidence of severe adverse events associated with baricitinib administration. The primary objective of the randomized phase (baricitinib cohort versus standard of care cohort) is to evaluate the number of patients who did not require mechanical oxygen support since start of therapy until day +14 or discharge (whichever it comes first). The secondary objectives of the study (only randomized phase of the study) are represented by the comparison between the two arms of the study in terms of mortality and toxicity at day+30. Moreover, a description of the immunological related changes between the two arms of the study will be reported.</AbstractText><AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">The trial is a phase I/II study with a safety run-in cohort (phase 1) followed by an open label phase II randomized controlled trial with an experimental arm compared to a standard of care arm.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The study will be performed at the Institut Catal&#xe0; d'Oncologia, a tertiary level oncological referral center in the Catalonia region (Spain). The eligibility criteria are: patients &gt; 18 years affected by oncological diseases; ECOG performance status &lt; 2 (Karnofsky score &gt; 60%); a laboratory confirmed infection with SARS-CoV-2 by means of real -time PCR; radiological signs of low respiratory tract disease; absence of organ dysfunction (a total bilirubin within normal institutional limits, AST/ALT&#x2264;2.5 X institutional upper limit of normal, alkaline phosphatase &#x2264;2.5 X institutional upper limit of normal, coagulation within normal institutional limits, creatinine clearance &gt;30 mL/min/1.73 m<sup>2</sup> for patients with creatinine levels above institutional normal); absence of HIV infection; no active or latent HBV or HCV infection. The exclusion criteria are: patients with oncological diseases who are not candidates to receive any active oncological treatment; hemodynamic instability at time of study enrollment; impossibility to receive oral medication; medical history of recent or active pulmonary embolism or deep venous thrombosis or patients at high-risk of suffering them (surgical intervention, immobilization); multi organ failure, rapid worsening of respiratory function with requirement of fraction of inspired oxygen (FiO<sub>2</sub>) &gt; 50% or high-flow nasal cannula before initiation of study treatment; uncontrolled intercurrent illness (ongoing or severe active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements); allergy to one or more of study treatments; pregnant or breastfeeding women; positive pregnancy test in a pre-dose examination. Patients should have the ability to understand, and the willingness to sign, a written informed consent document; the willingness to accept randomization to any assigned treatment arm; and must agree not to enroll in another study of an investigational agent prior to completion of Day +28 of study. An electronic Case Report Form in the Research Electronic Data Capture (REDCap) platform will be used to collect the data of the trial. Removal from the study will apply in case of unacceptable adverse event(s), development of an intercurrent illness, condition or procedural complication, which could interfere with the patient's continued participation and voluntary patient withdrawal from study treatment (all patients are free to withdraw from participation in this study at any time, for any reasons, specified or unspecified, and without prejudice).</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">Treatment will be administered on an inpatient basis. We will compare the experimental treatment with baricitinib plus the institutional standard of care compared with the standard of care alone. During the phase I, we will define the dose-limiting toxicity of baricitinib and the dose to be used in the phase 2 part of the study. The starting baricitinib dose will be an oral tablet 4 mg-once daily which can be reduced to 2 mg depending on the observed toxicity. The minimum duration of therapy will be 5 days and it can be extended to 7 days. The standard of care will include the following therapies. Antibiotics will be individualized based on clinical suspicion, including the management of febrile neutropenia. Prophylaxis of thromboembolic disease will be administered to all participants. Remdesivir administration will be considered only in patients with severe pneumonia (SatO<sub>2</sub> &lt;94%) with less than 7 days of onset of symptoms and with supplemental oxygen requirements but not using high-flow nasal cannula, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). In the randomized phase, tocilizumab or interferon will not be allowed in the experimental arm. Tocilizumab can be used in patients in the standard of care arm at the discretion of the investigator. If it is prescribed it will be used according to the following criteria: patients who, according to his baseline clinical condition, would be an ICU tributary, interstitial pneumonia with severe respiratory failure, patients who are not on mechanical ventilation or ECMO and who are still progressing with corticoid treatment or if they are not candidates for corticosteroids. Mild ARDS (PAFI &lt;300 mmHg) with radiological or blood gases deterioration that meets at least one of the following criteria: CRP &gt;100mg/L D-Dimer &gt;1,000&#x3bc;g/L LDH &gt;400U/L Ferritin &gt;700ng/ml Interleukin 6 &#x2265;40ng/L. The use of tocilizumab is not recommended if there are AST/ALT values greater than 10 times the upper limit of normal, neutrophils &lt;500 cells/mm3, sepsis due to other pathogens other than SARS-CoV-2, presence of comorbidity that can lead to a poor prognosis, complicated diverticulitis or intestinal perforation, ongoing skin infection. The dose will be that recommended by the Spanish Medicine Agency in patients &#x2265;75Kg: 600mg dose whereas in patients &lt;75kg: 400mg dose. Exceptionally, a second infusion can be assessed 12 hours after the first in those patients who experience a worsening of laboratory parameters after a first favourable response. The use of corticosteroids will be recommended in patients who have had symptoms for more than 7 days and who meet all the following criteria: need for oxygen support, non-invasive or invasive mechanical ventilation, acute respiratory failure or rapid deterioration of gas exchange, appearance or worsening of bilateral alveolar-interstitial infiltrates at the radiological level. In case of indication, it is recommended: dexamethasone 6mg/d p.o. or iv for 10 days or methylprednisolone 32mg/d orally or 30mg iv for 10 days or prednisone 40mg day p.o. for 10 days.</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">Phase 1 part: to describe the toxicity profile of baricitinib in COVID19 oncological patients during the 5-7 day treatment period and until day +14 or discharge (whichever it comes first). Phase 2 part: to describe the number of patients in the experimental arm that will not require mechanical oxygen support compared to the standard of care arm until day +14 or discharge (whichever it comes first).</AbstractText><AbstractText Label="RANDOMISATION" NlmCategory="METHODS">For the phase 2 of the study, the allocation ratio will be 1:1. Randomization process will be carried out electronically through the REDcap platform ( https://www.project-redcap.org/ ) BLINDING (MASKING): This is an open label study. No blinding will be performed.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">The first part of the study (safety run-in cohort) will consist in the enrollment of 6 to 12 patients. In this population, we will test the toxicity of the experimental treatment. An incidence of severe adverse events grade 3-4 (graded by Common Terminology Criteria for Adverse Events v.5.0) inferior than 33% will be considered sufficient to follow with the next part of the study. The second part of the study we will perform an interim analysis of efficacy at first 64 assessed patients and a definitive one will analyze 128 assessed patients. Interim and definitive tests will be performed considering in both cases an alpha error of 0.05. We consider for the control arm this rate is expected to be 0.60 and for the experimental arm of 0.80. Considering this data, a superiority test to prove a difference of 0.20 with an overall alpha error of 0.10 and a beta error of 0.2 will be performed. Considering a 5% of dropout rate, it is expected that a total of 136 patients, 68 for each study arm, will be required to complete study accrual.</AbstractText><AbstractText Label="TRIAL STATUS" NlmCategory="METHODS">Version 5.0. 14<sup>th</sup> October 2020 Recruitment started on the 16<sup>th</sup> of December 2020. Expected end of recruitment is June 2021.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">AEMPs: 20-0356 EudraCT: 2020-001789-12, https://www.clinicaltrialsregister.eu/ctr-search/search (Not publically available as Phase I trial) Clinical trials: BARCOVID19, https://www.clinicaltrials.gov/ (In progress) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Gonz&#xe1;lez</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mussetti</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albasanz-Puig</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureda</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona University, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudiol</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona University, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Oncology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Oncology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Haba Vaca</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Emergency Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coma</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Emergency Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz-Linares</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dura</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontanals</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palliative Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palliative Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma&#xf1;ez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">baricitinib</Keyword><Keyword MajorTopicYN="N">jak inhibitors</Keyword><Keyword MajorTopicYN="N">oncological patients</Keyword><Keyword MajorTopicYN="N">randomised controlled trial</Keyword><Keyword MajorTopicYN="N">respiratory insufficiency</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests in relation to the trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33546739</ArticleId><ArticleId IdType="pmc">PMC7862837</ArticleId><ArticleId IdType="doi">10.1186/s13063-021-05072-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-021-05072-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34686556</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Multicentre, longitudinal, observational cohort study to examine the relationship between neutrophil function and sepsis in adults and children with severe thermal injuries: a protocol for the Scientific Investigation of the Biological Pathways Following Thermal Injury-2 (SIFTI-2) study.</ArticleTitle><Pagination><StartPage>e052035</StartPage><MedlinePgn>e052035</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e052035</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-052035</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Burn-induced changes in the phenotype and function of neutrophils, cells which provide front-line protection against rapidly dividing bacterial infections, are emerging as potential biomarkers for the early prediction of sepsis. In a longitudinal study of adult burns patients, we recently demonstrated that a combined measurement of neutrophil phagocytic capacity, immature granulocyte (IG) count and plasma cell-free DNA (cfDNA) levels on the day of injury gave good discriminatory power for the prediction of later sepsis development. However, limited by a small sample size, single-centre design and focus on adult burns patients, these biomarkers require prospective validation in a larger patient cohort. The Scientific Investigation of the Biological Pathways Following Thermal Injury-2 study aims to prospectively validate neutrophil phagocytic activity, IG count and plasma cfDNA levels as early prognostic biomarkers of sepsis in thermally injured adult and paediatric patients.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">This multicentre, longitudinal, observational cohort study will enrol 245 paediatric and adult patients with moderate to severe burns within 24 hours of injury. Blood samples will be obtained at 19 postinjury time points (days 1-14, day 28, months 3, 6, 12 and 24) and analysed for neutrophil phagocytic activity, IG count and cfDNA levels. Patients will be screened daily for sepsis using the 2007 American Burn Association diagnostic criteria for sepsis. In addition, daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores will be recorded relationships between neutrophil phagocytic activity, IG count and plasma cfDNA levels on day 1 of injury and the development of sepsis will be examined using logistic regression models.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This study received ethics approval from the West Midlands, Coventry and Warwickshire Research Ethics Committee (REC reference:16/WM/0217). Findings will be presented at national and international conferences, and submitted for publication in peer-reviewed journals.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04693442.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazeldine</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4280-4889</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGee</LastName><ForeName>Kirsty C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Tarrah</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassouna</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Krupali</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imran</LastName><ForeName>Rizwana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1641-2478</Identifier><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Jonathan R B</ForeName><Initials>JRB</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamford</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St Andrews Centre for Plastic Surgery and Burns, Mid and South Essex NHS Foundation Trust, Essex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-1030-6786</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moiemen</LastName><ForeName>Naiem S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK naiem.moiemen2@nhs.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04693442</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult intensive &amp; critical care</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">paediatric intensive &amp; critical care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34686556</ArticleId><ArticleId IdType="pmc">PMC8543641</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-052035</ArticleId><ArticleId IdType="pii">bmjopen-2021-052035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jackson PC, Hardwicke J, Bamford A, et al. . Revised estimates of mortality from the Birmingham burn centre, 2001-2010: a continuing analysis over 65 years. Ann Surg 2014;259:979&#x2013;84. 10.1097/SLA.0b013e31829160ca</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31829160ca</ArticleId><ArticleId IdType="pubmed">23598383</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;lhan B, Kan&#x131;k Y&#xfc;ksek S, Hayran M, et al. . Infections in pediatric burn patients: an analysis of one hundred eighty-one patients. Surg Infect 2020;21:357&#x2013;62. 10.1089/sur.2019.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2019.010</ArticleId><ArticleId IdType="pubmed">31589562</ArticleId></ArticleIdList></Reference><Reference><Citation>Holl&#xe9;n L, Hughes R, Dodds N, et al. . Use of procalcitonin as a biomarker for sepsis in moderate to major paediatric burns. Trauma 2019;21:192&#x2013;200. 10.1177/1460408618760940</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1460408618760940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan KM, Jayaraman V, Mathivanan T, et al. . Profile of burn sepsis challenges and outcome in an exclusive children's hospital in Chennai, India. Ann Burns Fire Disasters 2012;25:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431721</ArticleId><ArticleId IdType="pubmed">23012610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann EA, Baun MM, Meininger JC, et al. . Comparison of mortality associated with sepsis in the burn, trauma, and general intensive care unit patient: a systematic review of the literature. Shock 2012;37:4&#x2013;16. 10.1097/SHK.0b013e318237d6bf</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318237d6bf</ArticleId><ArticleId IdType="pubmed">21941222</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. . The third International consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801&#x2013;10. 10.1001/jama.2016.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams FN, Herndon DN, Hawkins HK, et al. . The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009;13:R183. 10.1186/cc8170</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8170</ArticleId><ArticleId IdType="pmc">PMC2811947</ArticleId><ArticleId IdType="pubmed">19919684</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina JA, Rosique MJ, Rosique RG. Curbing inflammation in burn patients. Int J Inflam 2013;2013:1&#x2013;9. 10.1155/2013/715645</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/715645</ArticleId><ArticleId IdType="pmc">PMC3671671</ArticleId><ArticleId IdType="pubmed">23762773</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, et al. . American burn association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776&#x2013;90. 10.1097/BCR.0b013e3181599bc9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644&#x2013;55. 10.1378/chest.101.6.1644</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez Lopez O, Cambiaso-Daniel J, Branski LK, et al. . Predicting and managing sepsis in burn patients: current perspectives. Ther Clin Risk Manag 2017;13:1107&#x2013;17. 10.2147/TCRM.S119938</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S119938</ArticleId><ArticleId IdType="pmc">PMC5584891</ArticleId><ArticleId IdType="pubmed">28894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely AN, Fowler LA, Kagan RJ, et al. . Procalcitonin in pediatric burn patients: an early indicator of sepsis? J Burn Care Rehabil 2004;25:76&#x2013;80. 10.1097/01.BCR.0000105095.94766.89</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BCR.0000105095.94766.89</ArticleId><ArticleId IdType="pubmed">14726743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bargues L, Chancerelle Y, Catineau J, et al. . Evaluation of serum procalcitonin concentration in the ICU following severe burn. Burns 2007;33:860&#x2013;4. 10.1016/j.burns.2006.10.401</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2006.10.401</ArticleId><ArticleId IdType="pubmed">17532575</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gesten F, Prescott HC, et al. . Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235&#x2013;44. 10.1056/NEJMoa1703058</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1703058</ArticleId><ArticleId IdType="pmc">PMC5538258</ArticleId><ArticleId IdType="pubmed">28528569</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CN, Moore M, Dimisko L, et al. . Spontaneous neutrophil migration patterns during sepsis after major burns. PLoS One 2014;9:e114509. 10.1371/journal.pone.0114509</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0114509</ArticleId><ArticleId IdType="pmc">PMC4260850</ArticleId><ArticleId IdType="pubmed">25489947</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler KL, Ambravaneswaran V, Agrawal N, et al. . Burn injury reduces neutrophil directional migration speed in microfluidic devices. PLoS One 2010;5:e11921. 10.1371/journal.pone.0011921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011921</ArticleId><ArticleId IdType="pmc">PMC2912851</ArticleId><ArticleId IdType="pubmed">20689600</ArticleId></ArticleIdList></Reference><Reference><Citation>Arturson G. Neutrophil granulocyte functions in severely burned patients. Burns Incl Therm Inj 1985;11:309&#x2013;19. 10.1016/0305-4179(85)90093-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0305-4179(85)90093-2</ArticleId><ArticleId IdType="pubmed">4027746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson P, Dinsdale RJ, Wearn CM, et al. . Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burn-injured patients: a prospective observational cohort study. Ann Surg 2017;265:1241&#x2013;9. 10.1097/SLA.0000000000001807</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001807</ArticleId><ArticleId IdType="pubmed">27232244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerknes R, Vindenes H, Laerum OD. Altered neutrophil functions in patients with large burns. Blood Cells 1990;16:127&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190644</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinsdale RJ, Devi A, Hampson P, et al. . Changes in novel haematological parameters following thermal injury: a prospective observational cohort study. Sci Rep 2017;7:3211. 10.1038/s41598-017-03222-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03222-w</ArticleId><ArticleId IdType="pmc">PMC5468303</ArticleId><ArticleId IdType="pubmed">28607467</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith R. What is gillick competence? Hum Vaccin Immunother 2016;12:244&#x2013;7. 10.1080/21645515.2015.1091548</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1091548</ArticleId><ArticleId IdType="pmc">PMC4962726</ArticleId><ArticleId IdType="pubmed">26619366</ArticleId></ArticleIdList></Reference><Reference><Citation>. DOI.Jeschke MG, Chinkes DL, Finnerty CC, et al. . Pathophysiologic response to severe burn injury. Ann Surg 2008;248:387&#x2013;401. 10.1097/SLA.0b013e3181856241</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181856241</ArticleId><ArticleId IdType="pmc">PMC3905467</ArticleId><ArticleId IdType="pubmed">18791359</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnerty CC, Jeschke MG, Herndon DN, et al. . Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med 2008;14:553&#x2013;60. 10.2119/2007-00132.Finnerty</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/2007-00132.Finnerty</ArticleId><ArticleId IdType="pmc">PMC2424320</ArticleId><ArticleId IdType="pubmed">18548133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder PPG, Vlig M, Boekema BKHL, et al. . Persistent systemic inflammation in patients with severe burn injury is accompanied by influx of immature neutrophils and shifts in T cell subsets and cytokine profiles. Front Immunol 2020;11:621222. 10.3389/fimmu.2020.621222</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.621222</ArticleId><ArticleId IdType="pmc">PMC7879574</ArticleId><ArticleId IdType="pubmed">33584717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist M, H&#xe4;stbacka J, Glaumann C, et al. . The time-course of the inflammatory response to major burn injury and its relation to organ failure and outcome. Burns 2019;45:354&#x2013;63. 10.1016/j.burns.2018.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.09.001</ArticleId><ArticleId IdType="pubmed">30274808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Kulp GA, et al. . Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011;6:e21245. 10.1371/journal.pone.0021245</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021245</ArticleId><ArticleId IdType="pmc">PMC3138751</ArticleId><ArticleId IdType="pubmed">21789167</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehne MG, Sablotzki A, Hoffmann A, et al. . Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns 2002;28:535&#x2013;42. 10.1016/S0305-4179(02)00050-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(02)00050-5</ArticleId><ArticleId IdType="pubmed">12220910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur J, Yang HT, Chun W, et al. . Inflammatory cytokines and their prognostic ability in cases of major burn injury. Ann Lab Med 2015;35:105&#x2013;10. 10.3343/alm.2015.35.1.105</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2015.35.1.105</ArticleId><ArticleId IdType="pmc">PMC4272939</ArticleId><ArticleId IdType="pubmed">25553289</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BZ, McAlister S, McGuire HM, et al. . Pediatric burn survivors have long-term immune dysfunction with diminished vaccine response. Front Immunol 2020;11:1481. 10.3389/fimmu.2020.01481</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01481</ArticleId><ArticleId IdType="pmc">PMC7385079</ArticleId><ArticleId IdType="pubmed">32793203</ArticleId></ArticleIdList></Reference><Reference><Citation>Fear VS, Boyd JH, Rea S, et al. . Burn injury leads to increased long-term susceptibility to respiratory infection in both mouse models and population studies. PLoS One 2017;12:e0169302. 10.1371/journal.pone.0169302</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169302</ArticleId><ArticleId IdType="pmc">PMC5221812</ArticleId><ArticleId IdType="pubmed">28068397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft R, Herndon DN, Finnerty CC, et al. . Occurrence of multiorgan dysfunction in pediatric burn patients: incidence and clinical outcome. Ann Surg 2014;259:381&#x2013;7. 10.1097/SLA.0b013e31828c4d04</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828c4d04</ArticleId><ArticleId IdType="pmc">PMC3731402</ArticleId><ArticleId IdType="pubmed">23511841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37272946</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1529-7535</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title><ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Derivation, Validation, and Clinical Relevance of a Pediatric Sepsis Phenotype With Persistent Hypoxemia, Encephalopathy, and Shock.</ArticleTitle><Pagination><StartPage>795</StartPage><EndPage>806</EndPage><MedlinePgn>795-806</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0000000000003292</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Untangling the heterogeneity of sepsis in children and identifying clinically relevant phenotypes could lead to the development of targeted therapies. Our aim was to analyze the organ dysfunction trajectories of children with sepsis-associated multiple organ dysfunction syndrome (MODS) to identify reproducible and clinically relevant sepsis phenotypes and determine if they are associated with heterogeneity of treatment effect (HTE) to common therapies.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter observational cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Thirteen PICUs in the United States.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients admitted with suspected infections to the PICU between 2012 and 2018.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">We used subgraph-augmented nonnegative matrix factorization to identify candidate trajectory-based phenotypes based on the type, severity, and progression of organ dysfunction in the first 72 hours. We analyzed the candidate phenotypes to determine reproducibility as well as prognostic, therapeutic, and biological relevance. Overall, 38,732 children had suspected infection, of which 15,246 (39.4%) had sepsis-associated MODS with an in-hospital mortality of 10.1%. We identified an organ dysfunction trajectory-based phenotype (which we termed persistent hypoxemia, encephalopathy, and shock) that was highly reproducible, had features of systemic inflammation and coagulopathy, and was independently associated with higher mortality. In a propensity score-matched analysis, patients with persistent hypoxemia, encephalopathy, and shock phenotype appeared to have HTE and benefit from adjuvant therapy with hydrocortisone and albumin. When compared with other high-risk clinical syndromes, the persistent hypoxemia, encephalopathy, and shock phenotype only overlapped with 50%-60% of patients with septic shock, moderate-to-severe pediatric acute respiratory distress syndrome, or those in the top tier of organ dysfunction burden, suggesting that it represents a nonsynonymous clinical phenotype of sepsis-associated MODS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We derived and validated the persistent hypoxemia, encephalopathy, and shock phenotype, which is highly reproducible, clinically relevant, and associated with HTE to common adjuvant therapies in children with sepsis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University Feinberg School of Medicine and Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Informatics and Pediatrics, University of Colorado School of Medicine, Aurora, CO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atreya</LastName><ForeName>Mihir</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bubeck Wardenburg</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geva</LastName><ForeName>Alon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computational Health Informatics Program, Boston Children's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anaesthesia, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faustino</LastName><ForeName>E Vincent S</ForeName><Initials>EVS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farris</LastName><ForeName>Reid W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogerson</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sareen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Cohen Children's Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khemani</LastName><ForeName>Robinder G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD105939</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD096402</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Crit Care Med</MedlineTA><NlmUniqueID>100954653</NlmUniqueID><ISSNLinking>1529-7535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="Y">Shock, Septic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="Y">Brain Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Drs. Sanchez-Pinto, Bennett, and Shah&#x2019;s institutions received funding from the National Institute of Child Health and Human Development. Dr. Sanchez-Pinto&#x2019;s institution received funding from the National Institute of General Medical Sciences. Drs. Sanchez-Pinto, Bennett, Luo, Bubeck-Wardenburg, Faustino, Hall, Rogerson, Shah, Weiss, and Khemani received support for article research from the National Institutes of Health (NIH). Dr. Bennett&#x2019;s institution received funding from the National Center for Advancing Translational Sciences and the National Heart, Lung, and Blood Institute. Drs. Luo, Bubeck-Wardenburg, Faustino, Hall, Rogerson, Weiss, and Khemani&#x2019;s institutions received funding from the NIH. Dr. Bubeck-Wardenburg&#x2019;s institution received funding from the National Institute of Allergy and Infectious Diseases; she disclosed that she has a financial relationship with Aridis Pharmaceuticals related to intellectual property owned by the University of Chicago. Dr. Hall received funding from Abbvie, Kiadis, and the American Board of Pediatrics. Dr. Khemani received funding from OrangeMed and Bayer. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37272946</ArticleId><ArticleId IdType="mid">NIHMS1899354</ArticleId><ArticleId IdType="pmc">PMC10540758</ArticleId><ArticleId IdType="doi">10.1097/PCC.0000000000003292</ArticleId><ArticleId IdType="pii">00130478-990000000-00218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matics TJ, Sanchez-Pinto LN: Adaptation and validation of a pediatric Sequential Organ Failure Assessment score and evaluation of the sepsis-3 definitions in critically ill children. JAMA Pediatr. 2017; 171:e172352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Balamuth F, Hensley J, et al. : The epidemiology of hospital death following pediatric severe sepsis: when, why, and how children with sepsis die. Pediatr Crit Care Med. 2017; 18:823&#x2013;830</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581233</ArticleId><ArticleId IdType="pubmed">28549024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Stroup EK, Pendergrast T, et al. : Derivation and validation of novel phenotypes of multiple organ dysfunction syndrome in critically ill children. JAMA Netw Open. 2020; 3:e209271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="pubmed">32780121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, et al. : New or progressive multiple organ dysfunction syndrome in pediatric severe sepsis. Pediatr Crit Care Med. 2017; 18:8&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, et al. ; Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Global epidemiology of pediatric severe sepsis: The sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015; 191:1147&#x2013;1157</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd KE, Johnson SC, Agesa KM, et al. : Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet. 2020; 395:200&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970225</ArticleId><ArticleId IdType="pubmed">31954465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. : Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015; 191:309&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Berg RA, Wessel D, et al. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network: A multicenter network assessment of three inflammation phenotypes in pediatric sepsis-induced multiple organ failure. Pediatr Crit Care Med. 2019; 20:1137&#x2013;1146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121153</ArticleId><ArticleId IdType="pubmed">31568246</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah FA, Meyer NJ, Angus DC, et al. : A research agenda for precision medicine in sepsis and acute respiratory distress syndrome: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021; 204:891&#x2013;901</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534611</ArticleId><ArticleId IdType="pubmed">34652268</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Mao C, Su C, et al. : Sepsis subphenotyping based on organ dysfunction trajectory. Crit Care. 2022; 26:197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250715</ArticleId><ArticleId IdType="pubmed">35786445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. : Endotype transitions during the acute phase of pediatric septic shock reflect changing risk and treatment response. Crit Care Med. 2018; 46:e242&#x2013;e249</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5825261</ArticleId><ArticleId IdType="pubmed">29252929</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Kennedy JN, Wang S, et al. : Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019; 321:2003&#x2013;2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox DB, Lanspa MJ, Kuttler KG, et al. : Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. Intensive Care Med. 2015; 41:814&#x2013;822</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4607311</ArticleId><ArticleId IdType="pubmed">25851384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, et al. : Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019; 200:327&#x2013;335</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680307</ArticleId><ArticleId IdType="pubmed">30789749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Semler M, Qian ET, et al. : Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022;48:1582&#x2013;1592</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510534</ArticleId><ArticleId IdType="pubmed">36152041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Wolfe KS, Hrusch CL, et al. : Temperature trajectory subphenotypes correlate with immune responses in patients with sepsis. Crit Care Med. 2020; 48:1645&#x2013;1653</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837282</ArticleId><ArticleId IdType="pubmed">32947475</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Balamuth F, Chilutti M, et al. : Identification of pediatric sepsis for epidemiologic surveillance using electronic clinical data. Pediatr Crit Care Med. 2020; 21:113&#x2013;121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008717</ArticleId><ArticleId IdType="pubmed">32032262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott HF, Brilli RJ, Paul R, et al. ; Improving Pediatric Sepsis Outcomes (IPSO) Collaborative Investigators: Evaluating pediatric sepsis definitions designed for electronic health record extraction and multicenter quality improvement. Crit Care Med. 2020; 48:e916&#x2013;e926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677030</ArticleId><ArticleId IdType="pubmed">32931197</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. : The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. PLoS Med. 2007; 4:e296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2020495</ArticleId><ArticleId IdType="pubmed">17941714</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno R, Vincent JL, Matos R, et al. : The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a Prospective, Multicentre STUDY. Working group on sepsis related problems of the ESICM. Intensive Care Med. 1999; 25:686&#x2013;696</Citation><ArticleIdList><ArticleId IdType="pubmed">10470572</ArticleId></ArticleIdList></Reference><Reference><Citation>Raith EP, Udy AA, Bailey M, et al. ; Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE): Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017; 317:290&#x2013;300</Citation><ArticleIdList><ArticleId IdType="pubmed">28114553</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Liu VX, Iwashyna TJ, et al. : Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315:762&#x2013;774</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KGM, Altman DG, Reitsma JB, et al. : Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and elaboration. Ann Intern Med. 2015; 162:W1&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMerle KM, Angus DC, Baillie JK, et al. : Sepsis subclasses: A framework for development and interpretation. Crit Care Med. 2021; 49:748&#x2013;759</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627188</ArticleId><ArticleId IdType="pubmed">33591001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruse N, Kooistra EJ, Jansen A, et al. : Clinical sepsis phenotypes in critically ill COVID-19 patients. Crit Care. 2022; 26:244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361232</ArticleId><ArticleId IdType="pubmed">35945618</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee CS, Delucchi K, Parsons PE, et al. ; NHLBI ARDS Network: Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014; 2:611&#x2013;620</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154544</ArticleId><ArticleId IdType="pubmed">24853585</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahmer MK, Yang G, Zhang M, et al. ; RESTORE and BALI study investigators: Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: A latent class analysis. Lancet Respir Med. 2022; 10:289&#x2013;297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8897230</ArticleId><ArticleId IdType="pubmed">34883088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Delucchi KL, Chen Y, et al. : Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: A prospective study. Thorax. 2022; 77:13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688287</ArticleId><ArticleId IdType="pubmed">34253679</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipanah N, Calfee CS: Phenotyping in acute respiratory distress syndrome: State of the art and clinical implications. Curr Opin Crit Care. 2022; 28:1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782441</ArticleId><ArticleId IdType="pubmed">34670998</ArticleId></ArticleIdList></Reference><Reference><Citation>Famous KR, Delucchi K, Ware LB, et al. ; ARDS Network: Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017; 195:331&#x2013;338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5328179</ArticleId><ArticleId IdType="pubmed">27513822</ArticleId></ArticleIdList></Reference><Reference><Citation>Perizes EN, Chong G, Sanchez-Pinto LN: Derivation and validation of vasoactive inotrope score trajectory groups in critically ill children with shock. Pediatr Crit Care Med. 2022; 23:1017&#x2013;1026</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722555</ArticleId><ArticleId IdType="pubmed">36053068</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Kernan KK, Horvat CM, et al. : Why and how is hyperferritinemic sepsis different from sepsis without hyperferritinemia? Pediatr Crit Care Med. 2020; 21:509&#x2013;512</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121152</ArticleId><ArticleId IdType="pubmed">32358338</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Halstead ES, Hall MW, et al. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network Investigators: Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome. Pediatr Crit Care Med. 2017; 18:513&#x2013;523</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457354</ArticleId><ArticleId IdType="pubmed">28410274</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, Kernan KF, Fan Z, et al. : Machine learning derivation of four computable 24-h pediatric sepsis phenotypes to facilitate enrollment in early personalized anti-inflammatory clinical trials. Crit Care. 2022; 26:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9077858</ArticleId><ArticleId IdType="pubmed">35526000</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvat CM, Fabio A, Nagin DS, et al. ; on behalf of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network: Mortality risk in pediatric sepsis based on C-reactive protein and ferritin levels. Pediatr Crit Care Med. 2022; 23:968&#x2013;979</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722561</ArticleId><ArticleId IdType="pubmed">36178701</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold S, Steinmueller M, von Wulffen W, et al. : Lung epithelial apoptosis in influenza virus pneumonia: The role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med. 2008; 205:3065&#x2013;3077</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605231</ArticleId><ArticleId IdType="pubmed">19064696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KL, Suzuki Y, Nakano H, et al. : CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol. 2008; 180:2562&#x2013;2572</Citation><ArticleIdList><ArticleId IdType="pubmed">18250467</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates BM, Staricha KL, Koch CM, et al. : Inflammatory monocytes drive influenza a virus-mediated lung injury in juvenile mice. J Immunol. 2018; 200:2391&#x2013;2404</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860989</ArticleId><ArticleId IdType="pubmed">29445006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V: Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front Immunol. 2020; 11: 1722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417316</ArticleId><ArticleId IdType="pubmed">32849610</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Ferrando C, Mart&#xed;nez D, et al. ; dexamethasone in ARDS network: Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8:267&#x2013;276</Citation><ArticleIdList><ArticleId IdType="pubmed">32043986</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon K, Schlapbach LJ, Akech S, et al. ; Pediatric Sepsis Definition Taskforce of the Society of Critical Care Medicine: Criteria for pediatric sepsis&#x2014;a systematic review and meta-analysis by the pediatric sepsis definition taskforce. Crit Care Med. 2022; 50:21&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670345</ArticleId><ArticleId IdType="pubmed">34612847</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddali MV, Churpek M, Pham T, et al. ; LUNG SAFE Investigators and the ESICM Trials Group: Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: An observational, multicohort, retrospective analysis. Lancet Respir Med. 2022; 10:367&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976729</ArticleId><ArticleId IdType="pubmed">35026177</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlton EF, McHugh WM, McDonough K, et al. : Markers of endothelial dysfunction and cytokines in high-risk pediatric patients with severe sepsis. Am J Respir Crit Care Med. 2020; 201:380&#x2013;384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6999097</ArticleId><ArticleId IdType="pubmed">31597044</ArticleId></ArticleIdList></Reference><Reference><Citation>Badke CM, Carroll MS, Weese-Mayer DE, et al. : Association between heart rate variability and inflammatory biomarkers in critically ill children. Pediatr Crit Care Med. 2022; 23:e289&#x2013;e294</Citation><ArticleIdList><ArticleId IdType="pubmed">35293369</ArticleId></ArticleIdList></Reference><Reference><Citation>Badke CM, Marsillio LE, Carroll MS, et al. : Development of a heart rate variability risk score to predict organ dysfunction and death in critically ill children. Pediatr Crit Care Med. 2021; 22:e437&#x2013;e447</Citation><ArticleIdList><ArticleId IdType="pubmed">33710071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreif N: Learning from an association analysis using propensity scores. Pediatr Crit Care Med. 2021; 22:108810881092&#x2013;108810881092</Citation><ArticleIdList><ArticleId IdType="pubmed">34690327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24589345</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-7241</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><PubDate><Year>2014</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Scandinavian journal of trauma, resuscitation and emergency medicine</Title><ISOAbbreviation>Scand J Trauma Resusc Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Interleukin-6 as inflammatory marker referring to multiple organ dysfunction syndrome in severely injured children.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1757-7241-22-16</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the suggestion that the inflammatory response in traumatized children is functionally unique, prognostic markers predicting pediatric multiple organ failure are lacking. We intended to verify whether Interleukin-6 (IL-6) displays a pivotal role in pediatric trauma similar to adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Traumatized children less than 18 years of age with an Injury Severity Score &gt;9 points and consecutive admission to the hospital's pediatric intensive care unit were included. Organ function was evaluated according to the score by Marshall et al. while IL-6 levels were measured repetitively every morning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">59 traumatized children were included (8.4 &#xb1; 4.4 years; 57.6% male gender). Incidence of MODS was 11.9%. No differences were found referring to age, gender, injury distribution or overall injury severity between children with and without MODS. Increased IL-6 levels during hospital admission were associated with injury severity (Spearman correlation: r = 0.522, p &lt; 0.001), while an inconsistent association towards the development of MODS was proven at that time point (Spearman correlation: r = 0.180, p = 0.231; Pearson's correlation: r = 0.297, p = 0.045). However, increased IL-6 levels during the first two days were no longer associated with the injury severity but a significant correlation to MODS was measured.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The presented prospective study is the first providing evidence for a correlation of IL-6 levels with injury severity and the incidence of MODS in traumatized children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andruszkow</LastName><ForeName>Hagen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Janika</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sasse</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brunnemer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Andruszkow</LastName><ForeName>Julia Helga Karla</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>G&#xe4;nsslen</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Frink</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Trauma, Hand and Reconstructive Surgery, University Medical Center Marburg, Baldingerstr, 35043 Marburg, Germany. frink@med.uni-marburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Trauma Resusc Emerg Med</MedlineTA><NlmUniqueID>101477511</NlmUniqueID><ISSNLinking>1757-7241</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24589345</ArticleId><ArticleId IdType="pmc">PMC3942614</ArticleId><ArticleId IdType="doi">10.1186/1757-7241-22-16</ArticleId><ArticleId IdType="pii">1757-7241-22-16</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Valadka S, Poenaru D, Dueck A. Long-term disability after trauma in children. J Pediatr Surg. 2000;35:684&#x2013;687. doi: 10.1053/jpsu.2000.5943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jpsu.2000.5943</ArticleId><ArticleId IdType="pubmed">10813323</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalamon J, V Bismarck S, Schober PH, Hollwarth ME. Multiple trauma in pediatric patients. Pediatr Surg Int. 2003;19:417&#x2013;423. doi: 10.1007/s00383-003-0954-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00383-003-0954-0</ArticleId><ArticleId IdType="pubmed">12861420</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton SL. Early management of the child with multiple injuries. Clin Orthop Relat Res. 2000;376:6&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906852</ArticleId></ArticleIdList></Reference><Reference><Citation>Musgrave DS, Mendelson SA. Pediatric orthopedic trauma: principles in management. Crit Care Med. 2002;30:S431&#x2013;S443. doi: 10.1097/00003246-200211001-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200211001-00008</ArticleId><ArticleId IdType="pubmed">12528785</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelgawad AA, Kanlic EM. Orthopedic management of children with multiple injuries. J Trauma. 2011;70:1568&#x2013;1574. doi: 10.1097/TA.0b013e318204eafc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318204eafc</ArticleId><ArticleId IdType="pubmed">21817996</ArticleId></ArticleIdList></Reference><Reference><Citation>Letts M, Davidson D, Lapner P. Multiple trauma in children: predicting outcome and long-term results. Can J Surg. 2002;45:126&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686935</ArticleId><ArticleId IdType="pubmed">11939656</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkins CM, Bensard DD, Moore EE, McIntyre RC, Silliman CC, Biffl W, Harken AH, Partrick DA, Offner PJ. The injured child is resistant to multiple organ failure: a different inflammatory response? J Trauma. 2002;53:1058&#x2013;1063. doi: 10.1097/00005373-200212000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200212000-00005</ArticleId><ArticleId IdType="pubmed">12478028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, Glass NL, Yeh TS. Outcome of pediatric patients with multiple organ system failure. Crit Care Med. 1986;14:271&#x2013;274. doi: 10.1097/00003246-198604000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198604000-00002</ArticleId><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Joyal JS, Mariscalco MM, Leteurtre S, Leclerc F, Lacroix J. The pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2009;10:12&#x2013;22. doi: 10.1097/PCC.0b013e31819370a9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31819370a9</ArticleId><ArticleId IdType="pubmed">19057438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JH, Partrick DA, Johnston RB Jr. The inflammatory response to injury in children. Curr Opin Pediatr. 2010;22:315&#x2013;320. doi: 10.1097/MOP.0b013e328338da48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0b013e328338da48</ArticleId><ArticleId IdType="pubmed">20386451</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med. 1994;22:1025&#x2013;1031. doi: 10.1097/00003246-199406000-00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199406000-00023</ArticleId><ArticleId IdType="pubmed">8205810</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore FA, Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995;75:257&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">7899997</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36:691&#x2013;709. doi: 10.1016/j.injury.2004.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.12.037</ArticleId><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25:1789&#x2013;1795. doi: 10.1097/00003246-199711000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199711000-00014</ArticleId><ArticleId IdType="pubmed">9366759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24:1125&#x2013;1128. doi: 10.1097/00003246-199607000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199607000-00010</ArticleId><ArticleId IdType="pubmed">8674323</ArticleId></ArticleIdList></Reference><Reference><Citation>Partrick DA, Moore FA, Moore EE, Biffl WL, Sauaia A, Barnett CC Jr, Jack A. Barney resident research award winner: the inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure. Am J Surg. 1996;172:425&#x2013;429. doi: 10.1016/S0002-9610(96)00252-8. discussed 429-431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(96)00252-8</ArticleId><ArticleId IdType="pubmed">8942538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O&#x2019;Keefe G, Sperry J, Remick D, Tompkins R, Maier RV. Inflammation and the HOST Response to Injury Collaborative Research Program: Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock. 2010;34:346&#x2013;351. doi: 10.1097/SHK.0b013e3181d8e687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181d8e687</ArticleId><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135:291&#x2013;295. doi: 10.1001/archsurg.135.3.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.135.3.291</ArticleId><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med. 2011;26:73&#x2013;87. doi: 10.1177/0885066610384188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066610384188</ArticleId><ArticleId IdType="pmc">PMC6223019</ArticleId><ArticleId IdType="pubmed">21464062</ArticleId></ArticleIdList></Reference><Reference><Citation>Andruszkow H, Lefering R, Frink M, Mommsen P, Zeckey C, Rahe K, Krettek C, Hildebrand F. Survival benefit of helicopter emergency medical services compared to ground emergency medical services in traumatized patients. Crit Care. 2013;17:R124. doi: 10.1186/cc12796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc12796</ArticleId><ArticleId IdType="pmc">PMC4056624</ArticleId><ArticleId IdType="pubmed">23799905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Paffrath T, Linker R, Bouillon B, Neugebauer EA. Deutsche Gesellschaft fur Unfallchirurgie/German Society for Trauma S. Head injury and outcome&#x2013;what influence do concomitant injuries have? J Trauma. 2008;65:1036&#x2013;1043. doi: 10.1097/TA.0b013e318184ee48. discussion 1043-1034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318184ee48</ArticleId><ArticleId IdType="pubmed">19001971</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SP, O&#x2019;Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187&#x2013;196. doi: 10.1097/00005373-197403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197403000-00001</ArticleId><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC, Engelhardt W, Grabitz RG, Faymonville ME, Hornchen H, Messmer BJ, von Bernuth G. Multiple system organ failure after open heart surgery in infants and children. Thorac Cardiovasc Surg. 1993;41:49&#x2013;53. doi: 10.1055/s-2007-1013820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1013820</ArticleId><ArticleId IdType="pubmed">8367856</ArticleId></ArticleIdList></Reference><Reference><Citation>Feickert HJ, Schepers AK, Rodeck B, Geerlings H, Hoyer PF. Incidence, impact on survival, and risk factors for multi-organ system failure in children following liver transplantation. Pediatr Transplant. 2001;5:266&#x2013;273. doi: 10.1034/j.1399-3046.2001.005004266.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-3046.2001.005004266.x</ArticleId><ArticleId IdType="pubmed">11472605</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Bratton SL, Martin LD, Crawford SW, Weiss NS. Outcome of children who require mechanical ventilatory support after bone marrow transplantation. Crit Care Med. 2000;28:830&#x2013;835. doi: 10.1097/00003246-200003000-00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200003000-00036</ArticleId><ArticleId IdType="pubmed">10752837</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas NJ, Lucking SE, Dillon PW, Cilley RE. Is the injured child different or just treated differently with respect to the development of multiple organ dysfunction syndrome? J Trauma. 2003;55:181&#x2013;182. author repy 183-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons WS, Calkins CM, Moore EE, Bensard DD, Partrick DA, McIntyre RC, Harken AH. &#x201c;Resistance&#x201d; to the inflammatory response and multiple organ failure in children. J Trauma. 2003;55:182&#x2013;184. author reply 183-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingarelli B, Hake PW, O&#x2019;Connor M, Burroughs TJ, Wong HR, Solomkin JS, Lentsch AB. Lung injury after hemorrhage is age dependent: role of peroxisome proliferator-activated receptor gamma. Crit Care Med. 2009;37:1978&#x2013;1987. doi: 10.1097/CCM.0b013e31819feb4d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819feb4d</ArticleId><ArticleId IdType="pmc">PMC2765201</ArticleId><ArticleId IdType="pubmed">19384226</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnerty CC, Jeschke MG, Herndon DN, Gamelli R, Gibran N, Klein M, Silver G, Arnoldo B, Remick D, Tompkins RG. Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med. 2008;14:553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424320</ArticleId><ArticleId IdType="pubmed">18548133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, Carles M, Howard M, Pittet JF. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13:R174. doi: 10.1186/cc8152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma. 2008;65:646&#x2013;652. doi: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181820d48</ArticleId><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G, Di Rocco C. Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst. 2005;21:185&#x2013;193. doi: 10.1007/s00381-004-1032-1. discussion 194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00381-004-1032-1</ArticleId><ArticleId IdType="pubmed">15455248</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain C, Cohen D, Phillips R, Ott L, Young B. Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med. 1991;118:225&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1919295</ArticleId></ArticleIdList></Reference><Reference><Citation>Saissy JM, Cellard-Peyle F, Vitris M, Demaziere J, Gaye M, Poli L, Trossaert M, Dieye A, Sarthou JL. Severe malaria in an African seasonal endemic area: comparison of aspects in adults and children and prognostic value of cytokines. Presse Med. 1994;23:1426&#x2013;1430.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824455</ArticleId></ArticleIdList></Reference><Reference><Citation>From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest. 1997;111:744&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118716</ArticleId></ArticleIdList></Reference><Reference><Citation>Strecker W, Gebhard F, Perl M, Rager J, Buttenschon K, Kinzl L, Beck A. Biochemical characterization of individual injury pattern and injury severity. Injury. 2003;34:879&#x2013;887. doi: 10.1016/S0020-1383(03)00022-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(03)00022-6</ArticleId><ArticleId IdType="pubmed">14636727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39&#x2013;45. doi: 10.1001/archsurg.1994.01420250051006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F, Lacroix J, Leclerc F. Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making. 1999;19:399&#x2013;410. doi: 10.1177/0272989X9901900408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9901900408</ArticleId><ArticleId IdType="pubmed">10520678</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33:1484&#x2013;1491. doi: 10.1097/01.CCM.0000170943.23633.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000170943.23633.47</ArticleId><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36950051</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-7031</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of inflammation research</Title><ISOAbbreviation>J Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>Predictive Risk Factors of Pancreatic Exocrine Insufficiency Developed After Acute Pancreatitis: A Retrospective Cohort Study.</ArticleTitle><Pagination><StartPage>1157</StartPage><EndPage>1167</EndPage><MedlinePgn>1157-1167</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/JIR.S392932</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">The aim of this study was to compare the clinical characteristics of acute pancreatitis (AP) patients between those who developed pancreatic exocrine insufficiency (PEI) and those who did not, and to investigate the predictive factors of PEI.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">From October 1st 2019 to July 30th 2021, AP patients admitted at our center were included. The fecal elastase-1 assay was adopted for PEI diagnosis. The clinical characteristics, treatments, and outcomes between the patients with and without PEI were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, 63 males and 42 females were included. There were 27 patients with mild AP, 54 with moderately severe AP, and 24 with severe AP. The median modified computed tomography severity index (MCTSI) was 6.000(4.000, 8.000). During the follow-up, 38 patients developed PEI after AP. The univariate analysis showed that higher ASA grade (P = 0.006), more severe AP (P = 0.000), the presence of multiple organ dysfunction syndrome (P = 0.030), higher MCTSI (P = 0.000), the development of infected pancreatic necrosis (P = 0.002) and local complications (P = 0.000), higher levels of triacylglycerol (P = 0.022), video-assisted retroperitoneal debridement intervention (P = 0.015), and longer intensive care unit stay (P = 0.044) were correlated with PEI development. Furthermore, the logistic regression analyses showed that MCTSI during hospitalization is an independent risk factor for PEI development during the AP recovery period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">ASA grade, severity of AP, multiple organ dysfunction syndrome, MCTSI, infected pancreatic necrosis, local complications, higher levels of triacylglycerol, video-assisted retroperitoneal debridement intervention, and longer intensive care unit stay were potentially associated with PEI development during the AP recovery period. High MCTSI was independently associated with the development of PEI during the AP recovery period, which may help alert to the possibility of PEI to help with its early detection and treatment.</AbstractText><CopyrightInformation>&#xa9; 2023 Guo et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Guo</LastName><ForeName>Yulin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3563-8998</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Acute Pancreatitis Clinical Center of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2299-3977</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Acute Pancreatitis Clinical Center of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1766-0246</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Acute Pancreatitis Clinical Center of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ang</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2018-9678</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Acute Pancreatitis Clinical Center of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Feng</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7412-2455</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Acute Pancreatitis Clinical Center of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fei</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0532-9054</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Acute Pancreatitis Clinical Center of Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>J Inflamm Res</MedlineTA><NlmUniqueID>101512684</NlmUniqueID><ISSNLinking>1178-7031</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute pancreatitis</Keyword><Keyword MajorTopicYN="N">fecal elastase-1</Keyword><Keyword MajorTopicYN="N">modified computed tomography severity index</Keyword><Keyword MajorTopicYN="N">pancreatic exocrine insufficiency</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36950051</ArticleId><ArticleId IdType="pmc">PMC10025014</ArticleId><ArticleId IdType="doi">10.2147/JIR.S392932</ArticleId><ArticleId IdType="pii">392932</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dom&#xed;nguez-Mu&#xf1;oz J, Iglesias-Garc&#xed;a J, Iglesias-Rey M, et al. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2005;21:993&#x2013;1000. doi:10.1111/j.1365-2036.2005.02390.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02390.x</ArticleId><ArticleId IdType="pubmed">15813835</ArticleId></ArticleIdList></Reference><Reference><Citation>Duggan S, Smyth N, O&#x2019;Sullivan M, et al. The prevalence of malnutrition and fat-soluble vitamin deficiencies in chronic pancreatitis. Nutr Clin Pract. 2014;29(3):348&#x2013;354. doi:10.1177/0884533614528361</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0884533614528361</ArticleId><ArticleId IdType="pubmed">24727205</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J, et al. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis. J Clin Gastroenterol. 2018;52(8):e63&#x2013;e72. doi:10.1097/MCG.0000000000000917</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000917</ArticleId><ArticleId IdType="pubmed">28858943</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresnahan K, Tanumihardjo S. Undernutrition, the acute phase response to infection, and its effects on micronutrient status indicators. Adv Nutr. 2014;5(6):702&#x2013;711. doi:10.3945/an.114.006361</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.114.006361</ArticleId><ArticleId IdType="pmc">PMC4224207</ArticleId><ArticleId IdType="pubmed">25398733</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozos I, Marginean O. Links between vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015;2015:109275. doi:10.1155/2015/109275</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/109275</ArticleId><ArticleId IdType="pmc">PMC4427096</ArticleId><ArticleId IdType="pubmed">26000280</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkin BJA, Barkin Jamie S. Chronic pancreatitis and bone disease. J Clin Densitom. 2020;23(2):237&#x2013;243. doi:10.1016/j.jocd.2019.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocd.2019.08.004</ArticleId><ArticleId IdType="pubmed">31558406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintakuya R, Uemura K, Murakami Y, et al. Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. Pancreatology. 2017;17(1):70&#x2013;75. doi:10.1016/j.pan.2016.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2016.10.005</ArticleId><ArticleId IdType="pubmed">27743711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollemans RA, Hallensleben NDL, Mager DJ, et al. Pancreatic exocrine insufficiency following acute pancreatitis: systematic review and study level meta-analysis. Pancreatology. 2018;18:253&#x2013;262. doi:10.1016/j.pan.2018.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2018.02.009</ArticleId><ArticleId IdType="pubmed">29482892</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Mu&#xf1;oz J. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018;34(5):349&#x2013;354. doi:10.1097/MOG.0000000000000459</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000459</ArticleId><ArticleId IdType="pubmed">29889111</ArticleId></ArticleIdList></Reference><Reference><Citation>Laterza L, Scaldaferri F, Bruno G, et al. Pancreatic function assessment. Eur Rev Med Pharmacol Sci. 2013;17(Suppl):65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24443071</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;ser C, Brauer C, Aygen S, et al. Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. Scand J Gastroenterol. 1998;33:327&#x2013;334. doi:10.1080/00365529850170946</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365529850170946</ArticleId><ArticleId IdType="pubmed">9548629</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;ser C, M&#xf6;llgaard A, F&#xf6;lsch U. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996;39:580&#x2013;586. doi:10.1136/gut.39.4.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.39.4.580</ArticleId><ArticleId IdType="pmc">PMC1383273</ArticleId><ArticleId IdType="pubmed">8944569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikkens E, Cahen D, Kuipers E, et al. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24(3):337&#x2013;347. doi:10.1016/j.bpg.2010.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpg.2010.03.006</ArticleId><ArticleId IdType="pubmed">20510833</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks P, Freeman M. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379&#x2013;2400. doi:10.1111/j.1572-0241.2006.00856.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00856.x</ArticleId><ArticleId IdType="pubmed">17032204</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Party of the British Society of Gastroenterology; Association of Surgeons of Great Britain and Ireland; Pancreatic Society of Great Britain and ireland; Association of Upper GI Surgeons of Great Britain and Ireland. UK guidelines for the management of acute pancreatitis. Gut. 2005;Suppl 3:iii1&#x2013;iii9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867800</ArticleId><ArticleId IdType="pubmed">15831893</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102&#x2013;111. doi:10.1136/gutjnl-2012-302779</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302779</ArticleId><ArticleId IdType="pubmed">23100216</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeds J, Oppong K, Sanders D. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011;8:405&#x2013;415. doi:10.1038/nrgastro.2011.91</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2011.91</ArticleId><ArticleId IdType="pubmed">21629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Partelli S, Frulloni L, Minniti C, et al. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Dig Liver Dis. 2012;44(11):945&#x2013;951. doi:10.1016/j.dld.2012.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2012.05.017</ArticleId><ArticleId IdType="pubmed">22749648</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoeni R. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012;262(3):751&#x2013;764. doi:10.1148/radiol.11110947</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.11110947</ArticleId><ArticleId IdType="pubmed">22357880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollen T, Singh V, Maurer R, et al. Comparative evaluation of the modified CT severity index and CT severity index in assessing severity of acute pancreatitis. AJR Am J Roentgenol. 2011;197(2):386&#x2013;392. doi:10.2214/AJR.09.4025</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.09.4025</ArticleId><ArticleId IdType="pubmed">21785084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollemans R, Bakker O, Boermeester M, et al. Superiority of step-up approach vs open necrosectomy in long-term follow-up of patients with necrotizing pancreatitis. Gastroenterology. 2019;156(4):1016&#x2013;1026. doi:10.1053/j.gastro.2018.10.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.10.045</ArticleId><ArticleId IdType="pubmed">30391468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Li J, Cao F, et al. Infection recurrence following minimally invasive treatment in patients with infectious pancreatic necrosis. World J Gastroenterol. 2020;26(22):3087&#x2013;3097. doi:10.3748/wjg.v26.i22.3087</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v26.i22.3087</ArticleId><ArticleId IdType="pmc">PMC7304114</ArticleId><ArticleId IdType="pubmed">32587450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao F, Duan N, Gao C, et al. One-step verse step-up laparoscopic-assisted necrosectomy for infected pancreatic necrosis. J Dig Surg. 2020;37(3):211&#x2013;219. doi:10.1159/000501076</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000501076</ArticleId><ArticleId IdType="pubmed">31269486</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Bai Y, Li Q, et al. Reduced pancreatic exocrine function and organellar disarray in a canine model of acute pancreatitis. PLoS One. 2016;11(2):e0148458. doi:10.1371/journal.pone.0148458</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148458</ArticleId><ArticleId IdType="pmc">PMC4760769</ArticleId><ArticleId IdType="pubmed">26895040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sand J, Nordback I. Acute pancreatitis: risk of recurrence and late consequences of the disease. Nat Rev Gastroenterol Hepatol. 2009;6(8):470&#x2013;477. doi:10.1038/nrgastro.2009.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2009.106</ArticleId><ArticleId IdType="pubmed">19581905</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Wu D, Zeng Y, et al. Pancreatic exocrine function and morphology following an episode of acute pancreatitis. Pancreas. 2012;41(6):922&#x2013;927. doi:10.1097/MPA.0b013e31823d7f2d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0b013e31823d7f2d</ArticleId><ArticleId IdType="pubmed">22481293</ArticleId></ArticleIdList></Reference><Reference><Citation>Czak&#xf3; L, Yamamoto M, Otsuki M. Exocrine pancreatic function in rats after acute pancreatitis. Pancreas. 1997;15:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9211497</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss FU, Laemmerhirt F, Lerch MM. Acute pancreatitis: genetic risk and clinical implications. J Clin Med. 2021;10(2):190. doi:10.3390/jcm10020190</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10020190</ArticleId><ArticleId IdType="pmc">PMC7825757</ArticleId><ArticleId IdType="pubmed">33430357</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, de la Iglesia-Garc&#xed;a D, Baston-Rey I, et al. Exocrine pancreatic insufficiency following acute pancreatitis: systematic review and meta-analysis. Dig Dis Sci. 2019;64:1985&#x2013;2005. doi:10.1007/s10620-019-05568-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05568-9</ArticleId><ArticleId IdType="pmc">PMC6584228</ArticleId><ArticleId IdType="pubmed">31161524</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu J, Zhang J, Ke L, et al. Endocrine and exocrine pancreatic insufficiency after acute pancreatitis: long term follow-up study. BMC Gastroenterol. 2017;17:114. doi:10.1186/s12876-017-0663-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-017-0663-0</ArticleId><ArticleId IdType="pmc">PMC5658961</ArticleId><ArticleId IdType="pubmed">29078749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Fan Y, Pan P, et al. Blood urea nitrogen as a prognostic marker in severe acute pancreatitis. Dis Markers. 2022;2022:7785497. doi:10.1155/2022/7785497</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7785497</ArticleId><ArticleId IdType="pmc">PMC8983180</ArticleId><ArticleId IdType="pubmed">35392494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Hong W, Basharat Z, et al. Blood urea nitrogen as a predictor of severe acute pancreatitis based on the revised Atlanta criteria: timing of measurement and cutoff points. Can J Gastroenterol Hepatol. 2017;2017:9592831. doi:10.1155/2017/9592831</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/9592831</ArticleId><ArticleId IdType="pmc">PMC5406719</ArticleId><ArticleId IdType="pubmed">28487848</ArticleId></ArticleIdList></Reference><Reference><Citation>Garip G, Sarand&#xf6;l E, Kaya E. Effects of disease severity and necrosis on pancreatic dysfunction after acute pancreatitis. World J Gastroenterol. 2013;19:8065&#x2013;8070. doi:10.3748/wjg.v19.i44.8065</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v19.i44.8065</ArticleId><ArticleId IdType="pmc">PMC3848155</ArticleId><ArticleId IdType="pubmed">24307801</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;zenci D, Yaln&#x131;z M, Ispiro&#x11f;lu M. Comparison between prognostic indicators in organ insufficiency with acute pancreatitis. Ulus Travma Acil Cerrahi Derg. 2021;27:410&#x2013;420. doi:10.14744/tjtes.2020.18552</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/tjtes.2020.18552</ArticleId><ArticleId IdType="pubmed">34212994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekaran P, Gupta R, Shenvi S, et al. Prospective comparison of long term outcomes in patients with severe acute pancreatitis managed by operative and non operative measures. Pancreatology. 2015;15:478&#x2013;484. doi:10.1016/j.pan.2015.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2015.08.006</ArticleId><ArticleId IdType="pubmed">26364168</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiamah A, Psaltis E, Crook M, et al. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. Clinic Nutr. 2018;37:1810&#x2013;1822. doi:10.1016/j.clnu.2017.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2017.09.028</ArticleId><ArticleId IdType="pubmed">29056284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce J, Elliott A. Oxidant-impaired intracellular Ca2+ signaling in pancreatic acinar cells: role of the plasma membrane Ca2+-ATPase. Am J Physiol Cell Physiol. 2007;293:C938&#x2013;C950. doi:10.1152/ajpcell.00582.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00582.2006</ArticleId><ArticleId IdType="pubmed">17494627</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdivielso P, Ram&#xed;rez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25:689&#x2013;694. doi:10.1016/j.ejim.2014.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2014.08.008</ArticleId><ArticleId IdType="pubmed">25269432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ockenga J. Importance of nutritional management in diseases with exocrine pancreatic insufficiency. HPB. 2009;Suppl 3:11&#x2013;15. doi:10.1111/j.1477-2574.2009.00134.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1477-2574.2009.00134.x</ArticleId><ArticleId IdType="pmc">PMC2798168</ArticleId><ArticleId IdType="pubmed">20495627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanga RR, Tansel A, Sidiq S, et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(8):1220&#x2013;1228.e4. doi:10.1016/j.cgh.2018.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2018.01.027</ArticleId><ArticleId IdType="pmc">PMC6402774</ArticleId><ArticleId IdType="pubmed">29374614</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AE, Ooka K, Pothoulakis I, et al. Assessment of weight loss and gastrointestinal symptoms suggestive of exocrine pancreatic dysfunction after acute pancreatitis. Clin Transl Gastroenterol. 2020;11(12):e00283. doi:10.14309/ctg.0000000000000283</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000283</ArticleId><ArticleId IdType="pmc">PMC7743841</ArticleId><ArticleId IdType="pubmed">33464001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33246196</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Decreased serial scores of severe organ failure assessments are associated with survival in mechanically ventilated patients; the prospective Maastricht Intensive Care COVID cohort.</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>45</EndPage><MedlinePgn>38-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2020.11.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(20)30761-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">The majority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are admitted to the Intensive Care Unit (ICU) for mechanical ventilation. The role of multi-organ failure during ICU admission as driver for outcome remains to be investigated yet.</AbstractText><AbstractText Label="DESIGN AND SETTING">Prospective cohort of mechanically ventilated critically ill with SARS-CoV-2 infection.</AbstractText><AbstractText Label="PARTICIPANTS AND METHODS">94 participants of the MaastrICCht cohort (21% women) had a median length of stay of 16&#xa0;days (maximum of 77). After division into survivors (n&#xa0;=&#xa0;59) and non-survivors (n&#xa0;=&#xa0;35), we analysed 1555 serial SOFA scores using linear mixed-effects models.</AbstractText><AbstractText Label="RESULTS">Survivors improved one SOFA score point more per 5&#xa0;days (95% CI: 4-8) than non-survivors. Adjustment for age, sex, and chronic lung, renal and liver disease, body-mass index, diabetes mellitus, cardiovascular risk factors, and Acute Physiology and Chronic Health Evaluation II score did not change this result. This association was stronger for women than men (P-interaction&#xa0;=&#xa0;0.043).</AbstractText><AbstractText Label="CONCLUSIONS">The decrease in SOFA score associated with survival suggests multi-organ failure involvement during mechanical ventilation in patients with SARS-CoV-2. Surviving women appeared to improve faster than surviving men. Serial SOFA scores may unravel an unfavourable trajectory and guide decisions in mechanically ventilated patients with SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bels</LastName><ForeName>Julia L M</ForeName><Initials>JLM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: julia.bels@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kuijk</LastName><ForeName>Sander M J</ForeName><Initials>SMJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: sander.van.kuijk@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghossein-Doha</LastName><ForeName>Chahinda</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Department of Cardiology, Maastricht University Medical Centre+, Maastricht, the Netherlands; School for Oncology &amp; Developmental Biology (GROW), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: chahinda.ghossein@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijssen</LastName><ForeName>Fabian H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Pain Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: fabian.tijssen@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gassel</LastName><ForeName>Rob J J</ForeName><Initials>RJJ</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: r.vangassel@maastrichtuniversity.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tas</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: jeanette.tas@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collaborators</LastName><ForeName>MaastrICCht</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnabel</LastName><ForeName>Ronny M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands. Electronic address: r.schnabel@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aries</LastName><ForeName>Marcel J H</ForeName><Initials>MJH</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: marcel.aries@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Poll</LastName><ForeName>Marcel C G</ForeName><Initials>MCG</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: marcel.vande.poll@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmans</LastName><ForeName>Dennis C J J</ForeName><Initials>DCJJ</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands. Electronic address: d.bergmans@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meex</LastName><ForeName>Steven J R</ForeName><Initials>SJR</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht University Medical Centre+, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: steven.meex@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Mook</LastName><ForeName>Walther N K A</ForeName><Initials>WNKA</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School of Health Professions Education, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, the Netherlands. Electronic address: w.van.mook@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Horst</LastName><ForeName>Iwan C C</ForeName><Initials>ICC</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: iwan.vander.horst@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Bussel</LastName><ForeName>Bas C T</ForeName><Initials>BCT</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: bas.van.bussel@mumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="Y">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="Y">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">Repeated data</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SOFA score</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>27</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33246196</ArticleId><ArticleId IdType="pmc">PMC7669472</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2020.11.006</ArticleId><ArticleId IdType="pii">S0883-9441(20)30761-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gattinoni L., Coppola S., Cressoni M., Busana M., Rossi S., Chiumello D. Covid-19 does not lead to a &#x201c;typical&#x201d; acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201(10):1299&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233352</ArticleId><ArticleId IdType="pubmed">32228035</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi Y.M., Murthy S., Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020;46:833&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080134</ArticleId><ArticleId IdType="pubmed">32125458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wang X., Jia X., Li J., Hu K., Chen G., et al. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26:767&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159868</ArticleId><ArticleId IdType="pubmed">32304745</ArticleId></ArticleIdList></Reference><Reference><Citation>Organisation WH Epidemiology: Q&amp;A: similarities and differences - COVID19 and influenza. 2020. https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza viewed 16.04.2020.</Citation></Reference><Reference><Citation>Phua J., Weng L., Ling L., Egi M., Lim C.M., Divatia J.V., et al. Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir Med. 2020;8:506&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198848</ArticleId><ArticleId IdType="pubmed">32272080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis J.P.A., Axfors C., Contoupoulos-Ioannidis D.G. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020;188:109890. doi: 10.1016/j.envres.2020.109890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2020.109890</ArticleId><ArticleId IdType="pmc">PMC7327471</ArticleId><ArticleId IdType="pubmed">32846654</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;91:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol. 2020;5(7):831&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira M., Blin T., Collercandy N., Szychowiak P., Dequin P.F., Jouan Y., et al. Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA. Ann Intensive Care. 2020;10(1):43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167215</ArticleId><ArticleId IdType="pubmed">32307609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihle-Hansen H., Berge T., Tveita A., Ronning E.J., Erno P.E., Andersen E.L., et al. COVID-19: Symptoms, course of illness and use of clinical scoring systems for the first 42 patients admitted to a Norwegian local hospital. Tidsskr Nor Laegeforen. 2020;140(7)</Citation><ArticleIdList><ArticleId IdType="pubmed">32378844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X., Du R., Wang R., Cao T., Guan L., Yang C., et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151343</ArticleId><ArticleId IdType="pubmed">32224074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Yin Y., Hu C., Liu X., Zhang X., Zhou S., et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan. China Crit Care. 2020;24(1):188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192564</ArticleId><ArticleId IdType="pubmed">32354360</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Q., Wang P., Wang X., Qie G., Meng M., Tong X., et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020;130(5):390&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J., et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101507</ArticleId><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Piano S., Dalbeni A., Vettore E., Benfaremo D., Mattioli M., Gambino C.G., et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int. 2020;40(10):2394&#x2013;2406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307119</ArticleId><ArticleId IdType="pubmed">32526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar S., Lecourtois A., Diouf M., Goldberg E., Bourbon C., Arnaud E., et al. The association of lung ultrasound images with COVID-19 infection in an emergency room cohort. Anaesthesia. 2020;75:1620&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300460</ArticleId><ArticleId IdType="pubmed">32520406</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld S.C., Caridi-Scheible M., Blum J.M., Robichaux C., Kraft C., Jacob J.T., et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Critical Care Med. 2020;48(9):e799&#x2013;e804. Online First.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255393</ArticleId><ArticleId IdType="pubmed">32452888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M., et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. The Lancet. 2020;395(10239):1763&#x2013;1770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237188</ArticleId><ArticleId IdType="pubmed">32442528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Xu D., Fu S., Zhang J., Yang X., Xu L., et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: A cross-sectional study. Crit Care. 2020;24(1):219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223395</ArticleId><ArticleId IdType="pubmed">32410714</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R.H., Liu L.M., Yin W., Wang W., Guan L.L., Yuan M.L., et al. Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan. China Ann Am Thorac Soc. 2020;17(7):839&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328178</ArticleId><ArticleId IdType="pubmed">32255382</ArticleId></ArticleIdList></Reference><Reference><Citation>W-j Guan, Ni Z.-y., Hu Y., Liang W.-h., Ou C.-q., He J.-x., et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Tu G.W., Ju M.J., Yu S.J., Zheng J.L., Ma G.G., et al. Comparison of CRB-65 and quick sepsis-related organ failure assessment for predicting the need for intensive respiratory or vasopressor support in patients with COVID-19. J Infect. 2020;81(4):647&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204730</ArticleId><ArticleId IdType="pubmed">32389785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X., Li S., Fang M., Hu M., Bian Y., Ling J., et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Critical Care Med. 2020;48(8):e657&#x2013;e665. Online First.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217128</ArticleId><ArticleId IdType="pubmed">32697506</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonca A., Bruining H., et al. The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on Sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Raith E.P., Udy A.A., Bailey M., McGloughlin S., MacIsaac C., Bellomo R., et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">28114553</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour C.W., Kennedy J.N., Wang S., Chang C.H., Elliott C.F., Xu Z., et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahpori R., Stelfox H.T., Doig C.J., Boiteau P.J., Zygun D.A. Sequential organ failure assessment in H1N1 pandemic planning. Crit Care Med. 2011;39(4):827&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">21263327</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P., et al. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas J., van Gassel R.J.J., Heines S.J.H., Mulder M.M.G., Heijnen N.F.L., Acampo-de Jong M.J., et al. Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrICCht) BMJ Open. 2020;10(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526030</ArticleId><ArticleId IdType="pubmed">32994259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Kang H., Liu X., Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol. 2020;92(6):538&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233289</ArticleId><ArticleId IdType="pubmed">32096564</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman K.J., Greenland S., Lash T.L. 3th ed. Lippincott Williams &amp; Wilkins; 2008. Modern Epidemiology.</Citation></Reference><Reference><Citation>Knaus W.A., Zimmerman J.E., Wagner D.P., Draper E.A., Lawrence D.E. APACHE-acute physiology and chronic health evaluation: A physiologically based classification system. Crit Care Med. 1981;9(8):591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">7261642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli V., Fiorentino M., Cantaluppi V., Gesualdo L., Stallone G., Ronco C., et al. Acute kidney injury in SARS-CoV-2 infected patients. Crit Care. 2020;24(1):155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161433</ArticleId><ArticleId IdType="pubmed">32299479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso F.S., Pereira R., Germano N. Liver injury in critically ill patients with COVID-19: A case series. Crit Care. 2020;24(1):190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198236</ArticleId><ArticleId IdType="pubmed">32366282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei F., Liu Y.M., Zhou F., Qin J.J., Zhang P., Zhu L., et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72(2):389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267515</ArticleId><ArticleId IdType="pubmed">32359177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling L., So C., Shum H.P., Chan P.K.S., Lai C.K.C., Kandamby D.H., et al. Critically ill patients with COVID-19 in Hong Kong: A multicentre retrospective observational cohort study. Crit Care Resusc. 2020;22(2):119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10692444</ArticleId><ArticleId IdType="pubmed">32248675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J., et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194884</ArticleId><ArticleId IdType="pubmed">32311650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira F.L., Bota D.P., Bross A., Melot C., Vincent J.L. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz S., Arabi Y.M., Alhazzani W., Evans L., Citerio G., Fischkoff K., et al. Managing ICU surge during the COVID-19 crisis: Rapid guidelines. Intensive Care Med. 2020;46:1303&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276667</ArticleId><ArticleId IdType="pubmed">32514598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W., Zhang W., Jin R., Liang L., Xu B., Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: A retrospective cohort study. Infect Dis (Lond) 2020:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212540</ArticleId><ArticleId IdType="pubmed">32370577</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Cheng A., Lin S., Zhu Y., Chen G. Individualized prediction nomograms for disease progression in mild COVID-19. J Med Virol. 2020;92:2074&#x2013;2080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267495</ArticleId><ArticleId IdType="pubmed">32369205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L., Van Calster B., Bonten M.M.J., Collins G.S., Debray T.P.A., De Vos M., et al. Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal. BMJ. 2020;369:m1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakike E., Kyriazopoulou E., Tsangaris I., Routsi C., Vincent J.L., Giamarellos-Bourboulis E.J. The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: Analysis through a derivation and a validation cohort. Crit Care. 2019;23(1):387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884794</ArticleId><ArticleId IdType="pubmed">31783881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40278166</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-9116</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Vascular and endovascular surgery</Title><ISOAbbreviation>Vasc Endovascular Surg</ISOAbbreviation></Journal><ArticleTitle>A Systematic Review of Transcarotid Approach for Endovascular Aortic Repair in Treating Aortic Disease.</ArticleTitle><Pagination><StartPage>654</StartPage><EndPage>664</EndPage><MedlinePgn>654-664</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/15385744251335775</ELocationID><Abstract><AbstractText>PurposeThe purpose of this study is to evaluate the feasibility, efficacy, and safety of transcarotid approach endovascular aortic repair (EVAR) in patients where conventional femoral access is not possible.Materials and MethodsA systematic review of all articles discussing transcarotid approach EVAR published in the PubMed, Embase, Ovid, Web of Science, and Cochrane Library databases were conducted. This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.ResultsIn accordance with the inclusion criteria, 17 articles discussing transcarotid approach EVAR were retrieved, encompassing 18 patients. Among these patients, 6 patients were related to ascending aortic disease, including 4 cases of pseudoaneurysms, 1 case of penetrating ulcer, and 1 case of dissection. 9 patients had descending aortic disease, comprising 6 aneurysms, 2 penetrating ulcers, and 1 pseudoaneurysm. There were 3 cases of abdominal aortic disease, including 2 aneurysms and 1 endoleak. Among these patients, 10 cases had access through the left common carotid artery, and 8 cases had access through the right common carotid artery. One patient experienced spinal cord ischemia and subsequently died of multi-organ failure caused by acute pancreatitis. Additionally, there was one case of minor embolization in the nonsurgical carotid supply area. No cerebral infarctions were observed in the vascular territory of the ipsilateral carotid artery at the surgical approach site.ConclusionsResearch on transcarotid approach EVAR is limited and predominantly consists of case reports, with a notable absence of randomized controlled trials. This systematic review suggests that transcarotid approach EVAR may be a viable alternative for selecting patient groups when the conventional femoral artery approach is not feasible. These findings indicate that this method is associated with a relatively manageable perioperative complications and mortality rates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Haofan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9790-4679</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xingyou</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vascular Surgery, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Chengkai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Haoyue</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yihuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinlong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bowen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.</Affiliation><Identifier Source="RINGGOLD">12520</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Zhenya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vasc Endovascular Surg</MedlineTA><NlmUniqueID>101136421</NlmUniqueID><ISSNLinking>1538-5744</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="Y">Endovascular Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019917" MajorTopicYN="Y">Blood Vessel Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001018" MajorTopicYN="Y">Aortic Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017536" MajorTopicYN="Y">Carotid Artery, Common</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002406" MajorTopicYN="Y">Catheterization, Peripheral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094682" MajorTopicYN="N">Endovascular Aneurysm Repair</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alternative approach</Keyword><Keyword MajorTopicYN="N">aortic disease</Keyword><Keyword MajorTopicYN="N">aortoiliac artery occlusion</Keyword><Keyword MajorTopicYN="N">carotid artery access</Keyword><Keyword MajorTopicYN="N">endovascular aortic repair</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>7</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40278166</ArticleId><ArticleId IdType="doi">10.1177/15385744251335775</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33935162</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Association of Early Multiple Organ Dysfunction With Clinical and Functional Outcomes Over the Year Following Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study.</ArticleTitle><Pagination><StartPage>1769</StartPage><EndPage>1778</EndPage><MedlinePgn>1769-1778</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000005055</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Traumatic brain injury is a leading cause of death and disability in the United States. While the impact of early multiple organ dysfunction syndrome has been studied in many critical care paradigms, the clinical impact of early multiple organ dysfunction syndrome in traumatic brain injury is poorly understood. We examined the incidence and impact of early multiple organ dysfunction syndrome on clinical, functional, and disability outcomes over the year following traumatic brain injury.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING">Patients enrolled in the Transforming Clinical Research and Knowledge in Traumatic Brain Injury study, an 18-center prospective cohort study of traumatic brain injury patients evaluated in participating level 1 trauma centers.</AbstractText><AbstractText Label="SUBJECTS">Adult (age &gt; 17 yr) patients with moderate-severe traumatic brain injury (Glasgow Coma Scale &lt; 13). We excluded patients with major extracranial injury (Abbreviated Injury Scale score &#x2265; 3).</AbstractText><AbstractText Label="INTERVENTIONS">Development of early multiple organ dysfunction syndrome, defined as a maximum modified Sequential Organ Failure Assessment score greater than 7 during the initial 72 hours following admission.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">The main outcomes were: hospital mortality, length of stay, 6-month functional and disability domains (Glasgow Outcome Scale-Extended and Disability Rating Scale), and 1-year mortality. Secondary outcomes included: ICU length of stay, 3-month Glasgow Outcome Scale-Extended, 3-month Disability Rating Scale, 1-year Glasgow Outcome Scale-Extended, and 1-year Disability Rating Scale. We examined 373 subjects with moderate-severe traumatic brain injury. The mean (sd) Glasgow Coma Scale in the emergency department was 5.8 (3.2), with 280 subjects (75%) classified as severe traumatic brain injury (Glasgow Coma Scale 3-8). Among subjects with moderate-severe traumatic brain injury, 252 (68%) developed early multiple organ dysfunction syndrome. Subjects that developed early multiple organ dysfunction syndrome had a 75% decreased odds of a favorable outcome (Glasgow Outcome Scale-Extended 5-8) at 6 months (adjusted odds ratio, 0.25; 95% CI, 0.12-0.51) and increased disability (higher Disability Rating Scale score) at 6 months (adjusted mean difference, 2.04; 95% CI, 0.92-3.17). Subjects that developed early multiple organ dysfunction syndrome experienced an increased hospital length of stay (adjusted mean difference, 11.4 d; 95% CI, 7.1-15.8), with a nonsignificantly decreased survival to hospital discharge (odds ratio, 0.47; 95% CI, 0.18-1.2).</AbstractText><AbstractText Label="CONCLUSIONS">Early multiple organ dysfunction following moderate-severe traumatic brain injury is common and independently impacts multiple domains (mortality, function, and disability) over the year following injury. Further research is necessary to understand underlying mechanisms, improve early recognition, and optimize management strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnamoorthy</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC..</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temkin</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komisarow</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korley</LastName><ForeName>Fred K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laskowitz</LastName><ForeName>Daniel T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC..</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartz</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raghunathan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC..</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Amy J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vavilala</LastName><ForeName>Monica S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>and the Transforming Clinical Research and Knowledge in TBI (TRACK-TBI) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS109274</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085542" MajorTopicYN="Y">Functional Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015600" MajorTopicYN="N">Glasgow Coma Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023261" MajorTopicYN="N">Glasgow Outcome Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Drs. Krishnamoorthy&#x2019;s and Foreman&#x2019;s institutions received funding from the National Institutes of Health (NIH). Drs. Krishnamoorthy, Temkin, Foreman, Goldstein, and Vavilala received support for article research from the NIH. Dr. Temkin&#x2019;s institution also received funding from the U.S. Federal Government; she received funding from several pharmaceutical companies and the University of Southern California. Dr. Foreman&#x2019;s institution received funding from the National Institute of Neurological Disorders and Stroke, the Department of Defense, and the National Science Foundation; he received funding from UCB Pharma. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33935162</ArticleId><ArticleId IdType="mid">NIHMS1682406</ArticleId><ArticleId IdType="pmc">PMC8448900</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000005055</ArticleId><ArticleId IdType="pii">00003246-202110000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention (2019). Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths&#x2014;United States, 2014. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.</Citation></Reference><Reference><Citation>Mascia L, Sakr Y, Pasero D, Payen D, Reinhart K, Vincent JL. Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study. Intensive Care Med. 2008;34(4):720&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">18175107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar SN, Millham FH, Chang Y, et al.Presenting blood pressure in traumatic brain injury: a bimodal distribution of death. J Trauma. 2011;71(5):1179&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">21502878</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremitsky E, Omert L, Dunham CM, Protetch J, Rodriguez A. Harbingers of poor outcome the day after severe brain injury: hypothermia, hypoxia, and hypoperfusion. J Trauma. 2003;54(2):312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">12579057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner M, Stein DM, Hu PF, Aarabi B, Sheth K, Scalea TM. Traditional systolic blood pressure targets underestimate hypotension-induced secondary brain injury. J Trauma Acute Care Surg. 2012;72(5):1135&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22673237</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry C, Ley EJ, Bukur M, et al.Redefining hypotension in traumatic brain injury. Injury. 2012;43(11):1833&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pubmed">21939970</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray GD, Butcher I, McHugh GS, et al.Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma. 2007;24(2):329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">17375997</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisiku IP, Yamal JM, Doshi P, et al.The incidence of ARDS and associated mortality in severe TBI using the Berlin definition. J Trauma Acute Care Surg. 2016;80(2):308&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731296</ArticleId><ArticleId IdType="pubmed">26491799</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EM, Bellomo R, Nichol A, Harley N, Macisaac C, Cooper DJ. The incidence of acute kidney injury in patients with traumatic brain injury. Ren Fail. 2010;32(9):1060&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">20863210</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral L, Javierre CF, Ventura JL, Marcos P, Herrero JI, Manez R. Impact of non-neurological complications in severe traumatic brain injury outcome. Crit Care. 2012;16(2):R44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681369</ArticleId><ArticleId IdType="pubmed">22410278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramtinfar S, Chabok SY, Chari AJ, Reihanian Z, Leili EK, Alizadeh A. Early detection of nonneurologic organ failure in patients with severe traumatic brain injury: Multiple organ dysfunction score or sequential organ failure assessment? Indian J Crit Care Med. 2016;20(10):575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073771</ArticleId><ArticleId IdType="pubmed">27829712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodien YG, McCrea M, Dikmen S, et al.Optimizing Outcome Assessment in Multicenter TBI Trials: Perspectives From TRACK-TBI and the TBI Endpoints Development Initiative. J Head Trauma Rehabil. 2018;33(3):147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5940527</ArticleId><ArticleId IdType="pubmed">29385010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde EA, Whiteneck GG, Bogner J, et al.Recommendations for the use of common outcome measures in traumatic brain injury research. Arch Phys Med Rehabil. 2010;91(11):1650&#x2013;1660 e1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21044708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler AA 3rd, Truwit JD, Hite RD, et al.Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322(13):1261&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777268</ArticleId><ArticleId IdType="pubmed">31573637</ArticleId></ArticleIdList></Reference><Reference><Citation>Javed A, Guirgis FW, Sterling SA, et al.Clinical predictors of early death from sepsis. J Crit Care. 2017;42:30&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733694</ArticleId><ArticleId IdType="pubmed">28668774</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevskis EE, Pandharipande PP, Graves AJ, et al.Validity of a Modified Sequential Organ Failure Assessment Score Using the Richmond Agitation-Sedation Scale. Crit Care Med. 2016;44(1):138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748963</ArticleId><ArticleId IdType="pubmed">26457749</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmatinejad Z, Reihani H, Tohidinezhad F, et al.Predictive performance of the SOFA and mSOFA scoring systems for predicting in-hospital mortality in the emergency department. Am J Emerg Med. 2019;37(7):1237&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">30213476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23(1):374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880479</ArticleId><ArticleId IdType="pubmed">31775846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Hwang H, Yamal JM, et al.IMPACT probability of poor outcome and plasma cytokine concentrations are associated with multiple organ dysfunction syndrome following traumatic brain injury. J Neurosurg. 2019;131(6):1931&#x2013;1937.</Citation><ArticleIdList><ArticleId IdType="pubmed">30641838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeole U, Krishnakumar M, Gopalakrishna KN, Sekar A, Sadashiva N, Shukla D. Surgical outcomes in traumatic brain injuries with bilateral mass occupying lesions. Analysis of prognostic factors. Clin Neurol Neurosurg. 2020;196:106017.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619900</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosner MJ, Newsome HH, Becker DP. Mechanical brain injury: the sympathoadrenal response. J Neurosurg. 1984;61(1):76&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">6726414</ArticleId></ArticleIdList></Reference><Reference><Citation>Koiv L, Merisalu E, Zilmer K, Tomberg T, Kaasik AE. Changes of sympatho-adrenal and hypothalamo-pituitary-adrenocortical system in patients with head injury. Acta Neurol Scand. 1997;96(1):52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9262133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizoli SB, Jaja BN, Di Battista AP, et al.Catecholamines as outcome markers in isolated traumatic brain injury: the COMA-TBI study. Crit Care. 2017;21(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322658</ArticleId><ArticleId IdType="pubmed">28228155</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald SJ, Sharkey JM, Sun M, et al.Beyond the Brain: Peripheral Interactions after Traumatic Brain Injury. J Neurotrauma. 2020;37(5):770&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">32041478</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich M, Wafaisade A, Mansuri A, et al.Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA- Scores. Scand J Trauma Resusc Emerg Med. 2016;24(1):130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094147</ArticleId><ArticleId IdType="pubmed">27809885</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al.The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41(1):11&#x2013;17; discussion 17-19.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218290</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt B, Klingelhofer J, Perkes I, Czosnyka M. Cerebral autoregulatory response depends on the direction of change in perfusion pressure. J Neurotrauma. 2009;26(5):651&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">19281414</ArticleId></ArticleIdList></Reference><Reference><Citation>Casault C, Al Sultan AS, Banoei M, Couillard P, Kramer A, Winston BW. Cytokine Responses in Severe Traumatic Brain Injury: Where There Is Smoke, Is There Fire? Neurocrit Care. 2019;30(1):22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29569129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16294072</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5282</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Prone positioning improves oxygenation in post-traumatic lung injury--a prospective randomized trial.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>343</EndPage><MedlinePgn>333-41; discussion 341-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In a prospective randomized trial the effect of prone positioning on the duration of mechanical ventilation was evaluated in multiple trauma patients and was compared with patients ventilated in supine position.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Multiple trauma patients of the intensive care units of two university hospitals were considered eligible if they met the criteria for acute lung injury or the acute respiratory distress syndrome. Patients in the prone group (N = 21) were kept prone for at least eight hours and a maximum of 23 hours per day. Prone positioning was continued until a PaO2:FiO2 ratio of more than 300 was present in prone as well as supine position over a period of 48 hours. Patients in the supine group (N = 19) were positioned according to standard care guidelines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The duration of ventilatory support did not differ significantly (30 +/- 17 days in the prone group and 33 +/- 23 days in the supine group). Worst case analysis (death and deterioration of gas exchange) displayed ventilatory support for 41 +/- 29 days in the prone group and 61 +/- 35 days in the supine group (p = 0.06). The PaO2:FiO2 ratio increased significantly more in the prone group in the first four days (p = 0.03). The prevalence of Acute Respiratory Distress Syndrome (ARDS) following acute lung injury (p = 0.03) and the prevalence of pneumonia (p = 0.048) were reduced also. One patient in the prone and three patients in the supine group died due to multi organ failure (p = 0.27).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intermittent prone positioning was not able to reduce the duration of mechanical ventilation in this limited number of patients. However the oxygenation improved significantly over the first four days of treatment, and the prevalence of ARDS and pneumonia were reduced.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voggenreiter</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Hospital Mannheim, 68135 Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aufmkolk</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stiletto</LastName><ForeName>Raphael J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Baacke</LastName><ForeName>Markus G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Waydhas</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ose</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bock</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gotzen</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Obertacke</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Nast-Kolb</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011175" MajorTopicYN="N">Positive-Pressure Respiration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016684" MajorTopicYN="Y">Prone Position</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011659" MajorTopicYN="N">Pulmonary Gas Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016683" MajorTopicYN="N">Supine Position</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16294072</ArticleId><ArticleId IdType="doi">10.1097/01.ta.0000179952.95921.49</ArticleId><ArticleId IdType="pii">00005373-200508000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37700441</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2163-0763</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The journal of trauma and acute care surgery</Title><ISOAbbreviation>J Trauma Acute Care Surg</ISOAbbreviation></Journal><ArticleTitle>Association of fibrinolysis phenotype with patient outcomes following traumatic brain injury.</ArticleTitle><Pagination><StartPage>482</StartPage><EndPage>486</EndPage><MedlinePgn>482-486</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0000000000004122</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Impaired coagulation is associated with elevated risk of mortality in trauma patients. Prior studies have demonstrated increased mortality in patients with hyperfibrinolysis (HF) and fibrinolysis shutdown (SD). In addition, prior studies have demonstrated no effect of tranexamic acid (TXA) on fibrinolysis phenotypes. We examined the association of admission fibrinolysis phenotype with traumatic brain injury (TBI) patient outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were extracted from a placebo-controlled multicenter clinical trial. Patients &#x2265;15 years with TBI (Glasgow Coma Scale score, 3-12) and systolic blood pressure &#x2265;90 mm Hg were randomized in the out-of-hospital setting to receive placebo bolus/placebo infusion (Placebo), 1 gram (g) TXA bolus/1 g TXA infusion (bolus maintenance [BM]); or 2 g TXA bolus/placebo infusion (bolus only [BO]). Fibrinolysis phenotypes on admission were determined by clot lysis at 30 minutes (LY30): SD, &#x2264;0.8%; physiologic, 0.9% to 2.9%; HF, &#x2265;3%. Logistic regression was used to control for age, sex, penetrating injury, Injury Severity Score, maximum head AIS, and TXA treatment group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven hundred forty-seven patients met inclusion criteria. Fibrinolysis shutdown was the most common phenotype in all treatment groups and was associated with increased age, Injury Severity Score, and presence of intracranial hemorrhage (ICH). Inpatient mortality was 15.2% for SD and HF, and 10.6% for physiologic ( p = 0.49). No differences in mortality, disability rating scale at 6 months, acute kidney injury, acute respiratory distress syndrome, or multi-organ failure were noted between fibrinolysis phenotypes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SD is the most common phenotype expressed in moderate to severe TBI. In TBI, there is no association between fibrinolysis phenotype and mortality or other major complications.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Prognostic and Epidemiological; Level IV.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durbin</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Surgery, Oregon Health &amp; Science University (S.D., A.B., A.J., M.A.S.), Portland, Oregon; Department of Surgery, The Queen's Medical Center (A.B.), Honolulu, Hawaii; Department of Surgery, University of Texas Health Houston (B.C.), Houston, Texas; and Department of Surgery, The University of Chicago Medicine &amp; Biological Sciences (S.R.), Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Alicia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cotton</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rowell</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Martin A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL077866</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077871</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077887</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077863</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077873</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077881</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma Acute Care Surg</MedlineTA><NlmUniqueID>101570622</NlmUniqueID><ISSNLinking>2163-0755</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005342" MajorTopicYN="N">Fibrinolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001778" MajorTopicYN="Y">Blood Coagulation Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of Interest: All JTACS Disclosure forms have been supplied and are provided as supplemental digital content.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37700441</ArticleId><ArticleId IdType="mid">NIHMS1927958</ArticleId><ArticleId IdType="pmc">PMC10922039</ArticleId><ArticleId IdType="doi">10.1097/TA.0000000000004122</ArticleId><ArticleId IdType="pii">01586154-202403000-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moore HB, Moore EE, Liras I, Gonzalez E, Harvin J, Holcomb J, et al. Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients. J Am Coll Surg. 2016;222(4):347&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4834914</ArticleId><ArticleId IdType="pubmed">26920989</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair KA, Farrell DH, McCully BH, Rick EA, Dewey E, Hilliard C, et al. Fibrinolytic Activation in Patients with Progressive Intracranial Hemorrhage after Traumatic Brain Injury. J Neurotrauma. 2021;38(8):960&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054516</ArticleId><ArticleId IdType="pubmed">31382848</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque P, Calvo A, Lockie C, Sch&#xf6;chl H. Pathophysiology of Trauma-Induced Coagulopathy. Transfus Med Rev. 2021;35(4):80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">34610877</ArticleId></ArticleIdList></Reference><Reference><Citation>Maegele M, Aversa J, Marsee MK, McCauley R, Chitta S, Vyakaranam S, et al. Changes in Coagulation following Brain Injury. Semin Thromb Hemost. 2020;46(2):155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">32160642</ArticleId></ArticleIdList></Reference><Reference><Citation>Coagulopathy Maegele M. and Progression of Intracranial Hemorrhage in Traumatic Brain Injury: Mechanisms, Impact, and Therapeutic Considerations. Neurosurgery. 2021;89(6):954&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">34676410</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakae R, Murai Y, Morita A, Yokobori S. Coagulopathy and Traumatic Brain Injury: Overview of New Diagnostic and Therapeutic Strategies. Neurol Med Chir (Tokyo). 2022;62(6):261&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259082</ArticleId><ArticleId IdType="pubmed">35466118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhang F, Dong JF. Coagulopathy induced by traumatic brain injury: systemic manifestation of a localized injury. Blood. 2018;131(18):2001&#x2013;2006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934798</ArticleId><ArticleId IdType="pubmed">29507078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashuk JL, Moore EE, Sawyer M, Wohlauer M, Pezold M, Barnett C, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg. 2010;252(3):434&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739843</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon AL, McCully BH, Rick EA, Dewey E, Farrell DH, Morrison L, et al. Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury. J Trauma Acute Care Surg. 2020;89(5):900&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878849</ArticleId><ArticleId IdType="pubmed">33105308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowell SE, Meier EN, McKnight B, Kannas D, May S, Sheeham S, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489866</ArticleId><ArticleId IdType="pubmed">32897344</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore HB, Moore EE, Gonzalez E, Chapman M, Chin T, Silliman C, et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6):811&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4370273</ArticleId><ArticleId IdType="pubmed">25051384</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. Persistent Fibrinolysis Shutdown Is Associated with Increased Mortality in Severely Injured Trauma Patients. J Am Coll Surg. 2017;224(4):575&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">28017804</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizoso JP, Moore HB, Moore EE, Gilna G, Ghasabyan A, Chandler J, et al. Traumatic brain injury provokes low fibrinolytic activity in severely injured patients. J Trauma Acute Care Surg. 2022;93(1):8&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">35170585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakae R, Fujiki Y, Takayama Y, Kanaya T, Igarashi Y, Suzuki G, et al. Age-Related Differences in the Time Course of Coagulation and Fibrinolytic Parameters in Patients with Traumatic Brain Injury. International Journal of Molecular Sciences. 2020; 21(16):5613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460662</ArticleId><ArticleId IdType="pubmed">32764459</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao B, Xue T, Rong X, Yang Y, Wang Z, Chen Z, et al. Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randomized Controlled Trials. J Stroke Cerebrovasc Dis. 2021;30(1):105436.</Citation><ArticleIdList><ArticleId IdType="pubmed">33171426</ArticleId></ArticleIdList></Reference><Reference><Citation>Griemert EV, Schwarzmaier SM, Hummel R, G&#xf6;lz C, Yang D, Neuhaus W, et al. Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury. Ann Neurol. 2019;85(5):667&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593843</ArticleId><ArticleId IdType="pubmed">30843275</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts I, Belli A, Brenner A, Chaudhri R, Fawole B, Harris T, et al. (2018). Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Wellcome Open Res, 3, 86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081978</ArticleId><ArticleId IdType="pubmed">30175246</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EE, Moore HB, Kornblith L, Neal M, Hoffman M, Mutch N, et al. Trauma-induced coagulopathy [published correction appears in Nat Rev Dis Primers. 2022 Apr 22;8(1):25]. Nat Rev Dis Primers. 2021;7(1):30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107773</ArticleId><ArticleId IdType="pubmed">33927200</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson TN, Farrell DH, Rowell SE. Fibrinolysis in Traumatic Brain Injury: Diagnosis, Management, and Clinical Considerations. Semin Thromb Hemost. 2021;47(5):527&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">33878779</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11(2):307&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">23176206</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels JM, Moore EE, Silliman CC, Banerjee A, Cohen M, Ghasabyan A, et al. Severe traumatic brain injury is associated with a unique coagulopathy phenotype [published correction appears in J Trauma Acute Care Surg. 2020 Aug;89(2):419]. J Trauma Acute Care Surg. 2019;86(4):686&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6682404</ArticleId><ArticleId IdType="pubmed">30601456</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada T, Gando S, Maekaw K, Katabami K, Sageshima H, Hayakawa M, et al. Disseminated intravascular coagulation with increased fibrinolysis during the early phase of isolated traumatic brain injury. Crit Care. 2017;21(1):219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568862</ArticleId><ArticleId IdType="pubmed">28826407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucher D, Harmon L, Myer B, Ngyuen A, Rankin T, Cook A, et al. Critical traumatic brain injury is associated with worse coagulopathy. J Trauma Acute Care Surg. 2021;91(2):331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">34397954</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore HB, Moore EE, Huebner BR, Stettler GR, Nunns GR, Einersen PM, et al. Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis. J Surg Res. 2017;220:438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677580</ArticleId><ArticleId IdType="pubmed">28755903</ArticleId></ArticleIdList></Reference><Reference><Citation>Cralley A, Moore E, Coleman J, Vigneshwar N, Bartley M, Kissau D, et al. Hemorrhagic shock and tissue injury provoke distinct components of trauma-induced coagulopathy in a swine model. Eur J Trauma Emerg Surg. 2022;10.1007/s00068-022-02148-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-022-02148-x</ArticleId><ArticleId IdType="pmc">PMC10802987</ArticleId><ArticleId IdType="pubmed">36319860</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson J, Kaufman H, Moake J, O&#x2019;Gorman T, Hoots K, Wagner K, et al. The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery. 1989;24(6):825&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">2747858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada T, Shiraishi A, Gando S, Yamakawa K, Fujishima S, Saitoh D, et al. Pathophysiology of Coagulopathy Induced by Traumatic Brain Injury Is Identical to That of Disseminated Intravascular Coagulation With Hyperfibrinolysis. Front Med (Lausanne). 2021;8:767637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634586</ArticleId><ArticleId IdType="pubmed">34869481</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers SP, Dyer MR, Hassoune A, Brown JB, Sperry JL, Meyer MP, et al. (2020). Correlation of Thromboelastography with Apparent Rivaroxaban Concentration: Has Point-of-Care Testing Improved? Anesthesiology, 132(2), 280&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">31939843</ArticleId></ArticleIdList></Reference><Reference><Citation>Stillson JE, Bunch CM, Gillespie L, Khan R, Wierman M, Pulvirenti J, et al. (2021). Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage. Seminars in thrombosis and hemostasis, 47(4), 442&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">33607668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34054381</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1592-9558</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>Annals of burns and fire disasters</Title><ISOAbbreviation>Ann Burns Fire Disasters</ISOAbbreviation></Journal><ArticleTitle>Inflammatory and coagulative pathophysiology for the management of burn patients with COVID-19: systematic review of the evidence.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>9</EndPage><MedlinePgn>3-9</MedlinePgn></Pagination><Abstract><AbstractText>The pathogenesis of coronavirus disease 2019 (COVID-19) involves a prominent innate immune response to SARS-CoV-2 infection, including inflammatory cytokines, chemokines, the complement system and acute phase proteins. This hyperinflammatory response predisposes patients to thromboembolic disease, acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome. In burn injuries, damaged tissues induce a local and systemic inflammatory response through pathways associated to COVID-19. As such, a COVID-19 positive patient sustaining burn injuries may have an amplified response to the burn insult due to their baseline hyperinflammatory and hypercoagulable states. Burn patients may have compromised physiological reserve to withstand the insult of surgical intervention before reaching clinical instability. The concurrent pathogenesis of COVID-19 and the inflammatory response in burn injury have serious implications on the management of burn patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Euro-Mediterranean Council for Burns and Fire Disasters.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Benna</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Plastic and Reconstructive Surgery, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Ann Burns Fire Disasters</MedlineTA><NlmUniqueID>101251186</NlmUniqueID><ISSNLinking>1592-9558</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText>L&#x2019;infection par COVID- 19 peut entra&#xee;ner une r&#xe9;ponse explosive du syst&#xe8;me immunitaire avec s&#xe9;cr&#xe9;tion/activation de cytokines, ch&#xe9;mokines, compl&#xe9;ment et prot&#xe9;ines de l&#x2019;inflammation. Cette r&#xe9;ponse inflammatoire rend le patient &#xe0; risque de ph&#xe9;nom&#xe8;nes thrombo- emboliques, de l&#xe9;sions respiratoire pouvant conduire &#xe0; un SDRA et de d&#xe9;faillance multivisc&#xe9;rale. Cette cascade est proche de celle observ&#xe9;e en cas de br&#xfb;lure &#xe9;tendue si bien que les patients br&#xfb;l&#xe9;s- COVID19 pourraient avoir une r&#xe9;ponse immunitaire encore plus intense et n&#x2019;avoir plus aucune &#xab; r&#xe9;serve de d&#xe9;fense &#xbb; quand il faudra les op&#xe9;rer. La concomitance br&#xfb;lure- COVID19 peut ainsi avoir des implications majeures quant &#xe0; la prise en charge de la br&#xfb;lure.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Euro-Mediterranean Council for Burns and Fire Disasters.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">acute phase proteins</Keyword><Keyword MajorTopicYN="N">blood coagulation disorders</Keyword><Keyword MajorTopicYN="N">burn</Keyword><Keyword MajorTopicYN="N">chemokines</Keyword><Keyword MajorTopicYN="N">complement system proteins</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34054381</ArticleId><ArticleId IdType="pmc">PMC8126364</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Benna S. Pathophysiology of coronavirus disease 2019 for wound care professionalsX. Int Wound J. 2020;17:1935&#x2013;1940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536990</ArticleId><ArticleId IdType="pubmed">32986928</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S, Gohritz A. Availability of COVID-19 information from national and international burn society websites. Ann Burns Fire Disasters. 2020;33:177&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680204</ArticleId><ArticleId IdType="pubmed">33304206</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S, Gohritz A. Availability of COVID-19 information from national plastic surgery society websites. Ann Plast Surg. 2020;85:S171&#x2013;S171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299107</ArticleId><ArticleId IdType="pubmed">32379070</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Availability of COVID-19 information from national and international aesthetic surgery society websites. Aesthetic Plast Surg. 2020;44:1043&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7216851</ArticleId><ArticleId IdType="pubmed">32399908</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldometer: COVID-19 Coronavirus Pandemic.  [27th August 2020]; Available from: https://www.worldometers.info/coronavirus/ .</Citation></Reference><Reference><Citation>Al-Benna S. Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. Obes Med. doi.org/10.1016/j.obmed.2020.100283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368415</ArticleId><ArticleId IdType="pubmed">32835126</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020X;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75:2950&#x2013;2973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142:68&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">32293910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist M, H&#xe4;stbacka J, Glaumann C, Freden F. The time-course of the inflammatory response to major burn injury and its relation to organ failure and outcome. Burns. 2020;45:354&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">30274808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte M, Sorkin M, Al-Benna S, Stupka J. Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5. Springerplus. 2014;2:234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671105</ArticleId><ArticleId IdType="pubmed">23750330</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinstraesser L, Sorkin M, Jacobsen F, Al-Benna S. Evaluation of signal transduction pathways after transient cutaneous adenoviral gene delivery. BMC Immunol. 2011;12:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037344</ArticleId><ArticleId IdType="pubmed">21255430</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinstraesser L, Kraneburg UM, Hirsch T, Kesting M. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int J Mol Sci. 2009;10(9):3951&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2769137</ArticleId><ArticleId IdType="pubmed">19865528</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinstraesser L, Rittig A, Gevers K, Sorkin M. A human full-skin culture system for interventional studies. Eplasty. 2009;9:e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627306</ArticleId><ArticleId IdType="pubmed">19198642</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiol. 2011;216:322&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">20828865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesting MR, Loeffelbein DJ, Classen M, Slotta-Huspenina J. Repair of oronasal fistulas with human amniotic membrane in minipigs. Br J Oral Maxillofac Surg. 2010;48:131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">19477056</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilkorn DJ, Citak M, Fehmer T, Ring A. Characteristics and differences in necrotizing fasciitis and gas forming myonecrosis: a series of 36 patients. Scand J Surg. 2012;101:51&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">22414469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Finnerty CC, Kraft R. Survivors versus nonsurvivors postburn: differences in inflammatory and hypermetabolic trajectories. Ann Surg. 2014;259:814&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732513</ArticleId><ArticleId IdType="pubmed">23579577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei S, Jiang F, Su W, Chen C. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. E Clinical Medicine. 2020;21:100331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128617</ArticleId><ArticleId IdType="pubmed">32292899</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID Surg Collaborative: Mortality and pulmonary complications in patients undergoing surgery with perioperative SARSCoV-2 infection: an international cohort study . Lancet. 2020;396:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259900</ArticleId><ArticleId IdType="pubmed">32479829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LN, Tran DH, Dong KH. Prognosis value of serum cytokine levels among burn-induced ards patients. Ann Burns Fire Disasters. 2018;31:185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367859</ArticleId><ArticleId IdType="pubmed">30863250</ArticleId></ArticleIdList></Reference><Reference><Citation>Pileri D, Accardo Palombo A, D&#x2019;Amelio L, D&#x2019;Arpa N. Concentrations of cytokines IL-6 and IL-10 in plasma of burn patients: their relationship to sepsis and outcome. Ann Burns Fire Disasters. 2008;21:182&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188197</ArticleId><ArticleId IdType="pubmed">21991134</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Hafez NM, Saleh Hassan Y, El-Metwally TH. A study on biomarkers, cytokines, and growth factors in children with burn injuries. Ann Burns Fire Disasters. 2007;20:89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188064</ArticleId><ArticleId IdType="pubmed">21991076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddoura I, Abu-Sittah G, Ibrahim A, Karamanoukian R, Papazian N. Burn injury: review of pathophysiology and therapeutic modalities in major burns. Ann Burns Fire Disasters. 2017;30:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627559</ArticleId><ArticleId IdType="pubmed">29021720</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewo PI, Fadeyibi IO. Progress in burns research: a review of advances in burn pathophysiology. Ann Burns Fire Disasters. 2015;28:105&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837486</ArticleId><ArticleId IdType="pubmed">27252608</ArticleId></ArticleIdList></Reference><Reference><Citation>Aditianingsih D, Sinaga YB, Kartolo WY, Adiwongso ES, Madjid AS. Respiratory and coagulation dysfunctions on admission as independent predictors of in-hospital mortality in critically ill burn patients. Ann Burns Fire Disasters. 2019;32:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733210</ArticleId><ArticleId IdType="pubmed">31528149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam NN, Hung TD, Hung DK. Acute respiratory distress syndrome among severe burn patients in a developing country: application result of the Berlin definition. Ann Burns Fire Disasters. 2018;31:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6116651</ArticleId><ArticleId IdType="pubmed">30174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Taran A, Baciu N, Rafulea V, German A. Clinical and autopsy diagnoses of visceral affections of patients who died because of complicated burns with multi-organ failure. Ann Burns Fire Disasters. 2005;18:177&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188003</ArticleId><ArticleId IdType="pubmed">21991003</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Sittah GS, Sarhane KA, Dibo SA, Ibrahim A. Cardiovascular dysfunction in burns: review of the literature. Ann Burns Fire Disasters. 2012;25:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431724</ArticleId><ArticleId IdType="pubmed">23012613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanojcic M, Chen P, Xiu P, Jeschke MG. Impaired immune response in elderly burn patients: new insights into the immunesenescence phenotype. Ann Surg. 2016;264:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4899096</ArticleId><ArticleId IdType="pubmed">26649579</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151347</ArticleId><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley LF, Wohlford GF, Ting C, Alahmed A. Role for anti-cytokine therapies in severe coronavirus disease 2019. Crit Care Explor. 2020;2:e017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419062</ArticleId><ArticleId IdType="pubmed">32832913</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo P, Liu Y, Qiu L, Liu X. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92:814&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262125</ArticleId><ArticleId IdType="pubmed">32253759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18:1747&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906332</ArticleId><ArticleId IdType="pubmed">32302448</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Tacquard C, Severac F, Leonard-Lorant I. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhao B, Qu Y, Chen Y. Detectable serum SARSCoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxley TJ, Mocco J, Majidi S, Kellner CP. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7207073</ArticleId><ArticleId IdType="pubmed">32343504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Poterucha TJ, Poterucha P, Goldhaber SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">27975101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang F, Deng L, Zhang L, Cai Y. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35:1545&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088708</ArticleId><ArticleId IdType="pubmed">32133578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirmeier E, Eriksson LI, Lewald H. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7:129&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224322</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Concepts of management of plastic surgery services during the Coronavirus Disease 2019 pandemic. Eur J Plast Surg. doi.org/10.1007/s00238-020-01704-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357260</ArticleId><ArticleId IdType="pubmed">32836889</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Management of hand surgery services during the Coronavirus Disease 2019 pandemic. J Hand Microsurg. doi.org/10.1055/s-0040-1714440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9398571</ArticleId><ArticleId IdType="pubmed">36016638</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Impact of COVID-19 on surgical registrars&#x2019; education and training. S Afr J Surg. 2020;58:10&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Halvachizadeh S, Baradaran L, Cinelli P, Pfeifer R. How to detect a polytrauma patient at risk of complications: a validation and database analysis of four published scales. PLoS One. 2020;15:e0228082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980592</ArticleId><ArticleId IdType="pubmed">31978109</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Gene expression of angiotensin-converting enzyme 2 receptor in skin and the implications for COVID-19. Adv Skin Wound Care. 2021;34:31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">33323800</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Protective measures for burn care professionals during the coronavirus disease 2019 pandemic: systematic review. Ann Burns Fire Disasters. 2020;33:182&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680203</ArticleId><ArticleId IdType="pubmed">33304207</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S, Alzoubaidi D, Al-Ajam Y. Evidence-based burn care - an assessment of the methodological quality of research published in burn care journals from 1982 to 2008. Burns. 2010;36:1190&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">20621705</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. A discourse on the contributions of evidence-based medicine to wound care. Ostomy Wound Manage. 2010;56:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">20567054</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Benna S. Construction and use of wound care guidelines: an overview. Ostomy Wound Manage. 2012;58:37&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">22879315</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40290241</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1682-024X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pakistan journal of medical sciences</Title><ISOAbbreviation>Pak J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a Nomogram for the prediction of patients with sepsis-induced multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>1036</StartPage><EndPage>1046</EndPage><MedlinePgn>1036-1046</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12669/pjms.41.4.10421</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To develop and validate a model capable of predicting the risk of Sepsis-induced multiple organ dysfunction syndrome (SI-MODS) in hospitalized sepsis patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A retrospective cohort study was performed to analyze the clinical data of 415 patients admitted to Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing between January 2019 and January 2022. The least absolute shrinkage and selection operator (LASSO) regression analysis was employed to pinpoint potential variables. A nomogram was developed through multivariate logistic regression. For internal validation, the bootstrapping method was utilized. The nomogram's performance was assessed through calibration, discrimination, and clinical utility analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 415 patients, SI-MODS was identified in 46 individuals (11.1%). This model identified seven key variables. The model's internal validation yielded an area under the curve of 0.903 (95% CI: 0.863-0.943). The model's calibration was strong, and results from a decision curve analysis showed that the created nomogram provided a net benefit across a threshold probability range of 1-66% for predicting SI-MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our study develops a nomogram incorporating based on PaO2, LAC, multidrug resistant bacteria, septic shock, coagulation disorder, mechanical ventilation, and kidney failure can predict the risk of MODS in sepsis patients, which helps clinicians make risk based decisions and treatment strategies.</AbstractText><CopyrightInformation>Copyright: &#xa9; Pakistan Journal of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Jinling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jinling Ji, Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing, Medical University, Huai'an, Jiangsu223300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Qiong Wang, Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing, Medical University, Huai'an, Jiangsu223300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kai Wang, Department of Rheumatology, The Affiliated Huai'an No.1 People's Hospital of Nanjing, Medical University, Huai'an, Jiangsu223300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ting Shi, Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing, Medical University, Huai'an, Jiangsu223300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chang Li, Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing, Medical University, Huai'an, Jiangsu223300, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Pakistan</Country><MedlineTA>Pak J Med Sci</MedlineTA><NlmUniqueID>100913117</NlmUniqueID><ISSNLinking>1681-715X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nomogram</Keyword><Keyword MajorTopicYN="N">Probability</Keyword><Keyword MajorTopicYN="N">Risk</Keyword><Keyword MajorTopicYN="N">SI-MODS</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Variable</Keyword></KeywordList><CoiStatement>Conflicts of interest: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40290241</ArticleId><ArticleId IdType="pmc">PMC12022554</ArticleId><ArticleId IdType="doi">10.12669/pjms.41.4.10421</ArticleId><ArticleId IdType="pii">PJMS-41-1036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Qian D, Zhou D, Liu H, Xu D. Therapeutic effects of percutaneous coronary intervention on acute myocardial infarction complicated with multiple organ dysfunction syndrome. Pak J Med Sci. 2019;35(6):1701&#x2013;1706. doi:10.12669/pjms.35.6.1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861476</ArticleId><ArticleId IdType="pubmed">31777519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699&#x2013;709. doi:10.1056/NEJM200103083441001.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236773</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D, Group C-RS. Incidence and impact of organ dysfunctions associated with sepsis. Chest. 2005;127(3):942&#x2013;951. doi:10.1378/chest.127.3.942.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourd NM, Nikitas N. Multiple Organ Dysfunction Syndrome. J Intensive Care Med. 2020;35(12):1564&#x2013;1575. doi:10.1177/0885066619871452.</Citation><ArticleIdList><ArticleId IdType="pubmed">31455133</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CMS, Wanderley CWS, Veras FP, Sonego F, Nascimento DC, Gon&#xe7;alves AV, et al. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation. Blood. 2021;138(25):2702&#x2013;2713. doi:10.1182/blood.2021011525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8703366</ArticleId><ArticleId IdType="pubmed">34407544</ArticleId></ArticleIdList></Reference><Reference><Citation>Benscoter AL, Alten JA, Atreya MR, Cooper DS, Byrnes JW, Nelson DP, et al. Biomarker-based risk model to predict persistent multiple organ dysfunctions after congenital heart surgery:a prospective observational cohort study. Crit Care. 2023;27(1):193. doi:10.1186/s13054-023-04494-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10199562</ArticleId><ArticleId IdType="pubmed">37210541</ArticleId></ArticleIdList></Reference><Reference><Citation>Atreya MR, Banerjee S, Lautz AJ, Alder MN, Varisco BM, Wong HR, et al. Machine learning-driven identification of the gene-expression signature associated with a persistent multiple organ dysfunction trajectory in critical illness. EBioMedicine. 2024;99:104938. doi:10.1016/j.ebiom.2023.104938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10788426</ArticleId><ArticleId IdType="pubmed">38142638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chothani S, Sch&#xe4;fer S, Adami E, Viswanathan S, Widjaja AA, Langley SR, et al. Widespread Translational Control of Fibrosis in the Human Heart by RNA-Binding Proteins. Circulation. 2019;140(11):937&#x2013;951. doi:10.1161/circulationaha.119.039596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6749977</ArticleId><ArticleId IdType="pubmed">31284728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong H, Chen Y, Chen M, Li J, Zhang H, Yan S, et al. Advanced development and mechanism of sepsis-related acute respiratory distress syndrome. Front Med (Lausanne) 2022;9:1043859. doi:10.3389/fmed.2022.1043859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9701739</ArticleId><ArticleId IdType="pubmed">36452899</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score:a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;52. doi:10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD):the TRIPOD statement. Ann Intern Med. 2015;162(1):55&#x2013;63. doi:10.7326/M14-0697.</Citation><ArticleIdList><ArticleId IdType="pubmed">25560714</ArticleId></ArticleIdList></Reference><Reference><Citation>Calster BV, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, et al. Reporting and Interpreting Decision Curve Analysis:A Guide for Investigators. Eur Urol. 2018;74(6):796&#x2013;804. doi:10.1016/j.eururo.2018.08.038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6261531</ArticleId><ArticleId IdType="pubmed">30241973</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology:more than meets the eye. Lancet Oncol. 2015;16(4):e173&#x2013;180. doi:10.1016/S1470-2045(14)71116-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4465353</ArticleId><ArticleId IdType="pubmed">25846097</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385&#x2013;395. doi:10.1002/(sici)1097-0258(19970228)16:4&lt;385::aid-sim380&gt;3.0.co;2-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9044528</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M, He Q. Development of a prognostic nomogram for sepsis associated-acute respiratory failure patients on 30-day mortality in intensive care units:a retrospective cohort study. BMC Pulm Med. 2023;23(1):43. doi:10.1186/s12890-022-02302-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9885567</ArticleId><ArticleId IdType="pubmed">36717800</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Zheng L, Jiang Y, Jin L. A prediction model for predicting the risk of acute respiratory distress syndrome in sepsis patients:a retrospective cohort study. BMC Pulm Med. 2023;23(1):78. doi:10.1186/s12890-023-02365-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9994387</ArticleId><ArticleId IdType="pubmed">36890503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar NR, Balraj TA, Kempegowda SN, Prashant A. Multidrug-Resistant Sepsis:A Critical Healthcare Challenge. Antibiotics (Basel) 2024;13(1):46. doi:10.3390/antibiotics13010046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10812490</ArticleId><ArticleId IdType="pubmed">38247605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimah M, Brilli RJ. Coagulation dysfunction in sepsis and multiple organ system failure. Crit Care Clin. 2003;19(3):441&#x2013;58. doi:10.1016/s0749-0704(03)00008-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A, Koyner JL, Gomez H, Pickkers P, Forni L. Sepsis-associated acute kidney injury-treatment standard. Nephrol Dial Transplant. 2023;39(1):26&#x2013;35. doi:10.1093/ndt/gfad142.</Citation><ArticleIdList><ArticleId IdType="pubmed">37401137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Zhang H, Guo C. Establishment of a risk prediction model for cerebrogenic multiple organ dysfunction syndrome in patients with acute cerebral hemorrhage. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024;36(9):966&#x2013;971. doi:10.3760/cma.j.cn121430-20240202-00109.</Citation><ArticleIdList><ArticleId IdType="pubmed">39380519</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Villalba E, Cano-S&#xe1;nchez A, Alcaraz-Garc&#xed;a A, Cinesi-G&#xf3;mez C, Pi&#xf1;era-Salmer&#xf3;n P, Mar&#xed;n I, et al. Nomogram to predict a poor outcome in emergency patients with sepsis and at low risk of organ damage according to Sepsis-related Organ Failure Assessment (SOFA) Emergencias. 2017;29(2):81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">28825248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17992396</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1516-3180</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Sao Paulo medical journal = Revista paulista de medicina</Title><ISOAbbreviation>Sao Paulo Med J</ISOAbbreviation></Journal><ArticleTitle>Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial.</ArticleTitle><Pagination><StartPage>237</StartPage><EndPage>241</EndPage><MedlinePgn>237-41</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT AND OBJECTIVE" NlmCategory="OBJECTIVE">Sepsis and septic shock are very common conditions among critically ill patients that lead to multiple organ dysfunction syndrome (MODS) and death. Our purpose was to investigate the efficacy of early administration of dexamethasone for patients with septic shock, with the aim of halting the progression towards MODS and death.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Prospective, randomized, double-blind, single-center study, developed in a surgical intensive care unit at Hospital das Cl&#xed;nicas, Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study involved 29 patients with septic shock. All eligible patients were prospectively randomized to receive either a dose of 0.2 mg/kg of dexamethasone (group D) or placebo (group P), given three times at intervals of 36 hours. The patients were monitored over a seven-day period by means of the sequential organ failure assessment score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients treated with dexamethasone did not require vasopressor therapy for as much time over the seven-day period as did the placebo group (p = 0.043). Seven-day mortality was 67% in group P (10 out of 15) and 21% in group D (3 out of 14) (relative risk = 0.31, 95% confidence interval 0.11 to 0.88). Dexamethasone enhanced the effects of vasopressor drugs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early treatment with dexamethasone reduced the seven-day mortality among septic shock patients and showed a trend towards reduction of 28-day mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cicarelli</LastName><ForeName>Domingos Dias</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Department of Surgery, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, Porto, Portugal. dcicarelli@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Joaquim Edson</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Bense&#xf1;or</LastName><ForeName>F&#xe1;bio Ely Martins</ForeName><Initials>FE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Sao Paulo Med J</MedlineTA><NlmUniqueID>100897261</NlmUniqueID><ISSNLinking>1516-3180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="CONTEXTO E OBJETIVO:">Sepse e choque s&#xe9;ptico s&#xe3;o doen&#xe7;as muito comuns em pacientes gravemente enfermos, evoluindo muitas vezes com s&#xed;ndrome de disfun&#xe7;&#xe3;o de m&#xfa;ltiplos &#xf3;rg&#xe3;os (SDMO) e morte. A proposta do trabalho foi investigar a efic&#xe1;cia da administra&#xe7;&#xe3;o precoce de dexametasona a estes pacientes, tentando evitar a progress&#xe3;o do choque s&#xe9;ptico para SDMO e morte.</AbstractText><AbstractText Label="TIPO DE ESTUDO E LOCAL:">Estudo prospectivo, aleat&#xf3;rio, duplamente encoberto, monoc&#xea;ntrico, realizado na Unidade de Terapia Intensiva p&#xf3;s-operat&#xf3;ria do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="M&#xc9;TODOS:">Foram estudados 29 pacientes com choque s&#xe9;ptico. Os participantes foram aleatoriamente divididos em dois grupos que receberam 0,2 mg/kg de dexametasona (grupo D) ou placebo (grupo P), repetidas a cada 36 horas. Os pacientes foram acompanhados durante sete dias de interna&#xe7;&#xe3;o na Unidade de Terapia Intensiva atrav&#xe9;s do escore SOFA (Sequential Organ Failure Assessment).</AbstractText><AbstractText Label="RESULTADOS:">Os pacientes que receberam dexametasona necessitaram de menos tempo de tratamento com vasopressores durante o per&#xed;odo de sete dias (p = 0,043). A mortalidade em sete dias no grupo P foi de 67% (10 em 15) e no grupo D foi de 21% (3 em 14) (risco relativo = 0.31, intervalo de confian&#xe7;a 95% 0.11-0.88).</AbstractText><AbstractText Label="CONCLUS&#xc3;O:">O tratamento precoce com dexametasona dos pacientes com choque s&#xe9;ptico reduziu a mortalidade em sete dias de acompanhamento e mostrou tend&#xea;ncia de redu&#xe7;&#xe3;o da mortalidade em 28 dias.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> Not declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17992396</ArticleId><ArticleId IdType="pmc">PMC11020550</ArticleId><ArticleId IdType="doi">10.1590/s1516-31802007000400009</ArticleId><ArticleId IdType="pii">S1516-31802007000400009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519925</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094907</ArticleId><ArticleId IdType="pubmed">9876974</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569975</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321661</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9669790</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J, International Sepsis Forum Immunological therapy in sepsis: currently available. Intensive Care Med. 2001;27(Suppl 1):S93&#x2013;S103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicarelli DD, Bense&#xf1;or FE, Vieira JE. Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J. 2006;124(2):90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11060357</ArticleId><ArticleId IdType="pubmed">16878192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp. 1459&#x2013;1485.</Citation></Reference><Reference><Citation>Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora's Box. Anaesthesia. 2003;58(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12492660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group Multiple organ dysfunction: baseline and serial component scores. Crit Care Med. 2001;29(11):2046&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700393</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendon&#xe7;a A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettil&#xe4; V, Pettil&#xe4; M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163780</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf3;voa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">9840239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">15343024</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR. Medical epidemiology. 3rd ed. New York: McGraw-Hill; 2001.</Citation></Reference><Reference><Citation>MacLaren R, Jung R. Stress-dose corticosteroids therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">12222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794402</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288(7):886&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186608</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, S&#xe9;bille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186604</ArticleId></ArticleIdList></Reference><Reference><Citation>Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559592</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253&#x2013;S257.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682449</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GS, Bernard GR, International Sepsis Forum Airway and lung in sepsis. Intensive Care Med. 2001;27(Suppl 1):S63&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307371</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32015566</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Changes in inflammatory and vasoactive mediator profiles during valvular surgery with or without infective endocarditis: A case control pilot study.</ArticleTitle><Pagination><StartPage>e0228286</StartPage><MedlinePgn>e0228286</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0228286</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0228286</ELocationID><Abstract><AbstractText Label="BACKGROUND">More than 50% of patients with infective endocarditis (IE) develop an indication for surgery. Despite its benefit, surgery is associated with a high incidence of multiple organ dysfunction syndrome (MODS) and mortality, which may be linked to increased release of inflammatory mediators during cardiopulmonary bypass (CPB). We therefore assessed plasma cytokine profiles in patients undergoing valve surgery with or without IE.</AbstractText><AbstractText Label="METHODS">We performed a prospective case-control pilot study comparing patients undergoing cardiac valve surgery with or without IE. Plasma profiles of inflammatory mediators were measured at 7 defined time points and reported as median (interquartile). The degree of MODS was measured using sequential organ failure assessment (SOFA) score.</AbstractText><AbstractText Label="RESULTS">Between May and December 2016 we included 40 patients (20 in each group). Both groups showed similar distribution of age and gender. Patients with IE had higher preoperative SOFA (6.9&#xb1; 2.6 vs 3.8 &#xb1; 1.1, p&lt;0.001) and operative risk scores (EuroSCORE II 18.6&#xb1;17.4 vs. 1.8&#xb1;1.3, p&lt;0.001). In-hospital mortality was higher in IE patients (35% vs. 5%; p&lt;0.001). Multiple organ failure was the cause of death in all non-survivors. At the end of CPB, median levels of following inflammatory mediators were higher in IE compared to control group: IL-6 (119.73 (226.49) vs. 24.48 (40.09) pg/ml, p = 0.001); IL-18 (104.82 (105.99) vs. 57.30 (49.53) pg/ml, p&lt;0.001); Mid-regional pro-adrenomedullin (MR-proADM) (2.06 (1.58) vs. 1.11 (0.53) nmol/L, p = 0.003); MR- pro-atrial natriuretic peptide (MR-proANP) (479.49 (224.74) vs. 266.55 (308.26) pmol/l, p = 0.028). IL-1&#x3b2; and TNF- &#x3b1; were only detectable in IE patients and first after starting CPB. Plasma levels of IL-6, IL-18, MRproADM, and MRproANP during CPB were significantly lower in survivors than in those who died.</AbstractText><AbstractText Label="CONCLUSION">The presence of infective endocarditis during cardiac valve surgery is associated with increased inflammatory response as evident by higher plasma cytokine levels and other inflammatory mediators. Actively reducing inflammatory response appears to be a plausible therapeutic concept.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov, ID: NCT02727413.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diab</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1529-6046</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasar</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sponholz</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Clinical Studies, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletz</LastName><ForeName>Mathias W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University of Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunkhorst</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Clinical Studies, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doenst</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02727413</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="N">Endocarditis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006351" MajorTopicYN="N">Heart Valves</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All other authors declare no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32015566</ArticleId><ArticleId IdType="pmc">PMC6996967</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0228286</ArticleId><ArticleId IdType="pii">PONE-D-19-17603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation. 2010;121(9):1141&#x2013;52. 10.1161/CIRCULATIONAHA.108.773598</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.773598</ArticleId><ArticleId IdType="pubmed">20212293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, et al. A systematic review of population-based studies of infective endocarditis. Chest. 2007;132(3):1025&#x2013;35. 10.1378/chest.06-2048</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-2048</ArticleId><ArticleId IdType="pubmed">17873196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yew HS, Murdoch DR. Global trends in infective endocarditis epidemiology. Current infectious disease reports. 2012;14(4):367&#x2013;72. 10.1007/s11908-012-0265-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11908-012-0265-5</ArticleId><ArticleId IdType="pubmed">22592632</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr., Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Archives of internal medicine. 2009;169(5):463&#x2013;73. 10.1001/archinternmed.2008.603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2008.603</ArticleId><ArticleId IdType="pmc">PMC3625651</ArticleId><ArticleId IdType="pubmed">19273776</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvez-Acebal J, Rodriguez-Bano J, Martinez-Marcos FJ, Reguera JM, Plata A, Ruiz J, et al. Prognostic factors in left-sided endocarditis: results from the Andalusian multicenter cohort. BMC infectious diseases. 2010;10:17 10.1186/1471-2334-10-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-10-17</ArticleId><ArticleId IdType="pmc">PMC2822778</ArticleId><ArticleId IdType="pubmed">20096116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelsomino S, Maessen JG, van der Veen F, Livi U, Renzulli A, Luca F, et al. Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. The Annals of thoracic surgery. 2012;93(5):1469&#x2013;76. 10.1016/j.athoracsur.2011.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2011.11.025</ArticleId><ArticleId IdType="pubmed">22342063</ArticleId></ArticleIdList></Reference><Reference><Citation>Musci M, Weng Y, Hubler M, Chavez T, Qedra N, Kosky S, et al. Predictors of early mortality in patients with active infective native or prosthetic aortic root endocarditis undergoing homograft aortic root replacement. Clinical research in cardiology: official journal of the German Cardiac Society. 2009;98(7):443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">19350313</ArticleId></ArticleIdList></Reference><Reference><Citation>Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2002;21(2):232&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11825729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mota AL, Rodrigues AJ, Evora PR. [Adult cardiopulmonary bypass in the twentieth century: science, art or empiricism?]. Rev Bras Cir Cardiovasc. 2008;23(1):78&#x2013;92. 10.1590/s0102-76382008000100013</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0102-76382008000100013</ArticleId><ArticleId IdType="pubmed">18719832</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustamante J, Arevalo A, Tamayo E, Sarria C, Aguilar-Blanco EM, Heredia M, et al. Cytokine profiles linked to fatal outcome in infective prosthetic valve endocarditis. APMIS. 2014;122(6):526&#x2013;9. 10.1111/apm.12189</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.12189</ArticleId><ArticleId IdType="pubmed">24106887</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo IR, Ferrari TC, Teixeira-Carvalho A, Campi-Azevedo AC, Rodrigues LV, Guimaraes Junior MH, et al. Cytokine Signature in Infective Endocarditis. PLoS One. 2015;10(7):e0133631 10.1371/journal.pone.0133631</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133631</ArticleId><ArticleId IdType="pmc">PMC4520569</ArticleId><ArticleId IdType="pubmed">26225421</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr., Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000;30(4):633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10770721</ArticleId></ArticleIdList></Reference><Reference><Citation>Munzel U, Brunner E. Nonparametric methods in multivariate factorial designs. J Stat Plan Infer. 2000;88(1):117&#x2013;32.</Citation></Reference><Reference><Citation>Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardio-Thorac. 2002;21(2):232&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11825729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of internal medicine. 2007;167(15):1655&#x2013;63. 10.1001/archinte.167.15.1655</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.15.1655</ArticleId><ArticleId IdType="pmc">PMC4495652</ArticleId><ArticleId IdType="pubmed">17698689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustamante-Munguira J, Arevalo A, Sarria C, Saez C, Aguilar-Blanco EM, Almansa R, et al. The Role of Pro-Inflammatory Cytokines in Late Prosthetic Valve Endocarditis. Brit J Surg. 2014;101:14&#x2013;.</Citation></Reference><Reference><Citation>Kern WV, Engel A, Schieffer S, Prummer O, Kern P. Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis. Infection and immunity. 1993;61(12):5413&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281334</ArticleId><ArticleId IdType="pubmed">8225616</ArticleId></ArticleIdList></Reference><Reference><Citation>Capo C, Amirayan N, Ghigo E, Raoult D, Mege J. Circulating cytokine balance and activation markers of leucocytes in Q fever. Clin Exp Immunol. 1999;115(1):120&#x2013;3. 10.1046/j.1365-2249.1999.00786.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1999.00786.x</ArticleId><ArticleId IdType="pmc">PMC1905180</ArticleId><ArticleId IdType="pubmed">9933430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery&#x2014;a blinded, randomized, controlled pilot study using a novel adsorbent. Critical care. 2016;20:96 10.1186/s13054-016-1270-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1270-0</ArticleId><ArticleId IdType="pmc">PMC4826492</ArticleId><ArticleId IdType="pubmed">27059056</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatachalam K, Prabhu SD, Reddy VS, Boylston WH, Valente AJ, Chandrasekar B. Neutralization of Interleukin-18 Ameliorates Ischemia/Reperfusion-induced Myocardial Injury. Journal of Biological Chemistry. 2009;284(12):7853&#x2013;65. 10.1074/jbc.M808824200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808824200</ArticleId><ArticleId IdType="pmc">PMC2658078</ArticleId><ArticleId IdType="pubmed">19164288</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher CJ Jr., Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22(1):12&#x2013;21. 10.1097/00003246-199401000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199401000-00008</ArticleId><ArticleId IdType="pubmed">8124953</ArticleId></ArticleIdList></Reference><Reference><Citation>Elke G, Bloos F, Wilson DC, Meybohm P, Grp SCCT. Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores. Critical care. 2018;22 10.1186/s13054-018-1946-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-1946-8</ArticleId><ArticleId IdType="pmc">PMC5989334</ArticleId><ArticleId IdType="pubmed">29871660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad T, Fiuzat M, Felker GM, O'Connor C. Novel biomarkers in chronic heart failure. Nature reviews Cardiology. 2012;9(6):347&#x2013;59. 10.1038/nrcardio.2012.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2012.37</ArticleId><ArticleId IdType="pubmed">22450126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrmann P, Bahrmann A, Hofner B, Christ M, Achenbach S, Sieber CC, et al. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department. Eur Heart J Acute Cardiovasc Care. 2015;4(2):137&#x2013;47. 10.1177/2048872614541904</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872614541904</ArticleId><ArticleId IdType="pubmed">25002708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014;52(10):1447&#x2013;56. 10.1515/cclm-2014-0379</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2014-0379</ArticleId><ArticleId IdType="pubmed">24940718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y, Takata S, Kawahara Y, Takai Y, Chino N, Kimura T, et al. Molecular mechanism of action by atrial natriuretic peptide in rat vascular smooth muscle cells. Jpn Circ J. 1988;52(12):1430&#x2013;5. 10.1253/jcj.52.1430</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/jcj.52.1430</ArticleId><ArticleId IdType="pubmed">2853774</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Journal of the American College of Cardiology. 2010;55(19):2062&#x2013;76. 10.1016/j.jacc.2010.02.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.02.025</ArticleId><ArticleId IdType="pubmed">20447528</ArticleId></ArticleIdList></Reference><Reference><Citation>Guignant C, Venet F, Voirin N, Poitevin F, Malcus C, Bohe J, et al. Proatrial natriuretic peptide is a better predictor of 28-day mortality in septic shock patients than proendothelin-1. Clin Chem Lab Med. 2010;48(12):1813&#x2013;20. 10.1515/CCLM.2010.341</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM.2010.341</ArticleId><ArticleId IdType="pubmed">20704539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcmurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma Endothelin in Chronic Heart-Failure. Circulation. 1992;85(4):1374&#x2013;9. 10.1161/01.cir.85.4.1374</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.85.4.1374</ArticleId><ArticleId IdType="pubmed">1532540</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman BD, Machado FS, Tanowitz HB, Desruisseaux MS. Endothelin-1 and its role in the pathogenesis of infectious diseases. Life Sci. 2014;118(2):110&#x2013;9. 10.1016/j.lfs.2014.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2014.04.021</ArticleId><ArticleId IdType="pmc">PMC4538933</ArticleId><ArticleId IdType="pubmed">24780317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschaikowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med. 2000;28(6):1854&#x2013;60. 10.1097/00003246-200006000-00028</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200006000-00028</ArticleId><ArticleId IdType="pubmed">10890632</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem. 2006;52(6):1144&#x2013;51. 10.1373/clinchem.2005.065581</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2005.065581</ArticleId><ArticleId IdType="pubmed">16627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Buendgens L, Yagmur E, Bruensing J, Herbers U, Baeck C, Trautwein C, et al. C-terminal proendothelin-1 (CT-proET-1) is associated with organ failure and predicts mortality in critically ill patients. Journal of Intensive Care. 2017;5 10.1186/s40560-016-0201-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-016-0201-0</ArticleId><ArticleId IdType="pmc">PMC5359904</ArticleId><ArticleId IdType="pubmed">28331622</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Li X, Zhang X, Li Z, Wang L, Sun Y, et al. Elevated levels of plasma TNF-alpha are associated with microvascular endothelial dysfunction in patients with sepsis through activating the NF-kappaB and p38 mitogen-activated protein kinase in endothelial cells. Shock. 2014;41(4):275&#x2013;81. 10.1097/SHK.0000000000000116</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000116</ArticleId><ArticleId IdType="pubmed">24430552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittar MN, Carey JA, Barnard JB, Pravica V, Deiraniya AK, Yonan N, et al. Tumor necrosis factor alpha influences the inflammatory response after coronary surgery. The Annals of thoracic surgery. 2006;81(1):132&#x2013;7. 10.1016/j.athoracsur.2005.07.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2005.07.037</ArticleId><ArticleId IdType="pubmed">16368349</ArticleId></ArticleIdList></Reference><Reference><Citation>Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21(10 Suppl):S447&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8403983</ArticleId></ArticleIdList></Reference><Reference><Citation>Frencken JF, van Vught LA, Peelen LM, Ong DSY, Klein Klouwenberg PMC, Horn J, et al. An Unbalanced Inflammatory Cytokine Response Is Not Associated With Mortality Following Sepsis: A Prospective Cohort Study. Crit Care Med. 2017;45(5):e493&#x2013;e9. 10.1097/CCM.0000000000002292</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002292</ArticleId><ArticleId IdType="pubmed">28257334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862&#x2013;74. 10.1038/nri3552</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II dagger. Eur J Cardio-Thorac. 2012;41(4):734&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22378855</ArticleId></ArticleIdList></Reference><Reference><Citation>Remadi JP, Habib G, Nadji G, Brahim A, Thuny F, Casalta JP, et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. The Annals of thoracic surgery. 2007;83(4):1295&#x2013;302. 10.1016/j.athoracsur.2006.09.093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.09.093</ArticleId><ArticleId IdType="pubmed">17383330</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab M, Sponholz C, von Loeffelholz C, Scheffel P, Bauer M, Kortgen A, et al. Impact of perioperative liver dysfunction on in-hospital mortality and long-term survival in infective endocarditis patients. Infection. 2017;45(6):857&#x2013;66. 10.1007/s15010-017-1064-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-017-1064-6</ArticleId><ArticleId IdType="pubmed">28856632</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab M, Guenther A, Sponholz C, Lehmann T, Faerber G, Matz A, et al. Pre-operative stroke and neurological disability do not independently affect short- and long-term mortality in infective endocarditis patients. Clinical Research in Cardiology. 2016;105(10):847&#x2013;57. 10.1007/s00392-016-0993-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-016-0993-x</ArticleId><ArticleId IdType="pubmed">27122133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29740711</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1931-7573</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>Nanoscale research letters</Title><ISOAbbreviation>Nanoscale Res Lett</ISOAbbreviation></Journal><ArticleTitle>New Avenues for Nanoparticle-Related Therapies.</ArticleTitle><Pagination><StartPage>136</StartPage><MedlinePgn>136</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">136</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s11671-018-2548-8</ELocationID><Abstract><AbstractText>Development of nanoparticle-based drug delivery systems has been attempted for the treatment of cancer over the past decade. The enhanced permeability and retention (EPR) effect is the major mechanism to passively deliver nanodrugs to tumor tissue. However, a recent systematic review demonstrated limited success of these studies, with the clearance of nanoparticles by the mononuclear phagocytic system (MPS) being a major hurdle. Herein, we propose that nanotechnologists should reconsider their research focuses, aiming for therapeutic targets other than cancer. Treatments for diseases that do not (or less) rely on EPR should be considered, such as active targeting or MPS evasion systems. For example, systemic delivery of drugs through intravenous injection can be used to treat sepsis, multi-organ failure, metabolic disorders, blood diseases, immune and autoimmune diseases, etc. Local delivery of nanodrugs to organs such as the lung, rectum, or bladder may enhance the local drug concentration with less clearance via MPS. In transplant settings, ex vivo organ perfusion provides a new route to repair injury of isolated organs in the absence of MPS. Based on a similar concept, chemotherapy with in vivo lung perfusion techniques and other isolated organ perfusion provides opportunities for cancer therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, 101 College Street, Room: TMDT2-814, Toronto, Ontario, M5G 1L7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingyao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9188-8417</Identifier><AffiliationInfo><Affiliation>Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, 101 College Street, Room: TMDT2-814, Toronto, Ontario, M5G 1L7, Canada. mingyao.liu@utoronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, Canada. mingyao.liu@utoronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Toronto, Toronto, Canada. mingyao.liu@utoronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Canada. mingyao.liu@utoronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, University of Toronto, Toronto, Canada. mingyao.liu@utoronto.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-42546</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MOP-119514</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>PJT-148847</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nanoscale Res Lett</MedlineTA><NlmUniqueID>101279750</NlmUniqueID><ISSNLinking>1556-276X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ex vivo lung perfusion</Keyword><Keyword MajorTopicYN="N">Local delivery</Keyword><Keyword MajorTopicYN="N">Nanodrug delivery</Keyword><Keyword MajorTopicYN="N">Systemic diseases</Keyword><Keyword MajorTopicYN="N">Translational research</Keyword></KeywordList><CoiStatement>AUTHORS&#x2019; INFORMATION: Michael Zhao received his BSc degree from McGill University. He was a graduate student in Dr. Mingyao Liu&#x2019;s lab at the Institute of Medical Science, University of Toronto. Currently, he is a medical student at the Wayne State University School of Medicine. Dr. Mingyao Liu is a Professor of Surgery, Medicine and Physiology, and Director of Institute of Medical Science, at the Faculty of Medicine, University of Toronto. Dr. Liu holds the James and Mary Davie Chair in Lung Injury, Repair and Regeneration. He is also Head of the Respiratory and Critical Care Research and a Senior Scientist at the Toronto General Hospital Research Institute, University Health Network. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29740711</ArticleId><ArticleId IdType="pmc">PMC5940972</ArticleId><ArticleId IdType="doi">10.1186/s11671-018-2548-8</ArticleId><ArticleId IdType="pii">10.1186/s11671-018-2548-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136&#x2013;151. doi: 10.1016/j.addr.2010.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2010.04.009</ArticleId><ArticleId IdType="pubmed">20441782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. doi: 10.1038/natrevmats.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/natrevmats.2016.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1:10&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5689513</ArticleId><ArticleId IdType="pubmed">29313004</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano. 2013;7:7442&#x2013;7447. doi: 10.1021/nn404501g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn404501g</ArticleId><ArticleId IdType="pmc">PMC3914010</ArticleId><ArticleId IdType="pubmed">24490875</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S-D, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta. 2009;1788:2259&#x2013;2266. doi: 10.1016/j.bbamem.2009.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2009.06.022</ArticleId><ArticleId IdType="pmc">PMC2757503</ArticleId><ArticleId IdType="pubmed">19595666</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez PL, Harada T, Christian DA, et al. Minimal &#x201c;self&#x201d; peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science. 2013;339:971&#x2013;975. doi: 10.1126/science.1229568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1229568</ArticleId><ArticleId IdType="pmc">PMC3966479</ArticleId><ArticleId IdType="pubmed">23430657</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013;8:61&#x2013;68. doi: 10.1038/nnano.2012.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nnano.2012.212</ArticleId><ArticleId IdType="pmc">PMC3751189</ArticleId><ArticleId IdType="pubmed">23241654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartneck M, Warzecha KT, Tacke F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr. 2014;3:364&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273112</ArticleId><ArticleId IdType="pubmed">25568860</ArticleId></ArticleIdList></Reference><Reference><Citation>Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on small medicine: the state of nanomedicine products approved for use or in clinical trials. Nanomedicine. 2013;9:1&#x2013;14. doi: 10.1016/j.nano.2012.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2012.05.013</ArticleId><ArticleId IdType="pmc">PMC4467093</ArticleId><ArticleId IdType="pubmed">22684017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung S-Y, Oyaizu T, Yang H, et al. The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy. Biomaterials. 2011;32:4000&#x2013;4008. doi: 10.1016/j.biomaterials.2011.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.02.005</ArticleId><ArticleId IdType="pubmed">21376387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco S, Kanou T, Fung S-Y, et al. Formulation of hydrophobic therapeutics with self-assembling peptide and amino acid: a new platform for intravenous drug delivery. J Control Release. 2016;239:211&#x2013;222. doi: 10.1016/j.jconrel.2016.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.08.038</ArticleId><ArticleId IdType="pubmed">27586187</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Fung S-Y, Xu S, et al. Amino acid-dependent attenuation of toll-like receptor signaling by peptide-gold nanoparticle hybrids. ACS Nano. 2015;9:6774&#x2013;6784. doi: 10.1021/nn505634h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn505634h</ArticleId><ArticleId IdType="pubmed">26083966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, Zhao J, Yang H, et al. Effective delivery of a rationally designed intracellular peptide drug with gold nanoparticle-peptide hybrids. Nano. 2015;7:12356&#x2013;12360.</Citation><ArticleIdList><ArticleId IdType="pubmed">26151444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesharwani P, Gorain B, Low SY, et al. Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res Clin Pract. 2017;136:52&#x2013;77. doi: 10.1016/j.diabres.2017.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2017.11.018</ArticleId><ArticleId IdType="pubmed">29196152</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson CS, Madison AC, Shah A. Size matters&#x2014;nanotechnology and therapeutics in rheumatology and immunology. Curr Rheumatol Rev. 2014;10:11&#x2013;21. doi: 10.2174/1573403X10666140914155926.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403X10666140914155926</ArticleId><ArticleId IdType="pubmed">25229497</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxton DB. Nanomedicine for the management of lung and blood diseases. Nanomedicine. 2009;4:331&#x2013;339. doi: 10.2217/nnm.09.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm.09.8</ArticleId><ArticleId IdType="pmc">PMC6568266</ArticleId><ArticleId IdType="pubmed">19331540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar A-S, Nagy-Simon T, Tomuleasa C, et al. Nanomedicine approaches in acute lymphoblastic leukemia. J Control Release. 2016;238:123&#x2013;138. doi: 10.1016/j.jconrel.2016.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.07.035</ArticleId><ArticleId IdType="pubmed">27460684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine (Lond) 2013;8:773&#x2013;784. doi: 10.2217/nnm.13.48.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm.13.48</ArticleId><ArticleId IdType="pubmed">23656264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine. 2013;8:969&#x2013;981. doi: 10.2217/nnm.13.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm.13.49</ArticleId><ArticleId IdType="pmc">PMC3939602</ArticleId><ArticleId IdType="pubmed">23730696</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosperi D, Colombo M, Zanoni I, Granucci F. Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases. Semin Immunol. 2017;34:61&#x2013;67. doi: 10.1016/j.smim.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2017.08.010</ArticleId><ArticleId IdType="pmc">PMC5705526</ArticleId><ArticleId IdType="pubmed">28855088</ArticleId></ArticleIdList></Reference><Reference><Citation>Soica C, Coricovac D, Dehelean C, et al. Nanocarriers as tools in delivering active compounds for immune system related pathologies. Recent Pat Nanotechnol. 2016;10:128&#x2013;145. doi: 10.2174/1872210510999160427113345.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1872210510999160427113345</ArticleId><ArticleId IdType="pubmed">27502390</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlit H, Bellinghausen I, Frey H, Saloga J. Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy. 2017;72:1461&#x2013;1474. doi: 10.1111/all.13199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.13199</ArticleId><ArticleId IdType="pubmed">28474379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay S, Chen J-Y, Chen H-W, Hu C-MJ. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation. Nano. 2017;1:244&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646730</ArticleId><ArticleId IdType="pubmed">29071191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurien M, Penny H, Sanders DS. Impact of direct drug delivery via gastric access devices. Expert Opin Drug Deliv. 2015;12:455&#x2013;463. doi: 10.1517/17425247.2015.966683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2015.966683</ArticleId><ArticleId IdType="pubmed">25288354</ArticleId></ArticleIdList></Reference><Reference><Citation>Christophi GP, Rengarajan A, Ciorba MA. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol. 2016;9:125&#x2013;130. doi: 10.2147/CEG.S80237.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S80237</ArticleId><ArticleId IdType="pmc">PMC4876845</ArticleId><ArticleId IdType="pubmed">27274301</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmstr&#xf6;m P-U. Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol. 2003;47:109&#x2013;126. doi: 10.1016/S1040-8428(03)00075-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1040-8428(03)00075-1</ArticleId><ArticleId IdType="pubmed">12900005</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond I, Vasdev N, Ferguson J, et al. The clinical effectiveness of intravesical sodium hyaluronate (cystistat&#xae;) in patients with interstitial cystitis/painful bladder syndrome and recurrent urinary tract infections. Curr Urol. 2012;6:93&#x2013;98. doi: 10.1159/000343517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343517</ArticleId><ArticleId IdType="pmc">PMC3783338</ArticleId><ArticleId IdType="pubmed">24917721</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mary H, Del Rinc&#x3cc;n I, Cui Z. Nanomedicine for intra-articular drug delivery in rheumatoid arthritis. Curr Med Chem. 2016;23:2490&#x2013;2506. doi: 10.2174/0929867323666160530144445.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867323666160530144445</ArticleId><ArticleId IdType="pubmed">27237822</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Chao T, Brant J, et al. Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss. Adv Drug Deliv Rev. 2017;108:2&#x2013;12. doi: 10.1016/j.addr.2016.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2016.01.004</ArticleId><ArticleId IdType="pmc">PMC4940320</ArticleId><ArticleId IdType="pubmed">26796230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364:1431&#x2013;1440. doi: 10.1056/NEJMoa1014597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1014597</ArticleId><ArticleId IdType="pubmed">21488765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Liu W, Liu M. Ex vivo lung perfusion: scientific research and clinical application. Pract J Organ Transplant. 2017;5:177&#x2013;187.</Citation></Reference><Reference><Citation>Cypel M, Liu M, Rubacha M et al (2009) Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 1:4ra9. 10.1126/scitranslmed.3000266</Citation><ArticleIdList><ArticleId IdType="pubmed">20368171</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima D, Cypel M, Bonato R, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016;16:1229&#x2013;1237. doi: 10.1111/ajt.13562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13562</ArticleId><ArticleId IdType="pubmed">26730551</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordant P, Nakajima D, Kalaf R et al (2016) Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-hour preservation. J Hear Lung Transplant. 10.1016/j.healun.2016.04.017</Citation><ArticleIdList><ArticleId IdType="pubmed">27444694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Chen M, Tian F, et al (2017) &#x3b1;1-Anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. J Heart Lung Transplant 0: . doi: 10.1016/j.healun.2017.09.019</Citation><ArticleIdList><ArticleId IdType="pubmed">29153638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosgood SA, Barlow AD, Dormer J, Nicholson ML. The use of ex-vivo normothermic perfusion for the resuscitation and assessment of human kidneys discarded because of inadequate in situ perfusion. J Transl Med. 2015;13:329. doi: 10.1186/s12967-015-0691-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-015-0691-x</ArticleId><ArticleId IdType="pmc">PMC4609141</ArticleId><ArticleId IdType="pubmed">26474973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardehali A, Esmailian F, Deng M, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet. 2015;385:2577&#x2013;2584. doi: 10.1016/S0140-6736(15)60261-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60261-6</ArticleId><ArticleId IdType="pubmed">25888086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar R, Jassem W, Mergental H, et al. Liver transplantation after ex vivo normothermic machine preservation: a phase 1 (first-in-man) clinical trial. Am J Transplant. 2016;16:1779&#x2013;1787. doi: 10.1111/ajt.13708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13708</ArticleId><ArticleId IdType="pubmed">26752191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Qin L, Zhang J, et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. Nat Commun. 2017;8:191. doi: 10.1038/s41467-017-00297-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00297-x</ArticleId><ArticleId IdType="pmc">PMC5543113</ArticleId><ArticleId IdType="pubmed">28775323</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck Dos Santos P, Sakamoto J, Chen M, et al. Modified in vivo lung perfusion for local chemotherapy: a preclinical study with doxorubicin. Ann Thorac Surg. 2016;101:2132&#x2013;2140. doi: 10.1016/j.athoracsur.2015.12.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2015.12.043</ArticleId><ArticleId IdType="pubmed">26952295</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles MH, Coventry BJ. Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Manag Res. 2013;5:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753062</ArticleId><ArticleId IdType="pubmed">23990731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahrmeijer AL, Van Der Eb MM, Van Dierendonck JH, et al. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol. 1998;14:262&#x2013;268. doi: 10.1002/(SICI)1098-2388(199804/05)14:3&lt;262::AID-SSU11&gt;3.0.CO;2-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-2388(199804/05)14:3&lt;262::AID-SSU11&gt;3.0.CO;2-W</ArticleId><ArticleId IdType="pubmed">9548610</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6:180&#x2013;194. doi: 10.1177/1758834014529175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758834014529175</ArticleId><ArticleId IdType="pmc">PMC4107710</ArticleId><ArticleId IdType="pubmed">25057304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoroddu MA, Medici S, Ledda A, et al. Toxicity of nanoparticles. Curr Med Chem. 2014;21:3837&#x2013;3853. doi: 10.2174/0929867321666140601162314.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140601162314</ArticleId><ArticleId IdType="pubmed">25306903</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32743995</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>30</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January-May 2020.</ArticleTitle><Pagination><StartPage>e280</StartPage><MedlinePgn>e280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2020.35.e280</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The fatality rate of patients with coronavirus disease 2019 (COVID-19) varies among countries owing to demographics, patient comorbidities, surge capacity of healthcare systems, and the quality of medical care. We assessed the clinical outcomes of patients with COVID-19 during the first wave of the epidemic in Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a modified World Health Organization clinical record form, we obtained clinical data for 3,060 patients with COVID-19 treated at 55 hospitals in Korea. Disease severity scores were defined as: 1) no limitation of daily activities; 2) limitation of daily activities but no need for supplemental oxygen; 3) supplemental oxygen via nasal cannula; 4) supplemental oxygen via facial mask; 5) non-invasive mechanical ventilation; 6) invasive mechanical ventilation; 7) multi-organ failure or extracorporeal membrane oxygenation therapy; and 8) death. Recovery was defined as a severity score of 1 or 2, or discharge and release from isolation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the patients was 43 years of age; 43.6% were male. The median time from illness onset to admission was 5 days. Of the patients with a disease severity score of 3-4 on admission, 65 (71.5%) of the 91 patients recovered, and 7 (7.7%) died due to illness by day 28. Of the patients with disease severity scores of 5-7, 7 (19.5%) of the 36 patients recovered, and 8 (22.2%) died due to illness by day 28. None of the 1,324 patients who were &lt; 50 years of age died; in contrast, the fatality rate due to illness by day 28 was 0.5% (2/375), 0.9% (2/215), 5.8% (6/104), and 14.0% (7/50) for the patients aged 50-59, 60-69, 70-79, and &#x2265; 80 years of age, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In Korea, almost all patients of &lt; 50 years of age with COVID-19 recovered without supplemental oxygen. In patients of &#x2265; 50 years of age, the fatality rate increased with age, reaching 14% in patients of &#x2265; 80 years of age.</AbstractText><CopyrightInformation>&#xa9; 2020 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Ho Kyung</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0002-1207-0298</Identifier><AffiliationInfo><Affiliation>National Emergency Medical Center, National Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Yong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-4306-1597</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Center, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeonghun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9534-2921</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Busan Medical Center, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Haesook</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3554-6172</Identifier><AffiliationInfo><Affiliation>Department of Tuberculosis, Seoul Metropolitan Seobuk Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Young Soo</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0003-3586-9446</Identifier><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Seoul Metropolitan Seonam Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyewon</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3491-1059</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Chungju Medical Center, Chungju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Bo Ram</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-8810-1417</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Gyeonggi Provincial Medical Center Ansung Hospital, Anseong, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Neungsun</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4622-9655</Identifier><AffiliationInfo><Affiliation>Department of Infection Control, Chungcheongnam-do Gongju Medical Center, Gongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Hong Sang</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-4535-6305</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Young Mi</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-8314-6317</Identifier><AffiliationInfo><Affiliation>Department of Infection Control, Chungcheongnam-do Seosan Medical Center, Seosan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyung Hwa</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0003-2836-6963</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shon</LastName><ForeName>Jeung A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-9515-7665</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Yeongju Red Cross Hospital, Yeongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Chul</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-4410-5608</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joon Ho</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-4127-2312</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Gyeonggi Provincial Medical Center Uijeongbu Hospital, Uijeongbu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hyun Ha</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0002-9405-2121</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yukyung</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0660-9867</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea Workers' Compensation &amp; Welfare Services Daegu Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yu Min</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-4368-9878</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Myongji Hospital, Goyang, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0003-1179-1664</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Chungcheongnam-do Cheonan Medical Center, Cheonan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-9990-6042</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyun Jung</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-4104-9583</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Jeonllanam-do Suncheon Medical Center, Suncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Kyoung Ho</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-4517-3840</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0003-1104-268X</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Cheongju Medical Center, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyeongseok</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4539-079X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Yeon</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-2788-1392</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ja Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-1044-644X</Identifier><AffiliationInfo><Affiliation>Intensive Care Team, Gyeonggi Provincial Medical Center Paju Hospital, Paju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jihee</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5255-1352</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Eun Hwa</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0001-5814-7636</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Korea Worker's Compensation &amp; Welfare Service Changwon Hospital, Changwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Ki Hyun</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-7100-2519</Identifier><AffiliationInfo><Affiliation>National Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Myoung Don</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-2344-7695</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. mdohmd@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Korea National Committee for Clinical Management of COVID-19</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>4838-330-320-01</GrantID><Acronym>KCDC</Acronym><Agency>Korea Centers for Disease Control &amp; Prevention</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Korean Med Sci. 2020 Sep 28;35(38):e353. doi: 10.3346/jkms.2020.35.e353.</RefSource><PMID Version="1">32989937</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010356" MajorTopicYN="N">Patient Isolation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055872" MajorTopicYN="N">Surge Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cohort Study</Keyword><Keyword MajorTopicYN="N">Korea</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32743995</ArticleId><ArticleId IdType="pmc">PMC7402927</ArticleId><ArticleId IdType="doi">10.3346/jkms.2020.35.e280</ArticleId><ArticleId IdType="pii">35.e280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Coronavirus disease (COVID-2019) situation report-143.  [Updated 2020].  [Accessed 15 June, 2020].   https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation></Reference><Reference><Citation>Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci. 2020;35(5):e61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008073</ArticleId><ArticleId IdType="pubmed">32030925</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Centers for Disease control and Prevention. Coronavirus disease-19 main website.  [Updated 2020].  [Accessed June 15, 2020].   http://ncov.mohw.go.kr/en.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72&#x202f;314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. I.S.A.R.E.I.C., Global COVID-19: clinical platform: novel coronavius (&#x200e;COVID-19)&#x200e;: rapid version. Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Korea Centers for Disease control and Prevention. Press release. Coronavirus disease-19, Republic of Korea.  [Updated 2020].  [Accessed June 12, 2020].   http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&amp;brdGubun=125&amp;dataGubun=&amp;ncvContSeq=&amp;contSeq=&amp;board_idhttp://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&amp;brdGubun=125&amp;dataGubun=&amp;ncvContSeq=&amp;contSeq=&amp;board_id=</Citation></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30483-7. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020;35(13):e142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131901</ArticleId><ArticleId IdType="pubmed">32242348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NJ, Choe PG, Park SJ, Lim J, Lee WJ, Kang CK, et al. A cluster of tertiary transmissions of 2019 novel coronavirus (SARS-CoV-2) in the community from infectors with common cold symptoms. Korean J Intern Med. 2020;35(4):758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373952</ArticleId><ArticleId IdType="pubmed">32506866</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073313</ArticleId><ArticleId IdType="pubmed">32174069</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2007764. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pubmed">32649078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang E, Lee SY, Jung H, Kim MS, Cho B, Kim YS. Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea. Emerging. Emerg Infect Dis. 2020 doi: 10.3201/eid2610.201460. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201460</ArticleId><ArticleId IdType="pmc">PMC7510742</ArticleId><ArticleId IdType="pubmed">32568665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Hong CM, Kim DH, Lee TH, Lee J. Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis. 2020 doi: 10.3201/eid2610.201620. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201620</ArticleId><ArticleId IdType="pmc">PMC7510714</ArticleId><ArticleId IdType="pubmed">32568662</ArticleId></ArticleIdList></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411&#x2013;2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224609</ArticleId><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">22152134</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1008-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Chinese journal of traumatology = Zhonghua chuang shang za zhi</Title><ISOAbbreviation>Chin J Traumatol</ISOAbbreviation></Journal><ArticleTitle>Postoperative mortality and morbidity in octogenarians and nonagenarians with hip fracture: an analysis of perioperative risk factors.</ArticleTitle><Pagination><StartPage>323</StartPage><EndPage>328</EndPage><MedlinePgn>323-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the role of high risk factors in octogenarians and nonagenarians with hip trauma, which may lead to excessive mortality and morbi- dity postoperatively.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-four octogenarians and nonagenarians patients were enrolled in the study, receiving surgical repair of hip fracture in our hospital from January 2006 to January 2010. High risk factors were recorded preoperatively in detail. Complications and survival state were followed up by telephone for 2 years postoperatively. All the data were analyzed by Chi-square test with SPSS 13.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six males (48.1%), aged from 80 to 94 years with a mean age of 84.2 years, and twenty-eight females (51.9%), aged from 80 to 95 years with a mean age of 83.4 years, were presented in the cohort study. The hip traumas were caused by daily slight injuries (52 cases) and car accidents (2 cases), respectively. Twenty-eight patients (51.9%) with femoral neck fracture while 26 patients (48.1%) with intertrochanteric fracture were diagnosed through an anterior-posterior pelvic radiophotograph. In this series, 39 patients (72.2%) suffered from one or more comorbidities preoperatively. The morbidity was 48.1% and the major cause was urinary tract infection, while a significant difference was noted between females and males. The mortality was 20.4% with a predominant cause of acute renal failure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The gender should be considered as a critical high risk factor in octogenarians and nonagenarians with hip trauma postoperatively. Females are more likely to suffer complications postoperatively, which is especially obvious in senile patients over 80 years (P less than 0.05). Urinary tract infection is the most frequent complication after hip surgery, followed by low limb embolism and malnutrition. The mortality is dramatically greater in patients over 80 years old than those below, and major causes are acute renal failure, multiple organ dysfunction syndrome and mental deterioration. Multidisciplinary consultations and mental assessment are encouraged in patients over 80 years old after hip trauma and surgery. Hip fractures in octogenarians and nonagenarians deserve special attention because of their advanced age and comorbidities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Ren-Shi</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, First Hospital of Jilin University, Changchun 130021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Gui-Shan</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Hai-Yu</ForeName><Initials>HY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin J Traumatol</MedlineTA><NlmUniqueID>100886162</NlmUniqueID><ISSNLinking>1008-1275</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005265" MajorTopicYN="N">Femoral Neck Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22152134</ArticleId><ArticleId IdType="pii">S1008-1275(16)30003-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38409062</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2731-3786</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of anesthesia, analgesia and critical care</Title><ISOAbbreviation>J Anesth Analg Crit Care</ISOAbbreviation></Journal><ArticleTitle>The use of extracorporeal blood purification therapies and sequential extracorporeal support in patients with septic shock (EROICASS): a study protocol for a national, non-interventional, observational multicenter, prospective study.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s44158-024-00153-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Septic shock, a critical condition characterized by organ failure, presents a substantial mortality risk in intensive care units (ICUs), with the 28-day mortality rate possibly reaching 40%. Conventional management of septic shock typically involves the administration of antibiotics, supportive care for organ dysfunction, and, if necessary, surgical intervention to address the source of infection. In recent decades, extracorporeal blood purification therapies (EBPT) have emerged as potential interventions aimed at modulating the inflammatory response and restoring homeostasis in patients with sepsis. Likewise, sequential extracorporeal therapy in sepsis (SETS) interventions offer comprehensive organ support in the setting of multiple organ dysfunction syndrome (MODS). The EROICASS study will assess and describe the utilization of EBPT in patients with septic shock. Additionally, we will evaluate the potential association between EBPT treatment utilization and 90-day mortality in septic shock cases in Italy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The EROICASS study is a national, non-interventional, multicenter observational prospective cohort study. All consecutive patients with septic shock at participating centers will be prospectively enrolled, with data collection extending from intensive care unit (ICU) admission to hospital discharge. Variables including patient demographics, clinical parameters, EBPT/SETS utilization, and outcomes will be recorded using a web-based data capture system. Statistical analyses will encompass descriptive statistics, hypothesis testing, multivariable regression models, and survival analysis to elucidate the associations between EBPT/SETS utilization and patient outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The EROICASS study provides valuable insights into the utilization and outcomes of EBPT and SETS in septic shock management. Through analysis of usage patterns and clinical data, this study aims to guide treatment decisions and enhance patient care. The implications of these findings may impact clinical guidelines, potentially improving survival rates and patient outcomes in septic shock cases.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Rosa</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8987-4596</Identifier><AffiliationInfo><Affiliation>Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy. silvia.derosa@unitn.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy. silvia.derosa@unitn.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy. silvia.derosa@unitn.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Fiorenza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Intensive Care and Emergency, Fondazione IRRCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Clinical and Research Center, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pota</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umbrello</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Resuscitation and Anesthesia, ASST Ovest Milanese, Ospedale Nuovo Di Legnano, Legnano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotoia</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Anesthesia and Intensive Care Unit, University of Foggia, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasin</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalesso</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nephrology, University Hospital, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paternoster</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiac Resuscitation, Cardiovascular Anesthesia and Intensive Care, San Carlo Hospital, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, Intensive Care and Pain Medicine Section of Anesthesia, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassola</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miori</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantaluppi</LastName><ForeName>Vicenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, Nephrology and Kidney Transplantation Unit, "Maggiore Della Carit&#xe0;" University Hospital, University of Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marengo</LastName><ForeName>Marita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Specialist Medicine, Nephrology and Dialysis Unit, Azienda Sanitaria Locale (ASL) CN1, Cuneo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorentino</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical, Oncological, and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunori</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology and Dialysis, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellani</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giarratano</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical, Oncological, and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Intensive Care, and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Anesth Analg Crit Care</MedlineTA><NlmUniqueID>9918591885906676</NlmUniqueID><ISSNLinking>2731-3786</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EROICASS</Keyword><Keyword MajorTopicYN="N">Extracorporeal blood purification therapies</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Sepsis-associated AKI</Keyword><Keyword MajorTopicYN="N">Sequential extracorporeal support</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38409062</ArticleId><ArticleId IdType="pmc">PMC10898122</ArticleId><ArticleId IdType="doi">10.1186/s44158-024-00153-7</ArticleId><ArticleId IdType="pii">10.1186/s44158-024-00153-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304&#x2013;377. doi: 10.1007/s00134-017-4683-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-017-4683-6</ArticleId><ArticleId IdType="pubmed">28101605</ArticleId></ArticleIdList></Reference><Reference><Citation>Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif. 2012;33:88&#x2013;100. doi: 10.1159/000333845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000333845</ArticleId><ArticleId IdType="pubmed">22248671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A, Koyner JL, Gomez H, Pickkers P, Forni L, ADQI group. Sepsis-associated acute kidney injury - treatment standard. Nephrol Dial Transplant 2023:gfad142. 10.1093/ndt/gfad142.</Citation><ArticleIdList><ArticleId IdType="pubmed">37401137</ArticleId></ArticleIdList></Reference><Reference><Citation>Plataki M, Kashani K, Cabello-Garza J, Maldonado F, Kashyap R, Kor DJ, et al. Predictors of acute kidney injury in septic shock patients: an observational cohort study. Clin J Am Soc Nephrol. 2011;6:1744&#x2013;1751. doi: 10.2215/CJN.05480610.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05480610</ArticleId><ArticleId IdType="pubmed">21734090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35:1837&#x2013;43; quiz 1852. 10.1097/01.CCM.0000277041.13090.0A.</Citation><ArticleIdList><ArticleId IdType="pubmed">17581483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023;19:401&#x2013;417. doi: 10.1038/s41581-023-00683-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-023-00683-3</ArticleId><ArticleId IdType="pubmed">36823168</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Marengo M, Fiorentino M, Fanelli V, Brienza N, Fiaccadori E, et al. Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission. J Nephrol. 2023 doi: 10.1007/s40620-023-01637-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-023-01637-5</ArticleId><ArticleId IdType="pmc">PMC10543830</ArticleId><ArticleId IdType="pubmed">37439963</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Cutuli SL, Lorenzin A, Zanella M. Sequential extracorporeal therapy in sepsis. Contrib Nephrol. 2023;200:1&#x2013;11. doi: 10.1159/000527573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000527573</ArticleId><ArticleId IdType="pubmed">37290408</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Samoni S, Ronco C. Sequential extracorporeal therapy collaborative device and timely support for endotoxic, septic, and cardiac shock: a case report. Blood Purif. 2020;49:502&#x2013;508. doi: 10.1159/000505146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000505146</ArticleId><ArticleId IdType="pubmed">31865323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilakovac V, Fister K, Marusic M, Marusic A. Reliability of disclosure forms of authors&#x2019; contributions. Can Med Assoc J. 2006;176:41&#x2013;46. doi: 10.1503/cmaj.060687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.060687</ArticleId><ArticleId IdType="pmc">PMC1764586</ArticleId><ArticleId IdType="pubmed">17200389</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O&#x2019;Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53:330&#x2013;339. doi: 10.2307/2533118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2533118</ArticleId><ArticleId IdType="pubmed">9147598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant A, Mackraj I, Govender T. Advances in sepsis diagnosis and management: a paradigm shift towards nanotechnology. J Biomed Sci. 2021;28:6. doi: 10.1186/s12929-020-00702-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-00702-6</ArticleId><ArticleId IdType="pmc">PMC7790597</ArticleId><ArticleId IdType="pubmed">33413364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu J, Zhang C, Xiao J, Liu C, Wang S, et al. Non-invasive early prediction of septic acute kidney injury by Doppler-based renal resistive indexes combined with echocardiographic parameters: an experimental study. Front Med (Lausanne) 2021;8:723837. doi: 10.3389/fmed.2021.723837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.723837</ArticleId><ArticleId IdType="pmc">PMC8671634</ArticleId><ArticleId IdType="pubmed">34926487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30127093</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2046-6390</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Biology open</Title><ISOAbbreviation>Biol Open</ISOAbbreviation></Journal><ArticleTitle>Red cell distribution width as a predictor of multiple organ dysfunction syndrome in patients undergoing heart valve surgery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">bio036251</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1242/bio.036251</ELocationID><Abstract><AbstractText>The aim of the study was to evaluate the prognostic value of red cell distribution width (RDW) for multiple organ dysfunction syndrome (MODS) in the early postoperative period in patients undergoing valve replacement or repair surgery. A prospective study was conducted on a group of 713 patients with haemodynamically significant valvular heart disease who underwent elective valvular surgery. The primary end-point at the 30-day follow-up was postoperative MODS. The secondary end-point was death from all causes in patients with MODS. The postoperative MODS occurred in 72 patients. At multivariate analysis: RDW (OR 1.267; 95% CI 1.113-1.441; <i>P</i>=0.0003), creatinine (OR 1.007; 95% CI 1.001-1.013; <i>P</i>=0.02) and age (OR 1.047; 95% CI 1.019-1.077; <i>P</i>=0.001) remained independent predictors of the primary end-point. Receiver operator characteristics analysis determined a cut-off value of RDW for the prediction of the occurrence of the perioperative MODS at 14.3%. RDW (OR 1.448; 95% CI 1.057-1.984; <i>P</i>=0.02) and age (OR 1.057; 95% CI 1.007-1.117; <i>P</i>=0.04) were associated with an increased risk of death in patients with perioperative MODS. Elevated RDW is associated with a higher risk of MODS and death in patients with MODS following heart valve surgery.</AbstractText><CopyrightInformation>&#xa9; 2018. Published by The Company of Biologists Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duchnowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6506-5612</Identifier><AffiliationInfo><Affiliation>Institute of Cardiology, Department of Acquired Cardiac Defects, 04-628 Warsaw, Poland duchnowski@vp.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hryniewiecki</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Cardiology, Department of Acquired Cardiac Defects, 04-628 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku&#x15b;mierczyk</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cardiology, Department of Cardiosurgery and Transplantology, 04-628 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szymanski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Cardiology, Department of Acquired Cardiac Defects, 04-628 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biol Open</MedlineTA><NlmUniqueID>101578018</NlmUniqueID><ISSNLinking>2046-6390</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Red cell distribution width</Keyword><Keyword MajorTopicYN="N">Risk stratification</Keyword><Keyword MajorTopicYN="N">Valve surgery</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare no competing or financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30127093</ArticleId><ArticleId IdType="pmc">PMC6215413</ArticleId><ArticleId IdType="doi">10.1242/bio.036251</ArticleId><ArticleId IdType="pii">bio.036251</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen L. A., Felker G. M., Mehra M. R., Chiong J. R., Dunlap S. H., Ghali J. K., Lenihan D. J., Oren R. M., Wagoner L. E., Schwartz T. A. et al. (2010). Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J. Card. Fail. 16, 230-238. 10.1016/j.cardfail.2009.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2009.11.003</ArticleId><ArticleId IdType="pmc">PMC3894681</ArticleId><ArticleId IdType="pubmed">20206898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ani C. and Ovbiagele B. (2009). Elevated red blood cell distribution width predicts mortality in persons with known stroke. J. Neurol. Sci. 277, 103-108. 10.1016/j.jns.2008.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.10.024</ArticleId><ArticleId IdType="pubmed">19028393</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslan D., G&#xfc;mr&#xfc;k F., G&#xfc;rgey A. and Altay C. (2002). Importance of RDW value in differential diagnosis of hypochrome anemias. Am. J. Hematol. 69, 31-33. 10.1002/ajh.10011</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.10011</ArticleId><ArticleId IdType="pubmed">11835328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazick H. S., Chang D., Mahadevappa K., Gibbons F. K. and Christopher K. B. (2011). Red cell distribution width and all-cause mortality in critically ill patients. Crit. Care Med. 39, 1913-1921. 10.1097/CCM.0b013e31821b85c6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31821b85c6</ArticleId><ArticleId IdType="pmc">PMC4427349</ArticleId><ArticleId IdType="pubmed">21532476</ArticleId></ArticleIdList></Reference><Reference><Citation>Belletti A., Jacobs S., Affronti G., Mladenow A., Landoni G., Falk V. and Schoenrath F. (2017). Incidence and predictors of postoperative need for high-dose inotropic support in patients undergoing cardiac surgery for infective endocarditis. J. Cardiothorac. Vasc. Anesth. 17, 1053-1077.10.1053/j.jvca.2017.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2017.12.015</ArticleId><ArticleId IdType="pubmed">29338996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bion J. F. (2000). Susceptibility to critical illness: reserve, response and therapy. Intens. Care Med. 26, S057-S063. 10.1007/s001340051120</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340051120</ArticleId><ArticleId IdType="pubmed">10786960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang X.-W., Zhang S.-Y., Wang H., Zhang M.-M., Zheng W.-F., Ma H.-F., Gu Y.-F., Wei J.-H. and Qiu C.-G. (2018). Combined value of red blood cell distribution width and global registry of acute coronary events risk score on predicting long-term major adverse cardiac events in STEMI patients undergoing primary PCI. Oncotarget 9, 13971-13980. 10.18632/oncotarget.24128</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24128</ArticleId><ArticleId IdType="pmc">PMC5862630</ArticleId><ArticleId IdType="pubmed">29568409</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabbah S., Hammerman H., Markiewicz W. and Aronson D. (2010). Relation between red cell distribution width and clinical outcomes after acute myocardial infarction. Am. J. Cardiol. 105, 312-317. 10.1016/j.amjcard.2009.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2009.09.027</ArticleId><ArticleId IdType="pubmed">20102941</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Szyma&#x144;ski P., Or&#x142;owska-Baranowska E., Ku&#x15b;mierczyk M. and Hryniewiecki T. (2016). Raised red cell distribution width as a prognostic marker in aortic valve replacement surgery. Kardiol. Pol. 74, 547-552.</Citation><ArticleIdList><ArticleId IdType="pubmed">26502945</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Hryniewiecki T., Ku&#x15b;mierczyk M. and Szyma&#x144;ski P. (2017). Red cell distribution width is a prognostic marker of perioperative stroke in patients undergoing cardiac valve surgery. Interact. Cardiovasc. Thorac. Surg. 25, 925-929. 10.1093/icvts/ivx216</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivx216</ArticleId><ArticleId IdType="pubmed">29049563</ArticleId></ArticleIdList></Reference><Reference><Citation>Eremenko A. and Minbolatova N. (2015). Acute kidney injury in patients with multiple organ dysfunction syndrome in the early period after cardiac. Anesteziol. Reanimatol. 60, 38-42.</Citation><ArticleIdList><ArticleId IdType="pubmed">26852578</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Zamora M. D., Gordillo-Brenes A., Banderas-Bravo E., Arboleda-S&#xe1;nchez J. A., Hinojosa-P&#xe9;rez R., Aguilar-Alonso E., Herruzo-Aviles &#xc1;., Curiel-Balsera E., S&#xe1;nchez-Rodr&#xed;guez &#xc1;., Rivera-Fern&#xe1;ndez R. et al. (2018). Prolonged mechanical ventilation as a predictor of mortality after cardiac surgery. Respir. Care 63, 550-557. 10.4187/respcare.04915</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.04915</ArticleId><ArticleId IdType="pubmed">29382792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunziker S., Celi L. A., Lee J. and Howell M. D. (2012). Red cell distribution width improves the simplified acute physiology score for risk prediction in unselected critically ill patients. Critical. Care 16, 89 10.1186/cc11351</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11351</ArticleId><ArticleId IdType="pmc">PMC3580634</ArticleId><ArticleId IdType="pubmed">22607685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara H., Degirmenci S., Bayir A., Ak A., Akinci M., Dogru A., Akyurek F. and Kayis S. A. (2015). Red cell distribution width and neurological scoring systems in acute stroke patients. Neuropsychiatr. Dis. Treat. 11, 733-739. 10.2147/NDT.S81525</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S81525</ArticleId><ArticleId IdType="pmc">PMC4370912</ArticleId><ArticleId IdType="pubmed">25834448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Kim Y., Song T.-J., Park J., Lee H., Nam C., Nam H. and Heo J. (2012). Red blood cell distribution width is associated with poor clinical outcome in acute cerebral infarction. Thromb. Haemost. 108, 349-356. 10.1160/TH12-03-0165</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH12-03-0165</ArticleId><ArticleId IdType="pubmed">22739700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Lee K., Kim I., Jung S. and Kim M.-J. (2015). Red cell distribution width and early mortality in elderly patients with severe sepsis and septic shock. Clin. Exp. Emerg. Med. 30, 155-161. 10.15441/ceem.15.037</Citation><ArticleIdList><ArticleId IdType="doi">10.15441/ceem.15.037</ArticleId><ArticleId IdType="pmc">PMC5052839</ArticleId><ArticleId IdType="pubmed">27752590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima T., Yasuhara J., Kumamoto T., Shimizu H., Yoshiba S., Kobayashi T. and Sumitomo N. (2015). Usefulness of the red blood cell distribution width to predict heart failure in patients with a fontan circulation. Am. J. Cardiol. 116, 965-968. 10.1016/j.amjcard.2015.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.06.020</ArticleId><ArticleId IdType="pubmed">26239579</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwi&#x144;ski P., Ko&#x142;sut P., Sitko T., Zieli&#x144;ski T., Hoffman P., Hryniewiecki T., R&#xf3;&#x17c;a&#x144;ski J. and Ku&#x15b;mierczyk M. (2018). Results and factors associated with adverse outcome after tricuspid valve replacement. Kardiol. Pol. 76, 731-739. 10.5603/KP.a2018.0026</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.a2018.0026</ArticleId><ArticleId IdType="pubmed">29589379</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagnana M., Cervellin G., Meschi T. and Lippi G. (2011). The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin. Chem. Lab. Med. 50, 635-641.10.1515/cclm.2011.831</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm.2011.831</ArticleId><ArticleId IdType="pubmed">22505527</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H. J., Park J. T., Kim J.-K., Yoo D. E., Kim S. J., Han S. H., Kang S.-W., Choi K. H. and Yoo T.-H. (2012). Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol. Dial. Transplant. 27, 589-594. 10.1093/ndt/gfr307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfr307</ArticleId><ArticleId IdType="pubmed">21712489</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel K. V., Mohanty J. G., Kanapuru B., Hesdorffer C., Ershler W. B. and Rifkind J. M. (2013). Association of the red cell distribution width with red blood cell deformability. Adv. Exp. Med. Biol. 765, 211-216. 10.1007/978-1-4614-4989-8_29</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-4989-8_29</ArticleId><ArticleId IdType="pmc">PMC5939938</ArticleId><ArticleId IdType="pubmed">22879035</ArticleId></ArticleIdList></Reference><Reference><Citation>Poglajen G., Sever M., &#x10c;ernel&#x10d; P., Haddad F. and Vrtovec B. (2015). Increased red cell distribution width is associated with poor stem cell mobilization in patients with advanced chronic heart failure. Biomarkers 20, 365-370. 10.3109/1354750X.2015.1094137</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1354750X.2015.1094137</ArticleId><ArticleId IdType="pubmed">26472500</ArticleId></ArticleIdList></Reference><Reference><Citation>Poludasu S., Marmur J. D., Weedon J., Khan W. and Cavusoglu E. (2009). Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention. Thromb. Haemost. 102, 581-587. 10.1160/TH09-02-0127</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH09-02-0127</ArticleId><ArticleId IdType="pubmed">19718480</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvagno G. L., Sanchis-Gomar F., Picanza A. and Lippi G. (2015). Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit. Rev. Clin. Lab. Sci. 52, 86-105. 10.3109/10408363.2014.992064</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10408363.2014.992064</ArticleId><ArticleId IdType="pubmed">25535770</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;enol K., Saylam B., Kocaay F. and Tez M. (2013). Red cell distribution width as a predictor of mortality in acute pancreatitis. Am. J. Emerg. Med. 31, 687-689. 10.1016/j.ajem.2012.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2012.12.015</ArticleId><ArticleId IdType="pubmed">23399348</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman K. (1987). Postoperative multiple organ failure. Crit. Care Clin. 3, 429-440. 10.1016/S0749-0704(18)30554-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(18)30554-2</ArticleId><ArticleId IdType="pubmed">3332208</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung K. K., Groeneveld M., Lu J. J.-N., Van Diemen P., Jongkind V. and Wisselink W. (2016). Organ protection during aortic cross-clamping. Best Pract. Res. Clin. Anaesthesiol. 30, 305-315. 10.1016/j.bpa.2016.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpa.2016.07.005</ArticleId><ArticleId IdType="pubmed">27650341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X., Lee J. W., Bowser J. L., Neudecker V., Sridhar S. and Eltzschig H. K. (2018). Targeting hypoxia signaling for perioperative organ injury. Anesth. Analg. 126, 308-321. 10.1213/ANE.0000000000002288</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000002288</ArticleId><ArticleId IdType="pmc">PMC5735013</ArticleId><ArticleId IdType="pubmed">28759485</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Gu T., Xiu Z., Shi E. and Yu L. (2016). Mild hypothermia may offer some improvement to patients with MODS after CPB surgery. Braz. J. Cardiovasc. Surg. 31, 246-251. 10.5935/1678-9741.20160048</Citation><ArticleIdList><ArticleId IdType="doi">10.5935/1678-9741.20160048</ArticleId><ArticleId IdType="pmc">PMC5062708</ArticleId><ArticleId IdType="pubmed">27737408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32091503</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1529-7535</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title><ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Comparison of the Automated Pediatric Logistic Organ Dysfunction-2 Versus Manual Pediatric Logistic Organ Dysfunction-2 Score for Critically Ill Children.</ArticleTitle><Pagination><StartPage>e160</StartPage><EndPage>e169</EndPage><MedlinePgn>e160-e169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0000000000002235</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The Pediatric Logistic Organ Dysfunction-2 is a validated score that quantifies organ dysfunction severity and requires complex data collection that is time-consuming and subject to errors. We hypothesized that a computer algorithm that automatically collects and calculates the Pediatric Logistic Organ Dysfunction-2 (aPELOD-2) score would be valid, fast and at least as accurate as a manual approach (mPELOD-2).</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING">Single center tertiary medical and surgical pediatric critical care unit (Sainte-Justine Hospital, Montreal, Canada).</AbstractText><AbstractText Label="PATIENTS">Critically ill children participating in four clinical studies between January 2013 and August 2018, a period during which mPELOD-2 data were manually collected.</AbstractText><AbstractText Label="INTERVENTIONS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">The aPELOD-2 was calculated for all consecutive admissions between 2013 and 2018 (n = 5,279) and had a good survival discrimination with an area under the receiver operating characteristic curve of 0.84 (95% CI, 0.81-0.88). We also collected data from four single-center studies in which mPELOD-2 was calculated (n = 796, 57% medical, 43% surgical) and compared these measurements to those of the aPELOD-2. For those patients, median age was 15 months (interquartile range, 3-73 mo), median ICU stay was 5 days (interquartile range, 3-9 d), mortality was 3.9% (n = 28). The intraclass correlation coefficient between mPELOD-2 and aPELOD-2 was 0.75 (95% CI, 0.73-0.77). The Bland-Altman showed a bias of 1.9 (95% CI, 1.7-2) and limits of agreement of -3.1 (95% CI, -3.4 to -2.8) to 6.8 (95% CI, 6.5-7.2). The highest agreement (Cohen's Kappa) of the Pediatric Logistic Organ Dysfunction-2 components was noted for lactate level (0.88), invasive ventilation (0.86), and creatinine level (0.82) and the lowest for the Glasgow Coma Scale (0.52). The proportion of patients with multiple organ dysfunction syndrome was higher for aPELOD-2 (78%) than mPELOD-2 (72%; p = 0.002). The aPELOD-2 had a better survival discrimination (area under the receiver operating characteristic curve, 0.81; 95% CI, 0.72-0.90) over mPELOD-2 (area under the receiver operating characteristic curve, 0.70; 95% CI, 0.59-0.82; p = 0.01).</AbstractText><AbstractText Label="CONCLUSIONS">We successfully created a freely available automatic algorithm to calculate the Pediatric Logistic Organ Dysfunction-2 score that is less labor intensive and has better survival discrimination than the manual calculation. Use of an automated system could greatly facilitate integration of the Pediatric Logistic Organ Dysfunction-2 score at the bedside and within clinical decision support systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sauthier</LastName><ForeName>Micha&#xeb;l</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landry-Hould</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, EA 2694 - Sant&#xe9; Publique: &#xe9;pid&#xe9;miologie et qualit&#xe9; des soins, Service de r&#xe9;animation p&#xe9;diatrique, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emeriaud</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouvet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Crit Care Med</MedlineTA><NlmUniqueID>100954653</NlmUniqueID><ISSNLinking>1529-7535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Pediatr Crit Care Med. 2020 Apr;21(4):397-398. doi: 10.1097/PCC.0000000000002244.</RefSource><PMID Version="1">32251189</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32091503</ArticleId><ArticleId IdType="doi">10.1097/PCC.0000000000002235</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31821429</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>322</Volume><Issue>22</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>2179</StartPage><EndPage>2190</EndPage><MedlinePgn>2179-2190</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.17478</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The clinical consequences of red blood cell storage age for critically ill pediatric patients have not been examined in a large, randomized clinical trial.</AbstractText><AbstractText Label="OBJECTIVE">To determine if the transfusion of fresh red blood cells (stored &#x2264;7 days) reduced new or progressive multiple organ dysfunction syndrome compared with the use of standard-issue red blood cells in critically ill children.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Age of Transfused Blood in Critically-Ill Children trial was an international, multicenter, blinded, randomized clinical trial, performed between February 2014 and November 2018 in 50 tertiary care centers. Pediatric patients between the ages of 3 days and 16 years were eligible if the first red blood cell transfusion was administered within 7 days of intensive care unit admission. A total of 15&#x202f;568 patients were screened, and 13&#x202f;308 were excluded.</AbstractText><AbstractText Label="INTERVENTIONS">Patients were randomized to receive either fresh or standard-issue red blood cells. A total of 1538 patients were randomized with 768 patients in the fresh red blood cell group and 770 in the standard-issue group.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured for 28 days or to discharge or death.</AbstractText><AbstractText Label="RESULTS">Among 1538 patients who were randomized, 1461 patients (95%) were included in the primary analysis (median age, 1.8 years; 47.3% girls), in which there were 728 patients randomized to the fresh red blood cell group and 733 to the standard-issue group. The median storage duration was 5 days (interquartile range [IQR], 4-6 days) in the fresh group vs 18 days (IQR, 12-25 days) in the standard-issue group (P&#x2009;&lt;&#x2009;.001). There were no significant differences in new or progressive multiple organ dysfunction syndrome between fresh (147 of 728 [20.2%]) and standard-issue red blood cell groups (133 of 732 [18.2%]), with an unadjusted absolute risk difference of 2.0% (95% CI, -2.0% to 6.1%; P&#x2009;=&#x2009;.33). The prevalence of sepsis was 25.8% (160 of 619) in the fresh group and 25.3% (154 of 608) in the standard-issue group. The prevalence of acute respiratory distress syndrome was 6.6% (41 of 619) in the fresh group and 4.8% (29 of 608) in the standard-issue group. Intensive care unit mortality was 4.5% (33 of 728) in the fresh group vs 3.5 % (26 of 732) in the standard-issue group (P&#x2009;=&#x2009;.34).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT01977547.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spinella</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Universit&#xe9; de Montr&#xe9;al and Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Ottawa Hospital Research Institute, Departments of Medicine &amp; Surgery, University of Ottawa School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Universit&#xe9; de Montr&#xe9;al and Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de m&#xe9;decine, Centre de recherche du CHUM and Chaire de m&#xe9;decine transfusionnelle H&#xe9;ma-Qu&#xe9;bec-Bayer de l'Universit&#xe9; de Montr&#xe9;al, Centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, EA 2694-Sant&#xe9; publique: &#xe9;pid&#xe9;miologie et qualit&#xe9; des soins, CHU Lille, R&#xe9;animation P&#xe9;diatrique, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>The Children's Hospital of Philadelphia, Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bockelmann</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caro</LastName><ForeName>J Jaime</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>London School of Economics, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidera, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Bambino Ges&#xf9; Children's Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical, Department of Pediatrics, Centre Hospitalier Universitaire (CHU) Sainte-Justine Universit&#xe9; de Montr&#xe9;al and Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Critical Care and Cardiology, Department of Pediatrics, University of Rochester Golisano Children's Hospital, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerra</LastName><ForeName>Gonzalo Garcia</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stollery Children's Hospital, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Pediatrics, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transfusion, Tissue, Apheresis Services, Children's Healthcare of Atlanta, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nellis</LastName><ForeName>Marianne E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care, Department of Pediatrics, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarpal</LastName><ForeName>Amrita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Western University, Children's Hospital, London Health Sciences Centre, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Pediatric Hematology and Oncology, Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Minnesota Medical School, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Alexis F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Research CHU de Qu&#xe9;bec-Universit&#xe9; Laval Centre, Population Health and Optimal Health Practices and Research Unit, Trauma, Emergency, Critical Care Medicine, Universit&#xe9; Laval and Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ABC-PICU Investigators, the Canadian Critical Care Trials Group, the Pediatric Acute Lung Injury and Sepsis Investigators Network, the BloodNet Pediatric Critical Care Blood Research Network, and the Groupe Francophone de R&#xe9;animation et Urgences P</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01977547</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K08 GM129763</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL116383</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2019 Dec 10;322(22):2175-2176. doi: 10.1001/jama.2019.17476.</RefSource><PMID Version="1">31821418</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="Y">Blood Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012127" MajorTopicYN="N">Respiratory Distress Syndrome, Newborn</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Spinella reported that he served as a consultant for Hemanext, that his institution received funding for the ABC PICU trial, has equity in KaloCyte, and received grants from KaloCyte, the National Heart, Lung, and Blood Institute (NHLBI), and the US Department of Defense (DOD). Dr Tucci reported that her institution received funding for the ABC-PICU trial. Dr Fergusson reported that his institution received funding data management and analysis for the ABC-PICU trial. Dr Lacroix reported that his institution received funding for the ABC-PICU trial. Dr Leteurtre reported that he received grants from Health French Ministry and GFRUP. Dr Schechtman reported that his institution received funding for the ABC-PICU trial. Dr Doctor reported that his institution received funding for the ABC-PICU trial; that he has equity in KaloCyte; received grants from KaloCyte, the National Institutes of Health (NIH), the NHLBI, the DOD, Entegrion; and that he received personal fees from Fresenius Kabi and Biogen. Dr Berg reported that she received grants from NIH. Ms Bockelmann reported that her institution received funding for the ABC-PICU trial. Dr Caro reported that he received support from Evidera and grants from EURO 2020. Ms Clayton reported that her institution received funding for the ABC-PICU trial. Dr Josephson reported that she has consulted for Octapharma and Immucor, received nonfinancial support from Sysmex, and received grants from Medtronics. Dr Muszynski reported that she received grants from the NIH. Ms Schafer reported that her institution received funding for the ABC-PICU trial. Dr Steiner reported that she received grants from NIH. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Spinella</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bockelmann</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caro</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hume</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karam</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Javouhey</LastName><ForeName>&#xc9;tienne</ForeName><Initials>&#xc9;</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dean</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giroir</LastName><ForeName>Brett</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellamy</LastName><ForeName>Abbie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoehn</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poitras</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terrill</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramsay</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vo</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuire</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabri</LastName><ForeName>Elham</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baty</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Hongjie</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clayton</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xc9;meriaud</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robitaille</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanchette</LastName><ForeName>Joannie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haj-Moustafa</LastName><ForeName>Adnan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincent</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lagu&#xeb;</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumitrascu</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>French</LastName><ForeName>Mary-Ellen</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nait-Ladjemil</LastName><ForeName>Djouher</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghamraoui</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grisoni</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bensaadi</LastName><ForeName>Kahina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girouard</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia Guerra</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nahirniak</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>deMoissac</LastName><ForeName>Jodie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doepker</LastName><ForeName>Rosalyn</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarpal</LastName><ForeName>Amrita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunz</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cameron</LastName><ForeName>Saoirse</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsia</LastName><ForeName>Cyrus</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinney</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchison</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lau</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferri</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salehmohamed</LastName><ForeName>Hussein</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazarro</LastName><ForeName>Sonny</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>O&#x2019;Hearn</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labelle</LastName><ForeName>Roxane</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dugas</LastName><ForeName>Marc-Andr&#xe9;</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gosselin</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belleau</LastName><ForeName>Annie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilfoyle</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabani-Rad</LastName><ForeName>Meer-Taher</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Dori-Ann</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Dallas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishi</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontela</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whittemore</LastName><ForeName>Blair</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>O&#x2019;Donnell</LastName><ForeName>Shauna</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamica</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choong</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Korinne</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wensley</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Au</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krahnm</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schafer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Remy</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steibel</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Root Tallie</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henrichs</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sesok-Pizzini</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leonard</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muszynkski</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicol</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hensley</LastName><ForeName>Josey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsillio</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shukla</LastName><ForeName>Avani</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillen</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapru</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas-Shiraishi</LastName><ForeName>Ofelia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nellis</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Small</LastName><ForeName>Keshia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cushing</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avery</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerrigan</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelletier</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stidham</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mourani</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deschenes</LastName><ForeName>Jendar</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkes</LastName><ForeName>Meredith</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson</LastName><ForeName>Sheila</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woods</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Punzalan</LastName><ForeName>Rowena</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Connor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proytcheva</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hobson</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudgins</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaught</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winkler</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kong</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sewell</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lomeli</LastName><ForeName>Mayra</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perumbeti</LastName><ForeName>Ajay</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loftis</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaimon</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruzdoski</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayachandran</LastName><ForeName>Chaandini</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willson</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanford</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nerheim</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dodge Zantek</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Statlets</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krallman</LastName><ForeName>Kelli</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoneman</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paden</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skvarich</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jerry</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delaney</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luckett</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noland</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hupp</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozment</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandarenko</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeRidder</LastName><ForeName>Gustaaf</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adu-Darko</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fang</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorham</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quaid</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donovan</LastName><ForeName>Ramona</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roggeman</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saini</LastName><ForeName>Arun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>West</LastName><ForeName>Nico</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryder</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharron</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colvin</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bysani</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monjure</LastName><ForeName>Tracey</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Resch</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Den Berghe</LastName><ForeName>Williams</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frade-Proud&#x2019;Hon-Clerc</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dedurwaerder-Tollot</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baudelet</LastName><ForeName>Jean-Beno&#xee;t</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadik</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Resch</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dauger</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Bourgeois</LastName><ForeName>Fleur</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smaine</LastName><ForeName>Djamel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orliaguet</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albinni</LastName><ForeName>Souha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joram</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boureille</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaillot</LastName><ForeName>Th&#xe9;ophile</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herv&#xe9;</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brissaud</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beguet</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupic</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albinni</LastName><ForeName>Souha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xe9;ger</LastName><ForeName>Pierre-Louis</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallet</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cillis</LastName><ForeName>Annagrazia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montanari</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Picardo</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giugni</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cecchi</LastName><ForeName>Costanza</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allegro</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bambi</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nellis</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Tselia</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paret</LastName><ForeName>Gideon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardi</LastName><ForeName>Amir</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31821429</ArticleId><ArticleId IdType="pmc">PMC7081749</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.17478</ArticleId><ArticleId IdType="pii">2757226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Demaret P, Tucci M, Ducruet T, Trottier H, Lacroix J. Red blood cell transfusion in critically ill children (CME). Transfusion. 2014;54(2):365-375.</Citation><ArticleIdList><ArticleId IdType="pubmed">24517132</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekaran S, Kort E, Hackbarth R, et al. . Red cell transfusions as an independent risk for mortality in critically ill children. J Intensive Care. 2016;4:2. doi:10.1186/s40560-015-0122-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-015-0122-3</ArticleId><ArticleId IdType="pmc">PMC4704419</ArticleId><ArticleId IdType="pubmed">26744626</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Doctor A. Role of transfused red blood cells for shock and coagulopathy within remote damage control resuscitation. Shock. 2014;41(suppl 1):30-34. doi:10.1097/SHK.0000000000000089</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000089</ArticleId><ArticleId IdType="pubmed">24296434</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Carroll CL, Staff I, et al. . Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care. 2009;13(5):R151. doi:10.1186/cc8050</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8050</ArticleId><ArticleId IdType="pmc">PMC2784373</ArticleId><ArticleId IdType="pubmed">19772604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Patel RP, Marques MB, et al. ; PROPPR Study Group . Older blood is associated with increased mortality and adverse events in massively transfused trauma patients: secondary analysis of the PROPPR Trial. Ann Emerg Med. 2019;73(6):650-661. doi:10.1016/j.annemergmed.2018.09.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2018.09.033</ArticleId><ArticleId IdType="pmc">PMC6517091</ArticleId><ArticleId IdType="pubmed">30447946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack J, Kahn SR, Tinmouth A, Fergusson D, Hebert P, Lacroix J Dose-dependent effect of stored red blood: results of a sub-group analysis of the Age of Blood Evaluation (ABLE) Trial. Presented at: The 58th Annual American Society of Hematology Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA.</Citation></Reference><Reference><Citation>Weinberg JA, McGwin G Jr, Vandromme MJ, et al. . Duration of red cell storage influences mortality after trauma. J Trauma. 2010;69(6):1427-1431. doi:10.1097/TA.0b013e3181fa0019</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181fa0019</ArticleId><ArticleId IdType="pmc">PMC3136808</ArticleId><ArticleId IdType="pubmed">21150522</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson DA, H&#xe9;bert P, Hogan DL, et al. . Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308(14):1443-1451. doi:10.1001/2012.jama.11953</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2012.jama.11953</ArticleId><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al. . Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial. JAMA. 2015;314(23):2514-2523. doi:10.1001/jama.2015.13977</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.13977</ArticleId><ArticleId IdType="pubmed">26637812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert PC, Fergusson DA, et al. ; ABLE Investigators; Canadian Critical Care Trials Group . Age of transfused blood in critically ill adults. N Engl J Med. 2015;372(15):1410-1418. doi:10.1056/NEJMoa1500704</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1500704</ArticleId><ArticleId IdType="pubmed">25853745</ArticleId></ArticleIdList></Reference><Reference><Citation>Heddle NM, Cook RJ, Arnold DM, et al. . Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016;375(20):1937-1945. doi:10.1056/NEJMoa1609014</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609014</ArticleId><ArticleId IdType="pubmed">27775503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DJ, McQuilten ZK, Nichol A, et al. ; TRANSFUSE Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group . Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377(19):1858-1867. doi:10.1056/NEJMoa1707572</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707572</ArticleId><ArticleId IdType="pubmed">28952891</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner ME, Ness PM, Assmann SF, et al. . Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015;372(15):1419-1429. doi:10.1056/NEJMoa1414219</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="pubmed">25853746</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Dressler A, Tucci M, et al. ; Pediatric Acute Lung Injury and Sepsis Investigators Network . Survey of transfusion policies at US and Canadian children&#x2019;s hospitals in 2008 and 2009. Transfusion. 2010;50(11):2328-2335. doi:10.1111/j.1537-2995.2010.02708.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02708.x</ArticleId><ArticleId IdType="pubmed">20529008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M, Lacroix J, Fergusson D, et al. ; Canadian Critical Care Trials Group; Pediatric Critical Care Blood Research Network (BloodNet); Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network . The age of blood in pediatric intensive care units (ABC PICU): study protocol for a randomized controlled trial. Trials. 2018;19(1):404. doi:10.1186/s13063-018-2809-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-018-2809-y</ArticleId><ArticleId IdType="pmc">PMC6064163</ArticleId><ArticleId IdType="pubmed">30055634</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109(4):1033-1037. doi:10.1378/chest.109.4.1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison AL, Gillis J, O&#x2019;Connell AJ, Schell DN, Dossetor DR, Mellis C. Quality of life of survivors of pediatric intensive care. Pediatr Crit Care Med. 2002;3(1):1-5. doi:10.1097/00130478-200201000-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00130478-200201000-00001</ArticleId><ArticleId IdType="pubmed">12793913</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F; Groupe Francophone de R&#xe9;animation et d&#x2019;Urgences P&#xe9;diatriques (GFRUP) . PELOD-2: an update of the PEdiatric logistic organ dysfunction score. Crit Care Med. 2013;41(7):1761-1773. doi:10.1097/CCM.0b013e31828a2bbd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam O, Tucci M, Bateman ST, et al. . Association between length of storage of red blood cell units and outcome of critically ill children: a prospective observational study. Crit Care. 2010;14(2):R57. doi:10.1186/cc8953</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8953</ArticleId><ArticleId IdType="pmc">PMC2887178</ArticleId><ArticleId IdType="pubmed">20377853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauvin F, Spinella PC, Lacroix J, et al. ; Canadian Critical Care Trials Group and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network . Association between length of storage of transfused red blood cells and multiple organ dysfunction syndrome in pediatric intensive care patients. Transfusion. 2010;50(9):1902-1913. doi:10.1111/j.1537-2995.2010.02661.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02661.x</ArticleId><ArticleId IdType="pubmed">20456697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert PC, Hutchison JS, et al. ; TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network . Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609-1619. doi:10.1056/NEJMoa066240</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066240</ArticleId><ArticleId IdType="pubmed">17442904</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med. 1996;24(5):743-752. doi:10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis . International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8. doi:10.1097/01.PCC.0000149131.72248.E6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR, Artigas A, Brigham KL, et al. . The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-824. doi:10.1164/ajrccm.149.3.7509706</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.149.3.7509706</ArticleId><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas NJ, Shaffer ML, Willson DF, Shih MC, Curley MA. Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med. 2010;11(1):12-17. doi:10.1097/PCC.0b013e3181b0653d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b0653d</ArticleId><ArticleId IdType="pmc">PMC2936504</ArticleId><ArticleId IdType="pubmed">19561556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, Gauvin F, Skippen P, Cox P, Langley JM, Matlow A. Nosocomial infections in the PICU: Epidemiology and control In: Fuhrman BP, Zimmerman JJ, eds. Pediatric Critical Care. 2nd ed St Louis, MO: Mosby Year Book; 2006:1394-1421. doi:10.1016/B978-032301808-1.50093-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-032301808-1.50093-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Disease Control CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis. 1989;139(4):1058-1059. doi:10.1164/ajrccm/139.4.1058</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/139.4.1058</ArticleId><ArticleId IdType="pubmed">2539031</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference . The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33(7):1538-1548. doi:10.1097/01.CCM.0000168253.91200.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000168253.91200.83</ArticleId><ArticleId IdType="pubmed">16003060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AC. Clinical impact of blood storage lesions. Am J Hematol. 2010;85(2):117-122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20052749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour S, Acker JP, Chafets DM, et al. . Manufacturing method affects mitochondrial DNA release and extracellular vesicle composition in stored red blood cells. Vox Sang. 2016;111(1):22-32. doi:10.1111/vox.12390</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12390</ArticleId><ArticleId IdType="pubmed">26918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai-Adisaksopha C, Alexander PE, Guyatt G, et al. . Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. Vox Sang. 2017;112(3):268-278. doi:10.1111/vox.12495</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12495</ArticleId><ArticleId IdType="pubmed">28220494</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alessandro A, Zimring JC, Busch M. Chronological storage age and metabolic age of stored red blood cells: are they the same? Transfusion. 2019;59(5):1620-1623. doi:10.1111/trf.15248</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15248</ArticleId><ArticleId IdType="pubmed">30865302</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuilten ZK, French CJ, Nichol A, Higgins A, Cooper DJ. Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. Transfus Med Rev. 2018;32(2):77-88. doi:10.1016/j.tmrv.2018.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2018.02.002</ArticleId><ArticleId IdType="pubmed">29526337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38777667</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1409</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>The impact and validity of the Berlin criteria on burn-induced ARDS: Examining mortality rates, and inhalation injury influences. A single center observational cohort study.</ArticleTitle><Pagination><StartPage>1528</StartPage><EndPage>1535</EndPage><MedlinePgn>1528-1535</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.burns.2024.05.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0305-4179(24)00149-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">As several recent studies have shown low mortality rates in burn injury induced ARDS early (&#x2264;7 days) after the burn, the Berlin criteria for the ARDS diagnosis in this setting may be disputed. Related to this issue, the present study investigated the incidence, trajectory and risk factors of early Acute Respiratory Distress Syndrome (ARDS) and outcome in burn patients, as per the Berlin criteria, along with the concurrent prevalence and influence of inhalation injury, and ventilator-acquired pneumonia (VAP).</AbstractText><AbstractText Label="METHODS">Over a 2.5-year period, burn patients with Total Burn Surface Area (TBSA) exceeding 10% admitted to a national burn center were included. The subgroup of interest comprised patients with more than 48&#xa0;h of ventilatory support. This group was assessed for ARDS, inhalation injury, and VAP.</AbstractText><AbstractText Label="RESULTS">Out of 292 admissions, 62 sustained burns &gt;&#xa0;10% TBSA. Of these, 28 (45%) underwent ventilatory support for over 48&#xa0;h, almost all, 24 out of 28, meeting the criteria for ARDS early, within 7 days post-injury and with a P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2</sub> (PF) rat<sub>i</sub>o nadir at day 5. The mortality rate for this early ARDS group was under 10%, regardless of PF ratios (mean TBSA% 34,8%). Patients with concurrent inhalation injury and early ARDS showed significantly lower PF ratios (p&#xa0;&lt;&#xa0;0.001), and higher SOFA scores (p&#xa0;=&#xa0;0.004) but without impact on mortality. Organ failure, indicated by SOFA scores, peaked early (day 3) and declined in the first week, mirroring PF ratio trends (p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">The low mortality associated with early ARDS in burn patients in this study challenges the Berlin criteria's for the early ARDS diagnosis, which for its validity relies on that higher mortality is linked to worsening PF ratios. The finding suggests alternative mechanisms, leading to the early ARDS diagnosis, such as the significant impact of inhalation injury on early PF ratios and organ failure, as seen in this study. The concurrence of early organ failure with declining PF ratios, supports, as expected, the hypothesis of trauma-induced inflammation/multi-organ failure mechanisms contributing to early ARDS. The study highlights the complexity in differentiating between the contributions of inhalation injury to early ARDS and the related organ dysfunction early in the burn care trajectory. The Berlin criteria for the ARDS diagnosis may not be fully applicable in the burn care setting, where the low mortality significantly deviates from that described in the original Berlin ARDS criteria publication but is as expected when considering the actual not very extensive burn injury sizes/Baux scores as in the present study.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sjoberg</LastName><ForeName>Folke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden. Electronic address: folke.sjoberg@liu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmasry</LastName><ForeName>Moustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelrahman</LastName><ForeName>Islam</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Gusten</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology both at Link&#xf6;ping University Hospital and Link&#xf6;ping, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T-Elserafi</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology both at Link&#xf6;ping University Hospital and Link&#xf6;ping, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursing</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinvall</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015208" MajorTopicYN="Y">Smoke Inhalation Injury</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053717" MajorTopicYN="Y">Pneumonia, Ventilator-Associated</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001830" MajorTopicYN="N">Body Surface Area</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002059" MajorTopicYN="N">Burns, Inhalation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">Burns</Keyword><Keyword MajorTopicYN="N">Inhalation injury</Keyword><Keyword MajorTopicYN="N">Mortality ventilatory acquired pneumonia</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest On behalf of all co-authors, I hereby affirm no conflicts of interest associated with this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>22</Day><Hour>21</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38777667</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2024.05.005</ArticleId><ArticleId IdType="pii">S0305-4179(24)00149-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28719602</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study.</ArticleTitle><Pagination><StartPage>e1002338</StartPage><MedlinePgn>e1002338</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002338</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Almost all studies that have investigated the immune response to trauma have analysed blood samples acquired post-hospital admission. Thus, we know little of the immune status of patients in the immediate postinjury phase and how this might influence patient outcomes. The objective of this study was therefore to comprehensively assess the ultra-early, within 1-hour, immune response to trauma and perform an exploratory analysis of its relationship with the development of multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">The immune and inflammatory response to trauma was analysed in 89 adult trauma patients (mean age 41 years, range 18-90 years, 75 males) with a mean injury severity score (ISS) of 24 (range 9-66), from whom blood samples were acquired within 1 hour of injury (mean time to sample 42 minutes, range 17-60 minutes). Within minutes of trauma, a comprehensive leukocytosis, elevated serum pro- and anti-inflammatory cytokines, and evidence of innate cell activation that included neutrophil extracellular trap generation and elevated surface expression of toll-like receptor 2 and CD11b on monocytes and neutrophils, respectively, were observed. Features consistent with immune compromise were also detected, notably elevated numbers of immune suppressive CD16BRIGHT CD62LDIM neutrophils (82.07 x 106/l &#xb1; 18.94 control versus 1,092 x 106/l &#xb1; 165 trauma, p &lt; 0.0005) and CD14+HLA-DRlow/- monocytes (34.96 x 106/l &#xb1; 4.48 control versus 95.72 x 106/l &#xb1; 8.0 trauma, p &lt; 0.05) and reduced leukocyte cytokine secretion in response to lipopolysaccharide stimulation. Exploratory analysis via binary logistic regression found a potential association between absolute natural killer T (NKT) cell numbers and the subsequent development of MODS. Study limitations include the relatively small sample size and the absence of data relating to adaptive immune cell function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study highlighted the dynamic and complex nature of the immune response to trauma, with immune alterations consistent with both activation and suppression evident within 1 hour of injury. The relationship of these changes, especially in NKT cell numbers, to patient outcomes such as MODS warrants further investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazeldine</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4280-4889</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>David N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0003-2243-2325</Identifier><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toman</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Jonathan R B</ForeName><Initials>JRB</Initials><Identifier Source="ORCID">0000-0003-1789-5886</Identifier><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Zhangjie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinsdale</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crombie</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Midlands Air Ambulance, Unit 16 Enterprise Trading Estate, Brierley Hill, West Midlands, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duggal</LastName><ForeName>Niharika Arora</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4610-8909</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3211-9933</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28719602</ArticleId><ArticleId IdType="pmc">PMC5515405</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002338</ArticleId><ArticleId IdType="pii">PMEDICINE-D-17-00334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giannoudis PV. Current concepts of the inflammatory response after major trauma: an update. Injury. 2003; 34:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazeldine J, Hampson P, Lord JM. The diagnostic and prognostic value of systems biology research in major traumatic and thermal injury: a review. Burns and Trauma. 2016. 
doi: 10.1186/s41038-016-0059-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-016-0059-3</ArticleId><ArticleId IdType="pmc">PMC5030723</ArticleId><ArticleId IdType="pubmed">27672669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson P, Dinsdale RJ, Wearn CM, Bamford AL, Bishop JR, Hazeldine J, et al.
Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study. Ann.Surg. 2016. 
doi: 10.1097/SLA.0000000000001807
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001807</ArticleId><ArticleId IdType="pubmed">27232244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS ONE. 2013. 
8: e68963
doi: 10.1371/journal.pone.0068963
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068963</ArticleId><ArticleId IdType="pmc">PMC3722225</ArticleId><ArticleId IdType="pubmed">23894384</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Itagaki K, Sandler N, Gallo D, Galenkamp A, Kaczmarek E, et al.
Mitochondrial damage-associated molecular patterns from fractures suppress pulmonary immune responses via formyl peptide receptors 1 and 2. J.Trauma Acute.Care Surg. 2015;78: 272&#x2013;279. doi: 10.1097/TA.0000000000000509
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000509</ArticleId><ArticleId IdType="pmc">PMC4357317</ArticleId><ArticleId IdType="pubmed">25757111</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks W, Dropiewska G, Bryl E, Dudek R, Wieruszewski J, Stasiak M, et al. Immunomonitoring in patients with early moderate and severe head trauma. Cent. Eur. J. Public Health. 2013;38: 494&#x2013;499.</Citation></Reference><Reference><Citation>Perez-Barcena J, Regueiro V, Crespi C, Pierola J, Oliver A, Llompart-Pou JA, et al.
Expression of toll-like receptors 2 and 4 is upregulated during hospital admission in traumatic patients: lack of correlation with blunted innate immune responses. Ann.Surg. 2010;251: 521&#x2013;527. doi: 10.1097/SLA.0b013e3181cc8f84
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181cc8f84</ArticleId><ArticleId IdType="pubmed">20134316</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, et al.
Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc.Natl.Acad.Sci.U.S.A
2006;103: 15564&#x2013;15569. doi: 10.1073/pnas.0607028103
</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607028103</ArticleId><ArticleId IdType="pmc">PMC1592643</ArticleId><ArticleId IdType="pubmed">17032758</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, Cole E, De'Ath HD, Vulliamy P, Meier U, Pennington D, et al.
Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. Crit Care
2016;20: 176
doi: 10.1186/s13054-016-1341-2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1341-2</ArticleId><ArticleId IdType="pmc">PMC4895987</ArticleId><ArticleId IdType="pubmed">27268230</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van LA, et al.
Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients. Intensive Care Med. 2016;42: 551&#x2013;561. doi: 10.1007/s00134-015-4205-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4205-3</ArticleId><ArticleId IdType="pmc">PMC5413532</ArticleId><ArticleId IdType="pubmed">26912315</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch.Surg. 2000;135: 291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Arand M, Melzner H, Kinzl L, Bruckner UB, Gebhard F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch.Surg. 2001;386: 241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">11466564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F, Koenderman L, Althuizen M, Pillay J, Kamp V, Leenen LP. Kinetics of the innate immune response after trauma: implications for the development of late onset sepsis. Shock
2013;40: 21&#x2013;27. doi: 10.1097/SHK.0b013e318295a40a
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318295a40a</ArticleId><ArticleId IdType="pubmed">23603769</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser T, Hietbrink F, Groeneveld KM, Koenderman L, Leenen LP. Isolated blunt chest injury leads to transient activation of circulating neutrophils. Eur.J.Trauma Emerg.Surg. 2011;37: 177&#x2013;184. doi: 10.1007/s00068-010-0041-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-010-0041-x</ArticleId><ArticleId IdType="pmc">PMC3150797</ArticleId><ArticleId IdType="pubmed">21837259</ArticleId></ArticleIdList></Reference><Reference><Citation>West SD, Goldberg D, Ziegler A, Krencicki M, Du Clos TW, Mold C. Transforming growth factor-beta, macrophage colony-stimulating factor and C-reactive protein levels correlate with CD14(high)CD16+ monocyte induction and activation in trauma patients. PLoS ONE. 2012;7: e52406
doi: 10.1371/journal.pone.0052406
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052406</ArticleId><ArticleId IdType="pmc">PMC3532215</ArticleId><ArticleId IdType="pubmed">23285029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolach B, Sazbon L, Gavrieli R, Broda A, Schlesinger M. Early immunological defects in comatose patients after acute brain injury. J.Neurosurg. 2001;94: 706&#x2013;711. doi: 10.3171/jns.2001.94.5.0706
</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2001.94.5.0706</ArticleId><ArticleId IdType="pubmed">11354400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasten KR, Goetzman HS, Reid MR, Rasper AM, Adediran SG, Robinson CT, et al.
Divergent adaptive and innate immunological responses are observed in humans following blunt trauma. BMC.Immunol. 2010;11: 4
doi: 10.1186/1471-2172-11-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2172-11-4</ArticleId><ArticleId IdType="pmc">PMC2823662</ArticleId><ArticleId IdType="pubmed">20100328</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al.
A genomic storm in critically injured humans. J.Exp.Med. 2011;208: 2581&#x2013;2590. doi: 10.1084/jem.20111354
</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111354</ArticleId><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanzant EL, Hilton RE, Lopez CM, Zhang J, Ungaro RF, Gentile LF, et al.
Advanced age is associated with worsened outcomes and a unique genomic response in severely injured patients with hemorrhagic shock. Crit Care
2015. 
19: 77
doi: 10.1186/s13054-015-0788-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0788-x</ArticleId><ArticleId IdType="pmc">PMC4404112</ArticleId><ArticleId IdType="pubmed">25880307</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr SK, Butler KL, Hayden D, Tompkins RG, Serhan CN, Irimia D. Gene Expression of Proresolving Lipid Mediator Pathways Is Associated With Clinical Outcomes in Trauma Patients. Crit Care Med. 2015;43: 2642&#x2013;2650. doi: 10.1097/CCM.0000000000001312
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001312</ArticleId><ArticleId IdType="pmc">PMC4651815</ArticleId><ArticleId IdType="pubmed">26488221</ArticleId></ArticleIdList></Reference><Reference><Citation>Namas RA, Vodovotz Y, Almahmoud K, Abdul-Malak O, Zaaqoq A, Namas R, et al.
Temporal Patterns of Circulating Inflammation Biomarker Networks Differentiate Susceptibility to Nosocomial Infection Following Blunt Trauma in Humans. Ann.Surg. 2016; 263: 191&#x2013;198. doi: 10.1097/SLA.0000000000001001
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001001</ArticleId><ArticleId IdType="pmc">PMC5136774</ArticleId><ArticleId IdType="pubmed">25371118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Finnerty CC, Kraft R, Mlcak RP, Herndon DN. Survivors versus nonsurvivors postburn: differences in inflammatory and hypermetabolic trajectories. Ann.Surg. 2014;259: 814&#x2013;823. doi: 10.1097/SLA.0b013e31828dfbf1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828dfbf1</ArticleId><ArticleId IdType="pmc">PMC3732513</ArticleId><ArticleId IdType="pubmed">23579577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study. Shock
2015;43: 222&#x2013;227. doi: 10.1097/SHK.0000000000000294
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000294</ArticleId><ArticleId IdType="pmc">PMC4425645</ArticleId><ArticleId IdType="pubmed">25514427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, et al.
Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock
2010;34: 346&#x2013;351. doi: 10.1097/SHK.0b013e3181d8e687
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181d8e687</ArticleId><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira LC, Regner A, Miotto KD, Moura S, Ikuta N, Vargas AE, et al.
Increased levels of interleukin-6, -8 and -10 are associated with fatal outcome following severe traumatic brain injury. Brain Inj. 2014;28: 1311&#x2013;1316. doi: 10.3109/02699052.2014.916818
</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02699052.2014.916818</ArticleId><ArticleId IdType="pubmed">24830571</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007;28: 668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszynski JA, Nofziger R, Greathouse K, Nateri J, Hanson-Huber L, Steele L, et al.
Innate immune function predicts the development of nosocomial infection in critically injured children. Shock
2014;42: 313&#x2013;321. doi: 10.1097/SHK.0000000000000217
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000217</ArticleId><ArticleId IdType="pmc">PMC4167175</ArticleId><ArticleId IdType="pubmed">24978895</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel-Cheron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS ONE
2012;7: e33095
doi: 10.1371/journal.pone.0033095
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033095</ArticleId><ArticleId IdType="pmc">PMC3303782</ArticleId><ArticleId IdType="pubmed">22431998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C, et al.
Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care
2010;14: R208
doi: 10.1186/cc9331
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9331</ArticleId><ArticleId IdType="pmc">PMC3220028</ArticleId><ArticleId IdType="pubmed">21092108</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995. 57: 289&#x2013;300.</Citation></Reference><Reference><Citation>Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al.
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology
2010;21: 128&#x2013;138. doi: 10.1097/EDE.0b013e3181c30fb2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c30fb2</ArticleId><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J.Clin.Epidemiol. 2001;54: 774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470385</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CL, Tangsombatvisit S, Rosenberg JM, Mandelbaum G, Gillespie EC, Gozani OP, et al.
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res.Ther. 2012;14: R25
doi: 10.1186/ar3707
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3707</ArticleId><ArticleId IdType="pmc">PMC3392818</ArticleId><ArticleId IdType="pubmed">22300536</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Kamp VM, van HE, Visser T, Tak T, Lammers JW, et al.
A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J.Clin.Invest
2012; 122: 327&#x2013;336. doi: 10.1172/JCI57990
</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57990</ArticleId><ArticleId IdType="pmc">PMC3248287</ArticleId><ArticleId IdType="pubmed">22156198</ArticleId></ArticleIdList></Reference><Reference><Citation>Laborde RR, Lin Y, Gustafson MP, Bulur PA, Dietz AB. Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. Front Immunol. 2014;5: 147
doi: 10.3389/fimmu.2014.00147
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00147</ArticleId><ArticleId IdType="pmc">PMC3983500</ArticleId><ArticleId IdType="pubmed">24772111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff C, Biberthaler P, Mutschler WE, Faist E, Jochum M, Zedler S. Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study. Crit Care
2009; 13: R88
doi: 10.1186/cc7914
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7914</ArticleId><ArticleId IdType="pmc">PMC2717459</ArticleId><ArticleId IdType="pubmed">19519886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainer TH, Ng MH, Lam NY, Chan TY, Cocks RA. Role of monocyte L-selectin in the development of post-traumatic organ failure. Resuscitation 2001;51: 139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al.
Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J.Trauma Acute.Care Surg. 2012;72: 1491&#x2013;1501. doi: 10.1097/TA.0b013e318256e000
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318256e000</ArticleId><ArticleId IdType="pmc">PMC3705923</ArticleId><ArticleId IdType="pubmed">22695412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Terashima T, D'yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 1998;98: 2307&#x2013;2313.</Citation><ArticleIdList><ArticleId IdType="pubmed">9826319</ArticleId></ArticleIdList></Reference><Reference><Citation>Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med. 2013;41: 820&#x2013;832. doi: 10.1097/CCM.0b013e318274647d
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318274647d</ArticleId><ArticleId IdType="pubmed">23348516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Ramakers BP, Kamp VM, Loi AL, Lam SW, Hietbrink F, et al.
Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J.Leukoc.Biol. 2010;88: 211&#x2013;220. doi: 10.1189/jlb.1209793
</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1209793</ArticleId><ArticleId IdType="pubmed">20400675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauce D, Dong Y, Campillo-Gimenez L, Casulli S, Bayard C, Autran B, et al.
Reduced Oxidative Burst by Primed Neutrophils in the Elderly Individuals Is Associated With Increased Levels of the CD16bright/CD62Ldim Immunosuppressive Subset. J.Gerontol.A Biol.Sci.Med.Sci. 2017;72: 163&#x2013;172. doi: 10.1093/gerona/glw062
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw062</ArticleId><ArticleId IdType="pubmed">27069096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood
2011;117: 872&#x2013;881. doi: 10.1182/blood-2010-05-283820
</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-05-283820</ArticleId><ArticleId IdType="pmc">PMC3035079</ArticleId><ArticleId IdType="pubmed">21063024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al.
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate
2010;70: 443&#x2013;455. doi: 10.1002/pros.21078
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.21078</ArticleId><ArticleId IdType="pmc">PMC2935631</ArticleId><ArticleId IdType="pubmed">19902470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al.
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology
2008;135: 234&#x2013;243. doi: 10.1053/j.gastro.2008.03.020
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.03.020</ArticleId><ArticleId IdType="pubmed">18485901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al.
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology
2009;50: 799&#x2013;807. doi: 10.1002/hep.23054
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23054</ArticleId><ArticleId IdType="pmc">PMC6357774</ArticleId><ArticleId IdType="pubmed">19551844</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, et al.
IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer J. 2015; 5: e328
doi: 10.1038/bcj.2015.56
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bcj.2015.56</ArticleId><ArticleId IdType="pmc">PMC4526782</ArticleId><ArticleId IdType="pubmed">26230952</ArticleId></ArticleIdList></Reference><Reference><Citation>Aneja R, Odoms K, Dunsmore K, Shanley TP, Wong HR. Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. J.Immunol. 2006;177: 7184&#x2013;7192.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal J, Thurman GW, Cusack N, Peterson VM, Malech HL, Ambruso DR. Neutrophils from patients after burn injury express a deficiency of the oxidase components p47-phox and p67-phox. Blood 1996;88: 4321&#x2013;4329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943869</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG, Rhind SG, Rizoli SB, Cuschieri J, Baker AJ, Shek PN, et al.
Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury. Shock
2013;40: 366&#x2013;374. doi: 10.1097/SHK.0000000000000038
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000038</ArticleId><ArticleId IdType="pmc">PMC3913169</ArticleId><ArticleId IdType="pubmed">24088993</ArticleId></ArticleIdList></Reference><Reference><Citation>Benna JE, Dang PM, Gaudry M, Fay M, Morel F, Hakim J, et al. Phosphorylation of the respiratory burst oxidase subunit p67(phox) during human neutrophil activation. Regulation by protein kinase C-dependent and independent pathways. J.Biol.Chem. 1997; 272: 17204&#x2013;17208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauseef WM, Volpp BD, McCormick S, Leidal KG, Clark RA. Assembly of the neutrophil respiratory burst oxidase. Protein kinase C promotes cytoskeletal and membrane association of cytosolic oxidase components. J.Biol.Chem. 1991;266: 5911&#x2013;5917.</Citation><ArticleIdList><ArticleId IdType="pubmed">1848559</ArticleId></ArticleIdList></Reference><Reference><Citation>Raad H, Paclet MH, Boussetta T, Kroviarski Y, Morel F, Quinn MT, et al.
Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J. 2009;23: 1011&#x2013;1022. doi: 10.1096/fj.08-114553
</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-114553</ArticleId><ArticleId IdType="pmc">PMC2660639</ArticleId><ArticleId IdType="pubmed">19028840</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarlowe MH, Kannan KB, Itagaki K, Adams JM, Livingston DH, Hauser CJ. Inflammatory chemoreceptor cross-talk suppresses leukotriene B4 receptor 1-mediated neutrophil calcium mobilization and chemotaxis after trauma. J.Immunol. 2003;171: 2066&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pubmed">12902512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, et al.
Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PLoS ONE. 2014;9: e111755
doi: 10.1371/journal.pone.0111755
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111755</ArticleId><ArticleId IdType="pmc">PMC4230949</ArticleId><ArticleId IdType="pubmed">25392950</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Tohme S, Al-Khafaji AB, Tai S, Loughran P, Chen L, et al.
Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology
2015;62: 600&#x2013;614. doi: 10.1002/hep.27841
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27841</ArticleId><ArticleId IdType="pmc">PMC4515210</ArticleId><ArticleId IdType="pubmed">25855125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al.
Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care
2009;13: R174
doi: 10.1186/cc8152
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance HD, Vivian ME, Brohi K, Prowle JR, Pearse RM, Owen HC, et al.
Changes in gene expression following trauma are related to the age of transfused packed red blood cells. J.Trauma Acute.Care Surg. 2015;78: 535&#x2013;542. doi: 10.1097/TA.0000000000000534
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000534</ArticleId><ArticleId IdType="pubmed">25710424</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance HD, Brohi K, Pearse RM, Mein CA, Wozniak E, Prowle JR, et al.
Association between gene expression biomarkers of immunosuppression and blood transfusion in severely injured polytrauma patients. Ann.Surg. 2015; 261: 751&#x2013;759. doi: 10.1097/SLA.0000000000000653
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000000653</ArticleId><ArticleId IdType="pubmed">24670848</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32758298</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>699</StartPage><MedlinePgn>699</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">699</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-020-04632-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">&#x2022; Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19. &#x2022; Secondary objectives: &#x25e6; To evaluate the effect of IVM on ICU length of stay. &#x25e6; To evaluate the effect of IVM on the length of mechanical ventilation (MV). &#x25e6; To evaluate if the use of IVM is associated with an increase in the number of ventilator-free days. &#x25e6; To evaluate if the use of IVM is associated with a reduced number of failing organs as determined by the sequential organ failure assessment (SOFA) scale. &#x25e6; To evaluate if the use of IVM is associated with a reduction of the frequency and severity of COVID-19-associated thromboembolic phenomena. &#x25e6; To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6. &#x25e6; To evaluate if the use of IVM is associated with an improvement in hematologic parameters. &#x25e6; To evaluate if the use of IVM is associated with an improvement in biochemical parameters. &#x25e6; To evaluate if the use of IVM is associated with an improvement in blood gas analysis parameters. &#x25e6; To evaluate adverse events during the 28 day study period.</AbstractText><AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">Phase II, single center, double-blind, placebo-controlled randomized trial with a two-arm parallel group design and 2:1 allocation ratio.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Only critically ill adult patients that fulfill all of the inclusion criteria and none of the exclusion criteria will be included. The study will be conducted in a mixed ICU of a publicly funded tertiary referral center in Madrid, Spain with a 30-bed capacity and 1100 admissions per year. &#x2022; Inclusion criteria: &#x25e6; Patient, family member or legal guardian has provided written Informed Consent. &#x25e6; Age &#x3b5; 18 years. &#x25e6; Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR. &#x25e6; Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection. &#x25e6; ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission). &#x2022; Exclusion criteria: &#x25e6; Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization. &#x25e6; Liver enzymes &gt; 5 times the upper normal range. &#x25e6; Chronic kidney disease with GFR &lt; 30 mL/min/1.73 m<sup>2</sup> (stage 4 or greater) or need for hemodialysis. &#x25e6; Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion. &#x25e6; Terminal surgical or medical illness. &#x25e6; Autoimmune disease. &#x25e6; Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement.</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">All patients will receive standard-of-care treatment according to the current institutional protocols. In addition, patients will be randomized in a 2:1 ratio to receive: &#x2022; Experimental group (12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day. &#x2022; Control group (6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours. After 3 days of treatment, 3 intensive care physicians will evaluate the participant and decide whether or not to complete the treatment based on their clinical assessment: &#x2022; If objective or subjective signs of improvement or no worsening of the general clinical condition, respiratory failure, inflammatory state or multi-organ failure are observed, the participant will continue the treatment until completion. &#x2022; If an adverse effect or clinical impairment is observed that is objectively or subjectively attributable to the study drug the treatment will be stopped.</AbstractText><AbstractText Label="MAIN OUTCOME" NlmCategory="RESULTS">Mortality in each study group represented in frequency and time-to-event at day 28 after randomization RANDOMIZATION: The randomization sequence was created using SAS version 9.4 statistical software (programmed and validated macros) with a 2:1 allocation. No randomization seed was pre-specified. The randomization seed was generated using the time on the computer where the program was executed.</AbstractText><AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">Participants, caregivers and study groups will be blinded to arm allocation.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMIZED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">A total of 18 patients will be randomized in this trial: 12 to the experimental arm and 6 to the control arm.</AbstractText><AbstractText Label="TRIAL STATUS" NlmCategory="METHODS">Protocol version 2.0, June 5<sup>th</sup> 2020. Trial status: recruitment not started. The first patient is expected to be recruited in October 2020. The last patient is anticipated to be recruited in August 2021.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EU Clinical Trials Register. Date of trial registration: 10 July 2020. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rubio</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueira</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acu&#xf1;a-Castroviejo</LastName><ForeName>Dar&#xed;o</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERfes, Ibs Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Laboratories, San Cecilio University Hospital, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borobia</LastName><ForeName>Alberto M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Department, Clinical Trial Unit, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escames</LastName><ForeName>Germaine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain. gescames@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERfes, Ibs Granada, Granada, Spain. gescames@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Oliva</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2444-0556</Identifier><AffiliationInfo><Affiliation>Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain. pedro.oliva@salud.madrid.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain. pedro.oliva@salud.madrid.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="Y">Melatonin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">protocol</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>GE and DA-C are Scientific Advisors of Pharmamel LTD, the Sponsor of the clinical trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32758298</ArticleId><ArticleId IdType="pmc">PMC7403786</ArticleId><ArticleId IdType="doi">10.1186/s13063-020-04632-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-020-04632-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32355735</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2305-5839</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of translational medicine</Title><ISOAbbreviation>Ann Transl Med</ISOAbbreviation></Journal><ArticleTitle>Femoral arteriovenous fistula associated with surgery of proximal femoral fracture: a systematic review of the literature and case presentation.</ArticleTitle><Pagination><StartPage>291</StartPage><MedlinePgn>291</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">291</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21037/atm.2020.03.08</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Proximal femoral fracture (PFF), such as intertrochanteric femoral fracture or femur neck fracture, and its management are crucial issues to surgeons. PFF has been dramatically is becoming exponentially prevalent, and it is at high risk of complication and mortality because it is frequently associated with serious trauma and advanced age, especially in patients treated with anticoagulants or antiplatelet agents. Surgical management is essential for the treatment of PFF. Unfortunately, current surgical procedures have been related to accompanied by vascular complications, including laceration, hemorrhage, thrombosis, embolism, intimal flap tear and pseudoaneurysm. Furthermore, these vascular injuries following surgical management of PFF are potentially limb- and life-threatening. Of the complications after operation of PFF, femoral arteriovenous fistula (AVF) is rare, but remains a challenging problem because it is frequently associated with significantly high mortality and morbidity and is very difficult to treat.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature review was conducted using the PRISMA guidelines with no language restriction. We searched scientific publications via PubMed, Embase, Cochrane central register of controlled trial, Google Scholar, the KoreaMed and the Research Information Sharing Service database. The goal of this study was to report on the incidence, clinical presentation, diagnosis, treatment, associated complications, morbidity and mortality of femoral AVF caused by PFF and to draw special attention to its prevention and management.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 7 case reports on femoral AVF associated with operation of PFF were identified, and one our case was added to the systematic analysis. Of the 8 cases, 4 were male and 4 were female under the age of 67.87&#xb1;18.44; 6 (75.0%) survived without any events, 1 (12.5%) survived with a sequela of peroneal nerve impairment, and 1 (12.5%) died of multi-organ failure and hypovolemia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The incidence of femoral AVF associated with PFF is extremely low, though it appears to increase with the rising frequency of PFF. With a very few exceptions, complications following internal fixation are potentially limb- and life-threatening. There is still no definite consensus on the standardized diagnostic or therapeutic modalities. Therefore, surgeons should keep in mind that this serious complication requires early diagnosis and prompt treatment, which should not be underestimated. Femoral AVF following operation of PFF should be meticulously managed, because untreated fistulae result in serious unexpected complications including renin-mediated hypertension, high-output heart failure and venous and/or arterial insufficiency. Surgical treatment is still the gold standard for such cases, but in limited cases endovascular procedures using embolization and closure device can be a good treatment option.</AbstractText><CopyrightInformation>2020 Annals of Translational Medicine. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jun Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Song Am</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chee</LastName><ForeName>Hyun Keun</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jae Joon</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Seoul Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Pain Medicine, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung Myung</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yo Han</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Woo Surng</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University, Konkuk University Chungju Hospital, Chungju-si, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Transl Med</MedlineTA><NlmUniqueID>101617978</NlmUniqueID><ISSNLinking>2305-5839</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arteriovenous fistula (AVF)</Keyword><Keyword MajorTopicYN="N">femoral neck fractures</Keyword><Keyword MajorTopicYN="N">hip fractures</Keyword><Keyword MajorTopicYN="N">inter-trochanteric femoral fractures</Keyword><Keyword MajorTopicYN="N">vascular fistula</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32355735</ArticleId><ArticleId IdType="pmc">PMC7186609</ArticleId><ArticleId IdType="doi">10.21037/atm.2020.03.08</ArticleId><ArticleId IdType="pii">atm-08-06-291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lazarides MK, Arvanitis DP, Dayantas JN. Iatrogenic arterial trauma associated with hip joint surgery: an overview. Eur J Vasc Surg 1991;5:549-56. 10.1016/S0950-821X(05)80343-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0950-821X(05)80343-3</ArticleId><ArticleId IdType="pubmed">1959684</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanikas I, Lazarides M, Arvanitis D, et al. Iatrogenic arterial trauma associated with hip fracture surgery. Acta Chir Belg 1993;93:284-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8140841</ArticleId></ArticleIdList></Reference><Reference><Citation>Osagie L, Gallivan S, Pearse Y. Profunda femoris injury following lesser trochanter displacement: complications following intramedullary femoral nailing. Injury 2015;46:411-3. 10.1016/j.injury.2014.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2014.09.021</ArticleId><ArticleId IdType="pubmed">25458057</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton&#xed;cek J. Injuries to femoral vessels in fractures of the hip. Rozhl Chir 2009;88:203-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19645148</ArticleId></ArticleIdList></Reference><Reference><Citation>Waddell JP. editor. Complications of trochanteric fractures. In: Fractures of the proximal femur improving outcome. Philadelphia, PA: Saunders; 2011:151-84.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. 10.1136/bmj.b2535</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Barquet A, Gelink A, Giannoudis PV. Proximal femoral fractures and vascular injuries in adults: Incidence, aetiology and outcomes. Injury 2015;46:2297-313. 10.1016/j.injury.2015.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2015.10.021</ArticleId><ArticleId IdType="pubmed">26521991</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchell HB. Observations on bradycardia produced by occlusion of an artery proximal to an arteriovenous fistula (Nicoladoni-Branham sign). Med Clin North Am 1958;42:1029-35. 10.1016/S0025-7125(16)34255-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0025-7125(16)34255-9</ArticleId><ArticleId IdType="pubmed">13564989</ArticleId></ArticleIdList></Reference><Reference><Citation>Quilliam TA. Arteriovenous aneurysm as a complication of intertrochanteric fracture of the femur. Br J Surg 1947;34:327. 10.1002/bjs.18003413527</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.18003413527</ArticleId><ArticleId IdType="pubmed">20289133</ArticleId></ArticleIdList></Reference><Reference><Citation>Suren EG, Mellmann JR, Leitz KH. Vascular complications following alloplastic hip replacement. Arch Orthop Unfallchir 1976;85:217-24. 10.1007/BF00415461</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00415461</ArticleId><ArticleId IdType="pubmed">962692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf JW, Jr, Tegtmeyer CJ, Whitehill R, et al. Traumatic arteriovenous fistula of the popliteal artery associated with a closed subtrochanteric fracture: report of a case. Clin Orthop Relat Res 1978;133:227-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">688712</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaase JM, van Walsum AD, Vierhout PA, et al. Letsel van de arteria profunda femoris bij een pertrochantere femurfractuur. Ned Tijdschr Traum 1995;2:162-5.</Citation></Reference><Reference><Citation>Manner M, R&#xf6;sch B, Roy K. Vascular injuries complicating osteosynthesis in proximal femur fractures. Unfallchirurg 1999;102:227-31. 10.1007/s001130050395</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001130050395</ArticleId><ArticleId IdType="pubmed">10232039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kickuth R, Anderson S, Kocovic L, et al. Endovascular treatment of arterial injury as an uncommon complication after orthopedic surgery. J Vasc Interv Radiol 2006;17:791-9. 10.1097/01.RVI.0000217929.35607.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.RVI.0000217929.35607.15</ArticleId><ArticleId IdType="pubmed">16687744</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshy CG, Keshava SN, Surendrababu NR, et al. Endovascular management of posttraumatic arteriovenous fistulae. Cardiovasc Intervent Radiol 2009;32:1042-52. 10.1007/s00270-009-9636-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00270-009-9636-1</ArticleId><ArticleId IdType="pubmed">19597884</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller ME. Total hip prostheses. Clin Orthop Relat Res 1970;72:46-68.</Citation><ArticleIdList><ArticleId IdType="pubmed">5459808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitargil M, Ba&#x15f;bu&#x11f; HS, G&#xf6;&#xe7;er H, G&#xfc;nerhan Y, Karakurt A. Coronary angiography our approaches to vascular complications. Turkish J Vasc Surg 2014;23:164-8.</Citation></Reference><Reference><Citation>Kelm M, Perings SM, Jax T, et al. Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: implications for risk stratification and treatment. J Am Coll Cardiol 2002;40:291-7. 10.1016/S0735-1097(02)01966-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(02)01966-6</ArticleId><ArticleId IdType="pubmed">12106934</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust JC, Bredenberg CE, Murray DG. Mechanisms of arterial injuries associated with total hip replacement. Arch Surg 1981;116:345-9. 10.1001/archsurg.1981.01380150063017</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1981.01380150063017</ArticleId><ArticleId IdType="pubmed">7469777</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchholz HW, Elson RA, Engelbrecht E, et al. Management of deep infection of total hip replacement. J Bone Joint Surg Br 1981;63-B:342-53. 10.1302/0301-620X.63B3.7021561</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.63B3.7021561</ArticleId><ArticleId IdType="pubmed">7021561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergqvist D, Carlsson AS, Ericsson BF. Vascular complications after total hip arthroplasty. Acta Orthop Scand 1983;54:157-63. 10.3109/17453678308996548</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453678308996548</ArticleId><ArticleId IdType="pubmed">6845987</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkaczuk H. False aneurysm of the external iliac artery following hip endoprosthesis. Acta Orthop Scand 1976;47:317-9. 10.3109/17453677608991998</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453677608991998</ArticleId><ArticleId IdType="pubmed">952220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld NA, Stuchin SA, Pearl R, et al. The management of vascular injuries associated with total hip arthroplasty. J Vasc Surg 1990;11:549-55. 10.1016/0741-5214(90)90301-P</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0741-5214(90)90301-P</ArticleId><ArticleId IdType="pubmed">2182915</ArticleId></ArticleIdList></Reference><Reference><Citation>Korovesis P, Siablis D, Salonikidis P, et al. Abdominal-hip joint fistula. Complicated revision of total hip arthroplasty for false aneurysm of external iliac artery A case report. Clin Orthop Relat Res 1988;231:71-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">3370888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29178943</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial.</ArticleTitle><Pagination><StartPage>289</StartPage><MedlinePgn>289</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">289</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-017-1878-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sepsis and septic shock occur commonly in severe burns. Acute kidney injury (AKI) is also common and often results as a consequence of sepsis. Mortality is unacceptably high in burn patients who develop AKI requiring renal replacement therapy and is presumed to be even higher when combined with septic shock. We hypothesized that high-volume hemofiltration (HVHF) as a blood purification technique would be beneficial in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicenter, prospective, randomized, controlled clinical trial to evaluate the impact of HVHF on the hemodynamic profile of burn patients with septic shock and AKI involving seven burn centers in the United States. Subjects randomized to the HVHF were prescribed a dose of 70&#xa0;ml/kg/hour for 48&#xa0;hours while control subjects were managed in standard fashion in accordance with local practices.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a 4-year period, a total of nine subjects were enrolled for the intervention during the ramp-in phase and 28 subjects were randomized, 14 each into the control and HVHF arms respectively. The study was terminated due to slow enrollment. Ramp-in subjects were included along with those randomized in the final analysis. Our primary endpoint, the vasopressor dependency index, decreased significantly at 48&#xa0;hours compared to baseline in the HVHF group (p&#x2009;=&#x2009;0.007) while it remained no different in the control arm. At 14&#xa0;days, the multiple organ dysfunction syndrome score decreased significantly in the HVHF group when compared to the day of treatment initiation (p&#x2009;=&#x2009;0.02). No changes in inflammatory markers were detected during the 48-hour intervention period. No significant difference in survival was detected. No differences in adverse events were noted between the groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HVHF was effective in reversing shock and improving organ function in burn patients with septic shock and AKI, and appears safe. Whether reversal of shock in these patients can improve survival is yet to be determined.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov NCT01213914 . Registered 30 September 2010.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kevin K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Brooke Army Medical Center, Fort Sam Houston, TX, USA. kevin.k.chung.mil@mail.mil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Uniformed Services University of the Health Sciences, Bethesda, MD, USA. kevin.k.chung.mil@mail.mil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>Elsa C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>United States Army Institute of Surgical Research, Fort Sam Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>University of South Florida Tampa General Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlnoski</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>University of South Florida Tampa General Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickerson</LastName><ForeName>William L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>University of Tennessee Firefighters' Regional Burn Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold-Ross</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>University of Tennessee Firefighters' Regional Burn Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosier</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Loyola University Medical Center, Maywood, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halerz</LastName><ForeName>Marcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Loyola University Medical Center, Maywood, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprague</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Doctors Hospital Joseph M. Still Burn Center, Augusta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullins</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Doctors Hospital Joseph M. Still Burn Center, Augusta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Arizona Burn Center Maricopa Integrated Health Systems, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albrecht</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Arizona Burn Center Maricopa Integrated Health Systems, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnoldo</LastName><ForeName>Brett D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burris</LastName><ForeName>Agnes M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Sandra L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>University of California Davis, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Randomized controlled Evaluation of high-volume hemofiltration in adult burn patients with Septic shoCk and acUte kidnEy injury (RESCUE) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01213914</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>W81XWH-09-2-0194</GrantID><Agency>United States Army Medical Research and Materiel Command</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute kidney injury</Keyword><Keyword MajorTopicYN="N">Burns</Keyword><Keyword MajorTopicYN="N">High-volume hemofiltration</Keyword><Keyword MajorTopicYN="N">Multicenter</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword></KeywordList><CoiStatement>AUTHORS&#x2019; INFORMATION: Not applicable. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved in a multilevel institutional review process. The core protocol was initially reviewed by the United States Army Medical Research and Materiel Command (USAMRMC) Institutional Review Board (IRB) and reviewed again for final approval by the Army Human Research Protection Office (AHRPO). The core protocol was then submitted to each participating site&#x2019;s local IRB with site-specific addendums and approved again by AHRPO. All amendments to the core protocol required multilevel review with final approval by the AHRPO. A list of IRBs for each specific site is listed in Additional file 1. Informed consent was obtained from all participating subjects through their surrogates. CONSENT FOR PUBLICATION: All authors gave final approval of the final manuscript to be published. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Booker T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pamplin</LastName><ForeName>Jeremy C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Driscoll</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renz</LastName><ForeName>Evan M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lundy</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cancio</LastName><ForeName>Leopoldo C</ForeName><Initials>LC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruse</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>McFarren</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Kimberly S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Showkat</LastName><ForeName>Arif</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>Lekha</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Aneel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birmingham</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruce</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanford</LastName><ForeName>Arthur P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullins</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassan</LastName><ForeName>Zaheed</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaver</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fosters</LastName><ForeName>Kevin N</ForeName><Initials>KN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peck</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phelan</LastName><ForeName>Herb A</ForeName><Initials>HA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saxena</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howard</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhavsar</LastName><ForeName>Dhaval</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponnuru</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSouza</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarlagadda</LastName><ForeName>Sri G</ForeName><Initials>SG</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29178943</ArticleId><ArticleId IdType="pmc">PMC5702112</ArticleId><ArticleId IdType="doi">10.1186/s13054-017-1878-8</ArticleId><ArticleId IdType="pii">10.1186/s13054-017-1878-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzwater J, Purdue GF, Hunt JL, et al. The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma. 2003;54(5):959&#x2013;66. doi: 10.1097/01.TA.0000029382.26295.AB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000029382.26295.AB</ArticleId><ArticleId IdType="pubmed">12777910</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusselaers N, Monstrey S, Colpaert K, et al. Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis. Intensive Care Med. 2010;36:915&#x2013;25. doi: 10.1007/s00134-010-1861-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-1861-1</ArticleId><ArticleId IdType="pubmed">20333353</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart IJ, Tilley MA, Cotant CL, et al. Association of AKI with adverse outcomes in burned military casualties. Clin J Am Soc Nephrol. 2012;7(2):199&#x2013;206. doi: 10.2215/CJN.04420511.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04420511</ArticleId><ArticleId IdType="pubmed">22156751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41:3&#x2013;11. doi: 10.1097/SHK.0000000000000052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000052</ArticleId><ArticleId IdType="pmc">PMC3918942</ArticleId><ArticleId IdType="pubmed">24346647</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813&#x2013;8. doi: 10.1001/jama.294.7.813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.7.813</ArticleId><ArticleId IdType="pubmed">16106006</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung KK, Lundy JB, Matson JR, et al. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. Crit Care. 2009;13:R62. doi: 10.1186/cc7801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7801</ArticleId><ArticleId IdType="pmc">PMC2717417</ArticleId><ArticleId IdType="pubmed">19409089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356(9223):26&#x2013;30. doi: 10.1016/S0140-6736(00)02430-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)02430-2</ArticleId><ArticleId IdType="pubmed">10892761</ArticleId></ArticleIdList></Reference><Reference><Citation>Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28(11):3581&#x2013;7. doi: 10.1097/00003246-200011000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200011000-00001</ArticleId><ArticleId IdType="pubmed">11098957</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med. 2006;32(1):80&#x2013;6. doi: 10.1007/s00134-005-2815-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-005-2815-x</ArticleId><ArticleId IdType="pubmed">16328222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratanarat R, Brendolan A, Ricci Z, et al. Pulse high-volume hemofiltration in critically ill patients: a new approach for patients with septic shock. Semin Dial. 2006;19(1):69&#x2013;74. doi: 10.1111/j.1525-139X.2006.00121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-139X.2006.00121</ArticleId><ArticleId IdType="pubmed">16423184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885&#x2013;91. doi: 10.1038/nature01326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01326</ArticleId><ArticleId IdType="pubmed">12490963</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo LCP, Park M, Schettino GPP. Novel potential therapies for septic shock. Shock. 2008;30(Suppl 1):60&#x2013;6. doi: 10.1097/SHK.0b013e318181a425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318181a425</ArticleId><ArticleId IdType="pubmed">18704007</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden K, Stewart IJ, Kreyer SF, et al. Extracorporeal blood purification in burns: a review. Burns. 2014;40(6):1071&#x2013;8. doi: 10.1016/j.burns.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.01.013</ArticleId><ArticleId IdType="pubmed">24548734</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick EM, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis in adults. Cochrane Database Syst Rev. 2017;1:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464723</ArticleId><ArticleId IdType="pubmed">28141912</ArticleId></ArticleIdList></Reference><Reference><Citation>Joannes-Boyau O, Honore PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicenter randomized controlled trial. Intensive Care Med. 2013;39:1535&#x2013;46. doi: 10.1007/s00134-013-2967-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-013-2967-z</ArticleId><ArticleId IdType="pubmed">23740278</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg. 2008;248:387&#x2013;401. doi: 10.1097/SLA.0b013e318176c4b3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e318176c4b3</ArticleId><ArticleId IdType="pmc">PMC3905467</ArticleId><ArticleId IdType="pubmed">18791359</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587220</ArticleId><ArticleId IdType="pubmed">23401516</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28(6):776&#x2013;90. doi: 10.1097/BCR.0b013e3181599bc9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Palevsky PM, Zhang JH, O&#x2019;Connor TZ, et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359(1):7&#x2013;20. doi: 10.1056/NEJMoa0802639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0802639</ArticleId><ArticleId IdType="pmc">PMC2574780</ArticleId><ArticleId IdType="pubmed">18492867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz DN, Antonelli M, Fumagalli R, et al. Early use of Polymyxin B Hemoperfusion in Abdominal Septic Shock: the EUPHAS Randomized Controlled Trial. JAMA. 2009;301:2445&#x2013;52. doi: 10.1001/jama.2009.856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.856</ArticleId><ArticleId IdType="pubmed">19531784</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;52. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med. 2008;34(9):1646&#x2013;53. doi: 10.1007/s00134-008-1127-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1127-3</ArticleId><ArticleId IdType="pubmed">18542921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo R, Lipcsey M, Calzavacca P, et al. Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Med. 2013;39:429&#x2013;36. doi: 10.1007/s00134-012-2800-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-012-2800-0</ArticleId><ArticleId IdType="pubmed">23306586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MP, Cancio LC, Elster EA, et al. Burn wound healing and treatment: review and advancements. Crit Care. 2015;19:243. doi: 10.1186/s13054-015-0961-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0961-2</ArticleId><ArticleId IdType="pmc">PMC4464872</ArticleId><ArticleId IdType="pubmed">26067660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitzschke SL, Aden JK, Serio-Melvin ML, et al. Wound healing trajectories in burn patients and their impact on mortality. J Burn Care Res. 2014;35:474&#x2013;9. doi: 10.1097/BCR.0000000000000039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0000000000000039</ArticleId><ArticleId IdType="pubmed">25144807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan RJ, Peck MD, Ahrenholz DH, et al. Surgical management of the burn wound and the use of skin substitutes: an expert panel white paper. J Burn Care Res. 2014;34:e60&#x2013;79. doi: 10.1097/BCR.0b013e31827039a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e31827039a6</ArticleId><ArticleId IdType="pubmed">23446645</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamme K, Maddison L, Kruusat R, et al. Effects of high volume haemodiafiltration on inflammatory response profile and microcirculation in patients with septic shock. Biomed Res Int. 2015;2015:125615. doi: 10.1155/2015/125615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/125615</ArticleId><ArticleId IdType="pmc">PMC4429196</ArticleId><ArticleId IdType="pubmed">26064875</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Eng J Med. 2017;377:419&#x2013;30. doi: 10.1056/NEJMoa1704154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1704154</ArticleId><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz C, Hernandez G, Godoy C, et al. Sublingual microcirculatory changes during high-volume hemofiltration in hyperdynamic septic shock patients. Crit Care. 2010;14:R170. doi: 10.1186/cc9271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9271</ArticleId><ArticleId IdType="pmc">PMC3219271</ArticleId><ArticleId IdType="pubmed">20875109</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark E, Molnar A, Joannes-Boyau O, et al. High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis. Crit Care 2014;18:R7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057068</ArticleId><ArticleId IdType="pubmed">24398168</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268&#x2013;82. doi: 10.1097/CCM.0b013e3181aab3d0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181aab3d0</ArticleId><ArticleId IdType="pubmed">19487930</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgram I, Roberts JA, Wallis SC, et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2010;54:2974&#x2013;8. doi: 10.1128/AAC.01582-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01582-09</ArticleId><ArticleId IdType="pmc">PMC2897321</ArticleId><ArticleId IdType="pubmed">20479205</ArticleId></ArticleIdList></Reference><Reference><Citation>Akers KS, Rowan MP, Niece KL, et al. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;59:46&#x2013;52. doi: 10.1128/AAC.03783-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03783-14</ArticleId><ArticleId IdType="pmc">PMC4291386</ArticleId><ArticleId IdType="pubmed">25313211</ArticleId></ArticleIdList></Reference><Reference><Citation>Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2011;55:4639&#x2013;42. doi: 10.1128/AAC.00374-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00374-11</ArticleId><ArticleId IdType="pmc">PMC3186982</ArticleId><ArticleId IdType="pubmed">21825289</ArticleId></ArticleIdList></Reference><Reference><Citation>Terayama T, Yamakawa K, Umemura Y, et al. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis. Surg Infect. 2017;18:225&#x2013;33. doi: 10.1089/sur.2016.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2016.168</ArticleId><ArticleId IdType="pubmed">28092497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18:699. doi: 10.1186/s13054-014-0699-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-014-0699-2</ArticleId><ArticleId IdType="pmc">PMC4318234</ArticleId><ArticleId IdType="pubmed">25527094</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesecke S, Stecher SS, Gross S, et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. June 6 2017. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">28589286</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010;38:S534&#x2013;8. doi: 10.1097/CCM.0b013e3181f208ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181f208ac</ArticleId><ArticleId IdType="pubmed">21164394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter. 2012;2:1&#x2013;138. doi: 10.1038/kisup.2012.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2012.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum JA, Gomez H, Gomez A, et al. Acute dialysis quality initiative (ADQI) XIV sepsis phenotypes and targets for blood purification in sepsis: the Bogota consensus. Shock. 2015;45:242&#x2013;8. doi: 10.1097/SHK.0000000000000485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000485</ArticleId><ArticleId IdType="pubmed">26871663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40922409</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-6576</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta anaesthesiologica Scandinavica</Title><ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation></Journal><ArticleTitle>Pro- and Anti-Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study.</ArticleTitle><Pagination><StartPage>e70117</StartPage><MedlinePgn>e70117</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70117</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/aas.70117</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) in critical illness involves dysregulated immune and inflammatory responses, endotheliopathy, and coagulation activation. We investigated how three types of endotheliopathy biomarkers relate to pro- and anti-inflammatory responses and clinical outcomes in intensive care unit (ICU) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this secondary, explorative analysis of a prospective single-centre cohort (n&#x2009;=&#x2009;459), we assessed associations between endotheliopathy biomarkers (syndecan-1, soluble thrombomodulin (sTM), platelet endothelial cell adhesion molecule-1 (PECAM-1)) and inflammatory biomarkers (pro-inflammatory: IFN-&#x3d2;, IL-1&#x3b2;, IL-2, IL-6, IL-8, IL-12p70, TNF-&#x3b1;; anti-inflammatory: IL-4, IL-10, IL-13) at ICU admission using linear regression. Associations with 30-day clinical outcomes were analysed using linear and Cox regression. All models were adjusted for age, sex, septic shock, pre-ICU surgery and chronic disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher levels of all three endotheliopathy biomarkers were associated with higher levels of inflammatory biomarkers. PECAM-1, however, showed no significant association with IFN-&#x3d2;, IL-1&#x3b2; and IL-12p70. IL-4 was excluded from linear regression due to &gt;&#x2009;50% imputed values. Higher levels of all three endotheliopathy biomarkers were significantly associated with increased mean and maximum modified Sequential Organ Failure Assessment (mSOFA) scores over 30&#x2009;days, as well as with renal, hepatic, and coagulation failure, and 30-day all-cause mortality. Only sTM was significantly associated with cardiovascular failure; none were significantly associated with respiratory failure. Higher levels of sTM were associated with the highest levels of inflammatory biomarkers, the largest increases in mean and maximum mSOFA scores, and the highest hazard ratios for organ failure and 30-day all-cause mortality, compared with syndecan-1 and PECAM-1.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this cohort of critically ill ICU patients, endotheliopathy was associated with (1) higher levels of pro- and anti-inflammatory biomarkers at ICU admission and (2) MODS, single organ failure, and 30-day all-cause mortality. Among the three endotheliopathy biomarkers, sTM demonstrated the most consistent and strongest associations with both inflammatory biomarkers and clinical outcomes. These findings are exploratory and should be interpreted as hypothesis-generating.</AbstractText><AbstractText Label="EDITOR'S COMMENT" NlmCategory="UNASSIGNED">In this analysis of different biomarkers in a critically ill cohort, associations are demonstrated between markers related to endothelial stress, cytokines related to modulation of inflammation, and severity of illness scores.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Acta Anaesthesiologica Scandinavica published by John Wiley &amp; Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Humble</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7919-2946</Identifier><AffiliationInfo><Affiliation>Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf8;nemann-Lund</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruun-Rasmussen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bestle</LastName><ForeName>Morten H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-6585-2659</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>P&#xe4;r I</ForeName><Initials>PI</Initials><Identifier Source="ORCID">0000-0001-9778-5964</Identifier><AffiliationInfo><Affiliation>Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulsen</LastName><ForeName>Lone M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-7030-3395</Identifier><AffiliationInfo><Affiliation>Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathiesen</LastName><ForeName>Ole</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-4544-0619</Identifier><AffiliationInfo><Affiliation>Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Greater Copenhagen Health Science Partners</Agency><Country/></Grant><Grant><Agency>Region Zealand Health Science Research Fund</Agency><Country/></Grant><Grant><Agency>Clinical Academic Group (CAG) Center for Endotheliomics</Agency><Country/></Grant><Grant><Agency>Intensive Care Symposium Hindsgavl</Agency><Country/></Grant><Grant><Agency>A. P. Moller Foundation</Agency><Country/></Grant><Grant><Agency>King Christian X Fund</Agency><Country/></Grant><Grant><Agency>The Danish Society of Anaesthesiology and Intensive Care Medicine (DASAIM)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Anaesthesiol Scand</MedlineTA><NlmUniqueID>0370270</NlmUniqueID><ISSNLinking>0001-5172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019408">Platelet Endothelial Cell Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018180">Thrombomodulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019408" MajorTopicYN="N">Platelet Endothelial Cell Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018180" MajorTopicYN="N">Thrombomodulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40922409</ArticleId><ArticleId IdType="pmc">PMC12417775</ArticleId><ArticleId IdType="doi">10.1111/aas.70117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adhikari N. K., Fowler R. A., Bhagwanjee S., and Rubenfeld G. D., &#x201c;Critical Care and the Global Burden of Critical Illness in Adults,&#x201d; Lancet 376, no. 9749 (2010): 1339&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136988</ArticleId><ArticleId IdType="pubmed">20934212</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoli C. J., Reynolds M. A., Sinha M., Gitlin M., and Crouser E., &#x201c;Epidemiology and Costs of Sepsis in the United States&#x2014;An Analysis Based on Timing of Diagnosis and Severity Level,&#x201d; Critical Care Medicine 46, no. 12 (2018): 1889&#x2013;1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250243</ArticleId><ArticleId IdType="pubmed">30048332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiru B., DiNino E. K., Orenstein A., et&#xa0;al., &#x201c;The Economic and Humanistic Burden of Severe Sepsis,&#x201d; PharmacoEconomics 33, no. 9 (2015): 925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">25935211</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd K. E., Johnson S. C., Agesa K. M., et&#xa0;al., &#x201c;Global, Regional, and National Sepsis Incidence and Mortality, 1990&#x2013;2017: Analysis for the Global Burden of Disease Study,&#x201d; Lancet 395, no. 10219 (2020): 200&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970225</ArticleId><ArticleId IdType="pubmed">31954465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y., Jaschinski U., Wittebole X., et&#xa0;al., &#x201c;Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care Over Nations Audit,&#x201d; Open Forum Infectious Diseases 5, no. 12 (2018): ofy313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289022</ArticleId><ArticleId IdType="pubmed">30555852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Jones G., David S., Olariu E., and Cadwell K. K., &#x201c;Frequency and Mortality of Septic Shock in Europe and North America: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Critical Care 23, no. 1 (2019): 196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545004</ArticleId><ArticleId IdType="pubmed">31151462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pool R., Gomez H., and Kellum J. A., &#x201c;Mechanisms of Organ Dysfunction in Sepsis,&#x201d; Critical Care Clinics 34, no. 1 (2018): 63&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6922007</ArticleId><ArticleId IdType="pubmed">29149942</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall J. C., &#x201c;Inflammation, Coagulopathy, and the Pathogenesis of Multiple Organ Dysfunction Syndrome,&#x201d; Critical Care Medicine 29 (2001): S99&#x2013;S106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445742</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C. S., Seymour C. W., et&#xa0;al., &#x201c;The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis&#x2010;3),&#x201d; Journal of the American Medical Association 315, no. 8 (2016): 801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Aird W. C., &#x201c;The Role of the Endothelium in Severe Sepsis and Multiple Organ Dysfunction Syndrome,&#x201d; Blood 101, no. 10 (2003): 3765&#x2013;3777.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D. C. and June C. H., &#x201c;Cytokine Storm,&#x201d; New England Journal of Medicine 383, no. 23 (2020): 2255&#x2013;2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal S. M., Dellinger R. P., Vincent J. L., Masur H., and Angus D. C., &#x201c;The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?*,&#x201d; Critical Care Medicine 42, no. 7 (2014): 1714&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135726</ArticleId><ArticleId IdType="pubmed">24717456</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Stensballe J., and Ostrowski S. R., &#x201c;Shock Induced Endotheliopathy (SHINE) in Acute Critical Illness &#x2010; a Unifying Pathophysiologic Mechanism,&#x201d; Critical Care 21, no. 1 (2017): 25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299749</ArticleId><ArticleId IdType="pubmed">28179016</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a de Lomana A. L., Vilhj&#xe1;lmsson A. I., McGarrity S., et&#xa0;al., &#x201c;Metabolic Response in Endothelial Cells to Catecholamine Stimulation Associated With Increased Vascular Permeability,&#x201d; International Journal of Molecular Sciences 23, no. 6 (2022): 3162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950318</ArticleId><ArticleId IdType="pubmed">35328583</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedlicka J., Becker B. F., and Chappell D., &#x201c;Endothelial Glycocalyx,&#x201d; Critical Care Clinics 36, no. 2 (2020): 217&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">32172810</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T., Tanigami H., Suzuki K., and Shimaoka M., &#x201c;Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis,&#x201d; Critical Care Research and Practice 2012 (2012): 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299293</ArticleId><ArticleId IdType="pubmed">22482044</ArticleId></ArticleIdList></Reference><Reference><Citation>Morser J., &#x201c;Thrombomodulin Links Coagulation to Inflammation and Immunity,&#x201d; Current Drug Targets 13, no. 3 (2012): 421&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">22206250</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehme M. W. J., Galle P., and Stremmel W., &#x201c;Kinetics of Thrombomodulin Release and Endothelial Cell Injury by Neutrophil&#x2010;Derived Proteases and Oxygen Radicals,&#x201d; Immunology 107, no. 3 (2002): 340&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782804</ArticleId><ArticleId IdType="pubmed">12423310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii H. and Majerus P. W., &#x201c;Thrombomodulin Is Present in Human Plasma and Urine,&#x201d; Journal of Clinical Investigation 76, no. 6 (1985): 2178&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424339</ArticleId><ArticleId IdType="pubmed">3001144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lertkiatmongkol P., Liao D., Mei H., Hu Y., and Newman P. J., &#x201c;Endothelial Functions of Platelet/Endothelial Cell Adhesion Molecule&#x2010;1 (CD31),&#x201d; Current Opinion in Hematology 23, no. 3 (2016): 253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986701</ArticleId><ArticleId IdType="pubmed">27055047</ArticleId></ArticleIdList></Reference><Reference><Citation>Privratsky J. R. and Newman P. J., &#x201c;PECAM&#x2010;1: Regulator of Endothelial Junctional Integrity,&#x201d; Cell and Tissue Research 355, no. 3 (2014): 607&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975704</ArticleId><ArticleId IdType="pubmed">24435645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Ince C., and Pickkers P., &#x201c;Endothelial Dysfunction: A Therapeutic Target in Bacterial Sepsis?,&#x201d; Expert Opinion on Therapeutic Targets 25, no. 9 (2021): 733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">34602020</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas A., Lichtman A., and Pillai S., &#x201c;Innate Immunity: The Early Defense Against Infections,&#x201d; in Basic Immunology: Functions and Disorders of the Immune System, 6th ed., ed. Abbas A., Lichtman A., and Pillai S. (Elsevier, 2020), 24&#x2013;29.</Citation></Reference><Reference><Citation>Johansen M. E., Johansson P. I., Ostrowski S. R., et&#xa0;al., &#x201c;Profound Endothelial Damage Predicts Impending Organ Failure and Death in Sepsis,&#x201d; Seminars in Thrombosis and Hemostasis 41, no. 1 (2015): 16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25590523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf8;nemann&#x2010;Lund M., Itenov T. S., Larsson J. E., Lindegaard B., Johansson P. I., and Bestle M. H., &#x201c;Endotheliopathy Is Associated With Slower Liberation From Mechanical Ventilation: A Cohort Study,&#x201d; Critical Care 26, no. 1 (2022): 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801241</ArticleId><ArticleId IdType="pubmed">35094711</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Henriksen H. H., Stensballe J., et&#xa0;al., &#x201c;Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients,&#x201d; Annals of Surgery 265, no. 3 (2017): 597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5300027</ArticleId><ArticleId IdType="pubmed">27144442</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Haase N., Perner A., and Ostrowski S. R., &#x201c;Association Between Sympathoadrenal Activation, Fibrinolysis, and Endothelial Damage in Septic Patients: A Prospective Study,&#x201d; Journal of Critical Care 29, no. 3 (2014): 327&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">24581948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski S. R., Haase N., M&#xfc;ller R. B., et&#xa0;al., &#x201c;Association Between Biomarkers of Endothelial Injury and Hypocoagulability in Patients With Severe Sepsis: A Prospective Study,&#x201d; Critical Care 19, no. 1 (2015): 191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423170</ArticleId><ArticleId IdType="pubmed">25907781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski S. R., Pedersen S. H., Jensen J. S., Mogelvang R., and Johansson P. I., &#x201c;Acute Myocardial Infarction Is Associated With Endothelial Glycocalyx and Cell Damage and a Parallel Increase in Circulating Catecholamines,&#x201d; Critical Care 17, no. 1 (2013): R32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057225</ArticleId><ArticleId IdType="pubmed">23433357</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Bro&#x2010;Jeppesen J., Kjaergaard J., Wanscher M., Hassager C., and Ostrowski S. R., &#x201c;Sympathoadrenal Activation and Endothelial Damage Are Inter Correlated and Predict Increased Mortality in Patients Resuscitated After Out&#x2010;Of&#x2010;Hospital Cardiac Arrest. A Post Hoc Sub&#x2010;Study of Patients From the TTM&#x2010;Trial,&#x201d; PLoS One 10, no. 3 (2015): e0120914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366381</ArticleId><ArticleId IdType="pubmed">25789868</ArticleId></ArticleIdList></Reference><Reference><Citation>Itenov T. S., Jensen J. U., Ostrowski S. R., et&#xa0;al., &#x201c;Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients,&#x201d; Shock 47, no. 6 (2017): 696&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">28505627</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama S., Nunomiya S., Koyama K., et&#xa0;al., &#x201c;Markers of Acute Kidney Injury in Patients With Sepsis: The Role of Soluble Thrombomodulin,&#x201d; Critical Care 21 (2017): 229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574079</ArticleId><ArticleId IdType="pubmed">28841902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapru A., Calfee C. S., Liu K. D., et&#xa0;al., &#x201c;Plasma Soluble Thrombomodulin Levels Are Associated With Mortality in the Acute Respiratory Distress Syndrome,&#x201d; Intensive Care Medicine 41, no. 3 (2015): 470&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4500527</ArticleId><ArticleId IdType="pubmed">25643902</ArticleId></ArticleIdList></Reference><Reference><Citation>Damas P., Canivet J. L., De Groote D., et&#xa0;al., &#x201c;Sepsis and Serum Cytokine Concentrations,&#x201d; Critical Care Medicine 25, no. 3 (1997): 405&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogos C. A., Drosou E., Bassaris H. P., and Skoutelis A., &#x201c;Pro&#x2010; Versus Anti&#x2010;Inflammatory Cytokine Profile in Patients With Severe Sepsis: A Marker for Prognosis and Future Therapeutic Options,&#x201d; Journal of Infectious Diseases 181, no. 1 (2000): 176&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozza F. A., Salluh J. I., Japiassu A. M., et&#xa0;al., &#x201c;Cytokine Profiles as Markers of Disease Severity in Sepsis: A Multiplex Analysis,&#x201d; Critical Care 11, no. 2 (2007): R49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206478</ArticleId><ArticleId IdType="pubmed">17448250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jekarl D. W., Kim J. Y., Ha J. H., et&#xa0;al., &#x201c;Diagnosis and Prognosis of Sepsis Based on Use of Cytokines, Chemokines, and Growth Factors,&#x201d; Disease Markers 2019 (2019): 1089107&#x2013;1089111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754872</ArticleId><ArticleId IdType="pubmed">31583025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Gupta E., Kaushik S., Kumar Srivastava V., Mehta S., and Jyoti A., &#x201c;Evaluation of Oxidative Stress and Antioxidant Status: Correlation With the Severity of Sepsis,&#x201d; Scandinavian Journal of Immunology 87, no. 4 (2018): e12653.</Citation><ArticleIdList><ArticleId IdType="pubmed">29484685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Gupta E., Srivastava V. K., et&#xa0;al., &#x201c;Nitrosative Stress and Cytokines Are Linked With the Severity of Sepsis and Organ Dysfunction,&#x201d; British Journal of Biomedical Science 76, no. 1 (2019): 29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">30379116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharamti A. A., Samara O., Monzon A., et&#xa0;al., &#x201c;Proinflammatory Cytokines Levels in Sepsis and Healthy Volunteers, and Tumor Necrosis Factor&#x2010;Alpha Associated Sepsis Mortality: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cytokine 158 (2022): 156006.</Citation><ArticleIdList><ArticleId IdType="pubmed">36044827</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Stensballe J., Rasmussen L. S., and Ostrowski S. R., &#x201c;A High Admission Syndecan&#x2010;1 Level, a Marker of Endothelial Glycocalyx Degradation, Is Associated With Inflammation, Protein C Depletion, Fibrinolysis, and Increased Mortality in Trauma Patients,&#x201d; Annals of Surgery 254, no. 2 (2011): 194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">21772125</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee C. S., Janz D. R., Bernard G. R., et&#xa0;al., &#x201c;Distinct Molecular Phenotypes of Direct vs Indirect ARDS in Single&#x2010;Center and Multicenter Studies,&#x201d; Chest 147, no. 6 (2015): 1539&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451708</ArticleId><ArticleId IdType="pubmed">26033126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikacenic C., Hahn W. O., Price B. L., et&#xa0;al., &#x201c;Biomarkers of Endothelial Activation Are Associated With Poor Outcome in Critical Illness,&#x201d; PLoS One 10, no. 10 (2015): e0141251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4619633</ArticleId><ArticleId IdType="pubmed">26492036</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson&#x2010;Cohen C., Katz R., Price B. L., et&#xa0;al., &#x201c;Association of Markers of Endothelial Dysregulation Ang1 and Ang2 With Acute Kidney Injury in Critically Ill Patients,&#x201d; Critical Care 20, no. 1 (2016): 207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930837</ArticleId><ArticleId IdType="pubmed">27372077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Li L., Chen Y., et&#xa0;al., &#x201c;Syndecan&#x2010;1, an Indicator of Endothelial Glycocalyx Degradation, Predicts Outcome of Patients Admitted to an ICU With COVID&#x2010;19,&#x201d; Molecular Medicine 27, no. 1 (2021): 151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640509</ArticleId><ArticleId IdType="pubmed">34861818</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D. G., Egger M., Pocock S. J., G&#xf8;tzsche P. C., and Vandenbroucke J. P., &#x201c;The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,&#x201d; Lancet 370, no. 9596 (2007): 1453&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf8;nemann&#x2010;Lund M., Itenov T. S., Larsson J. E., Lindegaard B., Johansson P. I., and Bestle M. H., &#x201c;Novel Subgroups in Acute Respiratory Failure Based on the Trajectories of Three Endotheliopathy Biomarkers: A Cohort Study,&#x201d; Acta Anaesthesiologica Scandinavica 67, no. 7 (2023): 896&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">37042167</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Henriksen H. H., Karvelsson S. T., et&#xa0;al., &#x201c;LASSO Regression Shows Histidine and Sphingosine 1 Phosphate Are Linked to Both Sepsis Mortality and Endothelial Damage,&#x201d; European Journal of Medical Research 29 (2024): 71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10799523</ArticleId><ArticleId IdType="pubmed">38245777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen K. M., Itenov T. S., Stensballe J., et&#xa0;al., &#x201c;Changes in Nitric Oxide Inhibitors and Mortality in Critically Ill Patients: A Cohort Study,&#x201d; Annals of Intensive Care 14, no. 1 (2024): 133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11349968</ArticleId><ArticleId IdType="pubmed">39190083</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. Y., Kemp T. J., Pfeiffer R. M., Pinto L. A., Hildesheim A., and Purdue M. P., &#x201c;Impact of Freeze&#x2010;Thaw Cycles on Circulating Inflammation Marker Measurements,&#x201d; Cytokine 95 (2017): 113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411278</ArticleId><ArticleId IdType="pubmed">28260648</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng S. X., McElhaney J. E., Walston J. D., Xie D., Fedarko N. S., and Kuchel G. A., &#x201c;ELISA and Multiplex Technologies for Cytokine Measurement in Inflammation and Aging Research,&#x201d; Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63, no. 8 (2008): 879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562869</ArticleId><ArticleId IdType="pubmed">18772478</ArticleId></ArticleIdList></Reference><Reference><Citation>Humble C., Sch&#xf8;nemann&#x2010;Lund M., Bruun&#x2010;Rasmussen P., et&#xa0;al., &#x201c;Pro&#x2010; and Anti&#x2010;Inflammatory Response in Critically Ill Patients With Endothelial Damage (ENDO&#x2010;FLAME),&#x201d; OSF (2023), 10.17605/OSF.IO/CEWR9.</Citation><ArticleIdList><ArticleId IdType="doi">10.17605/OSF.IO/CEWR9</ArticleId></ArticleIdList></Reference><Reference><Citation>Textor J., van der Zander B., Gilthorpe M. S., Liskiewicz M., and Ellison G. T., &#x201c;Robust Causal Inference Using Directed Acyclic Graphs: The R Package &#x201c;Dagitty&#x201d;,&#x201d; International Journal of Epidemiology 45, no. 6 (2016): 1887&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">28089956</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A. C., Santhakumaran S., Al&#x2010;Beidh F., et&#xa0;al., &#x201c;Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis,&#x201d; New England Journal of Medicine 375, no. 17 (2016): 1638&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">27705084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle M. H., Clausen N. E., S&#xf8;e&#x2010;Jensen P., et&#xa0;al., &#x201c;Efficacy and Safety of Iloprost in Patients With Septic Shock&#x2010;Induced Endotheliopathy&#x2010;Protocol for the Multicenter Randomized, Placebo&#x2010;Controlled, Blinded, Investigator&#x2010;Initiated Trial,&#x201d; Acta Anaesthesiologica Scandinavica 64, no. 5 (2020): 705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186821</ArticleId><ArticleId IdType="pubmed">31950481</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Moreno R., Takala J., et&#xa0;al., &#x201c;The SOFA (Sepsis&#x2010;Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Failure. On Behalf of the Working Group on Sepsis&#x2010;Related Problems of the European Society of Intensive Care Medicine,&#x201d; Intensive Care Medicine 22, no. 7 (1996): 707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozenne B., S&#xf8;rensen A., Scheike T., Torp&#x2010;Pedersen C., and Gerds T., &#x201c;riskRegression: Predicting the Risk of an Event Using Cox Regression Models,&#x201d; R Journal 9 (2017): 440&#x2013;460.</Citation></Reference><Reference><Citation>Benjamini Y. and Hochberg Y., &#x201c;Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,&#x201d; Journal of the Royal Statistical Society. Series B, Statistical Methodology 57 (1995): 289&#x2013;300.</Citation></Reference><Reference><Citation>Altman D. G. and Bland J. M., &#x201c;How to Obtain the P Value From a Confidence Interval,&#x201d; BMJ 343 (2011): d2304.</Citation><ArticleIdList><ArticleId IdType="pubmed">22803193</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S. and Groothuis&#x2010;Oudshoorn K., &#x201c;Mice: Multivariate Imputation by Chained Equations in R,&#x201d; Journal of Statistical Software 45 (2011): 1&#x2013;67.</Citation></Reference><Reference><Citation>Lambden S., Laterre P. F., Levy M. M., and Francois B., &#x201c;The SOFA Score&#x2010;Development, Utility and Challenges of Accurate Assessment in Clinical Trials,&#x201d; Critical Care 23, no. 1 (2019): 374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880479</ArticleId><ArticleId IdType="pubmed">31775846</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevskis E. E., Pandharipande P. P., Graves A. J., et&#xa0;al., &#x201c;Validity of a Modified Sequential Organ Failure Assessment Score Using the Richmond Agitation&#x2010;Sedation Scale,&#x201d; Critical Care Medicine 44, no. 1 (2016): 138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748963</ArticleId><ArticleId IdType="pubmed">26457749</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbers J., Miller R., Walther A., et&#xa0;al., &#x201c;How to Deal With Non&#x2010;Detectable and Outlying Values in Biomarker Research: Best Practices and Recommendations for Univariate Imputation Approaches,&#x201d; Comprehensive Psychoneuroendocrinology 7 (2021): 100052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9216349</ArticleId><ArticleId IdType="pubmed">35757062</ArticleId></ArticleIdList></Reference><Reference><Citation>
R Core Team
, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2023), https://www.R&#x2010;project.org/.</Citation></Reference><Reference><Citation>Loisa P., Rinne T., Laine S., Hurme M., and Kaukinen S., &#x201c;Anti&#x2010;Inflammatory Cytokine Response and the Development of Multiple Organ Failure in Severe Sepsis,&#x201d; Acta Anaesthesiologica Scandinavica 47, no. 3 (2003): 319&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648199</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D. M., Kim&#x2010;Schulze S., Huang H. H., et&#xa0;al., &#x201c;An Inflammatory Cytokine Signature Predicts COVID&#x2010;19 Severity and Survival,&#x201d; Nature Medicine 26, no. 10 (2020): 1636&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana S., Kumari M., Bhardwaj N., Kumar S., Malhotra R., and Mathur P., &#x201c;T&#x2010;Helper&#x2010;17, Regulatory T&#x2010;Helper Cells Related Serum Markers and IL&#x2010;13 in the Outcome of Polytraumatic Patients With Bacteremia,&#x201d; Iranian Journal of Immunology 15, no. 4 (2018): 302&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">30593744</ArticleId></ArticleIdList></Reference><Reference><Citation>Platchek M., Lu Q., Tran H., and Xie W., &#x201c;Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery,&#x201d; SLAS Discovery 25, no. 10 (2020): 1197&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">32924773</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., S&#xf8;e&#x2010;Jensen P., Bestle M. H., et&#xa0;al., &#x201c;Prostacyclin in Intubated Patients With COVID&#x2010;19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial,&#x201d; American Journal of Respiratory and Critical Care Medicine 205, no. 3 (2022): 324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8886993</ArticleId><ArticleId IdType="pubmed">34813414</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;e&#x2010;Jensen P., Clausen N. E., Bestle M. H., et&#xa0;al., &#x201c;Efficacy and Safety of a 72&#x2010;h Infusion of Prostacyclin (1&#x2009;Ng/Kg/Min) in Mechanically Ventilated Patients With Pulmonary Infection and Endotheliopathy&#x2014;Protocol for the Multicenter Randomized, Placebo&#x2010;Controlled, Blinded, Investigator&#x2010;Initiated COMBAT&#x2010;ARF Trial,&#x201d; Acta Anaesthesiologica Scandinavica 69, no. 1 (2025): e14565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11660193</ArticleId><ArticleId IdType="pubmed">39704260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum J., Lameire N., Aspelin P., et&#xa0;al., &#x201c;KDIGO Clinical Practice Guideline for Acute Kidney Injury,&#x201d; Kidney International. Supplement 2, no. 1 (2012): 1&#x2013;138.</Citation></Reference><Reference><Citation>Zarbock A., Nadim M. K., Pickkers P., et&#xa0;al., &#x201c;Sepsis&#x2010;Associated Acute Kidney Injury: Consensus Report of the 28th Acute Disease Quality Initiative Workgroup,&#x201d; Nature Reviews. Nephrology 19, no. 6 (2023): 401&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">36823168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer L., Jordan B., Druml W., Bauer P., and Metnitz P. G. H., &#x201c;Incidence and Prognosis of Early Hepatic Dysfunction in Critically Ill Patients&#x2014;A Prospective Multicenter Study,&#x201d; Critical Care Medicine 35, no. 4 (2007): 1099&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334250</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrakos C., Velissaris D., Felleiter P., et&#xa0;al., &#x201c;Increased Mortality in Critically Ill Patients With Mild or Moderate Hyperbilirubinemia,&#x201d; Journal of Critical Care 40 (2017): 31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28314169</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jager W., Bourcier K., Rijkers G. T., Prakken B. J., and Seyfert&#x2010;Margolis V., &#x201c;Prerequisites for Cytokine Measurements in Clinical Trials With Multiplex Immunoassays,&#x201d; BMC Immunology 10 (2009): 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761376</ArticleId><ArticleId IdType="pubmed">19785746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn R. G., Patel V., and Dull R. O., &#x201c;Human Glycocalyx Shedding: Systematic Review and Critical Appraisal,&#x201d; Acta Anaesthesiologica Scandinavica 65, no. 5 (2021): 590&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">33595101</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. H., Kuo C. H., Shi G. Y., and Wu H. L., &#x201c;The Role of Thrombomodulin Lectin&#x2010;Like Domain in Inflammation,&#x201d; Journal of Biomedical Science 19, no. 1 (2012): 34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342133</ArticleId><ArticleId IdType="pubmed">22449172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26715920</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1658-3639</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of health sciences</Title><ISOAbbreviation>Int J Health Sci (Qassim)</ISOAbbreviation></Journal><ArticleTitle>A study of the clinical profile of acute pancreatitis and its correlation with severity indices.</ArticleTitle><Pagination><StartPage>410</StartPage><EndPage>417</EndPage><MedlinePgn>410-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute pancreatitis is a common disease with wide clinical variation and its incidence is increasing. Acute pancreatitis may vary in severity, from mild self-limiting pancreatic inflammation to pancreatic necrosis with life-threatening sequelae. Severity of acute pancreatitis is linked to the presence of systemic organ dysfunctions and/or necrotizing pancreatitis.</AbstractText><AbstractText Label="AIM AND OBJECTIVES" NlmCategory="OBJECTIVE">The present study was aimed to assess the clinical profile of acute pancreatitis and to assess the efficacy of various severity indices in predicting the outcome of patients.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">This was a prospective study done in Sri Ramachandra Medical College and Hospital from April 2012-September 2014. All patients with a diagnosis of acute pancreatitis were included in this study. Along with routine lab parameters, serum amylase, lipase, lipid profile, calcium, CRP, LDH, CT abdomen, CXR and 2D Echo was done for all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 110 patients were analysed. 50 patients required Intensive care, among them 9 patients (18%) died. 20 patients (18.2%) had MODS, 15 patients (13.6%) had pleural effusion, 9 patients (8.2%) had pseudocyst, 2 patients(1.8%) had hypotension, 2 patients(1.8%) had ARDS and 2 patients(1.8%) had DKA. In relation to various severity indices, high score of CRP, LDH and CT severity index was associated with increased morbidity and mortality. 15 patients (13.6%) underwent open necrosectomy surgery, 3 patients (2.7%) underwent laparoscopic necrosectomy and 7 patients (6.4%) were tried step up approach but could not avoid surgery. Step up approach and surgery did not have a significant reduction in the mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Initial assessment of severity by CRP, LDH and lipase could be reliable indicators of outcome in acute pancreatitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vengadakrishnan</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Professor, Department of General Medicine, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India Email: drkvk1975@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koushik</LastName><ForeName>A K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Resident, Department of General Medicine, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India Email: drakkoushik@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Health Sci (Qassim)</MedlineTA><NlmUniqueID>101528042</NlmUniqueID><ISSNLinking>1658-3639</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">C-Reactive Protein</Keyword><Keyword MajorTopicYN="N">LDH</Keyword><Keyword MajorTopicYN="N">Severity index</Keyword><Keyword MajorTopicYN="N">Step up approach</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26715920</ArticleId><ArticleId IdType="pmc">PMC4682595</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh VK, Bollen TL, Wu BU, et al. An assessment of the severity of interstitial pancreatitis. Clin Gastroenterol Hepatol. 2011;9:1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">21893128</ArticleId></ArticleIdList></Reference><Reference><Citation>Beger HG, Rau BM. Severe acute pancreatitis: Clinical course and management. World J Gastroenterol. 2007;13:5043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434632</ArticleId><ArticleId IdType="pubmed">17876868</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100216</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsmark CE, Baillie J AGA Institute Clinical Practice and Economics Committee, AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484894</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">23896955</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13:e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Windsor JA. A better way to predict the outcome in acute pancreatitis? Am J Gastroenterol. 2010;105:1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">20606665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu BU, Banks PA. Clinical management of patients with acute pancreatitis. Gastroenterology. 2013;144:1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">23622137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan S, Forsmark CE. The difficulty in predicting outcome in acute pancreatitis. Am J Gastroenterol. 2010;105:443.</Citation><ArticleIdList><ArticleId IdType="pubmed">20139877</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53:1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1774183</ArticleId><ArticleId IdType="pubmed">15306596</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert JH, Frossard JL, Mermillod B, et al. Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glasgow, Acute Physiology and Chronic Health Evaluation II scores, and various serum markers. World J Surg. 2002;26:612.</Citation><ArticleIdList><ArticleId IdType="pubmed">12098056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol. 2002;97:1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollen TL, Singh VK, Maurer R, et al. A comparative evaluation of radiologic and clinical scoring systems in the early prediction of severity in acute pancreatitis. Am J Gastroenterol. 2012;107:612.</Citation><ArticleIdList><ArticleId IdType="pubmed">22186977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu BU, Bakker OJ, Papachristou GI, et al. Blood urea nitrogen in the early assessment of acute pancreatitis: an international validation study. Arch Intern Med. 2011;171:669.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankisch PG, Weber-Dany B, Maisonneuve P, Lowenfels AB. High serum creatinine in acute pancreatitis: a marker for pancreatic necrosis? Am J Gastroenterol. 2010;105:1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">19997093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig W, Maksan SM, Foitzik T, et al. Reduction in mortality with delayed surgical therapy of severe pancreatitis. J Gastrointest Surg. 2002;6:481.</Citation><ArticleIdList><ArticleId IdType="pubmed">12023003</ArticleId></ArticleIdList></Reference><Reference><Citation>vanSantvoort HC, Bakker OJ, Bollen TL, et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. Gastroenterology. 2011;141:1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">21741922</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard TJ, Patel JB, Zyromski N, et al. Declining morbidity and mortality rates in the surgical management of pancreatic necrosis. J GastrointestSurg. 2007;11:43.</Citation><ArticleIdList><ArticleId IdType="pubmed">17390185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortel&#xe9; KJ, Girshman J, Szejnfeld D, et al. CT-guided percutaneous catheter drainage of acute necrotizing pancreatitis: clinical experience and observations in patients with sterile and infected necrosis. AJR Am J Roentgenol. 2009;192:110. 144:1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">19098188</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman ML, Werner J, van Santvoort HC, et al. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas. 2012;41:1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23086243</ArticleId></ArticleIdList></Reference><Reference><Citation>van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362:1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayumi T, Inui K, Maetani I, et al. Validity of the urinary trypsinogen-2 test in the diagnosis of acute pancreatitis. Pancreas. 2012;41:869.</Citation><ArticleIdList><ArticleId IdType="pubmed">22481290</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang QL, Qian ZX, Li H. A comparative study of the urinary trypsinogen-2, trypsinogen activation peptide, and the computed tomography severity index as early predictors of the severity of acute pancreatitis. Hepatogastroenterology. 2010;57:1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">21410075</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32154377</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2397-5776</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Trauma surgery &amp; acute care open</Title><ISOAbbreviation>Trauma Surg Acute Care Open</ISOAbbreviation></Journal><ArticleTitle>Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured.</ArticleTitle><Pagination><StartPage>e000398</StartPage><MedlinePgn>e000398</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e000398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/tsaco-2019-000398</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The recent decrease in multiple organ dysfunction syndrome (MODS)-associated and adult respiratory distress syndrome (ARDS)-associated mortality could be considered a success of improvements in trauma care. However, the incidence of infections remains high in patients with polytrauma, with high morbidity and hospital resources usage. Infectious complications might be a residual effect of the decrease in MODS-related/ARDS-related mortality. This study investigated the current incidence of infectious complications in polytrauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 5.5-year prospective population-based cohort study included consecutive severely injured patients (age &gt;15) admitted to a (Level-1) trauma center intensive care unit (ICU) who survived &gt;48&#x2009;hours. Demographics, physiologic and resuscitation parameters, multiple organ failure and ARDS scores, and infectious complications (pneumonia, fracture-related infection, meningitis, infections related to blood, wound, and urinary tract) were prospectively collected. Data are presented as median (IQR), p&lt;0.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">297 patients (216 (73%) men) were included with median age of 46 (27-60) years, median Injury Severity Score was 29 (22-35), 96% sustained blunt injuries. 44 patients (15%) died. One patient (2%) died of MODS and 1 died of ARDS. 134 patients (45%) developed 201 infectious complications. Pneumonia was the most common complication (50%). There was no difference in physiologic parameters on arrival in emergency department and ICU between patients with and without infectious complications. Patients who later developed infections underwent more often a laparotomy (32% vs 18%, p=0.009), had more often pelvic fractures (38% vs 25%, p=0.02), and received more blood products &lt;8&#x2009;hours. They had more often MODS (25% vs 13%, p=0.005), stayed longer on the ventilator (10 (5-15) vs 5 (2-8) days, p&lt;0.001), longer in ICU (11 (6-17) vs 6 (3-10) days, p&lt;0.001), and in hospital (30 (20-44) vs 16 (10-24) days, p&lt;0.001). There was however no difference in mortality (12% vs 17%, p=0.41) between both groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">45% of patients developed infectious complications. These patients had similar mortality rates, but used more hospital resources. With low MODS-related and ARDS-related mortality, infections might be a residual effect, and are one of the remaining challenges in the treatment of patients with polytrauma.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level 3.</AbstractText><AbstractText Label="STUDY TYPE" NlmCategory="METHODS">Population-based cohort study.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hietbrink</LastName><ForeName>Falco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trauma Surg Acute Care Open</MedlineTA><NlmUniqueID>101698646</NlmUniqueID><ISSNLinking>2397-5776</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32154377</ArticleId><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="doi">10.1136/tsaco-2019-000398</ArticleId><ArticleId IdType="pii">tsaco-2019-000398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Demetriades D, Kimbrell B, Salim A, Velmahos G, Rhee P, Preston C, Gruzinski G, Chan L. Trauma deaths in a mature urban trauma system: is "trimodal" distribution a valid concept? J Am Coll Surg 2005;201:343&#x2013;8. 10.1016/j.jamcollsurg.2005.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2005.05.003</ArticleId><ArticleId IdType="pubmed">16125066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Paffrath T, Bouamra O, Coats TJ, Woodford M, Jenks T, Wafaisade A, Nienaber U, Lecky F. Epidemiology of in-hospital trauma deaths. Eur J Trauma Emerg Surg 2012;38:3&#x2013;9. 10.1007/s00068-011-0168-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-011-0168-4</ArticleId><ArticleId IdType="pubmed">26815666</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JA, van Wessem KJP, McDougall D, Lee KA, Lyons T, Balogh ZJ. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surg 2010;34:158&#x2013;63. 10.1007/s00268-009-0266-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-009-0266-1</ArticleId><ArticleId IdType="pubmed">19882185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselink L, Spijkerman R, van Wessem KJP, Koenderman L, Leenen LPH, Huber-Lang M, Hietbrink F. Neutrophil heterogeneity and its role in infectious complications after severe trauma. World J Emerg Surg 2019;14:24 10.1186/s13017-019-0244-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-019-0244-3</ArticleId><ArticleId IdType="pmc">PMC6542247</ArticleId><ArticleId IdType="pubmed">31164913</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Incidence of acute respiratory distress syndrome and associated mortality in a polytrauma population. Trauma Surg Acute Care Open 2018;3:e000232 10.1136/tsaco-2018-000232</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2018-000232</ArticleId><ArticleId IdType="pmc">PMC6307585</ArticleId><ArticleId IdType="pubmed">30623025</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Reduction in mortality rates of Postinjury multiple organ dysfunction syndrome: a shifting paradigm? A prospective population-based cohort study. Shock 2018;49:33&#x2013;8. 10.1097/SHK.0000000000000938</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId><ArticleId IdType="pubmed">28682941</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, Leenen LPH. Demographic patterns and outcomes of patients in level I trauma centers in three international trauma systems. World J Surg 2015;39:2677&#x2013;84. 10.1007/s00268-015-3162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3162-x</ArticleId><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg 2013;74:774&#x2013;9. 10.1097/TA.0b013e31827a6e69</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg 2014;77:624&#x2013;9. 10.1097/TA.0000000000000406</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000406</ArticleId><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg 1994;129:39&#x2013;45. 10.1001/archsurg.1994.01420250051006</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, ARDS Definition Task Force . Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526&#x2013;33. 10.1001/jama.2012.5669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich M, Wafaisade A, Mansuri A, Koenen P, Probst C, Maegele M, Bouillon B, Sakka SG. Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA- Scores. Scand J Trauma Resusc Emerg Med 2016;24:130 10.1186/s13049-016-0321-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-016-0321-5</ArticleId><ArticleId IdType="pmc">PMC5094147</ArticleId><ArticleId IdType="pubmed">27809885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major trauma: a comparison of the Denver, sequential organ failure assessment, and Marshall scoring systems. J Trauma Acute Care Surg 2017;82:534&#x2013;41. 10.1097/TA.0000000000001328</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000001328</ArticleId><ArticleId IdType="pmc">PMC5328408</ArticleId><ArticleId IdType="pubmed">28030507</ArticleId></ArticleIdList></Reference><Reference><Citation>Oostdijk EAN, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EHR, Bernards AT, Purmer I, Brimicombe R, Bergmans D, et al. . Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 2014;312:1429&#x2013;37. 10.1001/jama.2014.7247</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.7247</ArticleId><ArticleId IdType="pubmed">25271544</ArticleId></ArticleIdList></Reference><Reference><Citation>Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309&#x2013;32. 10.1016/j.ajic.2008.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2008.03.002</ArticleId><ArticleId IdType="pubmed">18538699</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Surgeons Guide for the prevention of surgical site infection. Bull Am Coll Surg 2000;85:23&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11349547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole E, Davenport R, Willett K, Brohi K. The burden of infection in severely injured trauma patients and the relationship with admission shock severity. J Trauma Acute Care Surg 2014;76:730&#x2013;5. 10.1097/TA.0b013e31829fdbd7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31829fdbd7</ArticleId><ArticleId IdType="pubmed">24487318</ArticleId></ArticleIdList></Reference><Reference><Citation>Metsemakers WJ, Morgenstern M, McNally MA, Moriarty TF, McFadyen I, Scarborough M, Athanasou NA, Ochsner PE, Kuehl R, Raschke M, et al. . Fracture-related infection: a consensus on definition from an international expert group. Injury 2018;49:505&#x2013;10. 10.1016/j.injury.2017.08.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2017.08.040</ArticleId><ArticleId IdType="pubmed">28867644</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J-L, Ramsay G, et al. . 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250&#x2013;6. 10.1097/01.CCM.0000050454.01978.3B</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000050454.01978.3B</ArticleId><ArticleId IdType="pubmed">12682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wafaisade A, Lefering R, Bouillon B, Sakka SG, Thamm OC, Paffrath T, Neugebauer E, Maegele M, Trauma Registry of the German Society for Trauma Surgery . Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the trauma registry of the German Society for trauma surgery. Crit Care Med 2011;39:621&#x2013;8. 10.1097/CCM.0b013e318206d3df</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318206d3df</ArticleId><ArticleId IdType="pubmed">21242798</ArticleId></ArticleIdList></Reference><Reference><Citation>Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients. Arch Surg 2011;146:794&#x2013;801. 10.1001/archsurg.2011.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.2011.41</ArticleId><ArticleId IdType="pmc">PMC3336161</ArticleId><ArticleId IdType="pubmed">21422331</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JV, Gordon LE, Hall H, Heinzelmann M, Polk HC. Differences between bacterial species shown by simultaneous assessment of neutrophil phagocytosis and generation of reactive oxygen intermediates in trauma patients. Arch Surg 1999;134:1222&#x2013;7. discussion 1227-8 10.1001/archsurg.134.11.1222</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.134.11.1222</ArticleId><ArticleId IdType="pubmed">10555637</ArticleId></ArticleIdList></Reference><Reference><Citation>Pechous RD. With friends like these: the complex role of neutrophils in the progression of severe pneumonia. Front Cell Infect Microbiol 2017;7:160 10.3389/fcimb.2017.00160</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2017.00160</ArticleId><ArticleId IdType="pmc">PMC5410563</ArticleId><ArticleId IdType="pubmed">28507954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadjadi J, Cureton EL, Twomey P, Victorino GP. Transfusion, not just injury severity, leads to posttrauma infection: a matched cohort study. Am Surg 2009;75:307&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19385290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochicchio GV, Napolitano L, Joshi M, Bochicchio K, Meyer W, Scalea TM. Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study. World J Surg 2008;32:2185&#x2013;9. 10.1007/s00268-008-9655-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-008-9655-0</ArticleId><ArticleId IdType="pubmed">18575931</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362:1011&#x2013;6. 10.1016/S0140-6736(03)14409-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)14409-1</ArticleId><ArticleId IdType="pubmed">14522530</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitinck S, Jansen R, Rijkenberg S, Wester JPJ, Bosman RJ, van der Meer NJM, van der Voort PHJ. The ecological effects of selective decontamination of the digestive tract (SDD) on antimicrobial resistance: a 21-year longitudinal single-centre study. Crit Care 2019;23:208 10.1186/s13054-019-2480-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2480-z</ArticleId><ArticleId IdType="pmc">PMC6555978</ArticleId><ArticleId IdType="pubmed">31174575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40004859</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Translating Biomarker Research into Clinical Practice in Orthopaedic Trauma: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1329</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm14041329</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> Orthopaedic trauma management in polytrauma patients presents challenges, particularly in selecting between damage control orthopaedics (DCO) and early appropriate care (EAC). This systematic review evaluates these approaches and explores the role of biomarkers in optimising surgical timing. The primary objective of this review was to evaluate the potential clinical utility of biomarkers in guiding surgical timing and predicting perioperative complications. The secondary objective was to compare the effectiveness of DCO and EAC approaches, focusing on their impact on patient outcomes when controlled for Injury Severity Scores (ISSs). <b>Methods:</b> A systematic search of PubMed, MEDLINE, and Google Scholar identified studies focusing on fracture management (DCO versus EAC), timing protocols, and biomarkers in polytrauma patients. Twenty-seven studies met inclusion criteria. <b>Results:</b> Among the 27 studies, 12 evaluated biomarkers and 15 compared DCO and EAC. Point-of-care (POC) biomarkers, including lactate (<i>p</i> &lt; 0.001; OR 1.305), monocyte L-selectin (<i>p</i> = 0.001; OR 1.5), and neutrophil L-selectin (<i>p</i> = 0.005; OR 1.56), demonstrated predictive value for sepsis, infection, and morbidity. CD16bright/CD62Ldim neutrophils were significant predictors of infection (<i>p</i> = 0.002). Advanced biomarkers, such as IL-6, IL-10, RNA IL-7R, HMGB1, and leptin offered prognostic insights but required longer processing times. No clear superiority was identified between DCO and EAC, with comparable outcomes when injury severity scores (ISS) were controlled. <b>Conclusions:</b> This systematic review highlights the challenge of translating biomarker research into clinical practice, identifying several point-of-care and advanced laboratory biomarkers with significant potential to predict complications like sepsis, infection, and MODS. Future efforts should focus on refining biomarker thresholds, advancing point-of-care technologies, and validating their role in improving surgical timing and trauma care outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baur</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0002-9820-6025</Identifier><AffiliationInfo><Affiliation>Liberty University College of Osteopathic Medicine, Lynchburg, VA 24502, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saiz</LastName><ForeName>Augustine Mark</ForeName><Initials>AM</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-1955-8667</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, UC Davis Health, Sacramento, CA 95817, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">damage control orthopaedics</Keyword><Keyword MajorTopicYN="N">early appropriate care</Keyword><Keyword MajorTopicYN="N">orthopaedic trauma</Keyword><Keyword MajorTopicYN="N">surgical timing</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>26</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40004859</ArticleId><ArticleId IdType="pmc">PMC11856232</ArticleId><ArticleId IdType="doi">10.3390/jcm14041329</ArticleId><ArticleId IdType="pii">jcm14041329</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pape H.-C., Halvachizadeh S., Leenen L., Velmahos G.D., Buckley R., Giannoudis P.V. Timing of Major Fracture Care in Polytrauma Patients&#x2014;An Update on Principles, Parameters and Strategies for 2020. Injury. 2019;50:1656&#x2013;1670. doi: 10.1016/j.injury.2019.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2019.09.021</ArticleId><ArticleId IdType="pubmed">31558277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mock C., Joshipura M., Arreola-Risa C., Quansah R. An Estimate of the Number of Lives That Could Be Saved through Improvements in Trauma Care Globally. World J. Surg. 2012;36:959&#x2013;963. doi: 10.1007/s00268-012-1459-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-012-1459-6</ArticleId><ArticleId IdType="pubmed">22419411</ArticleId></ArticleIdList></Reference><Reference><Citation>Miclau T., Hoogervorst P., Shearer D.W., El Naga A.N., Working Z.M., Martin C., Pes&#xe1;ntez R., H&#xfc;ttl T., Kojima K.E., Sch&#xfc;tz M., et al. Current Status of Musculoskeletal Trauma Care Systems Worldwide. J. Orthop. Trauma. 2018;32:S64&#x2013;S70. doi: 10.1097/BOT.0000000000001301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000001301</ArticleId><ArticleId IdType="pubmed">30247404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogervorst P., Shearer D.W., Miclau T. The Burden of High-Energy Musculoskeletal Trauma in High-Income Countries. World J. Surg. 2020;44:1033&#x2013;1038. doi: 10.1007/s00268-018-4742-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-018-4742-3</ArticleId><ArticleId IdType="pubmed">30043200</ArticleId></ArticleIdList></Reference><Reference><Citation>Stinner D.J., Edwards D. Surgical Management of Musculoskeletal Trauma. Surg. Clin. N. Am. 2017;97:1119&#x2013;1131. doi: 10.1016/j.suc.2017.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suc.2017.06.005</ArticleId><ArticleId IdType="pubmed">28958361</ArticleId></ArticleIdList></Reference><Reference><Citation>Turen C.H., Dube M.A., LeCroy M.C. Approach to the Polytraumatized Patient With Musculoskeletal Injuries. J. Am. Acad. Orthop. Surg. 1999;7:154&#x2013;165. doi: 10.5435/00124635-199905000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/00124635-199905000-00002</ArticleId><ArticleId IdType="pubmed">10346824</ArticleId></ArticleIdList></Reference><Reference><Citation>Manikis P., Jankowski S., Zhang H., Kahn R.J., Vincent J.-L. Correlation of Serial Blood Lactate Levels to Organ Failure and Mortality After Trauma. Am. J. Emerg. Med. 1995;13:619&#x2013;622. doi: 10.1016/0735-6757(95)90043-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-6757(95)90043-8</ArticleId><ArticleId IdType="pubmed">7575797</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott D.C. An Evaluation of the End Points of Resuscitation. J. Am. Coll. Surg. 1998;187:536&#x2013;547. doi: 10.1016/S1072-7515(98)00232-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1072-7515(98)00232-4</ArticleId><ArticleId IdType="pubmed">9809573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauth A., Hildebrand F., Vallier H., Moore T., Leenen L., Mckinley T., Pape H.-C. Polytrauma: Update on Basic Science and Clinical Evidence. OTA Int. Open Access J. Orthop. Trauma. 2021;4:e116. doi: 10.1097/OI9.0000000000000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/OI9.0000000000000116</ArticleId><ArticleId IdType="pmc">PMC8016602</ArticleId><ArticleId IdType="pubmed">33937720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise P.M., Saiz A.M., Haller J., Wenke J.C., Schaer T., Schneider P., Morshed S., Bahney C.S. Preclinical Models of Orthopaedic Trauma: Orthopaedic Research Society (ORS) and Orthopaedic Trauma Association (OTA) Symposium 2022. OTA Int. 2024;7:e303. doi: 10.1097/OI9.0000000000000303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/OI9.0000000000000303</ArticleId><ArticleId IdType="pmc">PMC10936151</ArticleId><ArticleId IdType="pubmed">38487400</ArticleId></ArticleIdList></Reference><Reference><Citation>Spijkerman R., Hesselink L., Bongers S., Van Wessem K.J.P., Vrisekoop N., Hietbrink F., Koenderman L., Leenen L.P.H. Point-of-Care Analysis of Neutrophil Phenotypes: A First Step Toward Immuno-Based Precision Medicine in the Trauma ICU. Crit. Care Explor. 2020;2:e0158. doi: 10.1097/CCE.0000000000000158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000158</ArticleId><ArticleId IdType="pmc">PMC7371075</ArticleId><ArticleId IdType="pubmed">32766555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord J.M., Midwinter M.J., Chen Y.-F., Belli A., Brohi K., Kovacs E.J., Koenderman L., Kubes P., Lilford R.J. The Systemic Immune Response to Trauma: An Overview of Pathophysiology and Treatment. Lancet. 2014;384:1455&#x2013;1465. doi: 10.1016/S0140-6736(14)60687-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60687-5</ArticleId><ArticleId IdType="pmc">PMC4729362</ArticleId><ArticleId IdType="pubmed">25390327</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg D.S., Narayanan A.S., Moore T.A., Vallier H.A. Assessment of Resuscitation as Measured by Markers of Metabolic Acidosis and Features of Injury. Bone Jt. J. 2017;99-B:122&#x2013;127. doi: 10.1302/0301-620X.99B1.BJJ-2016-0418.R2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.99B1.BJJ-2016-0418.R2</ArticleId><ArticleId IdType="pubmed">28053267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sears B.W., Stover M.D., Callaci J. Pathoanatomy and Clinical Correlates of the Immunoinflammatory Response Following Orthopaedic Trauma. J. Am. Acad. Orthop. Surg. 2009;17:255&#x2013;265. doi: 10.5435/00124635-200904000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/00124635-200904000-00006</ArticleId><ArticleId IdType="pmc">PMC2675552</ArticleId><ArticleId IdType="pubmed">19307674</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A., Hern&#xe1;n M.A., Reeves B.C., Savovi&#x107; J., Berkman N.D., Viswanathan M., Henry D., Altman D.G., Ansari M.T., Boutron I., et al. ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Savovi&#x107; J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.-Y., Corbett M.S., Eldridge S.M., et al. RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Gao L., Zuo J., Wei J. Efficacy of Damage Control Orthopedics Strategy in the Management of Lower Limb Trauma. Surg. Open Sci. 2024;19:101&#x2013;104. doi: 10.1016/j.sopen.2024.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sopen.2024.03.008</ArticleId><ArticleId IdType="pmc">PMC11004641</ArticleId><ArticleId IdType="pubmed">38601733</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallier H.A., Cureton B.A., Ekstein C., Oldenburg F.P., Wilber J.H. Early Definitive Stabilization of Unstable Pelvis and Acetabulum Fractures Reduces Morbidity. J. Trauma Inj. Infect. Crit. Care. 2010;69:677&#x2013;684. doi: 10.1097/TA.0b013e3181e50914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181e50914</ArticleId><ArticleId IdType="pubmed">20838139</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallier H.A., Moore T.A., Como J.J., Wilczewski P.A., Steinmetz M.P., Wagner K.G., Smith C.E., Wang X.-F., Dolenc A.J. Complications Are Reduced with a Protocol to Standardize Timing of Fixation Based on Response to Resuscitation. J. Orthop. Surg. Res. 2015;10:155. doi: 10.1186/s13018-015-0298-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-015-0298-1</ArticleId><ArticleId IdType="pmc">PMC4590279</ArticleId><ArticleId IdType="pubmed">26429572</ArticleId></ArticleIdList></Reference><Reference><Citation>Von L&#xfc;bken F., Prause S., Lang P., Friemert B.D., Lefering R., Achatz G. Early Total Care or Damage Control Orthopaedics for Major Fractures? Results of Propensity Score Matching for Early Definitive versus Early Temporary Fixation Based on Data from the Trauma Registry of the German Trauma Society (TraumaRegister DGU&#xae;) Eur. J. Trauma Emerg. Surg. 2023;49:1933&#x2013;1946. doi: 10.1007/s00068-022-02215-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-022-02215-3</ArticleId><ArticleId IdType="pmc">PMC10449664</ArticleId><ArticleId IdType="pubmed">36662169</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto R., Udagawa K., Nishida Y., Ono S., Sasaki J. Damage Control Orthopedics and Decreased In-Hospital Mortality: A Nationwide Study. Injury. 2019;50:2240&#x2013;2246. doi: 10.1016/j.injury.2019.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2019.09.028</ArticleId><ArticleId IdType="pubmed">31591006</ArticleId></ArticleIdList></Reference><Reference><Citation>Enocson A., Lundin N. Early versus Late Surgical Treatment of Pelvic and Acetabular Fractures a Five-Year Follow-up of 419 Patients. BMC Musculoskelet. Disord. 2023;24:848. doi: 10.1186/s12891-023-06977-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-023-06977-8</ArticleId><ArticleId IdType="pmc">PMC10605968</ArticleId><ArticleId IdType="pubmed">37891518</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaski G.E., Metzger C., McCarroll T., Wessel R., Adler J., Cutshall A., Brown K., Vodovotz Y., Billiar T.R., McKinley T.O. Early Immunologic Response in Multiply Injured Patients With Orthopaedic Injuries Is Associated With Organ Dysfunction. J. Orthop. Trauma. 2019;33:220&#x2013;228. doi: 10.1097/BOT.0000000000001437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000001437</ArticleId><ArticleId IdType="pubmed">31008819</ArticleId></ArticleIdList></Reference><Reference><Citation>Enninghorst N., Toth L., King K.L., McDougall D., Mackenzie S., Balogh Z.J. Acute Definitive Internal Fixation of Pelvic Ring Fractures in Polytrauma Patients: A Feasible Option. J. Trauma Inj. Infect. Crit. Care. 2010;68:935&#x2013;941. doi: 10.1097/TA.0b013e3181d27b48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181d27b48</ArticleId><ArticleId IdType="pubmed">20386287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape H.-C., Van Griensven M., Rice J., G??nsslen A., Hildebrand F., Zech S., Winny M., Lichtinghagen R., Krettek C. Major Secondary Surgery in Blunt Trauma Patients and Perioperative Cytokine Liberation: Determination of the Clinical Relevance of Biochemical Markers. J. Trauma Inj. Infect. Crit. Care. 2001;50:989&#x2013;1000. doi: 10.1097/00005373-200106000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200106000-00004</ArticleId><ArticleId IdType="pubmed">11426112</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvin J.A., Harvin W.H., Camp E., Caga-Anan Z., Burgess A.R., Wade C.E., Holcomb J.B., Cotton B.A. Early Femur Fracture Fixation Is Associated with a Reduction in Pulmonary Complications and Hospital Charges: A Decade of Experience with 1,376 Diaphyseal Femur Fractures. J. Trauma Acute Care Surg. 2012;73:1442&#x2013;1449. doi: 10.1097/TA.0b013e3182782696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182782696</ArticleId><ArticleId IdType="pubmed">23188236</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole R.V., O&#x2019;Brien M., Scalea T.M., Habashi N., Pollak A.N., Turen C.H. Resuscitation Before Stabilization of Femoral Fractures Limits Acute Respiratory Distress Syndrome in Patients With Multiple Traumatic Injuries Despite Low Use of Damage Control Orthopedics. J. Trauma Inj. Infect. Crit. Care. 2009;67:1013&#x2013;1021. doi: 10.1097/TA.0b013e3181b890be.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181b890be</ArticleId><ArticleId IdType="pubmed">19901662</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold S.C., Lagazzi E., Wagner R.K., Rafaqat W., Abiad M., Argandykov D., Hoekman A.H., Panossian V., Nzenwa I.C., Cote M., et al. Two Big Bones, One Big Decision: When to Fix Bilateral Femur Fractures. Injury. 2024;55:111610. doi: 10.1016/j.injury.2024.111610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2024.111610</ArticleId><ArticleId IdType="pubmed">38861829</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T.-P., Chen Y.-T., Ko P.-Y., Wu C.-H., Yang T.-H., Hung K.-S., Wu P.-T., Wang C.-J., Yen Y.-T., Shan Y.-S. Is Delayed Fixation Worthwhile in Patients with Long Bone Fracture Concomitant with Mild Traumatic Brain Injury? A Propensity Score&#x2013;Matched Study. Injury. 2023;54:110804. doi: 10.1016/j.injury.2023.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2023.05.035</ArticleId><ArticleId IdType="pubmed">37225544</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass N.E., Burlew C.C., Hahnhaussen J., Weckbach S., Pieracci F.M., Moore E.E., Stahel P.F. Early Definitive Fracture Fixation Is Safely Performed in the Presence of an Open Abdomen in Multiply Injured Patients. J. Orthop. Trauma. 2017;31:624&#x2013;630. doi: 10.1097/BOT.0000000000000959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000000959</ArticleId><ArticleId IdType="pubmed">28827509</ArticleId></ArticleIdList></Reference><Reference><Citation>Andruszkow H., Dowrick A.S., Frink M., Zeckey C., Krettek C., Hildebrand F., Edwards E.R., Mommsen P. Surgical Strategies in Polytraumatized Patients with Femoral Shaft Fractures&#x2014;Comparing a German and an Australian Level I Trauma Centre. Injury. 2013;44:1068&#x2013;1072. doi: 10.1016/j.injury.2013.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2013.03.032</ArticleId><ArticleId IdType="pubmed">23639825</ArticleId></ArticleIdList></Reference><Reference><Citation>Testa G., Vescio A., Aloj D.C., Papotto G., Ferrarotto L., Mass&#xe9; A., Sessa G., Pavone V. Definitive Treatment of Femoral Shaft Fractures: Comparison between Anterograde Intramedullary Nailing and Monoaxial External Fixation. JCM. 2019;8:1119. doi: 10.3390/jcm8081119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8081119</ArticleId><ArticleId IdType="pmc">PMC6723720</ArticleId><ArticleId IdType="pubmed">31357687</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich M., Sch&#xe4;fer N., Caspers M., B&#xf6;hm J.K., St&#xfc;rmer E.K., Bouillon B., Maegele M. Temporal Phenotyping of Circulating Microparticles after Trauma: A Prospective Cohort Study. Scand. J. Trauma Resusc. Emerg. Med. 2018;26:33. doi: 10.1186/s13049-018-0499-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-018-0499-9</ArticleId><ArticleId IdType="pmc">PMC5921785</ArticleId><ArticleId IdType="pubmed">29703240</ArticleId></ArticleIdList></Reference><Reference><Citation>Haupt J., Krysiak N., Unger M., Bogner-Flatz V., Biberthaler P., Hanschen M., Van Griensven M., Haug A.T. The Potential of Adipokines in Identifying Multiple Trauma Patients at Risk of Developing Multiple Organ Dysfunction Syndrome. Eur. J. Med. Res. 2021;26:38. doi: 10.1186/s40001-021-00511-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00511-z</ArticleId><ArticleId IdType="pmc">PMC8086117</ArticleId><ArticleId IdType="pubmed">33931112</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J., Qian H., Wu G., Bao N., Song Y. Neutrophil-Derived Long Noncoding RNA IL-7R Predicts Development of Multiple Organ Dysfunction Syndrome in Patients with Trauma. Eur. J. Trauma Emerg. Surg. 2022;48:1545&#x2013;1553. doi: 10.1007/s00068-020-01403-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-020-01403-3</ArticleId><ArticleId IdType="pubmed">32524156</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape H.-C., Grimme K., Van Griensven M., Sott A.H., Giannoudis P., Morley J., Roise O., Ellingsen E., Hildebrand F., Wiese B., et al. Impact of Intramedullary Instrumentation versus Damage Control for Femoral Fractures on Immunoinflammatory Parameters: Prospective Randomized Analysis by the EPOFF Study Group. J. Trauma Inj. Infect. Crit. Care. 2003;55:7&#x2013;13. doi: 10.1097/01.TA.0000075787.69695.4E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000075787.69695.4E</ArticleId><ArticleId IdType="pubmed">12855874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape H.-C., Rixen D., Morley J., Husebye E.E., Mueller M., Dumont C., Gruner A., Oestern H.J., Bayeff-Filoff M., Garving C., et al. Impact of the Method of Initial Stabilization for Femoral Shaft Fractures in Patients With Multiple Injuries at Risk for Complications (Borderline Patients) Ann. Surg. 2007;246:491&#x2013;501. doi: 10.1097/SLA.0b013e3181485750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181485750</ArticleId><ArticleId IdType="pmc">PMC1959352</ArticleId><ArticleId IdType="pubmed">17717453</ArticleId></ArticleIdList></Reference><Reference><Citation>Rixen D., Steinhausen E., Sauerland S., Lefering R., Maegele M.G., Bouillon B., Grass G., Neugebauer E.A.M., Damage Control Study Group Randomized, Controlled, Two-Arm, Interventional, Multicenter Study on Risk-Adapted Damage Control Orthopedic Surgery of Femur Shaft Fractures in Multiple-Trauma Patients. Trials. 2016;17:47. doi: 10.1186/s13063-016-1162-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-016-1162-2</ArticleId><ArticleId IdType="pmc">PMC4727266</ArticleId><ArticleId IdType="pubmed">26809247</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs G.D., Lemmert K., Lott N.J., De Malmanche T., Balogh Z.J. Biomarkers to Guide the Timing of Surgery: Neutrophil and Monocyte L-Selectin Predict Postoperative Sepsis in Orthopaedic Trauma Patients. JCM. 2021;10:2207. doi: 10.3390/jcm10102207.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10102207</ArticleId><ArticleId IdType="pmc">PMC8160833</ArticleId><ArticleId IdType="pubmed">34065206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumsdaine W., Easton R.M., Lott N.J., White A., Malmanche T.L.D., Lemmert K., Weber D.G., Balogh Z.J. Neutrophil Oxidative Burst Capacity for Peri-Operative Immune Monitoring in Trauma Patients. Injury. 2014;45:1144&#x2013;1148. doi: 10.1016/j.injury.2014.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2014.04.019</ArticleId><ArticleId IdType="pubmed">24815374</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape H.-C., Griensven M.V., Hildebrand F.F., Tzioupis C.T., Sommer K.L., Krettek C.C., Giannoudis P.V. Systemic Inflammatory Response After Extremity or Truncal Fracture Operations. J. Trauma Inj. Infect. Crit. Care. 2008;65:1379&#x2013;1384. doi: 10.1097/TA.0b013e31818c8e8c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31818c8e8c</ArticleId><ArticleId IdType="pubmed">19077630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F., Koenderman L., Althuizen M., Leenen L.P.H. Modulation of the Innate Immune Response after Trauma Visualised by a Change in Functional PMN Phenotype. Injury. 2009;40:851&#x2013;855. doi: 10.1016/j.injury.2008.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2008.11.002</ArticleId><ArticleId IdType="pubmed">19339006</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards J.E., Matuszewski P.E., Grif S.M., Guillamondegui O.D., Obremskey W.T., Evans J.M. The Role of Elevated Lactate as a Risk Factor for Pulmonary Morbidity After Early Fixation of Femoral Shaft Fractures. J. Orthop. Trauma. 2016;30:312&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206261</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladipo V., Portney D., Haber J., Baker H., Strelzow J. Lactic Acid Levels Are Associated with Morbidity, Length of Stay, and Total Treatment Costs in Urban Trauma Patients with Lower Extremity Long Bone Fractures. Eur. J. Orthop. Surg. Traumatol. 2024;34:1963&#x2013;1970. doi: 10.1007/s00590-024-03877-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-024-03877-y</ArticleId><ArticleId IdType="pubmed">38480531</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida Y., Yamamoto R., Ono S., Sasaki J. Association between Preoperative Lactate Level and Early Complications after Surgery for Isolated Extremity Fracture. BMC Musculoskelet. Disord. 2024;25:314. doi: 10.1186/s12891-024-07409-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-024-07409-x</ArticleId><ArticleId IdType="pmc">PMC11036590</ArticleId><ArticleId IdType="pubmed">38654188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C., Kushner I. Acute-Phase Proteins and Other Systemic. New Engl. J. Med. 1999;340:448&#x2013;454. doi: 10.1056/NEJM199902113400607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199902113400607</ArticleId><ArticleId IdType="pubmed">9971870</ArticleId></ArticleIdList></Reference><Reference><Citation>Madry H., Gr&#xe4;ssel S., N&#xf6;th U., Relja B., Bernstein A., Docheva D., Kauther M.D., Katthagen J.C., Bader R., Van Griensven M., et al. The Future of Basic Science in Orthopaedics and Traumatology: Cassandra or Prometheus? Eur. J. Med. Res. 2021;26:56. doi: 10.1186/s40001-021-00521-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00521-x</ArticleId><ArticleId IdType="pmc">PMC8200553</ArticleId><ArticleId IdType="pubmed">34127057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J.-L., Quintairos E., Silva A., Couto L., Taccone F.S. The Value of Blood Lactate Kinetics in Critically Ill Patients: A Systematic Review. Crit Care. 2016;20:257. doi: 10.1186/s13054-016-1403-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1403-5</ArticleId><ArticleId IdType="pmc">PMC4983759</ArticleId><ArticleId IdType="pubmed">27520452</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich V., Johandl S., De Zwart P., Stockle U., Ochs B. Navigated TKA after Osteotomy versus Primary Navigated TKA: A Matched-Pair Analysis. Orthopedics. 2016;39:S77&#x2013;S82. doi: 10.3928/01477447-20160509-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20160509-22</ArticleId><ArticleId IdType="pubmed">27219735</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb J.B., Tilley B.C., Baraniuk S., Fox E.E., Wade C.E., Podbielski J.M., Del Junco D.J., Brasel K.J., Bulger E.M., Callcut R.A., et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma: The PROPPR Randomized Clinical Trial. JAMA. 2015;313:471. doi: 10.1001/jama.2015.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.12</ArticleId><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett M.D., Smith C.E. General Anesthesia for Trauma. In: Varon A.J., Smith C., editors. Essentials of Trauma Anesthesia. Cambridge University Press; Cambridge, UK: 2012. pp. 76&#x2013;94.</Citation></Reference><Reference><Citation>Chong M.A., Wang Y., Berbenetz N.M., McConachie I. Does Goal-Directed Haemodynamic and Fluid Therapy Improve Peri-Operative Outcomes?: A Systematic Review and Meta-Analysis. Eur. J. Anaesthesiol. 2018;35:469&#x2013;483. doi: 10.1097/EJA.0000000000000778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000778</ArticleId><ArticleId IdType="pubmed">29369117</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohi K., Singh J., Heron M., Coats T. Acute Traumatic Coagulopathy. J. Trauma Inj. Infect. Crit. Care. 2003;54:1127&#x2013;1130. doi: 10.1097/01.TA.0000069184.82147.06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000069184.82147.06</ArticleId><ArticleId IdType="pubmed">12813333</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin J.M., Barras W.P., Bree S., Williams N., McFarland C., Park C., Steinhiser D., Stone R.C., Stockinger Z. Anesthesia for Trauma Patients. Mil. Med. 2018;183:32&#x2013;35. doi: 10.1093/milmed/usy062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/milmed/usy062</ArticleId><ArticleId IdType="pubmed">30189066</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizamuddin J., O&#x2019;Connor M. Schwartz&#x2019;s Principles of Surgery. McGraw Hill Medical; New York, NY, USA: 2019. Chapter 46: Anesthesia for Surgical Patients.</Citation></Reference><Reference><Citation>Davis M.L., Rocca G.J.D., Brenner M., Cribari C., Cryer H.G., Ficke J.R., Hartsock L., Henley M.B., Henry P.D.G., Jenkins D.H., et al.  ACS Tqip Best Practices in the Management of Orthopaedic Trauma. Presented at the ACS Trauma Quality Improvement Program. 2015.  [(accessed on 1 February 2025)].  Available online:  https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.facs.org/media/mkbnhqtw/ortho_guidelines.pdf&amp;ved=2ahUKEwjp0NXBkb-LAxWUFFkFHUbkImsQFnoECAgQAQ&amp;usg=AOvVaw2wg6Vb-SqWCjcM2PBIKz83.</Citation></Reference><Reference><Citation>Bolcato V., Franzetti C., Fassina G., Basile G., Martinez R.M., Tronconi L.P. Comparative Study on Informed Consent Regulation in Health Care among Italy, France, United Kingdom, Nordic Countries, Germany, and Spain. J. Forensic Leg. Med. 2024;103:102674. doi: 10.1016/j.jflm.2024.102674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jflm.2024.102674</ArticleId><ArticleId IdType="pubmed">38502996</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35638038</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>Biliary complications after adult to adult right-lobe living donor liver transplantation (A-ARLLDLT): Analysis of 245 cases during 16 years period at a single high centre- A retrospective cohort study.</ArticleTitle><Pagination><StartPage>103577</StartPage><MedlinePgn>103577</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103577</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amsu.2022.103577</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Biliary complications (BCs) after adult to adult living donor liver transplantation (A-ALDLT) result in poor graft and patient survival. This study aimed to analyze these complications.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We retrospectively analyzed BCs in 245 recipients who underwent A-ALDLT using the right-lobe graft during 16 years period in our centre. The overall male/female ratio was 215/30.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">One hundred fifty-five BCs affected 102 of our recipients (95 early (&#x2264;3months) and 60 late (&#x2265;3months)). They were classified as 67/245(27.3%) early bile leak, 10/245(4.1%) early biliary stricture, 44/245(17.9%) late biliary stricture, 4/245(1.6%) early cholangitis, 10/245(4.1%) late cholangitis, 14/245(5.7%) early biloma, and 6/245(2.4%) late cholangitic abscesses. Multiple biliary anastomoses were independently correlated with Post liver transplantation (LT) overall BCs; moreover, post LT hepatic artery thrombosis or stenosis (HAT/S) was an independent predictor of overall BCs, strictures and leaks. The mortality affected 96(39.2%) cases mostly due to sepsis, bleeding and multi-organ failure (MOF). On the other hand, the biliary related mortality was 10.6% of cases. Multiple cholangitic hepatic abscesses were significant predictors of poor graft and patient outcomes. Conclusions: Multiple biliary anastomoses and post LT HAT/S lead to a poor biliary outcome, furthermore, cholangitis, cholangitic abscesses and sepsis lead to poor graft and patient outcomes, so proper management of those variables is mandatory to improve outcomes after A-ARLLDLT.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gad</LastName><ForeName>Emad Hamdy</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoup</LastName><ForeName>Eslam</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Amr M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhelbawy</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abd-Elsamee</LastName><ForeName>Mohammed Al-Sayed</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Radiology, National Liver Institute, Menoufiya University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallam</LastName><ForeName>Ahmed Nabil</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biliary complications</Keyword><Keyword MajorTopicYN="N">Liver transplantation</Keyword><Keyword MajorTopicYN="N">Morbidity</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>No conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>14</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35638038</ArticleId><ArticleId IdType="pmc">PMC9142388</ArticleId><ArticleId IdType="doi">10.1016/j.amsu.2022.103577</ArticleId><ArticleId IdType="pii">S2049-0801(22)00337-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atwal T., Pastrana M., Sandhu B. Post-liver transplant biliary complications. J. Clin. Exp. Hepatol. 2012;2:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3940277</ArticleId><ArticleId IdType="pubmed">25755409</ArticleId></ArticleIdList></Reference><Reference><Citation>Server S., Sabet S., Sahin T., Guven K., Ayd&#x131;n U., Tokat Y., et al. Novel application of internal-external drainage catheter as biliary stent for percutaneous transhepatic treatment of biliary strictures in living donor liver transplantation recipient patients. Transplant. Proc. 2019;51:2469&#x2013;2472.</Citation><ArticleIdList><ArticleId IdType="pubmed">31405740</ArticleId></ArticleIdList></Reference><Reference><Citation>Todo S., Furukawa H., Kamiyama T. How to prevent and manage biliary complications in living donor liver transplantation? J. Hepatol. 2005;43:22&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">15921817</ArticleId></ArticleIdList></Reference><Reference><Citation>Polese L., Cillo U., Brolese A., Boccagni P., Neri D., Bassi D., et al. Endoscopic treatment of bile duct complications after orthotopic liver transplantation. Transplant. Proc. 2007;39:1942&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pubmed">17692660</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidi R.F., Elias N., Ko D.S., Kawai T., Markmann J., Cosimi A.B., et al. Biliary reconstruction and complications after living-donor liver transplantation. HPB. 2009;11:505&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756638</ArticleId><ArticleId IdType="pubmed">19816615</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C.S., Jung B.H., Hwang S., Park Y.H., Kang S.H., Park G.C., et al. External biliary drainage in living donor liver transplantation using duct-to-duct anastomosis. Transplant. Proc. 2014;46:678&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">24767322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegadeesan M., Goyal N., Rastogi H., Gupta S. Percutaneous transhepatic biliary drainage for biliary stricture after endotherapy failure in living donor liver transplantation: a Single-centre experience from India. J. Clin. Exp. Hepatol. 2019;9:684&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6926189</ArticleId><ArticleId IdType="pubmed">31889748</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikan T., Emek E., Bozkurt B., Mammadov E., Ceyhan O., Sahin T., et al. Does multiple bile duct anastomosis in living donor liver transplantation affect the postoperative biliary complications? Transplant. Proc. 2019;51:2473&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pubmed">31405743</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung D.H., Ikegami T., Balci D., Bhangui P. Biliary reconstruction and complications in living donor liver transplantation. Int. J. Surg. 2020;82S:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387205</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes M.P., Fern&#xe1;ndez Aguilar J.L., de Cabo S.N., Le&#xf3;n D&#xed;az F.J., Rodr&#xed;guez M.P., P&#xe9;rez B.S., et al. Influence of bile duct diameter on biliary complications after liver transplantation. Transplant. Proc. 2020;52:569&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">32033832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.D., Jwa E.K., Choi D.L. Novel method for reconstructing multiple graft bile ducts during right lobe living donor liver transplant: dunking with mucosal eversion technique. Transplant. Proc. 2020;52:1807&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pubmed">32448651</ArticleId></ArticleIdList></Reference><Reference><Citation>Koksal A.S., Eminler A.T., Parlak E., Gurakar A. Management of biliary anastomotic strictures after liver transplantation. Transplant. Rev. 2017;31:207&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427741</ArticleId></ArticleIdList></Reference><Reference><Citation>Na B.G., Park G.C., Hwang S., Kim K.H., Ahn C.S., Moon D.B., et al. Biliary complications after single-and dual-graft living-donor liver transplantation using a right posterior section graft of donor with a type III portal vein variation. Transplant. Proc. 2020;52:1838&#x2013;1843.</Citation><ArticleIdList><ArticleId IdType="pubmed">32444130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew G., Agha R., for the STROCSS Group STROCSS 2021: strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery. Int. J. Surg. 2021;96</Citation><ArticleIdList><ArticleId IdType="pubmed">34774726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gad E.H., Alsebaey A., Lotfy M., Eltabbakh M., Sherif A.A. Complications and mortality after adult to adult living donor liver transplantation: a retrospective cohort study. Ann. Med. Surg. 2015;4(2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434206</ArticleId><ArticleId IdType="pubmed">26005570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gad E.H., Abdelsamee M.A., Kamel Y. Hepatic arterial and portal venous complications after adult and pediatric living donor liver transplantation, risk factors, management and outcome (A retrospective cohort study) Ann Med Surg (Lond) 2016;8:28&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878848</ArticleId><ArticleId IdType="pubmed">27257483</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoreem H., Gad E.H., Soliman H., Hegazy O., Saleh S., Zakaria H., et al. Small for size syndrome difficult dilemma: lessons from 10 years single centre experience in living donor liver transplantation. World J. Hepatol. 2017;9(21):930&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5545138</ArticleId><ArticleId IdType="pubmed">28824744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.W., Bae B.K., Lee J.M., Won J.H., Park Y.K., Xu W.G., et al. duct-to-duct biliary reconstructions and complications in 100 living donor liver transplantations. Transplant. Proc. 2009;41:1749&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">19545721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogiso S., Kamei H., Onishi Y., Kurata N., Jobara K., Kawashima H., et al. Decreased long-term graft survival in persistent biliary complications after right-lobe living-donor liver transplantation. Clin. Transplant. 2020;34</Citation><ArticleIdList><ArticleId IdType="pubmed">31846118</ArticleId></ArticleIdList></Reference><Reference><Citation>Larghi A., Tringali A., Rimbas M., Barbaro F., Perri V., Rizzatti G., et al. Endoscopic management of benign biliary strictures after liver transplantation. Liver Transplant. 2019;25:323&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">30329213</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaldo E.T., Austin M.T., Pinson C.W., Chari R.S. Management of the bile duct anastomosis and its complications after liver transplantation. Transplant. Rev. 2007;21:26&#x2013;33.</Citation></Reference><Reference><Citation>Sendino O., Fern&#xe1;ndez-Simon A., Law R., Abu Dayyeh B., Leise M., Chavez-Rivera K., et al. Endoscopic management of bile leaks after liver transplantation: an analysis of two high-volume transplant centers. U. Eur. Gatroenterol. J. 2018;6(1):89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802677</ArticleId><ArticleId IdType="pubmed">29435318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.S., Liu N.J., Lee C.F., Chou H.S., Wu T.J., Pan K.T., et al. Endoscopic management of biliary complications after adult right-lobe living donor liver transplantation without initial biliary decompression. Transplant. Proc. 2008;40:2542&#x2013;2545.</Citation><ArticleIdList><ArticleId IdType="pubmed">18929795</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.S., Kim M.-H., Lee S.K., Seo D.W., Lee S.S., Han J., et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest. Endosc. 2003;57:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12518136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawansa N., McCall J.L., Holden A., Plank L., Munn S.R. Biliary complications following orthotopic liver transplantation: a 10-year audit. HPB. 2011;13:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103095</ArticleId><ArticleId IdType="pubmed">21609371</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaprak O., Dayangac M., Akyildiz M., Demirbas T., Guler N., Bulutcu F., et al. Biliary complications after right lobe living donor liver transplantation: a single-centre experience. HPB. 2012;14:49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252991</ArticleId><ArticleId IdType="pubmed">22151451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez A.R., Morris M.C., Brown N.G., Winer L.K., Safdar K., Poreddy S., et al. Is surgery necessary? Endoscopic management of post-transplant biliary complications in the modern era. J. Gastrointest. Surg. 2020;24:1639&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">31228080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisatsune H., Yazumi S., Egawa H., Asada M., Hasegawa K., Kodama Y., et al. Endoscopic management of biliary strictures after duct-to-duct biliary reconstruction in right-lobe living-donor liver transplantation. Transplantation. 2003;76:810&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501859</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao H.B., Koshy A.K., Sudhindran S., Prabhu N.K., Venu R.P. Paradigm shift in the management of bile duct strictures complicating living donor liver transplantation. Indian J. Gastroenterol. 2019;38(6):488&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">32065353</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi M., Kumagi T., Kuroda T., Imamura Y., Kanemitsu K., Ogawa K., et al. Endoscopic stent placement above the sphincter of Oddi for biliary strictures after living donor liver transplantation. BMC Gastroenterol. 2020;20:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137274</ArticleId><ArticleId IdType="pubmed">32252630</ArticleId></ArticleIdList></Reference><Reference><Citation>You M.S., Paik W.H., Choi Y.H., Shin B.-S., Lee S.H., Ryu J.K., et al. Optimal biliary drainage for patients with biliary anastomotic strictures after right lobe living donor liver transplantation. Liver Transplant. 2019;25:1209&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pubmed">30980451</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., Kogure H., Nakai Y., Hamada T., Takahara N., Mizuno S., et al. Long&#x2010;term outcomes of endoscopic treatment for duct&#x2010;to&#x2010;duct anastomotic strictures after living donor liver transplantation. Liver Int. 2019;39:1954&#x2013;1963.</Citation><ArticleIdList><ArticleId IdType="pubmed">31436017</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.K., Yang J.-I., Lee J.K., Park J.K., Lee K.H., Lee K.T., et al. Long-term outcome of endoscopic retrograde biliary drainage of biliary stricture following living donor liver transplantation. Gut Liver. 2020;14:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974332</ArticleId><ArticleId IdType="pubmed">30970446</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S.I., Chung T.R., Cho J.H., Lee K.H., Joo S.M., Choi J.H., et al. Short fully covered self-expandable metal stent for treatment of proximal anastomotic benign biliary stricture after living-donor liver transplantation. Dig. Endosc. 2021;33(5):840&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">33043522</ArticleId></ArticleIdList></Reference><Reference><Citation>Moy B.T., Birk J.W. A Review on the management of biliary complications after orthotopic liver transplantation. J. Clin. Transl. Hepatol. 2019;7(1):61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6441650</ArticleId><ArticleId IdType="pubmed">30944822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.S., Chen C.L., Concejero A.M., Yap A.Q., Lin Y.H., Liu C.Y., et al. Early and long-term results of routine microsurgical biliary reconstruction in living donor liver transplantation. Liver Transplant. 2013;19:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">23197399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.H., Ko G.Y., Sung K.B., Yoon H.K., Gwon D.I., Kim K.R., et al. Bile leak following living donor liver transplantation: clinical efficacy of percutaneous transhepatic treatment. Liver Transplant. 2008;14:1142&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18668647</ArticleId></ArticleIdList></Reference><Reference><Citation>Icoz G., Kilic M., Zeytunlu M., Celebi A., Ersoz G., Killi R., et al. Biliary reconstructions and complications encountered in 50 consecutive right-lobe living donor liver transplantations. Liver Transplant. 2003;9(6):575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Wadhawan M., Taneja S., Shandil R. Biliary complications after liver transplantation. Apollo Med. 2012;9(1):32&#x2013;37.</Citation></Reference><Reference><Citation>Wang S.H., Lin P.Y., Wang J.Y., Lin H.C., Hsieh C.E., Chen Y.L. Predictors of biliary leakage after T-Tube removal in living donor liver transplantation recipients. Transplant. Proc. 2015;47:2488&#x2013;2492.</Citation><ArticleIdList><ArticleId IdType="pubmed">26518957</ArticleId></ArticleIdList></Reference><Reference><Citation>Czerwonko M.E., Huespe P., Elizondo C.M., Pekolj J., Gadano A., Barc&#xe1;n L., et al. Risk factors and outcomes of pyogenic liver abscess in adult liver recipients: a matched case-control study. HPB. 2018;20:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">29496466</ArticleId></ArticleIdList></Reference><Reference><Citation>Justo I., Jime&#x144;ez-Romero C., Manrique A., Caso O., Calvo J., Cambra F., et al. Management and outcome of liver abscesses after liver transplantation. World J. Surg. 2018;42:3341&#x2013;3349.</Citation><ArticleIdList><ArticleId IdType="pubmed">29633100</ArticleId></ArticleIdList></Reference><Reference><Citation>Girometti R., Pancot M., Como G., Zuiani C. Imaging of liver transplantation. Eur. J. Radiol. 2017;93:295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">28545872</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachopoulou O.A., Vogt D.P., Henderson J.M., Baker M., Keys T.F. Hepatic abscess after liver transplantation: 1990&#x2013;2000. Transplantation. 2003;75:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikeghbalian S., Salahi R., Salahi H., Bahador A., Kakaie F., Kazemi K., et al. Hepatic abscesses after liver transplant: 1997&#x2013;2008. Exp. Clin. Transplant. 2009;4:256&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20353378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharzehi K. Biliary strictures in the liver transplant patient. Tech. Gastrointest. Endosc. 2016;18:91&#x2013;97.</Citation></Reference><Reference><Citation>Hashimoto K., Miller C.M., Quintini C., Aucejo F.N., Hirose K., Uso T.D., et al. Is impaired hepatic arterial buffer response a risk factor for biliary anastomotic stricture in liver transplant recipients? Surgery. 2010;148:582&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">20227098</ArticleId></ArticleIdList></Reference><Reference><Citation>Na G.H., Kim D.G., Choi H.J., Han J.H., Hong T.H., You Y.K. Interventional treatment of biliary stricture after adult right-lobe living-donor liver transplantation with duct-to-duct anastomosis. HPB. 2014;16:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967882</ArticleId><ArticleId IdType="pubmed">23981034</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S.W., Kim D.S., Yu Y.D., Suh S.O. Clinical outcome of internal stent for biliary anastomosis in liver transplantation. Transplant. Proc. 2014;46:856&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">24767365</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;z&#xe7;elik &#xdc;., Eren E., Toka&#xe7; M., &#x15e;ahin T., Parlak H., Din&#xe7;kan A. Results of using the cystic duct for reconstruction of one of the multiple bile ducts in right lobe living donor liver transplantation. Transplant. Proc. 2021;53:1962&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">34233848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawachi S., Shimazu M., Wakabayashi G., Hoshino K., Tanabe M., Yoshida M., et al. Biliary complications in adult living donor liver transplantation with duct-to-duct hepaticocholedochostomy or Roux-en- Y hepaticojejunostomy biliary reconstruction. Surgery. 2002;132(1):48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Sato Y., Yamamoto S., Oya H., Hara Y., Watanabe T., et al. Long-term follow-up study of biliary reconstructions and complications after adult living donor liver transplantation: feasibility of duct-to-duct reconstruction with a t-tube stent. Transplant. Proc. 2009;41:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">19249531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciato G., Varotti G., Quintini C., Masetti M., Di Benedetto F., Grazi G.L., et al. Impact of biliary complications in right lobe living donor liver transplantation. Transpl. Int. 2006;19(2):122&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16441361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S.Y., Hu X.G., Lee H.Y., Won J.H., Kim J.W., Shen X.Y., et al. Long-term analysis of biliary complications after duct-to-duct biliary reconstruction in living donor liver transplantations. Liver Transplant. 2018;24:1050&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">29633539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hann A., Seth R., Mergental H., Hartog H., Alzoubi M., Stangou A., et al. Biliary strictures are associated with both early and late hepatic artery stenosis. Transplant. Direct. 2020;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738047</ArticleId><ArticleId IdType="pubmed">33335982</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nning J., Berglund E., Arnelo U., Ericzon B.G., Nowak G. Long-term outcome of endoscopic and percutaneous transhepatic approaches for biliary complications in liver transplant recipients. Transplant. Direct. 2019;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411220</ArticleId><ArticleId IdType="pubmed">30882037</ArticleId></ArticleIdList></Reference><Reference><Citation>Matar A.J., Driscoll K.R., Kenney L., Wichmann H.K., Magliocca J.F., Kitchens W.H. Biliary complications following adult deceased donor liver transplantation: risk factors and implications at a high-volume US center. Transplant. Direct. 2021;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425824</ArticleId><ArticleId IdType="pubmed">34514109</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro F., Tringali A., Larghi A., Baldan A., Onder G., Familiari P., et al. Endoscopic management of non-anastomotic biliary strictures following liver transplantation: long-term results from a single-centre experience. Dig. Endosc. 2021;33(5):849&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">33080081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25518299</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0125-2208</ISSN><JournalIssue CitedMedium="Print"><Volume>97 Suppl 8</Volume><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</Title><ISOAbbreviation>J Med Assoc Thai</ISOAbbreviation></Journal><ArticleTitle>A randomized trial between different suture materials (polydioxanone vs. poliglecaprone 25) and different suturing techniques (running subcuticular suture alone vs. with running horizontal mattress) in prevention of hypertrophic scar development in median sternotomy wound.</ArticleTitle><Pagination><StartPage>S88</StartPage><EndPage>S94</EndPage><MedlinePgn>S88-94</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hypertrophic scar development after median sternotomy wound in cardiac surgery patients is quite common in surgical practice and becomes a major concern nowadays.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare cosmetic outcome between different suture materials and different suture techniques for skin closure in median sternotomy wound.</AbstractText><AbstractText Label="MATERIAL AND METHOD" NlmCategory="METHODS">A randomized clinical trial was conducted in 80 patients who underwent cardiac surgery in Thammasat University Hospital, Thailand. In respect of the materials and the techniques used to suture the skin, the patients were randomly allocated to four groups. In group 1, the skin was closed with subcuticular running 4-0 Poliglecaprone 25 (Monocryl). In group 2, the skin was closed with subcuticular running 4-0 Polydioxanone (PDS). In group 3, the skin was closed with subcuticular running 4-0 Poliglecaprone 25 (Monocryl) and running horizontal mattress 6-0 Nylon. In group 4, the skin was closed with subcuticular running 4-0 Polydioxanone (PDS) and running horizontal mattress 6-0 Nylon. Postoperative evaluation was performed at 2 and 6 weeks, 3 and 6 months follow-up visits. The scar was analyzed in three parts: upper, middle and lower one third of the sternal wound. The outcome measures for surgical wound were width, height and overall appearance of the scar using the Vancouver scar scale (VSS). A linear visual analogue score (VAS) was preformed to assess pain and itch.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 6 months, there were no significant differences between 4 groups ofpatients in every parameters (width, height, VSS, pain score and itch score) at three different wound sites (upper middle and lower). There was a statistically significant and progressive increase in scar stretching, height and total VSSfrom top to bottom of the sternum with the same pattern in all groups ofpatients (p&lt;0. 05). At 6 months, scar showed a statistically significant difference in width when compares to6 weeks and 3 months (p&lt;O.001).Female had a statistically significant difference ofscar stretching at upper two third of the sternum (p&lt;0. 05). Female scar width was approximately 2folds greater than male patient. Duringfollow-up in group 3, two patients died postoperatively due to multi-organ failure and one patient developed wound infection.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There were no significant differences in cosmetic outcomes between different suture materials and different suture techniques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Homvises</LastName><ForeName>Boonlawat</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><MedlineTA>J Med Assoc Thai</MedlineTA><NlmUniqueID>7507216</NlmUniqueID><ISSNLinking>0125-2208</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004146">Dioxanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011091">Polyesters</NameOfSubstance></Chemical><Chemical><RegistryNumber>31621-87-1</RegistryNumber><NameOfSubstance UI="D016687">Polydioxanone</NameOfSubstance></Chemical><Chemical><RegistryNumber>41706-81-4</RegistryNumber><NameOfSubstance UI="C095495">glycolide E-caprolactone copolymer</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017439" MajorTopicYN="N">Cicatrix, Hypertrophic</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004146" MajorTopicYN="Y">Dioxanes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016687" MajorTopicYN="Y">Polydioxanone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011091" MajorTopicYN="Y">Polyesters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056346" MajorTopicYN="N">Sternotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013536" MajorTopicYN="Y">Suture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013537" MajorTopicYN="Y">Sutures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N">Thailand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25518299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35630062</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Volume, but Not the Location of Necrosis, Is Associated with Worse Outcomes in Acute Pancreatitis: A Prospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina58050645</ELocationID><Abstract><AbstractText>Background and Objectives: The course and clinical outcomes of acute pancreatitis (AP) are highly variable. Up to 20% of patients develop pancreatic necrosis. Extent and location of it might affect the clinical course and management. The aim was to determine the clinical relevance of the extent and location of pancreatic necrosis in patients with AP. Materials and Methods: A cohort of patients with necrotizing AP was collected from 2012 to 2018 at the Hospital of Lithuanian University of Health Sciences. Patients were allocated to subgroups according to the location (entire pancreas, left and right sides of pancreas) and extent (&lt;30%, 30&#x2212;50%, &gt;50%) of pancreatic necrosis. Patients were reviewed for demographic features, number of performed surgical interventions, local and systemic complications, hospital stay and mortality rate. All contrast enhanced computed tomography (CECT) scans were evaluated by at least two experienced abdominal radiologists. All patients were treated according to the standard treatment protocol based on current international guidelines. Results: The study included 83 patients (75.9% males (n = 63)) with a mean age of 53 &#xb1; 1.7. The volume of pancreatic necrosis exceeded 50% in half of the patients (n = 42, 51%). Positive blood culture (n = 14 (87.5%)), multiple organ dysfunction syndrome (n = 17 (73.9%)) and incidences of respiratory failure (n = 19 (73.1%)) were significantly more often diagnosed in patients with pancreatic necrosis exceeding 50% (p &lt; 0.05). Patients with &gt;50% of necrosis were significantly (p &lt; 0.05) more often diagnosed with moderately severe (n = 24 (41.4%)) and severe (n = 18 (72%)) AP. The number of surgical interventions (n = 18 (72%)) and ultrasound-guided interventions (n = 26 (65%)) was also significantly higher. In patients with whole-pancreas necrosis, incidence of renal insufficiency (n = 11 (64.7%)) and infected pancreatic necrosis (n = 19 (57.6%)) was significantly higher (p &lt; 0.05). Conclusions: The clinical course and outcome were worse in the case of pancreatic necrosis exceeding 50%, rendering the need for longer and more complex treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dekeryte</LastName><ForeName>Inga</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zviniene</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieliuniene</LastName><ForeName>Edita</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dambrauskas</LastName><ForeName>Zilvinas</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2173-1294</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ignatavicius</LastName><ForeName>Povilas</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6112-6235</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="Y">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute pancreatitis</Keyword><Keyword MajorTopicYN="N">computed tomography</Keyword><Keyword MajorTopicYN="N">management</Keyword><Keyword MajorTopicYN="N">necrotizing pancreatitis</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">surgery</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35630062</ArticleId><ArticleId IdType="pmc">PMC9144437</ArticleId><ArticleId IdType="doi">10.3390/medicina58050645</ArticleId><ArticleId IdType="pii">medicina58050645</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Grinsven J., van Brunschot S., Bakker O.J., Bollen T.L., Boermeester M.A., Bruno M.J., Dejong C.H., Dijkgraaf M.G., van Eijck C.H., Fockens P., et al. Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: An international expert survey and case vignette study. HPB. 2015;18:49&#x2013;56. doi: 10.1016/j.hpb.2015.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hpb.2015.07.003</ArticleId><ArticleId IdType="pmc">PMC4766363</ArticleId><ArticleId IdType="pubmed">26776851</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxhoorn L., Voermans R.P., Bouwense S.A., Bruno M.J., Verdonk R.C., Boermeester M.A., van Santvoort H.C., Besselink M.G. Acute Pancreatitis. Lancet. 2020;396:726&#x2013;734. doi: 10.1016/S0140-6736(20)31310-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31310-6</ArticleId><ArticleId IdType="pubmed">32891214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiantella W., Rondelli F., Boni M., Stella P., Polistena A., Sanguinetti A., Avenia N. Necrotizing pancreatitis: A review of the interventions. Int. J. Surg. 2015;28:S163&#x2013;S171. doi: 10.1016/j.ijsu.2015.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2015.12.038</ArticleId><ArticleId IdType="pubmed">26708848</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov M.S., Shanbhag S., Chakraborty M., Phillips A.R., Windsor J.A. Organ Failure and Infection of Pancreatic Necrosis as Determinants of Mortality in Patients with Acute Pancreatitis. Gastroenterology. 2010;139:813&#x2013;820. doi: 10.1053/j.gastro.2010.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.06.010</ArticleId><ArticleId IdType="pubmed">20540942</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks P.A., Freeman M.L., Fass R., Baroni D.S., Mutlu E.A., Bernstein D.E., Parkman H.P., Bharucha A.E., Prather C., Brugge W.R., et al. Practice Guidelines in Acute Pancreatitis. Am. J. Gastroenterol. 2006;101:2379&#x2013;2400. doi: 10.1111/j.1572-0241.2006.00856.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00856.x</ArticleId><ArticleId IdType="pubmed">17032204</ArticleId></ArticleIdList></Reference><Reference><Citation>Llukacaj A., Gjata A. The Importance of Haematocrit in Prediction of The Importance of Haematocrit in Prediction of Severe Acute Pancreatitis. Int. J. Sci. Res. 2016;5:ART2016404.</Citation></Reference><Reference><Citation>Yang Z., Dong L., Zhang Y., Yang C., Gou S., Li Y., Xiong J., Wu H., Wang C. Prediction of Severe Acute Pancreatitis Using a Decision Tree Model Based on the Revised Atlanta Classification of Acute Pancreatitis. PLoS ONE. 2015;10:e0143486. doi: 10.1371/journal.pone.0143486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143486</ArticleId><ArticleId IdType="pmc">PMC4651493</ArticleId><ArticleId IdType="pubmed">26580397</ArticleId></ArticleIdList></Reference><Reference><Citation>IAP/APA Evidence-Based Guidelines for the Management of Acute Pancreatitis. Pancreatology. 2013;13:E1&#x2013;E15. doi: 10.1016/j.pan.2013.07.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2013.07.063</ArticleId><ArticleId IdType="pubmed">24054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonk R.C., Sternby H., Dimova A., Ignatavicius P., Koiva P., Penttila A.K., Ilzarbe L., Regner S., Rosendahl J., Bollen T.L. Short Article: Presence, Extent and Location of Pancreatic Necrosis Are Independent of Aetiology in Acute Pan-creatitis. Eur. J. Gastroenterol. Hepatol. 2018;30:342. doi: 10.1097/MEG.0000000000001053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000001053</ArticleId><ArticleId IdType="pubmed">29280919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M.J., Neal C.P., Ngu W.S., Dennison A.R., Garcea G. Early warning score independently predicts adverse outcome and mortality in patients with acute pancreatitis. Langenbeck&#x2019;s Arch. Surg. 2017;402:811&#x2013;819. doi: 10.1007/s00423-017-1581-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00423-017-1581-x</ArticleId><ArticleId IdType="pmc">PMC5506178</ArticleId><ArticleId IdType="pubmed">28434059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepp&#xe4;niemi A., Tolonen M., Tarasconi A., Lohse H.A.S., Gamberini E., Kirkpatrick A.W., Ball C.G., Parry N., Sartelli M., Wolbrink D.R.J., et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J. Emerg. Surg. 2019;14:1&#x2013;20. doi: 10.1186/s13017-019-0247-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-019-0247-0</ArticleId><ArticleId IdType="pmc">PMC6567462</ArticleId><ArticleId IdType="pubmed">31210778</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron T.H., DiMaio C.J., Wang A.Y., Morgan K.A. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology. 2020;158:67&#x2013;75.e1. doi: 10.1053/j.gastro.2019.07.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.07.064</ArticleId><ArticleId IdType="pubmed">31479658</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Brunschot S., Hollemans R.A., Bakker O.J., Besselink M.G., Baron T.H., Beger H.G., Boermeester M.A., Bollen T.L., Bruno M.J., Carter R., et al. Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: A pooled analysis of individual data for 1980 patients. Gut. 2017;67:697&#x2013;706. doi: 10.1136/gutjnl-2016-313341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313341</ArticleId><ArticleId IdType="pubmed">28774886</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Santvoort H.C., Besselink M.G., Bakker O.J., Hofker H.S., Boermeester M.A., Dejong C.H., van Goor H., Schaapherder A.F., van Eijck C.H., Bollen T.L., et al. A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis. N. Engl. J. Med. 2010;362:1491&#x2013;1502. doi: 10.1056/NEJMoa0908821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908821</ArticleId><ArticleId IdType="pubmed">20410514</ArticleId></ArticleIdList></Reference><Reference><Citation>Manrai M., Kochhar R., Gupta V., Yadav T.D., Dhaka N., Kalra N., Sinha S.K., Khandelwal N. Outcome of Acute Pancreatic and Peripancreatic Collections Occurring in Patients with Acute Pancreatitis. Ann. Surg. 2018;267:357&#x2013;363. doi: 10.1097/SLA.0000000000002065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002065</ArticleId><ArticleId IdType="pubmed">27805963</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhan R.K., Jain S., Agarwal S., Harikrishnan S., Vadiraja P., Behera S., Jain S.K., Dhingra R., Dash N.R., Sahni P., et al. Primary and secondary organ failures cause mortality differentially in acute pancreatitis and should be distinguished. Pancreas. 2018;47:302&#x2013;307. doi: 10.1097/MPA.0000000000000998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0000000000000998</ArticleId><ArticleId IdType="pubmed">29401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Taydas O., Unal E., Karaosmanoglu A.D., Onur M.R., Akpinar E. Accuracy of early CT findings for predicting disease course in patients with acute pancreatitis. Jpn. J. Radiol. 2017;36:151&#x2013;158. doi: 10.1007/s11604-017-0709-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11604-017-0709-9</ArticleId><ArticleId IdType="pubmed">29164450</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamies-Guilabert J., Anto&#xf1;ana A.D.V., Collado J.J., Rudenko P., Meseguer A. Pancreatic necrosis volume&#x2014;A new imaging biomarker of acute pancreatitis severity. Eur. J. Radiol. 2020;130:109193. doi: 10.1016/j.ejrad.2020.109193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2020.109193</ArticleId><ArticleId IdType="pubmed">32768889</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., He J., Hu X., Xu S.-F., Su W., Luo J.-F., Wang Q.-F., Guo F. Acute necrotising pancreatitis: Measurements of necrosis volume and mean CT attenuation help early prediction of organ failure and need for intervention. Eur. Radiol. 2021;31:7705&#x2013;7714. doi: 10.1007/s00330-021-07840-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-021-07840-x</ArticleId><ArticleId IdType="pubmed">33758956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mole D.J., McClymont K.L., Lau S., Mills R., Stamp-Vincent C., Garden O.J., Parks R.W. Discrepancy Between the Extent of Pancreatic Necrosis and Multiple Organ Failure Score in Severe Acute Pancreatitis. World J. Surg. 2009;33:2427&#x2013;2432. doi: 10.1007/s00268-009-0161-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-009-0161-9</ArticleId><ArticleId IdType="pubmed">19641951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L., Yu C., Deng F., He W.H., Xia L., Zhou M., Lan G.L., Huang X., Lei Y.P., Zhou X.J., et al. New Risk Factors for Infected Pancreatic Necrosis Secondary to Severe Acute Pancreatitis: The Role of Initial Contrast-Enhanced Computed Tomography. Dig. Dis. Sci. 2019;64:553. doi: 10.1007/s10620-018-5359-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-018-5359-y</ArticleId><ArticleId IdType="pubmed">30465178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30795954</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2157</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title><ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>Perioperative immune function and pain control may underlie early hospital readmission and 90 day mortality following lung cancer resection: A prospective cohort study of 932 patients.</ArticleTitle><Pagination><StartPage>863</StartPage><EndPage>869</EndPage><MedlinePgn>863-869</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2019.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0748-7983(19)30270-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mortality following lung cancer resection has been shown to double between 30 and 90 days and readmission following surgery is associated with an increased risk of mortality. The aim of this study was to describe the causes of readmission and mortality and enable the identification of potentially modifiable factors associated with these events.</AbstractText><AbstractText Label="METHODS">Prospective cohort study at a United Kingdom tertiary referral centre conducted over 55 months. Binary logistic regression was used to identify factors associated with death within 90 days of surgery.</AbstractText><AbstractText Label="RESULTS">The 30 day and 90 day mortality rates were 1.4% and 3.3% respectively. The most common causes of death were pneumonia, lung cancer and Acute Respiratory Distress Syndrome/Multi Organ Failure. Potentially modifiable risk factors for death identified were: Postoperative pulmonary complications (Odds ratio 6.1), preoperative lymphocyte count (OR 0.25), readmission within 30 days (OR 4.2) and type of postoperative analgesia (OR for intrathecal morphine 4.8). The most common causes of readmission were pneumonia, shortness of breath and pain.</AbstractText><AbstractText Label="CONCLUSIONS">Postoperative mortality is not simply due to fixed factors; the impacts of age, gender and surgical procedure on postoperative survival are reduced when the postoperative course of recovery is examined. Perioperative immune function, as portrayed by the occurrence of infection and lower lymphocyte count in the immediate perioperative period, and pain control method are strongly associated with 90 day mortality; further studies in these fields are indicated as are studies of psychological factors in recovery.</AbstractText><AbstractText Label="CLINICAL REGISTRATION NUMBER">ISRCTN00061628.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oswald</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, United Kingdom; Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halle-Smith</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, United Kingdom. Electronic address: b.naidu@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webb</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agostini</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishay</LastName><ForeName>Ehab</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkat</LastName><ForeName>Maninder</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyn</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Babu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, United Kingdom; Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Surg Oncol</MedlineTA><NlmUniqueID>8504356</NlmUniqueID><ISSNLinking>0748-7983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Readmission</Keyword><Keyword MajorTopicYN="N">Thoracic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30795954</ArticleId><ArticleId IdType="doi">10.1016/j.ejso.2019.02.001</ArticleId><ArticleId IdType="pii">S0748-7983(19)30270-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40580881</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8171</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><PubDate><Year>2025</Year><Month>Jun</Month><Day>21</Day></PubDate></JournalIssue><Title>The American journal of emergency medicine</Title><ISOAbbreviation>Am J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Association of fission 1 with multiple organ dysfunction syndrome after multiple trauma: A prospective case control study.</ArticleTitle><Pagination><StartPage>180</StartPage><EndPage>186</EndPage><MedlinePgn>180-186</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajem.2025.06.050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-6757(25)00431-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Fission 1 (Fis1) plays a key role in mitochondrial division and is upregulated in pathological conditions, including trauma, sepsis, and ischemia-reperfusion injury. The goal of the study was to investigate Fis1 and other mitochondrial proteins involved in mitochondrial function and quality control as potential early biomarkers for the development of multiple organ dysfunction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included all multiple trauma patients presenting to the hospital within 24&#xa0;h of injury from September 1, 2022 to September 1, 2023. Patients were split into two groups the non-MODS group (n&#xa0;=&#xa0;66) and the MODS group (n&#xa0;=&#xa0;70) We obtained serum samples from all patients and using enzyme-linked immunosorbent assay (ELISA) measured concentrations of peroxisome proliferator-activated receptor-&#x3b3; coactivator-1&#x3b1; (PGC-1&#x3b1;), Fis1, mitofusin 2 (Mfn2), and Parkin. Concentrations of proteins were compared between groups and compared to a healthy control group. Additionally, demographic data and laboratory test results were collected from the patients. We used a logistic regression to identify if biomarkers were indepenteldy associated with the development of MODS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within 24&#xa0;h of injury, the median serum concentration of Parkin, Fis1, and PGC-1&#x3b1;, were significantly higher in the MODS group than in the control group. Similarily, compared to the non-MODS group, the median serum concentration of Fis1 and PGC-1&#x3b1; were significantly higher in the MODS group. Binary logistic regression analysis, adjusted for confounding factors, identified Fis1 as a predictive biomarker for MODS (OR&#xa0;=&#xa0;1.006, 95&#xa0;% CI: 1.002-1.009, P&#xa0;&lt;&#xa0;0.05)The area under the curve (AUC) for Fis1 in predicting MODS after multiple trauma was 0.777 (95&#xa0;% CI: 0.698-0.857), indicating a moderate diagnostic value.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study found that in patients with multiple trauma, Fis1 concentrations are associated with the development of MODS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Anjing</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China; Emergency Department, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Surgery Room, Affiliated Hospital of Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuhong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruilie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Changqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Electronic address: 657648878@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuanlan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Emergency Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Electronic address: 1135210228@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Emerg Med</MedlineTA><NlmUniqueID>8309942</NlmUniqueID><ISSNLinking>0735-6757</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fission 1</Keyword><Keyword MajorTopicYN="N">Multiple trauma;multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no know competing financial interests or personal relationships that could appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>28</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40580881</ArticleId><ArticleId IdType="doi">10.1016/j.ajem.2025.06.050</ArticleId><ArticleId IdType="pii">S0735-6757(25)00431-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31138135</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>The relationship of preoperative estimated glomerular filtration rate and outcomes after cardiovascular surgery in patients with normal serum creatinine: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>88</StartPage><MedlinePgn>88</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">88</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-019-0763-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although serum creatinine concentration has been traditionally used as an index of renal function in clinical practice, it is considered relatively inaccurate, especially in patients with mild renal dysfunction. This study investigated the usefulness of preoperative estimated glomerular filtration rate (eGFR) in predicting complications after cardiovascular surgery in patients with normal serum creatinine concentrations.</AbstractText><AbstractText Label="METHODS">This study included 2208 adults undergoing elective cardiovascular surgery. Preoperative eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration equations. The relationships between preoperative eGFR and 90&#x2009;day postoperative composite major complications were analyzed, including 90&#x2009;day all-cause mortality, major adverse cardiac and cerebrovascular events, severe acute kidney injury, respiratory and gastrointestinal complications, wound infection, sepsis, and multi-organ failure.</AbstractText><AbstractText Label="RESULTS">Of the 2208 included patients, 185 (8.4%) had preoperative eGFR &lt;&#x2009;60&#x2009;mL/min/1.73&#x2009;m<sup>2</sup> and 328 (14.9%) experienced postoperative major complications. Multivariable logistic regression analyses showed that preoperatively decreased eGFR was independently associated with an increased risk of composite 90&#x2009;day major postoperative complications (adjusted odds ratio: 1.232; 95% confidence interval [CI]: 1.148-1.322; P&#x2009;&lt;&#x2009;&#xa0;0.001). eGFR was a better discriminator of composite 90&#x2009;day major postoperative complications than serum creatinine, with estimated c-statistics of 0.724 (95% CI: 0.694-0.754) for eGFR and 0.712 (95% CI: 0.680-0.744) for serum creatinine (P&#x2009;=&#x2009;0.008).</AbstractText><AbstractText Label="CONCLUSIONS">Decreased eGFR was significantly associated with an increased risk of major complications after cardiovascular surgery in patients with preoperatively normal serum creatinine concentrations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Myung-Soo</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, College of Medicine, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Jae-Sik</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Jun-Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Chang-Hwa</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Seung Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun-Ho</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0002-6369-7429</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. leho@naver.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>In-Cheol</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013504" MajorTopicYN="N">Cardiovascular Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular surgery</Keyword><Keyword MajorTopicYN="N">Glomerular filtration rate, creatinine</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31138135</ArticleId><ArticleId IdType="pmc">PMC6540432</ArticleId><ArticleId IdType="doi">10.1186/s12871-019-0763-1</ArticleId><ArticleId IdType="pii">10.1186/s12871-019-0763-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang F, Dupuis JY, Nathan H, Williams K. An analysis of the association between preoperative renal dysfunction and outcome in cardiac surgery: estimated creatinine clearance or plasma creatinine level as measures of renal function. Chest. 2003;124:1852&#x2013;1862. doi: 10.1378/chest.124.5.1852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.124.5.1852</ArticleId><ArticleId IdType="pubmed">14605060</ArticleId></ArticleIdList></Reference><Reference><Citation>Miceli A, Bruno VD, Capoun R, Romeo F, Angelini GD, Caputo M. Occult renal dysfunction: a mortality and morbidity risk factor in coronary artery bypass grafting surgery. J Thorac Cardiovasc Surg. 2011;141:771&#x2013;776. doi: 10.1016/j.jtcvs.2010.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2010.08.016</ArticleId><ArticleId IdType="pubmed">20884025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooney JF, Ranasinghe I, Chow CK, et al. Preoperative estimates of glomerular filtration rate as predictors of outcome after surgery: a systematic review and meta-analysis. Anesthesiology. 2013;118:809&#x2013;824. doi: 10.1097/ALN.0b013e318287b72c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e318287b72c</ArticleId><ArticleId IdType="pubmed">23377223</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuRahma AF, Alhalbouni S, Abu-Halimah S, Dean LS, Stone PA. Impact of chronic renal insufficiency on the early and late clinical outcomes of carotid artery stenting using serum creatinine vs glomerular filtration rate. J Am Coll Surg. 2014;218:797&#x2013;805. doi: 10.1016/j.jamcollsurg.2013.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2013.12.038</ArticleId><ArticleId IdType="pmc">PMC4501578</ArticleId><ArticleId IdType="pubmed">24655873</ArticleId></ArticleIdList></Reference><Reference><Citation>Prowle JR, Kam EP, Ahmad T, Smith NC, Protopapa K, Pearse RM. Preoperative renal dysfunction and mortality after non-cardiac surgery. Br J Surg. 2016;103:1316&#x2013;1325. doi: 10.1002/bjs.10186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.10186</ArticleId><ArticleId IdType="pubmed">27346181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JS, Gu A, Wei C, et al. Preoperative estimated glomerular filtration rate is a marker for postoperative complications following revision total knee arthroplasty. J Arthroplast. 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30616975</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi MH, Schmidlin D, Schiferer A, et al. Impact of preoperative serum creatinine on short- and long-term mortality after cardiac surgery: a cohort study. Br J Anaesth. 2015;114:53&#x2013;62. doi: 10.1093/bja/aeu316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu316</ArticleId><ArticleId IdType="pubmed">25240162</ArticleId></ArticleIdList></Reference><Reference><Citation>Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003;24:881&#x2013;882. doi: 10.1016/S0195-668X(02)00799-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0195-668X(02)00799-6</ArticleId><ArticleId IdType="pubmed">12727160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011;124:381&#x2013;387. doi: 10.1161/CIRCULATIONAHA.110.015701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.015701</ArticleId><ArticleId IdType="pubmed">21730309</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001;16:1042&#x2013;1046. doi: 10.1093/ndt/16.5.1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/16.5.1042</ArticleId><ArticleId IdType="pubmed">11328914</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473&#x2013;2483. doi: 10.1056/NEJMra054415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra054415</ArticleId><ArticleId IdType="pubmed">16760447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeysundera DN, Karkouti K, Beattie WS, Rao V, Ivanov J. Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. Anesthesiology. 2006;104:65&#x2013;72. doi: 10.1097/00000542-200601000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200601000-00012</ArticleId><ArticleId IdType="pubmed">16394692</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi M, Goodarzynejad H, Karimi A, et al. Is preoperative serum creatinine a reliable indicator of outcome in patients undergoing coronary artery bypass surgery? J Thorac Cardiovasc Surg. 2009;137:304&#x2013;308. doi: 10.1016/j.jtcvs.2008.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2008.08.001</ArticleId><ArticleId IdType="pubmed">19185142</ArticleId></ArticleIdList></Reference><Reference><Citation>Cywinski JB, Mascha EJ, Kurz A, Sessler DI. Estimated glomerular filtration rate better predicts 30-day mortality after non-cardiac surgery than serum creatinine: a retrospective analysis of 92,888 patients. Can J Anaesth. 2015;62:745&#x2013;752. doi: 10.1007/s12630-015-0398-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-015-0398-8</ArticleId><ArticleId IdType="pubmed">25920903</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604&#x2013;612. doi: 10.7326/0003-4819-150-9-200905050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622&#x2013;627. doi: 10.1053/j.ajkd.2010.02.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2010.02.337</ArticleId><ArticleId IdType="pmc">PMC2846308</ArticleId><ArticleId IdType="pubmed">20338463</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A, Stevens PE. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49&#x2013;61. doi: 10.1038/ki.2013.444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.444</ArticleId><ArticleId IdType="pubmed">24284513</ArticleId></ArticleIdList></Reference><Reference><Citation>Joung KW, Jo JY, Kim WJ, et al. Association of preoperative uric acid and acute kidney injury following cardiovascular surgery. J Cardiothorac Vasc Anesth. 2014;28:1440&#x2013;1447. doi: 10.1053/j.jvca.2014.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2014.04.020</ArticleId><ArticleId IdType="pubmed">25245579</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806&#x2013;808. doi: 10.1136/bmj.39335.541782.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EH, Chin JH, Choi DK, et al. Postoperative hypoalbuminemia is associated with outcome in patients undergoing off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2011;25:462&#x2013;468. doi: 10.1053/j.jvca.2010.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.09.008</ArticleId><ArticleId IdType="pubmed">21093290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jammer I, Wickboldt N, Sander M, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European perioperative clinical outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015;32:88&#x2013;105. doi: 10.1097/EJA.0000000000000118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000118</ArticleId><ArticleId IdType="pubmed">25058504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen MS, Petersen EE, Dahl JB, Wetterslev J. Post-operative serious adverse events in a mixed surgical population - a retrospective register study. Acta Anaesthesiol Scand. 2016;60:1209&#x2013;1221. doi: 10.1111/aas.12762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.12762</ArticleId><ArticleId IdType="pubmed">27417678</ArticleId></ArticleIdList></Reference><Reference><Citation>Delong ER, Delong DM, Clarkepearson DI. Comparing the areas under 2 or more correlated receiver operating characteristic curves - a nonparametric approach. Biometrics. 1988;44:837&#x2013;845. doi: 10.2307/2531595.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Botev R, Mallie JP, Wetzels JF, Couchoud C, Schuck O. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin J Am Soc Nephrol. 2011;6:937&#x2013;950. doi: 10.2215/CJN.09241010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.09241010</ArticleId><ArticleId IdType="pubmed">21454722</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo BW, Koh YY, Toh QC, et al. Performance of the CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equations in a multiethnic Asian population. Singap Med J. 2014;55:656&#x2013;659. doi: 10.11622/smedj.2014181.</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/smedj.2014181</ArticleId><ArticleId IdType="pmc">PMC4292005</ArticleId><ArticleId IdType="pubmed">25630321</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong TD, Lee W, Yun YM, Chun S, Song J, Min WK. Development and validation of the Korean version of CKD-EPI equation to estimate glomerular filtration rate. Clin Biochem. 2016;49:713&#x2013;719. doi: 10.1016/j.clinbiochem.2016.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2016.01.023</ArticleId><ArticleId IdType="pubmed">26968101</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo BW, Zhang L, Guh JY, et al. Glomerular filtration rates in Asians. Adv Chronic Kidney Dis. 2018;25:41&#x2013;48. doi: 10.1053/j.ackd.2017.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2017.10.005</ArticleId><ArticleId IdType="pubmed">29499886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28007459</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1424-3911</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</Title><ISOAbbreviation>Pancreatology</ISOAbbreviation></Journal><ArticleTitle>Endothelial markers are associated with pancreatic necrosis and overall prognosis in acute pancreatitis: A preliminary cohort study.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>50</EndPage><MedlinePgn>45-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pan.2016.12.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1424-3903(16)31252-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endothelial injury is believed to play an important role in the evolution of pancreatic microcirculatory dysfunction and pancreatic necrosis (PN) in patients with acute pancreatitis (AP). The aim of this study was to investigate the role of three endothelial markers (von Willebrand factor, vWF; E-selectin; endothelial protein C receptor, EPCR) in the early phase of AP, especially the relationship between endothelial markers and PN.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From March 2015 to March 2016, 57 AP patients admitted within 72&#xa0;h of symptom onset in our hospital were included for this study. Blood samples were taken on admission and the clinical characteristics and outcomes of these patients were recorded. The levels of vWF, E-selectin and EPCR were measured using ELISA for analysis and compared with other severity markers of AP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All the three markers were significantly different in healthy control, mild, moderate and severe AP patients. Moreover, the endothelial markers, especially vWF, also showed significant difference in patients with different extent of PN, as well as those with or without MODS. Additionally, the levels of endothelial markers correlated well with other commonly used markers of AP severity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elevated endothelium-related mediators (vWF, E-selectin and EPCR) appear to participate in the development of PN and may be a potential indicator of overall prognosis. Our results may help clinicians better understand the pathophysiological process of the development of PN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yizhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China. Electronic address: kkb9832@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yiyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiqin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China. Electronic address: njzy_pancrea@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jieshou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pancreatology</MedlineTA><NlmUniqueID>100966936</NlmUniqueID><ISSNLinking>1424-3903</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019040">E-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074283">Endothelial Protein C Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478370">PROCR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546936">SELE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019040" MajorTopicYN="N">E-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074283" MajorTopicYN="N">Endothelial Protein C Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">E-selectin</Keyword><Keyword MajorTopicYN="N">Endothelial protein C receptor</Keyword><Keyword MajorTopicYN="N">Pancreatic necrosis</Keyword><Keyword MajorTopicYN="N">von Willebrand factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28007459</ArticleId><ArticleId IdType="doi">10.1016/j.pan.2016.12.005</ArticleId><ArticleId IdType="pii">S1424-3903(16)31252-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33933851</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19.</ArticleTitle><Pagination><StartPage>107569</StartPage><MedlinePgn>107569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2021.107569</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(21)00205-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To investigate the prognostic value of a novel immune-inflammatory index, the interleukin-6-to-lymphocyte ratio (IL-6/LY), with the clinical outcomes of severe coronavirus disease 2019 (COVID-19) cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cohort study of COVID-19 patients in Tongji Hospital, from January 2020 to February 2020, was evaluated. Kaplan-Meier method and the log-rank test was performed to analyze survival data. Univariate and multivariate analyses were performed with COX proportional hazard regression model. The primary and secondary outcomes were in-hospital mortality and multiple organ dysfunction syndrome (MODS), respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Total 320 adult patients were enrolled in our analyses. Patients were divided into low IL-6/LY group and high IL-6/LY group based on the cutoff value with 2.50. The Kaplan-Meier survival curves showed that high-value group (IL-6/LY&#xa0;&#x2265;&#xa0;2.50) had a greater risk of poor prognosis (P&#xa0;&lt;&#xa0;0.001, respectively). Multivariate analysis indicated that IL-6/LY was the independent risk predictor for in-hospital mortality (hazard ratio [HR],&#xa0;3.404; 95% confidence interval [CI],&#xa0;1.090-10.633, P&#xa0;=&#xa0;0.035) and MODS development (HR, 4.143; 95%CI, 1.321-12.986, P&#xa0;=&#xa0;0.015). Meanwhile, IL-6/LY was positively correlated with the MuLBSTA score (r&#xa0;=&#xa0;0.137, P&#xa0;=&#xa0;0.031), suggesting that IL-6/LY was associated with long-term mortality (90-day). Furthermore, kinetic analysis revealed that the dynamic changes of inflammatory immune indexes were related to the severity of the disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The elevated IL-6/LY was related with the increased risk of poor prognosis. Not only that, IL-6/LY could be used for risk stratification and early clinical identification of high-risk patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Boyi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiabao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Practice, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Zhilong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The Forth Hospital of Wuhan Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cuntai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: lihongniuniu2014@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Immune-inflammatory index</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Lymphocyte</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>20</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33933851</ArticleId><ArticleId IdType="pmc">PMC7953449</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2021.107569</ArticleId><ArticleId IdType="pii">S1567-5769(21)00205-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarzi-Puttini P., et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 2020;38(2):337&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">32202240</ArticleId></ArticleIdList></Reference><Reference><Citation>O. World Health, Coronavirus disease (COVID-19): Situation Report128. 2019:2020.</Citation></Reference><Reference><Citation>Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169239</ArticleId><ArticleId IdType="pubmed">29052924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.-W., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh M.D., et al. Viral load kinetics of MERS coronavirus infection. N. Engl. J. Med. 2016;375(13):1303&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">27682053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395(10223):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020:ciaa248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis. 2020:ciaa449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappelli F., et al. COVID-19 Immunopathology and Immunotherapy. Bioinformation. 2020;16(3):219&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147500</ArticleId><ArticleId IdType="pubmed">32308263</ArticleId></ArticleIdList></Reference><Reference><Citation>O. World Health . World Health Organization; Geneva: 2020. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance.</Citation></Reference><Reference><Citation>Ramirez M. Multiple organ dysfunction syndrome. Curr. Probl. Pediatr. Adolesc. Health Care. 2013;43(10):273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y., et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020:102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol. 2020;214:108393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102614</ArticleId><ArticleId IdType="pubmed">32222466</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39(5):529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chousterman B.G., et al. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017;39(5):517&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020:e200994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifaldi L., et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67(11):3037&#x2013;3046.</Citation><ArticleIdList><ArticleId IdType="pubmed">26251193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J. Infect. Dis. 2020;221(11):1762&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184346</ArticleId><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>S. Wan, et al., Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), medRxiv (2020) 2020.02.10.20021832.</Citation></Reference><Reference><Citation>Xu Z., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 2004;189(4):648&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109946</ArticleId><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecere T.E., et al. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4(5):833&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386620</ArticleId><ArticleId IdType="pubmed">22754651</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-H., et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J. Infect. 2020;80(4):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102535</ArticleId><ArticleId IdType="pubmed">32109443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.J., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufan A., et al. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk. J. Med. Sci. 2020;50(SI-1):620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195984</ArticleId><ArticleId IdType="pubmed">32299202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonggang Z., et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu B., et al. Why tocilizumab could be an effective treatment for severe COVID-19? J. Transl. Med. 2020;18(1):164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154566</ArticleId><ArticleId IdType="pubmed">32290839</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Busetto L., et al. Obesity and COVID-19: an Italian snapshot. Obesity (Silver Spring, Md.) 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283686</ArticleId><ArticleId IdType="pubmed">32463545</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020:e3319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J. Am. Coll. Cardiol. 2020;S0735-1097(20):35008&#x2013;35017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., et al. Coronavirus disease 2019: coronaviruses and blood safety. Transfus. Med. Rev. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135848</ArticleId><ArticleId IdType="pubmed">32107119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 2020;382(17):e38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir. Res. 2020;21(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156898</ArticleId><ArticleId IdType="pubmed">32293449</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32062616</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1349-3329</ISSN><JournalIssue CitedMedium="Internet"><Volume>250</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Tohoku journal of experimental medicine</Title><ISOAbbreviation>Tohoku J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Elevated Plasma Levels of Mitochondria-Derived Damage-Associated Molecular Patterns during Liver Transplantation: Predictors for Postoperative Multi-Organ Dysfunction Syndrome.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>93</EndPage><MedlinePgn>87-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1620/tjem.250.87</ELocationID><Abstract><AbstractText>The systemic cytokine response during surgery has been reported to be stimulated by the molecules released from damaged cells, called damage-associated molecular patterns (DAMPs). The relationship between DAMPs and liver transplantation has not been reported. We aimed to clarify the relationship between the plasma levels of DAMPs and the short-term post-transplant outcomes, including mortality and postoperative multi-organ dysfunction syndrome (MODS). This retrospective cohort study enrolled 61 patients who underwent liver transplantation. Mitochondrial DNA fragments, as mitochondria-derived DAMPs (mtDAMPs), were isolated from frozen plasma obtained at the start and the end of transplantation and were quantified by polymerase chain reaction. The short-term post-transplant outcomes were compared among the groups categorized based on the median value of the intraoperative fluctuation of mtDAMPs levels. The mtDAMPs levels were increased from the start to the end of transplantation in 52 recipients (85.2%, n = 61). Regarding mortality, no significant differences were noted between the high group (n = 30) and the low group (n = 31). The higher plasma levels of mtDAMPs were correlated with the longer duration of postoperative vasopressor support (P &lt; 0.05). Importantly, the rate of MODS on post-operative day 1 was significantly higher in the high group (high vs. low group: 21 patients [70%] vs. 11 patients [35.1%], P &lt; 0.01). In conclusion, mtDAMPs were increased in plasma during liver transplantation in most recipients. This elevation was not associated with mortality, but associated with the post-transplant recovery. Measuring plasma mtDAMPs may be helpful for predicting posttransplant recovery among liver-transplant recipients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagakawa</LastName><ForeName>Kantoku</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soyama</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adachi</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Takanobu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takatsuki</LastName><ForeName>Mitsuhisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eguchi</LastName><ForeName>Susumu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Tohoku J Exp Med</MedlineTA><NlmUniqueID>0417355</NlmUniqueID><ISSNLinking>0040-8727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067531">Alarmins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C507225">MT-ND6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="D009245">NADH Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C515075">NADH dehydrogenase subunit 1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000067531" MajorTopicYN="N">Alarmins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009245" MajorTopicYN="N">NADH Dehydrogenase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">damage-associated molecular patterns (DAMPs)</Keyword><Keyword MajorTopicYN="N">liver transplantation</Keyword><Keyword MajorTopicYN="N">surgical stress</Keyword><Keyword MajorTopicYN="N">systemic inflammatory response syndrome (SIRS)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32062616</ArticleId><ArticleId IdType="doi">10.1620/tjem.250.87</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31288746</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Clinical parameters and outcomes of necrotizing soft tissue infections secondary to gastrointestinal fistulas.</ArticleTitle><Pagination><StartPage>597</StartPage><MedlinePgn>597</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">597</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-019-4248-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Necrotizing soft tissue infections (NSTIs) is severe surgical infections which can occur following trauma or abdominal surgery. NSTIs secondary to gastrointestinal (GI) fistula is a rare but severe complication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort study was performed on all subjects presenting with GI fistulas associated NSTIs were included. Clinical characteristics, microbiological profile, operations performed, and outcomes of patients were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 2014 and 2017, 39 patients were finally enrolled. The mean age were 46.9&#x2009;years and male were the dominant. For the etiology of fistula, 25 (64.1%) of the patients was due to trauma. Overall, in-hospital death occurred in 15 (38.5%) patients. Microbiologic findings were obtained from 31 patients and Klebsiella pneumoniae was the most common species (41.0%). Eight patients were treated with an open abdomen; negative pressure wound therapy was used in 33 patients and only 2 patients received hyperbaric oxygen therapy. Younger age and delayed abdominal wall reconstruction repair were more common in trauma than in non-trauma. Non-survivors had higher APACHE II score, less source control&lt;&#x2009;48&#x2009;h and lower platelet count on admission than survivors. Multiple organ dysfunction syndrome, multidrug-resistant organisms and source control failure were the main cause of in-hospital mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Trauma is the main cause of GI fistulas associated NSTIs. Sepsis continues to be the most important factor related to mortality. Our data may assist providing enlightenment for quality improvement in these special populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Wenbin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, School of Medicine, Southeast University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Zhiwu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiuwen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Huajian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gefei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Guosheng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nthumba</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AIC Kijabe Hospital, Kijabe, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jianan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4697-4762</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China. jiananr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jieshou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BE2016752</GrantID><Agency>Key Project of Jiangsu Social Development</Agency><Country/></Grant><Grant><GrantID>16CXZ007</GrantID><Agency>Innovation Project of Military Medicine</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016154" MajorTopicYN="N">Digestive System Fistula</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="N">Hyperbaric Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007711" MajorTopicYN="N">Klebsiella pneumoniae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018461" MajorTopicYN="N">Soft Tissue Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gastrointestinal fistula</Keyword><Keyword MajorTopicYN="N">Necrotizing soft tissue infections</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31288746</ArticleId><ArticleId IdType="pmc">PMC6617561</ArticleId><ArticleId IdType="doi">10.1186/s12879-019-4248-0</ArticleId><ArticleId IdType="pii">10.1186/s12879-019-4248-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut. 2001;49(Suppl. 4):iv2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766897</ArticleId><ArticleId IdType="pubmed">11878790</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly PT, Teubner A, Lees NP, Anderson ID, Scott NA, Carlson GL. Outcome of reconstructive surgery for intestinal fistula in the open abdomen. Ann Surg. 2008;247(3):440&#x2013;444. doi: 10.1097/SLA.0b013e3181612c99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181612c99</ArticleId><ArticleId IdType="pubmed">18376187</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P, Novelli A, Menichetti F, Petrosillo N, Tinelli M, Tumbarello M, Sanguinetti M, Viale P, Venditti M, Viscoli C. Italian Society of Infectious and Tropical Diseases. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. J Chemother. 2017;29(4):197&#x2013;214. doi: 10.1080/1120009X.2017.1311398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1120009X.2017.1311398</ArticleId><ArticleId IdType="pubmed">28378613</ArticleId></ArticleIdList></Reference><Reference><Citation>Schecter WP, Hirshberg A, Chang DS, Harris HW, Napolitano LM, Wexner SD, Dudrick SJ. Enteric fistulas: principles of management. J Am Coll Surg. 2009;209(4):484&#x2013;491. doi: 10.1016/j.jamcollsurg.2009.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2009.05.025</ArticleId><ArticleId IdType="pubmed">19801322</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khoury G, Kaufman D, Hirshberg A. Improved control of exposed fistula in the open abdomen. J Am Coll Surg. 2008;206(2):397&#x2013;398. doi: 10.1016/j.jamcollsurg.2007.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2007.07.027</ArticleId><ArticleId IdType="pubmed">18222399</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams LJ, Zolfaghari S, Boushey RP. Complications of enterocutaneous fistulas and their management. Clin Colon Rectal Surg. 2010;23(3):209&#x2013;220. doi: 10.1055/s-0030-1263062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0030-1263062</ArticleId><ArticleId IdType="pmc">PMC2967321</ArticleId><ArticleId IdType="pubmed">21886471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram P, Treutner KH, Stumpf M, Schumpelick V. Postoperative necrotizing soft-tissue infections of the abdominal wall. Langenbeck&#x2019;s Arch Surg. 2000;385(1):39&#x2013;41. doi: 10.1007/s004230050009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004230050009</ArticleId><ArticleId IdType="pubmed">10664119</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotizing fasciitis. Br J Surg. 2013;101(1):e119&#x2013;ee25. doi: 10.1002/bjs.9371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9371</ArticleId><ArticleId IdType="pubmed">24338771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: current concepts and review of the literature. J Am Coll Surg. 2009;208(2):279&#x2013;288. doi: 10.1016/j.jamcollsurg.2008.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2008.10.032</ArticleId><ArticleId IdType="pubmed">19228540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JC, Zhang BR, Shi K, Zhang X, Xie CH, Wang J, Yu QH, Gao XX, Hong L, Yu JA. Necrotizing soft tissue infection: clinical characteristics and outcomes at a reconstructive center in Jilin Province. BMC Infect Dis. 2017;17(1):792. doi: 10.1186/s12879-017-2907-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2907-6</ArticleId><ArticleId IdType="pmc">PMC5745726</ArticleId><ArticleId IdType="pubmed">29281989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu GL, Wang L, Wei XM, Li M, Zhang J. Necrotizing fasciitis secondary to enterocutaneous fistula: three case reports. World J Gastroenterol. 2014;20(24):7988&#x2013;7992. doi: 10.3748/wjg.v20.i24.7988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i24.7988</ArticleId><ArticleId IdType="pmc">PMC4069328</ArticleId><ArticleId IdType="pubmed">24976737</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda M, Higashi Y, Shoji T, Hiraide T, Maruo H. Necrotizing fasciitis caused by a primary appendicocutaneous fistula. Surg Today. 2012;42(8):781&#x2013;784. doi: 10.1007/s00595-012-0140-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00595-012-0140-x</ArticleId><ArticleId IdType="pmc">PMC3396344</ArticleId><ArticleId IdType="pubmed">22318638</ArticleId></ArticleIdList></Reference><Reference><Citation>Husnoo N, Patil S, Jackson A, Khan M. Necrotising fasciitis secondary to a colocutaneous fistula. Ann R Coll Surg Engl. 2016;98(7):e130&#x2013;e132. doi: 10.1308/rcsann.2016.0177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1308/rcsann.2016.0177</ArticleId><ArticleId IdType="pmc">PMC5210003</ArticleId><ArticleId IdType="pubmed">27241606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter OL, Guillamondegui OD, May AK, Diaz JJ. Outcome of necrotizing skin and soft tissue infections. Surg Infect. 2008;9(4):443&#x2013;450. doi: 10.1089/sur.2007.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2007.053</ArticleId><ArticleId IdType="pubmed">18759681</ArticleId></ArticleIdList></Reference><Reference><Citation>Brafa A, Grimaldi L, Brandi C, Nisi G, Calabro M, Campa A, D'Aniello C. Abdominoplasty as a reconstructive surgical treatment of necrotising fasciitis of the abdominal wall. J Plast Reconstr Aesthet Surg. 2009;62(6):e136&#x2013;e139. doi: 10.1016/j.bjps.2008.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2008.07.031</ArticleId><ArticleId IdType="pubmed">19058770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertl CW, Carpp NC, Johnson J, Burke L. Evaluation of factors associated with death in patients with necrotizing fasciitis of the Abdominal Wall. Surg Infect. 2017;18(2):176&#x2013;180. doi: 10.1089/sur.2016.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2016.167</ArticleId><ArticleId IdType="pubmed">27929925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu WH, Lai LJ, Peng KT, Lee CY. Acute pyogenic inguinal abscess from complex soft-tissue infection or intra-abdominal pathology. Surg Infect. 2014;15(5):467&#x2013;473. doi: 10.1089/sur.2012.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2012.008</ArticleId><ArticleId IdType="pubmed">24818646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulla ZD, Gibbs SG, Aronoff DM. Correlates of length of stay, cost of care, and mortality among patients hospitalized for necrotizing fasciitis. Epidemiol Infect. 2007;135(5):868&#x2013;876. doi: 10.1017/S0950268806007448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268806007448</ArticleId><ArticleId IdType="pmc">PMC2870628</ArticleId><ArticleId IdType="pubmed">17083749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonne SL, Kadri SS. Evaluation and Management of Necrotizing Soft Tissue Infections. Infect Dis Clin N Am. 2017;31(3):497&#x2013;411. doi: 10.1016/j.idc.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2017.05.011</ArticleId><ArticleId IdType="pmc">PMC5656282</ArticleId><ArticleId IdType="pubmed">28779832</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10&#x2013;e52. doi: 10.1093/cid/ciu296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu296</ArticleId><ArticleId IdType="pubmed">24973422</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, et al. Assessment of clinical criteria for Sepsis: for the third international consensus definitions for Sepsis and septic shock (Sepsis-3) Jama. 2016;315(8):762&#x2013;774. doi: 10.1001/jama.2016.0288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0288</ArticleId><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomkin JS, Ristagno RL, Das AF, Cone JB, Wilson SE, Rotstein OD, Murphy BS, Severin KS, Bruss JB. Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis. 2013;56(12):1765&#x2013;1773. doi: 10.1093/cid/cit128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit128</ArticleId><ArticleId IdType="pubmed">23463643</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486&#x2013;552. doi: 10.1097/CCM.0000000000002255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002255</ArticleId><ArticleId IdType="pubmed">28098591</ArticleId></ArticleIdList></Reference><Reference><Citation>de Prost N, Sbidian E, Chosidow O, Brun-Buisson C, Amathieu R. Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey. Intensive Care Med. 2015;41(8):1506&#x2013;1508. doi: 10.1007/s00134-015-3916-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3916-9</ArticleId><ArticleId IdType="pubmed">26109399</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolandelli R, Roslyn JJ. Surgical management and treatment of sepsis associated with gastrointestinal fistulas. Surg Clin North Am. 1996;76(5):1111&#x2013;1122. doi: 10.1016/S0039-6109(05)70500-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6109(05)70500-4</ArticleId><ArticleId IdType="pubmed">8841366</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore SA, Levy BH, Prematilake C, Dissanaike S. The prediction predicament: rethinking necrotizing soft tissue infections mortality. Surg Infect. 2015;16(6):813&#x2013;821. doi: 10.1089/sur.2015.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2015.002</ArticleId><ArticleId IdType="pmc">PMC4663638</ArticleId><ArticleId IdType="pubmed">26258645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen IC, Li WC, Hong YC, Shie SS, Fann WC, Hsiao CT. The microbiological profile and presence of bloodstream infection influence mortality rates in necrotizing fasciitis. Crit Care. 2011;15(3):R152. doi: 10.1186/cc10278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc10278</ArticleId><ArticleId IdType="pmc">PMC3219026</ArticleId><ArticleId IdType="pubmed">21693053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng NC, Yu YC, Tai HC, Hsueh PR, Chang SC, Lai SY, Yi WC, Fang CT. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis. 2012;55(7):930&#x2013;939. doi: 10.1093/cid/cis565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis565</ArticleId><ArticleId IdType="pubmed">22715175</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GL, Patrick H, Amin AI, McPherson G, MacLennan G, Afolabi E, Mowatt G, Campbell B. Management of the open abdomen: a national study of clinical outcome and safety of negative pressure wound therapy. Ann Surg. 2013;257(6):1154&#x2013;1159. doi: 10.1097/SLA.0b013e31828b8bc8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828b8bc8</ArticleId><ArticleId IdType="pubmed">23478532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers WK, Garcia L. Intraabdominal hypertension, abdominal compartment syndrome, and the open abdomen. Chest. 2018;153(1):238&#x2013;250. doi: 10.1016/j.chest.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.07.023</ArticleId><ArticleId IdType="pubmed">28780148</ArticleId></ArticleIdList></Reference><Reference><Citation>Seternes A, Rekstad LC, Mo S, Klepstad P, Halvorsen DL, Dahl T, Bjorck M, Wibe A. Open abdomen treated with negative pressure wound therapy: indications, management and survival. World J Surg. 2017;41(1):152&#x2013;161. doi: 10.1007/s00268-016-3694-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-016-3694-8</ArticleId><ArticleId IdType="pubmed">27541031</ArticleId></ArticleIdList></Reference><Reference><Citation>Arif N, Yousfi S, Vinnard C. Deaths from necrotizing fasciitis in the United States, 2003-2013. Epidemiol Infect. 2016;144(6):1338&#x2013;1344. doi: 10.1017/S0950268815002745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268815002745</ArticleId><ArticleId IdType="pmc">PMC5725950</ArticleId><ArticleId IdType="pubmed">26548496</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass GE, Murphy GF, Esmaeili A, Lai LM, Nanchahal J. Systematic review of molecular mechanism of action of negative-pressure wound therapy. Br J Surg. 2014;101(13):1627&#x2013;1636. doi: 10.1002/bjs.9636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9636</ArticleId><ArticleId IdType="pubmed">25294112</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoye O, Talving P, Lam L, Smith J, Teixeira PG, Inaba K, Koronakis N, Demetriades D. Timing of redebridement after initial source control impacts survival in necrotizing soft tissue infection. Am Surg. 2013;79(10):1081&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">24160803</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao WN, Tsai CF, Chang HR, Chan KS, Su CH, Lee YT, Ueng KC, Chen CC, Chen SC, Lee MC. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg. 2013;206(1):32&#x2013;39. doi: 10.1016/j.amjsurg.2012.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2012.08.008</ArticleId><ArticleId IdType="pubmed">23414632</ArticleId></ArticleIdList></Reference><Reference><Citation>Montravers P, Blot S, Dimopoulos G, Eckmann C, Eggimann P, Guirao X, Paiva JA, Sganga G, De Waele J. Therapeutic management of peritonitis: a comprehensive guide for intensivists. Intensive Care Med. 2016;42(8):1234&#x2013;1247. doi: 10.1007/s00134-016-4307-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4307-6</ArticleId><ArticleId IdType="pubmed">26984317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30257648</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of risk factors for a fulminant Clostridium difficile infection after cardiac surgery: a single-center, retrospective cohort study.</ArticleTitle><Pagination><StartPage>133</StartPage><MedlinePgn>133</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">133</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-018-0597-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Clostridium difficile (CD) is the most common pathogen causing nosocomial diarrhea. The clinical presentation ranges from mild diarrhea to severe complications, including pseudomembranous colitis, toxic megacolon, sepsis, and multi-organ failure. When the disease takes a fulminant course, death ensues rapidly in severe and complex cases. Preventive screening or current prophylactic therapies are not useful. Therefore, this study was conducted to detect risk factors for a fulminant CD infection (CDI) in patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS">Between April 1999 and April 2011, a total of 41,466 patients underwent cardiac surgery at our institution. A review of our hospital database revealed 1256 patients (3.0%) with post-operative diarrheal disease who tested positive for CD; these patients comprised the cohort of this observational study. A fulminant CDI occurred in 153 of these patients (12.2%), which was diagnosed on the basis of gastrointestinal complications, e.g. pseudomembranous colitis, and/or the need for post-cardiac surgery laparotomy. Demographic, peri-operative, and survival data were analyzed, and predictors of a fulminant CDI were assessed by binary logistic regression analysis.</AbstractText><AbstractText Label="RESULTS">The 30-day mortality was 6.1% (n&#x2009;=&#x2009;77) for the entire cohort, with significantly higher mortality among patients with a fulminant CDI (21.6% vs. 4.0%, p&#x2009;&lt;&#x2009;&#xa0;0.001). Overall mortality (27.7%, n&#x2009;=&#x2009;348) was also higher for patients with a fulminant course of the disease (63.4% vs. 22.8%, p&#x2009;&lt;&#x2009;&#xa0;0.001), and a laparotomy was required in 36.6% (n&#x2009;=&#x2009;56) of the fulminant cases. Independent predictors of a fulminant CDI were: diabetes mellitus type 2 (OR 1.74, CI 1.15-2.63, p&#x2009;=&#x2009;0.008), pre-operative ventilation (OR 3.52, CI 1.32-9.35, p&#x2009;=&#x2009;0.012), utilization of more than 8&#xa0;units of red blood cell concentrates (OR 1.95, CI 1.01-3.76, p&#x2009;=&#x2009;0.046) or of more than 5 fresh-frozen plasma units (OR 3.38, CI 2.06-5.54, p&#x2009;&lt;&#x2009;&#xa0;0.001), and a cross-clamp time&#x2009;&gt;&#x2009;130&#xa0;min (OR 1.93, CI 1.12-3.33, p&#x2009;=&#x2009;0.017).</AbstractText><AbstractText Label="CONCLUSIONS">We identified several independent risk factors for the development of a fulminant CDI after cardiac surgery. Close monitoring of high-risk patients is important in order to establish an early onset of therapy and thus to prevent a CDI from developing a fulminant course after cardiac surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vondran</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany. m.vondran@hkz-rotenburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Thoracic and Vascular Surgery, University Hospital Marburg (UKGM), Baldingerstr, 35043, Marburg, Germany. m.vondran@hkz-rotenburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Center of Cardiovascular Diseases Rotenburg a. d. Fulda, Heinz-Meise-Str. 100, 36199, Rotenburg a. d. F, Germany. m.vondran@hkz-rotenburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schack</LastName><ForeName>Senta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbade</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binner</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mende</LastName><ForeName>Meinhard</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Clinical Trials, University of Leipzig, H&#xe4;rtelstra&#xdf;e 16/18, 04107, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastan</LastName><ForeName>Ardawan Julian</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Thoracic and Vascular Surgery, University Hospital Marburg (UKGM), Baldingerstr, 35043, Marburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Center of Cardiovascular Diseases Rotenburg a. d. Fulda, Heinz-Meise-Str. 100, 36199, Rotenburg a. d. F, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borger</LastName><ForeName>Michael Andrew</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3159-1440</Identifier><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany. thomas.schroeter@helios-gesundheit.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003015" MajorTopicYN="N">Clostridium Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004761" MajorTopicYN="N">Enterocolitis, Pseudomembranous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Clostridium difficile</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">High risk</Keyword><Keyword MajorTopicYN="N">Intensive care</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The local ethics committee approved the study (University of Leipzig, Az.: 212&#x2013;15-01062015). The study design, anonymous data acquisition, and the publication of the data were in accordance with the Declaration of Helsinki. CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30257648</ArticleId><ArticleId IdType="pmc">PMC6158878</ArticleId><ArticleId IdType="doi">10.1186/s12871-018-0597-2</ArticleId><ArticleId IdType="pii">10.1186/s12871-018-0597-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med. 1989;110:255&#x2013;257. doi: 10.7326/0003-4819-110-4-255.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-110-4-255</ArticleId><ArticleId IdType="pubmed">2643913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758&#x2013;764. doi: 10.7326/0003-4819-145-10-200611210-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-145-10-200611210-00008</ArticleId><ArticleId IdType="pubmed">17116920</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbut F, Leluan P, Antoniotti G, Collignon A, Sedallian A, Petit J. Value of routine stool cultures in hospitalized patients with diarrhea. Eur J Clin Microbiol Infect Dis. 1995;14:346&#x2013;349. doi: 10.1007/BF02116530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02116530</ArticleId><ArticleId IdType="pubmed">7649200</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohner P, Pittet D, Pepey B, Nije-Kinge T, Auckenthaler R. Etiological agents of infectious diarrhea: implications for requests for microbial culture. J Clin Microbiol. 1997;35:1427&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229762</ArticleId><ArticleId IdType="pubmed">9163457</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree T, Aitchison D, Meyers BF, Tymkew H, Smith JR, Guthrie TJ, et al. Clostridium difficile in cardiac surgery: risk factors and impact on postoperative outcome. Ann Thorac Surg. 2007;83:1396&#x2013;1402. doi: 10.1016/j.athoracsur.2006.10.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.10.067</ArticleId><ArticleId IdType="pubmed">17383346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesperance K, Causey MW, Spencer M, Steele SR. The morbidity of Clostridium difficile infection after elective colonic resection&#x2014;results from a national population database. Am J Surg. 2011;201:141&#x2013;148. doi: 10.1016/j.amjsurg.2010.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2010.09.017</ArticleId><ArticleId IdType="pubmed">21266214</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz P, Giannella M, Alcala L, Sarmiento E, Fernandez Yanez J, Palomo J, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007;26:907&#x2013;914. doi: 10.1016/j.healun.2007.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2007.07.010</ArticleId><ArticleId IdType="pubmed">17845929</ArticleId></ArticleIdList></Reference><Reference><Citation>Flagg A, Koch CG, Schiltz N, Chandran Pillai A, Gordon SM, Pettersson GB, et al. Analysis of Clostridium difficile infections after cardiac surgery: epidemiologic and economic implications from national data. J Thorac Cardiovasc Surg. 2014;148:2404&#x2013;2409. doi: 10.1016/j.jtcvs.2014.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.04.017</ArticleId><ArticleId IdType="pubmed">24823282</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavamurthy S, Koch CG, Fraser TG, Gordon SM, Houghtaling PL, Soltesz EG, et al. Clostridium difficile infection after cardiac surgery: prevalence, morbidity, mortality, and resource utilization. J Thorac Cardiovasc Surg. 2014;148:3157&#x2013;3165. doi: 10.1016/j.jtcvs.2014.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.08.017</ArticleId><ArticleId IdType="pubmed">25242055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire A, Dombrovskiy V, Batsides G, Scholz P, Solina A, Brownstone N, et al. The effect of Clostridium difficile infection on cardiac surgery outcomes. Surg Infect. 2015;16:24&#x2013;28. doi: 10.1089/sur.2013.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2013.097</ArticleId><ArticleId IdType="pubmed">25402213</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold G. Innere Medizin : eine vorlesungsorientierte Darstellung : 2017 : unter Ber&#xfc;cksichtigung des Gegenstandskataloges f&#xfc;r die &#xc4;rztliche Pr&#xfc;fung : mit ICD 10-Schl&#xfc;ssel im Text und Stichwortverzeichnis. K&#xf6;ln: Gerd Herold, 2017.</Citation></Reference><Reference><Citation>Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13:450&#x2013;455. doi: 10.1097/MCC.0b013e3282638879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0b013e3282638879</ArticleId><ArticleId IdType="pubmed">17599017</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutros M, Al-Shaibi M, Chan G, Cantarovich M, Rahme E, Paraskevas S, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation. 2012;93:1051&#x2013;1057. doi: 10.1097/TP.0b013e31824d34de.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e31824d34de</ArticleId><ArticleId IdType="pubmed">22441318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubberke ER, Riddle DJ, Practice ASTIDCo. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009;9 Suppl 4:S35&#x2013;S40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899697</ArticleId><ArticleId IdType="pubmed">20070693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2&#x2013;18. doi: 10.1111/j.1469-0691.2006.01580.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2006.01580.x</ArticleId><ArticleId IdType="pubmed">16965399</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonberg R, Gastmeier P. Clostridium-difficile-assoziierte Diarrh&#xf6;: Zunehmende Inzidenz in Deutschland. Epidemiol Bull. 2008;119.</Citation></Reference><Reference><Citation>Vonberg R-P, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients. Germany Emerging infectious diseases. 2007;13:179. doi: 10.3201/eid1301.060611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.060611</ArticleId><ArticleId IdType="pmc">PMC2913657</ArticleId><ArticleId IdType="pubmed">17370545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinkauf N, Weiss B, Jansen A, Eckmanns T, Bornhofen B, Kuehnen E, et al. Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill. 2007;12:E071115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18005642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346&#x2013;353. doi: 10.1086/338260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338260</ArticleId><ArticleId IdType="pubmed">11774082</ArticleId></ArticleIdList></Reference><Reference><Citation>Musa SA, Moran C, Thomson SJ, Cowan ML, McAnulty G, Grounds M, et al. Clostridium difficile-associated disease acquired in the cardiothoracic intensive care unit. J Cardiothorac Vasc Anesth. 2011;25:263&#x2013;267. doi: 10.1053/j.jvca.2010.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.05.004</ArticleId><ArticleId IdType="pubmed">20638863</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53:1173&#x2013;1178. doi: 10.1093/cid/cir668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cir668</ArticleId><ArticleId IdType="pubmed">21976459</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler DA, Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015;373:287&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">26176396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1&#x2013;15. doi: 10.1016/S0195-6701(98)90019-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0195-6701(98)90019-6</ArticleId><ArticleId IdType="pubmed">9777516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543&#x2013;1549. doi: 10.1086/523582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/523582</ArticleId><ArticleId IdType="pubmed">18190314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SM, Lee JJ, Yoon HJ. Clinical risk factors for Clostridium difficile-associated diseases. Braz J Infect Dis. 2012;16:256&#x2013;261. doi: 10.1590/S1413-86702012000300007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1413-86702012000300007</ArticleId><ArticleId IdType="pubmed">22729193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreugdenhil H, Heijnen C, Pl&#xf6;tz F, Zijlstra J, Jansen N, Haitsma J, et al. Mechanical ventilation of healthy rats suppresses peripheral immune function. Eur Respir J. 2004;23:122&#x2013;128. doi: 10.1183/09031936.03.00035003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.03.00035003</ArticleId><ArticleId IdType="pubmed">14738243</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunson M, Alexander J. Mechanisms of transfusion-induced immunosuppression. Transfusion. 1990;30:651&#x2013;658. doi: 10.1046/j.1537-2995.1990.30790385527.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.1990.30790385527.x</ArticleId><ArticleId IdType="pubmed">2205953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings DL, Chopra A, Chambers R, Morgan JA. Clinical outcomes associated with chronic antimicrobial suppression therapy in patients with continuous-flow left ventricular assist devices. Artif Organs. 2014;38:875&#x2013;879. doi: 10.1111/aor.12254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12254</ArticleId><ArticleId IdType="pubmed">24571683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Tillmann E, Subramanian S, Lehmkuhl L, Funkat AK, Leontyev S, et al. Visceral arterial compromise during intra-aortic balloon counterpulsation therapy. Circulation. 2010;122:S92&#x2013;S99. doi: 10.1161/CIRCULATIONAHA.109.929810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.929810</ArticleId><ArticleId IdType="pubmed">20837932</ArticleId></ArticleIdList></Reference><Reference><Citation>Vondran M, Rastan AJ, Tillmann E, Seeburger J, Schroter T, Dhein S, et al. Intra-aortic balloon pump malposition reduces visceral artery perfusion in an acute animal model. Artif Organs. 2016;40:334&#x2013;340. doi: 10.1111/aor.12563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12563</ArticleId><ArticleId IdType="pubmed">26366459</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin N Am. 2009;23:727&#x2013;743. doi: 10.1016/j.idc.2009.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2009.04.011</ArticleId><ArticleId IdType="pmc">PMC2726831</ArticleId><ArticleId IdType="pubmed">19665092</ArticleId></ArticleIdList></Reference><Reference><Citation>Carchman EH, Peitzman AB, Simmons RL, Zuckerbraun BS. The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease. J Trauma Acute Care Surg. 2012;73:789&#x2013;800. doi: 10.1097/TA.0b013e318265d19f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318265d19f</ArticleId><ArticleId IdType="pubmed">23026914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35067344</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Mortality in polytrauma patients with moderate to severe TBI on par with isolated TBI patients: TBI as last frontier in polytrauma patients.</ArticleTitle><Pagination><StartPage>1443</StartPage><EndPage>1448</EndPage><MedlinePgn>1443-1448</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2022.01.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0020-1383(22)00004-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mortality caused by Traumatic Brain Injury (TBI) remains high, despite improvements in trauma and critical care. Polytrauma is naturally associated with high mortality. This study compared mortality rates between isolated TBI (<sub>I</sub>TBI) patients and polytrauma patients with TBI (<sub>P</sub>TBI) admitted to ICU to investigate if concomitant injuries lead to higher mortality amongst TBI patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 3-year cohort study compared polytrauma patients with TBI (<sub>P</sub>TBI) with AIS head &#x2265;3 (and AIS of other body regions &#x2265;3) from a prospective collected database to isolated TBI (<sub>I</sub>TBI) patients from a retrospective collected database with AIS head &#x2265;3 (AIS of other body regions &#x2264;2), both admitted to a single level-I trauma center ICU. Patients &lt;16 years of age, injury caused by asphyxiation, drowning, burns and ICU transfers from and to other hospitals were excluded. Patient demographics, shock and resuscitation parameters, multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), and mortality data were collected and analyzed for group differences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">259 patients were included; 111 <sub>P</sub>TBI and 148 <sub>I</sub>TBI patients. The median age was 54 [33-67] years, 177 (68%) patients were male, median ISS was 26 [20-33]. Seventy-nine (31%) patients died. Patients with <sub>P</sub>TBI developed more ARDS (7% vs. 1%, p&#xa0;=&#xa0;0.041) but had similar MODS rates (18% vs. 10%, p&#xa0;=&#xa0;0.066). They also stayed longer on the ventilator (7 vs. 3 days, p=&lt;0.001), longer in ICU (9 vs. 4 days, p=&lt;0.001) and longer in hospital (24 vs. 11 days, p=&lt;0.001). TBI was the most prevalent cause of death in polytrauma patients. Patients with <sub>P</sub>TBI showed no higher in-hospital mortality rate. Moreover, mortality rates were skewed towards <sub>I</sub>TBI patients (24% vs. 35%, p&#xa0;=&#xa0;0.06).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">There was no difference in mortality rates between <sub>P</sub>TBI and <sub>I</sub>TBI patients, suggesting TBI-severity as the predominant factor for ICU mortality in an era of ever improving acute trauma care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niemeyer</LastName><ForeName>Mjs</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands. Electronic address: m.j.s.niemeyer@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jochems</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houwert</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Lph</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Kjp</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute care</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Multitrauma</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword><Keyword MajorTopicYN="N">TBI2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest, financially or otherwise.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35067344</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2022.01.009</ArticleId><ArticleId IdType="pii">S0020-1383(22)00004-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33178897</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2397-5776</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Trauma surgery &amp; acute care open</Title><ISOAbbreviation>Trauma Surg Acute Care Open</ISOAbbreviation></Journal><ArticleTitle>Dilemma of crystalloid resuscitation in non-exsanguinating polytrauma: what is too much?</ArticleTitle><Pagination><StartPage>e000593</StartPage><MedlinePgn>e000593</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e000593</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/tsaco-2020-000593</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aggressive crystalloid resuscitation increases morbidity and mortality in exsanguinating patients. Polytrauma patients with severe tissue injury and subsequent inflammatory response without major blood loss also need resuscitation. This study investigated crystalloid and blood product resuscitation in non-exsanguinating polytrauma patients and studied possible adverse outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 6.5-year prospective cohort study included consecutive trauma patients admitted to a Level 1 Trauma Center intensive care unit (ICU) who survived 48&#x2009;hours. Demographics, physiologic and resuscitation parameters in first 24&#x2009;hours, Denver Multiple Organ Failure scores, adult respiratory distress syndrome (ARDS) data and infectious complications were prospectively collected. Patients were divided in 5&#x2009;L crystalloid volume subgroups (0-5, 5-10, 10-15 and &gt;15&#x2009;L) to make clinically relevant comparisons. Data are presented as median (IQR); p value &lt;0.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">367 patients (70% men) were included with median age of 46 (28-61) years, median Injury Severity Score was 29 (22-35) and 95% sustained blunt injuries. 17% developed multiple organ dysfunction syndrome (MODS), 4% ARDS and 14% died. Increasing injury severity, acidosis and coagulopathy were associated with more crystalloid administration. Increasing crystalloid volumes were associated with more blood products, increased ventilator days, ICU length of stay, hospital length of stay, MODS, infectious complications and mortality rates. Urgent laparotomy was found to be the most important independent predictor for crystalloid resuscitation in multinominal regression analysis. Further, fresh frozen plasma (FFP) &lt;8&#x2009;hours was less likely to be administered in patients &gt;5&#x2009;L compared with the group 0-5&#x2009;L. With increasing crystalloid volume, the adjusted odds of MODS, ARDS and infectious complications increased 3-4-fold, although not statistically significant. Mortality increased 6-fold in patients who received &gt;15&#x2009;L crystalloids (p=0.03).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Polytrauma patients received large amounts of crystalloids with few FFPs &lt;24&#x2009;hours. In patients with &lt;10 L crystalloids, &lt;24-hour mortality and MODS rates were not influenced by crystalloid resuscitation. Mortality increased 6-fold in patients who received &gt;15&#x2009;L crystalloids &#x2264;24&#x2009;hours. Efforts should be made to balance resuscitation with modest crystalloids and sufficient amount of FFPs.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level 3.</AbstractText><AbstractText Label="STUDY TYPE" NlmCategory="METHODS">Population-based cohort study.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hietbrink</LastName><ForeName>Falco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trauma Surg Acute Care Open</MedlineTA><NlmUniqueID>101698646</NlmUniqueID><ISSNLinking>2397-5776</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">multiple trauma</Keyword><Keyword MajorTopicYN="N">resuscitation</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33178897</ArticleId><ArticleId IdType="pmc">PMC7594544</ArticleId><ArticleId IdType="doi">10.1136/tsaco-2020-000593</ArticleId><ArticleId IdType="pii">tsaco-2020-000593</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bickell WH, Wall MJ, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:1105&#x2013;9. 10.1056/NEJM199410273311701</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199410273311701</ArticleId><ArticleId IdType="pubmed">7935634</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam HB, Rhee P. New developments in fluid resuscitation. Surg Clin North Am 2007;87:55&#x2013;72. 10.1016/j.suc.2006.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suc.2006.09.015</ArticleId><ArticleId IdType="pubmed">17127123</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton BA, Guy JS, Morris JA, Abumrad NN. The cellular, metabolic, and systemic consequences of aggressive fluid resuscitation strategies. Shock 2006;26:115&#x2013;21. 10.1097/01.shk.0000209564.84822.f2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000209564.84822.f2</ArticleId><ArticleId IdType="pubmed">16878017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutcher ME, Kornblith LZ, Narayan R, Curd V, Daley AT, Redick BJ, Nelson MF, Fiebig EW, Cohen MJ. A paradigm shift in trauma resuscitation: evaluation of evolving massive transfusion practices. JAMA Surg 2013;148:834&#x2013;40. 10.1001/jamasurg.2013.2911</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2013.2911</ArticleId><ArticleId IdType="pubmed">23864019</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ND, Codner P, Greene W, Brasel K, Michetti C, AAST Critical Care Committee . Contemporary hemodynamic monitoring, fluid responsiveness, volume optimization, and endpoints of resuscitation: an AAST critical care Committee clinical consensus. Trauma Surg Acute Care Open 2020;5:e000411. 10.1136/tsaco-2019-000411</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2019-000411</ArticleId><ArticleId IdType="pmc">PMC7066619</ArticleId><ArticleId IdType="pubmed">32201737</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, Komadina R, Maegele M, Nardi G, Riddez L, et al. . The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019;23:98. 10.1186/s13054-019-2347-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2347-3</ArticleId><ArticleId IdType="pmc">PMC6436241</ArticleId><ArticleId IdType="pubmed">30917843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasotakis G, Sideris A, Yang Y, de Moya M, Alam H, King DR, Tompkins R, Velmahos G, Inflammation and Host Response to Injury Investigators . Aggressive early crystalloid resuscitation adversely affects outcomes in adult blunt trauma patients: an analysis of the glue grant database. J Trauma Acute Care Surg 2013;74:1215&#x2013;22. 10.1097/TA.0b013e3182826e13</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182826e13</ArticleId><ArticleId IdType="pmc">PMC3984883</ArticleId><ArticleId IdType="pubmed">23609270</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada MY, Ko A, Barmparas G, Smith EJT, Patel BK, Dhillon NK, Thomsen GM, Ley EJ. 10-Year trend in crystalloid resuscitation: reduced volume and lower mortality. Int J Surg 2017;38:78&#x2013;82. 10.1016/j.ijsu.2016.12.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2016.12.073</ArticleId><ArticleId IdType="pubmed">28040501</ArticleId></ArticleIdList></Reference><Reference><Citation>Maegele M, Fr&#xf6;hlich M, Caspers M, Kaske S. Volume replacement during trauma resuscitation: a brief synopsis of current guidelines and recommendations. Eur J Trauma Emerg Surg 2017;43:439&#x2013;43. 10.1007/s00068-017-0771-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-017-0771-0</ArticleId><ArticleId IdType="pubmed">28243715</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet J-F. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008;64:1211&#x2013;7. 10.1097/TA.0b013e318169cd3c</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318169cd3c</ArticleId><ArticleId IdType="pubmed">18469643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas CE. The water of life: a century of confusion. J Am Coll Surg 2001;192:86&#x2013;93. 10.1016/S1072-7515(00)00761-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1072-7515(00)00761-4</ArticleId><ArticleId IdType="pubmed">11192929</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLS Advanced Trauma Life Support&#xae;, student course manual. Tenth edition: American College of Surgeons, 2018.</Citation></Reference><Reference><Citation>Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, et al. . Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901&#x2013;11. 10.1056/NEJMoa1209759</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209759</ArticleId><ArticleId IdType="pubmed">23075127</ArticleId></ArticleIdList></Reference><Reference><Citation>Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PGR, Shulman I, Nelson J, Demetriades D. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957&#x2013;65. 10.1016/j.jamcollsurg.2010.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2010.01.031</ArticleId><ArticleId IdType="pubmed">20510805</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Z, Pati S, Potter D, Brown R, Holcomb JB, Grill R, Wataha K, Park PW, Xue H, Kozar RA, et al. . Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1. Shock 2013;40:195&#x2013;202. 10.1097/SHK.0b013e31829f91fc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31829f91fc</ArticleId><ArticleId IdType="pmc">PMC3764452</ArticleId><ArticleId IdType="pubmed">23807246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 2009;114:3033&#x2013;43. 10.1182/blood-2009-02-204966</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-02-204966</ArticleId><ArticleId IdType="pmc">PMC2756208</ArticleId><ArticleId IdType="pubmed">19638625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozar RA, Peng Z, Zhang R, Holcomb JB, Pati S, Park P, Ko TC, Paredes A. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg 2011;112:1289&#x2013;95. 10.1213/ANE.0b013e318210385c</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e318210385c</ArticleId><ArticleId IdType="pmc">PMC3102787</ArticleId><ArticleId IdType="pubmed">21346161</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, Leenen LPH. Demographic patterns and outcomes of patients in level I trauma centers in three international trauma systems. World J Surg 2015;39:2677&#x2013;84. 10.1007/s00268-015-3162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3162-x</ArticleId><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg 2013;74:774&#x2013;9. 10.1097/TA.0b013e31827a6e69</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg 2014;77:624&#x2013;9. 10.1097/TA.0000000000000406</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000406</ArticleId><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg 1994;129:39&#x2013;45. 10.1001/archsurg.1994.01420250051006</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. ARDS Definition Task Force . Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526&#x2013;33. 10.1001/jama.2012.5669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Hietbrink F, Leenen LPH. Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured. Trauma Surg Acute Care Open 2020;5:e000398. 10.1136/tsaco-2019-000398</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2019-000398</ArticleId><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="pubmed">32154377</ArticleId></ArticleIdList></Reference><Reference><Citation>Asensio JA, McDuffie L, Petrone P, Rolda&#x144; G, Forno W, Gambaro E, Salim A, Demetriades D, Murray J, Velmahos G, et al. . Reliable variables in the exsanguinated patient which indicate damage control and predict outcome. Am J Surg 2001;182:743&#x2013;51. 10.1016/S0002-9610(01)00809-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(01)00809-1</ArticleId><ArticleId IdType="pubmed">11839351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, Sakka SG, Bouillon B, Wafaisade A, Committee on Emergency Medicine, Intensive Care and Trauma Management of the German Trauma Society Sektion NIS . Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg 2014;76:921&#x2013;8. 10.1097/TA.0000000000000199</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Minei JP, Cuschieri J, Sperry J, Moore EE, West MA, Harbrecht BG, O'Keefe GE, Cohen MJ, Moldawer LL, Tompkins RG, et al. . The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock. Crit Care Med 2012;40:1129&#x2013;35. 10.1097/CCM.0b013e3182376e9f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182376e9f</ArticleId><ArticleId IdType="pmc">PMC3343366</ArticleId><ArticleId IdType="pubmed">22020243</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Leary MP, Keeley JA, Yule A, Suruki C, Plurad DS, Moazzez A, Neville AL, Putnam BA, Kim DY. Clinical predictors of early acute respiratory distress syndrome in trauma patients. Am J Surg 2016;212:1096&#x2013;100. 10.1016/j.amjsurg.2016.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2016.09.008</ArticleId><ArticleId IdType="pubmed">27780558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahr M, Jones G, O'Neal H, Duchesne J, Tatum D. Acute respiratory distress syndrome incidence, but not mortality, has decreased nationwide: a national trauma data bank study. Am Surg 2017;83:323&#x2013;31. 10.1177/000313481708300416</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000313481708300416</ArticleId><ArticleId IdType="pubmed">28424124</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Incidence of acute respiratory distress syndrome and associated mortality in a polytrauma population. Trauma Surg Acute Care Open 2018;3:e000232. 10.1136/tsaco-2018-000232</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2018-000232</ArticleId><ArticleId IdType="pmc">PMC6307585</ArticleId><ArticleId IdType="pubmed">30623025</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Reduction in mortality rates of postinjury multiple organ dysfunction syndrome: a shifting paradigm? A prospective population-based cohort study. Shock 2018;49:33&#x2013;8. 10.1097/SHK.0000000000000938</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId><ArticleId IdType="pubmed">28682941</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole E, Davenport R, Willett K, Brohi K. The burden of infection in severely injured trauma patients and the relationship with admission shock severity. J Trauma Acute Care Surg 2014;76:730&#x2013;5. 10.1097/TA.0b013e31829fdbd7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31829fdbd7</ArticleId><ArticleId IdType="pubmed">24487318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton GE, Du RE, Wei S, Harvin JA, Finkel KW, Wade CE, Kao LS. Positive fluid balance and association with post-traumatic acute kidney injury. J Am Coll Surg 2020;230:190&#x2013;9. 10.1016/j.jamcollsurg.2019.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2019.10.009</ArticleId><ArticleId IdType="pmc">PMC7220831</ArticleId><ArticleId IdType="pubmed">31733328</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DG, Nantais J, Rezende-Neto JB, Yazdani S, Vegas P, Rizoli S. Crystalloid resuscitation in trauma patients: deleterious effect of 5L or more in the first 24h. BMC Surg 2018;18:93. 10.1186/s12893-018-0427-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-018-0427-y</ArticleId><ArticleId IdType="pmc">PMC6219036</ArticleId><ArticleId IdType="pubmed">30400852</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida K, Nishimura T, Hagawa N, Kaga S, Noda T, Shinyama N, Yamamoto H, Mizobata Y. The impact of early administration of vasopressor agents for the resuscitation of severe hemorrhagic shock following blunt trauma. BMC Emerg Med 2020;20:26. 10.1186/s12873-020-00322-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12873-020-00322-1</ArticleId><ArticleId IdType="pmc">PMC7164243</ArticleId><ArticleId IdType="pubmed">32299385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohn SM, McCarthy J, Stewart RM, Jonas RB, Dent DL, Michalek JE. Impact of low-dose vasopressin on trauma outcome: prospective randomized study. World J Surg 2011;35:430&#x2013;9. 10.1007/s00268-010-0875-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-010-0875-8</ArticleId><ArticleId IdType="pubmed">21161222</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrois A, Hamada SR, Duranteau J. Fluid resuscitation and vasopressors in severe trauma patients. Curr Opin Crit Care 2014;20:632&#x2013;7. 10.1097/MCC.0000000000000159</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0000000000000159</ArticleId><ArticleId IdType="pubmed">25340381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26607226</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><PubDate><Year>2015</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Improvement of prognostic performance in severely injured patients by integrated clinico-transcriptomics: a translational approach.</ArticleTitle><Pagination><StartPage>414</StartPage><MedlinePgn>414</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">414</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-015-1127-y</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Severe trauma triggers a systemic inflammatory response that contributes to secondary complications, such as nosocomial infections, sepsis or multi-organ failure. The present study was aimed to identify markers predicting complications and an adverse outcome of severely injured patients by an integrated clinico-transcriptomic approach.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a prospective study, RNA samples from circulating leukocytes from severely injured patients (injury severity score&#x2009;&#x2265;&#x2009;17 points; n&#x2009;=&#x2009;104) admitted to a Level I Trauma Center were analyzed for dynamic changes in gene expression over a period of 21 days by quantitative RT-PCR. Transcriptomic candidates were selected based on whole genome screening of a representative discovery set (n&#x2009;=&#x2009;10 patients) or known mechanisms of the immune response, including mediators of inflammation (IL-8, IL-10, TNF-&#x3b1;, MIF, C5, CD59, SPHK1), danger signaling (HMGB1, TLR2, CD14, IL-33, IL-1RL1), and components of the heme degradation pathway (HP, CD163, HMOX1, BLVRA, BLVRB). Clinical markers comprised standard physiological and laboratory parameters and scoring systems routinely determined in trauma patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Leukocytes, thrombocytes and the expression of sphingosine kinase-1 (SPHK1), complement C5, and haptoglobin (HP) have been identified as markers with the best performance. Leukocytes showed a biphasic course with peaks on day 0 and day 11 after trauma, and patients with sepsis exhibited significantly higher leukocyte levels. Thrombocyte numbers showed a typical profile with initial thrombopenia and robust thrombocytosis in week 3 after trauma, ranging 2- to 3-fold above the upper normal value. 'Relative thrombocytopenia' was associated with multi-organ dysfunction, the development of sepsis, and mortality, the latter of which could be predicted within 3 days prior to the time point of death. SPHK1 expression at the day of admission indicated mortality with excellent performance. C5-expression on day 1 after trauma correlated with an increased risk for the development of nosocomial infections during the later course, while HP was found to be a marker for the development of sepsis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The combination of clinical and transcriptomic markers improves the prognostic performance and may represent a useful tool for individual risk stratification in trauma patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rittirsch</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. daniel.rittirsch@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenborn</LastName><ForeName>Veit</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. veitschoenborn@googlemail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindig</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care Therapy, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. sandro.lindig@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanner</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. elisabeth.wanner@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprengel</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. kai.sprengel@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nkel</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. sebguenkel@web.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaarschmidt</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care Therapy, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. barbara.schaarschmidt@med.uni-jena.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. barbara.schaarschmidt@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe4;rsmann</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. albers.sonja@web.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmen</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. hanspeter.simmen@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinelli</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. paolo.cinelli@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care Therapy, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. michael.bauer@med.uni-jena.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. michael.bauer@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claus</LastName><ForeName>Ralf A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care Therapy, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. ralf.claus@med.uni-jena.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena University Hospital, Erlanger Allee 101, D-07747, Jena, Germany. ralf.claus@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanner</LastName><ForeName>Guido A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Division of Trauma Surgery, Department of Surgery, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. guido.wanner@usz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003182">Complement C5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006242">Haptoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C022648">sphingosine kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003182" MajorTopicYN="N">Complement C5</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006242" MajorTopicYN="N">Haptoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26607226</ArticleId><ArticleId IdType="pmc">PMC4660831</ArticleId><ArticleId IdType="doi">10.1186/s13054-015-1127-y</ArticleId><ArticleId IdType="pii">10.1186/s13054-015-1127-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776&#x2013;87. doi: 10.1038/nri2402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2402</ArticleId><ArticleId IdType="pmc">PMC2786961</ArticleId><ArticleId IdType="pubmed">18802444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644&#x2013;55. doi: 10.1378/chest.101.6.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Faist E, Baue AE, Dittmer H, Heberer G. Multiple organ failure in polytrauma patients. J Trauma. 1983;23:775&#x2013;87. doi: 10.1097/00005373-198309000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198309000-00002</ArticleId><ArticleId IdType="pubmed">6620431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72:1491&#x2013;501. doi: 10.1097/TA.0b013e318256e000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318256e000</ArticleId><ArticleId IdType="pmc">PMC3705923</ArticleId><ArticleId IdType="pubmed">22695412</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208:2581&#x2013;90. doi: 10.1084/jem.20111354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111354</ArticleId><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma. 1996;40:501&#x2013;10. doi: 10.1097/00005373-199604000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199604000-00001</ArticleId><ArticleId IdType="pubmed">8614027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuenca AG, Gentile LF, Lopez MC, Ungaro R, Liu H, Xiao W, et al. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med. 2013;41:1175&#x2013;85. doi: 10.1097/CCM.0b013e318277131c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318277131c</ArticleId><ArticleId IdType="pmc">PMC3652285</ArticleId><ArticleId IdType="pubmed">23388514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney TE, Shidham A, Wong HR, Khatri P. A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. Sci Transl Med. 2015;7:287ra271. doi: 10.1126/scitranslmed.aaa5993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa5993</ArticleId><ArticleId IdType="pmc">PMC4734362</ArticleId><ArticleId IdType="pubmed">25972003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord JM, Midwinter MJ, Chen YF, Belli A, Brohi K, Kovacs EJ, et al. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. 2014;384:1455&#x2013;65. doi: 10.1016/S0140-6736(14)60687-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60687-5</ArticleId><ArticleId IdType="pmc">PMC4729362</ArticleId><ArticleId IdType="pubmed">25390327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Giannoudis P, Krettek C. The timing of fracture treatment in polytrauma patients: relevance of damage control orthopedic surgery. Am J Surg. 2002;183:622&#x2013;9. doi: 10.1016/S0002-9610(02)00865-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(02)00865-6</ArticleId><ArticleId IdType="pubmed">12095590</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondo MF, Schwab CW, McGonigal MD, Phillips GR, 3rd, Fruchterman TM, Kauder DR, et al. &#x201c;Damage control&#x201d;: an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma. 1993;35:375&#x2013;82. doi: 10.1097/00005373-199309000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199309000-00008</ArticleId><ArticleId IdType="pubmed">8371295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Huber-Lang M. Polytrauma&#x2014;pathophysiology and management principles. Langenbecks Arch Surg. 2008;393:825&#x2013;31. doi: 10.1007/s00423-008-0334-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00423-008-0334-2</ArticleId><ArticleId IdType="pubmed">18431593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, Ertel W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med. 2000;28:950&#x2013;7. doi: 10.1097/00003246-200004000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200004000-00007</ArticleId><ArticleId IdType="pubmed">10809265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 2008;26:711&#x2013;5. doi: 10.1016/j.ajem.2007.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2007.10.031</ArticleId><ArticleId IdType="pubmed">18606328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudilliere B, Fragiadakis GK, Bruggner RV, Nicolau M, Finck R, Tingle M, et al. Clinical recovery from surgery correlates with single-cell immune signatures. Sci Transl Med. 2014;6:255ra131. doi: 10.1126/scitranslmed.3009701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009701</ArticleId><ArticleId IdType="pmc">PMC4334126</ArticleId><ArticleId IdType="pubmed">25253674</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus RA, Otto GP, Deigner HP, Bauer M. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med. 2010;10:227&#x2013;35. doi: 10.2174/156652410790963358.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652410790963358</ArticleId><ArticleId IdType="pubmed">20196725</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13:R174. doi: 10.1186/cc8152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, et al. HMGB1 is markedly elevated within 6&#xa0;hours of mechanical trauma in humans. Shock. 2009;32:17&#x2013;22. doi: 10.1097/SHK.0b013e3181997173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181997173</ArticleId><ArticleId IdType="pmc">PMC4097145</ArticleId><ArticleId IdType="pubmed">19533845</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA, Jr, Auxiliadora-Martins M, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16:708&#x2013;12. doi: 10.1038/nm.2156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2156</ArticleId><ArticleId IdType="pubmed">20473304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsiger S, Simmen HP, Werner CM, Wanner GA, Rittirsch D. Danger signals activating the immune response after trauma. Mediators Inflamm. 2012;2012:315941. doi: 10.1155/2012/315941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/315941</ArticleId><ArticleId IdType="pmc">PMC3388465</ArticleId><ArticleId IdType="pubmed">22778496</ArticleId></ArticleIdList></Reference><Reference><Citation>Flierl MA, Rittirsch D, Nadeau BA, Day DE, Zetoune FS, Sarma JV, et al. Functions of the complement components C3 and C5 during sepsis. FASEB J. 2008;22:3483&#x2013;90. doi: 10.1096/fj.08-110595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-110595</ArticleId><ArticleId IdType="pmc">PMC2537435</ArticleId><ArticleId IdType="pubmed">18587006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, et al. Functional roles for C5a receptors in sepsis. Nat Med. 2008;14:551&#x2013;7. doi: 10.1038/nm1753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1753</ArticleId><ArticleId IdType="pmc">PMC2753858</ArticleId><ArticleId IdType="pubmed">18454156</ArticleId></ArticleIdList></Reference><Reference><Citation>Puneet P, Yap CT, Wong L, Lam Y, Koh DR, Moochhala S, et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science. 2010;328:1290&#x2013;4. doi: 10.1126/science.1188635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1188635</ArticleId><ArticleId IdType="pubmed">20522778</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Losche W, Kinscherf R, et al. Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J. 2005;19:1719&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16051685</ArticleId></ArticleIdList></Reference><Reference><Citation>Surbatovic M, Veljovic M, Jevdjic J, Popovic N, Djordjevic D, Radakovic S. Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma. Mediators Inflamm. 2013;2013:362793. doi: 10.1155/2013/362793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/362793</ArticleId><ArticleId IdType="pmc">PMC3859159</ArticleId><ArticleId IdType="pubmed">24371374</ArticleId></ArticleIdList></Reference><Reference><Citation>Park MS, Salinas J, Wade CE, Wang J, Martini W, Pusateri AE, et al. Combining early coagulation and inflammatory status improves prediction of mortality in burned and nonburned trauma patients. J Trauma. 2008;64(2 Suppl):S188&#x2013;94. doi: 10.1097/TA.0b013e318160a5a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318160a5a3</ArticleId><ArticleId IdType="pubmed">18376164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang CC, Hung CJ, Tsai MC, Yeh TM, Chuang YC. High concentrations of circulating macrophage migration inhibitory factor in patients with severe blunt trauma: is serum macrophage migration inhibitory factor concentration a valuable prognostic factor? Crit Care Med. 2004;32:734&#x2013;9. doi: 10.1097/01.CCM.0000117170.13320.F4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000117170.13320.F4</ArticleId><ArticleId IdType="pubmed">15090955</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa M, Katabami K, Wada T, Minami Y, Sugano M, Shimojima H, et al. Imbalance between macrophage migration inhibitory factor and cortisol induces multiple organ dysfunction in patients with blunt trauma. Inflammation. 2011;34:193&#x2013;7. doi: 10.1007/s10753-010-9223-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-010-9223-2</ArticleId><ArticleId IdType="pubmed">20499270</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi PC, Poole GV, Sachdev V, Zhou X, Jones Q. Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF) Res Commun Mol Pathol Pharmacol. 2000;107:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11334363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogner V, Keil L, Kanz KG, Kirchhoff C, Leidel BA, Mutschler W, et al. Very early posttraumatic serum alterations are significantly associated to initial massive RBC substitution, injury severity, multiple organ failure and adverse clinical outcome in multiple injured patients. Eur J Med Res. 2009;14:284&#x2013;91. doi: 10.1186/2047-783X-14-7-284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-783X-14-7-284</ArticleId><ArticleId IdType="pmc">PMC3458638</ArticleId><ArticleId IdType="pubmed">19661010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg. 1997;226:450&#x2013;8. doi: 10.1097/00000658-199710000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199710000-00006</ArticleId><ArticleId IdType="pmc">PMC1191059</ArticleId><ArticleId IdType="pubmed">9351713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendemans S, Ruchholtz S. German Society of Trauma S. S3 guideline on treatment of polytrauma/severe injuries. Trauma room care. Unfallchirurg. 2012;115:14&#x2013;21. doi: 10.1007/s00113-011-2103-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00113-011-2103-x</ArticleId><ArticleId IdType="pubmed">22274599</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250&#x2013;6. doi: 10.1097/01.CCM.0000050454.01978.3B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000050454.01978.3B</ArticleId><ArticleId IdType="pubmed">12682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117&#x2013;23. doi: 10.1001/jama.1995.03520260039030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03520260039030</ArticleId><ArticleId IdType="pubmed">7799491</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707&#x2013;10. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobisch-Hagen P, Jelkmann W, Mayr A, Wiedermann FJ, Fries D, Herold M, et al. Low platelet count and elevated serum thrombopoietin after severe trauma. Eur J Haematol. 2000;64:157&#x2013;63. doi: 10.1034/j.1600-0609.2000.90102.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0609.2000.90102.x</ArticleId><ArticleId IdType="pubmed">10997881</ArticleId></ArticleIdList></Reference><Reference><Citation>Salim A, Hadjizacharia P, DuBose J, Kobayashi L, Inaba K, Chan LS, et al. What is the significance of thrombocytosis in patients with trauma? J Trauma. 2009;66:1349&#x2013;54. doi: 10.1097/TA.0b013e318191b8af.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318191b8af</ArticleId><ArticleId IdType="pubmed">19430238</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Yang F, Dunn S, Gross AK, Smyth SS. Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res. 2011;127:184&#x2013;8. doi: 10.1016/j.thromres.2010.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2010.10.010</ArticleId><ArticleId IdType="pmc">PMC3042496</ArticleId><ArticleId IdType="pubmed">21075430</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood. 2006;107:637&#x2013;41. doi: 10.1182/blood-2005-06-2202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-06-2202</ArticleId><ArticleId IdType="pubmed">16179373</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzelt J, Mueller KA, Breuning S, Karathanos A, Schleicher R, Seizer P, et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis. 2015;238:289&#x2013;95. doi: 10.1016/j.atherosclerosis.2014.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2014.12.002</ArticleId><ArticleId IdType="pubmed">25544179</ArticleId></ArticleIdList></Reference><Reference><Citation>Stansbury LG, Hess AS, Thompson K, Kramer B, Scalea TM, Hess JR. The clinical significance of platelet counts in the first 24&#xa0;hours after severe injury. Transfusion. 2013;53:783&#x2013;9. doi: 10.1111/j.1537-2995.2012.03828.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2012.03828.x</ArticleId><ArticleId IdType="pubmed">22882316</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley RJ, Tipper JL, Bruse S, Baron RM, Tsalik EL, Huntley J, et al. Integrative &#x201c;omic&#x201d; analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes. Am J Respir Crit Care Med. 2014;190:445&#x2013;55. doi: 10.1164/rccm.201404-0624OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201404-0624OC</ArticleId><ArticleId IdType="pmc">PMC4214130</ArticleId><ArticleId IdType="pubmed">25054455</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med. 2013;5:195ra195. doi: 10.1126/scitranslmed.3005893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005893</ArticleId><ArticleId IdType="pmc">PMC3924586</ArticleId><ArticleId IdType="pubmed">23884467</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendez AJ. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim Biophys Acta. 2008;1784:66&#x2013;75. doi: 10.1016/j.bbapap.2007.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2007.07.013</ArticleId><ArticleId IdType="pubmed">17913601</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus RA, Dorer MJ, Bunck AC, Deigner HP. Inhibition of sphingomyelin hydrolysis: targeting the lipid mediator ceramide as a key regulator of cellular fate. Curr Med Chem. 2009;16:1978&#x2013;2000. doi: 10.2174/092986709788682182.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986709788682182</ArticleId><ArticleId IdType="pubmed">19519377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonitz JA, Son JY, Chandler B, Tomaio JN, Qin Y, Prescott LM, et al. A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome. Shock. 2014;42:448&#x2013;55. doi: 10.1097/SHK.0000000000000227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000227</ArticleId><ArticleId IdType="pmc">PMC4199915</ArticleId><ArticleId IdType="pubmed">25004059</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk AM, Martin M, Flierl MA, Rittirsch D, Helm M, Lampl L, et al. Early complementopathy after multiple injuries in humans. Shock. 2012;37:348&#x2013;54. doi: 10.1097/SHK.0b013e3182471795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3182471795</ArticleId><ArticleId IdType="pmc">PMC3306539</ArticleId><ArticleId IdType="pubmed">22258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185:5628&#x2013;36. doi: 10.4049/jimmunol.0903678.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903678</ArticleId><ArticleId IdType="pmc">PMC3123139</ArticleId><ArticleId IdType="pubmed">20870944</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682&#x2013;7. doi: 10.1038/nm1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1419</ArticleId><ArticleId IdType="pubmed">16715088</ArticleId></ArticleIdList></Reference><Reference><Citation>Raum MR, Nijsten MW, Vogelzang M, Schuring F, Lefering R, Bouillon B, et al. Emergency trauma score: an instrument for early estimation of trauma severity. Crit Care Med. 2009;37:1972&#x2013;7. doi: 10.1097/CCM.0b013e31819fe96a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819fe96a</ArticleId><ArticleId IdType="pubmed">19384227</ArticleId></ArticleIdList></Reference><Reference><Citation>Setzer F, Oberle V, Blass M, Moller E, Russwurm S, Deigner HP, et al. Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study. Platelets. 2006;17:571&#x2013;6. doi: 10.1080/09537100600760244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537100600760244</ArticleId><ArticleId IdType="pubmed">17127485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim FB, Pang SJ, Melendez AJ. Anaphylatoxin signaling in human neutrophils. A key role for sphingosine kinase. J Biol Chem. 2004;279:44802&#x2013;11. doi: 10.1074/jbc.M403977200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M403977200</ArticleId><ArticleId IdType="pubmed">15302883</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendez AJ, Ibrahim FB. Antisense knockdown of sphingosine kinase 1 in human macrophages inhibits C5a receptor-dependent signal transduction, Ca2+ signals, enzyme release, cytokine production, and chemotaxis. J Immunol. 2004;173:1596&#x2013;603. doi: 10.4049/jimmunol.173.3.1596.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.3.1596</ArticleId><ArticleId IdType="pubmed">15265887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16433601</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1096-2964</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>375</EndPage><MedlinePgn>369-75</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the large body of evidence suggesting a beneficial role of fever in the host response, antipyretic therapy is commonly employed for febrile critically ill patients. Our objective was to evaluate the impact of antipyretic therapy strategies on the outcomes of critically ill patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients admitted to the Trauma Intensive Care Unit over a nine-month period were eligible for inclusion, except those with traumatic brain injury. Patients were randomized on day three of the ICU stay into aggressive or permissive groups. The aggressive group received acetaminophen 650 mg every 6 h for temperature of &gt;38.5 degrees C and a cooling blanket was added for temperature of &gt;39.5 degrees C. The permissive group received no treatment for temperature of &gt;38.5 degrees C, but instead had treatment initiated at temperature of &gt;40 degrees C, at which time acetaminophen and cooling blankets were used until temperature was &lt;40 degrees C. Patient demographics, daily temperatures, systemic inflammatory response syndrome (SIRS) scores, multiple organ dysfunction syndrome (MODS) scores, and infections and complications were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between December, 2002 and September, 2003, 572 patients were screened, of whom 82 met criteria for enrollment. Forty-four patients were randomized to the aggressive group and 38 patients were randomized to the permissive group for a total of 961 and 751 ICU days, respectively. There were 131 infections in the aggressive group and 85 infections in the permissive group (4 +/- 6 vs. 3 +/- 2 infections per patient, p = 0.26). There were seven deaths in the aggressive group and only one death in the permissive group (p = 0.06, Fisher Exact Test). The study was stopped after the first interim analysis due to the mortality difference, related to the issues of waiver of consent and the mandate for minimal risk.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Aggressively treating fever in critically ill patients may lead to a higher mortality rate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulman</LastName><ForeName>Carl I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Division of Trauma and Surgical Critical Care, University of Miami Leonard M. Miller School of Medicine, Miami, Florida 33101, USA. carl@miami.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namias</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Doherty</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Elhaddad</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lasko</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Amortegui</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dy</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Dlugasch</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Baracco</LastName><ForeName>Gio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Surg Infect (Larchmt). 2010 Oct;11(5):495</RefSource><Note>Li, Pam [corrected to Li, Pamela]; Alhaddad, Ahmed [corrected to Elhaddad, Ahmed]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="N">Body Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001833" MajorTopicYN="N">Body Temperature Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16433601</ArticleId><ArticleId IdType="doi">10.1089/sur.2005.6.369</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26998845</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur J Cancer</ISOAbbreviation></Journal><ArticleTitle>Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>33</EndPage><MedlinePgn>22-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2016.01.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(16)00072-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To establishing whether neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is superior primary debulking surgery (PDS) in terms of clinical outcome as well as peri-operative morbidity in advanced epithelial ovarian cancer (AEOC) endowed with high tumour load (HTL).</AbstractText><AbstractText Label="MATERIAL AND METHODS">This is a single-Institution, superiority, randomised phase III trial enrolling supposed AEOC women. Patients considered pre-operatively eligible were triaged to staging laparoscopy to assess the predictive index (PI) of tumour load. All AEOC women with PI&#x2265;8 or&#x2264;12 (considered as HTL) were included. They were randomly assigned (1:1 ratio) to undergo either PDS followed by systemic adjuvant chemotherapy (arm A, standard), or NACT followed by IDS (NACT/IDS) (arm B, experimental). Co-primary outcome measures were postoperative complications (graded according to the Memorial Sloan Kettering Cancer Center&#xa0;surgical secondary events grading system) and progression free survival (PFS); secondary outcomes were overall survival, and quality of life (QoL). QoL was assessed using the EORTC QoL questionnaires. A sample size of 110 patients was required for the analysis of the first co-primary end-point (major peri-operative morbidity) whereas recruitment is still on-going to achieve the statistical power on PFS.</AbstractText><AbstractText Label="RESULTS">Between October 2011 and November 2014, we registered 280 AEOC. Of the 110 eligible women, 55 were assigned to arm A and 55 to arm B. Despite different extension of surgery, rates of complete residual disease (residual tumour=0&#xa0;cm) were superimposable between the groups (45.5% versus 57.7%; p=0.206). Twenty-nine patients (52.7%) in arm A experienced early grade III-IV complications versus three patients (5.7%) in IDS (p=0.0001). The most common complication was grade III and consisted of symptomatic pleural effusion requiring thoracic drainage (17/55 women (30.9%) in arm A versus 1/52 (1.9%) in arm B, p=0.0001). Three grade IV (5.4%) (i.e., two re-operations for postoperative haemorrhage and one septic multi-organ failure), and two grade V (3.6%) (two deaths for acute cardiopulmonary failure) early complications were observed in arm A only. Mean QoL scores of several scales/items were shown to ameliorate over time in both arms. Emotional functioning, cognitive functioning, nausea/vomiting, dyspnoea, insomnia and hair loss were statistically and clinically better in NACT/IDS compared to PDS arm.</AbstractText><AbstractText Label="CONCLUSIONS">Perioperative moderate/severe morbidity as well as QoL scores were shown to be more favourable in NACT/IDS arm than PDS in AEOC patients with very HTL. Completion of patient enrolment and analysis of survival data will clarify whether PDS with such a high rate of severe complications is an acceptable treatment in AEOC women with HTL.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagotti</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Minimally Invasive Gynecological Surgery, St. Maria Hospital, University of Perugia, Terni, Italy. Electronic address: anna.fagotti@rm.unicatt.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrandina</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizzielli</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanfani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti-Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallotta</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiantera</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Foundation for Research and Care "Giovanni Paolo II", Catholic University of the Sacred Heart and University of Molise, Campobasso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantini</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margariti</LastName><ForeName>Pasquale Alessandro</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gueli Alletti</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortorella</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scambia</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001828" MajorTopicYN="N">Body Image</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077216" MajorTopicYN="N">Carcinoma, Ovarian Epithelial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065426" MajorTopicYN="N">Cytoreduction Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced ovarian cancer</Keyword><Keyword MajorTopicYN="N">Cytoreduction</Keyword><Keyword MajorTopicYN="N">Laparoscopy</Keyword><Keyword MajorTopicYN="N">Peri-operative complications</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Randomised clinical trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26998845</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2016.01.017</ArticleId><ArticleId IdType="pii">S0959-8049(16)00072-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40295228</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>17</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Acute type A aortic dissection patients undergoing surgical repair during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>e42249</StartPage><MedlinePgn>e42249</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e42249</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000042249</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute type A aortic dissection (ATAAD) is a deadly form of acute aortic syndrome which necessitates emergency surgical repair. Coronavirus disease-19 (COVID-19) pandemic has caused a significant impact on surgery globally. The influence of the COVID-19 pandemic on ATAAD patients undergoing surgical repair remains undetermined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review and meta-analysis of studies comparing ATAAD patients undergoing aortic surgery before versus during the COVID-19 pandemic and literature review of published cases reporting COVID-19 patients undergoing surgical repair for ATAAD. PubMed, China National Knowledge Infrastructure, VIP, WANFANG, and SinoMed databases were searched for relevant studies and case reports till January 21st, 2023, and the database search was updated on January 3rd, 2024. Meta-analysis was performed by utilizing RevMan. Pooled odds ratio (OR) and 95% confidence interval (CI) were estimated for dichotomous data, and weighted mean difference (WMD) and 95% CI for continuous data, respectively. All P-values were 2-sided and statistical significance was defined as P&#x2005;&lt;&#x2005;.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Meta-analysis of 5 included studies comparing ATAAD patients undergoing aortic surgery before versus during the COVID-19 pandemic demonstrated that, the patients in Group During-Pandemic (DP) were older than those in Group Before-Pandemic (BP; P&#x2005;=&#x2005;.005), and the body mass index of the patients in Group DP was lower than that of the patients in Group BP (P&#x2005;=&#x2005;.002), more patients in Group DP were smokers (P&#x2005;=&#x2005;.02). Meta-analysis also showed that, either the composite incidence of mortality and morbidities or individual morbidity was comparable between 2 groups, except that more patients in Group DP developed pneumonia (P&#x2005;=&#x2005;.05). Literature reviews of 24 published cases reporting COVID-19 patients undergoing surgical repair for ATAAD demonstrated that, twenty (83.3%) patients recovered well after aortic surgery and were finally discharged from hospital. Unfortunately, 4 patients died postoperatively, 3 due to multiple organ failure and one due to respiratory failure (RF). Reported postoperative complications included hypoxia, endotracheal re-intubation, RF, renal failure, coagulopathy, fever, multi-organ failure and shock.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The hospitalized outcomes of ATAAD patients undergoing surgical repair before versus during the COVID-19 were mostly comparable. ATAAD patients with concomitant COVID-19 infection who underwent emergent surgical repair had a high risk of mortality and morbidities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yun-Tai</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Anesthesia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Chun-Mei</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Fuwai Yunnan Cardiovascular Hospital, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hong-Bai</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Anesthesia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Si-Cong</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taizhou Central Hospital, Jiaojiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Evidence in Cardiovascular Anesthesia (EICA) Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021-I2M-C&amp;T-B-038</GrantID><Agency>the Youth Teacher Training Program of Peking Union Medical College</Agency><Country/></Grant><Grant><GrantID>2024RCTJ-QN002</GrantID><Agency>Talent Trusteeship Program of Fuwai Yunnan Hospital Chinese Academy of Medical Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001014" MajorTopicYN="Y">Aortic Aneurysm</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000784" MajorTopicYN="Y">Aortic Dissection</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">acute type A aortic dissection</Keyword><Keyword MajorTopicYN="N">aortic surgery</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40295228</ArticleId><ArticleId IdType="pmc">PMC12040049</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000042249</ArticleId><ArticleId IdType="pii">00005792-202504250-00001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135038</ArticleId><ArticleId IdType="pubmed">31986257</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MK, Zidar DA, Bristow MR, et al. . COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021;128:1214&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048382</ArticleId><ArticleId IdType="pubmed">33856918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14:247&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Moneim A, Radwan MA, Yousef AI. COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication. Curr Med Res Opin. 2022;38:1071&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35575011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and cardiovascular disease: what we know in 2021. Curr Atheroscler Rep. 2021;23:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117457</ArticleId><ArticleId IdType="pubmed">33983522</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil F, Oleszak F, Stys T, Stys A. COVID-19 and cardiovascular disease: a comprehensive review. S D Med. 2022;75:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">35704865</ArticleId></ArticleIdList></Reference><Reference><Citation>Pina A, Castelletti S. COVID-19 and cardiovascular disease: a global perspective. Curr Cardiol Rep. 2021;23:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8374116</ArticleId><ArticleId IdType="pubmed">34410538</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A, Ahirwar AK, Sakarde A, et al. . COVID-19 and cardiovascular disease: a review of current knowledge. Horm Mol Biol Clin Investig. 2021;42:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">33544511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Song K, Huang Y. Coronavirus disease-2019 (COVID-19) and cardiovascular complications. J Cardiothorac Vasc Anesth. 2021;35:1860&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192093</ArticleId><ArticleId IdType="pubmed">32451271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman S, MacIsaac AI, Jennings GL, et al. . Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. Med J Aust. 2020;213:182&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32734645</ArticleId></ArticleIdList></Reference><Reference><Citation>Salabei JK, Asnake ZT, Ismail ZH, et al. . COVID-19 and the cardiovascular system: an update. Am J Med Sci. 2022;364:139&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8830924</ArticleId><ArticleId IdType="pubmed">35151635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramandi A, Akbarzadeh MA, Khaheshi I, Khalilian MR. Aortic dissection and Covid-19; a comprehensive systematic review. Curr Probl Cardiol. 2023;48:101129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817949</ArticleId><ArticleId IdType="pubmed">35139402</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri V, Recchia GE. Aortic pathology during COVID - 19 pandemics. clinical reports in literature and open questions on the two co-occurring conditions. Ann Vasc Surg. 2021;75:109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018903</ArticleId><ArticleId IdType="pubmed">33823253</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Leslie A, Hewitt JN, et al. . Cardiac surgery on patients with COVID-19: a systematic review and meta-analysis. ANZ J Surg. 2022;92:1007&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111466</ArticleId><ArticleId IdType="pubmed">35373439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Wang Y, Liu J, et al. . Early outcomes of Stanford type A aortic dissection under the coronavirus disease 2019 (COVID-19) pandemic: a multicentre study from Hubei province. Interact Cardiovasc Thorac Surg. 2020;31:834&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665539</ArticleId><ArticleId IdType="pubmed">33150432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R, Xu W, Wang Z, Yu C, Yang Y. Impact of COVID-19 on emergency management of acute type a aortic dissection: a single-center historic control study. Rev Cardiovasc Med. 2022;23:200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11273872</ArticleId><ArticleId IdType="pubmed">39077171</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaoutakis GJ, Wallen TJ, Desai N, et al. . Outcomes of acute type A aortic dissection during the COVID-19 pandemic: an analysis of the Society of Thoracic Surgeons Database. J Card Surg. 2022;37:4545&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">36378930</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugger H, Gollmer J, Pregartner G, et al. . Complications and mortality of cardiovascular emergency admissions during COVID-19 associated restrictive measures. PLoS One. 2020;15:e0239801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7514100</ArticleId><ArticleId IdType="pubmed">32970774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishikawa T, Ohashi T, Tadakoshi M, et al. . Effect of waiting time for COVID-19 screening on postoperative outcomes of type A aortic dissection: an institutional study. Asian Cardiovasc Thorac Ann. 2022;30:912&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9382570</ArticleId><ArticleId IdType="pubmed">35971227</ArticleId></ArticleIdList></Reference><Reference><Citation>Basheer A, Rasool M, Amin H, Saucier S. Acute aortic dissection in the Marfan syndrome during the COVID-19 epidemic. Proc (Bayl Univ Med Cent). 2021;35:88&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8682858</ArticleId><ArticleId IdType="pubmed">34970047</ArticleId></ArticleIdList></Reference><Reference><Citation>Engin M, Aydin U, Eskici H, Ata Y, T&#xfc;rk T. Type 1 acute aortic dissection in the early period after COVID-19 infection. Cureus. 2021;13:e13751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023408</ArticleId><ArticleId IdType="pubmed">33842128</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki MJ, Ansariaval Z, Alizadehasl A. Successful surgery in acute type a dissection in a patient with covid-19. Iran Heart J. 2020;21:135&#x2013;9.</Citation></Reference><Reference><Citation>Fukuhara S, Rosati CM, El-Dalati S. Acute type A aortic dissection during the COVID-19 outbreak. Ann Thorac Surg. 2020;110:e405&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175855</ArticleId><ArticleId IdType="pubmed">32333849</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens T, Vande Weygaerde Y, Vermassen J, Malfait T. Acute type A aortic dissection complicated by COVID-19 infection. Ann Thorac Surg. 2020;110:e421&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211729</ArticleId><ArticleId IdType="pubmed">32437675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori M, Geirsson A, Vallabhajosyula P, Assi R. Surgical management of thoracic aortic emergency with pre- and postoperative COVID-19 disease. J Card Surg. 2020;35:2832&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405051</ArticleId><ArticleId IdType="pubmed">32667075</ArticleId></ArticleIdList></Reference><Reference><Citation>Volvovitch D, Ram E, Cohen H, Kogan A, Sternik L, Raanani E. Acute pulmonary embolism following acute type A aortic dissection in a patient with COVID-19. J Card Surg. 2021;36:1566&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013687</ArticleId><ArticleId IdType="pubmed">33533105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Deng Q, Chi X, et al. . Successful anesthesia management in a patient with type A aortic dissection complicated by renal failure and suspected coronavirus disease. Semin Cardiothorac Vasc Anesth. 2021;25:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">33148132</ArticleId></ArticleIdList></Reference><Reference><Citation>Akgul A, Turkyilmaz S, Turkyilmaz G, Toz H. Acute aortic dissection surgery in a patient with COVID-19. Ann Thorac Surg. 2021;111:e1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298472</ArticleId><ArticleId IdType="pubmed">32562625</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020;31:1683&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460898</ArticleId><ArticleId IdType="pubmed">32371536</ArticleId></ArticleIdList></Reference><Reference><Citation>Firstenberg MS, Libby M, Ochs M, Hanna J, Mangino JE, Forrester J. Isolation protocol for a COVID-2019 patient requiring emergent surgical intervention: case presentation. Patient Saf Surg. 2020;14:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167216</ArticleId><ArticleId IdType="pubmed">32328170</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiampoura A, Perozo C, Varkaris A, et al. . Covid-19 positivity affects outcome of cardiac surgical patients. J Card Surg. 2020;35:3650&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33135241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Marco A, Harky A, Malvindi PG, et al. . Type A aortic syndromes in COVID-19 positive patients: case series from a UK multicentre study. J Card Surg. 2021;36:2692&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242607</ArticleId><ArticleId IdType="pubmed">33982333</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Zhao S, Han L, et al. . Anesthetic management of patients undergoing aortic dissection repair with suspected severe acute respiratory syndrome COVID-19 infection. J Cardiothorac Vasc Anesth. 2020;34:1402&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102517</ArticleId><ArticleId IdType="pubmed">32220557</ArticleId></ArticleIdList></Reference><Reference><Citation>Robu M, Marian DR, Vasile R, et al. . Delayed surgical management of acute type A aortic dissection in a patient with recent COVID-19 infection and post-COVID-19 bronchopneumonia-case report and review of literature. Medicina (Kaunas). 2022;58:1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9609154</ArticleId><ArticleId IdType="pubmed">36295518</ArticleId></ArticleIdList></Reference><Reference><Citation>Taccheri T, Calabrese M, Arlotta G, Corsi F, Cavaliere F. Anesthetic management of patients undergoing aortic dissection repair with suspected severe acute respiratory syndrome coronavirus disease 2019 (COVID-19) infection. J Cardiothorac Vasc Anesth. 2021;35:350&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301817</ArticleId><ArticleId IdType="pubmed">32646629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara S, Tang H, Kim KM, et al. . Type A aortic dissection during COVID-19 pandemic: report from tertiary aortic centers in the United States and China. Semin Thorac Cardiovasc Surg. 2021;33:303&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648657</ArticleId><ArticleId IdType="pubmed">33171243</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMartino RR, Sen I, Huang Y, et al. . Population-based assessment of the incidence of aortic dissection, intramural hematoma, and penetrating ulcer, and its associated mortality from 1995 to 2015. Circ Cardiovasc Qual Outcomes. 2018;11:e004689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6428412</ArticleId><ArticleId IdType="pubmed">30354376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Yao L, Wei T, et al. . Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042844</ArticleId><ArticleId IdType="pubmed">32083643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaghi S, Akbarzadeh MA. Acute type A aortic dissection in a patient with COVID-19. Future Cardiol. 2021;17:625&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505017</ArticleId><ArticleId IdType="pubmed">32945200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamishi S, Navaeian A, Shabanian R. Acute aortic dissection in a patient with Williams syndrome infected by COVID-19. Cardiol Young. 2021;31:132&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550877</ArticleId><ArticleId IdType="pubmed">33040742</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephen E, Al-Adawi SSH, Abdelhady I, Al Mawali H, Al-Wahaibi K. Managing vascular surgery emergencies and referrals during the COVID-19 pandemic at a tertiary centre in Oman. Sultan Qaboos Univ Med J. 2021;21:e116&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7968903</ArticleId><ArticleId IdType="pubmed">33777432</ArticleId></ArticleIdList></Reference><Reference><Citation>Irilouzadian R, Salehi Omran H, Alirezaei T. Fatal association of COVID-19 and acute type A aortic dissection. Clin Case Rep. 2022;10:e05617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939039</ArticleId><ArticleId IdType="pubmed">35356160</ArticleId></ArticleIdList></Reference><Reference><Citation>Idhrees M, Bashir M, Mousavizadeh M, Hosseini S. International study on impact of COVID-19 on cardiac and thoracic aortic aneurysm surgery. J Card Surg. 2021;36:1600&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436505</ArticleId><ArticleId IdType="pubmed">32789915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JR, Segal C, Howitt J, et al. ; Aortic Dissection Collaborative. A mixed method approach to understanding the impact of COVID-19 on patients with or at risk for aortic dissection. Semin Vasc Surg. 2022;35:100&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8864810</ArticleId><ArticleId IdType="pubmed">35501037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CH, Ma WG, Zhong YL, et al. . Management of acute type A aortic dissection during COVID-19 outbreak: experience from Anzhen. J Card Surg. 2021;36:1659&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">32939857</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Huang L, Zhao B, et al. . Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. J Thorac Cardiovasc Surg. 2020;160:585&#x2013;92.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252193</ArticleId><ArticleId IdType="pubmed">32414594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25853746</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>15</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Effects of red-cell storage duration on patients undergoing cardiac surgery.</ArticleTitle><Pagination><StartPage>1419</StartPage><EndPage>1429</EndPage><MedlinePgn>1419-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1414219</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some observational studies have reported that transfusion of red-cell units that have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse events. Patients undergoing cardiac surgery may be especially vulnerable to the adverse effects of transfusion.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized trial at multiple sites from 2010 to 2014. Participants 12 years of age or older who were undergoing complex cardiac surgery and were likely to undergo transfusion of red cells were randomly assigned to receive leukocyte-reduced red cells stored for 10 days or less (shorter-term storage group) or for 21 days or more (longer-term storage group) for all intraoperative and postoperative transfusions. The primary outcome was the change in Multiple Organ Dysfunction Score (MODS; range, 0 to 24, with higher scores indicating more severe organ dysfunction) from the preoperative score to the highest composite score through day 7 or the time of death or discharge.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median storage time of red-cell units provided to the 1098 participants who received red-cell transfusion was 7 days in the shorter-term storage group and 28 days in the longer-term storage group. The mean change in MODS was an increase of 8.5 and 8.7 points, respectively (95% confidence interval for the difference, -0.6 to 0.3; P=0.44). The 7-day mortality was 2.8% in the shorter-term storage group and 2.0% in the longer-term storage group (P=0.43); 28-day mortality was 4.4% and 5.3%, respectively (P=0.57). Adverse events did not differ significantly between groups except that hyperbilirubinemia was more common in the longer-term storage group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The duration of red-cell storage was not associated with significant differences in the change in MODS. We did not find that the transfusion of red cells stored for 10 days or less was superior to the transfusion of red cells stored for 21 days or more among patients 12 years of age or older who were undergoing complex cardiac surgery. (Funded by the National Heart, Lung, and Blood Institute; RECESS ClinicalTrials.gov number, NCT00991341.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From Fairview-University Medical Center, Minneapolis (M.E.S., S.P., J.M.), and Mayo Clinic, Rochester (G.A.N.) - both in Minnesota; Johns Hopkins University (P.M.N., G.W.) and University of Maryland (R.C.) - both in Baltimore; New England Research Institutes, Data Coordinating Center, Watertown (S.F.A., S.G.), Boston Children's Hospital (S.R.S.), Massachusetts General Hospital (L.B., C.P.S.), Brigham and Women's Hospital (R.M.K.), Tufts University (R.E.), St. Elizabeth's Medical Center (R.H.), and Beth Israel Deaconess Medical Center (L.U.), Boston, and Baystate Medical Center, Springfield (R.E.) - all in Massachusetts; University of Pittsburgh and University of Pittsburgh-Mercy Hospital, Pittsburgh (D.J.T., P.D.); Puget Sound Blood Center and University of Washington (M.D.) and Swedish Medical Center (S.Y.) - all in Seattle; Duke University, Durham (E.B.-G., J.H.L., T.L.O.), and University of North Carolina, Chapel Hill (Y.P.) - both in North Carolina; McMaster University, Hamilton, ON, Canada (M.A.B.); Indiana-Ohio Heart and St. Joseph Hospital (V.S.) - both in Fort Wayne, IN; Rutgers Robert Wood Johnson Medical School, New Brunswick (J.L.C.), and Newark Beth Israel Medical Center, Newark (R.K.) - both in New Jersey; University of Iowa, Iowa City (T.R.); Aurora St. Luke's Medical Center (K.E.P.) and Froedert Memorial Lutheran Hospital (J.G.M.), Milwaukee, and Aspirus Heart and Vascular Institute, Wausau (R.M.) - all in Wisconsin; Vanderbilt University, Nashville (P.P.Y.); University of Texas Southwestern Medical Center, Dallas (P.E.G.); Children's Healthcare of Atlanta, Emory University, and Emory University Hospital, Atlanta (C.D.J.); St. Luke's-Texas Heart Institute, Houston (A.B.); Weill Cornell Medical College (M.M.C.) and Columbia University Medical Center (E.A.H.) - both in New York; University of Florida, Gainesville (C.T.K.); University of Oklahoma, Oklahoma City (P.R.R.); and University of North Dakota School of Medicine and Health Sciences, Fargo (C.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ness</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Assmann</LastName><ForeName>Susan F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Triulzi</LastName><ForeName>Darrell J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Delaney</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett-Guerrero</LastName><ForeName>Elliott</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Blajchman</LastName><ForeName>Morris A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Scavo</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Jerrold H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Whitman</LastName><ForeName>Glenn</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pulkrabek</LastName><ForeName>Shelley</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ortel</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Bornikova</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Raife</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Puca</LastName><ForeName>Kathleen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Nuttall</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Pampee P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Youssef</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Engelman</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Greilich</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Bracey</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>Rhonda</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hunsaker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Uhl</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McFarland</LastName><ForeName>Janice G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yara</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cushing</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Klodell</LastName><ForeName>Charles T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Karanam</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Pamela R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Dyke</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hod</LastName><ForeName>Eldad A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Stowell</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00991341</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL101382</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072331</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025758</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):283-4. doi: 10.1056/NEJMc1505699.</RefSource><PMID Version="1">26176390</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):283. doi: 10.1056/NEJMc1505699.</RefSource><PMID Version="1">26176391</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001788" MajorTopicYN="N">Blood Grouping and Crossmatching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="Y">Blood Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25853746</ArticleId><ArticleId IdType="mid">NIHMS696944</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hess JR. An update on solutions for red cell storage. Vox Sang. 2006;91:13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess JR. Red cell changes during storage. Transfus Apher Sci. 2010;43:51&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A. 2007;104:17063&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040393</ArticleId><ArticleId IdType="pubmed">17940021</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani A, Steiner ME, Hebbel RP. The dynamic regulation of microcirculatory conduit function: features relevant to transfusion medicine. Transfus Apher Sci. 2010;43:61&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920132</ArticleId><ArticleId IdType="pubmed">20580315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. oxygen delivery in transfusion with &#x201c;fresh&#x201d; and &#x201c;old&#x201d; red blood cells: the experimental evidence. Transfus Apher Sci. 2010;43:69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918661</ArticleId><ArticleId IdType="pubmed">20646963</ArticleId></ArticleIdList></Reference><Reference><Citation>Triulzi DJ, Yazer MH. Clinical studies of the effect of blood storage on patient outcomes. Transfus Apher Sci. 2010;43:95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang. 2009;96:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19152602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009;49:1384&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of &#x201c;old&#x201d; (versus &#x201c;fresh&#x201d;) red blood cells: are we at equipoise? Transfusion. 2010;50:600&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Watering L. Red cell storage and prognosis. Vox Sang. 2011;100:36&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21175654</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Chin-Yee I, Fergusson D, et al. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg. 2005;100:1433&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Stafford-Smith M, Waweru PM, et al. A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion. 2009;49:1375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson DA, H&#xe9;bert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308:1443&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi MM, Yii M, Matata BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22:455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503942</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch CGH, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A. Effects of storage time of red cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46:1712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CH, Lau L, Krishnaswamy M, Gaskell M, Yii M. Age of transfused red cells and early outcomes after cardiac surgery. Ann Thorac Surg. 2008;86:554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640333</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgren G, Kamper-J&#xf8;rgensen M, Eloranta S, et al. Duration of red blood cell storage and survival of transfused patients. Transfusion. 2010;50:1185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3201703</ArticleId><ArticleId IdType="pubmed">20158690</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7) Transfus Apher Sci. 2010;43:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918709</ArticleId><ArticleId IdType="pubmed">20655807</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46:1120&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16836558</ArticleId></ArticleIdList></Reference><Reference><Citation>Roback JD, Grossman BJ, Harris T, Hillyer CD, editors. Technical manual. 17th. Bethesda, MD: AABB Press; 2011. p. 192.</Citation></Reference><Reference><Citation>Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">4612056</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood. 2011;118:6675&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242722</ArticleId><ArticleId IdType="pubmed">22021369</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker BI, Hinkins S.  The 2011 National blood collection and utilization survey report. Washington, DC: Department of Health and Human Services; 2013.   http://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/11-nbcus-report.pdf.</Citation></Reference><Reference><Citation>Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16607235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert P, Fergusson D, et al. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev. 2011;25:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21505984</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1672-0733</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban</Title><ISOAbbreviation>J Huazhong Univ Sci Technolog Med Sci</ISOAbbreviation></Journal><ArticleTitle>Clinical effects of intensive insulin therapy treating traumatic shock combined with multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>194</StartPage><EndPage>198</EndPage><MedlinePgn>194-198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11596-011-0251-4</ELocationID><Abstract><AbstractText>The therapeutic effects of intensive insulin therapy in treatment of traumatic shock combined with multiple organ dysfunction syndrome (MODS) were investigated. A total of 114 patients with traumatic shock combined with MODS were randomly divided into two groups: control group (n=56) treated with conventional therapy, and intensive insulin therapy group (n=58) treated with conventional therapy plus continuous insulin pumping to control the blood glucose level at range of 4.4-6.1 mmol/L. White blood cells (WBC) counts, prothrombin time (PT), serum creatinine (SCr), alanine aminotransferase (ALT), serum albumin and PaO(2) were measured before and at the day 1, 3, 5, 7 and 14 after treatment. The incidence of gastrointestinal dysfunction, the incidence of MODS, hospital stay and the mortality were also observed and compared. After intensive insulin therapy, the WBC counts, SCr, ALT and PT were significantly reduced (P&lt;0.05), but the level of serum albumin was significantly increased (P&lt;0.05) at the day 3, 5, 7 and 14. In the meantime, the PaO2 was significantly elevated at the day 3, 5 and 7 (P&lt;0.01) after intensive insulin therapy. The incidence of gastrointestinal dysfunction, the incidence of MODS, the length of hospital stay and the mortality were markedly decreased (P&lt;0.01). The results suggest early treatment with intensive insulin therapy is effective for traumatic shock combined with MODS and can decrease the length of hospital stay and the mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Jundong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongming</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, 400042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China. liurong301@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yongming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Huabo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Huinan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhanliang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Huazhong Univ Sci Technolog Med Sci</MedlineTA><NlmUniqueID>101169627</NlmUniqueID><ISSNLinking>1672-0733</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012774" MajorTopicYN="N">Shock, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21505984</ArticleId><ArticleId IdType="doi">10.1007/s11596-011-0251-4</ArticleId><ArticleId IdType="pii">10.1007/s11596-011-0251-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crit Care Med. 1995 Oct;23(10):1638-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Dec;15(12):739-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14659059</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Nov 8;345(19):1359-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11794168</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 2000 Feb;127(2):117-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10686974</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Clin. 2001 Jan;17(1):107-24</Citation><ArticleIdList><ArticleId IdType="pubmed">11219223</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2002 Oct;6(5):389-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12398773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 1995 Jul;4(1):39-40</Citation><ArticleIdList><ArticleId IdType="pubmed">7552775</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2004 Oct;32(10):2029-38</Citation><ArticleIdList><ArticleId IdType="pubmed">15483411</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Surg. 1997 Jul;84(7):920-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9240130</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 1998 Jan;175(1):76-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9445247</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 1985 Oct;120(10):1109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2002 Oct 15;106(16):2067-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12379575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrition. 2001 May;17(5):409-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11377135</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1999 May;88(5):1011-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10320160</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2007 Oct 14;13(38):5043-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17876868</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2004 Jan;89(1):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">14715853</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab. 2001 Apr;27(2 Pt 2):233-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11452216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 1985 Jun;74(6):1255-60</Citation><ArticleIdList><ArticleId IdType="pubmed">3889459</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2008;12(1):R29</Citation><ArticleIdList><ArticleId IdType="pubmed">18312617</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2010 Jul;24(7):2583-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20203087</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2000 Mar;66(3):284-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10759201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31629616</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1409</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>Early hypoalbuminemia is associated with 28-day mortality in severely burned patients: A retrospective cohort study.</ArticleTitle><Pagination><StartPage>630</StartPage><EndPage>638</EndPage><MedlinePgn>630-638</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.burns.2019.09.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0305-4179(19)30495-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Hypoalbuminemia is a frequent condition in the first 24&#x2009;h after a severe burn injury and is associated with worse outcomes.</AbstractText><AbstractText Label="METHODOLOGY">We investigated the relation between very early hypoalbuminemia (&lt;6&#x2009;h after admission) and clinical outcome in a retrospective cohort admitted to our unit for severe burn injuries between 2012 and 2017.</AbstractText><AbstractText Label="RESULTS">73 severely burned patients were included, with a delay of admission of 3 (2-4)&#x2009;h. In a context of early exogenous supply of albumin, admission and 4H Albuminemia (Alb4&#x2009;h) were significantly lower in deceased patients (respectively, 34 (29-37) vs 27 (23-30) g/l; p&#x2009;=&#x2009;0.009 and 27 (24-32) vs 21 (17-27) g/l; p&#x2009;=&#x2009;0.022) whereas albuminemia &#x2265;6&#x2009;h were not. The best threshold value of Alb4&#x2009;h to discriminate 28-day mortality was 23&#x2009;g/l. Patients with an Alb4&#x2009;h&#x2009;&lt;&#x2009;23&#x2009;g/l had a higher 28-day mortality than patients with an Alb4&#x2009;h&#x2009;&#x2265;&#x2009;23&#x2009;g/l (42% vs 11%; p&#x2009;=&#x2009;0.003); adjusted OR&#x2009;=&#x2009;4.47 (95% CI 1.15-17.36); p&#x2009;=&#x2009;0.03.</AbstractText><AbstractText Label="CONCLUSION">In severely burned patients receiving early albumin supply, early hypoalbuminemia is associated with higher mortality whereas later albuminemia (&#x2265;6&#x2009;h) is not. Exploration of whether early albumin infusion (8-12&#x2009;h post injury) may alter clinical outcome is warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd and ISBI. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Tymowski</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation CRI, Paris, France; Laboratoire d'Excellence (Labex) Inflammex, ComUE Sorbonne Paris Cit&#xe9;, Paris, France. Electronic address: chrisdetymowski@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallado</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France. Electronic address: simon.pallado@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anstey</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Royal Melbourne Hospital, Parkville, Melbourne, Australia. Electronic address: James.Anstey@mh.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depret</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: depret.francois@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Nabilla</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Biochemistry laboratory, Paris, France. Electronic address: nabillanabila.moreno@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benyamina</LastName><ForeName>Mourad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France. Electronic address: mourad.benyamina@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupaciu</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jully</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oueslati</LastName><ForeName>Haikel</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratani</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coutrot</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaussard</LastName><ForeName>Mait&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemet</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudoignon</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mimoun</LastName><ForeName>Maurice</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisi&#xe8;re, Plastic Surgery and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaouat</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisi&#xe8;re, Plastic Surgery and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: alexandre.mebazaa@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legrand</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: matthieu.m.legrand@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soussi</LastName><ForeName>Sabri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: sabri.soussi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PRONOBURN group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077324">Crystalloid Solutions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002053" MajorTopicYN="N">Burn Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077324" MajorTopicYN="N">Crystalloid Solutions</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034141" MajorTopicYN="N">Hypoalbuminemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albuminemia</Keyword><Keyword MajorTopicYN="N">Burn injury</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31629616</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2019.09.013</ArticleId><ArticleId IdType="pii">S0305-4179(19)30495-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28586262</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-9034</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of laparoendoscopic &amp; advanced surgical techniques. Part A</Title><ISOAbbreviation>J Laparoendosc Adv Surg Tech A</ISOAbbreviation></Journal><ArticleTitle>Effect of Laparoscopic Peritoneal Lavage and Drainage and Continuous Venovenous Diahemofiltration on Severe Acute Pancreatitis.</ArticleTitle><Pagination><StartPage>1145</StartPage><EndPage>1150</EndPage><MedlinePgn>1145-1150</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/lap.2016.0637</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute pancreatitis (SAP), one severe and fatal disease, the therapy of which is pretty hard. This study aimed to study the effect of laparoscopic peritoneal lavage and drainage (LPLD) and continuous venovenous diahemofiltration (CVVDH) on SAP.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Two hundred forty-five patients with SAP in total were randomly assigned into four groups according to the therapeutic plan: basic treatment; LPLD; CVVDH; or LPLD+CVVDH. Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, the ratios of multiple organ dysfunction syndrome (MODS), mortality, hospitalization time, hospitalization cost, ratios of complications, the abdominal distention relief time, abdominal pain relief time, plasma concentration of endotoxin, tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), interleukin (IL)-6, and IL-8 were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ratios of MODS, mortality, hospitalization time, hospitalization cost, the abdominal distention relief time, abdominal pain relief time, concentration of endotoxin, TNF-&#x3b1;, IL-6, IL-8, and APACHE II scores were significantly decreased in the CVVDH, LPLD, and CVVDH+LPLD groups, while ratios of recovery were significantly increased in the CVVDH, LPLD, and CVVDH+LPLD groups, especially in the CVVDH+LPLD group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LPLD and CVVDH are effective in the treatment of SAP by eliminating endotoxin, TNF-&#x3b1;, IL-6, and IL-8. The combination of CVVDH and LPLD can further improve the treatment effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guiliang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>2 Department of Scientific Research, Gannan Medical University , Gan Zhou, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Linfang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Jianbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shu-Feng</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>3 Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida , Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Xianzhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>4 Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University , Changsha, People's Republic of China .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Laparoendosc Adv Surg Tech A</MedlineTA><NlmUniqueID>9706293</NlmUniqueID><ISSNLinking>1092-6429</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010533" MajorTopicYN="N">Peritoneal Lavage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">continuous venovenous diahemofiltration</Keyword><Keyword MajorTopicYN="N">drainage</Keyword><Keyword MajorTopicYN="N">laparoscopic debridement</Keyword><Keyword MajorTopicYN="N">severe acute pancreatitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28586262</ArticleId><ArticleId IdType="doi">10.1089/lap.2016.0637</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26380001</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1940-5901</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>International journal of clinical and experimental medicine</Title><ISOAbbreviation>Int J Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy of limited fluid resuscitation in patients with hemorrhagic shock: a meta-analysis.</ArticleTitle><Pagination><StartPage>11645</StartPage><EndPage>11656</EndPage><MedlinePgn>11645-56</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">The objective of this meta-analysis was to evaluate the efficacy of limited fluid resuscitation during active hemorrhage compared with regular fluid resuscitation and provide strong evidences for the improvement of fluid resuscitation strategies in uncontrolled hemorrhagic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Electronic searches were performed using PubMed, Medline, Embase and CNKI in accordance with pre-set guidelines. Clinical trials and observation studies were included or excluded according to the criteria. The endpoints examined were mortality, hemoglobin (Hb), platelets (PLT), hematocrit (Hct), prothrombin Time (PT), activated partial thromboplastin time (APTT), base excess (BE), blood lactic acid (BLA) and the main complications, such as multiple organ dysfunction syndrome (MODS) and acute Respiratory Distress Syndrome (ARDS). Risk ratios (RR), mean differences (MDs) and 95% confidence intervals (95% Cl) were calculated using fixed/random effect model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search indentified 11 studies including 1482 subjects. 725 hemorrhagic patients were treated with limited fluid resuscitation while 757 patients undertook regular fluid resuscitation during active hemorrhage. Limited fluid resuscitation had its advantage to reduce the mortality in hemorrhagic shock (RR = 0.67; 95% CI = 0.56-0.81; P &lt; 0.0001) and easily controlled the blood routine index close to normal compared with regular fluid resuscitation (Hb: MD = 13.04; 95% CI = 2.69-23.38; P = 0.01. PLT: MD = 23.16; 95% CI = 6.41-39.91; P = 0.007. Hct: MD = 0.02; 95% CI = 0.02-0.03; P &lt; 0.00001). LFR also had shorter PT and APTT compared with RFR (PT: MD = -2.81; 95% CI = -3.44--2.17; P &lt; 0.00001 and APTT: MD = -5.14; 95% CI = -6.16--4.12; P &lt; 0.00001). As for blood gas analysis, LFR reduced the decrease of BE (MD = 2.48; 95% CI = 1.11-3.85; P = 0.0004) and increase of BLA (MD = -0.65; 95% CI = -0.85--0.44; P &lt; 0.00001). Besides, LFR may also reduce the occurrence of postoperative complications (MODS: RR= 0.37; 95% CI = 0.21-0.66; P = 0.0008. ARDS: RR = 0.35; 95% CI = 0.21-0.60; P &lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results provide convincing evidence that support the continued investigation and use of limited fluid resuscitation during active hemorrhage in the trauma setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Chenyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research Institute of Surgery, State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, Third Military Medical University Chongqing 400042, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Research Institute of Surgery, State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, Third Military Medical University Chongqing 400042, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Liangming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Research Institute of Surgery, State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, Third Military Medical University Chongqing 400042, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Clin Exp Med</MedlineTA><NlmUniqueID>101471010</NlmUniqueID><ISSNLinking>1940-5901</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Limited fluid resuscitation</Keyword><Keyword MajorTopicYN="N">hemorrhagic shock</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">trauma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26380001</ArticleId><ArticleId IdType="pmc">PMC4565384</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stern SA, Dronen SC, Birrer P, Wang X. Effect of blood pressure on hemorrhage volume and survival in a near-fatal hemorrhage model incorporating a vascular injury. Ann Emerg Med. 1993;22:155&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8427424</ArticleId></ArticleIdList></Reference><Reference><Citation>White NJ, Wang X, Liles C, Stern S. Fibrinogen concentrate improves survival during limited resuscitation of uncontrolled hemorrhagic shock in a Swine model. Shock. 2014;42:456&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206836</ArticleId><ArticleId IdType="pubmed">25337778</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184958</ArticleId></ArticleIdList></Reference><Reference><Citation>Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">15163774</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care. 2012;16:R94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580640</ArticleId><ArticleId IdType="pubmed">22624531</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ. 2013;346:f839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573769</ArticleId><ArticleId IdType="pubmed">23418281</ArticleId></ArticleIdList></Reference><Reference><Citation>Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367:1901&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23075127</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J. Hydroxyethyl starch 130/0.42 versus Ringer&#x2019;s acetate in severe sepsis. N Engl J Med. 2012;367:124&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">22738085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo R, Prowle JR, Echeverri JE, Ligabo V, Ronco C. Fluid management in septic acute kidney injury and cardiorenal syndromes. Contrib Nephrol. 2010;165:206&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">20427971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunn F, Trivedi D. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2012;7:CD001319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028006</ArticleId><ArticleId IdType="pubmed">22786474</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med. 2011;39:386&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">21248514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg. 2012;114:159&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">22184610</ArticleId></ArticleIdList></Reference><Reference><Citation>Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;2:CD000567.</Citation><ArticleIdList><ArticleId IdType="pubmed">23450531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA. 2013;309:678&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">23423413</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng ZS, Fan YN, Yin W. Meta-analysis of the efficacy of limited fluid resuscitation in traumatic hemorrhagic shock. J Trauma Surg. 2014;16:4.</Citation></Reference><Reference><Citation>Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma. 2002;52:1141&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12045644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickell WH, Wall MJ, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994;331:1105&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7935634</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison CA, Carrick MM, Norman MA, Scott BG, Welsh FJ, Tsai P, Liscum KR, Wall MJ, Mattox KL. Hypotensive resuscitation strategy reduces transfusion requirements and severe postoperative coagulopathy in trauma patients with hemorrhagic shock: preliminary results of a randomized controlled trial. J Trauma. 2011;70:652&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">21610356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivatury RR, Simon RJ, Havriliak D, Garcia C, Greenbarg J, Stahl WM. Gastric mucosal pH and oxygen delivery and oxygen consumption indices in the assessment of adequacy of resuscitation after trauma: a prospective, randomized study. J Trauma. 1995;39:128&#x2013;34. discussion 134-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7636904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570315</ArticleId><ArticleId IdType="pubmed">23043545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707819</ArticleId><ArticleId IdType="pubmed">23826681</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinman M, Cotton BA, Haut ER. Optimal fluid resuscitation in trauma: type, timing, and total. Curr Opin Crit Care. 2014;20:366&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979715</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrois A, Hamada SR, Duranteau J. Fluid resuscitation and vasopressors in severe trauma patients. Curr Opin Crit Care. 2014;20:632&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25340381</ArticleId></ArticleIdList></Reference><Reference><Citation>Maybauer MO, Asmussen S, Platts DG, Fraser JF, Sanfilippo F, Maybauer DM. Transesophageal echocardiography in the management of burn patients. Burns. 2014;40:630&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24035579</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan HP, Wu YJ, Yuan ZH. Clinical application of limited fluid resuscitation in treatment before operation of hepatic and splenic injury and haemorrhagic shock. Clin H Med Offic. 2012;40:3.</Citation></Reference><Reference><Citation>Li GH, Pu JY. The clinical observation of limited fluid resuscitation to traumatic hemorrhagic shock. China Medical Engineerin. 2014;22:1.</Citation></Reference><Reference><Citation>Liu YY, Zhou XP. The application and effect evaluation of limited fluid resuscitation in hemorrhagic shock. China Foreign Medical Treatment. 2012;31:2.</Citation></Reference><Reference><Citation>Wu PW. The effect of limited fluid resuscitation in obstetrics hemorrhagic shock. Chin Matern Child Health Care. 2012;27:2.</Citation></Reference><Reference><Citation>Yu YH, Huang LP, Song TR, Gong SP. The application of limited fluid resuscitation in obstetrics hemorrhagic shock. Chinese Journal of practical Gynecology and Obstetrics. 2009;25:3.</Citation></Reference><Reference><Citation>Fan HP, Yue MX, Wu YJ, Zheng QH. Early therapeutic effects of limited fluid resuscitation on severe pelvic fracture combined with hemorrhagic shock. J Trauma Surg. 2011;13:3.</Citation></Reference><Reference><Citation>He HL, Huang M, Luo HS. Clinical application of limited fluid resuscitation for hemorrhagic shock caused by acute upper gastrointestinal hemorrhage. Journal of Internal Intensive Medicine. 2012;18:2.</Citation></Reference><Reference><Citation>Li WH, Lin HF, Deng XB. clinical discussion of limited fluid resuscitation on hemorrhagic traumatic shock without controlling bleeding. Journal of Clinical Medical Engineering. 2012;19:2.</Citation></Reference><Reference><Citation>Lu B, Li MQ, Li JQ. The Use of Limited Fluid Resuscitation and Blood Pressure-Controlling Drugs in the Treatment of Acute Upper Gastrointestinal Hemorrhage Concomitant with Hemorrhagic Shock. Cell Biochem Biophys. 2015 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">25567656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KD, Gong BC, Chen GA, Ma WB. Clinical research of early restriction resuscitation treatment of hemorrhagic shock at Xining. Journal of Qinghai Medical College. 2006;27:4.</Citation></Reference><Reference><Citation>Tang T, Li WP. The curative effect analysis of limited fluid resuscitation to esophageal variceal bleeding combined with hemorrhagic shock. Modern Practical Medicine. 2013;25:3.</Citation></Reference><Reference><Citation>Wei SK, He Y, Huang YQ, Jiang YF, Liu M, Li Y, Bai SL, Li FJ. Clinical Analysis of 56 hemorrhagic patients with limited fluid resuscitation. Journal of Youjiang National Medical College. 2008;1:2.</Citation></Reference><Reference><Citation>Zheng WH, Wang XL, Xu H, Zhao SB. Effects of limited fluid resuscitation in treatment of hemorrhagic traumatic shock. China Journal of Emergency Resuscitation and Disaster Medicine. 2007;2:3.</Citation></Reference><Reference><Citation>Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR. Management of bleeding following major trauma: an updated European guideline. Crit Care. 2013;14:R52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887168</ArticleId><ArticleId IdType="pubmed">20370902</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Zhu Y, Tian K, Xue M, Peng X, Lan D, Liu L. Ideal resuscitation pressure for uncontrolled hemorrhagic shock in different ages and sexes of rats. Crit Care. 2013;17:R194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264615</ArticleId><ArticleId IdType="pubmed">24020401</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Zhu Y, Hu Y, Li L, Diao Y, Tang J, Liu L. Ideal permissive hypotension to resuscitate uncontrolled hemorrhagic shock and the tolerance time in rats. Anesthesiology. 2011;114:111&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21169800</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph LC, Takacs M, Davis KA. Resuscitation in the pediatric trauma population: admission base deficit remains an important prognostic indicator. J Trauma. 2002;53:838&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435932</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HB, Rivers EP, Havstad S, Knoblich B, Ressler JA, Muzzin AM, Tomlanovich MC. Critical care in the emergency department: A physiologic assessment and outcome evaluation. Acad Emerg Med. 2000;7:1354&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11099425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhian B, Kropfl A, Holzenbein T, Khadem A, Redl H, Bahrami S. Increased circulating D-lactate levels predict risk of mortality after hemorrhage and surgical trauma in baboons. Shock. 2012;37:473&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22266971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YQ, Cai XJ, Gu LH, Wang Q, Huang WD, Bao DG. Experimental study of controlled fluid resuscitation in the treatment of severe and uncontrolled hemorrhagic shock. J Trauma. 2007;63:798&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090008</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Lin X, Zhu Y, Li L, Liu L. Short-term, mild hypothermia can increase the beneficial effect of permissive hypotension on uncontrolled hemorrhagic shock in rats. Anesthesiology. 2012;116:1288&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">22546964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36498672</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>23</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Risk Factors of Sudden Cardiac Arrest during the Postoperative Period in Patient Undergoing Heart Valve Surgery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7098</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm11237098</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sudden cardiac arrest (SCA) is the sudden cessation of normal cardiac activity with hemodynamic collapse. This usually leads to sudden cardiac death (SCD) when cardiopulmonary resuscitation is not undertaken. In patients undergoing heart valve surgery, postoperative SCA is a complication with a high risk of death, cerebral hypoxia and multiple organ dysfunction syndrome (MODS). Therefore, knowledge of the predictors of postoperative SCA is extremely important as it enables the identification of patients at risk of this complication and the application of the special surveillance and therapeutic management in this group of patients. The aim of the study was to evaluate the usefulness of selected biomarkers in predicting postoperative SCA in patients undergoing heart valve surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study was conducted on a group of 616 consecutive patients with significant valvular heart disease that underwent elective valve surgery with or without coronary artery bypass surgery. The primary end-point at the intra-hospital follow-up was postoperative SCA. The secondary end-point was death from all causes in patients with postoperative SCA. Patients were observed until discharge from the hospital or until death. Logistic regression was used to assess the relationships between variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The postoperative SCA occurred in 14 patients. At multivariate analysis, only NT-proBNP (odds ratio (OR) 1.022, 95% confidence interval (CI) 1.012-1.044; <i>p</i> = 0.03) remained independent predictors of the primary end-point. Age and NT-proBNP were associated with an increased risk of death in patients with postoperative SCA.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of the presented study indicate that SCA in the early postoperative period in patients undergoing heart valve surgery is an unpredictable event with high mortality. The potential predictive ability of the preoperative NT-proBNP level for the occurrence of postoperative SCA and death in patients after SCA demonstrated in the study may indicate that the overloaded and damaged myocardium in patients undergoing heart valve surgery is particularly sensitive to non-physiological conditions prevailing in the perioperative period, which may cause serious hemodynamic disturbances in the postoperative period and lead to death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duchnowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6506-5612</Identifier><AffiliationInfo><Affiliation>Cardinal Wyszynski National Institute of Cardiology, Alpejska 42, 04-628 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">N-terminal of the prohormone brain natriuretic peptide predicts postoperative (NT-proBNP)</Keyword><Keyword MajorTopicYN="N">sudden cardiac arrest</Keyword><Keyword MajorTopicYN="N">valve surgery</Keyword></KeywordList><CoiStatement>The author declares no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36498672</ArticleId><ArticleId IdType="pmc">PMC9737591</ArticleId><ArticleId IdType="doi">10.3390/jcm11237098</ArticleId><ArticleId IdType="pii">jcm11237098</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zeppenfeld K., Tfelt-Hansen J., de Riva M., Gregers Winkel B., Behr E.R., Blom N.A., Charron P., Corrado D., Dagres N., de Chilou C., et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) Eur. Heart J. 2022;43:3997&#x2013;4126.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Priori S., Blomstr&#xf6;m-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., Elliot P.M., Fitzsimons D., Hatala R., Hindricks G., et al. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) Eur. Heart J. 2015;36:2793&#x2013;2867. doi: 10.1093/eurheartj/ehv316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv316</ArticleId><ArticleId IdType="pubmed">26320108</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Hryniewiecki T., Ku&#x15b;mierczyk M., Szyma&#x144;ski P. Postoperative high-sensitivity troponin T as a predictor of sudden cardiac arrest in patients undergoing cardiac surgery. Cardiol. J. 2019;26:777&#x2013;781. doi: 10.5603/CJ.a2019.0005.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2019.0005</ArticleId><ArticleId IdType="pmc">PMC8083033</ArticleId><ArticleId IdType="pubmed">30701514</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckart R.E., Shry E.A., Burke A.P., McNear J.A., Appel D.A., Castillo-Rojas L.M., Avedissian L., Pearse L.A., Potter R.N., Tremaine L., et al. Sudden death in young adults: An autopsy-based series of a population undergoing active surveillance. J. Am. Coll. Cardiol. 2011;58:1254&#x2013;1261. doi: 10.1016/j.jacc.2011.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.01.049</ArticleId><ArticleId IdType="pubmed">21903060</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Camp S.P., Bloor C.M., Mueller F.O., Cantu R.C., Olson H.G. Nontraumatic sports death in high school and college athletes. Med. Sci. Sport. Exerc. 1995;27:641&#x2013;647. doi: 10.1249/00005768-199505000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/00005768-199505000-00005</ArticleId><ArticleId IdType="pubmed">7674867</ArticleId></ArticleIdList></Reference><Reference><Citation>Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85:2&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">1728501</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott P.A., Barry J., Roberts P.R., Morgan J.M. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: A meta-analysis. Eur. J. Heart Fail. 2009;11:958&#x2013;966. doi: 10.1093/eurjhf/hfp123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfp123</ArticleId><ArticleId IdType="pubmed">19789399</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine Y.C., Rosenberg M.A., Mittleman M., Samuel M., Methachittiphan N., Link M., Josephon M.E., Buxton A.E. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm. 2014;11:1109&#x2013;1116. doi: 10.1016/j.hrthm.2014.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2014.04.024</ArticleId><ArticleId IdType="pubmed">24837348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipes D.P., Wellens H.J. Sudden cardiac death. Circulation. 1998;98:2334&#x2013;2351. doi: 10.1161/01.CIR.98.21.2334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.98.21.2334</ArticleId><ArticleId IdType="pubmed">9826323</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory Y., Turetz Y., Hiss Y., Lev B., Fisman E.Z., Pines A., Kramer M.R. Sudden unexpected death in persons less than 40 years of age. Am. J. Cardiol. 1991;68:1388&#x2013;1392. doi: 10.1016/0002-9149(91)90251-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(91)90251-F</ArticleId><ArticleId IdType="pubmed">1951130</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel A., Mueller C., Adams K., Jr., Anker S.D., Aspromonte N., Cleland J.G.F., Cohen-Solal A., Dahlstrom U., DeMaria A., Di Somma S., et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 2008;10:824&#x2013;839. doi: 10.1016/j.ejheart.2008.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2008.07.014</ArticleId><ArticleId IdType="pubmed">18760965</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvajal-Zarrabal O., Hayward-Jones P.M., Nolasco-Hipolito C., Barradas-Dermitz D.M., Calder&#xf3;n-Garcidue&#xf1;as A.L., L&#xf3;pez-Amador N. Use of cardiac injury markers in the postmortem diagnosis of sudden cardiac death. J. Forensic Sci. 2017;62:1332&#x2013;1335. doi: 10.1111/1556-4029.13397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1556-4029.13397</ArticleId><ArticleId IdType="pubmed">28111741</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi R., Dahili N.D., Anuar Zainun K., Mohd Kasim N.A., Md Noor S. Post mortem troponin T analysis in sudden death: Is it useful? Malays. J. Pathol. 2018;40:143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">30173231</ArticleId></ArticleIdList></Reference><Reference><Citation>Urena M., Webb J.G., Eltchaninoff H., Mu&#xf1;oz-Garc&#xed;a A.J., Bouleti C., Tamburino C., Nombela-Franco L., Nietlispach F., Moris C., Ruel M., et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: Incidence and predictors of advanced heart failure and sudden cardiac death. J. Am. Coll. Cardiol. 2015;65:437&#x2013;448. doi: 10.1016/j.jacc.2014.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.11.027</ArticleId><ArticleId IdType="pubmed">25660921</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho R.W., Bridges C.R., Kocovic D. Management of postoperative arrhythmias. Semin. Thorac. Cardiovasc. Surg. 2000;12:349&#x2013;361. doi: 10.1053/stcs.2000.21117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/stcs.2000.21117</ArticleId><ArticleId IdType="pubmed">11154730</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottipatty V., Kocovic D., Kinchla N., Couper G., Friedman P.L. Timing and impact of survival of in-hospital cardiac arrest after coronary artery bypass graft surgery (abstr) Circulation. 1993;88:1&#x2013;166.</Citation></Reference><Reference><Citation>Topol E.J., Lerman B.B., Baughman K.L., Platia E.V., Griffith L.S. De novo refrectory ventricular tachyarrhythmias after coronary revascularization. Am. J. CardioI. 1986;57:57&#x2013;59. doi: 10.1016/0002-9149(86)90951-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(86)90951-3</ArticleId><ArticleId IdType="pubmed">3484603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kron I.L., DiMarco P.J., Harman P.K., Crosby I.K., Mentzer R.M., Jr., Nolan S.P., Wellons H.A., Jr. Unanticipated postoperative ventricular tachyarrhythmias. Ann. Thorac. Surg. 1984;38:317&#x2013;322. doi: 10.1016/S0003-4975(10)62279-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(10)62279-5</ArticleId><ArticleId IdType="pubmed">6486948</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg J.S., Gaur A., Sciacca R., Tan E. New-onset Sustained ventricular tachycardia after cardiac surgery. Circulation. 1999;99:903&#x2013;908. doi: 10.1161/01.CIR.99.7.903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.99.7.903</ArticleId><ArticleId IdType="pubmed">10027813</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts E., Ludman A.J., Dworzynski K., Al-Mohammad A., Cowie M.R., McMurray J.J.V., Mant J., NICE Guideline Development Group for Acute Heart Failure The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910. doi: 10.1136/bmj.h910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h910</ArticleId><ArticleId IdType="pmc">PMC4353288</ArticleId><ArticleId IdType="pubmed">25740799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sezai A., Shiono M. Natriuretic peptides for perioperative management of cardiac surgery. J. Cardiol. 2016;67:15&#x2013;21. doi: 10.1016/j.jjcc.2015.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2015.09.011</ArticleId><ArticleId IdType="pubmed">26476499</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P. N-Terminal of the Prohormone Brain Natriuretic Peptide Predicts Postoperative Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation. J. Clin. Med. 2022;11:5493. doi: 10.3390/jcm11195493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195493</ArticleId><ArticleId IdType="pmc">PMC9570867</ArticleId><ArticleId IdType="pubmed">36233362</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., V&#xe1;nky F., Hultkvist H., Holm J., Yang Y., Svedjeholm R. NT-proBNP and postoperative heart failure in surgery for aortic stenosis. Open Heart. 2019;6:e001063. doi: 10.1136/openhrt-2019-001063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2019-001063</ArticleId><ArticleId IdType="pmc">PMC6546186</ArticleId><ArticleId IdType="pubmed">31218010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaphiriou A., Robb S., Murray-Thomas T., Mendez G., Fox K., McDonagh T., Hardman S.M.C., Dargie H.J., Cowie M.R. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. Eur. J. Heart Fail. 2005;7:537&#x2013;541. doi: 10.1016/j.ejheart.2005.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2005.01.022</ArticleId><ArticleId IdType="pubmed">15921792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin C., Shah A.S., McAllister D., Cowell S.J., Alam S., Langrish J.P., Strachan F.E., Hunter A.L., Choy A.M., Lang C.C., et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur. Heart J. 2014;35:2312&#x2013;2321. doi: 10.1093/eurheartj/ehu189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu189</ArticleId><ArticleId IdType="pmc">PMC4156973</ArticleId><ArticleId IdType="pubmed">24829362</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann F., Hermann S., St&#xf6;rk S., Niemann M., Frantz S., Lange V., Beer M., Gattenl&#xf6;hner S., Voelker W., Ertl G., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120:577&#x2013;584. doi: 10.1161/CIRCULATIONAHA.108.847772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.847772</ArticleId><ArticleId IdType="pubmed">19652094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P., Voors A., Anker S., Bueno H., Cleland J.G.F., Coats A.J.S., Gonz&#xe1;lez-Juanatey J.R., Harjola V.-P., Jankowska E.A., Jessup M., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The taskforce for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with thespecial contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;37:2129&#x2013;2200.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>van Peet P.G., de Craen A.J., Gussekloo J., de Ruijter W. Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old. Leiden 85-plus study. Age. 2014;36:9660. doi: 10.1007/s11357-014-9660-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-014-9660-1</ArticleId><ArticleId IdType="pmc">PMC4082596</ArticleId><ArticleId IdType="pubmed">24807464</ArticleId></ArticleIdList></Reference><Reference><Citation>Filsoufi F., Rahmanian P.B., Salzberg S., von Harbou K., Bodian C.A., Adams D.H. B-type natriuretic peptide (BNP) in patients undergoingmitral valve surgery. J. Card. Surg. 2008;23:600&#x2013;605. doi: 10.1111/j.1540-8191.2008.00683.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8191.2008.00683.x</ArticleId><ArticleId IdType="pubmed">18793229</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges A., Forestier F., Valli N., Plogin A., Janvier G., Bordenave L. Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. Eur. J. Cardio-Thorac. Surg. 2004;25:941&#x2013;945. doi: 10.1016/j.ejcts.2004.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2004.02.029</ArticleId><ArticleId IdType="pubmed">15144992</ArticleId></ArticleIdList></Reference><Reference><Citation>Perreas K., Samanidis G., Dimitriou S., Athanasiou A., Balanika M., Smirli A., Antzaka C., Politis K., Khoury M., Michalis A. NT-proBNP in the mitral valve surgery. Crit. Pathw. Cardiol. 2014;13:55&#x2013;61. doi: 10.1097/HPC.0000000000000007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HPC.0000000000000007</ArticleId><ArticleId IdType="pubmed">24827881</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichlin T., Schindler C., Drexler B., Twerenbold R., Reiter M., Zellweger C., Moehring B., Ziller R., Hoeller R., Gimenez M.R., et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch. Intern. Med. 2012;172:1211&#x2013;1218. doi: 10.1001/archinternmed.2012.3698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2012.3698</ArticleId><ArticleId IdType="pubmed">22892889</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov D., Abu-Tailakh M., Frieger M., Ganiel A., Tuvbin D., Wolak A. Plasma troponin levels after cardiac surgery vs. after myocardial infarction. Asian Cardiovasc. Thorac. Ann. 2006;14:530&#x2013;535. doi: 10.1177/021849230601400621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/021849230601400621</ArticleId><ArticleId IdType="pubmed">17130336</ArticleId></ArticleIdList></Reference><Reference><Citation>Opfermann U.T., Peivandi A.A., Dahm M., Hilgenstock H., Hafner G., Loos A., Oelert H. Postoperative patterns and kinetics of cTnI, cTnT, CK-MB-activity and CK-activity after elective aortic valve replacement. Swiss Med. Wkly. 2001;131:550&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">11759175</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P., Hryniewiecki T., Ku&#x15b;mierczyk M., Szymanski P. N-terminal of the prohormone brain natriuretic peptide is a predictor of hemodynamic instability in valve disease. Biomark. Med. 2019;13:353&#x2013;358. doi: 10.2217/bmm-2019-0002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2019-0002</ArticleId><ArticleId IdType="pubmed">30754988</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31640724</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>The risk factors for postoperative cerebral complications in patients with Stanford type a aortic dissection.</ArticleTitle><Pagination><StartPage>178</StartPage><MedlinePgn>178</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">178</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-019-1009-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postoperative cerebral complications (PCC) are common and serious postoperative complications for patients with Stanford type A aortic dissection (AAD). The aim of this study was to evaluate the risk factors for PCC in these patients and to provide a scientific basis for effective prevention of PCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective case-control study, 125 patients with AAD who underwent thoracotomy in our department from October 2017 to October 2018 in the department of cardiovascular surgery, Fujian Medical University Union Hospital were divided into two groups: patients with PCC (n&#x2009;=&#x2009;12), and patients without PCC (n&#x2009;=&#x2009;113). The general clinical data, the types of corrective surgeries, the intraoperative situations, the postoperative complications, and the midterm outcomes of the patients were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patients with PCC were significantly older than the patients without PCC (P&#x2009;=&#x2009;0.016), and the incidence of the preoperative cerebral disease history in the patients with PCC was significantly higher than those of the PCC (-) group (P&#x2009;=&#x2009;0.024). The Euro SCORE II of patients with PCC was dramatically higher than the patients without PCC (P&#x2009;=&#x2009;0.005). There were significant differences between the two groups in terms of the duration of cardiopulmonary bypass (CPB) (P&#x2009;=&#x2009;0.010) and the length of moderate hypothermic circulatory arrest (MHCA) combined with selective cerebral perfusion (SCP) (P&#x2009;=&#x2009;0.000). The monitoring of rcSO<sub>2</sub> indicated that there was significant difference between the two groups in terms of the bilateral baseline (P&#x2009;=&#x2009;0.000). Patients with PCC were observed to have experienced significantly longer intubation times (P&#x2009;=&#x2009;0.000), ICU stays (P&#x2009;=&#x2009;0.001), and postoperative hospital stays (P&#x2009;=&#x2009;0.009), and they also had dramatically higher rates of pulmonary infection (P&#x2009;=&#x2009;0.000), multiple organ dysfunction syndrome (P&#x2009;=&#x2009;0.041) and tracheotomy (P&#x2009;=&#x2009;0.022) after surgeries. The duration of MHCA+SCP (OR:9.009, P&#x2009;=&#x2009;0.034) and the average baseline value of rcSO<sub>2</sub> (OR:0.080, P&#x2009;=&#x2009;0.009) were ultimately identified as significant risk factors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PCC has a serious influence on the prognoses of patients following surgical treatment with AAD. The duration of MHCA+SCP and the average baseline value of rcSO<sub>2</sub> were the independent risk factors for PCC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1442-5654</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China. birdman1983@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Fang</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruo-Meng</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Liang-Wan</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000784" MajorTopicYN="N">Aortic Dissection</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001011" MajorTopicYN="N">Aorta</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003128" MajorTopicYN="N">Coma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055191" MajorTopicYN="N">Delayed Emergence from Anesthesia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007036" MajorTopicYN="N">Hypothermia, Induced</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="N">Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057234" MajorTopicYN="N">Preoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013575" MajorTopicYN="N">Syncope</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013908" MajorTopicYN="Y">Thoracotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aneurysm, dissecting</Keyword><Keyword MajorTopicYN="N">Circulatory arrest, deep hypothermia induced</Keyword><Keyword MajorTopicYN="N">Oximetry</Keyword><Keyword MajorTopicYN="N">Postoperative complications</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31640724</ArticleId><ArticleId IdType="pmc">PMC6805587</ArticleId><ArticleId IdType="doi">10.1186/s13019-019-1009-5</ArticleId><ArticleId IdType="pii">10.1186/s13019-019-1009-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Bartolomeo R, Berretta P, Pantaleo A, Murana G, Cefarelli M, Alfonsi J, et al. Long-term outcomes of open arch repair after a prior aortic operation: our experience in 154 patients. Ann Thorac Surg. 2017;103:1406&#x2013;1412. doi: 10.1016/j.athoracsur.2016.08.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.08.090</ArticleId><ArticleId IdType="pubmed">27825691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cefarelli M, Murana G, Surace GG, Castrovinci S, Jafrancesco G, Kelder JC, et al. Elective aortic arch repair: factors influencing neurologic outcome in 791 patients. Ann Thorac Surg. 2017;104:2016&#x2013;2023. doi: 10.1016/j.athoracsur.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.05.009</ArticleId><ArticleId IdType="pubmed">28760465</ArticleId></ArticleIdList></Reference><Reference><Citation>Czerny M, Kr&#xe4;henb&#xfc;hl E, Reineke D, Sodeck G, Englberger L, Weber A, et al. Mortality and neurologic injury after surgical repair with hypothermic circulatory arrest in acute and chronic proximal thoracic aortic pathology: effect of age on outcome. Circulation. 2011;124:1407&#x2013;1413. doi: 10.1161/CIRCULATIONAHA.110.010124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.010124</ArticleId><ArticleId IdType="pubmed">21875908</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early Management of Patients with Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2018;49:e46&#x2013;e110. doi: 10.1161/STR.0000000000000158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0000000000000158</ArticleId><ArticleId IdType="pubmed">29367334</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1883&#x2013;1948. doi: 10.5603/KP.2018.0161.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.2018.0161</ArticleId><ArticleId IdType="pubmed">29562304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Margolin R, Francis J, May L, Truman B, Speroff T, et al. Evaluation of delirium in critically ill patients: validation of the confusion assessment method for the intensive care unit (CAM-ICU) Crit Care Med. 2001;29:1370&#x2013;1379. doi: 10.1097/00003246-200107000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200107000-00012</ArticleId><ArticleId IdType="pubmed">11445689</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81&#x2013;84. doi: 10.1016/S0140-6736(74)91639-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(74)91639-0</ArticleId><ArticleId IdType="pubmed">4136544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzabazis A, Miller C, Dobrow MF, Zheng K. Delayed emergence after anesthesia. J Clin Anesth. 2015;27:353&#x2013;360. doi: 10.1016/j.jclinane.2015.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2015.03.023</ArticleId><ArticleId IdType="pubmed">25912729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond agitation-sedation scale (RASS) JAMA. 2003;289:2983&#x2013;2991. doi: 10.1001/jama.289.22.2983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.22.2983</ArticleId><ArticleId IdType="pubmed">12799407</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LW, Dai XF, Wu XJ, Liao DS, Hu YN, Zhang H, et al. Ascending aorta and Hemiarch replacement combined with modified triple-branched stent graft implantation for repair of acute DeBakey type I aortic dissection. Ann Thorac Surg. 2017;103:595&#x2013;601. doi: 10.1016/j.athoracsur.2016.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.06.017</ArticleId><ArticleId IdType="pubmed">27553503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Qi R, Zhu J, Liu Y, Chang Q, Zheng J. Repair of acute type a dissection: our experiences and results. Ann Thorac Surg. 2011;91:1147&#x2013;1152. doi: 10.1016/j.athoracsur.2010.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2010.12.005</ArticleId><ArticleId IdType="pubmed">21440135</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin W, Zhang X, Yang S, Li Y, Yuan J, Yang L, et al. Risk factors for multiple organ dysfunction syndrome in severe stroke patients. PLoS One. 2016;11:e0167189. doi: 10.1371/journal.pone.0167189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0167189</ArticleId><ArticleId IdType="pmc">PMC5125686</ArticleId><ArticleId IdType="pubmed">27893797</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YC, Qi ZW, Guo SG, Wang Z, Yu XZ, Ma S, et al. Role of corticotrophin releasing hormone in cerebral infarction-related gastrointestinal barrier dysfunction. World J Emerg Med. 2011;2:59&#x2013;65. doi: 10.5847/wjem.j.1920-8642.2011.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.5847/wjem.j.1920-8642.2011.01.011</ArticleId><ArticleId IdType="pmc">PMC4129739</ArticleId><ArticleId IdType="pubmed">25214985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CJ, Hung JW, Cho CY, Tseng CY, Chen HY, Lin FC, et al. Poststroke constipation in the rehabilitation ward: incidence, clinical course and associated factors. Singapore Med J. 2013;54:624&#x2013;629. doi: 10.11622/smedj.2013222.</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/smedj.2013222</ArticleId><ArticleId IdType="pubmed">24276098</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller BJ, Graf R, Jacobs AH. Pathophysiological changes of the gastrointestinal tract in ischemic stroke. Am J Gastroenterol. 2006;101:1655&#x2013;1665. doi: 10.1111/j.1572-0241.2006.00540.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00540.x</ArticleId><ArticleId IdType="pubmed">16863574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji R, Wang D, Shen H, Pan Y, Liu G, et al. Interrelationship among common medical complications after acute stroke: pneumonia plays an important role. Stroke. 2013;44:3436&#x2013;3444. doi: 10.1111/j.1572-0241.2006.00540.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00540.x</ArticleId><ArticleId IdType="pubmed">24178914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CM, Hsu HC, Chuang YW, Chang CH, Lin CH, Hong CZ. Study on factors affecting the occurrence of upper gastrointestinal bleeding in elderly acute stroke patients undergoing rehabilitation. J Nutr Health Aging. 2011;15:632&#x2013;636. doi: 10.1007/s12603-011-0052-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-011-0052-2</ArticleId><ArticleId IdType="pubmed">21968857</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Li J, Lv F, Li K, Luo T, Xie P. A multidetector CT angiography study of variations in the circle of Willis in a Chinese population. J Clin Neurosci. 2011;18:379&#x2013;383. doi: 10.1016/j.jocn.2010.07.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2010.07.137</ArticleId><ArticleId IdType="pubmed">21251838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575&#x2013;585. doi: 10.1016/j.cmet.2011.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.07.015</ArticleId><ArticleId IdType="pmc">PMC3217209</ArticleId><ArticleId IdType="pubmed">22055501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos D, van der Rijk MJ, Geeraedts TE, Hofman A, Krestin GP, Witteman JC, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke. 2012;43:1878&#x2013;1884. doi: 10.1161/STROKEAHA.111.648667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.648667</ArticleId><ArticleId IdType="pubmed">22569939</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooy MJ, Pretorius E. Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events. Curr Med Chem. 2014;21:2121&#x2013;2129. doi: 10.2174/0929867321666131227162950.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666131227162950</ArticleId><ArticleId IdType="pubmed">24372218</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LW, Dai XF, Lu L, Zhang GC, Cao H. Extensive primary repair of the thoracic aorta in acute type a aortic dissection by means of ascending aorta replacement combined with open placement of triple-branched stent graft: early results. Circulation. 2010;122:1373&#x2013;1378. doi: 10.1161/CIRCULATIONAHA.110.946012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.946012</ArticleId><ArticleId IdType="pubmed">20855660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Wang L, Zhang H, Wei W, Chen Y, Tang W, et al. Effect of mild hypothermia on cerebral microcirculation in a murine cardiopulmonary resuscitation model. Microcirculation. 2019. 10.1111/micc.12537.</Citation><ArticleIdList><ArticleId IdType="pubmed">30801897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ji B, Yang B, Liu G, Miao N, Yang J, et al. Real-time continuous neuromonitoring combines transcranial cerebral Doppler with near-infrared spectroscopy cerebral oxygen saturation during total aortic arch replacement procedure: a pilot study. ASAIO J. 2012;58:122&#x2013;126. doi: 10.1097/MAT.0b013e318241abd3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e318241abd3</ArticleId><ArticleId IdType="pubmed">22370681</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17702589</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1010-7940</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.</ArticleTitle><Pagination><StartPage>629</StartPage><EndPage>633</EndPage><MedlinePgn>629-33</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Levosimendan is a promising new inotrope. We investigate the proper time for its infusion during or after open-heart surgery to avoid complications related with low-output syndrome and high dosage of inotropes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-five consecutive patients were randomised to receive levosimendan in addition to the conventional therapy, its infusion starting in the operating theatre (Group OT) or in the ICU (Group ICU) when low-output syndrome was certified and were consequently dependent on classical inotropic support and IABP. Levosimendan was infused at a rate of 0.1 microg/kg min without loading dose, the infusion being for at least 24h to a maximum 48 h.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Levosimendan was well tolerated, with the simultaneous infusion of norepinephrine if required. Its efficacy was identical in both groups with improvement in the haemodynamic and functional status of patients (amelioration of stroke volume, cardiac index and mixed venous blood oxygen saturation, increase of left ventricular ejection fraction by echo study, de-escalation of traditional inotropes, subtraction of IABP and reduction in BNP plasma levels). The ICU stay and hospital stay were significantly decreased in patients of Group OT, compared to patients of Group ICU. Four patients died because of multiple organs dysfunction syndrome (MODS) due to sepsis (all patients of Group ICU).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Levosimendan is a safe and efficient choice in the management of low-output syndrome during and after open-heart surgery. The shortening of hospitalisation and the trend for better outcome confirm its clear superiority when the infusion starts from the operating theatre.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tasouli</LastName><ForeName>Androniki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ICU, Onassis Cardiac Surgery Center, Marathonamahon 18, 14572 Athens, Greece. atacard@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Kirillos</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Antoniou</LastName><ForeName>Theophanie</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kriaras</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Stavridis</LastName><ForeName>Georges</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Degiannis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Geroulanos</LastName><ForeName>Stephanos</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur J Cardiothorac Surg. 2008 Mar;33(3):521</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002303" MajorTopicYN="N">Cardiac Output, Low</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17702589</ArticleId><ArticleId IdType="doi">10.1016/j.ejcts.2007.07.010</ArticleId><ArticleId IdType="pii">S1010-7940(07)00624-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31376011</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2218</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Surgical endoscopy</Title><ISOAbbreviation>Surg Endosc</ISOAbbreviation></Journal><ArticleTitle>Laparoscopy versus conventional laparotomy in the management of abdominal trauma: a multi-institutional matched-pair study.</ArticleTitle><Pagination><StartPage>2237</StartPage><EndPage>2242</EndPage><MedlinePgn>2237-2242</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00464-019-07013-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Laparoscopy is being increasingly applied as either a diagnostic or therapeutic intervention in the management of abdominal trauma. However, its outcomes in comparison with conventional laparotomy remain unclear, especially in terms of therapeutic management.</AbstractText><AbstractText Label="METHODS">This retrospective cohort study included patients from three trauma centers in Beijing, China. Fifty-four patients undergoing laparoscopic interventions for abdominal trauma by experienced laparoscopists were enrolled in the laparoscopy group (LP group). Another 54 patients who underwent laparotomy (LT group) were matched according to the patients' baseline characteristics, causes of injury, and hemodynamic parameters. Perioperative clinical parameters and short-term survival were compared between these two groups.</AbstractText><AbstractText Label="RESULTS">The baseline characteristics were comparable between these two groups (LP vs. LT: Age, p&#x2009;=&#x2009;0.112; Sex, p&#x2009;=&#x2009;0.820; Injury severity score, p&#x2009;=&#x2009;0.158; Cause distribution, p&#x2009;=&#x2009;0.840). The most common cause was traffic accident (36.1%) and the most frequent surgical intervention was bowel repair/resection (34.3%) in our study. The operation time was similar in these two groups (LP vs. LT: 202.2&#x2009;&#xb1;&#x2009;72.58 vs. 194.11&#x2009;&#xb1;&#x2009;82.95&#xa0;min, p&#x2009;=&#x2009;0.295) while post-operative complication rate was slightly reduced in LP group (7.7% vs. 13.5%) with no statistical significance (p&#x2009;=&#x2009;0.383). Opioid use was lower in the LP than LT group (11.67&#x2009;&#xb1;&#x2009;4.08 vs. 26.0&#x2009;&#xb1;&#x2009;13.42 morphine equivalents (MEQ), p&#x2009;=&#x2009;0.034). The hospital stay was significantly shorter in the LP group (13.48&#x2009;&#xb1;&#x2009;10.9 vs. 18.64&#x2009;&#xb1;&#x2009;14.73&#xa0;days, p&#x2009;=&#x2009;0.021). One patient in the LT group died of an intra-abdominal abscess and multiple organ dysfunction syndrome 19&#xa0;days postoperatively, while all patients in the LP group recovered and were discharged.</AbstractText><AbstractText Label="CONCLUSION">Laparoscopy is feasible and safe in treating abdominal trauma patients in hemodynamically stable conditions performed by experienced surgeons. Laparoscopy might have the advantages of reduced pain and quicker recovery with similarly favorable clinical outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yunhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaoqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Hongqing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Shibo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kecheng</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jianxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feide</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The First Affiliated Hospital of the PLA General Hospital (304 Hospital), Beijing, 100048, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yixun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baohua</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China. drqiaozhi@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China. chenlinbj@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China. chenlinbj@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Surg Endosc</MedlineTA><NlmUniqueID>8806653</NlmUniqueID><ISSNLinking>0930-2794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000007" MajorTopicYN="N">Abdominal Injuries</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068476" MajorTopicYN="N" Type="Geographic">Beijing</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="N">Laparotomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal trauma</Keyword><Keyword MajorTopicYN="N">Hemodynamically stable</Keyword><Keyword MajorTopicYN="N">Laparoscopy</Keyword><Keyword MajorTopicYN="N">Laparotomy</Keyword><Keyword MajorTopicYN="N">Therapeutic value</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31376011</ArticleId><ArticleId IdType="doi">10.1007/s00464-019-07013-4</ArticleId><ArticleId IdType="pii">10.1007/s00464-019-07013-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Trauma. 1993 Jun;34(6):822-7; discussion 827-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8315677</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2015 Jun;39(6):1381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25446491</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J Traumatol. 2018 Apr;21(2):73-76</Citation><ArticleIdList><ArticleId IdType="pubmed">29395429</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2013 Mar;205(3):317-20; discussion 321</Citation><ArticleIdList><ArticleId IdType="pubmed">23375706</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2017 Aug;44:94-98</Citation><ArticleIdList><ArticleId IdType="pubmed">28629766</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2003 Mar;17(3):421-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12457215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laparoendosc Adv Surg Tech A. 2018 May;28(5):506-513</Citation><ArticleIdList><ArticleId IdType="pubmed">29293406</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2016 Oct;34:127-136</Citation><ArticleIdList><ArticleId IdType="pubmed">27575832</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2017 Aug;44:21-25</Citation><ArticleIdList><ArticleId IdType="pubmed">28529193</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Clin North Am. 2011 Feb;91(1):195-207</Citation><ArticleIdList><ArticleId IdType="pubmed">21184909</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Laparosc Endosc Percutan Tech. 2013 Dec;23(6):507-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24300927</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Emerg Surg. 2015 Mar 12;10:16</Citation><ArticleIdList><ArticleId IdType="pubmed">26056529</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2007 Jan;38(1):60-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17129583</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2016 Jan 14;22(2):668-80</Citation><ArticleIdList><ArticleId IdType="pubmed">26811616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2009 Sep;67(3):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19741405</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2016 Jul;47(7):1393-403</Citation><ArticleIdList><ArticleId IdType="pubmed">27157986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laparoendosc Adv Surg Tech A. 2017 Apr;27(4):383-387</Citation><ArticleIdList><ArticleId IdType="pubmed">28253051</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2008 Jan;22(1):228-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17721808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma Acute Care Surg. 2016 Aug;81(2):307-11</Citation><ArticleIdList><ArticleId IdType="pubmed">27032004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1974 Mar;14(3):187-96</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Med Clin North Am. 2018 Feb;36(1):149-160</Citation><ArticleIdList><ArticleId IdType="pubmed">29132574</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Surg. 2019 Dec;108(4):273-279</Citation><ArticleIdList><ArticleId IdType="pubmed">30522416</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2013 Jan;37(1):113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23052797</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2019 May;33(5):1618-1625</Citation><ArticleIdList><ArticleId IdType="pubmed">30209608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2004 Aug;240(2):205-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Laparosc Endosc Percutan Tech. 2018 Feb;28(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">28915204</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Today. 2017 Jul;47(7):802-809</Citation><ArticleIdList><ArticleId IdType="pubmed">27830364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28895204</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical transplantation</Title><ISOAbbreviation>Clin Transplant</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation in critically ill patients: Preoperative predictive factors of post-transplant mortality to avoid futility.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.13115</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The allocation of liver transplants to patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) with multi-organ failure who are admitted in ICU remains controversial due to their high post-transplant mortality rate and the absence of identified mortality risk factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a single-center retrospective cohort study to determine the post-transplant mortality rate of patients with ALF and ACLF requiring ICU care prior to liver transplant (LT) and identified pretransplant factors of post-transplant mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-four patients (29 with ALF and 55 with ACLF) received a liver transplant while they were hospitalized at the ICU. Their mean model for end-stage liver disease (MELD) score was 41, and their mean sequential organ failure assessment (SOFA) was 15 the day before transplant. The overall 1-year survival rate was 66%. In multivariate analysis, pretransplant lactate level and acute respiratory distress syndrome (ARDS) were the only two independent factors associated with post-transplant mortality. The absence of ARDS and a pretransplant lactate level&lt; 5 mmol/L led to the identification of a subgroup of ICU patients with a good 1-year post-transplant survival (&gt;80%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low lactatemia lactate level and the absence of ARDS could be useful criteria in selecting those patients in ICU who could be eligible for liver transplant.</AbstractText><CopyrightInformation>&#xa9; 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michard</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5605-9229</Identifier><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artzner</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebas</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besch</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Chirurgie G&#xe9;n&#xe9;rale et Transplantation h&#xe9;patique, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillot</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Gastro-Ent&#xe9;rologie, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faitot</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Chirurgie G&#xe9;n&#xe9;rale et Transplantation h&#xe9;patique, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Sant&#xe9; Publique, D&#xe9;partement d'Information M&#xe9;dicale, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachellier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Chirurgie G&#xe9;n&#xe9;rale et Transplantation h&#xe9;patique, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelain</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maestraggi</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1121, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Clin Transplant</MedlineTA><NlmUniqueID>8710240</NlmUniqueID><ISSNLinking>0902-0063</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017114" MajorTopicYN="N">Liver Failure, Acute</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018447" MajorTopicYN="Y">Medical Futility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">cirrhosis</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">lactate</Keyword><Keyword MajorTopicYN="N">liver failure</Keyword><Keyword MajorTopicYN="N">liver transplantation</Keyword><Keyword MajorTopicYN="N">prognostic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28895204</ArticleId><ArticleId IdType="doi">10.1111/ctr.13115</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25565642</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN><JournalIssue CitedMedium="Internet"><Volume>44 Suppl 1</Volume><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>An Evolving Uncontrolled Hemorrhage Model Using Cynomolgus Macaques.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>128</EndPage><MedlinePgn>123-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SHK.0000000000000322</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Trauma-induced hemorrhagic shock produces hemodynamic changes that often result in a systemic inflammatory response that can lead to multiple organ failure and death. In this prospective study, the pathophysiology of a nonhuman primate uncontrolled hemorrhagic shock model is evaluated with the goal of creating an acute systemic inflammatory syndrome response and a reproducible hemorrhage.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nonhuman primates were divided into 2 groups. A laparoscopic left hepatectomy was performed in groups A and B, 60% and 80%, respectively, resulting in uncontrolled hemorrhage. Resuscitation during the prehospital phase lasted 120 min and included a 0.9% saline bolus at 20 mL/kg. The hospital phase involved active warming, laparotomy, hepatorrhaphy for hemostasis, and transfusion of packed red blood cells (10 mL/kg). The animals were recovered and observed over a 14-day survival period with subsequent necropsy for histopathology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline demographics and clinical parameters of the two groups were similar. Group A (n = 7) underwent a 57.7% &#xb1; 2.4% left hepatectomy with a 33.9% &#xb1; 4.0% blood loss and 57% survival. Group B (n = 4) underwent an 80.0% &#xb1; 6.0% left hepatectomy with 56.0% &#xb1; 3.2% blood loss and 75% survival. Group B had significantly lower hematocrit (P &lt; 0.05) for all postinjury time points. Group A had significantly elevated creatinine on postoperative day 1. Nonsurvivors succumbed to an early death, averaging 36 h from the injury. Histopathologic evaluation of nonsurvivors demonstrated kidney tubular degeneration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nonhuman primates displayed the expected physiologic response to hemorrhagic shock due to liver trauma as well as systemic inflammatory response syndrome with resultant multiple organ dysfunction syndrome and either early death or subsequent recovery. Our next step is to establish a clinically applicable nonhuman primate polytrauma model, which reproduces the prolonged maladaptive immunologic reactivity and end-organ dysfunction consistent with multiple organ failure found in the critically injured patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bograd</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>*Department of Surgery, Walter Reed National Military Medical Center, Bethesda; and &#x2020;Department of Regenerative Medicine, Naval Medical Research Center, Silver Spring; &#x2021;Department of Surgery, Uniformed Services, University of the Health Sciences, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radowsky</LastName><ForeName>Jason S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Vicente</LastName><ForeName>Diego A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Earl H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Elster</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006498" MajorTopicYN="N">Hepatectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25565642</ArticleId><ArticleId IdType="doi">10.1097/SHK.0000000000000322</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28356852</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1452-8258</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical biochemistry</Title><ISOAbbreviation>J Med Biochem</ISOAbbreviation></Journal><ArticleTitle>Prognostic Value and Daily Trend of Interleukin-6, Neutrophil CD64 Expression, C-Reactive Protein and Lipopolysaccharide-Binding Protein in Critically Ill Patients: Reliable Predictors of Outcome or Not?</ArticleTitle><Pagination><StartPage>431</StartPage><EndPage>439</EndPage><MedlinePgn>431-439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/jomb-2015-0002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe sepsis and/or trauma complicated by multiple organ dysfunction syndrome are the leading causes of death in critically ill patients. The aim of this prospective single-centre study was to assess the prognostic value and daily trend of interleukin-6 (IL-6), neutrophil CD64 expression, C-reactive protein (CRP) and lipopolysaccharide-binding protein (LBP) regarding outcome in critically ill patients with severe trauma and/or severe sepsis. Outcome measure was hospital mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and two critically ill patients admitted to the intensive care unit of a tertiary university hospital were enrolled in this prospective study. Blood samples were collected on admission (day 1), days 2 and 3.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CD64 index was 1.6-fold higher on day 1 and 1.78-fold higher on day 2 in non-survivors (p&lt;0.05). The area under the curve (AUC) for the CD64 index on day 1 for outcome was 0.727. At a cut-off level of 2.80 sensitivity was 75% and specificity was 65%. Patients with CD64 index level on day 1 higher than 2.80 had 2.4-fold higher probability of dying. Odds ratio is 2.40; 95% CI 0.60-9.67.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CD64 index on day 1 is a fairly good predictor of outcome. AUCs for IL-6, CRP and LBP were &lt; 0.55, suggesting these biomarkers failed to predict outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Djordjevic</LastName><ForeName>Dragan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pejovic</LastName><ForeName>Janko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surbatovic</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jevdjic</LastName><ForeName>Jasna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medical Sciences, University of Kragujevac, Serbia; Clinical Center Kragujevac, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radakovic</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sector of Preventive Medicine, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veljovic</LastName><ForeName>Milic</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peric</LastName><ForeName>Aneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sector for pharmacy, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andjelic</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Nada</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Belgrade, Serbia; Clinic for Burns, Plastic and Reconstructive Surgery, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Serbia</Country><MedlineTA>J Med Biochem</MedlineTA><NlmUniqueID>101315490</NlmUniqueID><ISSNLinking>1452-8266</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="srp"><AbstractText Label="UVOD" NlmCategory="UNASSIGNED">Te&#x161;ka sepsa i/ili trauma kod koje se kao komplikacija javlja sindrom multiple organske disfunkcije je vode&#x107;i uzrok smrti kod kriti&#x10d;no obolelih. Cilj ove prospektivne studije je bio da se proceni prognosti&#x10d;ka vrednost i utvrdi kinetika inter-leukina-6 (IL-6), ekspresije CD64 na neutrofilima, C-reaktivnog proteina (CRP) i proteina koji vezuje lipopolisaharid (lipopolysaccharide-binding protein &#x2013; LBP) u smislu ishoda kod kriti&#x10d;no obolelih sa te&#x161;kom traumom i/ili te&#x161;kom sepsom. Mera ishoda je bio hospitalni mortalitet.</AbstractText><AbstractText Label="METODE" NlmCategory="METHODS">Sto dva kriti&#x10d;no obolela pacijenta primljena u jedini-cu intenzivne terapije tercijarne univerzitetske bolnice su obu-hva&#x107;ena prospektivnom studijom. Uzorci krvi su sakupljani na dan prijema (dan 1), a zatim drugog i tre&#x107;eg dana.</AbstractText><AbstractText Label="REZULTATI" NlmCategory="UNASSIGNED">CD64 indeks je bio 1,6 puta vi&#x161;i prvog dana i 1,78 puta vi&#x161;i drugog dana kod umrlih (p&lt;0,05). Vrednost AUC/ROC za CD64 indeks prvog dana u smislu predikcije ishoda je bila 0,727. Pri <i>cut-off</i> vrednosti od 2,80 senzitivnost je bila 75%, specifi&#x10d;nost 65% a OR 2,40 (95% CI 0,60&#x2013;9,67). Pacijenti sa nivoom CD64 indeksa prvog dana vi&#x161;im od 2,80 imali su 2,4 puta ve&#x107;u verovatno&#x107;u smrtnog ishoda.</AbstractText><AbstractText Label="ZAKLJU&#x10c;AK" NlmCategory="UNASSIGNED">Vrednost CD64 indeksa prvog dana je dobar prediktor ishoda. AUC/ROC vrednosti za IL-6, CRP i LBP su bile &lt; 0,55, pa se ovi biomarkeri nisu pokazali dobrim pre-diktorima ishoda.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">leukocytes</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28356852</ArticleId><ArticleId IdType="pmc">PMC4922357</ArticleId><ArticleId IdType="doi">10.1515/jomb-2015-0002</ArticleId><ArticleId IdType="pii">jomb-2015-0002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Surbatovic M, Radakovic S, Jovanovic K, Romic P. New strategies in multiple organ dysfunction syndrome therapy for sepsis. Srp Arh Celok Lek. 2005;133(7&#x2013;8):3791.83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16623265</ArticleId></ArticleIdList></Reference><Reference><Citation>Surbatovic M, Grujic K, Cikota B, Jevtic M, Filipovic N, Romic P, et al. Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and interleukin-1ra in critically ill patients. J Crit Care. 2010;25(3):542.e1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20163933</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AC, Simpson AJ, Walsh TS. Hyperinflammation and mediators of immune suppression in critical illness. In: Vincent JL, editor. Annual update in intensive care and emergency medicine. Berlin Heidelberg: Springer-Verlag; 2013. pp. 135&#x2013;44.</Citation></Reference><Reference><Citation>Surbatovic M, Radakovic S. Tumor necrosis factor-alpha levels early in severe acute pancreatitis: is there predictive value regarding severity and outcome? J Clin Gastroenterol. 2013;47(7):637&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23470643</ArticleId></ArticleIdList></Reference><Reference><Citation>Surbatovic M, Filipovic N, Radakovic S, Stankovic N, Slavkovic Z. Immune cytokine response in combat casualties: blast or explosive trauma with or without secondary sepsis. Mil Med. 2007;172(2):190&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17357775</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaini S, Graesboll Koldkjaer O, Pedersen C, Stenvang Pedersen S. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community acquired infections and sepsis: a prospective study. Crit Care. 2006;10:R53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550885</ArticleId><ArticleId IdType="pubmed">16569262</ArticleId></ArticleIdList></Reference><Reference><Citation>Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care. 2006;10:R63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550913</ArticleId><ArticleId IdType="pubmed">16635270</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi SS, Lewis SM, Gant VA, Treacher D, Davis BH, Brown KA. Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS) Clin Exp Immunol. 2001;125(2):258&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1906134</ArticleId><ArticleId IdType="pubmed">11529918</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis BH, Olsen SH, Ahmad E, Bigelow NC. Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch Pathol Lab Med. 2006;130(5):654&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16683883</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno RP, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med. 1999;25(7):686&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">10470572</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013;41(2):580&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">23353941</ArticleId></ArticleIdList></Reference><Reference><Citation>Meszaros K, Aberle S, White M, Parent JB. Immuno-reactivity and bioactivity of lipopolysaccharide binding protein in normal and heat-inactivated sera. Infect Immun. 1995;63(1):363&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC173003</ArticleId><ArticleId IdType="pubmed">7806380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hack CE, De Groot ER, Felt-Bersma RJF, Nuijens JH, Strack Van Schijndel RJM, Eerenberg-Belmer AJM, Thijs LG, Aarden LA. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74(5):1704&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2790194</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Meer W, van Dun L, Klein Gunnewiek J, Roemer B, Scott CS. Simultaneous determination of membrane CD64 and HLA-DR expression by blood neutrophils and monocytes using the monoclonal antibody fluorescence capability of routine haematology analyser. J Immunol Meth. 2006;311:207&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554067</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel-Bayarri V, Casanoves-Laparra EB, Pallas-Beneyto L, Sancho-Chinesta S, Martin-Osorio LF, Tormo-Calandin C, et al. Prognostic value of the biomarkers procalcitonin, interleukin-6 and C-reactive protein in severe sepsis. Med Intensiva. 2012;36(8):556&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">22495097</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med. 2002;28(9):1220&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209268</ArticleId></ArticleIdList></Reference><Reference><Citation>Suares-Santamaria M, Santolaria F, Perez-Ramirez A, Aleman-Valls MR, Martinez-Riera A, Gonzales-Reimers E, et al. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. Eur Cytokine Netw. 2010;21(1):19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">20146986</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraunberger P, Wang Y, Holler E, Parhofer KG, Nagel D, Walli AK, et al. Prognostic value of interleukin 6, procalcitonin and C-reactive protein levels in intensive care unit patients during first increase of fever. Shock. 2006;26(1):10&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheval C, Timsit JF, Garrouste-Orgeas M, Assicot M, De Jonghe B, Misset B, et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Intensive Care Med. 2000;26(Suppl 2):S153&#x2013;S158.</Citation><ArticleIdList><ArticleId IdType="pubmed">18470711</ArticleId></ArticleIdList></Reference><Reference><Citation>Devran O, Karakurt Z, Adiguzel N, Gungor G, Mocin YO, Balci MK, et al. C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit. Multidiscip Respir Med. 2012;7(1):47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529702</ArticleId><ArticleId IdType="pubmed">23171626</ArticleId></ArticleIdList></Reference><Reference><Citation>Povoa P, Teixeira-Pinto AM, Carneiro AH for the Portuguese Community-Acquired Sepsis Study Group (SACiUCI) C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care. 2011;15:R169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387609</ArticleId><ArticleId IdType="pubmed">21762483</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschaikowsky K, Hedwig&#x2013;Geissing M, Schmidt J, Braun GG. Lipopolysaccharide-Binding Protein for Monitoring of Postoperative Sepsis: Complemental to C-Reactive Protein or Redundant? PLoS ONE. 2011;6(8):e23615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161994</ArticleId><ArticleId IdType="pubmed">21901123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunkhorst F. Lipopolysaccharide binding protein in surgical intensive care unit: A marker of sepsis? Crit Care Med. 2008;36(7):2014&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18552695</ArticleId></ArticleIdList></Reference><Reference><Citation>Prucha M, Herold I, Zazula R, Dubska L, Dostal M, Hildebrand T, et al. Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care. 2003;7:R154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374378</ArticleId><ArticleId IdType="pubmed">14624690</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Perez-Mendez L, Espinosa E, Flores C, Blanco J, Muriel A, et al. Serum Lipopolysaccharide Binding Protein Levels Predict Severity of Lung Injury and Mortality in Patients with Severe Sepsis. PLoS ONE. 2009;4(8):e6818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730016</ArticleId><ArticleId IdType="pubmed">19718443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res. 2006;12(3):151&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16719987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann J. Neutrophil CD64 as a sepsis biomarker. Biochem Med. 2011;21(3):282&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">22420242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu KH, Chan MC, Wang JM, Lin LY, Wu CL. Comparison of Fcg receptor expression on neutrophils with procalcitonin for the diagnosis of sepsis in critically ill patients. Respirology. 2011;16(1):152&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">20946336</ArticleId></ArticleIdList></Reference><Reference><Citation>Song SH, Kim HK, Park MH, Cho Hl. Neutrophil CD64 expression is associated with severity and prognosis of disseminated intravascular coagulation. Thromb Res. 2008;121(4):499&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">17597188</ArticleId></ArticleIdList></Reference><Reference><Citation>Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, Augustatou K, et al. Neutrophil CD64 expression and serum IL-8: Sensitive early markers of severity and outcome in sepsis. Cytokine. 2006;36(5&#x2013;6):283&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cid J, Garcia-Pardo G, Aguinaco R, Sanchez R, Llorente A. Neutrophil CD64: diagnostic accuracy and prognostic value in patients presenting to the emergency department. Eur J Clin Microbiol Infect Dis. 2011;30(7):845&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21249409</ArticleId></ArticleIdList></Reference><Reference><Citation>Danikas DD, Karakantza M, Theodorou GL, Sakellaropoulos GC, Gogos CA. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp Immunol. 2008;154(1):87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561092</ArticleId><ArticleId IdType="pubmed">18727624</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CGM, et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med. 2000;26(7):883&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10990102</ArticleId></ArticleIdList></Reference><Reference><Citation>Surbatovic M, Veljovic M, Jevdjic J, Popovic N, Djordjevic D, Radakovic S. Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma. Mediators Inflamm. 2013;2013:362793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859159</ArticleId><ArticleId IdType="pubmed">24371374</ArticleId></ArticleIdList></Reference><Reference><Citation>Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O&#x2019;Grady NF. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4):203&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward PA. Immunosuppression in sepsis. JAMA. 2011;306(23):2618&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22187286</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet. 2006;368(9530):157&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829300</ArticleId></ArticleIdList></Reference><Reference><Citation>Raicevic R, Jovicic A, Dimitrijevic R, Surbatovic M, Marenovic T. Septic encephalopathy &#x2013; prognostic value of the intensity of consciousness disorder to the outcome of sepsis. Vojnosanit Pregl. 2001;58(2):151&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11475668</ArticleId></ArticleIdList></Reference><Reference><Citation>Surbatovic M, Jevdjic J, Veljovic M, Popovic N, Djordjevic D, Radakovic S. Immune response in severe infection: could life-saving drugs be potentially harmful? Scientific-World Journal. 2013;2013:961852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806431</ArticleId><ArticleId IdType="pubmed">24198733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23274325</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2329-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Annals of transplantation</Title><ISOAbbreviation>Ann Transplant</ISOAbbreviation></Journal><ArticleTitle>Fungal infection in patients after liver transplantation in years 2003 to 2012.</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>63</EndPage><MedlinePgn>59-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Fungal infections after liver transplantation have received considerable interests because of their association with substantial morbidity and mortality. This study investigated risk factors of fungal infection after liver transplantation.</AbstractText><AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">Retrospective analysis was performed based on clinical data from 120 patients with fungal infection after liver transplantation from January 1, 2003 to May 30, 2012. &#x3c7;2 test was used to analyze risk factors for fungal infections.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The fungal infection rate after liver transplantation is 13.5% (120/886) and the case fatality rate reaches 70.8%; most are infected by Candida albicans (67.5%), with infection located in the lung (73.3%). Acute physiology and chronic health evaluation scores of the infected group are higher than those of the control group 24 hours after the surgery (27.1&#xb1;5.2 vs. 21.9&#xb1;5.0). The percentage of primary liver cancer patients in the infected group was lower than in the control group (26.7% vs. 45.8%). Compared to the control group, the infected group had a higher percentage of patients with HBV, gestational diabetes mellitus, and multiple organ dysfunction syndrome. Percentages of patients with long continuous parenteral nutrition time, poorly controlled high blood sugar, long-term mechanical ventilation, and antibiotics use were higher in the infected group than in the control group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preoperative original attack, postoperative critical condition, chronically high blood sugar, long-term use of antibiotics, and mechanical ventilation are probably vital risk factors for fungal infection after liver transplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chun-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, First Affiliated Hospital of Sun Yat-Sen, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xiao-Shun</ForeName><Initials>XS</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Min-Ying</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wen-Feng</ForeName><Initials>WF</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Dong-Hua</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xue-Xia</ForeName><Initials>XX</Initials></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Xiang-Dong</ForeName><Initials>XD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Transplant</MedlineTA><NlmUniqueID>9802544</NlmUniqueID><ISSNLinking>1425-9524</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001228" MajorTopicYN="N">Aspergillosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002177" MajorTopicYN="N">Candidiasis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016469" MajorTopicYN="N">Fungemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008172" MajorTopicYN="N">Lung Diseases, Fungal</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014552" MajorTopicYN="N">Urinary Tract Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23274325</ArticleId><ArticleId IdType="doi">10.12659/aot.883695</ArticleId><ArticleId IdType="pii">883695</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17966933</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1221-9118</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Chirurgia (Bucharest, Romania : 1990)</Title><ISOAbbreviation>Chirurgia (Bucur)</ISOAbbreviation></Journal><ArticleTitle>Preventive strategies for septic complications of acute pancreatitis.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>388</EndPage><MedlinePgn>383-8</MedlinePgn></Pagination><Abstract><AbstractText>The diagram of the mortality of acute pancreatitis is characterized by two distinct peaks, in a similar manner to other generalized acute inflammatory responses. In the first phase, which is characterized by "hyper-inflammatory" mechanisms, death occurs due to overwhelming SIRS and subsequent multi-organ failure. The second peak of death is usually detected much later, at least two weeks after the onset of acute pancreatitis. Infection in necrotising pancreatitis is frequently observed in this so-called "compensatory antiinflammatory" phase. Since there has been no effective therapy evolved to prevent the activation of inflammatory and proteolytic cascades, the treatment of acute pancreatitis is merely symptomatic. Adequate fluid resuscitation and analgesia are the mainstays of treatment. In case of development of multi-organ failure, extensive medical and ventilatory supportive therapy is usually necessary. However, recent studies suggested certain methods might decrease the incidence of infection in pancreatic necrosis, which is usually due to bacterial translocation from the gut. Numerous attempts have been published in the literature to decrease the frequency of septic complications. Furthermore, the outcome of studies favouring antibiotic prophylaxis in acute pancreatitis were debatable. The development of multi-resistant strains of Gram-positive bacteria and Candida, due to long-term antibiotic use, is a strong argument against the indication of prophylactic antibiotic use. Recently, various clinical studies aimed to decrease bacterial translocation, including probiotic use and enteral feeding as part of the treatment. This paper provides a systematic review on data available in the evidence based literature on the use of antibiotics and the role of alternative and supportive therapy in the treatment of severe acute pancreatitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ol&#xe1;h</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Petz Alad&#xe1;r Teaching Hospital, Gyor, Hungary. olaha@petz.gyor.hu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardavi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bel&#xe1;gyi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Romics</LastName><ForeName>L</ForeName><Initials>L</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>Chirurgia (Bucur)</MedlineTA><NlmUniqueID>9213031</NlmUniqueID><ISSNLinking>1221-9118</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001424" MajorTopicYN="N">Bacterial Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010180" MajorTopicYN="N">Pancreatectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>41</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17966933</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40786094</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Clinical prediction model and 2-year mortality for multiple organ dysfunction in patients aged 80&#x202f;years or older following hip fracture surgery: a prospective cohort study.</ArticleTitle><Pagination><StartPage>1515557</StartPage><MedlinePgn>1515557</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1515557</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2025.1515557</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The prediction of postoperative complications is vital in the management of hip fracture. This study specifically examined the occurrence of multiple organ dysfunction syndrome in the elderly (MODSE) following hip fracture surgery and explored its predictive model and correlation with long-term mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This prospective cohort study included all patients aged 80&#x202f;years and older who underwent hip fracture surgery at a tertiary orthopedic hospital between January 2020 and March 2021. The patients were categorized into the MODSE and non-MODSE groups. The pre, peri, and postoperative variables were retrospectively screened to establish and validate prediction model for MODSE. The patients were subsequently followed up prospectively until 2&#x202f;years after discharge in order to explore the association between MODSE and long-term mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Significant discrepancies in clinical characteristics were observed between MODSE and non-MODSE patients. Those with a preoperative age-adjusted Charlson Comorbidity Index &gt; 5, Impaired swallowing, an Acute Physiology and Chronic Health Evaluation II score &#x2265; 12 within the initial 24&#x202f;h post-surgery, prothrombin time &gt; 14&#x202f;s, along with high-sensitivity cardiac troponin T&#x202f;&gt;&#x202f;14&#x202f;pg./mL and procalcitonin levels &gt; 0.25&#x202f;ng/mL on the first day after surgery were found to have a higher likelihood of developing MODSE. Moreover, the presence of MODSE correlated with a 3.13-fold and 2.88-fold increased risk of mortality at 1 and 2&#x202f;years post-discharge, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Predicting postoperative MODSE in elderly hip fracture patients is essential and feasible, as its occurrence represents poor outcome during hospitalization and predicts heightened long-term mortality rates.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Liu, Deng, Qin, Zhang, Yang, Feng and Yin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Infection Management Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Deng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Qin</LastName><ForeName>Zhijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Chenzhu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">hip fracture surgery</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">prediction model</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40786094</ArticleId><ArticleId IdType="pmc">PMC12331632</ArticleId><ArticleId IdType="doi">10.3389/fmed.2025.1515557</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexiou KI, Roushias A, Varitimidis SE, Malizos KN. Quality of life and psychological consequences in elderly patients after a hip fracture: a review. Clin Interv Aging. (2018) 13:143&#x2013;50. doi: 10.2147/CIA.S150067, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S150067</ArticleId><ArticleId IdType="pmc">PMC5790076</ArticleId><ArticleId IdType="pubmed">29416322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SR, Macey R, Parker MJ, Cook JA, Griffin XL. Arthroplasties for hip fracture in adults. Cochrane Database Syst Rev. (2022) 2022:CD013410. doi: 10.1002/14651858.CD013410.pub2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013410.pub2</ArticleId><ArticleId IdType="pmc">PMC8841979</ArticleId><ArticleId IdType="pubmed">35156194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu WJ, Zeng X, Liu Q. Aging tsunami coming: the main finding from China's seventh national population census. Aging Clin Exp Res. (2022) 34:1159&#x2013;63. doi: 10.1007/s40520-021-02017-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-021-02017-4</ArticleId><ArticleId IdType="pubmed">34727357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, et al. Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study. PLoS Med. (2020) 17:e1003180. doi: 10.1371/journal.pmed.1003180, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003180</ArticleId><ArticleId IdType="pmc">PMC7410202</ArticleId><ArticleId IdType="pubmed">32760065</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Medical Administration of National Health Commission of the People&#x2019;s Republic of China . Guideline for the diagnosis, treatment and management of older adults with hip fracture. (2022). (Chinese). Available online at:
https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fwww.nhc.gov.cn%2Fyzygj%2Fs7659%2F202212%2F7fa334c35f724362892e0d0ba35951c5%2Ffiles%2F4084ec42de9a44a397cc9e26d8b2138b.docx&amp;wdOrigin=BROWSELINK</Citation></Reference><Reference><Citation>Rocos B, Whitehouse MR, Kelly MB. Resuscitation in hip fractures: a systematic review. BMJ Open. (2017) 7:e015906. doi: 10.1136/bmjopen-2017-015906, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-015906</ArticleId><ArticleId IdType="pmc">PMC5623376</ArticleId><ArticleId IdType="pubmed">28473523</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsanos S, Sioutis S, Reppas L, Mitsiokapa E, Tsatsaragkou A, Mastrokalos D, et al. What do hip fracture patients die from? Eur J Orthop Surg Traumatol. (2023) 33:751&#x2013;7. doi: 10.1007/s00590-022-03250-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-022-03250-x</ArticleId><ArticleId IdType="pubmed">35377075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan KJ, Guerrero EM, Tainter D, Dial B, Milton-Cole R, Blair JA, et al. Prognostic factors of in-hospital complications after hip fracture surgery: a scoping review. Osteoporos Int. (2019) 30:1339&#x2013;51. doi: 10.1007/s00198-019-04976-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-019-04976-x</ArticleId><ArticleId IdType="pubmed">31037362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SW, Wang JD, Chen KJ, Wang YT, Wang XD, Mu CS. Diagnostic criteria of multipleorgan dysfunction syndrome in the elderly (draft, 2003). Chin Crit Care Med. (2004) 16:1. (Chinese)</Citation></Reference><Reference><Citation>Yang X, Qin Z, Li Y, Deng Y, Li M. Hypotension following hip fracture surgery in patients aged 80 years or older: a prospective cohort study. Heliyon. (2022) 8:e10202. doi: 10.1016/j.heliyon.2022.e10202, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2022.e10202</ArticleId><ArticleId IdType="pmc">PMC9404332</ArticleId><ArticleId IdType="pubmed">36033291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin B, Kili&#xe7; J, Ta&#x15f;kin G, Solmaz &#x130;, Tezel O, Ba&#x15f;g&#xf6;z BB. The comparison of scoring systems: SOFA, APACHE-II, LODS, MODS, and SAPS-II in critically ill elderly sepsis patients. J Infect Dev Ctries. (2024) 18:122&#x2013;30. doi: 10.3855/jidc.18526, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.18526</ArticleId><ArticleId IdType="pubmed">38377099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Z, Feng H, Meng X, Zhuang S, Liu Z, Ye K, et al. Age-specific 1-year mortality rates after hip fracture based on the populations in mainland China between the years 2000 and 2018: a systematic analysis. Arch Osteoporos. (2019) 14:55. doi: 10.1007/s11657-019-0604-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-019-0604-3</ArticleId><ArticleId IdType="pmc">PMC6535151</ArticleId><ArticleId IdType="pubmed">31129721</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergara I, Vrotsou K, Orive M, Gonzalez N, Garcia S, Quintana JM. Factors related to functional prognosis in elderly patients after accidental hip fractures: a prospective cohort study. BMC Geriatr. (2014) 14:124. doi: 10.1186/1471-2318-14-124, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2318-14-124</ArticleId><ArticleId IdType="pmc">PMC4280690</ArticleId><ArticleId IdType="pubmed">25425462</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth T, Kammerlander C, Gosch M, Luger TJ, Blauth M. Outcome in geriatric fracture patients and how it can be improved. Osteoporos Int. (2010) 21:615&#x2013;9. doi: 10.1007/s00198-010-1401-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-010-1401-4</ArticleId><ArticleId IdType="pubmed">21058001</ArticleId></ArticleIdList></Reference><Reference><Citation>Meals C, Roy S, Medvedev G, Wallace M, Neviaser RJ, O'Brien J. Identifying the risk of swallowing-related pulmonary complications in older patients with hip fracture. Orthopedics. (2016) 39:e93&#x2013;7. doi: 10.3928/01477447-20151222-07</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20151222-07</ArticleId><ArticleId IdType="pubmed">26726985</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Jia P, Zhang J, Wang X, Jiang H, Jiang W. Prevalence and risk factors of postoperative delirium in elderly hip fracture patients. J Int Med Res. (2016) 44:317&#x2013;27. doi: 10.1177/0300060515624936, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060515624936</ArticleId><ArticleId IdType="pmc">PMC5580064</ArticleId><ArticleId IdType="pubmed">26920926</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin KH, Han SB. Early postoperative hypoalbuminemia is a risk factor for postoperative acute kidney injury following hip fracture surgery. Injury. (2018) 49:1572&#x2013;6. doi: 10.1016/j.injury.2018.05.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.05.001</ArticleId><ArticleId IdType="pubmed">29908852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushirozako H, Ohishi T, Fujita T, Suzuki D, Yamamoto K, Banno T, et al. Does N-terminal pro-brain type natriuretic peptide predict cardiac complications after hip fracture surgery? Clin Orthop Relat Res. (2017) 475:1730&#x2013;6. doi: 10.1007/s11999-017-5245-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-017-5245-5</ArticleId><ArticleId IdType="pmc">PMC5406336</ArticleId><ArticleId IdType="pubmed">28101755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakomkin N, Goz V, Cheng JS, Brodke DS, Spiker WR. The utility of preoperative laboratories in predicting postoperative complications following posterolateral lumbar fusion. Spine J. (2018) 18:993&#x2013;7. doi: 10.1016/j.spinee.2017.10.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2017.10.010</ArticleId><ArticleId IdType="pubmed">29055738</ArticleId></ArticleIdList></Reference><Reference><Citation>Forget P, Moreau N, Engel H, Cornu O, Boland B, De Kock M, et al. The neutrophil-to-lymphocyte ratio (NLR) after surgery for hip fracture (HF). Arch Gerontol Geriatr. (2015) 60:366&#x2013;71. doi: 10.1016/j.archger.2014.11.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2014.11.008</ArticleId><ArticleId IdType="pubmed">25488015</ArticleId></ArticleIdList></Reference><Reference><Citation>National Clinical Guideline Centre (UK) . The management of hip fracture in adults. London: Royal College of Physicians (UK) (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22420011</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths R, Babu S, Dixon P, Freeman N, Hurford D, Kelleher E, et al. Guideline for the management of hip fractures 2020: guideline by the Association of Anaesthetists. Anaesthesia. (2021) 76:225&#x2013;37. doi: 10.1111/anae.15291, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15291</ArticleId><ArticleId IdType="pubmed">33289066</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco JF, da Casa C, Pablos-Hern&#xe1;ndez C, Gonz&#xe1;lez-Ram&#xed;rez A, Juli&#xe1;n-Enr&#xed;quez JM, D&#xed;az-&#xc1;lvarez A. 30-day mortality after hip fracture surgery: influence of postoperative factors. PLoS One. (2021) 16:e0246963. doi: 10.1371/journal.pone.0246963, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246963</ArticleId><ArticleId IdType="pmc">PMC7886122</ArticleId><ArticleId IdType="pubmed">33592047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterton BD, Moores TS, Ahmad S, Cattell A, Roberts PJ. Cause of death and factors associated with early in-hospital mortality after hip fracture. Bone Joint J. (2015) 97-B:246&#x2013;51. doi: 10.1302/0301-620X.97B2.35248, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.97B2.35248</ArticleId><ArticleId IdType="pubmed">25628290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd R, Baker G, MacDonald J, Thompson NW. Co-morbidities in patients with a hip fracture. Ulster Med J. (2019) 88:162&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790636</ArticleId><ArticleId IdType="pubmed">31619850</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RMY, Zu Y, Chau WW, Tso CY, Liu WH, Ng RWK, et al. High Charlson comorbidity index score is associated with early fracture-related complication for internal fixation of neck of femur fractures. Sci Rep. (2022) 12:4749. doi: 10.1038/s41598-022-08855-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08855-0</ArticleId><ArticleId IdType="pmc">PMC8934361</ArticleId><ArticleId IdType="pubmed">35306533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DL, Cong YX, Zhuang Y, Xu X, Zhang BF. Age-adjusted Charlson comorbidity index predicts postoperative mortality in elderly patients with hip fracture: a prospective cohort. Front Med (Lausanne). (2023) 10:1066145. doi: 10.3389/fmed.2023.1066145, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1066145</ArticleId><ArticleId IdType="pmc">PMC10027731</ArticleId><ArticleId IdType="pubmed">36960340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Wang X, Dou Y, Wang H, Zhang Y. Analysis of risk factors for perioperative mortality in elderly patients with intertrochanteric fracture. Eur J Orthop Surg Traumatol. (2019) 29:59&#x2013;63. doi: 10.1007/s00590-018-2285-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-018-2285-9</ArticleId><ArticleId IdType="pubmed">30120536</ArticleId></ArticleIdList></Reference><Reference><Citation>Love AL, Cornwell PL, Whitehouse SL. Oropharyngeal dysphagia in an elderly post-operative hip fracture population: a prospective cohort study. Age Ageing. (2013) 42:782&#x2013;5. doi: 10.1093/ageing/aft037, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/aft037</ArticleId><ArticleId IdType="pubmed">23531439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyburski JG, Dente C, Wilson RF, Steffes C, Devlin J, Carlin AM, et al. Differences in arterial and mixed venous IL-6 levels: the lungs as a source of cytokine storm in sepsis. Surgery. (2001) 130:748&#x2013;751. discussion 751-2. doi: 10.1067/msy.2001.118094</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/msy.2001.118094</ArticleId><ArticleId IdType="pubmed">11602907</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. (2016) 8:959&#x2013;70. doi: 10.2217/imt-2016-0020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2016-0020</ArticleId><ArticleId IdType="pubmed">27381687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce A, Pittet JF. Inflammatory response to trauma: implications for coagulation and resuscitation. Curr Opin Anaesthesiol. (2014) 27:246&#x2013;52. doi: 10.1097/ACO.0000000000000047, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0000000000000047</ArticleId><ArticleId IdType="pmc">PMC4124829</ArticleId><ArticleId IdType="pubmed">24419158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaint R, Afshari A, Bouillon B, Cerny V, Cimpoesu D, Curry N, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. (2023) 27:80. doi: 10.1186/s13054-023-04327-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04327-7</ArticleId><ArticleId IdType="pmc">PMC9977110</ArticleId><ArticleId IdType="pubmed">36859355</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet H, Chenevier-Gobeaux C, Villain C, Cohen-Bittan J, Ray P, Epelboin L, et al. Prognostic value of serum procalcitonin after orthopedic surgery in the elderly population. J Gerontol A Biol Sci Med Sci. (2017) 72:438&#x2013;43. doi: 10.1093/gerona/glw097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw097</ArticleId><ArticleId IdType="pubmed">27231388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsantes AG, Trikoupis IG, Papadopoulos DV, Tsante KA, Mavrogenis AF, Koulouvaris P, et al. Higher coagulation activity in hip fracture patients: a case-control study using rotational thromboelastometry. Int J Lab Hematol. (2021) 43:477&#x2013;84. doi: 10.1111/ijlh.13409, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13409</ArticleId><ArticleId IdType="pubmed">33231378</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomina MJ, M&#xe9;ndez E, Sabate A. Altered fibrinolysis during and after surgery. Semin Thromb Hemost. (2021) 47:512&#x2013;9. doi: 10.1055/s-0041-1722971, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1722971</ArticleId><ArticleId IdType="pubmed">33878781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultynck C, Munim N, Harrington DJ, Judd L, Ataklte F, Shah Z, et al. Prevalence of vitamin K deficiency in older people with hip fracture. Acta Clin Belg. (2020) 75:136&#x2013;40. doi: 10.1080/17843286.2018.1564174, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.2018.1564174</ArticleId><ArticleId IdType="pubmed">30618350</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin ZJ, Wu QY, Deng Y, Li X, Wei XD, Tang CJ, et al. Association between high-sensitivity troponin T on admission and organ dysfunction during hospitalization in patients aged 80 years and older with hip fracture: a single-centered prospective cohort study. Clin Interv Aging. (2021) 16:583&#x2013;91. doi: 10.2147/CIA.S303246, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S303246</ArticleId><ArticleId IdType="pmc">PMC8039433</ArticleId><ArticleId IdType="pubmed">33854308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Park HS, Lee DW. Outcome of nonoperative treatment for hip fractures in elderly patients: a systematic review of recent literature. J Orthop Surg (Hong Kong). (2020) 28:2309499020936848. doi: 10.1177/2309499020936848, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2309499020936848</ArticleId><ArticleId IdType="pubmed">32638635</ArticleId></ArticleIdList></Reference><Reference><Citation>Loggers SAI, Van Lieshout EMM, Joosse P, Verhofstad MHJ, Willems HC. Prognosis of nonoperative treatment in elderly patients with a hip fracture: a systematic review and meta-analysis. Injury. (2020) 51:2407&#x2013;13. doi: 10.1016/j.injury.2020.08.027, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2020.08.027</ArticleId><ArticleId IdType="pubmed">32907702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33129099</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>Pt B</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.</ArticleTitle><Pagination><StartPage>107088</StartPage><MedlinePgn>107088</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.107088</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(20)32189-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1&#x3b2;, IL-6, TNF-&#x3b1; and IL-18 were assessed by Real-time PCR and ELISA, respectively.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Our primary results indicated that the mRNA expression and cytokine secretion of IL-1&#x3b2;, IL-6, TNF-&#x3b1;, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P&#xa0;=&#xa0;0.0003, 0.0038, and 0.0001, respectively) and IL-1&#x3b2; gene expression and secretion level in serum and supernatant (P&#xa0;=&#xa0;0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-&#x3b1; concentration were not influenced by Nano-curcumin.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1&#x3b2; and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valizadeh</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdolmohammadi-Vahid</LastName><ForeName>Samaneh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danshina</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of propaedeutics of dental diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziya Gencer</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Yassawi International Kazakh-Turkish University Hospital, Turkistan, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ammari</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roshangar</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslani</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmaeilzadeh</LastName><ForeName>Abdolreza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaebi</LastName><ForeName>Mahnaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valizadeh</LastName><ForeName>Sepehr</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ahmadi.m@tbzmed.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008823">Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036103" MajorTopicYN="N">Nanotechnology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokine storm</Keyword><Keyword MajorTopicYN="N">IL-1&#x3b2;</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">Nano-curcumin</Keyword></KeywordList><CoiStatement>The authors declared that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33129099</ArticleId><ArticleId IdType="pmc">PMC7574843</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2020.107088</ArticleId><ArticleId IdType="pii">S1567-5769(20)32189-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiss S.R., Leibowitz J.L. Coronavirus pathogenesis, advances in virus research. Elsevier. 2011:85&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149603</ArticleId><ArticleId IdType="pubmed">22094080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Poh C.M., R&#xe9;nia L., MacAry P.A., Ng L.F. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 2005;69(4):635&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1306801</ArticleId><ArticleId IdType="pubmed">16339739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19), Statpearls [internet] StatPearls Publishing. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X. Coronavirus infections and immune responses. J. Med. Virol. 2020;92(4):424&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166547</ArticleId><ArticleId IdType="pubmed">31981224</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ma X. Acute respiratory failure in COVID-19: is it &#x201c;typical&#x201d; ARDS? Crit. Care. 2020;24:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202792</ArticleId><ArticleId IdType="pubmed">32375845</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Taghizadieh, H. Mikaeili, M. Ahmadi, H. Valizadeh, Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran, Respiratory medicine case reports (2020) 101090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219375</ArticleId><ArticleId IdType="pubmed">32405454</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Ghaebi, A. Osali, H. Valizadeh, L. Roshangar, M. Ahmadi, Vaccine development and therapeutic design for 2019&#x2010;nCoV/SARS&#x2010;CoV&#x2010;2: Challenges and chances, Journal of cellular physiology (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323389</ArticleId><ArticleId IdType="pubmed">32557648</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P., Ronconi G., Caraffa A., Gallenga C., Ross R., Frydas I., Kritas S. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents. 2020;34(2):1.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti C., Swartzwelter B., Koenders M.I., Azam T., Tengesdal I.W., Powers N., de Graaf D.M., Dinarello C.A., Joosten L.A. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res. Therapy. 2018;20(1):169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091035</ArticleId><ArticleId IdType="pubmed">30075804</ArticleId></ArticleIdList></Reference><Reference><Citation>Z.S. Ulhaq, G.V. Soraya, Interleukin-6 as a potential biomarker of COVID-19 progression, M&#xe9;decine et Maladies Infectieuses (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129451</ArticleId><ArticleId IdType="pubmed">32259560</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes Infect. 2020;9(1):1123&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmann M., Maini R.N., Woody J.N., Holgate S.T., Winter G., Rowland M., Richards D., Hussell T. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. The Lancet. 2020;395(10234):1407&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158940</ArticleId><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolati S., Ahmadi M., Aghebti-Maleki L., Nikmaram A., Marofi F., Rikhtegar R., Ayromlou H., Yousefi M. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacol. Rep. 2018;70(6):1158&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">30340096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavarpour-Bali H., Ghasemi-Kasman M., Pirzadeh M. Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomed. 2019;14:4449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592058</ArticleId><ArticleId IdType="pubmed">31417253</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535097</ArticleId><ArticleId IdType="pubmed">23143785</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1/A):363&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">12680238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewlings S.J., Kalman D.S. Curcumin: a review of its&#x2019; effects on human health. Foods. 2017;6(10):92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664031</ArticleId><ArticleId IdType="pubmed">29065496</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolati S., Ahmadi M., Rikhtegar R., Babaloo Z., Ayromlou H., Aghebati-Maleki L., Nouri M., Yousefi M. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. Int. Immunopharmacol. 2018;61:74&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">29852475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose S., Panda A.K., Mukherjee S., Sa G. Curcumin and tumor immune-editing: resurrecting the immune system. Cell division. 2015;10(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603973</ArticleId><ArticleId IdType="pubmed">26464579</ArticleId></ArticleIdList></Reference><Reference><Citation>Afolayan F.I., Erinwusi B., Oyeyemi O.T. Immunomodulatory activity of curcumin-entrapped poly d, l-lactic-co-glycolic acid nanoparticles in mice. Integrative Medicine Res. 2018;7(2):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035456</ArticleId><ArticleId IdType="pubmed">29989030</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi M.K., Mondal S.C., Gangwar M., Jana S. Immunomodulatory potential of nanocurcumin-based formulation. Inflammopharmacology. 2017;25(6):609&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">28921388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatamipour M., Sahebkar A., Alavizadeh S.H., Dorri M., Jaafari M.R. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iranian J. Basic Medical Sci. 2019;22(3):282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6528723</ArticleId><ArticleId IdType="pubmed">31156789</ArticleId></ArticleIdList></Reference><Reference><Citation>Corkum C.P., Ings D.P., Burgess C., Karwowska S., Kroll W., Michalak T.I. Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT&#x2122;) and standard density gradient. BMC immunology. 2015;16(1):1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549105</ArticleId><ArticleId IdType="pubmed">26307036</ArticleId></ArticleIdList></Reference><Reference><Citation>T. Okabayashi, H. Kariwa, S.i. Yokota, S. Iki, T. Indoh, N. Yokosawa, I. Takashima, H. Tsutsumi, N. Fujii, Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections, Journal of medical virology 78(4) (2006) 417-424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166776</ArticleId><ArticleId IdType="pubmed">16482545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020;46(5):846&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Z. Wang, B. Yang, Q. Li, L. Wen, R. Zhang, Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China, Clinical infectious diseases (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184452</ArticleId><ArticleId IdType="pubmed">32176772</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., De Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chem. Laboratory Medicine (CCLM) 2020;58(7):1021&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">32286245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G., Liu Y., Yi X., Wang Y., Qiao S., Li Z., Ni J., Song Z. Curcumin inhibiting Th17 cell differentiation by regulating the metabotropic glutamate receptor-4 expression on dendritic cells. Int. Immunopharmacol. 2017;46:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">28273557</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanzaro M., Corsini E., Rosini M., Racchi M., Lanni C. Immunomodulators inspired by nature: a review on curcumin and echinacea. Molecules. 2018;23(11):2778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278270</ArticleId><ArticleId IdType="pubmed">30373170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dei Cas M., Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 2019;11(9):2147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6770259</ArticleId><ArticleId IdType="pubmed">31500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Gera M., Sharma N., Ghosh M., Huynh D.L., Lee S.J., Min T., Kwon T., Jeong D.K. Nanoformulations of curcumin: an emerging paradigm for improved remedial application. Oncotarget. 2017;8(39):66680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630447</ArticleId><ArticleId IdType="pubmed">29029547</ArticleId></ArticleIdList></Reference><Reference><Citation>Z.Y. Ay, B. Bak&#x131;r, &#x15e;.B. Bozkurt, S.A. Kayis, S.S. Hakki, Positive effect of curcumin on experimental peridontitis via suppression of IL-1-beta and IL-6 expression level, International Journal for Vitamin and Nutrition Research (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32718217</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A., Hossain I., VanderMolen J., Nicol K. Comparison of remicade to curcumin for the treatment of Crohn&#x2019;s disease: A systematic review. Complementary Therapies Medicine. 2017;33:32&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouzaoui S., Rahim I., Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-&#x3b1;-induced oxidative stress, colitis and hepatotoxicity in mice. Int. Immunopharmacol. 2012;12(1):302&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">22036766</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa G., Maffioli P., Simental-Mendia L.E., Bo S., Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 2016;111:394&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">27392742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebkar A., Cicero A.F., Simental-Mend&#xed;a L.E., Aggarwal B.B., Gupta S.C. Curcumin downregulates human tumor necrosis factor-&#x3b1; levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 2016;107:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">27025786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27379496</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1438-8359</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of anesthesia</Title><ISOAbbreviation>J Anesth</ISOAbbreviation></Journal><ArticleTitle>Impact of aspirin use on morbidity and mortality in massively transfused cardiac surgery patients: a propensity score matched cohort study.</ArticleTitle><Pagination><StartPage>817</StartPage><EndPage>825</EndPage><MedlinePgn>817-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00540-016-2213-2</ELocationID><Abstract><AbstractText Label="PURPOSE">Aspirin may prevent organ dysfunction in critically ill patients and mitigate transfusion associated acute lung injury. We hypothesized that aspirin use might be associated with decreased morbidity and mortality in massively transfused cardiac surgery patients.</AbstractText><AbstractText Label="METHODS">A single center retrospective cohort study was performed using data from an 8.5-year period (2006-2014). Massive transfusion was defined as receiving at least 2400&#xa0;ml (8 units) of red blood cell units intraoperatively. A propensity score model was created to account for the likelihood of receiving aspirin and matched pairs were identified using global optimal matching. The primary endpoint, in-hospital mortality, was compared between aspirin users and non-users. Secondary outcomes including: ICU hours, mechanical lung ventilation hours, prolonged mechanical lung ventilation (&gt;24&#xa0;h), pneumonia, stroke, acute renal failure, atrial fibrillation, deep sternal wound infection, and multiple organ dysfunction syndrome were also compared.</AbstractText><AbstractText Label="RESULTS">Of 7492 cardiac surgery patients, 452 (6&#xa0;%) were massively transfused and mortality was 30.6&#xa0;%. There were 346 patients included in the matched cohort. No significant association was found between preoperative aspirin use and in-hospital mortality; absolute risk reduction with aspirin&#xa0;=&#xa0;7.5&#xa0;% (95&#xa0;% CI -2.0 to 16.9&#xa0;%, p&#xa0;=&#xa0;0.12). Preoperative aspirin use was associated with fewer total mechanical lung ventilation hours (p&#xa0;=&#xa0;0.02) and less prolonged mechanical lung ventilation; absolute risk reduction&#xa0;=&#xa0;11.0&#xa0;% (95&#xa0;% CI 1.1-20.5&#xa0;%, p&#xa0;=&#xa0;0.02).</AbstractText><AbstractText Label="CONCLUSIONS">Preoperative aspirin use is not associated with decreased in-hospital mortality in massively transfused cardiac surgery patients, but may be associated with less mechanical lung ventilation time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzeffi</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2955-4915</Identifier><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street S11C00, Baltimore, MD, 21201, USA. mmazzeffi@anes.umm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galvagno</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street S11C00, Baltimore, MD, 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gammie</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Cardiothoracic Surgery, 419 Redwood Street #360, Baltimore, MD, 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street S11C00, Baltimore, MD, 21201, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Anesth</MedlineTA><NlmUniqueID>8905667</NlmUniqueID><ISSNLinking>0913-8668</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="Y">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspirin</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Lung injury</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27379496</ArticleId><ArticleId IdType="doi">10.1007/s00540-016-2213-2</ArticleId><ArticleId IdType="pii">10.1007/s00540-016-2213-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Invest. 2009 Nov;119(11):3450-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19809160</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2006 Aug;53(8):781-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16873345</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2013 Aug;60(8):761-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23609882</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2011 Nov;39(11):2393-400</Citation><ArticleIdList><ArticleId IdType="pubmed">21725238</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Serv Res. 2014 Oct;49(5):1701-20</Citation><ArticleIdList><ArticleId IdType="pubmed">24779867</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2013 Oct;111(4):549-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23661406</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2011 Jul;101(1):44-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21438884</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2004 Oct;44(10):1453-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15383018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 1998 Jan;65(1):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9456103</ArticleId></ArticleIdList></Reference><Reference><Citation>Multivariate Behav Res. 2011 May;46(3):399-424</Citation><ArticleIdList><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2005 May;127(5):1622-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15888837</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jul 31;10(7):e0134670</Citation><ArticleIdList><ArticleId IdType="pubmed">26230605</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2015 Apr;55(4):782-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25393772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Card Anaesth. 2013 Apr-Jun;16(2):117-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23545866</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2007 May 1;115(17):2340-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17470708</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2009 Feb;102(2):168-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19151047</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2004 Sep;143(1):159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15289285</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2015 Aug;121(2):271-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25993389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiothorac Vasc Anesth. 2009 Feb;23(1):34-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19081268</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Nov 4;363(19):1791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">21047223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Card Surg. 2007 May-Jun;22(3):247-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17488432</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Hematol. 2007 Sep;14(5):455-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17934352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33520337</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2096-2878</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Liver research (Beijing, China)</Title><ISOAbbreviation>Liver Res</ISOAbbreviation></Journal><ArticleTitle>Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>27</EndPage><MedlinePgn>21-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.livres.2021.01.001</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current pandemic, can have multi-organ impact. Recent studies show that liver injury could be a manifestation of the disease, and that liver disease could also be related to a worse prognosis. Our aim was to compare the characteristics of patients with severe coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 who required intubation versus stable hospitalized patients to identify the early biochemical predictive factors of a severe course of COVID-19 and subsequent requirement for intubation, specifically in Mexican.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was an observational case-control study nested in a cohort study. Complete medical records of patients admitted for confirmed COVID-19 at a tertiary level center in Mexico City were reviewed. Clinical and biochemical data were collected, and the characteristics of patients who required invasive mechanical ventilation (IMV) (cases) were compared with stable hospitalized patients without ventilation (controls).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We evaluated 166 patients with COVID-19 due to SARS-CoV-2 infection; 114 (68.7%) were men, the mean age was 50.6&#xa0;&#xb1;&#xa0;13.3 years, and 27 (16.3%) required IMV. The comparative analysis between cases and controls showed (respectively) significantly lower blood oxygen saturation (SpO<sub>2</sub>) (73.5&#xa0;&#xb1;&#xa0;12.0% <i>vs</i>. 83.0&#xa0;&#xb1;&#xa0;6.8%, <i>P</i>&#xa0;&lt;&#xa0;0.0001) and elevated alanine aminotransferase (ALT) (128 (14-1123) IU/L <i>vs</i>. 33 (8-453) IU/L, <i>P</i>&#xa0;=&#xa0;0.003), aspartate aminotransferase (AST) (214 (17-1247) <i>vs</i>. 44 (12-498) IU/L, <i>P</i>&#xa0;=&#xa0;0.001), lactic dehydrogenase (LDH) (764.6&#xa0;&#xb1;&#xa0;401.9 IU/L <i>vs</i>. 461.0&#xa0;&#xb1;&#xa0;185.6 IU/L, <i>P</i>&#xa0;=&#xa0;0.001), and D-dimer (3463 (524-34,227) ng/mL <i>vs</i>. 829 (152-41,923) ng/mL, <i>P</i>&#xa0;=&#xa0;0.003) concentrations. Patients in the cases group were older (58.6&#xa0;&#xb1;&#xa0;12.7 years <i>vs</i>. 49.1&#xa0;&#xb1;&#xa0;12.8 years, <i>P</i>=0.001). Multivariate analysis showed that important factors at admission predicting the requirement for IMV during hospitalization for COVID-19 were AST &#x2265;250 IU/L (odds ratio (OR)&#xa0;=&#xa0;64.8, 95% confidence interval (CI) 7.5-560.3, <i>P&#xa0;&lt;</i> 0.0001) and D-dimer&#xa0;&#x2265;&#xa0;3500&#xa0;ng/mL (OR&#xa0;=&#xa0;4.1, 95% CI 1.2-13.7, <i>P</i>=0.02).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study confirms the importance of monitoring liver enzymes in hospitalized patients with COVID-19; seriously ill patients have significantly elevated AST and D-dimer concentrations, which have prognostic implications in the SARS-CoV-2 disease course.</AbstractText><CopyrightInformation>&#xa9; 2021 The Third Affiliated Hospital of Sun Yat-sen University. Publishing Services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Higuera-de la Tijera</LastName><ForeName>F&#xe1;tima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology and Hepatology Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serv&#xed;n-Caama&#xf1;o</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes-Herrera</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-L&#xf3;pez</LastName><ForeName>Argelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robiou-Vivero</LastName><ForeName>Enrique J A</ForeName><Initials>EJA</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Rivera</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galindo-Hern&#xe1;ndez</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapa-Azuela</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatology Clinic, Surgery Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Morales</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Care Unit, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosales-Salyano</LastName><ForeName>Victor H</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital General de M&#xe9;xico Dr. Eduardo Liceaga, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Liver Res</MedlineTA><NlmUniqueID>101705555</NlmUniqueID><ISSNLinking>2542-5684</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">D-dimer</Keyword><Keyword MajorTopicYN="N">Disease severity</Keyword><Keyword MajorTopicYN="N">Invasive mechanical ventilation (IMV)</Keyword><Keyword MajorTopicYN="N">Liver enzymes</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33520337</ArticleId><ArticleId IdType="pmc">PMC7831761</ArticleId><ArticleId IdType="doi">10.1016/j.livres.2021.01.001</ArticleId><ArticleId IdType="pii">S2542-5684(21)00001-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meng L., Qiu H., Wan L., et al. Intubation and ventilation amid the COVID-19 outbreak: wuhan&#x2019;s experience. Anesthesiology. 2020;132:1317&#x2013;1332. doi: 10.1097/ALN.0000000000003296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000003296</ArticleId><ArticleId IdType="pmc">PMC7155908</ArticleId><ArticleId IdType="pubmed">32195705</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris M., Benigni A., Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314&#x2013;322. doi: 10.1016/j.kint.2020.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.05.013</ArticleId><ArticleId IdType="pmc">PMC7246017</ArticleId><ArticleId IdType="pubmed">32461141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaim S., Chong J.H., Sankaranarayanan V., Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45:100618. doi: 10.1016/j.cpcardiol.2020.100618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100618</ArticleId><ArticleId IdType="pmc">PMC7187881</ArticleId><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rod J.E., Oviedo-Trespalacios O., Cortes-Ramirez J. A&#xa0;brief-review of the risk factors for covid-19 severity. Rev Saude Publica. 2020;54:60. doi: 10.11606/s1518-8787.2020054002481.</Citation><ArticleIdList><ArticleId IdType="doi">10.11606/s1518-8787.2020054002481</ArticleId><ArticleId IdType="pmc">PMC7263798</ArticleId><ArticleId IdType="pubmed">32491116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei F., Liu Y.M., Zhou F., et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72:389&#x2013;398. doi: 10.1002/hep.31301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31301</ArticleId><ArticleId IdType="pmc">PMC7267515</ArticleId><ArticleId IdType="pubmed">32359177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jothimani D., Venugopal R., Abedin M.F., Kaliamoorthy I., Rela M. COVID-19 and the liver. J&#xa0;Hepatol. 2020;73:1231&#x2013;1240. doi: 10.1016/j.jhep.2020.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7295524</ArticleId><ArticleId IdType="pubmed">32553666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper E.B., Asrani S.K. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J&#xa0;Hepatol. 2020;73:441&#x2013;445. doi: 10.1016/j.jhep.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.04.005</ArticleId><ArticleId IdType="pmc">PMC7194911</ArticleId><ArticleId IdType="pubmed">32298769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreivenaite E., Gedgaudas R., Valantiene I., Mickiene A., Kupcinskas J. COVID-19 in a patient with liver cirrhosis. J&#xa0;Gastrointestin Liver Dis. 2020;29:263&#x2013;266. doi: 10.15403/jgld-2440.</Citation><ArticleIdList><ArticleId IdType="doi">10.15403/jgld-2440</ArticleId><ArticleId IdType="pubmed">32530994</ArticleId></ArticleIdList></Reference><Reference><Citation>El Chaar M., King K., Galvez Lima A. Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates? Surg Obes Relat Dis. 2020;16:1096&#x2013;1099. doi: 10.1016/j.soard.2020.04.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soard.2020.04.038</ArticleId><ArticleId IdType="pmc">PMC7211681</ArticleId><ArticleId IdType="pubmed">32522406</ArticleId></ArticleIdList></Reference><Reference><Citation>Agren D. Understanding Mexican health worker COVID-19 deaths. Lancet. 2020;396:807. doi: 10.1016/S0140-6736(20)31955-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31955-3</ArticleId><ArticleId IdType="pmc">PMC7498199</ArticleId><ArticleId IdType="pubmed">32950079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N&#xa0;Engl J Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Shi S., Zhu J., Shi J., Dai K., Chen X. Analysis of 92 deceased patients with COVID-19. J&#xa0;Med Virol. 2020;10.1002/jmv.25891 doi: 10.1002/jmv.25891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25891</ArticleId><ArticleId IdType="pmc">PMC7262332</ArticleId><ArticleId IdType="pubmed">32293741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao R., Qiu Y., He J.S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667&#x2013;678. doi: 10.1016/S2468-1253(20)30126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30126-6</ArticleId><ArticleId IdType="pmc">PMC7217643</ArticleId><ArticleId IdType="pubmed">32405603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Tu W.J., Cheng W., et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71:748&#x2013;755. doi: 10.1093/cid/ciaa243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa243</ArticleId><ArticleId IdType="pmc">PMC7184479</ArticleId><ArticleId IdType="pubmed">32239127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Liang W., Jiang M., et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158:97&#x2013;105. doi: 10.1016/j.chest.2020.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.04.010</ArticleId><ArticleId IdType="pmc">PMC7158802</ArticleId><ArticleId IdType="pubmed">32304772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni A.V., Kumar P., Tevethia H.V., et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52:584&#x2013;599. doi: 10.1111/apt.15916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15916</ArticleId><ArticleId IdType="pmc">PMC7361465</ArticleId><ArticleId IdType="pubmed">32638436</ArticleId></ArticleIdList></Reference><Reference><Citation>Loganathan S., Kuppusamy M., Wankhar W., et al. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes. Respir Physiol Neurobiol. 2021;283:103548. doi: 10.1016/j.resp.2020.103548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2020.103548</ArticleId><ArticleId IdType="pmc">PMC7500408</ArticleId><ArticleId IdType="pubmed">32956843</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito C.A., Barros F.M., Lopes E.P. Mechanisms and consequences of COVID-19 associated liver injury: what can we affirm? World J Hepatol. 2020;12:413&#x2013;422. doi: 10.4254/wjh.v12.i8.413.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v12.i8.413</ArticleId><ArticleId IdType="pmc">PMC7475779</ArticleId><ArticleId IdType="pubmed">32952870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Medetalibeyoglu A., Catma Y., Senkal N., et al. The effect of liver test abnormalities on the prognosis of COVID-19. Ann Hepatol. 2020;19:614&#x2013;621. doi: 10.1016/j.aohep.2020.08.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aohep.2020.08.068</ArticleId><ArticleId IdType="pmc">PMC7481800</ArticleId><ArticleId IdType="pubmed">32920162</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xe9;llez L., Mart&#xed;n Mateos R.M. COVID-19 and liver disease: an update. Gastroenterol Hepatol. 2020;43:472&#x2013;480. doi: 10.1016/j.gastrohep.2020.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gastrohep.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7332955</ArticleId><ArticleId IdType="pubmed">32727662</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto-&#x15a;lusarczyk D., Grabo&#x144; W., Mielczarek-Puta M. Aminotransferaza asparaginianowa-kluczowy enzym w metabolizmie og&#xf3;lnoustrojowym cz&#x142;owieka [Aspartate aminotransferase-key enzyme in the human systemic metabolism] (in Polish) Postepy Hig Med Dosw (Online) 2016;70:219&#x2013;230. doi: 10.5604/17322693.1197373.</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/17322693.1197373</ArticleId><ArticleId IdType="pubmed">27117097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozawa Y., Shimizu T., Shishiba Y. Elevation of serum aminotransferase as a sign of multiorgan-disorders in severely emaciated anorexia nervosa. Intern Med. 1998;37:32&#x2013;39. doi: 10.2169/internalmedicine.37.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.37.32</ArticleId><ArticleId IdType="pubmed">9510397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Zhang H., Qiao R., et al. Thrombo-inflammatory features predicting mortality in patients with COVID-19: the FAD-85 score. J&#xa0;Int Med Res. 2020;48 doi: 10.1177/0300060520955037. 300060520955037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060520955037</ArticleId><ArticleId IdType="pmc">PMC7511832</ArticleId><ArticleId IdType="pubmed">32960106</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.., Qian Y.., Gu Q.., Tang J.. Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019 (in Chinese) Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:559&#x2013;563. doi: 10.3760/cma.j.cn121430-20200414-00518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn121430-20200414-00518</ArticleId><ArticleId IdType="pubmed">32576347</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Zhu C., Yang L., et al. Identification of risk factors for mortality associated with COVID-19. PeerJ. 2020;8:e9885. doi: 10.7717/peerj.9885.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9885</ArticleId><ArticleId IdType="pmc">PMC7473053</ArticleId><ArticleId IdType="pubmed">32953279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21575208</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2011</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Predictors of mortality and short-term physical and cognitive dependence in critically ill persons 75 years and older: a prospective cohort study.</ArticleTitle><Pagination><StartPage>35</StartPage><MedlinePgn>35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1477-7525-9-35</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study was to identify predictors of 3-month mortality in critically ill older persons under medical care and to assess the clinical impact of an ICU stay on physical and cognitive dependence and subjective health status in survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective observational cohort study including all older persons 75 years and older consecutively admitted into ICU during a one-year period, except those admitted after cardiac arrest, All patients were followed for 3 months or until death. Comorbidities were assessed using the Charlson index and physical dependence was evaluated using the Katz index of Activity of Daily Living (ADL). Cognitive dependence was determined by a score based on the individual components of the Lawton index of Daily Living and subjective health status was evaluated using the Nottingham Health Profile (NHP) score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred patients were included in the analysis. The mean age was 79.3 &#xb1; 3.4 years. The median Charlson index was 6 [IQR, 4 to 7] and the mean ADL and cognitive scores were 5.4 &#xb1; 1.1 and 1.2 &#xb1; 1.4, respectively, corresponding to a population with a high level of comorbidities but low physical and cognitive dependence. Mortality was 61/100 (61%) at 3 months. In multivariate analysis only comorbidities assessed by the Charlson index [Adjusted Odds Ratio, 1.6; 95% CI, 1.2-2.2; p &lt; 0.003] and the number of organ failures assessed by the SOFA score [Adjusted Odds Ratio, 2.5; 95% CI, 1.1-5.2; p &lt; 0.02] were independently associated with 3-month mortality. All 22 patients needing renal support after Day 3 died. Compared with pre-admission, physical (p = 0.04), and cognitive (p = 0.62) dependence in survivors had changed very little at 3 months. In addition, the mean NHP score was 213.1 &#xb1; 132.8 at 3 months, suggesting an acceptable perception of their quality of life.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In a selected population of non surgical patients 75 years and older, admission into the ICU is associated with a 3-month survival rate of 38% with little impact on physical and cognitive dependence and subjective health status. Nevertheless, a high comorbidity level (ie, Charlson index), multi-organ failure, and the need for extra-renal support at the early phase of intensive care could be considered as predictors of death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daubin</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Intensive Care, Avenue C&#xf4;te de Nacre, Caen University Hospital, 14033 Caen Cedex, France. daubin-c@chu-caen.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>S&#xe9;guin</LastName><ForeName>Am&#xe9;lie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gaillard</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Valette</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Pr&#xe9;vost</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Terzi</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Parienti</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>du Cheyron</LastName><ForeName>Damien</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003858" MajorTopicYN="Y">Dependency, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21575208</ArticleId><ArticleId IdType="pmc">PMC3112374</ArticleId><ArticleId IdType="doi">10.1186/1477-7525-9-35</ArticleId><ArticleId IdType="pii">1477-7525-9-35</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angus DC, Barnato AE, Linde-Zwirble WT, Weissfeld LA, Watson S, Rickert T, Rudenfeld GD. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med. 2004;32:638&#x2013;643. doi: 10.1097/01.CCM.0000114816.62331.08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000114816.62331.08</ArticleId><ArticleId IdType="pubmed">15090940</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrouste-Orgeas M, Timsit JF, Montuclard L, Colvez A, Gattolliat O, Philippart F, Rigal G, Misset B, Carlet J. Decision-making process, outcome, and 1-year quality of life of octogenarians referred for intensive care unit admission. Intensive Care Med. 2006;32:1045&#x2013;1051. doi: 10.1007/s00134-006-0169-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0169-7</ArticleId><ArticleId IdType="pubmed">16791667</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rooij SE, Govers A, Korevaar JC, Abu-Hanna A, Levi M, de Jonge E. Short-term and long-term mortality in very elderly patients admitted to an intensive care unit. Intensive Care Med. 2006;32:1039&#x2013;1044. doi: 10.1007/s00134-006-0171-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0171-0</ArticleId><ArticleId IdType="pubmed">16791666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy D, Juzwishin K, Yergens D, Noseworthy, Doig C. Outcomes of Elderly Survivors of Intensive Care: A Review of Lliterature. Chest. 2005;127:1764&#x2013;1774. doi: 10.1378/chest.127.5.1764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.127.5.1764</ArticleId><ArticleId IdType="pubmed">15888857</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlani P, Chenaud C, Mariotti N, Ricou B. Long-term outcome of elderly patients requiring intensive care admission for abdominal pathologies: survival and quality of life. Acta Anaesthesiology Scandinavia. 2007;51:530&#x2013;37. doi: 10.1111/j.1399-6576.2007.01273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2007.01273.x</ArticleId><ArticleId IdType="pubmed">17430312</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuclard L, Garrouste-Orgeas M, Timsit JF, Misset B, De Jonghe B, Carlet J. Outcome, functional autonomy, and quality of life of elderly patients with a long-term intensive care unit stay. Crit Care Med. 2000;28:3389&#x2013;95. doi: 10.1097/00003246-200010000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200010000-00002</ArticleId><ArticleId IdType="pubmed">11057791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigaud AS. La qualit&#xe9; de vie des personnes &#xe2;g&#xe9;es apr&#xe8;s un s&#xe9;jour en r&#xe9;animation. Annales de r&#xe9;adaptation et de m&#xe9;decine physique. 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17451834</ArticleId></ArticleIdList></Reference><Reference><Citation>Viricel L, Auboyer C, Sauron C, Mathern P, Gonthier R. Devenir et qualit&#xe9; de vie d'une population &#xe2;g&#xe9;e de plus de 80 ans trois mois apr&#xe8;s un s&#xe9;jour en r&#xe9;animation. Annales de r&#xe9;adaptation et de m&#xe9;decine physiques. 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17521767</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKensie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373&#x2013;383. doi: 10.1016/0021-9681(87)90171-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S, Dowtn TD, Cash HR. Progress in the development of the index of ADL. Gerontologist. 1970;10:20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">5420677</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. Am Geriatr Soc. 1992;40:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">1401698</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#xe7;a A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. J Am Med Assoc. 1993;270:2957&#x2013;2963. doi: 10.1001/jama.270.24.2957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.270.24.2957</ArticleId><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauss WA, Wagner DP, Draper EA, Zimmerman JE. APACHE II severity of disease classification system. Crit Care Med. 1985;13:818&#x2013;829. doi: 10.1097/00003246-198510000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198510000-00009</ArticleId><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucquet D, Condon S, Ritchie K. the French version of the Nottingham health profile. A comparison of items weights with those of the source version. Soc Sci Med. 1990;30:829&#x2013;835. doi: 10.1016/0277-9536(90)90207-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0277-9536(90)90207-9</ArticleId><ArticleId IdType="pubmed">2315749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dram&#xe9; M, Novella JL, Lang PO, Somme D, Jovenin N, Lani&#xe8;ce I, Couturier P, Heitz D, Gauvain JB, Voisin T, De Wazi&#xe8;res B, Gonthier R, Ankri J, Jeandel C, Saint-Jean O, Blanchard F, Jolly D. Derivation and validation of a mortality-risk index from a cohort of frail elderly patients hospitalised in medical wards via emergencies: the SAFES study. Eur J Epidemiol. 2008;23:783&#x2013;91. doi: 10.1007/s10654-008-9290-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-008-9290-y</ArticleId><ArticleId IdType="pubmed">18941907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288&#x2013;94. doi: 10.1016/j.jclinepi.2004.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2004.03.012</ArticleId><ArticleId IdType="pubmed">15617955</ArticleId></ArticleIdList></Reference><Reference><Citation>Buntinx F, Niclaes L, Suetens C, Jans B, Mertens R, Van den Akker M. Evaluation of Charlson's comorbidity index in elderly living in nursing homes. J Clin Epidemiol. 2002;55:1144&#x2013;7. doi: 10.1016/S0895-4356(02)00485-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(02)00485-7</ArticleId><ArticleId IdType="pubmed">12507679</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik PE. Management of the critically ill geriatric patient. Crit Care Med. 2006;34:S176&#x2013;182. doi: 10.1097/01.CCM.0000232624.14883.9A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000232624.14883.9A</ArticleId><ArticleId IdType="pubmed">16917421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass JE, Castriotta RJ, Malakoff F. Intensive care unit outcome in the very elderly. Crit Care Med. 1992;20:1666&#x2013;1671. doi: 10.1097/00003246-199212000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199212000-00011</ArticleId><ArticleId IdType="pubmed">1458943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelluri L, Pinsky MR, Grenvik AN. Outcome of intensive care of the "oldest-old" critically ill patients. Crit Care Med. 1992;20:757&#x2013;761. doi: 10.1097/00003246-199206000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199206000-00010</ArticleId><ArticleId IdType="pubmed">1597028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelluri G, Pinsky MR, Donahoe MP, Grenvik A. Long-term outcome of critically ill elderly patients requiring intensive care. JAMA. 1993;269:3119&#x2013;23. doi: 10.1001/jama.269.24.3119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.269.24.3119</ArticleId><ArticleId IdType="pubmed">8505814</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh GJ, Havill JH, Armistead SH, Ullal RR, Fayers TM. Follow up of elderly patients after cardiac surgery and intensive care unit admission, 1991 to 1995. N Z Med J. 1997;110:432&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">9418838</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumendil A, Maury E, Reinhard I, Luquel L, Offenstadt G, Guidet B. Prognosis of patients aged 80 years and over admitted in medical intensive care unit. Intensive Care Med. 2004;30:647&#x2013;654. doi: 10.1007/s00134-003-2150-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-2150-z</ArticleId><ArticleId IdType="pubmed">14985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vosylius S, Sipylaite J, Ivaskevicius J. Determinants of outcome in elderly patients admitted to the intensive care unit. Age Ageing. 2005;34:157&#x2013;162. doi: 10.1093/ageing/afi037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afi037</ArticleId><ArticleId IdType="pubmed">15713860</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardaine V, Dequin PF, Ripault H, Constans T, Gini&#xe8;s G. Outcome of older patients requiring ventilatory support in intensive care: impact of nutritional status. J Am Geriatr Soc. 2001;49:564&#x2013;570. doi: 10.1046/j.1532-5415.2001.49114.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2001.49114.x</ArticleId><ArticleId IdType="pubmed">11380748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaarlola A, Tallgren M, Pettil&#xe4; V. Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Crit Care Med. 2006;34:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">16763517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrand E, Robert R, Ingrand P, Lemaire F. French LATAREA Group. Withholding and withdrawal of life support in intensive-care units in France: a prospective survey. French LATAREA Group. Lancet. 2001;357:9&#x2013;14. doi: 10.1016/S0140-6736(00)03564-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)03564-9</ArticleId><ArticleId IdType="pubmed">11197395</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay E, Pochard F, Garrouste-Orgeas M, Moreau D, Montesino L, Adrie C, de Lassence A, Cohen Y, Timsit JF. Outcomerea Study Group. Decisions to forgo life-sustaining therapy in ICU patients independently predict hospital death. Intensive Care Med. 2003;29:1895&#x2013;1901. doi: 10.1007/s00134-003-1989-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-1989-3</ArticleId><ArticleId IdType="pubmed">14530857</ArticleId></ArticleIdList></Reference><Reference><Citation>Poses RM, Clish Mc, Smith WR. Prediction of survival of critically ill patients by admission comorbidities. J Clin Epidemiol. 1996;49:743&#x2013;747. doi: 10.1016/0895-4356(96)00021-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(96)00021-2</ArticleId><ArticleId IdType="pubmed">8691223</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres Olga H, Francia E, Longobardi V, Gich I, Benito S, Ruiz D. Short and long term outcomes of older patients in intermediate care units. Intensive Care Med. 2006;32:1052&#x2013;1059. doi: 10.1007/s00134-006-0170-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0170-1</ArticleId><ArticleId IdType="pubmed">16791668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LY, Moran JL, Clarke C, Martin J, Solomon PJ. Mortality and cost outcomes of elderly trauma patients admitted to intensive care and the general wards of an Australian tertiary referral hospital. Anaesth Intensive Care. 2009;37:773&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">19775042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Finn J, Knuiman M, Finn J, Webb SA. Combining multiple comorbidities with Acute Physiology Score to predict hospital mortality of critically ill patients: a linked data cohort study. Anaesthesia. 2007;62:1095&#x2013;1100. doi: 10.1111/j.1365-2044.2007.05231.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.2007.05231.x</ArticleId><ArticleId IdType="pubmed">17924888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Knuiman M, Finn J, Webb SA. Estimating long-term survival of critically ill patients: the PREDICT model. PLoS One. 2008;3:e3226. doi: 10.1371/journal.pone.0003226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003226</ArticleId><ArticleId IdType="pmc">PMC2528946</ArticleId><ArticleId IdType="pubmed">18797505</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabah A, Philippart F, Timsit JF, Willems V, Francais A, Leplege A, Carlet J, Bruel C, Misset B, Garrouste-Orgeas M. Quality of life in patients aged 80 or over after ICU discharge. Crit Care. 2010;14(1):R2. doi: 10.1186/cc8231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8231</ArticleId><ArticleId IdType="pmc">PMC2875504</ArticleId><ArticleId IdType="pubmed">20064197</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahul P, Perrot D, Tempelhoff G, Gaussorgues P, Jospe R, Ducreux JC, Dumont A, Motin J, Auboyer C, Robert D. Short- and long-term prognosis, functional outcome following ICU for elderly. Intensive Care Med. 1991;17:7&#x2013;10. doi: 10.1007/BF01708401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01708401</ArticleId><ArticleId IdType="pubmed">2037727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo M, Massaia M, Raspo S, Bosco F, Cena P, Molaschi M, Fabris F. Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. JAGS. 2003;51:519&#x2013;523. doi: 10.1046/j.1532-5415.2003.51161.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2003.51161.x</ArticleId><ArticleId IdType="pubmed">12657074</ArticleId></ArticleIdList></Reference><Reference><Citation>Niskanen M, Ruokonen E, Takala J, Rissanen P, Kari A. Quality of life after prolonged intensive care. Crit Care Med. 1999;27:1132&#x2013;1139. doi: 10.1097/00003246-199906000-00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199906000-00035</ArticleId><ArticleId IdType="pubmed">10397218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurel D, Loirat P, Saulnier F, Nicolas F, Brivet F. Quality of life 6 months after intensive care: results of a prospective multicenter study using a generic health status scale and a satisfaction scale. Intensive Care Med. 1997;23:331&#x2013;337. doi: 10.1007/s001340050336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050336</ArticleId><ArticleId IdType="pubmed">9083237</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines of intensive care unit admission discharge and triage. Society of Critical Care Medicine Task Force of American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med. 1999;27:633&#x2013;638. doi: 10.1097/00003246-199903000-00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199903000-00048</ArticleId><ArticleId IdType="pubmed">10199547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40731293</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial.</ArticleTitle><Pagination><StartPage>262</StartPage><MedlinePgn>262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-025-08979-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sepsis is the leading cause of death in critically ill patients, with an in-hospital mortality rate of approximately 25% to 40%. Coagulation activation serves as an initial factor to the progression of sepsis into multiple organ dysfunction syndrome (MODS). Therefore, anticoagulant therapy may be beneficial. Both preclinical experiments and clinical studies have evaluated the protective effect of nafamostat mesilate (NM) in sepsis. However, there is still a lack of randomized controlled trials (RCTs) to further confirm the therapeutic effect and safety of NM in sepsis patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, double-blind, RCT was designed to recruit 778 subjects who met Sepsis 3.0 criteria. Participants will be randomly assigned (1:1) to receive either intravenous administration of NM or glucose along with standard treatment. The primary outcome is the all-cause mortality rate in the intensive care unit (ICU), and the secondary outcomes include the improvement in SOFA scores, changes in Japanese Association for Acute Medicine (JAAM)/International Society on Thrombosis and Hemostasis (ISTH) scores, 28-day all-cause mortality rate, and the incidence of adverse events. The allocation will remain concealed from investigators, participants, and statisticians to maintain blinding.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The EASNMS trial aims to assess the efficacy and safety of NM for treating sepsis across various regions in China. As an additional treatment option, NM may potentially enhance the prognosis of sepsis patients.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">Ethical approval has been obtained from all ethics committees of the involved centers. The findings of this study will be shared in peer-reviewed journals and will be presented at conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT06078839. Registered on September 20, 2023.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Jianshuang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yuteng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China. vincentzh002@outlook.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EASNMS investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06078839</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2022YFC2304605</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Y25LQ0H97D</RegistryNumber><NameOfSubstance UI="C032855">nafamostat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001550">Benzamidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001550" MajorTopicYN="Y">Benzamidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="Y">Guanidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coagulation activation</Keyword><Keyword MajorTopicYN="N">Nafamostat mesilate</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study protocol has been approved by the Research and Ethics Committee of the First Affiliated Hospital of China Medical University ([2023] No. 453, Shenyang, China). The findings of this study will be shared in peer-reviewed journals and will be presented at conferences. Consent for publication: Not applicable. Competing interests: The principal investigators of this trial declare no competing financial or non-financial interests relevant to the conduct or outcomes of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40731293</ArticleId><ArticleId IdType="pmc">PMC12309187</ArticleId><ArticleId IdType="doi">10.1186/s13063-025-08979-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-025-08979-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801&#x2013;10. 10.1001/jama.2016.0287. Published Online First: 2016/02/24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552&#x2013;62. 10.1007/s00134-020-06151-x. Published Online First: 2020/06/24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381468</ArticleId><ArticleId IdType="pubmed">32572531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009&#x2013;2014. JAMA. 2017;318(13):1241&#x2013;9. 10.1001/jama.2017.13836. Published Online First: 2017/09/14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710396</ArticleId><ArticleId IdType="pubmed">28903154</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado FR, Cavalcanti AB, Bozza FA, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis. 2017;17(11):1180&#x2013;9. 10.1016/S1473-3099(17)30322-5. Published Online First: 2017/08/23.</Citation><ArticleIdList><ArticleId IdType="pubmed">28826588</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037. 10.1038/nrdp.2016.37. Published Online First: 2016/06/03.</Citation><ArticleIdList><ArticleId IdType="pubmed">27250996</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29(4):627&#x2013;42. 10.1016/j.ccm.2008.06.006. Published Online First: 2008/10/29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18954698</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191&#x2013;5. 10.1097/01.ccm.0000281468.94108.4b. Published Online First: 2007/09/15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855836</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Uchino S, Hayakawa M, et al. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2019;50:23&#x2013;30. 10.1016/j.jcrc.2018.11.009[publishedOnlineFirst:20181114]. Published Online First: 20181114.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471557</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Arakawa M, Di Nisio M, et al. Newly proposed sepsis-induced coagulopathy precedes international society on thrombosis and haemostasis overt-disseminated intravascular coagulation and predicts high mortality. J Intensive Care Med. 2020;35(7):643&#x2013;9. 10.1177/0885066618773679. Published Online First: 2018/05/04.</Citation><ArticleIdList><ArticleId IdType="pubmed">29720054</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology. 2020;132(5):1238&#x2013;45. 10.1097/ALN.0000000000003122. Published Online First: 2020/02/12.</Citation><ArticleIdList><ArticleId IdType="pubmed">32044801</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshiyama Y, Ozeki M, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis. Nihon Yakurigaku Zasshi. 1984;84(5):417&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">6519580</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41(2):155&#x2013;62. 10.1254/jjp.41.155. Published Online First: 1986/06/01.</Citation><ArticleIdList><ArticleId IdType="pubmed">2427760</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata M, Shirakawa T, Acharya B, et al. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 2006;52(3):272&#x2013;5. 10.1097/01.mat.0000209224.94089.bc. Published Online First: 2006/06/09.</Citation><ArticleIdList><ArticleId IdType="pubmed">16760715</ArticleId></ArticleIdList></Reference><Reference><Citation>Okajima K, Uchiba M, Murakami K. Nafamostat mesilate. Cardiovasc Drug Rev. 1995;13(1):51&#x2013;65.</Citation></Reference><Reference><Citation>Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial. 2003;7(5):483&#x2013;5. 10.1046/j.1526-0968.2003.00088.x. Published Online First: 2004/01/08.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao YG, Chen YC, Hao K, et al. An in vivo approach for globally estimating the drug flow between blood and tissue for nafamostat mesilate: the main hydrolysis site determination in human. Biol Pharm Bull. 2008;31(11):1985&#x2013;9. 10.1248/bpb.31.1985. Published Online First: 2008/11/05.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaori S, Fujiyama N, Kushihara M, et al. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet. 2006;21(2):147&#x2013;55. 10.2133/dmpk.21.147. Published Online First: 2006/05/17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Li S, Wan R, et al. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. Pancreas. 2015;44(4):561&#x2013;9. 10.1097/MPA.0000000000000310.</Citation><ArticleIdList><ArticleId IdType="pubmed">25822153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Lee SH, Park N, et al. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. BMC Gastroenterol. 2022;22(1):271. 10.1186/s12876-022-02345-3. Published Online First: 20220531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9153157</ArticleId><ArticleId IdType="pubmed">35641898</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CW, Kang DH, Kim GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009;69(4):e11&#x2013;8. 10.1016/j.gie.2008.10.046.</Citation><ArticleIdList><ArticleId IdType="pubmed">19327467</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. 10.1136/bmj.e7586. Published Online First: 20130108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Ding R, Sun H, et al. Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial. Trials. 2024;25(1):4. 10.1186/s13063-023-07853-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10759642</ArticleId><ArticleId IdType="pubmed">38167115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014;18(5):563. 10.1186/s13054-014-0563-4. Published Online First: 2014/10/17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213495</ArticleId><ArticleId IdType="pubmed">25318353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu S, Yu S, Wang L, et al. Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis. BMC Anesthesiol. 2022;22(1):28. 10.1186/s12871-021-01545-w. Published Online First: 2022/01/23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8777179</ArticleId><ArticleId IdType="pubmed">35062871</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Zou L, Pittet JF, et al. Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies. Anesth Analg. 2024;138(4):696&#x2013;711. 10.1213/ANE.0000000000006888. Published Online First: 2024/02/07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10916756</ArticleId><ArticleId IdType="pubmed">38324297</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989&#x2013;94. 10.1111/jth.14578. Published Online First: 2019/08/15.</Citation><ArticleIdList><ArticleId IdType="pubmed">31410983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabryelewicz A, Prokopowicz J, Bodzenta A, et al. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis. Digestion. 1988;40(1):19&#x2013;24. 10.1159/000199638.</Citation><ArticleIdList><ArticleId IdType="pubmed">3234615</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki M, Ozeki M, Sato T, et al. Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis. Nihon Yakurigaku Zasshi. 1984;84(4):363&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">6210233</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-S, Jeong S, Kim JM, et al. Preventative effect of nafamostat mesilate infusion into the main pancreatic duct on post-ERCP pancreatitis in a porcine model: initial pilot study. J Invest Surg. 2020;33(4):325&#x2013;31. 10.1080/08941939.2018.1511015.</Citation><ArticleIdList><ArticleId IdType="pubmed">30884994</ArticleId></ArticleIdList></Reference><Reference><Citation>Narumi K, Okada T, Lin Y, et al. Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2023;13(1):23012. 10.1038/s41598-023-50181-6. Published Online First: 20231227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10754829</ArticleId><ArticleId IdType="pubmed">38155200</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath IL, Kleiner D, Nagy R, et al. Nafamostat reduces the incidence of post-ERCP pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2024;115(2):206&#x2013;12. 10.1002/cpt.3118. Published Online First: 20231229.</Citation><ArticleIdList><ArticleId IdType="pubmed">38032816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura S, Umeda Y, Ogawa Y, et al. Effects of intermittent nafamostat mesylate in divided doses in patients with disseminated intravascular coagulation occurring with hematopoietic malignancies. Curr Ther Res. 1996;57(3):203&#x2013;14. 10.1016/s0011-393x(96)80126-3.</Citation></Reference><Reference><Citation>Tanaka S, Ohmine T. A case of abdominal aortic aneurysm presenting as symptomatic disseminated intravascular coagulation treated with endovascular aneurysm repair and postoperative administration of nafamostat mesylate. Surg Case Rep. 2024;10(1):124. 10.1186/s40792-024-01926-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11096137</ArticleId><ArticleId IdType="pubmed">38750283</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakata D, Fujiwara SI, Ikeda T, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109(2):141&#x2013;6. 10.1007/s12185-018-02567-w. Published Online First: 20181208.</Citation><ArticleIdList><ArticleId IdType="pubmed">30536180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamijo H, Mochizuki K, Nakamura Y, et al. Nafamostat mesylate improved survival outcomes of sepsis patients who underwent blood purification: a nationwide registry study in Japan. J Clin Med. 2020;9(8):2629. 10.3390/jcm9082629. Published Online First: 2020/08/23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7464767</ArticleId><ArticleId IdType="pubmed">32823637</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaeke P, De Man J, Hens S, et al. Sa1172 - effects of the non-selective protease inhibitor nafamostat mesylate on intestinal permeability and bacterial translocation in a murine model of sepsis. Gastroenterology. 2018;154(6):S267&#x2013;8. 10.1016/s0016-5085(18)31253-8.</Citation></Reference><Reference><Citation>Hryszko T, Inaba K, Ihara H, et al. Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. J Trauma. 2006;60(4):859&#x2013;64. 10.1097/01.ta.0000215566.74588.27. PublishedOnlineFirst:2006/04/14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16612309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27737408</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-9741</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Brazilian journal of cardiovascular surgery</Title><ISOAbbreviation>Braz J Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Mild Hypothermia May Offer Some Improvement to Patients with MODS after CPB Surgery.</ArticleTitle><Pagination><StartPage>246</StartPage><EndPage>251</EndPage><MedlinePgn>246-251</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5935/1678-9741.20160048</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0102-76382016000300246</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To summarize the effect of mild hypothermia on function of the organs in patients with multiple organ dysfunction syndrome after cardiopulmonary bypass surgery.</AbstractText><AbstractText Label="METHODS">The patients were randomly divided into two groups, northermia group (n=71) and hypothermia group (n=89). We immediately began cooling the hypothermia group when test results showed multiple organ dysfunction syndrome, meanwhile all patients of two groups were drawn blood to test blood gas, liver and kidney function, blood coagulation function, and evaluated the cardiac function using echocardiography from 12 to 36 hours. We compared the difference of intra-aortic balloon pump, extracorporeal membrane oxygenation rate and mortality within one month after intensive care unit admission.</AbstractText><AbstractText Label="RESULTS">Among the 160 patients, 36 died, 10 (11.24%) patients were from the hypothermia group and 26 (36.6%) from the northermia group (P&lt;0.05). In northermia group, 45 (63.38%) patients used intra-aortic balloon pump and 4 (5.63%), extracorporeal membrane oxygenation; in hypothermia group, 35 (39.32%) patients used intra-aortic balloon pump and 2 (2.25%), extracorporeal membrane oxygenation&#xff08;P&lt;0.05). The patients&#x2019; heart rate decreased significantly in the hypothermia group. The heart rate of hypothermia group is significantly slower than the northermia group at the 36th hour (P&lt;0.05). But the mean arterial pressure of hypothermia group is significantly higher than the northermia group at the 36th hour (P&lt;0.05). In hypothermia group, PO2, SvO2 and lactate were improved significantly compared to pre-cooling (P&lt;0.05), and they were significantly better than the northermia group at the 36th hour (P&lt;0.05%). Prothrombin time and activated partial thromboplastin time have no significantly difference between the two groups (P&gt;0.05). But the platelet count has significantly difference between the two groups at the 36th hour (P&lt;0.05). The aspartate transaminase, alanine transaminase and creatinine were improved significantly in the hypothermia group, and they were significantly better than the northermia group (P&lt;0.05).</AbstractText><AbstractText Label="CONCLUSION">Mild hypothermia is feasible and safe for patients with multiple organ dysfunction syndrome after cardiopulmonary bypass surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaoqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery ICU, The First Affiliated Hospital of China Medical University, Shenyang, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Tianxiang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery ICU, The First Affiliated Hospital of China Medical University, Shenyang, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiu</LastName><ForeName>Zongyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery ICU, The First Affiliated Hospital of China Medical University, Shenyang, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Enyi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery ICU, The First Affiliated Hospital of China Medical University, Shenyang, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery ICU, The First Affiliated Hospital of China Medical University, Shenyang, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Cardiovasc Surg</MedlineTA><NlmUniqueID>101677045</NlmUniqueID><ISSNLinking>0102-7638</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D062186" MajorTopicYN="N">Arterial Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007036" MajorTopicYN="N">Hypothermia, Induced</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>No conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27737408</ArticleId><ArticleId IdType="pmc">PMC5062708</ArticleId><ArticleId IdType="doi">10.5935/1678-9741.20160048</ArticleId><ArticleId IdType="pii">S0102-76382016000300246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">1597042</ArticleId></ArticleIdList></Reference><Reference><Citation>Umegaki T, Ikai H, Imanaka Y. The impact of acute organ dysfunction on patients' mortality with severe sepsis. J Anaesthesiol Clin Pharmacol. 2011;27(2):180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127295</ArticleId><ArticleId IdType="pubmed">21772676</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Authors/Task Force Members Chairpersons. ECG Subcommittee.Imaging Subcommittee. Classification Subcommittee. Intervention Subcommittee. Trials &amp; Registries Subcommittee. ESC Committee for Practice Guidelines Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">22958960</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwen Z, Chao W. Multi-center studies about the criterion of MODS. Chin J Surg. 2009;47(1):40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypothermia after Cardiac Arrest Study Group Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">11856793</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterbur K, Mann FA, Kuroki K, DeClue A. Multiple organ dysfunction syndrome in humans and animals. J Vet Intern Med. 2014;28(4):1141&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857933</ArticleId><ArticleId IdType="pubmed">24773159</ArticleId></ArticleIdList></Reference><Reference><Citation>Khadaroo RG, Marshall JC. ARDS and the multiple organ dysfunction syndrome. Common mechanisms of a common systemic process. Crit Care Clin. 2002;18(1):127&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910726</ArticleId></ArticleIdList></Reference><Reference><Citation>Morariu AM, Loef BG, Aarts LP, Rietman GW, Rakhorst G, van Oeveren W, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest. 2005;128(4):2677&#x2013;2687.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sablotzki A, Friedrich I, M&#xfc;hling J, Dehne MG, Spillner J, Silber RE, et al. The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion. 2002;17(2):103&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissier R, Chenoune M, Ghaleh B, Cohen MV, Downey JM, Berdeaux A. The small chill: mild hypothermia for cardioprotection? Cardiovasc Res. 2010;88(3):406&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972686</ArticleId><ArticleId IdType="pubmed">20621922</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdi I, Caputo M, Underwood M, Angelini GD, Bryan AJ. Influence of normothermic systemic perfusion temperature on cold myocardial protection during coronary artery bypass surgery. Cardiovasc Surg. 1999;7(3):369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">10386759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis ME, Al-Khalidi AH, Townend JN, Coote J, Bonser RS. The effects of hypothermia on human left ventricular contractile function during cardiac surgery. J Am Coll Cardiol. 2002;39(1):102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755294</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert NF, Meyer PE, Tauriainen MP, Chao RY, Patel JB, Malloy CR, et al. Effects of hypothermia on myocardial substrate selection. Ann Thorac Surg. 2002;74(4):1208&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12400770</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckberg GD, Brazier JR, Nelson RL, Goldstein SM, McConnell DH, Cooper N. Studies of the effects of hypothermia on reginal myocardial blood flow and metabolism during cardiopulmonary bypass-I. The adequately perfused beating, fibrillating, and arrested heart. J Thorac Cardiovasc Surg. 1977;73(1):87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">831012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning XH, Xu CS, Portman MA. Mitochondrial protein and HSP70 signaling after ischemia in hypothermic-adapted hearts augmented with glucose. Pt 2Am J Physiol. 1999;277(1):R11&#x2013;R17.</Citation><ArticleIdList><ArticleId IdType="pubmed">10409252</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346(8):557&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">11856794</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JL, Weissman C, Damask MC, Askanazi J, Hyman AI, Kinney JM. Physiologic requirements during rewarming: suppression of the shivering response. Crit Care Med. 1983;11(7):490&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">6407803</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank SM, Fleisher LA, Breslow MJ, Higgins MS, Olson KF, Kelly S, et al. Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomized clinical trial. JAMA. 1997;277(14):1127&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087467</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed? J Thorac Cardiovasc Surg. 2003;125(6):1438&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12830066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesel LM, Niederbichler AD, Ward PA. Complement-related molecular events in sepsis leading to heart failure. Mol Immunol. 2007;44(1-3):95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16875736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan LB. Cardiac pumping capability and prognosis in heart failure. Lancet. 1986;2(8520):328:1360&#x2013;328:1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">2878226</ArticleId></ArticleIdList></Reference><Reference><Citation>Alessio A, Martin M, Michael S, Birgit Z, Paul S, Jochen V, et al. Inotropic effects of experimental hyperthermia and hypothermia on left ventricular function in pigs-comparison with dobutamine. Crit Care Med. 2016;44(3):e158&#x2013;e167.</Citation><ArticleIdList><ArticleId IdType="pubmed">26474110</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tberg M, van der Pals J, Olivecrona GK, G&#xf6;tberg M, Koul S, Erlinge D. Mild hypothermia reduces acute mortality and improves hemodynamic outcome in a cardiogenic shock pig model. Resuscitation. 2010;81(9):1190&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">20627520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusuoka H, Ikoma Y, Futaki S, Suga H, Kitabatake A, Kamada T, et al. Positive inotropism in hypothermia partially depends on an increase in maximal Ca(2+)-activated force. Pt 2Am J Physiol. 1991;261(4):H1005&#x2013;H1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">1928384</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisser J, Martin J, Bisping E, Maier LS, Beyersdorf F, Hasenfuss G, et al. Influence of mild hypothermia on myocardial contractivity and circulatory function. Basic Res Cardiol. 2001;96(2):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11327339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypothermia after Cardiac Arrest Study Group Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">11856793</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346(8):557&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">11856794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristagno G, Tantillo S, Sun S, Weil MH, Tang W. Hypothermia improves ventricular myocyte contractility under conditions of normal perfusion and after an interval of ischemia. Resuscitation. 2010;81(7):898&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">20395031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shattock MS, Bers DM. Inotropic response to hypothermia and temperature-dependence of ryanodine action in isolated rabbit and rat ventricular muscle: implications for excitation-contraction coupling. Circ Res. 1987;61(6):761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">3677335</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao N, Lynch C., 3rd Effect of temperature on volatile anesthetic depression of myocardiac contractions. Anesth Analg. 1993;76(2):366&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">8424518</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunami M, Hearse DJ. The intropic consequences of cooling: studies in the isolated rat heart. Heart Vessels. 1989;5(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2584174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Naito Y, Nishioka T, Okamura Y. The effects of cardiac cooling under surface-induced hypothermia on the cardiac function in the in situ heart. Interact Cardiovasc Thorac Surg. 2005;4(2):101&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17670366</ArticleId></ArticleIdList></Reference><Reference><Citation>Suga H, Goto Y, Igarashi Y, Yasumura Y, Nozawa T, Futaki S, et al. Cardiac cooling increases Emax without affecting relation between O2 consumption and systolic pressure-volume area in dog left ventricle. Circ Res. 1998;63(1):61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">3383383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19519886</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study.</ArticleTitle><Pagination><StartPage>R88</StartPage><MedlinePgn>R88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc7914</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Severe tissue trauma results in a general inflammatory immune response (SIRS) representing an overall inflammatory reaction of the immune system. However, there is little known about the functional alterations of monocytes in the early posttraumatic phase, characterized by the battle of the individual with the initial trauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirteen patients with severe multiple injury; injury severity score (ISS) &gt;16 points (17 to 57) were included. The cytokine synthesis profiles of monocytes were characterized on admission, and followed up 6, 12, 24, 48, and 72 hours after severe multiple injury using flow cytometry. Whole blood was challenged with lipopolysaccharide (LPS) and subsequently analyzed for intracellular monocyte-related TNF-alpha, IL-1beta, IL-6, and IL-8. The degree of organ dysfunction was assessed using the multiple organ dysfunction syndrome (MODS)-score of Marshall on admission, 24 hours and 72 hours after injury.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our data clearly show that the capacity of circulating monocytes to produce these mediators de novo was significantly diminished very early reaching a nadir 24 hours after severe injury followed by a rapid and nearly complete recovery another 48 hours later compared with admission and controls, respectively. In contrast to the initial injury severity, there was a significant correlation detectable between the clinical signs of multiple organ dysfunction and the ex vivo cytokine response.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As our data derived from very narrow intervals of measurements, they might contribute to a more detailed understanding of the early immune alterations recognized after severe trauma. It can be concluded that indeed as previously postulated an immediate hyperactivation of circulating monocytes is rapidly followed by a substantial paralysis of cell function. Moreover, our findings clearly demonstrate that the restricted capacity of monocytes to produce proinflammatory cytokines after severe injury is not only an in vitro phenomenon but also undistinguishable associated with the onset of organ dysfunction in the clinical scenario.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>Chlodwig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Traumatology, Klinikum Rechts der Isar, Technische Universitaet, 81675 Munich, Germany. chlodwig.kirchhoff@mac.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mutschler</LastName><ForeName>Wolf E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Faist</LastName><ForeName>Eugen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jochum</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zedler</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="Y">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19519886</ArticleId><ArticleId IdType="pmc">PMC2717459</ArticleId><ArticleId IdType="doi">10.1186/cc7914</ArticleId><ArticleId IdType="pii">cc7914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077693</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11951032</ArticleId></ArticleIdList></Reference><Reference><Citation>Flohe S, Lendemans S, Schade FU, Kreuzfelder E, Waydhas C. Influence of surgical intervention in the immune response of severely injured patients. Intensive Care Med. 2004;30:96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">14605804</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, van Griensven M, Rice J, Gansslen A, Hildebrand F, Zech S, Winny M, Lichtinghagen R, Krettek C. Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma. 2001;50:989&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426112</ArticleId></ArticleIdList></Reference><Reference><Citation>Seekamp A, Jochum M, Ziegler M, van Griensven M, Martin M, Regel G. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. J Trauma. 1998;44:874&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoch RC, Rodriguez R, Manning T, Bishop M, Mead P, Shoemaker WC, Abraham E. Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med. 1993;21:839&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">8504650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast-Kolb D, Waydhas C, Gippner-Steppert C, Schneider I, Trupka A, Ruchholtz S, Zettl R, Schweiberer L, Jochum M. Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries. J Trauma. 1997;42:446&#x2013;454. discussion 454&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9095112</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992;216:117&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242583</ArticleId><ArticleId IdType="pubmed">1503516</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med. 1997;25:1813&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366763</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol. 2000;74:162&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608087</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrie C, Bachelet M, Vayssier-Taussat M, Russo-Marie F, Bouchaert I, Adib-Conquy M, Cavaillon JM, Pinsky MR, Dhainaut JF, Polla BS. Mitochondrial membrane potential and apoptosis peripheral blood monocytes in severe human sepsis. Am J Respir Crit Care Med. 2001;164:389&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">11500338</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora SK. Analysis of intracellular cytokines using flowcytometry. Methods Cell Sci. 2002;24:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815288</ArticleId></ArticleIdList></Reference><Reference><Citation>Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods. 1995;188:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8551029</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff C, Leidel BA, Kirchhoff S, Braunstein V, Bogner V, Kreimeier U, Mutschler W, Biberthaler P. Analysis of N-terminal pro-B-type natriuretic peptide and cardiac index in multiple injured patients: a prospective cohort study. Crit Care. 2008;12:R118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592747</ArticleId><ArticleId IdType="pubmed">18789145</ArticleId></ArticleIdList></Reference><Reference><Citation>WinMDI software </Citation></Reference><Reference><Citation>DeLong WG, Jr, Born CT. Cytokines in patients with polytrauma. Clin Orthop Relat Res. 2004;422:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose S, Marzi I. Mediators in polytrauma &#x2013; pathophysiological significance and clinical relevance. Langenbecks Arch Surg. 1998;383:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9776443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel C, Faist E, Zimmer S, Piltz S, Walz A, Rose R, Hocherl E, Herndon D, Schildberg FW. Kinetics of circulating adhesion molecules and chemokines after mechanical trauma and burns. Eur J Surg. 1996;162:763&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">8934104</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris BH, Gelfand JA. The immune response to trauma. Semin Pediatr Surg. 1995;4:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">7633853</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy T, Paterson H, Rogers S, Mannick JA, Lederer JA. Use of intracellular cytokine staining and bacterial superantigen to document suppression of the adaptive immune system in injured patients. Ann Surg. 2003;238:401&#x2013;410. discussion 410&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422703</ArticleId><ArticleId IdType="pubmed">14501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zedler S, Bone RC, Baue AE, von Donnersmarck GH, Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med. 1999;27:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9934895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods. 1993;159:197&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">8445253</ArticleId></ArticleIdList></Reference><Reference><Citation>Faist E, Storck M, Hultner L, Redl H, Ertel W, Walz A, Schildberg FW. Functional analysis of monocyte activity through synthesis patterns of proinflammatory cytokines and neopterin in patients in surgical intensive care. Surgery. 1992;112:562&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">1519173</ArticleId></ArticleIdList></Reference><Reference><Citation>Adib-Conquy M, Moine P, Asehnoune K, Edouard A, Espevik T, Miyake K, Werts C, Cavaillon JM. Toll-like receptor-mediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med. 2003;168:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10:233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1751079</ArticleId><ArticleId IdType="pubmed">17044947</ArticleId></ArticleIdList></Reference><Reference><Citation>Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Denny T, Deitch EA. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med. 2003;31:1722&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794411</ArticleId></ArticleIdList></Reference><Reference><Citation>Flohe S, Lendemans S, Selbach C, Waydhas C, Ackermann M, Schade FU, Kreuzfelder E. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med. 2003;31:2462&#x2013;2469.</Citation><ArticleIdList><ArticleId IdType="pubmed">14530752</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielmann S, Kerner T, Ahlers O, Keh D, Gerlach M, Gerlach H. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand. 2001;45:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207475</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med. 1995;23:1835&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A. Validation of postinjury multiple organ failure scores. Shock. 2009;31:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimopoulou I, Orfanos S, Kotanidou A, Livaditi O, Giamarellos-Bourboulis E, Athanasiou C, Korovesi I, Sotiropoulou C, Kopterides P, Ilias I, Kanellakopoulou K, Armaganidis A. Plasma pro- and anti-inflammatory cytokine levels and outcome prediction in unselected critically ill patients. Cytokine. 2008;41:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191577</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Remmers D, Grotz M, Schedel I, von Glinski S, Oberbeck R, Dahlweit M, Tscherne H. Levels of antibodies to endotoxin and cytokine release in patients with severe trauma: does posttraumatic dysergy contribute to organ failure? J Trauma. 1999;46:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">10338411</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly TJ, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994;22:768&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">8181284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21513997</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8332</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Lung cancer (Amsterdam, Netherlands)</Title><ISOAbbreviation>Lung Cancer</ISOAbbreviation></Journal><ArticleTitle>CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>257</EndPage><MedlinePgn>253-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lungcan.2011.03.006</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to assess the technical feasibility, efficacy, and complications of CT-guided interstitial brachytherapy for treating inoperable non-small cell lung cancer (NSCLC).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Twenty one patients were included in this prospective study. The median age was 72.6 years (57-85). Tumors were treated with brachytherapy that was positioned under CT-fluoroscopy. The treatment planning system (TPS) was used preoperatively to reconstruct three dimensional images of the tumor and to calculate the estimated seed number and distribution. The median matched peripheral dose (MPD) was 130 Gy (range, 100-160 Gy). All procedures were performed under local anesthesia. A follow-up CT was performed 6 weeks later and every 3 months post implantation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Follow-up period was 2-30 months. The mean diameter of the 21 lung tumors was 4.6 cm (range, 2.8-6.5 cm). The response rate of pain relief was 83.3% (10/12). The pain-free duration was 0-12 months (median: 6 months; 95% CI: 3-9 months). Overall responding rate (CR+PR) for this group of patients was 71.4%. Local tumor control rate was 85.7%. Six (28.6%) patients died as a result of primary tumor progression; thirteen (61.9%) patients died of multi-organ failure or other metastases. Two (9.5%) patients survived to follow-up. At the time of analysis, the median survival time for all patients was 10 months (95% CI: 6.6-13.4 months), with 1 year and 2 year survival rates were 42.4% and 6.5%, respectively. Median survival time for stage II, stage III, and stage IV was 20 months, 9 months, and 8 months, respectively. No major complications were observed. Minor complications (19%) included mild pneumothorax (n=1), hemosputum (n=1), pleural effusion (n=1), and localized skin erythema (n=1). None of these complications required further treatment, although hospital discharge was delayed. No (125)I seeds migrated to other tissues or organs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Minimally invasive CT-guided interstitial brachytherapy is safe, useful, less complicated and considered as a palliative treatment option for inoperable non-small cell lung cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhong-Min</ForeName><Initials>ZM</Initials><AffiliationInfo><Affiliation>School of Radiation Medicine and Public Health, Soochow University, 199 Ren Ai Road, Suzhou Industrial Park, Suzhou 215123, Jiangsu, China. wzm0722@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ke-Min</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fen-Ju</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Lung Cancer</MedlineTA><NlmUniqueID>8800805</NlmUniqueID><ISSNLinking>0169-5002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007456">Iodine Isotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001918" MajorTopicYN="Y">Brachytherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007456" MajorTopicYN="N">Iodine Isotopes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010996" MajorTopicYN="N">Pleural Effusion</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011030" MajorTopicYN="N">Pneumothorax</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21513997</ArticleId><ArticleId IdType="doi">10.1016/j.lungcan.2011.03.006</ArticleId><ArticleId IdType="pii">S0169-5002(11)00167-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32187391</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-2444</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JPEN. Journal of parenteral and enteral nutrition</Title><ISOAbbreviation>JPEN J Parenter Enteral Nutr</ISOAbbreviation></Journal><ArticleTitle>Meta-Analysis of Efficacy of Rhubarb Combined With Early Enteral Nutrition for the Treatment of Severe Acute Pancreatitis.</ArticleTitle><Pagination><StartPage>1066</StartPage><EndPage>1078</EndPage><MedlinePgn>1066-1078</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jpen.1789</ELocationID><Abstract><AbstractText Label="BACKGROUND">Whether to provide rhubarb combined with early enteral nutrition (rhubarb/EEN) to patients with severe acute pancreatitis (SAP) remains controversial. This study aimed to systematically explore the efficacy and safety of rhubarb/EEN in SAP patients.</AbstractText><AbstractText Label="METHODS">We performed searches in EMBASE, PubMed, Medline, Cochrane Library, Chinese Biomedicine Literature Database (SinoMed), Chinese Scientific Journal Database (VIP), Chinese National Knowledge Infrastructure (CNKI), and Wanfang database to identify relevant literature comparing rhubarb/EEN with EEN for SAP.</AbstractText><AbstractText Label="RESULTS">Eleven randomized controlled trials (724 patients) were included. Meta-analysis showed significantly shorter length of hospital stay (days) (mean difference [MD], -4.49; 95% CI, -6.09 to -2.90; P &lt; .00001), shorter length of intensive care unit stay (days) (MD, -2.82; 95% CI, -4.00 to -1.64; P &lt; .00001), shorter length of severe abdominal pain (days) (MD, -2.20; 95% CI, -2.50 to -1.90; P &lt; .00001), shorter length of abdominal distention (days) (MD, -2.31; 95% CI, -2.84 to -1.78; P &lt; .00001), shorter length of abnormal bowel sounds (days) (MD, -0.98; 95% CI, -1.12 to -0.88; P &lt; .00001), less hospitalization expenditure ($1422.75/&#xa5; 10,000) (MD, -1.40; 95% CI, -1.23 to -0.73; P &lt; .00001), and smaller Acute Physiology and Chronic Health Evaluation II scores (points) (MD, -2.18; 95% CI, -2.81 to -1.56; P &lt; .00001) in the rhubarb/EEN group than in the EEN group. Compared with EEN, rhubarb/EEN group had lower levels of white blood cells (10<sup>9</sup> /L) (MD, -2.77; 95% CI, -3.80 to -1.74; P &lt; .00001), C-reactive protein (mg/L) (MD, -10.71; 95% CI, -13.40 to -8.02; P &lt; .00001), and interleukin-6 (ng/L) (MD, -8.02; 95% CI, -11.38 to -4.65; P &lt; .00001). However, there were no significant differences (P &gt; .05) between the 2&#xa0;groups in terms of mortality rate (%) (P = .40), infection rate (%) (P = .28), and incidence of multiple organ dysfunction syndrome (%) (P = .09), but the overall effective rate was higher in the rhubarb/EEN group (MD, 2.57; 95% CI, 1.22 to &#x2248;5.42; P = .01).</AbstractText><AbstractText Label="CONCLUSIONS">Combination of EEN and rhubarb may improve the gastrointestinal function, inhibit systemic inflammation and disease severity, and enhance the efficacy of enteral nutrition, leading to better therapeutic effectiveness in SAP patients.</AbstractText><CopyrightInformation>&#xa9; 2020 American Society for Parenteral and Enteral Nutrition.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xinrong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-2561-8694</Identifier><AffiliationInfo><Affiliation>West China Hospital/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Guanda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>West China Hospital/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>West China Hospital/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JPEN J Parenter Enteral Nutr</MedlineTA><NlmUniqueID>7804134</NlmUniqueID><ISSNLinking>0148-6071</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="Y">Enteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012250" MajorTopicYN="Y">Rheum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">enteral nutrition</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">rhubarb</Keyword><Keyword MajorTopicYN="N">severe acute pancreatitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32187391</ArticleId><ArticleId IdType="doi">10.1002/jpen.1789</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Baron TH, Todd B. Managing severe acute pancreatitis. Cleve Clin J Med. 2013;80(6):354-359.</Citation></Reference><Reference><Citation>Hayden P, Wyncoll D. Severe acute pancreatitis. Crit Care Med. 2008;19(1):1-7.</Citation></Reference><Reference><Citation>Popa CC. Prognostic biological factors in severe acute pancreatitis. J Med Life. 2014:7(4):525-528.</Citation></Reference><Reference><Citation>Ji L, Sun B, Cheng CD, et&#xa0;al. Clinical experience on the employment of the staged step-up approach in the treatment of local complications secondary to severe acute pancreatitis. Zhonghua Wai Ke Za Zhi. 2016;54(11):839-843.</Citation></Reference><Reference><Citation>Whitcomb DC. Acute pancreatitis. N Engl J Med. 2006;354(20):2142-2150.</Citation></Reference><Reference><Citation>Li G, Shen X, Ke L, et&#xa0;al. Established enteral nutrition pathway in a severe acute pancreatitis patient with duodenum fistula: a case report. Eur J Clin Nutr. 2015;69(10):1176-1177.</Citation></Reference><Reference><Citation>Wu LM, Sankaran SJ, Plank LD, et&#xa0;al. Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis. Br J Surg. 2014;101(13):1644-1656.</Citation></Reference><Reference><Citation>Majidi S, Golembioski A, Wilson SL, et&#xa0;al. Acute pancreatitis: etiology, pathology, diagnosis, and treatment. South Med J. 2017;110(11):727-732.</Citation></Reference><Reference><Citation>Poropat G, Giljaca V, Hauser G, et&#xa0;al. Enteral nutrition formulations for acute pancreatitis. Cochrane Database Syst Rev. 2015;3(3):CD010605.</Citation></Reference><Reference><Citation>Mirtallo JM, Forbes A, Mcclave SA, et&#xa0;al. International consensus guidelines for nutrition therapy in pancreatitis. JPEN J Parenter Enteral Nutr. 2012;36(3):284.</Citation></Reference><Reference><Citation>Zou L, Ke L, Li W, et&#xa0;al. Enteral nutrition within 72 h after onset of acute pancreatitis vs delayed initiation. Eur J Clin Nutr. 2014;68(12):1288-1293.</Citation></Reference><Reference><Citation>Vaughn VM, Shuster D, Rogers MAM, et&#xa0;al. Early versus delayed feeding in patients with acute pancreatitis. Ann Intern Med. 2017;166(12):883-892.</Citation></Reference><Reference><Citation>Hu J, Li P, Zhang T. Rhubarb combined with trypsin inhibitor for severe acute pancreatitis: a systematic review and meta-analysis. Phytother Res. 2018;32(8):1450-1458.</Citation></Reference><Reference><Citation>Wang G, Sun B, Gao Y, et&#xa0;al. An experimental study of emodin assisted early enteral nutrition for the treatment of severe acute pancreatitis. Hepatogastroenterology. 2008;55(81):33-40.</Citation></Reference><Reference><Citation>Wang G, Sun B, Gao Y, et&#xa0;al. The effect of emodin-assisted early enteral nutrition on severe acute pancreatitis and secondary hepatic injury. Mediators Inflamm. 2007;2007(3):29638.</Citation></Reference><Reference><Citation>Page MJ, Moher D. Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and extensions: a scoping review. Syst Rev. 2017;6(1):263.</Citation></Reference><Reference><Citation>Beale RJ. [Practical guidelines for management of severe acute pancreatitis with integrated Chinese traditional and Western medicine (Draft)]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007;19(8):448-451.</Citation></Reference><Reference><Citation>Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. 1. 0. The Cochrane Collaboration; 2009.</Citation></Reference><Reference><Citation>Veroniki AA, Jackson D, Viechtbauer W, et&#xa0;al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55-79.</Citation></Reference><Reference><Citation>Luo J, Hu M. Clinical observation of dahuang tongbian granule combined with early enteral nutrition in treating severe pancreatitis. J Chin Med Mater. 2016;39(07):1667-1669.</Citation></Reference><Reference><Citation>Su SS, Bao LS. Dahuang Tongbian Granules plus early enteral nutrition for patients with severe acute pancreatitis: clinical efficacy and influence on intestinal mucosa barrier. World Chin J Digestol. 2016;24(17):2720-2725.</Citation></Reference><Reference><Citation>Zou H. Efficacy of enteral nutrition combined rhubarb in treatment of severe acute pancreatitis. Journal of Youjiang Medical University for Nationalities. 2015;37(4):555-556+564.</Citation></Reference><Reference><Citation>Wan B, Fu H, Yin J, et&#xa0;al. Efficacy of rhubarb combined with early enteral nutrition for the treatment of severe acute pancreatitis: a randomized controlled trial. Scand J Gastroenterol. 2014;49(11):1-10.</Citation></Reference><Reference><Citation>Wang L, Yan J, Wang F, et&#xa0;al. Study on the use of rhubarb in jejunal nutrition in the early stage of severe acute pancreatitis. Chinese Journal of Basic Chinese Medicine in Traditional Chinese Medicine. 2014;20(2):247-249.</Citation></Reference><Reference><Citation>Wang B, Fu HY, Yin JT, et&#xa0;al. Rhubarb combined with early enteral nutrition in the treatment of severe acute pancreatitis. J Chongqing Med Univ. 2014;38(1):61-64.</Citation></Reference><Reference><Citation>Zhu YB, Luan SM, Wang WY, et&#xa0;al. Clinical effect of enteral nutrition combined with rhubarb on severe acute pancreatitis. Zhejiang Practical Medicine. 2011;16(2):118-119.</Citation></Reference><Reference><Citation>Wu XL, Tao LP, Huang QK, et&#xa0;al. Clinical research of rhubarb combining with early enteral nutrition on severe acute pancreatitis. Chin J Clin Pharmacol Thera. 2011;16(1):61-66.</Citation></Reference><Reference><Citation>Wu XL. Effects of rhubarb combined with early enteral nutrition on immune function of severe acute pancreatitis patients. Journal of Hepatopancreatobiliary Surgery. 2010;22(1):38-41.</Citation></Reference><Reference><Citation>Wu XL, Huang ZM, Wu JS, et&#xa0;al. The effects of combination of rhubarb and early enteral nutrition on severe acute pancreatitis. Parenteral &amp; Enteral Nutrition. 2009;16(2):69-72.</Citation></Reference><Reference><Citation>Shen X, Jia YY, Yi XL, et&#xa0;al. Clinical study on the preventive and therapeutic effects of rhubarb on gastrointestinal hemorrhage in patients with severe acute pancreatitis. China Journal of Modern Medicine. 2003;13(17):118-119.</Citation></Reference><Reference><Citation>Martens E C, Mareike N, Desai MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol. 2018;16(8):457-470.</Citation></Reference><Reference><Citation>Alverdy JC, Chang EB. The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away. J Leukoc Biol. 2008;83(3):461-466.</Citation></Reference><Reference><Citation>Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol. 2014;20(38):13879-13892.</Citation></Reference><Reference><Citation>Zhang XM, Zhang ZY, Zhang CH, et&#xa0;al. Intestinal microbial community differs between acute pancreatitis patients and healthy volunteers. Biomed Environ Sci. 2018;31(1):81-86.</Citation></Reference><Reference><Citation>Li W, Liu JX, Zhao SQ, et&#xa0;al. Safety and efficacy of total parenteral nutrition versus total enteral nutrition for patients with severe acute pancreatitis: a meta-analysis. J Int Med Res. 2018;46(9):3948-3958.</Citation></Reference><Reference><Citation>Song JB, Zhong YL, Lu XG, et&#xa0;al. Enteral nutrition provided within 48 hours after admission in severe acute pancreatitis. Medicine. 2018;97(34):e11871.</Citation></Reference><Reference><Citation>Yu XZ, Li CY, Song HC, et&#xa0;al. Emodin attenuates autophagy response to protect the pancreas from acute pancreatitis failure. Pancreas. 2018;47(7):892-897.</Citation></Reference><Reference><Citation>Wang Y, Zhang X, Li C. Applying hot compresses with rhubarb and mirabilite to reduce pancreatic leakage occurrence in the treatment of severe acute pancreatitis. Iran J Public Health. 2017;46(1):136-138.</Citation></Reference><Reference><Citation>Zhou Y, Wang L, Huang X, et&#xa0;al. Add-on effect of crude rhubarb to somatostatin for acute pancreatitis: a meta-analysis of randomized controlled trials. J Ethnopharmacol. 2016;194:495-505.</Citation></Reference><Reference><Citation>Xiong YX, Chen L, Fan L, et&#xa0;al. Free total rhubarb anthraquinones protect intestinal injury via regulation of the intestinal immune response in a rat model of severe acute pancreatitis. Front Pharmacol. 2018;9:75.</Citation></Reference><Reference><Citation>Tang, QQ, Fang MY. Clinical observation of the effect of rhubarb nasal feeding and mirabilite external applying combined with western medicine on the treatment of severe acute pancreatitis. Pancreas. 2015;44(8):1419.</Citation></Reference><Reference><Citation>Yao P, Cui M, Li Y, et&#xa0;al. Effects of rhubarb on intestinal flora and toll-like receptors of intestinal mucosa in rats with severe acute pancreatitis. Pancreas. 2015;44(5):799-804.</Citation></Reference><Reference><Citation>Lu PF, Liao X, Xie YM, et&#xa0;al. The importance and necessity of establishing technical specifications for the registration of traditional Chinese medicine clinical studies. J Altern Complement Med. 2014;20(1):65-66.</Citation></Reference><Reference><Citation>Moher D, Hopewell S, Schulz KF, et&#xa0;al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2012;65(3):1. Published erratum appears in J Clin Epidemiol. 2010;63(8):e1-e37.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15048552</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0342-4642</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Effect of bicarbonate and lactate buffer on glucose and lactate metabolism during hemodiafiltration in patients with multiple organ failure.</ArticleTitle><Pagination><StartPage>1103</StartPage><EndPage>1110</EndPage><MedlinePgn>1103-10</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the effects of sodium bicarbonate and lactate for continuous veno-venous hemodiafiltration (CVVHDF) in critically ill patients.</AbstractText><AbstractText Label="DESIGN AND SETTINGS" NlmCategory="METHODS">Prospective crossed-over controlled trial in the surgical and medical ICUs of a university hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Eight patients with multiple organ dysfunction syndrome (MODS) requiring CVVHDF.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Each patient received the two buffers in a randomized sequence over two consecutive days.</AbstractText><AbstractText Label="MEASUREMENTS AND RESULTS" NlmCategory="RESULTS">The following variables were determined: acid-base parameters, lactate production and utilization ((13)C lactate infusion), glucose turnover (6,6(2)H(2)-glucose), gas exchange (indirect calorimetry). No side effect was observed during lactate administration. Baseline arterial acid-base variables were equal with the two buffers. Arterial lactate (2.9 versus 1.5 mmol/l), glycemia (+18%) and glucose turnover (+23%) were higher in the lactate period. Bicarbonate and glucose losses in CVVHDF were substantial, but not lactate elimination. Infusing (13)C lactate increased plasma lactate levels equally with the two buffers. Lactate clearance (7.8+/-0.8 vs 7.5+/-0.8 ml/kg per min in the bicarbonate and lactate periods) and endogenous production rates (14.0+/-2.6 vs 13.6+/-2.6 mmol/kg per min) were similar. (13)C lactate was used as a metabolic substrate, as shown by (13)CO(2) excretion. Glycemia and metabolic rate increased significantly and similarly during the two periods during lactate infusion.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lactate was rapidly cleared from the blood of critically ill patients without acute liver failure requiring CVVHDF, being transformed into glucose or oxidized. Lactate did not exert undesirable effects, except moderate hyperglycemia, and achieved comparable effects on acid-base balance to bicarbonate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bollmann</LastName><ForeName>Marc-Daniel</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit, University Hospital CHUV, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revelly</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Tappy</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Mette M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Schaller</LastName><ForeName>Marie-Denise</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Cayeux</LastName><ForeName>Marie-Christine</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chiol&#xe9;ro</LastName><ForeName>Ren&#xe9;-Louis</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002021">Buffers</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>8MDF5V39QO</RegistryNumber><NameOfSubstance UI="D017693">Sodium Bicarbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000136" MajorTopicYN="N">Acid-Base Equilibrium</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002021" MajorTopicYN="N">Buffers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017583" MajorTopicYN="N">Hemodiafiltration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017693" MajorTopicYN="N">Sodium Bicarbonate</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014882" MajorTopicYN="N">Water-Electrolyte Balance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15048552</ArticleId><ArticleId IdType="doi">10.1007/s00134-004-2251-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crit Care Med. 1997 Jan;25(1):4-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8989168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Nutr Metab. 1982;26(4):254-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7137947</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1992 Nov 26;327(22):1564-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1435883</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Clin Nutr Metab Care. 1999 Mar;2(2):161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10453348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 1989;4(9):800-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2516612</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 1999 Dec;27(12):2690-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10628611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Fail. 1990;12(2):99-101</Citation><ArticleIdList><ArticleId IdType="pubmed">2236733</ArticleId></ArticleIdList></Reference><Reference><Citation>QJM. 1998 Apr;91(4):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9666950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 2000 Oct;58(4):1751-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11012909</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1995 Apr;268(4 Pt 1):E630-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7733261</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1988 Apr;47(4):608-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3281434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 1999 Apr;229(4):505-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10203083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 2000 Oct;58(4):1765-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11012911</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1993 Dec 22-29;270(24):2957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1991 Oct;261(4 Pt 1):E457-65</Citation><ArticleIdList><ArticleId IdType="pubmed">1928337</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Physiol. 1978 Apr;33(1):9-26</Citation><ArticleIdList><ArticleId IdType="pubmed">27857</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 2001 Feb;12 Suppl 17:S15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11251027</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1993 Nov;58(5):608-13</Citation><ArticleIdList><ArticleId IdType="pubmed">8237864</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ren Replace Ther. 2002 Oct;9(4):282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12382232</ArticleId></ArticleIdList></Reference><Reference><Citation>JPEN J Parenter Enteral Nutr. 1980 Mar-Apr;4(2):147-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7401260</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1021-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9563714</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1999 Jul;277(1):E176-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10409142</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 1999 Nov;25(11):1244-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10654208</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1994 Jul;97(1):47-54</Citation><ArticleIdList><ArticleId IdType="pubmed">8030656</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Artif Organs. 1994 Jun;17(6):315-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7806416</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 1996 Jul;22(7):707-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1980 Feb;92(2 Pt 1):227-37</Citation><ArticleIdList><ArticleId IdType="pubmed">6766289</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Invest. 1993 Aug;23(8):448-54</Citation><ArticleIdList><ArticleId IdType="pubmed">8404995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29181605</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-086X</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cardiovascular and interventional radiology</Title><ISOAbbreviation>Cardiovasc Intervent Radiol</ISOAbbreviation></Journal><ArticleTitle>Symptomatic Heart Failure After Transjugular Intrahepatic Portosystemic Shunt Placement: Incidence, Outcomes, and Predictors.</ArticleTitle><Pagination><StartPage>564</StartPage><EndPage>571</EndPage><MedlinePgn>564-571</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00270-017-1848-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the incidence of symptomatic heart failure (SHF) occurring after transjugular intrahepatic portosystemic shunt (TIPS) placement, identify potential predictors of SHF, and evaluate clinical presentation and outcomes in cases of post-TIPS SHF.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospectively maintained TIPS database was used to identify patients who underwent new TIPS placements at a large urban tertiary care center between 1995 and 2014. SHF was defined as otherwise unexplained new-onset dyspnea, hypoxemia, radiologic pulmonary edema, an increased need for diuretics, or need for intubation within 7&#xa0;days after TIPS placement. Cases of deaths occurring within 7&#xa0;days due to septic shock, continuing gastrointestinal bleed, or multi-organ failure were excluded. A control group consisting of a random sample of 40 patients from the same TIPS database was created. Uni-variable analysis was performed to assess differences between patients with and without post-TIPS SHF.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 934 TIPS procedures performed during the study period, 883 met the inclusion criteria. Eight (0.9%) patients developed SHF, usually manifested by hypoxemia (50%) or dyspnea (25%) within 48&#xa0;h. Patients with SHF had higher pre-TIPS right atrial (p&#xa0;=&#xa0;0.03) and portal vein (p&#xa0;=&#xa0;0.01) pressures, higher albumin (p&#xa0;=&#xa0;0.02), and higher prothrombin time (p&#xa0;=&#xa0;0.02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Post-TIPS SHF is rare. Higher pre-TIPS right atrial and portal vein pressures are likely to predispose patients to this complication. Close monitoring may be warranted in these patients. In our eight patients, post-TIPS SHF did not result in poor outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Modha</LastName><ForeName>Kunjam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hospital Medicine, Cleveland Clinic, 9500 Euclid Avenue, M2 Annex, Cleveland, OH, 44195, USA. modhak@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Baljendra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Vascular and Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sands</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Vascular and Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carey</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Intervent Radiol</MedlineTA><NlmUniqueID>8003538</NlmUniqueID><ISSNLinking>0174-1551</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006975" MajorTopicYN="N">Hypertension, Portal</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011169" MajorTopicYN="N">Portal Vein</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019168" MajorTopicYN="N">Portasystemic Shunt, Transjugular Intrahepatic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac output</Keyword><Keyword MajorTopicYN="N">Cirrhosis</Keyword><Keyword MajorTopicYN="N">Hypervolemia</Keyword><Keyword MajorTopicYN="N">Portal hypertension</Keyword><Keyword MajorTopicYN="N">Portal pressure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29181605</ArticleId><ArticleId IdType="doi">10.1007/s00270-017-1848-1</ArticleId><ArticleId IdType="pii">10.1007/s00270-017-1848-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28682941</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Reduction in Mortality Rates of Postinjury Multiple Organ Dysfunction Syndrome: A Shifting Paradigm? A Prospective Population-Based Cohort Study.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>38</EndPage><MedlinePgn>33-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SHK.0000000000000938</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The incidence of multiple organ dysfunction syndrome (MODS) has decreased in the last decade by improvement in trauma care. However, it still remains a major cause of morbidity and mortality. This study investigated the current incidence and mortality of MODS in polytrauma patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A 3-year prospective study included consecutive trauma patients admitted to a Level-1 Trauma Center Intensive Care Unit (ICU). Isolated head injuries, drowning, asphyxiation, and burns were excluded. Demographics, Injury Severity Score (ISS), physiologic parameters, resuscitation parameters, and Denver multiple organ failure (MOF) scores were prospectively collected. Data are presented as median (interquartile range [IQR]), P&#x200a;&lt;&#x200a;0.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred fifty-seven patients were included. Median age was 45 (26-61) years, 118 males (75%), ISS was 29 (22-37), 151 (96%) patients had blunt injuries. Thirty-one patients developed MODS (20%). Twenty-seven patients (17%) died, 24 due to brain and/or spinal cord injuries (89%). Only one patient (3%) died of MODS. Median highest Denver MOF score was 4 (4-5). Median time to MODS onset was 3 (3-4) days after injury with a length of 2 (1-3) days. Only seven patients (23%) had MODS for more than 3 consecutive days. Patients who developed MODS were older, needed more blood products in the emergency department, more platelets &#x200a;&lt;&#x200a;8&#x200a;h and &lt;24&#x200a;h, stayed longer on the ventilator, longer in ICU and developed more often adult respiratory distress syndrome. There was however no difference in mortality between both groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this polytrauma population mortality was predominantly caused by brain injury. Even though MODS was still present in severely injured polytrauma patients, its presentation was only early onset, less severe during a shorter time period, and accompanied by lower mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28682941</ArticleId><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30152434</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1319-2442</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</Title><ISOAbbreviation>Saudi J Kidney Dis Transpl</ISOAbbreviation></Journal><ArticleTitle>Clinical spectrum of hospital acquired acute kidney injury: A prospective study from Central India.</ArticleTitle><Pagination><StartPage>946</StartPage><EndPage>955</EndPage><MedlinePgn>946-955</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/1319-2442.239650</ELocationID><Abstract><AbstractText>Acute kidney injury (AKI) is a common disorder worldwide that is associated with severe morbidity, mortality and cost. If managed adequately and in a timely manner, the majority of these cases are preventable, treatable and often reversible with simple measures. We conducted a two years prospective study of patients admitted to medical and surgical units of a tertiary care center in Central India to identify the causes of Hospital Acquired AKI (HAAKI) and its impact on patient outcomes. HAAKI occurred in 215 of 9,800 patients (2.1%). Sepsis (75; 34.88%), volume depletion and hypo perfusion (62; 28.83%), drugs (50; 23.25%), multifactorial (18; 8.37%) and radiocontrast agents (9; 4.2%) were the causes of HAAKI. Thirty-nine percent of patients had complete recovery and 9.3% had partial recovery of renal function. The overall inhospital mortality due to HAAKI was 41.86%. On multivariate analysis, oliguria, multi-organ failure, metabolic acidosis, anemia, and sepsis showed significant association with in-hospital mortality. The mortality and morbidity associated with HAAKI mandates the need for active measures to decrease its incidence. Knowledge of incidence and risk factors is crucial because it drives local and international efforts on detection and treatment. To the best of our knowledge, no epidemiological study has been conducted or published on HAAKI from the Central India.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Shraddha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Naresh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vohra</LastName><ForeName>Rubina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raju</LastName><ForeName>Bhavani M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Saudi Arabia</Country><MedlineTA>Saudi J Kidney Dis Transpl</MedlineTA><NlmUniqueID>9436968</NlmUniqueID><ISSNLinking>1319-2442</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020896" MajorTopicYN="N">Hypovolemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30152434</ArticleId><ArticleId IdType="doi">10.4103/1319-2442.239650</ArticleId><ArticleId IdType="pii">SaudiJKidneyDisTranspl_2018_29_4_946_239650</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25555146</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2210-2612</ISSN><JournalIssue CitedMedium="Print"><Volume>6C</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>International journal of surgery case reports</Title><ISOAbbreviation>Int J Surg Case Rep</ISOAbbreviation></Journal><ArticleTitle>Group A Streptococci: A rare and often misdiagnosed cause of spontaneous bacterial peritonitis in adults.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>255</EndPage><MedlinePgn>251-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijscr.2014.10.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2210-2612(14)00311-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Acute primary peritonitis due to group A Streptococci (GAS) is a rare but life-threatening infection. Unlike other forms of primary peritonitis it affects predominantly young previously healthy individuals and thus is often confused with the more frequent secondary peritonitis. A case series of three patients is presented as well as a review of the literature focusing on pitfalls in the diagnose and therapy of GAS peritonitis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis of three patients with primary GAS peritonitis was performed. Furthermore a systematic review of all cases of primary GAS peritonitis published from 1990 to 2013 was performed comparing demographics and clinical presentation, as well as radiological imaging, treatment and outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All three female patients presented initially with high fever, nausea and severe abdominal pain. Radiological imaging revealed intraperitoneal fluid collections of various degrees, but no underlying cause of peritonitis. Broad antibiotic treatment was started and surgical exploration was performed for acute abdomen in all three cases. Intraoperatively fibrinous peritonitis was observed, but the correct diagnosis was not made until microbiological analysis confirmed GAS peritonitis. One patient died within 24h after admission. The other two patients recovered after multiple surgeries and several weeks on the intensive care unit due to multiple organ dysfunction syndrome. The fulminant clinical course of the three patients resembled those of many of the published cases: flu-like symptoms, high fever, severe acute abdominal pain and fibrinous peritonitis without obvious infectious focus were the most common symptoms reported in the literature.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">GAS primary peritonitis should be considered in particular in young, previously healthy women who present with peritonitis but lack radiological findings of an infectious focus. The treatment of choice is immediate antibiotic therapy. Surgical intervention is difficult to avoid, since the diagnosis of GAS peritonitis is usually not confirmed until other causes of secondary peritonitis have been excluded.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malota</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Endocrine Surgery and Coloproctology, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany. Electronic address: mark.malota@klinikum-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felbinger</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care and Pain Medicine, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruppert</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Endocrine Surgery and Coloproctology, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfc;ssler</LastName><ForeName>Natascha C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Endocrine Surgery and Coloproctology, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Surg Case Rep</MedlineTA><NlmUniqueID>101529872</NlmUniqueID><ISSNLinking>2210-2612</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Group A Streptococcus</Keyword><Keyword MajorTopicYN="N">Peritonitis</Keyword><Keyword MajorTopicYN="N">abdominal pain</Keyword><Keyword MajorTopicYN="N">acute abdomen</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25555146</ArticleId><ArticleId IdType="pmc">PMC4347958</ArticleId><ArticleId IdType="doi">10.1016/j.ijscr.2014.10.060</ArticleId><ArticleId IdType="pii">S2210-2612(14)00311-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiest R., Krag A., Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012;61(February (2)):297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">22147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomkin J.S. Evaluating evidence and grading recommendations: the SIS/IDSA guidelines for the treatment of complicated intra-abdominal infections. Surg Infect. 2010;11(June (3)):269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20583865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamagni T.L., Efstratiou A., Vuopio-Varkila J. The epidemiology of severe Streptococcus pyogenes-associated disease in Europe. Eur Surveill. 2005;10:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">16280610</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J., Murchan S., O&#x2019;Flanagan D., Fitzpatrick F. Invasive Group A streptococcal disease in Ireland, 2004 to 2010. Eur Surveill. 2011;16 pii:19988.</Citation><ArticleIdList><ArticleId IdType="pubmed">22008200</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen R.D., Moser R., Schlup P., Neftel K.A. Fulminant group A streptococcal infections: Report of two cases. Klin Wochenschr. 1990;68:427&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190045</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., Pirofski L., Catalano M.T. Primary group A streptococcal peritonitis in adults. Am J Med. 1990;88:63N&#x2013;64N.</Citation><ArticleIdList><ArticleId IdType="pubmed">2195887</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier H., Halkic N. Streptococcal toxic shock syndrome revealed by a peritonitis. Swiss Surg. 2001;7:25&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11234313</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham J.C., Moss P.J., McKendrick M.W. Primary group A streptococcal peritonitis. Scand J Infect Dis. 1995;27:171&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">7660084</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitz M., Ehrenberg E., Grieco R. Primary peritonitis due to group A Streptococcus. J Clin Gastroenterol. 2000;30:325&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">10777203</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia S.M., Low D.E., Andrighetti S., Rau N.V. Group A streptococcal sepsis secondary to peritonitis and acute pelvic inflammatory disease. Eur J Clin Microbiol Infect Dis. 2001;20:437&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476452</ArticleId></ArticleIdList></Reference><Reference><Citation>Doloy A., Godin C., Decousser J.W. Primary peritonitis due to Streptococcus pyogenes with reduced susceptibility to fluoroquinolones. Diagn Microbiol Infect Dis. 2008;62:447&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">18842379</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lelyveld-Haas L.E., Dekkers A.J., Postma B., Tjan D.H. An unusual cause of a spontaneous bacterial peritonitis in a young healthy woman. N Z Med J. 2008;121:82&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">18670478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gribbin JC1, Cox C.J. Spontaneous bacterial peritonitis in a healthy adult male. Aust N Z J Surg. 1990;60(September (9)):723&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">2204334</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox K.L., Born M.W., Cohen M.A. Fulminant infection and toxic shock syndrome caused by Streptococcus pyogenes. J Emerg Med. 2002;22:357&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">12113845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueyama N., Kuwashima S., Nakayama A. Ileal adenomyoma accompanied by primary peritonitis: report of a case. Surg Today. 2001;31:826&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">11686566</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura K., Schroff R., Campbell R. Group A streptococcal puerperal sepsis with retroperitoneal involvement developing in a late postpartum woman: case report. Am Surg. 2004;70:730&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">15328810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez N.C., Lancaster B.A. A rare case of primary group A streptococcal peritonitis. Am Surg. 2001;67:633&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">11450776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanetake K., Hayashi M., Hino A. Primary peritonitis associated with streptococcal toxic shock-like syndrome: report of a case. Surg Today. 2004;34:1053&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580392</ArticleId></ArticleIdList></Reference><Reference><Citation>Brivet F.G., Smadja C., Hilbert U. Usefulness of abdominal CT scan in severe peritoneal sepsis linked to primary peritonitis. Scand J Infect Dis. 2005;37:76&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvis J., Trivedi S., Sheda S., Frizelle F.A. Primary peritonitis in adults: is it time to look for a better diagnostic classification? ANZ J Surg. 2006;76:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626348</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha P., Morewood T., Naftalin J., Hopkins S. Acute abdomen in a healthy woman: primary peritonitis due to Group A Streptococcus. J Obstet Gynaecol. 2006;26:700&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071450</ArticleId></ArticleIdList></Reference><Reference><Citation>Haap M., Haas C.S., Teichmann R. Mystery or misery? Primary group A streptococcal peritonitis in women: case report. Am J Crit Care. 2010;19:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635804</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D., Perpoint T., Dauwalder O. In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome. Eur J Clin Microbiol Infect Dis. 2009;28:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">19020908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella A., Kavanagh D.O., McGiobuin S. Primary peritonitis from an insect bite. Ir Med J. 2009;102:87&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">19489198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilanus A.M., de Geus H.R., Rijnders B.J. Severe group A streptococcal toxic shock syndrome presenting as primary peritonitis: a case report and brief review of the literature. Int J Infect Dis. 2010;14(Suppl. 3):e208&#x2013;e212.</Citation><ArticleIdList><ArticleId IdType="pubmed">19914115</ArticleId></ArticleIdList></Reference><Reference><Citation>Monneuse O., Tissot E., Gruner L. Diagnosis and treatment of spontaneous group A streptococcal peritonitis. Br J Surg. 2010;97:104&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">20013929</ArticleId></ArticleIdList></Reference><Reference><Citation>Legras A., LoDico R., Ferre R. Primary peritonitis due to Streptococcus A: laparoscopic treatment. J Vasc Surg. 2011;148:e315&#x2013;e317.</Citation><ArticleIdList><ArticleId IdType="pubmed">21889922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogami Y., Tsuji K. Case of streptococcal toxic shock syndrome caused by rapidly progressive group A hemolytic streptococcal infection during postoperative chemotherapy for cervical cancer. J Obstet Gynaecol Res. 2014;40(January (1)):250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">23937219</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S.Y., Kim Y.H., Park W.S. Acute phlegmonous gastritis complicated by delayed perforation. World J Gastroenterol. 2014;20(March (12)):3383&#x2013;3387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964411</ArticleId><ArticleId IdType="pubmed">24696618</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens D.L. Group A streptococcal sepsis. Curr Infect Dis Rep. 2003;5:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101722</ArticleId><ArticleId IdType="pubmed">13678567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray S., Morgan J. Two cases of group A streptococcal vulvovaginitis in premenopausal adults in a sexual health setting. Sex Health. 2006;3:187&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17044225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha N.K. Infectious disease emergencies. In: Carey W.D., editor. Cleveland Clinic: Current Clinical Medicine. Second ed. Saunders Elsevier; Philadelphia: 2009. pp. 733&#x2013;742.</Citation></Reference><Reference><Citation>Morgan M.S. Diagnosis and management of necrotizing fasciitis: a multiparametric approach. J Hosp Infect. 2010;75:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">20542593</ArticleId></ArticleIdList></Reference><Reference><Citation>Little P. Clinical score and rapid antigen detection test to guide antibiotic use for sore throats: randomised controlled trial of PRISM (primary care streptococcal management) BMJ. 2013;347(October):f5806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3805475</ArticleId><ArticleId IdType="pubmed">24114306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood T.F., Potter M.A., Jonasson O. Streptococcal toxic shocklike syndrome: the importance of surgical intervention. Ann Surg. 1993;217:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242748</ArticleId><ArticleId IdType="pubmed">8439208</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B., Andersson J., Holm S. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis. 1999;180:410&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">10395857</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens D.L., Gibbons A.E., Bergstrom R., Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">3292661</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael Haap Mystery or misery? Primary group A streptococcal peritonitis in women: case report. Am J Crit Care. 2010;19:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635804</ArticleId></ArticleIdList></Reference><Reference><Citation>Guss C., Larsen J.G. Group A beta-hemolytic streptococcal proctocolitis. Pediatr Infect Dis. 1984;3(September&#x2013;October (5)):442&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">6387643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger R.P., Levy M.M., Carlet J.M. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">18158437</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst F.M., Engel C., Bloos F. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184958</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood D.A., Roberts R.H. Management of primary group A streptococcal peritonitis: a systematic review. Surg Infect. 2013;14(April (2)):171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23464678</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto C.C. Peritonitis rates of the past thirty years: from improvement to stagnation. Perit Dial Int. 2014;34(March&#x2013;April (2)):151&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968099</ArticleId><ArticleId IdType="pubmed">24676740</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16542484</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>R40</StartPage><MedlinePgn>R40</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Disturbances in microcirculatory homeostasis have been hypothesized to play a key role in the pathophysiology of multiple organ dysfunction syndrome and vasopressor-associated ischemic skin lesions. The effects of a supplementary arginine vasopressin (AVP) infusion on microcirculation in vasodilatory shock and postoperative multiple organ dysfunction syndrome are unknown.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Included in the study were 18 patients who had undergone cardiac or major surgery and had a mean arterial blood pressure below 65 mmHg, despite infusion of more than 0.5 microg/kg per min norepinephrine. Patients were randomly assigned to receive a combined infusion of AVP/norepinephrine or norepinephrine alone. Demographic and clinical data were recorded at study entry and after 1 hour. A laser Doppler flowmeter was used to measure the cutaneous microcirculatory response at randomization and after 1 hour. Reactive hyperaemia and oscillatory changes in the Doppler signal were measured during the 3 minutes before and after a 5-minute period of forearm ischaemia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients receiving AVP/norepinephrine had a significantly higher mean arterial pressure (P = 0.047) and higher milrinone requirements (P = 0.025) than did the patients who received norepinephrine only at baseline. Mean arterial blood pressure significantly increased (P &lt; 0.001) and norepinephrine requirements significantly decreased (P &lt; 0.001) in the AVP/norepinephrine group. Patients in the AVP/norepinephrine group exhibited a significantly higher oscillation frequency of the Doppler signal before ischaemia and during reperfusion at randomization. During the study period, there were no differences in either cutaneous reactive hyperaemia or the oscillatory pattern of vascular tone between groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Supplementary AVP infusion in patients with advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome did not compromise cutaneous reactive hyperaemia and flowmotion when compared with norepinephrine infusion alone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luckner</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;nser</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Stadlbauer</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Viktoria D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Jochberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Hanno</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Pajk</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Hasibeder</LastName><ForeName>Walter R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Friesenecker</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Knotzer</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>113-79-1</RegistryNumber><NameOfSubstance UI="D001127">Arginine Vasopressin</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care. 2006;10(2):135. doi: 10.1186/cc4884.</RefSource><PMID Version="1">16594988</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001127" MajorTopicYN="N">Arginine Vasopressin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006940" MajorTopicYN="N">Hyperemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16542484</ArticleId><ArticleId IdType="pmc">PMC1550871</ArticleId><ArticleId IdType="doi">10.1186/cc4845</ArticleId><ArticleId IdType="pii">cc4845</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haisjackl M, Hasibeder W, Klaunzer S, Altenberger H, Koller W. Diminished reactive hyperemia in the skin of critically ill patients. Crit Care Med. 1990;18:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">2379393</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Creteur J, Preiser JC, Dubois MD, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166:98&#x2013;104. doi: 10.1164/rccm.200109-016OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200109-016OC</ArticleId><ArticleId IdType="pubmed">12091178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care. 2005:S9&#x2013;S12. doi: 10.1186/cc3748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc3748</ArticleId><ArticleId IdType="pmc">PMC3226162</ArticleId><ArticleId IdType="pubmed">16168075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;32:1825&#x2013;1831. doi: 10.1097/01.CCM.0000138558.16257.3F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000138558.16257.3F</ArticleId><ArticleId IdType="pubmed">15343008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Surviving Sepsis Campaign Management Guidelines Committee Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858&#x2013;873. doi: 10.1097/01.CCM.0000117317.18092.E4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000117317.18092.E4</ArticleId><ArticleId IdType="pubmed">15090974</ArticleId></ArticleIdList></Reference><Reference><Citation>Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med. 2004;32:S455&#x2013;S465. doi: 10.1097/01.CCM.0000142909.86238.B1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000142909.86238.B1</ArticleId><ArticleId IdType="pubmed">15542956</ArticleId></ArticleIdList></Reference><Reference><Citation>LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28:2729&#x2013;2732. doi: 10.1097/00003246-200008000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200008000-00007</ArticleId><ArticleId IdType="pubmed">10966242</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;nser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313&#x2013;2319. doi: 10.1161/01.CIR.0000066692.71008.BB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000066692.71008.BB</ArticleId><ArticleId IdType="pubmed">12732600</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576&#x2013;582. doi: 10.1097/00000542-200203000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200203000-00011</ArticleId><ArticleId IdType="pubmed">11873030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15103461</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesenecker B, Tsai AG, D&#xfc;nser MW, Mayr AJ, Martini J, Knotzer H, Hasibeder W, Intaglietta M. Oxygen distribution in microcirculation after arginine vasopressin-induced arteriolar vasoconstriction. Am J Physiol Heart Circ Physiol. 2004;287:H1792&#x2013;H1800. doi: 10.1152/ajpheart.00283.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00283.2004</ArticleId><ArticleId IdType="pubmed">15191895</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunser MW, Mayr AJ, Tur A, Pajk W, Friesenecker B, Knotzer H, Ulmer H, Hasibeder W. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med. 2003;31:1394&#x2013;1398. doi: 10.1097/01.CCM.0000059722.94182.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000059722.94182.79</ArticleId><ArticleId IdType="pubmed">12771608</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple organ failure. Generalized autodestructive inflammation? Arch Surg. 1985;120:1109&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbink EJ, Wollersheim H, Netten PM, Smits P. Reproducibility of skin microcirculatory measurements in humans, with special emphasis on capillaroscopy. Vasc Med. 2001;6:203&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958384</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JD, Cameron EM. Dynamics of skin blood flow in human sepsis. Intensive Care Med. 1995;21:669&#x2013;674. doi: 10.1007/BF01711546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01711546</ArticleId><ArticleId IdType="pubmed">8522672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson H, Aalkjaer C. Vasomotion: mechanisms and physiologic importance. Mol Interv. 2003;3:79&#x2013;89. doi: 10.1124/mi.3.2.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mi.3.2.79</ArticleId><ArticleId IdType="pubmed">14993429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschenbaum LA, Astiz ME, Rackow EC, Saha DC, Lin R. Microvascular response in patients with cardiogenic shock. Crit Care Med. 2000;28:1290&#x2013;1294. doi: 10.1097/00003246-200005000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200005000-00005</ArticleId><ArticleId IdType="pubmed">10834667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl WH, Gunther B, Inthorn D, Heberer G. Reactive hyperemia in patients with septic conditions. Surgery. 1988;103:440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">3353857</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer C, de Vries G, Davidge ST, Mayes DC. Reassessing the mathematical modelling of the contribution of vasomotion to vascular resistance. J Appl Physiol. 2002;92:888&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838438</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588&#x2013;595. doi: 10.1056/NEJMra002709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra002709</ArticleId><ArticleId IdType="pubmed">11529214</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth BL, Spitzer JA. Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol. 1987;252:E699&#x2013;E702.</Citation><ArticleIdList><ArticleId IdType="pubmed">3034072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez de Turco EB, Spitzer JA. Impairments in vasopressin-stimulated inositol lipid metabolism in hepatocytes of septic rats. Circ Shock. 1988;25:299&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">2844434</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer JA, Turco EB, Deaciuc IV, Roth BL. Perturbation of transmembrane signaling mechanisms in acute and chronic endotoxemia. Prog Clin Biol Res. 1987;236A:401&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">3039527</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. Intensive Care Med. 2003;29:1020&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">12736775</ArticleId></ArticleIdList></Reference><Reference><Citation>Boerma EC, Van der Voort PHJ, Ince C. Sublingual microcirculatory flow is impaired by the vasopressin-analogue terlipressin in a patient with catecholamine-resistant septic shock. Acta Anaesthesiol Scand. 2005;49:1387&#x2013;1390. doi: 10.1111/j.1399-6576.2005.00752.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2005.00752.x</ArticleId><ArticleId IdType="pubmed">16146482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowell LB. Cutaneous and skeletal muscle circulations. In: Rowell LB, editor. Human circulation Regulation during physical stress. New York, Oxford: Oxford University Press; 1986. pp. 96&#x2013;116.</Citation></Reference><Reference><Citation>Cryer HM, Garrison RN, Kaebnick HW, Harris PD, Flint LM. Skeletal microcirculatory responses to hyperdynamic Escherichia coli sepsis in unanesthetized rats. Arch Surg. 1987;122:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">3541855</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper RD, Pitt-Hyde M, Li F, Sibbald WJ, Potter RF. Microcirculatory changes in rat skeletal muscle in sepsis. Am J Respir Crit Care Med. 1996;154:931&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">8887588</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal SS. Regulation of blood flow in the microcirculation. Microcirculation. 2005;12:33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39918592</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>The optimal timing for definitive operative stabilization of pelvic fractures in polytrauma patients: effects on clinical outcomes - a systematic review.</ArticleTitle><Pagination><StartPage>100</StartPage><MedlinePgn>100</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-025-02774-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The optimal timing for definitive surgical treatment of pelvic fractures in polytrauma patients remains a topic of ongoing discussion due to the complexity of these injuries. This analysis therefore aims to systematically compare early versus late definitive operative stabilization of pelvic fractures on outcome in polytrauma patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, CENTRAL and Web of Science were systematically searched to identify relevant completed and ongoing studies from the inception of each database to March 13, 2023. Systematic reviews, randomized control trials (RCTs) and observational studies comparing early (&lt;&#x2009;24&#xa0;h) versus late (&gt;&#x2009;24&#xa0;h) definitive operative stabilization in adult polytrauma patients admitted to the ICU were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Since no systematic reviews and RCTs were available on this subject, one observational study was identified, including a total of 418 polytrauma patients (n<sub>early</sub> = 165, n<sub>late</sub> = 253), median age: 40.3 years (early 40.1 years, late 40.4 years). Early definitive stabilization was associated with a decreased risk of acute respiratory distress syndrome (ARDS) compared to late stabilization of unstable pelvis and acetabulum fractures (RR 0.38, 95% CI 0.18-0.81; RD 78 fewer per 1000, 95% CI 104 fewer to 24 fewer; 1 study, 418 participants; very low certainty of evidence). Furthermore, early definitive stabilization may decrease the risk of pneumonia compared to late stabilization of unstable pelvis and acetabulum fractures (RR 0.50, 95% CI 0.28-0.88; RD 85 fewer per 1000, 95% CI 122 fewer to 20 fewer); 1 study, 418 participants; very low certainty of evidence).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is limited evidence regarding early definitive fracture repair (&#x2264;&#x2009;24&#xa0;h) compared to late repair of pelvic fractures in polytrauma patients. One observational study showed a reduced incidence of septic respiratory complications, ARDS, and multi-organ failure (MOF) in polytrauma patients who received early definitive fracture repair.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dormann</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany. jdormann@ukaachen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horst</LastName><ForeName>Klemens</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Trauma and Reconstructive Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahms</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinfeld</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansems</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janka</LastName><ForeName>Heidrun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzendorf</LastName><ForeName>Maria-Inti</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breuer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benstoem</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Trauma and Reconstructive Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolierakis</LastName><ForeName>Eftychios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Trauma and Reconstructive Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010384" MajorTopicYN="Y">Pelvic Bones</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050723" MajorTopicYN="Y">Fractures, Bone</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005592" MajorTopicYN="Y">Fracture Fixation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Early stabilization</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Late stabilization</Keyword><Keyword MajorTopicYN="N">Pelvic fracture</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39918592</ArticleId><ArticleId IdType="pmc">PMC11805852</ArticleId><ArticleId IdType="doi">10.1007/s00068-025-02774-1</ArticleId><ArticleId IdType="pii">10.1007/s00068-025-02774-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>L&#xf6;gters T, Lefering R, Schneppendahl J, Alldinger I, Witte I, Windolf J, et al. Abbruch Der Schockraumdiagnostik Und Notfalloperation Beim Polytrauma &#x2013; Inzidenz und klinische Relevanz. Der Unfallchirurg. 2010;113l&#x2013;(10):832&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20393832</ArticleId></ArticleIdList></Reference><Reference><Citation>Enninghorst N, Toth L, King KL, McDougall D, Mackenzie S, Balogh ZJ. Acute definitive internal fixation of pelvic ring fractures in polytrauma patients: a feasible option. J Trauma Acute Care Surg. 2010;68(4):935&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20386287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertel W, Keel M, Eid K, Platz A, Trentz O. Control of severe hemorrhage using C-Clamp and pelvic packing in multiply injured patients with pelvic ring disruption. J Orthop Trauma. 2001;15(7):468&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimbanassi S, O&#x2019;Toole R, Maegele M, Henry S, Scalea TM, Bove F et al. Orthopedic injuries in patients with multiple injuries: results of the 11th trauma update international consensus conference Milan, December 11, 2017. Journal of Trauma and Acute Care Surgery. 2020;88(2):e53-e76.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150031</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz MRW, Allami MK, Harwood P, Pape HC, Krettek C, Giannoudis PV. Open pelvic fractures: epidemiology, current concepts of management and outcome. Injury. 2005;36(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15589906</ArticleId></ArticleIdList></Reference><Reference><Citation>Balogh Z, Caldwell E, Heetveld M, D&#x2019;Amours S, Schlaphoff G, Harris I, et al. Institutional practice guidelines on management of pelvic fracture-related hemodynamic instability: do they make a difference? J Trauma Acute Care Surg. 2005;58(4):778&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondo MF, Zonies DH. The damage control sequence, and underlying logic. Surg Clin North Am. 1997;77(4):761&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TH, Yoon YC, Chung JY, Song HK. Strategies for the management of hemodynamically unstable pelvic fractures: from preperitoneal pelvic packing to definitive internal fixation. Asian J Surg. 2019;42(11):941&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30685148</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer R, Klingebiel FK-L, Halvachizadeh S, Kalbas Y, Pape H-C. How to clear polytrauma patients for fracture fixation: results of a systematic review of the literature. Injury. 2023;54(2):292&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">36404162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Halvachizadeh S, Leenen L, Velmahos GD, Buckley R, Giannoudis PV. Timing of major fracture care in polytrauma patients &#x2013; an update on principles, parameters and strategies for 2020. Injury. 2019;50(10):1656&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31558277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Pfeifer R. Safe definitive orthopaedic surgery (SDS): repeated assessment for tapered application of early definitive care and damage control? An inclusive view of recent advances in polytrauma management. Injury. 2015;46(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25540874</ArticleId></ArticleIdList></Reference><Reference><Citation>Tscherne H. The treatment of the severly injured at an emergency station. Chirurg. 1966;37:249&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">5995039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan&#x2014;a web and mobile app for systematic reviews. Syst Reviews. 2016;5(1):210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Microsoft Corporation. (2018). Microsoft Excel [Version 2018].</Citation></Reference><Reference><Citation>Review Manager (RevMan). Version 5.3. The Cochrane Collaboration. 2020. Available at revman.cochrane.org.</Citation></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, Savovi&#x107; J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>GRADEpro Guideline Development Tool. McMaster University and Evidence Prime. 2023. Available at gradepro.org.</Citation></Reference><Reference><Citation>Vallier HA, Cureton BA, Ekstein C, Oldenburg FP, Wilber JH. Early definitive stabilization of unstable pelvis and acetabulum fractures reduces morbidity. J Trauma. 2010;69(3):677&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20838139</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor NA, Smith AA, Marr A, Stuke L, Greiffenstein P, Schoen J, et al. Does time to pelvic fixation influence outcomes in trauma patients? Am Surgeon&#x2122;. 2022;88(5):840&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34797191</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaney GL, Bulman J, King KL, Balogh ZJ. Time to definitive fixation of pelvic and acetabular fractures. J Trauma Acute Care Surg. 2020;89(4):730&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535089</ArticleId><ArticleId IdType="pubmed">33017134</ArticleId></ArticleIdList></Reference><Reference><Citation>Grey B, Rodseth RN, Muckart DJ. Early fracture stabilisation in the presence of subclinical hypoperfusion. Injury. 2013;44(2):217&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22995980</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas DG, Coleman JR, Moore EE, Dean CS, Parry JA, Elrick BP, et al. The association of surgical timing and injury severity with systemic complications in severely injured patients with pelvic ring injuries. J Orthop Trauma. 2021;35(4):171&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33727520</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaisier BR, Meldon SW, Super DM, Malangoni MA. Improved outcome after early fixation of acetabular fractures. Injury. 2000;31(2):81&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10748809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotwica Z, Balcewicz L, Jagodzi&#x144;ski Z. Head injuries coexistent with pelvic or lower extremity fractures&#x2013;early or delayed osteosynthesis. Acta Neurochir (Wien). 1990;102(1&#x2013;2):19&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">2305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Latenser BA, Gentilello LM, Tarver AA, Thalgott JS, Batdorf JW. Improved outcome with early fixation of skeletally unstable pelvic fractures. J Trauma. 1991;31(1):28&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">1986129</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst C, Probst T, Gaensslen A, Krettek C, Pape HC. Timing and duration of the initial pelvic stabilization after multiple trauma in patients from the German trauma registry: is there an influence on outcome? J Trauma. 2007;62(2):370&#x2013;7. discussion 6&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24594915</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Relationship between pre-implant interleukin-6 levels, inflammatory response, and early outcome in patients supported by left ventricular assist device: a prospective study.</ArticleTitle><Pagination><StartPage>e90802</StartPage><MedlinePgn>e90802</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e90802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0090802</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The immune response is crucial in the development of multi-organ failure (MOF) and complications in end-stage heart failure patients supported by left ventricular assist device (LVAD). However, at pre-implant, the association between inflammatory state and post-LVAD outcome is not yet clarified. Aim of the study was to assess the relationship among pre-implant levels of immune-related cytokines, postoperative inflammatory response and 3-month outcome in LVAD-patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 41 patients undergoing LVAD implantation, plasma levels of interleukin (IL)-6, IL-8, crucial for monocyte modulation, and urine neopterin/creatinine ratio (Neo/Cr), marker of monocyte activation, were assessed preoperatively, at 3 days, 1 and 4 weeks post-LVAD. MOF was evaluated by total sequential organ failure assessment (tSOFA) score. Intensive care unit (ICU)-death and/or post-LVAD tSOFA &#x2265;11 was considered as main adverse outcome. Length of ICU-stay, 1 week-tSOFA score, hospitalisation and 3-month survival were considered additional end-points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During ICU-stay, 8 patients died of MOF, while 8 of the survivors experienced severe MOF with postoperative tSOFA score &#x2265;11. Pre-implant level of IL-6 &#x2265; 8.3 pg/mL was identified as significant marker of discrimination between patients with or without adverse outcome (OR 6.642, 95% CI 1.201-36.509, p&#x200a;=&#x200a;0.030). Patients were divided according to pre-implant IL-6 cutoff of 8.3 pg/ml in A [3.5 (1.2-6.1) pg/mL] and B [24.6 (16.4-38.0) pg/mL] groups. Among pre-implant variables, only white blood cells count was independently associated with pre-implant IL-6 levels higher than 8.3 pg/ml (OR 1.491, 95% CI 1.004-2.217, p&#x200a;=&#x200a;0.048). The ICU-stay and hospitalisation resulted longer in B-group (p&#x200a;=&#x200a;0.001 and p&#x200a;=&#x200a;0.030, respectively). Postoperatively, 1 week-tSOFA score, IL-8 and Neo/Cr levels were higher in B-group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LVAD-candidates with elevated pre-implant levels of IL-6 are associated, after intervention, to higher release of monocyte activation related-markers, a clue for the development of MOF, longer clinical course and poor outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CNR Institute of Clinical Physiology, CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botta</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milazzo</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vecchi</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivella</LastName><ForeName>Maria Giovanna</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>CNR Institute of Clinical Physiology and University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paino</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigerio</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parodi</LastName><ForeName>Oberdan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CNR Institute of Clinical Physiology, CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>670-65-5</RegistryNumber><NameOfSubstance UI="D019798">Neopterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019798" MajorTopicYN="N">Neopterin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24594915</ArticleId><ArticleId IdType="pmc">PMC3942482</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0090802</ArticleId><ArticleId IdType="pii">PONE-D-13-27037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lund LH, Matthews J, Aaronson K (2010) Patient selection for left ventricular assist devices. Eur J Heart Fail 12: 434&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">20172939</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. ESC Committee for Practice Guidelines (CPG) (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">18826876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) American College of Cardiology Foundation; American Heart Association (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: e391&#x2013;e479.</Citation><ArticleIdList><ArticleId IdType="pubmed">19324966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SR, Mudge GH, Stewart Jr GC, Givertz MM (2009) Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 119: 2225&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pubmed">19398678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga T, Kinugawa K, Hatano M, Yao A, Nishimura T, et al. (2011) Age and preoperative total bilirubin level can stratify prognosis after extracorporeal pulsatile left ventricular assist device implantation. Circ J 75: 121&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">21116070</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso R, Trunfio S, Milazzo F, Campolo J, De Maria R, et al. (2010) Early expression of pro- and anti-Inflammatory cytokines in left ventricular assist device recipients with multiple organ failure syndrome. ASAIO J 56: 313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">20445439</ArticleId></ArticleIdList></Reference><Reference><Citation>Masai T, Sawa Y, Ohtake S, Nishida T, Nishimura M, et al. (2002) Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 73: 549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">11845873</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng MC, Edwards LB, Hertz MI, Rowe AW, Keck BM, et al. (2005) International Society for Heart and Lung Transplantation (2005) Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third Annual Report-2005. J Heart Lung Transplant 24: 1182&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143231</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso R, Verde A, Cabiati M, Milazzo F, Boroni C, et al. (2012) Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients. J Heart Lung Transplant 31: 625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">22386451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiel E, Vallet B, ten Cate H (2005) The endothelium in intensive care. Crit Care Clin 21: 403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, et al. (2005) ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26: 384&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681577</ArticleId></ArticleIdList></Reference><Reference><Citation>Minne L, Abu-Hanna A, de Jonge E (2008) Evaluation of SOFA-based models for predicting mortality in the ICU: a systematic review. Crit Care 12: R161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646326</ArticleId><ArticleId IdType="pubmed">19091120</ArticleId></ArticleIdList></Reference><Reference><Citation>Palardy M, Nohria A, Rivero J, Lakdawala N, Campbell P, et al. (2010) Right ventricular dysfunction during intensive pharmacologic unloading persists after mechanical unloading. J Card Fail 16: 218&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913073</ArticleId><ArticleId IdType="pubmed">20206896</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Greene T, Kusek JW, Beck GJ (2000) Simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11: 828A.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira FL, Bota DP, Bross A, M&#xe9;lot C, Vincent JL (2001) Serial evaluation of the t-SOFA score to predict outcome in critically ill patients. JAMA 286: 1754&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Cirillo P, Pacileo M, Petrillo G, D&#x2019;Ascoli GL, et al. (2011) Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharm 9: 188&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">21143176</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani ML, De Lutiis MA, Toniato E, Conti F, Felaco P, et al. (2012) Impact of RANTES, MCP-1 and IL-8 in mast cells. J Biol Regul Homeost Agents 24: 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20385066</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasier AR (2010) The nuclear factor-kB&#x2013;interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86: 211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912657</ArticleId><ArticleId IdType="pubmed">20202975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87: 241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926876</ArticleId></ArticleIdList></Reference><Reference><Citation>Herpfer I, Greilberger J, Ledinski G, Widner B, Fuchs D, et al. (2002) Neopterin and 7,8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or copper. Free Radic Res 36: 509&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch M, Boval B, Damy T, Ghendouz S, Vermes E, et al. (2012) Importance of monocyte deactivation in determining early outcome after ventricular assist device implantation. Int J Artif Organs 35: 169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">22461111</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DS, Thavichaigarn P, Pattanapanyasat K, Siritongtaworn P, Kongcharoen P, et al. (2005) Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. J Surg Res 29: 221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">16045935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, et al. (2006) Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 25: 129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525350</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, et al. (2000) Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 26: 883&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">10990102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33858393</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2482</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC surgery</Title><ISOAbbreviation>BMC Surg</ISOAbbreviation></Journal><ArticleTitle>A comparison of postoperative outcomes after open and laparoscopic reduction of Petersen's Hernia: a multicenter observational cohort study.</ArticleTitle><Pagination><StartPage>195</StartPage><MedlinePgn>195</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">195</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12893-021-01200-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this multicenter cohort study was to compare the clinical courses between open and laparoscopic Petersen's hernia (PH) reduction.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We retrospectively collected the clinical data of patients who underwent PH repair surgery after gastrectomy for gastric cancer from 2015-2018. Forty patients underwent PH reduction operations that were performed by six surgeons at four hospitals. Among the 40 patients, 15 underwent laparoscopic PH reduction (LPH), and 25 underwent open PH reduction (OPH), including 4 patients who underwent LPH but required conversion to OPH.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We compared the clinical factors between the LPH and OPH groups. In the clinical course, we found no differences in operation times or intraoperative bowel injury, morbidity, or mortality rates between the two groups (p&#x2009;&gt;&#x2009;0.05). However, the number of days on a soft fluid diet (OPH vs. LPH; 5.8 vs. 3.7&#xa0;days, p&#x2009;=&#x2009;0.03) and length of hospital stay (12.6 vs. 8.2&#xa0;days, p&#x2009;=&#x2009;0.04) were significantly less in the LPH group than the OPH group. Regarding postoperative complications, the OPH group had a case of pneumonia and sepsis with multi-organ failure, which resulted in mortality. In the LPH group, one patient experienced recurrence and required reoperation for PH.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Laparoscopic PH reduction was associated with a faster postoperative recovery period than open PH reduction, with a similar incidence of complications. The laparoscopic approach should be considered an appropriate strategy for PH reduction in selected cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Min</LastName><ForeName>Jae-Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Cancer Center, Dongnam Institute of Radiological and Medical Sciences, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Seo</LastName><ForeName>Kyung Won</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kosin University Gospel Hospital, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Sang-Ho</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0001-9061-6236</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea. jshgnu@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University College of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. jshgnu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ki Hyun</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kosin University Gospel Hospital, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ji-Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University Hospital, Jinju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Ki Young</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kosin University Gospel Hospital, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Han</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University College of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Eun-Jung</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Young-Tae</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Chi-Young</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju-Yeon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Young-Joon</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Surg</MedlineTA><NlmUniqueID>100968567</NlmUniqueID><ISSNLinking>1471-2482</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006555" MajorTopicYN="N">Hernia, Ventral</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059685" MajorTopicYN="N">Herniorrhaphy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gastric neoplasm</Keyword><Keyword MajorTopicYN="N">Internal hernia</Keyword><Keyword MajorTopicYN="N">Laparoscopy</Keyword><Keyword MajorTopicYN="N">Petersen&#x2019;s hernia</Keyword></KeywordList><CoiStatement>Dr. Jae-Seok Min, Kyung Won Seo, Ki Hyun Kim, Sang-Ho Jeong, Ji-ho Park, Ki Young Yoon, Tae-Han Kim, Eun-Jung Jung, Young-tae Ju, Chi-Young Jeong, Ju-Yeon Kim, Young-Joon Lee, and have no conflicts of interest or financial ties to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33858393</ArticleId><ArticleId IdType="pmc">PMC8051092</ArticleId><ArticleId IdType="doi">10.1186/s12893-021-01200-8</ArticleId><ArticleId IdType="pii">10.1186/s12893-021-01200-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petersen W. Ueber darmveschlingung nach der gastro-enterostomie. Arch Klin Chir. 1900;62:94&#x2013;114.</Citation></Reference><Reference><Citation>Kang KM, Cho YS, Min SH, Lee Y, Park KB, Park YS, Ahn SH, Park DJ, Kim HH. Internal hernia after gastrectomy for gastric cancer in minimally invasive surgery era. Gastric Cancer. 2019;22:1009&#x2013;1015. doi: 10.1007/s10120-019-00931-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-019-00931-1</ArticleId><ArticleId IdType="pmc">PMC6694080</ArticleId><ArticleId IdType="pubmed">30758761</ArticleId></ArticleIdList></Reference><Reference><Citation>Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group &amp; Review Panel Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer. 2019;19:1&#x2013;48. doi: 10.5230/jgc.2019.19.e8.</Citation><ArticleIdList><ArticleId IdType="doi">10.5230/jgc.2019.19.e8</ArticleId><ArticleId IdType="pmc">PMC6441770</ArticleId><ArticleId IdType="pubmed">30944757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ, Korean Laparo-endoscopic Gastrointestinal Surgery Study Group Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage i gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01) Ann Surg. 2016;263:28&#x2013;35. doi: 10.1097/SLA.0000000000001346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001346</ArticleId><ArticleId IdType="pubmed">26352529</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and mortality of laparoscopic versus open d2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34:1350&#x2013;1357. doi: 10.1200/JCO.2015.63.7215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.63.7215</ArticleId><ArticleId IdType="pubmed">26903580</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson M, Thune A, Nelvin L, Stiernstam M, Westman B, Lundell L. Randomized clinical trial of open versus laparoscopic cholecystectomy in the treatment of acute cholecystitis. Br J Surg. 2005;92:44&#x2013;49. doi: 10.1002/bjs.4836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.4836</ArticleId><ArticleId IdType="pubmed">15584058</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A, Snow V, Fitterman N, Hornbake ER, Lawrence VA, Smetana GW, Weiss K, Owens DK, Aronson M, Barry P, Casey DE, Jr, Cross JT, Jr, Fitterman N, Sherif KD, Weiss KB. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med. 2006;144:575&#x2013;580. doi: 10.7326/0003-4819-144-8-200604180-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-144-8-200604180-00008</ArticleId><ArticleId IdType="pubmed">16618955</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, Haglind E, P&#xe5;hlman L, Cuesta MA, Msika S, Morino M, Lacy AM. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6:477&#x2013;484. doi: 10.1016/S1470-2045(05)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(05)70221-7</ArticleId><ArticleId IdType="pubmed">15992696</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto T, Kawarai Lefor A. Laparoscopic reduction and closure of an internal hernia secondary to gynecologic surgery. Case Rep Surg. 2017;2017:5948962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5376451</ArticleId><ArticleId IdType="pubmed">28409048</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudsmedt F, Deylgat B, Coenegrachts K, Van De Moortele K, Dillemans B. Internal hernia after laparoscopic Roux-en-Y gastric bypass: a correlation between radiological and operative findings. Obes Surg. 2015;25:622&#x2013;627. doi: 10.1007/s11695-014-1433-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-014-1433-5</ArticleId><ArticleId IdType="pubmed">25218014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima K, Inokuchi M, Kato K, Motoyama K, Sugihara K. Petersen's hernia after laparoscopic distal gastrectomy with Roux-en-Y reconstruction for gastric cancer. Gastric Cancer. 2014;17:146&#x2013;151. doi: 10.1007/s10120-013-0256-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-013-0256-8</ArticleId><ArticleId IdType="pubmed">23558458</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenberg E, Szabo E, Agren G, Ottosson J, Marsk R, Lonroth H, Boman L, Magnuson A, Thorell A, Naslund I. Closure of mesenteric defects in laparoscopic gastric bypass: a multicentre, randomised, parallel, open-label trial. Lancet. 2016;387:1397&#x2013;1404. doi: 10.1016/S0140-6736(15)01126-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01126-5</ArticleId><ArticleId IdType="pubmed">26895675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22040928</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1409</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>Incidence of early burn-induced effects on liver function as reflected by the plasma disappearance rate of indocyanine green: a prospective descriptive cohort study.</ArticleTitle><Pagination><StartPage>214</StartPage><EndPage>224</EndPage><MedlinePgn>214-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.burns.2011.08.017</ELocationID><Abstract><AbstractText>Organ dysfunction and failure are important for burned patients as they increase morbidity and mortality. Recent evidence has suggested that organ injuries are occurring earlier after burns, and are more common than previously thought. In this study we have assessed the extent to which liver function, assessed by the plasma disappearance rate of indocyanine green (PDR(ICG)), is affected in patients with severe burns. This is a prospective, descriptive exploratory study at a national burn centre. Consecutive adult patients with a percent total body surface area burned (TBSA%) of 20% or more, were examined prospectively by dynamic (PDR(ICG)) and static liver function tests (plasma: bilirubin concentration, prothrombin complex, and alanine aminotransferase and alkaline phosphatase activities). Early liver dysfunction was common, as it is assessed by both dynamic (7 of 17) and static liver function tests (6-17 of 17). A regression model showed that changes in PDR(ICG) were associated with age, TBSA%, plasma bilirubin concentration, plasma C-reactive protein concentration, and cardiac index. Persistent and advanced hepatic dysfunction was associated with mortality. The PDR(ICG) seems to give a comprehensive assessment of liver function after major burns. Hepatic dysfunction seems to be as common as dysfunction in other organs. We interpret the recorded effects on liver function as part of a multiple organ dysfunction syndrome, primarily induced by the burn itself. However, this needs to be further investigated.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2011 Elsevier Ltd and ISBI. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinvall</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Burn Unit, Department of Hand and Plastic Surgery, Link&#xf6;ping University Hospital, Link&#xf6;ping, 58185, Sweden. ingrid.steinvall@lio.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fredrikson</LastName><ForeName>Mats</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bak</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Sjoberg</LastName><ForeName>Folke</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>IX6J1063HV</RegistryNumber><NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008107" MajorTopicYN="N">Liver Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22040928</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2011.08.017</ArticleId><ArticleId IdType="pii">S0305-4179(11)00255-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19770739</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome.</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>160</EndPage><MedlinePgn>152-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e3181b78671</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction with cardiogenic shock (CS) are often treated with intra-aortic balloon pump counterpulsation (IABP), even though the evidence to support this is limited. We determined whether IABP as an addition to PCI-centered therapy ameliorates multiorgan dysfunction syndrome (MODS) in patients with acute myocardial infarction complicated by CS.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective, randomized, controlled, open-label clinical trial recruiting patients between March 2003 and June 2004 (ClinicalTrials.gov ID NCT00469248).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary care university hospital.</AbstractText><AbstractText Label="PATIENTS AND INTERVENTIONS" NlmCategory="METHODS">Forty-five consecutive patients with AMI and CS undergoing PCI were randomized to treatment with or without IABP.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Acute Physiology and Chronic Health Evaluation (APACHE) II scores (primary outcome measure), hemodynamic values, inflammatory markers, and plasma brain natriuretic peptide (BNP) levels (secondary outcomes) were collected over 4 days from randomization. The prospective hypothesis was that adding IABP therapy to "standard care" would improve CS-triggered MODS. The addition of IABP to standard therapy did not result in a significant improvement in MODS (measured by serial APACHE II scoring over 4 days). IABP use had no significant effect on cardiac index or systemic inflammatory activation, although BNP levels were significantly lower in IABP-treated patients. Initial and serial APACHE II scoring correlated with mortality better than cardiac index, systemic inflammatory state, and BNP levels in this group of patients. Nonsurvivors had significantly higher initial APACHE II scores (29.9 +/- 2.88) than survivors (18.1 +/- 1.66, p &lt; .05). Nevertheless, discrepancies among patients within the groups cannot be ruled out and might interfere with our results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this randomized trial addressing addition of IABP in CS patients, mechanical support was associated only with modest effects on reduction of APACHE II score as a marker of severity of disease, improvement of cardiac index, reduction of inflammatory state, or reduction of BNP biomarker status compared with medical therapy alone. However, the limitations of our present trial preclude any definitive conclusion, but request for a larger prospective, randomized, multicentered trial with mortality as primary end point.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prondzinsky</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Department of Biometrics and Statistics (SU), Martin-Luther-University, Halle-Wittenberg, Halle/Saale, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemm</LastName><ForeName>Henning</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Swyter</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wegener</LastName><ForeName>Nikolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Justin M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Russ</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schlitt</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Buerke</LastName><ForeName>Ute</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Christoph</LastName><ForeName>Arnd</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thiery</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Buerke</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00469248</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2010 Jan;38(1):321-2. doi: 10.1097/CCM.0b013e3181c30c67.</RefSource><PMID Version="1">20023483</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015908" MajorTopicYN="N">Counterpulsation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19770739</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3181b78671</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22033056</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2012</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>The evaluation of the effect of body positioning on intra-abdominal pressure measurement and the effect of intra-abdominal pressure at different body positioning on organ function and prognosis in critically ill patients.</ArticleTitle><Pagination><StartPage>222.e1</StartPage><EndPage>222.e2226</EndPage><MedlinePgn>222.e1-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2011.08.010</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Current literatures confirmed the widespread and frequent development of both intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) among the critically ill with a significant associated risk of organ failure and increased mortality. The 2004 International ACS Consensus Conference committee proposed that intra-abdominal pressure (IAP) be measured in complete supine position; however, the supine position of intensive care unit (ICU) patients (&lt;30&#xb0; of bed increase) presented a significant risk for ventilator-associated pneumonia. Therefore, the potential contribution of head of bed (HOB) position in elevating IAP should be considered. The purpose of this study was to evaluate the effect of body positioning on IAP measurement and the effect of IAP at different body positions on organ function and prognosis in critically ill patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospective cohort study to investigate the effect of different patient positioning on IAP, organ function, and prognosis was conducted on 88 patients admitted to a medical-surgical ICU. On admission, patients' epidemiological data and risk factors for IAH were studied; daily mean IAPs, abdominal perfusion pressure, filtration gradient, Acute Physiology and Chronic Health Evaluation II score, sequential organ failure assessment score, and multiple organ dysfunction scores were registered; next, conventional hemodynamic variables, intrathoracic blood volume index, global end-diastolic volume index and extravascular lung water using the pulse contour cardiac output system were recorded. Intra-abdominal pressures were recorded through a bladder catheter every 4 hours on the first day. Intra-abdominal pressure was measured with the patient HOB increases from 0&#xb0; to 45&#xb0;. Mean arterial pressure was recorded simultaneously, whereas abdominal perfusion pressure and filtration gradient (FG) were also calculated simultaneously.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main results of this study were the incidence of IAH (28.4%) and ACS (2.3%) in ICU patients; the significant and independent relationship between IAP and HOB increases. Considering the absolute numbers of IAP, the HOB of 10&#xb0; and 20&#xb0; showed slight differences, whereas that of 30&#xb0; and 45&#xb0; showed clinically significant differences; HOB elevation was associated with clinically significant decreases in abdominal perfusion pressure and FG; patients with IAH were prone to the development of shock and multiple organ dysfunction syndrome and exhibited significantly lower intrathoracic blood volume index and global end-diastolic volume index and higher extravascular lung water.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is a significant and independent relationship between IAP and HOB positioning in critically ill patients, with the HOB of 30&#xb0; and 45&#xb0; showing significant difference. Abdominal perfusion pressure and FG are significantly decreased when the patient's HOB is elevated. The potential contribution of body position in elevating IAP should be considered in critically ill patients with the risk of IAH and ACS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Peking University Third Hospital, Beijing 100191, PR China. minyi0101@yahoo.com.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Gaiqi</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xi</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D034841" MajorTopicYN="N">Abdominal Cavity</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059325" MajorTopicYN="N">Intra-Abdominal Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056888" MajorTopicYN="N">Patient Positioning</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011312" MajorTopicYN="N">Pressure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22033056</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2011.08.010</ArticleId><ArticleId IdType="pii">S0883-9441(11)00386-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15142885</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>328</Volume><Issue>7451</Issue><PubDate><Year>2004</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery.</ArticleTitle><Pagination><StartPage>1281</StartPage><MedlinePgn>1281</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare postoperative complications in patients undergoing major surgery who received non-filtered or filtered red blood cell transfusions.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, randomised, double blinded trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">19 hospitals throughout the Netherlands (three university; 10 clinical; six general).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">1051 evaluable patients: 79 patients with ruptured aneurysm, 412 patients undergoing elective surgery for aneurysm, and 560 undergoing gastrointestinal surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The non-filtered products had the buffy coat removed and were plasma reduced. The filtered products had the buffy coat removed, were plasma reduced, and filtered before storage to remove leucocytes.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Mortality and duration of stay in intensive care. Secondary end points were occurrence of multi-organ failure, infections, and length of hospital stay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences were found in mortality (odds ratio for filtered v non-filtered 0.80, 95% confidence interval 0.53 to 1.21) and in mean stay in intensive care (- 0.4 day, - 1.6 to 0.6 day). In the filtered group the mean length of hospital stay was 2.4 days shorter (- 4.8 to 0.0 day; P = 0.050) and the incidence of multi-organ failure was 30% lower (odds ratio 0.70, 0.49 to 1.00; P = 0.050). There were no differences in rates of infection (0.98, 0.73 to 1.32).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of filtered transfusions in some types of major surgery may reduce the length of hospital stay and the incidence of postoperative multi-organ failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Joost A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center and Sanquin Blood Supply, PO Box 9600, 2300 RC Leiden, Netherlands. J.A.van_Hilten@lumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>Leo M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>van Bockel</LastName><ForeName>J Hajo</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>van de Velde</LastName><ForeName>Cornelis J H</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Kievit</LastName><ForeName>Job</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van den Hout</LastName><ForeName>Wilbert B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Geelkerken</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Roumen</LastName><ForeName>Rudi M H</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Wesselink</LastName><ForeName>Ronald M J</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Koopman-van Gemert</LastName><ForeName>Ankie W M M</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Koning</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Anneke</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001014" MajorTopicYN="N">Aortic Aneurysm</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001019" MajorTopicYN="N">Aortic Rupture</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007937" MajorTopicYN="N">Leukapheresis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15142885</ArticleId><ArticleId IdType="pmc">PMC420164</ArticleId><ArticleId IdType="doi">10.1136/bmj.38103.735266.55</ArticleId><ArticleId IdType="pii">bmj.38103.735266.55</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wobbes T, Bemelmans BL, Kuypers JH, Beerthuizen GI, Theeuwes Ag. Risk of postoperative septic complications after abdominal surgical treatment in relation to perioperative blood transfusion. Surg Gynecol Obstet 1990;171: 59-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto V, Baldonedo R, Nicolas C, BPreez A, Aza J. Relationship of transfusion and infectious complications after gastric carcinoma operation. Transfusion 1991;31: 114-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1996479</ArticleId></ArticleIdList></Reference><Reference><Citation>Spark JI, Chetter IC, Kester RC, Scott DJ. Allogeneic versus autologous blood during abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 1997;14: 482-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9467524</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29: 227-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy G, Neal KR. Differences in postoperative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomised and nonrandomised studies. Transfusion Med 1996;6: 325-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2000;97:5: 1180-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11222359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF. Leukocyte-reduced blood transfusions: Perioperative indications, adverse effects and cost analysis. Anesth Analg 2000;90: 1315-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10825313</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld AB, Raijmakers PG, Rauwerda JA, Hack CE. The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function. Eur J Vasc Endovasc Surg 1997;14: 351-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapaport FT, Dausset J. The possible role of leukocyte components in the production of the beneficial effects of blood transfusion in human transplantation. Transplant Proc 1983;15: 952-5.</Citation></Reference><Reference><Citation>Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann T, Lane TA. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The viral activation transfusion study: a randomised controlled trial. JAMA 2001;285: 1592-601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268267</ArticleId></ArticleIdList></Reference><Reference><Citation>Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnen AB, et al. Randomised controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344: 573-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914960</ArticleId></ArticleIdList></Reference><Reference><Citation>Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Qvist N, Georgsen J. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomised study. Int J Colorectal Dis 2001;16: 147-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459288</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LS, Anderson AJ, Christiansen PM, Hokland P, Juhl CO, Madsen G, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79: 513-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1611441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartter PI, Mohandas K, Azar P. Randomised trial comparing packed red blood cell transfusion with and without leukocyte depletion in gastrointestinal surgery. Am J Surg 1998;176: 462-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LS, Kissmeyer-Nielsen P, Wolff B. Randomised comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348: 841-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8826808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Multicentre randomised controlled trials in transfusion medicine. Transfusion Med Rev 2000;14: 137-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782498</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, et al. A beneficial effect of leukocyte depletion of transfused blood on postoperative mortality in patients undergoing cardiac surgery: a randomised clinical trial. Circulation 1998;97: 562-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9494026</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris RJ, te Boekhorst TP, Nuytinck JKS, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120: 1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342: 1334-49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathens AB, Marshall JC. Sepsis, SIRS and MODS: what's in a name? World J Surg 1996;20: 386-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8662129</ArticleId></ArticleIdList></Reference><Reference><Citation>Asimakopoulos G. Mechanisms of the systemic inflammatory response. Perfusion 1999;14: 269-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10456781</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of report of parallel-group randomised trials. Lancet 2001;357: 1191-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323066</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trial. Lancet 2000;255: 1064-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744093</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ system failure. Ann Surg 1985;202: 685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250999</ArticleId><ArticleId IdType="pubmed">4073980</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1985;16: 128-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841893</ArticleId></ArticleIdList></Reference><Reference><Citation>Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13: 487-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10180748</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg N, Heal JM, Cowles JW, Hicks GL Jr, Risher WH, Samuel PK, et al. Leukocyte-reduced transfusions in cardiac surgery. Results of an implementation trial. Am J Clin Pathol 2002;118: 376-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">12219779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgin YM, van de Watering LMG, Lorinser JE, Versteegh MIM, Eijsman L, van Oers MHJ, et al. The effect of prestorage-leukocyte-depletion of erythrocyte concentrates in cardiac surgery: a double-blind randomised clinical trial. Blood 2001;98(suppl): 828-9a.</Citation></Reference><Reference><Citation>Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, et al. Clinical outcomes following institutions of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003;289: 1941-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697796</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D, Hebert PC, Lee SK, Walker CR, Barrington KJ, Joseph L, et al. Clinical outcomes following institution of universal leukocyte depletion of blood transfusions for premature infants. JAMA 2003;289: 1950-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42: 1114-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12430666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23599623</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>13</Issue><PubDate><Year>2013</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Effects of different resuscitation fluid on severe acute pancreatitis.</ArticleTitle><Pagination><StartPage>2044</StartPage><EndPage>2052</EndPage><MedlinePgn>2044-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v19.i13.2044</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To compare effects of different resuscitation fluid on microcirculation, inflammation, intestinal barrier and clinical results in severe acute pancreatitis (SAP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and twenty patients with SAP were enrolled at the Pancreatic Disease Institute between January 2007 and March 2010. The patients were randomly treated with normal saline (NS group), combination of normal saline and hydroxyethyl starch (HES) (SH group), combination of normal saline, hydroxyethyl starch and glutamine (SHG group) in resuscitation. The ratio of normal saline to HES in the SH and SHG groups was 3:1. The glutamine (20% glutamine dipeptide, 100 mL/d) was supplemented into the resuscitation liquid in the SHG group. Complications and outcomes including respiratory and abdominal infection, sepsis, abdominal hemorrhage, intra-abdominal hypertension, abdominal compartment syndrome (ACS), renal failure, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), operation intervention, length of intensive care unit stay, length of hospital stay, and mortality at 60 d were compared. Moreover, blood oxygen saturation (SpO2), gastric intramucosal pH value (pHi), intra-abdominal pressure (IAP), inflammation cytokines, urine lactulose/mannitol (L/M) ratio, and serum endotoxin were investigated to evaluate the inflammatory reaction and gut barrier.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to the NS group, patients in the SH and SHG groups accessed the endpoint more quickly (3.9 &#xb1; 0.23 d and 4.1 &#xb1; 0.21 d vs 5.8 &#xb1; 0.25 d, P &lt; 0.05) with less fluid volume (67.26 &#xb1; 28.53 mL/kg/d, 61.79 &#xb1; 27.61 mL/kg per day vs 85.23 &#xb1; 21.27 mL/kg per day, P &lt; 0.05). Compared to the NS group, incidence of renal dysfunction, ARDS, MODS and ACS in the SH and SHG groups was obviously lower. Furthermore, incidence of respiratory and abdominal infection was significantly decreased in the SH and SHG groups, while no significant difference in sepsis was seen. Moreover, less operation time was needed in the SH and SHG group than the NS group, but the difference was not significant. The mortality did not differ significantly among these groups. Blood SpO2 and gastric mucosal pHi in the SH and SHG groups increased more quickly than in the NS group, while IAP was significantly decreased in the SH and SHG group. Moreover, the serum tumor necrosis factor-&#x3b1;, interleukin-8 and C-reactive protein levels in the SH and SHG groups were obviously lower than in the NS group at each time point. Furthermore, urine L/M ratio and serum endotoxin were significantly lower in the SH group and further decreased in the SHG group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results indicated that combination of normal saline, HES and glutamine are more efficient in resuscitation of SAP by relieving inflammation and sustaining the intestinal barrier.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun-Gang</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>He-Shui</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Shi-Chang</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Kui</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shuai</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chun-You</ForeName><Initials>CY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004731">Endotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006895">Hydroxyethyl Starch Derivatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0RH81L854J</RegistryNumber><NameOfSubstance UI="D005973">Glutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3OWL53L36A</RegistryNumber><NameOfSubstance UI="D008353">Mannitol</NameOfSubstance></Chemical><Chemical><RegistryNumber>451W47IQ8X</RegistryNumber><NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>4618-18-2</RegistryNumber><NameOfSubstance UI="D007792">Lactulose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004731" MajorTopicYN="N">Endotoxins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="Y">Fluid Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006895" MajorTopicYN="N">Hydroxyethyl Starch Derivatives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007792" MajorTopicYN="N">Lactulose</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008353" MajorTopicYN="N">Mannitol</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012965" MajorTopicYN="N">Sodium Chloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Capillary leakage syndrome</Keyword><Keyword MajorTopicYN="N">Inflammatory reaction</Keyword><Keyword MajorTopicYN="N">Intestinal barrier</Keyword><Keyword MajorTopicYN="N">Intra-abdominal hypertension</Keyword><Keyword MajorTopicYN="N">Microcirculation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23599623</ArticleId><ArticleId IdType="pmc">PMC3623981</ArticleId><ArticleId IdType="doi">10.3748/wjg.v19.i13.2044</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitchell RM, Byrne MF, Baillie J. Pancreatitis. Lancet. 2003;361:1447&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727412</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Whang EE, Brooks DC, Moore FD, Hughes MD, Sica GT, Zinner MJ, Ashley SW, Banks PA. Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis? Pancreas. 2002;25:229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnala PJ, Kuttila KT, Gr&#xf6;nroos JM, Havia TV, Nevalainen TJ, Niinikoski JH. Pancreatic tissue perfusion in experimental acute pancreatitis. Eur J Surg. 2001;167:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11759740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassi D, Kollias N, Fernandez-del Castillo C, Foitzik T, Warshaw AL, Rattner DW. Impairment of pancreatic microcirculation correlates with the severity of acute experimental pancreatitis. J Am Coll Surg. 1994;179:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069418</ArticleId></ArticleIdList></Reference><Reference><Citation>Beger HG, Rau B, Mayer J, Pralle U. Natural course of acute pancreatitis. World J Surg. 1997;21:130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CM, Schmidt J, Lewandrowski K, Compton CC, Rattner DW, Warshaw AL, Tompkins RG. Gut macromolecular permeability in pancreatitis correlates with severity of disease in rats. Gastroenterology. 1993;104:890&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">8440440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammori BJ, Leeder PC, King RF, Barclay GR, Martin IG, Larvin M, McMahon MJ. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg. 1999;3:252&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">10481118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicalese L, Sahai A, Sileri P, Rastellini C, Subbotin V, Ford H, Lee K. Acute pancreatitis and bacterial translocation. Dig Dis Sci. 2001;46:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11341659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S. Initial management of acute pancreatitis: critical issues during the first 72 hours. Am J Gastroenterol. 2004;99:2489&#x2013;2494.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571599</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckerwall G, Olin H, Andersson B, Andersson R. Fluid resuscitation and nutritional support during severe acute pancreatitis in the past: what have we learned and how can we do better? Clin Nutr. 2006;25:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerner T, Vollmar B, Menger MD, Waldner H, Messmer K. Determinants of pancreatic microcirculation in acute pancreatitis in rats. J Surg Res. 1996;62:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632634</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldt J. Volume therapy in the intensive care patient--we are still confused, but. Intensive Care Med. 2000;26:1181&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg. 2001;93:405&#x2013;409 , 3rd contents page.</Citation><ArticleIdList><ArticleId IdType="pubmed">11473870</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M. Resuscitation from septic shock with capillary leakage: hydroxyethyl starch (130 kd), but not Ringer&#x2019;s solution maintains plasma volume and systemic oxygenation. Shock. 2004;21:336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">15179134</ArticleId></ArticleIdList></Reference><Reference><Citation>Eibl G, Hotz HG, Faulhaber J, Kirchengast M, Buhr HJ, Foitzik T. Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis. Gut. 2000;46:390&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1727839</ArticleId><ArticleId IdType="pubmed">10673302</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol. 2003;20:429&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">12803259</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitag M, Standl TG, Kleinhans H, Gottschalk A, Mann O, Rempf C, Bachmann K, Gocht A, Petri S, Izbicki JR, et al. Improvement of impaired microcirculation and tissue oxygenation by hemodilution with hydroxyethyl starch plus cell-free hemoglobin in acute porcine pancreatitis. Pancreatology. 2006;6:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534248</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Liu J, Yu M, Zhu S, Xu J. Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and survival in rats challenged with polymicrobial sepsis. Clin Chim Acta. 2007;376:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">16942763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin H, Mercanligil SM, Inan&#xe7; N, Ok E. Effects of glutamine-enriched total parenteral nutrition on acute pancreatitis. Eur J Clin Nutr. 2007;61:1429&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17311061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce CB, Sadek SA, Walters AM, Goggin PM, Somers SS, Toh SK, Johns T, Duncan HD. A double-blind, randomised, controlled trial to study the effects of an enteral feed supplemented with glutamine, arginine, and omega-3 fatty acid in predicted acute severe pancreatitis. JOP. 2006;7:361&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G, Wang CY, Wang F, Xiong JX. Clinical study on nutrition support in patients with severe acute pancreatitis. World J Gastroenterol. 2003;9:2105&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4656684</ArticleId><ArticleId IdType="pubmed">12970916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489394</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonham MJ, Abu-Zidan FM, Simovic MO, Windsor JA. Gastric intramucosal pH predicts death in severe acute pancreatitis. Br J Surg. 1997;84:1670&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9448612</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda S, Hirasawa H, Shiga H, Matsuda K, Nakamura M, Watanabe E, Moriguchi T. Management of intra-abdominal hypertension in patients with severe acute pancreatitis with continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter. Ther Apher Dial. 2005;9:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16076382</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer P, Pernet P, Hejblum G, Baudel JL, Maury E, Offenstadt G, Guidet B. Haemodilution induced by hydroxyethyl starches 130/0.4 is similar in septic and non-septic patients. Acta Anaesthesiol Scand. 2008;52:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">18034867</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M. Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med. 2006;34:3005&#x2013;3010.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv R, Zhou W, Chu C, Xu J. Mechanism of the effect of hydroxyethyl starch on reducing pulmonary capillary permeability in a rat model of sepsis. Ann Clin Lab Sci. 2005;35:174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15943182</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Yan W, Liu X, Duan M, Zhang X, Xu J. Effects of hydroxyethyl starch 130/0.4 on pulmonary capillary leakage and cytokines production and NF-kappaB activation in CLP-induced sepsis in rats. J Surg Res. 2006;135:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616763</ArticleId></ArticleIdList></Reference><Reference><Citation>Handrigan MT, Burns AR, Donnachie EM, Bowden RA. Hydroxyethyl starch inhibits neutrophil adhesion and transendothelial migration. Shock. 2005;24:434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang K, Suttner S, Boldt J, Kumle B, Nagel D. Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth. 2003;50:1009&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;per J, Ahmed R, Sch&#xe4;fer T, Elster A, Enigk F, Habazettl H, Mousa S, Sch&#xe4;fer M, Welte M. Volume therapy with colloid solutions preserves intestinal microvascular perfusion in endotoxaemia. Resuscitation. 2008;76:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">17697734</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint RS, Phillips AR, Power SE, Dunbar PR, Brown C, Delahunt B, Cooper GJ, Windsor JA. Acute pancreatitis severity is exacerbated by intestinal ischemia-reperfusion conditioned mesenteric lymph. Surgery. 2008;143:404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291262</ArticleId></ArticleIdList></Reference><Reference><Citation>Warndorf MG, Kurtzman JT, Bartel MJ, Cox M, Mackenzie T, Robinson S, Burchard PR, Gordon SR, Gardner TB. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9:705&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3143229</ArticleId><ArticleId IdType="pubmed">21554987</ArticleId></ArticleIdList></Reference><Reference><Citation>Trikudanathan G, Navaneethan U, Vege SS. Current controversies in fluid resuscitation in acute pancreatitis: a systematic review. Pancreas. 2012;41:827&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">22781906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mole DJ, Hall A, McKeown D, Garden OJ, Parks RW. Detailed fluid resuscitation profiles in patients with severe acute pancreatitis. HPB (Oxford) 2011;13:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019542</ArticleId><ArticleId IdType="pubmed">21159104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40486199</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Anion gap associated with 28-days all-cause mortality in Acute cholangitis patients admitted to the intensive care unit in MIMIC-IV database: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>1591096</StartPage><MedlinePgn>1591096</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1591096</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2025.1591096</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Acute cholangitis, characterized by infection of the bile duct, represents a significant clinical challenge due to its association with heightened morbidity and mortality rates. This condition often culminates in severe complications, including sepsis and multi-organ failure, ultimately leading to increased healthcare burdens. The anion gap (AG) serves as a potential biomarker for systemic inflammation and has been proposed as a prognostic indicator. To evaluate its efficacy in predicting patient outcomes, a closer examination of AG levels and their relationship to mortality in acute cholangitis patients is warranted.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study employed a retrospective cohort design, utilizing data gleaned from the MIMIC-IV database. A total of 489 patients admitted to the Intensive Care Unit (ICU) with acute cholangitis were analyzed, and participants were stratified into quartiles according to their serum AG levels. Mortality rates, as well as the incidence of acute kidney injury (AKI) and sepsis, were meticulously recorded and analyzed to establish any significant correlations with AG levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The findings indicated a stark association between elevated AG quartiles and increased rates of AKI, sepsis, and overall mortality. Specifically, the 28-day mortality rate escalated markedly from 8.1% in the lowest AG quartile to 30.9% in the highest quartile (<i>p</i> &lt; 0.001). Furthermore, multivariate logistic regression analysis revealed that each unit increase in AG was associated with a 13% enhancement in mortality risk (OR 1.13, 95%CI 1.03-1.124, <i>p</i> = 0.010). An inverted J-shaped correlation between AG levels and mortality was also identified, indicating a potential inflection point at 18.13 mEq/L.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study elucidates the significant role of AG as a prognostic marker in critically ill patients with acute cholangitis, emphasizing its potential utility in guiding early intervention strategies to mitigate mortality risks. Future research endeavors should aim to explore the therapeutic implications of managing AG levels and assess their relevance in wider clinical contexts to enhance patient outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Huang, Yin and Han.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Yingjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Surgery, The First Affiliated Hospital of Xinjiang Medical University, &#xdc;r&#xfc;mqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yin</LastName><ForeName>Zhijie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Surgery, The First Affiliated Hospital of Xinjiang Medical University, &#xdc;r&#xfc;mqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Surgery, The First Affiliated Hospital of Xinjiang Medical University, &#xdc;r&#xfc;mqi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">28-days all-cause mortality</Keyword><Keyword MajorTopicYN="N">MIMIC-IV database</Keyword><Keyword MajorTopicYN="N">acute cholangitis</Keyword><Keyword MajorTopicYN="N">anion gap (AG)</Keyword><Keyword MajorTopicYN="N">intensive care unit (ICU)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40486199</ArticleId><ArticleId IdType="pmc">PMC12142621</ArticleId><ArticleId IdType="doi">10.3389/fmed.2025.1591096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>An Z, Braseth A, Sahar N. Acute cholangitis: Causes, diagnosis, and management. Gastroenterol Clin North Am. (2021) 50:403&#x2013;14. 10.1016/j.gtc.2021.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2021.02.005</ArticleId><ArticleId IdType="pubmed">34024448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu S, Nath P, Mallick B, Praharaj D, Giri S, Panigrahi S, et al. Etiological profile of obstructive jaundice and acute cholangitis: Three-year data from a tertiary care center in eastern India. Euroasian J Hepato-Gastroenterol. (2024) 14:187&#x2013;90. 10.5005/jp-journals-10018-1448</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10018-1448</ArticleId><ArticleId IdType="pmc">PMC11714100</ArticleId><ArticleId IdType="pubmed">39802848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Cheong Wah D, Christophi C, Muralidharan V. Acute cholangitis: Current concepts. ANZ J Surg. (2017) 87:554&#x2013;9. 10.1111/ans.13981</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.13981</ArticleId><ArticleId IdType="pubmed">28337833</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ferreira LEVV, Baron TH. Acute biliary conditions. Best Pract Res, Clin Gastroenterol. (2013) 27:745&#x2013;56. 10.1016/j.bpg.2013.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpg.2013.08.008</ArticleId><ArticleId IdType="pubmed">24160931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee F, Ohanian E, Rheem J, Laine L, Che K, Kim J. Delayed endoscopic retrograde cholangiopancreatography is associated with persistent organ failure in hospitalised patients with acute cholangitis. Aliment Pharmacol Ther. (2015) 42:212&#x2013;20. 10.1111/apt.13253</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13253</ArticleId><ArticleId IdType="pubmed">25997554</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher S, Stones W. A systematic review and diagnostic test accuracy meta-analysis of the validity of anion gap as a screening tool for hyperlactatemia. BMC Res Notes. (2017) 10:556. 10.1186/s13104-017-2853-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-017-2853-9</ArticleId><ArticleId IdType="pmc">PMC5670505</ArticleId><ArticleId IdType="pubmed">29100545</ArticleId></ArticleIdList></Reference><Reference><Citation>Achanti A, Szerlip H. Acid-base disorders in the critically ill patient. Clin j Am Soc Nephrol: CJASN. (2023) 18:102&#x2013;12. 10.2215/CJN.04500422</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04500422</ArticleId><ArticleId IdType="pmc">PMC10101555</ArticleId><ArticleId IdType="pubmed">35998977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Zhang Z, Lei Y, Ouyang Z, Kutty S, Liu Q, et al. The prediction value of serum anion gap for short-term mortality in pulmonary hypertension patients with sepsis: A retrospective cohort study. Front Med. (2024) 11:1499677. 10.3389/fmed.2024.1499677</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1499677</ArticleId><ArticleId IdType="pmc">PMC11748302</ArticleId><ArticleId IdType="pubmed">39839613</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Luo W, Wang Q, Chen Y, Bai F, Zeng Q, et al. Anion gap predicting 90-day mortality and guiding furosemide use in ARDS. Sci Rep. (2025) 15:4954. 10.1038/s41598-025-89163-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-025-89163-1</ArticleId><ArticleId IdType="pmc">PMC11811161</ArticleId><ArticleId IdType="pubmed">39930113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yang Q, Gao L, Chen W, Gao X, Li Y, et al. Association between serum anion gap and mortality in critically ill patients with COPD in ICU: Data from the MIMIC IV databas. Int J Chron Obstruct Pulmon Dis. (2024) 19:579&#x2013;87. 10.2147/COPD.S433619</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S433619</ArticleId><ArticleId IdType="pmc">PMC10911976</ArticleId><ArticleId IdType="pubmed">38444550</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson A, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, et al. MIMIC-IV, a freely accessible electronic health record dataset. Sci Data. (2023) 10:1. 10.1038/s41597-022-01899-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-022-01899-x</ArticleId><ArticleId IdType="pmc">PMC9810617</ArticleId><ArticleId IdType="pubmed">36596836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambden S, Laterre P, Levy M, Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. (2019) 23:374. 10.1186/s13054-019-2663-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2663-7</ArticleId><ArticleId IdType="pmc">PMC6880479</ArticleId><ArticleId IdType="pubmed">31775846</ArticleId></ArticleIdList></Reference><Reference><Citation>Aegerter P, Boumendil A, Retbi A, Minvielle E, Dervaux B, Guidet B. SAPS II. revisited. Intensive Care Med. (2005) 31:416&#x2013;23. 10.1007/s00134-005-2557-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-005-2557-9</ArticleId><ArticleId IdType="pubmed">15678308</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zheng H, Wu M, Wang Q, Yan S, Wang M, et al. Association between lactate-to-albumin ratio and 28-days all-cause mortality in patients with acute pancreatitis: A retrospective analysis of the MIMIC-IV database. Front Immunol. (2022) 13:1076121. 10.3389/fimmu.2022.1076121</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1076121</ArticleId><ArticleId IdType="pmc">PMC9795001</ArticleId><ArticleId IdType="pubmed">36591285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ji L, Oravecz Z, Brick T, Hunter M, Chow S. dynr.mi: An R program for multiple imputation in dynamic modeling. World Acad Sci Eng Technol. (2019) 13:302&#x2013;11. 10.5281/zenodo.3298841</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.3298841</ArticleId><ArticleId IdType="pmc">PMC6702040</ArticleId><ArticleId IdType="pubmed">31431819</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim S, Kim S, Lee J. Diagnostic test accuracy: Application and practice using R software. Epidemiol Health. (2019) 41:e2019007. 10.4178/epih.e2019007</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih.e2019007</ArticleId><ArticleId IdType="pmc">PMC6545496</ArticleId><ArticleId IdType="pubmed">30999739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozma M, G&#x103;man M, Srichawla B, Dhali A, Manan M, Nahian A, et al. Acute cholangitis: A state-of-the-art review. Ann Med Surg (Lond). (2024) 86:4560&#x2013;74. 10.1097/MS9.0000000000002169</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MS9.0000000000002169</ArticleId><ArticleId IdType="pmc">PMC11305776</ArticleId><ArticleId IdType="pubmed">39118745</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Pan S, Hong G, Chen K-W. A new nomogram for predicting 30-day in-hospital mortality rate of acute cholangitis patients in the intensive care unit. Emerg Med Int. (2023) 2023:9961438. 10.1155/2023/9961438</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/9961438</ArticleId><ArticleId IdType="pmc">PMC10435307</ArticleId><ArticleId IdType="pubmed">37599814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X, Peng S. The association between serum anion gap and all-cause mortality of unselected adult patients: A retrospective cohort study of &gt;20,000 patients. J Clin Lab Anal. (2023) 37:e24818. 10.1002/jcla.24818</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.24818</ArticleId><ArticleId IdType="pmc">PMC9833973</ArticleId><ArticleId IdType="pubmed">36550640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chionh C, Poh C, Roy D, Koduri S, Chow B, Tan P, et al. SSerum anion gap revisited: A verified reference interval for contemporary use. Intern Med J. (2022) 52:1531&#x2013;7. 10.1111/imj.15396</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.15396</ArticleId><ArticleId IdType="pubmed">34028972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla L, Jagasia D, Abell L, Seneff M, Egan M, Danino N, et al. Anion gap, anion gap corrected for albumin, and base deficit fail to accurately diagnose clinically significant hyperlactatemia in critically ill patients. J Intensive Care Med. (2008) 23:122&#x2013;7. 10.1177/0885066607312985</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066607312985</ArticleId><ArticleId IdType="pubmed">18431828</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Jo S, Lee D, An W, Jeong M, Son M. Dynamics of serum anion gaps with in-hospital mortality: analysis of the multi-open databases. PLoS One. (2024) 19:e0302206. 10.1371/journal.pone.0302206</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0302206</ArticleId><ArticleId IdType="pmc">PMC11020621</ArticleId><ArticleId IdType="pubmed">38625899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Lu J, Weng W, Yan Q. Association between anion gap and all-cause mortality of critically ill surgical patients: A retrospective cohort study. BMC Surg. (2023) 23:226. 10.1186/s12893-023-02137-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-023-02137-w</ArticleId><ArticleId IdType="pmc">PMC10413518</ArticleId><ArticleId IdType="pubmed">37559030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, He Z, Jin Y, Zhu S, Xu W, Li B, et al. Serum anion gap level predicts all-cause mortality in septic patients: A retrospective study based on the MIMIC III database. J Intensive Care Med. (2023) 38:349&#x2013;57. 10.1177/08850666221123483</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666221123483</ArticleId><ArticleId IdType="pubmed">36066040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, Lin J, Huo C, Yin D, Guo Q. Increased serum albumin corrected anion gap levels are associated with poor prognosis in septic patients with liver cirrhosis. Sci Rep. (2024) 14:21510. 10.1038/s41598-024-72703-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-72703-6</ArticleId><ArticleId IdType="pmc">PMC11401841</ArticleId><ArticleId IdType="pubmed">39277682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17309964</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of surgery (Chicago, Ill. : 1960)</Title><ISOAbbreviation>Arch Surg</ISOAbbreviation></Journal><ArticleTitle>Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>142</EndPage><MedlinePgn>134-42</MedlinePgn></Pagination><Abstract><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Infections and sepsis are major complications in secondary peritonitis and still represent a diagnostic challenge. We hypothesized that the laboratory marker procalcitonin would provide an early and reliable assessment of septic complications.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, international, multicenter inception cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Five European surgical referral centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Eighty-two patients with intraoperatively proven secondary peritonitis were enrolled within 96 hours of symptom onset.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Procalcitonin and the laboratory routine marker C-reactive protein (CRP) were prospectively assessed and monitored for a maximum of 21 consecutive days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Procalcitonin concentrations were most closely correlated with the development of septic multiorgan dysfunction syndrome (MODS), with peak levels occurring early after symptom onset or during the immediate postoperative course. No such correlation was observed for CRP. According to receiver operating characteristic analysis, a procalcitonin value of 10.0 ng/mL or greater on 2 consecutive days was superior to a CRP level of 210 mg/L or greater for predicting septic MODS, with sensitivity, specificity, and positive and negative predictive values of 65%, 92%, 83%, and 81% for procalcitonin and 67%, 58%, 49%, and 74% for CRP, respectively (P&lt;.001). Assessment of septic MODS was already possible on the first 2 postoperative days, with similar sensitivity and specificity. Persisting procalcitonin levels greater than 1.0 ng/mL beyond the first week after disease onset strongly indicated nonsurvival and were significantly better than CRP in assessing overall prognosis (P&lt;.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Procalcitonin monitoring is a fast and reliable approach to assessing septic MODS and overall prognosis in secondary peritonitis. This single-test marker improves stratification of patients who will develop clinically relevant complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rau</LastName><ForeName>Bettina M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of General, Visceral, and Vascular Surgery, University of the Saarland, Homburg/Saar, Germany. bettina.rau@uniklinikum-saarland.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigerio</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>B&#xfc;chler</LastName><ForeName>Markus W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Wegscheider</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Puolakkainen</LastName><ForeName>Pauli A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Beger</LastName><ForeName>Hans G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Martin K</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Surg</MedlineTA><NlmUniqueID>9716528</NlmUniqueID><ISSNLinking>0004-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606589">CALCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance UI="D002116">Calcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>JHB2QIZ69Z</RegistryNumber><NameOfSubstance UI="D015740">Calcitonin Gene-Related Peptide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Surg. 2007 Aug;142(8):803; author reply 803-4. doi: 10.1001/archsurg.142.8.803-a.</RefSource><PMID Version="1">17709736</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002116" MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015740" MajorTopicYN="N">Calcitonin Gene-Related Peptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17309964</ArticleId><ArticleId IdType="doi">10.1001/archsurg.142.2.134</ArticleId><ArticleId IdType="pii">142/2/134</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19077606</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-8809</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Decreasing magnitude of multiple organ dysfunction syndrome despite increasingly severe critical surgical illness: a 17-year longitudinal study.</ArticleTitle><Pagination><StartPage>1227</StartPage><EndPage>1235</EndPage><MedlinePgn>1227-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0b013e31818c12dd</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) remains prevalent and the leading cause of mortality in the surgical intensive care unit (ICU). Improvements in ICU care in the last 10 years (e.g., tight glycemic control, activated protein C, fewer transfusions causing fewer nosocomial infections) may have decreased the incidence, magnitude, and mortality of MODS, as hypothesized in this study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Longitudinal 17-year prospective study of 11,314 ICU patients (academic/tertiary unit, Level I trauma center), 5,157 (45.5%) of whom developed any degree of MODS (Marshall score, cumulative). Data collected included Admission Acute Physiology and Chronic Health Evaluation (APACHE)-II and APACHE-III scores, MOD score (MODsc), hospital mortality, and the incidence and magnitude of MODS. The ratio of MODsc: APACHE III was calculated. Analyses (X +/- SEM, chi2, repeated-measures ANOVA, linear and polynomial regression, c-statistic) were performed for calendar-year intervals beginning in 1990 through 2006.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among MODS patients, the mean MODsc was 6.3 +/- 0.1 points, and the mortality rate was 22%. The APACHE III score increased significantly (p &lt; 0.0001) over time, but the mortality rate was unchanged (r2 = 0.02). Adjusted for illness severity (MODsc:A3), the magnitude of MODS decreased significantly (p &lt; 0.0001) during the time period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite significant increases in admission APACHE III score over 17 years, the adjusted magnitude of MODS (MODsc:A3) decreased. Given the strong association between MODS and mortality for critically ill surgical patients, it is likely that the unchanged risk-adjusted mortality observed over time is due to the reduced magnitude of MODS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barie</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Critical Care and Trauma, Anne and Max A. Cohen Surgical Intensive Care Unit, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York 10065, USA. pbarie@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hydo</LastName><ForeName>Lynn J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Shou</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Eachempati</LastName><ForeName>Soumitra R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008432" MajorTopicYN="N">Mathematical Computing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009519" MajorTopicYN="N" Type="Geographic">New York City</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19077606</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31818c12dd</ArticleId><ArticleId IdType="pii">00005373-200812000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15288631</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2004</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-5884</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</Title><ISOAbbreviation>Eur J Vasc Endovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Cytokines, their genetic polymorphisms, and outcome after abdominal aortic aneurysm repair.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>280</EndPage><MedlinePgn>274-80</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Excessive cytokine production has been implicated in the development of organ failure. Polymorphic sites in cytokine genes have been shown to affect levels of production in vitro and may influence cytokine production in vivo. The aims of this study were to determine if cytokines or their genetic polymorphisms were related to outcome after abdominal aortic aneurysm (AAA) repair.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study of 135 patients undergoing open AAA repair. Plasma levels of TNF-alpha, IL-1beta, IL-6 and IL-10 were measured 24 h post-operatively and genotypes for the TNF-alpha -308, IL-1beta+3953, IL-6 -174, IL-10 -1082 and IL-10 -592 polymorphisms were determined for each patient.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After elective AAA high levels of IL-10 were associated with both prolonged critical care (P&lt;0.001) and hospital stay (P=0.001). The presence of a G allele at the IL-6 -174 locus was associated with a higher incidence of organ failure (P=0.04) and an A allele at TNF-alpha -308 with prolonged critical care stay (P=0.03). After ruptured AAA the development of multi-organ failure was associated with high levels of IL-6 (P=0.01) and TNF-alpha (P=0.04). High TNF-alpha levels were also associated with mortality (P=0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Post-operative cytokine levels are related to outcome after AAA repair. Cytokine gene polymorphisms may provide a method for determining which patients are at high risk of complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bown</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Leicester, Leicester, UK. mjb42@le.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horsburgh</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>P R F</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Sayers</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Vasc Endovasc Surg</MedlineTA><NlmUniqueID>9512728</NlmUniqueID><ISSNLinking>1078-5884</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017544" MajorTopicYN="N">Aortic Aneurysm, Abdominal</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001019" MajorTopicYN="N">Aortic Rupture</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15288631</ArticleId><ArticleId IdType="doi">10.1016/j.ejvs.2004.05.008</ArticleId><ArticleId IdType="pii">S107858840400245X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19835422</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2009</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-3907</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of proteome research</Title><ISOAbbreviation>J Proteome Res</ISOAbbreviation></Journal><ArticleTitle>Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach.</ArticleTitle><Pagination><StartPage>5423</StartPage><EndPage>5430</EndPage><MedlinePgn>5423-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/pr900576y</ELocationID><Abstract><AbstractText>Progression of critically ill patients from Systemic Inflammatory Response Syndrome (SIRS) to Multiple Organ Dysfunction Syndrome (MODS) accounts for more than 75% of deaths in adult surgical intensive care units. Currently, there is no practical clinical technique to predict the progression of SIRS or MODS. In this report, we describe an NMR-based metabonomic method to aid detection of these conditions based on abnormal metabolic signatures. We applied pattern recognition methods to analyze one-dimensional (1)H NMR spectra of SIRS and MODS patient sera. By using Principal Component Analysis (PCA) and Partial Least Squares-Discriminant Analysis (PLS-DA), we could distinguish critically ill patients (n = 52) from healthy controls (n = 26). After noise reduction by Orthogonal Signal Correction (OSC), PLS-DA was also able to clearly discriminate SIRS and MODS patients. The corresponding coefficients indicated that spectra responsible for the discrimination were located in delta3.06-3.86 NMR integral regions from SIRS, mainly composed of sugars, amino acids and glutamine signals, and delta1.18-1.3 and delta4.02-4.1 integral regions of MODS serum samples, principally consisted of various proton signals of fatty acyl chains and glycerol backbone of lipids, along with creatinine and lactate. Our results are consistent with the clinical observations that carbohydrate and amino acid levels changes in the early course of critical illness (SIRS stage) and significant disturbances in fat metabolism and development of organ abnormalities become the characteristics in the late stage (MODS). These data suggest that NMR-based metabonomic approach can be developed to diagnose the disease progress of critically ill patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Hailei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hospital of Nantong University, Nantong 226001, PR China. hlmao@sibs.ac.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huimin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Hongchang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hongsheng</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Donghai</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Proteome Res</MedlineTA><NlmUniqueID>101128775</NlmUniqueID><ISSNLinking>1535-3893</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002241">Carbohydrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005223">Fats</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002241" MajorTopicYN="N">Carbohydrates</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016002" MajorTopicYN="N">Discriminant Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005223" MajorTopicYN="N">Fats</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19835422</ArticleId><ArticleId IdType="doi">10.1021/pr900576y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22185191</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-8674</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>449</EndPage><MedlinePgn>443-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/sur.2011.133</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Septic shock causing or complicating critical surgical illness results in high mortality. Drotrecogin alfa (activated), known also as recombinant human activated protein C (rhAPC) has become controversial as therapy, owing to persisting questions of efficacy and safety. We hypothesized rhAPC to be effective therapy for critically ill surgical patients with septic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Open-label therapy with rhAPC (by predefined criteria) of 108 critically ill surgical patients. Treated patients were matched individually in prospect for age, gender, Acute Physiology and Chronic Health Evaluation (APACHE)-II and -III scores, site of infection, and organism (0-2 points each, maximum 12 points) with 108 patients from our 15,000-patient surgical intensive care unit database who did not receive rhAPC. No match was accepted if &lt;6 points. Multiple organ dysfunction (MOD) scores and data regarding cortisol concentrations, bleeding complications, and transfusion requirements were collected. The primary endpoint was 28-day mortality, with mortality for hospitalization and resolution of organ dysfunction as secondary endpoints. Statistical analyses included ANOVA, c statistic, binary logistic regression, and Kaplan-Meier time-to-event and Cox proportional hazards analyses; &#x3b1;=0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean match score was 9.2&#xb1;0.1 points (range, 6-12 points). Patients were well matched by all criteria, including baseline MOD score (9.5&#xb1;0.7 vs. 9.8&#xb1;0.3 points, p=0.66). Mean age was 68.1&#xb1;1.1 years (p=0.49), Mean APACHE-III score was 99.6&#xb1;1.5 points (p=0.87). Mean time to rhAPC administration was 25&#xb1;3 h. Survival at 28 days after rhAPC was 71.3% vs. 49.1% (p=0.001); hospital survival was 57.4% vs. 40.7% (p=0.02). By logistic regression, rhAPC therapy resulted in improved 28-day survival (OR 2.57, 95% CI 1.46-4.52, p=0.001) (model &#x3c7;2 11.244, p=0.001); and hospital survival (OR 1.96, 95% CI 1.14-3.36, p=0.015) (model &#x3c7;2 6.03, p=0.014). The MOD score decreased significantly (p=0.012) during rhAPC therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Therapy with rhAPC appeared to improve survival in surgical ICU patients with life-threatening infection characterized by septic shock and organ dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barie</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Division of Burns, Critical Care, and Trauma, Department of Surgery, Weill Cornell Medical College, New York, New York, USA. pbarie@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hydo</LastName><ForeName>Lynn J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Shou</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Eachempati</LastName><ForeName>Soumitra R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011486">Protein C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>JGH8MYC891</RegistryNumber><NameOfSubstance UI="C421124">drotrecogin alfa activated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011486" MajorTopicYN="N">Protein C</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22185191</ArticleId><ArticleId IdType="doi">10.1089/sur.2011.133</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36357273</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1008-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Chinese journal of traumatology = Zhonghua chuang shang za zhi</Title><ISOAbbreviation>Chin J Traumatol</ISOAbbreviation></Journal><ArticleTitle>Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: A double-blind, randomized clinical trial.</ArticleTitle><Pagination><StartPage>116</StartPage><EndPage>120</EndPage><MedlinePgn>116-120</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjtee.2022.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1008-1275(22)00106-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Patients with multiple traumas are at high risk of developing respiratory complications, including pneumonia and acute respiratory distress syndrome. Many pulmonary complications are associated with systemic inflammation and pulmonary neutrophilic infiltration. Leukotriene-receptor antagonists are anti-inflammatory and anti-oxidant drugs subsiding airway inflammation. The present study investigates the effectiveness of montelukast in reducing pulmonary complications among trauma patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, double-blind, placebo-control trial was conducted in patients with multiple blunt traumas and evidence of lung contusion detected via CT scan. We excluded patients if they met at least one of the following conditions: &lt; 16 years old, history of cardiopulmonary diseases or positive history of montelukast-induced hypersensitivity reactions. Patients were allocated to the treatment (10&#xa0;mg of montelukast) or placebo group using permuted block randomization method. The primary measured outcome was the volume of pulmonary contusion at the end of the trial. The secondary outcomes were intensive care unit and hospital length of stay, ventilation days, multi-organ failure, and the in-hospital mortality rate.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 65 eligible patients (treatment&#xa0;=&#xa0;31, placebo&#xa0;=&#xa0;34) were included for the final analysis. The treatment group had more pulmonary contusion volume (mean (SD), mm<sup>3</sup>) at the right (68726.97 (93656.54) vs. 59730.27 (76551.74)) and the left side (67501.71 (91514.04) vs. 46502.21 (80604.21)), higher initial C-reactive peptide level (12.16 (10.58) vs. 10.85 (17.87)) compared to the placebo group, but the differences were not statistically significant (p&#xa0;&gt;&#xa0;0.05). At the end of the study, the mean (SD) of pulmonary contusion volume (mm<sup>3</sup>) (right side&#xa0;=&#xa0;116748.74 (361705.12), left side&#xa0;=&#xa0;64522.03 (117266.17)) of the treatment group were comparable to that of the placebo group (right side&#xa0;=&#xa0;40051.26 (64081.56), left side&#xa0;=&#xa0;25929.12 (47417.13), p&#xa0;=&#xa0;0.228 and 0.082, respectively). Moreover, both groups have statistically similar hospital (mean (SD), days) (10.87 (9.83) vs. 13.05 (10.12)) and intensive care unit length of stays (mean (SD), days) (7.16 (8.15) vs. 7.82 (7.48)). Of note, the frequency of the in-hospital complications (treatment vs. control group) including acute respiratory distress syndrome (12.9% vs. 8.8%, p&#xa0;=&#xa0;0.71), pneumonia (19.4% vs. 17.6%, p&#xa0;=&#xa0;0.85), multi-organ failure (12.9% vs. 17.6%, p&#xa0;=&#xa0;0.58) and the mortality rate (22.6% vs. 14.7%, p&#xa0;=&#xa0;0.41) were comparable between the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Administrating montelukast has no preventive or therapeutic effects on lung contusion or its complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heydari</LastName><ForeName>Soleyman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Baqiyatallah University of Medical Sciences, Tehran, Iran; Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoshmohabat</LastName><ForeName>Hadi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akerdi</LastName><ForeName>Ali Taheri</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: ata.110.iran@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadpour</LastName><ForeName>Fathollah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paydar</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin J Traumatol</MedlineTA><NlmUniqueID>100886162</NlmUniqueID><ISSNLinking>1008-1275</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MHM278SD3E</RegistryNumber><NameOfSubstance UI="C093875">montelukast</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035441" MajorTopicYN="Y">Thoracic Wall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="Y">Wounds, Nonpenetrating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013898" MajorTopicYN="Y">Thoracic Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055370" MajorTopicYN="Y">Lung Injury</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003288" MajorTopicYN="Y">Contusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">Contusions</Keyword><Keyword MajorTopicYN="N">Injuries</Keyword><Keyword MajorTopicYN="N">Leukotrienes</Keyword><Keyword MajorTopicYN="N">Montelukast</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>22</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36357273</ArticleId><ArticleId IdType="pmc">PMC9558713</ArticleId><ArticleId IdType="doi">10.1016/j.cjtee.2022.10.002</ArticleId><ArticleId IdType="pii">S1008-1275(22)00106-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leonard J.M., Zhang C.X., Lu L., et al. Extrathoracic multiple trauma dysregulates neutrophil function and exacerbates pneumonia-induced lung injury. J&#xa0;Trauma Acute Care Surg. 2021;90:924&#x2013;934. doi: 10.1097/TA.0000000000003147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003147</ArticleId><ArticleId IdType="pmc">PMC8932930</ArticleId><ArticleId IdType="pubmed">34016916</ArticleId></ArticleIdList></Reference><Reference><Citation>Janicova A., Relja B. Neutrophil phenotypes and functions in trauma and trauma-related sepsis. Shock. 2021;56:16&#x2013;29. doi: 10.1097/SHK.0000000000001695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001695</ArticleId><ArticleId IdType="pubmed">33201022</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;rmann P., Auner B., Schimunek L., et al. Leukotriene B4 indicates lung injury and on-going inflammatory changes after severe trauma in a porcine long-term model. Prostaglandins Leukot Essent Fatty Acids. 2017;127:25&#x2013;31. doi: 10.1016/j.plefa.2017.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2017.09.014</ArticleId><ArticleId IdType="pubmed">29156155</ArticleId></ArticleIdList></Reference><Reference><Citation>Auner B., Geiger E.V., Henrich D., et al. Circulating leukotriene B4 identifies respiratory complications after trauma. Mediat Inflamm. 2012;2012 doi: 10.1155/2012/536156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/536156</ArticleId><ArticleId IdType="pmc">PMC3317019</ArticleId><ArticleId IdType="pubmed">22529525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y.Y., Sun B.W. Recent advances in neutrophil chemotaxis abnormalities during sepsis. Chin J Traumatol. 2022;S1008&#x2013;1275(22) doi: 10.1016/j.cjtee.2022.06.002. 00062-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjtee.2022.06.002</ArticleId><ArticleId IdType="pmc">PMC9751578</ArticleId><ArticleId IdType="pubmed">35786510</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan H., Gupta A., Singh T.G., et al. Mechanistic insight on the role of leukotriene receptors in ischemic&#x2013;reperfusion injury. Pharmacol Rep. 2021;73:1240&#x2013;1254. doi: 10.1007/s43440-021-00258-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00258-8</ArticleId><ArticleId IdType="pubmed">33818747</ArticleId></ArticleIdList></Reference><Reference><Citation>David B.A., Kubes P. Exploring the complex role of chemokines and chemoattractants in&#xa0;vivo on leukocyte dynamics. Immunol Rev. 2019;289:9&#x2013;30. doi: 10.1111/imr.12757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12757</ArticleId><ArticleId IdType="pubmed">30977202</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;rmann P., Wagner N., K&#xf6;hler K., et al. Monotrauma is associated with enhanced remote inflammatory response and organ damage, while polytrauma intensifies both in porcine trauma model. Eur J Trauma Emerg Surg. 2020;46:31&#x2013;42. doi: 10.1007/s00068-019-01098-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-019-01098-1</ArticleId><ArticleId IdType="pubmed">30864051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.I., Park J., Konecna B., et al. Plasma and wound fluids from trauma patients suppress neutrophil extracellular respiratory burst. J&#xa0;Trauma Acute Care Surg. 2022;92:330&#x2013;338. doi: 10.1097/TA.0000000000003461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003461</ArticleId><ArticleId IdType="pmc">PMC8792304</ArticleId><ArticleId IdType="pubmed">34789698</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A., Pergola C., Cuzzocrea S., et al. The role of 5-lipoxygenase and leukotrienes in shock and ischemia-reperfusion injury. Sci World J. 2007;7:56&#x2013;74. doi: 10.1100/tsw.2007.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1100/tsw.2007.34</ArticleId><ArticleId IdType="pmc">PMC5901353</ArticleId><ArticleId IdType="pubmed">17334599</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A., Baker C., Evans T., et al. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J. 2000;15:895&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">10853855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J.B., Eggler J.F. In: Inflammatory Cells and Mediators in Bronchial Asthma. Agrawal D.K., Townley R.G., editors. CRC Press, LLC; Boca Raton, FL: 1991. Leukotriene receptors in the airways; pp. 147&#x2013;169.</Citation></Reference><Reference><Citation>Al-Amran F.G., Hadi N.R., Hashim A.M. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. Eur J Cardio Thorac Surg. 2013;43:421&#x2013;427. doi: 10.1093/ejcts/ezs312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezs312</ArticleId><ArticleId IdType="pubmed">22851661</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Benna J., Hurtado-Nedelec M., Marzaioli V., et al. Priming of the neutrophil respiratory burst: role in host defense and inflammation. Immunol Rev. 2016;273:180&#x2013;193. doi: 10.1111/imr.12447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12447</ArticleId><ArticleId IdType="pubmed">27558335</ArticleId></ArticleIdList></Reference><Reference><Citation>Allayee H., Hartiala J., Lee W., et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest. 2007;132:868&#x2013;874. doi: 10.1378/chest.07-0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.07-0831</ArticleId><ArticleId IdType="pubmed">17646220</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.J., Chang W.A., Tsai P.H., et al. Montelukast induces apoptosis-inducing factor-mediated cell death of lung cancer cells. Int J Mol Sci. 2017;18:1353. doi: 10.3390/ijms18071353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18071353</ArticleId><ArticleId IdType="pmc">PMC5535846</ArticleId><ArticleId IdType="pubmed">28672809</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutton R.P., Stansbury L.G., Leone S., et al. Trauma mortality in mature trauma systems: are we doing better? An analysis of trauma mortality patterns, 1997&#x2013;2008. J&#xa0;Trauma. 2010;69:620&#x2013;626. doi: 10.1097/TA.0b013e3181bbfe2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181bbfe2a</ArticleId><ArticleId IdType="pubmed">20093983</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorreh F., Esmaeili M.H., Yousefichaijan P., et al. Efficacy of montelukast for prevention of upper respiratory tract infection in children: a randomized, placebo-controlled trial. Pharmaceut Sci. 2020;26:193&#x2013;197. doi: 10.34172/PS.2020.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/PS.2020.7</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht T., Rupprecht C., Harms D., et al. Leukotriene receptor blockade as a life-saving treatment in severe bronchopulmonary dysplasia. Respiration. 2014;88:285&#x2013;290. doi: 10.1159/000365488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365488</ArticleId><ArticleId IdType="pubmed">25195568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35379286</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study.</ArticleTitle><Pagination><StartPage>92</StartPage><MedlinePgn>92</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">92</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-022-03962-w</ELocationID><Abstract><AbstractText Label="BACKGROUND">Non-occlusive mesenteric ischemia (NOMI) is a life-threatening condition occurring in patients with shock and is characterized by vasoconstriction of the mesenteric arteries leading to intestinal ischemia and multi-organ failure. Although minimal invasive local intra-arterial infusion of vasodilators into the mesenteric circulation has been suggested as a therapeutic option in NOMI, current knowledge is based on retrospective case series and it remains unclear which patients might benefit. Here, we prospectively analyzed predictors of response to intra-arterial therapy in patients with NOMI.</AbstractText><AbstractText Label="METHODS">This is a prospective single-center observational study to analyze improvement of ischemia (indicated by reduction of blood lactate&#x2009;&gt;&#x2009;2&#xa0;mmol/l from baseline after 24&#xa0;h, primary endpoint) and 28-day mortality (key secondary endpoint) in patients with NOMI undergoing intra-arterial vasodilatory therapy. Predictors of response to therapy concerning primary and key secondary endpoint were identified using a) clinical parameters as well as b) data from 2D-perfusion angiography and c) experimental biomarkers of intestinal injury.</AbstractText><AbstractText Label="RESULTS">A total of 42 patients were included into this study. At inclusion patients had severe shock, indicated by high doses of norepinephrine (NE) (median (interquartile range (IQR)) 0.37 (0.21-0.60) &#x3bc;g/kg/min), elevated lactate concentrations (9.2 (5.2-13) mmol/l) and multi-organ failure. Patients showed a continuous reduction of lactate following intra-arterial prostaglandin infusion (baseline: (9.2 (5.2-13) mmol/l vs. 24&#xa0;h: 4.4 (2.5-9.1) mmol/l, p&#x2009;&lt;&#x2009;0.001) with 22 patients (52.4%) reaching a lactate reduction&#x2009;&gt;&#x2009;2&#xa0;mmol/l at 24&#xa0;h following intervention. Initial higher lactate concentrations and lower NE doses at baseline were independent predictors of an improvement of ischemia. 28-day mortality was 59% in patients with a reduction of lactate&#x2009;&gt;&#x2009;2&#xa0;mmol/l 24&#xa0;h after inclusion, while it was 85% in all other patients (hazard ratio 0.409; 95% CI, 0.14-0.631, p&#x2009;=&#x2009;0.005).</AbstractText><AbstractText Label="CONCLUSIONS">A reduction of lactate concentrations was observed following implementation of intra-arterial therapy, and lactate reduction was associated with better survival. Our findings concerning outcome predictors in NOMI patients undergoing intra-arterial prostaglandin therapy might help designing a randomized controlled trial to further investigate this therapeutic approach. Trial registration Retrospectively registered on January 22, 2020, at clinicaltrials.gov (REPERFUSE, NCT04235634), https://clinicaltrials.gov/ct2/show/NCT04235634?cond=NOMI&amp;draw=2&amp;rank=1 .</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rittgerodt</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pape</LastName><ForeName>Thorben</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Lena S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Diagnostic und Interventional Radiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wedemeyer</LastName><ForeName>Heiner</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeliger</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunkem&#xf6;ller</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuge</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knitsch</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fegbeutel</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillmann</LastName><ForeName>Hans-J&#xf6;rg</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Bernhard C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Diagnostic und Interventional Radiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoeper</LastName><ForeName>Marius M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>Jan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Diagnostic und Interventional Radiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>David</LastName><ForeName>Sascha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Stahl</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4833-6035</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany. stahl.klaus@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04235634</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>DA1209/4-3</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065666" MajorTopicYN="Y">Mesenteric Ischemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="Y">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Intestinal failure</Keyword><Keyword MajorTopicYN="N">Non-occlusive mesenteric ischemia</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35379286</ArticleId><ArticleId IdType="pmc">PMC8981621</ArticleId><ArticleId IdType="doi">10.1186/s13054-022-03962-w</ArticleId><ArticleId IdType="pii">10.1186/s13054-022-03962-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ende N. Infarction of the bowel in cardiac failure. N Engl J Med. 1958;258(18):879&#x2013;881. doi: 10.1056/NEJM195805012581804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM195805012581804</ArticleId><ArticleId IdType="pubmed">13541678</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl K, Busch M, Maschke SK, Schneider A, Manns MP, Fuge J, et al. A retrospective analysis of nonocclusive mesenteric ischemia in medical and surgical ICU patients: clinical data on demography, clinical signs, and survival. J Intensive Care Med. 2020;35(11):1162&#x2013;1172. doi: 10.1177/0885066619837911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619837911</ArticleId><ArticleId IdType="pmc">PMC7536530</ArticleId><ArticleId IdType="pubmed">30909787</ArticleId></ArticleIdList></Reference><Reference><Citation>Soussi S, Taccori M, De Tymowski C, Depret F, Chaussard M, Fratani A, et al. Risk factors for acute mesenteric ischemia in critically ill burns patients-a matched case-control study. Shock. 2019;51(2):153&#x2013;160. doi: 10.1097/SHK.0000000000001140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001140</ArticleId><ArticleId IdType="pubmed">29561390</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl K, Rittgerodt N, Busch M, Maschke SK, Schneider A, Manns MP, et al. Nonocclusive mesenteric ischemia and interventional local vasodilatory therapy: a meta-analysis and systematic review of the literature. J Intensive Care Med. 2020;35(2):128&#x2013;139. doi: 10.1177/0885066619879884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619879884</ArticleId><ArticleId IdType="pubmed">31645176</ArticleId></ArticleIdList></Reference><Reference><Citation>Clair DG, Beach JM. Mesenteric ischemia. N Engl J Med. 2016;374(10):959&#x2013;968. doi: 10.1056/NEJMra1503884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1503884</ArticleId><ArticleId IdType="pubmed">26962730</ArticleId></ArticleIdList></Reference><Reference><Citation>Samel S, Keese M, Kleczka M, Lanig S, Gretz N, Hafner M, et al. Microscopy of bacterial translocation during small bowel obstruction and ischemia in vivo&#x2014;a new animal model. BMC Surg. 2002;2:6. doi: 10.1186/1471-2482-2-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2482-2-6</ArticleId><ArticleId IdType="pmc">PMC126214</ArticleId><ArticleId IdType="pubmed">12174194</ArticleId></ArticleIdList></Reference><Reference><Citation>Piton G, Capellier G. Biomarkers of gut barrier failure in the ICU. Curr Opin Crit Care. 2016;22(2):152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">26808138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer SC, Gorich J, Oertel F, Scheld H, Heindel W. Non-occlusive mesenteric ischemia. Rofo. 2003;175(9):1177&#x2013;1183. doi: 10.1055/s-2003-41923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2003-41923</ArticleId><ArticleId IdType="pubmed">12964071</ArticleId></ArticleIdList></Reference><Reference><Citation>Trompeter M, Brazda T, Remy CT, Vestring T, Reimer P. Non-occlusive mesenteric ischemia: etiology, diagnosis, and interventional therapy. Eur Radiol. 2002;12(5):1179&#x2013;1187. doi: 10.1007/s00330-001-1220-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-001-1220-2</ArticleId><ArticleId IdType="pubmed">11976865</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilsed JV, Casamassima A, Kurihara H, Mariani D, Martinez I, Pereira J, et al. ESTES guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg. 2016;42(2):253&#x2013;270. doi: 10.1007/s00068-016-0634-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-016-0634-0</ArticleId><ArticleId IdType="pmc">PMC4830881</ArticleId><ArticleId IdType="pubmed">26820988</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockmann H, Roblick UJ, Kluge N, Kunze U, Schimmelpenning H, Kujath P, et al. Diagnosis and therapy of non-occlusive mesenteric ischemia (NOMI) Zentralbl Chir. 2000;125(2):144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">10743034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst S, Luther B, Zimmermann N, Bohner H, Wilke R, Feindt P, et al. Current diagnosis and therapy of non-occlusive mesenteric ischemia. Rofo. 2003;175(4):515&#x2013;523. doi: 10.1055/s-2003-38441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2003-38441</ArticleId><ArticleId IdType="pubmed">12677507</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler G, Bruch HP. The current status of the diagnosis and therapy of nonocclusive intestinal ischemia (NII) RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 1991;155(2):123&#x2013;127. doi: 10.1055/s-2008-1033232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1033232</ArticleId><ArticleId IdType="pubmed">1878538</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray T, Rodt T, Lee MJ. Two-dimensional perfusion angiography of the foot: technical considerations and initial analysis. J Endovasc Ther. 2016;23(1):58&#x2013;64. doi: 10.1177/1526602815621289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1526602815621289</ArticleId><ArticleId IdType="pubmed">26668130</ArticleId></ArticleIdList></Reference><Reference><Citation>Minko P, Groesdonk H, Stroeder J, Miodek J, Graeber S, Bucker A, et al. A scoring system for the assessment of angiographic findings in non-occlusive mesenteric ischemia (NOMI) Rofo. 2012;184(9):805&#x2013;809. doi: 10.1055/s-0032-1312750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1312750</ArticleId><ArticleId IdType="pubmed">22618477</ArticleId></ArticleIdList></Reference><Reference><Citation>Minko P, Stroeder J, Groesdonk HV, Graeber S, Klingele M, Buecker A, et al. A scoring-system for angiographic findings in nonocclusive mesenteric ischemia (NOMI): correlation with clinical risk factors and its predictive value. Cardiovasc Intervent Radiol. 2014;37(3):657&#x2013;663. doi: 10.1007/s00270-014-0844-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00270-014-0844-y</ArticleId><ArticleId IdType="pubmed">24477566</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuijls G, van Wijck K, Grootjans J, Derikx JP, van Bijnen AA, Heineman E, et al. Early diagnosis of intestinal ischemia using urinary and plasma fatty acid binding proteins. Ann Surg. 2011;253(2):303&#x2013;308. doi: 10.1097/SLA.0b013e318207a767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e318207a767</ArticleId><ArticleId IdType="pubmed">21245670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellekens D, Reisinger KW, Lenaerts K, Hadfoune M, Olde Damink SW, Buurman WA, et al. SM22 a plasma biomarker for human transmural intestinal ischemia. Ann Surg. 2018;268(1):120&#x2013;126. doi: 10.1097/SLA.0000000000002278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002278</ArticleId><ArticleId IdType="pubmed">28525410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara S, Sekine Y, Nishimura R, Tadasa K, Miyazaki S. Treatment of nonocclusive mesenteric ischemia with type B aortic dissection using intra-arterial catheterization after trauma surgery: case report. Surg Case Rep. 2018;4(1):5. doi: 10.1186/s40792-017-0412-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40792-017-0412-1</ArticleId><ArticleId IdType="pmc">PMC5758487</ArticleId><ArticleId IdType="pubmed">29313164</ArticleId></ArticleIdList></Reference><Reference><Citation>Winzer R, Fedders D, Backes M, Ittermann T, Grundling M, Mensel B, et al. Local intra-arterial vasodilator infusion in non-occlusive mesenteric ischemia significantly increases survival rate. Cardiovasc Intervent Radiol. 2020;43(8):1148&#x2013;1155. doi: 10.1007/s00270-020-02515-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00270-020-02515-4</ArticleId><ArticleId IdType="pmc">PMC8275548</ArticleId><ArticleId IdType="pubmed">32444922</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754&#x2013;1758. doi: 10.1001/jama.286.14.1754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.14.1754</ArticleId><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Diery H, Phillips A, Evennett N, Pandanaboyana S, Gilham M, Windsor JA. The pathogenesis of nonocclusive mesenteric ischemia: implications for research and clinical practice. J Intensive Care Med. 2019;34(10):771&#x2013;781. doi: 10.1177/0885066618788827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066618788827</ArticleId><ArticleId IdType="pubmed">30037271</ArticleId></ArticleIdList></Reference><Reference><Citation>Calame P, Nuzzo A, Ronot M. Local intra-arterial vasodilator infusion in non-occlusive mesenteric ischemia: Dealing with one consequence hoping to affect the cause? Cardiovasc Intervent Radiol. 2021;44(3):507&#x2013;508. doi: 10.1007/s00270-020-02696-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00270-020-02696-y</ArticleId><ArticleId IdType="pubmed">33161468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16878192</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1516-3180</ISSN><JournalIssue CitedMedium="Print"><Volume>124</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Sao Paulo medical journal = Revista paulista de medicina</Title><ISOAbbreviation>Sao Paulo Med J</ISOAbbreviation></Journal><ArticleTitle>Effects of single dose of dexamethasone on patients with systemic inflammatory response.</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>95</EndPage><MedlinePgn>90-5</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT AND OBJECTIVE" NlmCategory="OBJECTIVE">Systemic inflammatory response syndrome (SIRS) is a very common condition among critically ill patients. SIRS, sepsis, septic shock and multiple organ dysfunction syndrome (MODS) can lead to death. Our aim was to investigate the efficacy of a single dose of dexamethasone for blocking the progression of systemic inflammatory response syndrome.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Prospective, randomized, double-blind, single-center study in a postoperative intensive care unit (Surgical Support Unit) at Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study involved 29 patients with SIRS. All eligible patients were prospectively randomized to receive either a single dose of 0.2 mg/kg of dexamethasone or placebo, after SIRS was diagnosed. The patients were monitored over a seven-day period using Sequential Organ Failure Assessment score (SOFA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The respiratory system showed an improvement on the first day after dexamethasone was administered, demonstrated by the improved PaO2/FiO2 ratio (p &lt; 0.05). The cardiovascular system of patients requiring vasopressor therapy also improved over the first two days, with a better evolution in the dexamethasone group (p &lt; 0.05). Non-surviving patients presented higher lactate assays than did survivors (p &lt; 0.05) during this period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dexamethasone enhanced the effects of vasopressor drugs and evaluation of the respiratory system showed improvements (better PaO2/FiO2 ratio), one day after its administration. Despite these improvements, the single dose of dexamethasone did not block the evolution of SIRS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cicarelli</LastName><ForeName>Domingos Dias</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Surgical Support Unit, Anesthesia Division, Department of Surgery, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil. dcicarelli@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bense&#xf1;or</LastName><ForeName>F&#xe1;bio Ely Martins</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Joaquim Edson</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Sao Paulo Med J</MedlineTA><NlmUniqueID>100897261</NlmUniqueID><ISSNLinking>1516-3180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="CONTEXTO E OBJETIVO:">A s&#xed;ndrome da resposta inflamat&#xf3;ria sist&#xea;mica (SRIS) acomete muitos pacientes internados em unidades de terapia intensiva. A evolu&#xe7;&#xe3;o destes pacientes com SRIS para sepse, choque s&#xe9;ptico e s&#xed;ndrome da disfun&#xe7;&#xe3;o de m&#xfa;ltiplos &#xf3;rg&#xe3;os (SDMO) pode conduzi-los rapidamente para o &#xf3;bito. A proposta do trabalho &#xe9; avaliar a efic&#xe1;cia da dexametasona em dose &#xfa;nica como tratamento da SRIS.</AbstractText><AbstractText Label="TIPO DE ESTUDO E LOCAL:">Estudo prospectivo, aleat&#xf3;rio, duplamente encoberto, realizado na Unidade de Terapia Intensiva p&#xf3;s-operat&#xf3;ria (Unidade de Apoio Cir&#xfa;rgico) do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="M&#xc9;TODOS:">Foram estudados 29 pacientes com diagn&#xf3;stico de SRIS. Os participantes foram aleatoriamente divididos em dois grupos que receberam dexametasona (0,2 mg/kg em dose &#xfa;nica) ou placebo ap&#xf3;s o diagn&#xf3;stico de SRIS. Os pacientes foram acompanhados durante sete dias de interna&#xe7;&#xe3;o na UTI atrav&#xe9;s do escore SOFA <i>(Sequential Organ Failure Assessment)</i>.</AbstractText><AbstractText Label="RESULTADOS:">Os pacientes que receberam dexametasona apresentaram melhora do sistema respirat&#xf3;rio no primeiro dia, com aumento da rela&#xe7;&#xe3;o PaO<sub>2</sub>/FiO<sub>2</sub> (p &lt; 0,05). Entre os pacientes que faziam uso de vasopressores, os que receberam dexametasona tiveram diminui&#xe7;&#xe3;o da necessidade destas medica&#xe7;&#xf5;es nos primeiros dois dias ap&#xf3;s a dose de dexametasona (p &lt; 0,05).</AbstractText><AbstractText Label="CONCLUS&#xc3;O:">A dexametasona diminuiu a necessidade de medica&#xe7;&#xf5;es vasopressoras e causou aumento da rela&#xe7;&#xe3;o PaO<sub>2</sub>/FiO<sub>2</sub> no primeiro dia ap&#xf3;s sua administra&#xe7;&#xe3;o. Apesar destes efeitos, a dexametasona em dose &#xfa;nica n&#xe3;o bloqueou a evolu&#xe7;&#xe3;o dos pacientes com SRIS.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> Not declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16878192</ArticleId><ArticleId IdType="pmc">PMC11060357</ArticleId><ArticleId IdType="doi">10.1590/s1516-31802006000200008</ArticleId><ArticleId IdType="pii">S1516-31802006000200008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Sepsis, sepsis syndrome, and systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273(2):155&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273(2):117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799491</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094907</ArticleId><ArticleId IdType="pubmed">9876974</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappa B. Free Radic Biol Med. 2000;28(9):1317&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924851</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569975</ArticleId></ArticleIdList></Reference><Reference><Citation>Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24(1):163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8565523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bihari DJ, Tinker J. Steroids in intensive care. Br J Hosp Med. 1982;28(4):323&#x2013;324. 328-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">6753992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26(4):645&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumer W. Controversy in shock research. Pro: The role of steroids in septic shock. Circ Shock. 1981;8(6):667&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">7337944</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23(8):1430&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">7634816</ArticleId></ArticleIdList></Reference><Reference><Citation>Demling RH, Smith M, Gunther R, Wandzilak T. Endotoxin-induced lung injury in unanesthetized sheep: effect of methylprednisolone. Circ Shock. 1981;8(3):351&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">7249263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes GS., Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sci. 1984;35(23):2319&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">6390057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass EH. High-dose corticosteroids for septic shock. N Engl J Med. 1984;311(18):1178&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">6482936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheagren JN. Septic shock and corticosteroids. N Engl J Med. 1981;305(8):456&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">7254284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer V. Betamethasone sodium phosphate injection: highdose regimen in septic shock. Clin Ther. 1984;6(5):719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">6383616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Neugebauer E. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23(7):1294&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600840</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson DP. Corticosteroids in the treatment of septic shock and the adult respiratory distress syndrome. Med Clin North Am. 1983;67(3):717&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">6341730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottosson J, Brandberg A, Erikson B, Hedman L, Dawidson I, S&#xf6;derberg R. Experimental septic shock - effects of corticosteroids. Circ Shock. 1982;9(6):571&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">6758979</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995;21(3):204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig. 1994;72(10):782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">7865982</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186604</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J. From mega to more reasonable doses of corticosteroids: a decade to recreate hope. Crit Care Med. 1999;27(4):672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321643</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288(7):886&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186608</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321661</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9669790</ArticleId></ArticleIdList></Reference><Reference><Citation>Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora's Box. Anaesthesia. 2003;58(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12492660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbald WJ, Doig G, Inman KJ. Sepsis, SIRS and infection. Intensive Care Med. 1995;21(4):299&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">7650251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 9th ed. St Louis: McGraw-Hill; 1996. pp. 1459&#x2013;1485.</Citation></Reference><Reference><Citation>Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group Multiple organ dysfunction: baseline and serial component scores. Crit Care Med. 2001;29(11):2046&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700393</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25(11):1789&#x2013;1795.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366759</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendon&#xe7;a A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society on Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR. Quantification of organ dysfunction: seeking standardization. Crit Care Med. 1998;26(11):1767&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824054</ArticleId></ArticleIdList></Reference><Reference><Citation>Timsit JF, Fosse JP, Troch&#xe9; G, et al. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med. 2002;30(9):2003&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettila V, Pettila M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163780</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf3;voa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">9840239</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">12664219</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLaren R, Jung R. Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">12222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519925</ArticleId></ArticleIdList></Reference><Reference><Citation>Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559592</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J, International Sepsis Forum Immunological therapy in sepsis: currently available. Intensive Care Med. 2001;27(Suppl 1):S93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307373</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253&#x2013;S257.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682449</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GS, Bernard GR, International Sepsis Forum Airway and lung in sepsis. Intensive Care Med. 2001;27(Suppl 1):S63&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Gando S, Morimoto Y, Nanzaki S, Kemmotsu O. Serial measurement of arterial lactate concentrations as a prognostic indicator in relation to the incidence of disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Surg Today. 2001;31(10):853&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">11759877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello CA. The Acute-Phase response. In: Bennett JC, Plum F, editors. Cecil Textbook of Medicine. 20th ed. Philadelphia: Saunders; 1996. pp. 1567&#x2013;1569.</Citation></Reference><Reference><Citation>Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med. 2002;30(3):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">11990910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Sch&#xfc;ttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002;30(5):1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">12006796</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares AJ, David CMN. A avalia&#xe7;&#xe3;o do comportamento da prote&#xed;na C-reativa em pacientes com sepse na UTI. Rev Bras Ter Intensiva. 2002;14(4):156&#x2013;165.</Citation></Reference><Reference><Citation>Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32539903</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-6834</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infection control and hospital epidemiology</Title><ISOAbbreviation>Infect Control Hosp Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Variation in antibiotic use across intensive care units (ICU): A population-based cohort study in Ontario, Canada.</ArticleTitle><Pagination><StartPage>1035</StartPage><EndPage>1041</EndPage><MedlinePgn>1035-1041</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/ice.2020.217</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Antibiotics are commonly used in intensive care units (ICUs), yet differences in antibiotic use across ICUs are unknown. Herein, we studied antibiotic use across ICUs and examined factors that contributed to variation.</AbstractText><AbstractText Label="METHODS">We conducted a retrospective cohort study using data from Ontario's Critical Care Information System (CCIS), which included 201 adult ICUs and 2,013,397 patient days from January 2012 to June 2016. Antibiotic use was measured in days of therapy (DOT) per 1,000 patient days. ICU factors included ability to provide ventilator support (level 3) or not (level 2), ICU type (medical-surgical or other), and academic status. Patient factors included severity of illness using multiple-organ dysfunction score (MODS), ventilatory support, and central venous catheter (CVC) use. We analyzed the effect of these factors on variation in antibiotic use.</AbstractText><AbstractText Label="RESULTS">Overall, 269,351 patients (56%) received antibiotics during their ICU stay. The mean antibiotic use was 624 (range 3-1460) DOT per 1,000 patient days. Antibiotic use was significantly higher in medical-surgical ICUs compared to other ICUs (697 vs 410 DOT per 1,000 patient days; P &lt; .0001) and in level 3 ICUs compared to level 2 ICUs (751 vs 513 DOT per 1,000 patient days; P &lt; .0001). Higher antibiotic use was associated with higher severity of illness and intensity of treatment. ICU and patient factors explained 47% of the variation in antibiotic use across ICUs.</AbstractText><AbstractText Label="CONCLUSIONS">Antibiotic use varies widely across ICUs, which is partially associated with ICUs and patient characteristics. These differences highlight the importance of antimicrobial stewardship to ensure appropriate use of antibiotics in ICU patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Erika Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detsky</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdepartmental Division of Critical Care Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biostatistics Research Unit, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Chaim M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Control Hosp Epidemiol</MedlineTA><NlmUniqueID>8804099</NlmUniqueID><ISSNLinking>0899-823X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32539903</ArticleId><ArticleId IdType="doi">10.1017/ice.2020.217</ArticleId><ArticleId IdType="pii">S0899823X20002172</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28332853</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-0257</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Genetic testing and molecular biomarkers</Title><ISOAbbreviation>Genet Test Mol Biomarkers</ISOAbbreviation></Journal><ArticleTitle>Correlations Between LP-PLA2 Gene Polymorphisms and Susceptibility and Severity of Acute Pancreatitis in a Chinese Population.</ArticleTitle><Pagination><StartPage>206</StartPage><EndPage>212</EndPage><MedlinePgn>206-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/gtmb.2016.0243</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This case-control study explored correlations between LP-PLA2 gene polymorphisms (A379V, V279F, and R92H) and susceptibility and severity of acute pancreatitis (AP) in a Chinese population.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">From October 2013 to October 2015, 94 AP patients were chosen as the case group. According to the Acute Physiology and Chronic Health Evaluation (APACHE) II score standard, AP patients were divided into a mild AP (MAP) group (n&#x2009;=&#x2009;46) and severe AP (SAP) group (n&#x2009;=&#x2009;48). The 48 SAP patients were further divided into an SAP with multiple organ dysfunction syndrome (MODS) group (n&#x2009;=&#x2009;42) and SAP without MODS group (n&#x2009;=&#x2009;6). Meanwhile, 96 healthy subjects who received physical examinations at the study hospitals were selected as the control group. Serum lipoprotein-associated phospholipase A2 (LP-PLA2) levels were detected by an enzyme-linked immunosorbent assay (ELISA). The A379V (s1051931), V279F (rs16874954), and R92H (rs13989) polymorphisms of the LP-PLA2 gene were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were significant differences in the frequencies of the LP-PLA2 gene polymorphisms between the AP group and the control group. The distribution of V279F-AA+AC genotype and R92H-AA+AG genotype in the AP group was higher than that in the control group, whereas the SAP group and SAP with MODS group distributions were higher than those in the MAP group and SAP without MODS group (both p&#x2009;&lt;&#x2009;0.05). G-C-A, G-A-G, and G-C-G haploids formed by A379V, V279F, and R92H may be associated with AP susceptibility. LP-PLA2 gene polymorphisms could affect serum LP-PLA2 level, whereas the V279F-A allele gene, the R92H-A allele gene, serum LP-PLA2 level, and serum amylase may be independent risk factors for AP (all p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrated that the LP-PLA2 gene polymorphisms, V279F and R92H, may be associated with susceptibility to and severity of AP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Department of Emergency, Laiwu City People's Hospital , Laiwu, P.R. China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Chun-Xia</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>1 Department of Emergency, Laiwu City People's Hospital , Laiwu, P.R. China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Cai-Xia</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>2 Department of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University , Changchun, P.R. China .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genet Test Mol Biomarkers</MedlineTA><NlmUniqueID>101494210</NlmUniqueID><ISSNLinking>1945-0257</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.47</RegistryNumber><NameOfSubstance UI="D043203">1-Alkyl-2-acetylglycerophosphocholine Esterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.47</RegistryNumber><NameOfSubstance UI="C526684">PLA2G7 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D043203" MajorTopicYN="N">1-Alkyl-2-acetylglycerophosphocholine Esterase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A379V</Keyword><Keyword MajorTopicYN="N">LP-PLA2</Keyword><Keyword MajorTopicYN="N">R92H</Keyword><Keyword MajorTopicYN="N">V279F</Keyword><Keyword MajorTopicYN="N">acute pancreatitis susceptibility</Keyword><Keyword MajorTopicYN="N">gene polymorphism</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28332853</ArticleId><ArticleId IdType="doi">10.1089/gtmb.2016.0243</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38318959</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2753-670X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Postoperative intra-abdominal hypertension predicts worse hospital outcomes in children after cardiac surgery: a pilot study&#x2020;.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ivae019</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivae019</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our goal was to determine the incidence and characteristics of postoperative intra-abdominal hypertension (IAH) in paediatric patients undergoing open-heart surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-centre study included consecutive children (aged &lt;16&#x2009;years) who underwent open-heart surgery between July 2020 and February 2021. Patients who entered the study were followed until in-hospital death or hospital discharge. The study consisted of 2 parts. Part I was a prospective observational cohort study that was designed to discover the association between exposures and IAH. Postoperative intra-abdominal pressure was measured immediately after admission to the intensive care unit and every 6&#x2009;h thereafter. Part II was a cross-sectional study to compare the hospital-related adverse outcomes between the IAH and the no-IAH cohorts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Postoperatively, 24.7% (38/154) of the patients exhibited IAH, whereas 3.9% (6/154) developed abdominal compartment syndrome. The majority (29/38, 76.3%) of IAH cases occurred within the first 24&#x2009;h in the intensive care unit. Multivariable analysis showed that the Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery score [odds ratio (OR)&#x2009;=&#x2009;1.86, 95% confidence interval (CI) 1.23-2.83, P&#x2009;=&#x2009;0.004], right-sided heart lesion (OR&#x2009;=&#x2009;5.60, 95% CI 2.34-13.43, P&#x2009;&lt;&#x2009;0.001), redo sternotomy (OR&#x2009;=&#x2009;4.35, 95% CI 1.64-11.57, P&#x2009;=&#x2009;0.003), high baseline intra-abdominal pressure (OR&#x2009;=&#x2009;1.43, 95% CI 1.11-1.83, P&#x2009;=&#x2009;0.005), prolonged cardiopulmonary bypass duration (OR&#x2009;=&#x2009;1.01, 95% CI 1.00-1.01, P&#x2009;=&#x2009;0.005) and deep hypothermic circulatory arrest (OR&#x2009;=&#x2009;5.14, 95% CI 1.15-22.98, P&#x2009;=&#x2009;0.032) were independent predictors of IAH occurrence. IAH was associated with greater inotropic support (P&#x2009;&lt;&#x2009;0.001), more gastrointestinal complications (P&#x2009;=&#x2009;0.001), sepsis (P&#x2009;=&#x2009;0.003), multiple organ dysfunction syndrome (P&#x2009;&lt;&#x2009;0.001) and prolonged intensive care unit stay (z = -4.916, P&#x2009;&lt;&#x2009;0.001) and hospitalization (z = -4.710, P&#x2009;&lt;&#x2009;0.001). The occurrence of a composite outcome (P&#x2009;=&#x2009;0.009) was significantly increased in patients with IAH.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IAH is common in children undergoing cardiac surgery and is associated with worse hospital outcomes. Several factors may be associated with the development of IAH, including basic cardiac physiology and perioperative factors.</AbstractText><AbstractText Label="TRIAL INFORMATION" NlmCategory="UNASSIGNED">This study was registered in the Chinese Clinical Trial Registry (Trial number: ChiCTR2000034322)URL site: https://www.chictr.org.cn/hvshowproject.html?id=41363&amp;v=1.4.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Shuhua</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0191-4747</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yuxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yibing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shouping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lijing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal compartment syndrome</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Gastrointestinal complication</Keyword><Keyword MajorTopicYN="N">Intra-abdominal hypertension</Keyword><Keyword MajorTopicYN="N">Paediatrics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38318959</ArticleId><ArticleId IdType="pmc">PMC10882438</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivae019</ArticleId><ArticleId IdType="pii">7601456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dabrowski W, Rzecki Z.. Intra-abdominal and abdominal perfusion pressure in patients undergoing coronary artery bypass graft surgery. Acta Clin Belg 2009;64:216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19670561</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#x131;l&#x131;&#xe7; B, Yap&#x131;c&#x131; N, Yap&#x131;c&#x131; F, Kavakl&#x131; AS, Kudsio&#x11f;lu T, K&#x131;l&#x131;&#xe7; A. et al. Factors associated with increased intra-abdominal pressure in patients undergoing cardiac surgery. Turk Gogus Kalp Damar Cerrahisi Derg 2020;28:134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067007</ArticleId><ArticleId IdType="pubmed">32175154</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit M, Werner MJM, Lansink-Hartgring AO, Dieperink W, Zijlstra JG, van Meurs M.. How central obesity influences intra-abdominal pressure: a prospective, observational study in cardiothoracic surgical patients. Ann Intensive Care 20166:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056912</ArticleId><ArticleId IdType="pubmed">27726116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzeffi MA, Stafford P, Wallace K, Bernstein W, Deshpande S, Odonkor P. et al. Intra-abdominal Hypertension and Postoperative Kidney Dysfunction in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth 2016;30:1571&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">27590464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazer R, Albarrati A, Ullah A, Alamro S, Kashour T.. Intra-abdominal hypertension in obese patients undergoing coronary surgery: a prospective observational study. Surgery 2019;166:1128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson N, Efthymiou C.. Predictive risk factors for intra-abdominal hypertension after cardiac surgery. Interact CardioVasc Thorac Surg 2021. 10;32:719&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691507</ArticleId><ArticleId IdType="pubmed">33471093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, Pediatric Guidelines Sub-Committee for the World Society of the Abdominal Compartment Syndrome et al.Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med 2013;39:1190&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680657</ArticleId><ArticleId IdType="pubmed">23673399</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Bougmiza IM, Chehab MS, Bafaqih HA, AlMohaimeed SA, Malbrain ML.. Incidence, Risk Factors, and Prognosis of Intra-Abdominal Hypertension in Critically Ill Children: a Prospective Epidemiological Study. J Intensive Care Med 2016;31:403&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922384</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Ejike JC.. Intra-abdominal hypertension and abdominal compartment syndrome in pediatrics. A review. J Crit Care 2017;41:275&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">28614762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanayem NS, Dearani JA, Welke KF, B&#xe9;land MJ, Shen I, Ebels T.. Gastrointestinal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. Cardiol Young 2008;18 Suppl 2:240&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19063798</ArticleId></ArticleIdList></Reference><Reference><Citation>Butts RJ, Scheurer MA, Zyblewski SC, Wahlquist AE, Nietert PJ, Bradley SM. et al. A composite outcome for neonatal cardiac surgery research. J Thorac Cardiovasc Surg 2014;147:428&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004075</ArticleId><ArticleId IdType="pubmed">23587468</ArticleId></ArticleIdList></Reference><Reference><Citation>Moga MA, Manlhiot C, Marwali EM, McCrindle BW, Van Arsdell GS, Schwartz SM.. Hyperglycemia after pediatric cardiac surgery: impact of age and residual lesions. Crit Care Med 2011;39:266&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057314</ArticleId></ArticleIdList></Reference><Reference><Citation>Koponen T, Karttunen J, Musialowicz T, Pietil&#xe4;inen L, Uusaro A, Lahtinen P.. Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth 2019;122:428&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435836</ArticleId><ArticleId IdType="pubmed">30857599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalfino L, Sicolo A, Paparella D, Mongelli M, Rubino G, Brienza N.. Intra-abdominal hypertension in cardiac surgery. Interact CardioVasc Thorac Surg 2013;17:644&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781798</ArticleId><ArticleId IdType="pubmed">23820668</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaser AR, Bj&#xf6;rck M, De Keulenaer B, Regli A.. Abdominal compliance: a bench-to-bedside review. J Trauma Acute Care Surg 2015;78:1044&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25909429</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer D, D'Amours S, Aneman A.. Intra-abdominal hypertension in postoperative cardiac surgery patients. Crit Care Resusc 2014;16:214&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25161025</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes JH 4th, Connolly NC, Paull DL, Hill ME, Guyton SW, Ziegler SF. et al. Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm Res 2002;51:579&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofukuji M, Stahl GL, Metais C, Tomita M, Agah A, Bianchi C. et al. Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a. Ann Thorac Surg 2000;69:799&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10750764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramser M, Glauser PM, Glass TR, Weixler B, Grapow MTR, Hoffmann H. et al. Abdominal Decompression after Cardiac Surgery: outcome of 42 Patients with Abdominal Compartment Syndrome. World J Surg 2021;45:1242&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">33481080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO.. Gastrointestinal complications associated with the surgical treatment of heart disease in children. J Pediatr Surg 2017;52:414&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916446</ArticleId></ArticleIdList></Reference><Reference><Citation>Deindl P, Wagner J, Herden U, Schulz-J&#xfc;rgensen S, Schild R, Vettorazzi E. et al. Monitoring intra-abdominal pressure after liver transplantation in children. Pediatr Transplant 2019;23:e13565.</Citation><ArticleIdList><ArticleId IdType="pubmed">31471942</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham ML, Malbrain ML.. Cardiovascular implications of abdominal compartment syndrome. Acta Clin Belg 2007;62 Suppl 1:98&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469707</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16940457</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-972X</ISSN><JournalIssue CitedMedium="Print"><Volume>91</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Copeptin and arginine vasopressin concentrations in critically ill patients.</ArticleTitle><Pagination><StartPage>4381</StartPage><EndPage>4386</EndPage><MedlinePgn>4381-6</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Determination of arginine vasopressin (AVP) concentrations may be helpful to guide therapy in critically ill patients. A new assay analyzing copeptin, a stable peptide derived from the AVP precursor, has been introduced.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our objective was to determine plasma copeptin concentrations.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We conducted a post hoc analysis of plasma samples and data from a prospective study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The setting was a 12-bed general and surgical intensive care unit (ICU) in a tertiary university teaching hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Our subjects were 70 healthy volunteers and 157 ICU patients with sepsis, with systemic inflammatory response syndrome (SIRS), and after cardiac surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">There were no interventions.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Copeptin plasma concentrations, demographic data, AVP plasma concentrations, and a multiple organ dysfunction syndrome score were documented 24 h after ICU admission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AVP (P &lt; 0.001) and copeptin (P &lt; 0.001) concentrations were significantly higher in ICU patients than in controls. Patients after cardiac surgery had higher AVP (P = 0.003) and copeptin (P = 0.003) concentrations than patients with sepsis or SIRS. Independent of critical illness, copeptin and AVP correlated highly significantly with each other. Critically ill patients with sepsis and SIRS exhibited a significantly higher ratio of copeptin/AVP plasma concentrations than patients after cardiac surgery (P = 0.012). The American Society of Anesthesiologists' classification (P = 0.046) and C-reactive protein concentrations (P = 0.006) were significantly correlated with the copeptin/AVP ratio.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Plasma concentrations of copeptin and AVP in healthy volunteers and critically ill patients correlate significantly with each other. The ratio of copeptin/AVP plasma concentrations is increased in patients with sepsis and SIRS, suggesting that copeptin may overestimate AVP plasma concentrations in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jochberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. Stefan.Jochberger@uibk.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgenthaler</LastName><ForeName>Nils G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Viktoria D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Luckner</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Hanno</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hasibeder</LastName><ForeName>Walter R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Friesenecker</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>D&#xfc;nser</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006020">Glycopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C048197">copeptins</NameOfSubstance></Chemical><Chemical><RegistryNumber>113-79-1</RegistryNumber><NameOfSubstance UI="D001127">Arginine Vasopressin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001127" MajorTopicYN="N">Arginine Vasopressin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006020" MajorTopicYN="N">Glycopeptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013903" MajorTopicYN="N">Thoracic Surgery</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16940457</ArticleId><ArticleId IdType="doi">10.1210/jc.2005-2830</ArticleId><ArticleId IdType="pii">jc.2005-2830</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28721572</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1432-2323</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>World journal of surgery</Title><ISOAbbreviation>World J Surg</ISOAbbreviation></Journal><ArticleTitle>I-FABP is a Novel Marker for the Detection of Intestinal Injury in Severely Injured Trauma Patients.</ArticleTitle><Pagination><StartPage>3120</StartPage><EndPage>3127</EndPage><MedlinePgn>3120-3127</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00268-017-4124-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Intestinal injury is a rare injury in multiply traumatized patients, and its diagnosis remains difficult. Delayed diagnosis of an intestinal injury increases the risk of sepsis, multiple organ failure and mortality. The intestinal fatty acid-binding protein (I-FABP) is solely expressed in the intestine and is released extracellulary after tissue damage. This study evaluates the validity of I-FABP as an early biomarker to detect an abdominal injury and particularly an injury to the intestine.</AbstractText><AbstractText Label="PATIENTS AND METHODS">Patients with an Abbreviated Injury Scale (AIS) score for abdominal body region (AIS abdomen) &#x2265;3 were included in this study from 07/2006 to 12/2014. Of those, ten patients retrospectively had an intestinal injury (int. injury). According to the Injury Severity Score and the AIS abdomen, corresponding patients with an abdominal injury but without an intestinal injury (no int. injury) were included for matched-pair analysis. Twenty healthy volunteers served as controls. Plasma I-FABP levels were measured at admission to the emergency room and up to 10&#xa0;days daily (d1-d10).</AbstractText><AbstractText Label="RESULTS">Median I-FABP levels were significantly higher in the "int. injury" group compared to the "no int. injury" group [2101.0&#xa0;pg/ml (IQR&#xa0;=&#xa0;1248.1-4117.8) vs. 351.4&#xa0;pg/ml (IQR&#xa0;=&#xa0;287.6-963.3), p&#xa0;&lt;&#xa0;0.05]. Furthermore, I-FABP levels of both groups were significantly higher compared to the control group [Ctrl: 127.2&#xa0;pg/ml (IQR&#xa0;=&#xa0;57.4-310.6), p&#xa0;&lt;&#xa0;0.05]. The time course of I-FABP levels showed a peak on the day of admission and a decline to the control levels in the further post-traumatic course. The development of complications such as single- or multi-organ failure, sepsis, acute respiratory distress syndrome, pneumonia and mortality was higher in the "int. injury" group; however, this difference was not statistically significant.</AbstractText><AbstractText Label="CONCLUSION">This study confirmed our previous observation that I-FABP might be used as a suitable early biomarker for the detection of abdominal injuries in general. In addition and more specific, I-FABP may be a useful and promising parameter in the diagnosis of intestinal injuries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voth</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. maika.voth@kgu.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duchene</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auner</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lustenberger</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relja</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzi</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Surg</MedlineTA><NlmUniqueID>7704052</NlmUniqueID><ISSNLinking>0364-2313</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050556">Fatty Acid-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015998" MajorTopicYN="N">Abbreviated Injury Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000007" MajorTopicYN="N">Abdominal Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050556" MajorTopicYN="N">Fatty Acid-Binding Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28721572</ArticleId><ArticleId IdType="doi">10.1007/s00268-017-4124-2</ArticleId><ArticleId IdType="pii">10.1007/s00268-017-4124-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pneumologie. 2012 Dec;66(12):707-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23225407</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Surg. 2006 Sep-Oct;63(5):322-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16971202</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1998 Jul;45(1):69-75; discussion 75-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9680015</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2015 Apr;53(5):771-80</Citation><ArticleIdList><ArticleId IdType="pubmed">25324448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1993 Aug;35(2):267-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8355307</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Emerg Med. 2010 Jul;17(7):729-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20653587</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 1994 Dec;168(6):670-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7978016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Surg. 2015 Jul;50(7):1115-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25783297</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosens Bioelectron. 2005 Jun 15;20(12):2566-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15854826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 1995 May;36(5):788-91</Citation><ArticleIdList><ArticleId IdType="pubmed">7797132</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2013 Apr;205(4):414-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23375703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zentralbl Chir. 2014 Aug;139(4):445-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22773415</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2014 Dec;12(12):1495-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25046131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1996 Aug;41(2):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8760536</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2007 Dec;194(6):728-32; discussion 732-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18005762</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2015 Jan;46(1):100-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25267401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Surg. 1999 Oct;34(10 ):1453-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10549746</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Surg. 2005 Nov-Dec;62(6):549-53, quiz 553</Citation><ArticleIdList><ArticleId IdType="pubmed">16293484</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Clin North Am. 1991 Apr;71(2):399-418</Citation><ArticleIdList><ArticleId IdType="pubmed">2003258</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2006 Oct;72(10):955-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17058744</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Gastroenterol. 2014 Mar;48(3):253-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24100750</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1974 Mar;14(3):187-96</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2004 Nov;32(11):2234-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15640635</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2010 Jul;69(1):84-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20622582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirurg. 1999 Nov;70(11):1269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">10591763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2017 Jan;47(1):100-106</Citation><ArticleIdList><ArticleId IdType="pubmed">27559695</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2007 Nov;28(5):544-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17607153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirurg. 1993 Jul;64(7):552-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8375206</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2003 Apr;69(4):293-8; discussion 298-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12716086</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2002 Sep;137(9):1029-32; discussion 1032-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12215153</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1993 Dec 22-29;270(24):2957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulus Travma Acil Cerrahi Derg. 2009 Jan;15(1):45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19130330</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Biochem. 2003 Oct;36(7):529-35</Citation><ArticleIdList><ArticleId IdType="pubmed">14563446</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Protein Chem. 1994;45:89-151</Citation><ArticleIdList><ArticleId IdType="pubmed">8154375</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn Med. 1989 Aug;53(8):451-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2766714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2002 Oct;239(1-2):227-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12479590</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 1996 Jul;22(7):707-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):373-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25683524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol. 2011 Apr;46(4):492-500</Citation><ArticleIdList><ArticleId IdType="pubmed">21298292</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Imaging. 2013 Sep-Oct;37(5):884-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23886598</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1996 Aug 15;318 ( Pt 1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8761444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Gastroenterol. 2009 Sep;43(8):727-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19359998</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1972 Jul 7;177(4043):56-8</Citation><ArticleIdList><ArticleId IdType="pubmed">5041774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2003 Feb;54(2):289-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12579054</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chim Acta. 2005 Feb;352(1-2):15-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15653098</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Trauma Emerg Surg. 2013 Feb;39(1):9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26814918</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Trauma Emerg Surg. 2014 Feb;40(1):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26815780</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2015 Feb;43(2):117-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25394241</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Lipid Res. 1996 Sep;35(3):243-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9082452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15550474</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0009-9147</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical chemistry</Title><ISOAbbreviation>Clin Chem</ISOAbbreviation></Journal><ArticleTitle>Prognostic value of an early soluble L-selectin (sCD62L) assay for risk assessment in blunt multiple trauma: a metaanalysis.</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>24</EndPage><MedlinePgn>16-24</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">After severe trauma, decreased plasma concentrations of the soluble adhesion molecule L-selectin (sCD62L) have been linked to an increased incidence of lung failure and multiorgan dysfunction syndrome (MODS). Individual studies have had conflicting results, however. We examined multiple studies in an attempt to determine whether early sCD62L concentrations are predictive of major complications after severe trauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a systematic review of six electronic databases and a manual search for clinical studies comparing outcomes of multiply injured patients (Injury Severity Score &gt; or =16) depending on their early sCD62L blood concentrations. Because of various outcome definitions, acute lung injury (ALI) and adult respiratory distress syndrome (ARDS) were studied as a composite endpoint. Weighted mean differences (WMDs) in sCD62L concentrations were calculated between individuals with and without complications by fixed- and random-effects models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Altogether, 3370 citations were identified. Seven prospective studies including 350 patients were eligible for data synthesis. Published data showed the discriminatory features of sCD62L but did not allow for calculation of measures of test accuracy. Three of four studies showed lower early sCD62L concentrations among individuals progressing to ALI and ARDS (WMD = -229 microg/L; 95% confidence interval, -476 to 18 microg/L). No differences in sCD62L concentrations were noted among patients with or without later MODS. Nonsurvivors had significantly lower early sCD62L plasma concentrations (WMD = 121 microg/L; 95% confidence interval, 63-179 microg/L), but little information was available on potential confounders in this group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early decreased soluble L-selectin concentrations after multiple trauma may signal an increased likelihood of lung injury and ARDS. The findings of this metaanalysis warrant a large cohort study to develop selectin-based models targeting the risk of inflammatory complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stengel</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Division, Department of Orthopedic and Trauma Surgery, Unfallkrankenhaus Berlin, 12683 Berlin, Germany. dirk.stengel@ukb.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauwens</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Keh</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gerlach</LastName><ForeName>Herwig</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ekkernkamp</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tauber</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kerner</LastName><ForeName>Thoralf</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Chem</MedlineTA><NlmUniqueID>9421549</NlmUniqueID><ISSNLinking>0009-9147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126880-86-2</RegistryNumber><NameOfSubstance UI="D019041">L-Selectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019041" MajorTopicYN="N">L-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15550474</ArticleId><ArticleId IdType="doi">10.1373/clinchem.2004.040097</ArticleId><ArticleId IdType="pii">clinchem.2004.040097</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36158397</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>The Association Between Serum Lactate Concentration, Base Deficit, and Mortality in Polytrauma Patients as a Prognostic Factor: An Observational Study.</ArticleTitle><Pagination><StartPage>e28200</StartPage><MedlinePgn>e28200</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28200</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.28200</ELocationID><Abstract><AbstractText>Introduction In polytrauma patients, it is crucial to identify the severity of the injuries to ensure&#xa0;patient safety and survival. Polytrauma leads to hypotension and hypoperfusion, which results in an anaerobic metabolism with acidosis and a decrease in base excess. Thus, blood lactate levels above a certain threshold indicate the existence of global tissue hypoxia, which is a precursor to shock and multiple organ dysfunction syndrome (MODS).&#xa0;The serum lactate&#xa0;and base deficit (BD) levels are used in polytrauma patients as measures of damage severity and resuscitation endpoints and as&#xa0;a way to evaluate therapy efficacy and to predict outcomes. Thus, arterial blood gas analysis is of great value in assessing the status and prognosis of patients with polytrauma. There are few comparative studies on the predictive values of these markers in trauma patients. To determine which measure can more accurately predict the prognosis of polytrauma patients, the present study investigated the predictive values of mortality of these indicators for mortality within 48 hours of admission to the emergency room (ER) in patients with polytrauma. Methods This prospective study was designed for a single tertiary care center in northern India. We included 90 patients with polytrauma who were between the ages of 18 and 70 years, with the exception of pregnant women, who presented to the ER&#xa0;within six hours of injury with an injury severity score (ISS) &gt;16, serum lactate level &gt;2.0 mmol/L, and BD -4.0 mEq/L at the time of admission.&#xa0;If the patient's ISS was &gt;16 at the time of ER presentation, arterial blood samples were drawn to determine the serum lactate and BD level at the time of admission and at 12, 24, and 48 hours intervals after ER admission.&#xa0;The primary outcome&#xa0;was the change in serum lactate and BD level in polytrauma. The secondary outcomes were an association of serum lactate and BD with mortality and the correlation between serum lactate with the BD and ISS&#xa0;with mortality of polytrauma patients. The timing of all outcome assessments was at 48 hours after each patient's ER admission. Results Lactate clearance from 0-12 hours (t = 2.28, p &lt;0.05), 0-24 hours (t = 6.01, p &lt;0.001), and 0-48 hours (t = 7.98, p &lt;0.001)&#xa0;and a correction in BD from 0-24 (t = 2.68, p &lt;0.01 )&#xa0;and 0-48 hours (t = 5.46, p &lt;0.001) were significantly higher in nonsurvivors as compared with survivors. In survivors and nonsurvivors, mean serum lactate levels (2.46 &#xb1; 1.46 versus 4.15 &#xb1; 2.99, t = 3.31, p &lt;0.001, 95%Cl) and mean BD&#xa0;(-3.17 &#xb1; 2.58 versus -6.5 &#xb1; 4.91, t = 3.86, p &lt;0.001, 95%CI) had a statistically significant difference. The serum lactate and BD levels&#xa0;at time of ER admission (r L0, BD0 = -0.765, p &lt;0.01) and 48 hours after ER admission (r L48, BD 48 = -0.652, p &lt;0.001) were highly negatively correlated. Conclusion In polytrauma patients, serum lactate and BD are simple, quick, and independent biochemical predictors of 48-hour&#xa0;mortality, and this single arterial blood test would thereby improve decision-making for resuscitation effectiveness. Prolonged lactate and BD normalization time were associated with higher mortality. Serum lactate and BD are negatively correlated. A higher ISS&#xa0;at admission was associated with&#xa0;a higher incidence of mortality in polytrauma patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Jyoti et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jyoti</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Emergency Medicine, Paras HMRI (Hai Medicare and Research Institute) Hospital, Patna, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Trauma &amp; Emergency, All India Institute of Medical Sciences Patna, Patna, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halim</LastName><ForeName>Talat</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Trauma Surgery, Paras HMRI (Hai Medicare and Research Institute) Hospital, Patna, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hai</LastName><ForeName>Ahmed A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Surgery, Paras HMRI (Hai Medicare and Research Institute) Hospital, Patna, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">base deficit</Keyword><Keyword MajorTopicYN="N">hypoperfusion</Keyword><Keyword MajorTopicYN="N">injury severity score (iss)</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome (mods)</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">polytrauma</Keyword><Keyword MajorTopicYN="N">serum lactate</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36158397</ArticleId><ArticleId IdType="pmc">PMC9484334</ArticleId><ArticleId IdType="doi">10.7759/cureus.28200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Comparison of base excess, lactate and pH predicting 72-h mortality of multiple trauma. Qi J, Bao L, Yang P, Chen D. BMC Emerg Med. 2021;21:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262006</ArticleId><ArticleId IdType="pubmed">34233612</ArticleId></ArticleIdList></Reference><Reference><Citation>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789&#x2013;1858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>Predictors of death in trauma patients who are alive on arrival at hospital. Lichtveld RA, Panhuizen IF, Smit RB, Holtslag HR, van der Werken C. Eur J Trauma Emerg Surg. 2007;33:46&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">26815974</ArticleId></ArticleIdList></Reference><Reference><Citation>An evaluation of serial blood lactate measurement as an early predictor of shock and its outcome in patients of trauma or sepsis. Krishna U, Joshi SP, Modh M. Indian J Crit Care Med. 2009;13:66&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772249</ArticleId><ArticleId IdType="pubmed">19881186</ArticleId></ArticleIdList></Reference><Reference><Citation>Base deficit as an early marker of coagulopathy in trauma. Cheddie S, Muckart DJ, Hardcastle TC. https://pubmed.ncbi.nlm.nih.gov/23941752/ S Afr J Surg. 2013;51:88&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">23941752</ArticleId></ArticleIdList></Reference><Reference><Citation>Is arterial base deficit still a useful prognostic marker in trauma? A systematic review. Ibrahim I, Chor WP, Chue KM, Tan CS, Tan HL, Siddiqui FJ, Hartman M. Am J Emerg Med. 2016;34:626&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">26856640</ArticleId></ArticleIdList></Reference><Reference><Citation>Factors predicting the early mortality of trauma patients. Jin WY, Jeong JH, Kim DH, et al. Ulus Travma Acil Cerrahi Derg. 2018;24:532&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">30516252</ArticleId></ArticleIdList></Reference><Reference><Citation>Acid-base disorders as predictors of early outcomes in major trauma in a resource limited setting: An observational prospective study. Shane AI, Robert W, Arthur K, Patson M, Moses G. Pan Afr Med J. 2014;17:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149796</ArticleId><ArticleId IdType="pubmed">25184019</ArticleId></ArticleIdList></Reference><Reference><Citation>Venous glucose, serum lactate and base deficit as biochemical predictors of mortality in patients with polytrauma. Saad S, Mohamed N, Moghazy A, Ellabban G, El-Kamash S. Ulus Travma Acil Cerrahi Derg. 2016;22:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27135075</ArticleId></ArticleIdList></Reference><Reference><Citation>Returning from the acidotic abyss: Mortality in trauma patients with a pH&#xa0;&amp;lt;&#xa0;7.0. Ross SW, Thomas BW, Christmas AB, Cunningham KW, Sing RF. Am J Surg. 2017;214:1067&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">29079021</ArticleId></ArticleIdList></Reference><Reference><Citation>Morbidity and mortality in elderly trauma patients. Tornetta P 3rd, Mostafavi H, Riina J, et al. J Trauma. 1999;46:702&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lactate as predictor of mortality in polytrauma. Freitas AD, Franzon O. Arq Bras Cir Dig. 2015;28:163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737353</ArticleId><ArticleId IdType="pubmed">26537138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortality risk stratification in elderly trauma patients based on initial arterial lactate and base deficit levels. Neville AL, Nemtsev D, Manasrah R, Bricker SD, Putnam BA. https://pubmed.ncbi.nlm.nih.gov/22127083/ Am Surg. 2011;77:1337&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">22127083</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of serum lactate and base excess in predicting the survival outcome in polytrauma patients. Konduri S, Bollampally B, Satyanarayana S, Pelluri S. https://www.ijca.in/article-details/3686 Indian J Clin Anaesth. 2017;4:118&#x2013;121.</Citation></Reference><Reference><Citation>Renaissance of base deficit for the initial assessment of trauma patients: a base deficit-based classification for hypovolemic shock developed on data from 16,305 patients derived from the TraumaRegister DGU&#xae;. Mutschler M, Nienaber U, Brockamp T, et al. Crit Care. 2013;17:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672480</ArticleId><ArticleId IdType="pubmed">23497602</ArticleId></ArticleIdList></Reference><Reference><Citation>Base deficit is superior to lactate in trauma. Davis JW, Dirks RC, Kaups KL, Tran P. Am J Surg. 2018;215:682&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">29409590</ArticleId></ArticleIdList></Reference><Reference><Citation>Discordance between lactate and base deficit in the surgical intensive care unit: which one do you trust? Martin MJ, FitzSullivan E, Salim A, Brown CV, Demetriades D, Long W. Am J Surg. 2006;191:625&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">16647349</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiological and trauma injury and severity score (TRISS) analysis of trauma patients at a tertiary care centre in India. Goel A, Kumar S, Bagga MK. https://pubmed.ncbi.nlm.nih.gov/15372759/ Natl Med J India. 2004;17:186&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372759</ArticleId></ArticleIdList></Reference><Reference><Citation>Serum lactate as a predictor of early outcomes among trauma patients in Uganda. Okello M, Makobore P, Wangoda R, Upoki A, Galukande M. Int J Emerg Med. 2014;7:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105872</ArticleId><ArticleId IdType="pubmed">25097669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31008819</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-2291</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of orthopaedic trauma</Title><ISOAbbreviation>J Orthop Trauma</ISOAbbreviation></Journal><ArticleTitle>Early Immunologic Response in Multiply Injured Patients With Orthopaedic Injuries Is Associated With Organ Dysfunction.</ArticleTitle><Pagination><StartPage>220</StartPage><EndPage>228</EndPage><MedlinePgn>220-228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BOT.0000000000001437</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To quantify the acute immunologic biomarker response in multiply injured patients with axial and lower extremity fractures and to explore associations with adverse short-term outcomes including organ dysfunction and nosocomial infection (NI).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Level 1 academic trauma center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive multiply injured patients, 18-55 years of age, with major pelvic and lower extremity orthopaedic injuries (all pelvic/acetabular fractures, operative femur and tibia fractures) that presented as a trauma activation and admitted to the intensive care unit from April 2015 through October 2016. Sixty-one patients met inclusion criteria.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Blood was collected upon presentation to the hospital and at the following time points: 8, 24, 48 hours, and daily during intensive care unit admission. Blood was processed by centrifugation, separation into 1.0-mL plasma aliquots, and cryopreserved within 2 hours of collection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASUREMENTS" NlmCategory="METHODS">Plasma analyses of protein levels of cytokines/chemokines were performed using a Luminex panel Bioassay of 20 immunologic mediators. Organ dysfunction was measured by the Marshall Multiple Organ Dysfunction score (MODScore) and nosocomial infection (NI) was recorded. Patients were stratified into low (MODS &#x2264; 4; n = 34) and high (MODS &gt; 4; n = 27) organ dysfunction groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The MODS &gt;4 group had higher circulating levels of interleukin (IL)-6, IL-8, IL-10, monocyte chemoattractant protein-1 (MCP-1), IL-1 receptor antagonist (IL-1RA), and monokine induced by interferon gamma (MIG) compared with the MODS &#x2264;4 group at nearly all time points. MODS &gt;4 exhibited lower levels of IL-21 and IL-22 compared with MODS &#x2264;4. Patients who developed NI (n = 24) had higher circulating concentrations of IL-10, MIG, and high mobility group box 1 (HMGB1) compared with patients who did not develop NI (n = 37).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Temporal quantification of immune mediators identified 8 biomarkers associated with greater levels of organ dysfunction in polytrauma patients with major orthopaedic injuries.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaski</LastName><ForeName>Greg E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzger</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wessel</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutshall</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vodovotz</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinley</LastName><ForeName>Todd O</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Orthop Trauma</MedlineTA><NlmUniqueID>8807705</NlmUniqueID><ISSNLinking>0890-5339</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31008819</ArticleId><ArticleId IdType="doi">10.1097/BOT.0000000000001437</ArticleId><ArticleId IdType="pii">00005131-201905000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17215732</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5282</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Tissue oxygen saturation predicts the development of organ dysfunction during traumatic shock resuscitation.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>55</EndPage><MedlinePgn>44-54; discussion 54-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Near-infrared spectroscopy (NIRS) can continuously and noninvasively monitor tissue oxygen saturation (StO2) in muscle and may be an indicator of shock severity. Our purpose was to evaluate how well StO2 predicted outcome in high-risk torso trauma patients presenting in shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The primary outcome in this prospective study was multiple organ dysfunction syndrome (MODS). StO2 data were obtained upon hospital arrival and for 24 hours along with other known predictors of hypoperfusion and clinical outcomes. Clinicians were blinded to StO2 measurements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven Level I trauma centers enrolled 383 patients, 50 of whom developed MODS. Minimum StO2 performed similarly to maximum base deficit (BD) in discrimination of MODS patients. The sensitivity for both measures (StO2 cutoff = 75%; BD cutoff = 6 mEq/L) was 78%, the specificity was 34% to 39%, the positive predictive value was 18% to 20% and the negative predictive value was 88% to 91%. StO2 and BD were also comparable in predicting death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NIRS-derived muscle StO2 measurements perform similarly to BD in identifying poor perfusion and predicting the development of MODS or death after severe torso trauma, yet have the additional advantages of being continuous and noninvasive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Texas Health Science Center, San Antonio, Texas 78229, USA. cohn@uthscsa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathens</LastName><ForeName>Avery B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Puyana</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ernest E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Beilman</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><CollectiveName>StO2 in Trauma Patients Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012774" MajorTopicYN="N">Shock, Traumatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019265" MajorTopicYN="N">Spectroscopy, Near-Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17215732</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31802eb817</ArticleId><ArticleId IdType="pii">00005373-200701000-00005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22069445</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>11</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Reduction of plasma gelsolin levels correlates with development of multiple organ dysfunction syndrome and fatal outcome in burn patients.</ArticleTitle><Pagination><StartPage>e25748</StartPage><MedlinePgn>e25748</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25748</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0025748</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depletion of the circulating actin-binding protein, plasma gelsolin (pGSN) has been described in critically ill surgical patients. We hypothesized that the extent of pGSN reduction might correlate with different outcome of burn patients. The study was performed to evaluate the prognostic implications of pGSN levels on the development of multiple organ dysfunction syndrome (MODS) and fatal outcome in a group of severely burn patients.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">95 patients were included, and they were divided into three groups with different burn area: group I (n&#x200a;=&#x200a;33), group II (n&#x200a;=&#x200a;32) and group III (n&#x200a;=&#x200a;30). According to whether there was development of MODS or not, patients were divided into MODS group (n&#x200a;=&#x200a;28) and none-MODS group (n&#x200a;=&#x200a;67); then the patients with MODS were further divided into non-survivor group (n&#x200a;=&#x200a;17) and survivor group (n&#x200a;=&#x200a;11). The peripheral blood samples were collected on postburn days (PBD) 1, 3, 7, 14, and 21. The levels of pGSN were determined and T cells were procured from the blood. The contents of cytokines (IL-2, IL-4 and IFN-&#x3b3;) released by T cells were also measured. The related factors of prognosis were analyzed by using multivariate logistic regression analysis. The results showed that pGSN concentrations, as well as the levels of IL-2 and IFN-&#x3b3;, decreased markedly on PBD 1-21, whereas, the levels of IL-4 increased markedly in all burn groups as compared with normal controls (P&lt;0.05 or P&lt;0.01), and there were obviously differences between group I and group III (P&lt;0.05 or P&lt;0.01). The similar results were found in MODS patients and the non-survivor group as compared with those without MODS and the survival group on days 3-21 postburn (P&lt;0.05 or P&lt;0.01). Moreover, as the pGSN levels decreased, the incidence of septic complication as well as MODS remarkably increased.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">pGSN levels appear to be an early prognostic marker in patients suffering from major burns.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-feng</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Burns Institute, First Hospital Affiliated to the Chinese PLA General Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yong-ming</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jin-feng</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Ning</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Li-xin</ForeName><Initials>LX</Initials></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Zhi-yong</ForeName><Initials>ZY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018260">Gelsolin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018260" MajorTopicYN="N">Gelsolin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22069445</ArticleId><ArticleId IdType="pmc">PMC3206022</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0025748</ArticleId><ArticleId IdType="pii">PONE-D-11-07236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Accardo-Palumbo A, D'Amelio L, Pileri D, D'Arpa N, Mogavero R, et al. Reduction of plasma granzyme acorrelates with severity of sepsis in burn patients. Burns. 2010;36:811&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">20362398</ArticleId></ArticleIdList></Reference><Reference><Citation>Venet F, Tissot S, Debard AL, Faudot C, Cramp&#xe9; C, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med. 2007;35:1910&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568330</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin AC, Kaschube M, Wieschaus EF. Pulsed contractions of an actin-myosin network drive apical constriction. Nature. 2009;457:495&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822715</ArticleId><ArticleId IdType="pubmed">19029882</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA. 1990;87:1381&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53479</ArticleId><ArticleId IdType="pubmed">2154744</ArticleId></ArticleIdList></Reference><Reference><Citation>Erukhimov JA, Tang ZL, Johnson BA, Donahoe MP, Razzack JA, et al. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Respir Crit Care Med. 2000;16:288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">10903256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemric ME, Tracy PB, Haeberle JR. Caldesmon enhances the binding of myosin to the cytoskeleton during platelet activation. J Biol Chem. 1994;269:4125&#x2013;4128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottiez G, Haverland N, Ciborowski P. Mass spectrometric characterization of gelsolin isoforms. Rapid Commun Mass Spectrom. 2010;24:2620&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286873</ArticleId><ArticleId IdType="pubmed">20740538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferjani I, Fattoum A, Bettache N, Seantier B, Milhiet PE, et al. The gelsolin:calponin complex nucleates actin filaments with distinct morphologies. Biochem Biophys Res Commun. 2010;392:118&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035726</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee WL, et al. Ca2+ binding by domain plays a critical role in the activation and stabilization of gelsolin. Proc Natl Acad Sci USA. 2009;106:13713&#x2013;13718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720848</ArticleId><ArticleId IdType="pubmed">19666512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucki R, Levental I, Kulakowska A, Janmey PA. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci. 2008;9:541&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">19075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Patel SR, Christiani DC, Bajwa E, Stossel TP, et al. Plasma gelsolin depletion and circulating actin in sepsis: a pilot study. PLoS One. 2008;3:e3712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577888</ArticleId><ArticleId IdType="pubmed">19002257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest. 1986;78:736&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC423663</ArticleId><ArticleId IdType="pubmed">3018044</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol. 2004;96:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730154</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofidou-Solomidou M, Scherpereel A, Solomides CC, Muzykantov VR, Machtay M, et al. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung. 2002;180:91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">12172902</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker PM, Kazi AA, Wadgaonkar R, Pearse DB, Kwiatkowski D, et al. Pulmonary vascular permeability and ischemic injury in gelsolin-deficient mice. Am J Respir Cell Mol Biol. 2003;28:478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, et al. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007;35:849&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">17205019</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002;100:4367&#x2013;4371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006;243:399&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1448930</ArticleId><ArticleId IdType="pubmed">16495706</ArticleId></ArticleIdList></Reference><Reference><Citation>Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med. 1999;160:1673&#x2013;1681.</Citation><ArticleIdList><ArticleId IdType="pubmed">10556139</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol. 2007;292:C1323&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135294</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 1997;25:594&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrentieva A, Kontakiotis T, Bitzani M, Papaioannou-Gaki G, Parlapani A, et al. Early coagulation disorders after severe burn injury: impact on mortality. Intensive Care Med. 2008;34:700&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">18193192</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LN, Nguyen TG. Characteristics and outcomes of multiple organ dysfunction syndrome among severe-burn patients. Burns. 2009;35:937&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">19553020</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwacha MG, Schneider CP, Chaudry IH. Differential expression and tissue compartmentalization of the inflammatory response following thermal injury. Cytokine. 2002;17:266&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12027408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira FL, Bota DP, Bross A, M&#xe9;lot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH 4th, Gamelli RL, Palmieri TL, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28:776&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis TA, Stojadinovic A, Anam K, Amare M, Naik S, et al. Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. Int Wound J. 2009;6:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7951765</ArticleId><ArticleId IdType="pubmed">19291111</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JO, Shin SD, Kim J, Song KJ, Peck MD. Association between socioeconomic status and burn injury severity. Burns. 2009;35:482&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">19216029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med. 1992;326:1335&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">1314333</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNubile MJ. Plasma gelsolin as a biomarker of inflammation. Arthritis Res Ther. 2008;10:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656232</ArticleId><ArticleId IdType="pubmed">19105851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Bhan I, Thadhani R. The potential role of plasma gelsolin in dialysis-related protein-energy wasting. Blood Purif. 2010;29:99&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">20093811</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinardi L, Witke W. Gelsolin and diseases. Subcell Biochem. 2007;45:55&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">18193634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin&#x2013;actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis. 1988;138:429&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">2848430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengart MR, Arbabi S, Bauer GJ, Garcia I, Jelacic S, et al. The actin cytoskeleton: an essential component for enhanced TNFalpha production by adherent monocytes. Shock. 2002;17:109&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837785</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin Infect Dis. 1997;24:951&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry. 2005;44:9590&#x2013;9597.</Citation><ArticleIdList><ArticleId IdType="pubmed">16008344</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, et al. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Bio Chem. 2000;275:14573&#x2013;14578.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physio. 2004;96:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730154</ArticleId></ArticleIdList></Reference><Reference><Citation>Demling RH, Kramer G, Harms B. Role of thermal injury-induced hypoproteinemia on fluid flux and protein permeability in burned and nonburned tissue. Surgery. 1984;95:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6695330</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CH, James HJ, Ogle C, Fischer JE, Hasselgren PO. Influence of burn injury on protein metabolism in different types of skeletal muscle and the role of glucocorticoids. J Am Coll Surg. 1995;180:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">8000653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HH, Cheng BL, Chen QX, Wu SJ, Lv C, et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care. 2008;12:R106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575595</ArticleId><ArticleId IdType="pubmed">18706105</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LF, Yao YM, Dong N, Yu Y, He LX, et al. Association between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study. Crit Care. 2010;14:R3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875505</ArticleId><ArticleId IdType="pubmed">20064232</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LF, Yao YM, Zhang LT, Dong N, Yu Y, et al. The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats. Shock. 2009;31:322&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">18665051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao YM, Sheng ZY, Huang LF. The effect of a novel cytokine, high mobility group box 1 protein, on the development of traumatic sepsis. Chin J Integr Med. 2009;15:13&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LT, Yao YM, Yao FH, Huang LF, Dong N, et al. Association between high-mobility group box-1 protein release and immune function of dendritic cells in thermal injury. J Interferon Cytokine Res. 2010;30:487&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">20233162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23979273</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>258</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>598</EndPage><MedlinePgn>591-6; discussion 596-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0b013e3182a4ea46</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our objective was to execute a prospective cohort study to determine relationships between plasma mtDNA DAMP levels and the occurrence of systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and mortality.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mitochondrial DNA damage-associated molecular patterns (DAMPs) accumulate in the circulation after severe injury. Observations in animal models demonstrate that mtDNA DAMPs contribute to organ dysfunction; however, the link between plasma mtDNA DAMPs and outcome in severely injured human subjects has not been established.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">DNA was isolated from plasma samples taken from severely injured patients at hospital days 0, 1, and 2. Real-time PCR was used to quantify selected &#x2248;200 base pair sequences of mtDNA within the COX1, ND1, and ND6 genes, as well as from the D-Loop transcriptional regulatory region. MODS was defined as a Denver Multiple Organ Failure score of 4 or greater.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MtDNA DAMPs were quantified as PCR threshold cycle number. Lower threshold cycles indicate increased mtDNA DAMP content. Patients with SIRS had significantly increased mtDNA DAMP levels in all 4 sequences examined (32.14 &#xb1; 0.90 vs 29.00 &#xb1; 1.15 for COX1, 31.90 &#xb1; 0.47 vs 30.16 &#xb1; 1.42 for ND1, 32.40 &#xb1; 0.61 vs 28.94 &#xb1; 1.13 for ND6, and 33.12 &#xb1; 0.83 vs 28.30 &#xb1; 1.14 for D-Loop). Patients who developed MODS also had elevated mtDNA DAMP levels compared with those who did not (32.57 &#xb1; 0.74 vs 27.12 &#xb1; 0.66 for COX1, 32.45 &#xb1; 0.65 vs 28.20 &#xb1; 0.73 for ND1, 32.52 &#xb1; 0.56 vs 27.60 &#xb1; 0.79 for ND6, and 32.85 &#xb1; 0.75 vs 27.86 &#xb1; 1.27 for D-Loop). Patients with above-median mtDNA DAMP levels had a significantly elevated relative risk for mortality. Four patients died secondary to severe MODS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings comprise the first observational evidence that plasma mtDNA DAMPs is associated with the evolution of SIRS, MODS, and mortality in severely injured human subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Departments of *Surgery &#x2020;Center for Lung Biology &#x2021;Pharmacology, University of South Alabama College of Medicine, Mobile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yann-Leei</ForeName><Initials>YL</Initials></Author><Author ValidYN="Y"><LastName>Mulekar</LastName><ForeName>Sujata</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kuck</LastName><ForeName>Jamie L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Brevard</LastName><ForeName>Sidney B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Gillespie</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>William O</ForeName><Initials>WO</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01812941</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL058234</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL113614</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL076125</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051545">Cyclooxygenase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="C496511">PTGS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C507225">MT-ND6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="D009245">NADH Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C515075">NADH dehydrogenase subunit 1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051545" MajorTopicYN="N">Cyclooxygenase 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009245" MajorTopicYN="N">NADH Dehydrogenase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23979273</ArticleId><ArticleId IdType="mid">NIHMS554065</ArticleId><ArticleId IdType="pmc">PMC3935616</ArticleId><ArticleId IdType="doi">10.1097/SLA.0b013e3182a4ea46</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou Z, Daugherty WP, Sun D, et al. Protection of mitochondrial function and improvement in cognitive recovery in rats treated with hyperbaric oxygen following lateral fluid-percussion injury. J Neurosurg. 2007;106:687&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">17432723</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinbroum AA, Hochhauser E, Rudick V, et al. Multiple organ dysfunction after remote circulatory arrest: common pathway of radical oxygen species? J Trauma. 1999;47:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">10528603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson K, Flaring U, Guillet C, et al. Muscle mitochondrial activity increases rapidly after an endotoxin challenge in human volunteers. Acta Anaesthesiol Scand. 2009;53:299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">19243315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson K, Tjader I, Keller P, et al. Dysregulation of mitochondrial dynamics and the muscle transcriptome in ICU patients suffering from sepsis induced multiple organ failure. PLoS One. 2008;3:e3686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579334</ArticleId><ArticleId IdType="pubmed">18997871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson K, Rooyackers O. Mitochondrial function in sepsis: respiratory versus leg muscle. Crit Care Med. 2007;35:S449&#x2013;S53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17713392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G, Kong RH, Zhang LM, et al. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol. 2012;167:699&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575772</ArticleId><ArticleId IdType="pubmed">23003569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843437</ArticleId><ArticleId IdType="pubmed">20203610</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko DV, Agostinis P, Krysko O, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011;32:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">21334975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Sursal T, Adibnia Y, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One. 2013;8:e59989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603956</ArticleId><ArticleId IdType="pubmed">23527291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sursal T, Stearns-Kurosawa DJ, Itagaki K, et al. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock. 2013;39:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537509</ArticleId><ArticleId IdType="pubmed">23247122</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock. 2010;34:55&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">19997055</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mehdi AB, Pastukh VM, Swiger BM, et al. Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. Sci Signal. 2012:5:ra47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3565837</ArticleId><ArticleId IdType="pubmed">22763339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastukh VM, Zhang L, Ruchko MV, et al. Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences. Int J Chron Obstruct Pulmon Dis. 2011;6:209&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107697</ArticleId><ArticleId IdType="pubmed">21660298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, et al. Validation of postinjury multiple organ failure scores. Shock. 2009;31:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">1597042</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997;94:514&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19544</ArticleId><ArticleId IdType="pubmed">9012815</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishko V, Solomon M, Wilson GL, et al. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell pheno-types. Am J Physiol Lung Cell Mol Physiol. 2001;280:L1300&#x2013;L1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">11350811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruchko MV, Gorodnya OM, Zuleta A, et al. The DNA glycosylase Ogg1 defends against oxidant-induced mtDNA damage and apoptosis in pulmonary artery endothelial cells. Free Radic Biol Med. 2011;50:1107&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033972</ArticleId><ArticleId IdType="pubmed">20969951</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokolenko I, Venediktova N, Bochkareva A, et al. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009;37:2539&#x2013;2548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677867</ArticleId><ArticleId IdType="pubmed">19264794</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouteau J, Gorodnya O, Ruchko M, et al. Novel fusion protein constructs targeting DNA repair enzymes to mitochondria protect against pseudomonas aeruginosa-induced acute lung injury in intact rats [Abstracts, 2011 ATS International Conference]. Am J Resp Crit Care Med. 2011;183:A3763.</Citation></Reference><Reference><Citation>Hill JK, Obiako B, Gorodnya O, et al. A positive feedback cycle involving oxidative mitochondrial (mt) DNA damage and mtDNA damage associated molecular patterns (DAMPs) contributes to bacteria-induced endothelial barrier dysfunction in isolated rat lungs. Am J Resp Crit Care Med. 2013;187:A4978.</Citation></Reference><Reference><Citation>Gill R, Ruan X, Menzel CL, et al. Systemic inflammation and liver injury following hemorrhagic shock and peripheral tissue trauma involve functional TLR9 signaling on bone marrow-derived cells and parenchymal cells. Shock. 2011;35:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000874</ArticleId><ArticleId IdType="pubmed">20577143</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds RD, Vodovotz Y, Lagoa C, et al. Transcriptomic response of murine liver to severe injury and hemorrhagic shock: a dual-platform microarray analysis. Physiol Genomics. 2011;43(20):1170&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3217328</ArticleId><ArticleId IdType="pubmed">21828244</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer R, Kobbe P, Darwiche SS, et al. Role of hemorrhage in the induction of systemic inflammation and remote organ damage: analysis of combined pseudo-fracture and hemorrhagic shock. J Orthop Res. 2011;29:270&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20690183</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587220</ArticleId><ArticleId IdType="pubmed">23401516</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208:2581&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczor CA, Snyder JW, Shokolenko IN, et al. Targeting repair proteins to the mitochondria of mammalian cells through stable transfection, transient transfection, viral transduction, and TAT-mediated protein transduction. Methods Mol Biol. 2009;554:233&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">19513678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson AW, Grishko V, LeDoux SP, et al. Enhanced mtDNA repair capacity protects pulmonary artery endothelial cells from oxidant-mediated death. Am J Physiol Lung Cell Mol Physiol. 2002;283:L205&#x2013;L210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12060578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachek LI, Thornley NP, Grishko VI, et al. Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria. Diabetes. 2006;55:1022&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567524</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczor CA, Shokolenko IN, Boyd AK, et al. Mitochondrial DNA damage initiates a cell cycle arrest by a Chk2-associated mechanism in mammalian cells. J Biol Chem. 2009;284:36191&#x2013;36201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794735</ArticleId><ArticleId IdType="pubmed">19840931</ArticleId></ArticleIdList></Reference><Reference><Citation>Druzhyna NM, Hollensworth SB, Kelley MR, et al. Targeting human 8-oxoguanine glycosylase to mitochondria of oligodendrocytes protects against menadione-induced oxidative stress. Glia. 2003;42:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730957</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachek LI, Grishko VI, Ledoux SP, et al. Role of nitric oxide-induced mtDNA damage in mitochondrial dysfunction and apoptosis. Free Radic Biol Med. 2006;40:754&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouteau JM, Obiako B, Gorodnya OM, et al. Mitochondrial DNA integrity may be a determinant of endothelial barrier properties in oxidant-challenged rat lungs. Am J Physiol Lung Cell Mol Physiol. 2011;301:L892&#x2013;L898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233824</ArticleId><ArticleId IdType="pubmed">21890512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume M, Mouner M, Chouteau JM, et al. Mitochondrial-targeted DNA repair enzyme 8-oxoguanine DNA glycosylase 1 protects against ventilator-induced lung injury in intact mice. Am J Physiol Lung Cell Mol Physiol. 2013;304:L287&#x2013;L297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567361</ArticleId><ArticleId IdType="pubmed">23241530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebb SA, Decoux A, Waggoner A, et al. Mitochondrial DNA damage mediates hyperoxic dysmorphogenesis in rat fetal lung explants. Neonatology. 2012;103:91&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568246</ArticleId><ArticleId IdType="pubmed">23154780</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia N, Chavez E. Mitochondrial DNA fragments released through the permeability transition pore correspond to specific gene size. Life Sci. 2007;81:1160&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">17870132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>